FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Hegedus, A
   Nyamweya, S
   Zhang, Y
   Jaye, A
   Macallan, D
   Flanagan, K
AF Hegedus, A.
   Nyamweya, S.
   Zhang, Y.
   Jaye, A.
   Macallan, D.
   Flanagan, K.
TI Human lymphocyte dynamics and chronic viral infections
SO IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Congress of the British-Society-for-Immunology
CY DEC 06-10, 2010
CL Liverpool, ENGLAND
SP British Soc Immunol
C1 [Hegedus, A.; Zhang, Y.; Macallan, D.] St Georges Univ London, Ctr Infect, London, England.
   [Nyamweya, S.; Jaye, A.; Flanagan, K.] MRC Labs, Viral Dis Programme, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD DEC
PY 2010
VL 131
SU 1
BP 99
EP 99
PG 1
WC Immunology
SC Immunology
GA 689XL
UT WOS:000284964100307
OA No
DA 2017-08-15
ER

PT J
AU de Silva, T
   Weiss, RA
AF de Silva, Thushan
   Weiss, Robin A.
TI HIV-2 goes global: an unaddressed issue in Indian anti-retroviral
   programmes
SO INDIAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Editorial Material
ID IMMUNODEFICIENCY-VIRUS TYPE-2; WEST-AFRICA; HIV-2-INFECTED PATIENTS;
   DRUG-RESISTANCE; GUINEA-BISSAU; COHORT; EPIDEMIC; SUSCEPTIBILITY;
   TRANSMISSION; INDIVIDUALS
C1 [de Silva, Thushan; Weiss, Robin A.] UCL, MRC UCL Ctr Med Mol Virol, Div Infect & Immun, London WC1E 6BT, England.
   [de Silva, Thushan] Med Res Council UK Labs, Fajara, Gambia.
RP Weiss, RA (reprint author), UCL, MRC UCL Ctr Med Mol Virol, Div Infect & Immun, London WC1E 6BT, England.
EM r.weiss@ucl.ac.uk
CR Chiara M, 2010, INDIAN J MED RES, V132, P683
   da Silva ZJ, 2008, AIDS, V22, P1195, DOI 10.1097/QAD.0b013e328300a33d
   Desbois D, 2008, ANTIMICROB AGENTS CH, V52, P1545, DOI 10.1128/AAC.01284-07
   Drylewicz J, 2008, AIDS, V22, P457, DOI 10.1097/QAD.0b013e3282f4ddfc
   Gottlieb GS, 2009, CLIN INFECT DIS, V48, P476, DOI 10.1086/596504
   Gottlieb GS, 2002, J INFECT DIS, V185, P905, DOI 10.1086/339295
   Jallow S, 2006, AIDS, V20, P1455, DOI 10.1097/01.aids.0000233582.64467.8e
   Kannangai R, 2003, JAIDS-J ACQ IMM DEF, V32, P573, DOI 10.1097/00126334-200304150-00018
   Kannangai R, 2010, INDIAN J MED MICROBI, V28, P111, DOI 10.4103/0255-0857.62485
   Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100
   Masse S, 2007, ANTIMICROB AGENTS CH, V51, P3075, DOI 10.1128/AAC.00146-07
   Matheron S, 2006, AIDS, V20, P459, DOI 10.1097/01.aids.0000199829.57112.2f
   Pepin J, 2006, AIDS, V20, P1303
   POULSEN AG, 1993, J ACQ IMMUN DEF SYND, V6, P941
   Ruelle J, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-21
   van der Ende ME, 2003, AIDS, V17, pS55, DOI 10.1097/00002030-200317003-00008
   van der Loeff MFS, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-46
   van der Loeff MFS, 2002, AIDS, V16, P1775
NR 18
TC 2
Z9 2
U1 0
U2 1
PU INDIAN COUNCIL MEDICAL RES
PI NEW DELHI
PA PO BOX 4911 ANSARI NAGAR, NEW DELHI 110029, INDIA
SN 0971-5916
J9 INDIAN J MED RES
JI Indian J. Med. Res.
PD DEC
PY 2010
VL 132
IS 6
BP 660
EP 662
PG 3
WC Immunology; Medicine, General & Internal; Medicine, Research &
   Experimental
SC Immunology; General & Internal Medicine; Research & Experimental
   Medicine
GA 716YT
UT WOS:000287010100003
PM 21245611
OA gold
DA 2017-08-15
ER

PT J
AU Melin, M
   Trzcinski, K
   Antonio, M
   Meri, S
   Adegbola, R
   Kaijalainen, T
   Kayhty, H
   Vakevainen, M
AF Melin, Merit
   Trzcinski, Krzysztof
   Antonio, Martin
   Meri, Seppo
   Adegbola, Richard
   Kaijalainen, Tarja
   Kayhty, Helena
   Vakevainen, Merja
TI Serotype-Related Variation in Susceptibility to Complement Deposition
   and Opsonophagocytosis among Clinical Isolates of Streptococcus
   pneumoniae
SO INFECTION AND IMMUNITY
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; ACUTE OTITIS-MEDIA; HISTIDINE TRIAD
   PROTEINS; STANDARD REFERENCE SERUM; INVASIVE-DISEASE; CAPSULAR SEROTYPE;
   SURFACE PROTEIN; FACTOR-H; NASOPHARYNGEAL CARRIAGE; FUNCTIONAL
   ANTIBODIES
AB The polysaccharide capsule is a major virulence factor of Streptococcus pneumoniae; it affects complement resistance and shields the bacterium from phagocytes. Certain capsular serotypes appear to be better able to cause invasive disease than others. Serotypes 1 and 5 are common causes of invasive disease but are rarely isolated from healthy carriers, whereas serotypes 6B and 23F are more frequently isolated from carriage than invasive disease. We have recently shown that serotypes 6B and 19F differ in resistance to complement C3 deposition and opsonophagocytic killing. In this study we assessed the complement resistance and susceptibility to opsonophagocytosis of several other serotypes targeted by the pneumococcal conjugate vaccines. Clinical isolates of serotypes 1, 4, 5, 14, 18C, and 23F were tested along reference strains of corresponding capsular types. The concentration of anticapsular antibodies required for opsonophagocytic killing correlated inversely with C3 deposition on the serotype. Serotype 1 was the most resistant of the clinical isolates to C3 deposition and, along with serotypes 5 and 19F, required the highest concentration of capsule antibodies for opsonophagocytic killing, whereas serotype 23F was the most sensitive to opsonophagocytosis. Sensitivity to C3 deposition and opsonophagocytosis was associated with serotype-specific mortality of invasive pneumococcal disease, suggesting that the primary pathogens, such as serotypes 1 and 5, are more resistant to complement and require a higher concentration of capsule antibodies for opsonophagocytic killing than the opportunistic serotypes such as 6B and 23F, which are associated with a more severe disease outcome.
C1 [Melin, Merit; Kayhty, Helena; Vakevainen, Merja] Natl Inst Hlth & Welf, Dept Vaccinat & Immune Protect, Helsinki 00300, Finland.
   [Trzcinski, Krzysztof] UMC Utrecht WKZ, Dept Pediat Immunol & Infect Dis, Utrecht, Netherlands.
   [Antonio, Martin; Adegbola, Richard] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Meri, Seppo] Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland.
   [Meri, Seppo] Univ Helsinki, Cent Hosp Lab, HUSLAB, FIN-00014 Helsinki, Finland.
   [Kaijalainen, Tarja] Natl Inst Hlth & Welf, Dept Life Course & Serv, Oulu, Finland.
RP Melin, M (reprint author), Natl Inst Hlth & Welf, Dept Vaccinat & Immune Protect, Mannerheimintie 166, Helsinki 00300, Finland.
EM merit.melin@thl.fi
OI Trzcinski, Krzysztof/0000-0002-5433-8846; Meri,
   Seppo/0000-0001-9142-501X
FU Medical Research Council [MC_U190074190, MC_U190081991]
CR Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Antonio M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-198
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Bogaert D, 2004, VACCINE, V22, P4014, DOI 10.1016/j.vaccine.2004.03.049
   Brueggemann AB, 2004, J INFECT DIS, V190, P1203, DOI 10.1086/423820
   Brueggemann AB, 2003, J CLIN MICROBIOL, V41, P4966, DOI 10.1128/JCM.41.11.4966-4970.2003
   Brueggemann AB, 2003, J INFECT DIS, V187, P1424, DOI 10.1086/374624
   Burton RL, 2006, CLIN VACCINE IMMUNOL, V13, P1004, DOI 10.1128/CVI.00112-06
   Choi YH, 2002, BIOCHEMISTRY-US, V41, P15144, DOI 10.1021/bi020491v
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dave S, 2001, INFECT IMMUN, V69, P3435, DOI 10.1128/IAI.69.5.3435-3437.2001
   Ekstrom N, 2005, INFECT IMMUN, V73, P369, DOI 10.1128/IAI.73.1.369-377.2005
   Ekstrom N, 2007, INFECT IMMUN, V75, P1794, DOI 10.1128/IAI.01673-06
   Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602
   Hanage WP, 2005, INFECT IMMUN, V73, P431, DOI 10.1128/IAI.73.1.431-435.2005
   Harboe ZB, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000081
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   HOSTETTER MK, 1986, J INFECT DIS, V153, P682
   Hyams C, 2010, INFECT IMMUN, V78, P704, DOI 10.1128/IAI.00881-09
   Hyams C, 2010, INFECT IMMUN, V78, P716, DOI 10.1128/IAI.01056-09
   Janulczyk R, 2000, J BIOL CHEM, V275, P37257, DOI 10.1074/jbc.M004572200
   Jarva H, 2002, J IMMUNOL, V168, P1886
   Kilpi T, 2003, CLIN INFECT DIS, V37, P1155, DOI 10.1086/378744
   Kilpi T, 2001, PEDIATR INFECT DIS J, V20, P654, DOI 10.1097/00006454-200107000-00004
   Kim JS, 2005, ANAL BIOCHEM, V347, P262, DOI 10.1016/j.ab.2005.09.022
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Leimkugel J, 2005, J INFECT DIS, V192, P192, DOI 10.1086/431151
   Li J, 2007, INFECT IMMUN, V75, P5877, DOI 10.1128/lAI.00839-07
   Malley R, 2001, INFECT IMMUN, V69, P4870, DOI 10.1128/IAI.69.8.4870-4873.2001
   Melin M, 2010, INFECT IMMUN, V78, P2089, DOI 10.1128/IAI.00811-09
   Melin M, 2009, INFECT IMMUN, V77, P676, DOI 10.1128/IAI.01186-08
   O'Brien KL, 2003, LANCET, V362, P355, DOI 10.1016/S0140-6736(03)14022-6
   Ochs MM, 2008, MICROB PATHOGENESIS, V44, P204, DOI 10.1016/j.micpath.2007.09.007
   Ogunniyi AD, 2009, FASEB J, V23, P731, DOI 10.1096/fj.08-119537
   Porat N, 2001, J CLIN MICROBIOL, V39, P1827, DOI 10.1128/JCM.39.5.1827-1832.2001
   Prymula R, 2006, LANCET, V367, P740, DOI 10.1016/S0140-6736(06)68304-9
   Quataert SA, 2004, CLIN DIAGN LAB IMMUN, V11, P1064, DOI 10.1128/CDLI.11.6.1064-1069.2004
   QUATAERT SA, 1995, CLIN DIAGN LAB IMMUN, V2, P590
   Rajam G, 2007, CLIN VACCINE IMMUNOL, V14, P1223, DOI 10.1128/CVI.00184-07
   Robinson DA, 2001, J INFECT DIS, V183, P1501, DOI 10.1086/320194
   RomeroSteiner S, 1997, CLIN DIAGN LAB IMMUN, V4, P415
   Saaka M, 2008, VACCINE, V26, P3719, DOI 10.1016/j.vaccine.2008.04.066
   Sandgren A, 2004, J INFECT DIS, V189, P785, DOI 10.1086/381686
   Schuerman L, 2007, VACCINE, V25, P1962, DOI 10.1016/j.vaccine.2006.12.008
   Scott JAG, 1998, CLIN INFECT DIS, V27, P1442, DOI 10.1086/515013
   Simell B, 2008, CLIN VACCINE IMMUNOL, V15, P1391, DOI 10.1128/CVI.00110-08
   Sjostrom K, 2006, CLIN INFECT DIS, V42, P451, DOI 10.1086/499242
   Sleeman KL, 2006, J INFECT DIS, V194, P682, DOI 10.1086/505710
   Takala AK, 1996, J INFECT DIS, V173, P128
   Tu AHT, 1999, INFECT IMMUN, V67, P4720
   Varvio SL, 2009, J INFECT DIS, V200, P1144, DOI 10.1086/605651
   WATSON DA, 1990, INFECT IMMUN, V58, P3135
   Weinberger DM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000476
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   Whitney CG, 2006, LANCET, V368, P1495, DOI 10.1016/S0140-6736(06)69637-2
   Wuorimaa T, 2001, J INFECT DIS, V184, P1211, DOI 10.1086/323648
   Wuorimaa TK, 2005, VACCINE, V23, P5328, DOI 10.1016/j.vaccine.2005.06.023
NR 58
TC 20
Z9 22
U1 1
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD DEC
PY 2010
VL 78
IS 12
BP 5252
EP 5261
DI 10.1128/IAI.00739-10
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 680DW
UT WOS:000284213600027
PM 20855517
OA No
DA 2017-08-15
ER

PT J
AU Lee, CC
   Middaugh, NA
   Howie, SRC
   Ezzati, M
AF Lee, Chien-Chang
   Middaugh, Nicole A.
   Howie, Stephen R. C.
   Ezzati, Majid
TI Association of Secondhand Smoke Exposure with Pediatric Invasive
   Bacterial Disease and Bacterial Carriage: A Systematic Review and
   Meta-analysis
SO PLOS MEDICINE
LA English
DT Review
ID INFLUENZAE TYPE-B; RISK-FACTORS; MENINGOCOCCAL DISEASE;
   HAEMOPHILUS-INFLUENZAE; STREPTOCOCCUS-PNEUMONIAE; PNEUMOCOCCAL DISEASE;
   NEISSERIA-MENINGITIDIS; NASOPHARYNGEAL CARRIAGE; CIGARETTE-SMOKING;
   CONJUGATE VACCINE
AB Background: A number of epidemiologic studies have observed an association between secondhand smoke (SHS) exposure and pediatric invasive bacterial disease (IBD) but the evidence has not been systematically reviewed. We carried out a systematic review and meta-analysis of SHS exposure and two outcomes, IBD and pharyngeal carriage of bacteria, for Neisseria meningitidis (N. meningitidis), Haemophilus influenzae type B (Hib), and Streptococcus pneumoniae (S. pneumoniae).
   Methods and Findings: Two independent reviewers searched Medline, EMBASE, and selected other databases, and screened articles for inclusion and exclusion criteria. We identified 30 case-control studies on SHS and IBD, and 12 cross-sectional studies on SHS and bacterial carriage. Weighted summary odd ratios (ORs) were calculated for each outcome and for studies with specific design and quality characteristics. Tests for heterogeneity and publication bias were performed. Compared with those unexposed to SHS, summary OR for SHS exposure was 2.02 (95% confidence interval [CI] 1.52-2.69) for invasive meningococcal disease, 1.21 (95% CI 0.69-2.14) for invasive pneumococcal disease, and 1.22 (95% CI 0.93-1.62) for invasive Hib disease. For pharyngeal carriage, summary OR was 1.68 (95% CI, 1.19-2.36) for N. meningitidis, 1.66 (95% CI 1.33-2.07) for S. pneumoniae, and 0.96 (95% CI 0.48-1.95) for Hib. The association between SHS exposure and invasive meningococcal and Hib diseases was consistent regardless of outcome definitions, age groups, study designs, and publication year. The effect estimates were larger in studies among children younger than 6 years of age for all three IBDs, and in studies with the more rigorous laboratory-confirmed diagnosis for invasive meningococcal disease (summary OR 3.24; 95% CI 1.72-6.13).
   Conclusions: When considered together with evidence from direct smoking and biological mechanisms, our systematic review and meta-analysis indicates that SHS exposure may be associated with invasive meningococcal disease. The epidemiologic evidence is currently insufficient to show an association between SHS and invasive Hib disease or pneumococcal disease. Because the burden of IBD is highest in developing countries where SHS is increasing, there is a need for high-quality studies to confirm these results, and for interventions to reduce exposure of children to SHS.
C1 [Lee, Chien-Chang; Middaugh, Nicole A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Lee, Chien-Chang] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan.
   [Howie, Stephen R. C.] Med Res Council UK Labs, Bacterial Dis Programme, Fajara, Gambia.
   [Ezzati, Majid] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
   [Ezzati, Majid] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
   [Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, Sch Publ Hlth, London, England.
   [Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, MRC HPA Ctr Environm & Hlth, London, England.
RP Lee, CC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
EM majid.ezzati@imperial.ac.uk
OI LEE, CHIEN-CHANG/0000-0002-1243-2463
FU National Institute of Environmental Health Sciences [1R21ES017855-01];
   Bill & Melinda Gates Foundation
FX This work was supported by a grant from the National Institute of
   Environmental Health Sciences (1R21ES017855-01) and by a grant for CHERG
   to the US Fund for UNICEF and for the Global Burden of Diseases,
   Injuries, and Risk Factors Study. Both grants were from the Bill &
   Melinda Gates Foundation. The sponsors of the study had no role in study
   design, data collection, data analysis, data interpretation, writing of
   the report, or decision to submit the manuscript.
CR Arcavi L, 2004, ARCH INTERN MED, V164, P2206, DOI 10.1001/archinte.164.20.2206
   ARNOLD C, 1993, AM J EPIDEMIOL, V138, P333
   Ayyildiz A, 2003, INT J CLIN PRACT, V57, P686
   Baker M, 2000, PEDIATR INFECT DIS J, V19, P983, DOI 10.1097/00006454-200010000-00009
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Brent AJ, 2006, LANCET, V367, P482, DOI 10.1016/S0140-6736(06)68180-4
   California Environmental Protection Agency, 2005, PROP ID ENV TOB SMOK
   Cardozo DM, 2008, J MED MICROBIOL, V57, P185, DOI 10.1099/jmm.0.47470-0
   Centers for Disease Control and Prevention, 2005, MMWR-MORBID MORTAL W, V54, P893
   COCHI SL, 1986, J PEDIATR-US, V108, P887, DOI 10.1016/S0022-3476(86)80922-2
   Coen PG, 2006, INT J EPIDEMIOL, V35, P330, DOI 10.1093/ije/dyi295
   Coles CL, 2001, PEDIATR INFECT DIS J, V20, P289, DOI 10.1097/00006454-200103000-00014
   Davies AL, 1996, EPIDEMIOL INFECT, V117, P259
   De Wals P, 2004, JAMA-J AM MED ASSOC, V292, P2491, DOI 10.1001/jama.292.20.2491
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   DYE JA, 1994, THORAX, V49, P825, DOI 10.1136/thx.49.8.825
   Egger M, 1997, BRIT MED J, V315, P629
   Fischer M, 1997, PEDIATR INFECT DIS J, V16, P979, DOI 10.1097/00006454-199710000-00015
   FOGARTY J, 1995, EPIDEMIOL INFECT, V114, P451
   GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807
   Gaschler GJ, 2008, AM J RESP CELL MOL B, V38, P218
   GRAY BM, 1980, J INFECT DIS, V142, P923
   Green RM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006860
   Greenberg D, 2006, CLIN INFECT DIS, V42, P897, DOI 10.1086/500935
   Grein T, 2001, EPIDEMIOL INFECT, V127, P435
   Haddad MB, 2008, ANN EPIDEMIOL, V18, P139, DOI 10.1016/j.annepidem.2007.09.006
   HANEBERG B, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P169
   Harrison LH, 2009, VACCINE, V27, pB51, DOI 10.1016/j.vaccine.2009.04.063
   HARRISON LH, 1989, PEDIATRICS, V84, P255
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hodgson A, 2001, T ROY SOC TROP MED H, V95, P477, DOI 10.1016/S0035-9203(01)90007-0
   Honish L, 2008, CAN J PUBLIC HEALTH, V99, P46
   Jafari HS, 1999, AM J PUBLIC HEALTH, V89, P364, DOI 10.2105/AJPH.89.3.364
   Jha P., 2000, TOBACCO CONTROL DEV
   Kaijalainen T, 2008, CLIN MICROBIOL INFEC, V14, P507, DOI 10.1111/j.1469-0691.2008.01967.x
   KREMASTINOU J, 1994, SCAND J INFECT DIS, V26, P719, DOI 10.3109/00365549409008641
   Kremastinou J, 1999, FEMS IMMUNOL MED MIC, V23, P13, DOI 10.1111/j.1574-695X.1999.tb01711.x
   Kriz P, 2000, ARCH DIS CHILD, V83, P117, DOI 10.1136/adc.83.2.117
   Labout JAM, 2008, J PEDIATR, V153, P771, DOI 10.1016/j.jpeds.2008.05.061
   Levine OS, 2006, LANCET, V367, P1880, DOI 10.1016/S0140-6736(06)68703-5
   Lightwood JM, 2009, CIRCULATION, V120, P1373, DOI 10.1161/CIRCULATIONAHA.109.870691
   Lim SS, 2008, LANCET, V372, P2031, DOI 10.1016/S0140-6736(08)61869-3
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   MacLennan J, 2006, EMERG INFECT DIS, V12, P950
   Madhi SA, 2007, VACCINE, V25, P2451, DOI 10.1016/j.vaccine.2006.09.019
   Madhi SA, 2007, J INFECT DIS, V196, P1662, DOI 10.1086/522164
   Marti-Lliteras P, 2009, INFECT IMMUN, V77, P4232, DOI 10.1128/IAI.00305-09
   McCall BJ, 2004, INTERN MED J, V34, P464, DOI 10.1111/j.1445-5994.2004.00564.x
   McVernon J, 2008, ARCH DIS CHILD, V93, P670, DOI 10.1136/adc.2006.097501
   Moher D, 2009, ANN INTERN MED, V151, P264
   Moodley JR, 1999, S AFR MED J, V89, P56
   Moreno SG, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2981
   Morris SK, 2008, LANCET INFECT DIS, V8, P435, DOI 10.1016/S1473-3099(08)70152-X
   Muhlemann K, 1996, INT J EPIDEMIOL, V25, P1280, DOI 10.1093/ije/25.6.1280
   Mulholland EK, 2005, NEW ENGL J MED, V352, P75, DOI 10.1056/NEJMe048306
   Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7
   ODempsey TJD, 1996, INT J EPIDEMIOL, V25, P885, DOI 10.1093/ije/25.4.885
   Office of the Surgeon General, 2006, HLTH CONS INV EXP TO
   Oguzkaya-Artan M, 2008, JPN J INFECT DIS, V61, P70
   Pereiro I, 2004, J INFECTION, V48, P320, DOI 10.1016/j.jinf.2003.10.015
   Robinson P, 2001, EPIDEMIOL INFECT, V127, P261
   Sargent RP, 2004, BRIT MED J, V328, P977, DOI 10.1136/bmj.38055.715683.55
   Silfverdal SA, 1997, INT J EPIDEMIOL, V26, P443, DOI 10.1093/ije/26.2.443
   Sorensen HT, 2004, INT J EPIDEMIOL, V33, P816, DOI 10.1093/ije/dyh169
   STANWELLSMITH RE, 1994, EPIDEMIOL INFECT, V112, P315
   STUART JM, 1988, COMMUNITY MED, V10, P139
   STUART JM, 1989, LANCET, V2, P723
   SUNG RYT, 1995, ACTA PAEDIATR, V84, P1262, DOI 10.1111/j.1651-2227.1995.tb13545.x
   TAKALA AK, 1995, JAMA-J AM MED ASSOC, V273, P859, DOI 10.1001/jama.273.11.859
   TAKALA AK, 1989, J PEDIATR-US, V115, P694, DOI 10.1016/S0022-3476(89)80644-4
   Tully J, 2006, BRIT MED J, V332, P445, DOI 10.1136/bmj.38725.728472.BE
   VADHEIM CM, 1992, AM J EPIDEMIOL, V136, P221
   van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4
   van Deuren M, 2000, CLIN MICROBIOL REV, V13, P144
   Vergnano S, 2005, Arch Dis Child Fetal Neonatal Ed, V90, pF220, DOI 10.1136/adc.2002.022863
   Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868
   Watt JP, 2009, LANCET, V374, P903, DOI 10.1016/S0140-6736(09)61203-4
   World Health Organization, 2009, WHO REP GLOB TOB EP
   World Health Organization, 2005, MAK EV MOTH CHILD CO
   Wolff MC, 1999, AM J TROP MED HYG, V60, P263
   Yusuf HR, 1999, AM J PUBLIC HEALTH, V89, P712, DOI 10.2105/AJPH.89.5.712
NR 86
TC 27
Z9 28
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD DEC
PY 2010
VL 7
IS 12
AR e1000374
DI 10.1371/journal.pmed.1000374
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 697GA
UT WOS:000285499600001
PM 21151890
OA gold
DA 2017-08-15
ER

PT J
AU Aaby, P
   Martins, CL
   Garly, ML
   Bale, C
   Andersen, A
   Rodrigues, A
   Ravn, H
   Lisse, IM
   Benn, CS
   Whittle, HC
AF Aaby, Peter
   Martins, Cesario L.
   Garly, May-Lill
   Bale, Carlito
   Andersen, Andreas
   Rodrigues, Amabelia
   Ravn, Henrik
   Lisse, Ida M.
   Benn, Christine S.
   Whittle, Hilton C.
TI Non-specific effects of standard measles vaccine at 4.5 and 9 months of
   age on childhood mortality: randomised controlled trial
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID VITAMIN-A SUPPLEMENTATION; FEMALE-MALE MORTALITY;
   DIPHTHERIA-TETANUS-PERTUSSIS; RESPIRATORY SYNCYTIAL VIRUS;
   GUINEA-BISSAU; EDMONSTON-ZAGREB; RURAL BANGLADESH; ROUTINE VACCINATIONS;
   BCG VACCINE; WEST-AFRICA
AB Objective To examine in a randomised trial whether a 25% difference in mortality exists between 4.5 months and 3 years of age for children given two standard doses of Edmonston-Zagreb measles vaccines at 4.5 and 9 months of age compared with those given one dose of measles vaccine at 9 months of age (current policy).
   Design Randomised controlled trial.
   Setting The Bandim Health Project, Guinea-Bissau, which maintains a health and demographic surveillance system in an urban area.
   Participants 6648 children aged 4.5 months of age who had received three doses of diphtheria-tetanus-pertussis vaccine at least four weeks before enrolment. A large proportion of the children (80%) had previously taken part in randomised trials of neonatal vitamin A supplementation.
   Intervention Children were randomised to receive Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age (group A), no vaccine at 4.5 months and Edmonston-Zagreb measles vaccine at 9 months of age (group B), or no vaccine at 4.5 months and Schwarz measles vaccine at 9 months of age (group C).
   Main outcome measure Mortality rate ratio between 4.5 and 36 months of age for group A compared with groups B and C. Secondary outcomes tested the hypothesis that the beneficial effect was stronger in the 4.5 to 9 months age group, in girls, and in the dry season, but the study was not powered to test whether effects differed significantly between subgroups.
   Results In the intention to treat analysis of mortality between 4.5 and 36 months of age the mortality rate ratio of children who received two doses of Edmonston-Zagreb vaccine at 4.5 and 9 months of age compared with those who received a single dose of Edmonston-Zagreb vaccine or Schwarz vaccine at 9 months of age was 0.78 (95% confidence interval 0.59 to 1.05). In the analyses of secondary outcomes, the intention to treat mortality rate ratio was 0.67 (0.38 to 1.19) between 4.5 and 9 months and 0.83 (0.83 to 1.16) between 9 and 36 months of age. The effect on mortality between 4.5 and 36 months of age was significant for girls (intention to treat mortality rate ratio 0.64 (0.42 to 0.98)), although this was not significantly different from the effect in boys (0.95 (0.64 to 1.42)) (interaction test, P=0.18). The effect did not differ between the dry season and the rainy season. As neonatal vitamin A supplementation is not WHO policy, the analyses were done separately for the 3402 children who did not receive neonatal vitamin A. In these children, the two dose Edmonston-Zagreb measles vaccine schedule was associated with a significantly lower mortality between 4.5 and 36 months of age (intention to treat mortality rate ratio 0.59 (0.39 to 0.89)). The effect was again significant for girls but not statistically significant from the effect in boys. When measles cases were censored, the intention to treat mortality rate ratio was 0.65 (0.43 to 0.99).
   Conclusions Although the overall effect did not reach statistical significance, the results may indicate that a two dose schedule with Edmonston-Zagreb measles vaccine given at 4.5 and 9 months of age has beneficial nonspecific effects on children's survival, particularly for girls and for children who have not received neonatal vitamin A. This should be tested in future studies in different locations.
C1 [Aaby, Peter; Martins, Cesario L.; Garly, May-Lill; Bale, Carlito; Andersen, Andreas; Rodrigues, Amabelia; Ravn, Henrik; Benn, Christine S.] Indepth Network, Bandim Hlth Project, Bissau, Guinea Bissau.
   [Aaby, Peter; Garly, May-Lill; Andersen, Andreas; Ravn, Henrik; Benn, Christine S.] Statens Serum Inst, Danish Epidemiol Sci Ctr, Bandim Hlth Project, DK-2300 Copenhagen S, Denmark.
   [Lisse, Ida M.] Herlev Univ Hosp, Dept Pathol, DK-2730 Herlev, Denmark.
   [Whittle, Hilton C.] MRC Labs, Fajara, Gambia.
RP Aaby, P (reprint author), Indepth Network, Bandim Hlth Project, Bissau, Guinea Bissau.
EM p.aaby@bandim.org
FU Thrasher Foundation; DANIDA; Danish National Research Foundation; Fonden
   til Laegevidenskabens Fremme; Novo Nordisk Foundation
FX The research on the decline in maternal antibodies that inspired this
   trial was funded by the Thrasher Foundation. This study was mostly
   funded by DANIDA and the Danish National Research Foundation. The
   project also received support from Fonden til Laegevidenskabens Fremme
   and Novo Nordisk Foundation. The Bandim Health Project received support
   from DANIDA. PA holds a research professorship grant from the Novo
   Nordisk Foundation. The funding agencies had no role in the study
   design, data collection, data analysis, data interpretation, or the
   writing of the report.
CR AABY P, 1993, BRIT MED J, V307, P1308
   AABY P, 1989, PEDIATR INFECT DIS J, V8, P197
   Aaby P, 2006, VACCINE, V24, P4701, DOI 10.1016/j.vaccine.2006.03.038
   Aaby P, 2006, VACCINE, V24, P2764, DOI 10.1016/j.vaccine.2006.01.004
   AABY P, 1993, AM J EPIDEMIOL, V138, P746
   AABY P, 1988, LANCET, V2, P809
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 2003, PEDIATR INFECT DIS J, V22, P798, DOI 10.1097/01.inf.0000083821.33187.b5
   Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   Aaby P, 2003, INT J EPIDEMIOL, V32, P106, DOI 10.1093/ije/dyg005
   Aaby P, 2002, VACCINE, V21, P120, DOI 10.1016/S0264-410X(02)00430-9
   AABY P, 1984, J TROP PEDIATRICS, V30, P164
   Aaby P, 1996, AM J EPIDEMIOL, V143, P1035
   AABY P, 1981, LANCET, V2, P93
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   AABY P, 1993, J PEDIATR-US, V122, P904
   Aaby P, 1996, PEDIATR INFECT DIS J, V15, P39, DOI 10.1097/00006454-199601000-00009
   AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X
   Aaby P., 1997, PROSPECTIVE COMMUNIT, P276
   Aaby P, 2007, PEDIATR INFECT DIS J, V26, P247, DOI 10.1097/01.inf.0000256735.05098.01
   Aaby P, 2006, PEDIATR INFECT DIS J, V25, P721, DOI 10.1097/01.inf.0000227829.64686.ae
   Aaby P, 2010, PEDIATR INFECT DIS J, V29, P324, DOI 10.1097/INF.0b013e3181c15367
   Aaby P, 2009, LANCET, V373, P1428, DOI 10.1016/S0140-6736(09)60823-0
   Barnard A, 1996, IMMUNOLOGY, V87, P372, DOI 10.1046/j.1365-2567.1996.497560.x
   Benn CS, 2009, AM J CLIN NUTR, V90, P629, DOI 10.3945/ajcn.2009.27477
   Benn CS, 2008, BRIT MED J, V336, P1416, DOI 10.1136/bmj.39542.509444.AE
   Benn CS, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1101
   Benn CS, 2009, VACCINE, V27, P2891, DOI 10.1016/j.vaccine.2009.02.080
   Benn CS, 2009, INT J EPIDEMIOL, V38, P304, DOI 10.1093/ije/dyn195
   Bennett JV, 1999, PEDIATRICS, V104, P1123, DOI 10.1542/peds.104.5.1123
   CLEMENS JD, 1988, AM J EPIDEMIOL, V128, P1330
   Cooper WO, 2003, B WORLD HEALTH ORGAN, V81, P821
   DULOU AD, 1995, AM J EPIDEMIOL, V142, P643
   Expanded Programme on Immunization, 1982, WKLY EPIDEMIOL REC, V57, P89
   Expanded Programme on Immunization, 1992, WKLY EPIDEMIOL REC, V67, P357
   Fischer JE, 2000, J INFECT DIS, V182, P1029, DOI 10.1086/315806
   Garly ML, 2008, J PEDIATR, V153, P683, DOI 10.1016/j.jpeds.2008.04.069
   Garly ML, 1999, INT J EPIDEMIOL, V28, P347, DOI 10.1093/ije/28.2.347
   Garly ML, 2001, VACCINE, V19, P1951, DOI 10.1016/S0264-410X(00)00431-X
   GRAHAM BS, 1993, J IMMUNOL, V151, P2032
   HOLT EA, 1990, PEDIATRICS, V85, P188
   Holt EA, 1993, J INFECT DIS, V168, P1987
   Knudsen KM, 1996, INT J EPIDEMIOL, V25, P665, DOI 10.1093/ije/25.3.665
   KOENIG MA, 1990, B WORLD HEALTH ORGAN, V68, P441
   Lindblad EB, 1997, INFECT IMMUN, V65, P623
   Martins C, 2009, VACCINE, V27, P5220, DOI 10.1016/j.vaccine.2009.06.076
   Martins CL, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a661
   Moran TM, 1999, J INFECT DIS, V180, P579, DOI 10.1086/314952
   Roth A, 2010, BRIT MED J, V340, pc809
   Shann F, 2004, PEDIATR INFECT DIS J, V23, P555, DOI 10.1097/01.inf.0000130155.42392.04
   VANBALEN H, 1981, LANCET, V1, P764
   Veirum JE, 2005, VACCINE, V23, P1197, DOI 10.1016/j.vaccine.2004.02.053
   Welsh RM, 2002, NAT REV IMMUNOL, V2, P417, DOI 10.1038/nri820
   WHITTLE H, 1988, LANCET, V2, P811
   Whittle H, 1990, LANCET, V336, P1048
   2008, WKLY EPIDEMIOL REC, V83, P287
NR 56
TC 94
Z9 94
U1 0
U2 7
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-535X
J9 BRIT MED J
JI Br. Med. J.
PD NOV 30
PY 2010
VL 341
AR c6495
DI 10.1136/bmj.c6495
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA 691OG
UT WOS:000285090100006
PM 21118875
OA No
DA 2017-08-15
ER

PT J
AU Nakao, R
   Stromdahl, EY
   Magona, JW
   Faburay, B
   Namangala, B
   Malele, I
   Inoue, N
   Geysen, D
   Kajino, K
   Jongejan, F
   Sugimoto, C
AF Nakao, Ryo
   Stromdahl, Ellen Y.
   Magona, Joseph W.
   Faburay, Bonto
   Namangala, Boniface
   Malele, Imna
   Inoue, Noboru
   Geysen, Dirk
   Kajino, Kiichi
   Jongejan, Frans
   Sugimoto, Chihiro
TI Development of Loop-Mediated Isothermal Amplification (LAMP) Assays for
   Rapid Detection of Ehrlichia ruminantium
SO BMC MICROBIOLOGY
LA English
DT Article
ID AMBLYOMMA-VARIEGATUM TICKS; EMERGING HUMAN PATHOGEN; REAL-TIME PCR;
   COWDRIA-RUMINANTIUM; MOLECULAR-DETECTION; DNA AMPLIFICATION; AMERICAN
   MAINLAND; HEARTWATER; INFECTION; AGENT
AB Background: The rickettsial bacterium Ehrlichia ruminantium is the causative agent of heartwater, a potential zoonotic disease of ruminants transmitted by ticks of the genus Amblyomma. The disease is distributed in nearly all of sub-Saharan Africa and some islands of the Caribbean, from where it threatens the American mainland. This report describes the development of two different loop-mediated isothermal amplification (LAMP) assays for sensitive and specific detection of E. ruminantium.
   Results: Two sets of LAMP primers were designed from the pCS20 and sodB genes. The detection limits for each assay were 10 copies for pCS20 and 5 copies for sodB, which is at least 10 times higher than that of the conventional pCS20 PCR assay. DNA amplification was completed within 60 min. The assays detected 16 different isolates of E. ruminantium from geographically distinct countries as well as two attenuated vaccine isolates. No cross-reaction was observed with genetically related Rickettsiales, including zoonotic Ehrlichia species from the USA. LAMP detected more positive samples than conventional PCR but less than real-time PCR, when tested with field samples collected in sub-Saharan countries.
   Conclusions: Due to its simplicity and specificity, LAMP has the potential for use in resource-poor settings and also for active screening of E. ruminantium in both heartwater-endemic areas and regions that are at risk of contracting the disease.
C1 [Nakao, Ryo; Magona, Joseph W.; Kajino, Kiichi; Sugimoto, Chihiro] Hokkaido Univ, Res Ctr Zoonosis Control, Kita Ku, Sapporo, Hokkaido 0010020, Japan.
   [Stromdahl, Ellen Y.] USA, Publ Hlth Command Provis, Entomol Sci Program, Aberdeen Proving Ground, MD 21010 USA.
   [Magona, Joseph W.] Natl Livestock Resources Res Inst NaLIRRI, Tororo, Uganda.
   [Faburay, Bonto] Int Trypanotolerance Ctr, Banjul, Gambia.
   [Namangala, Boniface] Univ Zambia, Sch Vet Med, Dept Paraclin Studies, Lusaka, Zambia.
   [Malele, Imna] Tsetse & Trypanosomiasis Res Inst, Tanga, Tanzania.
   [Inoue, Noboru] Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Obihiro, Hokkaido 08085555, Japan.
   [Geysen, Dirk] Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
   [Jongejan, Frans] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, UCTD, NL-3584 CL Utrecht, Netherlands.
   [Jongejan, Frans] Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0110 Onderstepoort, South Africa.
   [Faburay, Bonto] Kansas State Univ, Coll Vet Med, Dept Diagnost Med Pathobiol, Manhattan, KS 66506 USA.
RP Sugimoto, C (reprint author), Hokkaido Univ, Res Ctr Zoonosis Control, Kita Ku, Kita 20,Nishi 10, Sapporo, Hokkaido 0010020, Japan.
EM sugimoto@czc.hokudai.ac.jp
RI Kajino, Kiichi/F-6873-2012; Nakao, Ryo/H-6889-2013
FU Japanese Society for the Promotion of Science (JSPS) for young
   scientists; Ministry of Education, Culture, Sports, Science and
   Technology of Japan (MEXT); Funding Research Center for Emerging and
   Re-emerging Infectious Disease, MEXT; MEXT
FX The cattle and goat owners are greatly acknowledged for their
   cooperation. We are thankful to all personnel who assisted in collection
   of field samples in Uganda, Tanzania, and Zambia. We also thank Dr.
   Amanda Loftis for her facilitating work with the USA ehrlichiae and for
   her assistance editing this manuscript. The first author was supported
   by a research grant fellowship from the Japanese Society for the
   Promotion of Science (JSPS) for young scientists. This work was
   supported by Grant-in-Aid for JSPS fellows and for Scientific Research
   from Ministry of Education, Culture, Sports, Science and Technology of
   Japan (MEXT), the program of Funding Research Center for Emerging and
   Re-emerging Infectious Disease, MEXT, and Asia-Africa S & T Strategic
   Cooperation Promotion Program by the Special Coordination Funds for
   Promoting Science & Technology, MEXT.
CR Allsopp MTEP, 2007, VET MICROBIOL, V124, P58, DOI 10.1016/j.vetmic.2007.03.012
   Allsopp MTEP, 2005, ANN NY ACAD SCI, V1063, P358, DOI 10.1196/annals.1355.060
   ANDERSON BE, 1992, INT J SYST BACTERIOL, V42, P299
   ANDREW HR, 1989, VET PARASITOL, V34, P261, DOI 10.1016/0304-4017(89)90056-3
   Bakheit MA, 2008, VET PARASITOL, V158, P11, DOI 10.1016/j.vetpar.2008.09.012
   BARRE N, 1987, ONDERSTEPOORT J VET, V54, P405
   Bekker CPJ, 2005, J BACTERIOL, V187, P4782, DOI 10.1128/JB.187.14.4782-4791.2005
   Bista BR, 2007, J CLIN MICROBIOL, V45, P1581, DOI 10.1128/JCM.01024-06
   Buller RS, 1999, NEW ENGL J MED, V341, P148, DOI 10.1056/NEJM199907153410303
   Burridge MJ, 2002, ANN NY ACAD SCI, V969, P269
   Childs JE, 2003, ANNU REV ENTOMOL, V48, P307, DOI 10.1146/annurev.ento.48.091801.112728
   DAWSON JE, 1991, J CLIN MICROBIOL, V29, P2741
   Enosawa M, 2003, J CLIN MICROBIOL, V41, P4359, DOI 10.1128/JCM.41.9.4359-4365.2003
   Faburay B, 2007, EXP APPL ACAROL, V42, P61, DOI 10.1007/s10493-007-9073-2
   Faburay B, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-85
   Inacio J, 2008, J CLIN MICROBIOL, V46, P713, DOI 10.1128/JCM.00514-07
   Iwamoto T, 2003, J CLIN MICROBIOL, V41, P2616, DOI 10.1128/JCM.41.6.2616-2622.2003
   JONGEJAN F, 1991, INFECT IMMUN, V59, P729
   Kuboki N, 2003, J CLIN MICROBIOL, V41, P5517, DOI 10.1128/JCM.41.12.5517-5524.2003
   Loftis AD, 2006, J VECTOR ECOL, V31, P213, DOI 10.3376/1081-1710(2006)31[213:IOAGWA]2.0.CO;2
   Loftis AD, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-54
   Louw M, 2005, SAMJ S AFR MED J, V95, P948
   Martinez D, 2004, ANN NY ACAD SCI, V1026, P106, DOI 10.1196/annals.1307.014
   Mori Y, 2001, BIOCHEM BIOPH RES CO, V289, P150, DOI 10.1006/bbrc.2001.5921
   Mukhebi AW, 1999, PREV VET MED, V39, P173, DOI 10.1016/S0167-5877(98)00143-3
   Notomi T, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e63
   Parida M, 2004, J CLIN MICROBIOL, V42, P257, DOI 10.1128/JCM.42.1.257-263.2004
   Peixoto CC, 2005, VET MICROBIOL, V107, P273, DOI 10.1016/j.vetmic.2005.02.001
   Perez M, 1996, J CLIN MICROBIOL, V34, P2133
   Peter TF, 2000, J CLIN MICROBIOL, V38, P1539
   PETER TF, 1995, J CLIN MICROBIOL, V33, P166
   Poon LLM, 2006, CLIN CHEM, V52, P303
   Reeves Will K, 2008, J Med Case Rep, V2, P139, DOI 10.1186/1752-1947-2-139
   RIKIHISA Y, 1991, CLIN MICROBIOL REV, V4, P286
   Semu SM, 2001, CLIN DIAGN LAB IMMUN, V8, P388, DOI 10.1128/CDLI.8.2.388-396.2001
   Steyn HC, 2008, VET MICROBIOL, V131, P258, DOI 10.1016/j.vetmic.2008.04.002
   Stromdahl EY, 2001, J MED ENTOMOL, V38, P67, DOI 10.1603/0022-2585-38.1.67
   Thekisoe OMM, 2009, J VET MED SCI, V71, P471, DOI 10.1292/jvms.71.471
   Tomita N, 2008, NAT PROTOC, V3, P877, DOI 10.1038/nprot.2008.57
   Tomlinson JA, 2007, APPL ENVIRON MICROB, V73, P4040, DOI 10.1128/AEM.00161-07
   Van Heerden H, 2004, VET MICROBIOL, V101, P279, DOI 10.1016/j.vetmic.2004.02.015
   WAGHELA SD, 1991, J CLIN MICROBIOL, V29, P2571
   WALKER JB, 1987, ONDERSTEPOORT J VET, V54, P353
   Qiao YM, 2007, BIOTECHNOL LETT, V29, P1939, DOI 10.1007/s10529-007-9472-9
   Yoshida A, 2005, J CLIN MICROBIOL, V43, P2418, DOI 10.1128/JCM.43.5.2418-2424.2005
NR 45
TC 33
Z9 34
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2180
J9 BMC MICROBIOL
JI BMC Microbiol.
PD NOV 19
PY 2010
VL 10
AR 296
DI 10.1186/1471-2180-10-296
PG 11
WC Microbiology
SC Microbiology
GA 692YO
UT WOS:000285192000001
PM 21087521
OA gold
DA 2017-08-15
ER

PT J
AU Holder, B
   Miles, DJC
   Kaye, S
   Crozier, S
   Mohammed, NI
   Duah, NO
   Roberts, E
   Ojuola, O
   Palmero, MS
   Touray, ES
   Waight, P
   Cotten, M
   Rowland-Jones, S
   van der Sande, M
   Whittle, H
AF Holder, Beth
   Miles, David J. C.
   Kaye, Steve
   Crozier, Sarah
   Mohammed, Nuredin Ibrahim
   Duah, Nancy O.
   Roberts, Elishia
   Ojuola, Olubukola
   Palmero, Melba S.
   Touray, Ebrima S.
   Waight, Pauline
   Cotten, Matthew
   Rowland-Jones, Sarah
   van der Sande, Marianne
   Whittle, Hilton
TI Epstein-Barr Virus but Not Cytomegalovirus Is Associated with Reduced
   Vaccine Antibody Responses in Gambian Infants
SO PLOS ONE
LA English
DT Article
ID T-CELL DIFFERENTIATION; PLASMODIUM-FALCIPARUM; NEISSERIA-MENINGITIDIS;
   DEVELOPING-COUNTRIES; MATERNAL ANTIBODIES; MEASLES; INFECTION;
   MORTALITY; MALARIA; IMMUNIZATION
AB Background: Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are persistent herpesviruses that have various immunomodulatory effects on their hosts. Both viruses are usually acquired in infancy in Sub-Saharan Africa, a region where childhood vaccines are less effective than in high income settings. To establish whether there is an association between these two observations, we tested the hypothesis that infection with one or both viruses modulate antibody responses to the T-cell independent meningococcal polysaccharide vaccine and the T-cell dependent measles vaccines.
   Methodology/Principal Findings: Infection with EBV and CMV was diagnosed by the presence of virus-specific IgM in the peripheral blood or by the presence of IgG at higher levels than that found in umbilical cord blood. Anti-meningococcus IgG and IgM were quantified by ELISA. Anti-measles antibody responses were quantified by haemagglutinin antibody inhibition assay. Infants infected with EBV had reduced IgG and IgM antibody responses to meningococcal polysaccharides and to measles vaccine. Infection with CMV alone predicted no changes in the response to meningococcal polysaccharide. While CMV alone had no discernable effect on the antibody response to measles, the response of infants infected with both CMV and EBV was similar to that of infants infected with neither, suggesting that the effects of CMV infection countered the effects of EBV on measles antibody responses.
   Conclusions: The results of this exploratory study indicate that infection with EBV is associated with reduced antibody responses to polysaccharides and to measles vaccine, but suggest that the response to T-cell dependent antigens such as measles haemagglutinin may be restored by infection with CMV.
C1 [Holder, Beth; Miles, David J. C.; Crozier, Sarah; Mohammed, Nuredin Ibrahim; Duah, Nancy O.; Roberts, Elishia; Ojuola, Olubukola; Palmero, Melba S.; Touray, Ebrima S.; Cotten, Matthew; Rowland-Jones, Sarah; Whittle, Hilton] MRC Labs Gambia, Banjul, Gambia.
   [Miles, David J. C.] Univ Cape Town, S African TB Vaccine Initiat, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
   [Kaye, Steve] Univ London Imperial Coll Sci Technol & Med, Jefferiss Trust Lab, London, England.
   [Crozier, Sarah] Univ Southampton, Southampton Gen Hosp, MRC Epidemiol Resource Ctr, Southampton, Hants, England.
   [Mohammed, Nuredin Ibrahim; Duah, Nancy O.] London Sch Hyg & Trop Med, London WC1, England.
   [Waight, Pauline] Hlth Protect Agcy Ctr Infect, Immunisat Dept, London, England.
   [van der Sande, Marianne] Ctr Infect Dis Control CIb, Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands.
   [van der Sande, Marianne] Univ Med Ctr Utrecht, Julius Ctr, Utrecht, Netherlands.
RP Holder, B (reprint author), MRC Labs Gambia, Banjul, Gambia.
EM hcwhittle@yahoo.co.uk
OI Crozier, Sarah/0000-0002-9524-1127; Duah, Nancy/0000-0001-8819-1793
FU MRC; Sukuta Health Centre; Western Division Health Team
FX The study was funded by the MRC. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.; The authors would like to thank the
   staff of the Sukuta birth cohort, Omar Badjie, Fatou Bah, Saihou Bobb,
   Sarah Burl, Janko Camara, Sulayman Colley, Momodou Cox, Isatou Drammeh,
   Mam Maram Drammeh, Momodou Lamin Fatty, Tisbeh Faye-Joof, Samboujang
   Makalo, John S Mendy, Ngui Ndow, Bala Musa Sambou, Sarjo Sanneh and Lady
   Chilel Sanyang. We are extremely grateful for the support of Sally
   Savage of Sukuta Health Centre and the Western Division Health Team, and
   to Professor Brian Greenwood of the London School of Hygiene and
   Tropical Medicine for advice and help. Some reagents for the
   meningococcus ELISA were a gift from Dr. Musa King of Chiron. The method
   for quantification of EBV DNA was adapted from methods developed by Prof
   A. Rickinson of the Division of Cancer Studies, University of
   Birmingham. Dr David Jefferies and Dr. John Townend of the MRC Unit, The
   Gambia provided statistical advice.
CR AABY P, 1990, J INFECT DIS, V162, P1043
   AABY P, 1995, BRIT MED J, V311, P481
   AABY P, 1984, AM J EPIDEMIOL, V120, P49
   Aaby P, 2007, PEDIATR INFECT DIS J, V26, P247, DOI 10.1097/01.inf.0000256735.05098.01
   Ben-Smith A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-139
   BIGGAR RJ, 1978, INT J CANCER, V22, P239, DOI 10.1002/ijc.2910220304
   BLAKEBROUGH IS, 1982, J INFECT DIS, V146, P626
   Cavanagh DR, 1998, J IMMUNOL, V161, P347
   Cisse B, 1999, AM J EPIDEMIOL, V149, P295
   Clute SC, 2005, J CLIN INVEST, V115, P3602, DOI 10.1172/JC125078
   Cohen JI, 2000, NEW ENGL J MED, V343, P481, DOI 10.1056/NEJM200008173430707
   DETHE G, 1978, NATURE, V274, P756, DOI 10.1038/274756a0
   Duah NO, 2010, PARASITE IMMUNOL, V32, P125, DOI 10.1111/j.1365-3024.2009.01165.x
   Dutta S, 2002, INFECT IMMUN, V70, P3101, DOI 10.1128/IAI.70.6.3101-3110.2002
   GHEESLING LL, 1994, J CLIN MICROBIOL, V32, P1475
   GRATAMA JW, 1987, BLOOD, V70, P516
   Grivel JC, 2005, J INFECT DIS, V192, P71, DOI 10.1086/430743
   Grivel JC, 2001, NAT MED, V7, P1232, DOI 10.1038/nm1101-1232
   Hochberg D, 2004, J VIROL, V78, P5194, DOI 10.1128/JVI.78.10.5194-5204.2004
   Janaszek W, 2003, VACCINE, V21, P473, DOI 10.1016/S0264-410X(02)00482-6
   Jaye A, 1998, J INFECT DIS, V177, P1282
   KAYE S, 2008, J INFECT DIS, V197
   KLEIN G, 1972, INT J CANCER, V10, P44, DOI 10.1002/ijc.2910100108
   Looney RJ, 1999, CLIN IMMUNOL, V90, P213, DOI 10.1006/clim.1998.4638
   Lynn TV, 2004, J INFECT DIS, V189, pS86, DOI 10.1086/377699
   MALFAIT P, 1994, PEDIATR INFECT DIS J, V13, P38, DOI 10.1097/00006454-199401000-00009
   Martro E, 2004, J MED VIROL, V72, P126, DOI 10.1002/jmv.10548
   Miles DJC, 2008, IMMUNOLOGY, V124, P388, DOI 10.1111/j.1365-2567.2007.02787.x
   Miles DJC, 2007, J VIROL, V81, P5766, DOI 10.1128/JVI.00052-07
   MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383
   *MIN HLTH N POL CO, 1966, B WORLD HEALTH ORGAN, V34, P865
   NORRBY E, 1972, INFECT IMMUN, V6, P240
   ODempsey TJD, 1996, ARCH DIS CHILD, V74, pF43, DOI 10.1136/fn.74.1.F43
   Olsson J, 2000, MECH AGEING DEV, V121, P187
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Polley SD, 2006, VACCINE, V24, P4233, DOI 10.1016/j.vaccine.2005.06.030
   REINGOLD AL, 1985, LANCET, V2, P114
   Saurwein-Teissl M, 2002, J IMMUNOL, V168, P5893
   Siegrist CA, 2003, VACCINE, V21, P3406, DOI 10.1016/S0264-410X(03)00342-6
   Sinclair J, 2006, J GEN VIROL, V87, P1763, DOI 10.1099/vir.0.81891-0
   SODERBERG C, 1993, J VIROL, V67, P3166
   Souza TA, 2007, J IMMUNOL, V179, P3153
   Sze DMY, 2000, J EXP MED, V192, P813, DOI 10.1084/jem.192.6.813
   Trzonkowski P, 2003, VACCINE, V21, P3826, DOI 10.1016/S0264-410X(03)00309-8
   Usen S, 2000, PEDIATR INFECT DIS J, V19, P444, DOI 10.1097/00006454-200005000-00010
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   Vitek CR, 1999, PEDIATR INFECT DIS J, V18, P620, DOI 10.1097/00006454-199907000-00010
   WHITTLE H, 1988, LANCET, V331, P963, DOI 10.1016/S0140-6736(88)91780-1
   WHITTLE HC, 1984, NATURE, V312, P449, DOI 10.1038/312449a0
   WHO, 2005, WKLY EPIDEMIOL REC, V80, P313
   World Health Organization, 2002, WKLY EPIDEMIOL REC, V77, P331
   WILLIAMSON WA, 1978, LANCET, V1, P1328
   Xiao LH, 1998, J INFECT DIS, V177, P437
NR 53
TC 11
Z9 11
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 17
PY 2010
VL 5
IS 11
AR e14013
DI 10.1371/journal.pone.0014013
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 681OY
UT WOS:000284327800005
PM 21103338
OA gold
DA 2017-08-15
ER

PT J
AU Sighoko, D
   Bah, E
   Haukka, J
   McCormack, VA
   Aka, EP
   Bourgeois, D
   Autier, P
   Byrnes, G
   Curado, MP
   Hainaut, P
AF Sighoko, Dominique
   Bah, Ebrima
   Haukka, Jari
   McCormack, Valerie A.
   Aka, Elizabeth Patu
   Bourgeois, Denis
   Autier, Philippe
   Byrnes, Graham
   Curado, Maria Paula
   Hainaut, Pierre
TI Population-based breast (female) and cervix cancer rates in the Gambia:
   evidence of ethnicity-related variations
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE breast; cervix; ethnicity
ID AFRICAN-AMERICAN WOMEN; HORMONE-RECEPTOR STATUS; SUB-SAHARAN AFRICA;
   TRANSIENT INCREASE; WEST-AFRICA; RISK; CARCINOMA; BIRTH; EXPRESSION;
   ESTROGEN
AB Since 1987, the Gambia National Cancer Registry has provided nationwide cancer registration for the Gambia. We used data from 1998 to 2006 to assess age-standardized incidence rates (ASRs) of 2 common cancers in women, breast and cervix. With an ASR of 15.42 (95% CI [14.18-16.66]) for cervix and 5.86 (95% CI [5.12-6.59]) for breast per 10(5) person-years, these cancers ranked first and third, respectively, among Gambian women (the second most common being liver, ASR 14.90). Incidence of both cancers, breast and cervix, increased rapidly at young ages to reach a peak at ages 40-44 years. Significant differences were observed in relation to ethnicity. Using the Mandinka (42% of the population) as a reference, breast cancer incidence rates were 2.16-fold higher (95% CI [1.33-3.52]) in Jola (10% of the population), specially at early-onset ages (before 40 years). For cervix cancer, highest rates were observed in Fula (18% of the population; risk ratio (RR): 1.84 (95% CI [1.44-2.36])). In contrast, a significantly lower risk was observed in the Serrahuleh (9% of the population; RR: 0.54 (95% CI [0.31-0.96]). This study revealed a preponderance of early-onset breast cancer among Gambian women similar to that seen in African women in more developed countries but also demonstrates large ethnic variations. It points to the need for further studies on cancer determinants to improve prevention, early detection and therapeutic management of these diseases in a low-resource setting in West Africa.
C1 [Sighoko, Dominique; Haukka, Jari; McCormack, Valerie A.; Autier, Philippe; Byrnes, Graham; Curado, Maria Paula; Hainaut, Pierre] Int Agcy Res Canc, F-69372 Lyon 08, France.
   [Sighoko, Dominique; Bourgeois, Denis] Fac Odontol Methode & Algorithmes Aide Decis, Lyon, France.
   [Bah, Ebrima] MRC Labs, IARC, Gambia Hepatitis Intervent Study, Banjul, Gambia.
RP Hainaut, P (reprint author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.
EM hainaut@iarc.fr
RI Hainaut, Pierre /B-6018-2012; Haukka, Jari/G-1484-2014; Autier,
   Philippe/A-4402-2014; Curado, Maria Paula/M-6200-2013
OI Hainaut, Pierre /0000-0002-1303-1610; Haukka, Jari/0000-0003-1450-6208;
   Autier, Philippe/0000-0003-1538-5321; Curado, Maria
   Paula/0000-0001-8172-2483
CR ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411
   AMIR H, 1994, E AFR MED J, V71, P215
   Anyanwu S N, 2000, West Afr J Med, V19, P120
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   Bird PA, 2008, ANN SURG ONCOL, V15, P1983, DOI 10.1245/s10434-008-9900-7
   Bowen RL, 2008, BRIT J CANCER, V98, P277, DOI 10.1038/sj.bjc.6604174
   BOYLE P, 1996, ENREGISTREMENT CANC, P135
   Brown SBF, 2009, BRIT J CANCER, V100, P807, DOI 10.1038/sj.bjc.6604934
   Chu KC, 2001, CANCER, V92, P37, DOI 10.1002/1097-0142(20010701)92:1<37::AID-CNCR1289>3.0.CO;2-F
   Coleman M P, 1991, IARC Sci Publ, P267
   DOLL R, 1982, CANC INCIDENCE 5 CON, V4
   Eniu A, 2006, BREAST J, V12, pS38, DOI 10.1111/j.1075-122X.2006.00202.x
   Fregene A, 2005, CANCER-AM CANCER SOC, V103, P1540, DOI 10.1002/cncr.20978
   Hennis AJ, 2009, INT J CANCER, V124, P429, DOI 10.1002/ijc.23889
   Ijaduola TG, 1998, J NATL MED ASSOC, V90, P547
   Ikpatt O F, 2003, Cent Afr J Med, V49, P122
   Ikpatt OF, 2002, ANTICANCER RES, V22, P3005
   JALLOW M, 2009, NAT GENET       0524
   Kirk GD, 2005, CANCER EPIDEM BIOMAR, V14, P373, DOI 10.1158/1055-9965.EPI-04-0161
   LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102
   Liu Q, 2002, CANCER CAUSE CONTROL, V13, P299, DOI 10.1023/A:1015287208222
   Lord SJ, 2008, CANCER EPIDEM BIOMAR, V17, P1723, DOI 10.1158/1055-9965.EPI-07-2824
   Ma HY, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1512
   Mbonde MP, 2000, ONCOL REP, V7, P277
   Mensah George A, 2003, Ethn Dis, V13, pS4
   Muguti G I, 1993, J R Coll Surg Edinb, V38, P75
   Muthuphei M. N., 1994, Central African Journal of Medicine, V40, P254
   Nemesure B, 2009, INT J CANCER, V124, P174, DOI 10.1002/ijc.23827
   Newman LA, 2005, ONCOLOGIST, V10, P1, DOI 10.1634/theoncologist.10-1-1
   Newman LA, 2004, CANCER, V101, P1261, DOI 10.1002/cncr.20501
   Palmer JR, 2003, J NATL CANCER I, V95, P478
   Parkin DM, 2001, CANCER CAUSE CONTROL, V12, P147, DOI 10.1023/A:1008966225984
   Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7
   Shaw M, 2001, SEX TRANSM INFECT, V77, P358, DOI 10.1136/sti.77.5.358
   Unwin N, 2001, B WORLD HEALTH ORGAN, V79, P947
   Ursin G, 2005, BRIT J CANCER, V93, P364, DOI 10.1038/sj.bjc.6602712
   Wall SR, 2005, BRIT J CANCER, V93, P1068, DOI 10.1038/sj.bjc.6602736
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
NR 38
TC 10
Z9 10
U1 2
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 15
PY 2010
VL 127
IS 10
BP 2248
EP 2256
DI 10.1002/ijc.25244
PG 9
WC Oncology
SC Oncology
GA 672DT
UT WOS:000283563900002
PM 20162609
OA No
DA 2017-08-15
ER

PT J
AU Dondorp, AM
   Fanello, CI
   Hendriksen, ICE
   Gomes, E
   Seni, A
   Chhaganlal, KD
   Bojang, K
   Olaosebikan, R
   Anunobi, N
   Maitland, K
   Kivaya, E
   Agbenyega, T
   Nguah, SB
   Evans, J
   Gesase, S
   Kahabuka, C
   Mtove, G
   Nadjm, B
   Deen, J
   Amumpaire, JM
   Nansumba, M
   Karema, C
   Umulisa, N
   Uwimana, A
   Mokuolu, OA
   Adedoyin, OT
   Johnson, WBR
   Tshefu, AK
   Onyamboko, MA
   Sakulthaew, T
   Ngum, WP
   Silamut, K
   Stepniewska, K
   Woodrow, CJ
   Bethell, D
   Wills, B
   Oneko, M
   Peto, TE
   von Seidlein, L
   Day, NPJ
   White, NJ
AF Dondorp, Arjen M.
   Fanello, Caterina I.
   Hendriksen, Ilse C. E.
   Gomes, Ermelinda
   Seni, Amir
   Chhaganlal, Kajal D.
   Bojang, Kalifa
   Olaosebikan, Rasaq
   Anunobi, Nkechinyere
   Maitland, Kathryn
   Kivaya, Esther
   Agbenyega, Tsiri
   Nguah, Samuel Blay
   Evans, Jennifer
   Gesase, Samwel
   Kahabuka, Catherine
   Mtove, George
   Nadjm, Behzad
   Deen, Jacqueline
   Amumpaire, Juliet Mwanga
   Nansumba, Margaret
   Karema, Corine
   Umulisa, Noella
   Uwimana, Aline
   Mokuolu, Olugbenga A.
   Adedoyin, Olanrewaju T.
   Johnson, Wahab B. R.
   Tshefu, Antoinette K.
   Onyamboko, Marie A.
   Sakulthaew, Tharisara
   Ngum, Wirichada Pan
   Silamut, Kamolrat
   Stepniewska, Kasia
   Woodrow, Charles J.
   Bethell, Delia
   Wills, Bridget
   Oneko, Martina
   Peto, Tim E.
   von Seidlein, Lorenz
   Day, Nicholas P. J.
   White, Nicholas J.
CA AQUAMAT Grp
TI Artesunate versus quinine in the treatment of severe falciparum malaria
   in African children (AQUAMAT): an open-label, randomised trial
SO LANCET
LA English
DT Article
ID CEREBRAL MALARIA; INTRAMUSCULAR ARTESUNATE; INTRAVENOUS QUININE;
   ARTEMETHER; DIHYDROARTEMISININ; PHARMACOKINETICS; MORTALITY
AB Background Severe malaria is a major cause of childhood death and often the main reason for paediatric hospital admission in sub Saharan Africa Quinine is still the established treatment of choice, although evidence from Asia suggests that artesunate is associated with a lower mortality We compared parenteral treatment with either artesunate or quinine in African children with severe malaria
   Methods This open label randomised trial was undertaken in 11 centres in nine African countries Children (<15 years) with severe falciparum malaria were randomly assigned to parenteral artesunate or parenteral quinine Randomisation was in blocks of 20, with study numbers corresponding to treatment allocations kept inside opaque sealed paper envelopes The trial was open label at each site, and none of the investigators or trialists apart from for the trial statistician had access to the summaries of treatment allocations The primary outcome measure was in hospital mortality analysed by intention to treat This trial is registered, number ISRCTN50258054
   Findings 5425 children were enrolled 2712 were assigned to artesunate and 2713 to quinine All patients were analysed for the primary outcome 230 (8 5%) patients assigned to artesunate treatment died compared with 297 (10 9%) assigned to quinine treatment (odds ratio [OR] stratified for study site 0 75 95% CI 0 63-0 90, relative reduction 22 5% 95% CI 8 1-36 9, p=0 0022) Incidence of neurological sequelae did not differ significantly between groups, but the development of coma (65/1832 [3 5%] with artesunate vs 91/1768 [5 1%] with quinine OR 0 69 95% CI 0 49-0 95, p=0 0231) convulsions (224/2712 [8 3%] vs 273/2713 [10 1%] OR 0 80, 0 66-0 97 p=0 0199) and deterioration of the coma score (166/2712 [6 1%] vs 208/2713 [7 7%], OR 0 78, 0 64-0 97, p=0 0245) were all significantly less frequent in artesunate recipients than in quinine recipients Post treatment hypoglycaemia was also less frequent in patients assigned to artesunate than in those assigned to quinine (48/2712 [1 8%] vs 75/2713 [2 8%] OR 0 63 0 43-0 91 p=0 0134) Artesunate was well tolerated with no serious drug related adverse effects
   Interpretation Artesunate substantially reduces mortality in African children with severe malaria These data together with a meta analysis of all trials comparing artesunate and quinine, strongly suggest that parenteral artesunate should replace quinine as the treatment of choice for severe falciparum malaria worldwide
C1 [Dondorp, Arjen M.; Fanello, Caterina I.; Hendriksen, Ilse C. E.; Sakulthaew, Tharisara; Ngum, Wirichada Pan; Silamut, Kamolrat; Stepniewska, Kasia; Woodrow, Charles J.; Day, Nicholas P. J.; White, Nicholas J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit MORU, Bangkok 10400, Thailand.
   [Gomes, Ermelinda; Seni, Amir; Chhaganlal, Kajal D.] Hosp Cent Beira, Beira, Mozambique.
   [Bojang, Kalifa; Olaosebikan, Rasaq; Anunobi, Nkechinyere] MRC Labs, Banjul, Gambia.
   [Agbenyega, Tsiri; Nguah, Samuel Blay; Evans, Jennifer] Komfo Anokye Hosp, Kumasi, Ghana.
   [Maitland, Kathryn; Kivaya, Esther] Kilifi Dist Gen Hosp, Kilifi, Kenya.
   [Gesase, Samwel; Kahabuka, Catherine] Magunga Distnct Hosp, NIMR Korogwe Res Lab, Tanga, Tanzania.
   [Nadjm, Behzad; Deen, Jacqueline] Teule Designated Dist Hosp, Muheza, Tanzania.
   [Mtove, George] NIMR Amani Ctr, Tanga, Tanzania.
   [Karema, Corine; Umulisa, Noella; Uwimana, Aline] Minist Hlth, Malaria Control Program, Kigali, Rwanda.
   [Mokuolu, Olugbenga A.; Adedoyin, Olanrewaju T.; Johnson, Wahab B. R.] Univ Ilorin, Teaching Hosp, Ilorin, Nigeria.
   [Amumpaire, Juliet Mwanga; Nansumba, Margaret] Mbarara Univ Sci & Technol, Mbarara, Uganda.
   [Amumpaire, Juliet Mwanga; Nansumba, Margaret] Epictr Res Base, Mbarara, Uganda.
   [Nansumba, Margaret; Tshefu, Antoinette K.] Kingasani Res Ctr, Kinshasa Sch Publ Hlth, Kinshasa, Congo.
   [Bethell, Delia; Peto, Tim E.] Univ Oxford, Nuffield Dept Clin Med, Oxford, England.
   [von Seidlein, Lorenz] Menzies Sch Hlth Res, Casuarina, NT, Australia.
   [Wills, Bridget] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam.
   [Oneko, Martina] KEMRI CDC Kisumu, Kisumu, Kenya.
RP White, NJ (reprint author), Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit MORU, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.
RI White, Nicholas/I-4629-2012
OI Akor, Francis/0000-0002-5181-8609; Nadjm, Behzad/0000-0002-7704-3629;
   Woodrow, Charles/0000-0002-5134-7165; Bojang,
   Kalifa/0000-0001-7506-0938; Maitland, Kathryn/0000-0002-0007-0645
FU National Institute for Health Research Oxford Biomedical Research
   Centre; Wellcome Trust [076908, 082541]; Wellcome Trust of Great Britain
FX TEP is funded by the National Institute for Health Research Oxford
   Biomedical Research Centre This trial was supported by grants 076908 and
   082541 from the Wellcome Trust and was coordinated as part of the
   Wellcome Trust Mahidol University Oxford Tropical Medicine Research
   Programme funded by the Wellcome Trust of Great Britain We thank all the
   patients and their families the directors and staff of the trial
   hospitals and the Bangkok coordinating centre and the many doctors
   research nurses and research assistants for their help and support the
   ministries of health and institutional authorities for their support
   Loice Magaria and Ghiorghis Belai for their assistance and support
   Novartis for providing artemether lumefantrine for several of the study
   sites Marja Schilstra for help with database construction Epicentre
   (Philippe Guerin and Elizabeth Ashley) for assistance in setting up the
   study in Uganda and Richard Peto for advice
CR Anstey NM, 2006, MED J AUSTRALIA, V184, P3
   The Artemether-Quinine Meta-analysis Study Group, 2001, T R SOC TROP MED HYG, V95, P637, DOI DOI 10.1016/S0035-9203(01)90104-X
   Bartoloni A, 2010, AM J TROP MED HYG, V83, P274, DOI 10.4269/ajtmh.2010.10-0128
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Cao X T, 1997, Trans R Soc Trop Med Hyg, V91, P335
   Chotivanich K, 2002, J INFECT DIS, V185, P1538, DOI 10.1086/340213
   Dondorp AM, 2008, J INFECT DIS, V197, P79, DOI 10.1086/523762
   Eltahir HG, 2010, T ROY SOC TROP MED H, V104, P684, DOI 10.1016/j.trstmh.2010.05.009
   Faiz MA, 2005, LANCET, V366, P717
   Gomes MF, 2009, LANCET, V373, P557, DOI 10.1016/S0140-6736(08)61734-1
   Gravenor MB, 1998, P NATL ACAD SCI USA, V95, P7620, DOI 10.1073/pnas.95.13.7620
   Gwer S, 2007, AM J TROP MED HYG, V77, P6
   HIEN TT, 1992, T ROY SOC TROP MED H, V86, P582, DOI 10.1016/0035-9203(92)90137-2
   Hien TT, 2004, ANTIMICROB AGENTS CH, V48, P4234, DOI 10.1128/AAC.48.11.4234-4239.2004
   Hien TT, 1996, NEW ENGL J MED, V335, P76, DOI 10.1056/NEJM199607113350202
   Idro R, 2005, LANCET NEUROL, V4, P827, DOI 10.1016/S1474-4422(05)70247-7
   Ilett KF, 2002, BRIT J CLIN PHARMACO, V53, P23, DOI 10.1046/j.0306-5251.2001.01519.x
   JELINEK T, 2005, EUROSURVEILLANCE, V10, P2841
   Lalloo DG, 2007, J INFECTION, V54, P111, DOI 10.1016/j.jinf.2006.12.003
   Lee SJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-149
   Lubell Y, 2009, TROP MED INT HEALTH, V14, P332, DOI 10.1111/j.1365-3156.2009.02227.x
   Mithwani S, 2004, BRIT J CLIN PHARMACO, V57, P146, DOI 10.1046/j.1365-2125.2003.01986.x
   MURPHY S, 1995, AM J TROP MED HYG, V53, P303
   Murphy SA, 1997, T ROY SOC TROP MED H, V91, P331, DOI 10.1016/S0035-9203(97)90097-3
   NEALON C, 2002, ANTIMICROB AGENTS CH, V6, P933
   Newton PN, 2003, CLIN INFECT DIS, V37, P7, DOI 10.1086/375059
   Phu NH, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-97
   Rosenthal PJ, 2008, NEW ENGL J MED, V358, P1829, DOI 10.1056/NEJMct0709050
   Silamut K, 2003, ANTIMICROB AGENTS CH, V47, P3795, DOI 10.1128/AAC.47.12.3795-3798.2003
   Stepniewska K, 2010, J INFECT DIS, V201, P570, DOI 10.1086/650301
   TERKUILE F, 1993, EXP PARASITOL, V76, P86
   UDOMSANGPETDI R, 1996, PLASRRIODIUMFALCIPAR, V173, P691
   White NJ, 2007, BRIT MED J, V334, P490, DOI 10.1136/bmj.39143.014005.1F
   White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107
   WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201
   World Health Organization, 1990, T R SOC TROP MED S2, V84, P1
   WHO, 2000, T R SOC TROP MED S1, V94, P1
   World Health Organization, 2010, TREATM MAL
   WIN K, 1992, B WORLD HEALTH ORGAN, V70, P777
   YEN LM, 1994, LANCET, V344, P786, DOI 10.1016/S0140-6736(94)92342-6
NR 40
TC 330
Z9 339
U1 6
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD NOV 13
PY 2010
VL 376
IS 9753
BP 1647
EP 1657
DI 10.1016/S0140-6736(10)61924-1
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 683DD
UT WOS:000284451000030
PM 21062666
OA No
HC Y
HP N
DA 2017-08-15
ER

PT J
AU Takem, EN
   Ameh, D
   Jeffries, D
   Lindsay, S
   Pinder, M
AF Takem, Ebako N.
   Ameh, David
   Jeffries, David
   Lindsay, Steve
   Pinder, Margaret
TI CASE DEFINITION FOR MALARIA IN ENDEMIC SETTINGS: ATTRIBUTABLE FRACTION
   IN THE GAMBIA USING MODELING METHODS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 59th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 03-07, 2010
CL Atlanta, GA
SP Amer Soc Trop Med & Hyg (ASTMH)
C1 [Takem, Ebako N.; Ameh, David; Jeffries, David; Pinder, Margaret] MRC Labs, Fajara, Gambia.
   [Lindsay, Steve] London Sch Hyg & Trop Med, London WC1, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2010
VL 83
IS 5
SU S
MA 46
BP 14
EP 15
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 832QF
UT WOS:000295819700047
OA No
DA 2017-08-15
ER

PT J
AU Sheehy, SH
   Duncan, CJ
   Elias, S
   Collins, K
   Ewer, K
   Edwards, N
   Blagborough, A
   Sinden, R
   Murphy, J
   Correa, S
   Hunt-Cooke, A
   Meyer, J
   Lillie, P
   Colloca, S
   Cortese, R
   Nicosia, A
   Poulton, I
   Long, CA
   Gilbert, SC
   Lawrie, A
   Hill, AV
   Draper, SJ
AF Sheehy, Susanne H.
   Duncan, Christopher J.
   Elias, Sean
   Collins, Katharine
   Ewer, Katie
   Edwards, Nick
   Blagborough, Andrew
   Sinden, Robert
   Murphy, Jitta
   Correa, Simon
   Hunt-Cooke, Angela
   Meyer, Joel
   Lillie, Patrick
   Colloca, Stefano
   Cortese, Riccardo
   Nicosia, Alfredo
   Poulton, Ian
   Long, Carole A.
   Gilbert, Sarah C.
   Lawrie, Alison
   Hill, Adrian V.
   Draper, Simon J.
TI HETEROLOGOUS PRIME-BOOST VACCINATION WITH ADCH63 AND MVA EXPRESSING MSP1
   CAN INDUCE PROTECTIVE EFFICACY AGAINST SPOROZOITE CHALLENGE IN
   VOLUNTEERS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 59th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 03-07, 2010
CL Atlanta, GA
SP Amer Soc Trop Med & Hyg (ASTMH)
C1 [Sheehy, Susanne H.; Duncan, Christopher J.; Hunt-Cooke, Angela; Meyer, Joel; Lillie, Patrick; Poulton, Ian; Lawrie, Alison] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [Elias, Sean; Collins, Katharine; Ewer, Katie; Edwards, Nick; Gilbert, Sarah C.; Hill, Adrian V.; Draper, Simon J.] Univ Oxford, Jenner Inst, Oxford, England.
   [Blagborough, Andrew; Sinden, Robert] Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, London, England.
   [Murphy, Jitta] Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, MD 20307 USA.
   [Correa, Simon] MRC Labs, Banjul, Gambia.
   [Colloca, Stefano; Cortese, Riccardo; Nicosia, Alfredo] Okairos SRL, Rome, Italy.
   [Long, Carole A.] NIAID, NIH, Rockville, MD USA.
RI Duncan, Christopher/A-2018-2012
OI Duncan, Christopher/0000-0003-4181-2315
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2010
VL 83
IS 5
SU S
MA 160
BP 48
EP 49
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 832QF
UT WOS:000295819700161
OA No
DA 2017-08-15
ER

PT J
AU Caputo, B
   Nwakanama, D
   Oriero, EC
   Jawara, M
   Dia, I
   Konate, L
   Canestrelli, D
   Petrarca, V
   Conway, D
   della Torre, A
AF Caputo, Beniamino
   Nwakanama, Davis
   Oriero, Eniyou C.
   Jawara, Mussa
   Dia, Ibrahima
   Konate, Lassana
   Canestrelli, Daniele
   Petrarca, Vincenzo
   Conway, David
   della Torre, Alessandra
TI THE WEST-SIDE STORY OF ANOPHELES GAMBIAE MOLECULAR FORM SPECIATION
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 59th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 03-07, 2010
CL Atlanta, GA
SP Amer Soc Trop Med & Hyg (ASTMH)
C1 [Caputo, Beniamino; Canestrelli, Daniele; Petrarca, Vincenzo; della Torre, Alessandra] Univ Rome Sapienza, Rome, Italy.
   [Nwakanama, Davis; Oriero, Eniyou C.; Jawara, Mussa; Conway, David] MRC, Banjul, Gambia.
   [Konate, Lassana] Univ Dakar, Dakar, Senegal.
   [Dia, Ibrahima] Inst Pasteur, Dakar, Senegal.
RI Caputo, Beniamino/I-2880-2015; Canestrelli, Daniele/N-1724-2015
OI Caputo, Beniamino/0000-0002-5650-8773; Canestrelli,
   Daniele/0000-0001-9351-4972
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2010
VL 83
IS 5
SU S
MA 307
BP 92
EP 92
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 832QF
UT WOS:000295819700307
OA No
DA 2017-08-15
ER

PT J
AU Boyle, MJ
   Wilson, DW
   Richards, JS
   Riglar, DT
   Tetteh, KK
   Conway, DJ
   Ralph, SA
   Baum, J
   Beeson, JG
AF Boyle, Michelle J.
   Wilson, Danny W.
   Richards, Jack S.
   Riglar, David T.
   Tetteh, Kevin K.
   Conway, David J.
   Ralph, Stuart A.
   Baum, Jake
   Beeson, James G.
TI ISOLATION OF VIABLE PLASMODIUM FALCIPARUM MEROZOITES TO DEFINE
   ERYTHROCYTE INVASION EVENTS AND ADVANCE VACCINE AND DRUG DEVELOPMENT
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 59th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 03-07, 2010
CL Atlanta, GA
SP Amer Soc Trop Med & Hyg (ASTMH)
C1 [Boyle, Michelle J.; Wilson, Danny W.; Richards, Jack S.; Riglar, David T.; Baum, Jake; Beeson, James G.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.
   [Tetteh, Kevin K.] London Sch Hyg & Trop Med, London WC1, England.
   [Conway, David J.] MRC Labs, Fajara, Gambia.
   [Ralph, Stuart A.] Univ Melbourne, Inst Bio21, Parkville, Vic 3052, Australia.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2010
VL 83
IS 5
SU S
MA 427
BP 127
EP 128
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 832QF
UT WOS:000295819700427
OA No
DA 2017-08-15
ER

PT J
AU Deitz, KC
   Reddy, MP
   Overgaard, HJ
   Satyanarayana, N
   Matias, A
   Jawara, M
   della Torre, A
   Abaga, S
   Pinto, J
   Caccone, A
   Slotman, MA
AF Deitz, Kevin C.
   Reddy, Michael P.
   Overgaard, Hans J.
   Satyanarayana, Neha
   Matias, Abrahan
   Jawara, Musa
   della Torre, Alessandra
   Abaga, Simon
   Pinto, Joao
   Caccone, Adalgisa
   Slotman, Michel A.
TI THE POPULATION STRUCTURE OF THE MALARIA VECTOR ANOPHELES MELAS IN WEST
   AFRICA
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 59th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 03-07, 2010
CL Atlanta, GA
SP Amer Soc Trop Med & Hyg (ASTMH)
C1 [Deitz, Kevin C.; Satyanarayana, Neha; Slotman, Michel A.] Texas A&M Univ, College Stn, TX USA.
   [Reddy, Michael P.] Yale Univ, New Haven, CT USA.
   [Overgaard, Hans J.] Norwegian Univ Life Sci, As, Norway.
   [Matias, Abrahan] Med Care Dev Int, Silver Spring, MD USA.
   [Jawara, Musa] MRC Labs, Fajara, Gambia.
   [della Torre, Alessandra] Univ Roma La Sapienza, Rome, Italy.
   [Abaga, Simon] Minist Hlth & Social Welf, Malabo, Equat Guinea.
   [Pinto, Joao] Univ Nova Lisboa, P-1200 Lisbon, Portugal.
   [Caccone, Adalgisa] Yale Univ, College Stn, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2010
VL 83
IS 5
SU S
MA 776
BP 229
EP 229
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 832QF
UT WOS:000295819701144
OA No
DA 2017-08-15
ER

PT J
AU Oduro, AR
   Bojang, K
   Conway, D
   Schellenberg, D
AF Oduro, Abraham R.
   Bojang, Kalifa
   Conway, David
   Schellenberg, David
TI EVALUATION OF DIFFERENT INDICES TO MONITOR MALARIA IN THE GAMBIA, WEST
   AFRICA
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 59th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 03-07, 2010
CL Atlanta, GA
SP Amer Soc Trop Med & Hyg (ASTMH)
C1 [Oduro, Abraham R.; Conway, David] Gambia London Sch Hyg & Trop Med, MRC, London, England.
   [Bojang, Kalifa] MRC, Banjul, Gambia.
   [Schellenberg, David] London Sch Hyg & Trop Med, London WC1, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2010
VL 83
IS 5
SU S
MA 782
BP 231
EP 231
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 832QF
UT WOS:000295819701150
OA No
DA 2017-08-15
ER

PT J
AU Koita, OA
   Doumbia, SO
   Ndiaye, D
   Nwakanma, D
   Diallo, A
   Bojang, K
   Conway, DJ
   Volkman, SK
   Milner, DA
   Muskavitch, MAT
   Keating, J
   Wirth, DF
   Krogstad, DJ
AF Koita, Ousmane A.
   Doumbia, Seydou O.
   Ndiaye, Daouda
   Nwakanma, Davis
   Diallo, Amadou
   Bojang, Kalifa
   Conway, David J.
   Volkman, Sarah K.
   Milner, Danny A., Jr.
   Muskavitch, Mard A. T.
   Keating, Joseph
   Wirth, Dyann F.
   Krogstad, Donald J.
TI CHALLENGES IN THE DEVELOPMENT, REVIEW AND APPROVAL OF MULTI-CENTER
   STUDIES OF MALARIA CONTROL AND ELIMINATION STRATEGIES
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 59th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 03-07, 2010
CL Atlanta, GA
SP Amer Soc Trop Med & Hyg (ASTMH)
C1 [Koita, Ousmane A.; Doumbia, Seydou O.; Diallo, Amadou] Univ Bamako, Bamako, Mali.
   [Ndiaye, Daouda] Univ Cheikh Anta Diop, Dakar, Senegal.
   [Nwakanma, Davis; Bojang, Kalifa; Conway, David J.] MRC Labs, Fajara, Gambia.
   [Volkman, Sarah K.; Milner, Danny A., Jr.; Wirth, Dyann F.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Muskavitch, Mard A. T.] Boston Coll, Chestnut Hill, MA 02167 USA.
   [Keating, Joseph; Krogstad, Donald J.] Tulane Sch Publ Hlth & Trop Med, New Orleans, LA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2010
VL 83
IS 5
SU S
MA 934
BP 279
EP 279
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 832QF
UT WOS:000295819701302
OA No
DA 2017-08-15
ER

PT J
AU Kirby, MJ
   Bah, P
   Jones, COH
   Kelly, AH
   Jasseh, M
   Lindsay, SW
AF Kirby, Matthew J.
   Bah, Pateh
   Jones, Caroline O. H.
   Kelly, Ann H.
   Jasseh, Momodou
   Lindsay, Steve W.
TI Social Acceptability and Durability of Two Different House Screening
   Interventions against Exposure to Malaria Vectors, Plasmodium falciparum
   Infection, and Anemia in Children in The Gambia, West Africa
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID INSECTICIDE IMPREGNATED BEDNETS; MOSQUITOS; GHANA; NETS
AB The social acceptability and durability of two house screening interventions were addressed using focus group discussions, questionnaires, indoor climate measurements and durability surveys Participants recognized that screening stopped mosquitoes (79-96%) and other insects (86-98%) entering their houses These and other benefits were appreciated by significantly more recipients of full screening than users of screened ceilings Full screened houses were 0 26 degrees C hotter at night (P = 0 05) than houses with screened ceilings and 0 51 degrees C (P < 0 001) hotter than houses with no screening (28 43 degrees C), though only 9% of full screened house users and 17% of screened ceiling users complained about the heat Although 71% of screened doors and 85% of ceilings had suffered some damage after 12 months, the average number of holes of any sue was <5 for doors and <7 for ceilings In conclusion, house screening is a well-appreciated and durable vector control tool
C1 [Kirby, Matthew J.; Jones, Caroline O. H.; Lindsay, Steve W.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Dis Control & Vector Biol Unit, London WC1E 7HT, England.
   [Jasseh, Momodou] Med Res Council UK, Banjul, Gambia.
RP Kirby, MJ (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Dis Control & Vector Biol Unit, Keppel St, London WC1E 7HT, England.
FU Vestergaard Frandsen group; Medical Council Laboratories in The Gambia;
   London School of Hygiene and Tropical Medicine; Medical Research Council
   UK; Gambian Government/MRC Ethics Committee Durham University
FX We think the participants the local communities and their leaders for
   giving us their time to discuss their perspectives on our research We
   thank all staff members of STOPMAL for their dedication to this project
   We are also grateful to all the organizations that have supported this
   research the Vestergaard Frandsen group Medical Council Laboratories in
   The Gambia the joint Gambian Government/MRC Ethics Committee Durham
   University and the London School of Hygiene and Tropical Medicine; This
   study was funded by Medical Research Council UK
CR Aikins MK, 1998, SOC SCI MED, V46, P181, DOI 10.1016/S0277-9536(97)00145-7
   ALAN JA, 2003, AM J TROP MED HYG, V68, P142
   Atieli H, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-108
   Binka FN, 1997, TROP MED INT HEALTH, V2, P499, DOI 10.1046/j.1365-3156.1997.d01-299.x
   Brabin BJ, 2001, J NUTR, V131, p636S
   BRICK CP, 2006, SOC SCI MED, V62, P2810
   DALESSANDRO U, 1994, B WORLD HEALTH ORGAN, V72, P391
   DAWSON S, 1991, APPL QUALITATIVE RES, P1
   Gyapong M, 1996, TROP MED INT HEALTH, V1, P328, DOI 10.1046/j.1365-3156.1996.d01-41.x
   HANAFIN JB, 1928, J R ARMY MED CORPS, V51, P127
   Jones Caroline, 2002, Trends in Parasitology, V18, P195, DOI 10.1016/S1471-4922(02)02272-9
   Kirby MJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-33
   Kirby MJ, 2009, LANCET, V374, P998, DOI 10.1016/S0140-6736(09)60871-0
   Kirby MJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-2
   Lindsay SW, 2002, TRENDS PARASITOL, V18, P510, DOI 10.1016/S1471-4922(02)02382-6
   MACCORMACK CP, 1986, J TROP MED HYG, V89, P295
   Mshinda H, 2004, LANCET INFECT DIS, V4, P264, DOI 10.1016/S1473-3099(04)01000-X
   Njie M, 2009, J MED ENTOMOL, V46, P505, DOI 10.1603/033.046.0314
   Ogoma SB, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-221
   Okrah J, 2002, TROP MED INT HEALTH, V7, P240, DOI 10.1046/j.1365-3156.2002.00856.x
   Orenstein A. J., 1912, P CANAL ZONE MED ASS, V5, P12
   Reilley B, 2002, TROP MED INT HEALTH, V7, P744, DOI 10.1046/j.1365-3156.2002.00919.x
   SNOW RW, 1994, ACTA TROP, V57, P289, DOI 10.1016/0001-706X(94)90074-4
   Watson RB, 1949, MALARIOLOGY COMPREHE, P1184
NR 24
TC 11
Z9 11
U1 0
U2 4
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2010
VL 83
IS 5
BP 965
EP 972
DI 10.4269/ajtmh.2010.10.0311
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 679TV
UT WOS:000284184600004
PM 21036822
OA No
DA 2017-08-15
ER

PT J
AU Osier, FHA
   Weedall, GD
   Verra, F
   Murungi, L
   Tetteh, KKA
   Bull, P
   Faber, BW
   Remarque, E
   Thomas, A
   Marsh, K
   Conway, DJ
AF Osier, Faith H. A.
   Weedall, Gareth D.
   Verra, Federica
   Murungi, Linda
   Tetteh, Kevin K. A.
   Bull, Pete
   Faber, Bart W.
   Remarque, Ed
   Thomas, Alan
   Marsh, Kevin
   Conway, David J.
TI Allelic Diversity and Naturally Acquired Allele-Specific Antibody
   Responses to Plasmodium falciparum Apical Membrane Antigen 1 in Kenya
SO INFECTION AND IMMUNITY
LA English
DT Article
ID MALARIA-VACCINE CANDIDATE; MEROZOITE SURFACE PROTEIN-2;
   IMMUNE-RESPONSES; CLINICAL MALARIA; POPULATION-STRUCTURE; MEDIATED
   INHIBITION; DNA POLYMORPHISM; DOMAIN-III; AMA1; SELECTION
AB Although Plasmodium falciparum apical membrane antigen 1 (AMA1) is a leading malaria vaccine candidate, extensive allelic diversity may compromise its vaccine potential. We have previously shown that naturally acquired antibodies to AMA1 were associated with protection from clinical malaria in this Kenyan population. To assess the impact of allelic diversity on naturally acquired immunity, we first sequenced the ectodomain-encoding region of P. falciparum ama1 from subjects with asymptomatic, mild, and severe malaria and measured allele frequency distributions. We then measured antibodies to three allelic AMA1 proteins (AMA1_3D7, AMA1_FVO, and AMA1_HB3) and used competition enzyme-linked immunosorbent assays (ELISAs) to analyze allele-specific antibodies. Seventy-eight unique haplotypes were identified from 129 alleles sampled. No clustering of allelic haplotypes with disease severity or year of sampling was observed. Differences in nucleotide frequencies in clinical (severe plus mild malaria) versus asymptomatic infections were observed at 16 polymorphic positions. Allele frequency distributions were indicative of balancing selection, with the strongest signature being identified in domain III (Tajima's D = 2.51; P < 0.05). Antibody reactivities to each of the three allelic AMA1 proteins were highly correlated (P < 0.001 for all pairwise comparisons). Although antibodies to conserved epitopes were abundant, 48% of selected children with anti-AMA1 IgG (n = 106) had detectable reactivity to allele-specific epitopes as determined by a competition ELISA. Antibodies to both conserved and allele-specific epitopes in AMA1 may contribute to clinical protection.
C1 [Osier, Faith H. A.; Murungi, Linda; Bull, Pete; Marsh, Kevin] KEMRI Ctr Geog Med Res, Kilifi, Kenya.
   [Osier, Faith H. A.; Weedall, Gareth D.; Verra, Federica; Tetteh, Kevin K. A.; Conway, David J.] London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Faber, Bart W.; Remarque, Ed; Thomas, Alan] BPRC, Dept Parasitol, NL-2280 GH Rijswijk, Netherlands.
   [Conway, David J.] MRC Labs, Banjul, Gambia.
RP Osier, FHA (reprint author), KEMRI Ctr Geog Med Res, POB 230-80108, Kilifi, Kenya.
EM fosier@kilifi.kemri-wellcome.org
OI Osier, Faith/0000-0001-7133-5375; Bull, Peter/0000-0002-7674-6752;
   Conway, David/0000-0002-8711-3037
FU Wellcome Trust [073591]
FX This work was supported by a research training fellowship awarded to
   FHAO by the Wellcome Trust, grant 073591.
CR Alexander DL, 2006, EUKARYOT CELL, V5, P1169, DOI 10.1128/EC.00040-06
   Alexander DL, 2005, PLOS PATHOG, V1, P137, DOI 10.1371/journal.ppat.0010017
   Anders RF, 1998, VACCINE, V16, P240, DOI 10.1016/S0264-410X(97)88331-4
   Babiker HA, 1997, AM J TROP MED HYG, V56, P141
   Bai T, 2005, P NATL ACAD SCI USA, V102, P12736, DOI 10.1073/pnas.0501808102
   BLAND JM, 1995, BRIT MED J, V310, P170
   Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358
   Cao J, 2009, PARASITOL INT, V58, P29, DOI 10.1016/j.parint.2008.09.005
   Coley AM, 2006, INFECT IMMUN, V74, P2628, DOI 10.1128/IAI.74.5.2628-2636.2006
   Coley AM, 2001, PROTEIN ENG, V14, P691, DOI 10.1093/protein/14.9.691
   Coley AM, 2007, PLOS PATHOG, V3, P1308, DOI 10.1371/journal.ppat.0030138
   Collins CR, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000273
   Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506
   Cortes A, 2005, INFECT IMMUN, V73, P422, DOI 10.1128/IAI.73.1.422-430.2005
   Cortes A, 2003, INFECT IMMUN, V71, P1416, DOI 10.1128/IAI.71.3.1416-1426.2003
   Crewther PE, 1996, INFECT IMMUN, V64, P3310
   Dicko A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001045
   Dutta S, 2007, P NATL ACAD SCI USA, V104, P12488, DOI 10.1073/pnas.0701464104
   FU YX, 1993, GENETICS, V133, P693
   Garg S, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-154
   Healer J, 2004, MOL MICROBIOL, V52, P159, DOI 10.1111/j.1365-2958.2003.03974.x
   HILL WG, 1968, GENETICS, V60, P615
   Hodder AN, 1996, J BIOL CHEM, V271, P29446
   Hoffmann EHE, 2001, ANN TROP MED PARASIT, V95, P117, DOI 10.1080/00034980120045833
   HUDSON RR, 1987, GENET RES, V50, P245
   HUDSON RR, 1985, GENETICS, V111, P147
   Kennedy MC, 2002, INFECT IMMUN, V70, P6948, DOI 10.1128/IAI.70.12.6948-6960.2002
   Kocken CHM, 2000, MOL BIOCHEM PARASIT, V109, P147, DOI 10.1016/S0166-6851(00)00250-4
   Kocken CHM, 2002, INFECT IMMUN, V70, P4471, DOI 10.1128/IAI.70.8.4471-4476.2002
   Kusi KA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008110
   Lal AA, 1996, INFECT IMMUN, V64, P1054
   Lalitha PV, 2004, INFECT IMMUN, V72, P4464, DOI 10.1128/IAI.72.8.4464-4470.2004
   LEWONTIN RC, 1964, GENETICS, V49, P49
   Mbogo CM, 2003, AM J TROP MED HYG, V68, P734
   MBOGO CNM, 1993, AM J TROP MED HYG, V49, P245
   Morahan BJ, 2009, EXP PARASITOL, V122, P280, DOI 10.1016/j.exppara.2009.04.013
   Mu JB, 2005, PLOS BIOL, V3, P1734, DOI 10.1371/journal.pbio.0030335
   Mueller MS, 2003, INFECT IMMUN, V71, P4749, DOI 10.1128/IAI.71.8.4749-4758.2003
   Mwangi TW, 2005, J INFECT DIS, V191, P1932, DOI 10.1086/430006
   Nair M, 2002, J MOL BIOL, V322, P741, DOI 10.1016/S0022-2836(02)00806-9
   Neafsey DE, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r171
   Osier FHA, 2007, PARASITE IMMUNOL, V29, P387, DOI 10.1111/j.1365-3024.2007.00951.x
   Osier FHA, 2008, INFECT IMMUN, V76, P2240, DOI 10.1128/IAI.01585-07
   Polley SD, 2006, VACCINE, V24, P4233, DOI 10.1016/j.vaccine.2005.06.030
   Polley SD, 2004, VACCINE, V23, P718, DOI 10.1016/j.vaccine.2004.05.031
   Polley SD, 2003, GENETICS, V165, P555
   Polley SD, 2001, GENETICS, V158, P1505
   Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359
   Schoepflin S, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-250
   TAJIMA F, 1989, GENETICS, V123, P585
   Takala SL, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000257
   THERA MA, 2009, AM SOC TROP MED HYG
   Udhayakumar V, 2001, AM J TROP MED HYG, V65, P100
   WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700
NR 54
TC 29
Z9 29
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD NOV
PY 2010
VL 78
IS 11
BP 4625
EP 4633
DI 10.1128/IAI.00576-10
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 665RB
UT WOS:000283052100019
PM 20732997
OA No
DA 2017-08-15
ER

PT J
AU Natividad, A
   Freeman, TC
   Jeffries, D
   Burton, MJ
   Mabey, DCW
   Bailey, RL
   Holland, MJ
AF Natividad, Angels
   Freeman, Tom C.
   Jeffries, David
   Burton, Matthew J.
   Mabey, David C. W.
   Bailey, Robin L.
   Holland, Martin J.
TI Human Conjunctival Transcriptome Analysis Reveals the Prominence of
   Innate Defense in Chlamydia trachomatis Infection
SO INFECTION AND IMMUNITY
LA English
DT Article
ID NATURAL-KILLER-CELLS; GENE-EXPRESSION PATTERNS; GAMMA IMMUNE EVASION;
   TH17 T-CELLS; IFN-GAMMA; GENITAL-INFECTION; DENDRITIC CELLS; NK CELLS;
   HLA-C; NEUTROPHIL RECRUITMENT
AB Trachoma is the leading infectious cause of blindness and is endemic in 52 countries. There is a critical need to further our understanding of the host response during disease and infection, as millions of individuals are still at risk of developing blinding sequelae. Infection of the conjunctival epithelial cells by the causative bacterium, Chlamydia trachomatis, stimulates an acute host response. The main clinical feature is a follicular conjunctivitis that is incompletely defined at the tissue-specific gene expression and molecular levels. To explore the features of disease and the response to infection, we measured host gene expression in conjunctival samples from Gambian children with active trachoma and healthy controls. Genome-wide expression and transcription network analysis identified signatures characteristic of the expected infiltrating immune cell populations, such as neutrophils and T/B lymphocytes. The expression signatures were also significantly enriched for genes in pathways which regulate NK cell activation and cytotoxicity, antigen processing and presentation, chemokines, cytokines, and cytokine receptors. The data suggest that in addition to polymorph and adaptive cellular responses, NK cells may contribute to a significant component of the conjunctival inflammatory response to chlamydial infection.
C1 [Holland, Martin J.] Univ London, Fac Infect & Trop Dis, Dept Clin Res, London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Freeman, Tom C.] Univ Edinburgh, Roslin Inst, RDSVS, Roslin Bioctr, Roslin EH25 9PS, Midlothian, Scotland.
   [Jeffries, David; Holland, Martin J.] MRC Labs, Viral Dis Programme, Banjul, Gambia.
RP Holland, MJ (reprint author), Univ London, Fac Infect & Trop Dis, Dept Clin Res, London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM Martin.Holland@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169;
   Freeman, Thomas/0000-0001-5235-8483
FU Wellcome Trust [079246/Z/06/Z]; MRC (United Kingdom), the Gambia
FX This work was supported by the Wellcome Trust (079246/Z/06/Z) and MRC
   (United Kingdom) core budget, the Gambia.
CR Agaugue S, 2008, BLOOD, V112, P1776, DOI 10.1182/blood-2008-02-135871
   Alvesalo J, 2008, J INFECT DIS, V197, P156, DOI 10.1086/524142
   Anderson SK, 2006, CURR TOP MICROBIOL, V298, P59
   Auer J, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2294
   Barteneva N, 1996, INFECT IMMUN, V64, P4830
   Baud D, 2008, CURR OPIN INFECT DIS, V21, P70, DOI 10.1097/QCO.0b013e3282f3e6a5
   Belay T, 2002, INFECT IMMUN, V70, P844, DOI 10.1128/IAI.70.2.844-850.2002
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Berry MPR, 2010, NATURE, V466, P973, DOI 10.1038/nature09247
   Brunham RC, 2005, NAT REV IMMUNOL, V5, P149, DOI 10.1038/nri1551
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537
   Cohen CR, 2005, J INFECT DIS, V192, P591, DOI 10.1086/432070
   COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543
   COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000
   COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555
   Coombes BK, 2001, INFECT IMMUN, V69, P1420, DOI 10.1128/IAI.69.3.1420-1427.2001
   de Oca RM, 2000, INFECT IMMUN, V68, P1746, DOI 10.1128/IAI.68.3.1746-1751.2000
   Dessus-Babus S, 2000, CELL MICROBIOL, V2, P317, DOI 10.1046/j.1462-5822.2000.00058.x
   Dessus-Babus S, 2002, INFECT IMMUN, V70, P3234, DOI 10.1128/IAI.70.6.3234-3248.2002
   Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767
   Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202
   Faal N, 2005, CLIN EXP IMMUNOL, V142, P347, DOI 10.1111/j.1365-2249.2005.02917.x
   Faal N, 2006, PLOS MED, V3, P1292, DOI 10.1371/journal.pmed.0030266
   Fortin CF, 2009, FASEB J, V23, P194, DOI 10.1096/fj.08-110213
   Freeman TC, 2007, PLOS COMPUT BIOL, V3, P2032, DOI 10.1371/journal.pcbi.0030206
   Gentil K, 2009, INFECT IMMUN, V77, P1606, DOI 10.1128/IAI.00671-08
   Gillette-Ferguson I, 2007, INFECT IMMUN, V75, P5908, DOI 10.1128/IAI.00991-07
   Griffiths MJ, 2005, J INFECT DIS, V191, P1599, DOI 10.1086/429297
   GUMPERZ JE, 1995, J EXP MED, V181, P1133, DOI 10.1084/jem.181.3.1133
   Hess S, 2003, CELL MICROBIOL, V5, P785, DOI 10.1046/j.1462-5822.2003.00319.x
   Hook CE, 2005, FEMS IMMUNOL MED MIC, V45, P113, DOI 10.1016/j.femsim.2005.02.010
   Hook CE, 2004, CLIN EXP IMMUNOL, V138, P54, DOI 10.1111/j.1365-2249.2004.02596.x
   Horowitz A, 2010, J IMMUNOL
   Horowitz A, 2010, J IMMUNOL, V184, P6043, DOI 10.4049/jimmunol.1000106
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, CURR PROTOC BIOINFOR, DOI [DOI 10.1002/0471250953.BI1311S27, 10.1002/0471250953.]
   Hume DA, 2010, GENOMICS, V95, P328, DOI 10.1016/j.ygeno.2010.03.002
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jiang XZ, 2010, IMMUNOLOGY, V129, P556, DOI 10.1111/j.1365-2567.2009.03157.x
   Khatri P, 2007, NUCLEIC ACIDS RES, V35, pW206, DOI 10.1093/nar/gkm327
   King M, 2009, DRUG TODAY, V45, P125
   Lad SP, 2005, J IMMUNOL, V174, P7186
   Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808
   Lin M, 2008, AM J PATHOL, V173, P144, DOI 10.2353/ajpath.2008.080081
   Liu W, 2008, IMMUNOLOGY, V123, P290, DOI 10.1111/j.1365-2567.2007.02642.x
   Mabbott NA, 2010, IMMUNOBIOLOGY, V215, P724, DOI 10.1016/j.imbio.2010.05.012
   Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   Maxion HK, 2004, INFECT IMMUN, V72, P6330, DOI 10.1128/IAI.72.11.6330-6340.2004
   Maxion HK, 2002, INFECT IMMUN, V70, P1538, DOI 10.1128/IAI.70.3.1538-1546.2002
   McClarty G, 2007, CURR OPIN MICROBIOL, V10, P47, DOI 10.1016/j.mib.2006.12.003
   Morrison RP, 2002, INFECT IMMUN, V70, P2741, DOI 10.1128/IAI.70.6.2741-2751.2002
   Natividad A, 2008, HUM MOL GENET, V17, P323, DOI 10.1093/hmg/ddm310
   Natividad A, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-40
   Natividad A, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-138
   Nelson DE, 2005, P NATL ACAD SCI USA, V102, P10658, DOI 10.1073/pnas.0504198102
   Pochetuhen K, 2007, AM J PATHOL, V171, P428, DOI 10.2353/ajpath.2007.061167
   Prasse A, 2006, AM J RESP CRIT CARE, V173, P781, DOI 10.1164/rccm.200509-1518OC
   Puccetti P, 2007, NAT REV IMMUNOL, V7, P817, DOI 10.1038/nri2163
   Rajagopalan S, 1999, J EXP MED, V189, P1093, DOI 10.1084/jem.189.7.1093
   Ramilo O, 2007, BLOOD, V109, P2066, DOI 10.1182/blood-2006-02-002477
   Rank RG, 2010, INFECT IMMUN, V78, P536, DOI 10.1128/IAI.00772-09
   RAPOZA PA, 1991, INVEST OPHTH VIS SCI, V32, P2919
   Ren Q, 2003, ANN NY ACAD SCI, V990, P701
   Roshick C, 2006, INFECT IMMUN, V74, P225, DOI 10.1128/IAI.74.1.225-238.2006
   Rottenberg ME, 2002, CURR OPIN IMMUNOL, V14, P444, DOI 10.1016/S0952-7915(02)00361-8
   Schachter J, 1999, CHLAMYDIA, P139
   Schrader S, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2209
   Single RM, 2007, NAT GENET, V39, P1114, DOI 10.1038/ng2077
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   Sporri R, 2008, J IMMUNOL, V181, P7121
   Starnbach MN, 2008, NAT REV IMMUNOL, V8, P313, DOI 10.1038/nri2272
   Stephens RS, 2003, TRENDS MICROBIOL, V11, P44, DOI 10.1016/S0966-842X(02)00011-2
   Stockinger B, 2007, SEMIN IMMUNOL, V19, P353, DOI 10.1016/j.smim.2007.10.008
   Stockinger B, 2007, CURR OPIN IMMUNOL, V19, P281, DOI 10.1016/j.coi.2007.04.005
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Theocharidis A, 2009, NAT PROTOC, V4, P1535, DOI 10.1038/nprot.2009.177
   THOMAS SM, 1993, J IMMUNOL, V150, P5529
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770
   Tseng CTK, 1998, INFECT IMMUN, V66, P5867
   Uhrberg M, 1997, IMMUNITY, V7, P753, DOI 10.1016/S1074-7613(00)80394-5
   Van Dongen S., 2000, GRAPH CLUSTERING FLO
   Virok D, 2003, J INFECT DIS, V188, P1310, DOI 10.1086/379047
   Wang SH, 1999, EUR J IMMUNOL, V29, P3782, DOI 10.1002/(SICI)1521-4141(199911)29:11<3782::AID-IMMU3782>3.0.CO;2-B
   Wilson MJ, 2000, P NATL ACAD SCI USA, V97, P4778, DOI 10.1073/pnas.080588597
   Xia MS, 2003, J INFECT DIS, V187, P424, DOI 10.1086/367962
   Yang X, 1998, IMMUNOLOGY, V94, P469
   Yang X, 1999, J IMMUNOL, V162, P1010
   YONEDA C, 1975, BRIT J OPHTHALMOL, V59, P116, DOI 10.1136/bjo.59.3.116
   Zaharik ML, 2007, IMMUNOLOGY, V120, P160, DOI 10.1111/j.1365-2567.2006.02488.x
NR 93
TC 28
Z9 28
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD NOV
PY 2010
VL 78
IS 11
BP 4895
EP 4911
DI 10.1128/IAI.00844-10
PG 17
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 665RB
UT WOS:000283052100048
PM 20823212
OA No
DA 2017-08-15
ER

PT J
AU Duke, T
   Graham, SM
   Cherian, MN
   Ginsburg, AS
   English, M
   Howie, S
   Peel, D
   Enarson, PM
   Wilson, IH
   Were, W
AF Duke, T.
   Graham, S. M.
   Cherian, M. N.
   Ginsburg, A. S.
   English, M.
   Howie, S.
   Peel, D.
   Enarson, P. M.
   Wilson, I. H.
   Were, W.
CA Union Oxygen Syst Working Grp
TI Oxygen is an essential medicine: a call for international action
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE oxygen; hypoxaemia; pneumonia; lung disease; health systems
ID PAPUA-NEW-GUINEA; RESPIRATORY-TRACT INFECTION; DEVELOPING-COUNTRIES;
   CHILD-MORTALITY; PULSE OXIMETRY; PREDICT HYPOXEMIA; SEVERE PNEUMONIA;
   GLOBAL OXIMETRY; CLINICAL SIGNS; HOSPITAL-CARE
AB Hypoxaemia is commonly associated with mortality in developing countries, yet feasible and cost-effective ways to address hypoxaemia receive little or no attention in current global health strategies. Oxygen treatment has been used in medicine for almost 100 years, but in developing countries most seriously ill newborns, children and adults do not have access to oxygen or the simple test that can detect hypoxaemia. Improving access to oxygen and pulse oximetry has demonstrated a reduction in mortality from childhood pneumonia by up to 35% in high-burden child pneumonia settings. The cost-effectiveness of an oxygen systems strategy compares favourably with other higher profile child survival interventions, such as new vaccines. In addition to its use in treating acute respiratory illness, oxygen treatment is required for the optimal management of many other conditions in adults and children, and is essential for safe surgery, anaesthesia and obstetric care. Oxygen concentrators provide the most consistent and least expensive source of oxygen in health facilities where power supplies are reliable. Oxygen concentrators are sustainable in developing country settings if a systematic approach involving nurses, doctors, technicians and administrators is adopted. Improving oxygen systems is an entry point for improving the quality of care. For these broad reasons, and for its vital importance in reducing deaths due to lung disease in 2010: Year of the Lung, oxygen deserves a higher priority on the global health agenda.
C1 [Duke, T.; Graham, S. M.] Univ Melbourne, Ctr Int Child Hlth, Dept Paediat, Melbourne, Vic, Australia.
   [Duke, T.; Graham, S. M.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Graham, S. M.; Enarson, P. M.] Int Union TB & Lung Dis, Lung Hlth Div, Paris, France.
   [Cherian, M. N.] WHO, Dept Essential Hlth Technol, CH-1211 Geneva, Switzerland.
   [Ginsburg, A. S.] PATH, Seattle, WA USA.
   [English, M.] Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Nairobi, Kenya.
   [Howie, S.] MRC, Banjul, Gambia.
   [Peel, D.] Ashdown Consultants, Hartfield, England.
   [Wilson, I. H.] World Federat Soc Anaesthesiologists, London, England.
   [Were, W.] WHO, Dept Child & Adolescent Hlth, CH-1211 Geneva, Switzerland.
RP Graham, SM (reprint author), Univ Melbourne, Ctr Int Child Hlth, Dept Paediat, Royal Childrens Hosp, Flemington Rd, Parkville, Vic 3052, Australia.
EM steve.graham@rch.org.au
FU Medical Research Council [MC_U190081957]; Wellcome Trust [076827,
   097170]
CR Belle J, 2010, J INFECT DEV COUNTR, V4, P419
   Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1
   Campbell H, 2008, PEDIATRICS, V121, pE984, DOI 10.1542/peds.2007-1395
   DJELANTIK IG, 2010, J TROP PAEDIAT, V49, P327
   Dobson M, 1996, LANCET, V347, P1597, DOI 10.1016/S0140-6736(96)91080-6
   Duke T, 2005, Arch Dis Child Fetal Neonatal Ed, V90, pF211, DOI 10.1136/adc.2003.048108
   Duke T, 2010, ANN TROP PAEDIATR, V30, P87, DOI 10.1179/146532810X12637745452356
   Duke T, 2009, ANN TROP PAEDIATR, V29, P165, DOI 10.1179/027249309X12467994190011
   Duke T, 2001, INT J TUBERC LUNG D, V5, P511
   Duke T, 2002, ARCH DIS CHILD, V86, P108, DOI 10.1136/adc.86.2.108
   Duke T, 2008, LANCET, V372, P1328, DOI 10.1016/S0140-6736(08)61164-2
   DYKE T, 1995, J TROP PEDIATRICS, V41, P196
   Enarson PM, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000137
   Enarson P, 2008, B WORLD HEALTH ORGAN, V86, P344, DOI 10.2471/BLT.07.048017
   English M, 2004, LANCET, V363, P1948, DOI 10.1016/S0140-6736(04)16408-8
   FENTON PM, 1989, ANAESTHESIA, V44, P498, DOI 10.1111/j.1365-2044.1989.tb11380.x
   HALDANE JS, 1920, P ROY SOC MED, V13, P76
   Hodges SC, 2007, ANAESTHESIA, V62, P4, DOI 10.1111/j.1365-2044.2006.04907.x
   Howie SRC, 2009, B WORLD HEALTH ORGAN, V87, P763, DOI 10.2471/BLT.08.058370
   Kingham TP, 2009, ARCH SURG-CHICAGO, V144, P122, DOI 10.1001/archsurg.2008.540
   Laman M, 2005, ANN TROP PAEDIATR, V25, P23, DOI 10.1179/146532805X23317
   Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5
   Litch JA, 2000, WILD ENVIRON MED, V11, P189, DOI 10.1580/1080-6032(2000)011[0189:OCFTDO]2.3.CO;2
   Lozano JM, 2001, INT J TUBERC LUNG D, V5, P496
   Matai S, 2008, ANN TROP PAEDIATR, V28, P71, DOI 10.1179/146532808X270716
   McCormick BA, 2007, ANAESTHESIA, V62, P54, DOI 10.1111/j.1365-2044.2007.05299.x
   Merry AF, 2009, ANAESTHESIA, V64, P1045, DOI 10.1111/j.1365-2044.2009.06104.x
   Mokuolu OA, 2002, ANN TROP PAEDIATR, V22, P209, DOI 10.1179/027249302125001499
   Mwaniki MK, 2009, B WORLD HEALTH ORGAN, V87, P263, DOI 10.2471/BLT.07.049148
   Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X
   ODRISCOLL BR, 2008, THORAX S6, V63, pNIL6, DOI DOI 10.1136/THX.2008.102947
   Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169
   Peel David, 2009, Journal of Clinical Engineering, V34, P205
   Rahnama'i M. S., 2006, Indian Journal of Pediatrics, V73, P771, DOI 10.1007/BF02790383
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   SCHNAPP LM, 1990, CHEST, V98, P1244, DOI 10.1378/chest.98.5.1244
   Schneider G, 2001, INT J TUBERC LUNG D, V5, P524
   Sinha A, 2007, LANCET, V369, P389, DOI 10.1016/S0140-6736(07)60195-0
   Subhi R, 2009, ARCH DIS CHILD, V94, P6, DOI 10.1136/adc.2008.138362
   Subhi R, 2009, LANCET INFECT DIS, V9, P219, DOI 10.1016/S1473-3099(09)70071-4
   Tin W, 2007, ARCH DIS CHILD-FETAL, V92, pF143, DOI 10.1136/adc.2005.092726
   [United Nations Children's Fund World Health Organization], 2006, PNEUM FORG KILL CHIL
   Usen S, 1999, BRIT MED J, V318, P86
   Walker IA, 2009, ANAESTHESIA, V64, P1051, DOI 10.1111/j.1365-2044.2009.06067.x
   Wandi F, 2006, ANN TROP PAEDIATR, V26, P277, DOI 10.1179/146532806X152791
   Weber MW, 1997, ARCH DIS CHILD, V76, P310
   Weber MW, 1998, LANCET, V351, P1589, DOI 10.1016/S0140-6736(05)61160-9
   *WHO, 2010, GLOB PULS OX PROJ
   *WHO, 2010, INT MAN EM ESS SURG
   *WHO, 2010, CLIN US OX GUID LIN
   World Health Organization, 2003, AN INFR SUPPL SURG C
   World Health Organisation, 2009, WHO MOD LIST ESS MED
   You D, 2010, LANCET, V375, P100, DOI 10.1016/S0140-6736(09)61601-9
NR 53
TC 30
Z9 30
U1 0
U2 3
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD NOV
PY 2010
VL 14
IS 11
BP 1362
EP 1368
PG 7
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 675KV
UT WOS:000283830500002
PM 20937173
OA No
DA 2017-08-15
ER

PT J
AU Onyekwelu, EU
AF Onyekwelu, E. U.
TI AN ANNOTATED COMPILATION OF CHILDHOOD PERVASIVE DISINTEGRATIVE SPECTRUM
   DISORDERS(PDD) CHECK LISTS WITH EMPHASIS ON DIFFERENTIAL ALGORITHMIC,
   DIAGNOSTIC THERAPEUTIC-INTERVENTIONAL APPROACH
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 [Onyekwelu, E. U.] Royal Victoria Teaching Hosp, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD NOV
PY 2010
VL 68
SU 1
MA 570
BP 292
EP 292
PG 1
WC Pediatrics
SC Pediatrics
GA V25LO
UT WOS:000208479700569
OA No
DA 2017-08-15
ER

PT J
AU Onyekwelu, EU
AF Onyekwelu, E. U.
TI SOME OCCASIONAL INTERVENTIONAL DIFFICULTIES IN
   CHILDHOOD-DIABETIC-KETOACIDOTIC(DKA)-HYPERGLYCEMIC-HYPEROSMOLAR(HHS)
   PRECOMA-COMA-STATES WITH UNUSUAL FEATURES/ASSOCIATIONS: THE ARGUMENT FOR
   A COMPREHENSIVE-SYSTEMATIC-EVALUATION OF CASES FOR A
   DIRECTED-TIMELY-APPOSITE-INTERVENTIONS
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 [Onyekwelu, E. U.] Royal Victoria Teaching Hosp, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD NOV
PY 2010
VL 68
SU 1
MA 578
BP 296
EP 297
PG 2
WC Pediatrics
SC Pediatrics
GA V25LO
UT WOS:000208479700577
OA No
DA 2017-08-15
ER

PT J
AU Onyekwelu, EU
AF Onyekwelu, E. U.
TI A CLOSER LOOK AT CRYPTOGENIC-ENCEPHALOPATHIES WITH DERANGED
   HEPATO-RENAL-MULTI- ORGANS-DYSFUNCTIONS CONSISTENT WITH REYES
   SYNDROME(RS) GUIDES SPECIFIC/INVASIVE INVESTIGATIONS/INTERVENTIONS AND
   FOLLOW UP
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 [Onyekwelu, E. U.] Royal Victoria Teaching Hosp, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD NOV
PY 2010
VL 68
SU 1
MA 605
BP 310
EP 310
PG 1
WC Pediatrics
SC Pediatrics
GA V25LO
UT WOS:000208479700604
OA No
DA 2017-08-15
ER

PT J
AU Onyekwelu, EU
AF Onyekwelu, E. U.
TI THE SPECTRUM OF COMPATIBLE LANDRY-GUILLAIN-BARRE SYNDROME IN CHILDHOOD.
   A SINGLE REFERRAL CENTRES EXPERIENCE: AN ANALYSIS OF 48 CASES
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 [Onyekwelu, E. U.] Royal Victoria Teaching Hosp, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD NOV
PY 2010
VL 68
SU 1
MA 651
BP 332
EP 333
PG 2
WC Pediatrics
SC Pediatrics
GA V25LO
UT WOS:000208479700650
OA No
DA 2017-08-15
ER

PT J
AU Onyekwelu, EU
AF Onyekwelu, E. U.
TI THE ANTECEDENTS, NATURAL HISTORY AND INTERVENTIONS OF BRACHIAL
   PLEXOPATHIES (BPS); WITH IMPLICATIONS FOR PATTERNS OF ACCIDENTAL AND
   NON-ACCIDENTAL INJURIES
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 [Onyekwelu, E. U.] Royal Victoria Teaching Hosp, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD NOV
PY 2010
VL 68
SU 1
MA 652
BP 333
EP 334
PG 2
WC Pediatrics
SC Pediatrics
GA V25LO
UT WOS:000208479700651
OA No
DA 2017-08-15
ER

PT J
AU Onyekwelu, EU
AF Onyekwelu, E. U.
TI AN OVERVIEW OF THE HETEROGENEITY AND COMPLEXITIES IN THE PATHOBIOLOGY,
   MOLECULAR MECHANISMS, NATURAL HISTORY AND INTERVENTIONS IN PAEDIATRIC
   MYASTHENIA GRAVIS(MG)
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 [Onyekwelu, E. U.] Royal Victoria Teaching Hosp, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD NOV
PY 2010
VL 68
SU 1
MA 653
BP 334
EP 334
PG 1
WC Pediatrics
SC Pediatrics
GA V25LO
UT WOS:000208479700652
OA No
DA 2017-08-15
ER

PT J
AU Onyekwelu, EU
AF Onyekwelu, E. U.
TI THE CLINICO-IMMUNOPATHO-RADIOLOGICAL SPECTRUM OF JUVENILE IDIOPATHIC
   ARTHRITIS (JIA) WITH THE INFLUENCE OF THE PRECEDENTS/ASSOCIATIONS OF ITS
   SUBTYPES ON INTERVENTIONS/OUTCOME
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 [Onyekwelu, E. U.] Royal Victoria Teaching Hosp, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD NOV
PY 2010
VL 68
SU 1
MA 847
BP 425
EP 425
PG 1
WC Pediatrics
SC Pediatrics
GA V25LO
UT WOS:000208479700846
OA No
DA 2017-08-15
ER

PT J
AU Onyekwelu, E
AF Onyekwelu, E.
CA Other Aspects Infect Dis
TI DIAGNOSTIC AND THERAPEUTIC ASPECTS OF CHILDHOOD TUBERCULOUS
   SPONDYLITIS(TBS) AND ITS DIFFERENTIALS WITH RELEVANCE TO INTERVENTIONS
   FOR ANGULAR KYPHOSIS/ABNORMAL NEUROLOGY
SO PEDIATRIC RESEARCH
LA English
DT Meeting Abstract
C1 [Onyekwelu, E.; Other Aspects Infect Dis] Royal Victoria Teaching Hosp, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
J9 PEDIATR RES
JI Pediatr. Res.
PD NOV
PY 2010
VL 68
SU 1
MA 867
BP 435
EP 435
PG 1
WC Pediatrics
SC Pediatrics
GA V25LO
UT WOS:000208479700866
OA No
DA 2017-08-15
ER

PT J
AU Harding-Esch, EM
   Edwards, T
   Mkocha, H
   Munoz, B
   Holland, MJ
   Burr, SE
   Sillah, A
   Gaydos, CA
   Stare, D
   Mabey, DCW
   Bailey, RL
   West, SK
AF Harding-Esch, Emma M.
   Edwards, Tansy
   Mkocha, Harran
   Munoz, Beatriz
   Holland, Martin J.
   Burr, Sarah E.
   Sillah, Ansumana
   Gaydos, Charlotte A.
   Stare, Dianne
   Mabey, David C. W.
   Bailey, Robin L.
   West, Sheila K.
CA PRET Partnership
TI Trachoma Prevalence and Associated Risk Factors in The Gambia and
   Tanzania: Baseline Results of a Cluster Randomised Controlled Trial
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID OCULAR CHLAMYDIAL INFECTION; FLY MUSCA-SORBENS; ACTIVE TRACHOMA;
   HOUSEHOLD DISTRIBUTION; FACIAL CLEANLINESS; AZITHROMYCIN; VILLAGE;
   STRATEGIES; PROVISION; DIAGNOSIS
AB Background: Blinding trachoma, caused by ocular infection with Chlamydia trachomatis, is targeted for global elimination by 2020. Knowledge of risk factors can help target control interventions.
   Methodology/Principal Findings: As part of a cluster randomised controlled trial, we assessed the baseline prevalence of, and risk factors for, active trachoma and ocular C. trachomatis infection in randomly selected children aged 0-5 years from 48 Gambian and 36 Tanzanian communities. Both children's eyes were examined according to the World Health Organization (WHO) simplified grading system, and an ocular swab was taken from each child's right eye and processed by Amplicor polymerase chain reaction to test for the presence of C. trachomatis DNA. Prevalence of active trachoma was 6.7% (335/5033) in The Gambia and 32.3% (1008/3122) in Tanzania. The countries' corresponding Amplicor positive prevalences were 0.8% and 21.9%. After adjustment, risk factors for follicular trachoma (TF) in both countries were ocular or nasal discharge, a low level of household head education, and being aged >= 1 year. Additional risk factors in Tanzania were flies on the child's face, being Amplicor positive, and crowding (the number of children per household). The risk factors for being Amplicor positive in Tanzania were similar to those for TF, with the exclusion of flies and crowding. In The Gambia, only ocular discharge was associated with being Amplicor positive.
   Conclusions/Significance: These results indicate that although the prevalence of active trachoma and Amplicor positives were very different between the two countries, the risk factors for active trachoma were similar but those for being Amplicor positive were different. The lack of an association between being Amplicor positive and TF in The Gambia highlights the poor correlation between the presence of trachoma clinical signs and evidence of C. trachomatis infection in this setting. Only ocular discharge was associated with evidence of C. trachomatis DNA in The Gambia, suggesting that at this low endemicity, this may be the most important risk factor.
C1 [Harding-Esch, Emma M.; Edwards, Tansy; Holland, Martin J.; Burr, Sarah E.; Mabey, David C. W.; Bailey, Robin L.] London Sch Hyg & Trop Med, Clin Res Unit, Dept Infect & Trop Dis, London WC1, England.
   [Mkocha, Harran] Kongwa Trachoma Project, Kongwa, Tanzania.
   [Munoz, Beatriz; Stare, Dianne; West, Sheila K.] Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21218 USA.
   [Holland, Martin J.; Burr, Sarah E.] MRC Labs, Banjul, Gambia.
   [Sillah, Ansumana] Gambian Dept State Hlth & Social Welf, Natl Eye Care Programme, Banjul, Gambia.
   [Gaydos, Charlotte A.] Johns Hopkins Med Inst, Div Infect Dis, Baltimore, MD 21205 USA.
RP Harding-Esch, EM (reprint author), London Sch Hyg & Trop Med, Clin Res Unit, Dept Infect & Trop Dis, London WC1, England.
EM emma.harding-esch@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276
FU Bill and Melinda Gates Foundation [48027]; Pfizer Inc through the
   International Trachoma Initiative
FX This work was supported by the Bill and Melinda Gates Foundation, grant
   number 48027. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.;
   Azithromycin was donated to the National Trachoma Control Programs of
   each country by Pfizer Inc through the International Trachoma
   Initiative. Many thanks to the laboratory at the Proctor Foundation run
   by Dr Thomas Lietman of the University of California San Francisco for
   the laboratory standardisation. We would also like to thank all the
   community leaders and children for participating in this project, and
   all the members of the PRET team.
CR Abdou A, 2007, BRIT J OPHTHALMOL, V91, P13, DOI 10.1136/bjo.2006.099507
   Baggaley RF, 2006, TROP MED INT HEALTH, V11, P220, DOI 10.1111/j.1365-3156.2005.01553.x
   BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944
   BAILEY R, 1991, T ROY SOC TROP MED H, V85, P824, DOI 10.1016/0035-9203(91)90470-J
   Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461
   BOBO L, 1991, LANCET, V338, P847, DOI 10.1016/0140-6736(91)91502-L
   BRECHNER RJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P687
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Dalesio N, 2004, J CLIN MICROBIOL, V42, P3300, DOI 10.1128/JCM.42.7.3300-3302.2004
   Dolin PJ, 1997, LANCET, V349, P1511, DOI 10.1016/S0140-6736(97)01355-X
   Edwards T, 2006, OPHTHALMOLOGY, V113, P548, DOI 10.1016/j.ophtha.2006.01.008
   Emerson PM, 2005, TROP MED INT HEALTH, V10, P706, DOI 10.1111/j.1365-3156.2005.01432.x
   Emerson PM, 2000, T ROY SOC TROP MED H, V94, P28, DOI 10.1016/S0035-9203(00)90427-9
   Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1
   Emerson PM, 2001, MED VET ENTOMOL, V15, P314, DOI 10.1046/j.0269-283x.2001.00318.x
   Faal H, 2000, BRIT J OPHTHALMOL, V84, P948, DOI 10.1136/bjo.84.9.948
   Fouad D, 2004, BRIT J OPHTHALMOL, V88, P614, DOI 10.1136/bjo.2003.026997
   Harding-Esch EM, 2008, T ROY SOC TROP MED H, V102, P1255, DOI 10.1016/j.trstmh.2008.04.022
   Harding-Esch EM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000573
   Holm SO, 2001, B WORLD HEALTH ORGAN, V79, P194
   Hsieh YH, 2000, AM J EPIDEMIOL, V152, P204, DOI 10.1093/aje/152.3.204
   *ITI, 2009, TANZ
   Kuper H, 2003, LANCET INFECT DIS, V3, P372, DOI 10.1016/S1473-3099(03)00659-5
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   Miller K, 2004, OPHTHAL EPIDEMIOL, V11, P255, DOI 10.1080/09286580490514577
   MONTGOMERY MA, 2009, T R SOC TROP MED HYG
   NGONDI J, 2009, T R SOC TROP MED HYG
   Polack SR, 2005, T ROY SOC TROP MED H, V99, P218, DOI 10.1016/j.trstmh.2004.06.010
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   Schemann JF, 2002, INT J EPIDEMIOL, V31, P194, DOI 10.1093/ije/31.1.194
   Simms VM, 2005, T ROY SOC TROP MED H, V99, P631, DOI 10.1016/j.trstmh.2004.10.004
   Solomon AW, 2008, NEW ENGL J MED, V358, P1870, DOI 10.1056/NEJMc0706263
   Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   WEST S, 1989, B WORLD HEALTH ORGAN, V67, P71
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   WEST SK, 1991, ARCH OPHTHALMOL-CHIC, V109, P855
   West SK, 1996, AM J EPIDEMIOL, V143, P73
   WEST SK, 1991, J INFECT DIS, V163, P752
   World Health Organization, 2004, 8 M WHO ALL GLOB EL
   *WHO, 2008, TRACH DAT FORM WHO A
   Wright HR, 2005, LANCET INFECT DIS, V5, P313, DOI 10.1016/S1473-3099(05)70116-X
   Zack R, 2008, T ROY SOC TROP MED H, V102, P426, DOI 10.1016/j.trstmh.2008.02.001
NR 46
TC 31
Z9 31
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2727
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD NOV
PY 2010
VL 4
IS 11
AR e861
DI 10.1371/journal.pntd.0000861
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 687GB
UT WOS:000284765900004
PM 21072224
OA gold
DA 2017-08-15
ER

PT J
AU Jaffar, S
   Lazarus, JV
   Onyebujoh, P
   Chakaya, J
   Garrib, A
   Mwaba, P
   Mboup, S
   Bellis, K
   Egwaga, S
   Corrah, T
   Coutinho, A
AF Jaffar, Shabbar
   Lazarus, Jeffrey V.
   Onyebujoh, Philip
   Chakaya, Jeremiah
   Garrib, Anupam
   Mwaba, Peter
   Mboup, Souleymane
   Bellis, Kevin
   Egwaga, Saidi
   Corrah, Tumani
   Coutinho, Alex
TI Health services strengthening in Africa - research is a key component
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Editorial Material
DE health services research; implementation research; Africa; chronic care;
   HIV; cardiovascular disease
ID MIDDLE-INCOME COUNTRIES; ANTIRETROVIRAL TREATMENT; HIV-CARE;
   HYPERTENSION; UGANDA; DELIVERY; PROGRAM; SYSTEMS; TRIAL; JINJA
C1 [Jaffar, Shabbar] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London, England.
   [Lazarus, Jeffrey V.] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland.
   [Onyebujoh, Philip] WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland.
   [Chakaya, Jeremiah] Kenya Govt Med Res Ctr, Nairobi, Kenya.
   [Garrib, Anupam] NHS Wandsworth, London, England.
   [Mwaba, Peter] Minist Hlth, Lusaka, Zambia.
   [Mboup, Souleymane] Univ Cheikh Anta Diop, Lab Bacteriol Virol, Dakar, Senegal.
   [Bellis, Kevin] HLSP, Communicable Dis, Pretoria, South Africa.
   [Egwaga, Saidi] Tanzania Minist Hlth & Social Welf, Natl TB & Leprosy Programme, Dar Es Salaam, Tanzania.
   [Corrah, Tumani] MRC, Fajara, Gambia.
   [Coutinho, Alex] Infect Dis Inst, Kampala, Uganda.
RP Jaffar, S (reprint author), London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London, England.
EM shabbar.jaffar@lshtm.ac.uk
OI Lazarus, Jeffrey/0000-0001-9618-2299
CR Addo J, 2007, HYPERTENSION, V50, P1012, DOI 10.1161/HYPERTENSIONAHA.107.093336
   Aikins AD, 2010, GLOBALIZATION HEALTH, V6, DOI 10.1186/1744-8603-6-5
   Amuron B, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-290
   Anyangwe Stella C E, 2007, Int J Environ Res Public Health, V4, P93, DOI 10.3390/ijerph2007040002
   Assefa Y, 2010, CURR OPIN HIV AIDS, V5, P78, DOI 10.1097/COH.0b013e328333b87a
   Brown MJ, 2006, BRIT MED J, V332, P833, DOI 10.1136/bmj.332.7545.833
   Callaghan M, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-8
   Haines A, 2004, B WORLD HEALTH ORGAN, V82, P724
   Hardon AP, 2007, AIDS CARE, V19, P658, DOI 10.1080/09540120701244943
   Harries AD, 2010, LANCET, V375, P1906, DOI 10.1016/S0140-6736(10)60409-6
   Hongoro C, 2004, LANCET, V364, P1451, DOI 10.1016/S0140-6736(04)17229-2
   Jaffar S, 2008, TROP MED INT HEALTH, V13, P795, DOI 10.1111/j.1365-3156.2008.02068.x
   Jaffar S, 2009, LANCET, V374, P2080, DOI 10.1016/S0140-6736(09)61674-3
   Lewin S, 2008, LANCET, V372, P928, DOI 10.1016/S0140-6736(08)61403-8
   Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9
   Mathers CD, 2009, BRIT MED BULL, V92, P7, DOI 10.1093/bmb/ldp028
   Mayosi BM, 2009, LANCET, V374, P934, DOI 10.1016/S0140-6736(09)61087-4
   Mgone CS, 2009, TROP MED INT HEALTH, V14, P1327, DOI 10.1111/j.1365-3156.2009.02391.x
   Miranda JJ, 2008, TROP MED INT HEALTH, V13, P1225, DOI 10.1111/j.1365-3156.2008.02116.x
   Ntusi Ntobeko B A, 2009, Expert Rev Cardiovasc Ther, V7, P169, DOI 10.1586/14779072.7.2.169
   Opie LH, 2005, CIRCULATION, V112, P3562, DOI 10.1161/CIRCULATIONAHA.105.539569
   Sanne I, 2010, LANCET, V376, P33, DOI 10.1016/S0140-6736(10)60894-X
   UK Clinical Research Collaborative, 2006, UK HLTH RES AN
   UNAIDS, 2009, AIDS EP UPD
   Van Damme W, 2008, SOC SCI MED, V66, P2108, DOI 10.1016/j.socscimed.2008.01.043
   Ware NC, 2009, PLOS MED, V6, P39, DOI 10.1371/journal.pmed.1000011
   World Health Organization, 2009, GLOB TUB CONTR SHORT
   World Health Organization, 2008, WORLD HLTH REP PRIM
   [World Heath Organisation (WHO) UNAIDS UNICEF], 2008, UN ACC SCAL UP PRIOR
   Zachariah R, 2009, T ROY SOC TROP MED H, V103, P549, DOI 10.1016/j.trstmh.2008.09.019
NR 30
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD NOV
PY 2010
VL 15
IS 11
BP 1270
EP 1273
DI 10.1111/j.1365-3156.2010.02626.x
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 667CA
UT WOS:000283169000001
PM 20731794
OA No
DA 2017-08-15
ER

PT J
AU de Silva, TI
   Turner, R
   Hue, S
   Trikha, R
   van Tienen, C
   Onyango, C
   Jaye, A
   Foley, B
   Whittle, H
   Rowland-Jones, SL
   Cotten, M
AF de Silva, Thushan I.
   Turner, Roxanne
   Hue, Stephane
   Trikha, Roochi
   van Tienen, Carla
   Onyango, Clayton
   Jaye, Assan
   Foley, Brian
   Whittle, Hilton
   Rowland-Jones, Sarah L.
   Cotten, Matthew
TI HIV-1 subtype distribution in the Gambia and the significant presence of
   CRF49_cpx, a novel circulating recombinant form
SO RETROVIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; DISEASE PROGRESSION; MOLECULAR
   EPIDEMIOLOGY; CENTRAL-AFRICA; SEQUENCE; SURVEILLANCE; DIVERSITY;
   INFECTION; COMPLEX; SENEGAL
AB Background: Detailed local HIV-1 sequence data are essential for monitoring the HIV epidemic, for maintaining sensitive sequence-based diagnostics, and to aid in designing vaccines.
   Results: Reported here are full envelope sequences derived from 38 randomly selected HIV-1 infections identified at a Gambian clinic between 1991 and 2009. Special care was taken to generate sequences from circulating viral RNA as uncloned products, either by limiting dilution or single genome amplification polymerase chain reaction (PCR). Within these 38 isolates, eight were subtyped as A and 18 as CRF02_AG. A small number of subtype B, C, D viruses were identified. Surprising, however, was the identification of six isolates with subtype J-like envelopes, a subtype found normally in Central Africa and the Democratic Republic of the Congo (DRC), with gag p24 regions that clustered with subtype A sequences. Near full-length sequence from three of these isolates confirmed that these represent a novel circulating recombinant form of HIV-1, now named CRF49_cpx.
   Conclusions: This study expands the HIV-1 sequence database from the Gambia and will provide important data for HIV diagnostics, patient care, and vaccine development.
C1 [de Silva, Thushan I.; Turner, Roxanne; Trikha, Roochi; van Tienen, Carla; Onyango, Clayton; Jaye, Assan; Whittle, Hilton; Cotten, Matthew] Med Res Council UK Labs, Fajara, Gambia.
   [de Silva, Thushan I.; Hue, Stephane] UCL, MRC UCL Ctr Med Mol Virol, Div Infect & Immun, London WC1E 6BT, England.
   [Rowland-Jones, Sarah L.] John Radcliffe Hosp, Human Immunol Unit, MRC, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
   [Foley, Brian] Los Alamos Natl Lab, Los Alamos, NM 87545 USA.
RP Cotten, M (reprint author), Med Res Council UK Labs, Atlantic Rd,POB 273, Fajara, Gambia.
EM matt.cotten@web.de
RI van Tienen, Carla/A-1119-2012
OI Hue, Stephane/0000-0002-8580-6905; Foley, Brian/0000-0002-1086-0296
FU Medical Research Council (UK)
FX TdS is supported by a Medical Research Council (UK) Clinical Research
   Training Fellowship. We would like to thank the patients and staff at
   the MRC (UK) Fajara Genitourinary Medicine (GUM) clinic for their
   participation in the HIV cohort, which made this study possible.
CR Abecasis AB, 2001, INFECT GENET EVOL, V10, P380
   Abecasis AB, 2007, J VIROL, V81, P8543, DOI 10.1128/JVI.00463-07
   Abraha A, 2009, J VIROL, V83, P5592, DOI 10.1128/JVI.02051-08
   Baeten JM, 2007, J INFECT DIS, V195, P1177, DOI 10.1086/512682
   BAROUCH DH, 2001, NAT MED, V16, P319
   Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004
   Bobkov A, 1996, AIDS RES HUM RETROV, V12, P169, DOI 10.1089/aid.1996.12.169
   Carr JK, 1998, VIROLOGY, V247, P22, DOI 10.1006/viro.1998.9211
   Cham F, 2000, AIDS RES HUM RETROV, V16, P1915, DOI 10.1089/08892220050195874
   FELSENSTEIN J, 1973, AM J HUM GENET, V25, P471
   HALL MG, 1999, NUCL ACIDS S SER, V41, P95
   Hamel DJ, 2007, AIDS RES HUM RETROV, V23, P1189, DOI 10.1089/aid.2007.0037
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   Invernizzi CF, 2009, J INFECT DIS, V200, P1202, DOI 10.1086/605894
   Kaleebu P, 2002, J INFECT DIS, V185, P1244, DOI 10.1086/340130
   Kanki PJ, 1999, J INFECT DIS, V179, P68, DOI 10.1086/314557
   Kiwanuka N, 2008, J INFECT DIS, V197, P707, DOI 10.1086/527416
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Laurent C, 2002, J INFECT DIS, V186, P486, DOI 10.1086/341833
   Lole KS, 1999, J VIROL, V73, P152
   Martinez-Cajas JL, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-11
   Meloni ST, 2004, J VIROL, V78, P12455, DOI 10.1128/JVI.78.22.12455-12461.2004
   Meloni ST, 2004, J VIROL, V78, P12438, DOI 10.1128/JVI.78.22.12438-12445.2004
   NDIAYE HD, 2009, J ACQUIR IMMUNE DEFI
   Njai HF, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-40
   Novitsky VA, 2000, AIDS RES HUM RETROV, V16, P1015, DOI 10.1089/08892220050058434
   Ping LH, 1999, J VIROL, V73, P6271
   Salazar-Gonzalez JF, 2008, J VIROL, V82, P3952, DOI 10.1128/JVI.02660-07
   SANTRA S, 2008, NAT MED, V16, P324
   Stothard P, 2000, BIOTECHNIQUES, V28, P1102
   Tscherning C, 1998, VIROLOGY, V241, P181, DOI 10.1006/viro.1997.8980
   van der Loeff MFS, 2006, INT J EPIDEMIOL, V35, P1322, DOI 10.1093/ije/dy1037
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   Vidal N, 2000, J VIROL, V74, P10498, DOI 10.1128/JVI.74.22.10498-10507.2000
   YANG ZB, 1994, J MOL EVOL, V39, P105
   Zhang M, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-25
   EBI CLUSTALW2
   LOS ALAMOS HIV DATAB
   PHYLOGENETIC ANAL US
   GAMBIAN 2003 CENSUS
   SEQUENCE MANIPULATIO
   [Anonymous], BIOEDIT
NR 42
TC 9
Z9 9
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD OCT 9
PY 2010
VL 7
AR 82
DI 10.1186/1742-4690-7-82
PG 14
WC Virology
SC Virology
GA 670JZ
UT WOS:000283419000001
PM 20932333
OA gold
DA 2017-08-15
ER

PT J
AU Hawkesworth, S
   Sawo, Y
   Fulford, AJC
   Goldberg, GR
   Jarjou, LMA
   Prentice, A
   Moore, SE
AF Hawkesworth, Sophie
   Sawo, Yankuba
   Fulford, Anthony J. C.
   Goldberg, Gail R.
   Jarjou, Landing M. A.
   Prentice, Ann
   Moore, Sophie E.
TI Effect of maternal calcium supplementation on offspring blood pressure
   in 5-to 10-y-old rural Gambian children
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; FOLLOW-UP; BODY-COMPOSITION; BIRTH-WEIGHT;
   PREGNANCY; WOMEN; INFANT; GROWTH; AGE; EDUCATION
AB Background: Evidence suggests that increased maternal calcium intake during pregnancy may result in lower offspring blood pressure, prompting calls for more robust data in this field, particularly in settings of habitually low calcium intake.
   Objective: The objective was to investigate the effect of maternal calcium supplementation on blood pressure in offspring by recruiting children born after a randomized, double-blind, placebo-controlled trial of calcium supplementation during pregnancy.
   Design: Children (n = 389) from a rural area of The Gambia (mean age: 7.4 +/- 1.2 y; range: 5-10 y), whose mothers received a calcium supplement (1500 mg Ca/d from 20 wk of gestation until delivery) or placebo, were followed up in West Africa. Blood pressure was assessed under standardized conditions with use of the Omron 705IT automated oscillometric device (Morton Medical Ltd, London, United Kingdom), and anthropometric and body composition (bioelectrical impedance) measurements were also made.
   Results: The analysis was restricted to 350 children born at term, which represented 64% of original trial births. There was no difference in systolic (adjusted mean difference: -0.04 mm Hg; 95% CI: -1.78, 1.69 mm Hg) or diastolic (adjusted mean difference: 0.25 mm Hg; 95% CI: -1.27, 1.77 mm Hg) blood pressure between children whose mothers had received calcium and those who received placebo. No interaction between childhood body mass index (in kg/m(2); mean: 14.0) and maternal calcium supplementation was observed in this study.
   Conclusion: Calcium supplementation in the second half of pregnancy in Gambian women with very low habitual calcium intakes may not result in lower offspring blood pressure at 5-10 y of age. Am J Clin Nutr 2010;92:741-7.
C1 [Hawkesworth, Sophie] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Nutr & Publ Hlth Intervent Res Unit, MRC,Int Nutr Grp, London WC1E 7HT, England.
   [Sawo, Yankuba; Fulford, Anthony J. C.; Goldberg, Gail R.; Jarjou, Landing M. A.; Prentice, Ann; Moore, Sophie E.] MRC Labs, Med Res Council Keneba, Fajara, Gambia.
   [Goldberg, Gail R.; Prentice, Ann] Med Res Council Human Nutr Res, Elsie Widdowson Lab, Cambridge, England.
RP Hawkesworth, S (reprint author), London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Nutr & Publ Hlth Intervent Res Unit, MRC,Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM sophie.hawkesworth@lshtm.ac.uk
OI Hawkesworth, Sophie/0000-0002-3554-242X
FU European Union [FOOD-CT-2005-007036]; UK Medical Research Council
FX Supported by the European Union Sixth Framework Programme for Research
   and Technical Development of the European Union Community "Early
   Nutrition Programming Project" (FOOD-CT-2005-007036) and the UK Medical
   Research Council.
CR Bakker R, 2008, AM J EPIDEMIOL, V168, P1374, DOI 10.1093/aje/kwn258
   Belizan JM, 1997, BRIT MED J, V315, P281
   Bergel E, 2002, BJOG-INT J OBSTET GY, V109, P540
   Bergel Eduardo, 2007, BMC Pediatr, V7, P15, DOI 10.1186/1471-2431-7-15
   COLE TJ, 1990, EUR J CLIN NUTR, V44, P45
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   Falkner B, 1996, PEDIATRICS, V98, P649
   Fewtrell MS, 2008, ARCH DIS CHILD, V93, P458, DOI 10.1136/adc.2007.127316
   Gillman MW, 2004, CIRCULATION, V110, P1990, DOI 10.1161/01.CIR.0000143199.93495.96
   Hatton DC, 2003, AM J HYPERTENS, V16, P801, DOI 10.1016/S0895-7061(03)01027-6
   Hawkesworth S, 2008, J NUTR, V138, P2468, DOI 10.3945/jn.108.098665
   Hiller JE, 2007, AUST NZ J OBSTET GYN, V47, P115, DOI 10.1111/j.1479-828X.2007.00696.x
   Hofmeyr GJ, 2007, BJOG-INT J OBSTET GY, V114, P933, DOI 10.1111/j.1471-0528.2007.01389.x
   Huxley RR, 2000, J HYPERTENS, V18, P815, DOI 10.1097/00004872-200018070-00002
   Jarjou LM, 2006, AM J CLIN NUTR, V83, P657
   Law CM, 1996, J HYPERTENS, V14, P935
   MCGARVEY ST, 1991, HYPERTENSION, V17, P218
   Morley R, 2004, INT J EPIDEMIOL, V33, P1304, DOI 10.1093/ije/dyh284
   Pickering TG, 2005, CIRCULATION, V111, P697, DOI 10.1161/01.CIR.0000154900.76284.F6
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   PRENTICE A, 1994, ADV EXP MED BIOL, V352, P243
   Prentice A, 2000, AM J CLIN NUTR, V71, p1312S
   Prins M, 2008, EUR J CLIN NUTR, V62, P1065, DOI 10.1038/sj.ejcn.1602830
   van Mierlo LAJ, 2006, J HUM HYPERTENS, V20, P571, DOI 10.1038/sj.jhh.1002038
   Wells JCK, 2002, INT J OBESITY, V26, P947, DOI 10.1038/sj.ijo.0802027
NR 25
TC 15
Z9 15
U1 0
U2 4
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD OCT
PY 2010
VL 92
IS 4
BP 741
EP 747
DI 10.3945/ajcn.2010.29475
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 655FU
UT WOS:000282234100010
PM 20668051
OA No
DA 2017-08-15
ER

PT J
AU Prentice, S
   Fulford, AJ
   Jarjou, LMA
   Goldberg, GR
   Prentice, A
AF Prentice, Sarah
   Fulford, Antony J.
   Jarjou, Landing M. A.
   Goldberg, Gail R.
   Prentice, Ann
TI Evidence for a downward secular trend in age of menarche in a rural
   Gambian population
SO ANNALS OF HUMAN BIOLOGY
LA English
DT Article
DE Menarche; age; Gambia; secular trend; interval regression
ID ADOLESCENT GIRLS; HYPOTHESIS; AFRICA
AB Menarcheal age is a key indicator of female maturity and development. Studies in many countries have reported a downward secular trend in age of menarche over the past century. This study presents data gained using the 'status quo' method and interval regression to estimate median menarcheal age of girls in a rural Gambian community. Cross-sectional studies carried out in 1989, 2000 and 2008 revealed a median menarcheal age of 16.06 (95% CI 15.67-16.45), 15.03 (95% CI 14.76-15.30) and 14.90 (95% CI 14.52-15.28), respectively. The average rate of decline of median age of menarche was amongst the most rapid yet reported, at 0.65 years of age per decade (p < 0.00001). There was no evidence for a change in the rate of decline over the two decades studied. These results probably reflect ongoing socio-economic development within the region.
C1 [Prentice, Sarah; Jarjou, Landing M. A.; Goldberg, Gail R.; Prentice, Ann] MRC Keneba, Banjul, Gambia.
   [Prentice, Sarah; Goldberg, Gail R.; Prentice, Ann] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge, England.
   [Fulford, Antony J.] London Sch Hyg & Trop Med, Nutr & Publ Hlth Intervent Res Unit, MRC Int Nutr Grp, London WC1, England.
RP Prentice, S (reprint author), MRC Keneba, POB 273, Banjul, Gambia.
EM rubach99@yahoo.com
FU UK Medical Research Council
FX All the authors were funded by the UK Medical Research Council. The
   authors report no conflicts of interest. The authors alone are
   responsible for the content and writing of the paper.
CR Adanu R M K, 2006, J Obstet Gynaecol, V26, P550, DOI 10.1080/01443610600811425
   Apraiz AG, 1999, AM J HUM BIOL, V11, P779, DOI 10.1002/(SICI)1520-6300(199911/12)11:6<779::AID-AJHB8>3.0.CO;2-7
   CHO GJ, 2009, EUR J PAEDIAT, DOI DOI 10.1007/S00431-009-0993-0991
   FRISCH RE, 1971, ARCH DIS CHILD, V46, P695
   Garnier D, 2005, AM J HUM BIOL, V17, P718, DOI 10.1002/ajhb.20435
   Gonzales GF, 1996, AM J HUM BIOL, V8, P457, DOI 10.1002/(SICI)1520-6300(1996)8:4<457::AID-AJHB5>3.0.CO;2-V
   Jones LL, 2009, AM J HUM BIOL, V21, P130, DOI 10.1002/ajhb.20836
   LIESTOL K, 1982, ANN HUM BIOL, V9, P521, DOI 10.1080/03014468200006051
   Loesch DZ, 1995, ANN HUM BIOL, V22, P479, DOI 10.1080/03014469500004152
   Loukid M, 1996, ANN HUM BIOL, V23, P333, DOI 10.1080/03014469600004562
   MALINA RM, 1983, ANN HUM BIOL, V10, P1, DOI 10.1080/03014468300006141
   Padez C, 2003, ANN HUM BIOL, V30, P487, DOI 10.1080/0301446031000111401
   Pasquet P, 1999, ANN HUM BIOL, V26, P89, DOI 10.1080/030144699283001
   Pawloski LR, 2002, AM J PHYS ANTHROPOL, V117, P364, DOI 10.1002/ajpa.10037
   Simondon KB, 1997, ANN HUM BIOL, V24, P521, DOI 10.1080/03014469700005282
   Thomas F, 2001, HUM BIOL, V73, P271, DOI 10.1353/hub.2001.0029
   Whincup PH, 2001, BRIT MED J, V322, P1095, DOI 10.1136/bmj.322.7294.1095
   2008, HUMAN DEV REPORTS
NR 18
TC 12
Z9 15
U1 1
U2 8
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0301-4460
J9 ANN HUM BIOL
JI Ann. Hum. Biol.
PD OCT
PY 2010
VL 37
IS 5
BP 717
EP 721
DI 10.3109/03014461003727606
PG 5
WC Anthropology; Biology; Public, Environmental & Occupational Health
SC Anthropology; Life Sciences & Biomedicine - Other Topics; Public,
   Environmental & Occupational Health
GA 663PV
UT WOS:000282900800009
PM 20465526
OA No
DA 2017-08-15
ER

PT J
AU Rajak, SN
   Makalo, P
   Sillah, A
   Holland, MJ
   Mabey, DCW
   Bailey, RL
   Burton, MJ
AF Rajak, Saul N.
   Makalo, Pateh
   Sillah, Ansumana
   Holland, Martin J.
   Mabey, David C. W.
   Bailey, Robin L.
   Burton, Matthew J.
TI Trichiasis Surgery in The Gambia: A 4-Year Prospective Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CHLAMYDIA-TRACHOMATIS INFECTION; BILAMELLAR TARSAL ROTATION;
   RANDOMIZED-TRIAL; RISK-FACTORS; RECURRENCE; AZITHROMYCIN; COMPLICATIONS;
   ENTROPION; BLINDNESS; SEQUELAE
AB PURPOSE. Trachoma is the leading infectious cause of blindness. Conjunctival Chlamydia trachomatis infection causes scarring, entropion, trichiasis, and blinding corneal opacification. Worldwide, there are 8 million people with trichiasis. Although trichiasis surgery can reduce the risk of blindness, retrospective data suggest that long-term recurrence rates may be high. A 4-year prospective investigation of recurrent trichiasis was conducted in The Gambia.
   METHODS. Patients with trichiasis were examined at baseline, 6 months, 1 year, and 4 years after posterior lamellar tarsal rotation surgery. Conjunctival swabs for bacteriology and PCR for C. trachomatis were collected at baseline, 6 months, and 1 year.
   RESULTS. Three hundred fifty-six Gambian patients were enrolled at baseline and 266 were reassessed at 4 years (94% of surviving patients). The recurrence rates were 32%, 40%, and 41% at 6 months, 1 year, and 4 years, respectively. At 4 years, 30% of patients had bilateral trichiasis and 21% had bilateral corneal opacity. Recurrence was associated with severe conjunctival inflammation and severe trichiasis (>10 lashes) at baseline.
   CONCLUSIONS. Trichiasis recurrence rates were high, and most cases recurred within 6 months of surgery. The results suggest that there are important aspects of surgical technique and quality that should to be addressed. Persistent inflammation is strongly associated with recurrence at 4 years. (Invest Ophthalmol Vis Sci. 2010;51:4996-5001) DOI:10.1167/iovs.105169
C1 [Rajak, Saul N.] Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Dept Infect & Trop Dis, London WC1E 7HT, England.
   [Sillah, Ansumana] Natl Eye Care Programme, Banjul, Gambia.
   [Makalo, Pateh; Holland, Martin J.] MRC Labs, Fajara, Gambia.
RP Rajak, SN (reprint author), Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM saul.rajak@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169
FU International Trachoma Initiative [01-030]; Wellcome Trust [059134,
   080741/Z/06/Z]; Band Aid Foundation/Fight for Sight
FX Supported principally by Grant 01-030 from the International Trachoma
   Initiative with the addition of Grant 059134 from the Wellcome
   Trust/Burroughs Wellcome Fund. MJB is supported by Grant 080741/Z/06/Z
   from the Wellcome Trust and SNR by the Band Aid Foundation/Fight for
   Sight. The funders had no part in the study design; in the collection,
   analysis, and interpretation of data; in the writing of the report; or
   in the decision to submit the paper for publication.
CR Adamu Y, 2002, ETHIOPIAN MED J, V40, P107
   Alemayehu W, 2004, OPHTHALMOLOGY, V111, P578, DOI 10.1016/j.ophtha.2003.06.030
   ALRAJHI AA, 1993, OPHTHALMOLOGY, V100, P1293
   BLODI BA, 1988, INT OPHTHALMOL, V12, P41, DOI 10.1007/BF00133780
   BOG H, 1993, BRIT J OPHTHALMOL, V77, P81, DOI 10.1136/bjo.77.2.81
   Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P1282, DOI 10.1136/bjo.2004.062489
   Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P575, DOI 10.1136/bjo.2004.055996
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   el Toukhy E, 2006, OPHTHAL PLAST RECONS, V22, P109, DOI 10.1097/01.iop.0000203494.49446.60
   ELRAKHAWY KE, 1988, INT OPHTHALMOL, V12, P31, DOI 10.1007/BF00133778
   Guzey M, 2001, EYE, V15, P297
   Khandekar R, 2001, Ophthalmic Epidemiol, V8, P155, DOI 10.1076/opep.8.2.155.4165
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   Merbs SL, 2005, OPHTHALMOLOGY, V112, P705, DOI 10.1016/j.ophtha.2004.10.037
   NASR AM, 1989, OPHTHALMIC SURG LAS, V20, P800
   Natividad A, 2007, GENES IMMUN, V8, P288, DOI 10.1038/sj.gene.6364384
   Natividad A, 2005, GENES IMMUN, V6, P332, DOI 10.1038/sj.gene.6364182
   Natividad A, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-40
   Rangwala A T, 1981, Indian J Ophthalmol, V29, P297
   Reacher NI, 1993, WHOPBL9329
   Reacher M H, 1990, Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique, V67, P233
   REACHER MH, 1992, ARCH OPHTHALMOL-CHIC, V110, P667
   REACHER MH, 1990, BRIT J OPHTHALMOL, V74, P109, DOI 10.1136/bjo.74.2.109
   Rosser DA, 2001, BRIT J OPHTHALMOL, V85, P432, DOI 10.1136/bjo.85.4.432
   TABBARA KF, 1980, OPHTHALMOLOGY, V87, P298
   Thanh TTK, 2004, BRIT J OPHTHALMOL, V88, P1114, DOI 10.1136/bjo.2003.039834
   West ES, 2005, INVEST OPHTH VIS SCI, V46, P447, DOI 10.1167/iovs.04-0600
   West SK, 2006, ARCH OPHTHALMOL-CHIC, V124, P309, DOI 10.1001/archopht.124.3.309
   *WHO, 1997, GLOB SCI M GEN JUN 1
   Win N, 1976, Rev Int Trach Pathol Ocul Trop Subtrop, V53, P111
   Woreta TA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1505, DOI 10.1001/archophthalmol.2009.278
   Zhang H, 2006, BRIT J OPHTHALMOL, V90, P943, DOI 10.1136/bjo.2006.093104
   Zhang H, 2004, ARCH OPHTHALMOL-CHIC, V122, P511, DOI 10.1001/archopht.122.4.511
NR 33
TC 19
Z9 19
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2010
VL 51
IS 10
BP 4996
EP 5001
DI 10.1167/iovs.10-5169
PG 6
WC Ophthalmology
SC Ophthalmology
GA 655UI
UT WOS:000282275500018
PM 20505197
OA No
DA 2017-08-15
ER

PT J
AU Hill, PC
   Ota, MOC
AF Hill, Philip C.
   Ota, Martin O. C.
TI Tuberculosis case-contact research in endemic tropical settings: design,
   conduct, and relevance to other infectious diseases
SO LANCET INFECTIOUS DISEASES
LA English
DT Review
ID INVASIVE PNEUMOCOCCAL DISEASE; SMEAR-POSITIVE TUBERCULOSIS; LINKED
   IMMUNOSPOT ASSAY; MYCOBACTERIUM-TUBERCULOSIS; HOUSEHOLD CONTACTS;
   STREPTOCOCCUS-PNEUMONIAE; PULMONARY TUBERCULOSIS; MENINGOCOCCAL DISEASE;
   RISK-FACTORS; SKIN-TEST
AB The study of the contacts of patients with tuberculosis has a long history. Where tuberculosis is endemic, regular recruitment of tuberculosis cases and their household contacts can be done for research and strategic intervention. This recruitment provides a platform whereby host, pathogen, and environmental factors related to tuberculosis can be investigated and new interventions can be assessed. We describe the types of study possible within a tuberculosis case-contact study platform and its essential components, including recruitment and follow-up of the patients with tuberculosis, their household contacts and community controls, assessments and sampling, and data management and processing. Sample handling and storage, local engagement, ethical challenges, and the strengths and weaknesses of study design are all important issues in case-contact research. A case-contact study platform is a powerful research tool to answer fundamental questions in tuberculosis and has relevance to the study of other major infectious diseases.
C1 [Hill, Philip C.] Univ Otago, Sch Med, Ctr Int Hlth, Dept Prevent & Social Med, Dunedin, New Zealand.
   [Ota, Martin O. C.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
RP Hill, PC (reprint author), Univ Otago, Sch Med, Ctr Int Hlth, Dept Prevent & Social Med, Dunedin, New Zealand.
EM philip.hill@otago.ac.nz
FU Medical Research Council [MC_U190071468]
CR Acosta CJ, 2007, VACCINE, V25, P2852, DOI 10.1016/j.vaccine.2006.09.079
   Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   Adetifa IMO, 2007, INT J TUBERC LUNG D, V11, P350
   ADETIFA IM, 2008, INT J LAB HEMATOL, V31, P615
   Aiken AM, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-66
   Angell M, 2000, NEW ENGL J MED, V342, P967, DOI 10.1056/NEJM200003303421309
   Antonio M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-198
   Aulchenko YS, 2007, BIOINFORMATICS, V23, P1294, DOI 10.1093/bioinformatics/btm108
   Baker M G, 2001, J Paediatr Child Health, V37, pS13
   Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897
   Brailey M, 1940, AM J PUBLIC HEALTH N, V30, P816, DOI 10.2105/AJPH.30.7.816
   Burl S, 2007, CLIN EXP IMMUNOL, V149, P117, DOI 10.1111/j.1365-2249.2007.03399.x
   Centers for Disease Control and Prevention (CDC), 2000, MMWR-MORBID MORTAL W, V49, P685
   Cehovin A, 2007, CLIN VACCINE IMMUNOL, V14, P796, DOI 10.1128/CVI.00093-07
   CHAPMAN JS, 1964, AM REV RESPIR DIS, V90, P48
   Chocano-Bedoya P, 2009, NUTR REV, V67, P289, DOI 10.1111/j.1753-4887.2009.00195.x
   Choi Y, 2009, GENET EPIDEMIOL, V33, P668, DOI 10.1002/gepi.20418
   Comstock GW, 1999, INT J TUBERC LUNG D, V3, P847
   COOKE RPD, 1989, BRIT MED J, V298, P555
   Corbett EL, 2007, PLOS MED, V4, P164, DOI 10.1371/journal.pmed.0040022
   Crampin AC, 2001, T ROY SOC TROP MED H, V95, P481, DOI 10.1016/S0035-9203(01)90009-4
   de Jong BC, 2007, INT J TUBERC LUNG D, V11, P450
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977
   de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504
   de Jong BC, 2009, J CLIN MICROBIOL, V47, P994, DOI 10.1128/JCM.01216-08
   Diaz R, 1998, INT J TUBERC LUNG D, V2, P743
   Doherty TM, 2005, J IMMUNOL METHODS, V298, P129, DOI 10.1016/j.jim.2005.01.013
   Dye C, 2008, J R SOC INTERFACE, V5, P653, DOI 10.1098/rsif.2007.1138
   Dyet KH, 2006, EPIDEMIOL INFECT, V134, P377, DOI 10.1017/S0950268805004954
   Eastwood SV, 2004, INT J TUBERC LUNG D, V8, P70
   Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192
   Fennelly KP, 2004, AM J RESP CRIT CARE, V169, P604, DOI 10.1164/rccm.200308-1101OC
   Floyd S, 2000, INT J TUBERC LUNG D, V4, P1133
   Frost WH, 1933, AM J PUBLIC HEALTH N, V23, P426, DOI 10.2105/AJPH.23.5.426
   GIBSON RS, 1984, SCI TOTAL ENVIRON, V39, P93, DOI 10.1016/0048-9697(84)90027-5
   Godfrey-Faussett R, 2002, INT J TUBERC LUNG D, V6, P796
   Gopinath K, 2009, INT J INFECT DIS, V13, P374, DOI 10.1016/j.ijid.2008.07.022
   GRAUBARD BI, 1994, STAT MED, V13, P509, DOI 10.1002/sim.4780130514
   GRAY BM, 1980, J INFECT DIS, V142, P923
   GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007
   Gustafson P, 2007, EPIDEMIOLOGY, V18, P340, DOI 10.1097/01.ede.0000259987.46912.2b
   Guwatudde D, 2003, AM J EPIDEMIOL, V158, P887, DOI 10.1093/aje/kwg227
   Hammond AS, 2008, J INFECT DIS, V197, P295, DOI 10.1086/524685
   Harper M, 2003, T ROY SOC TROP MED H, V97, P506, DOI 10.1016/S0035-9203(03)80007-X
   HENDLEY JO, 1975, J INFECT DIS, V132, P55
   Hesseling AC, 2002, INT J TUBERC LUNG D, V6, P1038
   Hill PC, 2005, J CLIN MICROBIOL, V43, P2070, DOI 10.1128/JCM.43.5.2070-2074.2005
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Hill PC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001379
   Hill PC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000183
   Hill PC, 2007, PLOS MED, V4, P1061, DOI 10.1371/journal.pmed.0040192
   Hill PC, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000068
   Hill PC, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-156
   Hill RC, 2005, INT J TUBERC LUNG D, V9, P1349
   Hjuler T, 2008, AM J EPIDEMIOL, V167, P814, DOI 10.1093/aje/kwm376
   Jackson-Sillah D, 2007, T ROY SOC TROP MED H, V101, P594, DOI 10.1016/j.trstmh.2007.02.001
   Jasmer RM, 2002, ANN INTERN MED, V137, P640
   Jeffries DJ, 2004, INT J TUBERC LUNG D, V8, P1095
   Johnson JL, 2001, AIDS, V15, P2137, DOI 10.1097/00002030-200111090-00009
   Kasse Y, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-143
   Kaufmann SHE, 2008, CELL HOST MICROBE, V4, P219, DOI 10.1016/j.chom.2008.08.002
   Keeler Emmett, 2006, Nature, V444 Suppl 1, P49, DOI 10.1038/nature05446
   Kruk A, 2008, PEDIATRICS, V121, pE1646, DOI 10.1542/peds.2007-3138
   Lawn SD, 2009, AIDS, V23, P1717, DOI 10.1097/QAD.0b013e32832d3b6d
   Lienhardt C, 2005, INT J EPIDEMIOL, V34, P914, DOI 10.1093/ije/dyi100
   Lienhardt C, 2003, PEDIATRICS, V111, pE608, DOI 10.1542/peds.111.5.e608
   Lienhardt C, 2002, EUR J IMMUNOL, V32, P1605, DOI 10.1002/1521-4141(200206)32:6<1605::AID-IMMU1605>3.0.CO;2-6
   Lim HJ, 2006, HIV CLIN TRIALS, V7, P172, DOI 10.1310/hct0704-172
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   Maher D, 2006, INT J TUBERC LUNG D, V10, P1091
   Marais BJ, 2006, ARCH DIS CHILD, V91, P762, DOI 10.1136/adc.2006.097220
   Marais BJ, 2009, J CLIN MICROBIOL, V47, P1338, DOI 10.1128/JCM.02490-08
   Marais BJ, 2006, PEDIATRICS, V118, pE1350, DOI 10.1542/peds.2006-0519
   Marais BJ, 2006, AM J RESP CRIT CARE, V173, P1078, DOI 10.1164/rccm.200511-1809SO
   Marais BJ, 2004, INT J TUBERC LUNG D, V8, P392
   MARKS MI, 1979, AM J EPIDEMIOL, V109, P563
   Martineau AR, 2007, J CLIN INVEST, V117, P1988, DOI 10.1172/JCI31097
   McPhedran FM, 1935, AM J HYG, V22, P565
   Meningococcal Disease Surveillance Group, 1976, J INFECT DIS, V134, P201
   Menzies D, 1999, AM J RESP CRIT CARE, V159, P15
   Mudido PM, 1999, INT J TUBERC LUNG D, V3, P891
   OLCEN P, 1981, SCAND J INFECT DIS, V13, P105
   Olesen R, 2007, GENES IMMUN, V8, P456, DOI 10.1038/sj.gene.6364410
   Pai M, 2009, INT J TUBERC LUNG D, V13, P84
   Pai M, 2010, NAT REV MICROBIOL, V8, P242, DOI 10.1038/nrmicro2236-c1
   Pakasi TA, 2009, EUR J CLIN NUTR, V63, P1130, DOI 10.1038/ejcn.2009.25
   PALMER CE, 1967, ARCH ENVIRON HEALTH, V15, P792
   Purcell B, 2004, BRIT MED J, V328, P1339, DOI 10.1136/bmj.328.7452.1339
   Rathman G, 2003, INT J TUBERC LUNG D, V7, P942
   RIEDO FX, 1995, PEDIATR INFECT DIS J, V14, P643, DOI 10.1097/00006454-199508000-00001
   ROUILLON A, 1976, TUBERCLE, V57, P275
   SHAW JB, 1954, AM REV TUBERC PULM, V69, P724
   Shimada J, 2002, J CLIN MICROBIOL, V40, P1851, DOI 10.1128/JCM.40.5.1851-1853.2002
   Simmons G, 2001, EUR J CLIN MICROBIOL, V20, P237, DOI 10.1007/s10096-001-8093-9
   Sleeman KL, 2005, PEDIATR INFECT DIS J, V24, P121, DOI 10.1097/01.inf.0000151030.10159.b1
   Sonnenberg P, 2005, J INFECT DIS, V191, P150, DOI 10.1086/426827
   Sterne JAC, 1996, TUBERCLE LUNG DIS, V77, P117, DOI 10.1016/S0962-8479(96)90025-8
   Sutherland JS, 2009, EUR J IMMUNOL, V39, P723, DOI 10.1002/eji.200838693
   Szot A, 2004, INT J MED INFORM, V73, P65, DOI 10.1016/j.ijmedinf.2003.10.002
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
   van Deuren M, 2000, CLIN MICROBIOL REV, V13, P144
   van Zyl S, 2006, INT J TUBERC LUNG D, V10, P13
   van Zyl-Smit RN, 2009, AM J RESP CRIT CARE, V180, P49, DOI 10.1164/rccm.200811-1704OC
   Veerapathran A, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000457
   Verver S, 2004, LANCET, V363, P212, DOI 10.1016/S0140-6736(03)15332-9
   Wassie L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001522
   Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201
   Whalen CC, 2006, AM J TROP MED HYG, V75, P55
   Young DB, 2009, TRENDS MICROBIOL, V17, P183, DOI 10.1016/j.tim.2009.02.005
   ZHANG D-R, 1991, Zhonghua Jiehe He Huxi Zazhi, V14, P170
   ZHANG DR, 1991, ZHONGHUA JIE HE HE H, V14, P192
   Zhang QB, 2007, J INFECT DIS, V195, P1194, DOI 10.1086/512617
   Zodpey Sanjoy P, 2007, Indian J Public Health, V51, P184
NR 113
TC 15
Z9 16
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD OCT
PY 2010
VL 10
IS 10
BP 723
EP 732
DI 10.1016/S1473-3099(10)70164-X
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA 663SW
UT WOS:000282911200020
PM 20883968
OA No
DA 2017-08-15
ER

PT J
AU Burton, MJ
   Holland, MJ
   Makalo, P
   Aryee, EAN
   Sillah, A
   Cohuet, S
   Natividad, A
   Alexander, NDE
   Mabey, DCW
   Bailey, RL
AF Burton, Matthew J.
   Holland, Martin J.
   Makalo, Pateh
   Aryee, Esther A. N.
   Sillah, Ansumana
   Cohuet, Sandra
   Natividad, Angels
   Alexander, Neal D. E.
   Mabey, David C. W.
   Bailey, Robin L.
TI Profound and Sustained Reduction in Chlamydia trachomatis in The Gambia:
   A Five-Year Longitudinal Study of Trachoma Endemic Communities
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID MASS ANTIBIOTIC-TREATMENT; INFECTIOUS TRACHOMA; FLY CONTROL;
   AZITHROMYCIN; PREVALENCE; EXPRESSION; CYTOKINE; TANZANIA; DISEASE; TRIAL
AB Background: The elimination of blinding trachoma focuses on controlling Chlamydia trachomatis infection through mass antibiotic treatment and measures to limit transmission. As the prevalence of disease declines, uncertainty increases over the most effective strategy for treatment. There are little long-term data on the effect of treatment on infection, especially in low prevalence settings, on which to base guidelines.
   Methodology/Principal Findings: The population of a cluster of 14 Gambian villages with endemic trachoma was examined on seven occasions over five years (baseline, 2, 6, 12, 17, 30 and 60 months). Mass antibiotic treatment was given at baseline only. All families had accessible clean water all year round. New latrines were installed in each household after 17 months. Conjunctival swab samples were collected and tested for C. trachomatis by PCR. Before treatment the village-level prevalence of follicular trachoma in 1 to 9 year olds (TF(%1-9)) was 15.4% and C. trachomatis was 9.7%. Antibiotic treatment coverage was 83% of the population. In 12 villages all baseline infection cleared and few sporadic cases were detected during the following five years. In the other two villages treatment was followed by increased infection at two months, which was associated with extensive contact with other untreated communities. The prevalence of infection subsequently dropped to 0% in these 2 villages and 0.6% for the whole population by the end of the study in the absence of any further antibiotic treatment. However, several villages had a TF(%1-9) of >10%, the threshold for initiating or continuing mass antibiotic treatment, in the absence of any detectable C. trachomatis.
   Conclusions/Significance: A single round of mass antibiotic treatment may be sufficient in low prevalence settings to control C. trachomatis infection when combined with environmental conditions, which suppress transmission, such as a good water supply and sanitation.
C1 [Burton, Matthew J.; Holland, Martin J.; Cohuet, Sandra; Natividad, Angels; Alexander, Neal D. E.; Mabey, David C. W.; Bailey, Robin L.] London Sch Hyg & Trop Med, London WC1, England.
   [Burton, Matthew J.; Holland, Martin J.; Makalo, Pateh; Aryee, Esther A. N.; Bailey, Robin L.] MRC Labs, Fajara, Gambia.
   [Sillah, Ansumana] Natl Eye Care Programme, Banjul, Gambia.
   [Cohuet, Sandra] Inst Veille Sanit, St Maurice, France.
RP Burton, MJ (reprint author), London Sch Hyg & Trop Med, London WC1, England.
EM matthew.burton@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169
FU Wellcome Trust [059134]; Pfizer [2005-0821]; International Trachoma
   Initiative (ITI)
FX The principal financial support for this study was provided by the
   Wellcome Trust/Burroughs Wellcome Fund (059134). Pfizer, the
   manufacturer, donated the azithromycin. In addition, the authors
   received a grant from Pfizer (2005-0821) to support the fieldwork and
   laboratory work costs for the final time point assessment in this study.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; The authors'
   group has received research grants for separate studies from the
   International Trachoma Initiative (ITI), which was set up by the Edna
   McConnell Clark Foundation and Pfizer Inc (the manufacturers of
   azithromycin). Prof. Mabey has received support from Pfizer to attend an
   international meeting on trachoma. Neither ITI nor Pfizer have had
   access to the authors' results, nor have they attempted to influence
   anything written in this paper. There are no other potential conflicts
   of interest.
CR Alexander NDE, 2005, T ROY SOC TROP MED H, V99, P175, DOI 10.1016/j.trstmh.2004.05.003
   Andreasen AA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000306
   ARMITAGE P, 2001, METHODS MED RES
   Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   BIEBESHEIMER JB, 2009, OPHTHALMOLOGY
   Biebesheimer JB, 2009, OPHTHALMOLOGY, V116, P2047, DOI 10.1016/j.ophtha.2009.04.041
   Burton MJ, 2007, INVEST OPHTH VIS SCI, V48, P4440, DOI 10.1167/iovs.07-0315
   Burton MJ, 2010, INVEST OPHTH VIS SCI, V51, P3583, DOI 10.1167/iovs.09-4550
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Chidambaram JD, 2006, JAMA-J AM MED ASSOC, V295, P1142, DOI 10.1001/jama.295.10.1142
   Chidambaram JD, 2004, EMERG INFECT DIS, V10, P1895
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   Dolin PJ, 1997, LANCET, V349, P1511, DOI 10.1016/S0140-6736(97)01355-X
   Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1
   Emerson PM, 2001, MED VET ENTOMOL, V15, P314, DOI 10.1046/j.0269-283x.2001.00318.x
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   Grassly NC, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000341
   Harding-Esch EM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000573
   Hoechsmann A, 2001, Ophthalmic Epidemiol, V8, P145, DOI 10.1076/opep.8.2.145.4169
   Kerry SM, 2001, STAT MED, V20, P377, DOI 10.1002/1097-0258(20010215)20:3<377::AID-SIM799>3.0.CO;2-N
   Lakew T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000376
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   Solomon AW, 2008, NEW ENGL J MED, V358, P1870, DOI 10.1056/NEJMc0706263
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   TAYLOR HR, 1985, B WORLD HEALTH ORGAN, V63, P559
   TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   West SK, 2006, LANCET, V368, P596, DOI 10.1016/S0140-6736(06)69203-9
   World Health Organization, 2004, 2 GLOB SCI M TRACH
   World Health Organization, 1997, GLOB SCI M GEN 17 20
   Wright HR, 2005, LANCET INFECT DIS, V5, P313, DOI 10.1016/S1473-3099(05)70116-X
NR 37
TC 20
Z9 20
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2727
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD OCT
PY 2010
VL 4
IS 10
AR e835
DI 10.1371/journal.pntd.0000835
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 672CC
UT WOS:000283559600008
OA gold
DA 2017-08-15
ER

PT J
AU Ssemanda, EN
   Munoz, B
   Harding-Esch, EM
   Edwards, T
   Mkocha, H
   Bailey, RL
   Sillah, A
   Stare, D
   Mabey, DCW
   West, SK
AF Ssemanda, Elizabeth N.
   Munoz, Beatriz
   Harding-Esch, Emma M.
   Edwards, Tansy
   Mkocha, Harran
   Bailey, Robin L.
   Sillah, Ansumana
   Stare, Dianne
   Mabey, David C. W.
   West, Sheila K.
CA PRET Project Team
TI Mass Treatment with Azithromycin for Trachoma Control: Participation
   Clusters in Households
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID CHLAMYDIA-TRACHOMATIS; COMMUNITY; TANZANIA; VILLAGE; IVERMECTIN;
   INFECTION; ONCHOCERCIASIS
AB Background: Mass treatment to trachoma endemic communities is a critical part of the World Health Organization SAFE strategy. However, non-participation may not be at random, affecting coverage surveys and effectiveness if infection is differential.
   Methodology/Principal Findings: As part of the Partnership for Rapid Elimination of Trachoma (PRET), 32 communities in Tanzania, and 48 in The Gambia had a detailed census taken followed by mass treatment with azithromycin. The target coverage in each community was >80% of children ages <10 years. Community treatment assistants observed treatment and recorded compliance, thus coverage at the community, household, and individual level could be determined. Within each community, we determined the actual proportions of households where all, some, or none of the children were treated. Assuming the coverage in children <10 years of the community was as observed and non-participation was at random, we did 500 simulations to derive expected proportions of households where all, some, or none of the children were treated. Clustering of household treatment was detected comparing greater-than-expected proportions of households where none or all of children were treated, and the intraclass correlation (ICC) was calculated. Tanzanian and Gambian mass treatment coverages for children <10 years of age ranged from 82-100% and 62-99%, respectively. Clustering of households where all children were treated or no children were treated was greater than expected. Compared to model simulations, all Tanzanian communities and 44 of 48 (91.7%) Gambian communities had significantly higher proportions of households where all children were treated. Furthermore, 30 of 32 (93.8%) Tanzanian communities and 34 of 48 (70.8%) Gambian communities had a significantly elevated proportion of households compared to the expected proportion where no children were treated. The ICC for Tanzania was 0.77 (95% CI 0.74-0.81) and for The Gambia was 0.55 (95% CI 0.51-0.59).
   Conclusions/Significance: In programs aiming for high coverage, complete compliance or non-compliance with mass treatment clusters within households. Non-compliance cannot be assumed to be at random.
C1 [Ssemanda, Elizabeth N.; Munoz, Beatriz; Stare, Dianne; West, Sheila K.] Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21218 USA.
   [Harding-Esch, Emma M.; Edwards, Tansy; Bailey, Robin L.; Mabey, David C. W.] London Sch Hyg & Trop Med, London WC1, England.
   [Mkocha, Harran] Kongwa Trachoma Project, Kongwa, Tanzania.
   [Sillah, Ansumana] Gambian Dept State Hlth & Social Welf, Minist Hlth, Natl Eye Care Programme, Banjul, Gambia.
RP Ssemanda, EN (reprint author), Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21218 USA.
EM essemand@jhsph.edu
OI Mabey, David/0000-0002-0031-8276
FU Bill and Melinda Gates Foundation; Prevent Blindness Senior Scientific
   Investigator award
FX This study was supported by a grant from the Bill and Melinda Gates
   Foundation. Azithromycin was donated to the country programs through a
   generous donation by Pfizer international. SKW is the recipient of a
   research to Prevent Blindness Senior Scientific Investigator award. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944
   Blake IM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000401
   Brieger WR, 2002, TROP MED INT HEALTH, V7, P11, DOI 10.1046/j.1365-3156.2002.00826.x
   Broman AT, 2006, INVEST OPHTH VIS SCI, V47, P99, DOI 10.1167/iovs.05-0326
   Cook JA, 2008, NEW ENGL J MED, V358, P1777, DOI 10.1056/NEJMp0708546
   Cromwell EA, 2009, INT HEALTH, V1, P182, DOI 10.1016/j.inhe.2009.09.002
   Desmond N, 2005, T ROY SOC TROP MED H, V99, P656, DOI 10.1016/j.trsmh.2005.03.006
   Gardon J, 1996, T ROY SOC TROP MED H, V90, P218, DOI 10.1016/S0035-9203(96)90219-9
   Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142
   KATZ J, 1988, INT J EPIDEMIOL, V17, P865, DOI 10.1093/ije/17.4.865
   La Vincente S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000444
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   Mathieu E, 2004, ANN TROP MED PARASIT, V98, P703, DOI 10.1179/000349804X3135
   Nuwaha F, 2005, TROP MED INT HEALTH, V10, P659, DOI 10.1111/j.1365-3156.2005.01436.x
   Polack SR, 2005, T ROY SOC TROP MED H, V99, P218, DOI 10.1016/j.trstmh.2004.06.010
   Rao MR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-29
   Solomon AW, 2006, TRACHOMA CONTROL GUI
   STARE D, 2010, OPHTHALMIC IN PRESS
   Tallo VL, 2008, B WORLD HEALTH ORGAN, V86, P765, DOI 10.2471/BLT.07.047563
   West SK, 2005, LANCET, V366, P1296, DOI 10.1016/S0140-6736(05)67529-0
   WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088
NR 21
TC 8
Z9 8
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2727
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD OCT
PY 2010
VL 4
IS 10
AR e838
DI 10.1371/journal.pntd.0000838
PG 5
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 672CC
UT WOS:000283559600011
OA gold
DA 2017-08-15
ER

PT J
AU Peterson, K
   Drame, D
AF Peterson, Kevin
   Drame, Diarre
TI Iatrogenic transmission of Trichomonas vaginalis by a traditional healer
SO SEXUALLY TRANSMITTED INFECTIONS
LA English
DT Article
ID INFECTION; HIV
AB A woman presenting to an STI/HIV clinic in The Gambia with T vaginalis and a history of a digital vaginal 'exam' by a traditional healer implies non-sexual transmission of trichomonas between patients and reinforces the role of practitioner hygiene in preventing spread of infections.
C1 [Peterson, Kevin; Drame, Diarre] MRC, Med Res Council Labs, Banjul, Gambia.
RP Peterson, K (reprint author), MRC, Med Res Council Labs, POB 273, Banjul, Gambia.
EM kpeterson@mrc.gm
FU Medical Research Council Laboratories, Fajara, The Gambia
FX Care for this patient and salaries of both authors were primarily funded
   by the Medical Research Council Laboratories, Fajara, The Gambia.
CR Acholonu A D, 1984, Afr J Sex Transmi Dis, V1, P27
   ADUSARKODIE Y, 1995, GENITOURIN MED, V71, P199
   BURCH TA, 1959, AM J TROP MED HYG, V8, P312
   Chersich MF, 2008, AIDS, V22, pS27, DOI 10.1097/01.aids.0000341775.94123.75
   ROSENFELD WD, 1989, PEDIATR CLIN N AM, V36, P489
   SIVAKUMAR K, 1989, GENITOURIN MED, V65, P399
   Sorvillo F, 2001, EMERG INFECT DIS, V7, P927
   WHITTINGTON MJ, 1957, BRIT J VENER DIS, V33, P80
NR 8
TC 5
Z9 6
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1368-4973
J9 SEX TRANSM INFECT
JI Sex. Transm. Infect.
PD OCT
PY 2010
VL 86
IS 5
BP 353
EP 354
DI 10.1136/sti.2010.043125
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 655CH
UT WOS:000282219700009
PM 20876753
OA No
DA 2017-08-15
ER

PT J
AU Jobarteh, M
   Malfroy, M
   Peterson, I
   Jeng, A
   Sarge-Njie, R
   Alabi, A
   Peterson, K
   Cotten, M
   Hall, A
   Rowland-Jones, S
   Whittle, H
   Tedder, R
   Jaye, A
   Mendy, M
AF Jobarteh, Modou
   Malfroy, Marine
   Peterson, Ingrid
   Jeng, Adam
   Sarge-Njie, Ramu
   Alabi, Abraham
   Peterson, Kevin
   Cotten, Matt
   Hall, Andrew
   Rowland-Jones, Sarah
   Whittle, Hilton
   Tedder, Richard
   Jaye, Assan
   Mendy, Maimuna
TI Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected
   Gambians
SO VIROLOGY JOURNAL
LA English
DT Article
ID SUB-SAHARAN AFRICA; PREGNANT-WOMEN; HEPATOCELLULAR-CARCINOMA;
   WEST-AFRICA; HOMOSEXUAL-MEN; GUINEA-BISSAU; CHRONIC CARRIERS;
   NATURAL-HISTORY; DISEASE BURDEN; LIVER-CANCER
AB Background: The prevalence of HIV/hepatitis co-infection in sub-Saharan Africa is not well documented, while both HIV and HBV are endemic in this area.
   Objective: The aim of this study is to determine the seroprevalence of HBV and HCV virus in HIV-infected subjects in the Gambia.
   Methods: Plasma samples from HIV infected patients (190 individuals with clinically defined AIDS and 382 individuals without AIDS) were tested retrospectively for the presence of HBV sero-markers and for serum HBV DNA, screened for HCV infection by testing for anti-HCV antibody and HCV RNA.
   Results: HBsAg prevalence in HIV-positive individuals is 12.2%. HIV/HBV co-infected individuals with CD4 count of < 200 cells uL-1 have a higher HBV DNA viral load than patients with higher CD4 count (log 4.0 vs. log 2.0 DNA copies/ml, p < 0.05). Males (OR = 1.8, 95% CI: 1.0, 3.2) were more likely to be HBsAg positive than female. HCV seroprevalence was 0.9% in HIV-positive individuals.
   Conclusion: The prevalence of HBsAg carriage in HIV-infected Gambians is similar to that obtained in the general population. However co-infected individuals with reduced CD4 levels, indicative of AIDS had higher prevalence of HBeAg retention and elevated HBV DNA levels compared to non-AIDS patients with higher CD4 count.
C1 [Jobarteh, Modou; Malfroy, Marine; Peterson, Ingrid; Jeng, Adam; Sarge-Njie, Ramu; Alabi, Abraham; Peterson, Kevin; Cotten, Matt; Rowland-Jones, Sarah; Whittle, Hilton; Jaye, Assan; Mendy, Maimuna] MRC, Banjul, Gambia.
   [Hall, Andrew] London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Tedder, Richard] Natl Hlth Protect Agcy, London NW9 5EQ, England.
   [Malfroy, Marine] Ctr Leon Berard, F-69373 Lyon, France.
   [Alabi, Abraham] US Dept Def HIV Program Nigeria, Maitama, Abuja, Nigeria.
   [Rowland-Jones, Sarah] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
RP Mendy, M (reprint author), MRC, POB 273, Banjul, Gambia.
EM maimunamendy@hotmail.com
RI Huang, Linlu/H-3410-2011
OI Jobarteh, Modou Lamin/0000-0002-7350-6980
FU Medical Research Council [MC_U190085854, MC_U190088481]
CR Ahmed SD, 1998, J INFECTION, V37, P248, DOI 10.1016/S0163-4453(98)91983-1
   BODSWORTH N, 1989, J INFECT DIS, V160, P577
   Colin JF, 1999, HEPATOLOGY, V29, P1306, DOI 10.1002/hep.510290447
   Collenberg E, 2006, J MED VIROL, V78, P683, DOI 10.1002/jmv.20593
   Debonne J M, 1999, Med Trop (Mars), V59, P508
   Diop-Ndiaye H, 2008, J MED VIROL, V80, P1332, DOI 10.1002/jmv.21236
   Gaeta GB, 2003, J HEPATOL, V39, P1036, DOI 10.1016/S0168-8278(03)00470-7
   Garcia-Calleja JM, 2006, SEX TRANSM INFECT S3, V82, P64
   Gilson RJC, 1997, AIDS, V11, P597, DOI 10.1097/00002030-199705000-00007
   Gismondi MI, 2004, J CLIN MICROBIOL, V42, P1298, DOI 10.1128/JCM.42.3.1298-1301.2004
   Goldstein ST, 2005, INT J EPIDEMIOL, V34, P1329, DOI 10.1093/ije/dyi206
   Hu KQ, 2002, J VIRAL HEPATITIS, V9, P243, DOI 10.1046/j.1365-2893.2002.00344.x
   Jallow S, 2009, CLIN INFECT DIS, V48, P1790, DOI 10.1086/599107
   Kesli R, 2009, J INT MED RES, V37, P1420
   KEW MC, 1983, HEPATOLOGY, V3, P65
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x
   Madhava V, 2002, LANCET INFECT DIS, V2, P293, DOI 10.1016/S1473-3099(02)00264-5
   Mboto C I, 2009, West Afr J Med, V28, P16
   Meda N, 1999, AIDS, V13, P1397, DOI 10.1097/00002030-199907300-00018
   Mendy ME, 2010, J VIRAL HEPATITIS, V17, P115, DOI 10.1111/j.1365-2893.2009.01168.x
   Mendy ME, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-23
   Mendy ME, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-49
   Mphahlele MJ, 2006, J CLIN VIROL, V35, P14, DOI 10.1016/j.jcv.2005.04.003
   Norrgren H, 1999, AIDS, V13, P701, DOI 10.1097/00002030-199904160-00011
   ODEHOURI K, 1989, AIDS, V3, P509, DOI 10.1097/00002030-198908000-00004
   Oshitani H, 1996, T ROY SOC TROP MED H, V90, P235, DOI 10.1016/S0035-9203(96)90227-8
   Paradis V, 1997, J CLIN PATHOL, V50, P401, DOI 10.1136/jcp.50.5.401
   Parkin DM, 2001, EUR J CANCER, V37, pS4
   Plamondon M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000372
   Puoti M, 2006, J HEPATOL, V44, pS65, DOI 10.1016/j.jhep.2005.11.015
   Rouet F, 2004, J MED VIROL, V74, P34, DOI 10.1002/jmv.20143
   Ruggieri A, 1996, J GEN VIROL, V77, P2073, DOI 10.1099/0022-1317-77-9-2073
   RYDER RW, 1992, MT SINAI J MED, V59, P487
   Thio CL, 2002, LANCET, V360, P1921, DOI 10.1016/S0140-6736(02)11913-1
   TIENEN C, J ACQUIR IMMUNE DEFI, V53, P640
   TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202
   Usuda S, 1999, J VIROL METHODS, V80, P97, DOI 10.1016/S0166-0934(99)00039-7
   van der Loeff MFS, 2006, INT J EPIDEMIOL, V35, P1322, DOI 10.1093/ije/dy1037
   van der Loeff MFS, 1999, AIDS, V13, pS69
   van der Loeff MFS, 2003, AIDS, V17, P2389, DOI 10.1097/01.aids.0000076344.42412.05
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   Viviani S, 2008, CANCER EPIDEM BIOMAR, V17, P3216, DOI 10.1158/1055-9965.EPI-08-0303
   Wang SH, 2009, HEPATOLOGY, V50, P1392, DOI 10.1002/hep.23163
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WHITTLE HC, 1983, LANCET, V1, P1203
   WHO, 1999, J VIRAL HEPATITUS, V6, P35
   Yuen MF, 2009, J HEPATOL, V50, P80, DOI 10.1016/j.jhep.2008.07.023
   2008 REPORT GLOBALL
NR 49
TC 23
Z9 23
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD SEP 15
PY 2010
VL 7
AR 230
DI 10.1186/1743-422X-7-230
PG 9
WC Virology
SC Virology
GA 659ZO
UT WOS:000282606400002
PM 20843322
OA gold
DA 2017-08-15
ER

PT J
AU Laiakis, EC
   Morris, GAJ
   Fornace, AJ
   Howie, SRC
AF Laiakis, Evagelia C.
   Morris, Gerard A. J.
   Fornace, Albert J., Jr.
   Howie, Stephen R. C.
TI Metabolomic Analysis in Severe Childhood Pneumonia in The Gambia, West
   Africa: Findings from a Pilot Study
SO PLOS ONE
LA English
DT Article
ID GAMMA-RADIATION EXPOSURE; URIC-ACID; PLATELET-FUNCTION; PROSTATE-CANCER;
   GUT MICROBIOTA; LUNG INJURY; CHILDREN; BIOMARKERS; MORTALITY; DISEASE
AB Background: Pneumonia remains the leading cause of death in young children globally and improved diagnostics are needed to better identify cases and reduce case fatality. Metabolomics, a rapidly evolving field aimed at characterizing metabolites in biofluids, has the potential to improve diagnostics in a range of diseases. The objective of this pilot study is to apply metabolomic analysis to childhood pneumonia to explore its potential to improve pneumonia diagnosis in a high-burden setting.
   Methodology/Principal Findings: Eleven children with World Health Organization (WHO)-defined severe pneumonia of non-homogeneous aetiology were selected in The Gambia, West Africa, along with community controls. Metabolomic analysis of matched plasma and urine samples was undertaken using Ultra Performance Liquid Chromatography (UPLC) coupled to Time-of-Flight Mass Spectrometry (TOFMS). Biomarker extraction was done using SIMCA-P+ and Random Forests (RF). 'Unsupervised' (blinded) data were analyzed by Principal Component Analysis (PCA), while 'supervised' (unblinded) analysis was by Partial Least Squares-Discriminant Analysis (PLS-DA) and Orthogonal Projection to Latent Structures (OPLS). Potential markers were extracted from S-plots constructed following analysis with OPLS, and markers were chosen based on their contribution to the variation and correlation within the data set. The dataset was additionally analyzed with the machine-learning algorithm RF in order to address issues of model overfitting and markers were selected based on their variable importance ranking. Unsupervised PCA analysis revealed good separation of pneumonia and control groups, with even clearer separation of the groups with PLS-DA and OPLS analysis. Statistically significant differences (p<0.05) between groups were seen with the following metabolites: uric acid, hypoxanthine and glutamic acid were higher in plasma from cases, while L-tryptophan and adenosine-5'-diphosphate (ADP) were lower; uric acid and L-histidine were lower in urine from cases. The key limitation of this study is its small size.
   Conclusions/Significance: Metabolomic analysis clearly distinguished severe pneumonia patients from community controls. The metabolites identified are important for the host response to infection through antioxidant, inflammatory and antimicrobial pathways, and energy metabolism. Larger studies are needed to determine whether these findings are pneumonia-specific and to distinguish organism-specific responses. Metabolomics has considerable potential to improve diagnostics for childhood pneumonia.
C1 [Laiakis, Evagelia C.; Fornace, Albert J., Jr.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC USA.
   [Laiakis, Evagelia C.; Fornace, Albert J., Jr.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC USA.
   [Morris, Gerard A. J.; Howie, Stephen R. C.] Med Res Council UK Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Fornace, Albert J., Jr.] Dankook Univ, WCU Res Ctr Nanobiomed Sci, Cheonan, South Korea.
RP Laiakis, EC (reprint author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Biochem & Mol & Cellular Biol, Washington, DC USA.
EM showie@mrc.gm
RI Fornace, Albert/A-7407-2008
OI Fornace, Albert/0000-0001-9695-085X; Laiakis,
   Evagelia/0000-0002-4924-9013
FU Georgetown University; Medical Research Council (UK); Ministry of
   Education, Science and Technology [R31-10069]
FX This study was funded by Georgetown University and the Medical Research
   Council (UK). This work was supported in part by grant R31-10069 (WCU
   program) through the National Research Foundation of Korea funded by the
   Ministry of Education, Science and Technology. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   BECKER BF, 1993, FREE RADICAL BIO MED, V14, P615, DOI 10.1016/0891-5849(93)90143-I
   Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Burian K, 2003, IMMUNOL LETT, V89, P229, DOI 10.1016/S0165-2478(03)00154-8
   CASIMIR GJ, 2009, SHOCK
   Cassiday Laura, 2009, J Proteome Res, V8, P5409, DOI 10.1021/pr9009832
   Combes A, 2009, CRIT CARE MED, V37, P2506, DOI 10.1097/CCM.0b013e3181a569df
   Fabre JE, 1999, NAT MED, V5, P1199
   *GAMB CENTR STAT D, 2003, 2003 CENS
   Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180
   Gasse P, 2009, AM J RESP CRIT CARE, V179, P903, DOI 10.1164/rccm.200808-1274OC
   Gear ARL, 2001, BLOOD, V97, P937, DOI 10.1182/blood.V97.4.937
   GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91
   Greenwood B, 2008, B WORLD HEALTH ORGAN, V86, P322, DOI 10.2471/BLT.08.053348
   Griffin JL, 2007, J PROTEOME RES, V6, P498, DOI 10.1021/pr060464h
   Henderson JP, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000305
   Hendriksen WT, 2008, INFECT IMMUN, V76, P1230, DOI 10.1128/IAI.01004-07
   Himmelreich U, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005328
   Howie SRC, 2006, LANCET, V368, P1646, DOI 10.1016/S0140-6736(06)69687-6
   JABS CM, 1995, EUR J SURG, V161, P147
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Jansson J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006386
   Jordan KW, 2007, EXPERT REV PROTEOMIC, V4, P389, DOI 10.1586/14789450.4.3.389
   Kinross J, 2009, CURR PHARM DESIGN, V15, P1537, DOI 10.2174/138161209788168119
   Lanz C, 2009, RADIAT RES, V172, P198, DOI 10.1667/RR1796.1
   Mahadevan S, 2008, ANAL CHEM, V80, P7562, DOI 10.1021/ac800954c
   Mathers C, GLOBAL BURDEN DIS 20
   Mene P, 2008, J HYPERTENS, V26, P2085, DOI 10.1097/HJH.0b013e32830e4945
   Morris GAJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001773
   Mulholland K, 2003, PEDIATR PULM, V36, P469, DOI 10.1002/ppul.10344
   Mulholland K, 2007, LANCET, V370, P285, DOI 10.1016/S0140-6736(07)61130-1
   MULLER A, 2008, J CELL MOL MED
   Murugappan S, 2006, FRONT BIOSCI, V11, P1977, DOI 10.2741/1939
   PATTERSON AD, 2009, MASS SPECTROM REV
   Patterson AD, 2008, ANAL CHEM, V80, P665, DOI [10.1021/ac701807v, 10.1021/ac701807]
   Qazi SA, 2007, GLOBAL ACTION PLAN P
   Reade MC, 2009, CRIT CARE MED, V37, P1655, DOI 10.1097/CCM.0b013e31819da853
   RODRIGUEZNUNEZ A, 1993, ACTA PAEDIATR, V82, P849, DOI 10.1111/j.1651-2227.1993.tb17625.x
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Schmidt H, 1997, J SURG RES, V71, P61, DOI 10.1006/jsre.1997.5098
   Scott JAG, 2008, PLOS MED, V5, P548, DOI 10.1371/journal.pmed.0050086
   Serkova NJ, 2008, AM J PHYSIOL-LUNG C, V295, pL152, DOI 10.1152/ajplung.00515.2007
   Serkova Natalie J., 2009, V520, P273, DOI 10.1007/978-1-60327-811-9_20
   Sintchenko V, 2007, NAT REV MICROBIOL, V5, P464, DOI 10.1038/nrmicro1656
   Slupsky CM, 2009, J PROTEOME RES, V8, P3029, DOI 10.1021/pr900103y
   Slupsky CM, 2009, J PROTEOME RES, V8, P5550, DOI 10.1021/pr9006427
   Smith-Vaughan H, 2006, BMC EAR NOSE THROAT, V6, DOI 10.1186/1472-6815-6-10
   Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762
   Tuohy KM, 2009, CURR PHARM DESIGN, V15, P1415, DOI 10.2174/138161209788168182
   Tyburski JB, 2008, RADIAT RES, V170, P1, DOI 10.1667/RR1265.1
   Tyburski JB, 2009, RADIAT RES, V172, P42, DOI 10.1667/RR1703.1
   United Nations Secretary-General, 2001, ROAD MAP IMPL UN MIL
   Waldram A, 2009, J PROTEOME RES, V8, P2361, DOI 10.1021/pr8009885
   *WHO, 2003, WHOFCHCAH039
   *WHO, 2002, REV GLOB BURD DIS GB, P2005
   Xu XA, 2006, J EXP MED, V203, P2907, DOI 10.1084/jem.20061232
   YUE S, HUNAN YI KE DA XUE X, V24, P287
NR 58
TC 35
Z9 36
U1 1
U2 28
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 9
PY 2010
VL 5
IS 9
AR e12655
DI 10.1371/journal.pone.0012655
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 648IW
UT WOS:000281687200016
OA gold
DA 2017-08-15
ER

PT J
AU Ding, SJ
   Schoenmakers, I
   Jones, K
   Koulman, A
   Prentice, A
   Volmer, DA
AF Ding, Shujing
   Schoenmakers, Inez
   Jones, Kerry
   Koulman, Albert
   Prentice, Ann
   Volmer, Dietrich A.
TI Quantitative determination of vitamin D metabolites in plasma using
   UHPLC-MS/MS
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE Vitamin D; Metabolites; Plasma; UHPLC; Tandem mass spectrometry;
   Quantification; Multiple reaction monitoring (MRM)
ID TANDEM MASS-SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; DIELS-ALDER
   DERIVATIZATION; COOKSON-TYPE REAGENT; 25-HYDROXYVITAMIN D-3; HUMAN
   SERUM; 24,25-DIHYDROXYVITAMIN D-3; GAS-CHROMATOGRAPHY; ASSAY; EXTRACTION
AB Vitamin D is an important determinant of bone health at all ages. The plasma concentrations of 25-hydroxy vitamin D (25-OH D) and other metabolites are used as biomarkers for vitamin sufficiency and function. To allow for the simultaneous determination of five vitamin D metabolites, 25-OH D(3), 25-OH D(2), 24,25-(OH)(2) D(3), 1,25-(OH)(2) D(3), and 1,25-(OH)(2) D(2), in low volumes of human plasma, an assay using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) was established. Plasma samples were spiked with isotope-labeled internal standards and pretreated using protein precipitation, solid-phase extraction (SPE) and a Diels-Alder derivatization step with 4-phenyl-1,2,4-triazoline-3,5-dione. The SPE recovery rates ranged from 55% to 85%, depending on the vitamin D metabolite; the total sample run time was < 5 min. Mass spectrometry was conducted using positive ion electrospray ionization in the multiple reaction monitoring mode on a quadrupole-quadrupole-linear ion trap instrument after pre-column addition of methylamine to increase the ionization efficiency. The intra- and inter-day relative standard deviations were 1.6-4.1% and 3.7-6.8%, respectively. The limit of quantitation for these compounds was determined to be between 10 and 20 pg/mL. The 25-OH D results were compared with values obtained for reference materials (DEQAS). In addition, plasma samples were analyzed with two additional Diasorin antibody assays. All comparisons with conventional methods showed excellent correlations (r (2) = 0.9738) for DEQAS samples, demonstrating the high degree of comparability of the new UHPLC-MS/MS technique to existing methods.
C1 [Volmer, Dietrich A.] Univ Saarland, Inst Bioanalyt Chem, D-66123 Saarbrucken, Germany.
   [Ding, Shujing; Schoenmakers, Inez; Koulman, Albert; Prentice, Ann; Volmer, Dietrich A.] Med Res Council Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   [Jones, Kerry] Med Res Council Keneba Field Site, Banjul, Keneba, Gambia.
RP Volmer, DA (reprint author), Univ Saarland, Inst Bioanalyt Chem, Campus B2 2,Raum 2-27, D-66123 Saarbrucken, Germany.
EM Dietrich.Volmer@mx.uni-saarland.de
RI Volmer, Dietrich/G-7900-2012; Jones, Kerry/D-2490-2014
OI Volmer, Dietrich/0000-0003-2820-1480; Jones, Kerry/0000-0002-7380-9797;
   Koulman, Albert/0000-0001-9998-051X
FU Medical Research Council [MC_U105960371]
CR Aronov PA, 2008, ANAL BIOANAL CHEM, V391, P1917, DOI 10.1007/s00216-008-2095-8
   Binkley N, 2004, J CLIN ENDOCR METAB, V89, P3152, DOI 10.1210/jc.2003-031979
   Bliesner D. M., 2006, VALIDATING CHROMATOG
   BLINKLEY N, 2008, J CLIN ENDOCR METAB, V93, P1804
   Bunch DR, 2009, CLIN CHEM LAB MED, V47, P1565, DOI 10.1515/CCLM.2009.342
   Carter GD, 2007, J STEROID BIOCHEM, V103, P480, DOI 10.1016/j.jsbmb.2006.11.007
   Carter GD, 2004, CLIN CHEM, V50, P2195, DOI 10.1373/clinchem.2004.040683
   Carter GD, 2009, ANN CLIN BIOCHEM, V46, P79, DOI 10.1258/acb.2008.008135
   Chen HP, 2008, CLIN CHIM ACTA, V391, P6, DOI 10.1016/j.cca.2008.01.017
   COLDWELL RD, 1995, J MASS SPECTROM, V30, P348, DOI 10.1002/jms.1190300218
   de Castro MDL, 1999, J PHARMACEUT BIOMED, V20, P1
   Dibba B, 2002, AM J CLIN NUTR, V76, P681
   Duan XT, 2010, ANAL CHEM, V82, P2488, DOI 10.1021/ac902869y
   Dusso AS, 2005, AM J PHYSIOL-RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004
   Eyles D, 2009, CLIN CHIM ACTA, V403, P145, DOI 10.1016/j.cca.2009.02.005
   Fraser WD, 2009, ANN CLIN BIOCHEM, V46, P3, DOI 10.1258/acb.2008.008225
   GAO S, 2005, J CHROMATOGR B, V82, P98
   Ginty F, 2005, BONE, V36, P101, DOI 10.1016/j.bone.2004.10.001
   Higashi T, 2003, ANAL SCI, V19, P941, DOI 10.2116/analsci.19.941
   Higashi T, 2002, J PHARMACEUT BIOMED, V29, P947, DOI 10.1016/S0731-7085(02)00135-8
   Higashi T, 2001, BIOL PHARM BULL, V24, P738, DOI 10.1248/bpb.24.738
   Higashi T, 2001, BIOMED CHROMATOGR, V15, P133, DOI 10.1002/bmc.43
   HIGASHI T, 2009, J CHROMATOGR B, V878, P1554
   Higashi T, 2008, ANAL BIOANAL CHEM, V391, P229, DOI 10.1007/s00216-007-1780-3
   Hojskov CS, 2010, CLIN CHIM ACTA, V411, P114, DOI 10.1016/j.cca.2009.10.010
   HORST RL, 2010, J STEROID B IN PRESS
   Horst RL, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P15
   Ishigai M, 1997, J CHROMATOGR B, V704, P11, DOI 10.1016/S0378-4347(97)00423-4
   JONES G, 1978, CLIN CHEM, V24, P287
   Knox S, 2009, ANN CLIN BIOCHEM, V46, P226, DOI 10.1258/acb.2009.008206
   Kushnir MM, 2010, AM J CLIN PATHOL, V134, P148, DOI 10.1309/AJCPPIA7DFBT4GKS
   Lensmeyer GL, 2006, CLIN CHEM, V52, P1120, DOI 10.1373/clinchem.2005.064956
   Lind C, 1997, CLIN CHEM, V43, P943
   Massart C, 2009, CLIN CHEM, V55, P1247, DOI 10.1373/clinchem.2008.122952
   Maunsell Z, 2005, CLIN CHEM, V51, P1683, DOI 10.1373/clinchem.2005.052936
   Murao N, 2005, ANAL BIOCHEM, V346, P158, DOI 10.1016/j.ab.2005.08.002
   *NAT I STAND TECH, SRM 972 VIT D HUM SE
   Norman AW, 2008, AM J CLIN NUTR, V88, p491S
   Omdahl J, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P85
   Phinney KW, 2008, AM J CLIN NUTR, V88, p511S
   Prentice A, 2008, AM J CLIN NUTR, V88, p500S
   Capote FP, 2007, RAPID COMMUN MASS SP, V21, P1745, DOI 10.1002/rcm.3014
   Roth HJ, 2008, ANN CLIN BIOCHEM, V45, P153, DOI 10.1258/acb.2007.007091
   Saenger AK, 2006, AM J CLIN PATHOL, V125, P914, DOI 10.1309/J32IJF7GTOPWN25AP
   SHIMADA K, 1995, BIOMED CHROMATOGR, V9, P229, DOI 10.1002/bmc.1130090508
   Shimada K, 2001, J CHROMATOGR A, V935, P141, DOI 10.1016/S0021-9673(01)00943-8
   Shimizu Masato, 1994, Vitamins (Kyoto), V68, P15
   Singh RJ, 2010, METHODS MOL BIOL, V603, P509, DOI 10.1007/978-1-60761-459-3_50
   Tai SSC, 2010, ANAL CHEM, V82, P1942, DOI 10.1021/ac9026862
   Terry AH, 2005, CLIN CHEM, V51, P1565, DOI 10.1373/clinchem.2005.054239
   Tsugawa N, 2005, ANAL CHEM, V77, P3001, DOI 10.1021/ac048249c
   van den Ouweland JMW, 2010, J CHROMATOGR B, V878, P1163, DOI 10.1016/j.jchromb.2010.03.035
   van Leeuwen JPTM, 2001, STEROIDS, V66, P375, DOI 10.1016/S0039-128X(00)00155-0
   VOGESER M, 2010, J STEROID B IN PRESS
   VOGESER M, 2004, CLIN CHEM, V50, P1145
   WATSON D, 1991, BIOMED CHROMATOGR, V5, P153, DOI 10.1002/bmc.1130050404
   Weiskopf AS, 2001, J MASS SPECTROM, V36, P71, DOI 10.1002/jms.105
   Yates AM, 2008, CLIN CHEM, V54, P2082, DOI 10.1373/clinchem.2008.110452
   YEUNG B, 1993, J CHROMATOGR, V645, P115, DOI 10.1016/0021-9673(93)80625-I
NR 59
TC 73
Z9 76
U1 1
U2 37
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD SEP
PY 2010
VL 398
IS 2
BP 779
EP 789
DI 10.1007/s00216-010-3993-0
PG 11
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 650IL
UT WOS:000281842400016
PM 20628873
OA No
DA 2017-08-15
ER

PT J
AU Scholze, J
   Alegria, E
   Ferri, C
   Langham, S
   Stevens, W
   Jeffries, D
   Uhl-Hochgraeber, K
AF Scholze, Jurgen
   Alegria, Eduardo
   Ferri, Claudio
   Langham, Sue
   Stevens, Warren
   Jeffries, David
   Uhl-Hochgraeber, Kerstin
TI Epidemiological and economic burden of metabolic syndrome and its
   consequences in patients with hypertension in Germany, Spain and Italy;
   a prevalence-based model
SO BMC PUBLIC HEALTH
LA English
DT Article
ID BLOOD-PRESSURE CONTROL; CARDIOVASCULAR-DISEASE; EUROPEAN-SOCIETY;
   LIFE-EXPECTANCY; RISK PROFILE; TASK-FORCE; POPULATION; COST; MORTALITY;
   MORBIDITY
AB Background: The presence of metabolic syndrome in patients with hypertension significantly increases the risk of cardiovascular disease, type 2 diabetes and mortality. Our aim is to estimate the epidemiological and economic burden to the health service of metabolic syndrome in patients with hypertension in three European countries in 2008 and 2020.
   Methods: An age, sex and risk group structured prevalence based cost of illness model was developed using the United States Adult Treatment Panel III of the National Cholesterol Education Program criteria to define metabolic syndrome. Data sources included published information and public use databases on disease prevalence, incidence of cardiovascular events, prevalence of type 2 diabetes, treatment patterns and cost of management in Germany, Spain and Italy.
   Results: The prevalence of hypertension with metabolic syndrome in the general population of Germany, Spain and Italy was 36%, 11% and 10% respectively. In subjects with hypertension 61%, 22% and 21% also had metabolic syndrome. Incident cardiovascular events and attributable mortality were around two fold higher in subjects with metabolic syndrome and prevalence of type 2 diabetes was around six-fold higher. The economic burden to the health service of metabolic syndrome in patients with hypertension was been estimated at (sic)24,427, (sic)1,900 and (sic)4,877 million in Germany, Spain and Italy and forecast to rise by 59%, 179% and 157% respectively by 2020. The largest components of costs included the management of prevalent type 2 diabetes and incident cardiovascular events. Mean annual costs per hypertensive patient were around three-fold higher in subjects with metabolic syndrome compared to those without and rose incrementally with the additional number of metabolic syndrome components present.
   Conclusion: The presence of metabolic syndrome in patients with hypertension significantly inflates economic burden and costs are likely to increase in the future due to an aging population and an increase in the prevalence of components of metabolic syndrome.
C1 [Scholze, Jurgen] Charite, Outpatient Clin, Dept Med, CCM, D-10117 Berlin, Germany.
   [Alegria, Eduardo] Policlin Gipuzkoa, Serv Cardiol, San Sebastian, Spain.
   [Ferri, Claudio] Univ Laquila, San Salvatore Hosp, Dept Internal Med & Publ Hlth, Div Internal Med,Hypertens & Cardiovasc Prevet Ct, Laquila, Italy.
   [Langham, Sue] Independent Hlth Econ, Manchester, Lancs, England.
   [Stevens, Warren] Independent Hlth Econ, Boston, MA USA.
   [Jeffries, David] Head Stat & Data Management, MRC Trop Dis Res Unit, Banjul, Gambia.
   [Uhl-Hochgraeber, Kerstin] Bayer Schering Pharma AG, Global Hlth Econ & Outcomes Res, Berlin, Germany.
RP Scholze, J (reprint author), Charite, Outpatient Clin, Dept Med, CCM, Luisenstr 11-13, D-10117 Berlin, Germany.
EM juergen.scholze@charite.de
OI Ferri, Claudio/0000-0002-3594-2503
FU Bayer Schering Pharma AG
FX This project was funded by Bayer Schering Pharma AG.
CR Andreadis EA, 2007, AM J HYPERTENS, V20, P558, DOI 10.1016/j.amjhyper.2006.12.001
   Assmann G, 2007, AM J CARDIOL, V99, P541, DOI 10.1016/j.amjcard.2006.08.045
   Barrios Vivencio, 2007, J Cardiometab Syndr, V2, P9, DOI 10.1111/j.1559-4564.2007.06313.x
   BERGHOFER A, 2008, BMC PUBLIC HEALTH, V8
   Breekveldt-Postma NS, 2008, CURR MED RES OPIN, V24, P121, DOI 10.1185/030079907X253843
   Chobanian AV, 2003, JAMA-J AM MED ASSOC, V289, P2560, DOI 10.1001/jama.289.19.2560
   Cordero A, 2006, AM J HYPERTENS, V19, P189, DOI 10.1016/j.amjhyper.2005.08.018
   Corrao G, 2008, J HYPERTENS, V26, P819, DOI 10.1097/HJH.0b013e3282f4edd7
   de la Sierra A, 2006, MED CLIN-BARCELONA, V126, P406, DOI 10.1157/13086123
   Degli Esposti E, 2001, J Hum Hypertens, V15, P329, DOI 10.1038/sj.jhh.1001178
   Elliott WJ, 2007, LANCET, V369, P201, DOI 10.1016/S0140-6736(07)60108-1
   Esposti LD, 2004, J CLIN HYPERTENS GRE, V6, P76, DOI 10.1111/j.1524-6175.2004.03044.x
   Ferrara LA, 2007, J HUM HYPERTENS, V21, P795, DOI 10.1038/sj.jhh.1002232
   Ford ES, 2005, DIABETES CARE, V28, P1769, DOI 10.2337/diacare.28.7.1769
   Galassi A, 2006, AM J MED, V119, P812, DOI 10.1016/j.amjmed.2006.02.031
   Gandjour A, 2007, HEALTH POLICY, V83, P257, DOI 10.1016/j.healthpol.2007.01.003
   Groves T, 2006, BRIT MED J, V333, P1081, DOI 10.1136/bmj.39038.449769.BE
   Hansson L, 2002, BLOOD PRESSURE, V11, P35, DOI 10.1080/080370502753543945
   *INT ASS STUD OB, 2009, AD OV OB EU 27
   Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683
   Jonsson B, 2002, DIABETOLOGIA, V45, pS5, DOI 10.1007/s00125-002-0858-x
   Kiiskinen U, 1998, J HYPERTENS, V16, P1103, DOI 10.1097/00004872-199816080-00004
   Kjeldsen SE, 2008, J HYPERTENS, V26, P2064, DOI 10.1097/HJH.0b013e32830c45c3
   Krauss Ronald M., 1998, Circulation, V98, P1472
   Kurtz TW, 2006, AM J MED, V119, p24S, DOI 10.1016/j.amjmed.2006.01.011
   Law MR, 2009, BMJ-BRIT MED J, V338, pb1665
   Lawes CMM, 2008, LANCET, V371, P1513, DOI 10.1016/S0140-6736(08)60655-8
   Maetzel A, 2004, ANN RHEUM DIS, V63, P395, DOI 10.1136/ard.2003.006031
   Mancia G, 2004, J HYPERTENS, V22, P51, DOI 10.1097/01.hjh.0000098194.36890.0e
   Mancia G, 2006, J HYPERTENS, V24, P837, DOI 10.1097/01.hjh.0000222752.67572.61
   Mancia G, 2007, EUR HEART J, V28, P1462, DOI 10.1093/eurheartj/ehm236
   Mancia G, 2007, HYPERTENSION, V49, P40, DOI 10.1161/01.HYP.0000251933.22091.24
   Mancia G, 2009, BLOOD PRESSURE, V18, P308, DOI 10.3109/08037050903450468
   Mar J, 2001, J HYPERTENS, V19, P149, DOI 10.1097/00004872-200101000-00020
   MATHES J, 2008, VALUE HLTH, V11
   Mullins CD, 2004, PHARMACOECONOMICS, V22, P1001, DOI 10.2165/00019053-200422150-00004
   *NAT I HLTH CLIN E, 2006, CG34 HYP NICE CLIN G
   Navarro J, 2007, BLOOD PRESSURE, V16, P20, DOI 10.1080/08037050701217817
   Neuhauser H, 2008, J PUBLIC HEALTH-HEID, V16, P221, DOI 10.1007/s10389-007-0168-3
   Noto D, 2008, ATHEROSCLEROSIS, V197, P147, DOI 10.1016/j.atherosclerosis.2007.03.005
   Perez-Fernandez R, 2007, J HUM HYPERTENS, V21, P366, DOI 10.1038/sj.jhh.1002158
   Pierdomenico SD, 2007, AM J HYPERTENS, V20, P1291, DOI 10.1016/j.amjhyper.2007.06.011
   Redon J, 2008, J HYPERTENS, V26, P1891, DOI 10.1097/HJH.0b013e328302ca38
   Redon J, 2009, J HYPERTENS, V27, P441, DOI 10.1097/HJH.0b013e32831e13e5
   ROBERT K, 2000, PUBLIC USE FILE BGS9
   Romero R, 2007, BLOOD PRESSURE, V16, P347, DOI 10.1080/08037050701715117
   ROVIRA J, 1992, J HUM HYPERTENS, V6, P481
   Sattar N, 2003, CIRCULATION, V108, P414, DOI 10.1161/01.CIR.0000080897.52664.94
   Schillaci G, 2006, HYPERTENSION, V47, P881, DOI 10.1161/01.HYP.0000216778.83626.39
   Schillaci G, 2004, J AM COLL CARDIOL, V43, P1817, DOI 10.1016/j.jacc.2003.12.049
   Scholze J, 2007, CIRCULATION, V115, P1991, DOI 10.1161/CIRCULATIONAHA.106.625400
   Segura Julian, 2007, J Clin Hypertens (Greenwich), V9, P595, DOI 10.1111/j.1524-6175.2007.06522.x
   STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434
   Taylor MJ, 2007, CURR MED RES OPIN, V23, P495, DOI 10.1185/030079906X167462
   WILLE E, 2010, EUR J HLTH EC
   2004, STAKEHOLDER INSIGHT
   [Anonymous], 2002, CIRCULATION, V106, P3143
NR 57
TC 31
Z9 35
U1 2
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD SEP 1
PY 2010
VL 10
AR 529
DI 10.1186/1471-2458-10-529
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 655HF
UT WOS:000282239200006
PM 20813031
OA gold
DA 2017-08-15
ER

PT J
AU Lutter, EI
   Bonner, C
   Holland, MJ
   Suchland, RJ
   Stamm, WE
   Jewett, TJ
   McClarty, G
   Hackstadt, T
AF Lutter, Erika I.
   Bonner, Christine
   Holland, Martin J.
   Suchland, Robert J.
   Stamm, Walter E.
   Jewett, Travis J.
   McClarty, Grant
   Hackstadt, Ted
TI Phylogenetic Analysis of Chlamydia trachomatis Tarp and Correlation with
   Clinical Phenotype
SO INFECTION AND IMMUNITY
LA English
DT Article
ID OUTER-MEMBRANE-PROTEIN; NEIGHBOR-JOINING METHOD; TRYPTOPHAN SYNTHASE;
   SEQUENCE-ANALYSIS; GENOME SEQUENCE; TISSUE TROPISM; STRAINS; GENE;
   POLYMORPHISMS; SEROVAR
AB Chlamydia trachomatis is the leading cause of infectious blindness worldwide and is the most commonly reported pathogen causing sexually transmitted infections. Tarp (translocated actin recruiting phosphoprotein), a type III secreted effector that mediates actin nucleation, is central to C. trachomatis infection. The phylogenetic analysis of tarP from reference strains as well as ocular, genital, and lymphogranuloma venereum (LGV) clinical isolates demonstrated an evolutionary relationship with disease phenotype, with LGV and ocular isolates branched into clades that were separate from the urogenital isolates. The sequence analysis of Tarp indicated a high degree of variability and identified trends within clinical groupings. Tarps from LGV strains contained the highest number of tyrosine-rich repeat regions (up to nine) and the fewest (two) predicted actin binding domains. The converse was noted for Tarp proteins from ocular isolates that contained up to four actin binding domains and as few as one tyrosine-rich repeat region. The results suggest that Tarp is among the few known genes to play a role in C. trachomatis adaptations to specific niches within the host.
C1 [Lutter, Erika I.; Jewett, Travis J.; Hackstadt, Ted] NIAID, Host Parasite Interact Sect, Intracellular Parasites Lab, NIH,Rocky Mt Labs, Hamilton, MT 59840 USA.
   [Bonner, Christine; McClarty, Grant] Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada.
   [Holland, Martin J.] London Sch Hyg & Trop Med, London WC1, England.
   [Holland, Martin J.] MRC Labs, Fajara, Gambia.
   [Suchland, Robert J.; Stamm, Walter E.] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA USA.
   [Jewett, Travis J.] Univ Cent Florida, Burnett Sch Biomed Sci, Orlando, FL 32816 USA.
RP Hackstadt, T (reprint author), NIAID, Host Parasite Interact Sect, Intracellular Parasites Lab, NIH,Rocky Mt Labs, 903 S 4th St, Hamilton, MT 59840 USA.
EM Ted_Hackstadt@NIH.gov
OI Hackstadt, Ted/0000-0003-1367-5528
FU NIAID/NIH; Canadian Institutes of Health Research [GR-13301]; Public
   Health Agency of Canada Office of the Chief Scientist
FX This work was supported by the Intramural Research Program of the
   NIAID/NIH. This work also was supported in part by research grants from
   the Canadian Institutes of Health Research (GR-13301 to G. McClarty) and
   the Public Health Agency of Canada Office of the Chief Scientist Fund
   (to G. McClarty).
CR Andreasen AA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000306
   BAVOIL P, 1984, INFECT IMMUN, V44, P479
   Belland RJ, 2001, P NATL ACAD SCI USA, V98, P13984, DOI 10.1073/pnas.241377698
   Betts HJ, 2009, CURR OPIN MICROBIOL, V12, P81, DOI 10.1016/j.mib.2008.11.009
   Brunelle BW, 2006, INFECT IMMUN, V74, P578, DOI 10.1128/IAI.74.1.578-585.2006
   Brunelle BW, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-r42
   Brunham RC, 2005, NAT REV IMMUNOL, V5, P149, DOI 10.1038/nri1551
   Brunham RC, 1996, J INFECT DIS, V173, P950
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Caldwell HD, 2003, J CLIN INVEST, V111, P1757, DOI 10.1172/JCI200317993
   CALDWELL HD, 1982, INFECT IMMUN, V35, P1024
   CALDWELL HD, 1982, INFECT IMMUN, V38, P745
   Carlson JH, 2005, INFECT IMMUN, V73, P6407, DOI 10.1128/IAI.73.10.6407-6418.2005
   Carlson JH, 2004, INFECT IMMUN, V72, P7063, DOI 10.1128/IAI.72.12.7063-7072.2004
   Clifton DR, 2005, INFECT IMMUN, V73, P3860, DOI 10.1128/IAI.73.7.3860-3868.2005
   Clifton DR, 2004, P NATL ACAD SCI USA, V101, P10166, DOI 10.1073/pnas.0402829101
   Cocchiaro JL, 2009, CELL MICROBIOL, V11, P1571, DOI 10.1111/j.1462-5822.2009.01364.x
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   DEAN D, 1995, J INFECT DIS, V172, P1013
   DOOLEY CA, 2004, 104 GEN M AM SOC MIC
   Elwell CA, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000021
   Faal N, 2006, PLOS MED, V3, P1292, DOI 10.1371/journal.pmed.0030266
   Fehlner-Gardiner C, 2002, J BIOL CHEM, V277, P26893, DOI 10.1074/jbc.M203937200
   Fields KA, 2003, MOL MICROBIOL, V48, P671, DOI 10.1046/j.1365-2958.2003.03462.x
   FITCH WM, 1993, MOL BIOL EVOL, V10, P892
   FROST EH, 1995, GENITOURIN MED, V71, P18
   FROST EH, 1991, J INFECT DIS, V163, P1103
   Geisler WM, 2002, SEX TRANSM DIS, V29, P189, DOI 10.1097/00007435-200204000-00001
   Geisler WM, 2003, SEX TRANSM DIS, V30, P160, DOI 10.1097/00007435-200302000-00013
   Gomes JP, 2006, J BACTERIOL, V188, P275, DOI 10.1128/JB.188.1.275-286.2006
   Gomes JP, 2004, J BACTERIOL, V186, P4295, DOI 10.1128/JB.186.13.4295-4306.2004
   GRAYSTON JT, 1975, J INFECT DIS, V132, P87
   HACKSTADT T, 1985, J BACTERIOL, V161, P25
   HATCH TP, 1984, J BACTERIOL, V157, P13
   Hsieh YH, 2001, MICROBES INFECT, V3, P447, DOI 10.1016/S1286-4579(01)01400-9
   Ikehata M, 2000, FEMS IMMUNOL MED MIC, V27, P35, DOI 10.1111/j.1574-695X.2000.tb01409.x
   JEWETT TJ, PLOS PATHOG IN PRESS
   Jewett TJ, 2008, BIOCHEM BIOPH RES CO, V371, P339, DOI 10.1016/j.bbrc.2008.04.089
   Jewett TJ, 2006, P NATL ACAD SCI USA, V103, P15599, DOI 10.1073/pnas.0603044103
   Klint M, 2007, J CLIN MICROBIOL, V45, P1410, DOI 10.1128/JCM.02301-06
   LAMPE MF, 1995, J INFECT DIS, V172, P589
   Lane BJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000014
   Mehlitz A, 2008, FEMS MICROBIOL LETT, V289, P233, DOI 10.1111/j.1574-6968.2008.01390.x
   Millman K, 2006, MICROBES INFECT, V8, P604, DOI 10.1016/j.micinf.2005.08.012
   Millman K, 2004, J BACTERIOL, V186, P2457, DOI 10.1128/JB.186.8.2457-2465.2004
   NEWHALL WJ, 1983, J BACTERIOL, V154, P998
   PERSSON K, 1990, P 7 INT S HUM CHLAM, P559
   Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397
   RODRIGUEZ P, 1994, J CLIN MICROBIOL, V32, P2921
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406
   Schachter J, 1999, CHLAMYDIA, P139
   SCHACHTER J, 1978, NEW ENGL J MED, V298, P428, DOI 10.1056/NEJM197802232980805
   SCHACHTER J, 1978, NEW ENGL J MED, V298, P490, DOI 10.1056/NEJM197803022980905
   Shaw AC, 2000, MICROBES INFECT, V2, P581, DOI 10.1016/S1286-4579(00)00368-3
   Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979
   Stephens RS, 1999, CHLAMYDIA, P9
   Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754
   Stevens MP, 2004, J CLIN MICROBIOL, V42, P2501, DOI 10.1128/JCM.42.6.2501-2507.2004
   Stothard DR, 2003, INFECT IMMUN, V71, P1200, DOI 10.1128/IAI.71.3.1200-1208.2003
   Stothard DR, 1998, INFECT IMMUN, V66, P3618
   SU H, 1990, INFECT IMMUN, V58, P1017
   Su H, 1996, P NATL ACAD SCI USA, V93, P11143, DOI 10.1073/pnas.93.20.11143
   Suchland RJ, 2008, INFECT IMMUN, V76, P5438, DOI 10.1128/IAI.00984-08
   Tamura K, 2004, P NATL ACAD SCI USA, V101, P11030, DOI 10.1073/pnas.0404206101
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Thomson NR, 2008, GENOME RES, V18, P161, DOI 10.1101/gr.7020108
   van der Pol B, 2001, J CLIN MICROBIOL, V39, P1008, DOI 10.1128/JCM.39.3.1008-1016.2001
   Wang J, 2009, VACCINE, V27, P2967, DOI 10.1016/j.vaccine.2009.02.095
   WANG SP, 1963, J IMMUNOL, V90, P849
   WANG SP, 1991, J INFECT DIS, V163, P403
   WANG SP, 1985, J INFECT DIS, V152, P791
   WANG SP, 1973, INFECT IMMUN, V7, P356
   Wang S.-P., 1971, TRACHOMA RELATED DIS, P305
NR 74
TC 24
Z9 25
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD SEP
PY 2010
VL 78
IS 9
BP 3678
EP 3688
DI 10.1128/IAI.00515-10
PG 11
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 639PM
UT WOS:000280986700004
PM 20605986
OA No
DA 2017-08-15
ER

PT J
AU Diness, BR
   Christoffersen, D
   Pedersen, UB
   Rodrigues, A
   Fischer, TK
   Andersen, A
   Whittle, H
   Yazdanbakhsh, M
   Aaby, P
   Benn, CS
AF Diness, Birgitte Rode
   Christoffersen, Dorthe
   Pedersen, Ulla Britt
   Rodrigues, Amabelia
   Fischer, Thea Kolsen
   Andersen, Andreas
   Whittle, Hilton
   Yazdanbakhsh, Maria
   Aaby, Peter
   Benn, Christine Stabell
TI The Effect of High-Dose Vitamin A Supplementation Given with Bacille
   Calmette-Guerin Vaccine at Birth on Infant Rotavirus Infection and
   Diarrhea: A Randomized Prospective Study from Guinea-Bissau
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID CHILDHOOD MORBIDITY; SOUTHERN INDIA; BCG VACCINE; WEST-AFRICA;
   MORTALITY; CHILDREN; IMPACT; TRIAL; EPISODES; DISEASE
AB Background. Prophylactic vitamin A supplementation (VAS) reduces mortality and may reduce morbidity associated with diarrhea in children 16 months of age. Rotavirus is the most common cause of acute dehydrating diarrhea among children worldwide.
   Methods. In a randomized placebo-controlled study of 50,000 IU of vitamin A versus placebo given with bacille Calmette-Guerin vaccine at birth, 287 infants were followed up with weekly interviews and stool sample obtainment to test the hypothesis that VAS reduced the risk of rotavirus infection.
   Results. VAS was associated with increased risk of rotavirus infection and diarrhea (incidence rate ratio [IRR] of infection, 1.72 [95% confidence interval (CI), 1.04-2.85]; IRR of diarrhea, 3.74 [95% CI, 1.40-9.98]) among children <6 months of age. There was no effect in older children. VAS had a beneficial effect on nonrotavirus diarrhea in boys <6 months of age (IRR, 0.51; 95% CI, 0.27-0.95) and a detrimental effect in girls >6 months of age (IRR, 1.84; 95% CI, 0.96-3.55).
   Conclusion. VAS at birth did not reduce rotavirus morbidity. The effect of VAS on nonrotavirus diarrhea may differ by sex, being more beneficial in boys.
C1 [Diness, Birgitte Rode; Fischer, Thea Kolsen; Aaby, Peter; Benn, Christine Stabell] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen S, Denmark.
   [Whittle, Hilton] MRC, Fajara, Gambia.
   [Yazdanbakhsh, Maria] Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands.
RP Diness, BR (reprint author), Statens Serum Inst, Bandim Hlth Project, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
EM Birgitte@Diness.dk
OI Fischer, Thea Kolsen/0000-0003-4812-980X
FU March of Dimes; European Commission [ICA4-CT-2002-10053]; Danish Medical
   Research Council, University of Copenhagen; Ville Heise Foundation;
   DANIDA; Danish National Research Foundation; Novo Nordisk Foundation;
   GAVI Alliance
FX March of Dimes, the European Commission, INCO-programme (contract
   ICA4-CT-2002-10053), the Danish Medical Research Council, University of
   Copenhagen, and the Ville Heise Foundation. The Bandim Health Project
   received support from DANIDA and the Danish National Research
   Foundation. PA holds a research professorship grant from the Novo
   Nordisk Foundation.; This article is part of a supplement entitled
   "Rotavirus Infection in Africa: Epidemiology, Burden of Disease, and
   Strain Diversity," which was prepared as a project of the Rotavirus
   Vaccine Program, a partnership among PATH, the World Health
   Organization, and the US Centers for Disease Control and Prevention, and
   was funded in full or in part by the GAVI Alliance.
CR Benn CS, 2008, BRIT MED J, V336, P1416, DOI 10.1136/bmj.39542.509444.AE
   Benn CS, 2005, BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55
   Benn CS, 1997, LANCET, V350, P101, DOI 10.1016/S0140-6736(96)12019-5
   BENN CS, 2006, J INFECT DIS, V194, P721, DOI 10.1086/506457
   DAULAIRE NMP, 1992, BRIT MED J, V304, P207
   Dibley MJ, 1996, J NUTR, V126, P434
   Diness BR, 2007, AM J CLIN NUTR, V86, P1152
   Fischer TK, 2002, J INFECT DIS, V186, P593, DOI 10.1086/342294
   Fisker AB, 2007, AM J CLIN NUTR, V86, P1032
   [Anonymous], 1993, LANCET, V342, P250
   Grotto I, 2003, J PEDIATR-US, V142, P297, DOI 10.1067/mpd.2003.116
   Humphrey JH, 1996, J PEDIATR-US, V128, P489, DOI 10.1016/S0022-3476(96)70359-1
   Long KZ, 2007, J INFECT DIS, V196, P978, DOI 10.1086/521195
   Long KZ, 2006, J INFECT DIS, V194, P1217, DOI 10.1086/508292
   Malaba LC, 2005, AM J CLIN NUTR, V81, P454
   Molbak K, 2000, VACCINE, V19, P393, DOI 10.1016/S0264-410X(00)00199-7
   RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401
   Rahmathullah L, 2003, BRIT MED J, V327, P254, DOI 10.1136/bmj.327.7409.254
   Ray PG, 2007, J MED VIROL, V79, P341, DOI 10.1002/jmv.20804
   Rodrigues A, 2007, PEDIATR INFECT DIS J, V26, P233, DOI 10.1097/01.inf.0000254389.65667.8b
   RUUSKA T, 1990, SCAND J INFECT DIS, V22, P259, DOI 10.3109/00365549009027046
   SOMMER A, 1986, LANCET, V1, P1169
   Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404
   Villamor E, 2005, CLIN MICROBIOL REV, V18, P446, DOI 10.1128/CNR.18.3.446-464.2005
   Villamor E., 2000, J INFECT DIS S, V182, P122
   [Anonymous], 1993, LANCET, V342, P7
NR 26
TC 13
Z9 13
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 1
PY 2010
VL 202
SU 1
BP S243
EP S251
DI 10.1086/653569
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 634ZA
UT WOS:000280623700035
PM 20684711
OA No
DA 2017-08-15
ER

PT J
AU Thye, T
   Vannberg, FO
   Wong, SH
   Owusu-Dabo, E
   Osei, I
   Gyapong, J
   Sirugo, G
   Sisay-Joof, F
   Enimil, A
   Chinbuah, MA
   Floyd, S
   Warndorff, DK
   Sichali, L
   Malema, S
   Crampin, AC
   Ngwira, B
   Teo, YY
   Small, K
   Rockett, K
   Kwiatkowski, D
   Fine, PE
   Hill, PC
   Newport, M
   Lienhardt, C
   Adegbola, RA
   Corrah, T
   Ziegler, A
   Morris, AP
   Meyer, CG
   Horstmann, RD
   Hill, AVS
AF Thye, Thorsten
   Vannberg, Fredrik O.
   Wong, Sunny H.
   Owusu-Dabo, Ellis
   Osei, Ivy
   Gyapong, John
   Sirugo, Giorgio
   Sisay-Joof, Fatou
   Enimil, Anthony
   Chinbuah, Margaret A.
   Floyd, Sian
   Warndorff, David K.
   Sichali, Lifted
   Malema, Simon
   Crampin, Amelia C.
   Ngwira, Bagrey
   Teo, Yik Y.
   Small, Kerrin
   Rockett, Kirk
   Kwiatkowski, Dominic
   Fine, Paul E.
   Hill, Philip C.
   Newport, Melanie
   Lienhardt, Christian
   Adegbola, Richard A.
   Corrah, Tumani
   Ziegler, Andreas
   Morris, Andrew P.
   Meyer, Christian G.
   Horstmann, Rolf D.
   Hill, Adrian V. S.
CA African TB Genetics Consortium
   Wellcome Trust Case Control Consor
TI Genome-wide association analyses identifies a susceptibility locus for
   tuberculosis on chromosome 18q11.2
SO NATURE GENETICS
LA English
DT Article
ID MYCOBACTERIUM-TUBERCULOSIS; WEST-AFRICA
AB We combined two tuberculosis genome-wide association studies from Ghana and The Gambia with subsequent replication in a combined 11,425 individuals. rs4331426, located in a gene-poor region on chromosome 18q11.2, was associated with disease (combined P = 6.8 x 10(-9), odds ratio = 1.19, 95% CI = 1.13-1.27). Our study demonstrates that genome-wide association studies can identify new susceptibility loci for infectious diseases, even in African populations, in which levels of linkage disequilibrium are particularly low.
C1 [Thye, Thorsten; Meyer, Christian G.; Horstmann, Rolf D.] Bernhard Nocht Inst Trop Med, Dept Mol Med, Hamburg, Germany.
   [Thye, Thorsten; Ziegler, Andreas] Univ Hosp Schleswig Holstein, Inst Med Biometry & Stat, Lubeck, Germany.
   [Vannberg, Fredrik O.; Wong, Sunny H.; Teo, Yik Y.; Small, Kerrin; Rockett, Kirk; Kwiatkowski, Dominic; Morris, Andrew P.; Hill, Adrian V. S.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Owusu-Dabo, Ellis; Enimil, Anthony] Kumasi Ctr Collaborat Res Trop Med, Kumasi, Ghana.
   [Owusu-Dabo, Ellis] Kwame Nkrumah Univ Sci & Technol, Coll Hlth Sci, Dept Community Hlth, Kumasi, Ghana.
   [Osei, Ivy; Gyapong, John; Chinbuah, Margaret A.] Ghana Hlth Serv, Hlth Res Unit, Accra, Ghana.
   [Sirugo, Giorgio; Sisay-Joof, Fatou; Hill, Philip C.; Newport, Melanie; Lienhardt, Christian; Adegbola, Richard A.; Corrah, Tumani] Med Res Ctr Labs, Banjul, Gambia.
   [Enimil, Anthony] Komfo Anokye Teaching Hosp, Kumasi, Ghana.
   [Floyd, Sian; Crampin, Amelia C.; Fine, Paul E.] London Sch Hyg & Trop Med, London WC1, England.
   [Warndorff, David K.; Sichali, Lifted; Malema, Simon; Ngwira, Bagrey; Fine, Paul E.] Karonga Prevent Study, Chilumba, Karonga Dist, Malawi.
RP Horstmann, RD (reprint author), Bernhard Nocht Inst Trop Med, Dept Mol Med, Hamburg, Germany.
EM horstmann@bnitm.de; adrian.hill@well.ox.ac.uk
RI Wong, Sunny/N-3754-2015
OI Wong, Sunny/0000-0002-3354-9310; Ziegler, Andreas/0000-0002-8386-5397;
   Small, Kerrin/0000-0003-4566-0005; Kwiatkowski,
   Dominic/0000-0002-5023-0176
FU Medical Research Council [G19/9, MC_U190071468]; Wellcome Trust [076438,
   079828, 084818]
CR Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621
   Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767
   Fitness J, 2004, AM J TROP MED HYG, V71, P341
   Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103
   Intemann CD, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000577
   Jallow M, 2009, NAT GENET, V41, P657, DOI 10.1038/ng.388
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702
   Thye T, 2009, HUM MOL GENET, V18, P381, DOI 10.1093/hmg/ddn352
   *WHO, 2009, LANCET, V373, P1145
   [Anonymous], 2003, WKLY EPIDEMIOL REC, V78, P122
   Ziegler A, 2009, GENET EPIDEMIOL, V33, pS45, DOI 10.1002/gepi.20472
NR 13
TC 161
Z9 169
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD SEP
PY 2010
VL 42
IS 9
BP 739
EP 741
DI 10.1038/ng.639
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA 644OM
UT WOS:000281388400005
PM 20694014
OA No
DA 2017-08-15
ER

PT J
AU Vester, U
   Hoelscher, M
   Fombah, A
   Tapgun, M
   Helmchen, U
   Corrah, T
   Hoyer, PF
AF Vester, U.
   Hoelscher, M.
   Fombah, A.
   Tapgun, M.
   Helmchen, U.
   Corrah, T.
   Hoyer, P. F.
TI Glomerular Diseases in the Gambia/Africa
SO PEDIATRIC NEPHROLOGY
LA English
DT Meeting Abstract
C1 [Vester, U.; Hoelscher, M.; Hoyer, P. F.] Univ Hosp, Essen, Germany.
   [Fombah, A.; Tapgun, M.; Corrah, T.] MRC Labs, Banjul, Gambia.
   [Helmchen, U.] Univ Hosp, Dept Pathol, Hamburg, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0931-041X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD SEP
PY 2010
VL 25
IS 9
MA 460
BP 1886
EP 1886
PG 1
WC Pediatrics; Urology & Nephrology
SC Pediatrics; Urology & Nephrology
GA 630BU
UT WOS:000280247200489
OA No
DA 2017-08-15
ER

PT J
AU de Jong, BC
   Antonio, M
   Gagneux, S
AF de Jong, Bouke C.
   Antonio, Martin
   Gagneux, Sebastien
TI Mycobacterium africanum-Review of an Important Cause of Human
   Tuberculosis in West Africa
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Review
ID PULMONARY TUBERCULOSIS; GENETIC DIVERSITY; MOLECULAR EPIDEMIOLOGY;
   GENOMIC DELETIONS; TUBERCLE-BACILLI; DRUG-RESISTANCE; COMPLEX STRAINS;
   BURKINA-FASO; VIRULENCE; THIACETAZONE
AB Mycobacterium africanum consists of two phylogenetically distinct lineages within the Mycobacterium tuberculosis complex, known as M. africanum West African 1 and M. africanum West African 2. These lineages are restricted to West Africa, where they cause up to half of human pulmonary tuberculosis. In this review we discuss the definition of M. africanum, describe the prevalence and restricted geographical distribution of M. africanum West African 1 and 2, review the occurrence of M. africanum in animals, and summarize the phenotypic differences described thus far between M. africanum and M. tuberculosis sensu stricto.
C1 [de Jong, Bouke C.; Antonio, Martin] Bacterial Dis Programme, MRC Labs, Fajara, Gambia.
   [de Jong, Bouke C.] NYU, Div Infect Dis, New York, NY USA.
   [de Jong, Bouke C.] Inst Trop Med, Mycobacteriol Unit, B-2000 Antwerp, Belgium.
   [Gagneux, Sebastien] MRC Natl Inst Med Res, London, England.
   [Gagneux, Sebastien] Swiss Trop & Publ Hlth Inst, Basel, Switzerland.
RP de Jong, BC (reprint author), Bacterial Dis Programme, MRC Labs, Fajara, Gambia.
EM bdejong@itg.be
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU Medical Research Council, United Kingdom; US National Institutes of
   Health [05TW006083, HHSN266200700022C, AI034238]
FX This work was supported by the Medical Research Council, United Kingdom,
   and by US National Institutes of Health grants 05TW006083 awarded to BD,
   and HHSN266200700022C and AI034238 awarded to SG. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Abate G, 2002, INT J TUBERC LUNG D, V6, P933
   Addo Kk, 2007, Ghana Med J, V41, P52
   Affolabi D, 2009, INT J TUBERC LUNG D, V13, P317
   Aldea M J, 1990, Enferm Infecc Microbiol Clin, V8, P64
   BARIL L, 1995, CLIN INFECT DIS, V21, P653
   Bercion R, 1997, INT J TUBERC LUNG D, V1, P110
   BHANOT N, 2008, INFECT DIS CLIN PRAC, V16, P327, DOI 10.1097/IPC.0b013e3181637a0f
   Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299
   Brudey K, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-23
   Cadmus S, 2006, J CLIN MICROBIOL, V44, P29, DOI 10.1128/JCM.44.1.29-34.2006
   CADMUS SI, 2010, TROP ANIM HLTH PROD
   CASTETS M, 1969, Bulletin de la Societe Medicale d'Afrique Noire de Langue Francaise, V14, P693
   Castets M, 1968, Rev Tuberc Pneumol (Paris), V32, P179
   Castets M, 1979, Med Trop (Mars), V39, P145
   Comas I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007815
   Comas I, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000600
   DAVID HL, 1978, INT J SYST BACTERIOL, V28, P467
   de Jong BC, 2007, INT J TUBERC LUNG D, V11, P450
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977
   de Jong BC, 2005, AIDS, V19, P1714, DOI 10.1097/01.aids.0000185991.54595.41
   de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504
   de Jong BC, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-11
   de Jong BC, 2010, FEMS IMMUNOL MED MIC, V58, P102, DOI 10.1111/j.1574-695X.2009.00628.x
   de Kantor I N, 1979, Bull Int Union Tuberc, V54, P173
   de Medeiros D, 1974, Bull Soc Med Afr Noire Lang Fr, V19, P96
   DEJONG BC, 2009, FEMS IMMUNO IN PRESS
   de Jong BC, 2009, J CLIN MICROBIOL
   DEKANTOR I, 1979, B ACAD VET FRANCE, V52, P499
   DEMERS AM, 2010, TUBERCULOSIS EDINB
   Desmond E, 2004, EMERG INFECT DIS, V10, P921
   DIARRA B, 2009, KEYST C OV CRIS TB A
   Diop S, 1976, Bull Soc Med Afr Noire Lang Fr, V21, P50
   Esteras MAR, 2003, ARCH BRONCONEUMOL, V39, P376
   Frothingham R, 1999, J CLIN MICROBIOL, V37, P1921
   FROTTIER J, 1990, B ACAD NAT MED PARIS, V174, P29
   Frottier J, 1990, B ACAD NATL MED, V174, P34
   Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103
   Gagneux S, 2007, LANCET INFECT DIS, V7, P328, DOI 10.1016/S1473-3099(07)70108-1
   Gao LY, 2004, MOL MICROBIOL, V53, P1677, DOI 10.1111/j.1365-2958.2004.04261.x
   Godreuil S, 2007, J CLIN MICROBIOL, V45, P921, DOI 10.1128/JCM.01918-06
   Goossens B, 1998, VET REC, V142, P277
   Goyal M, 1999, J INFECTION, V38, P171, DOI 10.1016/S0163-4453(99)90246-3
   GRANGE JM, 1989, EPIDEMIOL INFECT, V87, P127
   GROSSET J, 1971, Revue de Tuberculose et de Pneumologie, V35, P430
   GROSSET J, 1974, B INT UNION TUBERC, V230, P177
   Haas WH, 1997, J CLIN MICROBIOL, V35, P663
   Hershberg R, 2008, PLOS BIOL, V6, P2658, DOI 10.1371/journal.pbio.0060311
   Homolka S, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-103
   Huard RC, 2006, J BACTERIOL, V188, P4271, DOI 10.1128/JB.01783-05
   HUET M, 1971, Revue de Tuberculose et de Pneumologie, V35, P413
   Intemann CD, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000577
   Inwald J, 2003, TUBERCULOSIS, V83, P387, DOI 10.1016/j.tube.2003.08.018
   JANIER M, 1987, ANN DERMATOL VENER, V114, P1395
   JUNGBLUTH H, 1978, PRAX KLIN PNEUMOL, V32, P306
   Kallenius G, 1999, J CLIN MICROBIOL, V37, P3872
   KORSAK T, 1970, ACTA TUBERC PNEUMOL, V200, P388
   Ledru S, 1996, TUBERCLE LUNG DIS, V77, P429, DOI 10.1016/S0962-8479(96)90116-1
   MEISSNER G, 1969, ZENTBL BAKTERIOLOG P, V211, P69
   Meyer CG, 2008, TUBERCULOSIS, V88, P482, DOI 10.1016/j.tube.2008.05.004
   Mostowy S, 2004, J CLIN MICROBIOL, V42, P3594, DOI 10.1128/jcm.42.8.3594-3599.2004
   Mostowy S, 2002, J INFECT DIS, V186, P74, DOI 10.1086/341068
   Nerlich AG, 2009, INTERDISCIP PERSPECT, DOI DOI 10.1155/2009/437187
   Niang MN, 1999, MICROBES INFECT, V1, P1189, DOI 10.1016/S1286-4579(99)00243-9
   Niobe-Eyangoh SN, 2003, J CLIN MICROBIOL, V41, P2547, DOI 10.1128/JCM.41.6.2547-2553.2003
   NUNN P, 1991, LANCET, V337, P627
   ONIPEDE AO, 2005, AFRICAN J CLIN EXPT, V6, P167
   PARKHILL J, 2010, MYCOBACTERIUM GENOME
   PATTYN S R, 1970, Annales des Societes Belges de Medecine Tropicale de Parasitologie et de Mycologie, V50, P211
   PATTYN SR, 1978, ANN SOC BELG MED TR, V58, P59
   PEREZDEPEDR, 2008, ENFERM INFEC MICR CL, V26, P600
   PETIT JC, 1980, NOUV PRESSE MED, V9, P2845
   Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859
   Rahim Zeaur, 2007, Southeast Asian Journal of Tropical Medicine and Public Health, V38, P706
   Reparaz J, 1987, Rev Med Univ Navarra, V31, P103
   Rey J L, 1979, Med Trop (Mars), V39, P149
   SCHRODER KH, 1982, ZBL BAKT-INT J MED M, V251, P341
   Smith NH, 2009, NAT REV MICROBIOL, V7, P537, DOI 10.1038/nrmicro2165
   Streicher EM, 2007, J CLIN MICROBIOL, V45, P237, DOI 10.1128/JCM.01429-06
   THOREL MF, 1980, ANN INST PASTEUR MIC, VA131, P61
   THOREL MF, 1980, TUBERCLE, V61, P101, DOI 10.1016/0041-3879(80)90018-5
   Toure I M, 1982, Bull Int Union Tuberc, V57, P241
   Tsolaki AG, 2004, P NATL ACAD SCI USA, V101, P4865, DOI 10.1073/pnas.0305634101
   Unger F, 2003, RISK ASS MYCOBACTERI, P1
   Van Der Groen G, 1975, Ann Soc Belg Med Trop, V55, P647
   VANDERWERF TS, 1989, TUBERCLE, V70, P249, DOI 10.1016/0041-3879(89)90019-6
   Vasconcellos SEG, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-80
   Viana-Niero C, 2001, J CLIN MICROBIOL, V39, P57, DOI 10.1128/JCM.39.1.57-65.2001
   Zink AR, 2003, J CLIN MICROBIOL, V41, P359, DOI 10.1128/JCM.41.1.359-367.2003
NR 88
TC 79
Z9 79
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2727
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD SEP
PY 2010
VL 4
IS 9
AR e744
DI 10.1371/journal.pntd.0000744
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 655TB
UT WOS:000282271300003
PM 20927191
OA gold
DA 2017-08-15
ER

PT J
AU Adetifa, IMO
   Ota, MOC
   Walther, B
   Hammond, AS
   Lugos, MD
   Jeffries, DJ
   Donkor, SA
   Adegbola, RA
   Hill, PC
AF Adetifa, Ifedayo M. O.
   Ota, Martin O. C.
   Walther, Brigitte
   Hammond, Abdulrahman S.
   Lugos, Moses D.
   Jeffries, David J.
   Donkor, Simon A.
   Adegbola, Richard A.
   Hill, Philip C.
TI Decay Kinetics of an Interferon Gamma Release Assay with
   Anti-Tuberculosis Therapy in Newly Diagnosed Tuberculosis Cases
SO PLOS ONE
LA English
DT Article
ID T-CELL RESPONSES; LINKED IMMUNOSPOT ASSAY; MYCOBACTERIUM-TUBERCULOSIS;
   SKIN-TEST; PULMONARY TUBERCULOSIS; INFECTION; ELISPOT; CHILDREN; GAMBIA;
   CONTACTS
AB Background: Qualitative and quantitative changes in IGRA response offer promise as biomarkers to monitor Tuberculosis (TB) drug therapy, and for the comparison of new interventions. We studied the decay kinetics of TB-specific antigen T-cell responses measured with an in-house ELISPOT assay during the course of therapy.
   Methods: Newly diagnosed sputum smear positive TB cases with typical TB chest radiographs were recruited. All patients were given standard anti-TB treatment. Each subject was followed up for 6 months and treatment outcomes were documented. Blood samples were obtained for the ESAT-6 and CFP-10 (EC) ELISPOT at diagnosis, 1-, 2-, 4- and 6-months. Qualitative and quantitative reversion of the ELISPOT results were assessed with McNemar test, conditional logistic regression and mixed-effects hierarchical Poisson models.
   Results: A total of 116 cases were recruited and EC ELISPOT was positive for 87% (95 of 109) at recruitment. There was a significant decrease in the proportion of EC ELISPOT positive cases over the treatment period (p<0.001). Most of the reversion occurred between the start and first month of treatment and at completion at 6 months. ESAT-6 had higher median counts compared to CFP-10 at all time points. Counts for each antigen declined significantly with therapy (p<0.001). Reverters had lower median SFUs at the start of treatment compared to non-Reverters for both antigens. Apart from the higher median counts for non-Reverters, no other risk factors for non-reversion were found.
   Conclusions: TB treatment induces qualitative and quantitative reversion of a positive in-house IGRA in newly diagnosed cases of active TB disease. As this does not occur reliably in the majority of cured individuals, qualitative and quantitative reversion of an IGRA ELISPOT has limited clinical utility as a surrogate marker of treatment efficacy.
C1 [Adetifa, Ifedayo M. O.; Ota, Martin O. C.; Hammond, Abdulrahman S.; Lugos, Moses D.; Donkor, Simon A.; Adegbola, Richard A.; Hill, Philip C.] Med Res Council United Kingdom Labs, Bacterial Dis Programme, Fajara, Gambia.
   [Walther, Brigitte; Jeffries, David J.] Med Res Council United Kingdom Labs, Stat & Data Support Unit, Fajara, Gambia.
RP Adetifa, IMO (reprint author), Med Res Council United Kingdom Labs, Bacterial Dis Programme, Fajara, Gambia.
EM iadetifa@mrc.gm
RI Hammond, Abdulrahman/F-1541-2011
FU Medical Research Council, The Gambia; European and Developing Countries
   [CG_ta_2005_40203_001]
FX This study was funded by the Medical Research Council, The Gambia. IMOA
   received funding from the European and Developing Countries Trials
   Partnership through a career development fellowship (grant
   CG_ta_2005_40203_001). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   Adetifa IMO, 2007, INT J TUBERC LUNG D, V11, P350
   Adetifa IMO, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-122
   Adetifa IMO, 2010, PEDIATR INFECT DIS J, V29, P439, DOI 10.1097/INF.0b013e3181cb45da
   Aiken AM, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-66
   Bosshard V, 2009, RESP MED, V103, P30, DOI 10.1016/j.rmed.2008.09.012
   Carrara S, 2004, CLIN INFECT DIS, V38, P754, DOI 10.1086/381754
   CHEE CB, 2009, EUR RESP J
   Chee CBE, 2007, AM J RESP CRIT CARE, V175, P282, DOI 10.1164/rccm.200608-1109OC
   Connell TG, 2010, PEDIATR INFECT DIS J, V29, P285, DOI 10.1097/INF.0b013e3181c4822f
   Connell TG, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-138
   Crampin AC, 2010, AIDS, V24, P417, DOI 10.1097/QAD.0b013e32832f51cf
   Dheda K, 2007, J INFECTION, V55, P169, DOI 10.1016/j.jinf.2007.02.005
   Dheda K, 2009, CURR OPIN PULM MED, V15, P188, DOI 10.1097/MCP.0b013e32832a0adc
   Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002
   Dominguez J, 2009, DIAGN MICR INFEC DIS, V63, P43, DOI 10.1016/j.diagmicrobio.2008.09.010
   Goletti D, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-11
   Goletti D, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-5
   Herrmann JL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004130
   Hill PC, 2006, PEDIATRICS, V117, P1542, DOI 10.1542/peds.2005-2095
   Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Hill PC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001379
   Houben RMGJ, 2010, INT J TUBERC LUNG D, V14, P909
   Jeffries DJ, 2006, INT J TUBERC LUNG D, V10, P192
   Kaech SM, 2001, NAT IMMUNOL, V2, P415
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   Klenerman P, 2002, NAT REV IMMUNOL, V2, P263, DOI 10.1038/nri777
   Kobashi Y, 2009, J INFECTION, V58, P197, DOI 10.1016/j.jinf.2008.08.009
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lugos MD, 2009, IMMUNOL INVEST, V38, P341, DOI 10.1080/08820130902748744
   Menzies D, 2007, ANN INTERN MED, V146, P340
   Nicol MP, 2005, CLIN INFECT DIS, V40, P1301, DOI 10.1086/429245
   Pai Madhukar, 2006, J Occup Med Toxicol, V1, P7, DOI 10.1186/1745-6673-1-7
   Ribeiro S, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-23
   Sauzullo I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005187
   Vordermeier HM, 2002, INFECT IMMUN, V70, P3026, DOI 10.1128/IAI.70.6.3026-3032.2002
   WHO, 2009, WHOHTMTB2009420
   *WHO, 2007, 104 WHO
   Wilkinson KA, 2006, J INFECT DIS, V193, P354, DOI 10.1086/499311
NR 40
TC 16
Z9 16
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 1
PY 2010
VL 5
IS 9
AR e12502
DI 10.1371/journal.pone.0012502
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 645KT
UT WOS:000281456100014
OA gold
DA 2017-08-15
ER

PT J
AU Sutherland, JS
   de Jong, BC
   Jeffries, DJ
   Adetifa, IM
   Ota, MOC
AF Sutherland, Jayne S.
   de Jong, Bouke C.
   Jeffries, David J.
   Adetifa, Ifedayo M.
   Ota, Martin O. C.
TI Production of TNF-alpha, IL-12(p40) and IL-17 Can Discriminate between
   Active TB Disease and Latent Infection in a West African Cohort
SO PLOS ONE
LA English
DT Article
ID MYCOBACTERIUM-TUBERCULOSIS; INTERFERON-GAMMA; IFN-GAMMA; CELLS;
   ANTIGENS; INDUCTION; CYTOKINES; DIAGNOSIS; RESPONSES; DISTINCT
AB Background: Mycobacterium tuberculosis (MTb) infects approximately 2 billion people world-wide resulting in almost 2 million deaths per year. Determining biomarkers that distinguish different stages of tuberculosis (TB) infection and disease will provide tools for more effective diagnosis and ultimately aid in the development of new vaccine candidates. The current diagnostic kits utilising production of IFN-gamma in response to TB antigens can detect MTb infection but are unable to distinguish between infection and disease. The aim of this study was to assess if the use of a longer term assay and the analysis of multiple cytokines would enhance diagnosis of active TB in a TB-endemic population.
   Methods: We compared production of multiple cytokines (TNF-alpha, IFN-gamma, IL-10, IL-12(p40), IL-13, IL-17 and IL-18) following long-term (7 days) stimulation of whole-blood with TB antigens (ESAT-6/CFP-10 (EC), PPD or TB10.4) from TB cases (n=36) and their Mycobacterium-infected (TST+; n=20) or uninfected (TST-; n=19) household contacts (HHC).
   Results and Conclusions: We found that TNF-alpha production following EC stimulation and TNF-alpha and IL-12(p40) following TB10.4 stimulation were significantly higher from TB cases compared to TST+ HHC, while production of IFN-gamma and IL-13 were significantly higher from TST+ compared to TST- HHC following PPD or EC stimulation. Combined analysis of TNF-alpha, IL12( p40) and IL-17 following TB10.4 stimulation resulted in 85% correct classification into TB cases or TST+ HHC. 74% correct classification into TST+ or TST- HHC was achieved with IFN-gamma alone following TB10.4 stimulation (69% following EC) and little enhancement was seen with additional cytokines. We also saw a tendency for TB cases infected with M. africanum to have increased TNF-alpha and IL-10 production compared to those infected with M. tuberculosis. Our results provide further insight into the pathogenesis of tuberculosis and may enhance the specificity of the currently available diagnostic tests, particularly for diagnosis of active TB.
C1 [Sutherland, Jayne S.; de Jong, Bouke C.; Jeffries, David J.; Adetifa, Ifedayo M.; Ota, Martin O. C.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
RP Sutherland, JS (reprint author), MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
EM jsutherland@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675; Sutherland,
   Jayne/0000-0002-7083-4997
FU Bill & Melinda Gates Foundation; Medical Research Council (UK)
FX This work was jointly supported by the Bill & Melinda Gates Foundation
   (Grand Challenges for Global Health 6) (www.gatesfoundation.org) and the
   Medical Research Council (UK), The Gambia (www.mrc.gm). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Akgun M, 2005, RESPIROLOGY, V10, P295, DOI 10.1111/j.1440-1843.2005.00710.x
   Billeskov R, 2007, J IMMUNOL, V179, P3973
   Black GF, 2009, CLIN VACCINE IMMUNOL, V16, P1203, DOI 10.1128/CVI.00111-09
   Butera O, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-182
   Chegou Novel N, 2009, BMC Pulm Med, V9, P21, DOI 10.1186/1471-2466-9-21
   Cristianini N., 2000, INTRO SUPPORT VECTOR
   Cruz A, 2006, J IMMUNOL, V177, P1416
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977
   de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504
   de Jong BC, 2009, J CLIN MICROBIOL, V47, P994, DOI 10.1128/JCM.01216-08
   Demissie A, 2006, CLIN VACCINE IMMUNOL, V13, P179, DOI 10.1128/CVI.13.2.179-186.2006
   Dlugovitzky D, 1997, FEMS IMMUNOL MED MIC, V18, P203, DOI 10.1016/S0928-8244(97)00040-0
   DOCKRELL H, 2007, MICROBIOL TODAY  NOV
   Goldsack L, 2007, TUBERCULOSIS, V87, P465, DOI 10.1016/j.tube.2007.07.001
   GOLETTI D, 2009, EUR RESPIR J, V36, P135
   JORGENSEN B, 1987, J ROY STAT SOC B MET, V49, P127
   Kabeer BSA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009051
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110
   Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449
   Lalvani A, 2008, J INFECT DIS, V197, P941, DOI 10.1086/529049
   Martinez V, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-83
   Morosini M, 2005, INT J TUBERC LUNG D, V9, P753
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   Parida SK, 2010, DRUG DISCOV TODAY, V15, P148, DOI 10.1016/j.drudis.2009.10.005
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Scriba TJ, 2008, J IMMUNOL, V180, P1962
   Siawaya J. F. D., 2009, Clinical and Experimental Immunology, V156, P69, DOI 10.1111/j.1365-2249.2009.03875.x
   Sutherland JS, 2009, EUR J IMMUNOL, V39, P723, DOI 10.1002/eji.200838693
   van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000
   Verreck FAW, 2002, CLIN INFECT DIS, V35, P210, DOI 10.1086/341314
   Wallis RS, 2009, LANCET INFECT DIS, V9, P162, DOI 10.1016/S1473-3099(09)70042-8
   World Health Organization, 2008, TUB FACTS STOP TB PA, P1
NR 32
TC 54
Z9 55
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 24
PY 2010
VL 5
IS 8
AR e12365
DI 10.1371/journal.pone.0012365
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 641UD
UT WOS:000281154300008
PM 20811496
OA gold
DA 2017-08-15
ER

PT J
AU Burl, S
   Adetifa, UJ
   Cox, M
   Touray, E
   Whittle, H
   McShane, H
   Rowland-Jones, SL
   Flanagan, KL
AF Burl, Sarah
   Adetifa, Uche J.
   Cox, Momodou
   Touray, Ebrima
   Whittle, Hilton
   McShane, Helen
   Rowland-Jones, Sarah L.
   Flanagan, Katie L.
TI The Tuberculin Skin Test (TST) Is Affected by Recent BCG Vaccination but
   Not by Exposure to Non-Tuberculosis Mycobacteria (NTM) during Early Life
SO PLOS ONE
LA English
DT Article
ID CALMETTE-GUERIN VACCINATION; T-CELLS; IMMUNE-RESPONSES; VIRAL VACCINES;
   SCAR SIZE; REACTIVITY; INFANTS; HYPERSENSITIVITY; INTERLEUKIN-10;
   DEPRESSION
AB The tuberculin skin test (TST) is widely used in TB clinics to aid Mycobacterium tuberculosis (M.tb) diagnosis, but the definition and the significance of a positive test in very young children is still unclear. This study compared the TST in Gambian children at 41/2 months of age who either received BCG vaccination at birth (Group 1) or were BCG naive (Group 2) in order to examine the role of BCG vaccination and/or exposure to environmental mycobacteria in TST reactivity at this age. Nearly half of the BCG vaccinated children had a positive TST (>= 5 mm) whereas all the BCG naive children were non-reactive, confirming that recent BCG vaccination affects TST reactivity. The BCG naive children demonstrated in vitro PPD responses in peripheral blood in the absence of TST reactivity, supporting exposure to and priming by environmental mycobacterial antigens. Group 2 were then vaccinated at 41/2 months of age and a repeat TST was performed at 20-28 months of age. Positive reactivity (>= 5 mm) was evident in 11.1% and 12.5% infants from Group 1 and Group 2 respectively suggesting that the timing of BCG vaccination had little effect by this age. We further assessed for immune correlates in peripheral blood at 41/2 months of age. Mycobacterial specific IFN gamma responses were greater in TST responders than in non-responders, although the size of induration did not correlate with IFN gamma. However the IFN gamma: IL-10 ratio positively correlated with TST induration suggesting that the relationship between PPD induced IFN gamma and IL-10 in the peripheral blood may be important in controlling TST reactivity. Collectively these data provide further insights into how the TST is regulated in early life, and how a positive response might be interpreted.
C1 [Burl, Sarah; Adetifa, Uche J.; Cox, Momodou; Touray, Ebrima; Whittle, Hilton; Flanagan, Katie L.] Med Res Council UK Gambia, Fajara, Gambia.
   [McShane, Helen] Univ Oxford, Nuffield Dept Clin Med, Oxford, England.
   [McShane, Helen] Univ Oxford, Jenner Inst, Oxford, England.
   [Rowland-Jones, Sarah L.] Univ Oxford, WIMM, Oxford, England.
RP Burl, S (reprint author), Med Res Council UK Gambia, Fajara, Gambia.
EM sburl0712@gmail.com
FU Medical Research Council (MRC), The Gambia
FX This work was supported by The Medical Research Council (MRC), The
   Gambia. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR BRODY JA, 1964, NEW ENGL J MED, V271, P1294, DOI 10.1056/NEJM196412172712505
   BURL S, 2010, J IMMUNOLOG IN PRESS
   Cavani A, 2003, J IMMUNOL, V171, P5760
   Chan PC, 2008, INT J TUBERC LUNG D, V12, P1401
   CORRAH PT, 1994, THESIS OPEN U FAJARA
   Davids V, 2006, J INFECT DIS, V193, P531, DOI 10.1086/499825
   Delgado JC, 2002, P NATL ACAD SCI USA, V99, P7576, DOI 10.1073/pnas.062056099
   Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192
   FINNEY O, 2009, THESIS U LONDON LOND
   Floyd S, 2000, INT J TUBERC LUNG D, V4, P1133
   Ildirim I, 1995, PEDIATR INFECT DIS J, V14, P1060, DOI 10.1097/00006454-199512000-00006
   Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9
   Martins MVBS, 2007, TUBERCULOSIS, V87, P202, DOI 10.1016/j.tube.2006.07.006
   Menzies D, 2000, CLIN INFECT DIS, V31, pS71, DOI 10.1086/314075
   MENZIES R, 1992, AM REV RESPIR DIS, V145, P621
   Miles DJC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002905
   MiretCuadras P, 1996, TUBERCLE LUNG DIS, V77, P52, DOI 10.1016/S0962-8479(96)90076-3
   Mitchell AG, 1935, AM J DIS CHILD, V49, P695
   Nadler R, 2003, CLIN EXP IMMUNOL, V131, P206, DOI 10.1046/j.1365-2249.2003.02071.x
   Newport MJ, 2004, GENES IMMUN, V5, P122, DOI 10.1038/sj.gene.6364051
   Okan F, 2006, INT J TUBERC LUNG D, V10, P1337
   Ota MOC, 2006, J TROP PEDIATRICS, V52, P136, DOI 10.1093/tropej/fmi087
   PESANTI EL, 1994, AM J RESP CRIT CARE, V149, P1699
   RODYSILL KJ, 1989, J AM GERIATR SOC, V37, P435
   SANTIAGO EM, 2003, PEDIATRICS, V112, P298, DOI DOI 10.1542/PEDS.112.4.E298
   SEPULVEDA RL, 1994, TUBERCLE LUNG DIS, V75, P138, DOI 10.1016/0962-8479(94)90043-4
   Shingadia D, 2003, LANCET INFECT DIS, V3, P624, DOI 10.1016/S1473-3099(03)00771-0
   Sigmundsdottir H, 2004, CLIN IMMUNOL, V111, P119, DOI 10.1016/j.clim.2004.01.003
   STARR S, 1964, PEDIATRICS, V33, P769
   STARR S, 1964, NEW ENGL J MED, V270, P386, DOI 10.1056/NEJM196402202700802
   Sterne JAC, 1996, TUBERCLE LUNG DIS, V77, P117, DOI 10.1016/S0962-8479(96)90025-8
   *UNICEF, 2005, GLANC GAMB STAT
   Wang L, 2002, THORAX, V57, P804, DOI 10.1136/thorax.57.9.804
   WEIR RE, 1994, J IMMUNOL METHODS, V176, P93, DOI 10.1016/0022-1759(94)90353-0
NR 34
TC 19
Z9 21
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 19
PY 2010
VL 5
IS 8
AR e12287
DI 10.1371/journal.pone.0012287
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 640TN
UT WOS:000281075500019
PM 20808814
OA gold
DA 2017-08-15
ER

PT J
AU Ceesay, SJ
   Casals-Pascual, C
   Nwakanma, DC
   Walther, M
   Gomez-Escobar, N
   Fulford, AJC
   Takem, EN
   Nogaro, S
   Bojang, KA
   Corrah, T
   Jaye, MC
   Taal, MA
   Sonko, AAJ
   Conway, DJ
AF Ceesay, Serign J.
   Casals-Pascual, Climent
   Nwakanma, Davis C.
   Walther, Michael
   Gomez-Escobar, Natalia
   Fulford, Anthony J. C.
   Takem, Ebako N.
   Nogaro, Sarah
   Bojang, Kalifa A.
   Corrah, Tumani
   Jaye, Momodou Cherno
   Taal, Makie Abdoulie
   Sonko, Aja Adam Jagne
   Conway, David J.
TI Continued Decline of Malaria in The Gambia with Implications for
   Elimination
SO PLOS ONE
LA English
DT Article
ID GUINEA-BISSAU; SOUTH-AFRICA; WEST-AFRICA; TRANSMISSION; MORBIDITY;
   MORTALITY; CHILDREN; ERADICATION; COMBINATION; PROSPECTS
AB Background: A substantial decline in malaria was reported to have occurred over several years until 2007 in the western part of The Gambia, encouraging consideration of future elimination in this previously highly endemic region. Scale up of interventions has since increased with support from the Global Fund and other donors.
   Methodology/Principal Findings: We continued to examine laboratory records at four health facilities previously studied and investigated six additional facilities for a 7 year period, adding data from 243,707 slide examinations, to determine trends throughout the country until the end of 2009. We actively detected infections in a community cohort of 800 children living in rural villages throughout the 2008 malaria season, and assayed serological changes in another rural population between 2006 and 2009. Proportions of malaria positive slides declined significantly at all of the 10 health facilities between 2003 (annual mean across all sites, 38.7%) and 2009 (annual mean, 7.9%). Statistical modelling of trends confirmed significant seasonality and decline over time at each facility. Slide positivity was lowest in 2009 at all sites, except two where lowest levels were observed in 2006. Mapping households of cases presenting at the latter sites in 2007-2009 indicated that these were not restricted to a few residual foci. Only 2.8% (22/800) of a rural cohort of children had a malaria episode in the 2008 season, and there was substantial serological decline between 2006 and 2009 in a separate rural area.
   Conclusions: Malaria has continued to decline in The Gambia, as indicated by a downward trend in slide positivity at health facilities, and unprecedented low incidence and seroprevalence in community surveys. We recommend intensification of control interventions for several years to further reduce incidence, prior to considering an elimination programme.
C1 [Ceesay, Serign J.; Casals-Pascual, Climent; Nwakanma, Davis C.; Walther, Michael; Gomez-Escobar, Natalia; Fulford, Anthony J. C.; Takem, Ebako N.; Nogaro, Sarah; Bojang, Kalifa A.; Corrah, Tumani; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Casals-Pascual, Climent] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Fulford, Anthony J. C.; Conway, David J.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   [Jaye, Momodou Cherno] Royal Victoria Teaching Hosp, Natl Hlth Lab Serv, Banjul, Gambia.
   [Taal, Makie Abdoulie] Natl Publ Hlth Labs, Banjul, Gambia.
   [Sonko, Aja Adam Jagne] Natl Malaria Control Programme, Banjul, Gambia.
RP Ceesay, SJ (reprint author), MRC Labs, Banjul, Gambia.
EM dconway@mrc.gm
OI Bojang, Kalifa/0000-0001-7506-0938; Casals-Pascual,
   Climent/0000-0002-0867-8954; Conway, David/0000-0002-8711-3037
FU UK Medical Research Council (MRC)
FX Financial support for the research was provided by the UK Medical
   Research Council (MRC) (http://www.mrc.ac.uk/). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aguas R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001767
   Akpogheneta OJ, 2010, PARASITE IMMUNOL, V32, P296, DOI 10.1111/j.1365-3024.2009.01193.x
   *ALL PART PARL GRO, 2010, 6 ALL PART PARL GROU
   Behrens RH, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-235
   Bhattarai A, 2007, PLOS MED, V4, P1784, DOI 10.1371/journal.pmed.0040309
   BISOFFI Z, 2008, EURO SURVEILL, V13
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102
   Finney OC, 2009, EUR J IMMUNOL, V39, P1288, DOI 10.1002/eji.200839112
   Fulford AJC, 2006, PAEDIATR PERINAT EP, V20, P251, DOI 10.1111/j.1365-3016.2006.00714.x
   Gerritsen AAM, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-162
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   Hay SI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000048
   Kirby MJ, 2009, LANCET, V374, P998, DOI 10.1016/S0140-6736(09)60871-0
   Kleinschmidt I, 2001, TROP MED INT HEALTH, V6, P779, DOI 10.1046/j.1365-3156.2001.00790.x
   Kleinschmidt I, 2009, AM J TROP MED HYG, V80, P882
   Majambere S, 2010, AM J TROP MED HYG, V82, P176, DOI 10.4269/ajtmh.2010.09-0373
   MCGREGOR IA, 1956, BRIT MED J, V2, P686
   Mendis K, 2009, TROP MED INT HEALTH, V14, P802, DOI 10.1111/j.1365-3156.2009.02287.x
   *MICS, 2007, GAMB MULT IND CLUST, P1
   Mmbando BP, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-216
   Nyarango PM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-33
   O'Meara WP, 2008, LANCET, V372, P1555, DOI 10.1016/S0140-6736(08)61655-4
   Okiro Emelda A, 2009, BMC Med, V7, P75, DOI 10.1186/1741-7015-7-75
   PAMPANA E, 1963, TXB MALARIA ERADICAT, P508
   RAMROTH H, 2009, GLOB HLTH ACTION, V2, DOI DOI 10.3402/GHA.V3402I3400.1909
   Rodrigues A, 2008, TROP MED INT HEALTH, V13, P410, DOI 10.1111/j.1365-3156.2008.02016.x
   Satoguina J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-274
   Sharp BL, 2007, AM J TROP MED HYG, V76, P42
   Smith DL, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-87
   Snow RW, 2010, LANCET, V376, P137, DOI 10.1016/S0140-6736(10)60577-6
   Tatem AJ, 2010, P NATL ACAD SCI USA, V107, P12222, DOI 10.1073/pnas.1002971107
   Teklehaimanot HD, 2009, AM J TROP MED HYG, V80, P133
   World Health Organization, 2009, WHO WORLD MAL REP 20
   WHO, 2008, GLOB MAL CONTR EL RE
NR 35
TC 75
Z9 75
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 18
PY 2010
VL 5
IS 8
AR e12242
DI 10.1371/journal.pone.0012242
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 639XY
UT WOS:000281011600016
PM 20805878
OA gold
DA 2017-08-15
ER

PT J
AU Ryckman, KK
   Fielding, K
   Hill, AV
   Mendy, M
   Rayco-Solon, P
   Sirugo, G
   van der Sande, MA
   Waight, P
   Whittle, HC
   Hall, AJ
   Williams, SM
   Hennig, BJ
AF Ryckman, Kelli K.
   Fielding, Katherine
   Hill, Adrian V.
   Mendy, Maimuna
   Rayco-Solon, Pura
   Sirugo, Giorgio
   van der Sande, Marianne A.
   Waight, Pauline
   Whittle, Hilton C.
   Hall, Andrew J.
   Williams, Scott M.
   Hennig, Branwen J.
TI Host Genetic Factors and Vaccine-Induced Immunity to HBV Infection:
   Haplotype Analysis
SO PLOS ONE
LA English
DT Article
ID HEPATITIS-B-VIRUS; DISEASE SUSCEPTIBILITY; SURFACE-ANTIGEN;
   IMMUNOGENETICS; RESPONSES; TWINS
AB Hepatitis B virus (HBV) infection remains a significant health burden world-wide, although vaccines help decrease this problem. We previously identified associations of single nucleotide polymorphisms in several candidate genes with vaccine-induced peak antibody level (anti-HBs), which is predictive of long-term vaccine efficacy and protection against infection and persistent carriage; here we report on a haplotype-based analysis. A total of 688 SNPs from 117 genes were examined for a two, three and four sliding window haplotype analysis in a Gambian cohort. Analysis was performed on 197 unrelated individuals, 454 individuals from 174 families, and the combined sample (N = 651). Global and individual haplotype association tests were carried out (adjusted for covariates), employing peak anti-HBs level as outcome. Five genes (CD44, CD58, CDC42, IL19 and IL1R1) had at least one significant haplotype in the unrelated or family analysis as well as the combined analysis. Previous single locus results were confirmed for CD44 (combined global p = 9.1 x 10(-5) for rs353644-rs353630-rs7937602) and CD58 (combined global p = 0.008 for rs1414275-rs11588376-rs1016140). Haplotypes in CDC42, IL19 and IL1R1 also associated with peak anti-HBs level. We have identified strong haplotype effects on HBV vaccine-induced antibody level in five genes, three of which, CDC42, IL19 and IL1R1, did not show evidence of association in a single SNP analyses and corroborated the majority of these effects in two datasets. The haplotype analysis identified associations with HBV vaccine-induced immunity in several new genes.
C1 [Ryckman, Kelli K.; Williams, Scott M.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37203 USA.
   [Ryckman, Kelli K.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.
   [Rayco-Solon, Pura; Hennig, Branwen J.] London Sch Hyg & Trop Med, Med Res Council Int Nutr Grp, London WC1, England.
   [Hill, Adrian V.] Univ Oxford, Welcome Trust Ctr Human Genet, Oxford, England.
   [Hill, Adrian V.] Univ Oxford, Jenner Inst, Oxford, England.
   [Mendy, Maimuna; van der Sande, Marianne A.; Waight, Pauline; Whittle, Hilton C.] MRC Labs, Banjul, Gambia.
   [Rayco-Solon, Pura; Hennig, Branwen J.] MRC, Keneba, Gambia.
   [van der Sande, Marianne A.] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands.
   [Sirugo, Giorgio] Osped S Pietro FBF, Unita Genet Med, Rome, Italy.
RP Ryckman, KK (reprint author), Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37203 USA.
EM smwilliams@chgr.mc.vanderbilt.edu
RI Williams, Scott/B-9491-2012; Hennig, Branwen/M-6444-2014
FU Wellcome Trust [GR069267AIA]
FX The study was funded by a Wellcome Trust Advanced Fellowship grant to
   BJH (grant number GR069267AIA, http://www.wellcome.ac.uk/). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR ALPER CA, 1995, EXP CLIN IMMUNOGENET, V12, P171
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Brazzoli M, 2008, J VIROL, V82, P8316, DOI 10.1128/JVI.00665-08
   Clark AG, 2004, GENET EPIDEMIOL, V27, P321, DOI 10.1002/gepi.20025
   Commins S, 2008, J ALLERGY CLIN IMMUN, V121, P1108, DOI 10.1016/j.jaci.2008.02.026
   Davila S, 2010, GENES IMMUN, V11, P232, DOI 10.1038/gene.2010.1
   Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Hennig BJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001898
   Hodge JW, 2005, J IMMUNOL, V174, P5994
   Hohler T, 2002, J HEPATOL, V37, P387, DOI 10.1016/S0168-8278(02)00205-2
   Kimman TG, 2007, COMMUNITY GENET, V10, P201, DOI 10.1159/000106559
   Kimura K, 2009, J GASTROENTEROL, V44, P218, DOI 10.1007/s00535-008-2300-8
   Kruger A, 2005, CLIN EXP IMMUNOL, V140, P325, DOI 10.1111/j.1365-2249.2005.02765.x
   LIN TM, 1989, ANTICANCER RES, V9, P737
   Milich DR, 2003, AUTOIMMUN REV, V2, P248, DOI 10.1016/S1568-9972(03)00031-4
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Morris RW, 2002, GENET EPIDEMIOL, V23, P221, DOI 10.1002/gepi.10200
   Newport MJ, 2004, GENES IMMUN, V5, P122, DOI 10.1038/sj.gene.6364051
   Sirugo G, 2008, HUM GENET, V123, P557, DOI 10.1007/s00439-008-0511-y
   Stanley SL, 2007, J INFECT DIS, V196, P212, DOI 10.1086/518794
   Tan TL, 2008, BBA-MOL CELL RES, V1783, P360, DOI 10.1016/j.bbamcr.2007.10.024
   Thursz M, 2001, QJM-MON J ASSOC PHYS, V94, P287, DOI 10.1093/qjmed/94.6.287
   van der Sande MAB, 2006, J INFECT DIS, V193, P1528
   Van LH, 2001, ENV HLTH PERSPECT, V109, P757
   Wang CB, 2004, HEPATOLOGY, V39, P978, DOI 10.1002/hep.20142
   Zuckerman JN, 2006, J MED VIROL, V78, P169, DOI 10.1002/jmv.20524
   2009, HEPATITIS B FACT SHE
NR 29
TC 18
Z9 19
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 18
PY 2010
VL 5
IS 8
AR e12273
DI 10.1371/journal.pone.0012273
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 639XY
UT WOS:000281011600031
PM 20806065
OA gold
DA 2017-08-15
ER

PT J
AU Burl, S
   Adetifa, UJ
   Cox, M
   Touray, E
   Ota, MO
   Marchant, A
   Whittle, H
   McShane, H
   Rowland-Jones, SL
   Flanagan, KL
AF Burl, Sarah
   Adetifa, Uche J.
   Cox, Momodou
   Touray, Ebrima
   Ota, Martin O.
   Marchant, Arnaud
   Whittle, Hilton
   McShane, Helen
   Rowland-Jones, Sarah L.
   Flanagan, Katie L.
TI Delaying Bacillus Calmette-Guerin Vaccination from Birth to 4 1/2 Months
   of Age Reduces Postvaccination Th1 and IL-17 Responses but Leads to
   Comparable Mycobacterial Responses at 9 Months of Age
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID INTERFERON-GAMMA RESPONSE; BCG VACCINATION; IMMUNE-RESPONSES;
   ENVIRONMENTAL MYCOBACTERIA; BOVIS BCG; EARLY-LIFE; T-CELLS; PUBLISHED
   LITERATURE; PROTECTIVE EFFICACY; CYTOKINE PROFILES
AB Bacillus Camette-Guerin (BCG) vaccine is the only licensed vaccine against tuberculosis, yet its protective efficacy is highly variable between different geographical regions. We hypothesized that exposure to nontuberculous mycobacteria attenuates BCG immunogenicity by inducing mycobacterial-specific regulatory T cells (Tregs). Gambian neonates were recruited at birth and randomized to receive BCG vaccination either at birth or at 4 1/2 mo. Mycobacterial immune responses were assessed at birth, 4 1/2, and 9 mo of age. At 4 1/2 mo of age the BCG naive individuals had detectable mycobacterial responses, including increased IL-10 production suggesting environmental priming. Vaccination at birth significantly enhanced Th1, Th2, IL-6, IL-17, and Treg responses in mycobacterial cultures at 4 1/2 mo compared with the BCG naive group. Analyzing results at 4 1/2 mo postvaccination revealed lower IFN-gamma, IL-6, and IL-17 responses in the delayed BCG vaccine group compared with those vaccinated at birth, but this did not relate to Treg levels prevaccination. When comparing responses pre- and post-BCG vaccination in the delayed vaccine group, there was no priming of mycobacterial IL-17. Mycobacterial responses waned over 9 mo in those vaccinated at birth, leading to comparable mycobacterial immunity in both groups at 9 mo of age. Overall, these data suggest that vaccination at birth induces a broad Th1/Th2/IL-17/Treg mycobacterial response but the Th1/Th-17 response was reduced when delaying the vaccine. The evidence did not suggest that mycobacterial specific naturally occurring Tregs accounted for this attenuated immunogenicity. The Journal of Immunology, 2010, 185: 2620-2628.
C1 [Burl, Sarah; Adetifa, Uche J.; Cox, Momodou; Touray, Ebrima; Ota, Martin O.; Whittle, Hilton; Flanagan, Katie L.] Med Res Council United Kingdom, Fajara, Gambia.
   [Marchant, Arnaud] Univ Libre Bruxelles, Inst Med Immunol, Charleroi, Belgium.
   [McShane, Helen] Univ Oxford, Jenner Inst, Oxford, England.
   [Rowland-Jones, Sarah L.] Univ Oxford, John Radcliffe Hosp, Weatherhall Inst Mol Med, Oxford OX3 9DU, England.
RP Burl, S (reprint author), Med Res Council United Kingdom, POB 273, Fajara, Gambia.
EM sburl@mrc.gm
FU Medical Research Council, The Gambia
FX This work was supported by the Medical Research Council, The Gambia. A.
   M. is a Senior Research Associate of the Fonds National de la Recherche
   Scientifique, Belgium.
CR Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014
   APPELBERG R, 1994, IMMUNOBIOLOGY, V191, P520
   Arend SM, 2005, J INFECT DIS, V191, P1301, DOI 10.1086/428950
   Barrios C, 1996, EUR J IMMUNOL, V26, P1489, DOI 10.1002/eji.1830260713
   BENNETT JA, 1978, P NATL ACAD SCI USA, V75, P5142, DOI 10.1073/pnas.75.10.5142
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   Black GF, 2001, J INFECT DIS, V184, P322, DOI 10.1086/322042
   Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918
   Brandt L, 2002, INFECT IMMUN, V70, P672, DOI 10.1128/IAI.70.2.672-678.2002
   BROWN CA, 1985, TUBERCLE, V66, P251, DOI 10.1016/0041-3879(85)90062-5
   Buddle BM, 2002, VACCINE, V20, P1126, DOI 10.1016/S0264-410X(01)00436-4
   CLEMENS JD, 1983, JAMA-J AM MED ASSOC, V249, P2362, DOI 10.1001/jama.249.17.2362
   COLDITZ GA, 1995, PEDIATRICS, V96, P29
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   COMSTOCK GW, 1966, AM REV RESPIR DIS, V93, P171
   CORRAH PT, 1994, MRC GAMBIA
   Davids V, 2006, J INFECT DIS, V193, P531, DOI 10.1086/499825
   DECASSAN SC, 2010, CLIN VACCINE IMMUNOL
   Demangel C, 2005, INFECT IMMUN, V73, P2190, DOI 10.1128/IAI.73.4.2190-2196.2005
   EDWARDS ML, 1982, J INFECT DIS, V145, P733
   Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192
   Finan C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003485
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   FINNEY O, 2009, THESIS U LONDON LOND
   FLANAGAN KL, 2009, EUR J IMMUNOL
   FLESCH IEA, 1990, INFECT IMMUN, V58, P269
   Hanekom WA, 2005, ANN NY ACAD SCI, V1062, P69, DOI 10.1196/annals.1358.010
   HART PD, 1977, BRIT MED J, V2, P293
   Hill PC, 2005, J CLIN MICROBIOL, V43, P2070, DOI 10.1128/JCM.43.5.2070-2074.2005
   Howard CJ, 2002, CLIN EXP IMMUNOL, V130, P190, DOI 10.1046/j.1365-2249.2002.01987.x
   Hussey GD, 2002, IMMUNOLOGY, V105, P314, DOI 10.1046/j.1365-2567.2002.01366.x
   ILDIRIM I, 1992, ARCH DIS CHILD, V67, P80
   Jaron B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002833
   Kagina BMN, 2009, VACCINE, V27, P5488, DOI 10.1016/j.vaccine.2009.06.103
   KAMALA T, 1994, APPL ENVIRON MICROB, V60, P2180
   Kamala T, 1996, INDIAN J MED RES, V103, P201
   Lagranderie MRR, 1996, INFECT IMMUN, V64, P1
   Lalor MK, 2010, VACCINE, V28, P1635, DOI 10.1016/j.vaccine.2009.11.004
   LANCKRIET C, 1995, INT J EPIDEMIOL, V24, P1042, DOI 10.1093/ije/24.5.1042
   Larsen JM, 2007, IMMUNOLOGY, V121, P276, DOI 10.1111/j.1365-2567.2007.02575.x
   Li LQ, 2004, IMMUNITY, V20, P429, DOI 10.1016/S1074-7613(04)00072-X
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Mendez-Samperio P, 2008, CELL IMMUNOL, V251, P37, DOI 10.1016/j.cellimm.2008.03.002
   Miles DJC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002905
   Nabeshima Shigeki, 2005, Journal of Infection and Chemotherapy, V11, P18, DOI 10.1007/s10156-004-0357-8
   Newport MJ, 2004, GENES IMMUN, V5, P122, DOI 10.1038/sj.gene.6364051
   ORME IM, 1986, J EXP MED, V163, P203, DOI 10.1084/jem.163.1.203
   Ota MOC, 2002, J IMMUNOL, V168, P919
   PABST HF, 1989, AM REV RESPIR DIS, V140, P1007
   Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231
   Power CA, 1998, INFECT IMMUN, V66, P5743
   ROOK GAW, 1981, TUBERCLE, V62, P63, DOI 10.1016/0041-3879(81)90038-6
   Rook GAW, 2007, CURR MOL MED, V7, P327
   Rowe J, 2000, INFECT IMMUN, V68, P3873, DOI 10.1128/IAI.68.7.3873-3877.2000
   SCHRIER DJ, 1980, CELL IMMUNOL, V56, P347, DOI 10.1016/0008-8749(80)90110-0
   Scriba TJ, 2008, J IMMUNOL, V180, P1962
   Seah GT, 2000, J INFECT DIS, V181, P385, DOI 10.1086/315200
   Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7
   Smith D, 2000, CLIN INFECT DIS, V31, pS77, DOI 10.1086/314073
   Soares AP, 2008, J IMMUNOL, V180, P3569
   STANFORD JL, 1981, TUBERCLE, V62, P55, DOI 10.1016/0041-3879(81)90037-4
   SUDRE P, 1992, B WORLD HEALTH ORGAN, V70, P149
   SUTHERLAND I, 1979, TUBERCLE, V60, P225, DOI 10.1016/0041-3879(79)90003-5
   SUTHERLAND JS, 2009, EUR J IMMUNOL
   TIDJANI O, 1986, TUBERCLE, V67, P269, DOI 10.1016/0041-3879(86)90016-4
   Tripathy S P, 1983, Ann Natl Acad Med Sci, V19, P11
   *UNICEF, 2005, GLANC GAMB STAT
   Weir RE, 2006, CLIN EXP IMMUNOL, V146, P390, DOI 10.1111/j.1365-2249.2006.03222.x
   Weir RE, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-9
   WEISZFEILER JG, 1981, REV INFECT DIS, V3, P1081
   World Health Organization Geneva, 2004, WKLY EPIDEMIOL REC, V79, P25
   WHO, 2009, GLOB TUB CONTR EP ST
   Wu B, 2007, INFECT IMMUN, V75, P3658, DOI 10.1128/IAI.00244-07
   Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142
   Young SL, 2007, INFECT IMMUN, V75, P2833, DOI 10.1128/IAI.01826-06
NR 75
TC 40
Z9 40
U1 0
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD AUG 15
PY 2010
VL 185
IS 4
BP 2620
EP 2628
DI 10.4049/jimmunol.1000552
PG 9
WC Immunology
SC Immunology
GA 635NH
UT WOS:000280661900070
PM 20644160
OA No
DA 2017-08-15
ER

PT J
AU Southall, D
   Cham, M
   Sey, O
AF Southall, David
   Cham, Mamady
   Sey, Omar
TI Health workers lost to international bodies in poor countries
SO LANCET
LA English
DT Editorial Material
C1 [Southall, David] Maternal & Childhlth Advocacy Int, Nottingham NG1 5BB, England.
   [Cham, Mamady; Sey, Omar] Minist Hlth & Social Welf, Banjul, Gambia.
RP Southall, D (reprint author), Maternal & Childhlth Advocacy Int, Nottingham NG1 5BB, England.
EM davids@doctors.org.uk
CR *HLTH ALL INT, NGO COD COND HLTH SY
   *MCAI, MCAI ESS EMCH ESS SU
   *NUFF COUNC BIOETH, 2005, ETH HEALTHC REL RES
   Nuffield Council on Bioethics, 2002, ETH RES REL HEALTHC
   WHO, 2010, INCREASING ACCESS TO HEALTH WORKERS IN REMOTE AND RURAL AREAS THROUGH IMPROVED RETENTION: GLOBAL POLICY RECOMMENDATIONS, P1
   *WHO GLOB HTLH WOR, 2008, KAMP DECL AG GLOB AC
   [Anonymous], 2008, LANCET, V371, P623
NR 7
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD AUG 14
PY 2010
VL 376
IS 9740
BP 498
EP 499
DI 10.1016/S0140-6736(10)61157-9
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 643BE
UT WOS:000281266800010
PM 20709218
OA No
DA 2017-08-15
ER

PT J
AU Boyle, MJ
   Wilson, DW
   Richards, JS
   Riglar, DT
   Tetteh, KKA
   Conway, DJ
   Ralph, SA
   Baum, J
   Beeson, JG
AF Boyle, Michelle J.
   Wilson, Danny W.
   Richards, Jack S.
   Riglar, David T.
   Tetteh, Kevin K. A.
   Conway, David J.
   Ralph, Stuart A.
   Baum, Jake
   Beeson, James G.
TI Isolation of viable Plasmodium falciparum merozoites to define
   erythrocyte invasion events and advance vaccine and drug development
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE host cell invasion; immunity; inhibitors; malaria; imaging
ID GROWTH-INHIBITORY ANTIBODIES; APICAL MEMBRANE ANTIGEN-1; BLOOD-CELL
   INVASION; SURFACE PROTEIN-1; PROTEASE INHIBITORS; KNOWLESI MEROZOITES;
   MALARIA PARASITES; PROTECTION; IMMUNITY; APICAL-MEMBRANE-ANTIGEN-1
AB During blood-stage infection by Plasmodium falciparum, merozoites invade RBCs. Currently there is limited knowledge of cellular and molecular invasion events, and no established assays are available to readily measure and quantify invasion-inhibitory antibodies or compounds for vaccine and drug studies. We report the isolation of viable merozoites that retain their invasive capacity, at high purity and yield, purified by filtration of highly synchronous populations of schizonts. We show that the half-life of merozoite invasive capacity after rupture is 5 min at 37 degrees C, and 15 min at room temperature. Studying the kinetics of invasion revealed that 80% of invasion events occur within 10 min of mixing merozoites and RBCs. Invasion efficiency was maximum at low merozoite-to-RBC ratios and occurred efficiently in the absence of serum and with high concentrations of dialyzed nonimmune serum. We developed and optimized an invasion assay by using purified merozoites that enabled invasion-inhibitory activity of antibodies and compounds to be measured separately from other mechanisms of growth inhibition; the assay was more sensitive for detecting inhibitory activity than established growth-inhibition assays. Furthermore, with the use of purified merozoites it was possible to capture and fix merozoites at different stages of invasion for visualization by immunofluorescence microscopy and EM. We thereby demonstrate that processing of the major merozoite antigen merozoite surface protein-1 occurs at the time of RBC invasion. These findings have important implications for defining invasion events and molecular interactions, understanding immune interactions, and identifying and evaluating inhibitors to advance vaccine and drug development.
C1 [Boyle, Michelle J.; Wilson, Danny W.; Richards, Jack S.; Riglar, David T.; Baum, Jake; Beeson, James G.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.
   [Boyle, Michelle J.; Richards, Jack S.; Riglar, David T.] Univ Melbourne, Dept Med Biol, Melbourne, Vic 3010, Australia.
   [Tetteh, Kevin K. A.; Conway, David J.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Conway, David J.] MRC Labs, Banjul, Gambia.
   [Ralph, Stuart A.] Univ Melbourne, Mol Sci & Biotechnol Inst Bio21, Dept Biochem & Mol Biol, Melbourne, Vic 3010, Australia.
RP Beeson, JG (reprint author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.
EM beeson@wehi.edu.au
OI Richards, Jack/0000-0001-5786-6989; Boyle, Michelle/0000-0002-0268-232X;
   Baum, Jake/0000-0002-0275-352X; Conway, David/0000-0002-8711-3037
FU National Health and Medical Research Council of Australia; Independent
   Research Institutes Infrastructure Support Scheme grant; Australian
   Research Council; Australian Postgraduate Award; Victorian State
   Government; Pratt Foundation; University of Melbourne, School of
   Medicine, Dentistry and Health Sciences;  [FT0990350]
FX We thank Alan Cowman (Walter and Eliza Hall Institute, Australia), Paul
   Gilson and Brendan Crabb (Burnet Institute, Australia), Tony Hodder
   (Walter and Eliza Hall Institute, Australia), and Robin Anders (Latrobe
   University, Australia) for antibodies to RAP1, MSP1-19, AMA1, and MSP2,
   respectively, and helpful advice on the study; Julia Cutts for important
   experimental ideas; and Salenna Elliott for critical reading of the
   manuscript and the WEHI flow-cytometry services. RBCs and serum for
   parasite culture were provided by the Red Cross Blood Bank (Melbourne,
   Australia). Funding for the study was provided by a National Health and
   Medical Research Council of Australia Project grant and Career
   Development awards (J.G.B., J.B., and S.A.R.); a Postgraduate Research
   Scholarship (J.S.R.) and Independent Research Institutes Infrastructure
   Support Scheme grant; an Australian Research Council Future Fellowship
   (J.G.B.) and Grant FT0990350 (to S.A.R.); an Australian Postgraduate
   Award (M.J.B. and D.R.); an OIS Grant from the Victorian State
   Government; a Pratt Foundation Postgraduate Scholarship (D.T.R.); and a
   Top-Up Postgraduate Award from the University of Melbourne, School of
   Medicine, Dentistry and Health Sciences (M.J.B.).
CR Beeson JG, 1999, J INFECT DIS, V180, P464, DOI 10.1086/314899
   Bergmann-Leitner ES, 2006, AM J TROP MED HYG, V75, P437
   Blackman MJ, 2008, CELL MICROBIOL, V10, P1925, DOI 10.1111/j.1462-5822.2008.01176.x
   BLACKMAN MJ, 1994, METHOD CELL BIOL, V45, P213
   Boyle MJ, 2010, BLOOD, V115, P4559, DOI 10.1182/blood-2009-09-243725
   Coley AM, 2006, INFECT IMMUN, V74, P2628, DOI 10.1128/IAI.74.5.2628-2636.2006
   Cowman AF, 2006, CELL, V124, P755, DOI 10.1016/j.cell.2006.02.006
   DENNIS ED, 1975, PARASITOLOGY, V71, P475
   Doolan DL, 2009, CLIN MICROBIOL REV, V22, P13, DOI 10.1128/CMR.00025-08
   Dowse Timothy J., 2008, V47, P121
   Dutta S, 2003, P NATL ACAD SCI USA, V100, P12295, DOI 10.1073/pnas.2032858100
   Elliott SR, 2008, CLIN INFECT DIS, V46, P1794, DOI 10.1086/588049
   Fowkes FJI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000218
   Gilson PR, 2009, INT J PARASITOL, V39, P91, DOI 10.1016/j.ijpara.2008.09.007
   Glushakova S, 2009, CELL MICROBIOL, V11, P95, DOI 10.1111/j.1462-5822.2008.01242.x
   HADLEY T, 1983, EXP PARASITOL, V55, P306, DOI 10.1016/0014-4894(83)90027-9
   Harris KS, 2005, INFECT IMMUN, V73, P6981, DOI 10.1128/IAI.73.10.6981-6989.2005
   Harris PK, 2005, PLOS PATHOG, V1, P241, DOI 10.1371/journal.ppat.0010029
   Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001
   Holder AA, 2009, PARASITOLOGY, V136, P1445, DOI 10.1017/S0031182009990515
   JOHNSON JG, 1980, PARASITOLOGY, V80, P539
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   LeRoux M, 2009, TRENDS PARASITOL, V25, P474, DOI 10.1016/j.pt.2009.07.005
   McCallum FJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003571
   O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403
   O'Donnell RA, 2005, CURR OPIN MICROBIOL, V8, P422, DOI 10.1016/j.mib.2005.06.018
   Osier FHA, 2008, INFECT IMMUN, V76, P2240, DOI 10.1128/IAI.01585-07
   Persson KEM, 2006, J CLIN MICROBIOL, V44, P1665, DOI 10.1128/JCM.44.5.1665-1673.2006
   Polley SD, 2003, INFECT IMMUN, V71, P1833, DOI 10.1128/IAI.71.4.1833-1842.2003
   RAMASAMY R, 1987, IMMUNOL CELL BIOL, V65, P419, DOI 10.1038/icb.1987.48
   Richards JS, 2009, IMMUNOL CELL BIOL, V87, P377, DOI 10.1038/icb.2009.27
   Salmon BL, 2001, P NATL ACAD SCI USA, V98, P271, DOI 10.1073/pnas.011413198
   SCHOFIELD L, 1986, MOL BIOCHEM PARASIT, V18, P183, DOI 10.1016/0166-6851(86)90037-X
   Singh S, 2006, INFECT IMMUN, V74, P4573, DOI 10.1128/IAI.01679-05
   Singh S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000746
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Tonkin CJ, 2004, MOL BIOCHEM PARASIT, V137, P13, DOI 10.1016/j.molbiopara.2004.05.009
   Wilson DW, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-152
   Woehlbier U, 2006, INFECT IMMUN, V74, P1313, DOI 10.1128/IAI.74.2.1313-1322.2006
NR 39
TC 122
Z9 123
U1 3
U2 19
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 10
PY 2010
VL 107
IS 32
BP 14378
EP 14383
DI 10.1073/pnas.1009198107
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 636UD
UT WOS:000280767700073
PM 20660744
OA No
DA 2017-08-15
ER

PT J
AU Jarjou, LMA
   Laskey, MA
   Sawo, Y
   Goldberg, GR
   Cole, TJ
   Prentice, A
AF Jarjou, Landing M. A.
   Laskey, M. Ann
   Sawo, Yankuba
   Goldberg, Gail R.
   Cole, Timothy J.
   Prentice, Ann
TI Effect of calcium supplementation in pregnancy on maternal bone outcomes
   in women with a low calcium intake
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID MINERAL DENSITY; GAMBIAN WOMEN; LACTATION; ACCRETION; RECOVERY; WEIGHT;
   SIZE
AB Background: Mobilization of maternal bone mineral partly supplies calcium for fetal and neonatal bone growth and development.
   Objective: We investigated whether pregnant women with low calcium intakes may have a more extensive skeletal response postpartum that may compromise their short-or long-term bone health.
   Design: In a subset of participants (n = 125) in a double-blind, randomized, placebo-controlled trial (International Trial Registry: ISRCTN96502494) in pregnant women in The Gambia, West Africa, with low calcium intakes (approximate to 350 mg Ca/d), we measured bone mineral status of the whole body, lumbar spine, and hip by using dual-energy X-ray absorptiometry and measured bone mineral status of the forearm by using single-photon absorptiometry at 2, 13, and 52 wk lactation. We collected blood and urine from the subjects at 20 wk gestation and at 13 wk postpartum. Participants received calcium carbonate (1500 mg Ca/d) or a matching placebo from 20 wk gestation to parturition; participants did not consume supplements during lactation.
   Results: Women who received the calcium supplement in pregnancy had significantly lower bone mineral content (BMC), bone area (BA), and bone mineral density (BMD) at the hip throughout 12 mo lactation (mean +/- SE difference: BMC = -10.7 +/- 3.7%, P = 0.005; BA = -3.8 +/- 1.9%, P = 0.05; BMD = -6.9 +/- 2.6%, P = 0.01). The women also experienced greater decreases in bone mineral during lactation at the lumbar spine and distal radius and had biochemical changes consistent with greater bone mineral mobilization.
   Conclusions: Calcium supplementation in pregnant women with low calcium intakes may disrupt metabolic adaptation and may not benefit maternal bone health. Further study is required to determine if such effects persist long term or elicit compensatory changes in bone structure. Am J Clin Nutr 2010; 92: 450-7.
C1 [Prentice, Ann] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   [Cole, Timothy J.] UCL, Inst Child Hlth, MRC Ctr Epidemiol Child Hlth, London, England.
   [Jarjou, Landing M. A.; Sawo, Yankuba; Goldberg, Gail R.; Prentice, Ann] MRC, Keneba, Gambia.
RP Prentice, A (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Fulbourn Rd, Cambridge CB1 9NL, England.
EM ann.prentice@mrc-hnr.cam.ac.uk
OI Cole, Tim/0000-0001-5711-8200
FU United Kingdom MRC
FX Supported by the United Kingdom MRC. Shire Pharmaceuticals and Nycomed
   Pharma donated the supplement and placebo tablets.
CR Akesson A, 2004, ACTA OBSTET GYN SCAN, V83, P1049, DOI 10.1111/j.0001-6349.2004.00428.x
   Bringhurst F. R., 2002, PRINCIPLES BONE BIOL, P483
   Cole TJ, 2000, STAT MED, V19, P3109, DOI 10.1002/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F
   CROSS NA, 1995, J BONE MINER RES, V10, P1312
   FAIRWEATHERTAIT S, 1995, AM J CLIN NUTR, V62, P1188
   Hopkinson JM, 2000, J NUTR, V130, P777
   Jarjou LM, 2006, AM J CLIN NUTR, V83, P657
   KALKWARF HJ, 1995, OBSTET GYNECOL, V86, P26, DOI 10.1016/0029-7844(95)00083-4
   Karlsson C, 2001, OSTEOPOROSIS INT, V12, P828, DOI 10.1007/s001980170033
   Kolthoff N, 1998, CLIN SCI, V94, P405
   Krebs NF, 1997, AM J CLIN NUTR, V65, P1738
   Laskey MA, 1998, AM J CLIN NUTR, V67, P685
   Laskey MA, 2004, J CLIN DENSITOM, V7, P341, DOI 10.1385/JCD:7:3:341
   Laskey MA, 1999, OBSTET GYNECOL, V94, P608, DOI 10.1016/S0029-7844(99)00369-5
   Olausson H, 2008, AM J CLIN NUTR, V88, P1032
   Pearson D, 2004, BONE, V34, P570, DOI 10.1016/j.bone.2003.11.005
   Polatti F, 1999, OBSTET GYNECOL, V94, P52, DOI 10.1016/S0029-7844(99)00236-7
   PRENTICE A, 1993, BRIT J NUTR, V69, P885, DOI 10.1079/BJN19930088
   PRENTICE A, 1995, AM J CLIN NUTR, V62, P58
   PRENTICE A, 1994, AM J CLIN NUTR, V60, P837
   Prentice A, 1997, NEW ENGL J MED, V337, P558, DOI 10.1056/NEJM199708213370809
   Micronutrients Prentice A., 2003, J NUTR, V133, p1693S
   Prentice A., 2003, PEDIAT BONE BIOL DIS, P249, DOI 10.1016/B978-012286551-0/50012-9
   SOWERS M, 1993, JAMA-J AM MED ASSOC, V269, P3130, DOI 10.1001/jama.269.24.3130
   Villar J, 2006, AM J OBSTET GYNECOL, V194, P639, DOI 10.1016/j.ajog.2006.01.068
   Villar J, 2003, J NUTR, V133, p1606S
NR 26
TC 39
Z9 44
U1 0
U2 7
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD AUG
PY 2010
VL 92
IS 2
BP 450
EP 457
DI 10.3945/ajcn.2010.29217
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 628UZ
UT WOS:000280149700026
PM 20554790
OA No
DA 2017-08-15
ER

PT J
AU Holland, MJ
   Jeffries, D
   Pattison, M
   Korr, G
   Gall, A
   Joof, H
   Manjang, A
   Burton, MJ
   Mabey, DCW
   Bailey, RL
AF Holland, Martin J.
   Jeffries, David
   Pattison, Michael
   Korr, Gerit
   Gall, Alevtina
   Joof, Hassan
   Manjang, Ahmed
   Burton, Matthew J.
   Mabey, David C. W.
   Bailey, Robin L.
TI Pathway-Focused Arrays Reveal Increased Matrix Metalloproteinase-7
   (Matrilysin) Transcription in Trachomatous Trichiasis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CHLAMYDIA-MURIDARUM INFECTION; NECROSIS-FACTOR-ALPHA; COLLAGEN
   GENE-EXPRESSION; TOLL-LIKE RECEPTORS; REGULATORY T-CELLS;
   GRANULOMA-FORMATION; PULMONARY-FIBROSIS; EPITHELIAL-CELLS; CYTOKINE;
   MICE
AB PURPOSE. Several genes that are associated with protection from or susceptibility to trachomatous trichiasis (TT) have been identified through genetic association studies. Yet there have been few studies in which gene expression profiles were assessed in TT cases and disease-free controls. The purpose was to identify genes that are differentially expressed in the upper tarsal conjunctiva of subjects with TT.
   METHOD. Pathway-focused gene arrays were used to screen conjunctival RNA expression of 226 gene transcripts of interest. The screening was followed by validation of differentially expressed genes by qRT-PCR on an independent set of samples. Three different techniques were then used to test for quantitative differences in the recovered conjunctival protein fraction.
   RESULTS. Focused arrays identified a set of 13 differentially expressed genes. Validation by qRT-PCR confirmed differential expression in four of these genes (COL1A1, COL7A1, MMP7, and TLR6). Increased expression of MMP7 was the only consistent differentially regulated gene in the conjunctival samples of trichiasis subjects. MMP7 was present in isolated conjunctival proteins and in the tissue culture supernatants of peripheral blood lymphocytes after stimulation.
   CONCLUSIONS. There is an imbalance in extracellular matrix turnover with minimal contribution of adaptive immune responses at this stage of trichiasis. There was little evidence of broad differential expression in genes characteristic of polar responses of adaptive T cells or macrophages. The control of the MMP7 response and its activity appears significant in the fibrotic changes observed in TT. (Invest Ophthalmol Vis Sci. 2010; 51: 3893-3902) DOI: 10.1167/iovs.09-5054
C1 [Holland, Martin J.; Korr, Gerit; Burton, Matthew J.; Mabey, David C. W.; Bailey, Robin L.] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   [Holland, Martin J.; Jeffries, David; Pattison, Michael; Gall, Alevtina; Joof, Hassan; Manjang, Ahmed] MRC Labs, Banjul, Gambia.
RP Holland, MJ (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM martin.holland@lshtm.ac.uk
OI Pattison, Michael/0000-0001-7588-2560; Mabey, David/0000-0002-0031-8276;
   Burton, Matthew/0000-0003-1872-9169
FU Wellcome Trust [079246/Z/06/Z]; Medical Research Council, UK, in The
   Gambia
FX Supported by a grant from the Wellcome Trust (079246/Z/06/Z) with
   additional support from the Medical Research Council, UK, in The Gambia.
   The funders had no part in the study design; in the collection,
   analysis, and interpretation of data; in the writing of the report; or
   in the decision to submit the paper for publication.
CR Anand SP, 2009, CLIN IMMUNOL, V133, P126, DOI 10.1016/j.clim.2009.06.009
   Babu S, 2009, J INFECT DIS, V199, P1827, DOI 10.1086/599090
   Beeghly-Fadiel A, 2009, INT J CANCER, V124, P208, DOI 10.1002/ijc.23859
   Bobo L, 1996, INFECT IMMUN, V64, P3273
   Burl S, 2007, CLIN EXP IMMUNOL, V149, P117, DOI 10.1111/j.1365-2249.2007.03399.x
   Burton MJ, 2007, INVEST OPHTH VIS SCI, V48, P4440, DOI 10.1167/iovs.07-0315
   Burton MJ, 2010, INVEST OPHTH VIS SCI, V51, P3583, DOI 10.1167/iovs.09-4550
   Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P1282, DOI 10.1136/bjo.2004.062489
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Calonge MJ, 2004, J BIOL CHEM, V279, P23759, DOI 10.1074/jbc.M402178200
   Chen QS, 2005, J IMMUNOL, V174, P2305
   Chiaramonte MG, 1999, J IMMUNOL, V162, P920
   Churg A, 2003, AM J RESP CRIT CARE, V167, P1083, DOI 10.1164/rccm.200212-1396OC
   Cohen CR, 2005, J INFECT DIS, V192, P591, DOI 10.1086/432070
   Dheda K, 2005, AIDS, V19, P1601, DOI 10.1097/01.aids.0000183520.52760.ef
   Dheda K, 2005, ANAL BIOCHEM, V344, P141, DOI 10.1016/j.ab.2005.05.022
   El-Asrar A M, 2000, Br J Ophthalmol, V84, P85, DOI 10.1136/bjo.84.1.85
   EL-ASRAR A M A, 1989, British Journal of Ophthalmology, V73, P276, DOI 10.1136/bjo.73.4.276
   Faal N, 2006, PLOS MED, V3, P1292, DOI 10.1371/journal.pmed.0030266
   FEISE R, 2002, BMC MED RES METHODOL, P2
   Ghosh AK, 2002, EXP BIOL MED, V227, P301
   Ginderachter J. O., 2008, SELECTED ASPECTS CAN, P139, DOI 10.1007/978-1-4020-6729-7_9
   Gondek DC, 2009, J IMMUNOL, V183, P1313, DOI 10.4049/jimmunol.0900295
   HARDINGESCH EM, 2009, PLOS NEGLECT TROP D, V22, pE573
   Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091
   Holland MJ, 1996, CLIN EXP IMMUNOL, V105, P429, DOI 10.1046/j.1365-2249.1996.d01-792.x
   Huggett J, 2005, GENES IMMUN, V6, P279, DOI 10.1038/sj.gene.6364190
   Igietseme Joseph U., 1993, Regional Immunology, V5, P317
   Imtiaz MT, 2007, MICROBES INFECT, V9, P1561, DOI 10.1016/j.micinf.2007.08.010
   Imtiaz MT, 2006, INFECT IMMUN, V74, P5513, DOI 10.1128/IAI.00730-06
   Khandekar R, 2001, Ophthalmic Epidemiol, V8, P155, DOI 10.1076/opep.8.2.155.4165
   Kitamura T, 2009, LAB INVEST, V89, P98, DOI 10.1038/labinvest.2008.107
   Kouwenhoven M, 2001, J AUTOIMMUN, V16, P463, DOI 10.1006/jaut.2001.0505
   KROLL TC, 2002, NUCLEIC ACIDS RES, V30, P50
   Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6
   Lopez-Boado YS, 2000, J CELL BIOL, V148, P1305, DOI 10.1083/jcb.148.6.1305
   Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1
   Mans JJ, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-380
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   McGuire JK, 2003, AM J PATHOL, V162, P1831, DOI 10.1016/S0002-9440(10)64318-0
   Nesburn AB, 2007, J VIROL, V81, P7647, DOI 10.1128/JVI.00294-07
   Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497
   Pal S, 2006, IMMUNOLOGY, V117, P213, DOI 10.1111/j.1365-2567.2005.02281.x
   Patole PS, 2006, NEPHROL DIAL TRANSPL, V21, P3062, DOI 10.1093/ndt/gfl336
   Perry LL, 1997, J IMMUNOL, V158, P3344
   Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X
   Prasse A, 2006, AM J RESP CRIT CARE, V173, P781, DOI 10.1164/rccm.200509-1518OC
   Ramsey KH, 2005, INFECT IMMUN, V73, P6962, DOI 10.1128/IAI.73.10.6962-6973.2005
   Rasmussen SJ, 1997, J CLIN INVEST, V99, P77, DOI 10.1172/JCI119136
   Ritter Mirko, 2005, J Inflamm (Lond), V2, P16, DOI 10.1186/1476-9255-2-16
   Rosas IO, 2008, PLOS MED, V5, P623, DOI 10.1371/journal.pmed.0050093
   Satici A, 2003, OPHTHAL RES, V35, P301, DOI 10.1159/000074067
   Scott-Browne JP, 2007, J EXP MED, V204, P2159, DOI 10.1084/jem.20062105
   Shaykhiev R, 2009, J IMMUNOL, V183, P2867, DOI 10.4049/jimmunol.0900473
   Skwor TA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000264
   Stekel D., 2003, Microarray bioinformatics
   Suffia IJ, 2006, J EXP MED, V203, P777, DOI 10.1084/jem.20052056
   Takeda H, 2005, EXP DERMATOL, V14, P289, DOI 10.1111/j.0906-6705.2005.00316.x
   TZUMIN H, 2009, HEPATOLOGY, P9999
   von Toerne C, 2009, AM J TRANSPLANT, V9, P2223, DOI 10.1111/j.1600-6143.2009.02762.x
   Wang CB, 2005, J INFECT DIS, V191, P1084, DOI 10.1086/428592
   Wang SH, 1999, EUR J IMMUNOL, V29, P3782, DOI 10.1002/(SICI)1521-4141(199911)29:11<3782::AID-IMMU3782>3.0.CO;2-B
   Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113
   Yang X, 1999, J IMMUNOL, V162, P1010
NR 65
TC 16
Z9 16
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2010
VL 51
IS 8
BP 3893
EP 3902
DI 10.1167/iovs.09-5054
PG 10
WC Ophthalmology
SC Ophthalmology
GA 629JT
UT WOS:000280194100010
PM 20375326
OA No
DA 2017-08-15
ER

PT J
AU Mytton, OT
   Velazquez, A
   Banken, R
   Mathew, JL
   Ikonen, TS
   Taylor, K
   Painter, F
   Jean-Baptiste, R
   Poon, A
   Ruelas, E
AF Mytton, Oliver T.
   Velazquez, Adriana
   Banken, Reiner
   Mathew, Joseph L.
   Ikonen, Tuija S.
   Taylor, Kevin
   Painter, Frank
   Jean-Baptiste, Rachel
   Poon, Albert
   Ruelas, Enrique
TI Introducing new technology safely
SO QUALITY & SAFETY IN HEALTH CARE
LA English
DT Article
AB Aim This report considers the introduction of new technology and the implications for patient safety. Methods and discussion A distinction is made between 'conceptually' new and 'contextually' new technology. The life cycle of technology from development to routine use is discussed and the key role for regulation, health technology assessment, clinical engineering and surveillance in this life cycle considered. The limitations of each of these disciplines are also discussed. Special consideration is given to the needs of developing countries. Case study examples of particular challenges in the safe introduction of technology are presented.
C1 [Mytton, Oliver T.] WHO Patient Safety, Dept Hlth, London SW1A 2NL, England.
   [Velazquez, Adriana] WHO, CH-1211 Geneva, Switzerland.
   [Mathew, Joseph L.] Post Grad Inst Med Educ & Res, Chandigarh, India.
   [Ikonen, Tuija S.] Natl Inst Hlth & Welf, Helsinki, Finland.
   [Taylor, Kevin] UK Med Res Council, Fajara, Gambia.
   [Painter, Frank] Univ Connecticut, Storrs, CT 06269 USA.
   [Jean-Baptiste, Rachel] Univ Res Co, LLC, Bethesda, MD USA.
   [Poon, Albert] Hong Kong Govt, Elect & Mech Serv Dept, Hlth Sector Div, Kowloon, Hong Kong, Peoples R China.
   [Ruelas, Enrique] Secretariat Hlth, Minieria, Mexico.
RP Mytton, OT (reprint author), WHO Patient Safety, Dept Hlth, Richmond House,79 Whitehall, London SW1A 2NL, England.
EM oliver.mytton@dh.gsi.gov.uk
OI Mytton, Oliver/0000-0003-3218-9912
FU WHO
FX The project was funded by WHO Patient Safety.
CR Banta D, 2009, INT J TECHNOL ASSESS, V25, P7, DOI 10.1017/S0266462309090333
   Busse R, 2002, INT J TECHNOL ASSESS, V18, P361
   CUSCHIERI A, 1995, AM J SURG, V169, P9, DOI 10.1016/S0002-9610(99)80104-4
   Gagnon MP, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-54
   Garrido MV, 2008, HLTH TECHNOLOGY ASSE
   Kristensen F B, 2006, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, V49, P283, DOI 10.1007/s00103-005-1229-9
   MANUELE FA, 2003, PRACTICE SAFETY, P272
   *MED HEALTHC PROD, 2007, MHRA DEV B ADV INC R
   Medicines and Healthcare products Regulatory Agency, 2008, MED MED DEV REG WHAT
   National Institute for Clinical Excellence, 2000, GUID SEL PROSTH PRIM
   National Patient Safety Agency, 2009, NPSA2009RRR001
   *NAT REP LEARN SYS, 2008, NRLS QUART DAT SUMM
   Pena-Mohr J, 1987, Int J Technol Assess Health Care, V3, P281
   World Health Organization, 2007, 60 WORLD HLTH ASS WH
   World Health Organization, 2003, MED DEV REG GLOB OV
   2009, ECONOMIST, V391, P10
NR 16
TC 2
Z9 2
U1 1
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1475-3898
J9 QUAL SAF HEALTH CARE
JI Qual. Saf. Health Care
PD AUG
PY 2010
VL 19
SU 2
AR i9
DI 10.1136/qshc.2009.038554
PG 6
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 646YU
UT WOS:000281582700003
PM 20693217
OA No
DA 2017-08-15
ER

PT J
AU Bojang, K
AF Bojang, K.
TI Baseline epidemiological study in preparation for a Phase IIb proof of
   concept efficacy study of GMZ2 candidate malaria vaccine in children
   aged 12-84 months
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Bojang, K.] Med Res Council UK, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD AUG
PY 2010
VL 15
IS 8
BP S16
EP S16
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 626BE
UT WOS:000279939900057
OA No
DA 2017-08-15
ER

PT J
AU Hancox, E
AF Hancox, E.
TI The importance of introducing quality practices in clinical research
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Hancox, E.] Med Res Council UK, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD AUG
PY 2010
VL 15
IS 8
BP S31
EP S32
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 626BE
UT WOS:000279939900115
OA No
DA 2017-08-15
ER

PT J
AU Janha, R
AF Janha, R.
TI Variation in cytochrome P450 CYP2C19/CYP2C9 and efficacy of
   chlorproguanil and dapsone
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Janha, R.] Med Res Council UK, Danjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD AUG
PY 2010
VL 15
IS 8
BP S19
EP S19
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 626BE
UT WOS:000279939900068
OA No
DA 2017-08-15
ER

PT J
AU Nwakanma, D
AF Nwakanma, D.
TI Application of real-time quantitative polymerase chain reaction 'qPCR'
   in antimalarial drug trial
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Nwakanma, D.] Med Res Council UK, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD AUG
PY 2010
VL 15
IS 8
BP S16
EP S17
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 626BE
UT WOS:000279939900059
OA No
DA 2017-08-15
ER

PT J
AU Touray, K
AF Touray, K.
TI Spatial analysis of tuberculosis in an urban west-African setting: is
   there evidence of clustering?
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Touray, K.] Med Res Council UK, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD AUG
PY 2010
VL 15
IS 8
BP S27
EP S28
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 626BE
UT WOS:000279939900100
OA No
DA 2017-08-15
ER

PT J
AU Yindom, LM
AF Yindom, L. -M.
TI HLA alleles and KIR genes frequencies in HIV-2 infected individuals from
   two cohorts in West Africa
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Yindom, L. -M.] MRC Labs, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD AUG
PY 2010
VL 15
IS 8
BP S7
EP S7
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 626BE
UT WOS:000279939900025
OA No
DA 2017-08-15
ER

PT J
AU Darboe, MK
   Fulford, AJC
   Secka, O
   Prentice, AM
AF Darboe, Momodou K.
   Fulford, Anthony J. C.
   Secka, Ousman
   Prentice, Andrew M.
TI The dynamics of nasopharyngeal streptococcus pneumoniae carriage among
   rural Gambian mother-infant pairs
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID INVASIVE PNEUMOCOCCAL DISEASE; OTITIS-PRONE CHILDREN; CONJUGATE VACCINE;
   HAEMOPHILUS-INFLUENZAE; RESPIRATORY-TRACT; HEALTHY-CHILDREN;
   WEST-AFRICA; COLONIZATION; ATTACHMENT; LIFE
AB Background: Streptococcus pneumoniae is an important cause of community acquired pneumonia, sepsis, meningitis and otitis media globally and has been incriminated as a major cause of serious childhood bacterial infections in The Gambia. Better understanding of the dynamics of transmission and carriage will inform control strategies.
   Methods: This study was conducted among 196 mother-infant pairs recruited at birth from six villages in the West Kiang region of The Gambia. Nasopharyngeal swabs were collected from mother-infant pairs at birth (within 12 hours of delivery), 2, 5 and 12 months. Standard techniques of culture were used to identify carriage and serotype S. pneumoniae.
   Results: Of 46 serotypes identified, the 6 most common, 6A, 6B, 14, 15, 19F and 23F, accounted for 67.3% of the isolates from infants. Carriage of any serotype among infants rose from 1.5% at birth to plateau at approximately 80% by 2 m (prevalence at 2 m = 77%; 5 m = 86%; 12 m = 78%). Likewise, maternal carriage almost doubled in the first 2 months post-partum and remained elevated for the next 10 m (prevalence at birth = 13%; 2 m = 24%; 5 m = 22%; 12 m = 21%). Carriage was significantly seasonal in both infants and mothers with a peak in December and lowest transmission in August. The total number of different serotypes we isolated from each infant varied and less than would be expected had the serotypes assorted independently. In contrast, this variability was much as expected among mothers. The half-life of a serotype colony was estimated to be 1.90 m (CI(95%): 1.66-2.21) in infants and 0.75 m (CI(95%): 0.55-1.19) in mothers. While the odds for a serotype to be isolated from an infant increased by 9-fold if it had also been isolated from the mother, the population attributable fraction (PAF) of pneumococcal carriage in infants due to maternal carriage was only 9.5%. Some marked differences in dynamics were observed between vaccine and non-vaccine serotypes.
   Conclusions: Colonisation of the nasopharynx in Gambian infants by S. pneumoniae is rapid and highly dynamic. Immunity or inter-serotype competition may play a role in the dynamics. Reducing mother-infant transmission would have a minimal effect on infant carriage.
C1 [Darboe, Momodou K.; Fulford, Anthony J. C.; Prentice, Andrew M.] MRC, Int Nutr Grp, Keneba Field Stn, Banjul, Gambia.
   [Secka, Ousman] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
RP Darboe, MK (reprint author), MRC, Int Nutr Grp, Keneba Field Stn, POB 273, Banjul, Gambia.
EM mdarboe@mrc.gm
CR ANDERSSON B, 1986, J INFECT DIS, V153, P232
   Antonio M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-198
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   COX DR, 1983, BIOMETRIKA, V70, P269, DOI 10.1093/biomet/70.1.269
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dagan R, 1996, J INFECT DIS, V174, P1352
   Dagan R, 2005, J INFECT DIS, V192, P367, DOI 10.1086/431679
   Dagan R, 2003, PEDIATR INFECT DIS J, V22, P532, DOI 10.1097/00006454-200306000-00009
   Darboe MK, 2007, LANCET, V369, P2088, DOI 10.1016/S0140-6736(07)60981-7
   DOUGLAS RM, 1983, J INFECT DIS, V148, P131
   Douglas RM, 1999, CLIN INFECT DIS, V28, P192, DOI 10.1086/515112
   Goldblatt D, 2005, J INFECT DIS, V192, P387, DOI 10.1086/431524
   Granat SM, 2007, PEDIATR INFECT DIS J, V26, P319, DOI 10.1097/01.inf.0000257425.24492.11
   Granat SM, 2009, J INFECT DIS, V200, P99, DOI 10.1086/599364
   GRATTEN M, 1986, BIOL NEONATE, V50, P114
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Laval CB, 2006, CLIN MICROBIOL INFEC, V12, P50, DOI 10.1111/j.1469-0691.2005.01304.x
   Levidiotou S, 2006, FEMS IMMUNOL MED MIC, V48, P179, DOI 10.1111/j.1574-695X.2006.00126.x
   Lipsitch M, 1999, EMERG INFECT DIS, V5, P336
   Lipsitch M, 2000, VACCINE, V18, P2895, DOI 10.1016/S0264-410X(00)00046-3
   Lipsitch M, 2005, PLOS MED, V2, P62, DOI 10.1371/journal.pmed.0020015
   Lipsitch M, 2007, J INFECT DIS, V196, P1221, DOI 10.1086/521831
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   Marchisio P, 2002, EMERG INFECT DIS, V8, P479
   MBELLE N, 1997, INT C ANT AG CHEM SE, P13
   O'Brien Katherine L, 2003, Pediatr Infect Dis J, V22, pe1, DOI 10.1097/01.inf.0000049347.42983.77
   O'Brien KL, 2003, VACCINE, V21, P1815, DOI 10.1016/S0264-410X(02)00807-1
   O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI 10.1097/00006454-200302000-00009
   Obaro S, 2002, J MED MICROBIOL, V51, P98
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   Ozdemir B, 2008, J INFECTION, V56, P332, DOI 10.1016/j.jinf.2008.02.010
   Peltola H, 2001, CLIN INFECT DIS, V32, P64, DOI 10.1086/317534
   Poehling KA, 2006, JAMA-J AM MED ASSOC, V295, P1668, DOI 10.1001/jama.295.14.1668
   Principi N, 1999, PEDIATR INFECT DIS J, V18, P517, DOI 10.1097/00006454-199906000-00008
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
   Shann F, 2001, LANCET, V357, P2070, DOI 10.1016/S0140-6736(00)05226-0
   Shann F, 1995, CLIN INFECT DIS, V21, pS218
   STENFORS LE, 1993, ACTA OTO-LARYNGOL, V113, P191, DOI 10.3109/00016489309135791
   STENFORS LE, 1991, ACTA OTO-LARYNGOL, V111, P562, DOI 10.3109/00016489109138384
   STENFORS LE, 1992, J INFECT DIS, V165, P1148
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
   Vergison A, 2006, PEDIATRICS, V118, pE801, DOI 10.1542/peds.2005-3195
   Vives M, 1997, PEDIATR INFECT DIS J, V16, P852, DOI 10.1097/00006454-199709000-00007
NR 45
TC 24
Z9 24
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUL 5
PY 2010
VL 10
AR 195
DI 10.1186/1471-2334-10-195
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA 632EH
UT WOS:000280403100001
PM 20602782
OA gold
DA 2017-08-15
ER

PT J
AU Pinder, M
   Moorthy, VS
   Akanmori, BD
   Genton, B
   Brown, GV
AF Pinder, M.
   Moorthy, V. S.
   Akanmori, B. D.
   Genton, B.
   Brown, G. V.
TI MALVAC 2009: Progress and Challenges in Development of Whole Organism
   Malaria Vaccines for Endemic Countries, 3-4 June 2009, Dakar, Senegal
SO VACCINE
LA English
DT Editorial Material
DE Malaria vaccine; P. falciparum; Clinical trial; Conference report
ID PLASMODIUM-FALCIPARUM; GROWTH-RATES; EFFICACY; IMMUNITY; IMMUNIZATION;
   SPOROZOITES; TRIALS
AB Research and development into whole organism malaria vaccines is progressing rapidly thanks to the major investments over recent years from several funders, and the commitment and interest of many leading researchers. Progress includes the discovery of potential new candidate vaccines and the start of the first phase 1/2a clinical trial of the radiation attenuated sporozoite approach for Plasmodium falciparum, under US Food and Drug Administration regulatory oversight. A group of leading scientists, clinical trialists and stakeholders, together with representatives of regulatory authorities including some from African countries, met recently to document the issues that will require detailed consideration to assess this promising approach. Questions related to scale-up, quality, purity and consistency of a manufacturing process using mosquitoes to generate a commercial product, and demonstration of the stability of attenuated sporozoites will need further work. Should a high level of efficacy be demonstrated in clinical challenge studies, it will become a priority to agree in which populations and age groups questions about strain-transcendence and duration of efficacy should be answered, and how clinical development can progress with an approach based on cryopreservation in liquid nitrogen.
C1 [Moorthy, V. S.] WHO, Initiat Vaccine Res, CH-1211 Geneva 27, Switzerland.
   [Moorthy, V. S.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.
   [Pinder, M.] MRC Labs, Fajara, Gambia.
   [Akanmori, B. D.] WHO Reg Off Africa, Immunizat & Vaccines Dev Programme, Div Prevent & Control Communicable Dis, Brazzaville, Congo.
   [Genton, B.] Swiss Trop Inst, CH-4002 Basel, Switzerland.
   [Brown, G. V.] Univ Melbourne, Nossal Inst Global Hlth, Ctr Clin Res Excellence Infect Dis, Carlton, Vic 3010, Australia.
RP Moorthy, VS (reprint author), WHO, Initiat Vaccine Res, Ave Appia 20, CH-1211 Geneva 27, Switzerland.
EM moorthyv@who.int
CR Bejon P, 2008, NEW ENGL J MED, V359, P2521, DOI 10.1056/NEJMoa0807381
   Cheng Q, 1997, AM J TROP MED HYG, V57, P495
   CLYDE DF, 1990, B WORLD HEALTH ORGAN, V68, P9
   COX FEG, 1970, B WORLD HEALTH ORGAN, V43, P325
   Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409
   Kennedy MC, 2002, INFECT IMMUN, V70, P6948, DOI 10.1128/IAI.70.12.6948-6960.2002
   Lawrence G, 2000, VACCINE, V18, P1925, DOI 10.1016/S0264-410X(99)00444-2
   Malaria Vaccine Technology Roadmap, 2006, MAL VACC TECHN ROADM
   Moorthy VS, 2009, VACCINE, V27, P624, DOI 10.1016/j.vaccine.2008.11.034
   Pombo DJ, 2002, LANCET, V360, P610, DOI 10.1016/S0140-6736(02)09784-2
   Sanderson F, 2008, AM J TROP MED HYG, V78, P878
   SIDDIQUI WA, 1977, SCIENCE, V197, P388, DOI 10.1126/science.406671
NR 12
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUL 5
PY 2010
VL 28
IS 30
BP 4695
EP 4702
DI 10.1016/j.vaccine.2010.04.091
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 631KO
UT WOS:000280345700003
PM 20470799
OA No
DA 2017-08-15
ER

PT J
AU Leligdowicz, A
   Onyango, C
   Yindom, LM
   Peng, YC
   Cotten, M
   Jaye, A
   McMichael, A
   Whittle, H
   Dong, T
   Rowland-Jones, S
AF Leligdowicz, Aleksandra
   Onyango, Clayton
   Yindom, Louis-Marie
   Peng, YanChun
   Cotten, Matthew
   Jaye, Assan
   McMichael, Andrew
   Whittle, Hilton
   Dong, Tao
   Rowland-Jones, Sarah
TI Highly avid, oligoclonal, early-differentiated antigen-specific CD8(+) T
   cells in chronic HIV-2 infection
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Cellular immunity; Gag; HIV-2; T-cell receptor
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CELLULAR IMMUNE-RESPONSES; LONG-TERM
   SURVIVORS; CLASS-I; VIRAL LOAD; LONGITUDINAL ANALYSIS; LYMPHOCYTE
   RESPONSES; DISEASE PROGRESSION; PHENOTYPIC ANALYSIS; PD-1 EXPRESSION
AB HIV-1-specific CD8(+) T cells are present in most HIV-1-infected people and play an important role in controlling viral replication, but the characteristics of an effective HIV-specific T-cell response are largely unknown. The majority of HIV-2-infected people behave as long-term non-progressors while those who progress to AIDS do so in a manner indistinguishable from HIV-1. A detailed study of HIV-2 infection may identify protective immune responses. Robust gag p26-specific T-cell responses are elicited during HIV-2 infection and correlate with control of viremia. In this study, we analyzed features of an HLA-B*3501-restricted T-cell response to HIV-2 p26 that may contribute to virus control. In contrast to HIV-1, HIV-2-specific T cells are at an early stage of differentiation (CD27(+) CD28(+)), a finding that relates directly to CD4(+) T-cell levels and inversely to immune activation. The cells demonstrate IFN-gamma secretion, oligoclonal T-cell receptor V beta gene segment usage, exceptional avidity and secretion of pro-inflammatory cytokines. Despite the potentially strong selection pressure imposed on the virus by these cells, there was no evidence of HIV-2 sequence evolution. We propose that in chronic HIV-2 infection, the maintenance of early-differentiated, highly avid CD8(+) T cells could account for the non-progressive course of disease. Such responses may be desirable from an HIV vaccine.
C1 [Leligdowicz, Aleksandra; Peng, YanChun; McMichael, Andrew; Dong, Tao; Rowland-Jones, Sarah] John Radcliffe Hosp, Weatherall Inst Mol Med, Med Res Council Human Immunol Unit, Oxford OX3 9DU, England.
   [Leligdowicz, Aleksandra; Onyango, Clayton; Yindom, Louis-Marie; Cotten, Matthew; Jaye, Assan; Whittle, Hilton; Rowland-Jones, Sarah] MRC Labs, Fajara, Gambia.
RP Leligdowicz, A (reprint author), John Radcliffe Hosp, Weatherall Inst Mol Med, Med Res Council Human Immunol Unit, Oxford OX3 9DU, England.
EM aleksandra.leligdowicz@mail.mcgill.ca
OI Leligdowicz, Aleksandra/0000-0001-6055-4644
FU Medical Research Council, UK; Rhodes Trust
FX The authors thank the community cohort members in Caio, Guinea-Bissau,
   for their ongoing participation in research as well as Tim Vincent for
   management of the Caio field station research activity, Ramu Sarge Njie
   and Abraham Alabi for help with HIV serology and virus load
   determination (MRC Laboratories, The Gambia), Oluranti Oyeneye (MRC
   Laboratories, The Gambia) for help with sample shipment, and Ann
   Atzberger (WIMM, Oxford University, UK) for assistance with cell
   sorting. This study was supported by the Medical Research Council, UK,
   and the Rhodes Trust (Rhodes Scholarship to A. Leligdowicz).
CR Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003
   Alatrakchi N, 2006, AIDS, V20, P29, DOI 10.1097/01.aids.0000198077.30421.bf
   ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411
   Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784
   Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94
   Appay V, 2002, J IMMUNOL, V168, P3660
   Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63
   Bertoletti A, 1998, J VIROL, V72, P2439
   Betts MR, 1999, AIDS RES HUM RETROV, V15, P1219, DOI 10.1089/088922299310313
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   BORROW P, 1994, J VIROL, V68, P6103
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   Busch DH, 1999, J EXP MED, V189, P701, DOI 10.1084/jem.189.4.701
   Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   Dong T, 2004, J EXP MED, V200, P1547, DOI 10.1084/jem.20032044
   Duvall MG, 2008, EUR J IMMUNOL, V38, P350, DOI 10.1002/eji.200737768
   Duvall MG, 2006, J IMMUNOL, V176, P6973
   Gao XJ, 2001, NEW ENGL J MED, V344, P1668, DOI 10.1056/NEJM200105313442203
   Garcia KC, 2005, CELL, V122, P333, DOI 10.1016/j.cell.2005.07.015
   Geldmacher C, 2007, J VIROL, V81, P2440, DOI 10.1128/JVI.01847-06
   Gillespie GMA, 2005, EUR J IMMUNOL, V35, P1445, DOI 10.1002/eji.200526007
   GOTCH F, 1993, J IMMUNOL, V151, P3361
   Hendel H, 1999, J IMMUNOL, V162, P6942
   Jallow S, 2006, AIDS, V20, P1455, DOI 10.1097/01.aids.0000233582.64467.8e
   Jaye A, 2004, J INFECT DIS, V189, P498, DOI 10.1086/381185
   Jin X, 2002, J VIROL, V76, P12603, DOI 10.1128/JVI.76.24.12603-12610.2002
   KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261
   Kaslow RA, 2001, J VIROL, V75, P8681, DOI 10.1128/JVI.75.18.8681-8689.2001
   KATSIKIS PD, 1995, J EXP MED, V181, P2029, DOI 10.1084/jem.181.6.2029
   Kaul R, 2001, J CLIN INVEST, V107, P1303, DOI 10.1172/JCI12433
   Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365
   KOUP RA, 1994, J VIROL, V68, P4650
   LEHNER PJ, 1995, J EXP MED, V181, P79, DOI 10.1084/jem.181.1.79
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Leligdowicz A, 2010, J INFECT DIS, V201, P114, DOI 10.1086/648733
   LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.immunol.11.1.191
   Lopes AR, 2003, J IMMUNOL, V171, P307
   Martinez-Steele E, 2007, AIDS, V21, P317, DOI 10.1097/QAD.0b013e328011d7ab
   Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845
   Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010
   MOSS PAH, 1991, P NATL ACAD SCI USA, V88, P8987, DOI 10.1073/pnas.88.20.8987
   Ogg GS, 1999, J VIROL, V73, P9153
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   Onyango CO, 2010, VACCINE, V28, pB60, DOI 10.1016/j.vaccine.2009.08.060
   PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0
   Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020
   Papagno L, 2002, CLIN EXP IMMUNOL, V130, P509, DOI 10.1046/j.1365-2249.2002.02005.x
   Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   Sauce D, 2007, AIDS, V21, P2005
   Shimbara N, 1998, J BIOL CHEM, V273, P23062, DOI 10.1074/jbc.273.36.23062
   Sousa AE, 2001, J INFECT DIS, V184, P552, DOI 10.1086/322804
   Streeck H, 2007, J VIROL, V81, P7725, DOI 10.1128/JVI.00708-07
   Tomiyama H, 1997, J IMMUNOL, V158, P5026
   Turner SJ, 2006, NAT REV IMMUNOL, V6, P883, DOI 10.1038/nri1977
   WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0
   WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484
   Zheng NN, 2004, J VIROL, V78, P13934, DOI 10.1128/JVI.78.24.13934-13942.2004
NR 63
TC 13
Z9 13
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD JUL
PY 2010
VL 40
IS 7
BP 1963
EP 1972
DI 10.1002/eji.200940295
PG 10
WC Immunology
SC Immunology
GA 629SS
UT WOS:000280220600026
PM 20411566
OA No
DA 2017-08-15
ER

PT J
AU Sripada, S
   Townend, J
   Campbell, D
   Murdoch, L
   Mathers, E
   Bhattacharya, S
AF Sripada, Sreebala
   Townend, John
   Campbell, Doris
   Murdoch, Linda
   Mathers, Eileen
   Bhattacharya, Siladitya
TI Relationship between semen parameters and spontaneous pregnancy
SO FERTILITY AND STERILITY
LA English
DT Article
DE Semen parameters; semen analysis; spontaneous pregnancy
ID IN-VITRO FERTILIZATION; SPERM MORPHOLOGY; INTRAUTERINE INSEMINATION;
   SUBFERTILE POPULATION; INVITRO FERTILIZATION; GENERAL-POPULATION;
   PREDICTIVE-VALUE; FERTILE; QUALITY; COUPLES
AB Objective: To explore the association between semen parameters and spontaneous pregnancy.
   Design: Case-control study.
   Setting: Aberdeen Fertility Centre, Aberdeen, Scotland.
   Patient(s): A total of 1,426 untreated couples attending a subfertility clinic with no evidence of azoospermia, anovulation, or tubal disease were observed for 180 weeks. "Cases" were couples who achieved conception spontaneously within the follow-up period; controls were those who did not.
   Intervention(s): None.
   Main Outcome Measure(s): Sperm density, sperm motility, and sperm morphology.
   Result(s): In women who achieved spontaneous conception (n = 488) the mean (SD) age was 30.6 (4.8) years and median (interquartile range) parity was 1 (0-1), compared with 32.0 (5.4) years and 1 (0-1) in those who did not (n = 938). The median (interquartile range) duration of infertility was 24 (17-36) and 18 (14-24) months in nonpregnant and pregnant couples, respectively. After adjusting for male and female age, parity, year of first visit, and duration of infertility, sperm motility and normal morphology were significantly associated with spontaneous pregnancy, whereas sperm density was not. For motility, the area under the receiver operating characteristic curve was 0.545 (95% confidence interval 0.514-0.577). For morphology, the area under the receiver operating characteristic curve was 0.565 (95% confidence interval 0.534-0.597).
   Conclusion(s): In subfertile couples, sperm motility and morphology have limited predictive value for spontaneous conception. (Fertil Steril (R) 2010;94:624-30. (C) 2010 by American Society for Reproductive Medicine.)
C1 [Sripada, Sreebala; Campbell, Doris; Bhattacharya, Siladitya] Univ Aberdeen, Aberdeen Matern Hosp, Dept Obstet & Gynecol, Aberdeen AB25 2ZD, Scotland.
   [Townend, John] MRC, Banjul, Gambia.
   [Murdoch, Linda] Aberdeen Matern Hosp, Dugald Baird Ctr, Aberdeen, Scotland.
   [Mathers, Eileen] Aberdeen Matern Hosp, Androl Lab, Natl Hlth Serv Grampian, Aberdeen, Scotland.
RP Sripada, S (reprint author), Univ Aberdeen, Aberdeen Matern Hosp, Dept Obstet & Gynecol, Cornhill Rd, Aberdeen AB25 2ZD, Scotland.
EM ogy302@abdn.ac.uk
FU University of Aberdeen
FX This study was funded by the University of Aberdeen.
CR Batty GD, 2004, PAEDIATR PERINAT EP, V18, P221, DOI 10.1111/j.1365-3016.2004.00552.x
   Bonde JPE, 1998, LANCET, V352, P1172, DOI 10.1016/S0140-6736(97)10514-1
   Branigan EF, 1999, FERTIL STERIL, V71, P547, DOI 10.1016/S0015-0282(98)00503-2
   Bungum M, 2007, HUM REPROD, V22, P174, DOI 10.1093/humrep/del326
   CLAASSENS OE, 1992, HUM REPROD, V7, P242
   Coetzee K, 1998, HUM REPROD UPDATE, V4, P73, DOI 10.1093/humupd/4.1.73
   Collins JA, 2008, FERTIL STERIL, V89, P823, DOI 10.1016/j.fertnstert.2007.04.055
   Gauci MM, 2001, ANDROLOGIA, V33, P135
   Gunalp S, 2001, HUM REPROD, V16, P110, DOI 10.1093/humrep/16.1.110
   Guzick DS, 2001, NEW ENGL J MED, V345, P1388, DOI 10.1056/NEJMoa003005
   Ho LM, 2007, J ANDROL, V28, P158, DOI 10.2164/jandrol.106.000521
   IRVINE DS, 1994, HUM REPROD, V9, P2324
   Krause W, 1995, INT J ANDROL, V18, P32
   KRUGER TF, 1988, FERTIL STERIL, V49, P112
   KRUGER TF, 1986, FERTIL STERIL, V46, P1118
   Larsen L, 2000, HUM REPROD, V15, P1562, DOI 10.1093/humrep/15.7.1562
   LIU DY, 1990, HUM REPROD, V5, P298
   Menkveld R, 2001, HUM REPROD, V16, P1165, DOI 10.1093/humrep/16.6.1165
   Nallella KP, 2006, FERTIL STERIL, V85, P629, DOI 10.1016/j.fertnstert.2005.08.024
   Oehninger S, 1998, HUM REPROD, V13, P2161, DOI 10.1093/humrep/13.8.2161
   Ombelet W, 1997, HUM REPROD, V12, P987
   Ombelet W, 1997, HUM REPROD, V12, P1458, DOI 10.1093/humrep/12.7.1458
   Pandian Z, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003357.pub2
   PARINAUD J, 1993, FERTIL STERIL, V60, P888
   RONEL R, 1991, FERTIL STERIL, V55, P338
   Samphier ML, 1981, PROSPECTIVE LONGITUD, P61
   *SCOTL CENS RES ON, COMP POP PROF AB COU
   Shulman A, 1998, J ASSIST REPROD GEN, V15, P381, DOI 10.1023/A:1022585000740
   Slama R, 2002, HUM REPROD, V17, P503, DOI 10.1093/humrep/17.2.503
   Snick HKA, 1997, HUM REPROD, V12, P1582, DOI 10.1093/humrep/12.7.1582
   Thomson F, 2005, BJOG-INT J OBSTET GY, V112, P632, DOI 10.1111/j.1471-0528.2004.00489.x
   van der Merwe FH, 2005, GYNECOL OBSTET INVES, V59, P86, DOI 10.1159/000082368
   van der Steeg JW, 2007, HUM REPROD, V22, P536, DOI 10.1093/humrep/del378
   World Health Organization, 1993, LAB MAN EX HUM SEM S
   World Health Organization, 1999, LAB MAN EX HUM SEM S
   YOVICH J L, 1984, Journal of In Vitro Fertilization and Embryo Transfer, V1, P172, DOI 10.1007/BF01139210
   Zinaman MJ, 2000, J ANDROL, V21, P145
NR 37
TC 16
Z9 17
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD JUL
PY 2010
VL 94
IS 2
BP 624
EP 630
DI 10.1016/j.fertnstert.2009.02.085
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 623RF
UT WOS:000279758800032
PM 19361792
OA No
DA 2017-08-15
ER

PT J
AU Burton, MJ
   Bailey, RL
   Jeffries, D
   Rajak, SN
   Adegbola, RA
   Sillah, A
   Mabey, DCW
   Holland, MJ
AF Burton, Matthew J.
   Bailey, Robin L.
   Jeffries, David
   Rajak, Saul N.
   Adegbola, Richard A.
   Sillah, Ansumana
   Mabey, David C. W.
   Holland, Martin J.
TI Conjunctival Expression of Matrix Metalloproteinase and Proinflammatory
   Cytokine Genes after Trichiasis Surgery
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CHLAMYDIA-TRACHOMATIS INFECTION; NATURAL-HISTORY; ALPHA PROMOTER;
   GAMBIA; RISK; POLYMORPHISM; DISEASE; RECURRENCE; COMMUNITY; SEQUELAE
AB PURPOSE. Trachoma, the leading infectious cause of blindness, is a chronic inflammatory scarring condition. Blindness follows the development of trichiasis, which is treated surgically. Unfortunately, it frequently recurs, compromising the treatment. In this study, gene expression analysis was used to examine factors that may be involved in the inflammation and tissue remodeling after surgery.
   METHODS. Subjects were examined before and at 1 and 4 years after surgery. Conjunctival swab samples were collected for bacterial culture, Chlamydia trachomatis PCR, and RNA isolation at 1 year. Quantitative real-time PCR was performed to measure the expression of tumor necrosis factor-alpha (TNF), interleukin- 1 beta (IL1B), matrix metalloproteinase-1 (MMP1), MMP-2, MMP-9, tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), TIMP-2, and hypoxanthine phosphoribosyl transferase-1 (HPRT1).
   RESULTS. Two hundred forty individuals with trachomatous trichiasis were recruited. One year after surgery, recurrent trichiasis was associated with a reduced MMP-1/TIMP-1 ratio (P = 0.029). IL1B expression was elevated in the presence of either conjunctival bacterial infection (P = 0.011) or inflammation (P = 0.002). TNF expression was greater in the Mandinka ethnic group (P < 0.0001), and it was increased when clinical inflammation was associated with nonchlamydial bacterial infection (P = 0.012). MMP-9 expression increased when conjunctival inflammation was associated with bacterial infection (P = 0.007).
   CONCLUSIONS. Recurrent trichiasis was associated with a reduced MMP-1 to TIMP-1 ratio, which may favor the accumulation of fibrotic tissue. Nonchlamydial bacterial infection may induce factors that contribute to conjunctival tissue remodeling and recurrent trichiasis in trachoma. Prospective studies are needed to assess the potential importance of these and other factors in progressive disease. (Invest Ophthalmol Vis Sci. 2010;51:3583-3590) DOI: 10.1167/iovs.09-4550
C1 [Burton, Matthew J.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Int Ctr Eye Hlth, London WC1E 7HT, England.
   [Burton, Matthew J.; Bailey, Robin L.; Jeffries, David; Adegbola, Richard A.; Holland, Martin J.] MRC Labs, Fajara, Gambia.
   [Sillah, Ansumana] Natl Eye Care Programme, Banjul, Gambia.
RP Burton, MJ (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
EM matthew.burton@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169
FU International Trachoma Initiative [01-030]; Wellcome Trust [059134]
FX Supported by Grant 01-030 from the International Trachoma Initiative
   with additional support from the Wellcome Trust/Burroughs Wellcome Fund
   (059134).
CR Bowman RJC, 2001, OPHTHALMOLOGY, V108, P2219, DOI 10.1016/S0161-6420(01)00645-5
   Burton MJ, 2007, INVEST OPHTH VIS SCI, V48, P4440, DOI 10.1167/iovs.07-0315
   Burton MJ, 2006, INVEST OPHTH VIS SCI, V47, P847, DOI 10.1167/iovs.05-0714
   Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P1282, DOI 10.1136/bjo.2004.062489
   Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P575, DOI 10.1136/bjo.2004.055996
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Dawson CR, 1990, CHLAMYDIAL INFECT, P271
   EDWARDS DR, 1987, EMBO J, V6, P1899
   El-Asrar A M, 2000, Br J Ophthalmol, V84, P85, DOI 10.1136/bjo.84.1.85
   ELASRAR AMB, 1998, EYE, V12, P453
   Faal N, 2005, CLIN EXP IMMUNOL, V142, P347, DOI 10.1111/j.1365-2249.2005.02917.x
   Hall MC, 2003, J BIOL CHEM, V278, P10304, DOI 10.1074/jbc.M212334200
   Khandekar R, 2001, Ophthalmic Epidemiol, V8, P155, DOI 10.1076/opep.8.2.155.4165
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   McGonagle D, 2006, PLOS MED, V3, P1242, DOI 10.1371/journal.pmed.0030297
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   Natividad A, 2007, GENES IMMUN, V8, P288, DOI 10.1038/sj.gene.6364384
   Natividad A, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-40
   Rasmussen SJ, 1997, J CLIN INVEST, V99, P77, DOI 10.1172/JCI119136
   Reacher M H, 1990, Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique, V67, P233
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROTHERMEL CD, 1989, INFECT IMMUN, V57, P2705
   Rozeu S., 2000, BIOINFORMATICS METHO, P365, DOI DOI 10.1385/1-59259-192-2:365
   Skwor TA, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000264
   Swanborg Robert H., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000160
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375
   West ES, 2005, INVEST OPHTH VIS SCI, V46, P447, DOI 10.1167/iovs.04-0600
   West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158
   West SK, 2006, ARCH OPHTHALMOL-CHIC, V124, P309, DOI 10.1001/archopht.124.3.309
   *WHO, 2002, 2 GLOB SCI M TRACH G
   *WHO, 1996, GLOB SCI M GEN SWITZ
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
   Wolle MA, 2009, OPHTHALMOLOGY, V116, P243, DOI 10.1016/j.ophtha.2008.09.011
   Wong TTL, 2002, SURV OPHTHALMOL, V47, P239, DOI 10.1016/S0039-6257(02)00287-4
   Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412
NR 39
TC 23
Z9 23
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2010
VL 51
IS 7
BP 3583
EP 3590
DI 10.1167/iovs.09-4550
PG 8
WC Ophthalmology
SC Ophthalmology
GA 614HX
UT WOS:000279047500036
PM 20237245
OA No
DA 2017-08-15
ER

PT J
AU Schoenmakers, I
   Ginty, F
   Jarjou, LMA
   Nigdikar, S
   Bennett, J
   Laidlaw, A
   Prentice, A
AF Schoenmakers, I.
   Ginty, F.
   Jarjou, L. M. A.
   Nigdikar, S.
   Bennett, J.
   Laidlaw, A.
   Prentice, A.
TI Interrelation of parathyroid hormone and vitamin D metabolites in
   adolescents from the UK and The Gambia
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article; Proceedings Paper
CT 14th Workshop on Vitamin D
CY OCT 04-08, 2009
CL Burgge, BELGIUM
DE Parathyroid hormone; Vitamin D status; Vitamin D metabolites; Biomarkers
ID D INSUFFICIENCY; BONE; POPULATION; DIET
AB Parathyroid hormone (PTH) is used as a marker of vitamin D (VD) status. However, PTH depends on many other factors. The 24,25-dihydroxy VD (24,25VD) concentration may be a sensitive marker because its production is reduced in VD deficiency.
   The relationship between VD metabolites, their ratio and PTH was investigated in adolescents from the UK and The Gambia with different calcium intakes and VD status. In the UK, there was a significant positive (+ve) association between 25VD and both 1,25-dihydroxy VD (1,25VD) and 24,25VD and a negative (-ve) association with PTH. The 24,25:25VD ratio was consistent across the 25VD concentration range. There was a +ve association between PTH and 1,25:25VD, (1,25 + 24,25):25VD or 1,25:24,25VD, a -ve association with 24,25VD and none with 1,25VD or 24,25:25VD. Using LnPTH and 1,25:25VD ratio (but not 1,25VD:24,25VD or 25VD:24,25VD) increased uniformity between groups and strength of relationships compared to PTH and 1,25 or 25VD alone. In The Gambia, there was a significant -ve relationship between 25VD and PTH and none with 1,25VD. There was a +ve association between 1,25VD or 1,25:25VD and PTH.
   The more uniform prediction of PTH by the 1,25VD:25VD ratio may be because this better reflects the extent to which PTH-induced 1,25VD production can be met by VD supply. Further validation is needed. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Schoenmakers, I.; Ginty, F.; Nigdikar, S.; Bennett, J.; Laidlaw, A.; Prentice, A.] MRC Human Nutr Res, Cambridge CB1 9NL, England.
   [Jarjou, L. M. A.; Prentice, A.] MRC Labs, MRC Keneba, Banjul, Gambia.
RP Schoenmakers, I (reprint author), MRC Human Nutr Res, 120 Fulbourn Rd, Cambridge CB1 9NL, England.
EM Inez.Schoenmakers@mrc-hnr.cam.ac.uk
FU Medical Research Council [MC_U105960371]
CR Bates CJ, 2003, OSTEOPOROSIS INT, V14, P152, DOI 10.1007/s00198-002-1338-3
   Boyan BD, 2001, STEROIDS, V66, P363, DOI 10.1016/S0039-128X(00)00162-8
   Cadogan J, 1998, J BONE MINER RES, V13, P1602, DOI 10.1359/jbmr.1998.13.10.1602
   Chapuy MC, 1997, OSTEOPOROSIS INT, V7, P439, DOI 10.1007/s001980050030
   DELVIN EE, 1980, CLIN BIOCHEM, V13, P106, DOI 10.1016/S0009-9120(80)90735-3
   Dibba B, 2000, AM J CLIN NUTR, V71, P544
   Ginty F, 2004, NUTR ASPECTS OSTEOPO, P45, DOI 10.1016/B978-012141704-8/50043-X
   LEEUWENKAMP OR, 1993, EUR J CLIN CHEM CLIN, V31, P419
   Lo C. W., 1991, OSTEOPOROSIS 1990, P73
   Malabanan A, 1998, LANCET, V351, P805, DOI 10.1016/S0140-6736(05)78933-9
   Prentice A, 2008, AM J CLIN NUTR, V88, p500S
   Souberbielle JC, 2001, J CLIN ENDOCR METAB, V86, P3086, DOI 10.1210/jc.86.7.3086
   van Leeuwen JPTM, 2001, STEROIDS, V66, P375, DOI 10.1016/S0039-128X(00)00155-0
   Vieth R, 2003, J CLIN ENDOCR METAB, V88, P185, DOI 10.1210/jc.2002-021064
NR 14
TC 18
Z9 18
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD JUL
PY 2010
VL 121
IS 1-2
SI SI
BP 217
EP 220
DI 10.1016/j.jsbmb.2010.03.012
PG 4
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 634RC
UT WOS:000280600200046
PM 20214991
OA No
DA 2017-08-15
ER

PT J
AU Wong, SH
   Gochhait, S
   Malhotra, D
   Pettersson, FH
   Teo, YY
   Khor, CC
   Rautanen, A
   Chapman, SJ
   Mills, TC
   Srivastava, A
   Rudko, A
   Freidin, MB
   Puzyrev, VP
   Ali, S
   Aggarwal, S
   Chopra, R
   Reddy, BSN
   Garg, VK
   Roy, S
   Meisner, S
   Hazra, SK
   Saha, B
   Floyd, S
   Keating, BJ
   Kim, C
   Fairfax, BP
   Knight, JC
   Hill, PC
   Adegbola, RA
   Hakonarson, H
   Fine, PEM
   Pitchappan, RM
   Bamezai, RNK
   Hill, AVS
   Vannberg, FO
AF Wong, Sunny H.
   Gochhait, Sailesh
   Malhotra, Dheeraj
   Pettersson, Fredrik H.
   Teo, Yik Y.
   Khor, Chiea C.
   Rautanen, Anna
   Chapman, Stephen J.
   Mills, Tara C.
   Srivastava, Amit
   Rudko, Aleksey
   Freidin, Maxim B.
   Puzyrev, Valery P.
   Ali, Shafat
   Aggarwal, Shweta
   Chopra, Rupali
   Reddy, Belum S. N.
   Garg, Vijay K.
   Roy, Suchismita
   Meisner, Sarah
   Hazra, Sunil K.
   Saha, Bibhuti
   Floyd, Sian
   Keating, Brendan J.
   Kim, Cecilia
   Fairfax, Benjamin P.
   Knight, Julian C.
   Hill, Philip C.
   Adegbola, Richard A.
   Hakonarson, Hakon
   Fine, Paul E. M.
   Pitchappan, Ramasamy M.
   Bamezai, Rameshwar N. K.
   Hill, Adrian V. S.
   Vannberg, Fredrik O.
TI Leprosy and the Adaptation of Human Toll-Like Receptor 1
SO PLOS PATHOGENS
LA English
DT Article
ID SINGLE NUCLEOTIDE POLYMORPHISMS; GENOMEWIDE ASSOCIATION; LEPROMATOUS
   LEPROSY; POSITIVE SELECTION; INDIAN POPULATION; COMPLEX DISEASES;
   SUSCEPTIBILITY; VISUALIZATION; SEGREGATION; MORTALITY
AB Leprosy is an infectious disease caused by the obligate intracellular pathogen Mycobacterium leprae and remains endemic in many parts of the world. Despite several major studies on susceptibility to leprosy, few genomic loci have been replicated independently. We have conducted an association analysis of more than 1,500 individuals from different case-control and family studies, and observed consistent associations between genetic variants in both TLR1 and the HLA-DRB1/DQA1 regions with susceptibility to leprosy (TLR1 I602S, case-control P = 5.7x10(-8), OR = 0.31, 95% CI = 0.20-0.48, and HLA-DQA1 rs1071630, case-control P = 4.9610(-14), OR = 0.43, 95% CI = 0.35-0.54). The effect sizes of these associations suggest that TLR1 and HLA-DRB1/DQA1 are major susceptibility genes in susceptibility to leprosy. Further population differentiation analysis shows that the TLR1 locus is extremely differentiated. The protective dysfunctional 602S allele is rare in Africa but expands to become the dominant allele among individuals of European descent. This supports the hypothesis that this locus may be under selection from mycobacteria or other pathogens that are recognized by TLR1 and its co-receptors. These observations provide insight into the long standing host-pathogen relationship between human and mycobacteria and highlight the key role of the TLR pathway in infectious diseases.
C1 [Wong, Sunny H.; Pettersson, Fredrik H.; Teo, Yik Y.; Khor, Chiea C.; Rautanen, Anna; Chapman, Stephen J.; Mills, Tara C.; Freidin, Maxim B.; Roy, Suchismita; Fairfax, Benjamin P.; Knight, Julian C.; Hill, Adrian V. S.; Vannberg, Fredrik O.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Gochhait, Sailesh; Malhotra, Dheeraj; Srivastava, Amit; Ali, Shafat; Aggarwal, Shweta; Chopra, Rupali; Bamezai, Rameshwar N. K.] Jawaharlal Nehru Univ, Sch Life Sci, Natl Ctr Appl Human Genet, New Delhi 110067, India.
   [Khor, Chiea C.] Singapore Inst Clin Sci, Host Susceptibil Infect Program, Agcy Sci Technol & Res, Singapore, Singapore.
   [Rudko, Aleksey; Freidin, Maxim B.; Puzyrev, Valery P.] Russian Acad Med Sci, Res Inst Med Genet, Siberian Branch, Tomsk, Russia.
   [Reddy, Belum S. N.; Garg, Vijay K.] Lok Nayak Jai Prakash Hosp, Dept Dermatol & Sexually Transmitted Dis, Maulana Azad Med Coll, New Delhi, India.
   [Meisner, Sarah] Bath Royal United Hosp Trust, Bath, Avon, England.
   [Hazra, Sunil K.; Saha, Bibhuti] Calcutta Sch Trop Med, Kolkata, India.
   [Floyd, Sian; Fine, Paul E. M.] London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England.
   [Keating, Brendan J.] Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA.
   [Kim, Cecilia; Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Abramson Res Ctr, Philadelphia, PA 19104 USA.
   [Hill, Philip C.; Adegbola, Richard A.] MRC Labs, Fajara, Gambia.
   [Pitchappan, Ramasamy M.] Madurai Kamaraj Univ, Ctr Excellence Genom Sci, Madurai 625021, Tamil Nadu, India.
RP Wong, SH (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
EM vannberg@well.ox.ac.uk
RI ; Knight, Julian/C-7242-2009; Rudko, Aleksey/A-8059-2014; Puzyrev,
   Valery/A-7925-2014; Freidin, Maxim/A-8222-2014; Wong, Sunny/N-3754-2015;
   Puzyrev, Valery/S-3144-2016
OI Khor, Chiea Chuen/0000-0002-1128-4729; Knight,
   Julian/0000-0002-0377-5536; Freidin, Maxim/0000-0002-1439-6259; Wong,
   Sunny/0000-0002-3354-9310; Puzyrev, Valery/0000-0002-2113-4556
FU Wellcome Trust
FX This work was funded by the Wellcome Trust. S.J.C. is a Wellcome Trust
   Clinical Research Fellow. A. V. S. H. is a Wellcome Trust Principal
   Research Fellow. F.O.V. is supported by the Wellcome Trust. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR ABEL L, 1995, GENET EPIDEMIOL, V12, P63, DOI 10.1002/gepi.1370120107
   Alcais A, 2007, NAT GENET, V39, P517, DOI 10.1038/ng2000
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Bakker MI, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-40
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Boldsen JL, 2005, AM J PHYS ANTHROPOL, V126, P159, DOI 10.1002/ajpa.20085
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Cardon LR, 2003, LANCET, V361, P598, DOI 10.1016/S0140-6736(03)12520-2
   Chakravarti M.R., 1973, TOPICS HUMAN GENETIC, P1
   Cirl C, 2008, NAT MED, V14, P399, DOI 10.1038/nm1734
   Grossman SR, 2010, SCIENCE, V327, P883, DOI 10.1126/science.1183863
   GUINTO R S, 1954, Int J Lepr, V22, P273
   Haldane J. B. S., 1949, Ricerca Scientifica Suppl, P68
   Hawn TR, 2007, EUR J IMMUNOL, V37, P2280, DOI 10.1002/eji.200737034
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Ioannidis JPA, 2004, NAT GENET, V36, P1312, DOI 10.1038/ng1474
   Johnson CM, 2007, J IMMUNOL, V178, P7520
   Keating BJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003583
   Khor CC, 2007, NAT GENET, V39, P523, DOI 10.1038/ng1976
   Krutzik SR, 2003, NAT MED, V9, P525, DOI 10.1038/nm864
   Ma X, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001318
   Malhotra D, 2006, EUR J HUM GENET, V14, P438, DOI 10.1038/sj.ejhg.5201563
   Malhotra D, 2005, HUM GENET, V118, P295, DOI 10.1007/s00439-005-0042-8
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Medzhitov R, 2000, NEW ENGL J MED, V343, P338
   Monot M, 2005, SCIENCE, V308, P1040, DOI 10.1126/science.1109759
   Monot M, 2009, NAT GENET, V41, P1282, DOI 10.1038/ng.477
   NOORDEEN SK, 1972, INDIAN J MED RES, V60, P439
   Pickrell JK, 2009, GENOME RES, V19, P826, DOI 10.1101/gr.087577.108
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Reich D, 2009, NATURE, V461, P489, DOI 10.1038/nature08365
   SAPORTA L, 1994, BRIT J UROL, V74, P221, DOI 10.1111/j.1464-410X.1994.tb16590.x
   SHIELDS ED, 1987, J CLIN INVEST, V79, P1139, DOI 10.1172/JCI112930
   Siddiqui MR, 2001, NAT GENET, V27, P439, DOI 10.1038/86958
   SMITH DG, 1978, HUM BIOL, V50, P451
   Teo YY, 2010, GENET EPIDEMIOL, V34, P34, DOI 10.1002/gepi.20432
   Todd JA, 2007, NAT GENET, V39, P857, DOI 10.1038/ng2068
   VANEDEN W, 1980, J INFECT DIS, V141, P693
   VANEDEN W, 1985, J INFECT DIS, V151, P9
   WONG SH, 2010, N ENGL J MED
   Wong SH, 2010, NEW ENGL J MED, V362, P1447, DOI DOI 10.1056/NEJMC1001451
   Wong SH, 2010, NEW ENGL J MED, V362, P1446, DOI 10.1056/NEJMc1001451
   Wurfel MM, 2008, AM J RESP CRIT CARE, V178, P710, DOI 10.1164/rccm.200803-462OC
   Zhang FR, 2009, NEW ENGL J MED, V361, P2609, DOI 10.1056/NEJMoa0903753
NR 44
TC 72
Z9 72
U1 1
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD JUL
PY 2010
VL 6
IS 7
AR e1000979
DI 10.1371/journal.ppat.1000979
PG 9
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 633SW
UT WOS:000280527000013
PM 20617178
OA gold
DA 2017-08-15
ER

PT J
AU Cooper, M
   van der Loeff, MS
   McConkey, S
   Cooper, S
   Vincent, T
   Whittle, H
AF Cooper, Maxwell
   van der Loeff, Maarten Schim
   McConkey, Samuel
   Cooper, Sarah
   Vincent, Tim
   Whittle, Hilton
TI Cause of death among people with retroviral infection in rural
   Guinea-Bissau
SO TROPICAL DOCTOR
LA English
DT Article
ID MORTALITY; POPULATION
AB HIV-2 and HTLV-1 infection are both associated with increased mortality, but the causes of death are not well known. Relatives of 84 deceased persons from a rural part of Guinea-Bissau were interviewed using a standardised verbal autopsy questionnaire in the context of a large longitudinal community cohort study. The results were reviewed by two doctors to conclude cause of death. A cause of death was agreed upon for 49/84 subjects. Nineteen of these 49 were infected with HIV-2 alone and 7 with both HIV-2 and HTLV-1. Among these, the main causes of death were pulmonary tuberculosis (n = 5), AIDS (n = 5), cerebrovascular accident (n = 5), sepsis (n = 3) and hepatocellular carcinoma (n = 2). Death associated with traditional HIV-related causes were implicated in 13/26 (50%) of those with HIV-2.
C1 [van der Loeff, Maarten Schim] Univ Amsterdam, Acad Med Ctr, Ctr Infect & Immun, NL-1105 AZ Amsterdam, Netherlands.
   [McConkey, Samuel] Royal Coll Surgeons Ireland, Dept Int Hlth & Trop Med, Dublin 2, Ireland.
   [Cooper, Sarah] So Gen Hosp, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland.
   [Vincent, Tim] MRC, Caio Field Stn, Canchungo, Guinea Bissau.
   [Whittle, Hilton] MRC, Faijara, Gambia.
EM mjfcooper@clinmed.gla.ac.uk
RI McConkey, Samuel/E-7307-2012
OI McConkey, Samuel/0000-0001-9085-7793
CR Araujo AQC, 2006, LANCET NEUROL, V5, P1068, DOI 10.1016/S1474-4422(06)70628-7
   Ariyoshi K, 2003, J INFECT DIS, V188, P1648, DOI 10.1086/379780
   Becher H, 2008, AM J TROP MED HYG, V78, P106
   Holmgren B, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-85
   Martinez-Steele E, 2007, AIDS, V21, P317, DOI 10.1097/QAD.0b013e328011d7ab
NR 5
TC 3
Z9 3
U1 0
U2 3
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0049-4755
J9 TROP DOCT
JI Trop. Dr.
PD JUL
PY 2010
VL 40
IS 3
BP 181
EP 183
DI 10.1258/td.2010.090460
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 621FY
UT WOS:000279562200019
PM 20555052
OA No
DA 2017-08-15
ER

PT J
AU Okebe, JU
   Walther, B
   Bojang, K
   Drammeh, S
   Schellenberg, D
   Conway, DJ
   Walther, M
AF Okebe, Joseph U.
   Walther, Brigitte
   Bojang, Kawsu
   Drammeh, Silaba
   Schellenberg, David
   Conway, David J.
   Walther, Michael
TI Prescribing practice for malaria following introduction of
   artemether-lumefantrine in an urban area with declining endemicity in
   West Africa
SO MALARIA JOURNAL
LA English
DT Article
ID ARTEMISININ-COMBINATION THERAPY; CASE-MANAGEMENT; INTEGRATED MANAGEMENT;
   TANZANIAN DISTRICT; CHILDHOOD ILLNESS; HEALTH FACILITIES;
   RANDOMIZED-TRIAL; LOW TRANSMISSION; FEBRILE ILLNESS; GUINEA-BISSAU
AB Background: The decline in malaria coinciding with the introduction of newer, costly anti-malarials has prompted studies into the overtreatment for malaria mostly in East Africa. The study presented here describes prescribing practices for malaria at health facilities in a West African country.
   Methods: Cross-sectional surveys were carried out in two urban Gambian primary health facilities (PHFs) during and outside the malaria transmission season. Facilities were comparable in terms of the staffing compliment and capability to perform slide microscopy. Patients treated for malaria were enrolled after consultations and blood smears collected and read at a reference laboratory. Slide reading results from the PHFs were compared to the reference readings and the proportion of cases treated but with a negative test result at the reference laboratory was determined.
   Results: Slide requests were made for 33.2% (173) of those enrolled, being more frequent in children (0-15 yrs) than adults during the wet season (p = 0.003). In the same period, requests were commoner in under-fives compared to older children (p = 0.022); however, a positive test result was 4.4 times more likely in the latter group (p = 0.010). Parasitaemia was confirmed for only 4.7% (10/215) and 12.5% (37/297) of patients in the dry and wet seasons, respectively. The negative predictive value of a PHF slide remained above 97% in both seasons.
   Conclusions: The study provides evidence for considerable overtreatment for malaria in a West African setting comparable to reports from areas with similar low malaria transmission in East Africa. The data suggest that laboratory facilities may be under-used, and that adherence to negative PHF slide results could significantly reduce the degree of overtreatment. The "peak prevalence" in 5-15 year olds may reflect successful implementation of malaria control interventions in under-fives, but point out the need to extend such interventions to older children.
C1 [Okebe, Joseph U.; Conway, David J.; Walther, Michael] Med Res Council UK, Malaria Programme, Banjul, Gambia.
   [Walther, Brigitte] Med Res Council UK, Dept Stat, Banjul, Gambia.
   [Schellenberg, David] London Sch Hyg & Trop Med, Dis Control & Vector Biol Unit, Dept Infect & Trop Dis, London WC1E 7HT, England.
   [Conway, David J.] London Sch Hyg & Trop Med, Pathogen Mol Biol Unit, Dept Infect & Trop Dis, London WC1E 7HT, England.
RP Okebe, JU (reprint author), Med Res Council UK, Malaria Programme, Atlantic Blvd,POB 273, Banjul, Gambia.
EM jokebe@mrc.gm
OI Bojang, Kalifa/0000-0001-7506-0938; Conway, David/0000-0002-8711-3037
FU Wellcome Trust [083142/Z/07/Z]
FX The authors would like to acknowledge the support of the nurses and
   laboratory staff at the PHFs, the patients and their caregivers. The
   project was funded through a Wellcome Trust Masters Fellowship award to
   JUO (Ref: 083142/Z/07/Z). The funders however played no role in the
   study design, collection, analysis, interpretation of data, writing of
   the manuscript or the decision to submit the manuscript for publication.
CR Amexo M, 2004, LANCET, V364, P1896, DOI 10.1016/S0140-6736(04)17446-1
   Barat L, 1999, AM J TROP MED HYG, V60, P1024
   BASSETT MT, 1991, J TROP MED HYG, V94, P65
   Bisoffi Z, 2009, TROP MED INT HEALTH, V14, P491, DOI 10.1111/j.1365-3156.2009.02246.x
   Bouyou-Akotet MK, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-300
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Chandler CIR, 2008, TROP MED INT HEALTH, V13, P1131, DOI 10.1111/j.1365-3156.2008.02118.x
   Chandler CIR, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-53
   D'Acremont V, 2009, PLOS MED, V6, P4, DOI 10.1371/journal.pmed.0050252
   Delacollette C, 2009, SE ASIAN J TROP MED, V40, P674
   *DEP STAT HLTH SOC, 2005, GUID MAN MAL
   Drakeley C, 2005, PLOS MED, V2, P562, DOI 10.1371/journal.pmed.0020156
   DRAKELEY C, 2005, PLOS MED, V2, pE165
   Drakeley C, 2009, T ROY SOC TROP MED H, V103, P333, DOI 10.1016/j.trstmh.2008.10.003
   English M, 2009, PLOS MED, V6, P7, DOI 10.1371/journal.pmed.1000015
   Eriksen J, 2007, TROP MED INT HEALTH, V12, P52, DOI 10.1111/j.1365-3156.2006.01753.x
   Finney OC, 2009, EUR J IMMUNOL, V39, P1288, DOI 10.1002/eji.200839112
   Font F, 2001, TROP MED INT HEALTH, V6, P423, DOI 10.1046/j.1365-3156.2001.00727.x
   Gbotosho GO, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-313
   Giao PT, 2005, TROP MED INT HEALTH, V10, P919, DOI 10.1111/j.1365-3156.2005.01472.x
   Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7
   Hamer DH, 2007, JAMA-J AM MED ASSOC, V297, P2227, DOI 10.1001/jama.297.20.2227
   Msellem MI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000070
   Mwanziva C, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-232
   Nankabirwa J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-66
   Ndyomugyenyi R, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-39
   Nomhwange TI, 2009, TROP DOCT, V39, P90, DOI 10.1258/td.2008.080200
   Nsimba SED, 2002, TROP MED INT HEALTH, V7, P201, DOI 10.1046/j.1365-3156.2002.00847.x
   Nyarango PM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-33
   O'Meara WP, 2008, LANCET, V372, P1555, DOI 10.1016/S0140-6736(08)61655-4
   Ochola LB, 2006, LANCET INFECT DIS, V6, P582, DOI 10.1016/S1473-3099(06)70579-5
   Okiro EA, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-151
   Opoka RO, 2008, PEDIATR INFECT DIS J, V27, P319, DOI 10.1097/INF.0b013e31815d74dd
   Patwari A. K., 2002, Indian Journal of Pediatrics, V69, P41, DOI 10.1007/BF02723776
   Reyburn H, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-4
   Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55
   Reyburn H, 2007, BRIT MED J, V334, P403, DOI 10.1136/bmj.39073.496829.AE
   Rodrigues A, 2008, TROP MED INT HEALTH, V13, P410, DOI 10.1111/j.1365-3156.2008.02016.x
   Satoguina J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-274
   Shillcutt S, 2008, B WORLD HEALTH ORGAN, V86, P101, DOI 10.2471/BLT.07.042259
   Tarimo DS, 2001, ANN TROP MED PARASIT, V95, P437, DOI 10.1080/13648590120068971
   World Health Organization, 2010, GUID TREATM MAL
   Yeung S, 2009, LANCET, V374, P1418, DOI 10.1016/S0140-6736(09)61856-0
   Zakai Haytham A, 2003, J Egypt Soc Parasitol, V33, P979
   Zurovac D, 2008, TROP MED INT HEALTH, V13, P784, DOI 10.1111/j.1365-3156.2008.02072.x
NR 46
TC 11
Z9 11
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUN 24
PY 2010
VL 9
AR 180
DI 10.1186/1475-2875-9-180
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 629CD
UT WOS:000280170700001
PM 20573266
OA gold
DA 2017-08-15
ER

PT J
AU Bojang, K
   Akor, F
   Bittaye, O
   Conway, D
   Bottomley, C
   Milligan, P
   Greenwood, B
AF Bojang, Kalifa
   Akor, Francis
   Bittaye, Ousman
   Conway, David
   Bottomley, Christian
   Milligan, Paul
   Greenwood, Brian
TI A Randomised Trial to Compare the Safety, Tolerability and Efficacy of
   Three Drug Combinations for Intermittent Preventive Treatment in
   Children
SO PLOS ONE
LA English
DT Article
ID SULFADOXINE-PYRIMETHAMINE; PLASMODIUM-FALCIPARUM; SENEGALESE CHILDREN;
   WEST-AFRICA; MALARIA; AMODIAQUINE; IMPACT; REGIMENS; DENSITY; GAMBIA
AB Background: Results from trials of intermittent preventive treatment (IPT) in infants and children have shown that IPT provides significant protection against clinical malaria. Sulfadoxine-pyrimethamine (SP) given alone or in combination with other drugs has been used for most IPT programmes. However, SP resistance is increasing in many parts of Africa. Thus, we have investigated whether SP plus AQ, SP plus piperaquine (PQ) and dihydroartemisinin (DHA) plus PQ might be equally safe and effective when used for IPT in children in an area of seasonal transmission.
   Methods: During the 2007 malaria transmission season, 1008 Gambian children were individually randomized to receive SP plus amodiaquine (AQ), SP plus piperaquine (PQ) or dihydroartemisinin (DHA) plus PQ at monthly intervals on three occasions during the peak malaria transmission season. To determine the risk of side effects following drug administration, participants in each treatment group were visited at home three days after the start of each round of drug administration and a side effects questionnaire completed. To help establish whether adverse events were drug related, the same questionnaire was administered to 286 age matched control children recruited from adjacent villages. Morbidity was monitored throughout the malaria transmission season and study children were seen at the end of the malaria transmission season.
   Results: All three treatment regimens showed good safety profiles. No severe adverse event related to IPT was reported. The most frequent adverse events reported were coughing, diarrhoea, vomiting, abdominal pain and loss of appetite. Cough was present in 15.2%, 15.4% and 18.7% of study subjects who received SP plus AQ, DHA plus PQ or SP plus PQ respectively, compared to 19.2% in a control group. The incidence of malaria in the DHA plus PQ, SP plus AQ and SP plus PQ groups were 0.10 cases per child year (95% CI: 0.05, 0.22), 0.06 (95% CI: 0.022, 0.16) and 0.06 (95% CI: 0.02, 0.15) respectively. The incidence of malaria in the control group was 0.79 cases per child year (0.58, 1.08).
   Conclusion: All the three regimens of IPT in children were safe and highly efficacious
C1 [Bojang, Kalifa; Akor, Francis; Bittaye, Ousman; Conway, David] MRC Labs, Banjul, Gambia.
   [Bottomley, Christian; Milligan, Paul; Greenwood, Brian] London Sch Hyg & Trop Med, London WC1, England.
RP Bojang, K (reprint author), MRC Labs, Banjul, Gambia.
EM kbojang@mrc.gm
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Akor, Francis/0000-0002-5181-8609;
   Conway, David/0000-0002-8711-3037
FU Gates malaria partnership
FX The study received financial support from the Gates malaria partnership.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0
   Dicko A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-123
   Dunyo S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010014
   GOSLING R, DRUG OPTIONS I UNPUB
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Greenwood B, 2007, CLIN INFECT DIS, V45, P26, DOI 10.1086/518574
   Kweku M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004000
   Myint HY, 2007, T ROY SOC TROP MED H, V101, P858, DOI 10.1016/j.trstmh.2007.05.018
   Olliaro P, 1996, LANCET, V348, P1196, DOI 10.1016/S0140-6736(96)06217-4
   PHILLIPSHOWARD PA, 1990, J ROY SOC MED, V83, P82
   PUSSARD E, 1987, EUR J CLIN PHARMACOL, V33, P409, DOI 10.1007/BF00637639
   Schellenberg D, 2006, TRENDS PARASITOL, V22, P296, DOI 10.1016/j.pt.2006.05.006
   Sokhna C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001471
   Steketee RW, 1996, AM J TROP MED HYG, V55, P24
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   White NJ, 2005, PLOS MED, V2, P28, DOI 10.1371/journal.pmed.0020003
   World Health Organization, 2000, EM OTH COMM DIS STRA, P1
NR 18
TC 19
Z9 19
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 21
PY 2010
VL 5
IS 6
AR e11225
DI 10.1371/journal.pone.0011225
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 614KV
UT WOS:000279058300015
PM 20574538
OA gold
DA 2017-08-15
ER

PT J
AU Bojang, KA
   Milligan, PJM
   Conway, DJ
   Sisay-Joof, F
   Jallow, M
   Nwakanma, DC
   Abubakr, I
   Njie, F
   Greenwood, B
AF Bojang, Kalifa A.
   Milligan, Paul J. M.
   Conway, David J.
   Sisay-Joof, Fatou
   Jallow, Muminatou
   Nwakanma, Davis C.
   Abubakr, Ismaela
   Njie, Fanta
   Greenwood, Brian
TI Prevention of the Recurrence of Anaemia in Gambian Children Following
   Discharge from Hospital
SO PLOS ONE
LA English
DT Article
ID PLACEBO-CONTROLLED TRIAL; PLASMODIUM-FALCIPARUM;
   SULFADOXINE-PYRIMETHAMINE; AFRICAN CHILDREN; WESTERN KENYA;
   DIHYDROFOLATE-REDUCTASE; SENEGALESE CHILDREN; PRESCHOOL-CHILDREN;
   MALARIA; MORTALITY
AB Background: In malaria endemic countries, children who have experienced an episode of severe anaemia are at increased risk of a recurrence of anaemia. There is a need to find ways of protecting these at risk children from malaria and chemoprevention offers a potential way of achieving this objective.
   Methods: During the 2003 and 2004 malaria transmission seasons, 1200 Gambian children with moderate or severe anaemia (Hb concentration <7 g/dL) were randomised to receive either monthly sulfadoxine-pyrimethamine (SP) or placebo until the end of the malaria transmission season in which they were enrolled, in a double-blind trial. All study subjects were treated with oral iron for 28 days and morbidity was monitored through surveillance at health centres. The primary endpoint was the proportion of children with moderate or severe anaemia at the end of the transmission season. Secondary endpoints included the incidence of clinical episodes of malaria during the surveillance period, outpatient attendances, the prevalence of parasitaemia and splenomegaly, nutritional status at the end of the malaria transmission season and compliance with the treatment regimen.
   Results: The proportions of children with a Hb concentration of,7 g/dL at the end of the malaria transmission season were similar in the two study groups, 14/464 (3.0%) in children who received at least one dose of SP and 16/471 (3.4%) in those who received placebo, prevalence ratio 0.89 (0.44, 1.8) P = 0.742. The protective efficacy of SP against episodes of clinical malaria was 53% (95% CI 37%, 65%). Treatment with SP was safe and well tolerated; no serious adverse events related to SP administration were observed. Mortality following discharge from hospital was low among children who received SP or placebo (6 in the SP group and 9 in the placebo group respectively).
   Conclusions: Intermittent treatment with SP did not reduce the proportion of previously anaemic children with moderate or severe anaemia at the end of the malaria season, although it prevented malaria. The combination of appropriate antimalarial treatment plus one month of iron supplementation and good access to healthcare during follow-up proved effective in restoring haemoglobin to an acceptable level in the Gambian setting.
C1 [Bojang, Kalifa A.; Conway, David J.; Sisay-Joof, Fatou; Jallow, Muminatou; Nwakanma, Davis C.; Abubakr, Ismaela; Njie, Fanta] MRC Labs, Banjul, Gambia.
   [Milligan, Paul J. M.; Greenwood, Brian] London Sch Hyg & Trop Med, London WC1, England.
RP Bojang, KA (reprint author), MRC Labs, Banjul, Gambia.
EM kbojang@mrc.gm
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Conway, David/0000-0002-8711-3037
FU Gates malaria partnership
FX The study received financial support from the Gates malaria partnership.
   The funder had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aponte JJ, 2009, LANCET, V374, P1533, DOI 10.1016/S0140-6736(09)61258-7
   Barnes KI, 2006, CLIN PHARMACOL THER, V80, P582, DOI 10.1016/j.clpt.2006.08.016
   Biemba G, 2000, TROP MED INT HEALTH, V5, P9, DOI 10.1046/j.1365-3156.2000.00506.x
   Bojang KA, 1997, T ROY SOC TROP MED H, V91, P557, DOI 10.1016/S0035-9203(97)90025-0
   Brabin BJ, 2001, J NUTR, V131, p636S
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0
   CRAIGHEAD IB, 1993, TROP DOCT, V23, P59
   Desai MR, 2003, J INFECT DIS, V187, P658, DOI 10.1086/367986
   Dicko A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-123
   Dunyo S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010014
   Duraisingh MT, 1998, EXP PARASITOL, V89, P1, DOI 10.1006/expr.1998.4274
   EMERTON DG, 1993, T R SOC TROP MED HYG, V86, P476
   Ghattas H, 2003, LANCET, V361, P2048, DOI 10.1016/S0140-6736(03)13617-3
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3
   HEDBERG K, 1993, AM J TROP MED HYG, V48, P365
   Kweku M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004000
   Lackritz EM, 1997, AIDS, V11, P1487, DOI 10.1097/00002030-199712000-00013
   LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Ntab B, 2007, AM J TROP MED HYG, V77, P411
   PLOWE CV, 1995, AM J TROP MED HYG, V52, P565
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Schellenberg D, 1999, AM J TROP MED HYG, V61, P431
   Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2
   SLUTSKER L, 1994, T ROY SOC TROP MED H, V88, P548, DOI 10.1016/0035-9203(94)90157-0
   Sokhna C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001471
   Verhoef H, 2002, LANCET, V360, P908, DOI 10.1016/S0140-6736(02)11027-0
   WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174
   Zucker JR, 2003, AM J TROP MED HYG, V68, P386
   Zucker JR, 1996, AM J TROP MED HYG, V55, P655
NR 33
TC 6
Z9 6
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 21
PY 2010
VL 5
IS 6
AR e11227
DI 10.1371/journal.pone.0011227
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 614KV
UT WOS:000279058300016
PM 20574541
OA gold
DA 2017-08-15
ER

PT J
AU Young, JM
   Adetifa, IMO
   Ota, MOC
   Sutherland, JS
AF Young, James M.
   Adetifa, Ifedayo M. O.
   Ota, Martin O. C.
   Sutherland, Jayne S.
TI Expanded Polyfunctional T Cell Response to Mycobacterial Antigens in TB
   Disease and Contraction Post-Treatment
SO PLOS ONE
LA English
DT Article
ID TUBERCULOSIS-SPECIFIC CD4(+); PERIPHERAL-BLOOD; INTERFERON-GAMMA;
   MEMORY; INFECTION; DISTINCT
AB Background: T cells producing multiple factors have been shown to be required for protection from disease progression in HIV but we have recently shown this not to be the case in TB. Subjects with active disease had a greater proportion of polyfunctional cells responding to ESAT-6/CFP-10 stimulation than their infected but non-diseased household contacts (HHC). We therefore wanted to assess this profile in subjects who had successfully completed standard TB chemotherapy.
   Methods: We performed a cross-sectional study using PBMC from TB cases (pre- and post-treatment) and HHC. Samples were stimulated overnight with TB antigens (ESAT-6/CFP-10 and PPD) and their CD4+ and CD8+ T cells were assessed for production of CD107a, IFN-gamma, IL-2 and TNF-alpha and the complexity of the responses was determined using SPICE and PESTLE software.
   Results and Conclusions: We found that an increase in complexity (i.e., production of more than 1 factor simultaneously) of the T cell profile was associated with TB disease and that this was significantly reduced following TB treatment. This implies that T cells are able to respond adequately to TB antigens with active disease (at least initially) but the ability of this response to protect the host from disease progression is hampered, presumably due to immune evasion strategies by the bacteria. These findings have implications for the development of new diagnostics and vaccine strategies.
C1 [Young, James M.; Adetifa, Ifedayo M. O.; Ota, Martin O. C.; Sutherland, Jayne S.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
RP Young, JM (reprint author), Univ Manchester, Manchester M13 9PL, Lancs, England.
EM jsutherland@mrc.gm
OI Sutherland, Jayne/0000-0002-7083-4997
FU Bill & Melinda Gates Foundation; Medical Research Council (UK), Gambia
FX Jointly funded by Bill & Melinda Gates Foundation, Grand Challenge 6
   (http://www.gatesfoundation.org/Pages/home.aspx) and Medical Research
   Council (UK), The Gambia (www.mrc.gm). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ABEL B, 2010, AM J RESP CRIT  0218
   Balcewicz-Sablinska MK, 1998, J IMMUNOL, V161, P2636
   BEKKER G, 2000, INFECT IMMUN, V68, P954
   BETTS M, 2003, J IMMUNOL METHODS, V281, P650
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Beveridge NER, 2007, EUR J IMMUNOL, V37, P3089, DOI 10.1002/eji.2007375041
   Dlugovitzky D, 1999, SCAND J IMMUNOL, V49, P210, DOI 10.1046/j.1365-3083.1999.00492.x
   Goldsack L, 2007, TUBERCULOSIS, V87, P465, DOI 10.1016/j.tube.2007.07.001
   Goletti D, 2006, J INFECT DIS, V194, P984, DOI 10.1086/507427
   Guyot-Revol V, 2006, AM J RESP CRIT CARE, V173, P803, DOI 10.1164/rccm.200508-1294OC
   Hernandez-Pando R, 2009, ARCH IMMUNOL THER EX, V57, P355, DOI 10.1007/s00005-009-0042-9
   Hoang TTKT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005928
   Khader SA, 2008, CYTOKINE, V41, P79, DOI 10.1016/j.cyto.2007.11.022
   Morosini M, 2005, INT J TUBERC LUNG D, V9, P753
   Mueller H, 2008, CYTOKINE, V43, P143, DOI 10.1016/j.cyto.2008.05.002
   Scriba TJ, 2008, J IMMUNOL, V180, P1962
   Stenger S, 2005, ANN RHEUM DIS, V64, P24, DOI 10.1136/ard.2005.042531
   Sutherland JS, 2010, J IMMUNOL, V184, P6537, DOI 10.4049/jimmunol.1000399
   Sutherland JS, 2009, EUR J IMMUNOL, V39, P723, DOI 10.1002/eji.200838693
   *WHO, WHO 2008 TUB FACTS S, P1
   Young DB, 2009, TRENDS MICROBIOL, V17, P183, DOI 10.1016/j.tim.2009.02.005
NR 21
TC 43
Z9 43
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 21
PY 2010
VL 5
IS 6
AR e11237
DI 10.1371/journal.pone.0011237
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 614KV
UT WOS:000279058300021
PM 20574540
OA gold
DA 2017-08-15
ER

PT J
AU Bankole, AA
   Saegerman, C
   Berkvens, D
   Fretin, D
   Geerts, S
   Ieven, G
   Walravens, K
AF Bankole, A. A.
   Saegerman, C.
   Berkvens, D.
   Fretin, D.
   Geerts, S.
   Ieven, G.
   Walravens, K.
TI Phenotypic and genotypic characterisation of Brucella strains isolated
   from cattle in the Gambia
SO VETERINARY RECORD
LA English
DT Article
ID BOVINE BRUCELLOSIS; DIAGNOSIS; IDENTIFICATION; INFECTION; AFRICA; ASSAY
AB Thirty-five serum samples and six hygroma fluid samples were collected from sexually mature cattle in one herd with clinical signs of brucellosis (abortion and hygromas) in the Western Region of the Gambia in order to isolate and characterise Brucella species. Information on the sex, age, number of calvings, number of abortions, presence of hygromas, and presence of orchitis was also collected for each animal sampled. Twenty-six (74 per cent) of the serum samples were positive in the rose bengal test and 29 (83 per cent) were positive by indirect ELISA. Three isolates of Brucella, biotyped as Brucella abort us biovar 3, were cultured from six hygroma fluid samples. The multiple locus variable number tandem repeat analysis assay clustered the isolates as B abortus with the same profile for the three isolates, suggesting a common origin of contamination.
C1 [Berkvens, D.; Geerts, S.] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium.
   [Bankole, A. A.; Ieven, G.] Univ Antwerp Hosp, Dept Microbiol, Edegem, Belgium.
   [Saegerman, C.] Univ Liege, Fac Vet Med, Dept Infect & Parasit Dis, B-4000 Liege, Belgium.
   [Fretin, D.; Walravens, K.] Vet & Agrochem Res Ctr, Dept Bacteriol & Immunol, B-1190 Brussels, Belgium.
   [Bankole, A. A.] Int Trypanotolerance Ctr, Banjul, Gambia.
   [Berkvens, D.] Univ Ghent, Fac Biosci Engn, Dept Anim Prod, B-9000 Ghent, Belgium.
RP Berkvens, D (reprint author), Inst Trop Med, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.
EM dberkvens@itg.be
FU Flemish Inter-University Council (VLIR-UOS)
FX This study was conducted in the framework of PhD research activities
   financially supported by the Flemish Inter-University Council
   (VLIR-UOS).
CR Acha PN, 2003, ZOONOSES COMMUNICABL, V1, P40
   Agab H., 1997, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V50, P97
   Akakpo A. J., 1987, Revue Scientifique et Technique, Office International des Epizooties, V6, P981
   AKAKPO AJ, 1982, MED AFRIQUE NOIRE, V29, P847
   Alton GG, 1988, TECHNIQUES BRUCELLOS, p[29, 82]
   BISHOP GC, 1994, INFECTIOUS DIS LIVES, P1052
   Bornarel P., 1982, MED AFRIQUE NOIRE, V29, P829
   CAMUS E, 1980, REV ELEV MED VET PAY, V33, P262
   CARGILL C, 1985, AUST VET J, V62, P49
   CHANTAL J, 1980, REV MED VET-TOULOUSE, V131, P833
   CHOU RA, 2004, VET MICROBIOL, V103, P47
   Corbel M. J., 1984, BERGEYS MANUAL SYSTE, V1, P377
   *DEP LIV SERV, 1994, NAT LIV CENS 1993 19, P25
   DOMENECH J, 1983, REV ELEV MED VET PAY, V36, P19
   EZE E N, 1978, Bulletin of Animal Health and Production in Africa, V26, P29
   Fredslund J, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-315
   GODFROID J, 1994, ANN MED
   Hetzel M, 2004, TROP MED INT HEALTH, V9, P1132, DOI 10.1111/j.1365-3156.2004.01306.x
   Le Fleche P, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-9
   LIMET JN, 1988, ANN MED VET, V132, P565
   McDermott JJ, 2002, VET MICROBIOL, V90, P111, DOI 10.1016/S0378-1135(02)00249-3
   MUSA MT, 1990, J COMP PATHOL, V103, P95, DOI 10.1016/S0021-9975(08)80139-9
   MVLABANK M, 2009, MLVABANK BACTERIAL G
   Nielsen K, 2002, VET MICROBIOL, V90, P447, DOI 10.1016/S0378-1135(02)00229-8
   PLOMMET M, 1984, PREV VET MED, V2, P205, DOI 10.1016/0167-5877(84)90064-3
   Saegerman C, 2004, VET MICROBIOL, V100, P91, DOI 10.1016/j.vetmic.2004.02.003
   Saegerman C, 1999, VET REC, V145, P214
   SAEGERNIAN C, 2009, INFECT PARASITIC DIS, P971
   UNGER E, 2003, RISK ASSOCIATED BOVI, P16
   UNGER F, 2004, ASSESSMENT IMPACT ZO, P104
   VERGER JM, 1989, ANN RECH VET, V20, P93
   Whatmore AM, 2006, J CLIN MICROBIOL, V44, P1982, DOI 10.1128/JCM.02039-05
   Wilson K., 1990, CURRENT PROTOCOLS MO
NR 33
TC 11
Z9 11
U1 0
U2 5
PU BRITISH VETERINARY ASSOC
PI LONDON
PA 7 MANSFIELD ST, LONDON W1M 0AT, ENGLAND
SN 0042-4900
J9 VET REC
JI Vet. Rec.
PD JUN 12
PY 2010
VL 166
IS 24
BP 753
EP 756
DI 10.1136/vr.b4862
PG 4
WC Veterinary Sciences
SC Veterinary Sciences
GA 616VS
UT WOS:000279239300017
PM 20543166
OA No
DA 2017-08-15
ER

PT J
AU Savy, M
   Hennig, BJ
   Doherty, CP
   Fulford, AJ
   Bailey, R
   Holland, MJ
   Sirugo, G
   Rockett, KA
   Kwiatkowski, DP
   Prentice, AM
   Cox, SE
AF Savy, Mathilde
   Hennig, Branwen J.
   Doherty, Conor P.
   Fulford, Anthony J.
   Bailey, Robin
   Holland, Martin J.
   Sirugo, Giorgio
   Rockett, Kirk A.
   Kwiatkowski, Dominic P.
   Prentice, Andrew M.
   Cox, Sharon E.
TI Haptoglobin and Sickle Cell Polymorphisms and Risk of Active Trachoma in
   Gambian Children
SO PLOS ONE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; HEMOGLOBIN SCAVENGER RECEPTOR; GENETIC
   SUSCEPTIBILITY; CHLAMYDIA-PNEUMONIAE; INFECTIOUS-DISEASES; ENDEMIC
   POPULATION; SCARRING TRACHOMA; IRON RESTRICTION; SEX-DIFFERENCES; 2-2
   PHENOTYPE
AB Background: Susceptibility and resistance to trachoma, the leading infectious cause of blindness, have been associated with a range of host genetic factors. In vitro studies of the causative organism, Chlamydia trachomatis, demonstrate that iron availability regulates its growth, suggesting that host genes involved in regulating iron status and/or availability may modulate the risk of trachoma. The objective was to investigate whether haptoglobin (Hp) haplotypes constructed from the functional polymorphism (Hp1/Hp2) plus the functional promoter SNPs-61A-C (rs5471) and-101C-G (rs5470), or sickle cell trait (HbAS, rs334) were associated with risk of active trachoma when stratified by age and sex, in rural Gambian children.
   Methodology and Principal Findings: In two cross sectional surveys of children aged 6-78 months (n = 836), the prevalence of the clinical signs of active trachoma was 21.4%. Within boys, haplotype E (-101G, -61A, Hp1), containing the variant allele of the -101C-G promoter SNP, was associated with a two-fold increased risk of active trachoma (OR = 2.0 [1.17-3.44]). Within girls, an opposite association was non-significant (OR = 0.58 [0.32-1.04]; P = 0.07) and the interaction by sex was statistically significant (P = 0.001). There was no association between trachoma and HbAS.
   Conclusions: These data indicate that genetic variation in Hp may affect susceptibility to active trachoma differentially by sex in The Gambia.
C1 [Savy, Mathilde; Hennig, Branwen J.; Fulford, Anthony J.; Prentice, Andrew M.; Cox, Sharon E.] London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1, England.
   [Doherty, Conor P.; Bailey, Robin; Holland, Martin J.; Sirugo, Giorgio] MRC Labs, Fajara, Gambia.
   [Bailey, Robin; Holland, Martin J.] London Sch Hyg & Trop Med, Dept Infect Trop Dis, London WC1, England.
   [Sirugo, Giorgio] San Pietro Hosp, Dept Med Genet, Rome, Italy.
   [Rockett, Kirk A.; Kwiatkowski, Dominic P.] Wellcome Trust Ctr Human Genet, Oxford, England.
   [Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Malaria Programme, Hinxton, England.
RP Savy, M (reprint author), London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1, England.
EM Sharon.Cox@lshtm.ac.uk
RI Hennig, Branwen/M-6444-2014
OI Cox, Sharon/0000-0002-9908-2936; Kwiatkowski,
   Dominic/0000-0002-5023-0176
FU Medical Research Council, UK
FX This work was supported by the Medical Research Council, UK. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Abdou A, 2007, BRIT J OPHTHALMOL, V91, P13, DOI 10.1136/bjo.2006.099507
   Aidoo M, 2002, LANCET, V359, P1311, DOI 10.1016/S0140-6736(02)08273-9
   Al-Younes HM, 2001, CELL MICROBIOL, V3, P427, DOI 10.1046/j.1462-5822.2001.00125.x
   Allen SJ, 1997, P NATL ACAD SCI USA, V94, P14736, DOI 10.1073/pnas.94.26.14736
   Arredouani M, 2003, IMMUNOLOGY, V108, P144, DOI 10.1046/j.1365-2567.2003.01569.x
   Asleh R, 2003, CIRC RES, V92, P1193, DOI 10.1161/01.RES.0000076889.23082.F1
   Atik B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003600
   Atkinson SH, 2007, CLIN INFECT DIS, V44, P802, DOI 10.1086/511868
   ATKINSON SH, 2006, PLOS MED, V3, P172
   Cabrera G, 2005, J INFECT DIS, V191, P1631, DOI 10.1086/429832
   CLAYTON DG, SNPHAP PROGRAM ESTIM
   Clementi M, 2006, REPROD TOXICOL, V21, P345, DOI 10.1016/j.reprotox.2005.08.006
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Conway DJ, 1996, J INFECT DIS, V174, P643
   Courtright P, 2004, EMERG INFECT DIS, V10, P2012
   COX SE, 2008, TROP MED INT HLTH
   Cox SE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000362
   Delanghe JR, 2007, CLIN CHEM, V53, P1397, DOI 10.1373/clinchem.2007.088658
   Delanghe JR, 1998, AIDS, V12, P1027, DOI 10.1097/00002030-199809000-00009
   Elagib AA, 1998, T ROY SOC TROP MED H, V92, P309, DOI 10.1016/S0035-9203(98)91025-2
   Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394
   Freidank HM, 2001, J MED MICROBIOL, V50, P223
   Friis Henrik, 2003, JAIDS Journal of Acquired Immune Deficiency Syndromes, V33, P74
   Gambhir M, 2007, LANCET INFECT DIS, V7, P420, DOI 10.1016/S1473-3099(07)70137-8
   GRANT DJ, 1993, AM J HUM GENET, V52, P974
   GUETTA J, 2006, ATHEROSCLEROSIS
   Harding-Esch EM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000573
   Hill AVS, 2006, ANNU REV GENET, V40, P469, DOI 10.1146/annurev.genet.40.110405.090546
   *INT TRACH IN, 2006, ANN REP 2006
   Jallow M, 2009, NAT GENET
   Kasvosve I, 2002, CLIN CHEM LAB MED, V40, P810, DOI 10.1515/CCLM.2002.140
   Klein SL, 2004, PARASITE IMMUNOL, V26, P247, DOI 10.1111/j.0141-9838.2004.00710.x
   Koch W, 2003, CLIN CHEM, V49, P1937, DOI 10.1373/clinchem.2003.022442
   Koch W, 2002, CLIN CHEM, V48, P1377
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   Langlois M, 1997, EUR J CLIN CHEM CLIN, V35, P199
   Langlois MR, 2000, CLIN CHEM, V46, P1619
   Larue RW, 2007, INFECT IMMUN, V75, P2374, DOI 10.1128/IAI.01465-06
   Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1
   Melamed-Frank M, 2001, BLOOD, V98, P3693, DOI 10.1182/blood.V98.13.3693
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Minang JT, 2004, ACTA TROP, V90, P107, DOI 10.1016/j.actatropica.2003.10.016
   Moestrup SK, 2004, ANN MED, V36, P347, DOI 10.1080/07853890410033171
   Mozzato-Chamay N, 2000, J INFECT DIS, V182, P1545, DOI 10.1086/315891
   Mustafa S, 2004, DIABETES CARE, V27, P2103, DOI 10.2337/diacare.27.9.2103
   Natividad A, 2007, GENES IMMUN, V8, P288, DOI 10.1038/sj.gene.6364384
   Natividad A, 2005, GENES IMMUN, V6, P332, DOI 10.1038/sj.gene.6364182
   Natividad A, 2008, HUM MOL GENET, V17, P323, DOI 10.1093/hmg/ddm310
   Natividad A, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-138
   Okazaki T, 1997, CLIN CHEM, V43, P2012
   Quaye IK, 2006, J ATHEROSCLER THROMB, V13, P90
   Quaye IKE, 2000, HUM HERED, V50, P382, DOI 10.1159/000022944
   Quaye IK, 2008, T ROY SOC TROP MED H, V102, P735, DOI 10.1016/j.trstmh.2008.04.010
   Raulston JE, 1997, INFECT IMMUN, V65, P4539
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SINGH IP, 1986, HUM HERED, V36, P31, DOI 10.1159/000153596
   Sirugo G, 2004, NAT GENET, V36, P785, DOI 10.1038/ng0804-785
   Slepenkin A, 2007, INFECT IMMUN, V75, P3478, DOI 10.1128/IAI.00023-07
   Stephens RS, 2003, TRENDS MICROBIOL, V11, P44, DOI 10.1016/S0966-842X(02)00011-2
   Teye K, 2003, CLIN GENET, V64, P439, DOI 10.1034/j.1399-0004.2003.00149.x
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   vanOoij C, 1997, INFECT IMMUN, V65, P758
   Ward M, 1990, Scand J Infect Dis Suppl, V69, P137
   West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158
   Wieringa FT, 2007, BRIT J NUTR, V98, P1070, DOI [10.1017/SO007114507756945, 10.1017/S0007114507756945]
   Williams TN, 2005, PLOS MED, V2, P441, DOI 10.1371/journal.pmed.0020128
   Williams TN, 2005, J INFECT DIS, V192, P178, DOI 10.1086/430744
NR 67
TC 8
Z9 8
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 11
PY 2010
VL 5
IS 6
AR e11075
DI 10.1371/journal.pone.0011075
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 609NG
UT WOS:000278662900015
PM 20552021
OA gold
DA 2017-08-15
ER

PT J
AU van Tienen, C
   van der Loeff, MFS
   Peterson, I
   Cotten, M
   Holmgren, B
   Andersson, S
   Vincent, T
   Sarge-Njie, R
   Rowland-Jones, S
   Jaye, A
   Aaby, P
   Whittle, H
AF van Tienen, Carla
   van der Loeff, Maarten F. Schim
   Peterson, Ingrid
   Cotten, Matthew
   Holmgren, Birgitta
   Andersson, Soren
   Vincent, Tim
   Sarge-Njie, Ramu
   Rowland-Jones, Sarah
   Jaye, Assan
   Aaby, Peter
   Whittle, Hilton
TI HTLV-1 in rural Guinea-Bissau: prevalence, incidence and a continued
   association with HIV between 1990 and 2007
SO RETROVIROLOGY
LA English
DT Article
ID VIRUS TYPE-I; WEST-AFRICAN POPULATION; TO-FEMALE TRANSMISSION;
   RISK-FACTORS; PULMONARY TUBERCULOSIS; OCCUPATIONAL COHORT;
   CELL-ACTIVATION; PREGNANT-WOMEN; PROVIRUS LOAD; CIVIL-WAR
AB Background: HTLV-1 is endemic in Guinea-Bissau, and the highest prevalence in the adult population (5.2%) was observed in a rural area, Caio, in 1990. HIV-1 and HIV-2 are both prevalent in this area as well. Cross-sectional associations have been reported for HTLV-1 with HIV infection, but the trends in prevalence of HTLV-1 and HIV associations are largely unknown, especially in Sub Saharan Africa. In the current study, data from three cross-sectional community surveys performed in 1990, 1997 and 2007, were used to assess changes in HTLV-1 prevalence, incidence and its associations with HIV-1 and HIV-2 and potential risk factors.
   Results: HTLV-1 prevalence was 5.2% in 1990, 5.9% in 1997 and 4.6% in 2007. Prevalence was higher among women than men in all 3 surveys and increased with age. The Odds Ratio (OR) of being infected with HTLV-1 was significantly higher for HIV positive subjects in all surveys after adjustment for potential confounding factors. The risk of HTLV-1 infection was higher in subjects with an HTLV-1 positive mother versus an uninfected mother (OR 4.6, CI 2.6-8.0). The HTLV-1 incidence was stable between 1990-1997 (Incidence Rate (IR) 1.8/1,000 pyo) and 1997-2007 (IR 1.6/1,000 pyo) (Incidence Rate Ratio (IRR) 0.9, CI 0.4-1.7). The incidence of HTLV-1 among HIV-positive individuals was higher compared to HIV negative individuals (IRR 2.5, CI 1.0-6.2), while the HIV incidence did not differ by HTLV-1 status (IRR 1.2, CI 0.5-2.7).
   Conclusions: To our knowledge, this is the largest community based study that has reported on HTLV-1 prevalence and associations with HIV. HTLV-1 is endemic in this rural community in West Africa with a stable incidence and a high prevalence. The prevalence increases with age and is higher in women than men. HTLV-1 infection is associated with HIV infection, and longitudinal data indicate HIV infection may be a risk factor for acquiring HTLV-1, but not vice versa. Mother to child transmission is likely to contribute to the epidemic.
C1 [van Tienen, Carla; Peterson, Ingrid; Cotten, Matthew; Vincent, Tim; Sarge-Njie, Ramu; Jaye, Assan; Whittle, Hilton] MRC, Fajara, Gambia.
   [van der Loeff, Maarten F. Schim] Municipal Hlth Serv, Amsterdam, Netherlands.
   [van der Loeff, Maarten F. Schim] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
   [Holmgren, Birgitta] Lund Univ, Dept Lab Med, Div Med Microbiol Virol, Lund, Sweden.
   [Andersson, Soren] Swedish Inst Infect Dis Control, Stockholm, Sweden.
   [Rowland-Jones, Sarah] John Radcliffe Hosp, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
   [Aaby, Peter] Indepth Network, Projecto Saude Bandim, Bissau, Guinea Bissau.
RP van Tienen, C (reprint author), MRC, Fajara, Gambia.
EM cvantienen@mrc.gm
RI van Tienen, Carla/A-1119-2012
FU Medical Research Council [MC_U190081997, MC_U190085854]
CR Aaby P, 1996, AIDS, V10, P1585
   Arisawa K, 1998, JPN J CANCER RES, V89, P797
   Ariyoshi K, 2003, J INFECT DIS, V188, P1648, DOI 10.1086/379780
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Begaud E, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-35
   Brites C, 2009, AIDS REV, V11, P8
   Cooper S, 2009, J NEUROL NEUROSUR PS, V80, P66, DOI 10.1136/jnnp.2008.152819
   da Silva ZJ, 2008, AIDS, V22, P1195, DOI 10.1097/QAD.0b013e328300a33d
   DASILVA ZJ, 2009, AIDS
   DJOMAND G, 1995, J ACQ IMMUN DEF SYND, V10, P358
   FIGUEROA JP, 1995, J ACQ IMMUN DEF SYND, V9, P81
   Holmdahl R, 2007, ERNST SCHERING FOUND, V4, P1, DOI 10.1007/2789_2007_036
   Holmgren B, 1999, SCAND J INFECT DIS, V31, P459
   Holmgren B, 2002, J ACQ IMMUN DEF SYND, V30, P342, DOI 10.1097/01.QAI.0000013943.86473.3E
   IWATA K, 1994, JPN J CANCER RES, V85, P231
   Jensen ML, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000101
   Kaplan JE, 1996, J ACQ IMMUN DEF SYND, V12, P193
   Koning FA, 2005, J IMMUNOL, V175, P6117
   Krook A, 1997, J ACQ IMMUN DEF SYND, V15, P381
   LAGRENADE L, 1990, LANCET, V336, P1345
   Larsen O, 1998, AIDS, V12, P1707, DOI 10.1097/00002030-199813000-00020
   Larsen O, 2000, J ACQ IMMUN DEF SYND, V25, P157, DOI 10.1097/00126334-200010010-00010
   LEHESRAN JY, 1994, INT J EPIDEMIOL, V23, P812
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100
   Mansson F, 2007, SEX TRANSM INFECT, V83, P463, DOI 10.1136/sti.2007.025353
   Mansson F, 2009, AIDS, V23, P1575, DOI 10.1097/QAD.0b013e32832cedfb
   Marinho J, 2005, JAIDS-J ACQ IMM DEF, V40, P625, DOI 10.1097/01.qai.0000174252.73516.7a
   Melbye M, 1998, INT J CANCER, V76, P293, DOI 10.1002/(SICI)1097-0215(19980504)76:3<293::AID-IJC1>3.0.CO;2-Q
   Norrgren H, 1999, AIDS, V13, P701, DOI 10.1097/00002030-199904160-00011
   NORRGREN H, 1995, J ACQ IMMUN DEF SYND, V9, P422, DOI 10.1097/00042560-199508000-00014
   Norrgren HR, 2008, JAIDS-J ACQ IMM DEF, V48, P607, DOI 10.1097/QAI.0b013e31817efb83
   Nyambi PN, 1996, J ACQ IMMUN DEF SYND, V12, P187
   Olaleye DO, 1999, J TROP PEDIATRICS, V45, P66, DOI 10.1093/tropej/45.2.66
   Pepin J, 2006, AIDS, V20, P1303
   Plamondon M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000372
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
   Poulsen AG, 2000, SCAND J INFECT DIS, V32, P169
   Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   SAGAWA K, 1995, J CLIN INVEST, V95, P852, DOI 10.1172/JCI117735
   STUVER SO, 1993, J INFECT DIS, V167, P57
   TAKEZAKI T, 1995, J INFECT DIS, V171, P559
   Tortevoye P, 2005, AM J TROP MED HYG, V73, P560
   van der Loeff MFS, 2006, INT J EPIDEMIOL, V35, P1322, DOI 10.1093/ije/dy1037
   van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012
   Van Dooren S, 2001, MOL BIOL EVOL, V18, P661
   VANDERLOEFF MFS, 2003, ANTIVIR THER S, V8, pS187
   VANTIENEN C, 2009, J ACQUIR IM IN PRESS
   Verdonck K, 2007, INT J TUBERC LUNG D, V11, P1066
   Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
   von Elm E, 2007, PLOS MED, V4, P1623, DOI 10.1371/journal.pmed.0040296
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
   Zehender G, 2008, JAIDS-J ACQ IMM DEF, V47, P269
NR 54
TC 10
Z9 10
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD JUN 4
PY 2010
VL 7
AR 50
DI 10.1186/1742-4690-7-50
PG 9
WC Virology
SC Virology
GA 621AB
UT WOS:000279544200001
PM 20525366
OA gold
DA 2017-08-15
ER

PT J
AU Hill, PC
   Townend, J
   Antonio, M
   Akisanya, B
   Ebruke, C
   Lahai, G
   Greenwood, BM
   Adegbola, RA
AF Hill, Philip C.
   Townend, John
   Antonio, Martin
   Akisanya, Biodun
   Ebruke, Chinelo
   Lahai, George
   Greenwood, Brian M.
   Adegbola, Richard A.
TI Transmission of Streptococcus pneumoniae in Rural Gambian Villages: A
   Longitudinal Study
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; NASOPHARYNGEAL CARRIAGE;
   INVASIVE-DISEASE; CHILDREN; SEROTYPE; FAMILIES; TRIAL; COLONIZATION;
   HOUSEHOLD; COMMUNITY
AB Background. To prepare for national introduction of a pneumococcal vaccine of restricted valency, we studied the pattern of nasopharyngeal carriage of Streptococcus pneumoniae and its transmission in Gambian villages over time.
   Methods. We collected nasopharyngeal swab specimens every 2 weeks from 158 villagers in 19 households in 2 villages over 1 year. We studied the prevalence and duration of S. pneumoniae carriage, the effect of household size and composition on carriage, and sequence type-specific carriage within and between households.
   Results. Ninety-seven percent of children and 85% of adults carried S. pneumoniae at some time. Fifty-three serotypes were represented among 1522 isolates. Carriage was more common among children than adults for all serotypes studied except 9V. There was an overall trend toward shorter carriage with increasing age (P = .043) and significant differences in carriage duration between serotypes. For most serotypes, the odds of being a carrier were greater if there were other carriers in the household. The prevalence of carriage varied by serotype. Most notably, serotype 5 carriage occurred in only 1 village and was transient. Multilocus sequence typing of serotype 6B isolates from 1 village revealed 8 different sequence types and strong evidence of nonrandom distribution among households (P<.001). Study by sequence type suggested household spread starting most commonly in children, followed by spread to adults.
   Conclusions. This longitudinal carriage study in Gambian villages provides unique information on the pattern of spread of S. pneumoniae in rural Africa and a baseline for evaluating the impact of the introduction of pneumococcal conjugate vaccine into the region.
C1 [Hill, Philip C.] Univ Otago, Ctr Int Hlth, Sch Med, Dunedin 9054, New Zealand.
   [Hill, Philip C.; Townend, John; Antonio, Martin; Akisanya, Biodun; Ebruke, Chinelo; Lahai, George; Adegbola, Richard A.] MRC Labs, Bacterial Dis Programme, Fajara, Gambia.
   [Greenwood, Brian M.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   [Adegbola, Richard A.] Bill & Melinda Gates Fdn, Seattle, WA USA.
RP Hill, PC (reprint author), Univ Otago, Ctr Int Hlth, Sch Med, POB 913, Dunedin 9054, New Zealand.
EM Philip.hill@otago.ac.nz
FU Medical Research Council (United Kingdom)
FX The Medical Research Council (United Kingdom).
CR Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Albrich WC, 2007, CLIN INFECT DIS, V44, P1569, DOI 10.1086/517149
   Antonio M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-198
   Auranen K, 2000, J AM STAT ASSOC, V95, P1044, DOI 10.2307/2669741
   Brueggemann AB, 2003, J INFECT DIS, V187, P1424, DOI 10.1086/374624
   Cauchemez S, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-14
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Ekdahl K, 1997, CLIN INFECT DIS, V25, P1113, DOI 10.1086/516103
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Huang SS, 2009, PEDIATRICS, V124, pE1, DOI 10.1542/peds.2008-3099
   Hussain M, 2005, EPIDEMIOL INFECT, V133, P891, DOI 10.1016/S0950268805004012
   Kaye P, INVASIVE PNEUMOCOCCA
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Leino T, 2001, PEDIATR INFECT DIS J, V20, P1022, DOI 10.1097/00006454-200111000-00004
   Leowski J, 1986, World Health Stat Q, V39, P138
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   Melegaro A, 2007, AM J EPIDEMIOL, V166, P228, DOI 10.1093/aje/kwm076
   Millar EV, 2008, CLIN INFECT DIS, V47, P989, DOI 10.1086/591966
   MONTGOMERY JM, 1990, REV INFECT DIS, V12, pS1006
   O'Brien KL, 2003, LANCET, V362, P355, DOI 10.1016/S0140-6736(03)14022-6
   O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI 10.1097/00006454-200302000-00009
   Regev-Yochay G, 2004, CLIN INFECT DIS, V38, P632
   Reis JN, 2008, J INFECTION, V57, P204, DOI 10.1016/j.jinf.2008.06.017
   Sandgren A, 2004, J INFECT DIS, V189, P785, DOI 10.1086/381686
   Singleton RJ, 2007, JAMA-J AM MED ASSOC, V297, P1784, DOI 10.1001/jama.297.16.1784
   Sleeman KL, 2006, J INFECT DIS, V194, P682, DOI 10.1086/505710
   Smith-Vaughan H, 2009, CLIN VACCINE IMMUNOL, V16, P218, DOI 10.1128/CVI.00283-08
   Whitney CG, 2006, LANCET, V368, P1495, DOI 10.1016/S0140-6736(06)69637-2
NR 29
TC 48
Z9 48
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 1
PY 2010
VL 50
IS 11
BP 1468
EP 1476
DI 10.1086/652443
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 590AF
UT WOS:000277194800007
PM 20420503
OA No
DA 2017-08-15
ER

PT J
AU Flanagan, KL
   Burl, S
   Lohman-Payne, BL
   Plebanski, M
AF Flanagan, Katie L.
   Burl, Sarah
   Lohman-Payne, Barbara L.
   Plebanski, Magdalena
TI The challenge of assessing infant vaccine responses in resource-poor
   settings
SO EXPERT REVIEW OF VACCINES
LA English
DT Review
DE antibody; B cell; cord blood; developing country; immune response;
   infant; innate immunity; neonate; nonspecific effect; T cell; vaccine
ID BACILLUS-CALMETTE-GUERIN; REGULATORY T-CELLS; MEDIATED IMMUNE-RESPONSES;
   CORD BLOOD; DENDRITIC CELLS; INNATE IMMUNITY; BCG VACCINATION; HUMAN
   NEWBORNS; GUINEA-BISSAU; MALE MORTALITY
AB Newborns and infants are highly susceptible to infectious diseases, resulting in high mortality and morbidity, particularly in resource-poor settings. Many vaccines require several booster doses, resulting in an extensive vaccine schedule, and yet there is still inadequate protection from some of these diseases. This is partly due to the immaturity of the neonate and infant immune system. Little is known about the specific modifications to immunological assessment protocols in early life but increasing knowledge of infant immunology has helped provide better recommendations for assessing these responses. Since most new vaccines will eventually be deployed in low-income settings such as Africa, the logistics and resources of assessing immunity in such settings also need to be understood. In this article, we will review immunity to vaccines in early life, discuss the many challenges associated with assessing immunogenicity and provide practical tips.
C1 [Plebanski, Magdalena] Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia.
   [Flanagan, Katie L.; Burl, Sarah] Med Res Council UK Gambia, Fajara, Gambia.
   [Lohman-Payne, Barbara L.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
   [Lohman-Payne, Barbara L.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
RP Plebanski, M (reprint author), Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia.
EM magdalena.plebanski@med.monash.edu.au
FU MRC (UK); Australian National Health Medical Research Council (NHMRC);
   NIH [AI068431, HD023412, HD054314]; EDCTP [CT.2006.33111.002];
   CDC/PEPFAR [U62/CCU024512]; Elizabeth Glaser Pediatric AIDS Foundation
   [MV-00-9-900-01872-0-00]
FX Katie L Flanagan and Sarah Burl are funded by the MRC (UK). Magdalena
   Plebanski is funded by The Australian National Health Medical Research
   Council (NHMRC). Barbara L Lohman-Payne is funded by NIH grants
   AI068431, HD023412 and HD054314; EDCTP grant CT.2006.33111.002;
   CDC/PEPFAR grant U62/CCU024512; and Elizabeth Glaser Pediatric AIDS
   Foundation grant MV-00-9-900-01872-0-00. The authors have no other
   relevant affiliations or financial involvement with any organization or
   entity with a financial interest in or financial conflict with the
   subject matter or materials discussed in the manuscript apart from those
   disclosed.
CR Aaby P, 2006, VACCINE, V24, P4701, DOI 10.1016/j.vaccine.2006.03.038
   Aaby P, 2006, VACCINE, V24, P2764, DOI 10.1016/j.vaccine.2006.01.004
   Aaby P, 2007, PEDIATR INFECT DIS J, V26, P247, DOI 10.1097/01.inf.0000256735.05098.01
   Aaby P, 2007, VACCINE, V25, P1265, DOI 10.1016/j.vaccine.2006.10.007
   Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903
   Angelone DF, 2006, PEDIATR RES, V60, P205, DOI 10.1203/01.pdr.0000228319.10481.ea
   Ballou WR, 2009, PARASITE IMMUNOL, V31, P492, DOI 10.1111/j.1365-3024.2009.01143.x
   Belderbos ME, 2009, CLIN IMMUNOL, V133, P228, DOI 10.1016/j.clim.2009.07.003
   Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753
   Beveridge NER, 2007, EUR J IMMUNOL, V37, P3089, DOI 10.1002/eji.2007375041
   Breiman RF, 2004, LANCET, V364, P2204, DOI 10.1016/S0140-6736(04)17593-4
   BYRNE JA, 1994, J IMMUNOL, V152, P3098
   Calder PC, 2006, BRIT J NUTR, V96, P774, DOI 10.1079/BJN20061917
   *CMI, CMI TECHN STAND VACC
   COLDITZ GA, 1995, PEDIATRICS, V96, P29
   Cooper AM, 2008, IMMUNOL REV, V226, P191, DOI 10.1111/j.1600-065X.2008.00702.x
   Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703
   COURANT F, J CLIN ENDOCRINOL ME, V95, P82
   Cupedo T, 2005, EUR J IMMUNOL, V35, P383, DOI 10.1002/eji.200425763
   D'Angio Carl T, 2007, Paediatr Drugs, V9, P17, DOI 10.2165/00148581-200709010-00003
   D'Arena G, 1998, HAEMATOLOGICA, V83, P197
   Darrasse-Jeze G., 2006, IMMUNOL LETT, V102, P106
   Davila S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000218
   Diness BR, 2007, AM J CLIN NUTR, V86, P1152
   Ehreth J, 2003, VACCINE, V21, P596, DOI 10.1016/S0264-410X(02)00623-0
   Farrington CP, 2009, TROP MED INT HEALTH, V14, P977, DOI 10.1111/j.1365-3156.2009.02302.x
   Finan C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003485
   Fine PEM, 2009, TROP MED INT HEALTH, V14, P969, DOI 10.1111/j.1365-3156.2009.02301.x
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394
   FLANAGAN KL, 2010, J IMMUNOL, V40, P1062
   Gans HA, 2004, J INFECT DIS, V190, P83, DOI 10.1086/421032
   Godfrey WR, 2005, BLOOD, V105, P750, DOI 10.1182/blood-2004-06-2467
   Goriely S, 2001, J IMMUNOL, V166, P2141
   Hanekom WA, 2004, J IMMUNOL METHODS, V291, P185, DOI 10.1016/j.jim.2004.06.010
   Hanekom WA, 2005, ANN NY ACAD SCI, V1062, P69, DOI 10.1196/annals.1358.010
   International Conference on Harmonisation, INT C HARM TECHN REQ
   Jahn A, 2008, TROP MED INT HEALTH, V13, P129, DOI 10.1111/j.1365-3156.2007.01982.x
   Jonsdottir I, 2007, J COMP PATHOL, V137, pS20, DOI 10.1016/j.jcpa.2007.04.007
   Kessel A, 2006, CLIN EXP IMMUNOL, V145, P563, DOI 10.1111/j.1365-2249.2006.03170.x
   Kimman TG, 2007, COMMUNITY GENET, V10, P201, DOI 10.1159/000106559
   Kollmann TR, 2009, J IMMUNOL, V183, P7150, DOI 10.4049/jimmunol.0901481
   Krumbiegel D, 2007, HUM IMMUNOL, V68, P813, DOI 10.1016/j.humimm.2007.08.001
   Kruschinski C, 2004, HUM PATHOL, V35, P113, DOI 10.1016/S0046-8177(03)00422-2
   Ku CL, 2007, J MED GENET, V44, P16, DOI 10.1136/jmg.2006.044446
   Lehmann D, 2005, INT J EPIDEMIOL, V34, P138, DOI 10.1093/ije/dyh262
   Levy O, 2004, J IMMUNOL, V173, P4627
   Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075
   Levy O, 2006, BLOOD, V108, P1284, DOI 10.1182/blood-2005-12-4821
   Lohman BL, 2005, J VIROL, V79, P8121, DOI 10.1128/JVI.79.13.8121-8130.2005
   Low N, 2008, VACCINE, V26, P383, DOI 10.1016/j.vaccine.2007.11.010
   Marchant A, 2006, J INFECT DIS, V193, P1598, DOI 10.1086/503775
   Marchant A, 2005, CLIN EXP IMMUNOL, V141, P10, DOI 10.111/j.1365.2249.2005.02799.x
   Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510
   Mazzucchelli R, 2007, NAT REV IMMUNOL, V7, P144, DOI 10.1038/nri2023
   Meylan E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946
   Michaelsson J, 2006, J IMMUNOL, V176, P5741
   Miles DJC, 2008, J INFECT DIS, V197, P658, DOI 10.1086/527418
   Miles DJC, 2007, J VIROL, V81, P5766, DOI 10.1128/JVI.00052-07
   Mills KHG, 2009, IMMUNOL LETT, V122, P108, DOI 10.1016/j.imlet.2008.11.007
   Moore AC, 2005, J IMMUNOL, V175, P7264
   Moreau E, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/428593
   Moulton LH, 2005, TROP MED INT HEALTH, V10, P947, DOI 10.1111/j.1365-3156.2005.01434.x
   Naniche D, 2009, CURR TOP MICROBIOL, V330, P151
   Nardelli DT, 2004, CLIN DIAGN LAB IMMUN, V11, P1075, DOI 10.1128/CDLI.11.6.1075-1084.2004
   Ng WF, 2001, BLOOD, V98, P2736, DOI 10.1182/blood.V98.9.2736
   Ota MOC, 2002, J IMMUNOL, V168, P919
   Philbin VJ, 2009, PEDIATR RES, V65, p98R, DOI 10.1203/PDR.0b013e31819f195d
   Prescott SL, 2009, NESTLE NUTR WORKSHOP
   Prescott SL, 2009, NESTLE NUTR WORKS SE, V64, P185, DOI 10.1159/000235791
   Puig-Kroger A, 2000, J IMMUNOL, V165, P4338
   Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688
   Quinn KM, 2008, EUR J IMMUNOL, V38, P695, DOI 10.1002/eji.200737888
   Richmond P, 1999, J INFECT DIS, V179, P1569, DOI 10.1086/314753
   Rochman I, 2005, J IMMUNOL, V174, P4761
   Roth A, 2005, INT J EPIDEMIOL, V34, P540, DOI 10.1093/ije/dyh393
   Roth A, 2006, EPIDEMIOLOGY, V17, P562, DOI 10.1097/01.ede.0000231546.14749.ab
   Savy M, 2009, J NUTR, V139, p2154S, DOI 10.3945/jn.109.105312
   Seale AC, 2008, J CLIN LAB ANAL, V22, P153, DOI 10.1002/jcla.20234
   Senior K, 2009, LANCET INFECT DIS, V9, P730
   Siegrist CA, 2007, J COMP PATHOL, V137, pS4, DOI 10.1016/j.jcpa.2007.04.004
   Siegrist CA, 2009, NAT REV IMMUNOL, V9, P185, DOI 10.1038/nri2508
   Silfverdal SA, 2007, VACCINE, V25, P1497, DOI 10.1016/j.vaccine.2006.10.025
   Slyker JA, 2005, VACCINE, V23, P4711, DOI 10.1016/j.vaccine.2005.01.145
   Slyker JA, 2009, AIDS, V23, P2173, DOI 10.1097/QAD.0b013e32833016e8
   Soares AP, 2008, J IMMUNOL, V180, P3569
   Stober CB, 2005, J IMMUNOL, V175, P2517
   Szabolcs P, 2003, EXP HEMATOL, V31, P708, DOI 10.1016/S0301-472X(03)00160-7
   Takahata Y, 2004, EXP HEMATOL, V32, P622, DOI 10.1016/j.exphem.2004.03.012
   Tappero JW, 1999, JAMA-J AM MED ASSOC, V281, P1520, DOI 10.1001/jama.281.16.1520
   Tiru M, 2000, VACCINE, V18, P2295, DOI 10.1016/S0264-410X(99)00539-3
   Uehori J, 2003, INFECT IMMUN, V71, P4238, DOI 10.1128/IAI.71.8.4238-4249.2003
   Vanden Eijnden S, 2006, EUR J IMMUNOL, V36, P21, DOI 10.1002/eji.200535467
   Veirum JE, 2005, VACCINE, V23, P1197, DOI 10.1016/j.vaccine.2004.02.053
   Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1
   Vidor E, 2007, J COMP PATHOL, V137, pS62, DOI 10.1016/j.jcpa.2007.04.014
   von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298
   Waterhouse T, 2005, EXPERT REV VACCINES, V4, P1, DOI 10.1586/14760584.4.1.1
   Watkins MLV, 2008, CLIN VACCINE IMMUNOL, V15, P1666, DOI 10.1128/CVI.00202-08
   Wing K, 2002, IMMUNOLOGY, V106, P190, DOI 10.1046/j.1365-2567.2002.01412.x
   Yan SR, 2004, INFECT IMMUN, V72, P1223, DOI 10.1128/IAI.72.3.1233-1229.2004
NR 103
TC 10
Z9 11
U1 2
U2 4
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND
SN 1476-0584
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD JUN
PY 2010
VL 9
IS 6
BP 665
EP 674
DI 10.1586/ERV.10.41
PG 10
WC Immunology
SC Immunology
GA 618CO
UT WOS:000279329200015
PM 20518720
OA No
DA 2017-08-15
ER

PT J
AU Sutherland, JS
   Young, JM
   Peterson, KL
   Sanneh, B
   Whittle, HC
   Rowland-Jones, SL
   Adegbola, RA
   Jaye, A
   Ota, MOC
AF Sutherland, Jayne S.
   Young, James M.
   Peterson, Kevin L.
   Sanneh, Bakary
   Whittle, Hilton C.
   Rowland-Jones, Sarah L.
   Adegbola, Richard A.
   Jaye, Assan
   Ota, Martin O. C.
TI Polyfunctional CD4(+) and CD8(+) T Cell Responses to Tuberculosis
   Antigens in HIV-1-Infected Patients before and after Anti-Retroviral
   Treatment
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HIV-INFECTED PATIENTS; TUMOR-NECROSIS-FACTOR;
   MYCOBACTERIUM-TUBERCULOSIS; IMMUNE RECONSTITUTION; INTERFERON-GAMMA;
   SOUTH-AFRICA; TNF-ALPHA; THERAPY; RELEASE; MEMORY
AB Tuberculosis (TB) kills 2 million people per year and infection with HIV is the most potent known risk factor for progression to active TB. An understanding of the immune response to TB Ags in HIV-infected patients is required to develop optimal TB vaccines and diagnostics. We assessed polyfunctional (IFN-gamma+IL-2(+)TNF-alpha(+)) T cell responses to TB Ags in three groups of HIV-1-infected patients dependent on their TB status, CD4 counts, and anti-retroviral exposure. We found that although the proportion of IFN-gamma cells in response to TB Ags was higher in patients with low CD4 counts, the responding cells changed from a polyfunctional CD4(+) to a monofunctional CD8(+) response. The overall polyfunctionality of the cells was restored by 12 mo of anti-retroviral therapy and primarily involved CD4(+) T cells with an effector memory phenotype. These findings have major implications for diagnosis of TB and in vaccine development strategies for TB in HIV-1-infected patients. The Journal of Immunology, 2010, 184: 6537-6544.
C1 [Sutherland, Jayne S.; Young, James M.; Peterson, Kevin L.; Sanneh, Bakary; Whittle, Hilton C.; Rowland-Jones, Sarah L.; Adegbola, Richard A.; Jaye, Assan; Ota, Martin O. C.] MRC Labs, Banjul, Gambia.
RP Sutherland, JS (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM jsutherland@mrc.gm
OI Sutherland, Jayne/0000-0002-7083-4997
FU Medical Research Council (U.K.); Gambia; Bill and Melinda Gates
   Foundation
FX This work was supported by the Medical Research Council (U.K.), The
   Gambia, and the Bill and Melinda Gates Foundation as part of the Grand
   Challenges for Global Health 6: Biomarkers for TB (WP3).
CR Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112
   Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3
   Balcewicz-Sablinska MK, 1998, J IMMUNOL, V161, P2636
   Bekker LG, 2000, INFECT IMMUN, V68, P6954, DOI 10.1128/IAI.68.12.6954-6961.2000
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Beveridge NER, 2007, EUR J IMMUNOL, V37, P3089, DOI 10.1002/eji.2007375041
   Boom WH, 2007, J CLIN INVEST, V117, P2092, DOI 10.1172/JCI32933
   Bourgarit A, 2009, J IMMUNOL, V183, P3915, DOI 10.4049/jimmunol.0804020
   Bruns H, 2009, J CLIN INVEST, V119, P1167, DOI 10.1172/JCI38482
   Bucy RP, 1999, J CLIN INVEST, V103, P1391, DOI 10.1172/JCI5863
   Day CL, 2008, J INFECT DIS, V197, P990, DOI 10.1086/529048
   Geretti AM, 2010, CURR OPIN INFECT DIS, V23, P32, DOI 10.1097/QCO.0b013e328334fec4
   Goldsack L, 2007, TUBERCULOSIS, V87, P465, DOI 10.1016/j.tube.2007.07.001
   Hammond AS, 2008, J INFECT DIS, V197, P295, DOI 10.1086/524685
   Karam F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001441
   Lawn SD, 2008, AM J RESP CRIT CARE, V177, P680, DOI 10.1164/rccm.200709-1311PP
   Lawn SD, 2009, AIDS, V23, P1717, DOI 10.1097/QAD.0b013e32832d3b6d
   Leidl L, 2010, EUR RESPIR J, V35, P619, DOI 10.1183/09031936.00045509
   Lewinsohn DA, 2003, AM J RESP CRIT CARE, V168, P1346, DOI 10.1164/rccm.200306-837OC
   Meintjes G, 2008, AM J RESP CRIT CARE, V178, P1083, DOI 10.1164/rccm.200806-858OC
   Nunn P, 2005, NAT REV IMMUNOL, V5, P819, DOI 10.1038/nri1704
   Patel NR, 2007, J IMMUNOL, V179, P6973
   Rowland-Jones S, 2008, PLOS MED, V5, P721, DOI 10.1371/journal.pmed.0050103
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Stenger S, 2005, ANN RHEUM DIS, V64, P24, DOI 10.1136/ard.2005.042531
   Sutherland JS, 2009, EUR J IMMUNOL, V39, P723, DOI 10.1002/eji.200838693
   Tabarsi P, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-14
   Talati NJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-15
   TENACOKI NG, 2010, AM J RESP CRIT C MAY, P11
   WHO, 2009, TECHN CONS INT PREV, P1
   Wilkinson KA, 2009, AM J RESP CRIT CARE, V180, P674, DOI 10.1164/rccm.200904-0568OC
NR 31
TC 52
Z9 52
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JUN 1
PY 2010
VL 184
IS 11
BP 6537
EP 6544
DI 10.4049/jimmunol.1000399
PG 8
WC Immunology
SC Immunology
GA 606PP
UT WOS:000278439600069
PM 20435929
OA No
DA 2017-08-15
ER

PT J
AU Robertson, K
   Liner, J
   Hakim, J
   Sankale, JL
   Grant, I
   Letendre, S
   Clifford, D
   Diop, AG
   Jaye, A
   Kanmogne, G
   Njamnshi, A
   Langford, TD
   Weyessa, TG
   Wood, C
   Banda, M
   Hosseinipour, M
   Sacktor, N
   Nakasuja, N
   Bangirana, P
   Paul, R
   Joska, J
   Wong, J
   Boivin, M
   Holding, P
   Kammerer, B
   Van Rie, A
   Ive, P
   Nath, A
   Lawler, K
   Adebamowo, C
   Royal, W
   Joseph, J
AF Robertson, Kevin
   Liner, Jeff
   Hakim, James
   Sankale, Jean-Louis
   Grant, Igor
   Letendre, Scott
   Clifford, David
   Diop, Amadou Gallo
   Jaye, Assan
   Kanmogne, Georgette
   Njamnshi, Alfred
   Langford, T. Dianne
   Weyessa, Tufa Gemechu
   Wood, Charles
   Banda, Mwanza
   Hosseinipour, Mina
   Sacktor, Ned
   Nakasuja, Noeline
   Bangirana, Paul
   Paul, Robert
   Joska, John
   Wong, Joseph
   Boivin, Michael
   Holding, Penny
   Kammerer, Betsy
   Van Rie, Annelies
   Ive, Prudence
   Nath, Avindra
   Lawler, Kathy
   Adebamowo, Clement
   Royal, Walter, III
   Joseph, Jeymohan
CA NeuroAIDS Africa Conference
TI NeuroAIDS in Africa
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Review
DE HIV; neurodevelopment; neurology; neuropsychology; subtypes
ID RECONSTITUTION INFLAMMATORY SYNDROME; DISEASE PROGRESSION; UNINFECTED
   INFANTS; GENETIC SUBTYPES; HIV-1 SUBTYPES; CHILDREN; NEURODEVELOPMENT;
   SUSCEPTIBILITY; MANIFESTATIONS; RECOMBINANTS
AB In July 2009, the Center for Mental Health Research on AIDS at the National Institute of Mental Health organized and supported the meeting "NeuroAIDS in Africa." This meeting was held in Cape Town, South Africa, and was affiliated with the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Presentations began with an overview of the epidemiology of HIV in sub-Saharan Africa, the molecular epidemiology of HIV, HIV-associated neurocognitive disorders (HANDs), and HAND treatment. These introductory talks were followed by presentations on HAND research and clinical care in Botswana, Cameroon, Ethiopia, The Gambia, Kenya, Malawi, Nigeria, Senegal, South Africa, Uganda, and Zambia. Topics discussed included best practices for assessing neurocognitive disorders, patterns of central nervous system (CNS) involvement in the region, subtype-associated risk for HAND, pediatric HIV assessments and neurodevelopment, HIV-associated CNS opportunistic infections and immune reconstitution syndrome, the evolving changes in treatment implementation, and various opportunities and strategies for NeuroAIDS research and capacity building in the region. Journal of NeuroVirology (2010) 16, 189-202.
C1 [Robertson, Kevin] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA.
   [Hakim, James] Univ Zimbabwe, Harare, Zimbabwe.
   [Sankale, Jean-Louis] Globomics LLC, Decatur, GA USA.
   [Grant, Igor] Univ Calif San Diego, La Jolla, CA 92093 USA.
   [Letendre, Scott] Univ Calif San Diego, San Diego, CA 92103 USA.
   [Clifford, David] Washington Univ, Sch Med, St Louis, MO USA.
   [Diop, Amadou Gallo] Univ Dakar, Dakar, Senegal.
   [Jaye, Assan] MRC Labs, Gambia Unit, Banjul, Gambia.
   [Kanmogne, Georgette] Univ Nebraska Med Ctr, Omaha, NE USA.
   [Njamnshi, Alfred] Univ Yaounde, Yaounde, Cameroon.
   [Langford, T. Dianne] Temple Univ, Sch Med, Philadelphia, PA 19122 USA.
   [Weyessa, Tufa Gemechu] Univ Addis Ababa, Addis Ababa, Ethiopia.
   [Wood, Charles] Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE USA.
   [Banda, Mwanza] Univ Teaching Hosp, Lusaka, Zambia.
   [Hosseinipour, Mina] UNC Project, Lilongwe, Malawi.
   [Sacktor, Ned] Johns Hopkins Univ, Johns Hopkins Bayview Med Ctr, Baltimore, MD USA.
   [Nakasuja, Noeline; Bangirana, Paul] Makerere Univ, Kampala, Uganda.
   [Paul, Robert] Univ Missouri, St Louis, MO 63121 USA.
   [Joska, John] Univ Cape Town, ZA-7925 Cape Town, South Africa.
   [Wong, Joseph] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Boivin, Michael] Michigan State Univ, E Lansing, MI 48824 USA.
   [Holding, Penny] Case Western Reserve Univ, Cleveland, OH 44106 USA.
   [Kammerer, Betsy] Harvard Univ, Sch Med, Childrens Hosp Boston, Newton, MA USA.
   [Van Rie, Annelies] Univ N Carolina, Chapel Hill, NC USA.
   [Ive, Prudence] Helen Joseph Hosp, Clin HIV Res Unit, Gauteng, South Africa.
   [Lawler, Kathy] Univ Penn, Philadelphia, PA 19104 USA.
   [Adebamowo, Clement] Inst Human Virol, Off Strateg Informat & Res, Abuja, Nigeria.
   [Royal, Walter, III] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
   [Joseph, Jeymohan] NIMH, HIV Pathogenesis Neuropsychiat & Treatment Branch, Ctr Mental Hlth Res AIDS, NIH, Bethesda, MD 20892 USA.
RP Robertson, K (reprint author), Univ N Carolina, Dept Neurol, 170 Manning Dr, Chapel Hill, NC 27599 USA.
EM kevinr@neurology.unc.edu
RI Laughton, Barbara/Q-3496-2016; Van Rie, Annelies/C-2082-2017
OI Laughton, Barbara/0000-0001-7260-7723; Van Rie,
   Annelies/0000-0001-7666-3263; Bangirana, Paul/0000-0002-7136-0594;
   Adebamowo, Clement/0000-0002-6571-2880
FU Medical Research Council [MC_UP_A900_1121, MC_UP_A900_1125]; NIMH NIH
   HHS [R01 MH085602]; NINDS NIH HHS [R21 NS055639]
CR Abubakar A, 2008, ANN TROP PAEDIATR, V28, P217, DOI 10.1179/146532808X335679
   Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b
   Clifford DB, 2007, J NEUROVIROL, V13, P67, DOI 10.1080/13550280601169837
   Descamps D, 1997, J VIROL, V71, P8893
   Diamond G W, 1987, Arch Clin Neuropsychol, V2, P245, DOI 10.1016/0887-6177(87)90012-6
   EPSTEIN LG, 1986, PEDIATRICS, V78, P678
   Gupta Jayashree Das, 2007, J Neurovirol, V13, P195, DOI 10.1080/13550280701258407
   Hemelaar J, 2006, AIDS, V20, pW13, DOI 10.1097/01.aids.0000247564.73009.bc
   Hoelscher M, 2002, AIDS, V16, P2055, DOI 10.1097/00002030-200210180-00011
   Kanki PJ, 1999, J INFECT DIS, V179, P68, DOI 10.1086/314557
   LAEYENDECKER O, 2006, 13 C RETR OPP INF FE
   *LANL, 2010, HIV SEQ DAT
   Miller RF, 2004, ACTA NEUROPATHOL, V108, P17, DOI 10.1007/s00401-004-0852-0
   Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7
   Poveda E, 2008, AIDS, V22, P611, DOI 10.1097/QAD.0b013e3282f51eb9
   Ren J, 2002, P NATL ACAD SCI USA, V99, P14410, DOI 10.1073/pnas.222366699
   Riedel DJ, 2006, NAT CLIN PRACT NEURO, V2, P557, DOI 10.1038/ncpneuro0303
   Shelburne SA, 2006, J ANTIMICROB CHEMOTH, V57, P167, DOI 10.1093/jac/dki444
   Tscherning C, 1998, VIROLOGY, V241, P181, DOI 10.1006/viro.1997.8980
   Van Rie A, 2008, PEDIATRICS, V122, pE123, DOI 10.1542/peds.2007-2558
   Van Rie A, 2009, JAIDS-J ACQ IMM DEF, V52, P636, DOI 10.1097/QAI.0b013e3181b32646
   Vasan A, 2006, CLIN INFECT DIS, V42, P843, DOI 10.1086/499952
   Venkataramana A, 2006, NEUROLOGY, V67, P383, DOI 10.1212/01.wnl.0000227922.22293.93
   *WHO UNAIDS, 2008, REP GLOB AIDS EPID
   Williams PL, 2010, PEDIATRICS, V125, pE250, DOI 10.1542/peds.2009-1112
NR 25
TC 18
Z9 18
U1 5
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1355-0284
J9 J NEUROVIROL
JI J. Neurovirol.
PD JUN
PY 2010
VL 16
IS 3
BP 189
EP 202
DI 10.3109/13550284.2010.489597
PG 14
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA 619AL
UT WOS:000279398200001
PM 20500018
OA No
DA 2017-08-15
ER

PT J
AU Kelly, AH
   Ameh, D
   Majambere, S
   Lindsay, S
   Pinder, M
AF Kelly, Ann H.
   Ameh, David
   Majambere, Silas
   Lindsay, Steve
   Pinder, Margaret
TI 'Like sugar and honey': The embedded ethics of a larval control project
   in The Gambia
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE Africa; The Gambia; Research ethics; Social technology studies; Malaria;
   Embedding
ID CLINICAL-RESEARCH; INFORMED-CONSENT; MEDICAL-RESEARCH; VACCINE TRIAL;
   KENYAN COAST; BLOOD; COMMUNITY; COUNTRIES; VILLAGE; SCIENCE
AB This paper describes a malaria research project in The Gambia to provoke thinking on the social value of transnational research. The Larval Control Project (LCP) investigated the efficacy of a microbial insecticide to reduce vector density and, ultimately, clinical malaria in Gambian children. The LCP's protocol delineated a clinical surveillance scheme that involved Village Health Workers (VHWs) supported by project nurses. Combining insights from ethnographic fieldwork conducted at the Medical Research Council (MRC) Laboratories in Farafenni from 2005 to 2009, open-ended interviews with project nurses, and eight focus group discussions held with participant mothers in October 2007, we consider the social impact of the LCP's investigative method against the backdrop of several years of research activity. We found that while participants associated the LCP with the clinical care it provided, they also regarded the collaboration between the nurses and VHWs added additional benefits. Organised around the operational functions of the trial, small-scale collaborations provided the platform from which to build local capacity. While ethical guidelines emphasise the considerations that must be added to experimental endeavour in southern countries (e.g. elaborating processes of informed consent, developing strategies of community engagement or providing therapeutic access to participants after the trial concludes), these findings suggest that shifting attention from supplementing ethical protocols to the everyday work of research embedding ethics through scientific activity may provide a sounder basis to reinforce the relationship between scientific rigour and social value. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Kelly, Ann H.] Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England.
   [Ameh, David; Pinder, Margaret] MRC Labs, Fajara, Gambia.
   [Lindsay, Steve] Univ Durham, Sch Biol & Biomed Sci, Durham, England.
   [Majambere, Silas] Ifakara Hlth Inst, Dar Es Salaam, Tanzania.
   [Majambere, Silas] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
RP Kelly, AH (reprint author), Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Keppel St, London WC1E 7HT, England.
EM ann.kelly@lshtm.ac.uk
FU NIAID NIH HHS [U01 AI058250, AI058250]; Wellcome Trust
CR Anand S, 2004, LANCET, V364, P1603, DOI 10.1016/S0140-6736(04)17313-3
   Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209
   Benatar SR, 2007, INT J TUBERC LUNG D, V11, P617
   Benatar SR, 2005, PLOS MED, V2, P587, DOI 10.1371/journal.pmed.0020143
   Benatar SR, 2004, J LAW MED ETHICS, V32, P574, DOI 10.1111/j.1748-720X.2004.tb01963.x
   BHUTTA ZA, 2000, CMH WORKING PAPER SE
   Biehl J, 2007, WILL LIVE AIDS THERA
   Binka F, 2005, TROP MED INT HEALTH, V10, P207, DOI 10.1111/j.1365-3156.2004.01373.x
   Black N, 2001, BRIT MED J, V323, P275, DOI 10.1136/bmj.323.7307.275
   Bloor M., 2001, FOCUS GROUPS SOCIAL
   Callon Michel, 2003, TECHNOL SOC, V25, P193, DOI DOI 10.1016/S0160-791X(03)00021-6
   Cassidy R, 2009, AFR AFFAIRS, V108, P559, DOI 10.1093/afraf/adp057
   Cham K., 1987, Health Policy and Planning, V2, P214, DOI 10.1093/heapol/2.3.214
   Cooke B., 2001, PARTICIPATION NEW TY
   DAVIS D, 1994, PUBLIC ADMIN DEVELOP, V14, P253, DOI 10.1002/pad.4230140303
   Dawson S., 1993, MANUAL USE FOCUS GRO
   Emanuel EJ, 2004, J INFECT DIS, V189, P930, DOI 10.1086/381709
   Fairhead J, 2006, SOC SCI MED, V63, P1109, DOI 10.1016/j.socscimed.2006.02.018
   Geissler PW, 2008, SOC SCI MED, V67, P696, DOI [10.1016/j.socscimed.2008.02.004, 10.1016/.j.socscimed.2008.02.004]
   Gikonyo C, 2008, SOC SCI MED, V67, P708, DOI 10.1016/j.socscimed.2008.02.003
   GILSON L, 1989, Journal of Public Health Policy, V10, P518, DOI 10.2307/3342522
   Henderson GE, 2007, PLOS MED, V4, P1735, DOI 10.1371/journal.pmed.0040324
   Jacobs Lawrence R., 2000, POLITICIANS DONT PAN
   KELLY A, EVIDENCE ET IN PRESS
   King NMP, 2000, J LAW MED ETHICS, V28, P332, DOI 10.1111/j.1748-720X.2000.tb00685.x
   Lairumbi GM, 2008, SOC SCI MED, V67, P734, DOI 10.1016/j.socscimed.2008.02.016
   LAPAU B, 1983, Southeast Asian Journal of Tropical Medicine and Public Health, V14, P12
   Leach M., 2005, SCI CITIZENS GLOBALI
   Lezaun J, 2007, PUBLIC UNDERST SCI, V16, P279, DOI 10.1177/0963662507079371
   Macklin R., 2004, DOUBLE STANDARDS MED
   Majambere S, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-76
   MENON A, 1991, J TROP MED HYG, V94, P268
   Molyneux CS, 2004, SOC SCI MED, V59, P2547, DOI 10.1016/j.socscimed.2004.03.037
   Molyneux S, 2008, SOC SCI MED, V67, P685, DOI 10.1016/j.socscimed.2008.02.023
   *NUFF COUNC BIOETH, 2005, ETH RES REL HLTH CAR
   Panter-Brick C, 2006, SOC SCI MED, V62, P2810, DOI 10.1016/j.socscimed.2005.10.009
   Parker M, 2007, SOC SCI MED, V65, P2248, DOI 10.1016/j.socscimed.2007.08.003
   Petryna A., 2009, EXPT TRAVEL
   Rajan K. S., 2002, BIOSOCIALITIES GENET
   Rose N., 1999, POWERS FREEDOM REFRA
   RUEBUSH TK, 1994, SOC SCI MED, V39, P123, DOI 10.1016/0277-9536(94)90172-4
   Street A, 2009, BODY SOC, V15, P193, DOI 10.1177/1357034X09103442
   Timmermans S, 2009, SOC SCI MED, V69, P1784, DOI 10.1016/j.socscimed.2009.09.019
   The World Health Organization, 2006, WORLD HLTH REP 2006
   Will C., 2007, BIOSOCIETIES, V2, P85, DOI 10.1017/S1745855207005078
NR 45
TC 14
Z9 14
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD JUN
PY 2010
VL 70
IS 12
BP 1912
EP 1919
DI 10.1016/j.socscimed.2010.02.012
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 608HL
UT WOS:000278574300007
PM 20362381
OA No
DA 2017-08-15
ER

PT J
AU Touray, K
   Adetifa, IM
   Jallow, A
   Rigby, J
   Jeffries, D
   Cheung, YB
   Donkor, S
   Adegbola, RA
   Hill, PC
AF Touray, K.
   Adetifa, I. M.
   Jallow, A.
   Rigby, J.
   Jeffries, D.
   Cheung, Y. B.
   Donkor, S.
   Adegbola, R. A.
   Hill, P. C.
TI Spatial analysis of tuberculosis in an Urban West African setting: is
   there evidence of clustering?
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE tuberculosis; clustering; spatial analysis; Geographic Information
   Systems; The Gambia
ID GEOGRAPHICAL-DISTRIBUTION; PULMONARY TUBERCULOSIS; DOTS STRATEGY;
   UNITED-STATES; SOUTH-AFRICA; RISK-FACTORS; SPACE; TIME; OUTBREAK; GAMBIA
AB OBJECTIVES To describe the pattern of tuberculosis (TB) occurrence in Greater Banjul, The Gambia with Geographical Information Systems (GIS) and Spatial Scan Statistics (SaTScan) and to determine whether there is significant TB case clustering.
   METHODS In Greater Banjul, where 80% of all Gambian TB cases arise, all patients with TB registered at chest clinics between March 2007 and February 2008 were asked to participate. Demographic, clinical characteristics and GPS co-ordinates for the residence of each consenting TB case were recorded. A spatial scan statistic was used to identify purely spatial and space-time clusters of tuberculosis among permanent residents.
   RESULTS Of 1145 recruited patients with TB, 84% were permanent residents with 88% living in 37 settlements that had complete maps available down to settlement level. Significant high-and low-rate spatial and space-time clusters were identified in two districts. The most likely cluster of high rate from both the purely spatial analysis and the retrospective space-time analysis were from the same geographical area. A significant secondary cluster was also identified in one of the densely populated areas of the study region.
   CONCLUSIONS There is evidence of significant clustering of TB cases in Greater Banjul, The Gambia. Systematic use of cluster detection techniques for regular TB surveillance in The Gambia may aid effective deployment of resources. However, passive case detection dictates that community-based active case detection and risk factor surveys would help confirm the presence of true clusters and their causes.
C1 [Touray, K.; Adetifa, I. M.; Jeffries, D.; Donkor, S.; Adegbola, R. A.; Hill, P. C.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Jallow, A.] Minist Hlth, Natl TB & Leprosy Control Programme, Banjul, Gambia.
   [Rigby, J.] Natl Univ Ireland Maynooth, NCG, Maynooth, Kildare, Ireland.
   [Cheung, Y. B.] Singapore Clin Res Inst, Singapore, Singapore.
   [Hill, P. C.] Univ Otago, Sch Med, Ctr Int Hlth, Dunedin, New Zealand.
RP Touray, K (reprint author), MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
EM ktouray@mrc.gm
FU Global Fund to fight Aids, Tuberculosis and Malaria
FX This study was funded by the Global Fund to fight Aids, Tuberculosis and
   Malaria. We are grateful for the collaboration with the National
   Tuberculosis Program of the Gambia. The assistance rendered by our field
   staff Ebou Touray and Yamundow Jallow-Samba is highly appreciated.
   Babucarr Daffeh at the Gambia Bureau of Statistics assisted with the
   mapping of the study area. We thank all the study participants for their
   participation.
CR BEYERS N, 1996, S AFR MED J, V86, P41
   *CDC, 2006, MORB MORT WEEKL REP
   Chan-Yeung M, 2005, INT J TUBERC LUNG D, V9, P1320
   Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706
   Frank C, 2002, EMERG INFECT DIS, V8, P427
   Gaudart Jean, 2005, BMC Med Res Methodol, V5, P22, DOI 10.1186/1471-2288-5-22
   Gaudart J, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-286
   Hill PC, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-156
   Hjalmars U, 1996, STAT MED, V15, P707, DOI 10.1002/(SICI)1097-0258(19960415)15:7/9<707::AID-SIM242>3.3.CO;2-W
   Jacobson LM, 2005, TROP MED INT HEALTH, V10, P305, DOI 10.1111/j.1365-3156.2005.01392.x
   Jia ZW, 2008, EMERG INFECT DIS, V14, P1413, DOI 10.3201/eid1409.071543
   Kistemann T, 2002, SOC SCI MED, V55, P7, DOI 10.1016/S0277-9536(01)00216-7
   *KNCV, 2008, REP NETH TUB FDN KNC
   Kulldorff M, 1997, AM J EPIDEMIOL, V146, P161
   Kulldorff M, 2005, PLOS MED, V2, P216, DOI 10.1371/journal.pmed.0020059
   Lienhardt C, 2003, AM J RESP CRIT CARE, V168, P448, DOI 10.1164/rccm.200212-1483OC
   Maher D, 2005, CLIN CHEST MED, V26, P167, DOI 10.1016/j.ccm.2005.02.009
   Morrison AC, 1998, AM J TROP MED HYG, V58, P287
   Munch Z, 2003, INT J TUBERC LUNG D, V7, P271
   Nunes C, 2007, INT J HEALTH GEOGR, V6, DOI 10.1186/1476-072X-6-30
   Onozuka D, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-26
   Polack SR, 2005, T ROY SOC TROP MED H, V99, P218, DOI 10.1016/j.trstmh.2004.06.010
   Porter JDH, 1999, TROP MED INT HEALTH, V4, P631, DOI 10.1046/j.1365-3156.1999.00475.x
   Randremanana RV, 2009, TROP MED INT HEALTH, V14, P429, DOI 10.1111/j.1365-3156.2009.02239.x
   Richardson M, 2002, INT J TUBERC LUNG D, V6, P1001
   ROGERS DJ, 1993, PARASITOLOGY, V106, pS77
   Sasaki S, 2008, AM J TROP MED HYG, V79, P414
   Schellenberg JA, 1998, INT J EPIDEMIOL, V27, P323, DOI 10.1093/ije/27.2.323
   Tanser F, 1999, TROP MED INT HEALTH, V4, P634, DOI 10.1046/j.1365-3156.1999.00469.x
   Tanser F, 2002, INT J HEALTH GEOGR, V1, P4, DOI 10.1186/1476-072X-1-4
   Tiwari Neeraj, 2006, Int J Health Geogr, V5, P33, DOI 10.1186/1476-072X-5-33
   Uthman Olalekan A, 2008, World Health Popul, V10, P5
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   van Rie A, 1999, ARCH DIS CHILD, V80, P433
   Walsh SJ, 1997, J RHEUMATOL, V24, P2348
   World Health Organization, 2009, GLOB TUB CONTR SHORT
   World Health Organization, 2003, TREATM TUB GUID NAT
   *WHO, 2005, TB EM DECL ISS WHO R
   Wilkinson D, 1999, LANCET, V354, P394, DOI 10.1016/S0140-6736(99)01893-0
NR 39
TC 21
Z9 24
U1 0
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JUN
PY 2010
VL 15
IS 6
BP 664
EP 672
DI 10.1111/j.1365-3156.2010.02533.x
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 594IC
UT WOS:000277529100003
PM 20406427
OA No
DA 2017-08-15
ER

PT J
AU Onyango, CO
   Leligdowicz, A
   Yokoyama, M
   Sato, H
   Song, HH
   Nakayama, EE
   Shioda, T
   de Silva, T
   Townend, J
   Jaye, A
   Whittle, H
   Rowland-Jones, S
   Cotten, M
AF Onyango, Clayton O.
   Leligdowicz, Aleksandra
   Yokoyama, Masaru
   Sato, Hironori
   Song, Haihan
   Nakayama, Emi E.
   Shioda, Tatsuo
   de Silva, Thushan
   Townend, John
   Jaye, Assan
   Whittle, Hilton
   Rowland-Jones, Sarah
   Cotten, Matthew
TI HIV-2 capsids distinguish high and low virus load patients in a West
   African community cohort
SO VACCINE
LA English
DT Article
DE HIV-2; Capsid; TRIM5 alpha
ID NEIGHBOR-JOINING METHOD; OLD-WORLD MONKEYS; GUINEA-BISSAU; VIRAL LOAD;
   RURAL AREA; TYPE-2; INFECTION; PROTEIN; MECHANISM; RETROVIRUS
AB HIV-2 causes AIDS similar to HIV-1, however a considerable proportion of HIV-2 infected patients show no disease and have low plasma virus load (VL). An analysis of HIV-2 capsid (p26) variation demonstrated that proline at p26 positions 119, 159 and 178 are more frequent in lower VL subjects while non-proline residues at all three sites are more frequent in subjects with high VL. In vitro replication levels of viruses bearing changes at the three sites suggested that these three residues influence virus replication by altering susceptibility to TRIM5 alpha. These results provide new insights into HIV-2 pathogenesis. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Song, Haihan; Nakayama, Emi E.; Shioda, Tatsuo] Osaka Univ, Microbial Dis Res Inst, Dept Viral Infect, Osaka 5650871, Japan.
   [Onyango, Clayton O.; Leligdowicz, Aleksandra; de Silva, Thushan; Townend, John; Jaye, Assan; Whittle, Hilton; Rowland-Jones, Sarah; Cotten, Matthew] MRC Labs, Fajara, Gambia.
   [Yokoyama, Masaru; Sato, Hironori] Natl Inst Infect Dis, Ctr Pathogen Genom, Lab Viral Genom, Tokyo 2080011, Japan.
   [Leligdowicz, Aleksandra; Rowland-Jones, Sarah] John Radcliffe Hosp, Med Res Council Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
RP Shioda, T (reprint author), Osaka Univ, Microbial Dis Res Inst, Dept Viral Infect, Osaka 5650871, Japan.
EM conyango@mrc.gm; aleksandra.leligdowicz@mail.mcgill.ca;
   yokoyama@nih.go.jp; hirosato@nih.go.jp; haihansong@hotmail.com;
   emien@biken.osaka-u.ac.jp; shioda@biken.osaka-u.ac.jp; tdesilva@mrc.gm;
   jtownend@mrc.gm; ajaye@mrc.gm; hwhittle@mrc.gm;
   sarah.rowland-jones@ndm.ox.ac.uk; mcotten@mrc.gm
OI Leligdowicz, Aleksandra/0000-0001-6055-4644
FU Medical Research Council [G0801751, MC_U190085856]
CR Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006
   Baker D, 2001, SCIENCE, V294, P93, DOI 10.1126/science.1065659
   BARIN F, 1985, LANCET, V2, P1387
   Berry N, 1998, J Hum Virol, V1, P457
   Berry N, 2001, AIDS RES HUM RETROV, V17, P263, DOI 10.1089/088922201750063197
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Bhattacharya T, 2007, SCIENCE, V315, P1583, DOI 10.1126/science.1131528
   Briggs JAG, 2006, STRUCTURE, V14, P15, DOI 10.1016/j.str.2005.09.010
   Brumme ZL, 2008, AIDS, V22, P1277, DOI 10.1097/QAD.0b013e3283021a8c
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   Cowan S, 2002, P NATL ACAD SCI USA, V99, P11914, DOI 10.1073/pnas.162299499
   Creighton T.E., 1992, PROTEINS STRUCTURES
   Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849
   Ganser BK, 1999, SCIENCE, V283, P80, DOI 10.1126/science.283.5398.80
   Ganser-Pornillos BK, 2008, CURR OPIN STRUC BIOL, V18, P203, DOI 10.1016/j.sbi.2008.02.001
   GAO F, 1994, J VIROL, V68, P7433
   Goff SP, 2004, NATURE, V427, P791, DOI 10.1038/427791a
   Grassly NC, 1998, J VIROL, V72, P7895
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95
   Howard BR, 2003, NAT STRUCT BIOL, V10, P475, DOI 10.1038/nsb927
   Kawashima Y, 2009, NATURE, V458, P641, DOI 10.1038/nature07746
   KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581
   Kinomoto M, 2005, CLIN INFECT DIS, V41, P243, DOI 10.1086/431197
   Kinomoto M, 2005, J VIROL, V79, P5996, DOI 10.1128/JVI.79.10.5996-6004.2005
   Klenerman P, 2007, SCIENCE, V315, P1505, DOI 10.1126/science.1140768
   Lee K, 2001, ANTIMICROB AGENTS CH, V45, P138, DOI 10.1128/AAC.45.1.138-144.2001
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100
   MAMMANO F, 1994, J VIROL, V68, P4927
   Monaco-Malbet S, 2000, STRUCTURE, V8, P1069, DOI 10.1016/S0969-2126(00)00507-4
   Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660
   Mortuza GB, 2004, NATURE, V431, P481, DOI 10.1038/nature02915
   Norrgren H, 1997, J ACQ IMMUN DEF SYND, V16, P31
   Padua E, 2003, J GEN VIROL, V84, P1287, DOI 10.1099/vir.0.18908-0
   Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27
   POULSEN AG, 1989, LANCET, V1, P827
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   Rowland-Jones SL, 2007, NAT IMMUNOL, V8, P329, DOI 10.1038/ni0407-329
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406
   Shirakawa K, 2008, NAT STRUCT MOL BIOL, V15, P1184, DOI 10.1038/nsmb.1497
   Song H, 2007, J VIROL, V81, P7280, DOI 10.1128/JVI.00406-07
   Stremlau M, 2006, P NATL ACAD SCI USA, V103, P5514, DOI 10.1073/pnas.0509996103
   Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343
   Stremlau M, 2007, SCIENCE, V318, P1565, DOI 10.1126/science.1152905
   Tamura K, 2004, P NATL ACAD SCI USA, V101, P11030, DOI 10.1073/pnas.0404206101
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Towers G, 2000, P NATL ACAD SCI USA, V97, P12295, DOI 10.1073/pnas.200286297
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 50
TC 21
Z9 22
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD MAY 26
PY 2010
VL 28
SU 2
BP B60
EP B67
DI 10.1016/j.vaccine.2009.08.060
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 613ZI
UT WOS:000279023600012
PM 20510746
OA No
DA 2017-08-15
ER

PT J
AU Sartono, E
   Lisse, IM
   Terveer, EM
   van de Sande, PJM
   Whittle, H
   Fisker, AB
   Roth, A
   Aaby, P
   Yazdanbakhsh, M
   Benn, CS
AF Sartono, Erliyani
   Lisse, Ida M.
   Terveer, Elisabeth M.
   van de Sande, Paula J. M.
   Whittle, Hilton
   Fisker, Ane B.
   Roth, Adam
   Aaby, Peter
   Yazdanbakhsh, Maria
   Benn, Christine S.
TI Oral Polio Vaccine Influences the Immune Response to BCG Vaccination. A
   Natural Experiment
SO PLOS ONE
LA English
DT Article
ID INTERFERON-GAMMA-RECEPTOR; BACILLUS-CALMETTE-GUERIN; T-CELL RESPONSES;
   MYCOBACTERIAL INFECTION; VITAMIN-A; TUBERCULOSIS; MUTATION; INFANTS;
   GENE; SUSCEPTIBILITY
AB Background: Oral polio vaccine (OPV) is recommended to be given at birth together with BCG vaccine. While we were conducting two trials including low-birth-weight (LBW) and normal-birth-weight (NBW) infants in Guinea-Bissau, OPV was not available during some periods and therefore some infants did not receive OPV at birth, but only BCG. We investigated the effect of OPV given simultaneously with BCG at birth on the immune response to BCG vaccine.
   Methods and Findings: We compared the in vitro and the in vivo response to PPD in the infants who received OPV and BCG with that of infants who received BCG only. At age 6 weeks, the in vitro cytokine response to purified protein derivate (PPD) of M. Tuberculosis was reduced in LBW and NBW infants who had received OPV with BCG. In a pooled analysis receiving OPV with BCG at birth was associated with significantly lower IL-13 (p = 0.041) and IFN-gamma (p = 0.004) and a tendency for lower IL-10 (p = 0.054) in response to PPD. Furthermore, OPV was associated with reduced in vivo response to PPD at age 2 months, the prevalence ratio (PR) of having a PPD reaction being 0.75 (0.58-0.98), p = 0.033, and with a tendency for reduced likelihood of having a BCG scar (0.95 (0.91-1.00), p = 0.057)). Among children with a scar, OPV was associated with reduced scar size, the regression coefficient being -0.24 (-0.43-0.05), p = 0.012.
   Conclusions: This study is the first to address the consequences for the immune response to BCG of simultaneous administration with OPV. Worryingly, the results indicate that the common practice in low-income countries of administering OPV together with BCG at birth may down-regulate the response to BCG vaccine.
C1 [Sartono, Erliyani; Terveer, Elisabeth M.; van de Sande, Paula J. M.; Yazdanbakhsh, Maria] Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands.
   [Lisse, Ida M.] Herlev Univ Hosp, Dept Pathol, DK-2730 Herlev, Denmark.
   [Whittle, Hilton] MRC Labs, Fajara, Gambia.
   [Fisker, Ane B.; Benn, Christine S.] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen, Denmark.
   [Roth, Adam] Lund Univ, Dept Med Microbiol, Lund, Sweden.
   [Aaby, Peter] Indepth Network, Bandim Hlth Project, Bissau, Guinea Bissau.
RP Sartono, E (reprint author), Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands.
EM E.Sartono@lumc.nl
OI Fisker, Ane/0000-0002-8521-0992
FU European Commission [ICA4-CT-2002-10053]
FX The study was supported by the European Commission, INCO-programme
   (contract no. ICA4-CT-2002-10053). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Al-Attiyah R, 2003, FEMS IMMUNOL MED MIC, V38, P249, DOI 10.1016/S0928-8244(03)00166-4
   Allende LM, 2001, CLIN DIAGN LAB IMMUN, V8, P133, DOI 10.1128/CDLI.8.1.133-137.2001
   Anuradha B, 2008, PEDIATR INFECT DIS J, V27, P325, DOI 10.1097/INF.0b013e31816099e6
   Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Benn CS, 2008, BRIT MED J, V336, P1416, DOI 10.1136/bmj.39542.509444.AE
   Benn Christine Stabell, 2008, PLoS One, V3, pe4056, DOI 10.1371/journal.pone.0004056
   BOUROS D, 1991, CHEST, V99, P416, DOI 10.1378/chest.99.2.416
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243
   Cunningham JA, 2000, INT J TUBERC LUNG D, V4, P791
   Diness BR, 2007, AM J CLIN NUTR, V86, P1152
   Dogan E, 2005, RENAL FAILURE, V27, P425, DOI 10.1081/JDI-200065379
   Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901
   Eriksson M, 2007, CLIN EXP IMMUNOL, V150, P469, DOI 10.1111/j.1365-2249.2007.03515.x
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   Garly ML, 2001, VACCINE, V20, P468, DOI 10.1016/S0264-410X(01)00339-5
   GUNTHER J, 1982, EUR J IMMUNOL, V12, P247, DOI 10.1002/eji.1830120315
   Hirsch CS, 1999, J INFECT DIS, V180, P2069, DOI 10.1086/315114
   Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604
   Klein NP, 2010, J INFECT DIS, V201, P214, DOI 10.1086/649590
   Lalor MK, 2009, J INFECT DIS, V199, P795, DOI 10.1086/597069
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Marchant A, 2001, AM J RESP CELL MOL, V24, P187
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   Ota MOC, 2002, J IMMUNOL, V168, P919
   Stockinger B, 2004, SEMIN IMMUNOL, V16, P295, DOI 10.1016/j.smim.2004.08.010
   Vekemans J, 2002, CLIN EXP IMMUNOL, V127, P495, DOI 10.1046/j.1365-2249.2002.01788.x
NR 28
TC 16
Z9 16
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2010
VL 5
IS 5
AR e10328
DI 10.1371/journal.pone.0010328
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 600VQ
UT WOS:000278017400003
PM 20502641
OA gold
DA 2017-08-15
ER

PT J
AU van der Loeff, MFS
   Larke, N
   Kaye, S
   Berry, N
   Ariyoshi, K
   Alabi, A
   van Tienen, C
   Leligdowicz, A
   Sarge-Njie, R
   da Silva, Z
   Jaye, A
   Ricard, D
   Vincent, T
   Jones, SR
   Aaby, P
   Jaffar, S
   Whittle, H
AF van der Loeff, Maarten F. Schim
   Larke, Natasha
   Kaye, Steve
   Berry, Neil
   Ariyoshi, Koya
   Alabi, Abraham
   van Tienen, Carla
   Leligdowicz, Aleksandra
   Sarge-Njie, Ramu
   da Silva, Zacharias
   Jaye, Assan
   Ricard, Dominique
   Vincent, Tim
   Jones, Sarah Rowland
   Aaby, Peter
   Jaffar, Shabbar
   Whittle, Hilton
TI Undetectable plasma viral load predicts normal survival in
   HIV-2-infected people in a West African village
SO RETROVIROLOGY
LA English
DT Article
ID CD4 CELL PERCENTAGE; GUINEA-BISSAU; HIV-2 INFECTION; DUAL INFECTIONS;
   RURAL AREA; RNA LEVELS; MORTALITY; COHORT; GAMBIA; TRANSMISSION
AB Background: There have been no previous studies of the long-term survival and temporal changes in plasma viral load among HIV-2 infected subjects.
   Methods: 133 HIV-2 infected and 158 HIV-uninfected subjects from a rural area in North-west Guinea-Bissau, West Africa were enrolled into a prospective cohort study in 1991 and followed-up to mid-2009. Data were collected on four occasions during that period on HIV antibodies, CD4% and HIV-2 plasma viral load.
   Results: Median age (interquartile range [IQR]) of HIV-2 infected subjects at time of enrollment was 47 (36, 60) years, similar to that of HIV-uninfected control subjects, 49 (38, 62) (p = 0.4). Median (IQR) plasma viral load and CD4 percentage were 347 (50, 4,300) copies/ml and 29 (22, 35) respectively.
   Overall loss to follow-up to assess vital status was small, at 6.7% and 6.3% for HIV-2 infected and uninfected subjects respectively. An additional 17 (12.8%) and 16 (10.1%) of HIV-2 infected and uninfected subjects respectively were censored during follow-up due to infection with HIV-1. The mortality rate per 100 person-years (95% CI) was 4.5 (3.6, 5.8) among HIV-2 infected subjects compared to 2.1 (1.6, 2.9) among HIV-uninfected (age-sex adjusted rate ratio 1.9 (1.3, 2.8, p < 0.001) representing a 2-fold excess mortality rate associated with HIV-2 infection.
   Viral load measurements were available for 98%, 78%, 77% and 61% HIV-2 infected subjects who were alive and had not become super-infected with HIV-1, in 1991, 1996, 2003 and 2006 respectively. Median plasma viral load (RNA copies per ml) (IQR) did not change significantly over time, being 150 (50, 1,554; n = 77) in 1996, 203 (50, 2,837; n = 47) in 2003 and 171 (50, 497; n = 31) in 2006. Thirty seven percent of HIV-2 subjects had undetectable viraemia (< 100 copies/ml) at baseline: strikingly, mortality in this group was similar to that of the general population.
   Conclusions: A substantial proportion of HIV-2 infected subjects in this cohort have stable plasma viral load, and those with an undetectable viral load (37%) at study entry had a normal survival rate. However, the sequential laboratory findings need to be interpreted with caution given the number of individuals who could not be re-examined.
C1 [van der Loeff, Maarten F. Schim; Kaye, Steve; Alabi, Abraham; van Tienen, Carla; Leligdowicz, Aleksandra; Sarge-Njie, Ramu; Jaye, Assan; Ricard, Dominique; Jones, Sarah Rowland; Whittle, Hilton] MRC Labs Fajara, Banjul, Gambia.
   [Larke, Natasha; Jaffar, Shabbar] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   [Berry, Neil] Natl Inst Biol Stand & Controls HPA, Div Retrovirol, S Mimms, Herts, England.
   [Ariyoshi, Koya] Nagasaki Univ, Dept Clin Med, Inst Trop Med, Nagasaki 852, Japan.
   [da Silva, Zacharias; Vincent, Tim; Aaby, Peter] Indepth Network, Bandim Hlth Project, Bissau, Guinea Bissau.
RP Whittle, H (reprint author), MRC Labs Fajara, POB 273, Banjul, Gambia.
EM hwhittle@mrc.gm
RI van Tienen, Carla/A-1119-2012
OI Leligdowicz, Aleksandra/0000-0001-6055-4644
FU Ministry of Health from Guinea-Bissau; Medical Research Council, UK
FX This paper is dedicated to the memory of Andrew Wilkins who planned this
   study and executed so many fine epidemiological studies in West Africa.
   We would like to thank the participants in the study, as well as the
   team of field workers and laboratory staff. Special thanks to Akum
   Aveika Awasana, Marianne van der Sande, Sam McConkey, Carlos da Costa,
   Pauline Kaye, Sangeeta Dave, Akram Zaman and Francisco Dias. We
   acknowledge the continued support of the Ministry of Health from
   Guinea-Bissau.; The study was funded by the Medical Research Council,
   UK.
CR Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004
   Berry N, 1998, J Hum Virol, V1, P457
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   da Silva ZJ, 2008, AIDS, V22, P1195, DOI 10.1097/QAD.0b013e328300a33d
   Grassly NC, 1998, J VIROL, V72, P7895
   Hansmann A, 2005, JAIDS-J ACQ IMM DEF, V38, P335
   Holmgren B, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-85
   Jaffar S, 1997, J ACQ IMMUN DEF SYND, V16, P327
   Jaffar S, 2004, B WORLD HEALTH ORGAN, V82, P462
   Jaffar S, 2005, AIDS RES HUM RETROV, V21, P560, DOI 10.1089/aid.2005.21.560
   Keele BF, 2009, NATURE, V460, P515, DOI 10.1038/nature08200
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100
   Lisse IM, 1996, J ACQ IMMUN DEF SYND, V13, P355
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   Mellors JW, 1997, ANN INTERN MED, V126, P946
   Morgan D, 2002, AIDS, V16, P597, DOI 10.1097/00002030-200203080-00011
   O'Brien TR, 1998, J ACQ IMMUN DEF SYND, V18, P155
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   ONYANGO C, 2010, VACCINE IN PRESS
   POULSEN AG, 1993, J ACQ IMMUN DEF SYND, V6, P941
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   Rowland-Jones SL, 2007, NAT IMMUNOL, V8, P329, DOI 10.1038/ni0407-329
   van der Loeff MFS, 2002, AIDS, V16, P1775
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
   YINDOM LM, 2009, J VIROL
NR 30
TC 33
Z9 33
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD MAY 19
PY 2010
VL 7
AR 46
DI 10.1186/1742-4690-7-46
PG 10
WC Virology
SC Virology
GA 620ZU
UT WOS:000279543400001
PM 20482865
OA gold
DA 2017-08-15
ER

PT J
AU O'Grady, KAF
   Taylor-Thomson, DM
   Chang, AB
   Torzillo, PJ
   Morris, PS
   Mackenzie, GA
   Wheaton, GR
   Bauert, PA
   De Campo, MP
   De Campo, JF
   Ruben, AR
AF O'Grady, Kerry-Ann F.
   Taylor-Thomson, Debbie M.
   Chang, Anne B.
   Torzillo, Paul J.
   Morris, Peter S.
   Mackenzie, Grant A.
   Wheaton, Gavin R.
   Bauert, Paul A.
   De Campo, Margaret P.
   De Campo, John F.
   Ruben, Alan R.
TI Rates of radiologically confirmed pneumonia as defined by the World
   Health Organization in Northern Territory Indigenous children
SO MEDICAL JOURNAL OF AUSTRALIA
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; AUSTRALIAN ABORIGINAL CHILDREN;
   PLACEBO-CONTROLLED-TRIAL; INFLUENZAE TYPE-B; HAEMOPHILUS-INFLUENZAE;
   DISEASE BURDEN; OTITIS-MEDIA; BIRTH-WEIGHT; DOUBLE-BLIND; INFECTION
AB Objective: To determine the burden of hospitalised, radiologically confirmed pneumonia (World Health Organization protocol) in Northern Territory Indigenous children.
   Design, setting and participants: Historical, observational study of all hospital admissions for any diagnosis of NT resident Indigenous children, aged between >= 29 days and < 5 years, 1 April 1997 to 31 March 2005.
   Intervention: All chest radiographs taken during these admissions, regardless of diagnosis, were assessed for pneumonia in accordance with the WHO protocol.
   Main outcome measure: The primary outcome was endpoint consolidation (dense fluffy consolidation [alveolar infiltrate] of a portion of a lobe or the entire lung) present on a chest radiograph within 3 days of hospitalisation.
   Results: We analysed data on 24 115 hospitalised episodes of care for 9492 children and 13 683 chest radiographs. The average annual cumulative incidence of endpoint consolidation was 26.6 per 1000 population per year (95% Cl, 25.3-27.9); 57.5 per 1000 per year in infants aged 1-11 months, 38.3 per 1000 per year in those aged 12-23 months, and 13.3 per 1000 per year in those aged 24-59 months. In all age groups, rates of endpoint consolidation in children in the arid southern region of NT were about twice that of children in the tropical northern region.
   Conclusion: The rates of severe pneumonia in hospitalised NT Indigenous children are among the highest reported in the world. Reducing this unacceptable burden of disease should be a national health priority.
C1 [O'Grady, Kerry-Ann F.; Chang, Anne B.; Morris, Peter S.] Charles Darwin Univ, Child Hlth Div, Menzies Sch Hlth Res, Darwin, NT 0909, Australia.
   [O'Grady, Kerry-Ann F.] Univ Melbourne, Child Hlth Div, Sch Populat Hlth, Melbourne, Vic, Australia.
   [O'Grady, Kerry-Ann F.] Univ Melbourne, Child Hlth Div, Dept Pediat, Melbourne, Vic, Australia.
   [O'Grady, Kerry-Ann F.] Murdoch Childrens Res Inst, Child Hlth Div, Vaccine & Immunisat Res Grp, Melbourne, Vic, Australia.
   [Torzillo, Paul J.] Univ Sydney, Royal Prince Alfred Hosp, Dept Resp Med, Sydney, NSW 2006, Australia.
   [Torzillo, Paul J.] Univ Sydney, Royal Prince Alfred Hosp, Nganampa Hlth Serv, Sydney, NSW 2006, Australia.
   [Morris, Peter S.] Flinders Univ S Australia, Child Hlth Div, No Terr Clin Sch, Darwin, NT, Australia.
   [Mackenzie, Grant A.] Med Res Council UK Labs, Bacterial Dis Program, Fajara, Gambia.
   [Wheaton, Gavin R.] Flinders Univ S Australia, Fac Hlth Sci, Dept Clin Effectiveness, Womens & Childrens Hosp Adelaide,Sch Med, Adelaide, SA, Australia.
   [Bauert, Paul A.] Royal Darwin Hosp, Dept Paediat, Darwin, NT, Australia.
   [De Campo, Margaret P.; De Campo, John F.] Bond Univ, Dept Med, Gold Coast, Qld, Australia.
RP O'Grady, KAF (reprint author), Charles Darwin Univ, Child Hlth Div, Menzies Sch Hlth Res, Darwin, NT 0909, Australia.
EM k.ogrady@uq.edu.au
RI Chang, Anne/F-2066-2013; O'Grady, Kerry-Ann/F-2529-2010
OI O'Grady, Kerry-Ann/0000-0002-8159-2620
FU National Health and Medical Research Council (NHMRC); Australian Academy
   of Science; Wyeth Vaccines
FX Kerry-Ann O'Grady was supported by a National Health and Medical
   Research Council (NHMRC) Postgraduate Training Scholarship in Indigenous
   Health, and by the Australian Academy of Science's Douglas and Lola
   Douglas Scholarship in Medical Research.; Wyeth Vaccines provided
   funding for the study, but had no role in the design, data collection,
   analysis and interpretation, writing, or publication of the article.
   Kerry-Ann O'Grady has been a senior research officer on sponsored
   vaccine trials (GlaxoSmithKline, Wyeth, Merck Sharp & Dohme, Med-Immune,
   and CSL) and a recipient of funds for epidemiological research
   (GlaxoSmithKline).
CR *AUSTR BUR STAT, 2001, 20157 ABS
   Burgner David, 2005, Paediatr Respir Rev, V6, P94, DOI 10.1016/j.prrv.2005.03.004
   Carville KS, 2007, PEDIATR INFECT DIS J, V26, P210, DOI 10.1097/01.inf.000254148.09831.7f
   Chang AB, 2003, MED J AUSTRALIA, V178, P490
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Gessner BD, 2005, LANCET, V365, P43, DOI 10.1016/S0140-6736(04)17664-2
   GOGNA NK, 1986, AUST PAEDIATR J, V22, P281
   Hansen J, 2006, PEDIATR INFECT DIS J, V25, P779, DOI 10.1097/01.inf.0000232706.35674.2f
   Hortal M, 2007, INT J INFECT DIS, V11, P273, DOI 10.1016/j.ijid.2006.05.006
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   LEACH AJ, 1994, PEDIATR INFECT DIS J, V13, P983, DOI 10.1097/00006454-199411000-00009
   Levine OS, 1999, PEDIATR INFECT DIS J, V18, P1060, DOI 10.1097/00006454-199912000-00006
   Lucero MG, 2009, PEDIATR INFECT DIS J, V28, P455, DOI 10.1097/INF.0b013e31819637af
   Mackerras DEM, 2003, MED J AUSTRALIA, V178, P56
   Magree HC, 2005, B WORLD HEALTH ORGAN, V83, P427
   Paterson B, 1998, AUST NZ J PUBL HEAL, V22, P685, DOI 10.1111/j.1467-842X.1998.tb01470.x
   Rousham EK, 2002, ANN HUM BIOL, V29, P363, DOI 10.1080/03014460110088798
   RUBEN AR, 1995, MED J AUSTRALIA, V162, P400
   SmithVaughan HC, 1996, EPIDEMIOL INFECT, V116, P177
   Torzillo P, 1999, PEDIATR INFECT DIS J, V18, P714, DOI 10.1097/00006454-199908000-00012
   Valery PC, 2004, PEDIATR INFECT DIS J, V23, P902, DOI 10.1097/01.inf.0000142508.33623.2f
   World Health Organization Pneumonia Vaccine Trial Investigators Group, 2001, STAND INT CHEST RAD
NR 22
TC 21
Z9 21
U1 0
U2 2
PU AUSTRALASIAN MED PUBL CO LTD
PI PYRMONT
PA LEVEL 2, 26-32 PYRMONT BRIDGE RD, PYRMONT, NSW 2009, AUSTRALIA
SN 0025-729X
J9 MED J AUSTRALIA
JI Med. J. Aust.
PD MAY 17
PY 2010
VL 192
IS 10
BP 592
EP 595
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 602BM
UT WOS:000278113100013
PM 20477736
OA No
DA 2017-08-15
ER

PT J
AU Mackenzie, G
   Ceesay, SJ
   Hill, PC
   Walther, M
   Bojang, KA
   Satoguina, J
   Enwere, G
   D'Alessandro, U
   Saha, D
   Ikumapayi, UNA
   O'Dempsey, T
   Mabey, DCW
   Corrah, T
   Conway, DJ
   Adegbola, RA
   Greenwood, BM
AF Mackenzie, Grant
   Ceesay, Serign J.
   Hill, Philip C.
   Walther, Michael
   Bojang, Kalifa A.
   Satoguina, Judith
   Enwere, Godwin
   D'Alessandro, Umberto
   Saha, Debasish
   Ikumapayi, Usman N. A.
   O'Dempsey, Tim
   Mabey, David C. W.
   Corrah, Tumani
   Conway, David J.
   Adegbola, Richard A.
   Greenwood, Brian M.
TI A Decline in the Incidence of Invasive Non-Typhoidal Salmonella
   Infection in the Gambia Temporally Associated with a Decline in Malaria
   Infection
SO PLOS ONE
LA English
DT Article
ID PNEUMOCOCCAL DISEASE; WEST-AFRICA; MALAWIAN CHILDREN; KENYAN CHILDREN;
   BACTEREMIA; COMMUNITY; PNEUMONIA; MORTALITY; EFFICACY; VACCINE
AB Background: Malaria is a risk factor for invasive non-typhoidal Salmonella (NTS) infection in children. In the last 10 years, indices of malaria infection in The Gambia have fallen substantially.
   Methods: We compared temporal trends of childhood malaria and NTS infection in two Gambian locations. In Fajara, on the coast, the incidence of NTS infection at three time points between 1979 and 2005 was compared to the percentage of malaria positive outpatient thick blood films and the percentage of admissions associated with malaria over time. In Basse, in the eastern part of the country, the incidence of NTS infection at three time points between 1989 and 2008 was compared to the prevalence of malaria parasitaemia at four time points between 1992 and 2008.
   Results: The estimated incidence of NTS infection in Fajara fell from 60 (1979-1984) to 10 (2003-05) cases per 100,000 person years. The proportion of outpatients in Fajara with suspected malaria who were parasitaemic fell from 33% (1999) to 6% (2007) while the proportion of admissions associated with malaria fell from 14.5% (1999) to 5% (2007). In Basse, the estimated incidence of NTS infection fell from 105 (1989-1991) to 29 (2008) cases per 100,000 person years while the prevalence of malaria parasitaemia fell from 45% (1992) to 10% (2008). The incidence of pneumococcal bacteraemia in Fajara and Basse did not fall over the study period.
   Conclusions: These data support an association between malaria and NTS infection. Reductions in malaria infection may be associated with reduced rates of invasive childhood NTS infection.
C1 [Mackenzie, Grant; Ceesay, Serign J.; Walther, Michael; Bojang, Kalifa A.; Satoguina, Judith; Saha, Debasish; Ikumapayi, Usman N. A.; Corrah, Tumani; Conway, David J.; Adegbola, Richard A.] Med Res Council United Kingdom Gambia, Fajara, Gambia.
   [Hill, Philip C.] Univ Otago, Ctr Int Hlth, Dunedin, New Zealand.
   [Enwere, Godwin] Program Appropriate Technol Hlth, Meningitis Vaccine Program, Ferney Voltaire, France.
   [D'Alessandro, Umberto] Inst Trop Med, B-2000 Antwerp, Belgium.
   [O'Dempsey, Tim] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   [Mabey, David C. W.; Greenwood, Brian M.] London Sch Hyg & Trop Med, London WC1, England.
   [Adegbola, Richard A.] Bill & Melinda Gates Fdn, Seattle, WA USA.
RP Mackenzie, G (reprint author), Med Res Council United Kingdom Gambia, Fajara, Gambia.
EM gmackenzie@mrc.gm
RI D'Alessandro, Umberto/D-3457-2015
OI D'Alessandro, Umberto/0000-0001-6341-5009; Mabey,
   David/0000-0002-0031-8276; Bojang, Kalifa/0000-0001-7506-0938; Conway,
   David/0000-0002-8711-3037
FU Medical Research Council Fajara Clinical Service [MRC(UK)]; URR
   Salmonella disease epidemiology
FX Financial support for the studies which contributed data was as follows:
   Medical Research Council Fajara Clinical Service [MRC(UK)], URR
   Salmonella disease epidemiology 1989-91 [MRC(UK), United States Agency
   for International Development] and 2008 (GAVI's PneumoADIP), Hib vaccine
   trial (World Health Organization, USAID, The United Nations Children's
   Fund, United Nations Development Programme), Pneumococcal vaccine trial
   (National Institutes of Health, WHO, PATH, USAID, Wyeth), Insecticide
   Treated Net evaluation (UNDP, World Bank, WHO), Malaria vaccine trial
   [MRC(UK)], Malaria prevalence survey 2008 [MRC(UK)]. The authors thank
   MRC(UK) The Gambia for the administrative and infrastructure support
   which made possible all the studies which contributed to this report.
   The funders of the different studies had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Bojang KA, 1998, VACCINE, V16, P62, DOI 10.1016/S0264-410X(97)00159-X
   Brent AJ, 2006, PEDIATR INFECT DIS J, V25, P230, DOI 10.1097/01.inf.0000202066.02212.ff
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5
   *GAMB BUR STAT, 2002, GAMB MULT IND CLUST
   Gambia Bureau of Statistics, 2007, GAMB MULT IND CLUST
   *GAMB BUR STAT, 1998, GAMB MULT IND CLUST
   Graham SM, 2000, T ROY SOC TROP MED H, V94, P310, DOI 10.1016/S0035-9203(00)90337-7
   Graham SM, 2000, PEDIATR INFECT DIS J, V19, P1189, DOI 10.1097/00006454-200012000-00016
   Graham SM, 2009, LANCET, V373, P267, DOI 10.1016/S0140-6736(09)60073-8
   GREEN SDR, 1993, ANN TROP PAEDIATR, V13, P45
   Hill PC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-2
   MABEY DCW, 1987, J INFECT DIS, V155, P1319
   NESBITT A, 1989, J TROP PEDIATRICS, V35, P35
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   ODEMPSEY TJD, 1994, PEDIATR INFECT DIS J, V13, P122, DOI 10.1097/00006454-199402000-00009
   Poskitt EME, 1999, ARCH DIS CHILD, V80, P115
   Satoguina J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-274
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
   Walsh AL, 2000, PEDIATR INFECT DIS J, V19, P312, DOI 10.1097/00006454-200004000-00010
NR 24
TC 49
Z9 49
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 11
PY 2010
VL 5
IS 5
AR e10568
DI 10.1371/journal.pone.0010568
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 594UB
UT WOS:000277563200005
PM 20485496
OA gold
DA 2017-08-15
ER

PT J
AU Nuvor, SV
   Rowland-Jones, S
   Whittle, H
   Jaye, A
AF Nuvor, Samuel Victor
   Rowland-Jones, Sarah
   Whittle, Hilton
   Jaye, Assan
TI Comparison of Cytotoxic activity and Interferon-g secretion by Natural
   Killer Cells in HIV-1 and HIV-2 infected individuals
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Nuvor, Samuel Victor] Univ Cape Coast, Cape Coast, Ghana.
   [Rowland-Jones, Sarah] Wetherall Inst Mol Med, Oxford, England.
   [Whittle, Hilton; Jaye, Assan] MRC, Banjul, Gambia.
EM vnuvor@yahoo.com
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD MAY 11
PY 2010
VL 7
SU 1
BP 18
EP 18
AR P9
PG 1
WC Virology
SC Virology
GA 605EF
UT WOS:000278329600058
OA gold
DA 2017-08-15
ER

PT J
AU Adetifa, IMO
   Ota, MOC
   Jeffries, DJ
   Hammond, A
   Lugos, MD
   Donkor, S
   Patrick, O
   Adegbola, RA
   Hill, PC
AF Adetifa, Ifedayo M. O.
   Ota, Martin O. C.
   Jeffries, David J.
   Hammond, Abdulrahman
   Lugos, Moses D.
   Donkor, Simon
   Patrick, Owiafe
   Adegbola, Richard A.
   Hill, Philip C.
TI Commercial Interferon Gamma Release Assays Compared to the Tuberculin
   Skin Test for Diagnosis of Latent Mycobacterium tuberculosis Infection
   in Childhood Contacts in the Gambia
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE tuberculin skin test; interferon gamma release assays; children; latent
   tuberculosis infection; Bayesian modeling
ID LINKED IMMUNOSPOT ASSAY; CONDITIONAL DEPENDENCE; ACTIVE TUBERCULOSIS;
   BLOOD-TESTS; PREVALENCE; RESPONSES; CHILDREN; IMMUNODIAGNOSIS; EXPOSURE;
   ELISPOT
AB Background: We compared the performance of tuberculin skin test (TST), Quantiferon-TB Gold in-tube (QFT-GIT), and T-SPOT. TB in diagnosing latent tuberculosis (LTBI) among childhood TB contacts in a TB endemic setting with high BCG coverage. We evaluated the performance of interferon gamma release assays (IGRAs) and TST when combined in an algorithm.
   Methods: Childhood contacts of newly diagnosed TB patients were tested with TST, QFT-GIT, and T-SPOT. The level of exposure in contacts was categorized according to whether they slept in the same room, same house, or a different house as the index case. For the evaluation of combined test performance, prior estimates for prevalence of latent TB were used in Bayesian models that assumed conditional dependence between tests.
   Results: A total of 285 children were recruited. Overall, 26.5%, 33.0%, and 33.5% were positive for TST, T-SPOT, or QFT-GIT, respectively. All 3 tests responded to the gradient of sleeping proximity to the index case. Neither TST nor IGRA results were confounded by BCG vaccination. There was moderate agreement (kappa = 0.40-0.68) between all 3 tests. Combination of either IGRA with TST increased sensitivity (by 9.3%-9.6%) especially in contacts in the highest exposure category but was associated with loss of specificity (9.9%-11.3%).
   Conclusion: IGRAs and TST are similar in their diagnostic performance for LTBI. An approximate 10% sensitivity benefit for using the TST and an IGRA in combination is associated with a slightly greater specificity loss. Testing strategies combining an IGRA and TST with an "or" statement may be useful only in situations where there is a high pretest probability of latent infection.
C1 [Adetifa, Ifedayo M. O.; Ota, Martin O. C.; Hammond, Abdulrahman; Lugos, Moses D.; Donkor, Simon; Patrick, Owiafe; Adegbola, Richard A.] MRC UK Labs, Bacterial Dis Program, Banjul, Gambia.
   [Jeffries, David J.] Med Res Council UK Labs, Stat & Data Support Unit, Banjul, Gambia.
   [Hill, Philip C.] Univ Otago, Sch Med, Dept Prevent & Social Med, Ctr Int Hlth, Dunedin, New Zealand.
RP Adetifa, IMO (reprint author), MRC UK Labs, Bacterial Dis Program, POB 273, Banjul, Gambia.
EM iadetifa@mrc.gm
RI Hammond, Abdulrahman/F-1541-2011
FU Medical Research Council (UK) Laboratories; Gambia; European and
   Developing Countries' Clinical Trials Partnership (EDCTP)
FX Supported by Medical Research Council (UK) Laboratories, The Gambia and
   the European and Developing Countries' Clinical Trials Partnership
   (EDCTP). All of the QFT-GIT and about a third of T-SPOT. TB kits
   utilized for this study were provided free by Cellestis Limited,
   Carnegie, Australia and Oxford Immunotec Ltd., Abingdon, Oxford,
   respectively.
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   Adetifa IMO, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-122
   Arend SM, 2007, AM J RESP CRIT CARE, V175, P618, DOI 10.1164/rccm.200608-1099OC
   Canadian Tuberculosis Committee, 2008, CAN COMMUN DIS REP, V34, P1
   COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977
   Dendukuri N, 2001, BIOMETRICS, V57, P158, DOI 10.1111/j.0006-341X.2001.00158.x
   Dogra S, 2007, J INFECTION, V54, P267, DOI 10.1016/j.jinf.2006.04.007
   Dominguez J, 2008, CLIN VACCINE IMMUNOL, V15, P168, DOI 10.1128/CVI.00364-07
   Dosanjh DPS, 2008, ANN INTERN MED, V148, P325
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6
   Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962
   Goletti D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003417
   Hill PC, 2006, PEDIATRICS, V117, P1542, DOI 10.1542/peds.2005-2095
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Hill PC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001379
   Hill PC, 2007, PLOS MED, V4, P1061, DOI 10.1371/journal.pmed.0040192
   Hill PC, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000068
   Igari H, 2007, INT J TUBERC LUNG D, V11, P788
   JOSEPH L, 1995, AM J EPIDEMIOL, V141, P263
   Landis J. R., 1977, BIOMETRICS, V33, P174
   Lee JY, 2006, EUR RESPIR J, V28, P24, DOI 10.1183/09031936.06.00016906
   Marais BJ, 2006, AM J RESP CRIT CARE, V173, P1078, DOI 10.1164/rccm.200511-1809SO
   Mazurek Gerald H., 2005, Morbidity and Mortality Weekly Report, V54, P49
   Menzies D, 2008, ANN INTERN MED, V148, P398
   Menzies D, 2007, ANN INTERN MED, V146, P340
   Mudido PM, 1999, INT J TUBERC LUNG D, V3, P891
   Naseer A, 2007, EUR RESPIR J, V29, P1282, DOI 10.1183/09031936.0017807
   *NAT I HLTH CLIN E, 2006, CLIN GUIDELINE, V33, P1
   Orme I M, 1991, Bull Int Union Tuberc Lung Dis, V66, P7
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X
   Pai M, 2008, INT J TUBERC LUNG D, V12, P895
   Pai M, 2008, ANN INTERN MED, V149, P177
   Pai M, 2007, LANCET INFECT DIS, V7, P428, DOI 10.1016/S1473-3099(07)70086-5
   Rathman G, 2003, INT J TUBERC LUNG D, V7, P942
   Tavast Esko, 2009, BMC Res Notes, V2, P9, DOI 10.1186/1756-0500-2-9
   Trebucq A, 2005, INT J TUBERC LUNG D, V9, P1097
   VACEK PM, 1985, BIOMETRICS, V41, P959, DOI 10.2307/2530967
   van der Loeff MFS, 2002, AIDS, V16, P1775
   van Zyl-Smit RN, 2009, AM J RESP CRIT CARE, V180, P49, DOI 10.1164/rccm.200811-1704OC
   Vilaplana C, 2008, SCAND J IMMUNOL, V67, P610, DOI 10.1111/j.1365-3083.2008.02103.x
NR 41
TC 30
Z9 34
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAY 10
PY 2010
VL 29
IS 5
BP 439
EP 443
DI 10.1097/INF.0b013e3181cb45da
PG 5
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 590IJ
UT WOS:000277218600011
PM 20068506
OA No
DA 2017-08-15
ER

PT J
AU Shann, F
   Nohynek, H
   Scott, JA
   Hesseling, A
   Flanagan, KL
AF Shann, Frank
   Nohynek, Hanna
   Scott, J. Anthony
   Hesseling, Anneke
   Flanagan, Katie L.
CA Working Grp Nonspecific Effects Va
TI Randomized Trials to Study the Nonspecific Effects of Vaccines in
   Children in Low-Income Countries
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Editorial Material
DE immunologic memory; mortality; nonspecific effects; randomized
   controlled trial; vaccines
ID DIPHTHERIA-TETANUS-PERTUSSIS; BACILLUS-CALMETTE-GUERIN; FEMALE-MALE
   MORTALITY; TITER MEASLES-VACCINE; BIRTH-WEIGHT INFANTS; GUINEA-BISSAU;
   HETEROLOGOUS IMMUNITY; VITAMIN-A; BCG; INFECTIONS
AB The Expanded Program on Immunization (EPI) has led to large reductions in morbidity and mortality among children in low-income countries. However, the basic EPI schedule may no longer be optimal because of changes in vaccines, programs, and epidemiologic circumstances. In addition, evidence has accumulated that some EPI vaccines may have nonspecific effects that increase or decrease mortality from subsequent infections with other unrelated organisms. There is therefore a need for randomized trials to evaluate the effects of alternative EPI schedules on all-cause mortality, as well as vaccine efficacy against the target diseases. We have reviewed the available literature on the nonspecific effects of vaccines on mortality, and compiled a list of potential trials that might address this issue. We have then ranked the trials based on the potential importance of the results and the ethical and practical considerations. Trials of early BCG vaccination in low-birth-weight babies, early measles vaccination, and altered timing of DTP vaccination all have a high priority.
C1 [Shann, Frank] Royal Childrens Hosp, Intens Care Unit, Melbourne, Vic, Australia.
   [Nohynek, Hanna] Natl Publ Hlth Inst, Helsinki, Finland.
   [Scott, J. Anthony] KEMRI Wellcome Trust Collaborat Res Programme, Kilifi, Kenya.
   [Scott, J. Anthony] Univ Oxford, Nuffield Dept Clin Med, Oxford, England.
   [Hesseling, Anneke] Univ Stellenbosch, Desmond Tutu TB Ctr, Dept Paediat & Child Hlth, Cape Town, South Africa.
   [Flanagan, Katie L.] MRC Labs, Fajara, Gambia.
RP Shann, F (reprint author), Royal Childrens Hosp, Flemington Rd, Parkville, Vic 3052, Australia.
EM frank.shann@rch.org.au
OI Kallander, Karin/0000-0002-5778-5780
FU Medical Research Council [MC_U190088485]; Wellcome Trust [061089,
   081835]
CR Aaby P, 2006, VACCINE, V24, P2764, DOI 10.1016/j.vaccine.2006.01.004
   Aaby P, 2005, B WORLD HEALTH ORGAN, V83, P238
   Aaby P, 2004, INT J EPIDEMIOL, V33, P374, DOI 10.1093/ije/dyh005
   Aaby P, 2004, INT J EPIDEMIOL, V33, P367, DOI 10.1093/ije/dyh004
   Aaby P, 2003, PEDIATR INFECT DIS J, V22, P798, DOI 10.1097/01.inf.0000083821.33187.b5
   Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   Aaby P, 2007, PEDIATR INFECT DIS J, V26, P247, DOI 10.1097/01.inf.0000256735.05098.01
   APRILE MA, 1966, C J PUBLIC HEALTH, V57, P343
   Benn CS, 2008, BRIT MED J, V336, P1416, DOI 10.1136/bmj.39542.509444.AE
   Benn CS, 2009, INT J EPIDEMIOL, V38, P304, DOI 10.1093/ije/dyn195
   Chen HD, 2003, AM J PATHOL, V163, P1341, DOI 10.1016/S0002-9440(10)63493-1
   Didierlaurent A, 2007, IMMUNOLOGY, V122, P457, DOI 10.1111/j.1365-2567.2007.02729.x
   Dvoroznakova E, 2004, PARASITOL INT, V53, P315, DOI 10.1016/j.parint.2004.05.001
   Farrington CP, 2009, TROP MED INT HEALTH, V14, P977, DOI 10.1111/j.1365-3156.2009.02302.x
   Fine PEM, 2009, TROP MED INT HEALTH, V14, P969, DOI 10.1111/j.1365-3156.2009.02301.x
   Hesseling AC, 2007, VACCINE, V25, P6565, DOI 10.1016/j.vaccine.2007.06.045
   Hussey GD, 2002, IMMUNOLOGY, V105, P314, DOI 10.1046/j.1365-2567.2002.01366.x
   Kaur S, 2002, INDIAN J MED RES, V116, P64
   Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5
   Maizels RM, 2005, CURR OPIN IMMUNOL, V17, P656, DOI 10.1016/j.coi.2005.09.001
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Martins CL, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a661
   MOSS WJ, 2004, VACCINES, P169
   Ota MOC, 2002, J IMMUNOL, V168, P919
   Roth A, 2004, PEDIATR INFECT DIS J, V23, P544, DOI 10.1097/01.inf.0000129693.81082.a0
   Roth A, 2006, EXPERT REV VACCINES, V5, P277, DOI 10.1586/14760584-5.2.277
   Sajid MS, 2007, LIFE SCI, V80, P1966, DOI 10.1016/j.lfs.2007.02.025
   Selin LK, 2006, IMMUNOL REV, V211, P164, DOI 10.1111/j.0105-2896.2006.00394.x
   Shann F, 2004, PEDIATR INFECT DIS J, V23, P555, DOI 10.1097/01.inf.0000130155.42392.04
   TENDAM HG, 1980, B WORLD HEALTH ORGAN, V58, P37
   Welsh RM, 2002, NAT REV IMMUNOL, V2, P417, DOI 10.1038/nri820
   World Health Organization, 2006, WKLY EPIDEMIOL REC, V81, P2
   World Health Organisation, 2009, WKLY EPIDEMIOL REC, V84, P1
   *WHO, 2006, WORLD HLTH REP 2005, P186
NR 34
TC 24
Z9 25
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD MAY 10
PY 2010
VL 29
IS 5
BP 457
EP 461
DI 10.1097/INF.0b013e3181c91361
PG 5
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 590IJ
UT WOS:000277218600015
PM 20431383
OA No
DA 2017-08-15
ER

PT J
AU de Bono, S
   Schoenmakers, I
   Ceesay, M
   Mendy, M
   Laskey, MA
   Cole, TJ
   Prentice, A
AF de Bono, Stephanie
   Schoenmakers, Inez
   Ceesay, Mustapha
   Mendy, Michael
   Laskey, M. Ann
   Cole, Tim J.
   Prentice, Ann
TI Birth weight predicts bone size in young adulthood at cortical sites in
   men and trabecular sites in women from The Gambia
SO BONE
LA English
DT Article
DE Birth weight; Bone size; Gambia; Cortical; Trabecular
ID CHILDHOOD GROWTH; MINERAL DENSITY; HERTFORDSHIRE COHORT; POSTMENOPAUSAL
   WOMEN; FOREARM FRACTURES; PROXIMAL RADIUS; LATER LIFE; MASS; STRENGTH;
   DETERMINANTS
AB Fracture risk is determined by bone mass, size and architecture. Birth weight (Bwt) is reported to predict adult bone mass and density. Early life environment may therefore be a determinant of bone strength in later life. However such evidence was obtained using dual energy X-ray absorptiometry (DXA), which is known to be dependent on size.
   We used peripheral quantitative computed tomography (pQCT) and DXA to investigate Bwt as a determinant of bone size and cross section area (CSA), bone mineral content (BMC) and volumetric bone mineral density (vBMD) and areal BMD (aBMD) independent of current weight, height and age. The study population consisted of 68 males and 52 nulliparous females aged 17 to 21 years from Keneba, The Gambia. This population has a high prevalence of factors likely to influence skeletal development (poor nutrition, low calcium intake, late puberty and high physical activity).
   Measures of bone size and CSA, BMC and BMD were obtained using pQCT (Stratec 2000: at 4% and 66% radius: 4% and 50% tibia) and DXA (Lunar DPX; spine, hip, forearm and whole body). Sequential univariable (influence of Bwt on bone variables) and multivariable linear regression analyses (influence of Bwt on bone variables after adjusting for current height, weight and age) were used to investigate the independent effects of Bwt and attained size. Analyses were performed separately by sex.
   Bwt was a significant positive predictor of CSA at appendicular cortical sites in males and CSA and bone area at appendicular and most axial trabecular sites in females before and after adjustment for current height, weight and age. Bwt was not consistently related to BMC, vBMD or aBMD as measured by pQCT or DXA. Current weight was a positive predictor of aBMD and pQCT- and DXA-derived BMC in males and females. Height predicted aBMD and trabecular vBMD in males.
   In summary, Bwt significantly predicted attained CSA at cortical sites in males and at trabecular sites in females. Current weight was a positive predictor of BMC and aBMD in both sexes. This suggests that prenatal factors affecting fetal growth may influence adult bone strength independently of post-natal factors. (C) 2010 Elsevier Inc. All rights reserved.
C1 [de Bono, Stephanie; Schoenmakers, Inez; Laskey, M. Ann; Prentice, Ann] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   [Ceesay, Mustapha; Mendy, Michael; Prentice, Ann] MRC Keneba, Keneba, Gambia.
   [Cole, Tim J.] UCL, MRC, Inst Child Hlth, Ctr Epidemiol Child Hlth, London, England.
RP Schoenmakers, I (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
EM Inez.Schoenmakers@mrc-hnr.cam.ac.uk
RI Cole, Tim/B-7883-2008
OI Cole, Tim/0000-0001-5711-8200
FU Medical Research Council [G0700961, MC_U105960371]
CR Ahlborg HG, 2003, NEW ENGL J MED, V349, P327, DOI 10.1056/NEJMoa022464
   Antoniades L, 2003, RHEUMATOLOGY, V42, P791, DOI 10.1093/rheumatology/keg227
   Binkley TL, 2000, J CLIN DENSITOM, V3, P9, DOI 10.1385/JCD:3:1:009
   Bonjour J-P, 2003, NUTR ASPECTS BONE HL, P111, DOI DOI 10.1039/9781847551559-00111
   Bradney M, 1998, J BONE MINER RES, V13, P1814, DOI 10.1359/jbmr.1998.13.12.1814
   Cole TJ, 2000, STAT MED, V19, P3109, DOI 10.1002/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F
   Cooper C, 1997, ANN RHEUM DIS, V56, P17, DOI 10.1136/ard.56.1.17
   COOPER C, 1995, J BONE MINER RES, V10, P940
   Cooper C, 2001, OSTEOPOROSIS INT, V12, P623, DOI 10.1007/s001980170061
   Dennison EM, 2005, PEDIATR RES, V57, P582, DOI 10.1203/01.PDR.0000155754.67821.CA
   Dibba B, 2002, AM J CLIN NUTR, V76, P681
   Dibba B, 2000, AM J CLIN NUTR, V71, P544
   Duppe H, 1997, CALCIFIED TISSUE INT, V60, P405, DOI 10.1007/s002239900253
   Felsenberg D, 2005, CLIN THER, V27, P1, DOI 10.1016/j.clinthera.2004.12.020
   Gale CR, 2001, J CLIN ENDOCR METAB, V86, P267, DOI 10.1210/jc.86.1.267
   HAMED HM, 1993, OSTEOPOROSIS INT, V3, P1, DOI 10.1007/BF01623168
   Javaid M, 2008, J BONE MINER RES, V23, pS327
   Javaid MK, 2006, J BONE MINER RES, V21, P508, DOI 10.1359/JBMR.051214
   Khosla S, 2003, JAMA-J AM MED ASSOC, V290, P1479, DOI 10.1001/jama.290.11.1479
   Martin R. B., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P209
   MATKOVIC V, 2003, NUTR ASPECTS BONE HL
   Nieves JW, 2005, J BONE MINER RES, V20, P529, DOI 10.1359/JBMR.041005
   Oliver H, 2007, BONE, V41, P400, DOI 10.1016/j.bone.2007.05.007
   PRENTICE A, 1994, AM J CLIN NUTR, V60, P837
   Prevrhal S, 1999, PHYS MED BIOL, V44, P751, DOI 10.1088/0031-9155/44/3/017
   Rauch F., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P119
   Rauch F., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P194
   Schoenau E, 2002, BONE, V31, P110, DOI 10.1016/S8756-3282(02)00802-5
   Schoenau E, 2001, J CLIN ENDOCR METAB, V86, P613, DOI 10.1210/jc.86.2.613
   Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140-6736(02)08706-8
   Seeman E, 2003, NEW ENGL J MED, V349, P320, DOI 10.1056/NEJMp038101
   SINGH J, 1989, BRIT J NUTR, V62, P315, DOI 10.1079/BJN19890033
   Skaggs DL, 2001, J BONE MINER RES, V16, P1337, DOI 10.1359/jbmr.2001.16.7.1337
   Szulc P, 2006, BONE, V38, P595, DOI 10.1016/j.bone.2005.09.004
   Szulc P, 2006, J BONE MINER RES, V21, P1856, DOI 10.1359/JBMR.060904
   te Velde SJ, 2004, OSTEOPOROSIS INT, V15, P382, DOI 10.1007/s00198-003-1554-5
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756-3282(93)90081-K
   Yarbrough DE, 2000, OSTEOPOROSIS INT, V11, P626, DOI 10.1007/s001980070085
NR 38
TC 12
Z9 12
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD MAY
PY 2010
VL 46
IS 5
BP 1316
EP 1321
DI 10.1016/j.bone.2010.01.381
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 586VC
UT WOS:000276941000013
PM 20123139
OA No
DA 2017-08-15
ER

PT J
AU Bhattacharya, S
   Townend, J
   Bhattacharya, S
AF Bhattacharya, Sohinee
   Townend, John
   Bhattacharya, Siladitya
TI Recurrent miscarriage: Are three miscarriages one too many? Analysis of
   a Scottish population-based database of 151,021 pregnancies
SO EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
LA English
DT Article
DE Miscarriage; Recurrent miscarriage; Preterm delivery
ID SPONTANEOUS-ABORTION; RISK-FACTORS; TRIMESTER MISCARRIAGE; 1ST
   TRIMESTER; SMOKING; HISTORY; WOMEN; COHORT
AB Objective: To assess the risk of further miscarriage or preterm delivery in women with a history of miscarriages in previous pregnancies, adjusting for maternal age and smoking.
   Study design: Retrospective cohort study using all women with first pregnancies recorded between 1950 and 2000 in the Aberdeen Maternity and Neonatal Databank. Exposure was one or more spontaneous miscarriages, while outcomes assessed were further miscarriage or preterm delivery.
   Results: There were 143,595 pregnancies with none, 6,577 with one, 700 with two, 115 with three and 24 with four consecutive previous miscarriages. The odds of miscarriage were greater in pregnancies following one previous miscarriage than none {adj.O.R. 1.94(95% C.I. 1.80, 2.09)}. The risk of miscarriage following two miscarriages was greater than in pregnancies following one {adj.O.R. 1.56 (95% C.I. 1.28, 1.90)}. However, there was no further significant increase in odds of miscarriage for pregnancies following three {adj.O.R. 1.37 (95% C.I. 0.86, 2.17)} previous consecutive miscarriages. Odds of spontaneous preterm delivery were greater following one miscarriage than none {adj.O.R. 1.52 (95% C.I. 1.36, 1.69)} but no further increases in risk were seen.
   Conclusion: After adjusting for age and smoking, the risk of a further miscarriage increased sequentially in women who had one and two miscarriages. Three miscarriages did not increase the odds any further. One miscarriage was associated with an increased chance of spontaneous preterm delivery, but two or three miscarriages did not increase the odds any further. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Bhattacharya, Sohinee] Aberdeen Matern Hosp, Dugald Baird Ctr Res Womens Hlth, Aberdeen AB25 2ZD, Scotland.
   [Townend, John] MRC Labs Fajara, Banjul, Gambia.
   [Bhattacharya, Siladitya] Aberdeen Matern Hosp, Dept Obstet & Gynaecol, Aberdeen AB25 2ZD, Scotland.
RP Bhattacharya, S (reprint author), Aberdeen Matern Hosp, Dugald Baird Ctr Res Womens Hlth, Aberdeen AB25 2ZD, Scotland.
EM sohinee.bhattacharya@abdn.ac.uk; sohinee.bhattacharya@abdn.ac.uk
OI Bhattacharya, Sohinee/0000-0002-2358-5860
FU NHS Grampian Endowments
FX The authors would like to express their gratitude to NHS Grampian
   Endowments for funding this research. They would also like to thank Ms.
   Linda Murdoch for extracting and manipulating the data.
CR Basso O, 2007, PAEDIATR PERINAT EP, V21, P8, DOI 10.1111/j.1365-3016.2007.00831.x
   Bech BH, 2005, AM J EPIDEMIOL, V162, P983, DOI 10.1093/aje/kwi317
   Brigham SA, 1999, HUM REPROD, V14, P2868, DOI 10.1093/humrep/14.11.2868
   Brown JS, 2008, J EPIDEMIOL COMMUN H, V62, P16, DOI 10.1136/jech.2006.050369
   Chatenoud L, 1998, ANN EPIDEMIOL, V8, P520, DOI 10.1016/S1047-2797(98)00017-9
   Clifford K, 1997, HUM REPROD, V12, P387, DOI 10.1093/humrep/12.2.387
   de La Rochebrochard E, 2002, HUM REPROD, V17, P1649, DOI 10.1093/humrep/17.6.1649
   Hammoud AO, 2007, INT J GYNECOL OBSTET, V96, P28, DOI 10.1016/j.ijgo.2006.09.005
   HARLAP S, 1980, LANCET, V2, P173
   HUGHES N, 1991, J REPROD MED, V36, P165
   Jivraj S, 2001, HUM REPROD, V16, P102, DOI 10.1093/humrep/16.1.102
   Lauritsen J G, 1976, Acta Obstet Gynecol Scand Suppl, V52, P1
   Maconochie N, 2007, BJOG-INT J OBSTET GY, V114, P170, DOI 10.1111/j.1471-0528.2006.01193.x
   Malpas P, 1938, J OBSTET GYN BR COMM, V45, P932
   NAYLOR AF, 1979, FERTIL STERIL, V31, P282
   Nybo Andersen A.M., 2000, BRIT MED J, V320, P1708
   POLAND BJ, 1977, AM J OBSTET GYNECOL, V127, P685
   REGAN L, 1989, BRIT MED J, V299, P1082
   REGAN L, 1989, BRIT MED J, V299, P541
   REGINALD PW, 1987, BRIT J OBSTET GYNAEC, V94, P643, DOI 10.1111/j.1471-0528.1987.tb03168.x
   RISCH HA, 1988, AM J EPIDEMIOL, V128, P420
   STIRRAT GM, 1990, LANCET, V336, P728, DOI 10.1016/0140-6736(90)92215-4
   TULPPALA M, 1993, HUM REPROD, V8, P764
   WARBURTON D, 1964, AM J HUM GENET, V16, P1
   WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401
   WINDHAM GC, 1992, AM J EPIDEMIOL, V135, P1394
NR 26
TC 12
Z9 12
U1 1
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-2115
J9 EUR J OBSTET GYN R B
JI Eur. J. Obstet. Gynecol. Reprod. Biol.
PD MAY
PY 2010
VL 150
IS 1
BP 24
EP 27
DI 10.1016/j.ejogrb.2010.02.015
PG 4
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 598XM
UT WOS:000277873200005
PM 20207064
OA No
DA 2017-08-15
ER

PT J
AU Richards, AA
   Darboe, MK
   Tilling, K
   Smith, GD
   Prentice, AM
   Lawlor, DA
AF Richards, Anna A.
   Darboe, Momodou K.
   Tilling, Kate
   Smith, George Davey
   Prentice, Andrew M.
   Lawlor, Debbie A.
TI Breast milk sodium content in rural Gambian women: between- and
   within-women variation in the first 6 months after delivery
SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY
LA English
DT Article
DE breast milk; sodium; developing country
ID LATER BLOOD-PRESSURE; PRETERM INFANTS; MOTHERS; POSTPARTUM; LACTATION;
   NUTRITION; MASTITIS
AB It has been suggested that infancy is a particularly sensitive period with respect to the effect of dietary sodium on future risk of hypertension. One difficulty of researching the effects of early sodium intake on later health is accurately measuring sodium intake from breast milk. In observational studies, sodium content has been calculated by estimating breast milk volume consumed and assuming a fixed sodium concentration for all women at all times ( a standardised measure). The objectives of this study were to investigate the variation in breast milk sodium concentration in the first 6 months postpartum within women and test whether the pattern of change in sodium concentration differs between women. The study population was 197 rural Gambian women. Multilevel models were used to investigate whether the sodium content of breast milk changed over time within and between women. Fractional polynomials were used to identify the best-fitting functions of age to be included in the within and between variance functions.
   Sodium levels decreased with time; the reduction was initially rapid ( levels decreasing by 17.7% between 30 and 60 days after delivery). Immediately after birth, there was substantial variation in breast milk sodium content between women but this reduced with time. Our results suggest that it is not appropriate to use a standardised measure of breast milk sodium content when direct measurement is possible - particularly when there is a research interest in measuring sodium intake in very early infancy.
C1 [Smith, George Davey; Lawlor, Debbie A.] Univ Bristol, MRC Ctr Causal Anal Translat Epidemiol, Bristol BS8 2BN, Avon, England.
   [Richards, Anna A.; Tilling, Kate; Smith, George Davey; Lawlor, Debbie A.] Univ Bristol, Dept Social Med, Bristol BS8 2BN, Avon, England.
   [Prentice, Andrew M.] London Sch Hyg & Trop Med, Int Nutr Grp, London WC1, England.
   [Darboe, Momodou K.; Prentice, Andrew M.] MRC Labs, Keneba, Gambia.
RP Lawlor, DA (reprint author), Univ Bristol, MRC Ctr Causal Anal Translat Epidemiol, Oakfield House, Bristol BS8 2BN, Avon, England.
EM d.a.lawlor@bristol.ac.uk
RI Davey Smith, George/A-7407-2013
OI Davey Smith, George/0000-0002-1407-8314; Monsalve, Beatriz
   Elena/0000-0002-5994-866X; Lawlor, Debbie A/0000-0002-6793-2262;
   Tilling, Kate/0000-0002-1010-8926
FU Medical Research Council [G0600705]
CR Alaudeen S, 1988, Malays J Reprod Health, V6, P102
   ALLEN JC, 1991, AM J CLIN NUTR, V54, P69
   Brion MJ, 2008, EUR J CLIN NUTR, V62, P1162, DOI 10.1038/sj.ejcn.1602837
   Darboe MK, 2007, LANCET, V369, P2088, DOI 10.1016/S0140-6736(07)60981-7
   Filteau SM, 1999, AM J CLIN NUTR, V69, P953
   Geleijnse JM, 1997, HYPERTENSION, V29, P913
   Goldstein H, 2002, STAT MED, V21, P3291, DOI 10.1002/sim.1264
   HAZEBROEK A, 1983, ACTA PAEDIATR SCAND, V72, P459, DOI 10.1111/j.1651-2227.1983.tb09747.x
   HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370
   KEENAN BS, 1982, AM J CLIN NUTR, V35, P527
   KOO WWK, 1982, ARCH DIS CHILD, V57, P500
   LASKEY MA, 1990, ACTA PAEDIATR SCAND, V79, P507, DOI 10.1111/j.1651-2227.1990.tb11504.x
   LUCAS A, 1988, ARCH DIS CHILD, V63, P656
   Pomeranz A, 2002, J HYPERTENS, V20, P203, DOI 10.1097/00004872-200202000-00009
   Prentice A, 1984, Ann Trop Paediatr, V4, P19
   PRENTICE A, 1985, T ROY SOC TROP MED H, V79, P90, DOI 10.1016/0035-9203(85)90245-7
   PRENTICE AM, 1984, CLIN SCI, V66, P291
   *ROYAL SOC CHEM MA, 1991, COMP FOODS
   Singhal A, 2001, LANCET, V357, P413, DOI 10.1016/S0140-6736(00)04004-6
   Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070
   SULYOK E, 1980, Acta Paediatrica Academiae Scientiarum Hungaricae, V21, P159
   Tilling K, 2001, STAT MED, V20, P685, DOI 10.1002/sim.697.abs
   Wack RP, 1997, NUTRITION, V13, P774, DOI 10.1016/S0899-9007(97)00187-1
   Whitten C F, 1980, Acta Paediatr Scand Suppl, V279, P1
   Willumsen JF, 2000, ADV EXP MED BIOL, V478, P211
NR 25
TC 4
Z9 4
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0269-5022
J9 PAEDIATR PERINAT EP
JI Paediatr. Perinat. Epidemiol.
PD MAY
PY 2010
VL 24
IS 3
BP 255
EP 261
DI 10.1111/j.1365-3016.2010.01111.x
PG 7
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology;
   Pediatrics
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology;
   Pediatrics
GA 581DO
UT WOS:000276501800007
PM 20415755
OA No
DA 2017-08-15
ER

PT J
AU Roberts, CH
   Molina-Gonzalez, SJ
   Makalo, P
   Harding-Esch, EM
   Bailey, RL
   Mabey, DC
   Holland, MJ
AF Roberts, Chrissy H.
   Molina-Gonzalez, Sandra J.
   Makalo, Pateh
   Harding-Esch, Emma M.
   Bailey, Robin L.
   Mabey, David C.
   Holland, Martin J.
TI KIR 'B' group haplotypes co-segregate with scarring trachoma in Gambian
   families: preliminary indications of a role for KIR in the immune
   response to a bacterial infection
SO TISSUE ANTIGENS
LA English
DT Meeting Abstract
CT 24th European Immunogenetics and Histocompatibility Conference/17th
   Annual Meeting of the
   Italian-Society-for-Immunogenetics-and-Transplantation-Biology
CY MAY 15-18, 2010
CL Florence, ITALY
SP Italian Soc Immunogenet & Transplantat Biol
C1 [Roberts, Chrissy H.; Molina-Gonzalez, Sandra J.; Harding-Esch, Emma M.; Bailey, Robin L.; Mabey, David C.] London Sch Hyg & Trop Med, London WC1, England.
   [Makalo, Pateh; Holland, Martin J.] Med Res Labs 1, Fajara, Gambia.
   [Holland, Martin J.] London Sch Hyg, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD MAY
PY 2010
VL 75
IS 5
BP 487
EP 487
PG 1
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 583FO
UT WOS:000276659100055
OA No
DA 2017-08-15
ER

PT J
AU Drylewicz, J
   Eholie, S
   Maiga, M
   Zannou, DM
   Sow, PS
   Ekouevi, DK
   Peterson, K
   Bissagnene, E
   Dabis, F
   Thiebaut, R
AF Drylewicz, Julia
   Eholie, Serge
   Maiga, Moussa
   Zannou, Djimon Marcel
   Sow, Papa Salif
   Ekouevi, Didier K.
   Peterson, Kevin
   Bissagnene, Emmanuel
   Dabis, Francois
   Thiebaut, Rodolphe
CA Int Epidemiologic Databases Evalu
TI First-year lymphocyte T CD4(+) response to antiretroviral therapy
   according to the HIV type in the IeDEA West Africa collaboration
SO AIDS
LA English
DT Article
DE Africa; antiretroviral therapy; CD4(+) T lymphocytes; HIV-1; HIV-2;
   longitudinal study
ID RESOURCE-LIMITED SETTINGS; HIV-2-INFECTED PATIENTS;
   REVERSE-TRANSCRIPTASE; DRUG-RESISTANCE; IMMUNOLOGICAL RESPONSE;
   HIV-1-ASSOCIATED AIDS; HIV-2-INDUCED AIDS; CONTROLLED-TRIALS;
   COTE-DIVOIRE; INFECTION
AB Objective: To compare the lymphocyte T CD4(+) (CD4) response to combinations of antiretroviral therapy (ART) in HIV-1, HIV-2 and dually positive patients in West Africa.
   Design and setting: Collaboration of 12 prospective cohorts of HIV-infected adults followed in Senegal (2), Gambia (1), Mali (2), Benin (1) and Cote d'Ivoire (6).
   Subjects: Nine thousand, four hundred and eighty-two patients infected by HIV-1 only, 270 by HIV-2 only and 321 dually positive, who initiated an ART.
   Outcome measures: CD4 change over a 12-month period.
   Results: Observed CD4 cell counts at treatment initiation were similar in the three groups [overall median 155, interquartile range (IQR) 68; 249 cells/mu l). In HIV-1 patients, the most common ART regimen was two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI; N = 7714) as well as for dually positive patients (N 135). HIV-2 patients were most often treated with a protease inhibitor-based regimen (N 193) but 45 of them were treated with an NNRTI-containing ART. In those treated with a NNRTI-containing regimen, the estimated mean CD4 change between 3 and 12 months was significantly lower in HIV-2 (-41 cells/mu l per year) and dually positive patients (+12 cells/mu l per year) compared to HIV-1 patients (+69 cells/mu l per year, overall P value 0.01). The response in HIV-2 and dually positive patients treated by another regimen (triple NRTIs or protease inhibitor-containing ART) was not significantly different than the response obtained in HIV-1-only patients (all P values >0.30).
   Conclusion: An optimal CD4 response to ART in West Africa requires determining HIV type prior to initiation of antiretroviral drugs. NNRTIs are the mainstay of first-line ART in West Africa but are not adapted to the treatment of HIV-2 and dually positive patients. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Thiebaut, Rodolphe] Univ Bordeaux 2, ISPED, INSERM Epidemiol & Biostat U897, F-33076 Bordeaux, France.
   [Drylewicz, Julia; Ekouevi, Didier K.; Dabis, Francois; Thiebaut, Rodolphe] INSERM, U897, F-33076 Bordeaux, France.
   [Eholie, Serge; Bissagnene, Emmanuel] CHU Treichville, SMIT, Abidjan, Cote Ivoire.
   [Maiga, Moussa] Hop Gabriel Toure, Serv Hepatogastroenterol, Bamako, Mali.
   [Zannou, Djimon Marcel] Ctr Hosp Univ CHNU, Ctr Prise Charge Personnes Vivant Avec VIH PVVIH, Cotonou, Benin.
   [Sow, Papa Salif] CHU Fann, SMIT, Dakar, Senegal.
   [Ekouevi, Didier K.] CHU Treichville, Programme PAC CI, Abidjan, Cote Ivoire.
   [Peterson, Kevin] MRC, Banjul, Gambia.
RP Thiebaut, R (reprint author), Univ Bordeaux 2, ISPED, INSERM Epidemiol & Biostat U897, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM rodolphe.thiebaut@isped.u-bordeaux2.fr
RI EKOUEVI, Didier/E-7960-2014; Anglaret, Xavier/F-7333-2013
FU National Institute of Allergy and Infectious Diseases (NIAID)
   [5U01AI069919-03]; Eunice Kennedy Shriver National Institute of Child
   Health and Human Development (NICHD); National Cancer Institute (NCI)
FX This study was supported by the National Institute of Allergy and
   Infectious Diseases (NIAID, grant 5U01AI069919-03), together with the
   Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (NICHD) and the National Cancer Institute (NCI).
CR Benard A, 2009, AIDS, V23, P1171, DOI 10.1097/QAD.0b013e32832949f0
   Berry N, 1998, J Hum Virol, V1, P457
   Boileau C, 2008, JAIDS-J ACQ IMM DEF, V48, P476, DOI 10.1097/QAI.0b013e31817dc416
   Borget MY, 2009, J CLIN VIROL, V45, P72, DOI 10.1016/j.jcv.2009.03.011
   Brinkhof MWG, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000066
   Brower ET, 2008, CHEM BIOL DRUG DES, V71, P298, DOI [10.1111/j.1747-0285.2008.00647.x, 10.1111/j.1747.0285.2008.00647.x]
   Descamps D, 2004, J MED VIROL, V74, P197, DOI 10.1002/jmv.20174
   Drylewicz J, 2008, AIDS, V22, P457, DOI 10.1097/QAD.0b013e3282f4ddfc
   Eholie S, 2006, INT J EPIDEMIOL, V35, P1329, DOI 10.1093/ije/dyl156
   Etard JF, 2006, AIDS, V20, P1181, DOI 10.1097/01.aids.0000226959.87471.01
   Gottlieb GS, 2008, AIDS, V22, P2069, DOI 10.1097/QAD.0b013e32830edd44
   Gottlieb GS, 2009, CLIN INFECT DIS, V48, P476, DOI 10.1086/596504
   Hounton SH, 2008, AIDS CARE, V20, P582, DOI 10.1080/09540120701868303
   Jacqmin-Gadda H, 2007, COMPUT STAT DATA AN, V51, P5142, DOI 10.1016/j.csda.2006.05.021
   Jallow S, 2006, AIDS, V20, P1455, DOI 10.1097/01.aids.0000233582.64467.8e
   Jallow S, 2009, J CLIN MICROBIOL, V47, P2200, DOI 10.1128/JCM.01654-08
   Jallow S, 2009, CLIN INFECT DIS, V48, P1790, DOI 10.1086/599107
   Landman R, 2009, AIDS, V23, P426, DOI 10.1097/QAD.0b013e328321305a
   MacNeil A, 2007, J VIROL, V81, P5325, DOI 10.1128/JVI.02625-06
   Martinez-Steele E, 2007, AIDS, V21, P317, DOI 10.1097/QAD.0b013e328011d7ab
   Matheron S, 2006, AIDS, V20, P459, DOI 10.1097/01.aids.0000199829.57112.2f
   Matheron S, 2008, AIDS, V22, P2073, DOI 10.1097/QAD.0b013e32830edd59
   Nash D, 2008, AIDS, V22, P2291, DOI 10.1097/QAD.0b013e3283121ca9
   Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208
   Pujades-Rodriguez M, 2008, AIDS, V22, P1305, DOI 10.1097/QAD.0b013e3282fa75b9
   Ren J, 2002, P NATL ACAD SCI USA, V99, P14410, DOI 10.1073/pnas.222366699
   Rouet F, 2004, J CLIN MICROBIOL, V42, P4147, DOI 10.1128/JCM.42.9.4147-4153.2004
   Sarfo FS, 2009, J ANTIMICROB CHEMOTH, V64, P667, DOI 10.1093/jac/dkp216
   Schutten M, 2000, NEW ENGL J MED, V342, P1758, DOI 10.1056/NEJM200006083422317
   Smith RA, 2009, J INFECT DIS, V199, P1323, DOI 10.1086/597802
   Souville M, 2003, AIDS, V17, pS79, DOI 10.1097/00002030-200317003-00011
   Sow PS, 2007, JAIDS-J ACQ IMM DEF, V44, P262, DOI 10.1097/QAI.0b013e31802bf109
   Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782
   Thiebaut R, 2008, QJM-INT J MED, V101, P821, DOI 10.1093/qjmed/hcn099
   Thiebaut R, 2005, STAT MED, V24, P65, DOI 10.1002/sim.1923
   Toure S, 2008, AIDS, V22, P873, DOI 10.1097/QAD.0b013e3282f768f8
   Valadas E, 2009, CLIN INFECT DIS, V48, P1166, DOI 10.1086/597504
   van der Loeff MFS, 2006, INT J EPIDEMIOL, V35, P1322, DOI 10.1093/ije/dy1037
   van der Loeff MFS, 2008, AIDS, V22, P791
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   World Health Oganization, 2008, UN ACC SCAL PRIOR HI
   WHO, 2006, ANT THER HIV INF AD
   Witvrouw M, 2004, ANTIVIR THER, V9, P57
NR 43
TC 14
Z9 14
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD APR 24
PY 2010
VL 24
IS 7
BP 1043
EP 1050
DI 10.1097/QAD.0b013e3283377a06
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 582AN
UT WOS:000276567500014
PM 20397306
OA No
DA 2017-08-15
ER

PT J
AU Tshefu, AK
   Gaye, O
   Kayentao, K
   Thompson, R
   Bhatt, KM
   Sesay, SSS
   Bustos, DG
   Tjitra, E
   Bedu-Addo, G
   Borghini-Fuhrer, I
   Duparc, S
   Shin, CS
   Fleckenstein, L
AF Tshefu, Antoinette K.
   Gaye, Oumar
   Kayentao, Kassoum
   Thompson, Ricardo
   Bhatt, Kirana M.
   Sesay, Sanie S. S.
   Bustos, Dorina G.
   Tjitra, Emiliana
   Bedu-Addo, George
   Borghini-Fuhrer, Isabelle
   Duparc, Stephan
   Shin, Chang Sik
   Fleckenstein, Lawrence
CA Pyronaridine-Artesunate Study Team
TI Efficacy and safety of a fixed-dose oral combination of
   pyronaridine-artesunate compared with artemether-lumefantrine in
   children and adults with uncomplicated Plasmodium falciparum malaria: a
   randomised non-inferiority trial
SO LANCET
LA English
DT Article
ID IN-VITRO; PHARMACOKINETICS; BENFLUMETOL; AMODIAQUINE; THERAPIES; AFRICA
AB Background There is a need for new artemisinin-based combination therapies that are convenient, effective, and safe. We compared the efficacy and safety of pyronaridine-artesunate with that of artemether-lumefantrine for treatment of uncomplicated P falciparum malaria.
   Methods This phase 3, parallel-group, double-blind, randomised, non-inferiority trial was undertaken in seven sites in Africa and three sites in southeast Asia. In a double-dummy design, patients aged 3-60 years with uncomplicated P. falciparum malaria were randomly assigned in a 2:1 ratio to receive pyronaridine-artesunate once a day or artemether-lumefantrine twice a day, orally for 3 days, plus respective placebo. Randomisation was done by computer-generated randomisation sequence in blocks of nine by study centre. Intervention tablets contained 180 mg pyronaridine and 60 mg artesunate; control tablets contained 20 mg artemether and 120 mg lumefantrine. Both treatments were given according to bodyweight. The primary efficacy outcome was PCR-corrected adequate clinical and parasitological response (ACPR) rate at day 28 in the per-protocol population. Non-inferiority was shown if the lower limit of the two-sided 95% CI for the difference between groups was greater than -5%. This study is registered with ClinicalTrials.gov, number NCT00422084.
   Findings 1272 patients were randomly assigned to treatment (pyronaridine-artesunate, n=849; artemether-lumefantrine, n=423). The per-protocol population consisted of 784 patients in the pyronaridine-artesunate group and 386 patients in the artemether-lumefantrine group. PCR-corrected ACPR rate at day 28 was 99.5% (780 patients; 95% CI 98.7-99.9) in the pyronaridine-artesunate group and 99.2% (383 patients; 95% CI 97.7-99.8) in the artemether-lumefantrine group (treatment difference 0.3%, 95% CI -0.7 to 1.8; p=0.578). There were 509 (60.0%) adverse events in 849 patients assigned to pyronaridine-artesunate and 241 (57.0%) in 423 patients assigned to artemether-lumefantrine. The most frequent drug-related adverse event was eosinophilia (pyronaridine-artesunate, 53 events [6.2%]; artemether-lumefantrine 24 events [5.7%]). 21(2.5%) patients in the pyronaridine-artesunate group and seven (1.7%) in the artemether-lumefantrine group discontinued study drugs or were withdrawn from the study. Mild and transient increases in alanine aminotransferase and aspartate aminotransferase concentrations were seen in the pyronaridine-artesunate group but not in the artemether-lumefantrine group.
   Interpretation Efficacy of pyronaridine-artesunate was non-inferior to that of artemether-lumefantrine for treatment of uncomplicated falciparum malaria. Pyronaridine-artesunate should be considered for inclusion in malaria treatment programmes.
C1 [Tshefu, Antoinette K.] Univ Kinshasa, Fac Med, Ecole Sante Publ, Kinshasa, Zaire.
   [Gaye, Oumar] Univ Cheikh Anta Diop, Fac Med, Serv Parasitol, Dakar, Senegal.
   [Kayentao, Kassoum] Fac Med Pharm & Odontostomatol, Malaria Res & Training Ctr, Bamako, Mali.
   [Thompson, Ricardo] Natl Inst Hlth, Chokwe Hlth Res & Training Ctr, Chokwe, Mozambique.
   [Bhatt, Kirana M.] Univ Nairobi, UNITID Coll Hlth Sci, Nairobi, Kenya.
   [Sesay, Sanie S. S.] MRC Labs, Farafenni Field Stn, Fajara, Gambia.
   [Bustos, Dorina G.] Res Inst Trop Med, Manila, Philippines.
   [Tjitra, Emiliana] Minist Hlth, Natl Inst Hlth Res & Dev, Jakarta, Indonesia.
   [Bedu-Addo, George] Komfo Anokye Teaching Hosp, Kumasi, Ghana.
   [Shin, Chang Sik] Shin Poong Pharmaceut, Seoul, South Korea.
   [Fleckenstein, Lawrence] Univ Iowa, Iowa City, IA USA.
RP Borghini-Fuhrer, I (reprint author), Int Ctr Cointrin, Route Prebois 20,POB 1826, CH-1215 Geneva 15, Switzerland.
EM borghinii@mmv.org
OI Fleckenstein, Lawrence/0000-0001-5320-4531
FU Medicines for Malaria Venture; Shin Poong Pharmaceutical
FX The Medicines for Malaria Venture sponsored this trial as part of the
   clinical development programme of pyronaridine-artesunate. Shin Poong
   Pharmaceutical co-sponsored the trial. Naomi Richardson of Magenta
   Communications developed a first draft of this report from the approved
   study report and collated author contributions and was funded by the
   Medicines for Malaria Venture. We thank the study population and local
   staff, who made this study possible. We thank the following individuals
   for their assistance during the trial: Abdoulaye Djimde, Ogobara K
   Doumbo, and Moussa Niangaly from Mali; Paulo Arnaldo, Jeronimo Langa,
   Sergio Chicumbe, and Mbate Pedro Matandalasse from Mozambique; and
   Ignatius Baldeh from The Gambia. We would also like to acknowledge the
   contributions of Ghiorghis Belai, David Asante, and Pongphaya
   Choosakulchart (Family Health International), who were in charge of the
   study monitoring; Sarah Arbe-Bames, Eric Didillon, Audrey Mulder
   (Fulcrum Pharma, UK), and Claude Oeuvray (Medicines for Malaria Venture)
   for their dedicated work in the set-up and execution of this trial; and
   Hanspeter Marti and Hans-Peter Beck (Swiss Tropical Institute), who
   undertook central reading of the slides and PCR analysis. We thank
   Stephen Allen (Swansea University, UK), Robert Miller (Fulcrum Pharma,
   UK), J Carl Craft (Libertyville, USA), and Frank Stephen Wignall (Family
   Health International) for their participation in the Safety Monitoring
   Board. Statistical analysis was undertaken by Averion (Basel,
   Switzerland) and we acknowledge the dedicated work of Mikael Saulay and
   Arnaud Demange.
CR Abdulla S, 2008, LANCET, V372, P1819, DOI 10.1016/S0140-6736(08)61492-0
   Adjei GO, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-127
   Ezzet F, 2000, ANTIMICROB AGENTS CH, V44, P697, DOI 10.1128/AAC.44.3.697-704.2000
   Ezzet F, 1998, BRIT J CLIN PHARMACO, V46, P553, DOI 10.1046/j.1365-2125.1998.00830.x
   Faye B, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-80
   Felger Ingrid, 2002, Methods Mol Med, V72, P117, DOI 10.1385/1-59259-271-6:117
   Karunajeewa HA, 2008, NEW ENGL J MED, V359, P2545, DOI 10.1056/NEJMoa0804915
   Kurth F, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-79
   Martensson A, 2005, CLIN INFECT DIS, V41, P1079, DOI 10.1086/444460
   *MED MAL VENT WHO, 2008, METH TECHN CLIN TRIA
   Price R, 1999, AM J TROP MED HYG, V60, P547
   Ramharter M, 2008, J INFECT DIS, V198, P911, DOI 10.1086/591096
   Ratcliff A, 2007, LANCET, V369, P757, DOI 10.1016/S0140-6736(07)60160-3
   Ribeiro I R, 1998, Med Trop (Mars), V58, P50
   Ringwald P, 1998, CLIN INFECT DIS, V26, P946, DOI 10.1086/513942
   Ringwald P, 1996, LANCET, V347, P24, DOI 10.1016/S0140-6736(96)91558-5
   Sagara I, 2008, AM J TROP MED HYG, V79, P655
   Sinclair D, 2009, COCHRANE DB SYST REV, V3
   Suputtamongkol Y, 2001, BRIT J CLIN PHARMACO, V52, P655, DOI 10.1046/j.1365-2125.2001.01458.x
   van den Broek I, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-113
   Vivas L, 2008, ACTA TROP, V105, P222, DOI 10.1016/j.actatropica.2007.12.005
   Whitty CJM, 2005, CLIN INFECT DIS, V41, P1087, DOI 10.1086/444464
   World Health Organization (WHO), 2006, GUID TREATM MAL
   WHO, 2003, ASS MON ANT DRUG EFF
NR 24
TC 59
Z9 60
U1 1
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD APR 24
PY 2010
VL 375
IS 9724
BP 1457
EP 1467
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 590FL
UT WOS:000277210000032
PM 20417857
OA No
DA 2017-08-15
ER

PT J
AU de Souza, JB
   Okomo, U
   Alexander, ND
   Aziz, N
   Owens, BMJ
   Kaur, H
   Jasseh, M
   Muangnoicharoen, S
   Sumariwalla, PF
   Warhurst, DC
   Ward, SA
   Conway, DJ
   Ulloa, L
   Tracey, KJ
   Foxwell, BMJ
   Kaye, PM
   Walther, M
AF de Souza, J. Brian
   Okomo, Uduak
   Alexander, Neal D.
   Aziz, Naveed
   Owens, Benjamin M. J.
   Kaur, Harparkash
   Jasseh, Momodou
   Muangnoicharoen, Sant
   Sumariwalla, Percy F.
   Warhurst, David C.
   Ward, Stephen A.
   Conway, David J.
   Ulloa, Luis
   Tracey, Kevin J.
   Foxwell, Brian M. J.
   Kaye, Paul M.
   Walther, Michael
TI Oral Activated Charcoal Prevents Experimental Cerebral Malaria in Mice
   and in a Randomized Controlled Clinical Trial in Man Did Not Interfere
   with the Pharmacokinetics of Parenteral Artesunate
SO PLOS ONE
LA English
DT Article
ID SEVERE FALCIPARUM-MALARIA; TUMOR-NECROSIS-FACTOR; CELL DEFORMABILITY;
   IMMUNE-RESPONSE; KENYAN CHILDREN; EXPRESSION; QUININE; RECEPTOR;
   TANZANIA; HOST
AB Background: Safe, cheap and effective adjunct therapies preventing the development of, or reducing the mortality from, severe malaria could have considerable and rapid public health impact. Oral activated charcoal (oAC) is a safe and well tolerated treatment for acute poisoning, more recently shown to have significant immunomodulatory effects in man. In preparation for possible efficacy trials in human malaria, we sought to determine whether oAC would i) reduce mortality due to experimental cerebral malaria (ECM) in mice, ii) modulate immune and inflammatory responses associated with ECM, and iii) affect the pharmacokinetics of parenteral artesunate in human volunteers.
   Methods/Principal Findings: We found that oAC provided significant protection against P. berghei ANKA-induced ECM, increasing overall survival time compared to untreated mice (p<0.0001; hazard ratio 16.4; 95% CI 6.73 to 40.1). Protection from ECM by oAC was associated with reduced numbers of splenic TNF(+) CD4(+) T cells and multifunctional IFN gamma(+) TNF(+) CD4(+) and CD8(+) T cells. Furthermore, we identified a whole blood gene expression signature (68 genes) associated with protection from ECM. To evaluate whether oAC might affect current best available anti-malarial treatment, we conducted a randomized controlled open label trial in 52 human volunteers (ISRCTN NR. 64793756), administering artesunate ( AS) in the presence or absence of oAC. We demonstrated that co-administration of oAC was safe and well-tolerated. In the 26 subjects further analyzed, we found no interference with the pharmacokinetics of parenteral AS or its pharmacologically active metabolite dihydroartemisinin.
   Conclusions/Significance: oAC protects against ECM in mice, and does not interfere with the pharmacokinetics of parenteral artesunate. If future studies succeed in establishing the efficacy of oAC in human malaria, then the characteristics of being inexpensive, well-tolerated at high doses and requiring no sophisticated storage would make oAC a relevant candidate for adjunct therapy to reduce mortality from severe malaria, or for immediate treatment of suspected severe malaria in a rural setting.
C1 [de Souza, J. Brian; Alexander, Neal D.; Kaur, Harparkash; Jasseh, Momodou; Warhurst, David C.; Conway, David J.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   [de Souza, J. Brian] UCL, Dept Immunol, Div Infect & Immun, London, England.
   [Okomo, Uduak; Conway, David J.; Walther, Michael] MRC Labs, Banjul, Gambia.
   [Aziz, Naveed] Univ York, Dept Biol, Technol Facil, York YO10 5DD, N Yorkshire, England.
   [Owens, Benjamin M. J.; Kaye, Paul M.] Univ York, Hull York Med Sch, Ctr Immunol & Infect, York, N Yorkshire, England.
   [Muangnoicharoen, Sant; Ward, Stephen A.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   [Sumariwalla, Percy F.; Foxwell, Brian M. J.] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol, London, England.
   [Ulloa, Luis; Tracey, Kevin J.] N Shore LIJ Res Inst, Ctr Immunol & Inflammat, New York, NY USA.
RP de Souza, JB (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
EM pmk2@york.ac.uk; mwalther@mrc.gm
RI de Souza, Joseph/D-4979-2009
OI Ward, Steve/0000-0003-2331-3192; Tracey, Kevin J/0000-0003-1884-6314;
   Ulloa, Luis/0000-0002-7702-7549; Conway, David/0000-0002-8711-3037
FU British Medical Research Council [G0400786]; Medical Research Council
   Laboratories (UK); North Shore-LIJ Faculty Award; NIGMS; North Shore-LIJ
   GCRC [1MO1RR018535]
FX British Medical Research Council (#G0400786 to PMK;
   http://www.mrc.ac.uk/index.htm), the Medical Research Council
   Laboratories (UK) core funding to the MRC Gambia Unit, a North Shore-LIJ
   Faculty Award to LU, the NIGMS, and the North Shore-LIJ GCRC
   (#1MO1RR018535; http://www.feinsteininstitute.org/Feinstein/GCRC). BO is
   supported by a MRC Postgraduate Studentship. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR AKINTONWA A, 1990, VET HUM TOXICOL, V32, P567
   Armitage P., 2001, STAT METHODS MED RES
   BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3
   BERENDT AR, 1994, PARASITOL TODAY, V10, P412, DOI 10.1016/0169-4758(94)90238-0
   Berkley J, 2005, JAMA-J AM MED ASSOC, V294, P591, DOI 10.1001/jama.294.5.591
   Boggild AK, 2009, CLIN INFECT DIS, V49, P841, DOI 10.1086/605431
   BRADBERRY SM, 1995, J TOXICOL-CLIN TOXIC, V33, P407
   Brent AJ, 2006, PEDIATR INFECT DIS J, V25, P230, DOI 10.1097/01.inf.0000202066.02212.ff
   Chakravorty SJ, 2007, INT J PARASITOL, V37, P975, DOI 10.1016/j.ijpara.2007.02.006
   Chaussabel D, 2008, IMMUNITY, V29, P150, DOI 10.1016/j.immuni.2008.05.012
   Clark IA, 2003, PHARMACOL THERAPEUT, V99, P221, DOI 10.1016/S0163-7258(03)00060-3
   Clark IA, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-208
   CRANSTON HA, 1984, SCIENCE, V223, P400, DOI 10.1126/science.6362007
   de Souza JB, 2002, MICROBES INFECT, V4, P291, DOI 10.1016/S1286-4579(02)01541-1
   Delahaye NF, 2006, J INFECT DIS, V193, P312, DOI 10.1086/498579
   Dondorp AM, 1997, AM J TROP MED HYG, V57, P507
   Engwerda CR, 2002, AM J PATHOL, V161, P429, DOI 10.1016/S0002-9440(10)64199-5
   Faiz MA, 2005, LANCET, V366, P717
   Griffith JW, 2007, J INFECT DIS, V196, P1553, DOI 10.1086/522865
   Griffiths MJ, 2005, J INFECT DIS, V191, P1599, DOI 10.1086/429297
   HASAN MM, 1990, J PHARM PHARMACOL, V42, P85
   He XS, 2006, HEPATOLOGY, V44, P352, DOI 10.1002/hep.21267
   Hearn J, 2000, INFECT IMMUN, V68, P5364, DOI 10.1128/IAI.68.9.5364-5376.2000
   Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1
   Jackson GDF, 2000, INFECT IMMUN, V68, P4714, DOI 10.1128/IAI.68.8.4714-4719.2000
   Jankovic D, 2007, J EXP MED, V204, P273, DOI 10.1084/jem.20062175
   Kellum JA, 2002, CRIT CARE MED, V30, P1387, DOI 10.1097/00003246-200206000-00047
   LOCKEY D, 1989, BRIT J CLIN PHARMACO, V27, P92
   Lovegrove FE, 2007, AM J PATHOL, V171, P1894, DOI 10.2353/ajpath.2007.070630
   Lovegrove FE, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-295
   Makani J, 2003, QJM-INT J MED, V96, P355, DOI 10.1093/qjmed/hcg059
   Ockenhouse CF, 2006, INFECT IMMUN, V74, P5561, DOI 10.1128/IAI.00408-06
   Penet MF, 2008, P NATL ACAD SCI USA, V105, P1321, DOI 10.1073/pnas.0706867105
   PRESCOTT LF, 1989, BRIT J CLIN PHARMACO, V27, P95
   Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55
   Reyburn H, 2008, B WORLD HEALTH ORGAN, V86, P132, DOI 10.2471/BLT.07.041723
   Riley EM, 2006, PARASITE IMMUNOL, V28, P35, DOI 10.1111/j.1365-3024.2006.00775.x
   Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686
   Schofield L, 2006, CURR MOL MED, V6, P205, DOI 10.2174/156652406776055221
   Schulman G, 2006, BLOOD PURIFICAT, V24, P143, DOI 10.1159/000089451
   Serghides L, 2009, J INFECT DIS, V199, P1536, DOI 10.1086/598222
   SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X
   VANBELLE G, 1993, AM STAT, V47, P163
   vanHensbroek MB, 1996, J INFECT DIS, V174, P1091
   Wang E, 2008, IMMUNITY, V29, P9, DOI 10.1016/j.immuni.2008.07.002
   WHO, 2008, WHO WORLD MAL REP
NR 46
TC 3
Z9 3
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 15
PY 2010
VL 5
IS 4
AR e9867
DI 10.1371/journal.pone.0009867
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 583VD
UT WOS:000276707100001
PM 20419161
OA gold
DA 2017-08-15
ER

PT J
AU Kheir, A
   Nwakanma, D
   Al-Gazali, A
   Akbarova, Y
   Al-Saai, S
   Swedberg, G
   Babiker, HA
AF Kheir, Amani
   Nwakanma, Davis
   Al-Gazali, Aisha
   Akbarova, Yagut
   Al-Saai, Salma
   Swedberg, Gote
   Babiker, Hamza A.
TI Transmission and Cross-Mating of High-Level Resistance Plasmodium
   falciparum Dihydrofolate Reductase Haplotypes in The Gambia
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID ANOPHELES-GAMBIAE; DRUG-RESISTANCE; PYRIMETHAMINE-SULFADOXINE; MALARIA
   PARASITES; SELECTIVE SWEEPS; EASTERN SUDAN; AFRICA; POPULATION;
   MOSQUITOS; DHFR
AB A high-level pyrimethamine resistance Plasmodium falciparum lineage with triple dihydrofolate reductase (dhfr) mutations prevails across Africa. However, additional minority lineages were seen. We examined transmission success of mutant dhfr haplotypes among 22 children in The Gambia and 60 infected Anopheles gambiae mosquitoes fed on their blood. Additional polymorphic genes of the gametocyte-specific protein (pfg377) and merozoite surface protein-1 (MSP-1) were examined. Similarities were seen between pfg377 and MSP-1 alleles in children and mosquitoes and evidence of cross-mating between different parasite genotypes was seen in some infected mosquitoes, reflecting high transmission success of existing clones. With regard to dhfr, 16 haplotypes were seen among the children: 2 carried double mutations and 14 carried triple mutations. However, only nine haplotypes, all with triple mutations, were detected among mosquitoes. A single triple-mutant dhfr haplotype, similar to that in other countries in Africa, predominated among children (42%) and mosquitoes (60%), supporting the hypothesis of migration of this haplotype across Africa. However, evidence of cross-mating between the above haplotypes signifies the role of local evolution.
C1 [Al-Gazali, Aisha; Akbarova, Yagut; Al-Saai, Salma; Babiker, Hamza A.] Sultan Qaboos Univ, Dept Biochem, Fac Med, Alk Khojd, Oman.
   [Kheir, Amani; Swedberg, Gote] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsalal, Sweden.
   Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden.
   [Nwakanma, Davis] MRC Labs, Banjul, Gambia.
   [Babiker, Hamza A.] Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JR, Midlothian, Scotland.
RP Babiker, HA (reprint author), Sultan Qaboos Univ, Dept Biochem, Fac Med, POB 35, Alk Khod, Oman.
EM h.babiker@squ.edu.com
FU Medical Research Council, United Kingdom; Swedish International
   Development Cooperation Agency; Sultan Qaboos University, Oman
FX This work was supported by the Medical Research Council, United Kingdom;
   the Swedish International Development Cooperation Agency; and Sultan
   Qaboos University, Oman.
CR Abdel-Muhsin AA, 2003, PARASITOLOGY, V126, P391, DOI 10.1017/S0031182003003020
   Al-Saai S, 2009, INFECT GENET EVOL, V9, P778, DOI 10.1016/j.meegid.2009.04.010
   Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467
   BABIKER HA, 1994, PARASITOLOGY, V109, P413
   Babiker HA, 1997, AM J TROP MED HYG, V56, P141
   BURKOT TR, 1984, T ROY SOC TROP MED H, V78, P339, DOI 10.1016/0035-9203(84)90114-7
   Certain LK, 2008, J INFECT DIS, V197, P1743, DOI 10.1086/588198
   Cortese JF, 2002, J INFECT DIS, V186, P999, DOI 10.1086/342946
   Curtis J, 1998, J INFECT DIS, V177, P1429
   GRAVES PM, 1984, AM J TROP MED HYG, V33, P1045
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   Hallett RL, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010015
   Hill WG, 1995, P ROY SOC B-BIOL SCI, V262, P249, DOI 10.1098/rspb.1995.0203
   LINDSAY SW, 1991, J TROP MED HYG, V94, P313
   Mackinnon MJ, 1998, T ROY SOC TROP MED H, V92, P188, DOI 10.1016/S0035-9203(98)90745-3
   Maiga O, 2007, J INFECT DIS, V196, P165, DOI 10.1086/518512
   McCollum AM, 2006, J INFECT DIS, V194, P189, DOI 10.1086/504687
   McCollum AM, 2008, ANTIMICROB AGENTS CH, V52, P4089, DOI 10.1128/AAC.00623-08
   Menge DM, 2006, GENETICS, V173, P235, DOI 10.1534/genetics.105.055129
   Nair S, 2003, MOL BIOL EVOL, V20, P1526, DOI 10.1093/molbev/msg162
   Nassir E, 2005, INT J PARASITOL, V35, P49, DOI 10.1016/j.ijpara.2004.10.014
   Ndiaye D, 2006, ACTA TROP, V99, P106, DOI 10.1016/j.actatropica.2006.07.002
   Nwakanma D, 2008, INT J PARASITOL, V38, P219, DOI 10.1016/j.ijpara.2007.07.003
   PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897
   PLOWE CV, 1995, AM J TROP MED HYG, V52, P565
   Plowe CV, 1997, J INFECT DIS, V176, P1590
   RANFORDCARTWRIGHT LC, 1991, MOL BIOCHEM PARASIT, V49, P239, DOI 10.1016/0166-6851(91)90067-G
   Roper C, 2003, LANCET, V361, P1174, DOI 10.1016/S0140-6736(03)12951-0
   Roper C, 2004, SCIENCE, V305, P1124, DOI 10.1126/science.1098876
   Sutherland CJ, 2005, PLOS MED, V2, P338, DOI 10.1371/journal.pmed.0020092
   Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689
   Wargo AR, 2007, P NATL ACAD SCI USA, V104, P19914, DOI 10.1073/pnas.0707766104
   Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813
   Zwetyenga J, 1998, AM J TROP MED HYG, V59, P726
NR 34
TC 5
Z9 5
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD APR
PY 2010
VL 82
IS 4
BP 535
EP 541
DI 10.4269/ajtmh.2010.09-0378
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 577JR
UT WOS:000276219700006
PM 20348495
OA No
DA 2017-08-15
ER

PT J
AU Flanagan, KL
   Halliday, A
   Burl, S
   Landgraf, K
   Jagne, YJ
   Noho-Konteh, F
   Townend, J
   Miles, DJC
   van der Sande, M
   Whittle, H
   Rowland-Jones, S
AF Flanagan, Katie L.
   Halliday, Alice
   Burl, Sarah
   Landgraf, Katja
   Jagne, Ya Jankey
   Noho-Konteh, Fatou
   Townend, John
   Miles, David J. C.
   van der Sande, Marianne
   Whittle, Hilton
   Rowland-Jones, Sarah
TI The effect of placental malaria infection on cord blood and maternal
   immunoregulatory responses at birth
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE FOXP3; IL-10; Placental malaria; Treg
ID REGULATORY T-CELLS; PLASMODIUM-FALCIPARUM INFECTION; MEROZOITE SURFACE
   PROTEIN-1; IMMUNE-RESPONSES; IN-UTERO; CHONDROITIN SULFATE; DENDRITIC
   CELLS; EXPRESSION; FOXP3; PARASITE
AB Placental malaria (PM), a frequent infection of pregnancy, provides an ideal opportunity to investigate the impact on immune development of exposure of the foetal immune system to foreign Ag. We investigated the effect of PM on the regulatory phenotype and function of cord blood cells from healthy Gambian newborns and peripheral blood cells from their mothers, and analyzed for effects on the balance between regulatory and effector responses. Using the gold standard for classifying PM we further distinguished between resolved infection and acute or chronic PM active at the time of delivery. We show that exposure to malarial Ag in utero results in the expansion of malaria-specific FOXP3(+) Treg and more generalized FOXP3(+) CD4(+) Treg in chronic and resolved PM, alongside increased Th1 pro-inflammatory responses (IFN-gamma, TNF-alpha, IFN-gamma:IL-10) in resolved PM infection only. These observations demonstrate a clear effect of exposure to malarial Ag in foetal life on the immune environment at birth, with a regulatory response dominating in the newborns with ongoing chronic PM, while those with resolved infection produce both regulatory and inflammatory responses. The findings might explain some of the adverse effects on the health of babies born to women with PM.
C1 [Flanagan, Katie L.; Halliday, Alice; Burl, Sarah; Landgraf, Katja; Jagne, Ya Jankey; Noho-Konteh, Fatou; Townend, John; Miles, David J. C.; van der Sande, Marianne; Whittle, Hilton; Rowland-Jones, Sarah] MRC Labs, Fajara, Gambia.
   [Miles, David J. C.] Univ Cape Town, Inst Infect Dis & Mol Med, S African TB Vaccine Initiat, Observatory, South Africa.
   [Miles, David J. C.] Univ Cape Town, Sch Child & Adolescent Hlth, Observatory, South Africa.
   [van der Sande, Marianne] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Epidemiol, NL-3720 BA Bilthoven, Netherlands.
   [Rowland-Jones, Sarah] Univ Oxford, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford, England.
RP Flanagan, KL (reprint author), MRC Labs, Atlantic Blvd,POB 273, Fajara, Gambia.
EM kflanagan@mrc.gm
OI Halliday, Alice/0000-0001-8183-1110
FU Medical Research Council (UK)
FX This study was funded by the Medical Research Council (UK). We would
   like to thank the field workers and nurses based at Sukuta Health
   Centre, in particular Ebrima Touray and Sally Savage. We also
   acknowledge the support of the mothers and their babies without whom
   this study could not take place. We thank Momodou Cox, Momodou Fatty,
   Mariama Sanneh and Chilel Sanyang for technical assistance in the
   laboratory. Jean-Marie Dangou, Institute Pasteur, Dakar, Senegal,
   Momadou Jammeh, RVTH, Banjul, The Gambia and Modou Jallow, MRC, The
   Gambia performed the placental histology and slide reading. Ms Munira
   Grainger and Prof Anthony Holder, NIMR, London, UK provided the purified
   merozoites and Dr Britta Urban, CCVTM, Oxford provided the schizont
   extract and uninfected RBC control preparations.
CR Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014
   Angelone DF, 2006, PEDIATR RES, V60, P205, DOI 10.1203/01.pdr.0000228319.10481.ea
   Baecher-Allan C, 2006, J IMMUNOL, V176, P4622
   BISSEYE C, 2009, CLIN EXP IMMUNOL
   BLACKMAN MJ, 1994, METHOD CELL BIOL, V45, P213
   Broen K, 2007, MOL BIOCHEM PARASIT, V151, P1, DOI 10.1016/j.molbiopara.2006.10.001
   Brustoski K, 2006, J INFECT DIS, V193, P146, DOI 10.1086/498578
   Brustoski K, 2005, J IMMUNOL, V174, P1738
   Coban C, 2007, TRENDS MICROBIOL, V15, P271, DOI 10.1016/j.tim.2007.04.003
   CRISANTI A, 1990, IMMUNOL LETT, V25, P143, DOI 10.1016/0165-2478(90)90106-Z
   Fievet N, 1996, PARASITE IMMUNOL, V18, P483, DOI 10.1046/j.1365-3024.1996.d01-19.x
   Fievet Nadine, 2002, Malar J, V1, P16, DOI 10.1186/1475-2875-1-16
   Finney OC, 2009, EUR J IMMUNOL, V39, P1288, DOI 10.1002/eji.200839112
   Flanagan KL, 1999, EUR J IMMUNOL, V29, P1943, DOI 10.1002/(SICI)1521-4141(199906)29:06<1943::AID-IMMU1943>3.3.CO;2-T
   Flanagan KL, 2001, J IMMUNOL, V167, P4729
   Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502
   Godfrey WR, 2005, BLOOD, V105, P750, DOI 10.1182/blood-2004-06-2467
   Horrocks P, 2004, P NATL ACAD SCI USA, V101, P11129, DOI 10.1073/pnas.0402347101
   Ismail MR, 2000, HUM PATHOL, V31, P85, DOI 10.1016/S0046-8177(00)80203-8
   Ismaili J, 2003, CLIN EXP IMMUNOL, V133, P414, DOI 10.1046/j.1365-2249.2003.02243.x
   Ito T, 2008, IMMUNITY, V28, P870, DOI 10.1016/j.immuni.2008.03.018
   Kabyemela ER, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-26
   King CL, 2002, J IMMUNOL, V168, P356
   Kleinewietfeld M, 2005, BLOOD, V105, P2877, DOI 10.1182/blood-2004-07-2505
   Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200
   LeHesran JY, 1997, AM J EPIDEMIOL, V146, P826
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772
   Malhotra I, 2005, J CLIN MICROBIOL, V43, P3630, DOI 10.1128/JCM.43.8.3630-3635.2005
   Malhotra I, 2005, INFECT IMMUN, V73, P3462, DOI 10.1128/IAI.73.6.3462-3470.2005
   Malhotra I, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000116
   Mandron M, 2006, J ALLERGY CLIN IMMUN, V117, P1141, DOI 10.1016/j.jaci.2005.12.1360
   Mold JE, 2008, SCIENCE, V322, P1562, DOI 10.1126/science.1164511
   Plebanski M, 1999, IMMUNITY, V10, P651, DOI 10.1016/S1074-7613(00)80064-3
   RASHEED FN, 1995, PARASITE IMMUNOL, V17, P1, DOI 10.1111/j.1365-3024.1995.tb00960.x
   Reeder JC, 1999, P NATL ACAD SCI USA, V96, P5198, DOI 10.1073/pnas.96.9.5198
   RILEY EM, 1989, INFECT IMMUN, V57, P1281
   Scholzen A, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000543
   Schwarz NG, 2008, CLIN INFECT DIS, V47, P1017, DOI 10.1086/591968
   Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468
   Suguitan AL, 2003, J INFECT DIS, V188, P1074
   Takahata Y, 2004, EXP HEMATOL, V32, P622, DOI 10.1016/j.exphem.2004.03.012
   Theander Thor G., 1993, Immunology and Infectious Diseases (Oxford), V3, P97
   Todryk SM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002027
   Vanden Eijnden S, 2006, EUR J IMMUNOL, V36, P21, DOI 10.1002/eji.200535467
   Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343
   Wing K, 2002, IMMUNOLOGY, V106, P190, DOI 10.1046/j.1365-2567.2002.01412.x
NR 46
TC 22
Z9 22
U1 2
U2 2
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD APR
PY 2010
VL 40
IS 4
BP 1062
EP 1072
DI 10.1002/eji.200939638
PG 11
WC Immunology
SC Immunology
GA 590FS
UT WOS:000277210800016
PM 20039298
OA No
DA 2017-08-15
ER

PT J
AU van Tienen, C
   van der Loeff, MS
   Zaman, SMA
   Vincent, T
   Sarge-Njie, R
   Peterson, I
   Leligdowicz, A
   Jaye, A
   Rowland-Jones, S
   Aaby, P
   Whittle, H
AF van Tienen, Carla
   van der Loeff, Maarten Schim
   Zaman, Syed M. A.
   Vincent, Tim
   Sarge-Njie, Ramu
   Peterson, Ingrid
   Leligdowicz, Aleksandra
   Jaye, Assan
   Rowland-Jones, Sarah
   Aaby, Peter
   Whittle, Hilton
TI Two Distinct Epidemics: The Rise of HIV-1 and Decline of HIV-2 Infection
   Between 1990 and 2007 in Rural Guinea-Bissau
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV-1; HIV-2; Guinea-Bissau; rural population; incidence; prevalence
ID HUMAN-IMMUNODEFICIENCY-VIRUS; WEST-AFRICA; GAMBIAN PATIENTS;
   PREGNANT-WOMEN; COTE-DIVOIRE; VIRAL LOAD; PREVALENCE; TRENDS; COMMUNITY;
   COHORT
AB Objectives: To assess changes in HIV incidence and prevalence in Caio, a rural area of Guinea-Bissau, between 1990 and 2007.
   Design: Three cross-sectional community surveys.
   Methods: In 1990, 1997, and 2007, surveys were conducted among adults. The prevalence of HIV-1 and of HIV-2 was estimated for each survey, and incidence rates were calculated for the first (1990-1997) and second period (1997-2007).
   Results: The HIV-1 incidence was approximately 4.5/1000 person-years in the two periods, whereas the HIV-2 incidence decreased from 4.7 (95% confidence interval 3.6-6.2) in the first to 2.0 (95% confidence interval 1.4-3.0) per 1000 person-years in the second period (P < 0.001). HIV-1 prevalence rose from 0.5% in 1990 to 3.6% in 2007, and HIV-2 prevalence decreased from 8.3% in 1990 to 4.7% in 2007. HIV-1 prevalence was less than 2% in 15 to 24 year olds in all surveys and was highest (7.2%) in 2007 among 45 to 54 year olds. The HIV-2 prevalence was fivefold higher in older subjects (>= 45 yr) compared with those less than 45 years in both sexes in 2007.
   Conclusions: HIV-1 incidence is stable, and its prevalence is increasing, whereas HIV-2 incidence and prevalence are both declining. In contrast with what has been observed in other sub-Saharan countries, HIV-1 prevalence is lower in younger age groups than older age groups.
C1 [van Tienen, Carla; van der Loeff, Maarten Schim; Zaman, Syed M. A.; Vincent, Tim; Sarge-Njie, Ramu; Peterson, Ingrid; Leligdowicz, Aleksandra; Jaye, Assan; Rowland-Jones, Sarah; Whittle, Hilton] Med Res Labs, Fajara, Gambia.
   [van der Loeff, Maarten Schim] Municipal Hlth Serv, Amsterdam, Netherlands.
   [van der Loeff, Maarten Schim] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
   [Zaman, Syed M. A.] Hlth Protect Agcy Ctr Infect, London, England.
   [Leligdowicz, Aleksandra; Rowland-Jones, Sarah] John Radcliffe Hosp, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
   [Aaby, Peter] Indepth Network, Projecto Saude Bandim, Bissau, Guinea Bissau.
RP van Tienen, C (reprint author), Med Res Labs, POB 273,Atlantic Rd, Fajara, Gambia.
EM cvantienen@mrc.gm
RI van Tienen, Carla/A-1119-2012
OI Leligdowicz, Aleksandra/0000-0001-6055-4644
FU Medical Research Council
FX Supported by the Medical Research Council.
CR Aaby P, 1997, AIDS, V11, P939
   Aaby P, 1996, AIDS, V10, P1585
   Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   Ariyoshi K, 1997, AIDS, V11, P1053
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006
   Berry N, 1998, J Hum Virol, V1, P457
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Boerma JT, 2003, LANCET, V362, P1929, DOI 10.1016/S0140-6736(03)14967-7
   Buckner M, 1999, VIVRE PENSER SIDA AF, P389
   Buckner M, 2004, ENCY SEX GENDER MEN, P617
   Buve A, 2002, LANCET, V359, P2011, DOI 10.1016/S0140-6736(02)08823-2
   da Silva ZJ, 2008, AIDS, V22, P1195, DOI 10.1097/QAD.0b013e328300a33d
   DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083
   Diop OM, 2000, AIDS, V14, P1671, DOI 10.1097/00002030-200007280-00031
   DJOMAND G, 1995, J ACQ IMMUN DEF SYND, V10, P358
   GESKUS R, 2009, 13 INT WORKSH HIV OB
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   Holmgren B, 1999, SCAND J INFECT DIS, V31, P459
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   KESTENS L, 1992, AIDS, V6, P803, DOI 10.1097/00002030-199208000-00006
   Kwesigabo G, 2005, JAIDS-J ACQ IMM DEF, V40, P585, DOI 10.1097/01.qai.0000168183.22147.c4
   Lagarde E, 2003, INT J EPIDEMIOL, V32, P744, DOI 10.1093/ije/dyg111
   Larsen O, 1998, AIDS, V12, P1707, DOI 10.1097/00002030-199813000-00020
   Mansson F, 2007, SEX TRANSM INFECT, V83, P463, DOI 10.1136/sti.2007.025353
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Martinez-Steele E, 2007, AIDS, V21, P317, DOI 10.1097/QAD.0b013e328011d7ab
   Mbulaiteye SM, 2002, LANCET, V360, P41, DOI 10.1016/S0140-6736(02)09331-5
   Mekonnen Y, 2005, J HEALTH POPUL NUTR, V23, P358
   Morgan D, 2001, NAT MED, V7, P143, DOI 10.1038/84564
   Norrgren H, 1999, AIDS, V13, P701, DOI 10.1097/00002030-199904160-00011
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   POULSEN AG, 1989, LANCET, V1, P827
   Shafer LA, 2008, AIDS, V22, P1641, DOI 10.1097/QAD.0b013e32830a7502
   TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936
   UNAIDS, AIDS EP UPD
   van der Loeff MFS, 2006, INT J EPIDEMIOL, V35, P1322, DOI 10.1093/ije/dy1037
   van der Loeff MFS, 1999, AIDS, V13, pS69
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   van der Loeff MFS, 2002, AIDS, V16, P1775
   van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012
   Wawer MJ, 1997, AIDS, V11, P1023, DOI 10.1097/00002030-199708000-00011
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   Wiktor SZ, 1999, AIDS, V13, P695, DOI 10.1097/00002030-199904160-00010
   WILKINS A, 1991, AIDS, V5, P1529, DOI 10.1097/00002030-199112000-00018
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 46
TC 16
Z9 17
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR
PY 2010
VL 53
IS 5
BP 640
EP 647
DI 10.1097/QAI.0b013e3181bf1a25
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 574BZ
UT WOS:000275964700012
OA No
DA 2017-08-15
ER

PT J
AU Mwangome, M
   Prentice, A
   Plugge, E
   Nweneka, C
AF Mwangome, Martha
   Prentice, Andrew
   Plugge, Emma
   Nweneka, Chidi
TI Determinants of Appropriate Child Health and Nutrition Practices among
   Women in Rural Gambia
SO JOURNAL OF HEALTH POPULATION AND NUTRITION
LA English
DT Article
DE Child health; Child nutrition; Child nutrition disorders; Gender; Health
   education; Interventions; Knowledge, attitudes, practices; The Gambia
ID SEASONALITY; MORTALITY; SURVIVAL; TANZANIA; FAMILIES; VILLAGE; GROWTH
AB Health education and awareness involves providing knowledge about causes of illness and choices to promote a change in individual behaviour and, thus, improves survival of individuals. Studies have, however, shown that improved knowledge and awareness is not always translated into appropriate actions. This study aimed at exploring the factors determining mothers' choices of appropriate child health and nutrition practices in the Gambia. Eight focus-group discussions (FGDs) were held with 63 women whose children had been seen at the Keneba MRC Clinic within the 12 months preceding the study. The FGDs were analyzed using a thematic framework. Gender inequality, presence or absence of support networks, alternative explanatory models of malnutrition, and poverty were identified as the main factors that would determine the ability of a mother to practise what she knows about child health and nutrition. The findings highlight the need to consider the broader social, cultural and economic factors, including the value of involving men in childcare, when designing nutritional interventions.
C1 [Mwangome, Martha] Ctr Geog Med Res, Wellcome Trust Collaborat Res Programme, Kenya Med Res Inst, Kilifi, Kenya.
   [Prentice, Andrew; Nweneka, Chidi] Keneba Field Stn, MEd Res Council Labs, Banjul, Gambia.
   [Plugge, Emma] Univ Oxford, Dept Publ Hlth & Primary Hlth Care, Oxford OX3 7LZ, England.
RP Mwangome, M (reprint author), Ctr Geog Med Res, Wellcome Trust Collaborat Res Programme, Kenya Med Res Inst, POB 230, Kilifi, Kenya.
EM mmwangome@kilifi.kemri-wellcome.org
FU MRC Keneba
FX The authors acknowledge the support of Bakare Kante, Fatumata Sanyang,
   Fatumata Sidibeh, Sira Bah, all the staff at MRC Keneba and the
   community mothers, children, and families who willingly participated in
   the study.
CR Appoh LY, 2005, MATERN CHILD NUTR, V1, P100, DOI 10.1111/j.1740-8709.2005.00016.x
   Aubel J, 2004, SOC SCI MED, V59, P945, DOI 10.1016/j.socscimed.2003.11.044
   BABU SC, 1993, SOC SCI MED, V37, P1313, DOI 10.1016/0277-9536(93)90161-V
   BARNARD P, 2003, HOME BASED CTR BASED, P181
   Blossner M, 2005, ENV BURDEN DIS SERIE, V12
   de Onis M, 2004, JAMA-J AM MED ASSOC, V291, P2600, DOI 10.1001/jama.291.21.2600
   DENEGRI B, 2003, MAKING SENSE FOCUS G
   Dudgeon MR, 2004, SOC SCI MED, V59, P1379, DOI 10.1016/j.socscimed.2003.11.035
   Friedman JF, 2005, AM J TROP MED HYG, V73, P698
   Haidar J, 2005, East Afr Med J, V82, P625
   Hoare K, 1999, J TROP PEDIATRICS, V45, P208, DOI 10.1093/tropej/45.4.208
   Hoare K, 1994, Health Visit, V67, P102
   Hollos M, 2004, SOC SCI MED, V58, P1733, DOI 10.1016/S0277-9536(03)00365-4
   Knight KM, 2006, DIABETIC MED, V23, P485, DOI 10.1111/j.1464-5491.2005.01802.x
   LEE G, 2003, SOC SCI MED, V56, P449
   LOKDESSALLIEN R, 2000, REV POVERTY CONCEPTS, P1
   MCGREGOR IA, 1968, T ROY SOC TROP MED H, V62, P341, DOI 10.1016/0035-9203(68)90084-9
   Monte CMG, 1997, SOC SCI MED, V44, P1453, DOI 10.1016/S0277-9536(96)00241-9
   Muller O, 2005, CAN MED ASSOC J, V173, P279, DOI 10.1503/cmaj.050342
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
   Rayco-Solon P, 2004, TROP MED INT HEALTH, V9, P1151, DOI 10.1111/j.1365-3156.2004.01325.x
   Sear R, 2000, P ROY SOC B-BIOL SCI, V267, P1641, DOI 10.1098/rspb.2000.1190
   Sear R, 2002, DEMOGRAPHY, V39, P43, DOI 10.1353/dem.2002.0010
   Squires A, 2009, INT J NURS STUD, V46, P277, DOI 10.1016/j.ijnurstu.2008.08.006
   Thairu L, 2008, MATERN CHILD NUTR, V4, P194, DOI 10.1111/j.1740-8709.2008.00135.x
   WEAVER LT, 1993, LANCET, V341, P1327, DOI 10.1016/0140-6736(93)90827-4
   *WHO, 2006, A5913 WHO
NR 27
TC 17
Z9 18
U1 0
U2 3
PU I C D D R B-CENTRE HEALTH POPULATION RESEARCH
PI DHAKA
PA MOHAKHALI, 1212 DHAKA, BANGLADESH
SN 1606-0997
J9 J HEALTH POPUL NUTR
JI J. Heatlh Popul. Nutr.
PD APR
PY 2010
VL 28
IS 2
BP 167
EP 172
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA 583NH
UT WOS:000276683300009
PM 20411680
OA No
DA 2017-08-15
ER

PT J
AU Akpogheneta, OJ
   Dunyo, S
   Pinder, M
   Conway, DJ
AF Akpogheneta, O. J.
   Dunyo, S.
   Pinder, M.
   Conway, D. J.
TI Boosting antibody responses to Plasmodium falciparum merozoite antigens
   in children with highly seasonal exposure to infection
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE malaria; IgG; immunological memory; antibody avidity; malarial vaccine;
   merozoite antigens
ID VARIANT SURFACE-ANTIGENS; MALARIA MORBIDITY; ESCHERICHIA-COLI; CLINICAL
   MALARIA; PROTEIN-2; PROTECTION; KINETICS; AVIDITY; IMMUNOGENICITY;
   RECOGNITION
AB P>Longitudinal cohort studies are important to describe the dynamics of naturally acquired antibody response profiles to defined Plasmodium falciparum malaria antigens relative to clinical malaria episodes. In children under 7 years of age in The Gambia, serum IgG responses were measured to P. falciparum merozoite antigens AMA1, EBA175, MSP1(19), MSP2 and crude schizont extract, over a 10-month period. Persistence of antibody responses was measured in 152 children during the dry season when there was virtually no malaria transmission, and 103 children were monitored for new episodes of clinical malaria during the subsequent wet season when transmission occurred. Children who experienced clinical malaria had lower antibody levels at the start of the study than those who remained free from malaria. Associations between dry season antibody persistence and subsequent wet season antibody levels suggested robust immunological memory responses. Mean antibody levels to all antigens were elevated by the end of the wet season in children who experienced clinical malaria; each of these children had a boosted antibody response to at least one antigen. In all children, antibody avidities were lower against MSP2 than other antigens, a difference that did not change throughout the study period or in relation to clinical malaria episodes.
C1 [Akpogheneta, O. J.; Conway, D. J.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   [Akpogheneta, O. J.; Dunyo, S.; Pinder, M.; Conway, D. J.] MRC Labs, Fajara, Gambia.
RP Conway, DJ (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM o.akpogheneta@yahoo.com; david.conway@lshtm.ac.uk
OI Conway, David/0000-0002-8711-3037
FU Medical Research Council, UK
FX We thank the parents/guardians, the children and their communities for
   involvement in this study, and appreciate the support of many staff at
   the Medical Research Council Laboratories in The Gambia including
   fieldworkers Demba Sambou, Ebou Touray, Lamin Darboe, Amat Cham and
   Ebrima Fofana, laboratory staff Paul Gomez and Kintinu Dampha, and
   nursing staff Abdoulie Bah, Kamara Bayo and Kebba Jobe. We are grateful
   to Jana McBride, David Cavanagh, David Lanar and Kevin Tetteh for
   provision of recombinant antigens, and to Neal Alexander, Eleanor Riley
   and Kevin Tetteh and for helpful discussions on antibody response
   duration and measurement. The research was funded by the Medical
   Research Council, UK.
CR Achtman AH, 2007, PARASITE IMMUNOL, V29, P435, DOI 10.1111/j.1365-3024.2007.00960.x
   Akpogheneta OJ, 2008, INFECT IMMUN, V76, P1748, DOI 10.1128/IAI.01333-07
   AlYaman F, 1996, AM J TROP MED HYG, V54, P443
   ANDERS RF, 1986, PARASITE IMMUNOL, V8, P529, DOI 10.1111/j.1365-3024.1986.tb00867.x
   Biswas S, 2005, ANN TROP MED PARASIT, V99, P553, DOI 10.1179/136485905X51463
   BURGHAUS PA, 1994, MOL BIOCHEM PARASIT, V64, P165, DOI 10.1016/0166-6851(94)90144-9
   Cadman ET, 2008, INFECT IMMUN, V76, P3924, DOI 10.1128/IAI.00372-08
   Cavanagh DR, 1998, J IMMUNOL, V161, P347
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Coban C, 2004, INFECT IMMUN, V72, P584, DOI 10.1128/IAI.72.1.584-588.2004
   Daugherty JR, 1997, INFECT IMMUN, V65, P3631
   Dutta S, 2002, INFECT IMMUN, V70, P3101, DOI 10.1128/IAI.70.6.3101-3110.2002
   Ekstrom N, 2005, INFECT IMMUN, V73, P369, DOI 10.1128/IAI.73.1.369-377.2005
   Ferreira MU, 1996, AM J TROP MED HYG, V55, P315
   Giha HA, 2000, IMMUNOL LETT, V71, P117, DOI 10.1016/S0165-2478(99)00173-X
   Kinyanjui SM, 2003, J INFECT DIS, V187, P667, DOI 10.1086/373994
   Leoratti FMS, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-186
   Lynch MM, 2009, CLIN VACCINE IMMUNOL, V16, P293, DOI 10.1128/CVI.00230-08
   Metzger WG, 2003, PARASITE IMMUNOL, V25, P307, DOI 10.1046/j.1365-3024.2003.00636.x
   Ofori MF, 2002, INFECT IMMUN, V70, P2982, DOI 10.1128/IAI.70.6.2982-2988.2002
   Osier FHA, 2008, INFECT IMMUN, V76, P2240, DOI 10.1128/IAI.01585-07
   Polley SD, 2006, VACCINE, V24, P4233, DOI 10.1016/j.vaccine.2005.06.030
   Polley SD, 2004, VACCINE, V23, P718, DOI 10.1016/j.vaccine.2004.05.031
   Prince HE, 2001, CLIN DIAGN LAB IMMUN, V8, P904, DOI 10.1128/CDLI.8.5.904-908.2001
   RanfordCartwright LC, 1996, PARASITE IMMUNOL, V18, P411, DOI 10.1046/j.1365-3024.1996.d01-137.x
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   Suligoi B, 2003, JAIDS-J ACQ IMM DEF, V32, P424, DOI 10.1097/00126334-200304010-00012
   TAYLOR RR, 1995, INFECT IMMUN, V63, P4382
NR 28
TC 18
Z9 18
U1 0
U2 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD APR
PY 2010
VL 32
IS 4
BP 296
EP 304
DI 10.1111/j.1365-3024.2009.01193.x
PG 9
WC Immunology; Parasitology
SC Immunology; Parasitology
GA 566TJ
UT WOS:000275395800009
PM 20398230
OA No
DA 2017-08-15
ER

PT J
AU Aaby, P
   Martins, C
   Bale, C
   Garly, ML
   Rodrigues, A
   Biai, S
   Lisse, IM
   Whittle, H
   Benn, CS
AF Aaby, Peter
   Martins, Cesario
   Bale, Carlito
   Garly, May-Lill
   Rodrigues, Amabelia
   Biai, Sidu
   Lisse, Ida M.
   Whittle, Hilton
   Benn, Christine S.
TI Sex Differences in the Effect of Vaccines on the Risk of Hospitalization
   Due to Measles in Guinea-Bissau
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE BCG; diphtheria-tetanus-pertussis vaccine; measles infection; measles
   vaccine; nonspecific effects of vaccines; sex-differential effects
ID RESPIRATORY SYNCYTIAL VIRUS; FEMALE-MALE MORTALITY;
   DIPHTHERIA-TETANUS-PERTUSSIS; ROUTINE VACCINATIONS; COMMUNITY COHORT;
   PEDIATRIC WARD; IMMUNIZATION; INFECTION; RESPONSES; SURVIVAL
AB Background: Routine immunizations have non-specific and sex-differential effects on childhood mortality and morbidity in low-income countries; BCG and measles vaccine (MV) may reduce and diphtheria-tetanuspertussis vaccine (DTP) may increase the mortality of girls relative to boys.
   Setting: Urban area in Guinea-Bissau, with a demographic surveillance system and registration of all pediatric hospitalizations. Guinea-Bissau experienced a large outbreak of measles infection in 2003-2004.
   Design: We used hospital and community data to examine the impact of other vaccines on the risk of hospitalizations for measles infection. Vaccine efficacy (VE) against hospitalization for children aged 6 to 59 months of age was examined. We assessed whether VE depended on vaccination status for other vaccines and whether the pattern differed for boys and girls.
   Main Outcome Measure: Sex-specific vaccine efficacy against hospitalization for children aged 6 to 59 months of age.
   Results: The VE depended on sex and the sequence of vaccinations. The VE of MV against hospitalization for measles was better for girls than for boys. Among children who had received MV as the most recent vaccine VE against hospitalization was as high as 96% for girls, but only 81% for boys (P = 0.002). Among children who had received DTP simultaneously with MV or DTP after MV, VE declined for girls (91%) and increased for boys (90%). Compared with having received MV as most recent vaccination, DTP simultaneously with MV or DTP after MV improved the efficacy significantly for boys and the effect was significantly different for boys and girls (P = 0.023). The female-male risk ratio of hospitalization varied significantly, depending on the most recent vaccination (P = 0.014); it was 0.28 (0.11-0.68) for MV alone, but 1.21 (0.82-1.77) for DTP but no MV, and 1.13 (0.58-2.18) for DTP simultaneously with MV or after MV. Among MV-unvaccinated children, BCG-vaccinated girls had a lower risk of measles hospitalization than DTP-vaccinated girls (RR = 0.0 (0.0-0.99), exact test).
C1 [Aaby, Peter; Martins, Cesario; Bale, Carlito; Garly, May-Lill; Rodrigues, Amabelia; Biai, Sidu; Benn, Christine S.] Bandim Hlth Project, Indepth Network, Bissau, Guinea Bissau.
   [Aaby, Peter; Garly, May-Lill; Benn, Christine S.] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen, Denmark.
   [Biai, Sidu] Hosp Nacl Simao Mendes, Serv Pediat, Bissau, Guinea Bissau.
   [Lisse, Ida M.] Herlev Univ Hosp, Dept Pathol, DK-2730 Herlev, Denmark.
   [Whittle, Hilton] MRC Labs, Fajara, Gambia.
RP Aaby, P (reprint author), Bandim Hlth Project, Indepth Network, Apartado 861, Bissau, Guinea Bissau.
EM p.aaby@bandim.org
FU Danish Council for Development Research; Danish Medical Research
   Council; DANIDA; EU [ICA4-CT-2002-10053]; Novo Nordisk Foundation
FX Supported by the Danish Council for Development Research, Danish Medical
   Research Council, DANIDA and the EU Commission's INCO program
   (ICA4-CT-2002-10053). The Bandim Health Project received support from
   DANIDA. P.A. holds a research professorship grant from the Novo Nordisk
   Foundation.
CR Aaby P, 2004, VACCINE, V22, P3014, DOI 10.1016/j.vaccine.2004.02.009
   Aaby P, 2004, INT J EPIDEMIOL, V33, P367, DOI 10.1093/ije/dyh004
   AABY P, 1986, J INFECT DIS, V154, P858
   Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   Aaby P, 2002, VACCINE, V21, P15, DOI 10.1016/S0264-410X(02)00441-3
   Aaby P, 1992, Ann Epidemiol, V2, P257
   AABY P, 1984, AM J EPIDEMIOL, V120, P49
   Aaby P, 2007, PEDIATR INFECT DIS J, V26, P247, DOI 10.1097/01.inf.0000256735.05098.01
   Aaby P, 2006, PEDIATR INFECT DIS J, V25, P721, DOI 10.1097/01.inf.0000227829.64686.ae
   Akramuzzaman SM, 2002, B WORLD HEALTH ORGAN, V80, P776
   Benn CS, 2009, AM J CLIN NUTR, V90, P629, DOI 10.3945/ajcn.2009.27477
   Benn CS, 2009, INT J EPIDEMIOL, V38, P304, DOI 10.1093/ije/dyn195
   Fine PEM, 2007, TROP MED INT HEALTH, V12, P1, DOI 10.1111/j.1365-3156.2006.01794.x
   Fischer JE, 2000, J INFECT DIS, V182, P1029, DOI 10.1086/315806
   GRAHAM BS, 1993, J IMMUNOL, V151, P2032
   HUBER SA, 1994, J VIROL, V68, P5126
   Lim SS, 2008, LANCET, V372, P2031, DOI 10.1016/S0140-6736(08)61869-3
   Martins CL, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a661
   Moran TM, 1999, J INFECT DIS, V180, P579, DOI 10.1086/314952
   Pittman PR, 2002, VACCINE, V20, pS48, DOI 10.1016/S0264-410X(02)00172-X
   Prentice AM, 2009, INT J EPIDEMIOL, V38, P591, DOI 10.1093/ije/dyn363
   Rodrigues A, 2006, VACCINE, V24, P4737, DOI 10.1016/j.vaccine.2006.03.033
   Shann F, 2004, PEDIATR INFECT DIS J, V23, P555, DOI 10.1097/01.inf.0000130155.42392.04
   Stensballe LG, 2005, VACCINE, V23, P1251, DOI 10.1016/j.vaccine.2004.09.006
   Valentiner-Branth P, 2007, VACCINE, V25, P2733, DOI 10.1016/j.vaccine.2006.01.035
   Veirum JE, 2005, VACCINE, V23, P1197, DOI 10.1016/j.vaccine.2004.02.053
NR 26
TC 10
Z9 10
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD APR
PY 2010
VL 29
IS 4
BP 324
EP 328
DI 10.1097/INF.0b013e3181c15367
PG 5
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 581ZW
UT WOS:000276565600008
PM 19934785
OA No
DA 2017-08-15
ER

PT J
AU Jackson, AP
   Sanders, M
   Berry, A
   McQuillan, J
   Aslett, MA
   Quail, MA
   Chukualim, B
   Capewell, P
   MacLeod, A
   Melville, SE
   Gibson, W
   Barry, JD
   Berriman, M
   Hertz-Fowler, C
AF Jackson, Andrew P.
   Sanders, Mandy
   Berry, Andrew
   McQuillan, Jacqueline
   Aslett, Martin A.
   Quail, Michael A.
   Chukualim, Bridget
   Capewell, Paul
   MacLeod, Annette
   Melville, Sara E.
   Gibson, Wendy
   Barry, J. David
   Berriman, Matthew
   Hertz-Fowler, Christiane
TI The Genome Sequence of Trypanosoma brucei gambiense, Causative Agent of
   Chronic Human African Trypanosomiasis
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID VSG EXPRESSION SITE; PLASMODIUM-FALCIPARUM; ANTIGENIC VARIATION;
   SLEEPING SICKNESS; PHYLOGENETIC NETWORKS; GENE REPERTOIRES; RHODESIENSE;
   RESISTANCE; SERUM; RECOMBINATION
AB Background: Trypanosoma brucei gambiense is the causative agent of chronic Human African Trypanosomiasis or sleeping sickness, a disease endemic across often poor and rural areas of Western and Central Africa. We have previously published the genome sequence of a T. b. brucei isolate, and have now employed a comparative genomics approach to understand the scale of genomic variation between T. b. gambiense and the reference genome. We sought to identify features that were uniquely associated with T. b. gambiense and its ability to infect humans.
   Methods and Findings: An improved high-quality draft genome sequence for the group 1 T. b. gambiense DAL 972 isolate was produced using a whole-genome shotgun strategy. Comparison with T. b. brucei showed that sequence identity averages 99.2% in coding regions, and gene order is largely collinear. However, variation associated with segmental duplications and tandem gene arrays suggests some reduction of functional repertoire in T. b. gambiense DAL 972. A comparison of the variant surface glycoproteins (VSG) in T. b. brucei with all T. b. gambiense sequence reads showed that the essential structural repertoire of VSG domains is conserved across T. brucei.
   Conclusions: This study provides the first estimate of intraspecific genomic variation within T. brucei, and so has important consequences for future population genomics studies. We have shown that the T. b. gambiense genome corresponds closely with the reference, which should therefore be an effective scaffold for any T. brucei genome sequence data. As VSG repertoire is also well conserved, it may be feasible to describe the total diversity of variant antigens. While we describe several as yet uncharacterized gene families with predicted cell surface roles that were expanded in number in T. b. brucei, no T. b. gambiense-specific gene was identified outside of the subtelomeres that could explain the ability to infect humans.
C1 [Jackson, Andrew P.; Sanders, Mandy; Berry, Andrew; McQuillan, Jacqueline; Aslett, Martin A.; Quail, Michael A.; Berriman, Matthew; Hertz-Fowler, Christiane] Wellcome Trust Sanger Inst, Cambridge, England.
   [Chukualim, Bridget] Int Trypanotolerance Ctr, Banjul, Gambia.
   [Capewell, Paul; MacLeod, Annette; Barry, J. David] Univ Glasgow, Glasgow Biomed Res Ctr, Wellcome Ctr Mol Parasitol, Glasgow, Lanark, Scotland.
   [Gibson, Wendy] Univ Bristol, Sch Biol Sci, Bristol, Avon, England.
RP Jackson, AP (reprint author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge, England.
EM chf@sanger.ac.uk
RI Berriman, Matthew/A-7618-2011; Gibson, Wendy/E-4182-2014
OI Jackson, Andrew Paul/0000-0002-5704-8596
FU Wellcome Trust [WT085775/Z/08/Z]
FX The genome sequencing and annotation work was funded by the Wellcome
   Trust (grant number WT085775/Z/08/Z). The funder had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Altshuler D, 2000, NATURE, V407, P513
   Aslett M, 2010, NUCLEIC ACIDS RES, V38, pD457, DOI 10.1093/nar/gkp851
   Barry JD, 2003, INT J PARASITOL, V33, P29, DOI 10.1016/S0020-7519(02)00247-3
   Benz C, 2005, MOL BIOCHEM PARASIT, V143, P125, DOI 10.1016/j.molbiopara.2005.05.008
   Berberof M, 2001, MOL BIOCHEM PARASIT, V113, P127, DOI 10.1016/S0166-6851(01)00208-0
   Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642
   Borst P, 2001, MOL BIOCHEM PARASIT, V114, P17, DOI 10.1016/S0166-6851(01)00243-2
   Bruen TC, 2006, GENETICS, V172, P2665, DOI 10.1534/genetics.105.048975
   Bryant D, 2004, MOL BIOL EVOL, V21, P255, DOI 10.1093/molbev/msh018
   Bull PC, 2008, MOL MICROBIOL, V68, P1519, DOI 10.1111/j.1365-2958.2008.06248.x
   Callejas S, 2006, GENOME RES, V16, P1109, DOI 10.1101/gr.5147406
   Carver T, 2008, BIOINFORMATICS, V24, P2672, DOI 10.1093/bioinformatics/btn529
   DEGREEF C, 1994, MOL BIOCHEM PARASIT, V68, P277, DOI 10.1016/0166-6851(94)90172-4
   DEGREEF C, 1992, ANN SOC BELG MED TR, V72, P13
   DERO B, 1987, MOL BIOCHEM PARASIT, V26, P247, DOI 10.1016/0166-6851(87)90077-6
   DUKES P, 1989, T ROY SOC TROP MED H, V83, P636, DOI 10.1016/0035-9203(89)90379-9
   Faulkner SD, 2006, EUKARYOT CELL, V5, P1276, DOI 10.1128/EC.00116-06
   Felu C, 2007, AM J TROP MED HYG, V76, P922
   Fevre EM, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000333
   Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531
   GIBSON W C, 1986, Parasitology Today, V2, P255, DOI 10.1016/0169-4758(86)90011-6
   Goldovsky Leon, 2005, Appl Bioinformatics, V4, P71, DOI 10.2165/00822942-200504010-00009
   GRAY AR, 1972, T ROY SOC TROP MED H, V66, P263, DOI 10.1016/0035-9203(72)90158-7
   Hertz-Fowler C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003527
   Horn D, 2004, CURR MOL MED, V4, P563, DOI 10.2174/1566524043360078
   Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030
   Hutchinson OC, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-234
   Jackson AP, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-54
   JACKSON AP, 2009, GENOME RES      0910
   Kanmogne GD, 1997, ACTA TROP, V63, P75, DOI 10.1016/S0001-706X(96)00600-6
   POSADA D., 2006, BIOINFORMATICS, V22, P3096, DOI DOI 10.1093/BI0INF0RMATICS/BTL474
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Lowell JE, 2009, NAT BIOTECHNOL, V27, P323, DOI 10.1038/nbt0409-323
   Marcello L, 2007, GENOME RES, V17, P1344, DOI 10.1101/gr.6421207
   Pain A, 2008, NATURE, V455, P799, DOI 10.1038/nature07306
   PAINDAVOINE P, 1986, EMBO J, V5, P3631
   PAYS E, 1983, MOL BIOCHEM PARASIT, V7, P63, DOI 10.1016/0166-6851(83)90117-2
   Pays E, 2007, TRYPANOSOMES GENOME, P339
   Pays E, 2008, MICROBES INFECT, V10, P985, DOI 10.1016/j.micinf.2008.07.020
   Peacock CS, 2007, NAT GENET, V39, P839, DOI 10.1038/ng2053
   Perez-Morga D, 2005, SCIENCE, V309, P469, DOI 10.1126/science.1114566
   Priotto G, 2009, LANCET, V374, P56, DOI 10.1016/S0140-6736(09)61117-X
   Radwanska M, 2002, AM J TROP MED HYG, V67, P684
   Scherf A, 2008, ANNU REV MICROBIOL, V62, P445, DOI 10.1146/annurev.micro.61.080706.093134
   Simarro PP, 2008, PLOS MED, V5, P174, DOI 10.1371/journal.pmed.0050055
   Tami A, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-7
   Taylor JE, 2006, TRENDS GENET, V22, P614, DOI 10.1016/j.tig.2006.08.003
   Van Nieuwenhove S, 2000, B WORLD HEALTH ORGAN, V78, P1283
   Vanhollebeke B, 2008, SCIENCE, V320, P677, DOI 10.1126/science.1156296
   WHO, 1998, CONTR SURV AFR TRYP
   Xong HV, 1998, CELL, V95, P839
   Young R, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-385
NR 52
TC 61
Z9 68
U1 3
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2727
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD APR
PY 2010
VL 4
IS 4
AR e658
DI 10.1371/journal.pntd.0000658
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 590PX
UT WOS:000277240400016
PM 20404998
OA gold
DA 2017-08-15
ER

PT J
AU Auburn, S
   Fry, AE
   Clark, TG
   Campino, S
   Diakite, M
   Green, A
   Richardson, A
   Jallow, M
   Sisay-Joof, F
   Pinder, M
   Molyneux, ME
   Taylor, TE
   Haldar, K
   Rockett, KA
   Kwiatkowski, DP
AF Auburn, Sarah
   Fry, Andrew E.
   Clark, Taane G.
   Campino, Susana
   Diakite, Mahamadou
   Green, Angela
   Richardson, Anna
   Jallow, Muminatou
   Sisay-Joof, Fatou
   Pinder, Margaret
   Molyneux, Malcolm E.
   Taylor, Terrie E.
   Haldar, Kasturi
   Rockett, Kirk A.
   Kwiatkowski, Dominic P.
TI Further Evidence Supporting a Role for Gs Signal Transduction in Severe
   Malaria Pathogenesis
SO PLOS ONE
LA English
DT Article
ID G-PROTEIN BETA-3-SUBUNIT; ADENOSINE RECEPTORS; ADENYLYL-CYCLASE; ETHNIC
   DISTRIBUTION; BLOOD-PRESSURE; ASSOCIATION; GENE; POLYMORPHISM;
   HYPERTENSION; HAPLOTYPES
AB With the functional demonstration of a role in erythrocyte invasion by Plasmodium falciparum parasites, implications in the aetiology of common conditions that prevail in individuals of African origin, and a wealth of pharmacological knowledge, the stimulatory G protein (Gs) signal transduction pathway presents an exciting target for anti-malarial drug intervention. Having previously demonstrated a role for the G-alpha-s gene, GNAS, in severe malaria disease, we sought to identify other important components of the Gs pathway. Using meta-analysis across case-control and family trio (affected child and parental controls) studies of severe malaria from The Gambia and Malawi, we sought evidence of association in six Gs pathway candidate genes: adenosine receptor 2A (ADORA2A) and 2B (ADORA2B), beta-adrenergic receptor kinase 1 (ADRBK1), adenylyl cyclase 9 (ADCY9), G protein beta subunit 3 (GNB3), and regulator of G protein signalling 2 (RGS2). Our study amassed a total of 2278 cases and 2364 controls. Allele-based models of association were investigated in all genes, and genotype and haplotype-based models were investigated where significant allelic associations were identified. Although no significant associations were observed in the other genes, several were identified in ADORA2A. The most significant association was observed at the rs9624472 locus, where the G allele (similar to 20% frequency) appeared to confer enhanced risk to severe malaria [OR = 1.22 (1.09-1.37); P = 0.001]. Further investigation of the ADORA2A gene region is required to validate the associations identified here, and to identify and functionally characterize the responsible causal variant(s). Our results provide further evidence supporting a role of the Gs signal transduction pathway in the regulation of severe malaria, and request further exploration of this pathway in future studies.
C1 [Auburn, Sarah; Fry, Andrew E.; Campino, Susana; Diakite, Mahamadou; Green, Angela; Richardson, Anna; Rockett, Kirk A.; Kwiatkowski, Dominic P.] Wellcome Trust Ctr Human Genet, Oxford, England.
   [Jallow, Muminatou; Sisay-Joof, Fatou; Pinder, Margaret] MRC, Banjul, Gambia.
   [Auburn, Sarah; Clark, Taane G.; Campino, Susana; Rockett, Kirk A.; Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Hinxton, England.
   [Molyneux, Malcolm E.] Coll Med, Malawi Liverpool Wellcome Trust Programme Clin Tr, Blantyre, Malawi.
   [Molyneux, Malcolm E.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   [Taylor, Terrie E.] Univ Malawi, Coll Med, Blantyre Malaria Project, Blantyre, Malawi.
   [Taylor, Terrie E.] Michigan State Univ, Dept Internal Med, Coll Osteopath Med, E Lansing, MI 48824 USA.
   [Haldar, Kasturi] Univ Notre Dame, Ctr Rare & Neglected Dis, South Bend, IN USA.
RP Auburn, S (reprint author), Wellcome Trust Ctr Human Genet, Oxford, England.
EM sa3@sanger.ac.uk
RI Haldar, Kasturi/C-6685-2014
OI Kwiatkowski, Dominic/0000-0002-5023-0176; Auburn,
   Sarah/0000-0002-4638-536X
FU Medical Research Council (UK); National Institutes of Health (USA)
   [5R01AI034969-09]; Wellcome Trust Training Fellowship; Bill and Melinda
   Gates Foundation; Marie-Curie intra-European fellowship; International
   Atomic Energy Agency
FX The genetic component of this research was funded by a Medical Research
   Council (UK) (http://www.mrc.ac.uk/index.htm) grant to Prof. Dominic
   Kwiatkowski and a National Institutes of Health
   (USA)(http://www.nih.gov/) grant to Prof. Kasturi Haldar. SA was
   supported by a PhD studentship from the Medical Research council (UK)
   (http://www.mrc.ac.uk/index.htm). AEF was funded by a Wellcome Trust
   Training Fellowship (http://www.wellcome.ac.uk/). TC was funded by the
   Bill and Melinda Gates Foundation
   (http://www.gatesfoundation.org/Pages/home.aspx). SC was funded by a
   Marie-Curie intra-European fellowship (FP6)
   (http://cordis.europa.eu/mariecurie-actions/eif/home.html). MD was
   supported by a training fellowship from the International Atomic Energy
   Agency (http://www.iaea.org/). Sample collection in Malawi was supported
   by NIH grant 5R01AI034969-09 (http://www.nih.gov/). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Aidoo M, 2002, LANCET, V359, P1311, DOI 10.1016/S0140-6736(02)08273-9
   Auburn S, 2008, HUM GENET, V124, P499, DOI 10.1007/s00439-008-0575-8
   BRUNS RF, 1986, MOL PHARMACOL, V29, P331
   Cowman AF, 2006, CELL, V124, P755, DOI 10.1016/j.cell.2006.02.006
   Dong YB, 2004, PHARMACOGENETICS, V14, P419, DOI 10.1097/01.fpc.0000114748.08559.ad
   Fredholm BB, 2001, PHARMACOL REV, V53, P527
   Gonzalez JM, 2005, ENVIRON MICROBIOL, V7, P1024, DOI 10.1111/j.1462-2920.2005.00779.x
   GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7
   Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669
   Hanchard NA, 2006, AM J HUM GENET, V78, P153, DOI 10.1086/499252
   Harrison T, 2003, SCIENCE, V301, P1734, DOI 10.1126/science.1089324
   Hasko G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Jackson EK, 2008, HYPERTENSION, V51, P719, DOI 10.1161/HYPERTENSIONAHA.107.096297
   Kazeem GR, 2005, ANN HUM GENET, V69, P329, DOI 10.1046/j.1529-8817.2005.00156.x
   Langhorne J, 2008, NAT IMMUNOL, V9, P725, DOI 10.1038/ni.f.205
   Ledent C, 1997, NATURE, V388, P674
   Liclican EL, 2005, AM J PHYSIOL-RENAL, V289, pF386, DOI 10.1152/ajprenal.00421.2004
   Liclican EL, 2008, AM J PHYSIOL-RENAL, V295, pF1696, DOI 10.1152/ajprenal.90502.2008
   Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775
   Metaye T, 2005, CELL SIGNAL, V17, P917, DOI 10.1016/j.cellsig.2005.01.002
   MILLER LH, 1994, P NATL ACAD SCI USA, V91, P2415, DOI 10.1073/pnas.91.7.2415
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Murphy SC, 2006, PLOS MED, V3, P2403, DOI 10.1371/journal.pmed.0030528
   NETWORK MGE, 2008, NATURE, V456, P732
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Riddle EL, 2006, HYPERTENSION, V47, P415, DOI 10.1161/01.HYP.0000200714.81990.61
   Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795
   Rosskopf D, 2002, PHARMACOGENETICS, V12, P209, DOI 10.1097/00008571-200204000-00005
   Roy AA, 2006, CELL SIGNAL, V18, P336, DOI 10.1016/j.cellsig.2005.05.004
   Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140
   Siffert W, 1999, J AM SOC NEPHROL, V10, P1921
   Siffert W, 1998, NAT GENET, V18, P45, DOI 10.1038/ng0198-45
   Small KM, 2003, PHARMACOGENETICS, V13, P535, DOI 10.1097/01.fpc.0000054119.14659.01
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Tang CM, 2005, PHARMACOGENET GENOM, V15, P321
   Tantisira KG, 2005, HUM MOL GENET, V14, P1671, DOI 10.1093/hmg/ddi175
   Teo YY, 2009, HUM HERED, V67, P26, DOI 10.1159/000164396
   Thompson Miles D., 2008, V448, P77, DOI 10.1007/978-1-59745-205-2_6
   Wright S., 1986, EVOLUTION SELECTED P
NR 40
TC 8
Z9 8
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 1
PY 2010
VL 5
IS 3
AR e10017
DI 10.1371/journal.pone.0010017
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 580AG
UT WOS:000276418200065
PM 20386734
OA gold
DA 2017-08-15
ER

PT J
AU Secka, A
   Grimm, F
   Victor, B
   Marcotty, T
   De Deken, R
   Nyan, O
   Herera, O
   Van Marck, E
   Geerts, S
AF Secka, A.
   Grimm, F.
   Victor, B.
   Marcotty, T.
   De Deken, R.
   Nyan, O.
   Herera, O.
   Van Marck, E.
   Geerts, S.
TI Epilepsy is not caused by cysticercosis in The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE The Gambia; neurocysticercosis; antigen-ELISA; electro-immunotransfer
   blot; computed tomography; epilepsy; case-control study
ID LINKED IMMUNOELECTROTRANSFER BLOT; TAENIA-SOLIUM CYSTICERCOSIS;
   NEUROCYSTICERCOSIS; ANTIGENS; SEROPREVALENCE; BURUNDI; AFRICA; ELISA;
   ASSAY; SERUM
AB OBJECTIVE To determine whether epilepsy is caused by Taenia solium cysticercosis in The Gambia.
   METHODS Case-control study testing samples collected from 210 people with epilepsy and 420 matched controls by sex and age +/- 5 years from 69 different places around the country during the period October 2008-March 2009. All serum samples were subjected to an antigen detection ELISA (Ag-ELISA) and electro-immunotransfer blot (EITB), and the seropositives were further CT-scanned to determine the presence of cysticerci in the brain.
   RESULTS Although not significantly different (P = 0.668), circulating Taenia antigen was found by Ag-ELISA in 1.4% (95% CI: 0.3-4.1) of people with epilepsy and in 1.9% (95% CI: 0.8-3.7) of the controls. A non-significant (P = 0.4718) odds ratio of association 0.75 (95% CI: 0.13-3.15) between epilepsy and the presence of Taenia antigens was found. All 630 serum samples turned out seronegative by the EITB test. There were no intracranial cysts or cyst-like structures detected among the nine CT-scanned Ag-ELISA seropositives.
   CONCLUSION Epilepsy appears not to be caused by cysticercosis in The Gambia.
C1 [Victor, B.; Marcotty, T.; De Deken, R.; Geerts, S.] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium.
   [Secka, A.] Int Trypanotolerance Ctr, Banjul, Gambia.
   [Grimm, F.] Univ Zurich, Inst Parasitol, CH-8057 Zurich, Switzerland.
   [Nyan, O.; Herera, O.] Royal Victoria Teaching Hosp, Banjul, Gambia.
   [Van Marck, E.] Univ Antwerp, Pathol Lab, B-2020 Antwerp, Belgium.
RP Geerts, S (reprint author), Inst Trop Med, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.
EM s.geerts@itg.be
FU Flemish Inter-University Council (VLIR, Brussels, Belgium)
FX This study was funded by the Flemish Inter-University Council (VLIR,
   Brussels, Belgium). The help offered by the neurologist and radiologist
   at RVTH, the psychiatric unit staff at the polyclinic unit of RVTH and
   the technical/administrative staffs of ITC is gratefully acknowledged.
   The participation of the Gambia Epilepsy Association and study
   volunteers was very much appreciated.
CR BRANDT JRA, 1992, INT J PARASITOL, V22, P471, DOI 10.1016/0020-7519(92)90148-E
   Carabin H, 2006, TROP MED INT HEALTH, V11, P906, DOI 10.1111/j.1365-3156.2006.01627.x
   Carpio A, 2002, NEUROLOGY, V59, P1730
   Erhart A, 2002, T ROY SOC TROP MED H, V96, P270, DOI 10.1016/S0035-9203(02)90095-7
   Garcia HH, 2000, T ROY SOC TROP MED H, V94, P673, DOI 10.1016/S0035-9203(00)90228-1
   Garcia HH, 2003, LANCET, V362, P547, DOI 10.1016/S0140-6736(03)14117-7
   Houinato D, 1998, T ROY SOC TROP MED H, V92, P621, DOI 10.1016/S0035-9203(98)90785-4
   International League Against Epilepsy (ILAE), 1989, EPILEPSIA, V30, P389, DOI DOI 10.1111/J.1528-1157.1989.TB05316.X
   Nash T.E., 2005, WHO FAO OIE GUIDELIN, P11
   Nguekam, 2003, PARASITE, V10, P65
   NORLINAH I, 2003, NEUROL J S E ASIA, V8, P45
   Nsengiyumva G, 2003, EPILEPSIA, V44, P950, DOI 10.1046/j.1528-1157.2003.55302.x
   Prado-Jean A, 2007, TROP MED INT HEALTH, V12, P895, DOI 10.1111/j.1365-3156.2007.01860.x
   Preux PM, 2005, LANCET NEUROL, V4, P21, DOI 10.1016/S1474-4422(04)00963-9
   Rodriguez S, 2009, J INFECT DIS, V199, P1345, DOI 10.1086/597757
   Sokal RR, 1981, BIOMETRY, P229
   TSANG VCW, 1989, J INFECT DIS, V159, P50
   Vondou L, 2002, PARASITE, V9, P271
   WILSON M, 1991, J INFECT DIS, V164, P1007
NR 19
TC 8
Z9 8
U1 1
U2 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD APR
PY 2010
VL 15
IS 4
BP 476
EP 479
DI 10.1111/j.1365-3156.2010.02470.x
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 568NY
UT WOS:000275530600012
PM 20180937
OA No
DA 2017-08-15
ER

PT J
AU Roth, AE
   Benn, CS
   Ravn, H
   Rodrigues, A
   Lisse, IM
   Yazdanbakhsh, M
   Whittle, H
   Aaby, P
AF Roth, Adam Edvin
   Benn, Christine Stabell
   Ravn, Henrik
   Rodrigues, Amabelia
   Lisse, Ida Maria
   Yazdanbakhsh, Maria
   Whittle, Hilton
   Aaby, Peter
TI Effect of revaccination with BCG in early childhood on mortality:
   randomised trial in Guinea-Bissau
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID VITAMIN-A SUPPLEMENTATION; DIPHTHERIA-TETANUS-PERTUSSIS; FEMALE-MALE
   MORTALITY; ROUTINE VACCINATIONS; MEASLES IMMUNIZATION; TUBERCULIN
   REACTION; WEST-AFRICA; VACCINE; CHILDREN; SURVIVAL
AB Objective To determine whether BCG revaccination at 19 months of age reduces overall child mortality.
   Design Randomised trial, with follow-up to age 5.
   Setting A health project in Bissau, Guinea-Bissau, which maintains a health and demographic surveillance system in an urban area with 90 000 inhabitants.
   Participants 2871 children aged 19 months to 5 years with low or no reactivity to tuberculin and who were not severely sick on the day of enrolment. Intervention BCG vaccination or no vaccination (control).
   Main outcome measure Hazard ratios for mortality.
   Results 77 children died during follow-up. Compared with controls, the BCG revaccinated children had a hazard ratio of 1.20 (95% confidence interval 0.77 to 1.89). Two hundred and fifty children were admitted to hospital for the first time between enrolment and the end of the study, with an incidence rate ratio for BCG revaccinated children versus controls of 1.04 (0.81 to 1.33). The trial was stopped prematurely because of a cluster of deaths in the BCG arm of the study. This increase in mortality occurred at a time when many children had received missing vaccinations or vitamin A or iron supplementation; the hazard ratio for BCG revaccinated children compared with controls was 2.69 (1.05 to 6.88) in the period after these campaigns. Throughout the trial, the effect of BCG revaccination on mortality was significantly different (P=0.006) in children who had received diphtheria-tetanus-pertussis (DTP) booster vaccination before enrolment (hazard ratio 0.36, 0.13 to 0.99) and children who had not received the booster before enrolment (1.78, 1.04 to 3.04).
   Conclusions There was no overall beneficial effect of being revaccinated with BCG. The effect of BCG revaccination on mortality might depend on other health interventions.
C1 [Benn, Christine Stabell; Ravn, Henrik; Aaby, Peter] Statens Serum Inst, Bandim Hlth Project, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen S, Denmark.
   [Roth, Adam Edvin; Rodrigues, Amabelia; Aaby, Peter] Indepth Network, Bandim Hlth Project, Bissau, Guinea Bissau.
   [Roth, Adam Edvin] Lund Univ, Dept Med Microbiol, S-20502 Malmo, Sweden.
   [Lisse, Ida Maria] Herlev Univ Hosp, Dept Pathol, DK-2730 Herlev, Denmark.
   [Yazdanbakhsh, Maria] Leiden Univ, Dept Parasitol, NL-2300 RA Leiden, Netherlands.
   [Whittle, Hilton] MRC Labs, Fajara, Gambia.
RP Aaby, P (reprint author), Statens Serum Inst, Bandim Hlth Project, Danish Epidemiol Sci Ctr, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
EM p.aaby@bandim.org
FU EU [ICA4-CT-2002-10053]; Danish National Research Foundation; DANIDA;
   Novo Nordisk Foundation
FX The study was funded by the EU (ICA4-CT-2002-10053) and the Danish
   National Research Foundation. The Bandim Health Project received support
   from DANIDA. PA holds a research professorship grant from the Novo
   Nordisk Foundation. The funding agencies had no role in the study
   design, data collection, data analysis, data interpretation, or the
   writing of the report.
CR Aaby P, 2006, VACCINE, V24, P4701, DOI 10.1016/j.vaccine.2006.03.038
   Aaby P, 2004, INT J EPIDEMIOL, V33, P374, DOI 10.1093/ije/dyh005
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   Aaby P, 2002, VACCINE, V21, P15, DOI 10.1016/S0264-410X(02)00441-3
   Aaby P, 2007, PEDIATR INFECT DIS J, V26, P247, DOI 10.1097/01.inf.0000256735.05098.01
   Andersen P. K., 1993, STAT MODELS BASED CO
   ARONSON JD, 1948, AM REV TUBERC PULM, V58, P255
   Aydinlioglu H, 1993, Paediatr Perinat Epidemiol, V7, P334, DOI 10.1111/j.1365-3016.1993.tb00408.x
   Benn CS, 2009, AM J CLIN NUTR, V90, P629, DOI 10.3945/ajcn.2009.27477
   Benn CS, 2008, BRIT MED J, V336, P1416, DOI 10.1136/bmj.39542.509444.AE
   Benn CS, 2009, VACCINE, V27, P2891, DOI 10.1016/j.vaccine.2009.02.080
   Benn CS, 2009, INT J EPIDEMIOL, V38, P304, DOI 10.1093/ije/dyn195
   Benn CS, 2005, BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55
   Benn CS, 2003, INT J EPIDEMIOL, V32, P822, DOI 10.1093/ije/dyg208
   Breiman RF, 2004, LANCET, V364, P2204, DOI 10.1016/S0140-6736(04)17593-4
   da Silva ZJ, 2008, AIDS, V22, P1195, DOI 10.1097/QAD.0b013e328300a33d
   Fine PEM, 1996, LANCET, V348, P17
   Fisker AB, 2007, AM J CLIN NUTR, V86, P1032
   FOURIE PB, 1987, S AFR MED J, V72, P323
   Garly ML, 2004, PEDIATR INFECT DIS J, V23, P1086, DOI 10.1097/01.inf.0000145700.77286.94
   Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6
   Gustafson P, 2004, INT J EPIDEMIOL, V33, P163, DOI 10.1093/ije/dyh026
   Gustafson P, 2001, JAMA-J AM MED ASSOC, V286, P599, DOI 10.1001/jama.286.5.599
   Hesseling AC, 2006, CLIN INFECT DIS, V42, P548, DOI 10.1086/499953
   Ildirim I, 1995, PEDIATR INFECT DIS J, V14, P1060, DOI 10.1097/00006454-199512000-00006
   Jensen H, 2007, TROP MED INT HEALTH, V12, P5, DOI 10.1111/j.1365-3156.2006.01773.x
   Knudsen KM, 1996, INT J EPIDEMIOL, V25, P665, DOI 10.1093/ije/25.3.665
   Kohl KS, 2007, VACCINE, V25, P5821, DOI 10.1016/j.vaccine.2007.04.057
   LEVINE MI, 1946, AM REV TUBERC PULM, V53, P517
   Martins CL, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a661
   *MED RES COUNC TUB, 1959, BRIT MED J, V2, P379
   NAESLUND C, 1932, RESULTATS EXPERIENCE
   Rahman M, 2002, PREV MED, V35, P70, DOI 10.1006/pmed.2002.1043
   Rodrigues A, 2008, TROP MED INT HEALTH, V13, P410, DOI 10.1111/j.1365-3156.2008.02016.x
   Rodrigues A, 2007, TROP MED INT HEALTH, V12, P224, DOI 10.1111/j.1365-3165.2006.01766.x
   Rodrigues LC, 2005, LANCET, V366, P1290, DOI 10.1016/S0140-6736(05)67145-0
   ROSENTHAL S, 1961, AM REV RESPIR DIS, V84, P690
   Roth A, 2005, INT J EPIDEMIOL, V34, P540, DOI 10.1093/ije/dyh393
   Roth A, 2006, EXPERT REV VACCINES, V5, P277, DOI 10.1586/14760584-5.2.277
   Roth A, 2006, EPIDEMIOLOGY, V17, P562, DOI 10.1097/01.ede.0000231546.14749.ab
   Seng R, 2002, AIDS, V16, P1059, DOI 10.1097/00002030-200205030-00013
   Sergent E., 1960, ARCH I PASTEUR ALGER, V38, P131
   SERGENT EDMOND, 1954, ARCH INST PASTEUR ALGERIE, V32, P1
   SHAABAN MA, 1990, EUR RESPIR J, V3, P187
   Tala-Heikkila M, 1991, Bull Int Union Tuberc Lung Dis, V66, P57
   Veirum JE, 2005, VACCINE, V23, P1197, DOI 10.1016/j.vaccine.2004.02.053
NR 47
TC 39
Z9 39
U1 0
U2 2
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-535X
J9 BRIT MED J
JI Br. Med. J.
PD MAR 15
PY 2010
VL 340
AR c671
DI 10.1136/bmj.c671
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 573RA
UT WOS:000275931100010
PM 20231251
OA No
DA 2017-08-15
ER

PT J
AU Benn, CS
   Fisker, AB
   Napirna, BM
   Roth, A
   Diness, BR
   Lausch, KR
   Ravn, H
   Yazdanbakhsh, M
   Rodrigues, A
   Whittle, H
   Aaby, P
AF Benn, Christine Stabell
   Fisker, Ane Baerent
   Napirna, Bitiguida Mutna
   Roth, Adam
   Diness, Birgitte Rode
   Lausch, Karen Rokkedal
   Ravn, Henrik
   Yazdanbakhsh, Maria
   Rodrigues, Amabelia
   Whittle, Hilton
   Aaby, Peter
TI Vitamin A supplementation and BCG vaccination at birth in low
   birthweight neonates: two by two factorial randomised controlled trial
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID INFANT-MORTALITY; GUINEA-BISSAU; MORBIDITY; SEX; AGE; SURVIVAL;
   NEWBORNS; VACCINES; IMPACT; MO
AB Objective To investigate the effect of vitamin A supplementation and BCG vaccination at birth in low birthweight neonates.
   Design Randomised, placebo controlled, two by two factorial trial.
   Setting Bissau, Guinea-Bissau.
   Participants 1717 low birthweight neonates born at the national hospital.
   Intervention Neonates who weighed less than 2.5 kg were randomly assigned to 25 000 IU vitamin A or placebo, as well as to early BCG vaccine or the usual late BCG vaccine, and were followed until age 12 months.
   Main outcome measure Mortality, calculated as mortality rate ratios (MRRs), after follow-up to 12 months of age for infants who received vitamin A supplementation compared with those who received placebo.
   Results No interaction was observed between vitamin A supplementation and BCG vaccine allocation (P=0.73). Vitamin A supplementation at birth was not significantly associated with mortality: the MRR of vitamin A supplementation compared with placebo, controlled for randomisation to "early BCG" versus "no early BCG" was 1.08 (95% CI 0.79 to 1.47). Stratification by sex revealed a significant interaction between vitamin A supplementation and sex (P=0.046), the MRR of vitamin A supplementation being 0.74 ( 95% CI 0.45 to 1.22) in boys and 1.42 (95% CI 0.94 to 2.15) in girls. When these data were combined with data from a complementary trial among normal birthweight neonates in Guinea-Bissau, the combined estimate of the effect of neonatal vitamin A supplementation on mortality was 1.08 ( 95% CI 0.87 to 1.33); 0.80 ( 95% CI 0.58 to 1.10) in boys and 1.41 ( 95% CI 1.04 to 1.90) in girls (P=0.01 for interaction between neonatal vitamin A and sex).
   Conclusions The combined results of this trial and the complementary trial among normal birthweight neonates have now shown that, overall, it would not be beneficial to implement a neonatal vitamin A supplementation policy in Guinea-Bissau. Worryingly, the trials show that vitamin A supplementation at birth can be harmful in girls. Previous studies and future trials should investigate the possibility that vitamin A supplementation has sex differential effects.
C1 [Benn, Christine Stabell; Ravn, Henrik; Aaby, Peter] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen S, Denmark.
   [Benn, Christine Stabell; Fisker, Ane Baerent; Diness, Birgitte Rode; Lausch, Karen Rokkedal; Rodrigues, Amabelia; Aaby, Peter] Indepth Network, Bandim Hlth Project, Bissau, Guinea Bissau.
   [Napirna, Bitiguida Mutna] Hosp Nacl Simao Mendes, Bissau, Guinea Bissau.
   [Roth, Adam] Lund Univ, Dept Med Microbiol, Malmo, Sweden.
   [Yazdanbakhsh, Maria] Leiden Univ, Dept Parasitol, Leiden, Netherlands.
   [Whittle, Hilton] MRC Labs, Fajara, Gambia.
RP Benn, CS (reprint author), Statens Serum Inst, Bandim Hlth Project, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
EM cb@ssi.dk
OI Fisker, Ane/0000-0002-8521-0992
FU EU [ICA4-CT-2002-10053]; Danish Medical Research Council, University of
   Copenhagen, March of Dimes; Ville Heise Foundation; DANIDA; Danish
   National Research Foundation; Novo Nordisk Foundation
FX The study was funded by the EU (ICA4-CT-2002-10053), the Danish Medical
   Research Council, University of Copenhagen, March of Dimes, and the
   Ville Heise Foundation. The Bandim Health Project received support from
   DANIDA and the Danish National Research Foundation. PA holds a research
   professorship grant from the Novo Nordisk Foundation. The funding
   agencies had no role in the study design, in the data collection,
   analysis, and interpretation, or in the writing of the report.
CR Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   Abrams SA, 2008, PEDIATRICS, V122, P180, DOI 10.1542/peds.2008-0455
   Benn CS, 2009, AM J CLIN NUTR, V90, P629, DOI 10.3945/ajcn.2009.27477
   Benn CS, 2008, VACCINE, V26, P4111, DOI 10.1016/j.vaccine.2008.04.021
   Benn CS, 2008, BRIT MED J, V336, P1416, DOI 10.1136/bmj.39542.509444.AE
   Benn Christine Stabell, 2008, PLoS One, V3, pe4056, DOI 10.1371/journal.pone.0004056
   Benn CS, 2009, VACCINE, V27, P2891, DOI 10.1016/j.vaccine.2009.02.080
   Benn CS, 2009, INT J EPIDEMIOL, V38, P586, DOI 10.1093/ije/dyn364
   Benn CS, 2009, INT J EPIDEMIOL, V38, P304, DOI 10.1093/ije/dyn195
   Benn CS, 2005, BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55
   Benn CS, 2008, BMJ
   Cox D. R., 1984, ANAL SURVIVAL DATA
   Darlow BA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000501.pub2
   FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898
   Fisker AB, 2007, AM J CLIN NUTR, V86, P1032
   Gogia S, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b919
   Humphrey Jean H, 2006, J Infect Dis, V193, P860, DOI 10.1086/500366
   Humphrey JH, 1996, J PEDIATR-US, V128, P489, DOI 10.1016/S0022-3476(96)70359-1
   Klemm RDW, 2008, PEDIATRICS, V122, pE242, DOI 10.1542/peds.2007-3448
   Malaba LC, 2005, AM J CLIN NUTR, V81, P454
   Martins CL, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a661
   Newton S, 2005, J NUTR, V135, P2669
   Newton S, 2008, VACCINE, V26, P6608, DOI 10.1016/j.vaccine.2008.09.037
   Rahmathullah L, 2003, BRIT MED J, V327, P254, DOI 10.1136/bmj.327.7409.254
   Sachdev HPS, 2008, LANCET, V371, P1746, DOI 10.1016/S0140-6736(08)60750-3
   Benn CS, 2006, J INFECT DIS, V194, P719
   Tielsch JM, 2008, BRIT MED J, V336, P1385, DOI 10.1136/bmj.39575.486609.80
   Tielsch JM, 2008, SIGHT LIFE MAGAZINE, V2, P22
   Tolba AM, 1998, J TROP PEDIATRICS, V44, P174, DOI 10.1093/tropej/44.3.174
   WEST KP, 1995, AM J CLIN NUTR, V62, P143
   [Anonymous], GLOB PREV VIT A DEF
   *WHO UNICEF VACG, 1997, VIT A SUPPL GUID THE
   YASSAI MB, 1989, J TROP PEDIATRICS, V35, P247
   2008, WHO TECHN CONS NEON
NR 34
TC 66
Z9 67
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-535X
J9 BRIT MED J
JI Br. Med. J.
PD MAR 9
PY 2010
VL 340
AR c1101
DI 10.1136/bmj.c1101
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 570FC
UT WOS:000275656700001
PM 20215360
OA No
DA 2017-08-15
ER

PT J
AU Ideh, RC
   Rodrigues, O
   Armah, GE
   Batchilly, AS
AF Ideh, R. C.
   Rodrigues, O.
   Armah, G. E.
   Batchilly, A. S.
TI Paediatric rotavirus disease in The Gambia: A hospital based sentinel
   study
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Ideh, R. C.] MRC Labs Uk, Banjul, Gambia.
   [Rodrigues, O.] Univ Ghana, Sch Med, Korle Bu, Ghana.
   [Armah, G. E.] Noguchi Mem Inst Med Res, Legon, Ghana.
   [Batchilly, A. S.] Royal Victoria Teaching Hosp, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD MAR
PY 2010
VL 14
SU 1
BP E422
EP E423
DI 10.1016/j.ijid.2010.02.560
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 578MQ
UT WOS:000276298201520
OA gold
DA 2017-08-15
ER

PT J
AU Mackenzie, G
   Uchendu, U
   Ameh, D
   Adeyemi, O
   Saha, D
AF Mackenzie, G.
   Uchendu, U.
   Ameh, D.
   Adeyemi, O.
   Saha, D.
TI An alternative standard for radiological pneumonia in children
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Mackenzie, G.; Uchendu, U.; Ameh, D.; Adeyemi, O.; Saha, D.] Med Res Council UK Gambia, Basse, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD MAR
PY 2010
VL 14
SU 1
BP E434
EP E434
DI 10.1016/j.ijid.2010.02.584
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA 578MQ
UT WOS:000276298201544
OA gold
DA 2017-08-15
ER

PT J
AU Mackenzie, G
   Okoko, B
   Akinsola, A
   Idoko, OT
   Corrah, T
   Howie, S
   Mulholland, EK
   Greenwood, B
   Adegbola, RA
AF Mackenzie, G.
   Okoko, B.
   Akinsola, A.
   Idoko, O. T.
   Corrah, T.
   Howie, S.
   Mulholland, E. K.
   Greenwood, B.
   Adegbola, R. A.
TI Follow-up of Gambian 9-valent pneumococcal conjugate vaccine trial
   participants who experienced acute lower respiratory infection aged less
   than 2.5 years
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Mackenzie, G.; Okoko, B.; Akinsola, A.; Idoko, O. T.; Corrah, T.; Howie, S.] Med Res Council UK Gambia, Fajara, Gambia.
   [Mulholland, E. K.; Greenwood, B.] London Sch Hyg & Trop Med, London WC1, England.
   [Adegbola, R. A.] Bill & Melinda Gates Fdn, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD MAR
PY 2010
VL 14
SU 1
BP E395
EP E395
DI 10.1016/j.ijid.2010.02.498
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA 578MQ
UT WOS:000276298201458
OA gold
DA 2017-08-15
ER

PT J
AU Mackenzie, G
   Usuf, E
   Jasseh, M
   Nsekpong, D
   Ikumapayi, N
   Badji, H
   Saha, D
   Ameh, D
   Uchendu, U
   Corrah, T
   Hill, P
   Howie, S
   Greenwood, B
   Adegbola, RA
AF Mackenzie, G.
   Usuf, E.
   Jasseh, M.
   Nsekpong, D.
   Ikumapayi, N.
   Badji, H.
   Saha, D.
   Ameh, D.
   Uchendu, U.
   Corrah, T.
   Hill, P.
   Howie, S.
   Greenwood, B.
   Adegbola, R. A.
TI Population-based surveillance for pneumonia, sepsis and meningitis in
   all ages in The Gambia: Implications for pneumococcal vaccine
   introduction and surveillance in Africa
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Mackenzie, G.; Usuf, E.; Jasseh, M.; Ikumapayi, N.; Badji, H.; Saha, D.; Ameh, D.; Uchendu, U.; Corrah, T.; Greenwood, B.] Med Res Council UK Gambia, Fajara, Gambia.
   [Nsekpong, D.] Med Res Council UK Labs, Banjul, Gambia.
   [Hill, P.] Univ Otago, Dunedin, New Zealand.
   [Greenwood, B.] London Sch Hyg & Trop Med, London WC1, England.
   [Adegbola, R. A.] Bill & Melinda Gates Fdn, Seattle, WA USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD MAR
PY 2010
VL 14
SU 1
BP E27
EP E28
DI 10.1016/j.ijid.2010.02.1548
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 578MQ
UT WOS:000276298200069
OA gold
DA 2017-08-15
ER

PT J
AU Osier, FHA
   Murungi, LM
   Fegan, G
   Tuju, J
   Tetteh, KK
   Bull, PC
   Conway, DJ
   Marsh, K
AF Osier, F. H. A.
   Murungi, L. M.
   Fegan, G.
   Tuju, J.
   Tetteh, K. K.
   Bull, P. C.
   Conway, D. J.
   Marsh, K.
TI Allele-specific antibodies to Plasmodium falciparum merozoite surface
   protein-2 and protection against clinical malaria
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE allele-specific antibodies; clinical malaria; msp2 genotypes; Plasmodium
   falciparum
ID CROSS-REACTIVITY; HOLOENDEMIC AREA; RESPONSES; CHILDREN; TRANSMISSION;
   INFECTIONS; DIVERSITY; ANTIGENS; RECOGNITION; POPULATIONS
AB P>IgG and IgG3 antibodies to merozoite surface protein-2 (MSP-2) of Plasmodium falciparum have been associated with protection from clinical malaria in independent studies. We determined whether this protection was allele-specific by testing whether children who developed clinical malaria lacked IgG/IgG3 antibodies specific to the dominant msp2 parasite genotypes detected during clinical episodes. We analysed pre-existing IgG and IgG1/IgG3 antibodies to antigens representing the major dimorphic types of MSP-2 by ELISA. We used quantitative real-time PCR to determine the dominant msp2 alleles in parasites detected in clinical episodes. Over half (55%, 80/146) of infections contained both allelic types. Single or dominant IC1- and FC27-like alleles were detected in 46% and 42% of infections respectively, and both types were equally dominant in 12%. High levels of IgG/IgG3 antibodies to the FC27-like antigen were not significantly associated with a lower likelihood of clinical episodes caused by parasites bearing FC27-like compared to IC1-like alleles, and vice versa for IgG/IgG3 antibodies to the IC1-like antigen. These findings were supported by competition ELISAs which demonstrated the presence of IgG antibodies to allele-specific epitopes within both antigens. Thus, even for this well-studied antigen, the importance of an allele-specific component of naturally acquired protective immunity to malaria remains to be confirmed.
C1 [Osier, F. H. A.; Murungi, L. M.; Fegan, G.; Tuju, J.; Bull, P. C.; Marsh, K.] KEMRI Ctr Geog Med Res, Coast, Kilifi, Kenya.
   [Conway, D. J.] MRC Labs, Banjul, Gambia.
   [Fegan, G.; Tetteh, K. K.; Conway, D. J.] London Sch Hyg & Trop Med, London WC1, England.
RP Osier, FHA (reprint author), KEMRI Ctr Geog Med Res, POB 230-80108, Coast, Kilifi, Kenya.
EM fosier@kilifi.kemri-wellcome.org
OI Osier, Faith/0000-0001-7133-5375; Bull, Peter/0000-0002-7674-6752;
   Fegan, Greg/0000-0002-2663-2765; Conway, David/0000-0002-8711-3037
FU Wellcome Trust [073591]
FX This paper is published with the permission of the director of KEMRI. We
   thank the parents and children who participated in this study, as well
   as the KEMRI staff who made it possible. We thank Steven Muriithi and
   Brett Lowe (KEMRI-Kilifi), and Lindsay Stewart (LSHTM) and for their
   assistance with the work reported here. We thank David Cavanagh and Jana
   McBride for providing the plasmids that enabled production of the MSP-2
   recombinant proteins. This work was supported by a Research Training
   Fellowship awarded to F.H.A.O. by the Wellcome Trust, grant number
   073591.
CR Akpogheneta OJ, 2008, INFECT IMMUN, V76, P1748, DOI 10.1128/IAI.01333-07
   Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005
   Cheesman SJ, 2003, MOL BIOCHEM PARASIT, V131, P83, DOI 10.1016/S0166-6851(03)00195-6
   Contamin H, 1996, AM J TROP MED HYG, V54, P632
   Conway DJ, 2002, PARASITOLOGY, V125, pS3, DOI 10.1017/S0031182002002214
   COVELL G, 1951, BRIT MED BULL, V8, P51
   Crewther PE, 1996, INFECT IMMUN, V64, P3310
   Daubersies P, 1996, AM J TROP MED HYG, V54, P18
   Ekala MT, 2002, CLIN EXP IMMUNOL, V129, P326, DOI 10.1046/j.1365-2249.2002.01904.x
   Farnert A, 1997, AM J TROP MED HYG, V56, P538
   Felger I, 2003, PARASITE IMMUNOL, V25, P531, DOI 10.1111/j.0141-9838.2004.00664.x
   Franks S, 2003, INFECT IMMUN, V71, P3485, DOI 10.1128/IAI.71.6.3485-3495.2003
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Kanunfre KA, 2003, CLIN DIAGN LAB IMMUN, V10, P973, DOI 10.1128/CDLI.10.5.973-976.2003
   Kinyanjui SM, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-82
   LINES J, 1992, PARASITOL TODAY, V8, P381, DOI 10.1016/0169-4758(92)90176-3
   Low A, 2007, BIOPOLYMERS, V87, P12, DOI 10.1002/bip.20764
   Magesa SM, 2002, ACTA TROP, V84, P83, DOI 10.1016/S0001-706X(02)00179-1
   McKenzie FE, 2008, ADV PARASIT, V66, P1, DOI 10.1016/S0065-308X(08)00201-7
   Metzger WG, 2003, PARASITE IMMUNOL, V25, P307, DOI 10.1046/j.1365-3024.2003.00636.x
   Ofosu-Okyere A, 2001, PARASITOLOGY, V123, P113, DOI 10.1017/S0031182001008162
   Osier FHA, 2007, PARASITE IMMUNOL, V29, P387, DOI 10.1111/j.1365-3024.2007.00951.x
   Osier FHA, 2008, INFECT IMMUN, V76, P2240, DOI 10.1128/IAI.01585-07
   Polley SD, 2006, VACCINE, V24, P4233, DOI 10.1016/j.vaccine.2005.06.030
   Renia L, 1997, INFECT IMMUN, V65, P4419
   Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x
   Scopel KKG, 2007, AM J TROP MED HYG, V76, P1084
   Stanisic DI, 2009, INFECT IMMUN, V77, P1165, DOI 10.1128/IAI.01129-08
   Tami A, 2002, PARASITOLOGY, V124, P569, DOI 10.1017/S0031182002001713
   Taylor RR, 1998, AM J TROP MED HYG, V58, P406
   Weisman S, 2001, INFECT IMMUN, V69, P959, DOI 10.1128/IAI.69.2.959-967.2001
NR 31
TC 14
Z9 14
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD MAR
PY 2010
VL 32
IS 3
BP 193
EP 201
DI 10.1111/j.1365-3024.2009.01178.x
PG 9
WC Immunology; Parasitology
SC Immunology; Parasitology
GA 554CH
UT WOS:000274412600004
PM 20398182
OA No
DA 2017-08-15
ER

PT J
AU Nweneka, CV
   Doherty, CP
   Cox, S
   Prentice, A
AF Nweneka, Chidi V.
   Doherty, Conor P.
   Cox, Sharon
   Prentice, Andrew
TI Iron delocalisation in the pathogenesis of malarial anaemia
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Review
DE Malaria; Anaemia; Macrophage; Iron; Ferroportin; Hepcidin
ID TUMOR-NECROSIS-FACTOR; PLASMODIUM-FALCIPARUM MALARIA; COOMBS
   ANTIGLOBULIN REACTIONS; MIGRATION INHIBITORY FACTOR; PLACEBO-CONTROLLED
   TRIAL; COPPER-DEFICIENT SWINE; BLOOD-STAGE MALARIA; CHRONIC DISEASE;
   NITRIC-OXIDE; RETICULOENDOTHELIAL SYSTEM
AB There is consensus that the pathophysiology of malaria-associated anaemia is multifactorial, but the precise mechanisms behind many of the haematological changes during malaria remain unclear. In this review, we attempt to build a composite picture of the pathophysiology of malarial anaemia using evidence from experimental, human and animal studies. We propose that cytokine- and hepcidin-mediated iron delocalisation, a principal mechanism in the anaemia of inflammation, plays an important role in the aetiology of malarial anaemia, and can explain some of the clinical and laboratory findings. These mechanisms interact with other aetiological determinants, such as dietary iron and micronutrient supply, helminth load, other infections and genetic variation, in determining the severity and associated features of anaemia. We suggest that iron delocalisation as a mechanism for malarial anaemia could be exploited for the development of alternative therapeutic strategies for post-malaria anaemia. Crown Copyright (C) 2009 Published by Elsevier Ltd on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved.
C1 [Nweneka, Chidi V.; Prentice, Andrew] MRC Keneba, Nutr Programme, Banjul, Gambia.
   [Doherty, Conor P.] Univ Glasgow, Royal Hosp Sick Children, Dept Child Hlth, Glasgow, Lanark, Scotland.
   [Cox, Sharon; Prentice, Andrew] London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1, England.
RP Nweneka, CV (reprint author), MRC Keneba, Nutr Programme, POB 273, Banjul, Gambia.
EM cnweneka@mrc.gm
OI Cox, Sharon/0000-0002-9908-2936
FU UK Medical Research Council
FX Funding: This work was funded by the UK Medical Research Council.
CR Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200
   ABDALLA S, 1980, BRIT J HAEMATOL, V46, P171, DOI 10.1111/j.1365-2141.1980.tb05956.x
   ALAM J, 1989, J BIOL CHEM, V264, P17637
   Andrews NC, 2004, J CLIN INVEST, V113, P1251, DOI 10.1172/JCI200421441
   Atkinson SH, 2008, BLOOD, V112, P4276, DOI 10.1182/blood-2008-06-162008
   Ayi K, 2004, BLOOD, V104, P3364, DOI 10.1182/blood-2003-11-3820
   BENNETT RM, 1974, ANN RHEUM DIS, V33, P147, DOI 10.1136/ard.33.2.147
   Biemba G, 2000, TROP MED INT HEALTH, V5, P256, DOI 10.1046/j.1365-3156.2000.00545.x
   BIRGEGARD G, 1984, SCAND J HAEMATOL, V33, P43
   Bojang KA, 1997, T ROY SOC TROP MED H, V91, P557, DOI 10.1016/S0035-9203(97)90025-0
   Bouton C, 1998, J BIOL CHEM, V273, P9403, DOI 10.1074/jbc.273.16.9403
   Brabin BJ, 2001, J NUTR, V131, p636S
   Brattig NW, 2008, MICROBES INFECT, V10, P885, DOI 10.1016/j.micinf.2008.05.002
   BYRD TF, 1989, J CLIN INVEST, V83, P1457, DOI 10.1172/JCI114038
   Canonne-Hergaux F, 2006, AM J PHYSIOL-GASTR L, V290, pG156, DOI 10.1152/ajpgi.00227.2005
   CARTWRIGHT GE, 1946, J CLIN INVEST, V25, P65, DOI 10.1172/JCI101690
   Chang KH, 2004, INT J PARASITOL, V34, P1501, DOI 10.1016/j.ijpara.2004.10.008
   Chang KH, 2004, KIDNEY INT, V65, P1640, DOI 10.1111/j.1523-1755.2004.00573.x
   Christensen EI, 2001, AM J PHYSIOL-RENAL, V280, pF562
   CLARK IA, 1988, BRIT J HAEMATOL, V70, P99, DOI 10.1111/j.1365-2141.1988.tb02440.x
   Clark IA, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-85
   Clark Ian A, 2008, Travel Med Infect Dis, V6, P67, DOI 10.1016/j.tmaid.2007.07.002
   Crawley J, 2004, AM J TROP MED HYG, V71, P25
   CUSTER G, 1982, AM J HEMATOL, V13, P23, DOI 10.1002/ajh.2830130105
   DAN BS, 1997, BR J NUTR, V78, P751
   Doherty CP, 2007, J NUTR, V137, P1341
   Doherty CP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002133
   Doherty CP, 2002, J PEDIATR GASTR NUTR, V34, P346, DOI 10.1097/00005176-200204000-00004
   Dondorp AM, 1999, AM J TROP MED HYG, V60, P733
   Dondorp AM, 2002, T ROY SOC TROP MED H, V96, P282, DOI 10.1016/S0035-9203(02)90100-8
   Donovan A, 2000, NATURE, V403, P776
   Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003
   Ekvall H, 2003, CURR OPIN HEMATOL, V10, P108, DOI 10.1097/00062752-200303000-00002
   Ekvall H, 2001, T ROY SOC TROP MED H, V95, P611, DOI 10.1016/S0035-9203(01)90095-1
   Evans KJ, 2006, BLOOD, V107, P1192
   FACER CA, 1980, CLIN EXP IMMUNOL, V39, P279
   FACER CA, 1979, CLIN EXP IMMUNOL, V35, P119
   FILLET G, 1989, BLOOD, V74, P844
   FILLET G, 1974, J CLIN INVEST, V53, P1527, DOI 10.1172/JCI107703
   Fleming RE, 2001, P NATL ACAD SCI USA, V98, P8160, DOI 10.1073/pnas.161296298
   Galy B, 2008, CELL METAB, V7, P79, DOI 10.1016/j.cmet.2007.10.006
   Ganz T, 2006, PEDIATR BLOOD CANCER, V46, P554, DOI 10.1002/pbc.20656
   Ganz T, 2005, CELL METAB, V1, P155, DOI 10.1016/j.cmet.2005.02.005
   Ganz T, 2006, HEMATOL-AM SOC HEMAT, V29-35, P507
   Ghosh K, 2007, PARASITOL RES, V101, P1463, DOI 10.1007/s00436-007-0742-1
   Goka BQ, 2001, T ROY SOC TROP MED H, V95, P545, DOI 10.1016/S0035-9203(01)90036-7
   GREENBERG GR, 1947, J CLIN INVEST, V26, P121, DOI 10.1172/JCI101784
   Greenberg P L, 2001, Hematology Am Soc Hematol Educ Program, P479
   GUPTA CM, 1982, NATURE, V299, P259, DOI 10.1038/299259a0
   Harris ZL, 1998, AM J CLIN NUTR S, V67, p972S
   HAURANI FI, 1972, J RETICULOENDOTH SOC, V12, P29
   Helleberg M, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-56
   Jakeman GN, 1999, PARASITOLOGY, V119, P127, DOI 10.1017/S0031182099004564
   Johnson D, 2004, FEBS LETT, V573, P195, DOI 10.1016/j.febslet.2004.07.081
   JOOTAR S, 1993, CLIN LAB HAEMATOL, V15, P87
   Jurado RL, 1997, CLIN INFECT DIS, V25, P888, DOI 10.1086/515549
   Kim S, 2003, BIOMETALS, V16, P125, DOI 10.1023/A:1020788603046
   KLEBER EE, 1981, SCAND J HAEMATOL, V27, P209
   Knutson M, 2003, CRIT REV BIOCHEM MOL, V38, P61, DOI 10.1080/713609210
   Knutson MD, 2005, P NATL ACAD SCI USA, V102, P1324, DOI 10.1073/pnas.0409409102
   KONDO H, 1988, HEPATOLOGY, V8, P32, DOI 10.1002/hep.1840080108
   KONIJN AM, 1977, BRIT J HAEMATOL, V37, P7, DOI 10.1111/j.1365-2141.1977.tb08806.x
   Kozyraki R, 2001, J MOL MED-JMM, V79, P161, DOI 10.1007/s001090100193
   Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   KUHNS WJ, 1950, J CLIN INVEST, V29, P1505, DOI 10.1172/JCI102392
   Kurtzhals JAL, 1998, LANCET, V351, P1768, DOI 10.1016/S0140-6736(97)09439-7
   Kurtzhals JAL, 1997, BRIT J HAEMATOL, V97, P169, DOI 10.1046/j.1365-2141.1997.82654.x
   Lackritz E M, 1998, AIDS, V12 Suppl A, pS81
   Laftah AH, 2006, BIOCHEM J, V397, P61, DOI 10.1042/BJ20060215
   LEE GR, 1968, J CLIN INVEST, V47, P2058, DOI 10.1172/JCI105891
   Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102
   LETENDRE ED, 1984, INFECT IMMUN, V44, P320
   Locke A, 1932, J CLIN INVEST, V11, P527, DOI 10.1172/JCI100432
   LOOAREESUWAN S, 1987, NEW ENGL J MED, V317, P675, DOI 10.1056/NEJM198709103171105
   LOOAREESUWAN S, 1987, BRIT J HAEMATOL, V67, P473, DOI 10.1111/j.1365-2141.1987.tb06171.x
   LOOAREESUWAN S, 1991, ACTA TROP, V48, P263, DOI 10.1016/0001-706X(91)90014-B
   Loreal O, 2002, J HEPATOL, V36, P851, DOI 10.1016/S0168-8278(02)00042-9
   Mackenzie EL, 2008, ANTIOXID REDOX SIGN, V10, P997, DOI [10.1089/ars.2007.1893, 10.1089/ars.007.1893]
   Martiney JA, 2000, INFECT IMMUN, V68, P2259, DOI 10.1128/IAI.68.4.2259-2267.2000
   McDermid JM, 2006, CLIN SCI, V110, P503, DOI 10.1042/CS20050273
   McDevitt MA, 2006, J EXP MED, V203, P1185, DOI 10.1084/jem.20052398
   McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6
   Means RT, 2004, BLOOD REV, V18, P219, DOI 10.1016/S0268-960X9(03)00066-3
   MEANS RT, 1992, BLOOD, V80, P1639
   Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3
   MENKIN VALY, 1931, JOUR EXP MED, V53, P919, DOI 10.1084/jem.53.6.919
   MENKIN VALY, 1930, JOUR EXP MED, V51, P879, DOI 10.1084/jem.51.6.879
   Meyer LA, 2001, J BIOL CHEM, V276, P36857, DOI 10.1074/jbc.M105361200
   MILLER KL, 1989, INFECT IMMUN, V57, P1542
   MILLER KL, 1989, EXP HEMATOL, V17, P379
   Moura E, 1998, BLOOD, V92, P2511
   Muckenthaler MU, 2008, ANNU REV NUTR, V28, P197, DOI 10.1146/annurev.nutr.28.061807.155521
   Mulero V, 1999, BLOOD, V94, P2383
   Murphy SC, 2001, AM J TROP MED HYG, V64, P57
   Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235
   Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945
   Nemeth E, 2008, CURR OPIN HEMATOL, V15, P169, DOI 10.1097/MOH.0b013e3282f73335
   Newton CRJC, 1997, TROP MED INT HEALTH, V2, P165, DOI 10.1046/j.1365-3156.1997.d01-238.x
   Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4
   Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498
   Nweneka CV, 2007, BJOG-INT J OBSTET GY, V114, P1581, DOI 10.1111/j.1471-0528.2007.01532.x
   Odunukwe NN, 2000, TROP MED INT HEALTH, V5, P582, DOI 10.1046/j.1365-3156.2000.00601.x
   Ojukwu JU, 2009, COCHRANE DB SYST REV, V3
   Pantaleo A, 2008, AUTOIMMUN REV, V7, P457, DOI 10.1016/j.autrev.2008.03.017
   PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267
   Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781
   Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200
   Pawluczkowycz AW, 2007, J IMMUNOL, V179, P5543
   PHILLIPS RE, 1986, Q J MED, V58, P305
   Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200
   Planche T, 2003, CLIN INFECT DIS, V37, P890, DOI 10.1086/377536
   Planche T, 2005, CURR OPIN INFECT DIS, V18, P369, DOI 10.1097/01.qco.0000180161.38530.81
   Prentice AM, 2007, FOOD NUTR BULL, V28, pS524
   Prentice AM, 2007, J NUTR, V137, P1334
   Price RN, 2001, AM J TROP MED HYG, V65, P614
   RAGAN HA, 1969, AM J PHYSIOL, V217, P1320
   RAMA R, 1988, BIOCHIM BIOPHYS ACTA, V968, P51, DOI 10.1016/0167-4889(88)90043-2
   Recalcati S, 1998, BLOOD, V91, P1059
   RENCRICCA NJ, 1974, INFECT IMMUN, V10, P831
   RICHARDSON DR, 1995, BLOOD, V86, P3211
   Roestenberg M, 2007, T ROY SOC TROP MED H, V101, P643, DOI 10.1016/j.trstmh.2007.02.023
   Roy CN, 2001, HUM MOL GENET, V10, P2181, DOI 10.1093/hmg/10.20.2181
   SAITO K, 1986, BRIT J HAEMATOL, V62, P275, DOI 10.1111/j.1365-2141.1986.tb02930.x
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Sharma N, 2005, BIOCHEM J, V390, P437, DOI 10.1042/BJ20050256
   TAKETANI S, 1990, J BIOL CHEM, V265, P13981
   Thawani N, 2006, EXP HEMATOL, V34, P1451, DOI 10.1016/j.exphem.2006.06.014
   Vedovato M, 2002, COMP CLIN PATH, V11, P148, DOI [10.1007/s005800200014, DOI 10.1007/S005800200014]
   Verhoef H, 2002, BLOOD, V100, P3489, DOI 10.1182/blood-2001-12-0228
   Verroust PJ, 2002, NEPHROL DIAL TRANSPL, V17, P1867, DOI 10.1093/ndt/17.11.1867
   Voulgari PV, 1999, CLIN IMMUNOL, V92, P153, DOI 10.1006/clim.1999.4736
   Waitumbi JN, 2000, BLOOD, V95, P1481
   Weinstein DA, 2002, BLOOD, V100, P3776, DOI 10.1182/blood-2002-04-1260
   WEISS G, 1993, EMBO J, V12, P3651
   Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809
   Weiss G, 1997, J IMMUNOL, V158, P420
   Weiss G, 2002, BLOOD REV, V16, P87, DOI 10.1054/blre.2002.0193
   Wickramasinghe SN, 2000, BEST PRACT RES CL HA, V13, P277, DOI 10.1053/beha.1999.0072
   Yang FM, 2002, J BIOL CHEM, V277, P39786, DOI 10.1074/jbc.M201485200
   YAP GS, 1994, INFECT IMMUN, V62, P357
NR 141
TC 16
Z9 16
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD MAR
PY 2010
VL 104
IS 3
BP 175
EP 184
DI 10.1016/j.trstmh.2009.08.007
PG 10
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 574OJ
UT WOS:000276000000001
PM 19783267
OA No
DA 2017-08-15
ER

PT J
AU Majambere, S
   Pinder, M
   Fillinger, U
   Ameh, D
   Conway, DJ
   Green, C
   Jeffries, D
   Jawara, M
   Milligan, PJ
   Hutchinson, R
   Lindsay, SW
AF Majambere, Silas
   Pinder, Margaret
   Fillinger, Ulrike
   Ameh, David
   Conway, David J.
   Green, Clare
   Jeffries, David
   Jawara, Musa
   Milligan, Paul J.
   Hutchinson, Robert
   Lindsay, Steven W.
TI Is Mosquito Larval Source Management Appropriate for Reducing Malaria in
   Areas of Extensive Flooding in The Gambia? A Cross-over Intervention
   Trial
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID DAR-ES-SALAAM; MICROBIAL LARVICIDES; BREEDING SITES; WEST-AFRICA;
   TREATED NETS; COMPLEX; IMPACT; KENYA; IDENTIFICATION; SUPPRESSION
AB Larviciding to control malaria was assessed in rural areas with extensive seasonal flooding, Larval and adult mosquitoes and malaria incidence were surveyed routinely in four 100-km(2) areas either Side of the Gambia River. Baseline data were collected in 2005. Microbial larvicide was applied to all water bodies by hand application with water-dispersible granular formulations and corn granules weekly from May to November in two areas in 2006 and in the other two areas in 2007 in a cross-over design. The intervention was associated with a reduction in habitats with late stage anopheline larvae and all 88% reduction in larval densities (P < 0.001). The effect of the intervention oil mosquito densities was not pronounced and Was Confounded by the distance Of villages to the major breeding sites and year (P = 0.002). There was no reduction in clinical Malaria or anemia. Ground applications of non-residual larvicides with simple equipment Lire not effective in riverine areas with extensive flooding, where many habitats are poorly demarcated, highly mobile, and inaccessible on foot.
C1 [Majambere, Silas; Pinder, Margaret; Green, Clare; Hutchinson, Robert; Lindsay, Steven W.] Univ Durham, Sci Labs, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
   [Ameh, David; Conway, David J.; Jeffries, David] MRC Labs, Fajara, Gambia.
   [Fillinger, Ulrike; Milligan, Paul J.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Lindsay, SW (reprint author), Univ Durham, Sci Labs, Sch Biol & Biomed Sci, South Rd, Durham DH1 3LE, England.
EM smajambere@ihi.or.tz; mpinder@mrc.gm; ulrike.fillinger@lshtm.ac.uk;
   dameh@mrc.gm; dconway@mrc.gm; clare.green@ucl.ac.uk; djeffries@mrc.gm;
   paul.milligan@lshtm.ac.uk; R.A.Hutchinson@insects.org;
   s.w.lindsay@durham.ac.uk
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Fillinger,
   Ulrike/0000-0002-4037-431X; Conway, David/0000-0002-8711-3037
FU Gambian Department of State for Health; National Institutes of Health [1
   UO1 AI658250-01]
FX We thank the study children, their parents. village health workers and
   the Gambian Department of State for Health for their continuous Support
   for this work. We are grateful to the National Malaria Control Program
   of The Gambia for their active collaboration with the larviciding
   operations. We acknowledge Paul Emerson, Amy Ratcliffe, and Miguel A.
   San Joaquin Polo for their help at the early stages of the study. We
   also thank the Medical Research Council and Durham University associates
   of the LCP trial and other Support staff. in particular Sabine Schindler
   and Momodou Jasseh.; This study was supported by the National Institutes
   of Health (grant 1 UO1 AI658250-01).
CR BEIER JC, 1990, J AM MOSQUITO CONTR, V6, P105
   Bogh C, 2003, B ENTOMOL RES, V93, P279, DOI 10.1079/BER2003239
   Bogh C, 2007, AM J TROP MED HYG, V76, P875
   BURKOT TR, 1984, AM J TROP MED HYG, V33, P783
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Chandre F, 1999, B WORLD HEALTH ORGAN, V77, P230
   CHAVASSE DC, 1995, MED VET ENTOMOL, V9, P147, DOI 10.1111/j.1365-2915.1995.tb00171.x
   Clarke SE, 2002, T ROY SOC TROP MED H, V96, P499, DOI 10.1016/S0035-9203(02)90419-0
   Corbel V, 2003, J MED ENTOMOL, V40, P985, DOI 10.1603/0022-2585-40.6.985
   Feachem R, 2008, LANCET, V371, P1633, DOI [10.1016/S0140-6736(08)60424-9, 10.1016/S1473-3099(08)70045-8]
   Fillinger U, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-20
   Fillinger U, 2006, TROP MED INT HEALTH, V11, P1629, DOI 10.1111/j.1365-3156.2006.01733.x
   Fillinger U, 2009, B WORLD HEALTH ORGAN, V87, P655, DOI 10.2471/BLT.08.055632
   Fillinger U, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-62
   Geissbuhler Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005107
   GIGLIOLI M E, 1964, Riv Malariol, V43, P245
   Keiser J, 2004, AM J TROP MED HYG, V71, P118
   Killeen Gerry F, 2002, Malar J, V1, P8, DOI 10.1186/1475-2875-1-8
   Kirby MJ, 2009, LANCET, V374, P998, DOI 10.1016/S0140-6736(09)60871-0
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P45, DOI 10.1016/0035-9203(93)90175-P
   LINDSAY SW, 1991, MED VET ENTOMOL, V5, P477, DOI 10.1111/j.1365-2915.1991.tb00576.x
   Majambere S, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-76
   Majambere S, 2008, AM J TROP MED HYG, V79, P19
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   Shililu JI, 2003, J AM MOSQUITO CONTR, V19, P251
   Shililu J, 2007, AM J TROP MED HYG, V76, P103
   Walker K, 2007, MED VET ENTOMOL, V21, P2, DOI 10.1111/j.1365-2915.2007.00674.x
   WHO, 2004, GLOB STRAT FRAM INT
   WHO, 2008, WKLY EPIDEMIOL REC, V20, P177
   World Health Organization, 2008, WORLD MAL REP 2008
NR 30
TC 25
Z9 25
U1 0
U2 10
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD FEB
PY 2010
VL 82
IS 2
BP 176
EP 184
DI 10.4269/ajtmh.2010.09-0373
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 552CC
UT WOS:000274263300003
PM 20133989
OA No
DA 2017-08-15
ER

PT J
AU de Jong, BC
   Adetifa, I
   Walther, B
   Hill, PC
   Antonio, M
   Ota, M
   Adegbola, RA
AF de Jong, Bouke C.
   Adetifa, Ifedayo
   Walther, Brigitte
   Hill, Philip C.
   Antonio, Martin
   Ota, Martin
   Adegbola, Richard A.
TI Differences between tuberculosis cases infected with Mycobacterium
   africanum, West African type 2, relative to Euro-American Mycobacterium
   tuberculosis: an update
SO FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY
LA English
DT Article
DE Mycobacterium africanum; Mycobacterium tuberculosis; the Gambia;
   phenotypic differences; HIV
ID PULMONARY TUBERCULOSIS; COMPLEX; GAMBIA; PATHOGEN
AB Mycobacterium africanum (MAF) is a common cause of human pulmonary tuberculosis in West Africa. We previously described phenotypic differences between MAF and Mycobacterium tuberculosis (MTB) among 290 patients. In the present analysis, we compared 692 tuberculosis patients infected with the two most common lineages within the (MTB) complex found in the Gambia, namely MAF West African type 2 (39% prevalence) and Euro-American MTB (55% prevalence). We identified additional phenotypic differences between infections with these two organisms. MAF patients were more likely to be older and HIV infected. In addition, they had worse disease on chest X-ray, despite complaining of cough for an equal duration, and were more likely severely malnourished. In this cohort, the prevalence of MAF did not change significantly over a 7-year period.
C1 [de Jong, Bouke C.; Adetifa, Ifedayo; Walther, Brigitte; Antonio, Martin; Ota, Martin; Adegbola, Richard A.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [de Jong, Bouke C.] NYU, New York, NY USA.
   [Hill, Philip C.] Univ Otago, Dunedin, New Zealand.
RP de Jong, BC (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM bdejong@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU Medical Research Council; NIH [TW006083]
FX We thank the staff of the tuberculosis field team and diagnostics
   laboratory for their hard work and the patients for their participation.
   The work was funded by the Medical Research Council and by NIH grant
   TW006083 awarded to B.D.
CR Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299
   Castets M, 1968, Rev Tuberc Pneumol (Paris), V32, P179
   de Jong BC, 2007, INT J TUBERC LUNG D, V11, P450
   de Jong BC, 2005, AIDS, V19, P1714, DOI 10.1097/01.aids.0000185991.54595.41
   de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504
   de Jong BC, 2009, J CLIN MICROBIOL, V47, P994, DOI 10.1128/JCM.01216-08
   Diop S, 1976, Bull Soc Med Afr Noire Lang Fr, V21, P50
   Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103
   Hershberg R, 2008, PLOS BIOL, V6, P2658, DOI 10.1371/journal.pbio.0060311
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Kallenius G, 1999, J CLIN MICROBIOL, V37, P3872
   Meyer CG, 2008, TUBERCULOSIS, V88, P482, DOI 10.1016/j.tube.2008.05.004
   Mostowy S, 2004, J CLIN MICROBIOL, V42, P3594, DOI 10.1128/jcm.42.8.3594-3599.2004
   Niobe-Eyangoh SN, 2003, J CLIN MICROBIOL, V41, P2547, DOI 10.1128/JCM.41.6.2547-2553.2003
   Streicher EM, 2007, J CLIN MICROBIOL, V45, P237, DOI 10.1128/JCM.01429-06
   *WHO ANTHR, 2009, WHO ANTHR PERS COMP
NR 16
TC 21
Z9 21
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0928-8244
J9 FEMS IMMUNOL MED MIC
JI FEMS Immunol. Med. Microbiol.
PD FEB
PY 2010
VL 58
IS 1
BP 102
EP 105
DI 10.1111/j.1574-695X.2009.00628.x
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 543DB
UT WOS:000273549200010
PM 20002176
OA No
DA 2017-08-15
ER

PT J
AU Gomez-Escobar, N
   Amambua-Ngwa, A
   Walther, M
   Okebe, J
   Ebonyi, A
   Conway, DJ
AF Gomez-Escobar, Natalia
   Amambua-Ngwa, Alfred
   Walther, Michael
   Okebe, Joseph
   Ebonyi, Augustine
   Conway, David J.
TI Erythrocyte Invasion and Merozoite Ligand Gene Expression in Severe and
   Mild Plasmodium falciparum Malaria
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID RECEPTOR SPECIFICITY; BINDING LIGAND; GLYCOPHORIN-B; PATHWAYS;
   PARASITES; SELECTION; ANTIGENS; CELLS; POLYMORPHISMS; HETEROGENEITY
AB Erythrocyte invasion is central to malaria parasite replication and virulence. Plasmodium falciparum parasites use different alternative erythrocyte receptors and vary in expression of erythrocyte-binding antigenic (EBA) proteins and reticulocyte-binding protein homologues (Rh). Parasite invasion phenotypes and schizont-stage transcript expression profiles of the 8 eba and Rh protein-coding genes without internal stop codons were determined for 163 clinical isolates cultured ex vivo in The Gambia. There was extensive diversity in ability to invade erythrocytes treated with neuraminidase, trypsin, or chymotrypsin, and severe malaria isolates were less restricted by trypsin treatment than were mild malaria isolates (Pp. 015). Expression profiles of the eba and Rh genes showed distinct clusters indicating coordinated alternative transcription. The most divergent of 5 major clusters was dominated by Rh2b, with virtually no expression of eba175 or eba140 genes (which were dominant in the other 4 clusters). Particular transcripts were significantly correlated with parasitemia (Rh5 was positively correlated and eba140 negatively correlated; P < .001 for both) and age of patients (eba181 was positively correlated and eba175 negatively correlated; P < .01 for both) but not with invasion phenotypes or severity of malaria. Severe and mild malaria isolates were also evenly represented across the different expression clusters.
C1 [Conway, David J.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Gomez-Escobar, Natalia; Amambua-Ngwa, Alfred; Walther, Michael; Okebe, Joseph; Ebonyi, Augustine; Conway, David J.] MRC Labs, Banjul, Gambia.
RP Conway, DJ (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM dconway@mrc.gm
OI Conway, David/0000-0002-8711-3037
FU UK Medical Research Council
FX Financial support: none reported. UK Medical Research Council.
CR Baum J, 2003, GENETICS, V163, P1327
   Baum J, 2003, INFECT IMMUN, V71, P1856, DOI 10.1128/IAI.71.4.1856-1863.2003
   Baum J, 2005, PLOS PATHOG, V1, P299, DOI 10.1371/journal.ppat.0010037
   Baum J, 2009, INT J PARASITOL, V39, P371, DOI 10.1016/j.ijpara.2008.10.006
   Bei AK, 2007, MOL BIOCHEM PARASIT, V153, P66, DOI 10.1016/j.molbiopara.2007.01.007
   Blair PL, 2002, NUCLEIC ACIDS RES, V30, P2224, DOI 10.1093/nar/30.10.2224
   Chung WY, 2008, PARASITOL RES, V102, P259, DOI 10.1007/s00436-007-0756-8
   Cortes A, 2007, PLOS PATHOG, V3, P1023, DOI 10.1371/journal.ppat.0030107
   Cowman AF, 2006, CELL, V124, P755, DOI 10.1016/j.cell.2006.02.006
   Deans AM, 2007, INFECT IMMUN, V75, P3014, DOI 10.1128/IAI.00249-07
   DOLAN SA, 1990, J CLIN INVEST, V86, P618, DOI 10.1172/JCI114753
   Duraisingh MT, 2003, EMBO J, V22, P1047, DOI 10.1093/emboj/cdg096
   GAO X, 2008, PLOS PATHOG, V4, P1
   Gaur D, 2006, MOL BIOCHEM PARASIT, V145, P205, DOI 10.1016/j.molbiopara.2005.10.004
   Gaur D, 2004, INT J PARASITOL, V34, P1413, DOI 10.1016/j.ijpara.2004.10.010
   Gaur D, 2007, P NATL ACAD SCI USA, V104, P17789, DOI 10.1073/pnas.0708772104
   HADLEY TJ, 1987, J CLIN INVEST, V80, P1190, DOI 10.1172/JCI113178
   Hayton K, 2008, CELL HOST MICROBE, V4, P40, DOI 10.1016/j.chom.2008.06.001
   Iyer J, 2007, MOL MICROBIOL, V65, P231, DOI 10.1111/j.1365-2958.2007.05791.x
   Jennings CV, 2007, INFECT IMMUN, V75, P3531, DOI 10.1128/IAI.00122-07
   Lobo CA, 2004, INFECT IMMUN, V72, P5886, DOI 10.1128/IAI.72.10.5886-5891.2004
   Maier AG, 2003, NAT MED, V9, P87, DOI 10.1038/nm807
   Maier AG, 2009, INFECT IMMUN, V77, P1689, DOI 10.1128/IAI.01331-08
   Mayer DCG, 2009, P NATL ACAD SCI USA, V106, P5348, DOI 10.1073/pnas.0900878106
   Mayer DCG, 2004, P NATL ACAD SCI USA, V101, P2518, DOI 10.1073/pnas.0307318101
   Mayer DCG, 2002, J EXP MED, V196, P1523, DOI 10.1084/jem.20020750
   MITCHELL GH, 1986, BLOOD, V67, P1519
   Nery S, 2006, MOL BIOCHEM PARASIT, V149, P208, DOI 10.1016/j.molbiopara.2006.05.014
   Ohas EA, 2004, INFECT IMMUN, V72, P735, DOI 10.1128/IAI.72.2.735-741.2004
   Okenu DMN, 2000, INFECT IMMUN, V68, P5559, DOI 10.1128/IAI.68.10.5559-5566.2000
   Okoyeh JN, 1999, INFECT IMMUN, V67, P5784
   Osier FHA, 2008, INFECT IMMUN, V76, P2240, DOI 10.1128/IAI.01585-07
   Persson KEM, 2008, J CLIN INVEST, V118, P342, DOI 10.1172/JCI32138
   Rayner JC, 2001, J EXP MED, V194, P1571, DOI 10.1084/jem.194.11.1571
   SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226
   Snounou G, 1999, T ROY SOC TROP MED H, V93, P369, DOI 10.1016/S0035-9203(99)90120-7
   Stubbs J, 2005, SCIENCE, V309, P1384, DOI 10.1126/science.1115257
   Taylor HM, 2002, INFECT IMMUN, V70, P5779, DOI 10.1128/IAI.70.10.5779-5789.2002
   Triglia T, 2005, MOL MICROBIOL, V55, P162, DOI 10.1111/j.1365-2958.2004.04388.x
   Verra F, 2006, MOL BIOCHEM PARASIT, V149, P182, DOI 10.1016/j.molbiopara.2006.05.010
NR 40
TC 38
Z9 38
U1 1
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD FEB 1
PY 2010
VL 201
IS 3
BP 444
EP 452
DI 10.1086/649902
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 541SO
UT WOS:000273441000019
PM 20050806
OA No
DA 2017-08-15
ER

PT J
AU Mendy, ME
   Welzel, T
   Lesi, OA
   Hainaut, P
   Hall, AJ
   Kuniholm, MH
   McConkey, S
   Goedert, JJ
   Kaye, S
   Rowland-Jones, S
   Whittle, H
   Kirk, GD
AF Mendy, M. E.
   Welzel, T.
   Lesi, O. A.
   Hainaut, P.
   Hall, A. J.
   Kuniholm, M. H.
   McConkey, S.
   Goedert, J. J.
   Kaye, S.
   Rowland-Jones, S.
   Whittle, H.
   Kirk, G. D.
TI Hepatitis B viral load and risk for liver cirrhosis and hepatocellular
   carcinoma in The Gambia, West Africa
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Article
DE Africa; cirrhosis; HBV; HCC; viral load
ID VIRUS-INFECTION; E-ANTIGEN; AFLATOXIN EXPOSURE; CHRONIC CARRIERS; DNA
   LEVEL; CANCER; SEROCONVERSION; ETIOLOGY; MUTATION; DISEASE
AB The main objectives of this study were to define the occurrence and levels of hepatitis B virus (HBV) DNA in asymptomatic HBV carriers, cirrhosis patients and hepatocellular carcinoma (HCC) cases from The Gambia, and to evaluate the risk for cirrhosis or HCC associated with HBV viremia. We used sensitive real-time quantitative PCR assays to measure HBV DNA in samples from a case-control study consisting of 60 asymptomatic HBV carriers, 53 cirrhotic patients and 129 HCC cases. Logistic regression was used to estimate the risks of cirrhosis and HCC associated with HBV-DNA levels and HBV e antigenemia (HBeAg) detection (a surrogate marker for viral replication). Detectable HBV viremia and HBeAg positivity were both significantly associated with cirrhosis (increasing risk by fourfold and 11-fold respectively) and with HCC (increasing risk by sixfold and threefold respectively). HBV-DNA levels were significantly higher in both HCC cases and cirrhotic patients compared to asymptomatic carriers (P < 0.01 for both). High-level HBV DNA (> 10 000 copies/mL) was strongly associated with both HCC and cirrhosis (17- and 39-fold increased risk). Lower level HBV viremia (200-10 000 copies/mL) conferred a significant risk of HCC, although the association with cirrhosis was not significant. In conclusion, we find that high HBV-DNA levels are strongly associated with the serious sequelae of HBV infection, independent of HBeAg status. While risk for cirrhosis and for HCC notably increases at HBV-DNA levels 10 000 copies/mL, low-level viremia was also associated with significant risk for HCC.
C1 [Mendy, M. E.; Rowland-Jones, S.; Whittle, H.] MRC, Viral Dis Programme, Banjul, Gambia.
   [Welzel, T.; Goedert, J. J.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.
   [Lesi, O. A.] Univ Lagos, Teaching Hosp, Lagos, Nigeria.
   [Hainaut, P.] Int Agcy Res Canc, F-69372 Lyon, France.
   [Hall, A. J.] London Sch Hyg & Trop Med, London WC1, England.
   [Kuniholm, M. H.; Kirk, G. D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [McConkey, S.] Royal Coll Surgeons Ireland, Dublin 2, Ireland.
   [Kaye, S.] Univ London Imperial Coll Sci Technol & Med, London, England.
RP Mendy, ME (reprint author), MRC, Viral Dis Programme, Atlantic Blvd,POB 273, Banjul, Gambia.
EM mmendy@mrc.gm
RI McConkey, Samuel/E-7307-2012
OI McConkey, Samuel/0000-0001-9085-7793
FU National Cancer Institute [N02-CP40521]; Medical Research Council
   (Fajara, The Gambia and United Kingdom)
FX We would like to thank the staff of the Gambia Liver Cancer Study and
   The Gambia Hepatitis Intervention Study and the staff and participants
   at the Bansang, Medical Research Council and Royal Victoria hospitals
   for their contributions. We thank Adam-Jeng Barry for excellent
   technical assistance. We gratefully acknowledge the financial support of
   the National Cancer Institute (Contract N02-CP40521) and Medical
   Research Council (Fajara, The Gambia and United Kingdom).
CR Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65
   Chen G, 2006, AM J GASTROENTEROL, V101, P1797, DOI 10.1111/j.1572-0241.2006.00647.x
   Chu CM, 2007, J VIRAL HEPATITIS, V14, P147, DOI 10.1111/j.1365-2893.2006.00810.x
   Chu CJ, 2002, HEPATOLOGY, V35, P1274, DOI 10.1053/jhep.2002.33161
   Chu CM, 2004, AM J MED, V116, P829, DOI 10.1016/j.amjmed.2003.12.040
   Hung CH, 2003, J GASTROENTEROL, V38, P153, DOI 10.1007/s005350300025
   Iloeje UH, 2006, GASTROENTEROLOGY, V130, P678, DOI 10.1053/j.gastro.2005.11.016
   Kirk GD, 2005, CANCER EPIDEM BIOMAR, V14, P373, DOI 10.1158/1055-9965.EPI-04-0161
   Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kirk GD, 2006, CARCINOGENESIS, V27, P2070, DOI 10.1093/carcin/bgl060
   Kuniholm MH, 2008, ENVIRON HEALTH PERSP, V116, P1553, DOI 10.1289/ehp.11661
   Liaw YF, 2006, ANTIVIR THER, V11, P669
   LIN DY, 1993, J CLIN ULTRASOUND, V21, P303, DOI 10.1002/jcu.1870210502
   Liu CJ, 2006, J INFECT DIS, V193, P1258, DOI 10.1086/502978
   Mendy ME, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-23
   Mendy ME, 1999, BRIT J BIOMED SCI, V56, P34
   Milich D, 2003, HEPATOLOGY, V38, P1075, DOI 10.1053/jhep.2003.50453
   Parkin DM, 2001, EUR J CANCER, V37, pS4
   Tang BQ, 2004, J MED VIROL, V72, P35, DOI 10.1002/jmv.10559
   Tsai FC, 2007, J VIRAL HEPATITIS, V14, P153, DOI 10.1111/j.1365-2893.2006.00780.x
   WHITTLE HC, 1983, LANCET, V1, P1203
   Wu CF, 2008, CARCINOGENESIS, V29, P106, DOI 10.1093/carcin/bgm252
   Yang HI, 2002, NEW ENGL J MED, V347, P168, DOI 10.1056/NEJMoa013215
   Yu MW, 2005, J NATL CANCER I, V97, P265, DOI 10.1093/jnci/dji043
NR 26
TC 37
Z9 39
U1 0
U2 2
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1352-0504
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD FEB
PY 2010
VL 17
IS 2
BP 115
EP 122
DI 10.1111/j.1365-2893.2009.01168.x
PG 8
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA 545KV
UT WOS:000273731900005
PM 19874478
OA No
DA 2017-08-15
ER

PT J
AU Sankaranarayanan, R
   Swaminathan, R
   Brenner, H
   Chen, KX
   Chia, KS
   Chen, JG
   Law, SCK
   Ahn, YO
   Xiang, YB
   Yeole, BB
   Shin, HR
   Shanta, V
   Woo, ZH
   Martin, N
   Sumitsawan, Y
   Sriplung, H
   Barboza, AO
   Eser, S
   Nene, BM
   Suwanrungruang, K
   Jayalekshmi, P
   Dikshit, R
   Wabinga, H
   Esteban, DB
   Laudico, A
   Bhurgri, Y
   Bah, E
   Al-Hamdan, N
AF Sankaranarayanan, Rengaswamy
   Swaminathan, Rajaraman
   Brenner, Hermann
   Chen, Kexin
   Chia, Kee Seng
   Chen, Jian Guo
   Law, Stephen C. K.
   Ahn, Yoon-Ok
   Xiang, Yong Bing
   Yeole, Balakrishna B.
   Shin, Hai Rim
   Shanta, Viswanathan
   Woo, Ze Hong
   Martin, Nimit
   Sumitsawan, Yupa
   Sriplung, Hutcha
   Barboza, Adolfo Ortiz
   Eser, Sultan
   Nene, Bhagwan M.
   Suwanrungruang, Krittika
   Jayalekshmi, Padmavathiamma
   Dikshit, Rajesh
   Wabinga, Henry
   Esteban, Divina B.
   Laudico, Adriano
   Bhurgri, Yasmin
   Bah, Ebrima
   Al-Hamdan, Nasser
TI Cancer survival in Africa, Asia, and Central America: a population-based
   study
SO LANCET ONCOLOGY
LA English
DT Article
ID ALTERNATIVE APPROACH; PATIENT SURVIVAL; REGISTRIES
AB Background Population-based cancer survival data, a key indicator for monitoring progress against cancer, are not widely available from countries in Africa, Asia, and Central America. The aim of this study is to describe and discuss cancer survival in these regions.
   Methods Survival analysis was done for 341658 patients diagnosed with various cancers from 1990 to 2001 and followed up to 2003, from 25 population-based cancer registries in 12 countries in sub-Saharan Africa (The Gambia, Uganda), Central America (Costa Rica), and Asia (China, India, Pakistan, Philippines, Saudi Arabia, Singapore, South Korea, Thailand, Turkey). 5-year age-standardised relative survival (ASRS) and observed survival by clinical extent of disease were determined.
   Findings For cancers in which prognosis depends on stage at diagnosis, survival was highest in China, South Korea, Singapore, and Turkey and lowest in Uganda and The Gambia. 5-year ASRS ranged from 76-82% for breast cancer, 63-79% for cervical cancer, 71-78% for bladder cancer, and 44-60% for large-bowel cancers in China, Singapore, South Korea, and Turkey. Survival did not exceed 22% for any cancer site in The Gambia; in Uganda, survival did not exceed 13% for any cancer site except breast (46%). Variations in survival correlated with early detection initiatives and level of development of health services.
   Interpretation The wide variation in cancer survival between regions emphasises the need for urgent investments in improving awareness, population-based cancer registration, early detection programmes, health-services infrastructure, and human resources.
C1 [Sankaranarayanan, Rengaswamy] Int Agcy Res Canc, Early Detect & Prevent Sect, Screening Grp, F-69372 Lyon, France.
   [Swaminathan, Rajaraman; Shanta, Viswanathan] Canc Inst WIA, Div Epidemiol, Chennai, Tamil Nadu, India.
   [Swaminathan, Rajaraman; Shanta, Viswanathan] Canc Inst WIA, Canc Registry, Chennai, Tamil Nadu, India.
   [Brenner, Hermann] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, D-6900 Heidelberg, Germany.
   [Chen, Kexin] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China.
   [Chia, Kee Seng] Natl Univ Singapore, Ctr Mol Epidemiol, Singapore 117548, Singapore.
   [Chen, Jian Guo] Qidong Liver Canc Inst, Qidong Canc Registry, Jiangsu, Peoples R China.
   [Law, Stephen C. K.] Hosp Author, Hong Kong Canc Registry, Hong Kong, Hong Kong, Peoples R China.
   [Ahn, Yoon-Ok] Seoul Natl Univ, Coll Med, Seoul Canc Registry, Seoul, South Korea.
   [Xiang, Yong Bing] Shanghai Canc Inst, Dept Epidemiol, Shanghai, Peoples R China.
   [Yeole, Balakrishna B.] Indian Canc Soc, Bombay Canc Registry, Mumbai, Maharashtra, India.
   [Shin, Hai Rim] Natl Canc Ctr, Res Inst, Busan Canc Registry, Kyonggi Do, South Korea.
   [Woo, Ze Hong] Inha Univ, Incheon Canc Registry, Inchon, South Korea.
   [Martin, Nimit] Lampang Canc Ctr, Lampang Canc Registry, Lampang, Thailand.
   [Sumitsawan, Yupa] Chiang Mai Univ, Dept Otolaryngol, Chiang Mai 50000, Thailand.
   [Sriplung, Hutcha] Prince Songkla Univ, Songkhla Canc Registry, Hat Yai, Thailand.
   [Barboza, Adolfo Ortiz] Costa Rica Natl Tumor Registry, San Jose, Costa Rica.
   [Eser, Sultan] Izmir Prov Hlth Directorate, Izmir Canc Registry, Alsancak, Turkey.
   [Nene, Bhagwan M.] Nargis Dutt Mem Canc Hosp, Barshi Canc Registry, Barshi, India.
   [Suwanrungruang, Krittika] Khon Kaen Univ, Srinagarind Hosp, Canc Unit, Khon Kaen, Thailand.
   [Jayalekshmi, Padmavathiamma] Nat Background Radiat Registry, Karunagappally, Kerala, India.
   [Dikshit, Rajesh] Tata Mem Hosp, Mumbai 400012, Maharashtra, India.
   [Wabinga, Henry] Makerere Univ, Fac Med, Kampala Canc Registry, Kampala, Uganda.
   [Esteban, Divina B.] Rizal Med Ctr, Rizal Canc Registry, Pasig, Philippines.
   [Laudico, Adriano] Manila Canc Registry, Philippine Canc Soc, Manila, Philippines.
   [Bhurgri, Yasmin] Liaquat Natl Med Coll, Karachi Canc Registry, Karachi, Pakistan.
   [Bah, Ebrima] Natl Canc Registry Gambia, Banjul, Gambia.
   [Al-Hamdan, Nasser] King Fahad Med City, Fac Med, Riyadh, Saudi Arabia.
RP Sankaranarayanan, R (reprint author), Int Agcy Res Canc, Early Detect & Prevent Sect, Screening Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.
EM sankar@iarc.fr
RI CHIA, Kee Seng/C-5790-2011; Ahn, Yoon-Ok/J-5530-2012; Brenner,
   Hermann/B-4627-2017
OI Brenner, Hermann/0000-0002-6129-1572; Sriplung,
   Hutcha/0000-0002-8483-0460
FU Association for International Cancer Research (AICR); Association pour
   la Recherche sur le Cancer (ARC); Bill & Melinda Gates Foundation; IARC
FX We are grateful to the following organisations for funding support to
   cancer survival studies: Association for International Cancer Research
   (AICR; St Andrews, UK), Association pour la Recherche sur le Cancer
   (ARC, Villejuif, France), and the Bill & Melinda Gates Foundation
   (Seattle, USA). Final analysis was carried out during the post-doctoral
   fellowship awarded by IARC to RSw. We thank Evelyn Bayle, IARC, for her
   help in the preparation of the manuscript.
CR Berrino F, 1995, IARC SCI PUBLICATION, V132
   Brenner H, 2004, EUR J CANCER, V40, P2317, DOI 10.1016/j.ejca.2004.07.007
   Brenner H, 2002, EUR J CANCER, V38, P690, DOI 10.1016/S0959-8049(02)00003-5
   Brenner H, 1996, CANCER, V78, P2004, DOI 10.1002/(SICI)1097-0142(19961101)78:9<2004::AID-CNCR23>3.0.CO;2-#
   Brenner H, 2009, INT J CANCER, V125, P432, DOI 10.1002/ijc.24344
   Coleman MP, 2008, LANCET ONCOL, V9, P730, DOI [10.1016/S1470-2045(08)70179-7, 10.1016/S470-2045(08)70179-7]
   Curado MP, 2007, IARC SCI PUBLICATION, V160
   Cutler SJ, 1958, J CHRON DIS, V6, P699, DOI DOI 10.1016/0021-9681(58)90126-7
   EDERER F, 1961, MONOGR NATL CANC I, V6, P101
   Ferlay J, 2004, 5 IARC
   HAKULINEN T, 1982, BIOMETRICS, V38, P933, DOI 10.2307/2529873
   JENSEN OM, 1999, IARC SCI PUBLICATION, V95
   KUNE GA, 1990, DIS COLON RECTUM, V33, P938, DOI 10.1007/BF02139103
   Lopez ADAO, 2001, 40 GPE WHO
   Parkin DM, 2005, 7 IARC, V7
   Ries LAG, 2006, SEER CANC STAT REV 1
   Sankaranarayanan R, 1998, IARC SCI PUBLICATION, V145
   Sankaranarayanan R, 1996, CANCER, V78, P2461, DOI 10.1002/(SICI)1097-0142(19961215)78:12<2461::AID-CNCR2>3.0.CO;2-N
   Sant M, 2009, EUR J CANCER, V45, P931, DOI 10.1016/j.ejca.2008.11.018
   Sriamporn S, 2004, BRIT J CANCER, V91, P106, DOI 10.1038/sj.bjc.6601959
   SWAMINATHAN R, 2002, INT J CANCER S, V13, P172
   SWAMINATHAN R, 1998, IARC SCI PUBLICATION, V145
   Swaminathan R, 2008, B WORLD HEALTH ORGAN, V86, P509, DOI 10.2471/BLT.07.046979
   Tsukuma H, 2006, JPN J CLIN ONCOL, V36, P602, DOI 10.1093/jjco/hyl068
   World Health Organization (WHO), 1992, INT STAT CLASS DIS R, V1-3
NR 25
TC 152
Z9 162
U1 1
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1470-2045
J9 LANCET ONCOL
JI Lancet Oncol.
PD FEB
PY 2010
VL 11
IS 2
BP 165
EP 173
DI 10.1016/S1470-2045(09)70335-3
PG 9
WC Oncology
SC Oncology
GA 563SC
UT WOS:000275152900024
PM 20005175
OA No
DA 2017-08-15
ER

PT J
AU Duah, NO
   Miles, DJC
   Whittle, HC
   Conway, DJ
AF Duah, N. O.
   Miles, D. J. C.
   Whittle, H. C.
   Conway, D. J.
TI Acquisition of antibody isotypes against Plasmodium falciparum blood
   stage antigens in a birth cohort
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE acquired immunity; antibody isotypes; birth cohort; blood stage
   antigens; Plasmodium falciparum
ID MEROZOITE SURFACE PROTEIN-1; GLUTAMATE-RICH PROTEIN; CLINICAL MALARIA;
   WEST-AFRICA; 19-KILODALTON DOMAIN; GHANAIAN CHILDREN; ESCHERICHIA-COLI;
   PROTECTION; RESPONSES; AREA
AB P>Information on the period during which infants lose their maternally derived antibodies to malaria and begin to acquire naturally their own immune responses against parasite antigens is crucial for understanding when malaria vaccines may be best administered. This study investigated the rates of decline and acquisition of serum antibody isotypes IgG1, IgG2, IgG3, IgG4, IgM and IgA to Plasmodium falciparum antigens apical membrane antigen (AMA1), merozoite surface proteins (MSP1-19, MSP2 and MSP3) in a birth cohort of 53 children living in an urban area in the Gambia, followed over the first 3 years of life (sampled at birth, 4, 9, 18 and 36 months). Antigen-specific maternally transferred antibody isotypes of all IgG subclasses were detected at birth and were almost totally depleted by 4 months of age. Acquisition of specific antibody isotypes to the antigens began with IgM, followed by IgG1 and IgA. Against the MSP2 antigen, IgG1 but not IgG3 responses were observed in the children, in contrast with the maternally derived antibodies to this antigen that were mostly IgG3. This confirms that IgG subclass responses to MSP2 are strongly dependent on age or previous malaria experience, polarized towards IgG1 early in life and to IgG3 in older exposed individuals.
C1 [Duah, N. O.; Conway, D. J.] London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1, England.
   [Duah, N. O.; Miles, D. J. C.; Whittle, H. C.; Conway, D. J.] MRC Labs, Fajara, Gambia.
   [Miles, D. J. C.] Univ Cape Town, Inst Infect Dis & Mol Med, S African TB Vaccine Initiat, ZA-7925 Cape Town, South Africa.
RP Duah, NO (reprint author), Univ Ghana, Noguchi Mem Inst Med Res, POB LG581, Legon Accra, Ghana.
EM nduah@noguchi.mimcom.org
OI Duah, Nancy/0000-0001-8819-1793; Conway, David/0000-0002-8711-3037
FU Medical Research Council (MRC) of the UK; Association of Commonwealth
   Universities
FX We are grateful to the children of Sukuta and their parents and
   guardians for participation in this study. We thank Onome Akpogheneta,
   Kevin Tetteh, Patrick Corran, David Lanar and Spencer Polley for helping
   with provision of recombinant antigens, and Jana McBride and David
   Cavanagh for plasmid clones for expression of the MSP2 antigens. We
   acknowledge the excellent work of the laboratory and field workers of
   the Medical Research Council Laboratories (MRC) in The Gambia. We
   appreciate the work done by Ebrima S. Touray and other field workers of
   the Sukuta Birth Cohort. This research was funded by the Medical
   Research Council (MRC) of the UK, and a studentship award from the
   Association of Commonwealth Universities.
CR Achidi EA, 1996, ACTA TROP, V61, P315, DOI 10.1016/0001-706X(96)00014-9
   Akpogheneta OJ, 2008, INFECT IMMUN, V76, P1748, DOI 10.1128/IAI.01333-07
   Aribot G, 1996, AM J TROP MED HYG, V54, P449
   Aubouy A, 2007, INFECT GENET EVOL, V7, P147, DOI 10.1016/j.meegid.2006.07.001
   Aucan C, 2000, INFECT IMMUN, V68, P1252, DOI 10.1128/IAI.68.3.1252-1258.2000
   BOUHAROUNTAYOUN H, 1992, INFECT IMMUN, V60, P1473
   Brabin B., 1990, Tropical Diseases Bulletin, V87, pR1
   Branch OH, 1998, AM J TROP MED HYG, V58, P211
   BURGHAUS PA, 1994, MOL BIOCHEM PARASIT, V64, P165, DOI 10.1016/0166-6851(94)90144-9
   Cavanagh DR, 2004, INFECT IMMUN, V72, P6492, DOI 10.1128/IAI.72.11.6492.6502.2004
   Cavanagh DR, 2001, INFECT IMMUN, V69, P1207, DOI 10.1128/IAI.69.2.1207-1211.2001
   Cavanagh DR, 1998, J IMMUNOL, V161, P347
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Deloron P, 1997, CLIN EXP IMMUNOL, V110, P212
   Dodoo D, 1999, INFECT IMMUN, V67, P2131
   Dodoo D, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-142
   Dutta S, 2002, INFECT IMMUN, V70, P3101, DOI 10.1128/IAI.70.6.3101-3110.2002
   EDOZIEN JC, 1962, LANCET, V2, P951
   Eisen DP, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-86
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   GROUX H, 1990, RES IMMUNOL, V141, P529, DOI 10.1016/0923-2494(90)90021-P
   Iriemenam NC, 2009, VACCINE, V27, P62, DOI 10.1016/j.vaccine.2008.10.025
   Kitua AY, 1999, PARASITE IMMUNOL, V21, P307, DOI 10.1046/j.1365-3024.1999.00230.x
   Lusingu JPA, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-48
   MCGREGOR I. A., 1964, TRANS ROY SOC TROP MED HYG, V58, P80, DOI 10.1016/0035-9203(64)90073-2
   MCGREGOR IA, 1960, W AFR MED J, V9, P260
   Metzger WG, 2003, PARASITE IMMUNOL, V25, P307, DOI 10.1046/j.1365-3024.2003.00636.x
   Ndungu FM, 2002, PARASITE IMMUNOL, V24, P77, DOI 10.1046/j.0141-9838.2001.00440.x
   Nebie I, 2008, INFECT IMMUN, V76, P759, DOI 10.1128/IAI.01147-07
   Okenu DMN, 2000, INFECT IMMUN, V68, P5559, DOI 10.1128/IAI.68.10.5559-5566.2000
   Osier FHA, 2007, PARASITE IMMUNOL, V29, P387, DOI 10.1111/j.1365-3024.2007.00951.x
   Osier FHA, 2008, INFECT IMMUN, V76, P2240, DOI 10.1128/IAI.01585-07
   PASVOL G, 1977, NATURE, V270, P171, DOI 10.1038/270171a0
   Polley SD, 2006, VACCINE, V24, P4233, DOI 10.1016/j.vaccine.2005.06.030
   Polley SD, 2004, VACCINE, V23, P718, DOI 10.1016/j.vaccine.2004.05.031
   Polley SD, 2007, J INFECT DIS, V195, P279, DOI 10.1086/509806
   Riley EM, 2000, INFECT IMMUN, V68, P5856, DOI 10.1128/IAI.68.10.5856-5863.2000
   Roussilhon C, 2007, PLOS MED, V4, P1791, DOI 10.1371/journal.pmed.0040320
   Shi YP, 1996, INFECT IMMUN, V64, P2716
   Singh S, 2004, J INFECT DIS, V190, P1010, DOI 10.1086/423208
   Snow RW, 1998, J INFECT DIS, V177, P819
   Soe S, 2004, INFECT IMMUN, V72, P247, DOI 10.1128/IAI.72.1.247-252.2004
   Stanisic DI, 2009, INFECT IMMUN, V77, P1165, DOI 10.1128/IAI.01129-08
   TAYLOR RR, 1995, INFECT IMMUN, V63, P4382
   Taylor RR, 1998, AM J TROP MED HYG, V58, P406
   Tongren JE, 2006, INFECT IMMUN, V74, P257, DOI 10.1128/IAI.74.1.257-264.2006
   Tongren JE, 2005, INFECT IMMUN, V73, P8119, DOI 10.1128/IAI.73.12.8119-8129.2005
   Toure FS, 2006, CLIN MED RES, V4, P175, DOI [10.3121/cmr.4.3.175, 10.3121/cmr.4.1.1]
NR 48
TC 16
Z9 16
U1 0
U2 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD FEB
PY 2010
VL 32
IS 2
BP 125
EP 134
DI 10.1111/j.1365-3024.2009.01165.x
PG 10
WC Immunology; Parasitology
SC Immunology; Parasitology
GA 543DS
UT WOS:000273551200005
PM 20070826
OA No
DA 2017-08-15
ER

PT J
AU Finney, OC
   Riley, EM
   Walther, M
AF Finney, Olivia C.
   Riley, Eleanor M.
   Walther, Michael
TI Regulatory T cells in malaria - friend or foe?
SO TRENDS IN IMMUNOLOGY
LA English
DT Review
ID PLASMODIUM-FALCIPARUM MALARIA; GROWTH-FACTOR-BETA; TGF-BETA; CEREBRAL
   MALARIA; CHILDHOOD MALARIA; CLINICAL IMMUNITY; BALB/C MICE; INFECTION;
   RESPONSES; PARASITE
AB T cell-mediated inflammatory immune responses contribute to both the clearance and pathology of malaria infections; the host's ability to down-regulate inflammation once parasitemia is controlled is crucial to avoid immune-mediated pathology but remains poorly understood. Various regulatory populations of T lymphocytes can modulate inflammatory immune responses and there has been considerable recent interest in the potential for regulatory T cells to modify the outcome of both murine and human malaria infections. Here, we review these studies, focussing in particular on recent studies in humans, propose a model by which different regulatory T cell populations might contribute to the control of inflammation at different stages of infection and discuss the implications for the design of safe and effective malaria vaccines.
C1 [Finney, Olivia C.; Walther, Michael] MRC Labs, Malaria Programme, Banjul, Gambia.
   [Finney, Olivia C.; Riley, Eleanor M.] Univ London London Sch Hyg & Trop Med, Immunol Unit, Dept Infect & Trop Med, London WC1E 7HT, England.
RP Walther, M (reprint author), MRC Labs, Malaria Programme, POB 273, Banjul, Gambia.
EM mwalther@mrc.gm
RI Riley, Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570
FU Medical Research Council [MC_U190081986, MC_U190085848]
CR AKBAR AN, 1993, J EXP MED, V178, P427, DOI 10.1084/jem.178.2.427
   Akbar AN, 2007, NAT REV IMMUNOL, V7, P231, DOI 10.1038/nri2037
   Amante FH, 2007, AM J PATHOL, V171, P548, DOI 10.2353/ajpath.2007.061033
   Artavanis-Tsakonas K, 2003, CLIN EXP IMMUNOL, V133, P145, DOI 10.1046/j.1365-2249.2003.02174.x
   Baecher-Allan C, 2002, J IMMUNOL, V169, P6210
   Bejon P, 2007, J IMMUNOL, V179, P4193
   Belkaid Y, 2003, EXPERT OPIN BIOL TH, V3, P875, DOI 10.1517/14712598.3.6.875
   Belkaid Y, 2006, IMMUNOL REV, V212, P287, DOI 10.1111/j.0105-2896.2006.00409.x
   Brandenburg S, 2008, EUR J IMMUNOL, V38, P1643, DOI 10.1002/eji.200737791
   Brustoski K, 2006, J INFECT DIS, V193, P146, DOI 10.1086/498578
   Cambos M, 2008, INT J PARASITOL, V38, P229, DOI 10.1016/j.ijpara.2007.07.006
   Chaiyaroj SC, 2004, ACTA TROP, V89, P319, DOI 10.1016/j.actatropica.2003.10.010
   Chen G, 2009, PARASITOLOGY, V136, P1107, DOI 10.1017/S0031182009990370
   Chen X, 2007, J IMMUNOL, V179, P154
   CHIZZOLINI C, 1990, CLIN EXP IMMUNOL, V79, P95
   Couper KN, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000004
   Couper KN, 2008, J IMMUNOL, V180, P5771
   Couper KN, 2007, J IMMUNOL, V178, P4136
   Day NPJ, 1999, J INFECT DIS, V180, P1288, DOI 10.1086/315016
   Dodoo D, 2002, J INFECT DIS, V185, P971, DOI 10.1086/339408
   Dooms H, 2006, IMMUNOL REV, V211, P23, DOI 10.1111/j.0105-2896.2006.00387.x
   Egan AF, 2002, BLOOD, V99, P3863, DOI 10.1182/blood.V99.10.3863
   Farouk SE, 2005, MICROBES INFECT, V7, P110, DOI 10.1016/j.micinf.2004.09.012
   FINNEY OC, 2009, THESIS LONDON SCH HY
   Finney OC, 2010, EUR J IMMUNOL, V40, P47, DOI 10.1002/eji.200939708
   Finney OC, 2009, EUR J IMMUNOL, V39, P1288, DOI 10.1002/eji.200839112
   Hay SI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000048
   Hisaeda H, 2005, EUR J IMMUNOL, V35, P3516, DOI 10.1002/eji.200526073
   Hisaeda H, 2004, NAT MED, V10, P29, DOI 10.1038/nm975
   Hisaeda H, 2008, J IMMUNOL, V180, P2496
   Horwitz DA, 2008, TRENDS IMMUNOL, V29, P429, DOI 10.1016/j.it.2008.06.005
   Jailwala P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006527
   Jangpatarapongsa K, 2008, EUR J IMMUNOL, V38, P2697, DOI 10.1002/eji.200838186
   Jankovic D, 2007, J EXP MED, V204, P273, DOI 10.1084/jem.20062175
   Jones TR, 2002, AM J TROP MED HYG, V66, P672
   Korenromp EL, 2003, LANCET INFECT DIS, V3, P349, DOI 10.1016/S1473-3099(03)00657-1
   Kurtzhals JAL, 1998, LANCET, V351, P1768, DOI 10.1016/S0140-6736(97)09439-7
   Lamb Tracey J., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406010581
   Li C, 2003, INFECT IMMUN, V71, P4850, DOI 10.1128/IAI.71.9.4850-4856.2003
   Long TTA, 2003, INT J PARASITOL, V33, P175, DOI 10.1016/S0020-7519(02)00261-8
   Makobongo MO, 2003, P NATL ACAD SCI USA, V100, P2628, DOI 10.1073/pnas.0337659100
   Minigo G, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000402
   Modiano D, 2001, T ROY SOC TROP MED H, V95, P149, DOI 10.1016/S0035-9203(01)90141-5
   Moore AC, 2005, J IMMUNOL, V175, P7264
   Ndugwa RP, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-15
   Nie CQ, 2007, INFECT IMMUN, V75, P2275, DOI 10.1128/IAI.01783-06
   Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141
   Omer FM, 2003, J EXP MED, V198, P1817, DOI 10.1084/jem.20030713
   Omer FM, 2000, PARASITOL TODAY, V16, P18, DOI 10.1016/S0169-4758(99)01562-8
   Perkins DJ, 2000, J INFECT DIS, V182, P988, DOI 10.1086/315762
   Ratcliff A, 2007, LANCET, V369, P757, DOI 10.1016/S0140-6736(07)60160-3
   Rhee MSM, 2001, CLIN EXP IMMUNOL, V126, P503, DOI 10.1046/j.1365-2249.2001.01681.x
   Riley EM, 2006, PARASITE IMMUNOL, V28, P35, DOI 10.1111/j.1365-3024.2006.00775.x
   Roberts L, 2007, SCIENCE, V318, P1544, DOI 10.1126/science.318.5856.1544
   Rouse BT, 2006, IMMUNOL REV, V212, P272, DOI 10.1111/j.0105-2896.2006.00412.x
   Schofield L, 2006, CURR MOL MED, V6, P205, DOI 10.2174/156652406776055221
   Scholzen A, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000543
   Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010
   Strauch UG, 2005, GUT, V54, P1546, DOI 10.1136/gut.2004.059451
   Sugimoto N, 2006, INT IMMUNOL, V18, P1197, DOI 10.1093/intimm/dx1060
   Todryk SM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002027
   Todryk SM, 2009, EUR J IMMUNOL, V39, P3042, DOI 10.1002/eji.200939434
   Torcia MG, 2008, P NATL ACAD SCI USA, V105, P646, DOI 10.1073/pnas.0709969105
   Vigario AM, 2007, INT J PARASITOL, V37, P963, DOI 10.1016/j.ijpara.2007.01.004
   Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941
   Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   *WHO, 2000, T ROY SOC TROP MED H, V94
   Wu Y, 2007, EXP PARASITOL, V115, P301, DOI 10.1016/j.exppara.2006.09.015
   Yeo TW, 2007, J EXP MED, V204, P2693, DOI 10.1084/jem.20070819
   Zheng SG, 2007, J IMMUNOL, V178, P2018
NR 71
TC 39
Z9 40
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4906
J9 TRENDS IMMUNOL
JI Trends Immunol.
PD FEB
PY 2010
VL 31
IS 2
BP 63
EP 70
DI 10.1016/j.it.2009.12.002
PG 8
WC Immunology
SC Immunology
GA 564KY
UT WOS:000275214300005
PM 20056484
OA No
DA 2017-08-15
ER

PT J
AU Perry, S
   de Jong, BC
   Solnick, JV
   Sanchez, MD
   Yang, SF
   Lin, PL
   Hansen, LM
   Talat, N
   Hill, PC
   Hussain, R
   Adegbola, RA
   Flynn, J
   Canfield, D
   Parsonnet, J
AF Perry, Sharon
   de Jong, Bouke C.
   Solnick, Jay V.
   Sanchez, Maria de la Luz
   Yang, Shufang
   Lin, Philana Ling
   Hansen, Lori M.
   Talat, Najeeha
   Hill, Philip C.
   Hussain, Rabia
   Adegbola, Richard A.
   Flynn, JoAnne
   Canfield, Don
   Parsonnet, Julie
TI Infection with Helicobacter pylori Is Associated with Protection against
   Tuberculosis
SO PLOS ONE
LA English
DT Article
ID HEALTHY-YOUNG ADULTS; CYNOMOLGUS MACAQUES; ELISPOT; DISEASE; GAMBIA;
   ASTHMA; RISK; ACQUISITION; IMMUNOLOGY; STRATEGIES
AB Background: Helicobacter pylori, a lifelong and typically asymptomatic infection of the stomach, profoundly alters gastric immune responses, and may benefit the host in protection against other pathogens. We explored the hypothesis that H. pylori contributes to the control of infection with Mycobacterium tuberculosis.
   Methodology/Principal Findings: We first examined M. tuberculosis-specific IFN-gamma and H. pylori antibody responses in 339 healthy Northern Californians undergoing routine tuberculin skin testing. Of 97 subjects (29%) meeting criteria for latent tuberculosis (TB) infection (LTBI), 45 (46%) were H. pylori seropositive. Subjects with LTBI who were H. pylori-seropositive had 1.5-fold higher TB antigen-induced IFN-gamma responses (p = 0.04, ANOVA), and a more Th-1 like cytokine profile in peripheral blood mononuclear cells, compared to those who were H. pylori seronegative. To explore an association between H. pylori infection and clinical outcome of TB exposure, we evaluated H. pylori seroprevalence in baseline samples from two high risk TB case-contact cohorts, and from cynomolgus macaques experimentally challenged with M. tuberculosis. Compared to 513 household contacts who did not progress to active disease during a median 24 months follow-up, 120 prevalent TB cases were significantly less likely to be H. pylori infected (AOR: 0.55, 95% CI 0.0.36-0.83, p = 0.005), though seroprevalence was not significantly different from non-progressors in 37 incident TB cases (AOR: 1.35 [95% CI 0.63-2.9] p = 0.44). Cynomolgus macaques with natural H. pylori infection were significantly less likely to progress to TB 6 to 8 months after M. tuberculosis challenge (RR: 0.31 [95% CI 0.12-0.80], p = 0.04).
   Conclusions/Significance: H. pylori infection may induce bystander effects that modify the risk of active TB in humans and non-human primates. That immunity to TB may be enhanced by exposure to other microbial agents may have important implications for vaccine development and disease control.
C1 [Perry, Sharon; Sanchez, Maria de la Luz; Yang, Shufang; Parsonnet, Julie] Stanford Univ, Div Infect Dis & Geog Med, Sch Med, Stanford, CA 94305 USA.
   [de Jong, Bouke C.; Hill, Philip C.; Adegbola, Richard A.] MRC Labs, Fajara, Gambia.
   [Flynn, JoAnne] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA.
   [Flynn, JoAnne] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA.
   [Solnick, Jay V.; Hansen, Lori M.; Canfield, Don] Univ Calif Davis, Sch Med, Ctr Comparat Med, Dept Med, Davis, CA 95616 USA.
   [Solnick, Jay V.; Hansen, Lori M.; Canfield, Don] Univ Calif Davis, Sch Med, Ctr Comparat Med, Dept Microbiol & Immunol, Davis, CA 95616 USA.
   [Lin, Philana Ling] Univ Pittsburgh, Childrens Hosp, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA.
   [Talat, Najeeha; Hussain, Rabia] Aga Khan Univ, Dept Pathol & Microbiol, Karachi, Pakistan.
RP Perry, S (reprint author), Stanford Univ, Div Infect Dis & Geog Med, Sch Med, Stanford, CA 94305 USA.
EM shnperry@stanford.edu
RI Hussain, Rabia/E-9982-2015; de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675; Solnick, Jay/0000-0002-7435-8393
FU National Institutes of Health (NIH) [K23-AI054443, R01-AI42801,
   R01-AI42081, HL075845]; Thrasher Fund; Bill & Melinda Gates Foundation
FX This research was supported by National Institutes of Health (NIH)
   K23-AI054443 (S.P.), NIH R01-AI42801 (J.P.), NIH R01-AI42081 (J.S.), NIH
   HL075845 (J.L.F), the Thrasher Fund, and the Bill & Melinda Gates
   Foundation. The funders had no role in the study design, data
   collection, analysis, decision to publish or preparation of the
   manuscript.
CR AFFIFI AA, 1990, PRINCIPAL COMPONENTS, P371
   Barton ES, 2007, NATURE, V447, P326, DOI 10.1038/nature05762
   Blaser MJ, 2008, GUT, V57, P561, DOI 10.1136/gut.2007.133462
   Capuano SV, 2003, INFECT IMMUN, V71, P5831, DOI 10.1128/IAI.71.10.5831-5844.2003
   de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504
   Dethlefsen L, 2007, NATURE, V449, P811, DOI 10.1038/nature06245
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Hanekom WA, 2008, PLOS MED, V5, P1033, DOI 10.1371/journal.pmed.0050145
   Hill PC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001379
   Hill PC, 2007, PLOS MED, V4, P1061, DOI 10.1371/journal.pmed.0040192
   Hosmer D., 1989, APPL LOGISTIC REGRES
   Hussain R, 2007, CLIN VACCINE IMMUNOL, V14, P1578, DOI 10.1128/CVI.00289-07
   Jackson-Sillah D, 2007, T ROY SOC TROP MED H, V101, P594, DOI 10.1016/j.trstmh.2007.02.001
   Jeffries DJ, 2006, INT J TUBERC LUNG D, V10, P192
   Kaufmann SHE, 2005, NAT MED, V11, pS33, DOI 10.1038/nm1221
   Kaufmann SHE, 2001, NAT REV IMMUNOL, V1, P20, DOI 10.1038/35095558
   Lin PL, 2006, INFECT IMMUN, V74, P3790, DOI 10.1128/IAI.00064-06
   LIN PL, 2009, INFECT IMMUNOL
   Linz B, 2007, NATURE, V445, P915, DOI 10.1038/nature05562
   Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412
   McIntire JJ, 2004, SPRINGER SEMIN IMMUN, V25, P335, DOI 10.1007/s00281-003-0141-3
   McShane H, 2005, MICROBES INFECT, V7, P962, DOI 10.1016/j.micinf.2005.03.009
   MITCHELL HM, 1992, J INFECT DIS, V166, P149
   Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777
   Noverr MC, 2004, TRENDS MICROBIOL, V12, P562, DOI 10.1016/j.tim.2004.10.008
   Parsonnet J, 1997, J INFECT DIS, V175, P1240
   PerezPerez GI, 1997, INT J CANCER, V72, P453, DOI 10.1002/(SICI)1097-0215(19970729)72:3<453::AID-IJC13>3.0.CO;2-D
   Perry S, 2004, J INFECT DIS, V190, P303, DOI 10.1086/421705
   Perry S, 2008, CLIN VACCINE IMMUNOL, V15, P425, DOI 10.1128/CVI.00398-07
   REPLOGLE ML, 1995, AM J EPIDEMIOL, V142, P856
   Romero-Gallo J, 2002, CLIN DIAGN LAB IMMUN, V9, P1313, DOI 10.1128/CDLI.9.6.1313-1317.2002
   Roussos A, 2006, RESPIRATION, V73, P708, DOI 10.1159/000093816
   Saunders BM, 2007, IMMUNOL CELL BIOL, V85, P103, DOI 10.1038/sj.icb.7100027
   Solnick JV, 2003, J CLIN MICROBIOL, V41, P5511, DOI 10.1128/JCM.41.12.5511-5516.2003
   Solnick JV, 1999, LAB ANIM SCI, V49, P197
   Torres MA, 2003, EPIDEMIOL INFECT, V130, P87, DOI 10.1017/S0950268802007653
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   World Health Organization, 2008, GLOB TB CONTR SURV P
   Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579
   Winthrop KL, 2006, NAT CLIN PRACT RHEUM, V2, P602, DOI 10.1038/ncprheum0336
NR 40
TC 53
Z9 55
U1 4
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 20
PY 2010
VL 5
IS 1
AR e8804
DI 10.1371/journal.pone.0008804
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 546AI
UT WOS:000273779000030
PM 20098711
OA gold
DA 2017-08-15
ER

PT J
AU de Jong, BC
   Hammond, A
   Otu, JK
   Antonio, M
   Adegbola, RA
   Ota, MO
AF de Jong, Bouke C.
   Hammond, Abdulrahman
   Otu, Jacob K.
   Antonio, Martin
   Adegbola, Richard A.
   Ota, Martin O.
TI Immunogenicity of antigens from the TbD1 region present in M. africanum
   and missing from "modern" M. tuberculosis: a cross-sectional study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID LINKED IMMUNOSPOT ASSAY; MYCOBACTERIUM-TUBERCULOSIS; SKIN-TEST;
   DIAGNOSIS; GAMBIA; INFECTION; COMPLEX
AB Background: Currently available tools cannot be used to distinguish between sub-species of the M. tuberculosis complex causing latent tuberculosis (TB) infection. M. africanum causes up to half of TB in West-Africa and its relatively lower progression to disease suggests the presence of a large reservoir of latent infection relative to M. tuberculosis.
   Methods: We assessed the immunogenicity of the TbD1 region, present in M. africanum and absent from "modern" M. tuberculosis, in an ELISPOT assay using cells from confirmed M. africanum or M. tuberculosis infected TB patients without HIV infection in the Gambia.
   Results: Antigens from the TbD1 region induced IFN gamma responses in only 35% patients and did not discriminate between patients infected with M. africanum vs. M. tuberculosis, while PPD induced universally high responses.
   Conclusions: Further studies will need to assess other antigens unique to M. africanum that may induce discriminatory immune responses.
C1 [de Jong, Bouke C.; Hammond, Abdulrahman; Otu, Jacob K.; Antonio, Martin; Adegbola, Richard A.; Ota, Martin O.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [de Jong, Bouke C.; Ota, Martin O.] NYU, New York, NY 10016 USA.
   [Hammond, Abdulrahman] Univ Bamako, FMPOS, Bamako, Mali.
RP de Jong, BC (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM bdejong@mrc.gm
RI Hammond, Abdulrahman/F-1541-2011; de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU Medical Research Council, the Gambia; National Institutes of Health
   (NIH) [K01-TW00608]
FX We thank Michel Klein and Cees Franken for the mmpL6 and mmpS6 antigens,
   the TB patients and their contacts for their participation in the study,
   and Neneh Sallah for her help in genotyping the isolates. The study was
   funded by the Medical Research Council, the Gambia, and BCD was
   supported by the National Institutes of Health (NIH), grant
   K01-TW006083. The study sponsors had no involvement in the study design,
   in the collection, analysis and interpretation of data; in the writing
   of the manuscript; and in the decision to submit the manuscript for
   publication.
CR Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   de Jong BC, 2007, INT J TUBERC LUNG D, V11, P450
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977
   de Jong BC, 2009, J CLIN MICROBIOL, V47, P994, DOI 10.1128/JCM.01216-08
   Hill PC, 2005, J CLIN MICROBIOL, V43, P2070, DOI 10.1128/JCM.43.5.2070-2074.2005
   Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Jeffries DJ, 2006, INT J TUBERC LUNG D, V10, P192
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907
   UNGER F, 2003, 1 ITC, P1
NR 11
TC 2
Z9 2
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JAN 19
PY 2010
VL 10
AR 11
DI 10.1186/1471-2334-10-11
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA 557IO
UT WOS:000274663000001
PM 20085647
OA gold
DA 2017-08-15
ER

PT J
AU Walther, B
   Miles, DJC
   Crozier, S
   Waight, P
   Palmero, MS
   Ojuola, O
   Touray, E
   van der Sande, M
   Whittle, H
   Rowland-Jones, S
   Flanagan, KL
AF Walther, Brigitte
   Miles, David J. C.
   Crozier, Sarah
   Waight, Pauline
   Palmero, Melba S.
   Ojuola, Olubukola
   Touray, Ebrima
   van der Sande, Marianne
   Whittle, Hilton
   Rowland-Jones, Sarah
   Flanagan, Katie L.
TI Placental Malaria is associated with reduced early life weight
   development of affected children independent of low birth weight
SO MALARIA JOURNAL
LA English
DT Article
ID PLASMODIUM-FALCIPARUM INFECTION; INTRAUTERINE GROWTH-RETARDATION;
   CHONDROITIN-SULFATE-A; SUB-SAHARAN AFRICA; INFANT-MORTALITY; PREGNANCY
   OUTCOMES; PERIURBAN AREA; GUINEA-BISSAU; RISK-FACTORS; IN-UTERO
AB Background: Infection with Plasmodium falciparum during pregnancy contributes substantially to the disease burden in both mothers and offspring. Placental malaria may lead to intrauterine growth restriction or preterm delivery resulting in low birth weight (LBW), which, in general, is associated with increased infant morbidity and mortality. However, little is known about the possible direct impact of the specific disease processes occurring in PM on longer term outcomes such as subsequent retarded growth development independent of LBW.
   Methods: In an existing West-African cohort, 783 healthy infants with a birth weight of at least 2,000 g were followed up during their first year of life. The aim of the study was to investigate if Plasmodium falciparum infection of the placenta, assessed by placental histology, has an impact on several anthropometric parameters, measured at birth and after three, six and 12 months using generalized estimating equations models adjusting for moderate low birth weight.
   Results: Independent of LBW, first to third born infants who were exposed to either past, chronic or acute placental malaria during pregnancy had significantly lower weight-for-age (-0.43, 95% CI: -0.80;-0.07), weight-for-length (-0.47, 95% CI: -0.84; -0.10) and BMI-for-age z-scores (-0.57, 95% CI: -0.84; -0.10) compared to infants born to mothers who were not diagnosed with placental malaria (p = 0.019, 0.013, and 0.012, respectively). Interestingly, the longitudinal data on histology-based diagnosis of PM also document a sharp decline of PM prevalence in the Sukuta cohort from 16.5% in 2002 to 5.4% in 2004.
   Conclusions: It was demonstrated that PM has a negative impact on the infant's subsequent weight development that is independent of LBW, suggesting that the longer term effects of PM have been underestimated, even in areas where malaria transmission is declining.
C1 [Walther, Brigitte; Miles, David J. C.; Crozier, Sarah; Waight, Pauline; Palmero, Melba S.; Ojuola, Olubukola; Touray, Ebrima; van der Sande, Marianne; Whittle, Hilton; Rowland-Jones, Sarah; Flanagan, Katie L.] MRC Labs, Banjul, Gambia.
   [Miles, David J. C.] Univ Cape Town, S African TB Vaccine Initiat, Inst Infect Dis & Mol Med, Observatory, South Africa.
   [Miles, David J. C.] Univ Cape Town, Sch Child & Adolescent Hlth, Observatory, South Africa.
   [Crozier, Sarah] Univ Southampton, MRC Epidemiol Resource Ctr, Southampton Gen Hosp, Southampton, Hants, England.
   [Waight, Pauline] Hlth Protect Agcy Ctr Infect, Immunizat Dept, Hlth Protect Agcy Ctr Infect, London, England.
   [Palmero, Melba S.] Adventist Community Serv Alaska, Anchorage, AK USA.
   [Ojuola, Olubukola] Bronx Lebanon Hosp Ctr, Dept Pediat, Bronx, NY 10456 USA.
   [van der Sande, Marianne] Natl Inst Publ Hlth & Environm, Epidemiol & Surveillance Unit, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands.
   [Rowland-Jones, Sarah] John Radcliffe Hosp, MRC Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
RP Walther, B (reprint author), MRC Labs, Atlantic Blvd,POB 273, Banjul, Gambia.
EM bwalther@mrc.gm
OI Crozier, Sarah/0000-0002-9524-1127
FU MRC (UK) Laboratories, Fajara, The Gambia
FX This study was funded by the MRC (UK) Laboratories, Fajara, The Gambia.
CR Ashworth A, 1998, EUR J CLIN NUTR, V52, pS34
   Ashworth A, 1998, EUR J CLIN NUTR S1, V52, pS41
   Barker DJ, 1992, FETAL INFANT ORIGINS
   Beeson JG, 2002, INFECT IMMUN, V70, P5412, DOI 10.1128/IAI.70.10.5412-5415.2002
   Bhattarai A, 2007, PLOS MED, V4, P1784, DOI 10.1371/journal.pmed.0040309
   Bisseye C, 2009, CLIN EXP IMMUNOL, V158, P287, DOI 10.1111/j.1365-2249.2009.04014.x
   Brabin B, 1997, ANN HUM BIOL, V24, P547, DOI 10.1080/03014469700005312
   Brabin BJ, 2004, PLACENTA, V25, P359, DOI 10.1016/j.placenta.2003.10.019
   Brabin B, 2001, J NUTR S2, V131, P604
   Broen K, 2007, MOL BIOCHEM PARASIT, V151, P1, DOI 10.1016/j.molbiopara.2006.10.001
   Brustoski K, 2006, J INFECT DIS, V193, P146, DOI 10.1086/498578
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   Cot M, 2003, AM J EPIDEMIOL, V157, P203, DOI 10.1093/aje/kwf192
   Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X
   Duffy PE, 1999, BIOCHEM SOC T, V27, P478
   DUIJTS L, 2008, NEONATOLOGY, V95, P149
   FLANAGAN K, EUR J IMMUNOL
   Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502
   Fried M, 2006, EXP PARASITOL, V113, P36, DOI 10.1016/j.exppara.2005.12.003
   GARNER P, 1992, LANCET, V340, P1021, DOI 10.1016/0140-6736(92)93022-F
   GBoS, 2007, GAMB MULT IND CLUST
   GREENWOOD AM, 1992, T ROY SOC TROP MED H, V86, P483, DOI 10.1016/0035-9203(92)90078-Q
   Guyatt HL, 2004, CLIN MICROBIOL REV, V17, P760, DOI 10.1128/CMR.17.4.760-769.2004
   Guyatt HL, 2001, T ROY SOC TROP MED H, V95, P569, DOI 10.1016/S0035-9203(01)90082-3
   Hirve S S, 1994, Indian Pediatr, V31, P1221
   Ismail MR, 2000, HUM PATHOL, V31, P85, DOI 10.1016/S0046-8177(00)80203-8
   Kabyemela ER, 2008, INFECT IMMUN, V76, P1527, DOI 10.1128/IAI.00964-07
   Kalanda BF, 2005, EARLY HUM DEV, V81, P841, DOI 10.1016/j.earlhumdev.2005.06.006
   Kassam SN, 2006, INT J GYNECOL OBSTET, V93, P225, DOI 10.1016/j.ijgo.2006.02.021
   Kasumba IN, 2000, ANN TROP MED PARASIT, V94, P7, DOI 10.1080/00034980057563
   KORAM KA, 1995, T ROY SOC TROP MED H, V89, P146, DOI 10.1016/0035-9203(95)90471-9
   KORENROMP EL, 2004, MAL INC EST COUNTR L
   KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663
   LeHesran JY, 1997, AM J EPIDEMIOL, V146, P826
   Linnemann K, 2001, BIOCHEM SOC T, V29, P86, DOI 10.1042/0300-5127:0290086
   Luxemburger C, 2001, AM J EPIDEMIOL, V154, P459, DOI 10.1093/aje/154.5.459
   Malhotra I, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000116
   MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204
   Menendez C, 2000, J INFECT DIS, V181, P1740, DOI 10.1086/315449
   Mockenhaupt FP, 2006, P NATL ACAD SCI USA, V103, P177, DOI 10.1073/pnas.0506803102
   Moore SE, 2006, P NUTR SOC, V65, P311, DOI 10.1079/PNS2006503
   Moormann AM, 1999, J INFECT DIS, V180, P1987, DOI 10.1086/315135
   Murphy SC, 2001, AM J TROP MED HYG, V64, P57
   Mutabingwa TK, 2005, PLOS MED, V2, P1260, DOI 10.1371/journal.pmed.0020407
   NYARANGO PM, 2006, MALAR J, V5
   O'Meara WP, 2008, LANCET, V372, P1555, DOI 10.1016/S0140-6736(08)61655-4
   Okiro EA, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-151
   Rodrigues A, 2008, TROP MED INT HEALTH, V13, P410, DOI 10.1111/j.1365-3156.2008.02016.x
   Rogerson SJ, 2003, REDOX REP, V8, P295, DOI 10.1179/135100003225002970
   Rogerson SJ, 2003, AM J TROP MED HYG, V68, P115
   Sarr D, 2006, AM J TROP MED HYG, V75, P171
   Satoguina J, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-274
   Schwarz NG, 2008, CLIN INFECT DIS, V47, P1017, DOI 10.1086/591968
   Shulman CE, 2002, LANCET, V360, P494, DOI 10.1016/S0140-6736(02)09662-9
   Shulman CE, 2001, TROP MED INT HEALTH, V6, P770, DOI 10.1046/j.1365-3156.2001.00786.x
   Steketee RW, 2001, AM J TROP MED HYG, V64, P28
   Suguitan AL, 2003, AM J TROP MED HYG, V69, P574
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   van der Sande MAB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000492
   Van Geertruyden JP, 2004, AM J TROP MED HYG, V71, P35
   VICTORA CG, 1988, PEDIATRICS, V81, P807
   von Tempelhoff GF, 2008, CLIN APPL THROMB-HEM, V14, P19, DOI 10.1177/1076029607304748
   Walther B, 2007, ANN TROP MED PARASIT, V101, P657, DOI 10.1179/136485907X229013
   World Health Organization, 2008, WORLD MAL REP 2008
   WHO, 2006, WHO CHILD GROWTH STA
NR 66
TC 9
Z9 9
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JAN 14
PY 2010
VL 9
AR 16
DI 10.1186/1475-2875-9-16
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 571EC
UT WOS:000275733300002
PM 20074331
OA gold
DA 2017-08-15
ER

PT J
AU Sanneh, AFNS
   Pollock, JI
AF Sanneh, A. F. N. S.
   Pollock, J., I
TI Comparison of Pulmonary TB DOTS clinic medication before and after the
   introduction of daily DOTS treatment and attitudes of treatment
   defaulters in the Western Division of the Gambia
SO AFRICAN HEALTH SCIENCES
LA English
DT Article
DE Tuberculosis; Medication policies; Gambia
ID TUBERCULOSIS TREATMENT
AB Background: Over a third of the world's population is infected with the tuberculin bacteria. In 1993 WHO launched the DOTS-strategy to enhance treatment compliance. Despite Gambia's adaption in 1985 it falls below WHO target of 85% cure rate. The defaulter rate was 14% in 2001, which reached 16% in the urban areas of the Western Division in 2003.
   Objectives: This study aimed to compare TB treatment and outcomes before and after the introduction of daily directly observed therapy (DOTS) medication and the perceptions/attitudes of defaulters in the Western Division of the Gambia.
   Methods: The study employed a mixed study design; a quantitative cross sectional study that reviewed the clinic records of pulmonary TB patients before and after the introduction of daily TB-DOTS medication and an in-depth interview of defaulters on the daily medication. The study was conducted at the Brikama TB-clinic in Gambia, located at the main hospital of Brikama serving all satellite villages. It registers on average 110/100 000 new smear-positive pulmonary TB-cases per annum.
   The quantitative arm compared clinic-based records of TB-DOTS medication before and after the introduction of daily medication. The qualitative arm explored the perceptions of daily medication defaulters.
   Results: There was no statistically significant difference between the treatment outcomes of the two medication policies. However patients were less likely to have had three sputum tests reviewed in the daily medication period (22% v 72% Odds Ratio 6.2 (p <0.001). However, they reported that daily medication with its fixed-dose combination was more convenient.
   Conclusion: Patients' full compliance with daily medication was hindered by socio-economic factors. The daily medication with its increased workload undermines the proper implementation of fundamental DOTS-elements, particularly follow up and sputum review.
C1 [Sanneh, A. F. N. S.; Pollock, J., I] Univ W England, Fac Hlth & Social Care, Bristol BS16 1DD, Avon, England.
RP Sanneh, AFNS (reprint author), Kombo Cent Western Div, POB 5242,Brikama Town, Brikama, Gambia.
EM fnssanneh@yahoo.com
CR *DEP STAT HLT GAMB, 1997, MAN NAT TUB LEPR CON
   *DEP STAT HLTH GAM, 2005, CAS NOT RAT PROGR RE
   Diwan VK, 1999, LANCET, V353, P1000, DOI 10.1016/S0140-6736(99)01318-5
   Harper M, 2003, T ROY SOC TROP MED H, V97, P506, DOI 10.1016/S0035-9203(03)80007-X
   Jaiswal A, 2003, TROP MED INT HEALTH, V8, P625, DOI 10.1046/j.1365-3156.2003.01061.x
   Johansson E, 1999, INT J TUBERC LUNG D, V3, P862
   Khan MA, 2002, HEALTH POLICY PLANN, V17, P178, DOI 10.1093/heapol/17.2.178
   KHAN MA, 2000, SOC SCI MED, V50, P247
   *WHO, 1997, PPEPAC975 WHO
   *WHO, 2005, GLOB TB FACT SHEET 2
NR 10
TC 3
Z9 3
U1 0
U2 1
PU MAKERERE UNIV, FAC MED
PI KAMPALA
PA PO BOX 7072, KAMPALA, 00000, UGANDA
SN 1680-6905
J9 AFR HEALTH SCI
JI Afr. Health Sci.
PY 2010
VL 10
IS 2
BP 165
EP 171
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 687NK
UT WOS:000284785000013
PM 21326970
OA No
DA 2017-08-15
ER

PT J
AU Hegazi, A
   Bailey, RL
   Ahadzie, B
   Alabi, A
   Peterson, K
AF Hegazi, A.
   Bailey, R. L.
   Ahadzie, B.
   Alabi, A.
   Peterson, K.
TI Literacy, education and adherence to antiretroviral therapy in The
   Gambia
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
DE adherence; HIV; literacy; education; Koranic education
ID HIV-INFECTION; MEDICATION ADHERENCE; HEALTH LITERACY; COTE-DIVOIRE;
   BARRIERS; TRANSMISSION; PREDICTORS; OUTCOMES; PREVENT; AFRICA
AB We examined the relationship of patients' literacy and education to antiretroviral therapy (ART) adherence in an urban treatment centre in The Gambia. Information on education and literacy systematically collected before ART initiation was compared against selected adherence outcomes. Formally educated patients were significantly more likely to achieve virological suppression at both six and 12 months (87% vs. 67%, OR=3.13, P=0.03; 88% vs. 63%, OR=4.49, P=0.007, respectively). Literate patients had similar benefit at 12 months (OR=3.39 P=0.03), with improved virological outcomes associated with degree of literacy (P=0.003). A trend towards similar results was seen at 6 months for Koranically educated patients; however, this was no longer apparent at 12 months. No significant correlation was seen between socio-demographic characteristics and missed appointments. Our study suggests that literacy, formal education and possibly Koranic education may impact favourably on adherence to ART.
C1 [Hegazi, A.; Bailey, R. L.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Ahadzie, B.; Alabi, A.; Peterson, K.] MRC Labs, Banjul, Gambia.
RP Hegazi, A (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM ahegazi@doctors.net.uk
CR Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008
   Byakika-Tusiime J, 2005, INT J STD AIDS, V16, P38, DOI 10.1258/0956462052932548
   Catz SL, 2000, HEALTH PSYCHOL, V19, P124, DOI 10.1037/0278-6133.19.2.124
   Cohen MS, 2007, ANN INTERN MED, V146, P591
   Dahab M, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-63
   Diabate S, 2007, AIDS, V21, P1799, DOI 10.1097/QAD.0b013e3282a5667b
   EASTON P, 1999, IK NOTES INDIGENOUS, P1
   Eholie SP, 2007, JAIDS-J ACQ IMM DEF, V45, P355
   *GAMB CENTR STAT D, 2003, POP HOUS CENS 2003 C
   *GAMB DEP STAT BAS, 2007, POL DOC ED STAT BRIE
   Gifford AL, 2000, J ACQ IMMUN DEF SYND, V23, P386
   Golin CE, 2002, J GEN INTERN MED, V17, P756, DOI 10.1046/j.1525-1497.2002.11214.x
   Gordon Raymond G., 2005, ETHNOLOGUE LANGUAGES
   Iliyasu Z, 2005, Niger J Med, V14, P290
   Kalichman SC, 1999, J GEN INTERN MED, V14, P267, DOI 10.1046/j.1525-1497.1999.00334.x
   Karcher Heiko, 2006, MedGenMed, V8, P12
   Karcher H, 2007, TROP MED INT HEALTH, V12, P687, DOI 10.1111/j.1365-3156.2007.01830.x
   LANIECE L, 2003, AIDS S3, V17, pS103
   LUCKO HW, 2001, ENGLISH W AFRICA
   Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679
   Mouala Christian, 2006, Sante, V16, P119
   Nachega JB, 2008, AIDS, V22, P2117, DOI 10.1097/QAD.0b013e328310407e
   Orrell C, 2003, AIDS, V17, P1369, DOI 10.1097/01.aids.0000060398.18106.f6
   Paasche-Orlow MK, 2006, J GEN INTERN MED, V21, P835, DOI 10.1111/j.1525-1497.2006.00527.x
   Painter TM, 2005, INT J STD AIDS, V16, P237, DOI 10.1258/0956462053420158
   Paterson DL, 2002, JAIDS, V31, pS103
   Paterson DL, 2000, ANN INTERN MED, V133, P21
   Tadios Yonas, 2006, Ethiop Med J, V44, P237
   Watt MH, 2009, SOC SCI MED, V68, P1793, DOI 10.1016/j.socscimed.2009.02.037
   Weiser S, 2003, JAIDS-J ACQ IMM DEF, V34, P281, DOI 10.1097/00126334-200311010-00004
   Wolf MS, 2007, PATIENT EDUC COUNS, V65, P253, DOI 10.1016/j.pec.2006.08.006
NR 31
TC 7
Z9 7
U1 1
U2 1
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0954-0121
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PY 2010
VL 22
IS 11
BP 1340
EP 1345
AR PII 925786302
DI 10.1080/09540121003693514
PG 6
WC Health Policy & Services; Public, Environmental & Occupational Health;
   Psychology, Multidisciplinary; Respiratory System; Social Sciences,
   Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Psychology; Respiratory System; Biomedical Social Sciences
GA 660YH
UT WOS:000282684800005
PM 20711888
OA No
DA 2017-08-15
ER

PT J
AU Mboto, CI
   Fielder, M
   Davies-Russell, A
   Jewell, AP
AF Mboto, C. I.
   Fielder, M.
   Davies-Russell, A.
   Jewell, A. P.
TI Hepatitis C virus prevalence and serotypes associated with HIV in The
   Gambia
SO BRITISH JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
DE Hepatitis C; HIV; Prevalence; Serotyping
ID WEST-AFRICA; GENERAL-POPULATION; LIVER-CANCER; INFECTION; HCV; RISK;
   ANTIBODIES; DIVERSITY; GENOTYPES; DISEASE
AB Hepatitis C virus (HCV) serotypes are important in the epidemiology and pathogenesis of HCV-related disease, but little is known of this connection in West Africa. Co-infection with human immunodeficiency virus (HIV) is associated with significant morbidity and mortality. This study aims to determine the prevalence of HCV and its serotypes associated with HIV in The Gambia. A total of 1500 individuals referred to the Royal Victoria Teaching Hospital for HIV serology between July and December, 2002 were screened for antibodies to HIV and subsequently for HCV, and seropositive samples were typed. This study shows HIV and HCV prevalence of 6.7% and 1.6 %, respectively, with a co-infection rate of 0.6%. Serotype 2 showed the highest prevalence (58.1 %), followed by serotype 1 (19.4%). Prevalence of HCV serotype 3 was 6.5 % and five samples were untypeable. Co-infection of HIV-1 with HCV serotype 1 showed a prevalence of 44.4%, and with HCV serotype 2 of 33.3%. The findings support the evidence to suggest the West African subregion as the origin of HCV serotype 2. It also demonstrates the need for routine HCV screening of HIV-infected persons and blood donations, and calls for further studies to elucidate the sources of the HCV virus.
C1 [Jewell, A. P.] Kingston Univ, Fac Hlth & Social Care Sci, London SW17 0RE, England.
   [Jewell, A. P.] St Georges Univ London, London, England.
   [Mboto, C. I.] Royal Victoria Hosp, Banjul, Gambia.
   [Fielder, M.; Davies-Russell, A.] Kingston Univ, Sch Life Sci, Surrey, England.
RP Jewell, AP (reprint author), Kingston Univ, Fac Hlth & Social Care Sci, London SW17 0RE, England.
EM a.jewell@kingston.ac.uk
CR AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901
   Bortolotti F, 1997, J PEDIATR-US, V130, P990, DOI 10.1016/S0022-3476(97)70289-0
   Candotti D, 2003, J VIROL, V77, P7914, DOI 10.1128/JVI.77.14.7914-7923.2003
   Chen Min, 1999, Zhonghua Yufang Yixue Zazhi, V33, P158
   COURSAGET P, 1990, RES VIROLOGY, V141, P449, DOI 10.1016/0923-2516(90)90045-K
   De Cock L, 2003, INFECTION, V31, P92, DOI 10.1007/s15010-002-3001-5
   Dodig M, 2001, J CLIN GASTROENTEROL, V33, P367, DOI 10.1097/00004836-200111000-00005
   Fletcher Shona, 2003, J Assoc Nurses AIDS Care, V14, p87S, DOI 10.1177/1055329003255815
   Galel SA, 2002, TRANSFUSION, V42, P1507, DOI 10.1046/j.1537-2995.2002.00236.x
   Guadagnino V, 1997, HEPATOLOGY, V26, P1006, DOI 10.1002/hep.510260431
   Guettouche T, 2005, ANTIVIR THER, V10, P593
   Haushofer AC, 2001, J CLIN VIROL, V20, P41, DOI 10.1016/S1386-6532(00)00154-2
   Hyder Qurratulain, 2009, JPMA Journal of the Pakistan Medical Association, V59, P430
   Jeannel D, 1998, J MED VIROL, V55, P92
   Ka MM, 1995, ANN GASTROENT HEPATO, V31, P329
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   Ola S O, 2002, West Afr J Med, V21, P215
   Passos EP, 2002, HUM REPROD, V17, P2085, DOI 10.1093/humrep/17.8.2085
   Pawlotsky JM, 1996, J INFECT DIS, V174, P1
   Songsivilai S, 1998, CLIN DIAGN LAB IMMUN, V5, P737
   Soriano V, 2005, ANTIVIR THER, V10, P167
   Terrault NA, 2002, HEPATOLOGY, V36, pS99, DOI 10.1053/jhep.2002.36797
   *UNAIDS WHO, 2002, UN REP GLOB HIV AID
   Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506
   Yoo TW, 2005, J INFECT DIS, V191, P4, DOI 10.1086/426513
NR 26
TC 3
Z9 3
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0967-4845
J9 BRIT J BIOMED SCI
JI Br. J. Biomed. Sci.
PY 2010
VL 67
IS 3
BP 140
EP 144
PG 5
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 649DV
UT WOS:000281748800007
PM 20973409
OA No
DA 2017-08-15
ER

PT J
AU Akolo, C
   Adetifa, I
   Shepperd, S
   Volmink, J
AF Akolo, Christopher
   Adetifa, Ifedayo
   Shepperd, Sasha
   Volmink, Jimmy
TI Treatment of latent tuberculosis infection in HIV infected persons
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE AIDS-Related Opportunistic Infections [prevention & control];
   Antitubercular Agents [therapeutic use]; HIV Infections [complications];
   Isoniazid [therapeutic use]; Randomized Controlled Trials as Topic;
   Tuberculosis, Pulmonary [prevention & control]; Adult; Humans
ID ISONIAZID PREVENTIVE THERAPY; ACTIVE ANTIRETROVIRAL THERAPY;
   HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL;
   CHEMOPROPHYLAXIS REGIMENS; SOUTH-AFRICA; ADULTS; RISK; COHORT;
   PYRAZINAMIDE
AB Background
   Individuals with human immunodeficiency virus (HIV) infection are at an increased risk of developing active tuberculosis (TB). It is known that treatment of latent TB infection (LTBI), also referred to as TB preventive therapy or chemoprophylaxis, helps to prevent progression to active disease in HIV negative populations. However, the extent and magnitude of protection (if any) associated with preventive therapy in those infected with HIV should be quantified. This present study is an update of the original review.
   Objectives
   To determine the effectiveness of TB preventive therapy in reducing the risk of active tuberculosis and death in HIV-infected persons.
   Search strategy
   This review was updated using the Cochrane Controlled Trials Register (CCTR), MEDLINE, EMBASE, AIDSLINE, AIDSTRIALS, AIDSearch, NLM Gateway and AIDSDRUGS (publication date from 01 July 2002 to 04 April 2008). We also scanned reference lists of articles and contacted authors and other researchers in the field in an attempt to identify additional studies that may be eligible for inclusion in this review.
   Selection criteria
   We included randomized controlled trials in which HIV positive individuals were randomly allocated to TB preventive therapy or placebo, or to alternative TB preventive therapy regimens. Participants could be tuberculin skin test positive or negative, but without active tuberculosis.
   Data collection and analysis
   Three reviewers independently applied the study selection criteria, assessed study quality and extracted data. Effects were assessed using relative risk for dichotomous data and mean differences for continuous data.
   Main results
   12 trials were included with a total of 8578 randomized participants. TB preventive therapy (any anti-TB drug) versus placebo was associated with a lower incidence of active TB (RR 0.68, 95% CI 0.54 to 0.85). This benefit was more pronounced in individuals with a positive tuberculin skin test (RR 0.38, 95% CI 0.25 to 0.57) than in those who had a negative test (RR 0.89, 95% CI 0.64 to 1.24). Efficacy was similar for all regimens (regardless of drug type, frequency or duration of treatment). However, compared to INH monotherapy, short-course multi-drug regimens were much more likely to require discontinuation of treatment due to adverse effects. Although there was reduction in mortality with INH monotherapy versus placebo among individuals with a positive tuberculin skin test (RR 0.74, 95% CI 0.55 to 1.00) and with INH plus rifampicin versus placebo regardless of tuberculin skin test status (RR 0.69, 95% CI 0.50 to 0.95), overall, there was no evidence that TB preventive therapy versus placebo reduced all-cause mortality (RR 0.94, 95% CI 0.85 to 1.05).
   Authors' conclusions
   Treatment of latent tuberculosis infection reduces the risk of active TB in HIV positive individuals especially in those with a positive tuberculin skin test. The choice of regimen will depend on factors such as availability, cost, adverse effects, adherence and drug resistance. Future studies should assess these aspects. In addition, trials evaluating the long-term effects of anti-tuberculosis chemoprophylaxis, the optimal duration of TB preventive therapy, the influence of level of immunocompromise on effectiveness and combination of anti-tuberculosis chemoprophylaxis with antiretroviral therapy are needed.
C1 [Akolo, Christopher; Shepperd, Sasha] Univ Oxford, Dept Publ Hlth, Oxford OX3 7LF, England.
   [Adetifa, Ifedayo] Med Res Council UK Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Volmink, Jimmy] Univ Stellenbosch, Fac Hlth Sci, ZA-7505 Tygerberg, South Africa.
RP Akolo, C (reprint author), Univ Oxford, Dept Publ Hlth, Oxford OX3 7LF, England.
EM akolochris@yahoo.com
FU Department of Public Health, University of Oxford, UK; AIDS Treatment
   Care Unit, Department of HIV/AIDS, World Health Organisation, Geneva,
   Switzerland; NIHR, UK
FX Internal sources; Department of Public Health, University of Oxford,
   UK.; External sources; AIDS Treatment Care Unit, Department of HIV/AIDS,
   World Health Organisation, Geneva, Switzerland.; Sasha Shepperd is
   funded by an NIHR Research Scientist in Evidence Synthesis Award, UK.
CR Akileswaran C, 2005, CLIN INFECT DIS, V41, P376, DOI 10.1086/431482
   Alfaro EM, 2000, MED CLIN-BARCELONA, V115, P161
   American Thoracic Society (ATS), 1990, AM J RESP CRIT CARE, V142, P725
   Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3
   Balcells ME, 2006, EMERG INFECT DIS, V12, P744
   Centre for Disease Control and Prevention (CDC), 1998, MMWR-MORBID MORTAL W, V47, P1
   Churchyard GJ, 2007, J INFECT DIS, V196, pS52, DOI 10.1086/518662
   Costagliola D, 2005, CLIN INFECT DIS, V41, P1772
   Daniel T M, 2000, TUBERCULOSIS COMPREH, P187
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   Fitzgerald DW, 2000, LANCET, V356, P1470, DOI 10.1016/S0140-6736(00)02870-1
   Fitzgerald DW, 2001, J ACQ IMMUN DEF SYND, V28, P305
   Gordin F, 2000, JAMA-J AM MED ASSOC, V283, P1445, DOI 10.1001/jama.283.11.1445
   Gordin FM, 1997, NEW ENGL J MED, V337, P315, DOI 10.1056/NEJM199707313370505
   GRACIA ML, 1993, 9 INT C AIDS
   Grant AD, 2005, JAMA-J AM MED ASSOC, V293, P2719, DOI 10.1001/jama.293.22.2719
   Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X
   Harries A. D., 1994, P241
   Hawken MP, 1997, AIDS, V11, P875, DOI 10.1097/00002030-199707000-00006
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Lawn SD, 2005, AIDS, V19, P2109, DOI 10.1097/01.aids.0000194808.20035.c1
   Lim JH, 2006, KOREAN J RADIOL, V7, P4
   MATTEELLI A, 1998, 12 WORLD AIDS C
   McShane H, 2005, INT J STD AIDS, V16, P95, DOI 10.1258/0956462053057576
   MENDELSON M, 2007, BR MED B
   Mohammed A, 2007, INT J TUBERC LUNG D, V11, P1114
   Mwinga A, 1998, AIDS, V12, P2447, DOI 10.1097/00002030-199818000-00014
   Nelson K, 2007, EPIDEMIOLOGY, V18, P348, DOI 10.1097/01.ede.0000259985.76928.64
   O'Brien RJ, 1994, TUBERCULOSIS BACK FU, P151
   PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6
   Quigley MA, 2001, AIDS, V15, P215, DOI 10.1097/00002030-200101260-00011
   Rivero A, 2003, ENFERM INFEC MICR CL, V21, P287, DOI 10.1157/13048575
   Rivero A, 2007, ENFERM INFEC MICR CL, V25, P305, DOI 10.1157/13102265
   Saenghirunvattana Sawang, 1996, Journal of the Medical Association of Thailand, V79, P285
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901
   SMIEJA MJ, 2003, COCHRANE LIB
   Watkins RE, 2000, INT J TUBERC LUNG D, V4, P895
   Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201
   World Health Organization, 2008, GLOB TUB CONTR SURV
   *WHO, 2008, REP JOINT WORLD HLTH
   World Health Organization, 2004, INT POL COLL TB HIV
   World Health Organization, 2008, GLOB TUB CONTR EP ST
   World Health Organization, 1998, WHOTB98255
   Wilkinson D, 1998, BRIT MED J, V317, P625
   Williams BG, 2003, SCIENCE, V301, P1535, DOI 10.1126/science.1086845
   WOLDEHANNA S, 2004, COCHRANE DB SYST REV
NR 46
TC 132
Z9 138
U1 2
U2 17
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1469-493X
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2010
IS 1
AR CD000171
DI 10.1002/14651858.CD000171.pub3
PG 81
WC Medicine, General & Internal
SC General & Internal Medicine
GA 557FC
UT WOS:000274654000013
PM 20091503
OA No
DA 2017-08-15
ER

PT J
AU Finney, OC
   Riley, EM
   Walther, M
AF Finney, Olivia C.
   Riley, Eleanor M.
   Walther, Michael
TI Phenotypic analysis of human peripheral blood regulatory T cells
   (CD4(+)FOXP3(+)CD127(lo/-)) ex vivo and after in vitro restimulation
   with malaria antigens
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Human; Malaria; Regulation; Treg; Treg phenotype
ID DENDRITIC CELLS; CHEMOKINE RECEPTOR; CUTTING EDGE; EXPRESSION DEFINES;
   HOMING RECEPTORS; HODGKIN-LYMPHOMA; L-SELECTIN; MEMORY; SUPPRESSION;
   TOLERANCE
AB Regulatory T cells (Treg) play crucial roles in regulating autoimmune responses and immunity to tumors and infectious diseases. However, numerous subpopulations of Treg are now being described and the utility of various Treg markers is being reassessed. Here we report the results of a detailed phenotypic comparison of two supposedly regulatory human T-cell populations, namely CD4(+)FOXP3(+) T cells and CD4(+)CD25(hi) T cells. We find that CD4(+)FOXP3(+) cells are extremely heterogeneous with respect to CD25 expression and that FOXP3(+) and CD25hi CD4+ T cells differ in their expression of chemokine receptors (CCR), CD95 and Bcl-2, suggestive of distinct migration characteristics and susceptibility to apoptosis. Further, we propose that CD25 expression should be regarded as an activation marker rather than as a defining marker of Treg. Lastly, CD4(+)FOXP3(+) T cells activated in vitro with malaria antigen expressed the highest levels of CCR4 and CD95, and the lowest levels of CCR7, indicating that they are most likely generated from effector memory cells during an immune response and rapidly succumb to apoptosis at the end of the response.
C1 [Finney, Olivia C.; Walther, Michael] MRC Labs, Malaria Programme, Banjul, Gambia.
   [Finney, Olivia C.; Riley, Eleanor M.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Immunol Unit, London WC1, England.
RP Walther, M (reprint author), MRC Labs, Malaria Programme, POB 273, Fajara, Gambia.
EM olivia.finney@sbri.org; mwalther@mrc.gm
RI Riley, Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570
FU UK Medical Research Council; MRC
FX The authors thank all the donors in Brefet and Bakau and MRC, as well as
   the field workers and nurses involved in the project. Special thanks are
   due to Emma Lawrence for her help with the cell culture and staining,
   and Idrissa Sambou for kindly preparing malaria antigens for the study.
   The authors are grateful to David Conway for his support and advice
   throughout the study. This work was supported by the UK Medical Research
   Council. O. C. F. was supported by an MRC postgraduate training
   scholarship.
CR Akbar AN, 2003, IMMUNOLOGY, V109, P319, DOI 10.1046/j.1365-2567.2003.01678.x
   AKBAR AN, 1993, IMMUNOL TODAY, V14, P526, DOI 10.1016/0167-5699(93)90181-J
   AKBAR AN, 1993, J EXP MED, V178, P427, DOI 10.1084/jem.178.2.427
   Akbar AN, 2007, NAT REV IMMUNOL, V7, P231, DOI 10.1038/nri2037
   Andrew DP, 2001, J IMMUNOL, V166, P103
   Annunziato F, 2002, J EXP MED, V196, P379, DOI 10.1084/jem.20020110
   Azuma T, 2003, CANCER RES, V63, P4516
   Baecher-Allan C, 2001, J IMMUNOL, V167, P1245
   Bai YL, 2002, J IMMUNOL, V168, P1579
   Brandenburg S, 2008, EUR J IMMUNOL, V38, P1643, DOI 10.1002/eji.200737791
   Campanelli AP, 2006, J INFECT DIS, V193, P1313, DOI 10.1086/502980
   Campbell JJ, 2001, J IMMUNOL, V166, P877
   Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495
   Cavassani KA, 2006, J IMMUNOL, V177, P5811
   Cederbom L, 2000, EUR J IMMUNOL, V30, P1538, DOI 10.1002/1521-4141(200006)30:6<1538::AID-IMMU1538>3.0.CO;2-X
   Colantonio L, 2002, EUR J IMMUNOL, V32, P3506, DOI 10.1002/1521-4141(200212)32:12<3506::AID-IMMU3506>3.0.CO;2-#
   Costantino CM, 2008, EUR J IMMUNOL, V38, P921, DOI 10.1002/eji.200738104
   Couper KN, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000004
   Couper KN, 2007, J IMMUNOL, V178, P4136
   Eksteen B, 2006, J IMMUNOL, V177, P593
   Epple HJ, 2006, BLOOD, V108, P3072, DOI 10.1182/blood-2006-04-016923
   Finney OC, 2009, EUR J IMMUNOL, V39, P1288, DOI 10.1002/eji.200839112
   Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263
   Fritzsching B, 2005, J IMMUNOL, V175, P32
   Fritzsching B, 2006, BLOOD, V108, P3371, DOI 10.1182/blood-2006-02-005660
   Ghiringhelli F, 2005, J EXP MED, V202, P1075, DOI 10.1084/jem.20051511
   Guyot-Revol V, 2006, AM J RESP CRIT CARE, V173, P803, DOI 10.1164/rccm.200508-1294OC
   Hirahara K, 2006, J IMMUNOL, V177, P4488
   Hoffmann P, 2009, EUR J IMMUNOL, V39, P1088, DOI 10.1002/eji.200838904
   Hougardy JM, 2007, AM J RESP CRIT CARE, V176, P409, DOI 10.1164/rccm.200701-084OC
   Ishida T, 2006, CANCER RES, V66, P5716, DOI 10.1158/0008-5472.CAN-06-0261
   Jailwala P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006527
   Jameson SC, 2005, SEMIN IMMUNOL, V17, P231, DOI 10.1016/j.smim.2005.02.003
   Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285
   Katou F, 2001, AM J PATHOL, V158, P1263, DOI 10.1016/S0002-9440(10)64077-1
   Kleinewietfeld M, 2005, BLOOD, V105, P2877, DOI 10.1182/blood-2004-07-2505
   Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728
   Lee I, 2005, J EXP MED, V201, P1037, DOI 10.1084/jem.20041709
   Lee JH, 2007, J IMMUNOL, V178, P301
   lellem A., 2001, J EXP MED, V194, P847
   Lim AYF, 2006, IMMUNOL CELL BIOL, V84, P530, DOI 10.1111/j.1440-1711.2006.01467.x
   Lim HW, 2005, J IMMUNOL, V175, P4180
   Lim HW, 2004, J CLIN INVEST, V114, P1640, DOI 10.1172/JCI200422325
   Lim HW, 2006, J IMMUNOL, V177, P840
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772
   McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7
   Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019
   Onishi Y, 2008, P NATL ACAD SCI USA, V105, P10113, DOI 10.1073/pnas.0711106105
   Piccirillo CA, 2001, J IMMUNOL, V167, P1137
   Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3
   Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295
   Ribeiro-Rodrigues R, 2006, CLIN EXP IMMUNOL, V144, P25, DOI 10.1111/j.1365-2249.2006.03027.x
   Salhi A, 2008, J IMMUNOL, V180, P6139
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Samy ET, 2005, J EXP MED, V202, P771, DOI 10.1084/jem.20041033
   Scholzen A, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000543
   Seddiki N, 2006, BLOOD, V107, P2830, DOI 10.1182/blood-2005-06-2403
   Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468
   Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759
   SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282
   Suffia IJ, 2006, J EXP MED, V203, P777, DOI 10.1084/jem.20052056
   Szanya V, 2002, J IMMUNOL, V169, P2461
   Taams LS, 2005, HUM IMMUNOL, V66, P222, DOI 10.1016/j.himimm.2004.12.006
   Taams LS, 2001, EUR J IMMUNOL, V31, P1122, DOI 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P
   Tadokoro CE, 2006, J EXP MED, V203, P505, DOI 10.1084/jem.20050783
   Tang QZ, 2006, NAT IMMUNOL, V7, P83, DOI 10.1038/ni1289
   Tarbell KV, 2006, SEMIN IMMUNOL, V18, P93, DOI 10.1016/j.smim.2006.01.009
   Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287
   Tosello V, 2008, CLIN IMMUNOL, V126, P291, DOI 10.1016/j.clim.2007.11.008
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Unger WWJ, 2003, INT IMMUNOL, V15, P731, DOI 10.1093/intimm/dxg069
   Urban BC, 2002, CURR OPIN IMMUNOL, V14, P458, DOI 10.1016/S0952-7915(02)00368-0
   Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900
   Valmori D, 2005, J CLIN INVEST, V115, P1953, DOI 10.1172/JCI23963
   van der Burg SH, 2007, P NATL ACAD SCI USA, V104, P12087, DOI 10.1073/pnas.0704672104
   Vignali DAAA, 2008, EUR J IMMUNOL, V38, P908, DOI 10.1002/eji.200738114
   Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941
   Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   Wysocki CA, 2005, BLOOD, V106, P3300, DOI 10.1182/blood-2005-04-1632
   Yang ZZ, 2006, BLOOD, V107, P3639, DOI 10.1182/blood-2005-08-3376
NR 81
TC 16
Z9 17
U1 1
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD JAN
PY 2010
VL 40
IS 1
BP 47
EP 60
DI 10.1002/eji.200939708
PG 14
WC Immunology
SC Immunology
GA 549IP
UT WOS:000274041800007
PM 19877016
OA No
DA 2017-08-15
ER

PT J
AU Leligdowicz, A
   Feldmann, J
   Jaye, A
   Cotten, M
   Dong, T
   McMichael, A
   Whittle, H
   Rowland-Jones, S
AF Leligdowicz, Aleksandra
   Feldmann, Jerome
   Jaye, Assan
   Cotten, Matthew
   Dong, Tao
   McMichael, Andrew
   Whittle, Hilton
   Rowland-Jones, Sarah
TI Direct Relationship between Virus Load and Systemic Immune Activation in
   HIV-2 Infection
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID T-CELL-ACTIVATION; ACTIVE ANTIRETROVIRAL THERAPY; VIRAL LOAD; SEROLOGIC
   MARKERS; TYPE-1 INFECTION; GUINEA-BISSAU; LEVEL VIREMIA; HLA-DR; CD4(+);
   SURVIVAL
AB Immune activation is a hallmark of disease progression in human immunodeficiency virus (HIV) type 1 (HIV-1) and HIV type 2 (HIV-2) infection. However, the relationship between viremia and systemic immune activation is unclear. We assessed the relationship between HIV-2 plasma virus load and immune system activation in a cross-sectional study in a community cohort of HIV-1-positive, HIV-2-positive, and HIV-negative patients, in which many HIV-2-positive patients had nonprogressing infection. HLA-DR and CD38 expression on CD4(+) and CD8(+) T cells was measured, as were plasma beta(2)-microglobulin levels. These markers were related to clinical (virus load and CD4(+) cell count) and immunological (HIV-2-specific interferon gamma secretion) correlates of delayed disease progression. A consistent positive correlation was identified between the level of HIV-2 viremia and immune activation. We propose that increasing virus load may contribute to systemic immune activation in HIV-2 infection.
C1 [Leligdowicz, Aleksandra; Dong, Tao; McMichael, Andrew; Rowland-Jones, Sarah] John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford OX3 9DS, England.
   [Leligdowicz, Aleksandra; Feldmann, Jerome; Jaye, Assan; Cotten, Matthew; Whittle, Hilton; Rowland-Jones, Sarah] MRC Labs, Fajara, Gambia.
RP Leligdowicz, A (reprint author), John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford OX3 9DS, England.
EM aleksandra.leligdowicz@mail.mcgill.ca
OI Leligdowicz, Aleksandra/0000-0001-6055-4644
FU Medical Research Council, United Kingdom; Rhodes Trust
FX Medical Research Council, United Kingdom; Rhodes Trust (Rhodes
   Scholarship to A. L.).
CR Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003
   Appay V, 2008, J PATHOL, V214, P231, DOI 10.1002/path.2276
   Bentwich Z, 1998, CLIN EXP IMMUNOL, V111, P1
   Berry N, 1998, J Hum Virol, V1, P457
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Betts MR, 2004, J IMMUNOL, V172, P6407
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Duvall MG, 2008, EUR J IMMUNOL, V38, P350, DOI 10.1002/eji.200737768
   FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305
   Foxall RB, 2008, J VIROL, V82, P9795, DOI 10.1128/JVI.01217-08
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Gottlieb GS, 2002, J INFECT DIS, V185, P905, DOI 10.1086/339295
   Grossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380
   Grossman Z, 2002, NAT MED, V8, P319, DOI 10.1038/nm0402-319
   Grossman Z, 1998, P NATL ACAD SCI USA, V95, P6314, DOI 10.1073/pnas.95.11.6314
   HANNIBAL MC, 1993, J VIROL, V67, P5035
   Hanson A, 2005, AIDS RES HUM RETROV, V21, P791, DOI 10.1089/aid.2005.21.791
   Hazenberg MD, 2003, AIDS, V17, P1881, DOI 10.1097/01.aids.0000076311.76477.6e
   Hazenberg MD, 2000, BLOOD, V95, P249
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Jaffar S, 2005, AIDS RES HUM RETROV, V21, P560, DOI 10.1089/aid.2005.21.560
   KESTENS L, 1994, CLIN EXP IMMUNOL, V95, P436
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Lempicki RA, 2000, P NATL ACAD SCI USA, V97, P13778, DOI 10.1073/pnas.250472097
   Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83
   Michel P, 2000, J INFECT DIS, V181, P64, DOI 10.1086/315170
   Milush JM, 2007, J IMMUNOL, V179, P3047
   Ostrowski MA, 1998, J VIROL, V72, P7772
   Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020
   PRINCE HE, 1990, J ACQ IMMUN DEF SYND, V3, P525
   Scriba TJ, 2005, J CLIN INVEST, V115, P443, DOI 10.1172/JCI200523084
   Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8
   Sousa AE, 2002, J IMMUNOL, V169, P3400
   Stuart JWTC, 2000, J ACQ IMMUN DEF SYND, V25, P203
   van der Sande MAB, 2004, JAIDS-J ACQ IMM DEF, V37, P1288, DOI 10.1097/01.qai.0000122708.59121.03
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
   Zinkernagel RM, 1996, SCIENCE, V271, P173, DOI 10.1126/science.271.5246.173
NR 40
TC 26
Z9 26
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 1
PY 2010
VL 201
IS 1
BP 114
EP 122
DI 10.1086/648733
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 536XU
UT WOS:000273078000015
PM 19938978
OA No
DA 2017-08-15
ER

PT J
AU Cole-Ceesay, R
   Cherian, M
   Sonko, A
   Shivute, N
   Cham, M
   Davis, M
   Fatty, F
   Wieteska, S
   Baro, M
   Watson, D
   Phillips, B
   MacDonald, R
   Hayden, B
   Southall, D
AF Cole-Ceesay, Ramou
   Cherian, Meena
   Sonko, Alieu
   Shivute, Nestor
   Cham, Mamady
   Davis, Michael
   Fatty, Famara
   Wieteska, Susan
   Baro, Momodou
   Watson, Diane
   Phillips, Barbara
   MacDonald, Rhona
   Hayden, Brigid
   Southall, David
TI Strengthening the emergency healthcare system for mothers and children
   in The Gambia
SO REPRODUCTIVE HEALTH
LA English
DT Article
AB A system to improve the management of emergencies during pregnancy, childbirth, infancy and childhood in a region of The Gambia (Brikama) with a population of approximately 250,000 has been developed.
   This was accomplished through formal partnership between the Gambian Ministry of Health, the World Health Organisation, Maternal Childhealth Advocacy International and the Advanced Life Support Group.
   Since October 2006, the hospital in Brikama has been renovated and equipped and more efficiently provided with emergency medicines. An emergency ambulance service now links the community with the hospital through a mobile telephone system. Health professionals from community to hospital have been trained in obstetric, neonatal and paediatric emergency management using skills' based education. The programme was evaluated in log books detailing individual resuscitations and by external assessment.
   The hospital now has constant water and electricity, a functioning operating theatre and emergency room; the maternity unit and children's wards have better emergency equipment and there is a more reliable supply of oxygen and emergency drugs, including misoprostol (for treating post partum haemorrhage) and magnesium sulphate (for severe pre-eclampsia). There is also a blood transfusion service.
   Countrywide, 217 doctors, nurses, and midwives have undergone accredited training in the provision of emergency maternal, newborn and child care, including for major trauma. 33 have received additional education through Generic Instructor Courses and 15 have reached full instructor status. 83 Traditional Birth Attendants and 48 Village Health Workers have been trained in the recognition and initial management of emergencies, including resuscitation of the newborn. Eleven and ten nurses underwent training in peri-operative nursing and anaesthetics respectively, to address the acute shortage required for emergency Caesarean section.
   Between May 2007 and March 2010, 109 patients, mostly pregnant mothers, were stabilised and transported to hospital by the new emergency ambulance service.
   293 resuscitation attempts were documented in personal logbooks.
   A sustainable system for better managing emergencies has been established and is helping to negate the main obstacle impeding progress: the country's lack of available trained medical and nursing staff. However, insufficient attention was paid to improving staff morale and accommodation representing significant failings of the programme.
C1 [Cole-Ceesay, Ramou] Govt Gambia, State Dept, Banjul, Gambia.
   [Cherian, Meena] WHO Geneva, Dept Essential Hlth Technol, Emergency & Essential Surg Care Clin Procedures U, Geneva, Switzerland.
   [Sonko, Alieu] Brikama Major Hlth Ctr, Head Off, Brikama, Gambia.
   [Shivute, Nestor] HO Country Off, Banjul, Gambia.
   [Cham, Mamady] Gambian Govt, Minist Hlth, Banjul, Gambia.
   [Davis, Michael] Adv Life Support Grp, Educ Dept, Manchester M27 0LA, Lancs, England.
   [Fatty, Famara] Minist Hlth, Famara Fatty Reprod & Child Hlth Unit, Banjul, Gambia.
   [Wieteska, Susan; Phillips, Barbara] Adv Life Support Grp, Head Off, Manchester M27 0LA, Lancs, England.
   [Baro, Momodou] Royal Victoria Teaching Hosp, Anaesthet Dept, Banjul, Gambia.
   [Watson, Diane] Royal Gwent Hosp, Anaesthet Dept, Newport, Gwent, Wales.
   [MacDonald, Rhona; Hayden, Brigid; Southall, David] MCAI, Head Off, Nottingham NG1 5BB, England.
RP Southall, D (reprint author), MCAI, Head Off, 83 Derby Rd, Nottingham NG1 5BB, England.
EM director@mcai.org.uk
CR Bullock I, 2008, POCKET GUIDE TEACHIN
   Child Friendly Healthcare Initiative (CFHI, MAT CHILDH ADV INT
   Chan M, 2005, REPROD HLTH, V2, P3
   de Bernis L, 2003, BRIT MED BULL, V67, P39, DOI 10.1093/bmb/ldg017
   Hafeez A, 2004, BRIT MED J, V328, P834, DOI 10.1136/bmj.328.7443.834
   Igberase GO, 2007, J OBSTET GYNAECOL, V27, P275, DOI 10.1080/01443610701213687
   Kowalewski M, 2000, Afr J Reprod Health, V4, P100, DOI 10.2307/3583247
   Leigh B, 2008, INT J GYNECOL OBSTET, V101, P107, DOI 10.1016/j.ijgo.2008.01.012
   Lema V M, 2005, East Afr Med J, V82, P3
   [Anonymous], PATHW EM CAR PREGN C
   Manuals and Pocketbooks of Emergency Healthcare. Maternal and Childhealth Advocacy International and the Advanced Life Support Group, MAN POCK EM HEALTHC
   [Anonymous], CONT LIST PORT EM KI
   Onah H E, 2005, J Obstet Gynaecol, V25, P569, DOI 10.1080/01443610500231484
   Prytherch Helen, 2007, BMC Pregnancy Childbirth, V7, P16, DOI 10.1186/1471-2393-7-16
   Ramji Siddarth, 2006, Indian Pediatr, V43, P1029
   Southall D, 2010, LANCET, V376, P498, DOI 10.1016/S0140-6736(10)61157-9
   Southall DP, 2000, PEDIATRICS, V106, P1054, DOI 10.1542/peds.106.5.1054
   [Anonymous], 2008, STAT WORLDS CHILDR
   Walraven G, 2000, B WORLD HEALTH ORGAN, V78, P603
   WHO, 1999, RED MAT MORT JOINT W
   WHO, 2006, INT MAN PREGN CHILDB
   World Health Organization, 2005, POCK BOOK HOSP CAR C
   World Health Organization Department of Reproductive Health and Research, 2007, INT MAN PREGN CHILDB
   Zafar S, 2009, RESUSCITATION, V80, P449, DOI 10.1016/j.resuscitation.2008.11.026
NR 24
TC 18
Z9 18
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4755
J9 REPROD HEALTH
JI Reprod. Health
PY 2010
VL 7
AR 21
DI 10.1186/1742-4755-7-21
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V27IT
UT WOS:000208607600003
PM 20718979
OA gold
DA 2017-08-15
ER

PT J
AU Natividad, A
   Hull, J
   Luoni, G
   Holland, M
   Rockett, K
   Joof, H
   Burton, M
   Mabey, D
   Kwiatkowski, D
   Bailey, R
AF Natividad, Angels
   Hull, Jeremy
   Luoni, Gaia
   Holland, Martin
   Rockett, Kirk
   Joof, Hassan
   Burton, Matthew
   Mabey, David
   Kwiatkowski, Dominic
   Bailey, Robin
TI Innate immunity in ocular Chlamydia trachomatis infection: contribution
   of IL8 and CSF2 gene variants to risk of trachomatous scarring in
   Gambians
SO BMC MEDICAL GENETICS
LA English
DT Article
ID RESPIRATORY SYNCYTIAL VIRUS; NEUTROPHIL GELATINASE; MATRIX
   METALLOPROTEINASES; HAPLOTYPE RECONSTRUCTION; RHEUMATOID-ARTHRITIS;
   SUSCEPTIBILITY LOCUS; POPULATION; CYTOKINE; INTERLEUKIN-8; DISEASE
AB Background: Trachoma, a chronic keratoconjunctivitis caused by Chlamydia trachomatis, is the world's commonest infectious cause of blindness. Blindness is due to progressive scarring of the conjunctiva (trachomatous scarring) leading to in-turning of eyelashes (trichiasis) and corneal opacification. We evaluated the contribution of genetic variation across the chemokine and cytokine clusters in chromosomes 4q and 5q31 respectively to risk of scarring trachoma and trichiasis in a large case-control association study in a Gambian population.
   Methods: Linkage disequilibrium (LD) mapping was used to investigate risk effects across the 4q and 5q31 cytokine clusters in relation to the risk of scarring sequelae of ocular Ct infection. Disease association and epistatic effects were assessed in a population based study of 651 case-control pairs by conditional logistic regression (CLR) analyses.
   Results: LD mapping suggested that genetic effects on risk within these regions mapped to the pro-inflammatory innate immune genes interleukin 8 (IL8) and granulocyte-macrophage colony stimulatory factor (CSF2) loci. The IL8-251 rare allele (IL8-251 TT) was associated with protection from scarring trachoma (OR = 0.29 p = 0.027). The intronic CSF2_27348 A allele in chromosome 5q31 was associated with dose dependent protection from trichiasis, with each copy of the allele reducing risk by 37% (p = 0.005). There was evidence of epistasis, with effects at IL8 and CSF2 loci interacting with those previously reported at the MMP9 locus, a gene acting downstream to IL8 and CSF2 in the inflammatory cascade.
   Conclusion: innate immune response SNP-haplotypes are linked to ocular Ct sequelae. This work illustrates the first example of epistatic effects of two genes on trachoma.
C1 [Natividad, Angels; Holland, Martin; Burton, Matthew; Mabey, David; Bailey, Robin] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Hull, Jeremy; Luoni, Gaia; Rockett, Kirk; Kwiatkowski, Dominic] Univ Oxford, Ctr Human Genet, Wellcome Trust, Oxford, England.
   [Holland, Martin; Joof, Hassan] MRC Labs, Fajara, Gambia.
   [Natividad, Angels] Fac Med Necker Enfants Malad, INSERM, U550, Lab Genet Humaine Malad Infect, F-75015 Paris, France.
RP Natividad, A (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM angels.natividad@inserm.fr; jhull@molbiol.ox.ac.uk; gaia@well.ox.ac.uk;
   mholland@mrc.gm; Kirk.Rockett@well.ox.ac.uk; hmjoof@yahoo.co.uk;
   matthew.burton@lshtm.ac.uk; david.mabey@lshtm.ac.uk;
   dominic@well.ox.ac.uk; robin.bailey@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Kwiatkowski,
   Dominic/0000-0002-5023-0176; Burton, Matthew/0000-0003-1872-9169
FU Medical Research Council, UK; The Wellcome Trust, UK
FX We thank the study participants, field workers and laboratory staff at
   the Medical Research Council Laboratories in The Gambia for their
   assistance. This work was supported by the Medical Research Council, UK
   and The Wellcome Trust, UK.
CR Barteneva N, 1996, INFECT IMMUN, V64, P4830
   Bobo LD, 1997, J INFECT DIS, V176, P1524
   Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Dautry-Varsat A, 2005, CELL MICROBIOL, V7, P1714, DOI 10.1111/j.1462-5822.2005.00627.x
   Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023
   Hull J, 2004, HUM GENET, V114, P272, DOI 10.1007/s00439-003-1038-x
   Hull J, 2001, AM J HUM GENET, V69, P413, DOI 10.1086/321291
   Kim MP, 2005, INFECT IMMUN, V73, P632, DOI 10.1128/IAI.73.1.632-634.2005
   Lu H, 2002, J IMMUNOL, V169, P6324
   Luoni G, 2005, GENES IMMUN, V6, P723, DOI 10.1038/sj.gene.6364250
   Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112
   Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1
   Mansur AH, 1998, CLIN EXP ALLERGY, V28, P141
   MARSH CB, 1994, CHEST, V105, P1855, DOI 10.1378/chest.105.6.1855
   MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x
   Maxion HK, 2004, INFECT IMMUN, V72, P6330, DOI 10.1128/IAI.72.11.6330-6340.2004
   Morre SA, 2003, J INFECT DIS, V187, P341, DOI 10.1086/346044
   Morre SA, 2003, J INFECT DIS, V187, P342
   Mozzato-Chamay N, 2001, GENES IMMUN, V2, P153, DOI 10.1038/sj.gene.6363753
   Mozzato-Chamay N, 2000, J INFECT DIS, V182, P1545, DOI 10.1086/315891
   Natividad A, 2007, GENES IMMUN, V8, P288, DOI 10.1038/sj.gene.6364384
   Natividad A, 2005, GENES IMMUN, V6, P332, DOI 10.1038/sj.gene.6364182
   NATIVIDAD A, 2006, INVESTIGATION GENETI
   Natividad A, 2008, HUM MOL GENET, V17, P323, DOI 10.1093/hmg/ddm310
   Pastey MK, 1999, J VIROL, V73, P7262
   Ramsey KH, 2005, INFECT IMMUN, V73, P6962, DOI 10.1128/IAI.73.10.6962-6973.2005
   Rasmussen SJ, 1997, J CLIN INVEST, V99, P77, DOI 10.1172/JCI119136
   Rioux JD, 2001, NAT GENET, V29, P223, DOI 10.1038/ng1001-223
   Schachter J, 1990, Scand J Infect Dis Suppl, V69, P55
   Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Stephens RS, 2003, TRENDS MICROBIOL, V11, P44, DOI 10.1016/S0966-842X(02)00011-2
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Tokuhiro S, 2003, NAT GENET, V35, P341, DOI 10.1038/ng1267
   Van Den Steen PE, 2002, FASEB J, V16, DOI 10.1096/fj.01-0688com
   Van den Steen PE, 2000, BLOOD, V96, P2673
   West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158
NR 40
TC 14
Z9 14
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD DEC 16
PY 2009
VL 10
AR 138
DI 10.1186/1471-2350-10-138
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 547SK
UT WOS:000273909300001
PM 20015396
OA gold
DA 2017-08-15
ER

PT J
AU Helbok, R
   Kendjo, E
   Issifou, S
   Lackner, P
   Newton, CR
   Kombila, M
   Agbenyega, T
   Bojang, K
   Dietz, K
   Schmutzhard, E
   Kremsner, PG
AF Helbok, Raimund
   Kendjo, Eric
   Issifou, Saadou
   Lackner, Peter
   Newton, Charles R.
   Kombila, Maryvonne
   Agbenyega, Tsiri
   Bojang, Kalifa
   Dietz, Klaus
   Schmutzhard, Erich
   Kremsner, Peter Gottfried
TI The Lambarene Organ Dysfunction Score (LODS) Is a Simple Clinical
   Predictor of Fatal Malaria in African Children
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; DISCRIMINATE DIFFERENT LEVELS; GAMBIAN
   CHILDREN; PROGNOSTIC VALUE; FEATURES; INDICATORS; SEVERITY
AB Background. Plasmodium falciparum malaria accounts for >1 million deaths annually, mostly among young children in sub-Saharan Africa. Identifying those individuals who are likely to die is crucial. Several factors have been independently associated with death. Because malaria is a systemic disease, a quantitative score combining such risk factors may be superior.
   Methods. We used both forward and backward stepwise logistic regression to select the best predictors of death, as evaluated for 23,890 African children with severe P. falciparum malaria. The study was conducted from December 2000 through May 2005 in 6 hospital-based research units (in Banjul in the Gambia, Blantyre in Malawi, Kilifi in Kenya, Kumasi in Ghana, and Lambarene and Libreville in Gabon) in a network established to study severe malaria in African children (ie, the SMAC Network).
   Results. The Lambarene Organ Dysfunction Score (LODS) combines 3 variables: coma, prostration, and deep breathing. A LODS >0 (odd ratio, 9.6; 95% confidence interval, 8.0-11.4) has 85% sensitivity to predict death, and a LODS <3 is highly (98%) specific for survival.
   Conclusions. The LODS is a simple clinical predictor of fatal malaria in African children. This score provides accurate and rapid identification of children needing either referral or increased attention.
C1 [Helbok, Raimund; Kendjo, Eric; Issifou, Saadou; Kremsner, Peter Gottfried] Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon.
   [Kombila, Maryvonne] Univ Hlth Sci Libreville, Fac Med, Dept Parasitol Mycol & Trop Med, Libreville, Gabon.
   [Helbok, Raimund; Lackner, Peter; Schmutzhard, Erich] Innsbruck Med Univ, Dept Clin Neurol, Innsbruck, Austria.
   [Kendjo, Eric; Issifou, Saadou; Kremsner, Peter Gottfried] Univ Tubingen, Inst Trop Med, Tubingen, Germany.
   [Dietz, Klaus] Univ Tubingen, Dept Med Biometry, Tubingen, Germany.
   [Newton, Charles R.] Kenya Govt Med Res Ctr, Ctr Geog Med, Kilifi, Kenya.
   [Newton, Charles R.] UCL, Inst Child Hlth, Neurosci Unit, London, England.
   [Agbenyega, Tsiri] Univ Sci & Technol Kumasi, Sch Med Sci, Kumasi, Ghana.
   [Bojang, Kalifa] MRC Labs, Banjul, Gambia.
RP Helbok, R (reprint author), Anichstr 35, A-6020 Innsbruck, Austria.
EM raimund.helbok@uki.at
RI Dietz, Klaus/R-9268-2016; Newton, 21/B-7578-2014
OI Dietz, Klaus/0000-0001-8503-9737; Newton, 21/0000-0002-6999-5507;
   Bojang, Kalifa/0000-0001-7506-0938
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health [AI45955]; Wellcome Trust [070114/Z/02/Z]
FX Financial support: National Institute of Allergy and Infectious
   Diseases, National Institutes of Health (grant AI45955); Wellcome Trust
   (grant 070114/Z/02/Z to C. R. N.).
CR Allen SJ, 1996, QJM-MON J ASSOC PHYS, V89, P779
   Bojang KA, 1997, ANN TROP PAEDIATR, V17, P355
   English M, 1996, AM J TROP MED HYG, V55, P521
   Evans JA, 2006, J PEDIATR-US, V149, P676, DOI 10.1016/j.peds.2006.07.040
   Helbok R, 2003, AM J TROP MED HYG, V68, P372
   Helbok R, 2005, AM J TROP MED HYG, V72, P150
   Helbok R, 2006, AM J TROP MED HYG, V75, P443
   Issifou S, 2007, AM J TROP MED HYG, V77, P1015
   Kremsner PG, 2009, J INFECT DIS, V199, P142, DOI 10.1086/595295
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Newton CRJC, 2005, CLIN INFECT DIS, V41, P948, DOI 10.1086/432941
   ROSSET S, 2004, ACM INT C P SERIES, V69, P89
   Schellenberg D, 1999, AM J TROP MED HYG, V61, P431
   Severe falciparum malaria. World Health Organization Communicable Diseases Cluster, 2000, T R SOC TROP MED HYG, pS1
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Taylor T, 2006, T ROY SOC TROP MED H, V100, P615, DOI 10.1016/j.trstmh.2005.09.021
   TAYLOR TE, 1993, Q J MED, V86, P99
   WALLER D, 1995, CLIN INFECT DIS, V21, P577
NR 19
TC 20
Z9 20
U1 0
U2 6
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 15
PY 2009
VL 200
IS 12
BP 1834
EP 1841
DI 10.1086/648409
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 520UH
UT WOS:000271874000005
PM 19911989
OA No
DA 2017-08-15
ER

PT J
AU Feldmann, J
   Leligdowicz, A
   Jaye, A
   Dong, T
   Whittle, H
   Rowland-Jones, SL
AF Feldmann, Jerome
   Leligdowicz, Aleksandra
   Jaye, Assan
   Dong, Tao
   Whittle, Hilton
   Rowland-Jones, Sarah L.
TI Downregulation of the T-Cell Receptor by Human Immunodeficiency Virus
   Type 2 Nef Does Not Protect against Disease Progression
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID PROVIRAL LOAD; NATURAL INFECTION; IMMUNE ACTIVATION; HIV-2 INFECTION;
   SOOTY MANGABEYS; LEVEL VIREMIA; PATHOGENESIS; CD4(+); AIDS; INDIVIDUALS
AB Chronic immune activation is thought to play a major role in human immunodeficiency virus (HIV) pathogenesis, but the relative contributions of multiple factors to immune activation are not known. One proposed mechanism to protect against immune activation is the ability of Nef proteins from some HIV and simian immunodeficiency virus strains to downregulate the T-cell receptor (TCR)-CD3 complex of the infected cell, thereby reducing the potential for deleterious activation. HIV type 1 (HIV-1) Nef has lost this property. In contrast to HIV-1, HIV-2 infection is characterized by a marked disparity in the disease course, with most individuals maintaining a normal life span. In this study, we examined the relationship between the ability of HIV-2 Nef proteins to downregulate the TCR and immune activation, comparing progressors and nonprogressors. Representative Nef variants were isolated from 28 HIV-2-infected individuals. We assessed their abilities to downregulate the TCR from the surfaces of CD4 T cells. In the same individuals, the activation of peripheral lymphocytes was evaluated by measurement of the expression levels of HLA-DR and CD38. We observed a striking correlation of the TCR downregulation efficiency of HIV-2 Nef variants with immune activation in individuals with a low viral load. This strongly suggests that Nef expression can influence the activation state of the immune systems of infected individuals. However, the efficiency of TCR downregulation by Nef was not reduced in progressing individuals, showing that TCR downregulation does not protect against progression in HIV-2 infection.
C1 [Feldmann, Jerome; Leligdowicz, Aleksandra; Jaye, Assan; Whittle, Hilton; Rowland-Jones, Sarah L.] MRC Labs, Fajara, Gambia.
   [Feldmann, Jerome; Dong, Tao; Rowland-Jones, Sarah L.] John Radcliffe Hosp, MRC Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 0DW, England.
RP Feldmann, J (reprint author), Inst Pasteur, 28 Rue Dr Roux, Paris, France.
EM jfeldman@pasteur.fr
OI Leligdowicz, Aleksandra/0000-0001-6055-4644
FU HFSPO; Rhodes Trust; Medical Research Council United Kingdom
FX J.F. was supported by a long-term fellowship from HFSPO and A. L. by the
   Rhodes Trust, and the study was funded by the Medical Research Council
   United Kingdom.
CR Bell I, 1998, J GEN VIROL, V79, P2717
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430
   Clerici M, 2000, AIDS, V14, P2083, DOI 10.1097/00002030-200009290-00003
   Damond F, 2001, J CLIN MICROBIOL, V39, P4264, DOI 10.1128/JCM.39.12.4264-4268.2001
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Grossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380
   Hanson A, 2005, AIDS RES HUM RETROV, V21, P791, DOI 10.1089/aid.2005.21.791
   Hirsch VM, 2004, AIDS REV, V6, P40
   HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0
   Holm GH, 2005, J VIROL, V79, P6299, DOI 10.1128/JVI.79.10.6299-6311.2005
   Huigen MCDG, 2004, EUR J CLIN INVEST, V34, P57, DOI 10.1111/j.1365-2362.2004.01282.x
   Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
   Jobe O, 1999, CLIN EXP IMMUNOL, V116, P474
   Kawai T, 2007, J BIOCHEM, V141, P137, DOI 10.1093/jb/mvm032
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Ling BH, 2004, J VIROL, V78, P8902, DOI 10.1128/JVI.78.16.8902-8908.2004
   Lukwiya M, 2001, J ACQ IMMUN DEF SYND, V28, P429
   Popper SJ, 2000, J VIROL, V74, P1554, DOI 10.1128/JVI.74.3.1554-1557.2000
   Rowland-Jones SL, 2007, NAT IMMUNOL, V8, P329, DOI 10.1038/ni0407-329
   Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033
   Schindler M, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000107
   Schmidt HA, 2007, CURR PROTOC BIOINFOR, V6
   Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8
   Sumpter B, 2007, J IMMUNOL, V178, P1680
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 27
TC 10
Z9 10
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD DEC 15
PY 2009
VL 83
IS 24
BP 12968
EP 12972
DI 10.1128/JVI.01252-09
PG 5
WC Virology
SC Virology
GA 521PB
UT WOS:000271932900030
PM 19812166
OA No
DA 2017-08-15
ER

PT J
AU Jawara, M
   Smallegange, RC
   Jeffries, D
   Nwakanma, DC
   Awolola, TS
   Knols, BGJ
   Takken, W
   Conway, DJ
AF Jawara, Musa
   Smallegange, Renate C.
   Jeffries, David
   Nwakanma, Davis C.
   Awolola, Taiwo Samson
   Knols, Bart G. J.
   Takken, Willem
   Conway, David J.
TI Optimizing Odor-Baited Trap Methods for Collecting Mosquitoes during the
   Malaria Season in The Gambia
SO PLOS ONE
LA English
DT Article
ID VOLATILE ORGANIC-COMPOUNDS; VECTOR ANOPHELES-GAMBIAE; MM-X TRAPS;
   CARBON-DIOXIDE; HUMAN SKIN; SEMIFIELD CONDITIONS; MOLECULAR-FORMS;
   COMPLEX; DIPTERA; ATTRACTIVENESS
AB Background: Baited traps are potential tools for removal or surveillance of disease vectors. To optimize the use of counter-flow traps baited with human odor ( nylon socks that had been worn for a single day) to capture wild mosquitoes in the Gambia, investigations were conducted at a field experimental site.
   Methodology/Principal Findings: Experiments employing Latin square design were conducted with a set of six huts to investigate the effects of the following on overnight mosquito trap catches: (1) placement of traps indoors or immediately outdoors, CO2 supply, and presence of a human subject in the hut; (2) trap height for collecting mosquitoes immediately outdoors; (3) height and distance from hut; (4) interaction between multiple traps around a single hut and entry of mosquitoes into huts. A total of 106,600 adult mosquitoes (9.1% Anopheles gambiae s.l., 4.0% other Anopheles species) were collected over 42 nights. The high numbers of An. gambiae s.l. and other mosquitoes collected by odor-baited traps required CO2 but were largely independent of the presence of a person sleeping in the hut or of trap placement indoors or outdoors. For outdoor collection that is considered less intrusive, traps opening 15 cm above the floor of the hut veranda were more highly effective than traps at other heights or further from the hut. There was no significant evidence of saturation or competition by the traps, with multiple traps around a hut each collecting almost as many mosquitoes as single traps and no effect on the numbers of mosquitoes entering the huts.
   Conclusions/Significance: The outdoor trapping protocol is convenient to compare attractiveness of different odors or synthetic chemicals to malaria vectors and other wild mosquitoes. The finding that such traps are reliably attractive in the presence or absence of a human volunteer encourages their potential development as standardised surveillance tools.
C1 [Jawara, Musa; Jeffries, David; Nwakanma, Davis C.; Awolola, Taiwo Samson; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Smallegange, Renate C.; Knols, Bart G. J.; Takken, Willem] Wageningen Univ, Entomol Lab, Wageningen, Netherlands.
RP Jawara, M (reprint author), MRC Labs, Banjul, Gambia.
EM dconway@mrc.gm
OI Conway, David/0000-0002-8711-3037
FU Foundation for the National Institutes of Health; Bill and Melinda Gates
   Foundation, through the Grand Challenges in Global Health Initiative
   [121]; Medical Research Council of the United Kingdom
FX This work was funded as part of a grant from the Foundation for the
   National Institutes of Health and the Bill and Melinda Gates Foundation,
   through the Grand Challenges in Global Health Initiative ( GCGH# 121
   grant co-ordinated by Dr. Larry Zwiebel), and by the Medical Research
   Council of the United Kingdom. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bernier UR, 2000, ANAL CHEM, V72, P747, DOI 10.1021/ac990963k
   Braks MAH, 1999, PARASITOL TODAY, V15, P409, DOI 10.1016/S0169-4758(99)01514-8
   Caputo B, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-182
   Cook SM, 2007, ANNU REV ENTOMOL, V52, P375, DOI 10.1146/annurev.ento.52.110405.091407
   Cooper RD, 2004, J AM MOSQUITO CONTR, V20, P239
   Cork A, 1996, CIBA F SYMP, V200, P71
   Costantini C, 1996, MED VET ENTOMOL, V10, P220, DOI 10.1111/j.1365-2915.1996.tb00734.x
   Curran AM, 2005, J CHEM ECOL, V31, P1607, DOI 10.1007/s10886-005-5801-4
   DAY JF, 1994, AM J TROP MED HYG, V50, P126
   Fanello C, 2002, MED VET ENTOMOL, V16, P461, DOI 10.1046/j.1365-2915.2002.00393.x
   Gallagher M, 2008, BRIT J DERMATOL, V159, P780, DOI 10.1111/j.1365-2133.2008.08748.x
   GILLIES MT, 1969, B ENTOMOL RES, V59, P441
   Healy TP, 2000, MED VET ENTOMOL, V14, P195, DOI 10.1046/j.1365-2915.2000.00238.x
   Jawara M, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-156
   Kirby MJ, 2009, LANCET, V374, P998, DOI 10.1016/S0140-6736(09)60871-0
   Kline DL, 2007, J AM MOSQUITO CONTR, V23, P241, DOI 10.2987/8756-971X(2007)23[241:STAMTT]2.0.CO;2
   LINDSAY SW, 1993, J MED ENTOMOL, V30, P368
   Lindsay SW, 2003, TROP MED INT HEALTH, V8, P512, DOI 10.1046/j.1365-3156.2003.01059.x
   Meijerink J, 2001, J INSECT PHYSIOL, V47, P455, DOI 10.1016/S0022-1910(00)00136-0
   Njiru BN, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-39
   Omolo MO, 2004, PHYTOCHEMISTRY, V65, P2797, DOI 10.1016/j.phytochem.2004.08.035
   Qiu YT, 2007, J MED ENTOMOL, V44, P970, DOI 10.1603/0022-2585(2007)44[970:AOMTBW]2.0.CO;2
   Schmied WH, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-230
   Seyoum A, 2002, AM J TROP MED HYG, V67, P191
   Takken W, 1999, ANNU REV ENTOMOL, V44, P131, DOI 10.1146/annurev.ento.44.1.131
   Tan CH, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-52
NR 26
TC 25
Z9 26
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 4
PY 2009
VL 4
IS 12
AR e8167
DI 10.1371/journal.pone.0008167
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 533MY
UT WOS:000272829200007
PM 19997640
OA gold
DA 2017-08-15
ER

PT J
AU Satoguina, J
   Walther, B
   Drakeley, C
   Nwakanma, D
   Oriero, EC
   Correa, S
   Corran, P
   Conway, DJ
   Walther, M
AF Satoguina, Judith
   Walther, Brigitte
   Drakeley, Christopher
   Nwakanma, Davis
   Oriero, Eniyou C.
   Correa, Simon
   Corran, Patrick
   Conway, David J.
   Walther, Michael
TI Comparison of surveillance methods applied to a situation of low malaria
   prevalence at rural sites in The Gambia and Guinea Bissau
SO MALARIA JOURNAL
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; MEROZOITE SURFACE PROTEIN; NETS
   MOSQUITO-NETS; TREATED BED NETS; WEST-AFRICA; ANOPHELES-GAMBIAE; FINE
   SPECIFICITY; TRANSMISSION; MORTALITY; TRIAL
AB Background: Health record-based observations from several parts of Africa indicate a major decline in malaria, but up-to-date information on parasite prevalence in West-Africa is sparse. This study aims to provide parasite prevalence data from three sites in the Gambia and Guinea Bissau, respectively, and compares the usefulness of PCR, rapid diagnostic tests (RDT), serology and slide-microscopy for surveillance.
   Methods: Cross-sectional surveys in 12 villages at three rural sites were carried out in the Gambia and Guinea Bissau in January/February 2008, shortly following the annual transmission season.
   Results: A surprisingly low microscopically detectable parasite prevalence was detected in the Gambia (Farafenni: 10.9%, CI95%: 8.7-13.1%; Basse: 9.0%, CI95%: 7.2-10.8%), and Guinea Bissau (Caio: 4%, CI95%: 2.6-5.4%), with low parasite densities (geometric mean: 104 parasites/mu l, CI95%: 76-143/mu l). In comparison, PCR detected a more than three times higher proportion of parasite carriers, indicating its usefulness to sensitively identify foci where malaria declines, whereas the RDT had very low sensitivity. Estimates of force of infection using age sero-conversion rates were equivalent to an EIR of approximately 1 infectious bite/person/year, significantly less than previous estimates. The sero-prevalence profiles suggest a gradual decline of malaria transmission, confirming their usefulness in providing information on longer term trends of transmission. A greater variability in parasite prevalence among villages within a site than between sites was observed with all methods. The fact that serology equally captured the inter-village variability, indicates that the observed heterogeneity represents a stable pattern.
   Conclusion: PCR and serology may be used as complementary tools to survey malaria in areas of declining malaria prevalence such as the Gambia and Guinea Bissau.
C1 [Satoguina, Judith; Walther, Brigitte; Nwakanma, Davis; Oriero, Eniyou C.; Conway, David J.; Walther, Michael] MRC Labs, Banjul, Gambia.
   [Drakeley, Christopher; Correa, Simon; Corran, Patrick; Conway, David J.] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   [Corran, Patrick] Natl Inst Biol Stand & Controls, Biotherapeut Div, Potters Bar EN6 3QG, Herts, England.
RP Walther, M (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM jsatoguina@mrc.gm; bwalther@mrc.gm; chris.drakeley@lshtm.ac.uk;
   dnwakanma@mrc.gm; eoriero@mrc.gm; scorrea@mrc.gm;
   Patrick.Corran@lshtm.ac.uk; DConway@mrc.gm; MWalther@mrc.gm
OI Conway, David/0000-0002-8711-3037
FU Wellcome Trust [078925]
FX We are indebted to all participants who volunteered for this study, and
   to the fieldworkers, nurses and drivers who conducted these surveys. We
   would also like to express our gratitude to senior staff Dr Kalifa
   Bojang, Tim Vincent, Dr Momodou Jasseh, and Jon Baker for facilitating
   the work at the various sites. Special thanks go in particular to Dr
   David Parker for help with the data management and data clearance, Dr
   David Jeffries for statistical advice, and to Drs Augustine Ebonyi and
   Joseph Okebe for helping with some of the surveys. CD is supported by
   Wellcome Trust grant (078925).
CR ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O
   Babiker HA, 2008, TRENDS PARASITOL, V24, P525, DOI 10.1016/j.pt.2008.08.001
   Binka FN, 2002, T ROY SOC TROP MED H, V96, P597, DOI 10.1016/S0035-9203(02)90321-4
   Bousema JT, 2006, J INFECT DIS, V193, P1151, DOI 10.1086/503051
   BRADLEY AK, 1986, LANCET, V2, P204
   BRUCECHWATT LJ, 1973, LANCET, V2, P547
   CAMPBELL H, 1987, LANCET, V1, P859
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Clarke SE, 2002, T ROY SOC TROP MED H, V96, P499, DOI 10.1016/S0035-9203(02)90419-0
   Coleman RE, 2004, J MED ENTOMOL, V41, P201, DOI 10.1603/0022-2585-41.2.201
   Corran P, 2007, TRENDS PARASITOL, V23, P575, DOI 10.1016/j.pt.2007.08.023
   Corran PH, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-195
   Corran PH, 2004, INFECT IMMUN, V72, P6185, DOI 10.1128/IAI.72.10.6185-6189.2004
   DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1
   Diallo DA, 2004, B WORLD HEALTH ORGAN, V82, P85
   Drakeley CJ, 2000, T ROY SOC TROP MED H, V94, P472, DOI 10.1016/S0035-9203(00)90056-7
   Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102
   Dunyo S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010014
   Finney OC, 2009, EUR J IMMUNOL, V39, P1288, DOI 10.1002/eji.200839112
   Grabowsky M, 2008, NATURE, V451, P1051, DOI 10.1038/4511051a
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   Hay SI, 2008, LANCET INFECT DIS, V8, P369, DOI 10.1016/S1473-3099(08)70069-0
   Iqbal J, 2002, J CLIN MICROBIOL, V40, P4675, DOI 10.1128/JCM.40.12.4675-4678.2002
   JAENSON TGT, 1994, T ROY SOC TROP MED H, V88, P620, DOI 10.1016/0035-9203(94)90197-X
   Jawara M, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-156
   Kirby MJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-2
   LISSE IM, 1994, T ROY SOC TROP MED H, V88, P709, DOI 10.1016/0035-9203(94)90242-9
   MCGREGOR IA, 1952, T ROY SOC TROP MED H, V46, P403, DOI 10.1016/0035-9203(52)90058-8
   *MICS, 2002, GAMB MULT IND CLUST, P1
   *MICS, 2007, GAMB MULT IND CLUST, P1
   NWAKANMA DC, 2009, J INFECT DIS I, V99, P1567
   Nyarango PM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-33
   O'Meara WP, 2008, LANCET, V372, P1555, DOI 10.1016/S0140-6736(08)61655-4
   Okech BA, 2004, INFECT IMMUN, V72, P1557, DOI 10.1128/IAI.72.3.1557-1567.2004
   Okell LC, 2009, J INFECT DIS, V200, P1509, DOI 10.1086/644781
   Okiro EA, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-151
   Reyburn H, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-4
   Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55
   Riley E, 1996, PARASITOL TODAY, V12, P410, DOI 10.1016/0169-4758(96)80633-8
   Rodrigues A, 2008, TROP MED INT HEALTH, V13, P410, DOI 10.1111/j.1365-3156.2008.02016.x
   Ross R, 1911, PREVENTION MALARIA
   Schneider P, 2007, AM J TROP MED HYG, V76, P470
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P212, DOI 10.1016/0035-9203(88)90414-2
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Stewart L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006083
   Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689
   THACKER SB, 1988, EPIDEMIOL REV, V10, P164
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   *UNICEF, 2007, MAL CHILDR PROGR INT, P1
   von Seidlein L, 2003, T ROY SOC TROP MED H, V97, P217
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
   1997, B WHO S1, V75, P19
NR 53
TC 30
Z9 30
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD DEC 2
PY 2009
VL 8
AR 274
DI 10.1186/1475-2875-8-274
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 530JG
UT WOS:000272585100001
PM 19954532
OA gold
DA 2017-08-15
ER

PT J
AU Peterson, I
   Borrell, LN
   El-Sadr, W
   Teklehaimanot, A
AF Peterson, Ingrid
   Borrell, Luisa N.
   El-Sadr, Wafaa
   Teklehaimanot, Awash
TI A Temporal-Spatial Analysis of Malaria Transmission in Adama, Ethiopia
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID RISK-FACTORS; WESTERN KENYA; EL-NINO; EPIDEMIC; INTERVENTIONS;
   HIGHLANDS; AREA; PATTERNS; AFRICA; IMPACT
AB Urban malaria is a growing problem in Africa. Small-scale spatial studies are useful in identifying foci of malaria transmission in urban communities. A population-based cohort study comprising 8,088 individuals was conducted in Adama, Ethiopia. During a single malaria season, the Kulldorff scan statistic identified one temporally stable spatial malaria cluster within 350 m of a major Anopheles breeding site. Factors associated with malaria incidence were residential proximity to vector breeding site, poor house condition (incidence rate ratio [IRR] = 2.0, 95% confidence interval [CI] = 1.4, 2.9), and a high level of vegetation (IRR = 1.8, 95% CI = 1.0, 3.3). Maximum (IRR = 1.4,95% CI = 1.1, 1.9) and minimum daily temperatures (degrees C; IRR = 1.3, 95% CI = 1.2, 1.5) were positively associated with malaria incidence after a 1-month delay. Rainfall was positively associated with malaria incidence after a 10-day delay. Findings support the use of small scale mapping and targeted vector control in urban malaria control programs in Africa.
C1 [Peterson, Ingrid] MRC Labs, Banjul, Fajara, Gambia.
   CUNY, Lehman Coll, Dept Hlth Sci, New York, NY 10021 USA.
   [Borrell, Luisa N.] CUNY, Lehman Coll, Dept Hlth Sci, Bronx, NY 10468 USA.
   [El-Sadr, Wafaa] Columbia Univ, Mailman Sch Publ Heath, Int Ctr AIDS Care & Treatment Programs, New York, NY 10032 USA.
   Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA.
   [Teklehaimanot, Awash] Columbia Univ, Ctr Global Hlth & Econ Dev, Earth Inst, New York, NY 10027 USA.
RP Peterson, I (reprint author), MRC Labs, POB 277, Banjul, Fajara, Gambia.
EM idpet2@gmail.com
CR Abeku TA, 2004, PARASITOLOGY, V128, P585, DOI 10.1017/S003182004005013
   Abeku TA, 2003, ACTA TROP, V87, P331, DOI 10.1016/S0001-706X(03)00123-2
   Abeku TA, 2002, TROP MED INT HEALTH, V7, P851, DOI 10.1046/j.1365-3156.2002.00924.x
   Brooker S, 2004, TROP MED INT HEALTH, V9, P757, DOI 10.1111/j.1365-3156.2004.01272.x
   Carter R, 2000, B WORLD HEALTH ORGAN, V78, P1401
   Craig MH, 2004, TROP MED INT HEALTH, V9, P1258, DOI 10.1111/j.1365-3156.2004.01341.x
   De Castro MC, 2004, AM J TROP MED HYG, V71, P103
   Ernst KC, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-78
   Freeman T, 1996, T ROY SOC TROP MED H, V90, P232, DOI 10.1016/S0035-9203(96)90224-2
   Ghebreyesus TA, 2000, T ROY SOC TROP MED H, V94, P17, DOI 10.1016/S0035-9203(00)90424-3
   Gu WD, 2005, AM J TROP MED HYG, V73, P546
   Gunawardena DM, 1998, AM J TROP MED HYG, V58, P533
   Hay S, 2003, TRENDS PARASITOL, V19, P394, DOI 10.1016/S1471-4922(03)00190-9
   Hay SI, 2003, LANCET, V361, P1705, DOI 10.1016/S0140-6736(03)13366-1
   Keiser J, 2004, AM J TROP MED HYG, V71, P118
   Kilian AHD, 1999, T ROY SOC TROP MED H, V93, P22, DOI 10.1016/S0035-9203(99)90165-7
   Killeen Gerry F, 2002, Malar J, V1, P8, DOI 10.1186/1475-2875-1-8
   KORAM KA, 1995, T ROY SOC TROP MED H, V89, P146, DOI 10.1016/0035-9203(95)90471-9
   Kulldorff M, 1997, COMMUN STAT-THEOR M, V26, P1481, DOI 10.1080/03610929708831995
   Lengeler C., 2000, COCHRANE DB SYST REV, DOI 10.1002/14651858.cd000363
   Lindblade KA, 1999, T ROY SOC TROP MED H, V93, P480, DOI 10.1016/S0035-9203(99)90344-9
   Lindsay SW, 1998, B WORLD HEALTH ORGAN, V76, P33
   Marsh K., 2002, ESSENTIAL MALARIOLOG, P252
   Peterson I, 2009, AM J TROP MED HYG, V80, P103
   Ribeiro JMC, 1996, B WORLD HEALTH ORGAN, V74, P299
   Robert V, 2003, AM J TROP MED HYG, V68, P169
   Service Mike W., 2002, P59
   Teklehaimanot HD, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-41
   Thompson R, 1997, AM J TROP MED HYG, V57, P550
   TURNER G, 2002, ESSENTIAL MALARIOLOG, P236
   UN Population Division, 2006, WORLD URB PROSP 2005
   WILPEN LG, 2005, GIS TUTORIAL WORKBOO, V9
   Yohannes M, 1996, ETHIOPIAN MED J, V34, P83
   INTRO MALARIA
NR 34
TC 17
Z9 20
U1 0
U2 5
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2009
VL 81
IS 6
BP 944
EP 949
DI 10.4269/ajtmh.2009.08-0662
PG 6
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 531YN
UT WOS:000272709600005
PM 19996421
OA No
DA 2017-08-15
ER

PT J
AU Mendy, M
   Walton, R
AF Mendy, Maimuna
   Walton, Robert
TI Molecular pathogenesis and early detection of hepatocellular carcinoma -
   Perspectives from West Africa
SO CANCER LETTERS
LA English
DT Review
DE Hepatocellular carcinoma; Molecular pathogenesis; Early detection
ID HEPATITIS-B-VIRUS; IMMUNOGLOBULIN-LIKE RECEPTOR; KILLER-CELL ACTIVITY;
   ALPHA-FETOPROTEIN; LIVER-CANCER; GLYPICAN-3 EXPRESSION; PHYLOGENETIC
   ANALYSIS; CLINICAL-EVALUATION; SOUTHERN-AFRICA; HUMAN-DISEASE
AB This article reviews mechanisms involved in development of hepatocellular carcinoma and how host and environmental factors interact at a molecular level to cause cancer. These processes are intimately linked with strategies for early detection since molecular intermediates on the carcinogenesis pathway can now be detected with increasing levels of sensitivity. Similarly host factors influencing response to environmental agents, together with substances produced by early cancers, can be assayed in fine detail with new and emerging technologies. These advances in the field of biomarkers may lead to more rapid diagnosis and ultimately to improved survival as novel therapeutic strategies are adopted. (C) 2009 Published by Elsevier Ireland Ltd.
C1 [Walton, Robert] Barts & London Med School, Ctr Hlth Sci, London E1 2AT, England.
   [Mendy, Maimuna] MRC Labs, Fajara, Gambia.
RP Walton, R (reprint author), Barts & London Med School, Ctr Hlth Sci, Abernethy Bldg, London E1 2AT, England.
EM robert.walton@clinpharm.ox.ac.uk
OI Walton, Robert/0000-0001-7700-1907
FU Medical Research Council [MC_U190081996, MC_U190092710]
CR ALPERT ME, 1968, NEW ENGL J MED, V278, P984, DOI 10.1056/NEJM196805022781804
   Amini-Bavil-Olyaee S, 2005, J MED VIROL, V75, P227, DOI 10.1002/jmv.20261
   Attia K, 2008, WORLD J GASTROENTERO, V14, P286, DOI 10.3748/wjg.14.286
   Baumert TF, 2007, WORLD J GASTROENTERO, V13, P82
   BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J
   Bedossa P, 2003, HEPATOLOGY, V38, P1449, DOI 10.1016/j.hep.2003.09.022
   Beneduce L, 2005, CANCER, V103, P2558, DOI 10.1002/cncr.21106
   Beneduce L, 2004, INT J BIOL MARKER, V19, P155
   Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807
   Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557
   BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0
   Carrington M, 2006, CURR TOP MICROBIOL, V298, P225
   Carrington M, 2005, J EXP MED, V201, P1069, DOI 10.1081/jem.20042158
   Carvalho RJ, 2008, LIVER INT, V28, P486, DOI 10.1111/j.1478-3231.2008.01675.x
   CHANG MH, 1995, HEPATOLOGY, V22, P1387, DOI 10.1016/0270-9139(95)90141-8
   Chen YY, 2006, CELL MOL IMMUNOL, V3, P373
   Chiu CM, 2007, P NATL ACAD SCI USA, V104, P2571, DOI 10.1073/pnas.0609498104
   CHUANG WL, 1990, CANCER, V65, P926, DOI 10.1002/1097-0142(19900215)65:4<926::AID-CNCR2820650418>3.0.CO;2-U
   Clarke W, 2003, CLIN CHEM LAB MED, V41, P1562, DOI 10.1515/CCLM.2003.239
   Cui R, 2003, BRIT J CANCER, V88, P1878, DOI 10.1038/sj.bjc.6601018
   D'Amico F, 2007, PHARMACOGENOMICS, V8, P645, DOI 10.2217/14622416.8.6.645
   Dai Chia-Yen, 2000, Kaohsiung Journal of Medical Sciences, V16, P500
   Di Maio M, 2008, WORLD J GASTROENTERO, V14, P1682, DOI 10.3748/wjg.14.1682
   Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2
   Dumpis U, 2001, J HEPATOL, V35, P99, DOI 10.1016/S0168-8278(01)00064-2
   Fang ZL, 2008, AM J GASTROENTEROL, V103, P2254, DOI 10.1111/j.1572-0241.2008.01974.x
   Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087
   Giannelli G, 2005, INT J CANCER, V117, P506, DOI 10.1002/ijc.21189
   Gillespie GMA, 2007, AIDS RES HUM RETROV, V23, P451, DOI 10.1089/aid.2006.0165
   Hansasuta P, 2004, EUR J IMMUNOL, V34, P1673, DOI 10.1002/eji.200425089
   Hippo Y, 2004, CANCER RES, V64, P2418, DOI 10.1158/0008-5472.CAN-03-2191
   Jie X, 2007, ONCOGENE, V26, P5741, DOI 10.1038/sj.onc.1210362
   Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279
   KEW MC, 1981, HEPATOLOGY, V1, P366, DOI 10.1002/hep.1840010415
   Khien VV, 2001, INT J BIOL MARKER, V16, P105
   Kirk GD, 2005, CANCER EPIDEM BIOMAR, V14, P373, DOI 10.1158/1055-9965.EPI-04-0161
   Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kovacic MB, 2005, CANCER EPIDEM BIOMAR, V14, P2673, DOI 10.1158/1055-9965.EPI-05-0229
   Kramvis A, 2005, VACCINE, V23, P2409, DOI 10.1016/j.vaccine.2004.10.045
   Kramvis A, 1998, J HEPATOL, V28, P132, DOI 10.1016/S0168-8278(98)80212-2
   Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547
   Lesi O A, 2004, Niger Postgrad Med J, V11, P91
   Lin CL, 2008, J BIOMED SCI, V15, P137, DOI 10.1007/s11373-007-9225-8
   LINDH M, 1997, J INFECT DIS, V175, P1283
   Liu CJ, 2006, J INFECT DIS, V194, P594, DOI 10.1086/505883
   LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S
   Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1
   Lok ASF, 2001, HEPATOLOGY, V34, P1225, DOI 10.1053/jhep.2001.29401
   Lopez-Vazquez A, 2007, TISSUE ANTIGENS, V69, P241, DOI 10.1111/j.1399-0039.2006.77341.x
   Lopez-Vazquez A, 2005, J INFECT DIS, V192, P162, DOI 10.1086/430351
   Luo JH, 2006, HEPATOLOGY, V44, P1012, DOI 10.1002/hep.21328
   Madhava V, 2002, LANCET INFECT DIS, V2, P293, DOI 10.1016/S1473-3099(02)00264-5
   Magnius LO, 1995, INTERVIROLOGY, V38, P24
   Man XB, 2005, LIVER INT, V25, P962, DOI 10.1111/j.1478-3231.2005.01100.x
   Marrero JA, 2006, CURR OPIN GASTROEN, V22, P248, DOI 10.1097/01.mog.0000218961.86182.8c
   Marrero JA, 2004, GASTROENTEROLOGY, V127, pS113, DOI 10.1053/j.gastro.2004.09.024
   Marrero Jorge A, 2005, Clin Liver Dis, V9, P235, DOI 10.1016/j.cld.2004.12.006
   Martin MP, 2005, CURR OPIN IMMUNOL, V17, P510, DOI 10.1016/j.coi.2005.07.012
   Mendy M, 2005, J VIRAL HEPATITIS, V12, P642, DOI 10.1111/j.1365-2893.2005.00641.x
   Mendy ME, 2008, J CLIN MICROBIOL, V46, P2723, DOI 10.1128/JCM.01622-07
   Mendy ME, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-49
   Montesano R, 1997, J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844
   Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485
   Ngo Y, 2006, CLIN CHEM, V52, P1887, DOI 10.1373/clinchem.2006.070961
   Pang RWC, 2008, ANN SURG ONCOL, V15, P962, DOI 10.1245/s10434-007-9730-z
   PARKIN DM, 2002, CA CANC J CLIN, V55, P74
   PATERSON AC, 1985, HEPATOLOGY, V5, P72, DOI 10.1002/hep.1840050116
   Poon TCW, 2005, CLIN CHEM, V51, P328, DOI 10.1373/clinchem.2004.041764
   Poon TCW, 2003, CLIN CHEM, V49, P752, DOI 10.1373/49.5.752
   Poynard T, 2004, COMP HEPATOL, V3, P8, DOI DOI 10.1186/1476-5926-3-8
   Qi Y, 2006, PLOS PATHOG, V2, P741, DOI 10.1371/journal.ppat.0020079
   SAITOH S, 1994, RADIOLOGY, V193, P67
   Shi J, 2005, BRIT J CANCER, V92, P607, DOI 10.1038/sj.bjc.6602333
   Smela ME, 2001, CARCINOGENESIS, V22, P535, DOI 10.1093/carcin/22.4.535
   Soresi M, 2003, ANTICANCER RES, V23, P1747
   Spangenberg HC, 2001, J VIROL, V75, P10630, DOI 10.1128/JVI.75.22.10630-10642.2001
   Stuyver L, 2000, J GEN VIROL, V81, P67
   Sylla A, 1999, MUTAT RES-FUND MOL M, V428, P187, DOI 10.1016/S1383-5742(99)00046-0
   TAKASHIMA T, 1982, RADIOLOGY, V145, P635
   TAKETA K, 1990, HEPATOLOGY, V12, P1420, DOI 10.1002/hep.1840120625
   Taketomi A, 1998, CANCER, V83, P58, DOI 10.1002/(SICI)1097-0142(19980701)83:1<58::AID-CNCR8>3.0.CO;2-A
   Thananchai H, 2007, J IMMUNOL, V178, P33
   Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339
   Tsai JF, 1997, BRIT J CANCER, V75, P1460, DOI 10.1038/bjc.1997.250
   Turner PC, 2005, LANCET, V365, P1950, DOI 10.1016/S0140-6736(05)66661-5
   Viviani S, 2008, CANCER EPIDEM BIOMAR, V17, P3216, DOI 10.1158/1055-9965.EPI-08-0303
   Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346
   Westin J, 1999, LIVER, V19, P183, DOI 10.1111/j.1478-3231.1999.tb00033.x
   Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1<1::AID-IJC1>3.0.CO;2-I
   Wouters BG, 2008, SEMIN RADIAT ONCOL, V18, P115, DOI 10.1016/j.semradonc.2007.10.008
   Wright TL, 2006, AM J GASTROENTEROL, V101, pS1, DOI 10.1111/j.1572-0241.2006.00469.x
   YANO M, 1993, GUT, V34, pS13, DOI 10.1136/gut.34.2_Suppl.S13
   Zhi-Ming L, 2007, CROAT MED J, V48, P800, DOI 10.3325/cmj.2007.6.800
   Zhu ZW, 2001, GUT, V48, P558, DOI 10.1136/gut.48.4.558
NR 95
TC 5
Z9 7
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD DEC 1
PY 2009
VL 286
IS 1
SI SI
BP 44
EP 51
DI 10.1016/j.canlet.2009.04.039
PG 8
WC Oncology
SC Oncology
GA 526IZ
UT WOS:000272282900009
PM 19523756
OA No
DA 2017-08-15
ER

PT J
AU Bisseye, C
   van der Sande, M
   Morgan, WD
   Holder, AA
   Pinder, M
   Ismaili, J
AF Bisseye, C.
   van der Sande, M.
   Morgan, W. D.
   Holder, A. A.
   Pinder, M.
   Ismaili, J.
TI Plasmodium falciparum infection of the placenta impacts on the T helper
   type 1 (Th1)/Th2 balance of neonatal T cells through CD4(+)CD25(+)
   forkhead box P3(+) regulatory T cells and interleukin-10
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE CBMC; placental malaria; Th1/Th2; T-regs
ID MALARIA INFECTION; DENDRITIC CELLS; BLOOD; ANTIGENS; SURFACE; WEIGHT;
   GAMBIA
AB Placental malaria infection affects the T helper type 1 (Th1)/Th2 balance in neonatal children. We investigated a potential role of regulatory T cells in this balance by comparing T cell responses of cord blood mononuclear cells (CBMC) from parasitized and non-parasitized placenta of Gambian women. CBMC were depleted of CD4(+)CD25(+) forkhead box P3 (FoxP3)(+) regulatory T cells and analysed in vitro for their ability to produce interferon (IFN)-gamma, sCD30 and interleukin (IL)-10 in response to phytohaemagglutinin (PHA), live Plasmodium falciparum, schizont extracts and the recombinant P. falciparum-blood stage antigen merozoite surface protein 1 (MSP1(19)). As expected, lower IFN-gamma and higher sCD30 responses were observed for the cells from the parasitized group. In addition, higher IL-10 levels were produced by CBMC from the parasitized group. Depletion of regulatory T cells decreased IL-10 production, which resulted in a restoration of IFN-gamma expression in response to all stimuli. The Th2 marker sCD30 remained significantly higher in the parasitized group in response to malaria protein antigens while similar levels were recovered between both groups in response to live P. falciparum. Similar effects were observed by adding an antibody that blocks IL-10 function. These results suggest that the impact of P. falciparum infection on Th1 differentiation of neonatal T cells can be ascribed to regulatory T cells through production of IL-10.
C1 [Bisseye, C.; van der Sande, M.; Pinder, M.; Ismaili, J.] MRC Labs, Banjul, Gambia.
   [Morgan, W. D.; Holder, A. A.] Natl Inst Med Res, Div Parasitol, London NW7 1AA, England.
RP Ismaili, J (reprint author), Inst Pasteur, IBL, F-59019 Lille, France.
EM jamilune@yahoo.com
RI Holder, Anthony/A-7554-2013
OI Holder, Anthony/0000-0002-8490-6058
FU Medical Research Council, UK; European Commission [QLK2-CT-2002-01197]
FX This study was funded by the Medical Research Council, UK and by the
   European Commission through the EUROMAL-VAC Consortium, contract
   QLK2-CT-2002-01197. We are again grateful to the mothers and their
   babies enrolled into the 2001 study, to the staff of Sukuta Health
   Centre and to the Department of State for Health. We thank Simon Correa
   and Saikou Keita for the technical support.
CR Brustoski K, 2006, J INFECT DIS, V193, P146, DOI 10.1086/498578
   FREEMAN RR, 1983, J EXP MED, V158, P1647, DOI 10.1084/jem.158.5.1647
   Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503
   Goriely S, 2001, J IMMUNOL, V166, P2141
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Hisaeda H, 2004, NAT MED, V10, P29, DOI 10.1038/nm975
   Ismaili J, 2003, CLIN EXP IMMUNOL, V133, P414, DOI 10.1046/j.1365-2249.2003.02243.x
   JEFF EM, 2008, SCIENCE, V322, P1562
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   Malhotra I, 2008, J IMMUNOL, V180, P3383
   MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0
   Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753
   Okoko BJ, 2002, J HEALTH POPUL NUTR, V20, P4
   PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87
   Peng JC, 2006, IMMUNOL CELL BIOL, V84, P227, DOI 10.1111/j.1440-1711.2006.01419.x
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900
   Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006
NR 18
TC 21
Z9 21
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD DEC
PY 2009
VL 158
IS 3
BP 287
EP 293
DI 10.1111/j.1365-2249.2009.04014.x
PG 7
WC Immunology
SC Immunology
GA 513GS
UT WOS:000271311200005
PM 19758375
OA No
DA 2017-08-15
ER

PT J
AU Walther, M
   Jallow, IK
   Jeffries, D
   Walther, B
AF Walther, Michael
   Jallow, Isatou K.
   Jeffries, David
   Walther, Brigitte
TI Bioactive TGF-beta levels can be preserved in plasma samples collected
   into heparin but not EDTA
SO CYTOKINE
LA English
DT Article
DE TGF-beta; ELISA; Effects of anti-coagulant
ID TRANSFORMING-GROWTH-FACTOR; MOLECULAR-WEIGHT COMPLEX; ACTIVATION; CELLS;
   MECHANISM; GROWTH-FACTOR-BETA-1; PLATELETS; THROMBIN
AB Quantifying TGF-beta is important for many research areas since its effects often are dose-dependently bidirectional. The post-transcriptional control of TGF-beta bioavailability points out the need to determine TGF-beta at the protein level. Studies measuring TGF-beta in peripheral blood have to avoid contamination with platelet-derived TGF-beta. Techniques to obtain platelet-poor plasma have been suggested, however, the impact of different anti-coagulants on artificial TGF-beta contamination has not been studied in detail. Here, we compare TGF-beta levels in blood samples collected into heparin and EDTA tubes, stored for 0.5-18 h at various temperatures. We show that contamination with latent TGF-beta can only be prevented by collecting the sample on ice. Importantly, levels of bioactive TGF-beta in blood collected into heparin but not EDTA tubes remained stable up to 18 h, even when kept at RT. Further in vitro experiments indicate that heparin prevents the activation of latent TGF-beta into its bioactive form probably by virtue of accelerating the complex-formation between AT-III and thrombin. Where precise measurement of latent TGF-beta in blood samples is required, samples need to be collected on ice; bioactive TGF-beta can be detected reliably in samples collected into heparin tubes even when stored at RT. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Walther, Michael; Jallow, Isatou K.; Jeffries, David; Walther, Brigitte] MRC Labs, Banjul, Gambia.
RP Walther, M (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM mwalther@mrc.gm
FU MRC (UK)
FX All the work was funded by the MRC (UK). The funding body had no impact
   on the study design, collection, analysis or interpretation of the data,
   the writing of the ms, or the decision to submit the ms for publication.
CR Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229
   BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N
   BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821
   Brown P D, 1990, Growth Factors, V3, P35, DOI 10.3109/08977199009037500
   GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429
   Gorelik L, 2002, J EXP MED, V195, P1499, DOI 10.1084/jem.20012076
   Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704
   Green David, 2006, Hemodial Int, V10 Suppl 2, pS2, DOI 10.1111/j.1542-4758.2006.00119.x
   Green EA, 2003, P NATL ACAD SCI USA, V100, P10878, DOI 10.1073/pnas.1834400100
   Jenkins G, 2008, INT J BIOCHEM CELL B, V40, P1068, DOI 10.1016/j.biocel.2007.11.026
   Jenkins RG, 2006, J CLIN INVEST, V116, P1606, DOI 10.1172/JCI27183
   Kitisin K., 2007, SCI STKE, pcm1, DOI DOI 10.1126/STKE.3992007CM1
   KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439
   LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361
   NUNES I, 1995, J IMMUNOL, V155, P1450
   Omer FM, 2003, J EXP MED, V198, P1817, DOI 10.1084/jem.20030713
   Omer FM, 2000, PARASITOL TODAY, V16, P18, DOI 10.1016/S0169-4758(99)01562-8
   PIRCHER R, 1986, BIOCHEM BIOPH RES CO, V136, P30, DOI 10.1016/0006-291X(86)90872-7
   Rifkin DB, 2005, J BIOL CHEM, V280, P7409, DOI 10.1074/jbc.R400029200
   ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494
   ROSENBERG RD, 1978, ANNU REV MED, V29, P367, DOI 10.1146/annurev.me.29.020178.002055
   ROSENBERG RD, 1977, FED PROC, V36, P10
   SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783
   TAIPALE J, 1992, J BIOL CHEM, V267, P25378
   VanWaarde MAWH, 1997, ANAL BIOCHEM, V247, P45, DOI 10.1006/abio.1997.2026
   WAKEFIELD LM, 1995, CLIN CANCER RES, V1, P129
   WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646
   Yang ZW, 2007, J CELL BIOL, V176, P787, DOI 10.1083/jcb.200611044
NR 28
TC 4
Z9 4
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
J9 CYTOKINE
JI Cytokine
PD DEC
PY 2009
VL 48
IS 3
BP 267
EP 272
DI 10.1016/j.cyto.2009.08.004
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 521JF
UT WOS:000271916300015
PM 19748283
OA No
DA 2017-08-15
ER

PT J
AU Adetifa, IMO
   Hill, PC
   Jeffries, DJ
   Jackson-Sillah, D
   Ibanga, HB
   Bah, G
   Donkor, S
   Corrah, T
   Adegbola, RA
AF Adetifa, I. M. O.
   Hill, P. C.
   Jeffries, D. J.
   Jackson-Sillah, D.
   Ibanga, H. B.
   Bah, G.
   Donkor, S.
   Corrah, T.
   Adegbola, R. A.
TI Haematological values from a Gambian cohort - possible reference range
   for a West African population
SO INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
LA English
DT Article
DE Reference values; haematology; erythrocytes; leucocytes; platelets;
   Gambia
ID IMMUNOHEMATOLOGICAL REFERENCE RANGES; BLOOD LYMPHOCYTE SUBPOPULATIONS;
   REFERENCE INTERVALS; IRON-DEFICIENCY; HEMOGLOBIN; ANEMIA; PARAMETERS;
   CHILDREN; TROMSO; ADULTS
AB P>The objective of this study was to establish haematological reference ranges for the West African subregion using a Gambian cohort. We analysed full blood counts from 1279 subjects aged >= 1 year. Anthropometric and body composition measurements were performed. Haematological mean values, medians and 90% reference values were calculated and related to malnutrition in children and thinness and/or obesity in adults. Haemoglobin (Hb) and mean corpuscular volume (MCV) significantly increased with age (P < 0.00001). There were gender-related changes in Hb from 15 years of age (P = 0.001) and for MCV only in adults (P = 0.0002). Hb was significantly reduced in underweight and stunted children (P = 0.0001 and 0.0002, respectively) but was unaffected by thinness or obesity in adults. White blood cell (WBC) and platelet counts were highest under 5 years and declined significantly with age (P < 0.0001 and 0.0001). While, there were no gender-related differences with WBC, there were higher WBC counts in underweight (P = 0.0001) and stunted (P < 0.0001) children. Adult females had significantly higher mean platelet counts compared with males (P = 0.006). The mean and median values of haematological parameters in The Gambia are similar to other standards but the 90% reference range for each parameter encompasses lower values when compared with Western standards.
C1 [Adetifa, I. M. O.; Hill, P. C.; Jackson-Sillah, D.; Ibanga, H. B.; Donkor, S.; Corrah, T.; Adegbola, R. A.] MRC UK Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Jeffries, D. J.] MRC UK Labs, Stat & Data Support Unit, Banjul, Gambia.
   [Bah, G.] MRC UK Labs, Haematol Diagnost Lab, Banjul, Gambia.
RP Adetifa, IMO (reprint author), MRC UK Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM iadetifa@mrc.gm
FU Medical Research Council
CR ALLEN SJ, 1993, T ROY SOC TROP MED H, V87, P282, DOI 10.1016/0035-9203(93)90129-E
   Bain BJ, 1996, J CLIN PATHOL, V49, P664, DOI 10.1136/jcp.49.8.664
   Beutler E., 2001, WILLIAMS HEMATOLOGY
   CASTRO OL, 1987, PUBLIC HEALTH REP, V102, P232
   Cheng Calvino Ka-Wing, 2004, Lab Hematol, V10, P42, DOI 10.1532/LH96.04010
   EDWIN B, 2007, AM J HEMATOL, V82, P611
   ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5
   HANNET I, 1992, IMMUNOL TODAY, V13, P215, DOI 10.1016/0167-5699(92)90157-3
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   JOHNSONSPEAR MA, 1994, AM J CLIN NUTR, V60, P117
   Kadikoylu G, 2006, J NATL MED ASSOC, V98, P398
   Kargbo R B, 1999, West Afr J Med, V18, P24
   Keung YK, 2004, CLIN APPL THROMB-HEM, V10, P387, DOI 10.1177/107602960401000412
   KRATZ AO, 2005, HARRISONS PRINCIPLES
   Lewis S, 2001, DACIE LEWISS PRACTIC
   Lugada ES, 2004, CLIN DIAGN LAB IMMUN, V11, P29, DOI 10.1128/CDLI.11.1.29-34.2004
   Menard D, 2003, CLIN DIAGN LAB IMMUN, V10, P443, DOI 10.1128/CDLI.10.3.443-445.2003
   Nicholson JF, 2000, NELSON TXB PEDIAT, P2181
   Parent AS, 2003, ENDOCR REV, V24, P668, DOI 10.1210/er.2002-0019
   Quinto L, 2006, TROP MED INT HEALTH, V11, P1741, DOI 10.1111/j.1365-3156.2006.01764.x
   Royston P, 2000, STAT MED, V19, P2943, DOI 10.1002/1097-0258(20001115)19:21<2943::AID-SIM559>3.0.CO;2-5
   Royston P, 1998, J R STAT SOC A STAT, V161, P79, DOI 10.1111/1467-985X.00091
   SAXENA S, 1990, ARCH PATHOL LAB MED, V114, P715
   SHIMAKAWA T, 1993, J CLIN EPIDEMIOL, V46, P1257, DOI 10.1016/0895-4356(93)90090-N
   Skjelbakken T, 2005, EUR J HAEMATOL, V74, P381, DOI 10.1111/j.1600-0609.2004.00392.x
   Skjelbakken T, 2006, EUR J EPIDEMIOL, V21, P493, DOI 10.1007/s10654-006-9032-y
   Taylor MRH, 1997, CLIN LAB HAEMATOL, V19, P1, DOI 10.1046/j.1365-2257.1997.00204.x
   Tsegaye A, 1999, CLIN DIAGN LAB IMMUN, V6, P410
   Wamani Henry, 2007, BMC Pediatr, V7, P17, DOI 10.1186/1471-2431-7-17
   WHO, 1995, PHYS STAT US INT ANT
   *WHO BLOOD TRANSF, 2002, CLIN US BLOOD MED OB
   Wintrobe M, 1999, WINTROBES CLIN HAEMA
   Wright E, 1996, STATA TECH B, V6, P24
NR 33
TC 18
Z9 18
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1751-5521
J9 INT J LAB HEMATOL
JI Int. J. Lab. Hematol.
PD DEC
PY 2009
VL 31
IS 6
BP 615
EP 622
DI 10.1111/j.1751-553X.2008.01087.x
PG 8
WC Hematology
SC Hematology
GA 509YM
UT WOS:000271055200004
PM 18631172
OA No
DA 2017-08-15
ER

PT J
AU Harding-Esch, EM
   Edwards, T
   Sillah, A
   Sarr, I
   Roberts, CH
   Snell, P
   Aryee, E
   Molina, S
   Holland, MJ
   Mabey, DCW
   Bailey, RL
AF Harding-Esch, Emma M.
   Edwards, Tansy
   Sillah, Ansumana
   Sarr, Isatou
   Roberts, Chrissy H.
   Snell, Paul
   Aryee, Esther
   Molina, Sandra
   Holland, Martin J.
   Mabey, David C. W.
   Bailey, Robin L.
TI Active Trachoma and Ocular Chlamydia trachomatis Infection in Two
   Gambian Regions: On Course for Elimination by 2020?
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID ANTIBIOTIC-TREATMENT; CLINICAL-DIAGNOSIS; LOW-PREVALENCE; COMMUNITY;
   AZITHROMYCIN; IDENTIFICATION; AMPLIFICATION; PSITTACI; PROGRAM; DISEASE
AB Background: Trachoma has been endemic in The Gambia for decades. National trachoma control activities have been in place since the mid-1980's, but with no mass antibiotic treatment campaign. We aimed to assess the prevalence of active trachoma and of actual ocular Chlamydia trachomatis infection as measured by polymerase chain reaction (PCR) in the two Gambian regions that had had the highest prevalence of trachoma in the last national survey in 1996 prior to planned national mass antibiotic treatment distribution in 2006.
   Methodology/Principal Findings: Two stage random sampling survey in 61 randomly selected Enumeration Areas (EAs) in North Bank Region (NBR) and Lower River Region (LRR). Fifty randomly selected children aged under 10 years were examined per EA for clinical signs of trachoma. In LRR, swabs were taken to test for ocular C. trachomatis infection. Unadjusted prevalences of active trachoma were calculated, as would be done in a trachoma control programme. The prevalence of trachomatous inflammation, follicular (TF) in the 2777 children aged 1-9 years was 12.3% (95% CI 8.8%-17.0%) in LRR and 10.0% (95% CI 7.7%-13.0%) in NBR, with significant variation within divisions (p<0.01), and a design effect of 3.474. Infection with C. trachomatis was found in only 0.3% (3/940) of children in LRR.
   Conclusions/Significance: This study shows a large discrepancy between the prevalence of trachoma clinical signs and ocular C. trachomatis infection in two Gambian regions. Assessment of trachoma based on clinical signs alone may lead to unnecessary treatment, since the prevalence of active trachoma remains high but C. trachomatis infection has all but disappeared. Assuming that repeated infection is required for progression to blinding sequelae, blinding trachoma is on course for elimination by 2020 in The Gambia.
C1 [Harding-Esch, Emma M.; Edwards, Tansy; Roberts, Chrissy H.; Molina, Sandra; Holland, Martin J.; Mabey, David C. W.; Bailey, Robin L.] London Sch Hyg & Trop Med, London WC1, England.
   [Sillah, Ansumana] Minist Hlth, Natl Eye Care Programme, Banjul, Gambia.
   [Sarr, Isatou; Snell, Paul; Aryee, Esther; Holland, Martin J.] MRC Labs, Fajara, Gambia.
   [Snell, Paul] Univ Bristol, Dept Social Med, ALSPAC, Bristol, Avon, England.
RP Harding-Esch, EM (reprint author), London Sch Hyg & Trop Med, London WC1, England.
EM robin.bailey@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276
FU Wellcome Trust [078460/Z/05/Z]
FX We are grateful to the Wellcome Trust (www.wellcome.ac.uk) for funding
   this study (grant number 078460/Z/05/Z). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BAILEY RL, 1994, J INFECT DIS, V170, P709
   Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461
   Bataille M, 1999, FORENSIC SCI INT, V99, P165, DOI 10.1016/S0379-0738(98)00185-6
   BENNETT S, 1991, World Health Statistics Quarterly, V44, P98
   Bird M, 2003, J INFECT DIS, V187, P1669, DOI 10.1086/374743
   Burton MJ, 2006, CLIN INFECT DIS, V42, P463, DOI 10.1086/499814
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Chernesky M, 2006, J CLIN MICROBIOL, V44, P1084, DOI 10.1128/JCM.44.3.1084-1086.2006
   Cumberland P, 2008, INT J EPIDEMIOL, V37, P549, DOI 10.1093/ije/dyn045
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   de Barbeyrac B, 2007, CLIN MICROBIOL INFEC, V13, P689, DOI 10.1111/j.1469-0691.2007.01741.x
   Dean D, 2008, PLOS MED, V5, P57, DOI 10.1371/journal.pmed.0050014
   DETELS R, 1966, AM J EPIDEMIOL, V84, P81
   Diamant J, 2001, Ophthalmic Epidemiol, V8, P109, DOI 10.1076/opep.8.2.109.4156
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   Dolin PJ, 1997, LANCET, V349, P1511, DOI 10.1016/S0140-6736(97)01355-X
   *DPI, 2003, GAMB BUR STAT POP SE
   DWYER RSC, 1972, BRIT J VENER DIS, V48, P452
   Faal H, 2000, BRIT J OPHTHALMOL, V84, P948, DOI 10.1136/bjo.84.9.948
   Faal N, 2006, PLOS MED, V3, P1292, DOI 10.1371/journal.pmed.0030266
   GRAYSTON JT, 1985, REV INFECT DIS, V7, P717
   Harding-Esch EM, 2008, T ROY SOC TROP MED H, V102, P1255, DOI 10.1016/j.trstmh.2008.04.022
   KUO CC, 1986, J CLIN MICROBIOL, V24, P1034
   Landis J. R., 1977, BIOMETRICS, V33, P174
   Lietman T, 1998, CLIN INFECT DIS, V26, P1335, DOI 10.1086/516373
   Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1
   Michel CEC, 2006, LANCET, V367, P1585, DOI 10.1016/S0140-6736(06)68695-9
   Miller K, 2004, OPHTHAL EPIDEMIOL, V11, P255, DOI 10.1080/09286580490514577
   NGONDI J, 2009, T R SOC TROP MED HYG
   PORCO T, 2009, JAMA
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ritterband DC, 1998, REV MED VIROL, V8, P187, DOI 10.1002/(SICI)1099-1654(1998100)8:4<187::AID-RMV221>3.0.CO;2-S
   Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5
   Shattock RM, 1998, SEX TRANSM INFECT, V74, P289
   Solomon AW, 2008, NEW ENGL J MED, V358, P1870, DOI 10.1056/NEJMc0706263
   Solomon AW, 2004, CLIN MICROBIOL REV, V17, P982, DOI 10.1128/CMR.17.4.982-1011.2004
   Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   Solomon AW, 2006, TRACHOMA CONTROL GUI
   Thein J, 2002, OPHTHALMIC EPIDEMIOL, V9, P263, DOI 10.1076/opep.9.4.263.1508
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   *WHO, 1997, PLANN M GLOB EL TRAC
   *WHO, 2004, REP 8 M WHO ALL GLOB
   Wright HR, 2005, LANCET INFECT DIS, V5, P313, DOI 10.1016/S1473-3099(05)70116-X
NR 45
TC 31
Z9 32
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD DEC
PY 2009
VL 3
IS 12
AR e573
DI 10.1371/journal.pntd.0000573
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 536RB
UT WOS:000273060400015
PM 20027217
OA gold
DA 2017-08-15
ER

PT J
AU Hontelez, JAC
   van der Loeff, MFS
   Peterson, I
   Peterson, K
   Ahadzie, B
   Cotten, M
   Sarge-Njie, R
   Whittle, H
AF Hontelez, Jan A. C.
   van der Loeff, Maarten F. Schim
   Peterson, Ingrid
   Peterson, Kevin
   Ahadzie, Bankhole
   Cotten, Matthew
   Sarge-Njie, Ramu
   Whittle, Hilton
TI Declining Trend of Serological Syphilis Among Genitourinary Medicine
   Patients in the Gambia, West Africa
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID SEXUALLY-TRANSMITTED-DISEASES; GENITAL ULCER DISEASE; HIV-INFECTION;
   PREVALENCE; WOMEN; TRANSMISSION; COMMUNITY; EPIDEMIC; BOTSWANA; BURDEN
AB Background: Syphilis is a common disease in Africa and maybe an important contributor to the HIV epidemic. Trends in syphilis prevalence are important in their own right and because syphilis is a cofactor for HIV infection. In this study we analyzed trends in serological syphilis prevalence at a sexually transmitted infections (STI) clinic in The Gambia.
   Methods: At the Genitourinary Medicine clinic of the Medical Research Council in The Gambia patients were routinely screened for syphilis using a 2-test algorithm, measuring rapid plasma reagin followed by the Treponema pallidum haemagglutination assay. Serological syphilis was defined as both tests being positive. We determined year to year trends in serological syphilis. Logistic regression was used to identify risk factors.
   Results: Over the period 1994-2007, 23,674 people were tested for syphilis. The prevalence of serological syphilis dropped from 11.2% in 1994 to 1.5% in 2007 (P <0.0001; chi(2) test for trend). Significant risk factors for serological syphilis in women were found to be ethnicity, commercial sex work, and HIV infection. No associations between serological syphilis and possible risk factors in men were found.
   Conclusions: This Study identified a strong and significant downward trend in the prevalence of serological syphilis among patients attending the Genitourinary Medicine clinic in The Gambia in the period 1994-2007. These results Suggest that syphilis prevalence may be declining in the general population, in the absence of a targeted control program. Research is needed to identify the reasons for this decline.
C1 [van der Loeff, Maarten F. Schim] Municipal Hlth Serv Amsterdam, NL-1000 CE Amsterdam, Netherlands.
   [Hontelez, Jan A. C.; Peterson, Ingrid; Peterson, Kevin; Ahadzie, Bankhole; Cotten, Matthew; Sarge-Njie, Ramu; Whittle, Hilton] MRC Labs, Fajara, Gambia.
RP van der Loeff, MFS (reprint author), Municipal Hlth Serv Amsterdam, POB 2200, NL-1000 CE Amsterdam, Netherlands.
EM mschim@ggd.amsterdam.nl
FU MRC (UK)
FX Funding for this project was provided by MRC (UK).
CR Adjei AA, 2003, JPN J INFECT DIS, V56, P165
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Creek TL, 2005, SEX TRANSM INFECT, V81, P453, DOI 10.1136/sti.2004.014068
   Dickerson MC, 1996, SEX TRANSM DIS, V23, P429, DOI 10.1097/00007435-199609000-00015
   Fleming DT, 1999, SEX TRANSM INFECT, V75, P3
   French P, 2007, BRIT MED J, V334, P143, DOI 10.1136/bmj.39085.518148.BE
   GREENWOOD AM, 1992, J INFECT DIS, V166, P842
   Johnson L, 2007, SAMJ S AFR MED J, V97, P658
   LARGARDE E, 2003, INT J STD AIDS, V14, P208
   Lynn WA, 2004, LANCET INFECT DIS, V4, P456, DOI 10.1016/S1473-3099(04)01061-8
   McFADZEAN J. A., 1957, TRANS ROY SOC TROP MED AND HYG, V51, P169, DOI 10.1016/0035-9203(57)90062-7
   Nagot N, 2004, SEX TRANSM INFECT, V80, P124, DOI 10.1136/sti.2002.004150
   Ozumba UC, 1999, SEX TRANSM INFECT, V75, P120
   Paz-Bailey G, 2005, CLIN INFECT DIS, V41, P1304, DOI 10.1086/496979
   Ratcliffe AA, 2000, B WORLD HEALTH ORGAN, V78, P570
   Riedner G, 2007, SEX TRANSM INFECT, V83, P91, DOI 10.1136/sti.2006.021287
   Scheer S, 2001, LANCET, V357, P432, DOI 10.1016/S0140-6736(00)04007-1
   Shaw M, 2001, SEX TRANSM INFECT, V77, P358, DOI 10.1136/sti.77.5.358
   van der Loeff MFS, 2006, INT J EPIDEMIOL, V35, P1322, DOI 10.1093/ije/dy1037
   Walker GJA, 2007, SEMIN FETAL NEONAT M, V12, P198, DOI 10.1016/j.siny.2007.01.019
   Walraven G, 2001, LANCET, V357, P1161, DOI 10.1016/S0140-6736(00)04333-6
   Global prevalence and incidence of curable STIs, 2001, WHOCDSCDREDC200110
   Zetola NM, 2007, CLIN INFECT DIS, V44, P1222, DOI 10.1086/513427
NR 23
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD DEC
PY 2009
VL 36
IS 12
BP 745
EP 749
DI 10.1097/OLQ.0b013e3181af6de0
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 523RN
UT WOS:000272092300002
PM 19704397
OA No
DA 2017-08-15
ER

PT J
AU Hamdi, L
   Creidy, R
   Rince, P
   Abbed, K
   Clavel, J
   Raphael, M
   Landman-Parker, J
   Besson, C
AF Hamdi, Leila
   Creidy, Rita, Jr.
   Rince, Patricia
   Abbed, Karim
   Clavel, Jacqueline
   Raphael, Martine, Sr.
   Landman-Parker, Judith
   Besson, Caroline
TI A Study of Immune Deficiency as Risk Factor of Hodgkin's Lymphoma in
   Children.
SO BLOOD
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the American-Society-of-Hematology
CY DEC 05-08, 2009
CL New Orleans, LA
SP Amer Soc Hematol
C1 [Hamdi, Leila] INSERM, U802, Le Kremlin Bicetre, France.
   [Rince, Patricia] Univ Paris 11, Le Kremlin Bicetre, Gambia.
   [Abbed, Karim] CHU Bicetre, Le Kremlin Bicetre, France.
   [Raphael, Martine, Sr.] Univ Paris 11, Le Kremlin Bicetre, France.
   [Landman-Parker, Judith] Univ Paris 06, Hop Trousseau, Dept Hem Onc Pediat, Paris, France.
   [Besson, Caroline] Hop Bicetre, Paris, France.
   [Clavel, Jacqueline] INSERM, F-94275 Le Kremlin Bicetre, France.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 20
PY 2009
VL 114
IS 22
BP 624
EP 624
PG 1
WC Hematology
SC Hematology
GA 532DS
UT WOS:000272725801739
OA No
DA 2017-08-15
ER

PT J
AU Nweneka, CV
   Tapha-Sosseh, N
   Sosa, A
AF Nweneka, Chidi Victor
   Tapha-Sosseh, Ndey
   Sosa, Anibal
TI Curbing the menace of antimicrobial resistance in developing countries
SO HARM REDUCTION JOURNAL
LA English
DT Article
ID IN-VITRO ACTIVITY; ANTIBIOTIC-RESISTANCE; STREPTOCOCCUS-PNEUMONIAE;
   SURVEILLANCE; TELITHROMYCIN; CONSUMPTION; PREVALENCE; MACROLIDE; ENGLAND
AB Several reports suggest that antimicrobial resistance is an increasing global problem; but like most pandemics, the greatest toll is in the less developed countries. The dismally low rate of discovery of antimicrobials compared to the rate of development of antimicrobial resistance places humanity on a very dangerous precipice. Since antimicrobial resistance is part of an organism's natural survival instinct, total eradication might be unachievable; however, it can be reduced to a level that it no longer poses a threat to humanity. While inappropriate antimicrobial consumption contributes to the development of antimicrobial resistance, other complex political, social, economic and biomedical factors are equally important. Tackling the menace therefore should go beyond the conventional sensitization of members of the public and occasional press releases to include a multi-sectoral intervention involving the formation of various alliances and partnerships. Involving civil society organisations like the media could greatly enhance the success of the interventions
C1 [Nweneka, Chidi Victor] Keneba Field Stn, Med Res Council Labs, Banjul, Gambia.
   [Tapha-Sosseh, Ndey] Alliance Prudent Use Antibiot, Serekunda, Gambia.
   [Sosa, Anibal] APUA, Boston, MA 02111 USA.
RP Nweneka, CV (reprint author), Keneba Field Stn, Med Res Council Labs, POB 273, Banjul, Gambia.
EM cnweneka@mrc.gm; nsosseh@hotmail.com; anibal.sosa@tufts.edu
CR Andrews JR, 2007, J INFECT DIS, V196, pS482, DOI 10.1086/521121
   de Kraker M., 2007, EUROSURVEILLANCE, V12
   Denys GA, 2007, AM J INFECT CONTROL, V35, P521, DOI 10.1016/i.ajic.2006.11.004
   Felmingham D, 2002, J ANTIMICROB CHEMOTH, V50, P25, DOI 10.1093/jac/dkf808
   Felmingham D, 2007, J INFECTION, V55, P111, DOI 10.1016/j.jinf.2007.04.006
   FINLAND M, 1979, REV INFECT DIS, V1, P4
   Frank U, 2006, EUR J CLIN MICROBIOL, V25, P815, DOI 10.1007/s10096-006-0211-2
   Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0
   Johnson AP, 2005, J ANTIMICROB CHEMOTH, V56, P455, DOI 10.1093/jac/dki266
   Jones RN, 1996, DIAGN MICR INFEC DIS, V25, P153, DOI 10.1016/S0732-8893(96)00099-5
   Larson E, 2007, ANNU REV PUBL HEALTH, V28, P435, DOI 10.1146/annurev.publhealth.28.021406.144020
   Livermore DM, 2000, J ANTIMICROB CHEMOTH, V46, P411, DOI 10.1093/jac/46.3.411
   Planta MB, 2007, J AM BOARD FAM MED, V20, P533, DOI 10.3122/jabfm.2007.06.070019
   Potz NAC, 2006, J ANTIMICROB CHEMOTH, V58, P320, DOI 10.1093/jac/dkl217
   Priest P, 2001, BRIT MED J, V323, P1037, DOI 10.1136/bmj.323.7320.1037
   Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701
   Sharma Rashmi, 2005, Indian J Med Sci, V59, P120
   Zhang RF, 2006, GLOBALIZATION HEALTH, V2, DOI 10.1186/1744-8603-2-6
   2000, ANTIMICROBIAL RESIST
   ANTIMICROBIAL RESIST
NR 20
TC 2
Z9 3
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-7517
J9 HARM REDUCT J
JI Harm Reduct. J.
PD NOV 19
PY 2009
VL 6
AR 31
DI 10.1186/1477-7517-6-31
PG 4
WC Substance Abuse
SC Substance Abuse
GA 542YI
UT WOS:000273534900001
PM 19922676
OA gold
DA 2017-08-15
ER

PT J
AU Hoskin, PJ
   Lowry, L
   Horwich, A
   Jack, A
   Mead, B
   Hancock, BW
   Smith, P
   Qian, WD
   Patrick, P
   Popova, B
   Pettitt, A
   Cunningham, D
   Pettengell, R
   Sweetenham, J
   Linch, D
   Johnson, PWM
AF Hoskin, Peter J.
   Lowry, Lisa
   Horwich, Alan
   Jack, Andrew
   Mead, Ben
   Hancock, Barry W.
   Smith, Paul
   Qian, Wendi
   Patrick, Philippa
   Popova, Bilyana
   Pettitt, Andrew
   Cunningham, David
   Pettengell, Ruth
   Sweetenham, John
   Linch, David
   Johnson, Peter W. M.
TI Randomized Comparison of the Stanford V Regimen and ABVD in the
   Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer
   Research Institute Lymphoma Group Study ISRCTN 64141244
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Proceedings Paper
CT 50th Annual Meeting of the American-Society-of-Hematology
CY DEC 06-09, 2008
CL San Francisco, CA
SP Amer Soc Hematol
ID INVOLVED-FIELD RADIOTHERAPY; CLINICAL-TRIAL; DISEASE; CHEMOTHERAPY;
   HYBRID; STAGE; BULKY; MOPP
AB Purpose
   This multicenter, prospective, randomized controlled trial compared the efficacy and toxicity of two chemotherapy regimens in advanced Hodgkin's lymphoma (HL): the weekly alternating Stanford V and the standard, twice-weekly regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).
   Patients and Methods
   Patients had stage IIB, III, or IV disease or had stages I to IIA disease with bulky disease or other adverse features. Radiotherapy was administered in both arms to sites of previous bulk (>5 cm) and to splenic deposits, although this was omitted in the latter part of the trial for patients achieving complete remission (CR) in the ABVD arm. A total of 520 patients were randomly assigned and were assessed for the primary outcome measure of progression-free survival (PFS). Five hundred patients received protocol treatment, and radiotherapy was administered to 73% in the Stanford V arm and to 53% in the ABVD arm.
   Results
   The overall response rates after completion of all treatment were 91% for Stanford V and 92% for ABVD. During a median follow-up of 4.3 years, there was no evidence of a difference in projected 5-year PFS and overall survival (OS) rates (76% and 90%, respectively, for ABVD; 74% and 92%, respectively, for Stanford V). More pulmonary toxicity was reported for ABVD, whereas other toxicities were more frequent with Stanford V.
   Conclusion
   In a large, randomized trial, the efficacies of Stanford V and ABVD were comparable when given in combination with appropriate radiotherapy.
C1 [Hoskin, Peter J.] Mt Vernon Hosp, Mt Vernon Canc Ctr, Lymphoma Trials Off, Dept Clin Oncol, Northwood HA6 2RN, Middx, England.
   UCL, Canc Trials Ctr, London WC1E 6BT, England.
   MRC, Canc Trials Unit, Banjul, Gambia.
   St George Hosp, Sch Med, London, England.
   UCL, Inst Canc, London WC1E 6BT, England.
   St James Inst Oncol, Haematol Malignancy Diagnost Serv, Leeds, W Yorkshire, England.
   Univ Southampton, Canc Res United Kingdom Clin Ctr, Southampton SO9 5NH, Hants, England.
   Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England.
   Univ Liverpool, Liverpool L69 3BX, Merseyside, England.
   Taussig Canc Inst, Cleveland Clin, Cleveland, OH USA.
RP Hoskin, PJ (reprint author), Mt Vernon Hosp, Mt Vernon Canc Ctr, Lymphoma Trials Off, Dept Clin Oncol, Rickmansworth Rd, Northwood HA6 2RN, Middx, England.
EM peterhoskin@nhs.net
RI shaoping, liang/I-3447-2012
OI Cunningham, David/0000-0001-5158-1069; Johnson,
   Peter/0000-0003-2306-4974
FU Cancer Research UK [C2422/A2858]
CR Aleman BMP, 2003, NEW ENGL J MED, V348, P2396, DOI 10.1056/NEJMoa022628
   BARTLETT NL, 1995, J CLIN ONCOL, V13, P1080
   CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102
   Canellos GP, 2002, NEW ENGL J MED, V346, P1417, DOI 10.1056/NEJM200205023461821
   CHISESI T, 2008, BLOOD S, V112, P11
   Diehl V, 1998, J CLIN ONCOL, V16, P3810
   Diez P, 2007, BRIT J RADIOL, V80, P816, DOI 10.1259/bjr/56458296
   Duggan DB, 2003, J CLIN ONCOL, V21, P607, DOI 10.1200/JCO.2003.12.086
   Federico M, 2009, J CLIN ONCOL, V27, P805, DOI 10.1200/JCO.2008.17.0910
   GIANNI AM, 2008, J CLIN ONCOL S, V26, pS15
   Gobbi PG, 2005, J CLIN ONCOL, V23, P9198, DOI 10.1200/JCO.2005.02.907
   Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104
   Hasenclever D, 2001, ANN HEMATOL, V80, pB89
   Horning SJ, 2000, J CLIN ONCOL, V18, P972
   Horning SJ, 2002, J CLIN ONCOL, V20, P630, DOI 10.1200/JCO.20.3.630
   Johnson PWM, 2005, J CLIN ONCOL, V23, P9208, DOI 10.1200/JCO.2005.03.2151
   JOHNSON PWM, 2008, BLOOD, V112, P11
   KLIMM BC, 2005, J CLIN ONCOL S, V23, pS16
   LISTER TA, 1989, J CLIN ONCOL, V7, P1630
   Radford JA, 2002, J CLIN ONCOL, V20, P2988, DOI 10.1200/JCO.2002.11.107
   SANTORO A, 1987, J CLIN ONCOL, V5, P27
   Simmonds PD, 1997, ANN ONCOL, V8, P259, DOI 10.1023/A:1008282020341
NR 22
TC 83
Z9 85
U1 0
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD NOV 10
PY 2009
VL 27
IS 32
BP 5390
EP 5396
DI 10.1200/JCO.2009.23.3239
PG 7
WC Oncology
SC Oncology
GA 516GT
UT WOS:000271530900017
PM 19738111
OA No
DA 2017-08-15
ER

PT J
AU Bojang, KA
   Sesay, S
   Sowe, M
   Conway, D
   Milligan, P
   Greenwood, B
AF Bojang, Kalifa A.
   Sesay, Sanie
   Sowe, Maimuna
   Conway, David
   Milligan, Paul
   Greenwood, Brian
TI A STUDY OF INTERMITTENT PREVENTIVE TREATMENT AND HOME BASED MANAGEMENT
   OF MALARIA IN A RURAL AREA OF THE GAMBIA
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 58th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY NOV 18-22, 2009
CL Washington, DC
SP Amer Soc Trop Med & Hyg
C1 [Bojang, Kalifa A.; Sesay, Sanie; Sowe, Maimuna; Conway, David] MRC Labs, Banjul, Gambia.
   [Milligan, Paul; Greenwood, Brian] London Sch Hyg & Trop Med, London WC1, England.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2009
VL 81
IS 5
SU S
MA 509
BP 145
EP 145
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 521WK
UT WOS:000271956700507
OA No
DA 2017-08-15
ER

PT J
AU Bailey, RL
   Natividad-Sancho, A
   Fowler, A
   Peeling, RWW
   Mabey, DCW
   Whittle, HC
   Jepson, AP
AF Bailey, R. L.
   Natividad-Sancho, A.
   Fowler, A.
   Peeling, R. W. W.
   Mabey, D. C. W.
   Whittle, H. C.
   Jepson, A. P.
TI HOST GENETIC CONTRIBUTION TO THE CELLULAR IMMUNE RESPONSE TO CHLAMYDIA
   TRACHOMATIS: HERITABILITY ESTIMATE FROM A GAMBIAN TWIN STUDY
SO DRUGS OF TODAY
LA English
DT Article
ID SCARRING TRACHOMA; INFECTION; RISK; ANTIGENS; SUSCEPTIBILITY;
   POLYMORPHISMS; PROMOTER; SEQUELAE
AB If the cellular immune response to Chlamydia trachomatis is subject to genetic influences, the degree and mechanisms of such genetic control may have important implications for vaccine development. We estimated the relative contribution of host genetics to the total variation in lymphoproliferative responses to C. trachomatis antigen by analyzing these responses in 64 Gambian twin pairs from trachoma endemic areas. Zygosity was determined by restriction fragment length polymorphism analysis of minisatellite probes and microsatellite typing. Proliferative responses to serovar A elementary body antigen were estimated in monozygotic (MZ) and dizygotic (DZ) twin pairs. We found a stronger correlation and lower within-pair variability in these responses in MZ than in DZ twin pairs. The heritability estimate was 0.39 (P = 0.07) suggesting that host genetic factors contributed 39% of the variation. A better understanding of these genetic influences will contribute to the elucidation of preventive therapies far ocular C. trachomatis infection and may identify important mechanisms in protection for rational vaccine construction.
C1 [Bailey, R. L.; Natividad-Sancho, A.; Mabey, D. C. W.] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, Room 256C,Keppel St, London WC1E 7HT, England.
   [Fowler, A.; Jepson, A. P.] Wellcome Trust Ctr Human Genet, Oxford, England.
   [Peeling, R. W. W.] Lab Ctr Dis Control, Winnipeg, MB, Canada.
   [Whittle, H. C.] MRC Labs, Fajara, Gambia.
RP Bailey, RL (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, Room 256C,Keppel St, Keppel St, London WC1E 7HT, England.
EM Robin.Bailey@lshtm.ac.uk
FU Wellcome Trust; Edna McConnell Clark Foundation; International Trachoma
   Initiative; DfiD; Medical Research Council; European Commission
   [LSHG-CT-2007-037637]
FX The aims of this work are in tine with the European EpiGenChlamydia
   Consortium which is supported by the European Commission within the
   Sixth Framework Programme through contract no. LSHG-CT-2007-037637. See
   www.EpiGenChtamydia.eu for more details about this Consortium.
CR BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944
   BAILEY RL, 1995, INFECT IMMUN, V63, P389
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   HAYES LJ, 1995, J INFECT DIS, V172, P268
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   Igietseme Joseph U., 1993, Regional Immunology, V5, P317
   KHOURY MJ, 1994, FUNDAMENTALS GENETIC, P176
   Kwiatkowski D, 2000, BRIT MED J, V321, P1061, DOI 10.1136/bmj.321.7268.1061
   MABEY DCW, 1991, CLIN EXP IMMUNOL, V86, P37
   MORRISON RP, 1995, INFECT IMMUN, V63, P4661
   Mozzato-Chamay N, 2001, GENES IMMUN, V2, P153, DOI 10.1038/sj.gene.6363753
   Mozzato-Chamay N, 2000, J INFECT DIS, V182, P1545, DOI 10.1086/315891
   Natividad A, 2007, GENES IMMUN, V8, P288, DOI 10.1038/sj.gene.6364384
   Natividad A, 2005, GENES IMMUN, V6, P332, DOI 10.1038/sj.gene.6364182
   NATIVIDAD A, 2006, THESIS LONDON U
   Natividad A, 2008, HUM MOL GENET, V17, P323, DOI 10.1093/hmg/ddm310
   Peeling RW, 1998, J INFECT DIS, V177, P256, DOI 10.1086/517367
   Petronis A, 2006, TRENDS GENET, V22, P347, DOI 10.1016/j.tig.2006.04.010
   West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158
   Youssoufian H, 2002, NAT REV GENET, V3, P748, DOI 10.1038/nrg906
NR 21
TC 20
Z9 20
U1 0
U2 1
PU PROUS SCIENCE, SA
PI BARCELONA
PA PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN
SN 1699-3993
J9 DRUG TODAY
JI Drugs Today
PD NOV
PY 2009
VL 45
BP 45
EP 50
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 522RD
UT WOS:000272015100008
PM 20011694
OA No
DA 2017-08-15
ER

PT J
AU Natividad-Sancho, A
   Holland, MJ
   Mabey, DCW
   Bailey, RL
AF Natividad-Sancho, A.
   Holland, M. J.
   Mabey, D. C. W.
   Bailey, R. L.
TI HOST GENETIC STUDIES IN HUMAN OCULAR CHLAMYDIAL INFECTION
SO DRUGS OF TODAY
LA English
DT Article
ID TRACHOMATIS-ENDEMIC POPULATION; TUMOR-NECROSIS-FACTOR; LINKAGE
   DISEQUILIBRIUM; MURIDARUM INFECTION; SCARRING TRACHOMA; ALPHA GENE;
   SUSCEPTIBILITY; RESPONSES; PROMOTER; ANTIGENS
AB Several human and animal models and methods hove been used to dissect genetic contributions to immunity pathogenesis of chlamydial diseases. Considerable achievements have been mode in this field of host genetics. The hope is that these studies will lead to medical applications by helping to elicit the function of genes that involved in host defense against chlamydia and in progression to severe sequelae. In the present article, we review a selection of findings in the forward genetics of ocular Chlamydia trachomatis infection in humans.
C1 [Natividad-Sancho, A.; Holland, M. J.; Mabey, D. C. W.; Bailey, R. L.] Univ London, London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Holland, M. J.] MRC Labs, Banjul, Gambia.
RP Bailey, RL (reprint author), Univ London, London Sch Hyg & Trop Med, Room 256C,Keppel St, London WC1E 7HT, England.
EM Robin.Bailey@lshtm.ac.uk
FU Wellcome Trust and Medical Research Council, UK; European Commission
   [LSHG-CT-2007-037637]
FX We apologize to our colleagues whose studies were not cited owing to
   space limitations. We owe a great debt to Dominic Kwiatkowski, Kirk
   Rockett and all members of the laboratory at the Wellcome Trust Centre
   for Human Genetics, Oxford University, for helpful guidance, discussion
   and technical support of these studies. We warmly thank our case-control
   subjects and their families for their participation and trust. Our study
   has been supported by grants from the Wellcome Trust and Medical
   Research Council, UK. This work was supported by the European Commission
   within the Sixth Framework Programme through the EpiGenChlamydia project
   (contract no. LSHG-CT-2007-037637). See www.EpiGenChlamydia.eu for more
   details.
CR BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944
   BAILEY RL, 1995, INFECT IMMUN, V63, P389
   BAILEY RL, 1998, P 9 INT S HUM CHLAM, P474
   BEATTY WL, 1994, MICROBIOL REV, V58, P686
   Bobo L, 1996, INFECT IMMUN, V64, P3273
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Chidambaram JD, 2005, BRIT J OPHTHALMOL, V89, P789, DOI 10.1136/bjo.2005.065847
   COLLIER IE, 1992, J BIOL CHEM, V267, P6776
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Conway DJ, 1996, J INFECT DIS, V174, P643
   El-Asrar A M, 2000, Br J Ophthalmol, V84, P85, DOI 10.1136/bjo.84.1.85
   Faal N, 2005, CLIN EXP IMMUNOL, V142, P347, DOI 10.1111/j.1365-2249.2005.02917.x
   Gibson AW, 2001, J IMMUNOL, V166, P3915
   Hanchard N, 2006, IMMUNOGENETICS, V58, P465, DOI 10.1007/s00251-006-0118-1
   HOLLAND MJ, 1993, J INFECT DIS, V168, P1528
   Holland MJ, 1996, CLIN EXP IMMUNOL, V105, P429, DOI 10.1046/j.1365-2249.1996.d01-792.x
   Igietseme JU, 1998, MICROBIOL IMMUNOL, V42, P617
   Kaiko GE, 2008, J IMMUNOL, V180, P2225
   Kanda N, 1999, BIOCHEM BIOPH RES CO, V256, P41, DOI 10.1006/bbrc.1999.0281
   Knight JC, 2004, NAT GENET, V36, P394, DOI 10.1038/ng1331
   Koch O, 2005, GENES IMMUN, V6, P312, DOI 10.1038/sj.gene.6364214
   Lu H, 2002, J IMMUNOL, V169, P6324
   Luoni G, 2005, GENES IMMUN, V6, P723, DOI 10.1038/sj.gene.6364250
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   Mozzato-Chamay N, 2000, J INFECT DIS, V182, P1545, DOI 10.1086/315891
   Natividad A, 2007, GENES IMMUN, V8, P288, DOI 10.1038/sj.gene.6364384
   Natividad A, 2005, GENES IMMUN, V6, P332, DOI 10.1038/sj.gene.6364182
   NATIVIDAD A, 2006, THESIS LONDON U
   Natividad A, 2008, HUM MOL GENET, V17, P323, DOI 10.1093/hmg/ddm310
   Ohman H, 2006, GENES IMMUN, V7, P243, DOI 10.1038/sj.gene.6364293
   Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047
   PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0
   Ramsey KH, 2005, INFECT IMMUN, V73, P6962, DOI 10.1128/IAI.73.10.6962-6973.2005
   Shah AA, 2005, SEX TRANSM DIS, V32, P49, DOI 10.1097/01.olq.0000148299.14513.11
   Shipley JM, 1996, J BIOL CHEM, V271, P4335
   Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x
   West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158
   White AG, 1997, BRIT J OPHTHALMOL, V81, P431, DOI 10.1136/bjo.81.6.431
   Wilson JN, 2005, GENES IMMUN, V6, P462, DOI 10.1038/sj.gene.6364227
   Yang X, 1996, J IMMUNOL, V156, P4338
NR 40
TC 0
Z9 0
U1 0
U2 1
PU PROUS SCIENCE, SA
PI BARCELONA
PA PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN
SN 1699-3993
J9 DRUG TODAY
JI Drugs Today
PD NOV
PY 2009
VL 45
BP 61
EP 66
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 522RD
UT WOS:000272015100010
PM 20011696
OA No
DA 2017-08-15
ER

PT J
AU Todryk, SM
   Walther, M
   Bejon, P
   Hutchings, C
   Thompson, FM
   Urban, BC
   Porter, DW
   Hill, AVS
AF Todryk, Stephen M.
   Walther, Michael
   Bejon, Philip
   Hutchings, Claire
   Thompson, Fiona M.
   Urban, Britta C.
   Porter, David W.
   Hill, Adrian V. S.
TI Multiple functions of human T cells generated by experimental malaria
   challenge
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Effector; Malaria; Memory; Regulation; T cells
ID PLASMODIUM-FALCIPARUM; DENDRITIC CELL; MEDIATED PROTECTION; GAMMA
   RESPONSES; IMMUNE-RESPONSE; MEMORY; VACCINE; INFECTION; EFFECTOR; STAGE
AB Protective immunity generated following malaria infection may be comprised of Ab or T cells against malaria Ag of different stages; however, the short-lived immunity that is observed suggests deficiency in immune memory or regulatory activity. in this study, cellular immune responses were investigated in individuals receiving Plasmodium falciparum sporozoite challenge by the natural (mosquito bite) route as part of a malaria vaccine efficacy trial. Parasitemia, monitored by blood film microscopy and PCR, was subsequently cleared with drugs. All individuals demonstrated stable IFN-gamma, IL-2 and IL-4 ex vivo ELISPOT effector responses against P. falciparum-infected RBC (iRBC) Ag, 28 and 90 days after challenge. However, infected RBC-specific central memory responses, as measured by IFN-gamma cultured ELISPOT, were low and unstable over time, despite CD4(+) T cells being highly proliferative by CFSE dilution, and showed an inverse relationship to parasite density. In support of the observation of poor memory, co-culture experiments showed reduced responses to common recall Ag, indicating malaria-specific regulatory activity. This activity could not be accounted for by the expression of IL-10, TGF-beta, FOXP3 or CTLA-4, but proliferating T cells expressed high levels of CD95, indicating a pro-apoptotic phenotype. Lastly, there was an: inverse relationship between FOXP3 expression, when measured 10 days after challenge, and ex vivo IFN-gamma measured more than 100 days later. This study shows that malaria infection elicits specific Th1 and Th2 effector cells, but concomitant weak central memory and regulatory activity, which may help to explain the short-lived immunity observed.
C1 [Todryk, Stephen M.] Northumbria Univ, Sch Appl Sci, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England.
   [Todryk, Stephen M.; Bejon, Philip; Hutchings, Claire; Thompson, Fiona M.; Porter, David W.; Hill, Adrian V. S.] Univ Oxford, Churchill Hosp, Nuffield Dept Med, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [Walther, Michael] MRC Labs, Fajara, Gambia.
   [Bejon, Philip; Urban, Britta C.] Ctr Geog Med Res Coast, Wellcome Trust Collaborat Res Programme, Kenya Med Res Inst, KEMRI, Kilifi, Kenya.
   [Hutchings, Claire; Porter, David W.; Hill, Adrian V. S.] Univ Oxford, Jenner Inst, Oxford, England.
RP Todryk, SM (reprint author), Northumbria Univ, Sch Appl Sci, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England.
EM stephen.todryk@northumbria.ac.uk
OI Urban, Britta/0000-0002-4197-8393
FU Wellcome Trust; Medical Research Council; Northumbria University
   Research Development Fund; NIHR
FX S. T. acknowledges support from the Wellcome Trust, the Medical Research
   Council and the Northumbria University Research Development Fund. A. V.
   S. H. is a Wellcome Trust Principal Research Fellow. We are grateful to
   Helen Fletcher for help with qPCR. This work was funded in part by an
   NIHR grant to the Oxford Biomedical Research Centre.
CR Achtman AH, 2005, CURR TOP MICROBIOL, V297, P71
   Andrews L, 2005, AM J TROP MED HYG, V73, P191
   Artavanis-Tsakonas K, 2003, CLIN EXP IMMUNOL, V133, P145, DOI 10.1046/j.1365-2249.2003.02174.x
   Bejon P, 2007, J IMMUNOL, V179, P4193
   Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
   Doolan DL, 2006, CURR MOL MED, V6, P169, DOI 10.2174/156652406776055249
   Godkin AJ, 2002, J IMMUNOL, V169, P2210
   GREENWOOD BM, 1972, LANCET, V1, P169
   Harari A, 2005, J IMMUNOL, V174, P1037
   Hisaeda H, 2004, NAT MED, V10, P29, DOI 10.1038/nm975
   HO M, 1986, J INFECT DIS, V153, P763
   Kaiko GE, 2008, IMMUNOLOGY, V123, P326, DOI 10.1111/j.1365-2567.2007.02719.x
   Keating SM, 2005, J IMMUNOL, V175, P5675
   Kemp K, 2002, CLIN EXP IMMUNOL, V127, P151, DOI 10.1046/j.1365-2249.2002.01714.x
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Luty AJF, 1999, J INFECT DIS, V179, P980, DOI 10.1086/314689
   MANDEL TE, 1980, IMMUNOL REV, V53, P29, DOI 10.1111/j.1600-065X.1980.tb01039.x
   Mayxay M, 2001, T ROY SOC TROP MED H, V95, P179, DOI 10.1016/S0035-9203(01)90156-7
   McKinstry KK, 2008, IMMUNOL RES, V40, P114, DOI 10.1007/s12026-007-8004-y
   Millington OR, 2007, PLOS PATHOG, V3, P1380, DOI 10.1371/journal.ppat.0030143
   Pombo DJ, 2002, LANCET, V360, P610, DOI 10.1016/S0140-6736(02)09784-2
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702
   Saparov A, 1999, IMMUNITY, V11, P271, DOI 10.1016/S1074-7613(00)80102-8
   Sponaas AM, 2006, J EXP MED, V203, P1427, DOI 10.1084/jem.20052450
   Struik SS, 2004, IMMUNOL REV, V201, P268, DOI 10.1111/j.0105-2896.2004.00181.x
   Sutherland CJ, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-161
   Thompson FM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001493
   Todryk S, 2009, EUR J IMMUNOL, V39, P2007, DOI 10.1002/eji.200939529
   Todryk SM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002027
   Todryk SM, 2007, NAT REV MICROBIOL, V5, P487, DOI 10.1038/nrmicro1712
   Todryk SM, 2009, IMMUNOLOGY, V128, P83, DOI 10.1111/j.1365-2567.2009.03073.x
   Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900
   Vuola JM, 2005, J IMMUNOL, V174, P449
   Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006
   Walther M, 2006, J IMMUNOL, V177, P5736
   Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102
   WELSH RM, 1995, J CELL BIOCHEM, V59, P135, DOI 10.1002/jcb.240590202
   Wipasa J, 2001, J IMMUNOL, V167, P3903
   Wykes M, 2007, CELL MICROBIOL, V9, P300, DOI 10.1111/j.1462-5822.2006.00865.x
NR 39
TC 20
Z9 20
U1 0
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD NOV
PY 2009
VL 39
IS 11
BP 3042
EP 3051
DI 10.1002/eji.200939434
PG 10
WC Immunology
SC Immunology
GA 524EH
UT WOS:000272126100013
PM 19658096
OA No
DA 2017-08-15
ER

PT J
AU Duffy, CW
   Morrison, LJ
   Black, A
   Pinchbeck, GL
   Christley, RM
   Schoenefeld, A
   Tait, A
   Turner, CMR
   MacLeod, A
AF Duffy, Craig W.
   Morrison, Liam J.
   Black, Alana
   Pinchbeck, Gina L.
   Christley, Robert M.
   Schoenefeld, Andreas
   Tait, Andy
   Turner, C. Michael R.
   MacLeod, Annette
TI Trypanosoma vivax displays a clonal population structure
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Article
DE Trypanosoma vivax; Population genetics; Mating; Microsatellites;
   Multilocus genotypes
ID BOVINE TRYPANOSOMIASIS; BRUCEI-GAMBIENSE; DUTTONELLA VIVAX; MOLECULAR
   EPIDEMIOLOGY; AFRICAN TRYPANOSOMES; TSETSE-FLIES; EAST-AFRICA;
   WEST-AFRICA; T-VIVAX; CATTLE
AB African animal trypanosomiasis, or Nagana, is a debilitating and economically costly disease with a major impact on animal health in sub-Saharan Africa. Trypanosoma vivax, one of the principal trypanosome species responsible for the disease, infects a wide host range including cattle, goats, horses and donkeys and is transmitted both cyclically by tsetse flies and mechanically by other biting flies, resulting in a distribution covering large swathes of South America and much of sub-Saharan Africa. While there is evidence for mating in some of the related trypanosome species, Trypanosoma brucei, Trypanosoma congolense and Trypanosoma cruzi, very little work has been carried out to examine this question in T. vivax. Understanding whether mating occurs in T vivax will provide insight into the dynamics of trait inheritance, for example the spread of drug resistance, as well as examining the origins of meiosis in the order Kinetoplastida. With this in mind we have identified orthologues of eight core meiotic genes within the genome, the presence of which imply that the potential for mating exists in this species. In order to address whether mating occurs, we have investigated a sympatric field population of T vivax collected from livestock in The Gambia, using microsatellite markers developed for this species. Our analysis has identified a clonal population structure showing significant linkage disequilibrium, homozygote deficits and disagreement with Hardy-Weinberg predictions at six microsatellite loci, indicative of a lack of mating in this population of T vivax. Crown Copyright (c) 2009 Published by Elsevier Ltd. All rights reserved.
C1 [Duffy, Craig W.; Morrison, Liam J.; Tait, Andy; MacLeod, Annette] Univ Glasgow, Wellcome Ctr Mol Parasitol, Glasgow Biomed Res Ctr, Fac Vet Med, Glasgow G12 8TA, Lanark, Scotland.
   [Duffy, Craig W.; Black, Alana; Turner, C. Michael R.] Univ Glasgow, Div Infect & Immun, Fac Biomed & Life Sci, Glasgow Biomed Res Ctr, Glasgow G12 8TA, Lanark, Scotland.
   [Pinchbeck, Gina L.; Christley, Robert M.] Univ Liverpool, Fac Vet Sci, Leahurst CH64 7TE, Neston, England.
   [Schoenefeld, Andreas] Int Trypanotolerance Ctr, Banjul, Gambia.
RP MacLeod, A (reprint author), Univ Glasgow, Wellcome Ctr Mol Parasitol, Glasgow Biomed Res Ctr, Fac Vet Med, 120 Univ Pl, Glasgow G12 8TA, Lanark, Scotland.
EM gvwa08@udcf.gla.ac.uk
OI Duffy, Craig/0000-0001-9359-4888; Christley, Robert/0000-0001-9250-3032
FU Wellcome Trust [, 079703]
CR ALLSOPP BA, 1985, INT J PARASITOL, V15, P265, DOI 10.1016/0020-7519(85)90063-3
   Osorio ALAR, 2008, MEM I OSWALDO CRUZ, V103, P1, DOI 10.1590/S0074-02762008000100001
   Auty H, 2008, VET PARASITOL, V154, P233, DOI 10.1016/j.vetpar.2008.02.034
   Batista JS, 2007, VET PARASITOL, V143, P174, DOI 10.1016/j.vetpar.2006.08.017
   Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573
   Brisse S, 2003, INFECT GENET EVOL, V2, P173, DOI 10.1016/S1567-1348(02)00097-7
   Catley A, 2002, MED VET ENTOMOL, V16, P55, DOI 10.1046/j.0269-283x.2002.00346.x
   Cherenet T, 2006, VET PARASITOL, V140, P251, DOI 10.1016/j.vetpar.2006.04.004
   Cortez AP, 2006, PARASITOLOGY, V133, P159, DOI 10.1017/S0031182006000254
   de Freitas JM, 2006, PLOS PATHOG, V2, P226, DOI 10.1371/journal.ppat.0020024
   De Meeus T, 2006, INFECT GENET EVOL, V6, P163, DOI 10.1016/j.meegid.2005.02.004
   Delafosse A, 2006, PREV VET MED, V74, P108, DOI 10.1016/j.prevetmed.2005.10.006
   Desquesnes M, 2004, VET PARASITOL, V119, P9, DOI 10.1016/j.vetpar.2003.10.015
   DIRIE MF, 1993, J EUKARYOT MICROBIOL, V40, P132, DOI 10.1111/j.1550-7408.1993.tb04892.x
   EI-Sayed N. M., 2005, SCIENCE, V309, P409
   FASOGBON AI, 1990, INT J PARASITOL, V20, P389, DOI 10.1016/0020-7519(90)90156-H
   Faye D, 2001, VET PARASITOL, V101, P101, DOI 10.1016/S0304-4017(01)00503-9
   GARDINER PR, 1987, PARASITOL TODAY, V3, P49, DOI 10.1016/0169-4758(87)90213-4
   GARDINER PR, 1989, ADV PARASIT, V28, P229, DOI 10.1016/S0065-308X(08)60334-6
   GASHUMBA JK, 1988, PARASITOLOGY, V96, P475
   Gaunt MW, 2003, NATURE, V421, P936, DOI 10.1038/nature01438
   Gibson W, 2007, INT J PARASITOL, V37, P829, DOI 10.1016/j.ijpara.2007.03.002
   Haas S, 1998, NUCLEIC ACIDS RES, V26, P3006, DOI 10.1093/nar/26.12.3006
   Halkett F, 2005, TRENDS ECOL EVOL, V20, P194, DOI 10.1016/j.tree.2005.01.001
   Hoare C, 1972, TRYPANOSOMES MAMMALS
   Jamonneau V, 2003, INFECT GENET EVOL, V3, P143, DOI 10.1016/S1567-1348(03)00069-8
   Jones TW, 2001, TRENDS PARASITOL, V17, P99, DOI 10.1016/S1471-4922(00)01777-3
   Kalu AU, 2001, SMALL RUMINANT RES, V40, P109, DOI 10.1016/S0921-4488(00)00215-7
   KILGOUR V, 1977, ANN TROP MED PARASIT, V71, P387
   KILGOUR V, 1975, ANN TROP MED PARASIT, V69, P329
   Koffi M, 2009, P NATL ACAD SCI USA, V106, P209, DOI 10.1073/pnas.0811080106
   Koffi M, 2007, INFECT GENET EVOL, V7, P675, DOI 10.1016/j.meegid.2007.07.001
   Lai DH, 2008, P NATL ACAD SCI USA, V105, P1999, DOI 10.1073/pnas.0711799105
   MacLeod A, 2000, P NATL ACAD SCI USA, V97, P13442, DOI 10.1073/pnas.230434097
   MacLeod A, 1999, MOL BIOCHEM PARASIT, V102, P237, DOI 10.1016/S0166-6851(99)00101-2
   MacLeod A, 2005, MOL BIOCHEM PARASIT, V143, P12, DOI 10.1016/j.molbiopara.2005.04.009
   MacLeod A, 2001, PHILOS T ROY SOC B, V356, P1035, DOI 10.1098/rstb.2001.0892
   Magona JW, 2008, ACTA TROP, V107, P186, DOI 10.1016/j.actatropica.2008.05.019
   MASIGA DK, 1992, INT J PARASITOL, V22, P909, DOI 10.1016/0020-7519(92)90047-O
   Maynard- Smith J, 1993, P NATIONAL ACADEMY S, V90, P4384
   MCNAMARA JJ, 1995, T ROY SOC TROP MED H, V89, P388, DOI 10.1016/0035-9203(95)90021-7
   Morrison LJ, 2007, AM J TROP MED HYG, V76, P1132
   Morrison LJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005564
   Morrison LJ, 2008, INFECT GENET EVOL, V8, P847, DOI 10.1016/j.meegid.2008.08.005
   Njiokou F, 2004, ACTA TROP, V92, P139, DOI 10.1016/j.actatropica.2004.04.011
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   Peakall R, 2006, MOL ECOL NOTES, V6, P288, DOI 10.1111/j.1471-8286.2005.01155.x
   Pinchbeck GL, 2008, BMC VET RES, V4, DOI 10.1186/1746-6148-4-7
   Ramesh MA, 2005, CURR BIOL, V15, P185, DOI 10.1016/j.cub.2005.01.003
   Rodrigues AC, 2008, PARASITOLOGY, V135, P1317, DOI 10.1017/S0031182008004848
   Schurko AM, 2008, BIOESSAYS, V30, P579, DOI 10.1002/bies.20764
   Shaw A, 2004, TRYPANOSOMIASES
   Silva RAMS, 1998, VET PARASITOL, V76, P153, DOI 10.1016/S0304-4017(97)00005-8
   SIMO G, 2007, EXP PARASITOL, V118, P172
   Sinshaw A, 2006, VET PARASITOL, V142, P35, DOI 10.1016/j.vetpar.2006.06.032
   Stenberg P, 2003, MOL ECOL NOTES, V3, P329, DOI 10.1046/j.1471-8286.2003.00408.x
   Stevens JR, 1999, PARASITOLOGY, V118, P107, DOI 10.1017/S0031182098003473
   Taylor KA, 1999, MEM I OSWALDO CRUZ, V94, P239, DOI 10.1590/S0074-02761999000200022
   TIBAYRENC M, 1990, P NATL ACAD SCI USA, V87, P2414, DOI 10.1073/pnas.87.7.2414
   TIBAYRENC M, 1991, P NATL ACAD SCI USA, V88, P5129, DOI 10.1073/pnas.88.12.5129
   TURNER CMR, 1990, PARASITOLOGY, V101, P377
   Waiswa C, 2004, ANN TROP MED PARASIT, V98, P21, DOI 10.1179/000349804225003073
   Westenberger SJ, 2005, GENETICS, V171, P527, DOI 10.1534/genetics.104.038745
   YOUNG CJ, 1983, ANN TROP MED PARASIT, V77, P467
NR 64
TC 24
Z9 24
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-7519
J9 INT J PARASITOL
JI Int. J. Parasit.
PD NOV
PY 2009
VL 39
IS 13
BP 1475
EP 1483
DI 10.1016/j.ijpara.2009.05.012
PG 9
WC Parasitology
SC Parasitology
GA 502YB
UT WOS:000270495800007
PM 19520081
OA No
DA 2017-08-15
ER

PT J
AU Dione, MM
   Ieven, M
   Garin, B
   Marcotty, T
   Geerts, S
AF Dione, Michel M.
   Ieven, Margareta
   Garin, Benoit
   Marcotty, Tanguy
   Geerts, Stanny
TI Prevalence and Antimicrobial Resistance of Salmonella Isolated from
   Broiler Farms, Chicken Carcasses, and Street-Vended Restaurants in
   Casamance, Senegal
SO JOURNAL OF FOOD PROTECTION
LA English
DT Article
ID RISK-FACTORS; PATHOGENS; DAKAR
AB This study was undertaken to determine the prevalence and distribution of Salmonella on 57 randomly selected broiler farms at the end of the rearing period and in chicken products in urban and periurban areas in Casamance, Senegal, and to evaluate the antimicrobial resistance profiles of the Salmonella serovars. Salmonella was detected in chicken feces, on carcass skin, and in muscle on 35.1, 38.6, and 29.8% of farms, respectively. Salmonella was found in chicken meat servings from 14.3% of the 42 street restaurants and in 40.4% of the 285 chicken carcasses examined. The prevalence on skin and in Muscle was significantly associated with the detection of Salmonella in feces (P <= 0.001). Eighteen Salmonella serovars were identified; the most common were Brancaster (57.9%), Goelzau (10.7%), Kentucky (8.4%). and Hadar (7.3%). High levels of resistance were found to trimethoprim-sulfamethoxazole, tetracycline, trimethoprim, streptomycin, and sulfonamides. All Salmonella serovars were susceptible to fluoroquinolones and third-generation cephalosporins. A large proportion of the isolates belonging to 11 serovars were resistant to two or more antibiotics. Salmonella continues to be of serious concern in the broiler production chain in Senegal.
C1 [Marcotty, Tanguy; Geerts, Stanny] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Dione, Michel M.] Int Trypanotolerance Ctr, Banjul, Gambia.
   [Ieven, Margareta] Univ Antwerp, B-2020 Antwerp, Belgium.
   [Garin, Benoit] Inst Pasteur, Dakar, Senegal.
RP Geerts, S (reprint author), Inst Trop Med, B-2000 Antwerp, Belgium.
EM sgeerts@itg.be
FU Flemish Interuniversity Council (VLIR-UOS, Brussels, Belgium)
FX This work was financially supported by the Flemish Interuniversity
   Council (VLIR-UOS, Brussels, Belgium). We highly appreciate the support
   of the Pasteur Institute (Dakar, Senegal) for the conventional
   serotyping and the help of the Institute of Tropical Medicine (Antwerp,
   Belgium) for the statistical analysis.
CR Bada-Alambedji R, 2006, BRAZ J MICROBIOL, V37, P510, DOI 10.1590/S1517-83822006000400020
   Bonfiglio G, 2002, INT J ANTIMICROB AG, V20, P387, DOI 10.1016/S0924-8579(02)00208-X
   Cardinale E., 2003, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V56, P13
   Cardinale E, 2005, INT J FOOD MICROBIOL, V103, P157, DOI 10.1016/j.ijfoodmicro.2004.12.023
   Cardinale E, 2004, PREV VET MED, V63, P151, DOI 10.1016/j.prevetmed.2004.03.002
   CARDINALE E, 2002, FOOD SAFETY MANAGEME, P4
   Carli KT, 2001, J FOOD PROTECT, V64, P1832
   Dominguez C, 2002, INT J FOOD MICROBIOL, V72, P165, DOI 10.1016/S0168-1605(01)00638-9
   GARIN B, COMMUNICATION
   GRUNONT PAD, 2007, ANTIGENIC FORMULAE S
   Okeke IN, 2007, EMERG INFECT DIS, V13, P1640, DOI 10.3201/eid1311.070674
   QUYNH L, 2006, ANN NY ACAD SCI, V1081, P257
   UTTENDAELE MR, 1998, INT J FOOD MICROBIOL, V40, P1
   World Health Organization, 2000, WHOCDS20002
   2008, RECOMANDATIONS COMIT
NR 15
TC 13
Z9 14
U1 0
U2 6
PU INT ASSOC FOOD PROTECTION
PI DES MOINES
PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA
SN 0362-028X
J9 J FOOD PROTECT
JI J. Food Prot.
PD NOV
PY 2009
VL 72
IS 11
BP 2423
EP 2427
PG 5
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 518UR
UT WOS:000271720700029
PM 19903412
OA No
DA 2017-08-15
ER

PT J
AU Savy, M
   Edmond, K
   Fine, PEM
   Hall, A
   Hennig, BJ
   Moore, SE
   Mulholland, K
   Schaible, U
   Prentice, AM
AF Savy, Mathilde
   Edmond, Karen
   Fine, Paul E. M.
   Hall, Andrew
   Hennig, Branwen J.
   Moore, Sophie E.
   Mulholland, Kim
   Schaible, Ulrich
   Prentice, Andrew M.
TI Landscape Analysis of Interactions between Nutrition and Vaccine
   Responses in Children
SO JOURNAL OF NUTRITION
LA English
DT Review
ID VITAMIN-A SUPPLEMENTATION; CELL-MEDIATED-IMMUNITY; PROTEIN-CALORIE
   MALNUTRITION; CHRONIC-HEMODIALYSIS PATIENTS; IRON-DEFICIENT CHILDREN;
   ORAL CHOLERA VACCINE; PNEUMOCOCCAL CONJUGATE VACCINE; RANDOMIZED
   CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; HEPATITIS-B VACCINATION
AB The world's poorest children are likely to be malnourished when receiving their childhood vaccines. It is uncertain whether this affects vaccine efficacy and whether the coadministration of nutrient supplements with vaccines has beneficial or detrimental effects. More recently, a detrimental interaction between vitamin A (VA) supplementation (VAS) and the killed diphtheria-tetanus-pertussis vaccine given in early childhood has been suggested. This report provides a critical review of the published interactions between nutritional status and/or supplementation and vaccine responses in children. Due to an absence of evidence for most nutrients, this analysis focused on protein-energy, vitamins A and D, and iron and zinc. All vaccines were considered. Both observational studies and clinical trials that led to peer-reviewed publications in English or French were included. These criteria led to a pool of 58 studies for protein-energy malnutrition, 43 for VA, 4 for vitamin D, 10 for iron, and 22 for zinc. Our analysis indicates that malnutrition has surprisingly little or no effect on vaccine responses. Evidence for definitive adjunctive effects of micronutrient supplementation at the time of vaccination is also weak. Overall, the paucity, poor quality, and heterogeneity of data make it difficult to draw firm conclusions. The use of simple endpoints that may not correlate strongly with disease protection adds uncertainty. A detailed examination of the immunological mechanisms involved in potential interactions, employing modern methodologies, is therefore required. This would also help us understand the proposed, but still unproven, negative interactions between VAS and vaccine safety, a resolution of which is urgently required. J. Nutr. 139: 2154S-2218S, 2009.
C1 [Savy, Mathilde] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Nutr & Publ Hlth Intervent Res Unit, London WC1E 7HT, England.
   [Edmond, Karen; Fine, Paul E. M.; Hall, Andrew; Mulholland, Kim] London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England.
   [Schaible, Ulrich] London Sch Hyg & Trop Med, Immunol Unit, London WC1E 7HT, England.
   [Moore, Sophie E.] MRC, Int Nutr Grp, Keneba, Gambia.
RP Savy, M (reprint author), London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Nutr & Publ Hlth Intervent Res Unit, Keppel St, London WC1E 7HT, England.
EM Mathilde.Savy@lshtm.ac.uk
RI Hennig, Branwen/M-6444-2014
FU Medical Research Council [MC_U123292699, MC_U123292700, MC_U123292701]
CR AABY P, 1995, BRIT MED J, V311, P481
   Ada G, 2001, NEW ENGL J MED, V345, P1042, DOI 10.1056/NEJMra011223
   Ahmed T, 2009, VACCINE, V27, P1433, DOI 10.1016/j.vaccine.2008.12.036
   Albert MJ, 2003, J INFECT DIS, V187, P909, DOI 10.1086/368132
   Antonen JA, 2000, NEPHRON, V86, P56, DOI 10.1159/000045713
   Arya S, 2000, Indian Pediatr, V37, P1341
   BAER CL, 1986, W INDIAN MED J, V35, P106
   BAGCHI K, 1980, BRIT MED J, V280, P1249
   Bahl R, 2002, EUR J CLIN NUTR, V56, P321, DOI 10.1038/sj/ejcn/1601325
   Bahl R, 1999, J NUTR, V129, P1569
   Bao B, 2006, TOXICOL LETT, V166, P222, DOI 10.1016/j.toxlet.2006.07.306
   BAQUI AH, 1995, ACTA PAEDIATR, V84, P863, DOI 10.1111/j.1651-2227.1995.tb13781.x
   Benn CS, 2009, AM J CLIN NUTR, V90, P629, DOI 10.3945/ajcn.2009.27477
   Benn CS, 2008, BRIT MED J, V336, P1416, DOI 10.1136/bmj.39542.509444.AE
   Benn CS, 2007, VACCINE, V25, P777, DOI 10.1016/j.vaccine.2006.09.044
   Benn CS, 2005, BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55
   BENN CS, 1995, LANCET, V346, P503
   Benn CS, 1997, LANCET, V350, P101, DOI 10.1016/S0140-6736(96)12019-5
   Benn CS, 2003, INT J EPIDEMIOL, V32, P822, DOI 10.1093/ije/dyg208
   Benn CS, 2002, LANCET, V359, P1313, DOI 10.1016/S0140-6736(02)08274-0
   Berger J, 2000, EUR J CLIN NUTR, V54, P29, DOI 10.1038/sj.ejcn.1600888
   Beverley PCL, 2002, BRIT MED BULL, V62, P15, DOI 10.1093/bmb/62.1.15
   Bhaskaram P, 1998, Indian Pediatr, V35, P217
   BHASKARAM P, 1989, NUTR RES, V9, P1017, DOI 10.1016/S0271-5317(89)80062-4
   Bhaskaram P., 1997, Indian Journal of Pediatrics, V64, P503, DOI 10.1007/BF02737757
   Bhutta ZA, 2008, LANCET, V371, P417, DOI 10.1016/S0140-6736(07)61693-6
   Brock JH, 2000, P NUTR SOC, V59, P537, DOI 10.1017/S002966510000077X
   BRODERSEN HP, 1995, NEPHROL DIAL TRANSPL, V10, P1780
   BROWN KH, 1980, AM J CLIN NUTR, V33, P212
   BROWN RE, 1966, TROP GEOGR MED, V18, P125
   BROWN RE, 1966, TROP GEOGR MED, V18, P129
   BRUSSOW H, 1995, CLIN DIAGN LAB IMMUN, V2, P62
   Cantorna MT, 2008, MOL ASPECTS MED, V29, P369, DOI 10.1016/j.mam.2008.04.004
   Cantorna MT, 2004, AM J CLIN NUTR, V80, p1717S
   CHANDRA RK, 1984, AM J CLIN NUTR, V40, P131
   CHANDRA RK, 1975, BRIT MED J, V2, P583
   CHANDRA RK, 1975, J PEDIATR-US, V86, P899, DOI 10.1016/S0022-3476(75)80221-6
   CHANDRA RK, 1991, AM J CLIN NUTR, V53, P1087
   Chen S, 2007, J IMMUNOL, V179, P1634
   Cherian T, 2003, VACCINE, V21, P2418, DOI 10.1016/S0264-410X(03)00060-4
   CHOPRA K, 1989, J TROP PEDIATRICS, V35, P19
   COOVADIA HM, 1974, AM J CLIN NUTR, V27, P665
   Crogan NL, 2005, GERIATR NURS, V26, P188, DOI 10.1016/j.gerinurse.2005.03.007
   Daniel C, 2008, J PHARMACOL EXP THER, V324, P23, DOI 10.1124/jpet.107.127209
   DAO H, 1992, J TROP PEDIATRICS, V38, P179
   Darboe MK, 2007, LANCET, V369, P2088, DOI 10.1016/S0140-6736(07)60981-7
   Daynes RA, 1996, INFECT IMMUN, V64, P1100
   deFrancisco A, 1996, T ROY SOC TROP MED H, V90, P441, DOI 10.1016/S0035-9203(96)90540-4
   DEFRANCISCO A, 1993, LANCET, V342, P526, DOI 10.1016/0140-6736(93)91648-6
   Deloria-Knoll M, 2006, VACCINE, V24, P1670, DOI 10.1016/j.vaccine.2005.09.047
   DHUR A, 1989, COMP BIOCHEM PHYS A, V94, P11, DOI 10.1016/0300-9629(89)90776-7
   Diness BR, 2007, AM J CLIN NUTR, V86, P1152
   DOHERTY JF, 1994, CLIN SCI, V86, P347
   DOSSETOR J, 1977, BRIT MED J, V1, P1633
   Drakesmith H, 2008, NAT REV MICROBIOL, V6, P541, DOI 10.1038/nrmicro1930
   DUCHATEAU J, 1981, AM J MED, V70, P1001, DOI 10.1016/0002-9343(81)90849-4
   EKUNWE EO, 1985, J TROP PEDIATRICS, V31, P290
   ElGamal Y, 1996, J TROP PEDIATRICS, V42, P144, DOI 10.1093/tropej/42.3.144
   ELMOLLA A, 1973, J TROP MED HYG, V76, P248
   Enioutina EY, 1999, VACCINE, V17, P3050, DOI 10.1016/S0264-410X(99)00147-4
   Ertesvag A, 2009, SEMIN IMMUNOL, V21, P36, DOI 10.1016/j.smim.2008.06.005
   Faulk W P, 1975, Trop Dis Bull, V72, P89
   FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898
   Fine PEM, 2009, TROP MED INT HEALTH, V14, P969, DOI 10.1111/j.1365-3156.2009.02301.x
   Fraker PJ, 2004, ANNU REV NUTR, V24, P277, DOI 10.1146/annurev.nutr.24.012003.132454
   Fraker P. J., 2000, J NUTR S, V130, P1399
   Fulop T, 1999, J GERONTOL A-BIOL, V54, pM59, DOI 10.1093/gerona/54.2.M59
   GALAN P, 1992, BIOL TRACE ELEM RES, V32, P421, DOI 10.1007/BF02784628
   Gardner EM, 2000, MECH AGEING DEV, V117, P29, DOI 10.1016/S0047-6374(00)00134-2
   Girodon F, 1999, ARCH INTERN MED, V159, P748, DOI 10.1001/archinte.159.7.748
   GLASS RI, 1989, PEDIATR INFECT DIS J, V8, P105
   GLASZIOU PP, 1993, BRIT MED J, V306, P366
   Gorstein Jonathan, 2003, Food and Nutrition Bulletin, V24, P319
   GREENWOOD BM, 1986, ANN TROP MED PARASIT, V80, P537
   GREENWOOD BM, 1980, T ROY SOC TROP MED H, V74, P340, DOI 10.1016/0035-9203(80)90095-4
   GREKAS D, 1992, RENAL FAILURE, V14, P575, DOI 10.3109/08860229209047668
   HAFEZ M, 1977, J TROP MED HYG, V80, P36
   HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904
   Hanekom WA, 2000, J PEDIATR-US, V136, P550, DOI 10.1016/S0022-3476(00)90024-6
   HARLAND P S, 1965, East Afr Med J, V42, P233
   HERESI GP, 1981, AM J CLIN NUTR, V34, P909
   HEYWORTH B, 1977, T ROY SOC TROP MED H, V71, P251, DOI 10.1016/0035-9203(77)90019-0
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Humphrey JH, 1996, J PEDIATR-US, V128, P489, DOI 10.1016/S0022-3476(96)70359-1
   Ibs KH, 2003, J NUTR, V133, P1452
   Idindili B, 2007, AM J CLIN NUTR, V85, P1312
   Idris S, 1983, Ann Trop Paediatr, V3, P63
   IFEKWUNIGWE AE, 1980, AM J CLIN NUTR, V33, P621
   Ivanov AP, 2006, J INFECT DIS, V193, P598, DOI 10.1086/499970
   Jason J, 2002, INFECT IMMUN, V70, P6188, DOI 10.1128/IAI.70.11.6188-6195.2002
   Jensen H, 2007, TROP MED INT HEALTH, V12, P5, DOI 10.1111/j.1365-3156.2006.01773.x
   Karlsen TH, 2003, INFECT IMMUN, V71, P3909, DOI 10.1128/IAI.71.7.3909-3913.2003
   KEEN CL, 1990, ANNU REV NUTR, V10, P415, DOI 10.1146/annurev.nu.10.070190.002215
   KIELMANN AA, 1976, B WORLD HEALTH ORGAN, V54, P477
   Kim CH, 2008, CLIN DEV IMMUNOL, P1, DOI 10.1155/2008/416910
   Klemm RDW, 2008, PEDIATRICS, V122, pE242, DOI 10.1542/peds.2007-3448
   KRANTMAN HJ, 1982, AM J DIS CHILD, V136, P840
   Kreft B, 2000, BIOGERONTOLOGY, V1, P61, DOI 10.1023/A:1010077622172
   Kriesel JD, 1999, VACCINE, V17, P1883, DOI 10.1016/S0264-410X(98)00476-9
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   KUTTY P M, 1981, Acta Vitaminologica et Enzymologica, V3, P231
   Kutukculer N, 2000, VACCINE, V18, P2979, DOI 10.1016/S0264-410X(00)00097-9
   KUVIBIDILA S, 1987, NUTR RES, V7, P989, DOI 10.1016/S0271-5317(87)80169-0
   KUVIBIDILA S, 1990, AM J CLIN NUTR, V51, P228
   Lastra MD, 1997, ARCH MED RES, V28, P67
   MACDOUGALL LG, 1975, J PEDIATR-US, V86, P833, DOI 10.1016/S0022-3476(75)80211-3
   MACDOUGALL LG, 1978, S AFR MED J, V53, P405
   Mahalanabis D, 1997, NUTR RES, V17, P649, DOI 10.1016/S0271-5317(97)00035-3
   Mahon BD, 2003, J CELL BIOCHEM, V89, P922, DOI 10.1002/jcb.10580
   Malaba LC, 2005, AM J CLIN NUTR, V81, P454
   Man WDC, 1998, TROP MED INT HEALTH, V3, P678
   Manicassamya S, 2009, SEMIN IMMUNOL, V21, P22, DOI 10.1016/j.smim.2008.07.007
   Marshall R, 1974, J Trop Pediatr Environ Child Health, V20, P126
   Martines J, 1998, LANCET, V352, P1257
   MATHEWS JD, 1972, LANCET, V2, P675
   McMurray D N, 1979, Bull Pan Am Health Organ, V13, P52
   MCMURRAY DN, 1981, AM J CLIN NUTR, V34, P68
   Moe SM, 2001, AM J KIDNEY DIS, V38, P792, DOI 10.1053/ajkd.2001.27697
   MOHAMMED I, 1982, T ROY SOC TROP MED H, V76, P351, DOI 10.1016/0035-9203(82)90188-2
   MONJOUR L, 1984, B SOC PATHOL EXOT, V77, P271
   Moore SE, 2003, ACTA PAEDIATR, V92, P170
   Moore SE, 2002, ARCH DIS CHILD, V87, P192, DOI 10.1136/adc.87.3.192
   Moore SE, 2006, TROP MED INT HEALTH, V11, P1529, DOI 10.1111/j.1365-3156.2006.01700.x
   Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378
   Muhlemann K, 1997, AM J PUBLIC HEALTH, V87, P113, DOI 10.2105/AJPH.87.1.113
   Mullick S, 2006, INDIAN J MED RES, V124, P647
   MUNOZ C, 1994, NUTR RES, V14, P347, DOI 10.1016/S0271-5317(05)80173-3
   Munoz C, 2007, BRIT J NUTR, V98, pS24, DOI 10.1017/S0007114507833046
   Murphy KM, 2007, JANEWAYS IMMUNOBIOLO
   NALDER BN, 1972, J NUTR, V102, P535
   Nante JE, 2008, EUR J CLIN NUTR, V62, P842, DOI 10.1038/sj.ejcn.1602796
   NARAIN R, 1979, INDIAN J MED RES, V69, P6
   Nassar M. F., 2007, Eastern Mediterranean Health Journal, V13, P1031
   NEUMANN CG, 1975, AM J CLIN NUTR, V28, P89
   Newton S, 2005, J NUTR, V135, P2669
   Newton S, 2007, VACCINE, V25, P4514, DOI 10.1016/j.vaccine.2007.03.002
   Newton S, 2007, J NUTR, V137, P1272
   Newton S, 2008, VACCINE, V26, P6608, DOI 10.1016/j.vaccine.2008.09.037
   The Nordic Cochrane Center The Cochrane Collaboration, 2008, REV MAN REVMAN VERS
   Oppenheimer SJ, 2001, J NUTR, V131, p616S
   Oppenheimer SJ., 2001, J NUTR, V131, p633S
   ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212
   Osendarp SJM, 2007, VACCINE, V25, P3347, DOI 10.1016/j.vaccin
   Osendarp SJM, 2006, J TROP PEDIATRICS, V52, P316, DOI 10.1093/tropej/fml012
   Peces R, 1997, AM J KIDNEY DIS, V29, P239, DOI 10.1016/S0272-6386(97)90036-6
   Penna G, 2005, BLOOD, V106, P3490, DOI 10.1182/blood-2005-05-2044
   Pichler J, 2002, PEDIATR RES, V52, P12, DOI 10.1023/01.PDR.0000017267.23950.48
   Plotkin SA, 2001, PEDIATR INFECT DIS J, V20, P63, DOI 10.1097/00006454-200101000-00013
   Plotkin SA, 2004, VACCINES
   Plotkin SA, 2008, CLIN INFECT DIS, V47, P401, DOI 10.1086/589862
   Powell G M, 1982, Ann Trop Paediatr, V2, P143
   Prasad AS, 2008, MOL MED, V14, P353, DOI 10.2119/2008-00033.Prasad
   PRASAD AS, 1995, NUTRITION, V11, P93
   Prentice AM, 2009, INT J EPIDEMIOL, V38, P591, DOI 10.1093/ije/dyn363
   PRETORIUS PJ, 1962, AM J CLIN NUTR, V10, P379
   Provinciali M, 1998, AGE AGEING, V27, P715, DOI 10.1093/ageing/27.6.715
   Qadri F, 2004, VACCINE, V22, P416, DOI 10.1016/j.vaccine.2003.07.005
   RAFII M, 1977, CLIN IMMUNOL IMMUNOP, V8, P1, DOI 10.1016/0090-1229(77)90085-X
   Rahman MM, 1998, NUTR RES, V18, P1125, DOI 10.1016/S0271-5317(98)00094-3
   Rahman MM, 1999, J NUTR, V129, P2192
   RAHMAN MM, 1995, EUR J CLIN NUTR, V49, P439
   Rahmathullah L, 2003, BRIT MED J, V327, P254, DOI 10.1136/bmj.327.7409.254
   REDDY V, 1964, INDIAN J MED RES, V52, P1154
   Remarque E. J., 1993, Aging Immunology and Infectious Disease, V4, P17
   Ross AC, 2007, VITAM HORM, V75, P197, DOI 10.1016/S0083-6729(06)75008-7
   SALIMONU LS, 1982, BRIT J NUTR, V48, P7, DOI 10.1079/BJN19820082
   SATYANARAYANA K, 1980, AM J CLIN NUTR, V33, P2334
   Schaible Ulrich E., 2004, Nature Reviews Microbiology, V2, P946, DOI 10.1038/nrmicro1046
   SCHLESINGER L, 1974, AM J CLIN NUTR, V27, P615
   Scrimshaw Nevin S., 1997, American Journal of Clinical Nutrition, V66, p464S
   Semba RD, 1997, PUBLIC HEALTH, V111, P245, DOI 10.1038/sj.ph.1900366
   SEMBA RD, 1992, J NUTR, V122, P101
   SEMBA RD, 1994, CLIN DIAGN LAB IMMUN, V1, P172
   Semba RD, 2001, ACTA PAEDIATR, V90, P1107, DOI 10.1080/080352501317061477
   Semba RD, 1999, J NUTR, V129, P2203
   SEMBA RD, 1995, LANCET, V345, P1330
   Shankar AH, 1998, AM J CLIN NUTR, V68, p447S
   Shinde P, 2006, BIOL TRACE ELEM RES, V112, P247, DOI 10.1385/BTER:112:3:247
   Siddiqui F Q, 2001, East Mediterr Health J, V7, P799
   SIDELL N, 1990, J INVEST DERMATOL, V95, P597, DOI 10.1111/1523-1747.ep12505593
   SINHA DP, 1976, LANCET, V2, P531
   Smith R, 2005, BRIT MED J, V331, P288, DOI 10.1136/bmj.331.7511.288
   STABELL C, 1995, EUR J CLIN NUTR, V49, P73
   STEPHENSEN BC, 2009, AM J CLIN NUTR, V90, P457
   Stephensen CB, 2003, INT J EPIDEMIOL, V32, P828, DOI 10.1093/ije/dyg208
   Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167
   STIEDEMANN M, 1980, NUTR REP INT, V21, P931
   SUSKIND R, 1976, AM J CLIN NUTR, V29, P836
   THIBAULT H, 1993, EUR J PEDIATR, V152, P120, DOI 10.1007/BF02072487
   Tielsch JM, 2008, BRIT MED J, V336, P1385, DOI 10.1136/bmj.39575.486609.80
   Uematsu S, 2008, NAT IMMUNOL, V9, P769, DOI 10.1038/ni.1622
   UNICEF WHO, 2008, COUNTD 2015 MAT NEWB
   Van der Stede Y, 2004, CLIN EXP IMMUNOL, V135, P380, DOI 10.1111/j.1365-2249.2004.02377.x
   Van Loveren H, 2001, ENVIRON HEALTH PERSP, V109, P757
   vanDillen J, 1996, LANCET, V347, P1705, DOI 10.1016/S0140-6736(96)91541-X
   Verminnen K, 2005, VACCINE, V23, P4509, DOI 10.1016/j.vaccine.2005.04.014
   Villamor E, 2005, CLIN MICROBIOL REV, V18, P446, DOI 10.1128/CNR.18.3.446-464.2005
   Weiss G, 2002, EUR J CLIN INVEST, V32, P70, DOI 10.1046/j.1365-2362.2002.0320s1070.x
   WESLEY A, 1979, T ROY SOC TROP MED H, V73, P710, DOI 10.1016/0035-9203(79)90026-9
   WEST KP, 1995, AM J CLIN NUTR, V62, P143
   White C, 2004, BRIT MED J, V328, P67, DOI 10.1136/bmj.328.7431.67
   *WHO, 2000, REP INF CONS VIT A S
   Willy MEP, 1998, PEDIATR INFECT DIS J, V17, P526, DOI 10.1097/00006454-199806000-00021
NR 203
TC 39
Z9 39
U1 2
U2 11
PU AMER SOC NUTRITIONAL SCIENCE
PI BETHESDA
PA 9650 ROCKVILLE PIKE, RM L-2407A, BETHESDA, MD 20814 USA
SN 0022-3166
J9 J NUTR
JI J. Nutr.
PD NOV
PY 2009
VL 139
IS 11
BP 2154S
EP 2218S
DI 10.3945/jn.109.105312
PG 65
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 509WS
UT WOS:000271050600023
PM 19793845
OA No
DA 2017-08-15
ER

PT J
AU Cheung, YB
   Zaman, SMA
   Nsekpong, ED
   Van Beneden, CA
   Adegbola, RA
   Greenwood, B
   Cutts, FT
AF Cheung, Yin-Bun
   Zaman, Syed M. A.
   Nsekpong, Ekpedeme David
   Van Beneden, Chris A.
   Adegbola, Richard A.
   Greenwood, Brian
   Cutts, Felicity T.
TI Nasopharyngeal Carriage of Streptococcus pneumoniae in Gambian Children
   who Participated in a 9-valent Pneumococcal Conjugate Vaccine Trial and
   in Their Younger Siblings
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE antibiotic resistance; carriage; conjugate vaccine; Streptococcus
   pneumoniae
ID ACUTE OTITIS-MEDIA; DAY-CARE-CENTERS; INVASIVE-DISEASE;
   DEVELOPING-WORLD; SEROTYPE 19A; IMMUNOGENICITY; COLONIZATION;
   POPULATION; EFFICACY; IMPACT
AB Background: Nasopharyngeal carriage of Streptococcus pneumoniae is extremely prevalent in The Gambia. We studied the effects of vaccination with pneumococcal conjugate vaccines on the carriage of individual serotypes and on antimicrobial resistance in vaccinated children and their younger siblings.
   Methods: A longitudinal study of a subsample of children (n = 2342) who participated in a randomized, placebo controlled trial of a 9-valent pneumococcal conjugate vaccines (PCV-9) in The Gambia, and a crosssectional study of non-PCV-9-vaccinated younger siblings (n = 675).
   Results: Recipients of PCV-9 were less likely to carry vaccine serotypes 4, 6B, 9V, 14, 19F, and 23F but more likely to carry vaccine-associated 19A and 9 nonvaccine serotypes at approximately 6 months postvaccination (age, 12 months) than were controls (each P < 0.05). At approximately 16 months postvaccination, carriage of vaccine-associated-serotype 6A was also significantly reduced (P < 0.01) while 3 other nonvaccine serotypes were more prevalent in the PCV-9 recipients (each P < 0.05). At 16 months, but not 6 months, postvaccination PCV-9 recipients had lower rate of carrying isolates resistant to tetracycline and trimethoprim-sulfamethoxazole (TMP-SMZ) than controls (risk ratio: 0.90 and 0.95, respectively; each P < 0.05). There was no difference in patterns of carriage of pneumococci in younger siblings of PCV-9 or placebo recipients.
   Conclusions: The effects of 9-valent pneumococcal conjugate vaccines on carriage of pneumococci persisted for at least 16 months postvaccination in Gambian children. Vaccination had no indirect effect on carriage in younger siblings and there was limited impact on antibiotic resistance.
C1 [Cheung, Yin-Bun] Singapore Clin Res Inst, Dept Biostat, Singapore 138669, Singapore.
   [Cheung, Yin-Bun] Duke NUS Grad Med Sch, Off Clin Sci, Singapore, Singapore.
   [Nsekpong, Ekpedeme David; Adegbola, Richard A.; Cutts, Felicity T.] MRC Labs, Banjul, Gambia.
   [Van Beneden, Chris A.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA.
   [Greenwood, Brian] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London, England.
RP Cheung, YB (reprint author), Singapore Clin Res Inst, Dept Biostat, Nanos 02-01,31 biopolis Way, Singapore 138669, Singapore.
EM yinbun.cheung@scri.edu.sg
FU The Johns Hopkins University; The Boards of the Global Alliance for
   Vaccines and Immunizations and the Vaccine Fund; MAID; NIH
   [N01-AI-5477]; Children's Vaccine Program at PATH
FX Supported by The Johns Hopkins University with funds provided by The
   Boards of the Global Alliance for Vaccines and Immunizations and the
   Vaccine Fund. Also, supported by grants from MAID, NIH through contract
   N01-AI-5477, and the Children's Vaccine Program at PATH.
CR Abdullahi O, 2008, PEDIATR INFECT DIS J, V27, P59, DOI 10.1097/INF.0b013e31814da70c
   Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Brueggemann AB, 2003, J INFECT DIS, V187, P1424, DOI 10.1086/374624
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dagan R, 2003, PEDIATR INFECT DIS J, V22, P532, DOI 10.1097/00006454-200306000-00009
   Dagan R, 2002, J INFECT DIS, V185, P927, DOI 10.1086/339525
   Dagan R, 2009, J INFECT DIS, V199, P776, DOI 10.1086/597044
   Dinleyici EC, 2008, EXPERT REV VACCINES, V7, P1367, DOI 10.1586/14760584.7.9.1367
   FARELL DJ, 2007, PEDIATR INFECT DIS J, V26, P123
   Givon-Lavi N, 2003, PEDIATR INFECT DIS J, V22, P524, DOI 10.1097/00006454-200306000-00008
   Greenwood B, 1999, PHILOS T ROY SOC B, V354, P777, DOI 10.1098/rstb.1999.0430
   Hansen J, 2006, PEDIATR INFECT DIS J, V25, P779, DOI 10.1097/01.inf.0000232706.35674.2f
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Kayhty H, 2006, EXPERT REV VACCINES, V5, P651, DOI 10.1586/14760584.5.5.651
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009
   MEHTA CR, 1995, STAT MED, V14, P2143, DOI 10.1002/sim.4780141908
   Millar EV, 2008, CLIN INFECT DIS, V47, P989, DOI 10.1086/591966
   Millar EV, 2006, CLIN INFECT DIS, V43, P8, DOI 10.1086/504802
   Moore MR, 2008, J INFECT DIS, V197, P1016, DOI 10.1086/528996
   O'Brien KL, 2007, J INFECT DIS, V196, P1211, DOI 10.1086/521833
   O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI 10.1097/00006454-200302000-00009
   Obaro SK, 2000, PEDIATR INFECT DIS J, V19, P463, DOI 10.1097/00006454-200005000-00014
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7
   Park SY, 2008, PEDIATR INFECT DIS J, V27, P335, DOI 10.1097/INF.0b013e318161434d
   Saaka M, 2008, VACCINE, V26, P3719, DOI 10.1016/j.vaccine.2008.04.066
   Saha SK, 2003, J CLIN MICROBIOL, V41, P5582, DOI 10.1128/JCM.41.12.5582-5587.2003
   Scott JAG, 2007, VACCINE, V25, P2398, DOI 10.1016/j.vaccine.2006.09.008
   Veenhoven RH, 2004, CLIN INFECT DIS, V39, P911, DOI 10.1086/422651
   Whitney CG, 2006, LANCET, V368, P1495, DOI 10.1016/S0140-6736(06)69637-2
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 33
TC 47
Z9 47
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD NOV
PY 2009
VL 28
IS 11
BP 990
EP 995
DI 10.1097/INF.0b013e3181a78185
PG 6
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA 512MO
UT WOS:000271253800010
PM 19536041
OA No
DA 2017-08-15
ER

PT J
AU Awolola, TS
   Oduola, OA
   Strode, C
   Koekemoer, LL
   Brooke, B
   Ranson, H
AF Awolola, T. S.
   Oduola, O. A.
   Strode, C.
   Koekemoer, L. L.
   Brooke, B.
   Ranson, H.
TI Evidence of multiple pyrethroid resistance mechanisms in the malaria
   vector Anopheles gambiae sensu stricto from Nigeria
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE Anopheles; Malaria; Metabolism; Pyrethroid; Insecticide resistance;
   Nigeria
ID INSECTICIDE RESISTANCE; DROSOPHILA-MELANOGASTER; CUTICULAR HYDROCARBONS;
   DETOXIFICATION GENES; ELEVATED OXIDASE; MOLECULAR-FORMS; AEDES-AEGYPTI;
   WEST-AFRICA; EXPRESSION; STRAINS
AB Pyrethroid insecticide resistance in Anopheles gambiae sensu stricto is a major concern to malaria vector control programmes. Resistance is mainly due to target-site insensitivity arising from a single point mutation, often referred to as knockdown resistance (kdr). Metabolic-based resistance mechanisms have also been implicated in pyrethroid resistance in East Africa and are currently being investigated in West Africa. Here we report the co-occurrence of both resistance mechanisms in a population of An. gambiae s.s. from Nigeria. Bioassay, synergist and biochemical analysis carried out on resistant and susceptible strains of An. gambiae s.s. from the same geographical area revealed >50% of the West African kdr mutation in the resistant mosquitoes but <3% in the susceptible mosquitoes. Resistant mosquitoes synergized using pyperonyl butoxide before permethrin exposure showed a significant increase in mortality compared with the non-synergized. Biochemical assays showed an increased level of monooxygenase but not glutathione-S-transferase or esterase activities in the resistant mosquitoes. Microarray analysis using the An. gambiae detox-chip for expression of detoxifying genes showed five over-expressed genes in the resistant strain when compared with the susceptible one. Two of these, CPLC8 and CPLC#, are cuticular genes not implicated in pyrethroid metabolism in An. gambiae s.s, and could constitute a novel set of candidate genes that warrant further investigation. (C) 2008 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
C1 [Awolola, T. S.; Oduola, O. A.] Nigerian Inst Med Res, Lagos, Nigeria.
   [Strode, C.; Ranson, H.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   [Koekemoer, L. L.; Brooke, B.] Natl Inst Communicable Dis, Vector Control Reference Unit, Johannesburg, South Africa.
   [Koekemoer, L. L.; Brooke, B.] Natl Hlth Lab Serv, Div Virol & Communicable Dis Surveillance, Sch Pathol, Johannesburg, South Africa.
   [Koekemoer, L. L.; Brooke, B.] Univ Witwatersrand, Johannesburg, South Africa.
RP Awolola, TS (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM awololas@hotmail.com
OI Strode, Clare/0000-0003-2833-8073; Ranson, Hilary/0000-0003-2332-8247
FU Multilateral Initiative on Malaria (MIM) project through the
   UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training
   in Tropical Diseases (TDR) [A60039]
FX This investigation received financial support from the Multilateral
   Initiative on Malaria (MIM) project through the UNICEF/UNDP/World
   Bank/WHO Special Programme for Research and Training in Tropical
   Diseases (TDR) through grant number A60039 to TSA.
CR Ahmad M, 2006, PEST MANAG SCI, V62, P805, DOI 10.1002/ps.1225
   Amenya DA, 2008, INSECT MOL BIOL, V17, P19, DOI 10.1111/j.1365-2583.2008.00776.x
   Anyanwu GI, 1997, ANN TROP MED PARASIT, V91, P649
   Anyanwu GI, 2000, MEM I OSWALDO CRUZ, V95, P295, DOI 10.1590/S0074-02762000000300003
   Awolola TS, 2005, ACTA TROP, V95, P204, DOI 10.1016/j.actatropica.2005.06.002
   Awolola TS, 2003, TROP MED INT HEALTH, V8, P420, DOI 10.1046/j.1365-3156.2003.01034.x
   Awolola TS, 2002, ANN TROP MED PARASIT, V96, P849, DOI 10.1179/000349802125002581
   Barillas-Mury C, 1999, EMBO J, V18, P959, DOI 10.1093/emboj/18.4.959
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Brogdon WG, 1998, J AM MOSQUITO CONTR, V14, P159
   Brogdon WG, 1997, J AM MOSQUITO CONTR, V13, P233
   Brooke BD, 2001, B ENTOMOL RES, V91, P265, DOI 10.1079/BER2001108
   Chandre F, 1999, J AM MOSQUITO CONTR, V15, P53
   Chou Jeff W., 2005, Journal of Bioinformatics and Computational Biology, V3, P225, DOI 10.1142/S0219720005001028
   Clayton JD, 1998, J MUSCLE RES CELL M, V19, P117, DOI 10.1023/A:1005304527563
   Coleman M, 2006, J MED ENTOMOL, V43, P663, DOI 10.1603/0022-2585(2006)43[663:DAEDSS]2.0.CO;2
   Corbel V, 2007, ACTA TROP, V101, P207, DOI 10.1016/j.actatropica.2007.01.005
   David JP, 2005, P NATL ACAD SCI USA, V102, P4080, DOI 10.1073/pnas.0409348102
   della Torre A, 2001, INSECT MOL BIOL, V10, P9, DOI 10.1046/j.1365-2583.2001.00235.x
   Diabate Abdoulaye, 2003, Journal of Medical Entomology, V40, P195
   Ding YC, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-35
   Edwards MJ, 1997, INSECT BIOCHEM MOLEC, V27, P1063, DOI 10.1016/S0965-1748(97)00093-3
   ELLIOTT R, 1956, NATURE, V177, P532, DOI 10.1038/177532a0
   Etang J, 2003, J MED ENTOMOL, V40, P491, DOI 10.1603/0022-2585-40.4.491
   Hemingway J, 2000, ANNU REV ENTOMOL, V45, P371, DOI 10.1146/annurev.ento.45.1.371
   HEMINGWAY J, 2001, BIOCHEM J, V359, P295
   Isoe J, 2007, INSECT MOL BIOL, V16, P83, DOI 10.1111/j.1365-2583.2006.00704.x
   Kristan M, 2003, MED VET ENTOMOL, V17, P326, DOI 10.1046/j.1365-2915.2003.00449.x
   Martinez-Torres D, 1998, INSECT MOL BIOL, V71, P79
   Muller P, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-36
   N'Guessan R, 2007, EMERG INFECT DIS, V13, P199
   Penilla RP, 1998, MED VET ENTOMOL, V12, P217
   Pinto J, 2006, MED VET ENTOMOL, V20, P27, DOI 10.1111/j.1365-2915.2006.00611.x
   Poupardin R, 2008, INSECT BIOCHEM MOLEC, V38, P540, DOI 10.1016/j.ibmb.2008.01.004
   R Development Core Team, R PROJ STAT COMP
   Ranson H, 2000, INSECT MOL BIOL, V9, P491, DOI 10.1046/j.1365-2583.2000.00209.x
   Ranson H, 2002, INSECT MOL BIOL, V11, P409, DOI 10.1046/j.1365-2583.2002.00350.x
   Rouault JD, 2004, GENETICA, V120, P195, DOI 10.1023/B:GENE.0000017641.75820.49
   Santolamazza F, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-74
   Singh SP, 2001, EUR J BIOCHEM, V268, P2912, DOI 10.1046/j.1432-1327.2001.02179.x
   Strode C, 2006, INSECT MOL BIOL, V15, P523, DOI 10.1111/j.1365-2583.2006.00667.x
   Vontas J, 2007, INSECT MOL BIOL, V16, P315, DOI 10.1111/j.1365-2583.2007.00728.x
   Vontas JG, 2001, BIOCHEM J, V357, P65, DOI 10.1042/0264-6021:3570065
   Vulule JM, 1999, MED VET ENTOMOL, V13, P239, DOI 10.1046/j.1365-2915.1999.00177.x
   Watson GS, 2008, BIOPHYS J, V94, P3352, DOI 10.1529/biophysj.107.109348
   WHO, 1998, WHOCDSCPCMAL9812
   WHO [ World Health Organization], 2006, WHOCDSNTDWHOPESGCDPP
NR 47
TC 51
Z9 55
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD NOV
PY 2009
VL 103
IS 11
BP 1139
EP 1145
DI 10.1016/j.trstmh.2008.08.021
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 519OP
UT WOS:000271776800010
PM 18829056
OA No
DA 2017-08-15
ER

PT J
AU Sutherland, JS
   Jeffries, DJ
   Donkor, S
   Walther, B
   Hill, PC
   Adetifa, IMO
   Adegbola, RA
   Ota, MOC
AF Sutherland, Jayne S.
   Jeffries, David J.
   Donkor, Simon
   Walther, Brigitte
   Hill, Philip C.
   Adetifa, Ifedayo M. O.
   Adegbola, Richard A.
   Ota, Martin O. C.
TI High granulocyte/lymphocyte ratio and paucity of NKT cells defines TB
   disease in a TB-endemic setting
SO TUBERCULOSIS
LA English
DT Article
DE Tuberculosis disease; Latent TB infection; Granulocytes; NKT cells; B
   cells; T cells
ID MYCOBACTERIUM-TUBERCULOSIS INFECTION; B-CELLS; PULMONARY TUBERCULOSIS;
   ACTIVE TUBERCULOSIS; LYMPHOCYTES; PROGRESSION; CORRELATE; ANTIGENS;
   SUBSETS; MEMORY
AB Most people infected with Mycobacterium tuberculosis, the causative agent of tuberculosis (TB) actually maintain a strong immune response and are able to control bacterial growth (deemed latently infected (LTBI)), while approximately 10% progress to disease resulting in almost 2 million deaths per year. Determining the immune 'footprint' at specific stages of infection and disease will allow for better diagnostics, treatments and ultimately development of new vaccine candidates. In this study we performed multi-factorial flow cytometry on fresh blood from 56 TB cases, 46 Tuberculin Skin Test (TST) positive (LTBI) and 39 TST negative household contacts. We found a highly significant increase in granulocytes and decrease in B cells and invariant (V alpha 24 + V beta 11+) NKT cells in TB cases compared to TST+ contacts (p < 0.0001, p = 0.007 and p = 0.01 respectively) which were restored to LTBI levels following 6 months of TB treatment. Using support vector analysis, we found a combination of granulocyte and lymphocyte and/or NKT cell proportions allowed almost 90% correct classification into M. tuberculosis infection or disease. This work has important public health benefits in regards to diagnosis and treatment of TB in sub-Saharan Africa and in furthering our understanding of the requirements for protective immunity to TB. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Sutherland, Jayne S.; Jeffries, David J.; Donkor, Simon; Walther, Brigitte; Hill, Philip C.; Adetifa, Ifedayo M. O.; Adegbola, Richard A.; Ota, Martin O. C.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
RP Sutherland, JS (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM jsutherland@mrc.com
OI Sutherland, Jayne/0000-0002-7083-4997
FU Bill and Melinda Gates Foundation; Medical Research Council, UK
FX This work was supported by the Bill and Melinda Gates Foundation and the
   Medical Research Council, UK.
CR Bejamini Y., 1995, J R STAT SOC B, V57, P289
   Caccamo N, 2006, J IMMUNOL, V177, P1780
   Condos R, 1998, AM J RESP CRIT CARE, V157, P729
   Cristianini N., 2000, INTRO SUPPORT VECTOR
   de Jong BC, 2007, INT J TUBERC LUNG D, V11, P450
   de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504
   DOHERTY M, 2009, CURR OPIN PULM MED, V15, P1
   Galli G, 2003, J EXP MED, V197, P1051, DOI 10.1084/jem.20021616
   Godfrey DI, 2004, J CLIN INVEST, V114, P1379, DOI 10.1172/JCI200423594
   Goletti D, 2006, J INFECT DIS, V194, P984, DOI 10.1086/507427
   Goletti D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003417
   Hirsch CS, 2001, J INFECT DIS, V183, P779, DOI 10.1086/318817
   Im JS, 2008, CLIN IMMUNOL, V127, P214, DOI 10.1016/j.clim.2007.12.005
   Kaufmann SHE, 2008, CELL HOST MICROBE, V4, P219, DOI 10.1016/j.chom.2008.08.002
   Kinjo Y, 2006, NAT IMMUNOL, V7, P978, DOI 10.1038/ni1380
   Kursar M, 2007, J IMMUNOL, V178, P2661
   Lang GA, 2008, BLOOD, V111, P2158, DOI 10.1182/blood-2007-10-117309
   Lewinsohn DA, 2003, AM J RESP CRIT CARE, V168, P1346, DOI 10.1164/rccm.200306-837OC
   Li BQ, 1996, J IMMUNOL, V157, P4222
   Lin H, 2006, EXP HEMATOL, V34, P289, DOI 10.1016/j.exphem.2005.12.008
   Maglione PJ, 2007, J IMMUNOL, V178, P7222
   Martineau AR, 2007, J CLIN INVEST, V117, P1988, DOI 10.1172/JCI31097
   RACKE FK, 2002, FRONT BIOSCI, V7, P978
   Riedel DD, 1997, INFECT IMMUN, V65, P4620
   Rodrigues DSS, 2002, CLIN EXP IMMUNOL, V128, P149, DOI 10.1046/j.1365-2249.2002.01809.x
   Roy S, 2008, J IMMUNOL, V180, P1729
   Sada-Ovalle I, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000239
   Snyder-Cappione JE, 2007, J INFECT DIS, V195, P1361, DOI 10.1086/513567
   Sud D, 2006, J IMMUNOL, V176, P4296
   SUTHERLAND JS, EUR J IMMUNOL, V39, P1
   Taub DD, 2005, IMMUNOL REV, V205, P72, DOI 10.1111/j.0105-2896.2005.00275.x
   Veenstra H, 2006, CLIN EXP IMMUNOL, V145, P252, DOI 10.1111/j.1365-2249.2006.03144.x
   Vordermeier HM, 1996, CLIN EXP IMMUNOL, V106, P312, DOI 10.1046/j.1365-2249.1996.d01-845.x
   Walzl G, 2008, J INFECTION, V57, P103, DOI 10.1016/j.jinf.2008.06.007
   *WHO, 2009, WORLD HLTH REP, P120
NR 35
TC 27
Z9 28
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1472-9792
J9 TUBERCULOSIS
JI Tuberculosis
PD NOV
PY 2009
VL 89
IS 6
BP 398
EP 404
DI 10.1016/j.tube.2009.07.004
PG 7
WC Immunology; Microbiology; Respiratory System
SC Immunology; Microbiology; Respiratory System
GA 521QN
UT WOS:000271937600002
PM 19683473
OA No
DA 2017-08-15
ER

PT J
AU Howie, SRC
   Hill, S
   Ebonyi, A
   Krishnan, G
   Njie, O
   Sanneh, M
   Jallow, M
   Stevens, W
   Taylor, K
   Weber, MW
   Njai, PC
   Tapgun, M
   Corrah, T
   Mulholland, K
   Peel, D
   Njie, M
   Hill, PC
   Adegbola, RA
AF Howie, Stephen R. C.
   Hill, Sarah
   Ebonyi, Augustine
   Krishnan, Gautam
   Njie, Ousman
   Sanneh, Momodou
   Jallow, Mariatou
   Stevens, Warren
   Taylor, Kevin
   Weber, Martin W.
   Njai, Pamela Collier
   Tapgun, Mary
   Corrah, Tumani
   Mulholland, Kim
   Peel, David
   Njie, Malick
   Hill, Philip C.
   Adegbola, Richard A.
TI Meeting oxygen needs in Africa: an options analysis from the Gambia
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID PAPUA-NEW-GUINEA; DEVELOPING-COUNTRIES; WEST-AFRICA; CONCENTRATORS;
   EQUIPMENT; PNEUMONIA; CYLINDERS; MORTALITY
AB Objective To compare oxygen supply options for health facilities in the Gambia and develop a decision-Making algorithm for choosing oxygen delivery systems in Africa and the rest of the developing world.
   Methods Oxygen cylinders and concentrators were compared in terms of functionality and cost. Interviews with key informants using locally developed and adapted WHO instruments, operational assessments, cost-modelling and cost measurements were undertaken to determine whether oxygen cylinders or concentrators were the better choice. An algorithm and a software tool to guide the choice of oxygen delivery system were constructed.
   Findings In the Gambia, oxygen concentrators have significant advantages compared to cylinders where power is reliable; in other settings, cylinders are preferable as long as transporting them is feasible. Cylinder costs are greatly influenced by leakage, which is common, whereas concentrator costs are affected by the cost of power far more than by capital costs. Only two of 12 facilities in the Gambia were found suitable for concentrators; at the remaining 10 facilities, cylinders were the better option.
   Conclusion Neither concentrators nor cylinders are well suited to every situation, but a simple options assessment can determine which is better in each setting. Nationally this would result in improved supply and lower costs by comparison with conventional cylinders alone, although ensuring a reliable supply would remain a challenge. The decision algorithm and software tool designed for the Gambia could be applied in other developing countries.
C1 [Howie, Stephen R. C.; Ebonyi, Augustine; Sanneh, Momodou; Adegbola, Richard A.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Hill, Sarah] Univ Otago, Dept Publ Hlth, Wellington, New Zealand.
   [Krishnan, Gautam; Taylor, Kevin] MRC Labs, Dept Biomed Engn, Banjul, Gambia.
   [Njie, Ousman] Dept State Hlth & Social Welf, Integrated Management Childhood Illness Programme, Banjul, Gambia.
   [Stevens, Warren; Mulholland, Kim] London Sch Hyg & Trop Med, London WC1, England.
   [Weber, Martin W.] WHO, Dept Child & Adolescent Hlth, CH-1211 Geneva, Switzerland.
   [Njai, Pamela Collier; Tapgun, Mary; Corrah, Tumani] MRC Labs, Clin Serv Dept, Banjul, Gambia.
   [Peel, David] Ashdown Consultants, Uckfield, E Sussex, England.
   [Hill, Philip C.] Univ Otago, Ctr Int Hlth, Dunedin, New Zealand.
RP Howie, SRC (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM showie@mrc.gm
FU Medical Research Council [MC_U190081957]
CR Akehurst R, 2000, PHARMACOECONOMICS, V17, P443
   *AM HOSP ASS, 1998, EST US LIV DEPR HOSP
   Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8
   *CENTR BANK GAMB, OFF EXCH RAT VAL PUR
   Coster G, 2000, HLTH NEEDS ASSESSMEN
   Dobson M, 1996, LANCET, V347, P1597, DOI 10.1016/S0140-6736(96)91080-6
   DOBSON MB, 1992, TROP DOCT, V22, P56
   DOBSON MB, 1991, ANAESTHESIA, V46, P217, DOI 10.1111/j.1365-2044.1991.tb09413.x
   Dobson MB, 2001, INT J TUBERC LUNG D, V5, P520
   Duke T, 2008, LANCET, V372, P1328, DOI 10.1016/S0140-6736(08)61164-2
   *EM CAR RES I, 2004, PLYM M PA ECRI
   Enarson P, 2008, B WORLD HEALTH ORGAN, V86, P344, DOI 10.2471/BLT.07.048017
   Hill SE, 2009, INT J TUBERC LUNG D, V13, P587
   Howie SR, 2008, B WORLD HEALTH ORGAN, V86, P52, DOI 10.2471/BLT.07.042994
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Junge S, 2006, TROP MED INT HEALTH, V11, P367, DOI 10.1111/j.1365-3156.2006.01570.x
   Litch JA, 2000, WILD ENVIRON MED, V11, P189, DOI 10.1580/1080-6032(2000)011[0189:OCFTDO]2.3.CO;2
   McPake B., 2002, HLTH EC INT PERSPECT
   Mokuolu OA, 2002, ANN TROP PAEDIATR, V22, P209, DOI 10.1179/027249302125001499
   Oduro K A, 1992, West Afr J Med, V11, P244
   PEDERSEN J, 1991, BRIT J ANAESTH, V66, P264, DOI 10.1093/bja/66.2.264
   Perrelet A, 2004, INT J TUBERC LUNG D, V8, P1138
   Schneider G, 2001, INT J TUBERC LUNG D, V5, P524
   Shrestha BM, 2002, CAN J ANAESTH, V49, P8
   Singh V, 2000, J Assoc Physicians India, V48, P701
   Sinha A, 2007, LANCET, V369, P389, DOI 10.1016/S0140-6736(07)60195-0
   Stevens A, 1997, HLTH CARE NEEDS ASSE
   Weber MW, 1998, LANCET, V351, P1589, DOI 10.1016/S0140-6736(05)61160-9
   *WHO, 2003, REP WHO INF CONS CLI
   World Health Organization, 2000, WHOFCHCAH001
   WHO (World Health Organization), 1993, OX THER AC RESP INF
   World Health Organization, 2005, REV GLOB BURD DIS GB
   World Health Organization [webpage on the Internet], DIS ADJ LIF YEARS DA
   WOOD PB, 1985, TROP DOCT, V15, P26
   Wright J., 1998, HLTH NEEDS ASSESSMEN
   *XE COM, CURR HIST RAT TABL
NR 36
TC 18
Z9 19
U1 1
U2 4
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD OCT
PY 2009
VL 87
IS 10
BP 763
EP 771
DI 10.2471/BLT.08.058370
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 505LN
UT WOS:000270695100010
PM 19876543
OA No
DA 2017-08-15
ER

PT J
AU Alegria, E
   Pinol, C
   Langham, S
   Stevens, W
   Jeffries, D
AF Alegria, E.
   Pinol, C.
   Langham, S.
   Stevens, W.
   Jeffries, D.
TI PREVALENCE AND ECONOMIC BURDEN OF HYPERTENSION IN PATIENTS WITH
   METABOLIC SYNDROME IN SPAIN: AN EPIDEMIOLOGICAL COST-OF-ILLNESS MODEL
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Alegria, E.] Univ Navarra Clin, Navarra, Spain.
   [Pinol, C.] Bayer HealthCare, Barcelona, Spain.
   [Jeffries, D.] MRC, Trop Dis Res Unit, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD OCT
PY 2009
VL 12
IS 7
BP A325
EP A325
DI 10.1016/S1098-3015(10)74598-8
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 495GH
UT WOS:000269878100523
OA No
DA 2017-08-15
ER

PT J
AU Kirby, MJ
   Ameh, D
   Bottomley, C
   Green, C
   Jawara, M
   Milligan, PJ
   Snell, PC
   Conway, DJ
   Lindsay, SW
AF Kirby, Matthew J.
   Ameh, David
   Bottomley, Christian
   Green, Clare
   Jawara, Musa
   Milligan, Paul J.
   Snell, Paul C.
   Conway, David J.
   Lindsay, Steve W.
TI Effect of two different house screening interventions on exposure to
   malaria vectors and on anaemia in children in The Gambia: a randomised
   controlled trial
SO LANCET
LA English
DT Article
ID PLASMODIUM-FALCIPARUM INFECTION; ANOPHELES-GAMBIAE; AFRICAN CHILDREN;
   REDUCE EXPOSURE; RISK-FACTORS; WEST-AFRICA; IDENTIFICATION;
   TRANSMISSION; RESISTANCE; MOSQUITOS
AB Background House screening should protect people against malaria. We assessed whether two types of house screening-full screening of windows, doors, and closing eaves, or installation of screened ceilings-could reduce house entry of malaria vectors and frequency of anaemia in children in an area of seasonal malaria transmission.
   Methods During 2006 and 2007, 500 occupied houses in and near Farafenni town in The Gambia, an area with low use of insecticide-treated bednets, were randomly assigned to receive full screening, screened ceilings, or no screening (control). Randomisation was done by computer-generated list, in permuted blocks of five houses in the ratio 2:2:1. Screening was not treated with insecticide. Exposure to mosquitoes indoors was assessed by fortnightly light trap collections during the transmission season. Primary endpoints included the number of female Anopheles gambiae sensu lato mosquitoes collected per trap per night. Secondary endpoints included frequency of anaemia (haemoglobin concentration <80 g/L) and parasitaemia at the end of the transmission season in children (aged 6 months to 10 years) who were living in the study houses. Analysis was by modified intention to treat (ITT), including all randomised houses for which there were some outcome data and all children from those houses who were sampled for haemoglobin and parasitaemia. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN51184253.
   Findings 462 houses were included in the modified ITT analysis (full screening, n=188; screened ceilings, n=178; control, n=96). The mean number of A gambiae caught in houses without screening was 37.5 per trap per night (95% CI 31.6-43-3), compared with 15.2 (12.9-17-4) in houses with full screening (ratio of means 0.41, 95% CI 0.31-0.54; p<0.0001) and 19.1 (16.1-22.1) in houses with screened ceilings (ratio 0.53, 0.40-0.70; p<0.0001). 755 children completed the study, of whom 731 had complete clinical and covariate data and were used in the analysis of clinical outcomes. 30 (19%) of 158 children from control houses had anaemia, compared with 38 (12%) of 309 from houses with full screening (adjusted odds ratio [OR] 0.53, 95% CI 0.9-0.97; p=0.04), and 31 (12%) of 264 from houses with screened ceilings (OR 0.51, 0.27-0.96; p=0.04). Frequency of parasitaemia did not differ between intervention and control groups.
   Interpretation House screening substantially reduced the number of mosquitoes inside houses and could contribute to prevention of anaemia in children.
   Funding Medical Research Council.
C1 [Kirby, Matthew J.; Green, Clare; Lindsay, Steve W.] Univ Durham, Sci Labs, Durham DH1 3LE, England.
   [Ameh, David; Jawara, Musa; Milligan, Paul J.; Snell, Paul C.; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Snell, Paul C.] Univ Bristol, Dept Social Med, Bristol, Avon, England.
RP Lindsay, SW (reprint author), Univ London London Sch Hyg & Trop Med, Dis Control & Vector Biol Unit, Keppel St, London WC1E 7HT, England.
EM Steve.Lindsay@lshtm.ac.uk
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Conway, David/0000-0002-8711-3037
FU Medical Research Council, UK
FX We are grateful for the helpful comments made by the reviewers. We thank
   Paul Emerson and Amy Ratcliffe for their help in designing an early
   version of the study. We are grateful for the donations of netting from
   the Vestergaard-Frandsen group and in particular the efforts of the
   director of development, Torben Frandsen, and associates in transporting
   the netting to The Gambia. We thank Rob Hutchinson who helped develop
   methods for erecting the screening and the carpentry team that installed
   it; M RC and Durham University associates of the STOPMAL trial and other
   support staff at M RC Farafenni and MRC Fajara, in particular Chloe Day,
   Erin Dilger, Margaret Pinder, Pateh Bah, Ensa Touray, Pa Chebou Same,
   Manikumba Sanneh, and Roger Conteh; Momodou Jasseh and Sarah Crozier as
   members ofthe data monitoring and ethics committee, and the late Chris
   Curtis, chairman of the TSC and the other committee members Robin Bailey
   and Peter Billingsley; and Ann Kelly and Caroline Jones of the London
   School of Hygiene and Tropical Medicine for help with the acceptability
   studies. We also thank the study children and their parents for their
   continuous support for this work. This study was funded by the Medical
   Research Council, UK.
CR Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   Beier JC, 1999, AM J TROP MED HYG, V61, P109
   Bodker R, 2006, AM J TROP MED HYG, V74, P716
   Bogh C, 2007, AM J TROP MED HYG, V76, P875
   Breman JG, 2004, AM J TROP MED HYG, V71, P1
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   BURKOT TR, 1984, AM J TROP MED HYG, V33, P783
   BUTRAPORN P, 1986, Southeast Asian Journal of Tropical Medicine and Public Health, V17, P386
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Celli A, 1901, COLLECTED PAPERS MAL, p[1899, 1]
   CLARKE S, 2001, THESIS U COPENHAGEN
   Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X
   Curtis CF, 1998, TROP MED INT HEALTH, V3, P619
   Ghebreyesus TA, 2000, T ROY SOC TROP MED H, V94, P17, DOI 10.1016/S0035-9203(00)90424-3
   Goodman CA, 2001, TROP MED INT HEALTH, V6, P280, DOI 10.1046/j.1365-3156.2001.00700.x
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P182, DOI 10.1016/0035-9203(89)90635-4
   Jambou R, 2005, LANCET, V366, P1960, DOI 10.1016/S0140-6736(05)67787-2
   Keiser J, 2005, LANCET INFECT DIS, V5, P695, DOI 10.1016/S1473-3099(05)70268-1
   Kerah-Hinzoumbe C, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-192
   Kilian AHD, 2000, TROP MED INT HEALTH, V5, P3, DOI 10.1046/j.1365-3156.2000.00509.x
   Killeen GF, 2002, LANCET INFECT DIS, V2, P618, DOI 10.1016/S1473-3099(02)00397-3
   Kirby MJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-33
   Kirby MJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-2
   Kobbe Robin, 2007, Clin Infect Dis, V45, P16, DOI 10.1086/518575
   Korenromp EL, 2004, TROP MED INT HEALTH, V9, P1050, DOI 10.1111/j.1365-3156.2004.01317.x
   Lengeler C, 2004, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000363.PUB2
   LINDSAY SW, 1995, MED VET ENTOMOL, V9, P50, DOI 10.1111/j.1365-2915.1995.tb00116.x
   Lindsay SW, 2003, TROP MED INT HEALTH, V8, P512, DOI 10.1046/j.1365-3156.2003.01059.x
   Lindsay SW, 2002, TRENDS PARASITOL, V18, P510, DOI 10.1016/S1471-4922(02)02382-6
   *REP GAMB, 2001, NAT SURV PREV VIT A
   [Anonymous], KEY MAL FACTS
   Rowland M, 2000, TROP MED INT HEALTH, V5, P472, DOI 10.1046/j.1365-3156.2000.00581.x
   Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   Smith DL, 2005, NATURE, V438, P492, DOI 10.1038/nature04024
   Smith T, 1998, AM J TROP MED HYG, V59, P252
   SPIELMAN A, 2001, NATURAL HIST OUR MOS
   Takken W, 1990, WAGENINGEN AGR U PAP
   WHO, 1982, WHO OFFS PUBL, V66
   WHO, 2004, GLOB STRAT FRAM INT
   World Health Organization, 2008, WHO REP GLOB TOB EP, P1
NR 41
TC 86
Z9 87
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD SEP 19
PY 2009
VL 374
IS 9694
BP 998
EP 1009
DI 10.1016/S0140-6736(09)60871-0
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 498PK
UT WOS:000270154100030
PM 19732949
OA No
DA 2017-08-15
ER

PT J
AU Petry, CJ
   Rayco-Solon, P
   Fulford, AJC
   Stead, JDH
   Wingate, DL
   Ong, KK
   Sirugo, G
   Prentice, AM
   Dunger, DB
AF Petry, Clive J.
   Rayco-Solon, Pura
   Fulford, Anthony J. C.
   Stead, John D. H.
   Wingate, Dianne L.
   Ong, Ken K.
   Sirugo, Giorgio
   Prentice, Andrew M.
   Dunger, David B.
TI Common polymorphic variation in the genetically diverse African insulin
   gene and its association with size at birth
SO HUMAN GENETICS
LA English
DT Article
ID FAMILY-BASED ASSOCIATION; FOR-GESTATIONAL-AGE; INS-VNTR LOCUS; VARIABLE
   NUMBER; TANDEM REPEATS; FETAL-GROWTH; LINKAGE DISEQUILIBRIUM;
   QUANTITATIVE TRAITS; TRANSMISSION-DISEQUILIBRIUM; WEIGHT-GAIN
AB The insulin variable number of tandem repeats (INS VNTR) has been variably associated with size at birth in non-African populations. Small size at birth is a major determinant of neonatal mortality, so the INS VNTR may influence survival. We tested the hypothesis, therefore, that genetic variation around the INS VNTR in a rural Gambian population, who experience seasonal variation in nutrition and subsequently birth weight, may be associated with foetal and early growth. Six polymorphisms flanking the INS VNTR were genotyped in over 2,500 people. Significant associations were detected between the maternally inherited SNP 27 (rs689) allele and birth length [effect size 17.5 (5.2-29.8) mm; P = 0.004; n = 361]. Significant associations were also found between the maternally inherited African-specific SNP 28 (rs5506) allele and post-natal weight gain [effect size 0.19 (0.05-0.32) z score points/year; P = 0.005; n = 728). These results suggest that in the Gambian population studied there are associations between polymorphic variation in the genetically diverse INS gene and foetal and early growth characteristics, which contribute to overall polygenic associations with these traits.
C1 [Petry, Clive J.; Wingate, Dianne L.; Ong, Ken K.; Dunger, David B.] Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 0QQ, England.
   [Rayco-Solon, Pura; Fulford, Anthony J. C.; Prentice, Andrew M.] London Sch Hyg & Trop Med, Int Nutr Grp, MRC, London WC1E 7HT, England.
   [Rayco-Solon, Pura; Fulford, Anthony J. C.; Sirugo, Giorgio; Prentice, Andrew M.] MRC Labs, MRC Keneba, Banjul, Gambia.
   [Stead, John D. H.] Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England.
   [Ong, Ken K.] MRC, Epidemiol Unit, Cambridge CB2 0QQ, England.
RP Petry, CJ (reprint author), Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Box 116,Hills Rd, Cambridge CB2 0QQ, England.
EM cjp1002@cam.ac.uk
RI Petry, Clive/L-7750-2015
OI Petry, Clive/0000-0002-6642-9825; Dunger, Professor
   David/0000-0002-2566-9304
FU Wellcome Trust; Medical Research Council; National Institute for Health
   Research (NIHR); Cambridge Comprehensive Biomedical Research Centre
FX The authors wish to thank the villagers of Keneba, Manduar and Kantong
   Kunda for their willing participation in this and other studies over the
   years. Funding for the genotyping part of this study was kindly provided
   by the Wellcome Trust. Core funding for the prospective study of early
   growth in the West Kiang District was provided by the Medical Research
   Council. We also acknowledge the National Institute for Health Research
   (NIHR) Cambridge Comprehensive Biomedical Research Centre.
CR Adkins RM, 2008, INT J OBESITY, V32, P372, DOI 10.1038/sj.ijo.0803700
   Allison DB, 1997, AM J HUM GENET, V60, P676
   Barratt BJ, 2004, DIABETES, V53, P1884, DOI 10.2337/diabetes.53.7.1884
   Bennett AJ, 2004, DIABETES, V53, P2126, DOI 10.2337/diabetes.53.8.2126
   Carter KW, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-60
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5
   Dunger DB, 2007, DIABETES CARE, V30, pS150, DOI 10.2337/dc07-s208
   Dunger DB, 1998, NAT GENET, V19, P98, DOI 10.1038/ng0598-98
   Eaves IA, 1999, NAT GENET, V22, P324
   George V, 1999, AM J HUM GENET, V65, P236, DOI 10.1086/302444
   Gu DF, 2002, HUM GENET, V110, P173, DOI 10.1007/s00439-001-0663-5
   Heude B, 2006, J CLIN ENDOCR METAB, V91, P2770, DOI 10.1210/jc.2005-2055
   Kaku K, 2007, ACTA PAEDIATR, V96, P363, DOI 10.1111/j.1651-2227.2006.00120.x
   Kralovicova J, 2006, DIABETES, V55, P260, DOI 10.2337/diabetes.55.01.06.db05-0773
   Landmann E, 2006, PEDIATRICS, V118, P2374, DOI 10.1542/peds.2006-0146
   Lange C, 2002, AM J HUM GENET, V71, P1330, DOI 10.1086/344696
   Lange C, 2004, AM J HUM GENET, V74, P367, DOI 10.1086/381563
   Lindsay RS, 2003, DIABETES, V52, P187, DOI 10.2337/diabetes.52.1.187
   LUSTIG O, 1994, MOL REPROD DEV, V38, P239, DOI 10.1002/mrd.1080380302
   Mathews F, 1999, BRIT MED J, V319, P339
   MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204
   Mitchell SMS, 2004, J CLIN ENDOCR METAB, V89, P310, DOI 10.1210/jc.2003-030605
   Mook-Kanamori DO, 2007, EUR J ENDOCRINOL, V157, P741, DOI 10.1530/EJE-07-0378
   Moore GE, 2001, DIABETES, V50, P199, DOI 10.2337/diabetes.50.1.199
   Moore VM, 2004, J NUTR, V134, P1820
   Ong KK, 2004, DIABETES, V53, P1128, DOI 10.2337/diabetes.53.4.1128
   Ong KKL, 2002, PEDIATR RES, V52, P863, DOI 10.1203/01.PDR.0000036602.81878.6D
   Osada H, 2007, TOHOKU J EXP MED, V212, P27, DOI 10.1620/tjem.212.27
   Paquette J, 1998, J BIOL CHEM, V273, P14158, DOI 10.1074/jbc.273.23.14158
   Parra EJ, 1998, AM J HUM GENET, V63, P1839, DOI 10.1086/302148
   Petry CJ, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-22
   PRENTICE AM, 1987, AM J CLIN NUTR, V46, P912
   Rayco-Solon P, 2004, TROP MED INT HEALTH, V9, P1151, DOI 10.1111/j.1365-3156.2004.01325.x
   Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010
   Sirugo G, 2004, NAT GENET, V36, P785, DOI 10.1038/ng0804-785
   [Anonymous], 2007, STAT VERS 10
   Stead JDH, 2003, GENOME RES, V13, P2101, DOI 10.1101/gr.948003
   Stead JDH, 2002, AM J HUM GENET, V71, P1273, DOI 10.1086/344513
   Stringer Ch., 1996, AFRICAN EXODUS ORIGI
   Taillon-Miller P, 2000, NAT GENET, V25, P324
   Victora CG, 2001, INT J EPIDEMIOL, V30, P1325, DOI 10.1093/ije/30.6.1325
   Vu-Hong TA, 2006, J CLIN ENDOCR METAB, V91, P2437, DOI 10.1210/jc.2005-2245
   WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624
NR 44
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
J9 HUM GENET
JI Hum. Genet.
PD SEP
PY 2009
VL 126
IS 3
BP 375
EP 384
DI 10.1007/s00439-009-0681-2
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 495RJ
UT WOS:000269912400003
PM 19434426
OA No
DA 2017-08-15
ER

PT J
AU Mureithi, MW
   Finn, A
   Ota, MO
   Zhang, QB
   Davenport, V
   Mitchell, TJ
   Williams, NA
   Adegbola, RA
   Heyderman, RS
AF Mureithi, Marianne W.
   Finn, Adam
   Ota, Martin O.
   Zhang, Qibo
   Davenport, Victoria
   Mitchell, Timothy J.
   Williams, Neil A.
   Adegbola, Richard A.
   Heyderman, Robert S.
TI T Cell Memory Response to Pneumococcal Protein Antigens in an Area of
   High Pneumococcal Carriage and Disease
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 8th European Meeting on the Molecular Biology of the Pneumococcus
CY APR 14-17, 2007
CL Oeiras, PORTUGAL
SP Univ Texas Hlth Sci Ctr, Execut Res Comm Res Fund
ID STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE;
   NEISSERIA-MENINGITIDIS; MUCOSAL ANTIBODY; GAMMA-INTERFERON; MOUSE MODEL;
   PNEUMOLYSIN; IMMUNITY; CHILDREN; COLONIZATION
AB Background. Streptococcus pneumoniae is a leading cause of vaccine-preventable disease worldwide. Pneumococcal protein antigens are currently under study as components of potential vaccines that offer protection against multiple serotypes. We have therefore characterized T cell pneumococcal immunity acquired through asymptomatic carriage.
   Methods. Peripheral blood mononuclear cells from 40 healthy Gambian adults were stimulated with supernatants derived from S. pneumoniae strain (D39), 2 isogenic mutant strains lacking either pneumolysin or choline binding protein A, and recombinant pneumolysin. Immune responses were measured by cellular proliferation and by interleukin-10 (IL-10) and interferon-gamma (IFN-gamma) enzyme-linked immunosorbent spot and bioplex cytokine assays. Nasopharyngeal swabs were cultured to determine carriage rates.
   Results. S. pneumoniae nasopharyngeal carriage was detected in 60% of individuals. Both effector and resting (or central) CD4(+) T cell memory were frequently present to a range of pneumococcal antigens. However, the level of the effector memory response did not relate to current nasopharyngeal carriage. Pneumolysin was not immunodominant in these T cell responses but induced a distinct proinflammatory profile (high IFN-gamma, IL-12[p40], and L-17 levels and low IL-10 and IL-13 levels).
   Conclusions. In this population, T cell-mediated immunological memory potentially capable of pathogen clearance and immune surveillance is common but is not associated with the absolute interruption of pneumococcal carriage. How this naturally acquired immune memory influences pneumococcal vaccine efficacy remains to be determined.
C1 [Mureithi, Marianne W.; Ota, Martin O.; Adegbola, Richard A.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Mureithi, Marianne W.; Finn, Adam; Zhang, Qibo; Davenport, Victoria; Williams, Neil A.; Heyderman, Robert S.] Univ Bristol, Sch Med Sci, Dept Cellular & Mol Med, Bristol BS8 1TD, Avon, England.
   [Mitchell, Timothy J.] Univ Glasgow, Div Infect & Immun, Glasgow, Lanark, Scotland.
   [Heyderman, Robert S.] Malawi Liverpool Wellcome Trust Clin Res Program, Blantyre, Malawi.
RP Mureithi, MW (reprint author), Ragon Inst Harvard MIT & MGH, 149 13th St,Rm 5218,MGH E, Charlestown, MA 02129 USA.
EM mmureithi@partners.org
OI Mitchell, Timothy/0000-0002-8309-5556
FU Medical Research Council
CR Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467
   Albrich WC, 2007, LANCET, V370, P218, DOI 10.1016/S0140-6736(07)61119-2
   Ariga H, 2007, IMMUNOLOGY, V122, P210, DOI 10.1111/j.1365-2567.2007.02630.x
   Basset A, 2007, INFECT IMMUN, V75, P5460, DOI 10.1128/IAI.00773-07
   Bernatoniene J, 2005, DRUGS, V65, P229, DOI 10.2165/00003495-200565020-00005
   Bernatoniene J, 2008, J INFECT DIS, V198, P1823, DOI 10.1086/593177
   Berry AM, 1999, INFECT IMMUN, V67, P981
   Brueggemann AB, 2003, J INFECT DIS, V187, P1424, DOI 10.1086/374624
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Davenport V, 2003, J IMMUNOL, V171, P4263
   Davenport V, 2007, CELL MICROBIOL, V9, P1050, DOI 10.1111/j.1462-5822.2006.00851.x
   Flanagan KL, 2001, J IMMUNOL, V167, P4729
   Giefing C, 2008, J EXP MED, V205, P117, DOI 10.1084/jem.20071168
   Godkin AJ, 2002, J IMMUNOL, V169, P2210
   Guthrie T, 2004, J INFECT DIS, V190, P1927, DOI 10.1086/425517
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Jefferies JMC, 2007, J INFECT DIS, V196, P936, DOI 10.1086/520091
   Kadioglu A, 2004, INFECT IMMUN, V72, P2689, DOI 10.1128/IAI.72.5.2689-2697.2004
   Klugman KP, 2007, CURR OPIN INFECT DIS, V20, P11, DOI 10.1097/QCO.0b013e328012c5f1
   Lanzavecchia A, 2005, CURR OPIN IMMUNOL, V17, P326, DOI 10.1016/j.coi.2005.04.010
   Lanzavecchia A, 2000, SCIENCE, V290, P92, DOI 10.1126/science.290.5489.92
   Lesprit P, 2007, AIDS, V21, P2425
   Lu YJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000159
   Malley R, 2006, INFECT IMMUN, V74, P2187, DOI 10.1128/IAI.74.4.2187-2195.2006
   Malley R, 2005, P NATL ACAD SCI USA, V102, P4848, DOI 10.1073/pnas.0501254102
   Mannering SI, 2003, J IMMUNOL METHODS, V283, P173, DOI 10.1016/j.jim.2003.09.004
   MITCHELL TJ, 1990, NUCLEIC ACIDS RES, V18, P4010, DOI 10.1093/nar/18.13.4010
   Mulholland EK, 2005, NEW ENGL J MED, V352, P75, DOI 10.1056/NEJMe048306
   O'Garra A, 2007, NAT REV IMMUNOL, V7, P425, DOI 10.1038/nri2097
   Obaro S, 2002, J MED MICROBIOL, V51, P98
   Ogunniyi AD, 2007, INFECT IMMUN, V75, P1843, DOI 10.1128/IAI.01384-06
   Ogunniyi AD, 2001, INFECT IMMUN, V69, P5997, DOI 10.1128/IAI.69.10.5997-6003.2001
   Pathan AA, 2000, EUR J IMMUNOL, V30, P2713, DOI 10.1002/1521-4141(200009)30:9<2713::AID-IMMU2713>3.0.CO;2-4
   Paton JC, 1996, TRENDS MICROBIOL, V4, P103, DOI 10.1016/0966-842X(96)81526-5
   Reiner SL, 2007, SCIENCE, V317, P622, DOI 10.1126/science.1143775
   Rubins JB, 1997, INFECT IMMUN, V65, P2975
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702
   Sallusto F, 2000, CURR TOP MICROBIOL, V251, P167
   Srivastava A, 2005, INFECT IMMUN, V73, P6479, DOI 10.1128/IAI.73.10.6479-6487.2005
   Trzcinski K, 2005, INFECT IMMUN, V73, P7043, DOI 10.1128/IAI.73.10.7043-7046.2005
   Trzcinski K, 2008, INFECT IMMUN, V76, P2678, DOI 10.1128/IAI.00141-08
   Tuomanen EI, 1997, PEDIATR RES, V42, P253, DOI 10.1203/00006450-199709000-00001
   Whitney CG, 2005, PEDIATR INFECT DIS J, V24, P729, DOI 10.1097/01.inf.0000174138.25465.ec
   WILLIAMS NA, 1991, IMMUNOLOGY, V72, P34
   Zhang QB, 2006, EUR J IMMUNOL, V36, P46, DOI 10.1002/eji.200535101
   Zhang QB, 2007, J INFECT DIS, V195, P1194, DOI 10.1086/512617
   Zhang QB, 2006, INFECT IMMUN, V74, P4735, DOI 10.1128/IAI.00165-06
NR 48
TC 31
Z9 31
U1 0
U2 6
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 1
PY 2009
VL 200
IS 5
BP 783
EP 793
DI 10.1086/605023
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 479TN
UT WOS:000268683900017
PM 19642930
OA No
DA 2017-08-15
ER

PT J
AU Janha, RE
   Sisay-Joof, F
   Hamid-Adiamoh, M
   Worwui, A
   Chapman, HL
   Opara, H
   Dunyo, S
   Milligan, P
   Rockett, K
   Winstanley, P
   Pirmohamed, M
   Miller, AK
   Conway, DJ
   Walton, RT
AF Janha, Ramatoulie E.
   Sisay-Joof, Fatoumatta
   Hamid-Adiamoh, Majidah
   Worwui, Archibald
   Chapman, Hannah L.
   Opara, Hyginus
   Dunyo, Sam
   Milligan, Paul
   Rockett, Kirk
   Winstanley, Peter
   Pirmohamed, Munir
   Miller, Ann K.
   Conway, David J.
   Walton, Robert T.
TI Effects of genetic variation at the CYP219/CYP2C9 locus on
   pharmacokinetics of chlorcycloguanil in adult Gambians
SO PHARMACOGENOMICS
LA English
DT Article
DE chlorcycloguanil; CYP2C19; CYP2C9; drug metabolism; pharmacokinetics;
   polymorphisms
ID PROTON PUMP INHIBITORS; CYP2C19; PROGUANIL; METABOLISM; CYCLOGUANIL;
   POLYMORPHISM; FALCIPARUM; MALARIA
AB Antimalarial biguanides are metabolized by CYP2C19, thus genetic variation at the CYP2C locus might affect pharmacokinetics and so treatment outcome for malaria. Materials & methods: Polymorphisms in CYP2C19 and CYP2C9 in 43 adult Gambians treated with chlorproguanil/dapsone for uncomplicated malaria were assessed. Chlorcycloguanil pharmacokinetics were measured and associations with CYP2C19 and CYP2C9 alleles and CYP2C19 metabolizer groups investigated. Results: All CYP2C19/CYP2C9 alleles obeyed Hardy-Weinberg equilibrium. There were 15 CYP2C19/2C9 haplotypes with a common haplotype frequency of 0.23. Participants with the CYP2C19*17 allele had higher chlorcycloguanil area under the concentration versus curve at 24 h (AUC(0-24)) than those without (geometric means: 317 vs 216 ng.h/ml; ratio of geometric means: 1.46; 95% Cl: 1.03 to 2.09; p = 0.0363) and higher C(max) (geometric mean ratio: 1.52; 95% Cl: 1.13 to 2.05; p = 0.0071). Conclusion: CYP2C19*17 determines antimalarial biguanide metabolic profile at the CYP2C19/CYP2C9 locus.
C1 [Janha, Ramatoulie E.; Sisay-Joof, Fatoumatta; Hamid-Adiamoh, Majidah; Worwui, Archibald; Chapman, Hannah L.; Opara, Hyginus; Dunyo, Sam; Conway, David J.; Walton, Robert T.] MRC Labs, Banjul, Gambia.
   [Milligan, Paul] London Sch Hyg & Trop Med, London WC1, England.
   [Rockett, Kirk] Wellcome Trust Ctr Human Genet, Oxford, England.
   [Winstanley, Peter; Pirmohamed, Munir] Univ Liverpool, Liverpool L69 3BX, Merseyside, England.
   [Walton, Robert T.] Univ Oxford, Oxford, England.
RP Janha, RE (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM rjanha@mrc.gm
RI Pirmohamed, Munir/H-6004-2011; Milligan, Paul/D-8985-2017
OI Pirmohamed, Munir/0000-0002-7534-7266; Milligan,
   Paul/0000-0003-3430-3395
FU Medical Research Council [G0700837, MC_U190081977]
CR Allabi AC, 2003, BRIT J CLIN PHARMACO, V56, P653, DOI 10.1046/j.1365-2125.2003.01937.x
   Blaisdell J, 2002, PHARMACOGENETICS, V12, P703, DOI 10.1097/00008571-200212000-00004
   CHILUBA E M, 1987, African Journal of Medicine and Medical Sciences, V16, P43
   Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487
   Gill HJ, 1995, BRIT J CLIN PHARMACO, V40, P531
   Herrlin K, 2000, CLIN PHARMACOL THER, V68, P189, DOI 10.1067/mcp.2000.108583
   Kaneko A, 1999, J INFECT DIS, V179, P974, DOI 10.1086/314683
   Klotz U, 2004, BASIC CLIN PHARMACOL, V95, P2
   Lu AH, 2000, ACTA PHARMACOL SIN, V21, P747
   PETERSEN E, 1991, J TROP MED HYG, V94, P199
   Richardson A, 2001, GENES IMMUN, V2, P343, DOI 10.1038/sj.gene.6363789
   Schroth W, 2007, J CLIN ONCOL, V25, P5187, DOI 10.1200/JCO.2007.12.2705
   Schwab M, 2004, CLIN PHARMACOL THER, V76, P201, DOI 10.1016/j.clpt.2004.05.002
   Sim SC, 2006, CLIN PHARMACOL THER, V79, P103, DOI 10.1016/j.clpt.2005.10.002
   Srivastava IK, 1999, ANTIMICROB AGENTS CH, V43, P1334
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Stewart LB, 2004, ANN TROP MED PARASIT, V98, P763, DOI 10.1179/000349804X3144
   WANGBOONSKUL J, 1993, EUR J CLIN PHARMACOL, V44, P247, DOI 10.1007/BF00271366
   WATKINS WM, 1984, ANN TROP MED PARASIT, V78, P273
   WHO, 2008, WHOHTMGMP20081
   WRIGHT JD, 1995, BRIT J CLIN PHARMACO, V39, P441
   Zanger UM, 2008, ANAL BIOANAL CHEM, V392, P1093, DOI 10.1007/s00216-008-2291-6
NR 22
TC 8
Z9 8
U1 1
U2 3
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PD SEP
PY 2009
VL 10
IS 9
BP 1423
EP 1431
DI 10.2217/PGS.09.72
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 507MQ
UT WOS:000270858700012
PM 19761366
OA No
DA 2017-08-15
ER

PT J
AU Meyer, CG
   Thye, T
   Intemann, C
   Herb, F
   Owusu-Dabo, E
   Gyapong, J
   Niemann, S
   Vannberg, F
   Adegbola, R
   Ehlers, S
   Hill, A
   Horstmann, R
AF Meyer, C. G.
   Thye, T.
   Intemann, C.
   Herb, F.
   Owusu-Dabo, E.
   Gyapong, J.
   Niemann, S.
   Vannberg, F.
   Adegbola, R.
   Ehlers, S.
   Hill, A.
   Horstmann, R.
TI Human genetic factors in pulmonary tuberculosis: candidate genes and a
   genome-wide association study
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Meyer, C. G.; Thye, T.; Intemann, C.; Herb, F.; Horstmann, R.] Bernhard Nocht Inst Trop Med, Hamburg, Germany.
   [Owusu-Dabo, E.] KN Univ Sci & Technol, Kumasi, Ghana.
   [Gyapong, J.] Minist Hlth, Hlth Res Unit, Accra, Ghana.
   [Niemann, S.; Ehlers, S.] Res Ctr Borstel, Borstel, Germany.
   [Vannberg, F.; Hill, A.] Jenner Inst, Oxford, England.
   [Adegbola, R.] MRC Labs, Banjul, Gambia.
RI Ehlers, Stefan/B-4075-2010
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2009
VL 14
BP 41
EP 42
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 487HZ
UT WOS:000269264000122
OA No
DA 2017-08-15
ER

PT J
AU Fine, PEM
   Williams, TN
   Aaby, P
   Kallander, K
   Moulton, LH
   Flanagan, KL
   Smith, PG
   Benn, CS
AF Fine, Paul E. M.
   Williams, Thomas N.
   Aaby, Peter
   Kallander, Karin
   Moulton, Lawrence H.
   Flanagan, Katie L.
   Smith, Peter G.
   Benn, Christine S.
CA Working Grp Non Specific Effects V
TI Epidemiological studies of the 'non-specific effects' of vaccines: I -
   data collection in observational studies
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE vaccines; mortality; non-specific effects; study design
ID DIPHTHERIA-TETANUS-PERTUSSIS; CALMETTE-GUERIN VACCINATION; VITAMIN-A
   SUPPLEMENTATION; GUINEA-BISSAU; MEASLES VACCINATION; CHILDHOOD
   MORTALITY; RURAL BANGLADESH; ROUTINE IMMUNIZATIONS; INFANT-MORTALITY;
   NORTHERN MALAWI
AB Routine vaccination programmes have led to substantial declines in the incidence of most of the target diseases. In these circumstances, vaccine effects beyond those on the target diseases may become evident. Several studies have suggested that certain vaccines may influence mortality in low income settings in ways that cannot be attributed to effects on target diseases. Trials of such 'non-specific' effects are difficult if not impossible to organise; and observational studies of them are prone to serious confounding, because those who do or do not receive vaccines are likely to differ in many ways, some of which relate to their subsequent risk of early death, independent of vaccination. They are also prone to other biases, including the selective loss of vaccination records for children who die. We review these potential sources of bias and suggest what and how data may be collected to optimise the validity of such studies.
C1 [Fine, Paul E. M.; Smith, Peter G.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Williams, Thomas N.] Kilifi Dist Hosp, Ctr Geog Med Res Coast, Kenya Med Res Inst, Kilifi, Kenya.
   [Williams, Thomas N.] John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.
   [Williams, Thomas N.] John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.
   [Aaby, Peter; Benn, Christine S.] Indepth Network, Projecto Saude Bandim, Bissau, Guinea Bissau.
   [Aaby, Peter; Benn, Christine S.] Statens Serum Inst, Danish Epidemiol Sci Ctr, Bandim Hlth Project, DK-2300 Copenhagen, Denmark.
   [Kallander, Karin] Karolinska Inst, Div Int Hlth, Stockholm, Sweden.
   [Kallander, Karin] Makerere Univ, Sch Publ Hlth, Kampala, Uganda.
   [Moulton, Lawrence H.] Johns Hopkins Univ, Dept Int Hlth, Baltimore, MD USA.
   [Flanagan, Katie L.] MRC Labs, Fajara, Gambia.
RP Fine, PEM (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM paul.fine@lshtm.ac.uk
OI Kallander, Karin/0000-0002-5778-5780; Moulton,
   Lawrence/0000-0001-7041-7387; Bork, Kirsten/0000-0002-5909-7332
FU Medical Research Council [G0700837, MC_U190088485]; Wellcome Trust
   [061089, 076934, 081835]
CR Aaby P, 2004, VACCINE, V22, P3014, DOI 10.1016/j.vaccine.2004.02.009
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   Aaby P, 1998, LANCET, V352, P1229, DOI 10.1016/S0140-6736(05)60575-2
   Aaby P, 2007, TROP MED INT HEALTH, V12, P15, DOI 10.1111/j.1365-3156.2006.01774.x
   Aaby P, 2006, PEDIATR INFECT DIS J, V25, P721, DOI 10.1097/01.inf.0000227829.64686.ae
   Benn CS, 2009, INT J EPIDEMIOL, V38, P304, DOI 10.1093/ije/dyn195
   Benn CS, 2003, INT J EPIDEMIOL, V32, P822, DOI 10.1093/ije/dyg208
   Breiman RF, 2004, LANCET, V364, P2204, DOI 10.1016/S0140-6736(04)17593-4
   Chan GJ, 2007, INT J EPIDEMIOL, V36, P1022, DOI 10.1093/ije/dym142
   CHEN RT, 1994, INT J EPIDEMIOL, V23, P185, DOI 10.1093/ije/23.1.185
   CLEMENS JD, 1988, AM J EPIDEMIOL, V128, P1330
   CUTTS FT, 1991, INT J EPIDEMIOL, V20, P1099, DOI 10.1093/ije/20.4.1099
   CUTTS FT, 1989, INT J EPIDEMIOL, V18, P427, DOI 10.1093/ije/18.2.427
   Czaja C, 2005, ANN EPIDEMIOL, V15, P253, DOI 10.1016/j.annepidem.2004.07.091
   DULOU AD, 1995, AM J EPIDEMIOL, V142, P643
   FARRINGTON CP, 2009, TROPICAL ME IN PRESS
   FINE PEM, 1992, AM J EPIDEMIOL, V136, P121
   Floyd S, 2000, INT J TUBERC LUNG D, V4, P1133
   Garly ML, 2004, PEDIATR INFECT DIS J, V23, P1086, DOI 10.1097/01.inf.0000145700.77286.94
   HOLT EA, 1990, PEDIATRICS, V85, P188
   Jahn A, 2008, TROP MED INT HEALTH, V13, P129, DOI 10.1111/j.1365-3156.2007.01982.x
   Jensen H, 2005, BRIT MED J, V330, P845, DOI 10.1136/bmj.330.7495.845-a
   Jensen H, 2007, TROP MED INT HEALTH, V12, P5, DOI 10.1111/j.1365-3156.2006.01773.x
   Kabir Z, 2003, B WORLD HEALTH ORGAN, V81, P244
   KOENIG MA, 1990, B WORLD HEALTH ORGAN, V68, P441
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Kumar G., 2000, Indian Journal of Pediatrics, V67, P411, DOI 10.1007/BF02859456
   Luman ET, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-99
   Miller E, 2003, ARCH DIS CHILD, V88, P222, DOI 10.1136/adc.88.3.222
   Moulton LH, 2005, TROP MED INT HEALTH, V10, P947, DOI 10.1111/j.1365-3156.2005.01434.x
   Pereira SM, 2001, INT J TUBERC LUNG D, V5, P1067
   Roth A, 2005, VACCINE, V23, P3991, DOI 10.1016/j.vaccine.2004.10.022
   Roth A, 2004, PEDIATR INFECT DIS J, V23, P544, DOI 10.1097/01.inf.0000129693.81082.a0
   Roth A, 2006, EXPERT REV VACCINES, V5, P277, DOI 10.1586/14760584-5.2.277
   Simpson DM, 2001, AM J PREV MED, V20, P6, DOI 10.1016/S0749-3797(01)00286-0
   Smith PJ, 2001, AM J PREV MED, V20, P17, DOI 10.1016/S0749-3797(01)00285-9
   Smith PJ, 2005, VITAL HLTH STAT 2, V138, P1
   Steenhuis TJ, 2008, CLIN EXP ALLERGY, V38, P79, DOI 10.1111/j.1365-2222.2007.02859.x
   VALADEZ JJ, 1992, AM J PUBLIC HEALTH, V82, P120, DOI 10.2105/AJPH.82.1.120
   Vaugelade J, 2004, BRIT MED J, V329, P1309, DOI 10.1136/bmj.38261.496366.82
   Veirum JE, 2005, VACCINE, V23, P1197, DOI 10.1016/j.vaccine.2004.02.053
   [Anonymous], 1981, LANCET, V1, P764
NR 43
TC 18
Z9 18
U1 0
U2 6
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2009
VL 14
IS 9
BP 969
EP 976
DI 10.1111/j.1365-3156.2009.02301.x
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 487HY
UT WOS:000269263800001
PM 19531117
OA No
DA 2017-08-15
ER

PT J
AU Micheli, A
   Sanz, N
   Mwangi-Powell, F
   Coleman, MP
   Neal, C
   Ullrich, A
   Travado, L
   Santini, LA
   Grassi, L
   De Lorenzo, F
   Costa, A
   Dangou, JM
   Bisanti, L
   Costantini, AS
   Abu-Rmeileh, N
   Kamal, M
   Federico, M
   Saracci, R
   Rennert, G
   Stefanini, A
   Cavalli, F
   Cazap, E
   Redmond, K
   O'Reilly, S
   Muti, P
   Casali, P
   Gatta, G
   Ferrari, A
   Koifman, S
   Bah, E
   Pastore, G
   Barr, R
   Lombardo, C
   Frazzingaro, C
   Ciampichini, R
   Baili, P
AF Micheli, Andrea
   Sanz, Natalia
   Mwangi-Powell, Faith
   Coleman, Michel P.
   Neal, Claire
   Ullrich, Andreas
   Travado, Luzia
   Santini, Luiz Antonio
   Grassi, Luigi
   De Lorenzo, Francesco
   Costa, Alberto
   Dangou, Jean-Marie
   Bisanti, Luigi
   Costantini, Adele Seniori
   Abu-Rmeileh, Niveen
   Kamal, Mostafa
   Federico, Massimo
   Saracci, Rodolfo
   Rennert, Gad
   Stefanini, Angelo
   Cavalli, Franco
   Cazap, Eduardo
   Redmond, Kathy
   O'Reilly, Susan
   Muti, Paola
   Casali, Paolo
   Gatta, Gemma
   Ferrari, Andrea
   Koifman, Sergio
   Bah, Ebrima
   Pastore, Guido
   Barr, Ronald
   Lombardo, Claudio
   Frazzingaro, Cristina
   Ciampichini, Roberta
   Baili, Paolo
CA ICCC 3 Session B Grp
TI International collaborations in cancer control and the Third
   International Cancer Control Congress
SO TUMORI
LA English
DT Article; Proceedings Paper
CT 3rd International Cancer Control Congress
CY NOV 08-11, 2009
CL Cernobbio, ITALY
DE ICCC-3; cancer control; international collaboration
ID EUROPEAN PSYCHO-ONCOLOGY; YOUNG-ADULTS; SELF-MANAGEMENT; ADOLESCENTS;
   SURVIVAL; MORBIDITY; COMMUNICATION; POPULATION; PHYSICIANS; DISTRESS
AB Over the past few decades, there has been growing support for the idea that cancer needs an interdisciplinary approach. Therefore, the international cancer community has developed several strategies as outlined in the WHO non-communicable diseases Action Plan (which includes cancer control) as the World Health Assembly and the UICC World Cancer Declaration, which both include primary prevention, early diagnosis, treatment, and palliative care. This paper highlights experiences/ideas in cancer control for international collaborations between low, middle, and high income countries, including collaborations between the European Union (EU) and African Union (AU) Member States, the Latin-American and Caribbean countries, and the Eastern Mediterranean countries. These proposals are presented within the context of the global vision on cancer control set forth by WHO in partnership with the International Union Against Cancer (UICC), in addition to issues that should be considered for collaborations at the global level: cancer survival (similar to the project CONCORD), cancer control for youth and adaptation of Clinical Practice Guidelines. Since cancer control is given lower priority on the health agenda of low and middle income countries and is less represented in global health efforts in those countries, EU and AU cancer stakeholders are working to put cancer control on the agenda of the EU-AU treaty for collaborations, and are proposing to consider palliative care, population-based cancer registration, and training and education focusing on primary prevention as core tools. A Community of Practice, such as the Third International Cancer Control Congress (ICCC-3), is an ideal place to share new proposals, learn from other experiences, and formulate new ideas. The aim of the ICCC-3 is to foster new international collaborations to promote cancer control actions in low and middle income countries. The development of supranational collaborations has been hindered by the fact that cancer control is not part of the objectives of the Millennium Development Goals (MGGs). As a consequence, less resources of development aids are allocated to control NCDs including cancer.
C1 [Micheli, Andrea; Sanz, Natalia; Frazzingaro, Cristina; Ciampichini, Roberta; Baili, Paolo] Ist Nazl Tumori, Descript Studies & Hlth Planning Unit, Fdn IRCCS, I-20133 Milan, Italy.
   [Mwangi-Powell, Faith] APCA, Kampala, Uganda.
   [Coleman, Michel P.] London Sch Hyg & Trop Med, London WC1, England.
   [Ullrich, Andreas] WHO, Dis & Hlth Promot, CH-1211 Geneva, Switzerland.
   [Travado, Luzia] High Commiss Hlth, Lisbon, Portugal.
   [Santini, Luiz Antonio] INCA, Natl Canc Inst Brazil, Rio De Janeiro, Brazil.
   [Grassi, Luigi] Univ Ferrara, Sect Psychiat, I-44100 Ferrara, Italy.
   [De Lorenzo, Francesco] Italian Federat Volunteer Assoc Oncol, Rome, Italy.
   [Costa, Alberto] European Sch Oncol, Milan, Italy.
   [Dangou, Jean-Marie] WHO, Reg Off Africa, Brazzaville, Congo.
   [Bisanti, Luigi] Local Hlth Author Milan, Epidemiol Unit, Milan, Italy.
   [Costantini, Adele Seniori] ISPO Canc Prevent & Res Inst, Occupat & Environm Epidemiol Unit, Florence, Italy.
   [Abu-Rmeileh, Niveen] Birzeit Univ, Inst Community & Publ Hlth, West Bank, Palestinian Author, Birzeit, Israel.
   [Kamal, Mostafa] Egyptian Smoking Prevent Res Inst, Cairo, Egypt.
   [Federico, Massimo] Modena Canc Registry, Modena, Italy.
   [Saracci, Rodolfo] CNR, IFC, Pisa, Italy.
   [Rennert, Gad] Technion Israel Inst Technol, Natl Israeli Breast Program, Minist Hlth, IL-32000 Haifa, Israel.
   [Rennert, Gad] Technion Israel Inst Technol, Israel Canc Assoc, Dept Community Med & Epidemiol, Carmel Med Ctr, IL-32000 Haifa, Israel.
   [Rennert, Gad] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-32000 Haifa, Israel.
   [Rennert, Gad] Technion Israel Inst Technol, Colorectal Canc Detect Program, IL-32000 Haifa, Israel.
   [Stefanini, Angelo] Consulate Gen Italy, Off Dev Cooperat, Jerusalem, Israel.
   [Cavalli, Franco] Int Union Canc UICC, Geneva, Switzerland.
   [Cazap, Eduardo] SLACOM, Buenos Aires, DF, Argentina.
   [Redmond, Kathy] European Sch Oncol, Canc World Magazine & Media Program, Milan, Italy.
   [O'Reilly, Susan] Univ British Columbia, Dept Med, British Columbia Canc Agcy, Div Med Oncol, Vancouver, BC, Canada.
   [Muti, Paola] Italian Natl Canc Inst Regina Elena, Rome, Italy.
   [Casali, Paolo] Ist Nazl Tumori, Med Oncol Unit, Fdn IRCCS, I-20133 Milan, Italy.
   [Gatta, Gemma] Ist Nazl Tumori, Evaluat Epidemiol Unit, Fdn IRCCS, I-20133 Milan, Italy.
   [Ferrari, Andrea] Ist Nazl Tumori, Paedriat Oncol Unit, Fdn IRCCS, I-20133 Milan, Italy.
   [Bah, Ebrima] IARC, Banjul, Gambia.
   [Pastore, Guido] Childhood Canc Registry Piedmont, Turin, Italy.
   [Barr, Ronald] McMaster Univ, Hamilton, ON, Canada.
   [Lombardo, Claudio] Natl Inst Canc Res, Genoa, Italy.
   [Lombardo, Claudio] Alleanza Contro Cancro, Rome, Italy.
RP Micheli, A (reprint author), Ist Nazl Tumori, Descript Studies & Hlth Planning Unit, Fdn IRCCS, Via Venezian 1, I-20133 Milan, Italy.
EM andrea.micheli@istitutotumori.mi.it
RI ; Federico, Massimo/J-5984-2014; Baili, Paolo/J-7422-2016; Federico,
   Massimo/A-6801-2012; Gatta, Gemma/B-8627-2017; Trama,
   Annalisa/C-1092-2017; casali, Paolo Giovanni/D-1524-2017; Sant,
   Milena/D-2362-2017; Di Salvo, Francesca/E-2840-2017
OI Travado, Luzia/0000-0003-3509-3035; Coleman, Michel/0000-0001-8940-3807;
   Federico, Massimo/0000-0002-5074-3262; Baili, Paolo/0000-0003-0335-2418;
   Federico, Massimo/0000-0002-9889-3796; Gatta, Gemma/0000-0003-4160-6458;
   Trama, Annalisa/0000-0001-8220-9833; casali, Paolo
   Giovanni/0000-0003-4056-8023; Sant, Milena/0000-0002-4148-8597; Di
   Salvo, Francesca/0000-0003-2537-081X; Micheli,
   Andrea/0000-0002-4558-4754; Ferrari, Andrea/0000-0002-4724-0517
FU Cancer Research UK [11700]
CR *AFR U, AFR HLTH STRAT 2007
   Baili P, 2008, TUMORI, V94, P658
   Barr RD, 2006, CANCER, V106, P1425, DOI 10.1002/cncr.21773
   BLEYER A, 2006, NATL CANC I PUB
   Bleyer A, 2008, NAT REV CANCER, V8, P288, DOI 10.1038/nrc2349
   Boyle P, 2008, WORLD CANC REPORT 20
   *BRAZ MIN SAUD, 2002, AC ENF CONTR CANC PR, P380
   *BRAZ MIN SAUD, 2002, VIV MULH CANC COL UT, P78
   Cole CH, 2004, MED J AUSTRALIA, V180, P52
   Coleman MP, 2008, LANCET ONCOL, V9, P730, DOI [10.1016/S1470-2045(08)70179-7, 10.1016/S470-2045(08)70179-7]
   Corazziari I, 2004, EUR J CANCER, V40, P2307, DOI 10.1016/j.ejca.2004.07.002
   DOMER T, 2000, PALLIATIVE PRACTICE, P26
   *EUR U AFR, 2009, UN MILL DEV GOALS
   FERNANDEZ Jose Angel, 2006, REV PSICOPATOLOGIA P, V1, P1
   Freedman LS, 2006, NIH PUB, V06-5873
   Garcia M, 2007, GLOBAL CANC FACTS FI
   Gatta G, 2009, EUR J CANCER, V45, P992, DOI 10.1016/j.ejca.2008.11.042
   Gil F, 2005, SUPPORT CARE CANCER, V13, P600, DOI 10.1007/s00520-005-0780-0
   Grassi L, 2004, J AFFECT DISORDERS, V83, P243, DOI 10.1016/j.jad.2004.07.004
   Grassi L, 2005, J CANCER EDUC, V20, P79, DOI 10.1207/s15430154jce2002_7
   GRASSI L, 2009, PSYCHOSOMAT IN PRESS
   Grassi L, 2009, J AFFECT DISORDERS, V114, P193, DOI 10.1016/j.jad.2008.07.016
   Kaur JS, 2000, MAYO CLIN PROC, V75, P181
   Kennedy A., 2008, Eastern Mediterranean Health Journal, V14, P502
   KERR D, 2008, EXAMPLE AFRICA
   Lingwood RJ, 2008, NAT REV CANCER, V8, P398, DOI 10.1038/nrc2372
   Loh SY, 2007, ASIA-PAC J PUBLIC HE, V19, P52
   Loh SY, 2006, J U MALAYA MED CTR, V9, P3
   Lorig K, 2001, KEY ASPECTS OF PREVENTING AND MANAGING CHRONIC ILLNESS, P35
   Medical Research Council, 2000, FRAM DEV EV RCTS COM
   Micheli A, 2003, EUR J PUBLIC HEALTH, V13, P116, DOI 10.1093/eurpub/13.suppl_1.116
   Newman S, 2004, LANCET, V364, P1523, DOI 10.1016/S0140-6736(04)17277-2
   NGANDWE C, 2007, BMC INFECT DIS, V16, P7
   Omar S., 2007, Eastern Mediterranean Health Journal, V13, P1486
   Parkin DM, 2008, LANCET ONCOL, V9, P683, DOI 10.1016/S1470-2045(08)70175-X
   Pentheroudakis G, 2005, ANN ONCOL, V16, P181, DOI 10.1093/annonc/mdi036
   Pritchard-Jones K, 2006, EUR J CANCER, V42, P2183, DOI 10.1016/j.ejca.2006.06.006
   Ries LAG, 1999, NATL CANC I PUB
   Sloan FA, 2007, CANC CONTROL OPPORTU
   Soerjomataram I, 2007, INT J CANCER, V120, P1336, DOI 10.1002/ijc.22459
   Soliman Hatem, 2008, Cancer Control, V15, P55
   Stiller CA, 2007, CANCER TREAT REV, V33, P631, DOI 10.1016/j.ctrv.2007.01.001
   Travado L, 2005, PSYCHO-ONCOL, V14, P661, DOI 10.1002/pons.890
   *UICC, WORLD CANC DECL
   *UN, 2008, GOAL 8 DEV GLOB PART
   US Department of Health and Human Services National Diabetes Education Program, 2006, NIH PUBL, V06-5334
   Verdecchia A, 2008, EUR J PUBLIC HEALTH, V18, P527, DOI 10.1093/eurpub/ckn022
   Wagner E H, 1998, Eff Clin Pract, V1, P2
   Wenger E, 2002, CULTIVATING COMMUNIT, P4
   World Health Organization (WHO), QUICK CANC FACTS
   World Health Organisation, 2002, NAT CANC CONTR PROGR
   World Health Organization, 2003, STRAT IMPR STRENGTH
   World Health Organization, 2008, GLOB BURD DIS 2004 U
   *WHO, 2009, CANC CONTR KNOWL ACT
   *WHO AFRO, 2008, WHO PROP STRAT PREV
NR 55
TC 6
Z9 6
U1 2
U2 11
PU PENSIERO SCIENTIFICO EDITOR
PI ROME
PA VIA BRADANO 3/C, 00199 ROME, ITALY
SN 0300-8916
J9 TUMORI
JI Tumori
PD SEP-OCT
PY 2009
VL 95
IS 5
BP 579
EP 596
PG 18
WC Oncology
SC Oncology
GA 529AV
UT WOS:000272489000003
PM 19999949
OA No
DA 2017-08-15
ER

PT J
AU Martins, C
   Bale, C
   Garly, ML
   Rodrigues, A
   Lisse, IM
   Andersen, A
   Eriksson, M
   Benn, CS
   Whittle, H
   Aaby, P
AF Martins, Cesario
   Bale, Carlitos
   Garly, May-Lill
   Rodrigues, Amabelia
   Lisse, Ida M.
   Andersen, Andreas
   Eriksson, Mia
   Benn, Christine S.
   Whittle, Hilton
   Aaby, Peter
TI Girls may have lower levels of maternal measles antibodies and higher
   risk of subclinical measles infection before the age of measles
   vaccination
SO VACCINE
LA English
DT Article
DE Measles vaccine; Maternal antibodies; Sex-differences
ID VITAMIN-A SUPPLEMENTATION; GUINEA-BISSAU; TETANUS ANTIBODIES; PLACENTAL
   MALARIA; WEST-AFRICAN; BCG VACCINE; MORTALITY; TRIAL; SURVIVAL
AB Background: Previous studies have suggested that girls may have lower maternal measles antibody levels than boys. Girls might therefore be more likely to contract measles infection before the normal age of measles vaccination at 9 months of age.
   Methods: In connection with a clinical trial of different measles vaccination strategies, we collected pre-measles vaccination blood samples at 4.5 months of age from two subgroups of children. Samples from these children were used to assess possible differences in maternal antibody levels for boys and girls. At 9 months of age another subgroup of children was sampled before the normal measles vaccination; these samples were used to assess the frequency of subdinical measles infection among boys and girls.
   Results: We determined measles-specific antibody levels for 812 children at 4.5 months of age and for 896 children at 9 months of age. At 4.5 months of age girls were less likely to have protective maternal antibody levels, the male-female ratio for protective antibody level being 1.23 (1.00-1.51). Among children sampled at 9 months of age, girls were more likely to have protective levels, the female-male ratio for having protective antibody levels being 1.65 (0.98-2.78) (p = 0.054) and the geometric mean titre was significantly higher for girls (p = 0.007). Children who lived in houses with known measles cases were more likely to have protective levels at 9 months of age even though they had not reported measles infection. Since we had excluded children with known measles infection, girls may have been more likely to have had subdinical measles infection. Combining clinical and possible subdinical measles infection, girls tended to be more likely than boys to contract measles infection before 9 months of age, the RR being 1.36 (0.97-1.90).
   Conclusions: Girls lost maternal measles antibodies more rapidly than boys and well before 9 months of age. They may be More likely to Contract subdinical measles infection before the current age of measles vaccination. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Martins, Cesario; Bale, Carlitos; Garly, May-Lill; Rodrigues, Amabelia; Andersen, Andreas; Aaby, Peter] Indepth Network, Bandim Hlth Project, Bissau, Guinea Bissau.
   [Garly, May-Lill; Eriksson, Mia; Benn, Christine S.; Aaby, Peter] Statens Serum Inst, Bandim Hlth Project, Copenhagen, Denmark.
   [Lisse, Ida M.] Herlev Univ Hosp, Dept Pathol, DK-2730 Herlev, Denmark.
   [Whittle, Hilton] MRC Labs, Fajara, Gambia.
RP Martins, C (reprint author), Indepth Network, Bandim Hlth Project, Apartado 861, Bissau, Guinea Bissau.
EM c.martins@bandim.org
OI Sondergaard, Mia Johanna/0000-0002-9382-3748
FU Danish Council for Development Research; Novo Nordisk Foundation
FX The study received financial support from the Danish Council for
   Development Research. PA holds a research professorship grant from the
   Novo Nordisk Foundation.
CR Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   Aaby P, 2002, VACCINE, V21, P15, DOI 10.1016/S0264-410X(02)00441-3
   AABY P, 1994, EPIDEMIOL INFECT, V112, P413
   AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X
   AABY P, 2009, PIDJ IN PRESS
   Benn CS, 2008, BRIT MED J, V336, P1416, DOI 10.1136/bmj.39542.509444.AE
   Benn CS, 1997, LANCET, V350, P101, DOI 10.1016/S0140-6736(96)12019-5
   BRAIR ME, 1994, LANCET, V343, P208, DOI 10.1016/S0140-6736(94)90991-1
   Cisse B, 2001, THESIS LONDON SCH HY
   DINESS BR, 2007, THESIS U COPENHAGEN
   Fisker AB, 2007, AM J CLIN NUTR, V86, P1032
   JENSEN TG, 1994, VACCINE, V12, P1026, DOI 10.1016/0264-410X(94)90340-9
   MARTINS CL, 2008, BRIT MED J, V337, pE661
   MARTINS CL, 2002, NIVEIS ANTICORPOS SA
   Moraes-Pinto MI, 1998, ARCH DIS CHILD-FETAL, V79, pF202
   NORRBY E, 1962, P SOC EXP BIOL MED, V111, P814
   Okoko BJ, 2001, J HEALTH POPUL NUTR, V19, P59
   Whittle H, 1990, LANCET, V336, P1048
NR 18
TC 16
Z9 16
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD AUG 20
PY 2009
VL 27
IS 38
BP 5220
EP 5225
DI 10.1016/j.vaccine.2009.06.076
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 484UB
UT WOS:000269071900011
PM 19596409
OA No
DA 2017-08-15
ER

PT J
AU Jeffries, DJ
   Abernethy, N
   de Jong, BC
AF Jeffries, David J.
   Abernethy, Neil
   de Jong, Bouke C.
TI Supervised learning for the automated transcription of spacer
   classification from spoligotype films
SO BMC BIOINFORMATICS
LA English
DT Article
ID MYCOBACTERIUM-TUBERCULOSIS COMPLEX; STRAINS; DIFFERENTIATION;
   EPIDEMIOLOGY; DIAGNOSIS; ASSAY
AB Background: Molecular genotyping of bacteria has revolutionized the study of tuberculosis epidemiology, yet these established laboratory techniques typically require subjective and laborious interpretation by trained professionals. In the context of a Tuberculosis Case Contact study in The Gambia we used a reverse hybridization laboratory assay called spoligotype analysis. To facilitate processing of spoligotype images we have developed tools and algorithms to automate the classification and transcription of these data directly to a database while allowing for manual editing.
   Results: Features extracted from each of the 1849 spots on a spoligo film were classified using two supervised learning algorithms. A graphical user interface allows manual editing of the classification, before export to a database. The application was tested on ten films of differing quality and the results of the best classifier were compared to expert manual classification, giving a median correct classification rate of 98.1% (inter quartile range: 97.1% to 99.2%), with an automated processing time of less than 1 minute per film.
   Conclusion: The software implementation offers considerable time savings over manual processing whilst allowing expert editing of the automated classification. The automatic upload of the classification to a database reduces the chances of transcription errors.
C1 [Jeffries, David J.; de Jong, Bouke C.] MRC Labs, Fajara, Gambia.
   [Abernethy, Neil] Univ Washington, Dept Med Educ & Biomed Informat, Seattle, WA 98195 USA.
   [de Jong, Bouke C.] NYU, Div Infect Dis & Immunol, New York, NY 10003 USA.
RP Jeffries, DJ (reprint author), MRC Labs, Fajara, Gambia.
EM djeffries@mrc.gm; neila@u.washington.edu; bdejong@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU NIH [TW006083]
FX We thank Christopher Sola for his insightful comments. This work was
   supported by MRC funds and by NIH grant TW006083. We'd like to thank Dr.
   Margaret Pinder for her assistance with the preparation of the paper.
CR Cowan LS, 2004, J CLIN MICROBIOL, V42, P474, DOI 10.1128/JCM.42.1.474-477.2004
   Cristianini N, 2002, INTRO SUPPORT VECTOR
   Dale JW, 2001, INT J TUBERC LUNG D, V5, P216
   Daley CL, 2005, CLIN CHEST MED, V26, P217, DOI 10.1016/j.ccm.2005.02.005
   Demsar J, 2006, J MACH LEARN RES, V7, P1
   Driscoll JR, 2002, EMERG INFECT DIS, V8, P1306
   Eilers PHC, 1996, STAT SCI, V11, P89, DOI 10.1214/ss/1038425655
   Ferdinand S, 2004, RES MICROBIOL, V155, P647, DOI 10.1016/j.resmic.2004.04.013
   Filliol I, 2003, J CLIN MICROBIOL, V41, P1963, DOI 10.1128/JCM.41.5.1963.1970.2003
   Gori A, 2005, MOL CELL PROBE, V19, P236, DOI 10.1016/j.mcp.2005.01.001
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907
   Kremer K, 1999, J CLIN MICROBIOL, V37, P2607
   Malik AN, 2005, LANCET INFECT DIS, V5, P174, DOI 10.1016/S1473-3099(05)01310-1
   Mardia K. V., 1979, MULTIVARIATE ANAL
   RIPLEY BD, 2004, PATTERN RECOGNITION
   Sebban M, 2002, BIOINFORMATICS, V18, P235, DOI 10.1093/bioinformatics/18.2.235
   Tang C, 2008, BIOINFORMATICS, V24, P2414, DOI 10.1093/bioinformatics/btn434
   van der Zanden AGM, 2002, J CLIN MICROBIOL, V40, P4628, DOI 10.1128/JCM.40.12.4625-4639.2002
NR 19
TC 4
Z9 4
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
   4LB, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD AUG 12
PY 2009
VL 10
AR 248
DI 10.1186/1471-2105-10-248
PG 11
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA 489LU
UT WOS:000269422400001
PM 19674444
OA gold
DA 2017-08-15
ER

PT J
AU Betson, M
   Jawara, M
   Awolola, TS
AF Betson, Martha
   Jawara, Musa
   Awolola, Taiwo Samson
TI Status of insecticide susceptibility in Anopheles gambiae s.l. from
   malaria surveillance sites in The Gambia
SO MALARIA JOURNAL
LA English
DT Article
ID PYRETHROID INSECTICIDES; NORTHERN CAMEROON; MOLECULAR-FORMS;
   BURKINA-FASO; WEST-AFRICA; RESISTANCE; ARABIENSIS; AREA; PERMETHRIN;
   NIGERIA
AB Background: Vector control is an effective way of reducing malaria transmission. The main vector control methods include the use of insecticide-treated bed nets and indoor residual spraying (IRS). Both interventions rely on the continuing susceptibility of Anopheles to a limited number of insecticides. However, insecticide resistance, in particular pyrethroid-DDT cross-resistance, is a challenge facing malaria vector control in Africa because pyrethroids represent the only class of insecticides approved for treating bed nets and DDT is commonly used for IRS. Here baseline data are presented on the insecticide susceptibility levels of malaria vectors prior to The Gambian indoor residual spraying intervention programme.
   Methods: Anopheles larvae were collected from six malaria surveillance sites (Brikama, Essau, Farafenni, Mansakonko, Kuntaur and Basse) established by the National Malaria Control Programme and the UK Medical Research Council Laboratories in The Gambia. The mosquitoes were reared to adulthood and identified using morphological keys and a species-specific polymerase chain reaction assay. Two-to three-day old adult female mosquitoes were tested for susceptibility to permethrin, deltamethrin and DDT using standard WHO protocols, insecticide susceptibility test kits and treated papers.
   Results: All Anopheles mosquitoes tested belonged to the Anopheles gambiae complex. Anopheles arabiensis was predominant (54.1%), followed by An. gambiae s.s. (26.1%) and Anopheles melas (19.8%). Anopheles gambiae s.s. and An. arabiensis were found at all six sites. Anopheles melas was recorded only at Brikama. Mosquitoes from two of the six sites (Brikama and Basse) were fully susceptible to all three insecticides tested. However, DDT resistance was found in An. gambiae from Essau where the 24 hours post-exposure mortality was <80% but 88% for permethrin and 92% for deltamethrin.
   Conclusion: This current survey of insecticide resistance in Anopheles provides baseline information for monitoring resistance in The Gambia and highlights the need for routine resistance surveillance as an integral part of the proposed nation wide IRS intervention using DDT.
C1 [Jawara, Musa; Awolola, Taiwo Samson] MRC Labs, Malaria Res Programme, Banjul, Gambia.
   [Betson, Martha] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   [Betson, Martha] Nat Hist Museum, Dept Zool, London SW7 5BD, England.
RP Awolola, TS (reprint author), MRC Labs, Malaria Res Programme, POB 273, Banjul, Gambia.
EM m.betson@nhm.ac.uk; mjawara@mrc.gm; sawolola@mrc.gm
RI Betson, Martha/D-3818-2014
OI Betson, Martha/0000-0002-4220-3290
FU Medical Research Council, UK
FX We are very grateful for the field assistance of W. Njie, S. Kanteh, Z.
   Conteh and A. Jallow, and the technical assistance of L. Camara. Sincere
   thanks go to Dr David Conway, Head of the Malaria Research Programme at
   the MRC Laboratories, The Gambia for supporting the work. This research
   was funded by the Medical Research Council, UK.
CR Armitage P., 1994, STAT METHODS MED RES
   Awolola TS, 2005, ACTA TROP, V95, P204, DOI 10.1016/j.actatropica.2005.06.002
   Awolola TS, 2002, ANN TROP MED PARASIT, V96, P849, DOI 10.1179/000349802125002581
   Bryan J.H., 1987, Parassitologia (Rome), V29, P221
   Casimiro S, 2006, J MED ENTOMOL, V43, P267, DOI 10.1603/0022-2585(2006)043[0267:IRIAFD]2.0.CO;2
   Casimiro S, 2006, J MED ENTOMOL, V43, P276, DOI 10.1603/0022-2585(2006)043[0276:IRIAAA]2.0.CO;2
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Chandre F, 1999, B WORLD HEALTH ORGAN, V77, P230
   Chandre F, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P319
   Chen H, 2008, J MED ENTOMOL, V45, P242, DOI 10.1603/0022-2585(2008)45[242:MLAKRK]2.0.CO;2
   Chouaibou M, 2008, TROP MED INT HEALTH, V13, P476, DOI 10.1111/j.1365-3156.2008.02025.x
   Coetzee M., 2006, Bulletin de la Societe de Pathologie Exotique, V99, P400
   Dabire KR, 2009, TROP MED INT HEALTH, V14, P396, DOI 10.1111/j.1365-3156.2009.02243.x
   Diabate A, 2004, TROP MED INT HEALTH, V9, P1267, DOI 10.1111/j.1365-3156.2004.01336.x
   Diabate A., 2002, Parassitologia (Rome), V44, P157
   Elissa N, 1994, Sante, V4, P95
   ELISSA N, 1993, ANN SOC BELG MED TR, V73, P291
   Etang J, 2003, J MED ENTOMOL, V40, P491, DOI 10.1603/0022-2585-40.4.491
   Faye O, 1991, Dakar Med, V36, P170
   Finney D. J., 1971, PROBIT ANAL
   GILLET J.D., 1972, COMMON AFRICAN MOSQU
   Gillies MT, 1987, PUBLICATIONS S AFRIC, V55, P143
   Hargreaves K, 2000, MED VET ENTOMOL, V14, P181, DOI 10.1046/j.1365-2915.2000.00234.x
   HEMINGWAY J, 1983, T ROY SOC TROP MED H, V77, P106, DOI 10.1016/0035-9203(83)90030-5
   Hemingway J, 2004, INSECT BIOCHEM MOLEC, V34, P653, DOI 10.1016/j.ibmb.2004.03.018
   Himeidan YE, 2007, AM J TROP MED HYG, V77, P1066
   Kamau L, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-46
   Kelly-Hope L, 2008, LANCET INFECT DIS, V8, P387, DOI 10.1016/S1473-3099(08)70045-8
   Kirby MJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-2
   Kristan M, 2003, MED VET ENTOMOL, V17, P326, DOI 10.1046/j.1365-2915.2003.00449.x
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90171-L
   Majambere S, 2008, AM J TROP MED HYG, V79, P19
   Manirakiza P, 2003, ARCH ENVIRON CON TOX, V44, P171, DOI 10.1007/s00244-002-2006-5
   Mosha FW, 2008, ANN TROP MED PARASIT, V102, P367, DOI 10.1179/136485908X278829
   Mostafa Azza A., 2001, Journal of the Egyptian Society of Parasitology, V31, P177
   Muller P, 2008, MOL ECOL, V17, P1145, DOI 10.1111/j.1365-294X.2007.03617.x
   Munhenga G, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-247
   N'Guessan R, 2003, MED VET ENTOMOL, V17, P19, DOI 10.1046/j.1365-2915.2003.00406.x
   NAJERA JA, 2002, WHOCDSWHOPES20025REV
   NDJEMAI HN, T R SOC TRO IN PRESS
   Pages F, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-178
   Pinto J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001243
   RAMPHUL U, T R SOC TRO IN PRESS
   Ranson H, 2000, INSECT MOL BIOL, V9, P491, DOI 10.1046/j.1365-2583.2000.00209.x
   Santolamazza F, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-74
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   Sharp BL, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-52
   Vulule JM, 1999, MED VET ENTOMOL, V13, P239, DOI 10.1046/j.1365-2915.1999.00177.x
   World Health Organization, 1998, WHOCDSMAL9812, P15
   *WHO, 2006, IND REIS SPRAYING US
NR 50
TC 7
Z9 7
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 5
PY 2009
VL 8
AR 187
DI 10.1186/1475-2875-8-187
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 495EU
UT WOS:000269874200002
PM 19656399
OA gold
DA 2017-08-15
ER

PT J
AU Cheeseman, IH
   Gomez-Escobar, N
   Carret, CK
   Ivens, A
   Stewart, LB
   Tetteh, KKA
   Conway, DJ
AF Cheeseman, Ian H.
   Gomez-Escobar, Natalia
   Carret, Celine K.
   Ivens, Alasdair
   Stewart, Lindsay B.
   Tetteh, Kevin K. A.
   Conway, David J.
TI Gene copy number variation throughout the Plasmodium falciparum genome
SO BMC GENOMICS
LA English
DT Article
ID SEGMENTAL DUPLICATIONS; MULTIDRUG-RESISTANCE; CONTINUOUS CULTURE;
   MALARIA PARASITES; SELECTIVE SWEEPS; POLYMORPHISMS; MICROARRAY;
   DIVERSITY; DELETIONS; VARIANTS
AB Background: Gene copy number variation (CNV) is responsible for several important phenotypes of the malaria parasite Plasmodium falciparum, including drug resistance, loss of infected erythrocyte cytoadherence and alteration of receptor usage for erythrocyte invasion. Despite the known effects of CNV, little is known about its extent throughout the genome.
   Results: We performed a whole-genome survey of CNV genes in P. falciparum using comparative genome hybridisation of a diverse set of 16 laboratory culture-adapted isolates to a custom designed high density Affymetrix GeneChip array. Overall, 186 genes showed hybridisation signals consistent with deletion or amplification in one or more isolate. There is a strong association of CNV with gene length, genomic location, and low orthology to genes in other Plasmodium species. Sub-telomeric regions of all chromosomes are strongly associated with CNV genes independent from members of previously described multigene families. However, similar to 40% of CNV genes were located in more central regions of the chromosomes. Among the previously undescribed CNV genes, several that are of potential phenotypic relevance are identified.
   Conclusion: CNV represents a major form of genetic variation within the P. falciparum genome; the distribution of gene features indicates the involvement of highly non-random mutational and selective processes. Additional studies should be directed at examining CNV in natural parasite populations to extend conclusions to clinical settings.
C1 [Cheeseman, Ian H.; Stewart, Lindsay B.; Tetteh, Kevin K. A.; Conway, David J.] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   [Cheeseman, Ian H.; Gomez-Escobar, Natalia; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Carret, Celine K.; Ivens, Alasdair] Wellcome Trust Sanger Inst, Hinxton, Cambs, England.
RP Cheeseman, IH (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM ian.cheeseman@lshtm.ac.uk; ngescobar@mrc.gm; ckc@sanger.ac.uk;
   alicat@sanger.ac.uk; lindsay.stewart@lshtm.ac.uk;
   kevin.tetteh@lshtm.ac.uk; dconway@mrc.gm
OI cheeseman, ian/0000-0003-4426-4027; Conway, David/0000-0002-8711-3037
FU Wellcome Trust programme [074695/Z/04/B]
FX This work was supported by Wellcome Trust programme grant number
   074695/Z/04/B to DJC, an MRC PhD studentship for IHC, and core funding
   to the MRC Gambia Unit. We are grateful to Chris Newbold, Dominic
   Kwiatkowski, Matt Berriman, Daniel Jeffares and Neil Abernathy for
   helpful discussions.
CR Anderson TJC, 2005, ANTIMICROB AGENTS CH, V49, P2180, DOI 10.1128/AAC.49.6.2180-2188.2005
   Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047
   Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517
   BIGGS BA, 1989, P NATL ACAD SCI USA, V86, P2428, DOI 10.1073/pnas.86.7.2428
   Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005
   Carret CK, 2005, MOL BIOCHEM PARASIT, V144, P177, DOI 10.1016/j.molbiopara.2005.08.010
   Carter NP, 2007, NAT GENET, V39, pS16, DOI 10.1038/ng2028
   Carvalho CMB, 2008, GENOME RES, V18, P1724, DOI 10.1101/gr.080697.108
   Conrad DF, 2006, NAT GENET, V38, P75, DOI 10.1038/ng1697
   Conrad DF, 2007, NAT GENET, V39, pS30, DOI 10.1038/ng2042
   Cooke GS, 2003, AM J TROP MED HYG, V69, P565
   Cooper GM, 2007, NAT GENET, V39, pS22, DOI 10.1038/ng2054
   CORCORAN LM, 1986, CELL, V44, P87, DOI 10.1016/0092-8674(86)90487-3
   Cortes A, 2007, PLOS PATHOG, V3, P1023, DOI 10.1371/journal.ppat.0030107
   COWMAN AF, 1994, P NATL ACAD SCI USA, V91, P1143, DOI 10.1073/pnas.91.3.1143
   de Smith AJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003104
   Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gresham D, 2006, SCIENCE, V311, P1932, DOI 10.1126/science.1123726
   Gu ZL, 2003, NATURE, V421, P63, DOI 10.1038/nature01198
   Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717
   HINTERBERG K, 1994, EMBO J, V13, P4174
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jeffares DC, 2007, NAT GENET, V39, P120, DOI 10.1038/ng1931
   Jiang HY, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-398
   Kidgell Claire, 2006, PLoS Pathogens, V2, P562, DOI 10.1371/journal.ppat.0020057
   Kooij TWA, 2005, PLOS PATHOG, V1, P349, DOI 10.1371/journal.ppat.0010044
   Maier AG, 2007, BLOOD, V109, P1289, DOI 10.1182/blood-2006-08-043364
   Marques-Bonet T, 2009, NATURE, V457, P877, DOI 10.1038/nature07744
   Mok BW, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-46
   Mu JB, 2005, PLOS BIOL, V3, P1734, DOI 10.1371/journal.pbio.0030335
   Mu JB, 2007, NAT GENET, V39, P126, DOI 10.1038/ng1924
   Nair S, 2007, MOL BIOL EVOL, V24, P562, DOI 10.1093/molbev/msl185
   Nair S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000243
   Nguyen DQ, 2006, PLOS GENET, V2, P198, DOI 10.1371/journal.pgen.0020020
   ODUOLA AMJ, 1988, EXP PARASITOL, V67, P354, DOI 10.1016/0014-4894(88)90082-3
   POLOGE LG, 1990, MOL CELL BIOL, V10, P3243
   Ribacke U, 2007, MOL BIOCHEM PARASIT, V155, P33, DOI 10.1016/j.molbiopara.2007.05.005
   Shaffer LG, 2000, ANNU REV GENET, V34, P297, DOI 10.1146/annurev.genet.34.1.297
   Taylor HM, 2000, MOL BIOCHEM PARASIT, V110, P391, DOI 10.1016/S0166-6851(00)00286-3
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Trenholme KR, 2000, P NATL ACAD SCI USA, V97, P4029, DOI 10.1073/pnas.040561197
   UDEINYA IJ, 1983, EXP PARASITOL, V56, P207, DOI 10.1016/0014-4894(83)90064-4
   Vermeesch JR, 2005, J HISTOCHEM CYTOCHEM, V53, P413, DOI 10.1369/jhc.4A6436.2005
   Volkman SK, 2007, NAT GENET, V39, P113, DOI 10.1038/ng1930
   Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813
NR 46
TC 20
Z9 20
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD AUG 4
PY 2009
VL 10
AR 353
DI 10.1186/1471-2164-10-353
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 490OL
UT WOS:000269510300001
PM 19653891
OA gold
DA 2017-08-15
ER

PT J
AU Black, GF
   Thiel, BA
   Ota, MO
   Parida, SK
   Adegbola, R
   Boom, WH
   Dockrell, HM
   Franken, KLMC
   Friggen, AH
   Hill, PC
   Klein, MR
   Lalor, MK
   Mayanja, H
   Schoolnik, G
   Stanley, K
   Weldingh, K
   Kaufmann, SHE
   Walzl, G
   Ottenhoff, THM
AF Black, Gillian F.
   Thiel, Bonnie A.
   Ota, Martin O.
   Parida, Shreemanta K.
   Adegbola, Richard
   Boom, W. Henry
   Dockrell, Hazel M.
   Franken, Kees L. M. C.
   Friggen, Annemiek H.
   Hill, Philip C.
   Klein, Michel R.
   Lalor, Maeve K.
   Mayanja, Harriet
   Schoolnik, Gary
   Stanley, Kim
   Weldingh, Karin
   Kaufmann, Stefan H. E.
   Walzl, Gerhard
   Ottenhoff, Tom H. M.
CA GCGH Biomarkers TB Consortium
TI Immunogenicity of Novel DosR Regulon-Encoded Candidate Antigens of
   Mycobacterium tuberculosis in Three High-Burden Populations in Africa
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID BOVIS BCG VACCINATION; T-CELL ANTIGENS; IMMUNE-RESPONSES;
   ALPHA-CRYSTALLIN; HYPOXIC RESPONSE; DORMANCY REGULON; NORTHERN MALAWI;
   INFECTED MICE; PROTEINS; GAMMA
AB Increasing knowledge about DosR regulon-encoded proteins has led us to produce novel Mycobacterium tuberculosis antigens for immunogenicity testing in human populations in three countries in Africa to which tuberculosis (TB) is endemic. A total of 131 tuberculin skin test-positive and/or ESAT-6/CFP10-positive, human immunodeficiency virus-negative adult household contacts of active pulmonary TB cases from South Africa (n = 56), The Gambia (n = 26), and Uganda (n = 49) were tested for gamma interferon responses to 7 classical and 51 DosR regulon-encoded M. tuberculosis recombinant protein antigens. ESAT-6/CFP10 fusion protein evoked responses in >75% of study participants in all three countries. Of the DosR regulon-encoded antigens tested, Rv1733c was the most commonly recognized by participants from both South Africa and Uganda and the third most commonly recognized antigen in The Gambia. The four most frequently recognized DosR regulon-encoded antigens in Uganda (Rv1733c, Rv0081, Rv1735c, and Rv1737c) included the three most immunogenic antigens in South Africa. In contrast, Rv3131 induced the highest percentage of responders in Gambian contacts (38%), compared to only 3.4% of Ugandan contacts and no South African contacts. Appreciable percentages of TB contacts with a high likelihood of latent M. tuberculosis infection responded to several novel DosR regulon-encoded M. tuberculosis proteins. In addition to significant similarities in antigen recognition profiles between the three African population groups, there were also disparities, which may stem from genetic differences between both pathogen and host populations. Our findings have implications for the selection of potential TB vaccine candidates and for determining biosignatures of latent M. tuberculosis infection, active TB disease, and protective immunity.
C1 [Black, Gillian F.; Stanley, Kim; Walzl, Gerhard] Univ Stellenbosch, Fac Hlth Sci, Dept Biomed Sci, ZA-7505 Cape Town, South Africa.
   [Thiel, Bonnie A.; Boom, W. Henry] Case Western Reserve Univ, Sch Med, Dept Med, TB Res Unit, Cleveland, OH 44106 USA.
   [Thiel, Bonnie A.; Boom, W. Henry] Univ Hosp Cleveland, Case Med Ctr, Cleveland, OH 44106 USA.
   [Ota, Martin O.; Adegbola, Richard; Hill, Philip C.] MRC, Bacterial Dis Programme, Banjul, Gambia.
   [Parida, Shreemanta K.; Kaufmann, Stefan H. E.] Max Planck Inst Infect Biol, Dept Immunol, D-10117 Berlin, Germany.
   [Boom, W. Henry; Mayanja, Harriet] Makerere Univ, Dept Med, Kampala, Uganda.
   [Dockrell, Hazel M.; Lalor, Maeve K.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   [Franken, Kees L. M. C.; Friggen, Annemiek H.; Klein, Michel R.; Ottenhoff, Tom H. M.] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2300 RC Leiden, Netherlands.
   [Franken, Kees L. M. C.; Friggen, Annemiek H.; Klein, Michel R.; Ottenhoff, Tom H. M.] Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands.
   [Schoolnik, Gary] Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA.
   [Weldingh, Karin] Statens Serum Inst, Dept Infect Dis Immunol, DK-2300 Copenhagen, Denmark.
RP Black, GF (reprint author), Univ Stellenbosch, Fac Hlth Sci, Dept Biomed Sci, Fisan Bldg,Tygerberg Hosp Campus, ZA-7505 Cape Town, South Africa.
EM gfb@sun.ac.za
RI Kaufmann, Stefan HE/I-5454-2014
OI Kaufmann, Stefan HE/0000-0001-9866-8268; Mayanja-Kizza,
   Harriet/0000-0002-9297-6208; Parida, Shreemanta K/0000-0003-2129-6691;
   Dockrell, Hazel/0000-0003-1869-9107; Walzl, Gerhard/0000-0003-2487-125X;
   van der Spuy, Gian/0000-0002-9067-5903; Sutherland,
   Jayne/0000-0002-7083-4997
FU Bill and Melinda Gates Foundation through Grand Challenges in Global
   Health (GCGH) [37772]
FX This research is supported by the Bill and Melinda Gates Foundation
   through Grand Challenges in Global Health (GCGH), grant no. 37772.
CR Black GF, 2001, J INFECT DIS, V184, P322, DOI 10.1086/322042
   Black GF, 2001, INT J TUBERC LUNG D, V5, P664
   Caccamo N, 2002, J INFECT DIS, V186, P991, DOI 10.1086/344174
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   Demissie A, 2006, CLIN VACCINE IMMUNOL, V13, P179, DOI 10.1128/CVI.13.2.179-186.2006
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Flores L, 2007, J CLIN MICROBIOL, V45, P3393, DOI 10.1128/JCM.00828-07
   Franken KLMC, 2000, PROTEIN EXPRES PURIF, V18, P95, DOI 10.1006/prep.1999.1162
   Geluk A, 2007, INFECT IMMUN, V75, P2914, DOI 10.1128/IAI.01990-06
   Hammond AS, 2005, CLIN EXP IMMUNOL, V140, P109, DOI 10.1111/j.1365-2249.2005.02751.x
   Hesseling AC, 2007, VACCINE, V25, P14, DOI 10.1016/j.vaccine.2006.07.020
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Honaker RW, 2008, INFECT IMMUN, V76, P2587, DOI 10.1128/IAI.01235-07
   Hougardy JM, 2007, AM J RESP CRIT CARE, V176, P409, DOI 10.1164/rccm.200701-084OC
   Kaufmann SHE, 2007, NAT REV MICROBIOL, V5, P491, DOI 10.1038/nrmicro1688
   Lalor MK, 2009, J INFECT DIS, V199, P795, DOI 10.1086/597069
   Lalvani A, 2008, J INFECT DIS, V197, P941, DOI 10.1086/529049
   Leyten EMS, 2006, MICROBES INFECT, V8, P2052, DOI 10.1016/j.micinf.2006.03.018
   Lin MY, 2007, INFECT IMMUN, V75, P3523, DOI 10.1128/IAI.01999-06
   Lombard Z, 2006, TISSUE ANTIGENS, V67, P97, DOI 10.1111/j.1399-0039.2006.00530.x
   Moise Leonard, 2007, Med Health R I, V90, P301
   OTTENHOFF THM, 1988, J EXP MED, V168, P1947, DOI 10.1084/jem.168.5.1947
   OTTENHOFF THM, 2009, EUR J IMMUN IN PRESS
   Parrish NM, 1998, TRENDS MICROBIOL, V6, P107, DOI 10.1016/S0966-842X(98)01216-5
   Rojas RE, 2005, J INFECT DIS, V192, P1806, DOI 10.1086/497146
   Roupie V, 2007, INFECT IMMUN, V75, P941, DOI 10.1128/IAI.01137-06
   Rustad TR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001502
   Sander C, 2007, CLIN EXP IMMUNOL, V147, P401, DOI 10.1111/j.1365-2249.2006.03306.x
   Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846
   Schuck SD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005590
   Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498
   Skjot RLV, 2000, INFECT IMMUN, V68, P214
   Smith SM, 2000, J IMMUNOL, V165, P7088
   Timm J, 2003, P NATL ACAD SCI USA, V100, P14321, DOI 10.1073/pnas.2436197100
   Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205
   World Health Organization, 2008, GLOB TUB CONTR SURV
   Wilkinson KA, 2005, J IMMUNOL, V174, P4237
   Wilkinson RJ, 1998, SCAND J IMMUNOL, V48, P403
   Yuan Ying, 1996, Journal of Bacteriology, V178, P4484
NR 39
TC 102
Z9 118
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD AUG
PY 2009
VL 16
IS 8
BP 1203
EP 1212
DI 10.1128/CVI.00111-09
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 476PX
UT WOS:000268455800015
PM 19553548
OA No
DA 2017-08-15
ER

PT J
AU Clark, TG
   Fry, AE
   Auburn, S
   Campino, S
   Diakite, M
   Green, A
   Richardson, A
   Teo, YY
   Small, K
   Wilson, J
   Jallow, M
   Sisay-Joof, F
   Pinder, M
   Sabeti, P
   Kwiatkowski, DP
   Rockett, KA
AF Clark, Taane G.
   Fry, Andrew E.
   Auburn, Sarah
   Campino, Susana
   Diakite, Mahamadou
   Green, Angela
   Richardson, Anna
   Teo, Yik Y.
   Small, Kerrin
   Wilson, Jonathan
   Jallow, Muminatou
   Sisay-Joof, Fatou
   Pinder, Margaret
   Sabeti, Pardis
   Kwiatkowski, Dominic P.
   Rockett, Kirk A.
TI Allelic heterogeneity of G6PD deficiency in West Africa and severe
   malaria susceptibility
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE genetic association study; G6PD deficiency; Plasmodium falciparum;
   allelic heterogeneity
ID GLUCOSE-6-PHOSPHATE DEHYDROGENASE; PLASMODIUM-FALCIPARUM;
   NATURAL-SELECTION; COSTA-RICA; RED-CELLS; CHILDREN; ASSOCIATION;
   RESISTANCE; VARIANT; DISEQUILIBRIUM
AB Several lines of evidence link glucose-6-phosphate dehydrogenase ( G6PD) deficiency to protection from severe malaria. Early reports suggested most G6PD deficiency in sub-Saharan Africa was because of the 202A/376G G6PD A-allele, and recent association studies of G6PD deficiency have employed genotyping as a convenient way to determine enzyme status. However, further work has suggested that other G6PD deficiency alleles are relatively common in some regions of West Africa. To investigate the consequences of unrecognized allelic heterogeneity on association studies, in particular studies of G6PD deficiency and malaria, we carried out a case-control analysis of 2488 Gambian children with severe malaria and 3875 controls. No significant association was found between severe malaria and the 202A/376G G6PD A-allele when analyzed alone, but pooling 202A/376G with other deficiency alleles revealed the signal of protection ( male odds ratio ( OR) 0.77, 95% CI 0.62-0.95, P = 0.016; female OR 0.71, 95% CI 0.56-0.89, P = 0.004). We have identified the 968C mutation as the most common G6PD A-allele in The Gambia. Our results highlight some of the consequences of allelic heterogeneity, particularly the increased type I error. They also suggest that G6PD-deficient male hemizygotes and female heterozygotes are protected from severe malaria. European Journal of Human Genetics ( 2009) 17, 1080-1085; doi:10.1038/ejhg.2009.8; published online 18 February 2009
C1 [Clark, Taane G.; Fry, Andrew E.; Diakite, Mahamadou; Green, Angela; Richardson, Anna; Teo, Yik Y.; Small, Kerrin; Wilson, Jonathan; Kwiatkowski, Dominic P.; Rockett, Kirk A.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Clark, Taane G.; Auburn, Sarah; Campino, Susana; Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Cambridge, England.
   [Jallow, Muminatou; Sisay-Joof, Fatou; Pinder, Margaret] MRC Labs, Banjul, Fajara, Gambia.
   [Sabeti, Pardis] Broad Inst, Cambridge, MA USA.
   [Sabeti, Pardis] Harvard Univ, Ctr Syst Biol, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.
RP Clark, TG (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
EM tgc@well.ox.ac.uk
OI Small, Kerrin/0000-0003-4566-0005; Kwiatkowski,
   Dominic/0000-0002-5023-0176; Auburn, Sarah/0000-0002-4638-536X
FU Bill and Melinda Gates Foundation; Wellcome Trust [GR074586AIA]; Medical
   Research Council UK; International Atomic Energy Agency (IAEA)
FX The authors thank the patients from the Gambian study population, as
   well as the many investigators involved in the original study for their
   contributions. The authors also thank Bronwyn MacInnis, Malcolm
   Molyneux, Shivang Shah and Tom Williams for useful comments on this
   paper. Funding for this work came from the Bill and Melinda Gates
   Foundation, Wellcome Trust, and Medical Research Council UK. AEF was
   funded by a Wellcome Trust Clinical Research Training Fellowship
   (GR074586AIA). MD was supported by a training fellowship from the
   International Atomic Energy Agency (IAEA).
CR ALLISON AC, 1961, BRIT MED J, V1, P1346
   BEUTLER E, 1991, HUM GENET, V87, P462
   BEUTLER E, 1989, BLOOD, V74, P2550
   BIENZLE U, 1972, LANCET, V1, P107
   BUTLER T, 1973, MIL MED, V138, P153
   Cappadoro M, 1998, BLOOD, V92, P2527
   Clark TG, 2009, J INFECT DIS, V199, P569, DOI 10.1086/596320
   De Araujo C, 2006, HAEMATOL-HEMATOL J, V91, P262
   GILLES HM, 1967, LANCET, V1, P138
   Gonzalez JM, 2005, ENVIRON MICROBIOL, V7, P1024, DOI 10.1111/j.1462-2920.2005.00779.x
   GREENE LS, 1993, YEARB PHYS ANTHROPOL, V36, P153
   Guindo A, 2007, PLOS MED, V4, P516, DOI 10.1371/journal.pmed.0040066
   HIRONO A, 1988, P NATL ACAD SCI USA, V85, P3951, DOI 10.1073/pnas.85.11.3951
   KAR S, 1992, HUM BIOL, V64, P187
   Kwiatkowski DP, 2005, AM J HUM GENET, V77, P171, DOI 10.1086/432519
   Longmate JA, 2001, AM J HUM GENET, V68, P1229, DOI 10.1086/320106
   LUZZATTO L, 1995, EXPERIENTIA, V51, P206, DOI 10.1007/BF01931096
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Mason PJ, 2007, BLOOD REV, V21, P267, DOI 10.1016/j.blre.2007.05.002
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Ross P, 1998, NAT BIOTECHNOL, V16, P1347, DOI 10.1038/4328
   Ruwende C, 1998, J MOL MED-JMM, V76, P581, DOI 10.1007/s001090050253
   RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0
   SAENZ GF, 1984, ACTA HAEMATOL-BASEL, V72, P37
   Scriver C, 1995, GLUCOSE 6 PHOSPHATE
   Slager SL, 2000, GENET EPIDEMIOL, V18, P143, DOI 10.1002/(SICI)1098-2272(200002)18:2<143::AID-GEPI4>3.0.CO;2-5
   Terwilliger JD, 2006, EUR J HUM GENET, V14, P426, DOI 10.1038/sj.ejhg.5201583
   Tishkoff SA, 2001, SCIENCE, V293, P455, DOI 10.1126/science.1061573
   Tripathy V, 2007, J POSTGRAD MED, V53, P193
   USANGA EA, 1985, NATURE, V313, P793, DOI 10.1038/313793a0
   World Health Organization, 1990, T R SOC TROP MED S2, V84, P1
   Wilson JN, 2005, GENES IMMUN, V6, P462, DOI 10.1038/sj.gene.6364227
   ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847
NR 33
TC 57
Z9 59
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD AUG
PY 2009
VL 17
IS 8
BP 1080
EP 1085
DI 10.1038/ejhg.2009.8
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 474DD
UT WOS:000268261700015
PM 19223928
OA No
DA 2017-08-15
ER

PT J
AU Onyekwelu, EU
AF Onyekwelu, E. U.
TI Cranial computer assisted tomographic features in hydrocephalus:
   implications for the involved aetiopathogenic mechanisms/management
   options
SO VIRCHOWS ARCHIV
LA English
DT Meeting Abstract
C1 [Onyekwelu, E. U.] Royal Victoria Teaching Hosp, Banjul, Greater Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0945-6317
J9 VIRCHOWS ARCH
JI Virchows Arch.
PD AUG
PY 2009
VL 455
BP 436
EP 437
PG 2
WC Pathology
SC Pathology
GA 474TT
UT WOS:000268307701188
OA No
DA 2017-08-15
ER

PT J
AU Jarju, LBS
   Fillinger, U
   Green, C
   Louca, V
   Majambere, S
   Lindsay, SW
AF Jarju, Lamin B. S.
   Fillinger, Ulrike
   Green, Clare
   Louca, Vasilis
   Majambere, Silas
   Lindsay, Steven W.
TI Agriculture and the promotion of insect pests: rice cultivation in river
   floodplains and malaria vectors in The Gambia
SO MALARIA JOURNAL
LA English
DT Article
ID MOSQUITO SPECIES DIPTERA; WESTERN KENYA; ANOPHELES-ARABIENSIS;
   SPATIAL-DISTRIBUTION; GAMBUSIA-AFFINIS; AQUATIC INSECTS; IMMATURE
   STAGES; BREEDING SITES; COTE-DIVOIRE; FIELDS
AB Background: Anthropogenic modification of natural habitats can create conditions in which pest species associated with humans can thrive. In order to mitigate for these changes, it is necessary to determine which aspects of human management are associated with the promotion of those pests. Anopheles gambiae, the main Africa malaria vector, often breeds in rice fields. Here the impact of the ancient practice of 'swamp rice' cultivation, on the floodplains of the Gambia River, on the production of anopheline mosquitoes was investigated.
   Methods: Routine surveys were carried out along 500 m transects crossing rice fields from the landward edge of the floodplains to the river during the 2006 rainy season. Aquatic invertebrates were sampled using area samplers and emergence traps and fish sampled using nets. Semi-field experiments were used to investigate whether nutrients used for swamp rice cultivation affected mosquito larval abundance.
   Results: At the beginning of the rainy season rice is grown on the landward edge of the floodplain; the first area to flood with fresh water and one rich in cattle dung. Later, rice plants are transplanted close to the river, the last area to dry out on the floodplain. Nearly all larval and adult stages of malaria vectors were collected 0-100 m from the landward edge of the floodplains, where immature rice plants were grown. These paddies contained stagnant freshwater with high quantities of cattle faeces. Semi-field studies demonstrated that cattle faeces nearly doubled the number of anopheline larvae compared with untreated water.
   Conclusion: Swamp rice cultivation creates ideal breeding sites for malaria vectors. However, only those close to the landward edge harboured vectors. These sites were productive since they were large areas of standing freshwater, rich in nutrients, protected from fish, and situated close to human habitation, where egg-laying mosquitoes from the villages had short distances to fly. The traditional practice of 'swamp rice' cultivation uses different bodies of water on the floodplains to cultivate rice during the rainy season. A consequence of this cultivation is the provizion of ideal conditions for malaria vectors to thrive. As the demand for locally-produced rice grows, increased rice farming will generate great numbers of vectors; emphasizing the need to protect local communities against malaria.
C1 [Green, Clare; Louca, Vasilis; Lindsay, Steven W.] Univ Durham, Sch Biol & Biomed Sci, Durham, England.
   [Jarju, Lamin B. S.] Natl Malaria Control Programme, Banjul, Gambia.
   [Fillinger, Ulrike] London Sch Hyg & Trop Med, Dis Control & Vector Biol Unit, London WC1, England.
   [Majambere, Silas] Ifakara Hlth Inst, Dar Es Salaam, Tanzania.
RP Lindsay, SW (reprint author), Univ Durham, Sch Biol & Biomed Sci, Durham, England.
EM lbsjarju@yahoo.ac.uk; ulrike.fillinger@lshtm.ac.uk;
   clare.green@ucl.ac.uk; Vasilis.louca@durham.ac.uk; smajambere@ihi.or.tz;
   Steve.Lindsay@lshtm.ac.uk
OI Fillinger, Ulrike/0000-0002-4037-431X
FU National Institutes of Health [1 UO1 AI058250-01]
FX We thank the people of Tamba Koto for their cooperation during the
   study. We are also grateful to Pierre Gomes for providing the rainfall
   data, for the support of the Divizional Health Management team and the
   assistance of the MRC's Laboratories in The Gambia. The study received
   financial support from the National Institutes of Health Grant 1 UO1
   AI058250-01.
CR AGYENSAMPONG M, 1994, COLLOQ SEMI, P185
   ANDIS MD, 1984, MOSQ NEWS, V44, P371
   AUDIBERT M, 1990, AM J TROP MED HYG, V42, P550
   Bogh C, 2003, B ENTOMOL RES, V93, P279, DOI 10.1079/BER2003239
   Bogh C, 2007, AM J TROP MED HYG, V76, P875
   CHANDLER JA, 1975, B ENTOMOL RES, V65, P295
   Clesceri L. C., 1998, STANDARD METHODS EXA
   CUTHBERT ID, 1992, LIMNOL OCEANOGR, V37, P1319
   DAVIES IJ, 1984, IBP HDB, V17, P161
   Diuk-Wasser MA, 2007, AM J TROP MED HYG, V76, P869
   Doannio JMC, 2002, B SOC PATHOL EXOT, V95, P11
   Dossou-Yovo J, 1998, B SOC PATHOL EXOT, V91, P327
   Faye O, 1995, ANN SOC BELG MED TR, V75, P179
   Ferree MA, 2001, WATER RES, V35, P327, DOI 10.1016/S0043-1354(00)00222-0
   Fillinger U, 2003, TROP MED INT HEALTH, V8, P37, DOI 10.1046/j.1365-3156.2003.00979.x
   FILLINGER U, 2009, MALARIA J, V8, pE62
   Fillinger U, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-62
   GBAKIMA AA, 1994, PUBLIC HEALTH, V108, P149, DOI 10.1016/S0033-3506(05)80020-4
   Gillies M. T., 1968, ANOPHELINAE AFRICA S
   Gimnig JE, 2002, J MED ENTOMOL, V39, P162, DOI 10.1603/0022-2585-39.1.162
   Gimnig JE, 2001, J MED ENTOMOL, V38, P282, DOI 10.1603/0022-2585-38.2.282
   HOMSKI D, 1994, HYDROBIOLOGIA, V284, P137, DOI 10.1007/BF00006885
   Ijumba JN, 2001, MED VET ENTOMOL, V15, P1, DOI 10.1046/j.1365-2915.2001.00279.x
   Klinkenberg E, 2005, EMERG INFECT DIS, V11, P1290
   Klinkenberg E, 2003, ACTA TROP, V85, P71, DOI 10.1016/S0001-706X(02)00254-1
   Lacey L.A., 1990, J AM MOSQ CONTROL S2, V6, P1
   LESAGE L, 1979, ENTOMOL NEWS, V90, P65
   LINDEN AL, 1990, J AM MOSQUITO CONTR, V6, P115
   LINDSAY SW, 1991, J TROP MED HYG, V94, P313
   Louca V., 2008, FRESH BIOL, V54, P254
   LOUCA V, ROLE FISH P IN PRESS
   Majambere S, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-76
   Majambere S, 2008, AM J TROP MED HYG, V79, P19
   Minakawa N, 1999, AM J TROP MED HYG, V61, P1010
   Muirhead-Thomson R C, 1951, MOSQUITO BEHAV RELAT
   MUKIAMA TK, 1989, INSECT SCI APPL, V10, P55
   Mutero CM, 2000, ACTA TROP, V76, P253, DOI 10.1016/S0001-706X(00)00109-1
   Muturi EJ, 2007, J MED ENTOMOL, V44, P336, DOI 10.1603/0022-2585(2007)44[336:MSSAPF]2.0.CO;2
   Muturi EJ, 2006, J VECTOR ECOL, V31, P129, DOI 10.3376/1081-1710(2006)31[129:MSDAAI]2.0.CO;2
   Mwangangi J, 2006, J VECTOR ECOL, V31, P245, DOI 10.3376/1081-1710(2006)31[245:DOISOA]2.0.CO;2
   Oerke EC, 2006, J AGR SCI, V144, P31, DOI 10.1017/S0021859605005708
   OOMEN JMV, 1988, PUBLICATION INT I LA, V45
   PARKS M, 1799, TRAVELS INTERIOR DIS
   Paugy D, 2003, FRESH BRACKISH WATER
   ROBERT V, 1992, ACTA TROP, V52, P201, DOI 10.1016/0001-706X(92)90036-W
   Sanford MR, 2005, J MED ENTOMOL, V42, P766, DOI 10.1603/0022-2585(2005)042[0766:EOINEO]2.0.CO;2
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   Service M., 1993, MOSQUITO ECOLOGY FIE
   SERVICE MW, 1977, J MED ENTOMOL, V13, P535
   SERVICE MW, 1989, PARASITOL TODAY, V5, P162, DOI 10.1016/0169-4758(89)90083-5
   SNOW WF, 1983, J TROP MED HYG, V86, P237
   Southwood TRE, 1978, ECOLOGICAL METHODS P
   Staedke SG, 2003, AM J TROP MED HYG, V69, P244
   Stagliano DM, 1998, J N AM BENTHOL SOC, V17, P37, DOI 10.2307/1468050
   SURTEES G, 1970, T ROY SOC TROP MED H, V64, P511, DOI 10.1016/0035-9203(70)90071-4
   TRAPE JF, 1992, AM J TROP MED HYG, V47, P181
   WEBB JLA, 1992, AFR AFFAIRS, V91, P543
   *WHO, 2005, US FISH MOSQ CONTR
NR 58
TC 10
Z9 10
U1 1
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUL 27
PY 2009
VL 8
AR 170
DI 10.1186/1475-2875-8-170
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 495EG
UT WOS:000269872800001
PM 19635125
OA gold
DA 2017-08-15
ER

PT J
AU Erskine, J
AF Erskine, Jamie
TI Home management of malaria
SO LANCET
LA English
DT Letter
C1 Sibanor Hlth Ctr, Sibanor, Gambia.
RP Erskine, J (reprint author), Sibanor Hlth Ctr, Sibanor, Gambia.
EM jamieerskine@doctors.org.uk
CR Kallander K, 2009, LANCET, V373, P1582, DOI 10.1016/S0140-6736(09)60359-7
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD JUL 25
PY 2009
VL 374
IS 9686
BP 289
EP 290
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 477GW
UT WOS:000268508200019
PM 19632487
OA No
DA 2017-08-15
ER

PT J
AU Matee, MI
   Manyando, C
   Ndumbe, PM
   Corrah, T
   Jaoko, WG
   Kitua, AY
   Ambene, HPA
   Ndounga, M
   Zijenah, L
   Ofori-Adjei, D
   Agwale, S
   Shongwe, S
   Nyirenda, T
   Makanga, M
AF Matee, Mecky I.
   Manyando, Christine
   Ndumbe, Peter M.
   Corrah, Tumani
   Jaoko, Walter G.
   Kitua, Andrew Y.
   Ambene, Herman P. A.
   Ndounga, Mathieu
   Zijenah, Lynn
   Ofori-Adjei, David
   Agwale, Simon
   Shongwe, Steven
   Nyirenda, Thomas
   Makanga, Michael
TI European and Developing Countries Clinical Trials Partnership (EDCTP):
   the path towards a true partnership
SO BMC PUBLIC HEALTH
LA English
DT Article
AB Background: European and Developing Countries Clinical Trials Partnership (EDCTP) was founded in 2003 by the European Parliament and Council. It is a partnership of 14 European Union (EU) member states, Norway, Switzerland, and Developing Countries, formed to fund acceleration of new clinical trial interventions to fight the human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), malaria and tuberculosis (TB) in the sub-Saharan African region. EDCTP seeks to be synergistic with other funding bodies supporting research on these diseases.
   Methods: EDCTP promotes collaborative research supported by multiple funding agencies and harnesses networking expertise across different African and European countries. EDCTP is different from other similar initiatives. The organisation of EDCTP blends important aspects of partnership that includes ownership, sustainability and responds to demand-driven research. The Developing Countries Coordinating Committee (DCCC); a team of independent scientists and representatives of regional health bodies from sub-Saharan Africa provides advice to the partnership. Thus EDCTP reflects a true partnership and the active involvement and contribution of these African scientists ensures joint ownership of the EDCTP programme with European counterparts.
   Results: The following have been the major achievements of the EDCTP initiative since its formation in 2003; i) increase in the number of participating African countries from two to 26 in 2008 ii) the cumulative amount of funds spent on EDCTP projects has reached (sic) 150 m, iii) the cumulative number of clinical trials approved has reached 40 and iv) there has been a significant increase number and diversity in capacity building activities.
   Conclusion: While we recognise that EDCTP faced enormous challenges in its first few years of existence, the strong involvement of African scientists and its new initiatives such as unconditional funding to regional networks of excellence in sub-Saharan Africa is envisaged to lead to a sustainable programme. Current data shows that the number of projects supported by EDCTP is increasing. DCCC proposes that this success story of true partnership should be used as model by partners involved in the fight against other infectious diseases of public health importance in the region.
C1 [Matee, Mecky I.] Muhimbili Univ Hlth & Allied Sci, Dept Microbiol & Immunol, Dar Es Salaam, Tanzania.
   [Manyando, Christine] Trop Dis Res Ctr, Ndola, Zambia.
   [Ndumbe, Peter M.] Univ Buea, Fac Hlth Sci, Buea, Cameroon.
   [Corrah, Tumani] MRC, Banjul, Gambia.
   [Jaoko, Walter G.] Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya.
   [Kitua, Andrew Y.] Natl Inst Med Res, Dar Es Salaam, Tanzania.
   [Ambene, Herman P. A.] Org Coordinat Lutte Endemies Afrique Cent OCEAC, Yaounde, Cameroon.
   [Ndounga, Mathieu] Ctr Etud Resources Vegetales, Brazzaville, Congo.
   [Zijenah, Lynn] Univ Zimbabwe, Sch Med, Dept Immunol, Harare, Zimbabwe.
   [Ofori-Adjei, David] Univ Ghana, Coll Hlth Sci, Noguchi Mem Inst Med Res, Accra, Ghana.
   [Agwale, Simon] Innovat Biotech, Keffi, Nasarawa State, Nigeria.
   [Shongwe, Steven] WHO Reg Off E, Cent & Sourthen Africa, Arusha, Tanzania.
   [Nyirenda, Thomas; Makanga, Michael] EDCTP Africa Off, Cape Town, South Africa.
RP Matee, MI (reprint author), Muhimbili Univ Hlth & Allied Sci, Dept Microbiol & Immunol, POB 65001, Dar Es Salaam, Tanzania.
EM mmateemi@yahoo.com; cmanyando@yahoo.com; pndumbe@yahoo.com;
   tcorrah@mrc.gm; wjaoko@kaviuon.org; akitua@nimr.or.tz;
   hpaawono@yahoo.fr; ngoualandounga@yahoo.fr; sodai@mweb.co.zw;
   Dofori-Adjei@noguchi.mimcom.org; sagwale@innovativebiotechng.com;
   sshongwe@yahoo.com; nyirenda@edctp.org; makanga@edctp.org
OI Ofori-Adjei, David/0000-0003-1912-4188
CR *COMM EUR COMM, 2004, 2 COMM EUR COMM
   *ECA, AB DECL HIV AIDS TUB
   *ECA, AFR DEV FOR 2000 REP
   Global Forum for Health Research, 2004, 10 90 REP HLTH RES 2
   LANSANG MAD, 1994, ACTA TROP, V57, P139, DOI 10.1016/0001-706X(94)90004-3
   MEDAGLINI D, 2003, VACCINE, V21, P116
   Olliaro Piero, 2004, J HIV Ther, V9, P53
   The PLoS Medicine Editors, 2004, PLOS MED, V1, pe71
   2007, EUROPE DEV COUNTRIES
   2006, UNIVERSAL ACCESS HIV
   EUROPE DEV COUNTRIES
NR 11
TC 20
Z9 20
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
   4LB, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD JUL 20
PY 2009
VL 9
AR 249
DI 10.1186/1471-2458-9-249
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 480WL
UT WOS:000268767600001
PM 19619283
OA gold
DA 2017-08-15
ER

PT J
AU Fry, AE
   Ghansa, A
   Small, KS
   Palma, A
   Auburn, S
   Diakite, M
   Green, A
   Campino, S
   Teo, YY
   Clark, TG
   Jeffreys, AE
   Wilson, J
   Jallow, M
   Sisay-Joof, F
   Pinder, M
   Griffiths, MJ
   Peshu, N
   Williams, TN
   Newton, CR
   Marsh, K
   Molyneux, ME
   Taylor, TE
   Koram, KA
   Oduro, AR
   Rogers, WO
   Rockett, KA
   Sabeti, PC
   Kwiatkowski, DP
AF Fry, Andrew E.
   Ghansa, Anita
   Small, Kerrin S.
   Palma, Alejandro
   Auburn, Sarah
   Diakite, Mahamadou
   Green, Angela
   Campino, Susana
   Teo, Yik Y.
   Clark, Taane G.
   Jeffreys, Anna E.
   Wilson, Jonathan
   Jallow, Muminatou
   Sisay-Joof, Fatou
   Pinder, Margaret
   Griffiths, Michael J.
   Peshu, Norbert
   Williams, Thomas N.
   Newton, Charles R.
   Marsh, Kevin
   Molyneux, Malcolm E.
   Taylor, Terrie E.
   Koram, Kwadwo A.
   Oduro, Abraham R.
   Rogers, William O.
   Rockett, Kirk A.
   Sabeti, Pardis C.
   Kwiatkowski, Dominic P.
TI Positive selection of a CD36 nonsense variant in sub-Saharan Africa, but
   no association with severe malaria phenotypes
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; INTERCELLULAR-ADHESION MOLECULE-1;
   CELL-LINE PANEL; HUMAN GENOME; CYTOADHERENCE CHARACTERISTICS; HAPLOTYPE
   RECONSTRUCTION; INFECTED ERYTHROCYTES; ENDOTHELIAL-CELLS;
   NATURAL-SELECTION; GENOTYPE DATA
AB The prevalence of CD36 deficiency in East Asian and African populations suggests that the causal variants are under selection by severe malaria. Previous analysis of data from the International HapMap Project indicated that a CD36 haplotype bearing a nonsense mutation (T1264G; rs3211938) had undergone recent positive selection in the Yoruba of Nigeria. To investigate the global distribution of this putative selection event, we genotyped T1264G in 3420 individuals from 66 populations. We confirmed the high frequency of 1264G in the Yoruba (26%). However, the 1264G allele is less common in other African populations and absent from all non-African populations without recent African admixture. Using long-range linkage disequilibrium, we studied two West African groups in depth. Evidence for recent positive selection at the locus was demonstrable in the Yoruba, although not in Gambians. We screened 70 variants from across CD36 for an association with severe malaria phenotypes, employing a case-control study of 1350 subjects and a family study of 1288 parent-offspring trios. No marker was significantly associated with severe malaria. We focused on T1264G, genotyping 10 922 samples from four African populations. The nonsense allele was not associated with severe malaria (pooled allelic odds ratio 1.0; 95% confidence interval 0.89-1.12; P = 0.98). These results suggest a range of possible explanations including the existence of alternative selection pressures on CD36, co-evolution between host and parasite or confounding caused by allelic heterogeneity of CD36 deficiency.
C1 [Fry, Andrew E.; Ghansa, Anita; Small, Kerrin S.; Auburn, Sarah; Diakite, Mahamadou; Green, Angela; Campino, Susana; Teo, Yik Y.; Clark, Taane G.; Jeffreys, Anna E.; Wilson, Jonathan; Griffiths, Michael J.; Rockett, Kirk A.; Kwiatkowski, Dominic P.] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Ghansa, Anita; Koram, Kwadwo A.] Noguchi Mem Inst Med Res, Legon, Ghana.
   [Palma, Alejandro; Sabeti, Pardis C.] Broad Inst, Cambridge, MA 02142 USA.
   [Jallow, Muminatou; Sisay-Joof, Fatou; Pinder, Margaret] MRC, Banjul, Gambia.
   [Griffiths, Michael J.; Peshu, Norbert; Williams, Thomas N.; Newton, Charles R.; Marsh, Kevin] Kenya Govt Med Res Ctr, Ctr Geog Med Res Coast, Kilifi, Kenya.
   [Williams, Thomas N.; Marsh, Kevin] John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DS, England.
   [Newton, Charles R.] UCL, Inst Child Hlth, London WC1N 1EH, England.
   [Molyneux, Malcolm E.] Malawi Liverpool Wellcome Trust Programme Clin Tr, Blantyre, Malawi.
   [Molyneux, Malcolm E.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   [Taylor, Terrie E.] Coll Med, Blantyre Malaria Project, Blantyre, Malawi.
   [Taylor, Terrie E.] Michigan State Univ, Dept Internal Med, Coll Osteopath Med, E Lansing, MI 48824 USA.
   [Oduro, Abraham R.] Navrongo Hlth Res Ctr, Navrongo, Ghana.
   [Rogers, William O.] Naval Med Res Unit 2, Jakarta, Indonesia.
   [Sabeti, Pardis C.] Harvard Univ, Ctr Syst Biol, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.
RP Fry, AE (reprint author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
EM afry@well.ox.ac.uk
RI Newton, Charles/C-6222-2009; Newton, 21/B-7578-2014
OI Newton, 21/0000-0002-6999-5507; Small, Kerrin/0000-0003-4566-0005;
   Kwiatkowski, Dominic/0000-0002-5023-0176; Auburn,
   Sarah/0000-0002-4638-536X
FU Medical Research Council [, G0600230, G19/9]; NIAID NIH HHS [AI95363];
   Wellcome Trust [076934, GR074586AIA]
CR Aitman TJ, 2000, NATURE, V405, P1015, DOI 10.1038/35016636
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Amodu OK, 2005, ACTA TROP, V95, P248, DOI 10.1016/j.actatropica.2005.05.011
   ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918
   Ayodo G, 2007, AM J HUM GENET, V81, P234, DOI 10.1086/519221
   Bamshad MJ, 2003, AM J HUM GENET, V72, P578, DOI 10.1086/368061
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497
   Cann HM, 2002, SCIENCE, V296, P261
   Curtis BR, 1996, TRANSFUSION, V36, P331, DOI 10.1046/j.1537-2995.1996.36496226147.x
   Curtis BR, 2002, TRANSFUSION, V42, P1173, DOI 10.1046/j.1537-2995.2002.00176.x
   Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Fry AE, 2008, HUM MOL GENET, V17, P567, DOI 10.1093/hmg/ddm331
   Fry AE, 2006, AM J HUM GENET, V78, P1053, DOI 10.1086/504160
   Gonzalez JM, 2005, ENVIRON MICROBIOL, V7, P1024, DOI 10.1111/j.1462-2920.2005.00779.x
   Gonzalez JR, 2007, BIOINFORMATICS, V23, P644, DOI 10.1093/bioinformatics/btm025
   Heddini A, 2001, INFECT IMMUN, V69, P5849, DOI 10.1128/IAI.69.9.5849-5856.2001
   IKEDA H, 1989, VOX SANG, V57, P213
   KASHIWAGI H, 1995, J CLIN INVEST, V95, P1040, DOI 10.1172/JCI117749
   Kashiwagi H, 2001, HUM GENET, V108, P459, DOI 10.1007/s004390100525
   Laugerette F, 2005, J CLIN INVEST, V115, P3177, DOI 10.1172/JCI25299
   Lepretre F, 2004, DIABETES METAB, V30, P459, DOI 10.1016/S1262-3636(07)70143-X
   Longmate JA, 2001, AM J HUM GENET, V68, P1229, DOI 10.1086/320106
   Love-Gregory L, 2008, HUM MOL GENET, V17, P1695, DOI 10.1093/hmg/ddn060
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   McGilvray ID, 2000, BLOOD, V96, P3231
   Newbold C, 1999, INT J PARASITOL, V29, P927, DOI 10.1016/S0020-7519(99)00049-1
   Newbold C, 1997, AM J TROP MED HYG, V57, P389
   Omi K, 2003, AM J HUM GENET, V72, P364, DOI 10.1086/346091
   Pain A, 2001, P NATL ACAD SCI USA, V98, P1805, DOI 10.1073/pnas.98.4.1805
   Pain A, 2001, LANCET, V357, P1502, DOI 10.1016/S0140-6736(00)04662-6
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Qamar R, 2002, AM J HUM GENET, V70, P1107, DOI 10.1086/339929
   Rogerson SJ, 1999, AM J TROP MED HYG, V61, P467
   Rosenberg NA, 2006, ANN HUM GENET, V70, P841, DOI 10.1111/j.1469-1809.2006.00285.x
   Sabeti PC, 2006, SCIENCE, V312, P1614, DOI 10.1126/science.1124309
   Sabeti PC, 2005, PLOS BIOL, V3, P1963, DOI 10.1371/journal.pbio.0030378
   Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140
   SAVILL J, 1991, CHEST, V99, pS6, DOI 10.1378/chest.99.3_Supplement.6S-a
   Silamut K, 1999, AM J PATHOL, V155, P395, DOI 10.1016/S0002-9440(10)65136-X
   Slager SL, 2000, GENET EPIDEMIOL, V18, P143, DOI 10.1002/(SICI)1098-2272(200002)18:2<143::AID-GEPI4>3.0.CO;2-5
   Smith TG, 2003, INFECT IMMUN, V71, P393, DOI 10.1128/IAI.71.1.393-400.2003
   Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Traore B, 2000, AM J TROP MED HYG, V62, P38
   TURNER GDH, 1994, AM J PATHOL, V145, P1057
   Udomsangpetch R, 1997, J IMMUNOL, V158, P4358
   Urban BC, 2001, P NATL ACAD SCI USA, V98, P8750, DOI 10.1073/pnas.151028698
   URWIJITAROON Y, 1995, TRANSFUSION, V35, P868, DOI 10.1046/j.1537-2995.1995.351096026370.x
   World Health Organization, 1990, T R SOC TROP MED S2, V84, P1
   Yanai H, 2000, THROMB HAEMOSTASIS, V84, P436
   Yanai H, 2007, J MED GENET, V44, P445, DOI 10.1136/jmg.2007.050070
   ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847
NR 56
TC 32
Z9 34
U1 1
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUL 15
PY 2009
VL 18
IS 14
BP 2683
EP 2692
DI 10.1093/hmg/ddp192
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 463OJ
UT WOS:000267441200015
PM 19403559
OA No
DA 2017-08-15
ER

PT J
AU Moore, SE
   Prentice, AM
   Wagatsuma, Y
   Fulford, AJC
   Collinson, AC
   Raqib, R
   Vahter, M
   Persson, LA
   Arifeen, SE
AF Moore, S. E.
   Prentice, A. M.
   Wagatsuma, Y.
   Fulford, A. J. C.
   Collinson, A. C.
   Raqib, R.
   Vahter, M.
   Persson, L. A.
   Arifeen, S. E.
TI Early-life nutritional and environmental determinants of thymic size in
   infants born in rural Bangladesh
SO ACTA PAEDIATRICA
LA English
DT Article
DE Bangladesh; Birth weight; Immunity; Thymus
ID BREAST-FED INFANTS; ARSENIC EXPOSURE; ANTIBODY-RESPONSES; BIRTH-WEIGHT;
   ADULTS BORN; VACCINATION; MORTALITY; PREGNANCY; PAKISTAN; FORMULA
AB The aim was to assess the impact of nutritional status and environmental exposures on infant thymic development in the rural Matlab region of Bangladesh.
   In a cohort of N(max) 2094 infants born during a randomized study of combined interventions to improve maternal and infant health, thymic volume (thymic index, TI) was assessed by ultrasonography at birth and at 8, 24 and 52 weeks of age. Data on birth weight, infant anthropometry and feeding status were also collected.
   At all ages, TI was positively associated with infant weight and strongly associated with the month of measurement. Longer duration of exclusive breastfeeding resulted in a larger TI at 52 weeks. TI at birth and at 8 weeks correlated positively with birth weight, but by 24 and 52 weeks and when adjusted for infant weight this effect was no longer present. Thymic size was not affected by pre-natal maternal supplementation or by socioeconomic status but was correlated to arsenic exposure during pregnancy.
   In this population of rural Bangladeshi infants, thymic development is influenced by both nutritional and environmental exposures early in life. The long-term functional implications of these findings warrant further investigation.
C1 [Moore, S. E.; Prentice, A. M.; Fulford, A. J. C.] MRC Labs, MRC Keneba, Banjul, Gambia.
   [Collinson, A. C.] Royal Devon & Exeter Hosp Wonford, Directorate Child & Womens Hlth, Exeter, Devon, England.
   [Raqib, R.; Arifeen, S. E.] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
   [Vahter, M.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden.
   [Persson, L. A.] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden.
   [Prentice, A. M.; Fulford, A. J. C.] London Sch Hyg & Trop Med, Nutr & Publ Hlth Intervent Res Unit, Int Nutr Grp, MRC, London WC1, England.
   [Wagatsuma, Y.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Epidemiol, Tsukuba, Ibaraki, Japan.
RP Moore, SE (reprint author), MRC Labs, MRC Keneba, POB 273, Banjul, Gambia.
EM Sophie.Moore@lshtm.ac.uk
OI Raqib, Rubhana/0000-0002-8116-4511
FU UNICEF; Department for International Development (DfID); Swedish
   International Development Cooperation Agency (Sida); United States
   Agency for International Development (USAID); Child Health and Nutrition
   Research Initiative (CHNRI); UK Medical Research Council; Sida and the
   Karolinska Institute
FX We acknowledge the contribution of the families in Matlab participating
   in the MINIMat project. We are grateful to all the staff from the
   MINIMat study and specifically acknowledge the help of Dr Momtaz Begum
   for overseeing the thymic measurements. The MINIMat project has been
   financially supported by UNICEF, the Department for International
   Development (DfID), Swedish International Development Cooperation Agency
   (Sida), the United States Agency for International Development (USAID),
   Government of Japan and the Child Health and Nutrition Research
   Initiative (CHNRI). This sub-study of thymic development was supported
   by the UK Medical Research Council. Arsenic assessments were financed by
   Sida and the Karolinska Institute.
CR Aaby P, 2002, ACTA PAEDIATR, V91, P698, DOI 10.1080/080352502760069142
   Chevalier Philipe, 1994, Journal of Nutritional Immunology, V3, P27, DOI 10.1300/J053v03n01_04
   Collinson AC, 2003, ACTA PAEDIATR, V92, P1014, DOI 10.1080/08035250310004379
   Concha G, 1998, TOXICOL SCI, V44, P185, DOI 10.1093/toxsci/44.2.185
   Fangstrom B, 2008, ENVIRON HEALTH PERSP, V116, P963, DOI 10.1289/ehp.11094
   Fulford AJC, 2006, PAEDIATR PERINAT EP, V20, P251, DOI 10.1111/j.1365-3016.2006.00714.x
   Gwatkin D, 2000, SOCIOECONOMIC DIFFER
   Hasselbalch H, 1999, ACTA RADIOL, V40, P41
   Hasselbalch H, 1996, EUR RADIOL, V6, P700
   Hasselbalch H, 1996, ACTA PAEDIATR, V85, P1029, DOI 10.1111/j.1651-2227.1996.tb14211.x
   IARC, 2004, SOM DRINK WAT DIS CO
   Indrio F, 2007, PEDIATR RES, V62, P98, DOI 10.1203/pdr.0b013e31806772d3
   Jeppesen DL, 2004, PEDIATR ALLERGY IMMU, V15, P127, DOI 10.1111/j.1399-3038.2004.00032.x
   Livak F, 1996, MOL CELL BIOL, V16, P609
   McDade TW, 2001, AM J CLIN NUTR, V74, P543
   Moore SE, 2004, AM J CLIN NUTR, V80, P453
   Moore SE, 2008, VACCINE, V26, P158, DOI 10.1016/j.vaccine.2007.11.007
   Moore SE, 2007, AM J CLIN NUTR, V85, P1075
   Moore SE, 2006, P NUTR SOC, V65, P311, DOI 10.1079/PNS2006503
   Moore SE, 2006, TROP MED INT HEALTH, V11, P1529, DOI 10.1111/j.1365-3156.2006.01700.x
   Ngom PT, 2004, AM J CLIN NUTR, V80, P722
   PARENT G, 1994, AM J CLIN NUTR, V60, P274
   Rahman A, 2007, AM J EPIDEMIOL, V165, P1389, DOI 10.1093/aje/kwm025
   Rahman A, 2009, AM J EPIDEMIOL, V169, P304, DOI 10.1093/aje/kwn332
   Rahman M, 2006, J EPIDEMIOL COMMUN H, V60, P242, DOI 10.1136/jech.2005.040212
   Savino W, 2002, EUR J CLIN NUTR, V56, pS46, DOI 10.1038/sj.ejcn.1601485
   Savino Wilson, 2006, PLoS Pathogens, V2, P472, DOI 10.1371/journal.ppat.0020062
   Vahter ME, 2006, J HEALTH POPUL NUTR, V24, P236
   *WHO, 2001, 224 WHO
   World Health Organization, 2001, GLOB STRAT INF YOUNG
   Yekeler E, 2004, J ULTRAS MED, V23, P1321
NR 31
TC 50
Z9 51
U1 1
U2 9
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0803-5253
J9 ACTA PAEDIATR
JI Acta Paediatr.
PD JUL
PY 2009
VL 98
IS 7
BP 1168
EP 1175
DI 10.1111/j.1651-2227.2009.01292.x
PG 8
WC Pediatrics
SC Pediatrics
GA 453TS
UT WOS:000266636400020
PM 19432828
OA No
DA 2017-08-15
ER

PT J
AU McDermid, JM
   van der Loeff, MFS
   Jaye, A
   Hennig, BJ
   Bates, C
   Todd, J
   Sirugo, G
   Hill, AV
   Whittle, HC
   Prentice, AM
AF McDermid, Joann M.
   van der Loeff, Maarten F. Schim
   Jaye, Assan
   Hennig, Branwen J.
   Bates, Chris
   Todd, Jim
   Sirugo, Giorgio
   Hill, Adrian V.
   Whittle, Hilton C.
   Prentice, Andrew M.
TI Mortality in HIV infection is independently predicted by host iron
   status and SLC11A1 and HP genotypes, with new evidence of a
   gene-nutrient interaction
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HAPTOGLOBIN POLYMORPHISM; FORMERLY NRAMP1;
   SERUM FERRITIN; TRANSFERRIN RECEPTOR; CONTROLLED-TRIAL; ANEMIA;
   TUBERCULOSIS; SUPPLEMENTATION; SURVIVAL
AB Background: Iron-related genes and iron status may independently contribute to variable HIV outcomes. The nature of the biologically plausible gene-nutrient interaction remains unknown.
   Objectives: The objectives were to investigate whether iron-related genotypes and clinically abnormal iron status independently predict mortality in HIV and whether a gene-nutrient interaction exists.
   Design: Baseline plasma, DNA, and clinical data were obtained from 1362 HIV-seropositive Gambian adults followed for 11.5 y to ascertain all-cause mortality. Iron status was estimated on the basis of plasma iron, soluble transferrin receptor (sTfR), ferritin, transferrin, transferrin index, and log(sTfR/ferritin). One haptoglobin (HP) and 5 SLC11A1 (NRAMP1) polymorphisms were genotyped.
   Results: SLC11A1-SLC3 and CAAA polymorphisms were the best independent genetic predictors of mortality [adjusted mortality rate ratio (95% CI)]: SLC3: G/C = 0.59 (95% CI: 0.45, 0.85), CAAA: del/ins = 1.51 (95% CI: 1.10, 2.07). In an adjusted model that included all polymorphisms, SLC1: 199/199, SLC1: other/other, SLC6a:A/A, and CAAA: del/ins were associated with significantly greater mortality, whereas Hp 2-1 and SLC3: G/C were protective. In unadjusted analyses, all biomarker concentrations were significantly associated with mortality. In an extension of previous findings, both low and elevated iron states were associated with mortality, but the nature of the risk was variable, with linear, inversely linear, and U-shaped associations depending on the biomarker. Mortality was significantly lower in HIV-2 than in HIV-1 infection in the presence of abnormal (low or elevated) iron status. A gene-iron interaction was detected (likelihood-ratio test P = 0.018); however, subject numbers restricted category-specific interpretation.
   Conclusions: Iron-related genes, iron status, and their interaction predict mortality in HIV. These findings illustrate the complexity and uncertainty surrounding best practice for managing abnormal iron status and anemia during HIV infection and in regions with a high risk of infection. Am J Clin Nutr 2009; 90: 225-33.
C1 [McDermid, Joann M.] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA.
   [McDermid, Joann M.; Hennig, Branwen J.; Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp,Dept Epidemiol & Populat Hlth, Nutr & Publ Hlth Intervent Res Unit, London WC1, England.
   [van der Loeff, Maarten F. Schim; Jaye, Assan; Sirugo, Giorgio; Whittle, Hilton C.] MRC Labs, Fajara, Gambia.
   [Todd, Jim] London Sch Hyg & Trop Med, Trop Epidemiol Grp, Infect Dis Epidemiol Unit, Dept Epidemiol & Populat Hlth, London WC1, England.
   [Sirugo, Giorgio] Osped San Pietro FBF, Rome, Italy.
   [Hennig, Branwen J.; Hill, Adrian V.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Bates, Chris] Med Res Council Human Nutr Res, Micronutrient Status Res Sect, Cambridge, England.
RP McDermid, JM (reprint author), Cornell Univ, Div Nutr Sci, 310 Savage Hall, Ithaca, NY 14853 USA.
EM jmm585@cornell.edu
RI Hennig, Branwen/M-6444-2014
FU Bristol Myers Squibb Mead Johnson Unrestricted Grant Programme; Canadian
   Institutes for Health Research; Canadian Women's Club Centennial
   Scholarship Fund; Gordon Smith Travel Scholarship; Medical Research
   Council (United Kingdom); Overseas Research Student Awards Scheme;
   Wellcome Trust
FX Supported by the Bristol Myers Squibb Mead Johnson Unrestricted Grant
   Programme, the Canadian Institutes for Health Research, Canadian Women's
   Club Centennial Scholarship Fund, the Gordon Smith Travel Scholarship,
   the Medical Research Council (United Kingdom), and the Overseas Research
   Student Awards Scheme and the Wellcome Trust.
CR Adetifa I, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006736.pub2
   Allen J, 1998, CLIN CHEM, V44, P35
   Arredouani M, 2003, IMMUNOLOGY, V108, P144, DOI 10.1046/j.1365-2567.2003.01569.x
   Blackwell JM, 2001, CELL MICROBIOL, V3, P773, DOI 10.1046/j.1462-5822.2001.00150.x
   Delanghe JR, 1998, AIDS, V12, P1027, DOI 10.1097/00002030-199809000-00009
   FIELDSGARDNER C, 1997, CLIN GUIDE NUTR HIV
   Forbes JR, 2001, TRENDS MICROBIOL, V9, P397, DOI 10.1016/S0966-842X(01)02098-4
   Friis H, 2001, AM J CLIN NUTR, V73, P1066
   Friis Henrik, 2003, JAIDS Journal of Acquired Immune Deficiency Syndromes, V33, P74
   Gibson R., 1990, PRINCIPLES NUTR ASSE
   Gordeuk VR, 2006, HAEMATOL-HEMATOL J, V91, P739
   Kasvosve I, 2000, CLIN CHEM, V46, P1535
   Kasvosve I, 2000, INT J TUBERC LUNG D, V4, P771
   Kasvosve I, 2002, CLIN CHEM LAB MED, V40, P810, DOI 10.1515/CCLM.2002.140
   Khumalo H, 1998, CLIN CHEM, V44, P40
   Kupka R, 2007, J NUTR, V137, P2317
   Langlois MR, 2000, CLIN CHEM, V46, P1619
   Langlois MR, 1997, AM J CLIN NUTR, V66, P606
   Langlois MR, 1996, CLIN CHEM, V42, P1589
   Li HT, 2006, INT J TUBERC LUNG D, V10, P3
   Lundgren JD, 2003, CLIN INFECT DIS, V37, pS297, DOI 10.1086/376909
   McDermid JM, 2007, JAIDS-J ACQ IMM DEF, V46, P498
   McDermid JM, 2006, CLIN SCI, V110, P503, DOI 10.1042/CS20050273
   Mocroft A, 1999, AIDS, V13, P943, DOI 10.1097/00002030-199905280-00010
   Moore RD, 1999, CLIN INFECT DIS, V29, P44, DOI 10.1086/520178
   O'Brien ME, 2005, JAIDS-J ACQ IMM DEF, V40, P219, DOI 10.1097/01.qai.0000166374.16222.a2
   Olsen A, 2006, ANN TROP MED PARASIT, V100, P251, DOI 10.1179/136485906X91486
   Olsen A, 2004, JAIDS-J ACQ IMM DEF, V36, P637, DOI 10.1097/00126334-200405010-00013
   RAWAT R, 2008, PUBLIC HLTH NUTR
   Sahiratmadja E, 2007, BRIT J NUTR, V98, P684, DOI 10.1017/S0007114507742691
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Semba RD, 2007, JAIDS-J ACQ IMM DEF, V45, P298
   Stephenson J, 2002, JAMA-J AM MED ASSOC, V288, P151, DOI 10.1001/jama.288.2.151
   Sullivan PS, 1998, BLOOD, V91, P301
   van der Loeff MFS, 2002, AIDS, V16, P1775
   van der Sande MAB, 2004, JAIDS-J ACQ IMM DEF, V37, P1288, DOI 10.1097/01.qai.0000122708.59121.03
   van der Sande MAB, 2004, AIDS, V18, P1933, DOI 10.1097/00002030-200409240-00009
   Vineis P, 2006, ANN NY ACAD SCI, V1076, P163, DOI 10.1196/annals.1371.060
   Weiss G, 2005, BEST PRACT RES CL HA, V18, P183, DOI 10.1016/j.beha.2004.09.001
   Wyllie S, 2002, MICROBES INFECT, V4, P351, DOI 10.1016/S1286-4579(02)01548-4
   Yano A, 1998, ACTA MED OKAYAMA, V52, P173
   Zaccariotto TR, 2006, J CLIN PATHOL, V59, P550, DOI 10.1136/jcp.2005.027375
NR 42
TC 29
Z9 29
U1 1
U2 2
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JUL 1
PY 2009
VL 90
IS 1
BP 225
EP 233
DI 10.3945/ajcn.2009.27709
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 462RK
UT WOS:000267373200030
PM 19474129
OA No
DA 2017-08-15
ER

PT J
AU Jones, HL
   Jammeh, L
   Ebrim, A
   Bikwe, M
   Owes, S
   Fulford, AJ
   Pettifor, JM
   Prentice, A
AF Jones, H. L.
   Jammeh, L.
   Ebrim, A.
   Bikwe, M.
   Owes, S.
   Fulford, A. J.
   Pettifor, J. M.
   Prentice, A.
TI The prevalence of rickets-like bone deformities in rural Gambian
   children
SO BONE
LA English
DT Meeting Abstract
CT 5th International Conference on Childrens Bone Health
CY JUN 23-26, 2009
CL Cambridge, ENGLAND
C1 [Jones, H. L.; Prentice, A.] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge, England.
   [Jones, H. L.; Jammeh, L.; Ebrim, A.; Bikwe, M.; Owes, S.; Fulford, A. J.; Prentice, A.] MRC Keneba, Keneba, Gambia.
   [Fulford, A. J.] London Sch Hyg & Trop Med, MRC Int Grp, London WC1, England.
   [Pettifor, J. M.] Chris Hani Baragwanath Hosp, MRC, Mineral Metab Res Unit, Dept Paediat, Johannesburg, South Africa.
   [Pettifor, J. M.] Univ Witwatersrand, Johannesburg, South Africa.
RI Pettifor, John/D-5943-2012
OI Pettifor, John/0000-0003-1155-0334
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD JUL
PY 2009
VL 45
BP S83
EP S84
DI 10.1016/j.bone.2009.04.114
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 458PV
UT WOS:000267036900106
OA No
DA 2017-08-15
ER

PT J
AU Jallow, S
   Alabi, A
   Sarge-Njie, R
   Peterson, K
   Whittle, H
   Corrah, T
   Jaye, A
   Cotten, M
   Vanham, G
   McConkey, SJ
   Rowland-Jones, S
   Janssens, W
AF Jallow, Sabelle
   Alabi, Abraham
   Sarge-Njie, Ramu
   Peterson, Kevin
   Whittle, Hilton
   Corrah, Tumani
   Jaye, Assan
   Cotten, Matthew
   Vanham, Guido
   McConkey, Samuel J.
   Rowland-Jones, Sarah
   Janssens, Wouter
TI Virological Response to Highly Active Antiretroviral Therapy in Patients
   Infected with Human Immunodeficiency Virus Type 2 (HIV-2) and in
   Patients Dually Infected with HIV-1 and HIV-2 in The Gambia and
   Emergence of Drug-Resistant Variants
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID PLASMA VIRAL LOAD; PROTEASE INHIBITORS; HIV-2-INFECTED PATIENTS;
   IMMUNOLOGICAL RESPONSE; REVERSE-TRANSCRIPTASE; IMMUNE-RESPONSES;
   GUINEA-BISSAU; POL GENE; MUTATIONS; LOPINAVIR
AB Drug design, antiretroviral therapy (ART), and drug resistance studies have focused almost exclusively on human immunodeficiency virus type 1 (HIV-1), resulting in limited information for patients infected with HIV-2 and for those dually infected with HIV-1 and HIV-2. In this study, 20 patients, 12 infected with HIV- 2 and 8 dually infected with HIV- 1 and HIV- 2, all treated with zidovudine (ZDV), lamivudine (3TC), and lopinavir-ritonavir (LPV/r), were followed up longitudinally for about 3 years. For 19/20 patients, viral loads were reduced to undetectable levels; the patient whose viral load remained detectable reported adverse effects associated with LPV/r that had caused him to stop taking all the drugs. HIV- 2 strains containing mutations in both the protease and the reverse transcriptase gene that may confer drug resistance were observed in two patients with viral rebound, as early as 130 days (4.3 months) after the initiation of therapy. We conclude that the combination of ZDV, 3TC, and LPV/r is able to provide efficient and durable suppression of HIV-1 and HIV-2 for as long as 3 years in HIV-2-infected and dually infected patients. However, the emergence of HIV-1 and HIV-2 strains containing drug-resistant mutations can compromise the efficacy of this highly active ART.
C1 [Jallow, Sabelle; Alabi, Abraham; Sarge-Njie, Ramu; Peterson, Kevin; Whittle, Hilton; Corrah, Tumani; Jaye, Assan; Cotten, Matthew; McConkey, Samuel J.; Rowland-Jones, Sarah] MRC Labs, MRC, Banjul, Gambia.
   [Jallow, Sabelle; Vanham, Guido; Janssens, Wouter] Univ Antwerp, Inst Trop Med, Dept Microbiol, B-2020 Antwerp, Belgium.
   [Vanham, Guido] Univ Antwerp, Dept Biomed Sci, B-2020 Antwerp, Belgium.
   [Rowland-Jones, Sarah] John Radcliffe Hosp, MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
RP Jallow, S (reprint author), MRC Labs, Viral Dis Program, POB 273, Fajara, Gambia.
EM sabelle.jallow@ndm.ox.ac.uk
RI McConkey, Samuel/E-7307-2012
OI McConkey, Samuel/0000-0001-9085-7793
FU Medical Research Council [G0801751]
CR Adje-Toure CA, 2003, AIDS, V17, pS49
   ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462
   ANDREASSON PA, 1993, AIDS, V7, P989
   Berry N, 1998, J Hum Virol, V1, P457
   Bock PJ, 2001, AIDS, V15, pS35, DOI 10.1097/00002030-200100005-00006
   Brandin E, 2003, AIDS RES HUM RETROV, V19, P543, DOI 10.1089/088922203322230905
   Brower ET, 2008, CHEM BIOL DRUG DES, V71, P298, DOI [10.1111/j.1747-0285.2008.00647.x, 10.1111/j.1747.0285.2008.00647.x]
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   Colson P, 2005, J MED VIROL, V75, P381, DOI 10.1002/jmv.20296
   Colson P, 2004, J CLIN MICROBIOL, V42, P570, DOI 10.1128/JCM.42.2.570-577.2004
   COURPOTIN C, 1994, PEDIATR INFECT DIS J, V13, P502
   Damond F, 2005, J CLIN MICROBIOL, V43, P484, DOI 10.1128/JCM.43.1.484-487.2005
   Damond F, 2008, AIDS, V22, P665, DOI 10.1097/QAD.0b013e3282f51203
   DASILVA BF, 2005, 10 EUR AIDS C
   Descamps D, 1997, J VIROL, V71, P8893
   Friend J, 2004, AIDS, V18, P1965, DOI 10.1097/00002030-200409240-00016
   Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102
   Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101
   Hansmann A, 2005, JAIDS-J ACQ IMM DEF, V38, P335
   Hightower Maia, 2003, Braz J Infect Dis, V7, P7, DOI 10.1590/S1413-86702003000100002
   Holmgren B, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-85
   Isaka Y, 2001, ARCH VIROL, V146, P743, DOI 10.1007/s007050170143
   Jallow S, 2007, J CLIN MICROBIOL, V45, P1565, DOI 10.1128/JCM.02220-06
   Jallow S, 2006, AIDS, V20, P1455, DOI 10.1097/01.aids.0000233582.64467.8e
   Jaye A, 2004, J INFECT DIS, V189, P498, DOI 10.1086/381185
   Johnson Victoria A, 2008, Top HIV Med, V16, P62
   Johnson Victoria A, 2006, Top HIV Med, V14, P125
   Kagan RM, 2005, PROTEIN SCI, V14, P1870, DOI 10.1110/ps.051347405
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   Kaye S, 2003, CLIN CHEM, V49, P325, DOI 10.1373/49.2.325
   Kempf DJ, 2002, ANTIVIR THER, V7, P165
   Kuritzkes DR, 2004, JAIDS-J ACQ IMM DEF, V36, P600, DOI 10.1097/00126334-200405010-00008
   Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552
   MacNeil A, 2007, J VIROL, V81, P5325, DOI 10.1128/JVI.02625-06
   Manasa J, 2007, CLIN VACCINE IMMUNOL, V14, P293, DOI 10.1128/CVI.00416-06
   Mandy Francis F, 2003, MMWR Recomm Rep, V52, P1
   Masquelier B, 2002, ANTIMICROB AGENTS CH, V46, P2926, DOI 10.1128/AAC.46.9.2926-2932.2002
   Masse S, 2007, ANTIMICROB AGENTS CH, V51, P3075, DOI 10.1128/AAC.00146-07
   Mo HM, 2005, J VIROL, V79, P3329, DOI 10.1128/JVI.79.6.3329-3338.2005
   MOST J, 1994, LANCET, V344, P1572, DOI 10.1016/S0140-6736(94)90380-8
   Mullins C, 2004, CLIN INFECT DIS, V38, P1771, DOI 10.1086/421390
   Nkengasong JN, 2004, AIDS REV, V6, P4
   Ntemgwa M, 2007, ANTIMICROB AGENTS CH, V51, P604, DOI 10.1128/AAC.00870-06
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pichova I, 1997, Leukemia, V11 Suppl 3, P120
   Pomerantz RJ, 2003, NAT MED, V9, P867, DOI 10.1038/nm0703-867
   Popper SJ, 1999, J INFECT DIS, V180, P1116, DOI 10.1086/315010
   Poveda E, 2004, AIDS RES HUM RETROV, V20, P347, DOI 10.1089/088922204322996590
   Rodes B, 2006, J ANTIMICROB CHEMOTH, V57, P709, DOI 10.1093/jac/dkl034
   Rodes B, 2000, J CLIN MICROBIOL, V38, P1370
   Schutten M, 2000, NEW ENGL J MED, V342, P1758, DOI 10.1056/NEJM200006083422317
   SHAHARABANY M, 1992, J BIOL CHEM, V267, P3674
   TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675
   van der Loeff MFS, 1999, AIDS, V13, pS69
   van der Loeff MFS, 2002, AIDS, V16, P1775
NR 55
TC 25
Z9 26
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUL
PY 2009
VL 47
IS 7
BP 2200
EP 2208
DI 10.1128/JCM.01654-08
PG 9
WC Microbiology
SC Microbiology
GA 467CC
UT WOS:000267713000031
PM 19420165
OA No
DA 2017-08-15
ER

PT J
AU Meehan, A
   Mackenzie, G
   Shingadia, D
   Booy, R
AF Meehan, Andrea
   Mackenzie, Grant
   Shingadia, Delane
   Booy, Robert
TI Protecting children with HIV against pneumococcal disease
SO LANCET INFECTIOUS DISEASES
LA English
DT Letter
ID CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; COLONIZATION; IMPACT
C1 [Meehan, Andrea] Hosp Teule, Diana Ctr HIV & Palliat Care, Muheza, Tanzania.
   [Meehan, Andrea; Booy, Robert] Childrens Hosp Westmead, Natl Ctr Immunisat Res & Surveillance Vaccine Pre, Westmead, NSW, Australia.
   [Meehan, Andrea; Booy, Robert] Univ Sydney, Sydney, NSW 2006, Australia.
   [Booy, Robert] Queen Marys Sch Med & Dent Barts & London, Acad Unit Child Hlth, London, England.
   [Mackenzie, Grant] MRC Labs, Fajara, Gambia.
   [Shingadia, Delane] Great Ormond St Hosp Sick Children, London, England.
RP Meehan, A (reprint author), Hosp Teule, Diana Ctr HIV & Palliat Care, Muheza, Tanzania.
EM robertb2@chw.edu.au
CR Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Bliss SJ, 2008, LANCET INFECT DIS, V8, P67, DOI 10.1016/S1473-3099(07)70242-6
   Centers for Disease Control and Prevention (CDC), 2008, MMWR-MORBID MORTAL W, V57, P1148
   Ghaffar F, 1999, PEDIATR INFECT DIS J, V18, P638, DOI 10.1097/00006454-199907000-00016
   Hausdorff WP, 2005, LANCET INFECT DIS, V5, P83
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171
   Madhi SA, 2005, CLIN INFECT DIS, V40, P1511, DOI 10.1086/429828
   Madhi SA, 2000, PEDIATR INFECT DIS J, V19, P1141, DOI 10.1097/00006454-200012000-00004
   Millar EV, 2007, CLIN INFECT DIS, V44, P1173, DOI 10.1086/513199
   Park IH, 2007, J CLIN MICROBIOL, V45, P1225, DOI 10.1128/JCM.02199-06
   *PNE VACC ACC DEV, RWAND BEC 1 DEV NAT
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   [Anonymous], 2007, WKLY EPIDEMIOL REC, V82, P93
NR 16
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUL
PY 2009
VL 9
IS 7
BP 394
EP 395
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 465KK
UT WOS:000267582600002
PM 19555896
OA No
DA 2017-08-15
ER

PT J
AU Jallow, S
   Vincent, T
   Leligdowicz, A
   De Silva, T
   Van Tienen, C
   Alabi, A
   Sarge-Njie, R
   Aaby, P
   Corrah, T
   Whittle, H
   Jaye, A
   Vanham, G
   Rowland-Jones, S
   Janssens, W
AF Jallow, Sabelle
   Vincent, Tim
   Leligdowicz, Aleksandra
   De Silva, Thushan
   Van Tienen, Carla
   Alabi, Abraham
   Sarge-Njie, Ramu
   Aaby, Peter
   Corrah, Tumani
   Whittle, Hilton
   Jaye, Assan
   Vanham, Guido
   Rowland-Jones, Sarah
   Janssens, Wouter
TI Presence of a Multidrug-Resistance Mutation in an HIV-2 Variant
   Infecting a Treatment-Naive Individual in Caio, Guinea Bissau
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID ANTIRETROVIRAL-DRUG-RESISTANCE; TRANSMISSION; TYPE-1; ASSAY
AB We report the possible transmission of drug-resistant human immunodeficiency virus type 2. A 66-year-old woman from rural Guinea Bissau who had no obvious antiretroviral exposure was found to harbor a variant with the multidrug-resistance mutation Q151M. Finding this mutation among a drug-naive population presents an important public health issue that needs to be addressed for treatment to be effective.
C1 [Jallow, Sabelle; Vincent, Tim; Leligdowicz, Aleksandra; De Silva, Thushan; Van Tienen, Carla; Alabi, Abraham; Sarge-Njie, Ramu; Corrah, Tumani; Whittle, Hilton; Jaye, Assan; Rowland-Jones, Sarah] MRC Labs, Fajara, Gambia.
   [Jallow, Sabelle; Vanham, Guido; Janssens, Wouter] Univ Antwerp, Inst Trop Med, Dept Microbiol, B-2020 Antwerp, Belgium.
   [Vanham, Guido] Univ Antwerp, Dept Biomed Sci, B-2020 Antwerp, Belgium.
   [Vincent, Tim; Aaby, Peter] Indepth Network, Bandim Hlth Project, Bissau, Guinea Bissau.
   [Leligdowicz, Aleksandra; Rowland-Jones, Sarah] John Radcliffe Hosp, MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
RP Jallow, S (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM sjallow@mrc.gm
RI van Tienen, Carla/A-1119-2012
OI Leligdowicz, Aleksandra/0000-0001-6055-4644
FU Institute of Tropical Medicine in Antwerp, Belgium
FX This work was partially funded by the Medical Research Council (United
   Kingdom). S. J. was supported by an Institute of Tropical
   Medicine/Belgian Directorate General for Development Cooperation
   doctoral scholarship from the Institute of Tropical Medicine in Antwerp,
   Belgium.
CR Brenner B, 2000, INT J ANTIMICROB AG, V16, P429, DOI 10.1016/S0924-8579(00)00270-3
   Hecht FM, 2005, CLIN INFECT DIS, V41, P1324, DOI 10.1086/496988
   Jallow S, 2007, J CLIN MICROBIOL, V45, P1565, DOI 10.1128/JCM.02220-06
   Kosalaraksa P, 1999, J VIROL, V73, P5356
   Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552
   Maljkovic I, 2003, AIDS RES HUM RETROV, V19, P989, DOI 10.1089/088922203322588341
   Nkengasong JN, 2004, AIDS REV, V6, P4
   Rodes B, 2000, J CLIN MICROBIOL, V38, P1370
   Routy JP, 2000, J ACQ IMMUN DEF SYND, V24, P425
   Stekler J, 2007, J INFECT DIS, V196, P336, DOI 10.1086/519173
   van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012
   Yerly S, 1999, LANCET, V354, P729, DOI 10.1016/S0140-6736(98)12262-6
NR 12
TC 3
Z9 3
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 15
PY 2009
VL 48
IS 12
BP 1790
EP 1793
DI 10.1086/599107
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 450YY
UT WOS:000266439100027
PM 19438401
OA No
DA 2017-08-15
ER

PT J
AU Mabuka, JM
   Mackelprang, RD
   Lohman-Payne, B
   Majiwa, M
   Bosire, R
   John-Stewart, G
   Rowland-Jones, S
   Overbaugh, J
   Farquhar, C
AF Mabuka, Jennifer M.
   Mackelprang, Romel D.
   Lohman-Payne, Barbara
   Majiwa, Maxwell
   Bosire, Rose
   John-Stewart, Grace
   Rowland-Jones, Sarah
   Overbaugh, Julie
   Farquhar, Carey
TI CCR2-641 Polymorphism Is Associated With Lower Maternal HIV-1 Viral Load
   and Reduced Vertical HIV-1 Transmission
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Letter
ID TO-CHILD TRANSMISSION; DISEASE PROGRESSION; CCR5-DELTA-32; INFECTION;
   MORTALITY; ALLELES
C1 [Mabuka, Jennifer M.; Lohman-Payne, Barbara; Majiwa, Maxwell; Bosire, Rose] Univ Nairobi, Dept Paediat, Nairobi, Kenya.
   [Mabuka, Jennifer M.; Majiwa, Maxwell; John-Stewart, Grace] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Mackelprang, Romel D.; John-Stewart, Grace; Farquhar, Carey] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Lohman-Payne, Barbara; John-Stewart, Grace; Farquhar, Carey] Univ Washington, Dept Med, Seattle, WA 98195 USA.
   [Rowland-Jones, Sarah] Univ Oxford, Nuffield Dept Med, Oxford, England.
   [Rowland-Jones, Sarah] MRC Labs, Viral Dis Programme, Faraja, Gambia.
   [Overbaugh, Julie] Fred Hutchinson Canc Res Inst, Div Human Biol, Seattle, WA USA.
RP Mabuka, JM (reprint author), Univ Nairobi, Dept Paediat, Nairobi, Kenya.
FU FIC NIH HHS [D43 TW000007, K01 TW006080]; Medical Research Council
   [MC_U137884180]; NIAID NIH HHS [P30 AI027757]; NICHD NIH HHS [HD41879,
   HD23412, K23 HD041879, R01 HD023412]; NIDCR NIH HHS [DE14826, R01
   DE014826, R01 DE014826-01]
CR Brouwer KC, 2005, AIDS RES HUM RETROV, V21, P358, DOI 10.1089/aid.2005.21.358
   Ioannidis JPA, 2003, AIDS, V17, P1631, DOI 10.1097/01.aids.0000060411.18106.0f
   Mariani R, 1999, J VIROL, V73, P2450
   Mulherin SA, 2003, AIDS, V17, P377, DOI 10.1097/01.aids.0000050783.28043.3e
   Obimbo EM, 2004, PEDIATR INFECT DIS J, V23, P536, DOI 10.1097/01.inf.0000129692.42964.30
   Otieno PA, 2007, J INFECT DIS, V195, P220, DOI 10.1086/510245
   Pedersen BR, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000838
   Singh KK, 2008, JAIDS-J ACQ IMM DEF, V49, P259, DOI 10.1097/QAI.0b013e318186eaa4
   Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959
NR 9
TC 6
Z9 6
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN 1
PY 2009
VL 51
IS 2
BP 235
EP 237
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 451IJ
UT WOS:000266463600021
PM 19465829
OA No
DA 2017-08-15
ER

PT J
AU Nwakanma, DC
   Gomez-Escobar, N
   Walther, M
   Crozier, S
   Dubovsky, F
   Malkin, E
   Locke, E
   Conway, DJ
AF Nwakanma, Davis C.
   Gomez-Escobar, Natalia
   Walther, Michael
   Crozier, Sarah
   Dubovsky, Filip
   Malkin, Elissa
   Locke, Emily
   Conway, David J.
TI Quantitative Detection of Plasmodium falciparum DNA in Saliva, Blood,
   and Urine
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 56th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY NOV 04-08, 2007
CL Philadelphia, PA
SP Amer Soc Trop Med & Hyg
ID POLYMERASE-CHAIN-REACTION; MALARIA PARASITE DENSITY; CASE DEFINITIONS;
   LABORATORY DIAGNOSIS; PCR; INFECTIONS; SENSITIVITY; VACCINE; THICK;
   DYNAMICS
AB Background. Current methods for detecting malaria parasites are invasive and associated with poor compliance when repeated sampling is required. New methods to detect and quantify parasites in a less-invasive manner would greatly enhance the potential for longitudinal surveillance in clinical trials.
   Methods. Saliva, urine, and blood samples from 386 Gambian outpatients with suspected malaria infections were analyzed by nested polymerase chain reaction (nPCR) to detect infection and to evaluate diagnostic accuracy in comparison to expert microscopy. The amount of parasite DNA in malaria-positive samples was estimated using real-time quantitative PCR (qPCR).
   Results. Blood parasite density as estimated by qPCR correlated well with parasite counts established by microscopy (rho = 0.94; P < .001). qPCR results for saliva had a significant correlation with microscopy counts (rho = 0.58; P < .001), whereas qPCR results for urine had a positive but poor correlation with microscopy counts (rho = 0.20; P = .117). The mean amounts of parasite DNA quantified in blood were greater than the mean amounts quantified in saliva and urine samples obtained concurrently from the same individual, by similar to 600-fold and similar to 2500-fold, respectively. When nPCR results were compared with microscopy results, nPCR of saliva had a sensitivity of 73% and a specificity of 97%; its sensitivity increased to 82% in samples with a parasite density of >= 1000 parasites/mu L. nPCR of urine had a sensitivity of 32% and a specificity of 98%.
   Conclusion. Saliva sampling is a promising less-invasive approach for detecting malaria infection.
C1 [Nwakanma, Davis C.; Gomez-Escobar, Natalia; Walther, Michael; Crozier, Sarah; Conway, David J.] Med Res Council United Kingdom Labs, Banjul, Gambia.
   [Dubovsky, Filip; Malkin, Elissa; Locke, Emily] Hlth Malaria Vaccine Initiat, Program Appropriate Technol, Bethesda, MD USA.
RP Nwakanma, DC (reprint author), Med Res Council United Kingdom Labs, POB 273, Banjul, Gambia.
EM dnwakanma@mrc.gm
OI Crozier, Sarah/0000-0002-9524-1127; Conway, David/0000-0002-8711-3037
CR Andrews L, 2005, AM J TROP MED HYG, V73, P191
   Bejon P, 2007, PLOS MED, V4, P1333, DOI 10.1371/journal.pmed.0040251
   Bejon P, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-104
   BLAND JM, 1986, LANCET, V1, P307
   Chandler CIR, 2006, TROP MED INT HEALTH, V11, P1178, DOI 10.1111/j.1365-3156.2006.01672.x
   Cohen J, 1960, EDUC PSYCHOL MEAS, V20, P46
   Collins WE, 1999, AM J TROP MED HYG, V61, P4
   de Monbrison F, 2003, T ROY SOC TROP MED H, V97, P387, DOI 10.1016/S0035-9203(03)90065-4
   Delley V, 2000, TROP MED INT HEALTH, V5, P404, DOI 10.1046/j.1365-3156.2000.00566.x
   DOWLING MAC, 1966, B WORLD HEALTH ORGAN, V34, P249
   Farnert A, 1997, AM J TROP MED HYG, V56, P538
   Good MF, 2001, NAT REV IMMUNOL, V1, P117, DOI 10.1038/35100540
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   Hermsen CC, 2001, MOL BIOCHEM PARASIT, V118, P247, DOI 10.1016/S0166-6851(01)00379-6
   Imoukhuede EB, 2007, AM J TROP MED HYG, V76, P486
   Jafari S, 2004, J INFECT DIS, V189, P195, DOI 10.1086/380910
   KARLSEN F, 1995, J VIROL METHODS, V55, P153, DOI 10.1016/0166-0934(95)00053-W
   Mharakurwa S, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-103
   MILNE LM, 1994, J CLIN PATHOL, V47, P740, DOI 10.1136/jcp.47.8.740
   MOLINEAUX L, 1980, GARKI PROJECT RES EP, P110
   Moody A, 2002, CLIN MICROBIOL REV, V15, P66, DOI 10.1128/CMR.15.1.66-78.2002
   Moorthy Vasee, 2007, Vaccine, V25, P5115, DOI 10.1016/j.vaccine.2007.01.085
   Morassin B, 2002, AM J TROP MED HYG, V66, P503
   Mwangi TW, 2005, J INFECT DIS, V191, P1932, DOI 10.1086/430006
   O'Meara WP, 2007, AM J TROP MED HYG, V77, P246
   Oyedeji SI, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-112
   Perandin F, 2004, J CLIN MICROBIOL, V42, P1214, DOI 10.1128/JCM.42.3.1214-1219.2004
   Rafael Maria E, 2006, Nature, V444 Suppl 1, P39, DOI 10.1038/nature05445
   Rogers WO, 2006, J INFECT DIS, V193, P467, DOI 10.1086/499314
   Rougemont M, 2004, J CLIN MICROBIOL, V42, P5636, DOI 10.1128/JCM.42.12.5636-5643.2004
   SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P181, DOI 10.1016/0035-9203(85)90329-3
   Warhurst DC, 1996, J CLIN PATHOL, V49, P533, DOI 10.1136/jcp.49.7.533
NR 34
TC 51
Z9 53
U1 0
U2 6
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 1
PY 2009
VL 199
IS 11
BP 1567
EP 1574
DI 10.1086/598856
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 444SL
UT WOS:000266000600003
PM 19432544
OA No
DA 2017-08-15
ER

PT J
AU Jallow, M
   Teo, YY
   Small, KS
   Rockett, KA
   Deloukas, P
   Clark, TG
   Kivinen, K
   Bojang, KA
   Conway, DJ
   Pinder, M
   Sirugo, G
   Sisay-Joof, F
   Usen, S
   Auburn, S
   Bumpstead, SJ
   Campino, S
   Coffey, A
   Dunham, A
   Fry, AE
   Green, A
   Gwilliam, R
   Hunt, SE
   Inouye, M
   Jeffreys, AE
   Mendy, A
   Palotie, A
   Potter, S
   Ragoussis, J
   Rogers, J
   Rowlands, K
   Somaskantharajah, E
   Whittaker, P
   Widden, C
   Donnelly, P
   Howie, B
   Marchini, J
   Morris, A
   SanJoaquin, M
   Achidi, EA
   Agbenyega, T
   Allen, A
   Amodu, O
   Corran, P
   Djimde, A
   Dolo, A
   Doumbo, OK
   Drakeley, C
   Dunstan, S
   Evans, J
   Farrar, J
   Fernando, D
   Hien, TT
   Horstmann, RD
   Ibrahim, M
   Karunaweera, N
   Kokwaro, G
   Koram, KA
   Lemnge, M
   Makani, J
   Marsh, K
   Michon, P
   Modiano, D
   Molyneux, ME
   Mueller, I
   Parker, M
   Peshu, N
   Plowe, CV
   Puijalon, O
   Reeder, J
   Reyburn, H
   Riley, EM
   Sakuntabhai, A
   Singhasivanon, P
   Sirima, S
   Tall, A
   Taylor, TE
   Thera, M
   Troye-Blomberg, M
   Williams, TN
   Wilson, M
   Kwiatkowski, DP
AF Jallow, Muminatou
   Teo, Yik Ying
   Small, Kerrin S.
   Rockett, Kirk A.
   Deloukas, Panos
   Clark, Taane G.
   Kivinen, Katja
   Bojang, Kalifa A.
   Conway, David J.
   Pinder, Margaret
   Sirugo, Giorgio
   Sisay-Joof, Fatou
   Usen, Stanley
   Auburn, Sarah
   Bumpstead, Suzannah J.
   Campino, Susana
   Coffey, Alison
   Dunham, Andrew
   Fry, Andrew E.
   Green, Angela
   Gwilliam, Rhian
   Hunt, Sarah E.
   Inouye, Michael
   Jeffreys, Anna E.
   Mendy, Alieu
   Palotie, Aarno
   Potter, Simon
   Ragoussis, Jiannis
   Rogers, Jane
   Rowlands, Kate
   Somaskantharajah, Elilan
   Whittaker, Pamela
   Widden, Claire
   Donnelly, Peter
   Howie, Bryan
   Marchini, Jonathan
   Morris, Andrew
   SanJoaquin, Miguel
   Achidi, Eric Akum
   Agbenyega, Tsiri
   Allen, Angela
   Amodu, Olukemi
   Corran, Patrick
   Djimde, Abdoulaye
   Dolo, Amagana
   Doumbo, Ogobara K.
   Drakeley, Chris
   Dunstan, Sarah
   Evans, Jennifer
   Farrar, Jeremy
   Fernando, Deepika
   Hien, Tran Tinh
   Horstmann, Rolf D.
   Ibrahim, Muntaser
   Karunaweera, Nadira
   Kokwaro, Gilbert
   Koram, Kwadwo A.
   Lemnge, Martha
   Makani, Julie
   Marsh, Kevin
   Michon, Pascal
   Modiano, David
   Molyneux, Malcolm E.
   Mueller, Ivo
   Parker, Michael
   Peshu, Norbert
   Plowe, Christopher V.
   Puijalon, Odile
   Reeder, John
   Reyburn, Hugh
   Riley, Eleanor M.
   Sakuntabhai, Anavaj
   Singhasivanon, Pratap
   Sirima, Sodiomon
   Tall, Adama
   Taylor, Terrie E.
   Thera, Mahamadou
   Troye-Blomberg, Marita
   Williams, Thomas N.
   Wilson, Michael
   Kwiatkowski, Dominic P.
CA Wellcome Trust Case Control Consor
   Malaria Genomic Epidemiology Netwo
TI Genome-wide and fine-resolution association analysis of malaria in West
   Africa
SO NATURE GENETICS
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; BETA-GLOBIN GENE; LINKAGE DISEQUILIBRIUM;
   NATURAL-SELECTION; HAPLOTYPE MAP; GENOTYPE DATA; HEMOGLOBIN-C; CHILDREN;
   POPULATION; POWER
AB We report a genome-wide association (GWA) study of severe malaria in The Gambia. The initial GWA scan included 2,500 children genotyped on the Affymetrix 500K GeneChip, and a replication study included 3,400 children. We used this to examine the performance of GWA methods in Africa. We found considerable population stratification, and also that signals of association at known malaria resistance loci were greatly attenuated owing to weak linkage disequilibrium (LD). To investigate possible solutions to the problem of low LD, we focused on the HbS locus, sequencing this region of the genome in 62 Gambian individuals and then using these data to conduct multipoint imputation in the GWA samples. This increased the signal of association, from P = 4 x 10(-7) to P = 4 x 10(-14), with the peak of the signal located precisely at the HbS causal variant. Our findings provide proof of principle that fine-resolution multipoint imputation, based on population-specific sequencing data, can substantially boost authentic GWA signals and enable fine mapping of causal variants in African populations.
C1 [Teo, Yik Ying; Small, Kerrin S.; Rockett, Kirk A.; Clark, Taane G.; Auburn, Sarah; Campino, Susana; Fry, Andrew E.; Green, Angela; Jeffreys, Anna E.; Mendy, Alieu; Ragoussis, Jiannis; Rogers, Jane; Rowlands, Kate; Donnelly, Peter; Marchini, Jonathan; Morris, Andrew; Kwiatkowski, Dominic P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Jallow, Muminatou; Bojang, Kalifa A.; Conway, David J.; Pinder, Margaret; Sirugo, Giorgio; Sisay-Joof, Fatou; Usen, Stanley] MRC Labs, Banjul, Gambia.
   [Rockett, Kirk A.; Deloukas, Panos; Clark, Taane G.; Kivinen, Katja; Auburn, Sarah; Bumpstead, Suzannah J.; Campino, Susana; Coffey, Alison; Dunham, Andrew; Gwilliam, Rhian; Hunt, Sarah E.; Inouye, Michael; Palotie, Aarno; Potter, Simon; Somaskantharajah, Elilan; Whittaker, Pamela; Widden, Claire; SanJoaquin, Miguel; Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Cambridge, England.
   [Donnelly, Peter; Howie, Bryan; Marchini, Jonathan] Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
   [SanJoaquin, Miguel; Molyneux, Malcolm E.] Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi.
   [Achidi, Eric Akum] Univ Buea, Buea, South West Prov, Cameroon.
   [Agbenyega, Tsiri; Evans, Jennifer] Kwame Nkrumah Univ Sci & Technol, Kumasi, Ghana.
   [Allen, Angela; Michon, Pascal; Mueller, Ivo; Reeder, John] Papua New Guinea Inst Med Res, Madang, Papua N Guinea.
   [Allen, Angela] Univ Oxford, Weatherall Inst Mol Med, Oxford, England.
   [Amodu, Olukemi] Univ Ibadan, Coll Med, Inst Child Hlth, Ibadan, Nigeria.
   [Corran, Patrick] Natl Inst Biol Stand & Controls, Potters Bar, Herts, England.
   [Djimde, Abdoulaye; Dolo, Amagana; Doumbo, Ogobara K.; Thera, Mahamadou] Univ Bamako, Malaria Res & Training Ctr, Bamako, Mali.
   [Drakeley, Chris; Reyburn, Hugh; Riley, Eleanor M.] London Sch Hyg & Trop Med, London WC1, England.
   [Drakeley, Chris; Reyburn, Hugh; Riley, Eleanor M.] Kilimanjaro Christian Med Ctr, Joint Malaria Programme, Moshi, Tanzania.
   [Dunstan, Sarah; Farrar, Jeremy; Hien, Tran Tinh] Univ Oxford, Hosp Trop Dis, Clin Res Unit, Ho Chi Minh City, Vietnam.
   [Evans, Jennifer; Horstmann, Rolf D.] Bernhard Nocht Inst Trop Med, Dept Mol Med, Hamburg, Germany.
   [Fernando, Deepika; Karunaweera, Nadira] Univ Colombo, Fac Med, Colombo, Sri Lanka.
   [Ibrahim, Muntaser] Univ Khartoum, Inst Endem Dis, Khartoum, Sudan.
   [Kokwaro, Gilbert; Marsh, Kevin; Peshu, Norbert; Williams, Thomas N.] Kenyan Med Res Inst KEMRI, Wellcome Trust Programme, Kilifi, Kenya.
   [Koram, Kwadwo A.; Wilson, Michael] Univ Ghana, Noguchi Mem Inst Med Res, Accra, Ghana.
   [Lemnge, Martha] Natl Inst Med Res, Dar Es Salaam, Tanzania.
   [Makani, Julie] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania.
   [Modiano, David] Univ Roma La Sapienza, Rome, Italy.
   [Parker, Michael] Univ Oxford, Dept Publ Hlth & Primary Hlth Care, Ethox Ctr, Oxford, England.
   [Plowe, Christopher V.; Taylor, Terrie E.] Blantyre Malaria Project, Blantyre 3, Malawi.
   [Plowe, Christopher V.] Univ Maryland, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21201 USA.
   [Puijalon, Odile; Sakuntabhai, Anavaj] Inst Pasteur, Unite Immunol Mol Parasites, Paris, France.
   [Singhasivanon, Pratap] Mahidol Univ, Fac Trop Med, Bangkok, Thailand.
   [Sirima, Sodiomon] Ctr Natl Rech & Format Paludisme, Ouagadougou, Burkina Faso.
   [Tall, Adama] Inst Pasteur, Dakar, Senegal.
   [Taylor, Terrie E.] Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA.
   [Troye-Blomberg, Marita] Stockholm Univ, Wenner Gren Inst, S-10691 Stockholm, Sweden.
RP Kwiatkowski, DP (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
EM dominic@sanger.ac.uk
RI ; mangano, valentina/I-2456-2012; Deloukas, Panos/B-2922-2013; Mueller,
   Ivo/C-7251-2013; Riley, Eleanor/C-8960-2013; Makani, Julie/N-9370-2013;
   Breen, Gerome/A-5540-2010; Troye-Blomberg, Marita/B-9210-2016; Makani,
   Julie/E-8525-2017; eyre, stephen/K-3776-2017
OI Farrar, Jeremy/0000-0002-2700-623X; Mead, Daniel/0000-0001-7717-4330;
   Manske, Magnus/0000-0001-5916-0947; Singhasivanon,
   Pratap/0000-0002-9759-1702; Moyes, Catherine/0000-0002-8028-4079;
   Dominiczak, Anna/0000-0003-4913-3608; Auburn, Sarah/0000-0002-4638-536X;
   Conway, David/0000-0002-8711-3037; Mangano, Valentina
   D/0000-0002-2021-6162; Deloukas, Panos/0000-0001-9251-070X; Mueller,
   Ivo/0000-0001-6554-6889; Riley, Eleanor/0000-0003-3447-3570; Makani,
   Julie/0000-0002-4801-6250; Breen, Gerome/0000-0003-2053-1792;
   Troye-Blomberg, Marita/0000-0002-2804-0325; Makani,
   Julie/0000-0002-4801-6250; eyre, stephen/0000-0002-1251-6974; Oluoch,
   Tom/0000-0001-9621-5900; Lango Allen, Hana/0000-0002-7803-8688; Hunt,
   Sarah/0000-0002-8350-1235; Zeggini, Eleftheria/0000-0003-4238-659X;
   Dunger, Professor David/0000-0002-2566-9304; Amodu,
   Olukemi/0000-0003-1477-4229; Walton, Robert/0000-0001-7700-1907;
   Dunstan, Sarah/0000-0001-7873-933X; Kivinen, Katja/0000-0002-1135-7625;
   Small, Kerrin/0000-0003-4566-0005; Kwiatkowski,
   Dominic/0000-0002-5023-0176
FU Wellcome Trust [077383/Z/05/Z]; Bill & Melinda Gates Foundation;
   Foundation for the National Institutes of Health [566]; Medical Research
   Council [G0600230]
FX We thank the Gambian children and their parents and guardians who made
   this study possible; and the doctors, nurses and fieldworkers at the
   Royal Victoria Hospital, Banjul and other health clinics who assisted
   with this work. MalariaGEN's primary funding is from the Wellcome Trust
   (grant number 077383/Z/05/Z) and from the Bill & Melinda Gates
   Foundation, through the Foundation for the National Institutes of Health
   (grant number 566) as part of the Grand Challenges in Global Health
   initiative. The Wellcome Trust (Sanger Institute core funding) and the
   Medical Research Council (grant number G0600230) provide additional
   support for genotyping, bioinformatics and analysis. The MalariaGEN
   Resource Centre is part of the European Union Network of Excellence on
   the Biology and Pathology of Malaria Parasites.
CR Agarwal A, 2000, BLOOD, V96, P2358
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Barrett JC, 2006, NAT GENET, V38, P659, DOI 10.1038/ng1801
   Bhangale TR, 2008, NAT GENET, V40, P841, DOI 10.1038/ng.180
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Cappellini MD, 2008, LANCET, V371, P64, DOI 10.1016/S0140-6736(08)60073-2
   CHAKRAVARTI A, 1984, AM J HUM GENET, V36, P1239
   CHEBLOUNE Y, 1988, P NATL ACAD SCI USA, V85, P4431, DOI 10.1073/pnas.85.12.4431
   Conrad DF, 2006, NAT GENET, V38, P1251, DOI 10.1038/ng1911
   de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669
   Dudbridge F, 2008, GENET EPIDEMIOL, V32, P227, DOI 10.1002/gepi.20297
   FLINT J, 1986, NATURE, V321, P744, DOI 10.1038/321744a0
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Fry AE, 2008, HUM MOL GENET, V17, P567, DOI 10.1093/hmg/ddm331
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   Guindo A, 2007, PLOS MED, V4, P516, DOI 10.1371/journal.pmed.0040066
   Hanchard N, 2007, BMC GENET, V8, DOI 10.1186/1471-2156-8-52
   Kwiatkowski D, 2008, NATURE, V456, P732, DOI 10.1038/nature07632
   Mackinnon MJ, 2005, PLOS MED, V2, P1253, DOI 10.1371/journa;.pmed.0020340
   Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Mockenhaupt FP, 2004, BLOOD, V104, P2003, DOI 10.1182/blood-2003-11-4090
   Modiano D, 2008, HUM MOL GENET, V17, P789, DOI 10.1093/hmg/ddm350
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   PAGNIER J, 1984, P NATL ACAD SCI-BIOL, V81, P1771, DOI 10.1073/pnas.81.6.1771
   Pe'er I, 2006, NAT GENET, V38, P663, DOI 10.1038/ng1816
   Pe'er I, 2008, GENET EPIDEMIOL, V32, P381, DOI 10.1002/gepi.20303
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Pritchard JK, 2000, GENETICS, V155, P945
   Romans P, 1999, AM J TROP MED HYG, V60, P22
   RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0
   Scheet P, 2006, AM J HUM GENET, V78, P629, DOI 10.1086/502802
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Taylor T, 2006, T ROY SOC TROP MED H, V100, P615, DOI 10.1016/j.trstmh.2005.09.021
   Tishkoff SA, 2002, NAT REV GENET, V3, P611, DOI 10.1038/nrg865
   Tishkoff SA, 2001, SCIENCE, V293, P455, DOI 10.1126/science.1061573
   World Health Organization, 2000, T R SOC TROP MED S1, V94, pS1, DOI DOI 10.1016/S0035-9203(00)90300-6
   Williams TN, 2005, BLOOD, V106, P368, DOI 10.1182/blood-2005-01-0313
NR 38
TC 195
Z9 197
U1 2
U2 39
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD JUN
PY 2009
VL 41
IS 6
BP 657
EP 665
DI 10.1038/ng.388
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 450OW
UT WOS:000266411700014
PM 19465909
OA No
DA 2017-08-15
ER

PT J
AU Gambhir, M
   Basanez, MG
   Burton, MJ
   Solomon, AW
   Bailey, RL
   Holland, MJ
   Blake, IM
   Donnelly, CA
   Jabr, I
   Mabey, DC
   Grassly, NC
AF Gambhir, Manoj
   Basanez, Maria-Gloria
   Burton, Matthew J.
   Solomon, Anthony W.
   Bailey, Robin L.
   Holland, Martin J.
   Blake, Isobel M.
   Donnelly, Christl A.
   Jabr, Ibrahim
   Mabey, David C.
   Grassly, Nicholas C.
TI The Development of an Age-Structured Model for Trachoma Transmission
   Dynamics, Pathogenesis and Control
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID CHLAMYDIA-TRACHOMATIS; LYMPHATIC FILARIASIS; ENDEMIC POPULATION;
   BLINDING TRACHOMA; SCARRING TRACHOMA; NATURAL-HISTORY; MASS TREATMENT;
   INFECTION; RISK; POLYMORPHISMS
AB Background: Trachoma, the worldwide leading infectious cause of blindness, is due to repeated conjunctival infection with Chlamydia trachomatis. The effects of control interventions on population levels of infection and active disease can be promptly measured, but the effects on severe ocular sequelae require long-term monitoring. We present an age-structured mathematical model of trachoma transmission and disease to predict the impact of interventions on the prevalence of blinding trachoma.
   Methodology/Principal Findings: The model is based on the concept of multiple reinfections leading to progressive conjunctival scarring, trichiasis, corneal opacity and blindness. It also includes aspects of trachoma natural history, such as an increasing rate of recovery from infection and a decreasing chlamydial load with subsequent infections that depend upon a ( presumed) acquired immunity that clears infection with age more rapidly. Parameters were estimated using maximum likelihood by fitting the model to pre-control infection prevalence data from hypo-, meso- and hyperendemic communities from The Gambia and Tanzania. The model reproduces key features of trachoma epidemiology: 1) the age-profile of infection prevalence, which increases to a peak at very young ages and declines at older ages; 2) a shift in this prevalence peak, toward younger ages in higher force of infection environments; 3) a raised overall profile of infection prevalence with higher force of infection; and 4) a rising profile, with age, of the prevalence of the ensuing severe sequelae (trachomatous scarring, trichiasis), as well as estimates of the number of infections that need to occur before these sequelae appear.
   Conclusions/Significance: We present a framework that is sufficiently comprehensive to examine the outcomes of the A (antibiotic) component of the SAFE strategy on disease. The suitability of the model for representing population-level patterns of infection and disease sequelae is discussed in view of the individual processes leading to these patterns.
C1 [Gambhir, Manoj; Donnelly, Christl A.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, MRC Ctr Outbreak Anal & Modelling, London, England.
   [Burton, Matthew J.; Solomon, Anthony W.] London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1, England.
   [Bailey, Robin L.; Holland, Martin J.; Mabey, David C.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Clin Res Unit, London WC1, England.
   [Holland, Martin J.] MRC Labs, Viral Dis Programme, Banjul, Gambia.
   [Jabr, Ibrahim] Int Trachoma Initiat, New York, NY USA.
RP Gambhir, M (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, MRC Ctr Outbreak Anal & Modelling, London, England.
EM m.gambhir@imperial.ac.uk
OI Mabey, David/0000-0002-0031-8276; Blake, Isobel/0000-0002-3977-1318;
   Grassly, Nicholas/0000-0001-6067-4507; Donnelly,
   Christl/0000-0002-0195-2463; Burton, Matthew/0000-0003-1872-9169;
   Solomon, Anthony/0000-0001-7101-6649
FU International Trachoma Initiative (ITI) f; Medical Research Council, UK
FX We thank the International Trachoma Initiative (ITI) for financing the
   development of the trachoma models presented here. M-GB thanks the
   Medical Research Council, UK, for a Career Establishment Grant. NCG
   acknowledges the Royal Society for a University Research Fellowship. MJB
   thanks the Wellcome Trust for a fellowship. IMB thanks the Medical
   Research Council, UK, for a PhD studentship. CAD and NCG acknowledge the
   Medical Research Council, UK, for Centre funding support. The field
   studies were supported by a Wellcome Trust-Burroughs Wellcome grant to
   DCM and RLB. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Abu El-Asrar AM, 1998, EYE, V12, P453
   Alves APX, 2002, OPHTHALMIC EPIDEMIOL, V9, P29
   Anderson R. M., 1992, INFECT DIS HUMANS DY, P768
   Anderson R.M., 1992, INFECT DIS HUMANS DY
   Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   BAILEY RL, 1993, EPIDEMIOL INFECT, V111, P315
   Brunham RC, 2005, NAT REV IMMUNOL, V5, P149, DOI 10.1038/nri1551
   Burton MJ, 2006, INVEST OPHTH VIS SCI, V47, P847, DOI 10.1167/iovs.05-0714
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Chan MS, 1998, AM J TROP MED HYG, V59, P606
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Conway DJ, 1996, J INFECT DIS, V174, P643
   Debattista J, 2003, FERTIL STERIL, V79, P1273, DOI 10.1016/S0015-0282(03)00396-0
   Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1
   Emerson PM, 2002, OPHTHALMIC EPIDEMIOL, V9, P105, DOI 10.1076/opep.9.2.105.1522
   Faal N, 2006, PLOS MED, V3, P1292, DOI 10.1371/journal.pmed.0030266
   Filipe JAN, 2005, P NATL ACAD SCI USA, V102, P15265, DOI 10.1073/pnas.0502659102
   Gambhir M, 2007, LANCET INFECT DIS, V7, P420, DOI 10.1016/S1473-3099(07)70137-8
   Grassly NC, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000341
   GRAYSTON JT, 1985, REV INFECT DIS, V7, P717
   HAYES LJ, 1992, J INFECT DIS, V166, P1173
   Kuper H, 2003, LANCET INFECT DIS, V3, P372, DOI 10.1016/S1473-3099(03)00659-5
   Lee DC, 2005, AM J TROP MED HYG, V72, P468
   Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451
   Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1
   Mariotti SP, 2004, NEW ENGL J MED, V351, P2004, DOI 10.1056/NEJMe048205
   Mozzato-Chamay N, 2001, GENES IMMUN, V2, P153, DOI 10.1038/sj.gene.6363753
   Mozzato-Chamay N, 2000, J INFECT DIS, V182, P1545, DOI 10.1086/315891
   Munoz B, 1997, TROP MED INT HEALTH, V2, P1030, DOI 10.1046/j.1365-3156.1997.d01-186.x
   Natividad A, 2007, GENES IMMUN, V8, P288, DOI 10.1038/sj.gene.6364384
   Natividad A, 2005, GENES IMMUN, V6, P332, DOI 10.1038/sj.gene.6364182
   Natividad A, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-40
   Norman RA, 2000, EPIDEMIOL INFECT, V124, P529, DOI 10.1017/S0950268899003702
   Ray KJ, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-91
   Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   Taylor H R, 1987, Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique, P175
   TAYLOR HR, 1987, J IMMUNOL, V138, P3023
   TAYLOR HR, 2008, TRACHOMA
   West ES, 2005, INVEST OPHTH VIS SCI, V46, P83, DOI 10.1167/iovs.04-0327
   World Health Organization, 2006, WHO STAT INF SYST WH
   World Health Organization, 2003, 2 GLOB SCI M TRACH
   Woolhouse MEJ, 1998, PARASITOL TODAY, V14, P428, DOI 10.1016/S0169-4758(98)01318-0
NR 43
TC 16
Z9 16
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2009
VL 3
IS 6
AR e462
DI 10.1371/journal.pntd.0000462
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 475XS
UT WOS:000268401000013
PM 19529762
OA gold
DA 2017-08-15
ER

PT J
AU Seth-Smith, HMB
   Harris, SR
   Persson, K
   Marsh, P
   Barron, A
   Bignell, A
   Bjartling, C
   Clark, L
   Cutcliffe, LT
   Lambden, PR
   Lennard, N
   Lockey, SJ
   Quail, MA
   Salim, O
   Skilton, RJ
   Wang, YB
   Holland, MJ
   Parkhill, J
   Thomson, NR
   Clarke, IN
AF Seth-Smith, Helena M. B.
   Harris, Simon R.
   Persson, Kenneth
   Marsh, Pete
   Barron, Andrew
   Bignell, Alexandra
   Bjartling, Carina
   Clark, Louise
   Cutcliffe, Lesley T.
   Lambden, Paul R.
   Lennard, Nicola
   Lockey, Sarah J.
   Quail, Michael A.
   Salim, Omar
   Skilton, Rachel J.
   Wang, Yibing
   Holland, Martin J.
   Parkhill, Julian
   Thomson, Nicholas R.
   Clarke, Ian N.
TI Co-evolution of genomes and plasmids within Chlamydia trachomatis and
   the emergence in Sweden of a new variant strain
SO BMC GENOMICS
LA English
DT Article
ID LYMPHOGRANULOMA-VENEREUM; CRYPTIC PLASMID; COMMON PLASMID; PROTEIN PGP3;
   SEQUENCE; POLYMORPHISMS; DIVERSITY; GENES; ALIGNMENT; PATHOGEN
AB Background: Chlamydia trachomatis is the most common cause of sexually transmitted infections globally and the leading cause of preventable blindness in the developing world. There are two biovariants of C trachomatis: 'trachoma', causing ocular and genital tract infections, and the invasive 'lymphogranuloma venereum' strains. Recently, a new variant of the genital tract C trachomatis emerged in Sweden. This variant escaped routine diagnostic tests because it carries a plasmid with a deletion. Failure to detect this strain has meant it has spread rapidly across the country provoking a worldwide alert. In addition to being a key diagnostic target, the plasmid has been linked to chlamydial virulence. Analysis of chlamydial plasmids and their cognate chromosomes was undertaken to provide insights into the evolutionary relationship between chromosome and plasmid. This is essential knowledge if the plasmid is to be continued to be relied on as a key diagnostic marker, and for an understanding of the evolution of Chlamydia trachomatis.
   Results: The genomes of two new C trachomatis strains were sequenced, together with plasmids from six C trachomatis isolates, including the new variant strain from Sweden. The plasmid from the new Swedish variant has a 377 bp deletion in the first predicted coding sequence, abolishing the site used for PCR detection, resulting in negative diagnosis. In addition, the variant plasmid has a 44 bp duplication downstream of the deletion. The region containing the second predicted coding sequence is the most highly conserved region of the plasmids investigated. Phylogenetic analysis of the plasmids and chromosomes are fully congruent. Moreover this analysis also shows that ocular and genital strains diverged from a common C trachomatis progenitor.
   Conclusion: The evolutionary pathways of the chlamydial genome and plasmid imply that inheritance of the plasmid is tightly linked with its cognate chromosome. These data suggest that the plasmid is not a highly mobile genetic element and does not transfer readily between isolates. Comparative analysis of the plasmid sequences has revealed the most conserved regions that should be used to design future plasmid based nucleic acid amplification tests, to avoid diagnostic failures.
C1 [Cutcliffe, Lesley T.; Lambden, Paul R.; Lockey, Sarah J.; Salim, Omar; Skilton, Rachel J.; Wang, Yibing; Clarke, Ian N.] Southampton Gen Hosp, Univ Med Sch, Mol Microbiol Grp, Southampton SO16 6YD, Hants, England.
   [Seth-Smith, Helena M. B.; Harris, Simon R.; Barron, Andrew; Bignell, Alexandra; Clark, Louise; Lennard, Nicola; Quail, Michael A.; Parkhill, Julian; Thomson, Nicholas R.] Wellcome Trust Sanger Inst, Pathogen Sequencing Unit, Cambridge CB10 1SA, England.
   [Persson, Kenneth] Malmo Univ Hosp, Dept Clin Microbiol, SE-20502 Malmo, Sweden.
   [Marsh, Pete] Southampton Gen Hosp, Hlth Protect Agcy S E, Southampton SO16 6YD, Hants, England.
   [Bjartling, Carina] Malmo Univ Hosp, Dept Obstet & Gynaecol, SE-20502 Malmo, Sweden.
   [Holland, Martin J.] MRC, Viral Dis Programme, Banjul, Gambia.
   [Clarke, Ian N.] Univ London London Sch Hyg & Trop Med, Clin Res Unit, Dept Infect & Trop Dis, London WC1E 7HT, England.
RP Clarke, IN (reprint author), Southampton Gen Hosp, Univ Med Sch, Mol Microbiol Grp, Southampton SO16 6YD, Hants, England.
EM hss@sanger.ac.uk; sh16@sanger.ac.uk;
   Kenneth.Persson@mikrobiol.mas.lu.se; P.Marsh@soton.ac.uk;
   ab5@sanger.ac.uk; al1@sanger.ac.uk; Carina.Bjartling@skane.se;
   lnc@sanger.ac.uk; L.T.Cutcliffe@soton.ac.uk; prl1@soton.ac.uk;
   njl@sanger.ac.uk; lockey_sarah@hotmail.com; mq1@sanger.ac.uk;
   O.Salim@soton.ac.uk; R.J.Skilton@soton.ac.uk; Yibing.Wang@soton.ac.uk;
   Martin.Holland@lshtm.ac.uk; parkhill@sanger.ac.uk; nrt@sanger.ac.uk;
   inc@soton.ac.uk
RI Parkhill, Julian/G-4703-2011; Harris, Simon/K-1318-2013
OI Parkhill, Julian/0000-0002-7069-5958; Harris, Simon/0000-0003-1512-6194;
   Clarke, Ian/0000-0002-4938-1620; Salim, Omar/0000-0002-2562-4827
FU Wellcome Trust; MRC Sexual Health and HIV Research Strategy Committee
   [G0601640]
FX We are grateful to Dr. Harlan Caldwell and Dr. Grant McClarty for supply
   of chromosomal DNA for strain B/TZIA828/OT. This strain was originally
   isolated by Dr. West from a child with trachoma in Tanzania in 1998. We
   are grateful for Dr. West and Dr. Hsieh for helpful discussions about
   the origin of this isolate [38]. We thank the core sequencing and
   informatics teams at the Sanger Institute for their assistance. This
   work was supported by The Wellcome Trust and the MRC Sexual Health and
   HIV Research Strategy Committee G0601640 to INC and PM. All views
   expressed are those of the authors and not necessarily those of the M RC
   or Health Departments.
CR Belland RJ, 2001, P NATL ACAD SCI USA, V98, P13984, DOI 10.1073/pnas.241377698
   Berriman Matt, 2003, Briefings in Bioinformatics, V4, P124, DOI 10.1093/bib/4.2.124
   Brunelle BW, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-r42
   Caldwell HD, 2003, J CLIN INVEST, V111, P1757, DOI 10.1172/JCI200317993
   Carlson JH, 2005, INFECT IMMUN, V73, P6407, DOI 10.1128/IAI.73.10.6407-6418.2005
   Carlson JH, 2004, INFECT IMMUN, V72, P7063, DOI 10.1128/IAI.72.12.7063-7072.2004
   Carlson JH, 2008, INFECT IMMUN, V76, P2273, DOI 10.1128/IAI.00102-08
   Carver TJ, 2005, BIOINFORMATICS, V21, P3422, DOI 10.1093/bioinformatics/bti553
   COMANDUCCI M, 1994, INFECT IMMUN, V62, P5491
   COMANDUCCI M, 1993, J GEN MICROBIOL, V139, P1083
   COMANDUCCI M, 1988, MOL MICROBIOL, V2, P531, DOI 10.1111/j.1365-2958.1988.tb00060.x
   COMANDUCCI M, 1990, PLASMID, V23, P149, DOI 10.1016/0147-619X(90)90034-A
   Darling ACE, 2004, GENOME RES, V14, P1394, DOI 10.1101/gr.2289704
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Farencena A, 1997, INFECT IMMUN, V65, P2965
   Gerbase AC, 1998, LANCET, V351, P2
   HACKSTADT T, 1991, P NATL ACAD SCI USA, V88, P3937, DOI 10.1073/pnas.88.9.3937
   Herrmann B, 2008, EMERG INFECT DIS, V14, P1462, DOI 10.3201/eid1409.080153
   Hsieh YH, 2001, MICROBES INFECT, V3, P447, DOI 10.1016/S1286-4579(01)01400-9
   Li ZY, 2008, INFECT IMMUN, V76, P3415, DOI 10.1128/IAI.01377-07
   Nunes A, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r153
   O'Connell CM, 2007, J IMMUNOL, V179, P4027
   Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088
   PETERSON EM, 1990, PLASMID, V23, P144, DOI 10.1016/0147-619X(90)90033-9
   Pickett MA, 2005, MICROBIOL-SGM, V151, P893, DOI 10.1099/mic.0.27625-0
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397
   RICCI S, 1995, GENE, V154, P93, DOI 10.1016/0378-1119(94)00825-D
   RICCI S, 1993, MOL GEN GENET, V237, P318
   Ripa T, 2006, EUROSURVEILLANCE, V11
   Ripa T, 2007, SEX TRANSM DIS, V34, P255, DOI 10.1097/OLQ.0b013e31805ce2b9
   SCHACHTER J, 1983, BRIT MED BULL, V39, P151
   Schachter J, 1990, Scand J Infect Dis Suppl, V69, P55
   SCHACHTER J, 1969, J BACTERIOL, V99, P636
   Skipp P, 2005, PROTEOMICS, V5, P1558, DOI 10.1002/pmic.200401044
   Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446
   Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754
   STEPHENS RS, 1992, INFECT AGENT DIS, V1, P279
   Stothard DR, 1998, INFECT IMMUN, V66, P6010
   TAM JE, 1992, PLASMID, V27, P231, DOI 10.1016/0147-619X(92)90025-6
   Thomas NS, 1997, MICROBIOL-SGM, V143, P1847
   Thomson NR, 2008, GENOME RES, V18, P161, DOI 10.1101/gr.7020108
   WARD ME, 1983, BRIT MED BULL, V39, P109
   WATSON MW, 1989, FEMS MICROBIOL LETT, V65, P293
   YUAN Y, 1989, INFECT IMMUN, V57, P1040
NR 45
TC 63
Z9 71
U1 1
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
   4LB, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD MAY 21
PY 2009
VL 10
AR 239
DI 10.1186/1471-2164-10-239
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 467KA
UT WOS:000267736300002
PM 19460133
OA gold
DA 2017-08-15
ER

PT J
AU Benn, CS
   Rodrigues, A
   Yazdanbakhsh, M
   Fisker, AB
   Ravn, H
   Whittle, H
   Aaby, P
AF Benn, Christine Stabell
   Rodrigues, Amabelia
   Yazdanbakhsh, Maria
   Fisker, Ane Barent
   Ravn, Henrik
   Whittle, Hilton
   Aaby, Peter
TI The effect of high-dose vitamin A supplementation administered with BCG
   vaccine at birth may be modified by subsequent DTP vaccination
SO VACCINE
LA English
DT Article
DE Vitamin A; BCG vaccine; DTP vaccine; Mortality
ID EARLY INFANT-MORTALITY; GUINEA-BISSAU; ROUTINE VACCINATIONS;
   RANDOMIZED-TRIAL; CHILD SURVIVAL; PEDIATRIC WARD; RESPONSES; IMPACT;
   IMMUNIZATIONS; MORBIDITY
AB Unexpectedly, we found no overall beneficial effect on mortality in a randomised trial of vitamin A supplementation (VAS) or placebo administered with BCG vaccine at birth in Guinea-Bissau. We conducted in explorative analysis to examine whether subsequent diptheria-tetanus-pertussis (DTP) vaccinations had modified the effect of VAS at birth. VAS was associated with a weak tendency for decreased mortality as long as BCG was the most recent vaccination, the mortality rate ratio being 0.86 (0.48-1.54): 0.82 (0.32-2.08) in girls and 0.89 (0.43-1.88) in boys. However, after DTP vaccination VAS at birth was associated with increased mortality in girls (2.19 (1.09-4.38)), whereas no difference was seen for boys (0.90 (0.44-1.82)) (p = 0.08 for equal effect of VAS in the two sexes if DTP is the last vaccine). The explanation for the lack of beneficial effect in our setting may have been that VAS at birth interacted negatively with subsequent DTP vaccinations in girls. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Benn, Christine Stabell; Ravn, Henrik] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen, Denmark.
   [Rodrigues, Amabelia; Fisker, Ane Barent; Aaby, Peter] Indepth Network, Bandim Hlth Project, Guinea Bissau, Papua N Guinea.
   [Yazdanbakhsh, Maria] Leiden Univ, Med Ctr, Dept Immunoparasitol, NL-2300 RA Leiden, Netherlands.
   [Whittle, Hilton] MRC Labs, Fajara, Gambia.
RP Benn, CS (reprint author), Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen, Denmark.
EM cb@ssi.dk
OI Fisker, Ane/0000-0002-8521-0992
CR Aaby P, 2004, VACCINE, V22, P3014, DOI 10.1016/j.vaccine.2004.02.009
   Aaby P, 2004, INT J EPIDEMIOL, V33, P367, DOI 10.1093/ije/dyh004
   Aaby P, 2002, VACCINE, V21, P15, DOI 10.1016/S0264-410X(02)00441-3
   Aaby P, 2009, INT J EPIDEMIOL, V38, P320, DOI 10.1093/ije/dyn005
   Benn CS, 2008, VACCINE, V26, P4111, DOI 10.1016/j.vaccine.2008.04.021
   Benn CS, 2008, BRIT MED J, V336, P1416, DOI 10.1136/bmj.39542.509444.AE
   Benn CS, 2007, VACCINE, V25, P777, DOI 10.1016/j.vaccine.2006.09.044
   Benn Christine Stabell, 2008, PLoS One, V3, pe4056, DOI 10.1371/journal.pone.0004056
   Benn CS, 2009, INT J EPIDEMIOL, V38, P304, DOI 10.1093/ije/dyn195
   Benn CS, 2005, BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55
   Benn CS, 1997, LANCET, V350, P101, DOI 10.1016/S0140-6736(96)12019-5
   Benn CS, 2003, INT J EPIDEMIOL, V32, P822, DOI 10.1093/ije/dyg208
   BENN CS, 2006, J INFECT DIS, V194, P721, DOI 10.1086/506457
   Bhutta ZA, 2008, LANCET, V371, P417, DOI 10.1016/S0140-6736(07)61693-6
   Cox D. R., 1984, ANAL SURVIVAL DATA
   Diness BR, 2007, AM J CLIN NUTR, V86, P1152
   DINESS BR, J INFECT DI IN PRESS
   DINESS BR, EFFECT HIGH DO UNPUB
   Fisker AB, 2007, AM J CLIN NUTR, V86, P1032
   Hoag KA, 2002, J NUTR, V132, P3736
   Humphrey Jean H, 2006, J Infect Dis, V193, P860, DOI 10.1086/500366
   Humphrey JH, 1996, J PEDIATR-US, V128, P489, DOI 10.1016/S0022-3476(96)70359-1
   Jensen H, 2007, TROP MED INT HEALTH, V12, P5, DOI 10.1111/j.1365-3156.2006.01773.x
   Klemm RDW, 2008, PEDIATRICS, V122, pE242, DOI 10.1542/peds.2007-3448
   Malaba LC, 2005, AM J CLIN NUTR, V81, P454
   Martins CL, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a661
   Moulton LH, 2005, TROP MED INT HEALTH, V10, P947, DOI 10.1111/j.1365-3156.2005.01434.x
   Rahmathullah L, 2003, BRIT MED J, V327, P254, DOI 10.1136/bmj.327.7409.254
   Rowe J, 2000, INFECT IMMUN, V68, P3873, DOI 10.1128/IAI.68.7.3873-3877.2000
   Sachdev HPS, 2008, LANCET, V371, P1746, DOI 10.1016/S0140-6736(08)60750-3
   Tielsch JM, 2008, BRIT MED J, V336, P1385, DOI 10.1136/bmj.39575.486609.80
   Veirum JE, 2005, VACCINE, V23, P1197, DOI 10.1016/j.vaccine.2004.02.053
   Villamor E, 2005, CLIN MICROBIOL REV, V18, P446, DOI 10.1128/CNR.18.3.446-464.2005
   West Jr K, 2007, 1 MICR FOR M IST TUR
NR 34
TC 40
Z9 40
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD MAY 11
PY 2009
VL 27
IS 21
BP 2891
EP 2898
DI 10.1016/j.vaccine.2009.02.080
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 445AX
UT WOS:000266023100025
PM 19428899
OA No
DA 2017-08-15
ER

PT J
AU Lemieux, JE
   Gomez-Escobar, N
   Feller, A
   Carret, C
   Amambua-Ngwa, A
   Pinches, R
   Day, F
   Kyes, SA
   Conway, DJ
   Holmes, CC
   Newbold, CI
AF Lemieux, Jacob E.
   Gomez-Escobar, Natalia
   Feller, Avi
   Carret, Celine
   Amambua-Ngwa, Alfred
   Pinches, Robert
   Day, Felix
   Kyes, Sue A.
   Conway, David J.
   Holmes, Chris C.
   Newbold, Chris I.
TI Statistical estimation of cell-cycle progression and lineage commitment
   in Plasmodium falciparum reveals a homogeneous pattern of transcription
   in ex vivo culture
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE malaria; microarray
ID MALARIA PARASITES; RED-CELLS; DISCOVERY; IDENTIFICATION; SEPARATION;
   PROTEINS; SURFACE; BLOOD
AB We have cultured Plasmodium falciparum directly from the blood of infected individuals to examine patterns of mature-stage gene expression in patient isolates. Analysis of the transcriptome of P. falciparum is complicated by the highly periodic nature of gene expression because small variations in the stage of parasite development between samples can lead to an apparent difference in gene expression values. To address this issue, we have developed statistical likelihood-based methods to estimate cell cycle progression and commitment to asexual or sexual development lineages in our samples based on microscopy and gene expression patterns. In cases subsequently matched for temporal development, we find that transcriptional patterns in ex vivo culture display little variation across patients with diverse clinical profiles and closely resemble transcriptional profiles that occur in vitro. These statistical methods, available to the research community, assist in the design and interpretation of P. falciparum expression profiling experiments where it is difficult to separate true differential expression from cell-cycle dependent expression. We reanalyze an existing dataset of in vivo patient expression profiles and conclude that previously observed discrete variation is consistent with the commitment of a varying proportion of the parasite population to the sexual development lineage.
C1 [Lemieux, Jacob E.; Pinches, Robert; Day, Felix; Kyes, Sue A.; Newbold, Chris I.] John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
   [Gomez-Escobar, Natalia; Amambua-Ngwa, Alfred; Conway, David J.] MRC Labs, Fajara, Gambia.
   [Feller, Avi; Holmes, Chris C.] Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
   [Carret, Celine] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
   [Holmes, Chris C.] MRC, Didcot OX11 0RD, Oxon, England.
RP Newbold, CI (reprint author), John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
EM cnewbold@hammer.imm.ox.ac.uk
OI Day, Felix/0000-0003-3789-7651; Newbold, Chris/0000-0002-9274-3789;
   Conway, David/0000-0002-8711-3037
FU Wellcome Trust; Medical Research Council; Rhodes Trust; Wellcome Trust
   Vacation Scholarship 2008
FX We thank the malaria patients and their parents for participation in
   this study; clinical, laboratory, and field staff at each of the health
   facilities who supported the research; Drs. David Baker and David
   Warhurst for their expert advice on gametocyte morphology; and the
   Computational Biological Research Group and Dr. Simon McGowan for
   database support. This work was supported by a Wellcome Trust grant ( to
   C. I. N.), a Medical Research Council grant ( to D. C.), the Rhodes
   Trust (J.E.L. and A. F.), a Wellcome Trust Vacation Scholarship 2008
   (F.D.)
CR Benjamini Y, 2001, ANN STAT, V29, P1165
   Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005
   Bozdech Z, 2008, P NATL ACAD SCI USA, V105, P16290, DOI 10.1073/pnas.0807404105
   BRUCE MC, 1990, PARASITOLOGY, V100, P191
   Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101
   Cortes A, 2007, PLOS PATHOG, V3, P1023, DOI 10.1371/journal.ppat.0030107
   Dahl EL, 2006, ANTIMICROB AGENTS CH, V50, P3124, DOI 10.1128/AAC.00394-06
   Daily JP, 2007, NATURE, V450, P1091, DOI 10.1038/nature06311
   Daily JP, 2005, J INFECT DIS, V191, P1196, DOI 10.1086/428289
   De Silva EK, 2008, P NATL ACAD SCI USA, V105, P8393, DOI 10.1073/pnas.0801993105
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Heard NA, 2005, P NATL ACAD SCI USA, V102, P16939, DOI 10.1073/pnas.0408393102
   KWIATKOWSKI D, 1989, J EXP MED, V169, P357, DOI 10.1084/jem.169.1.357
   Kyes SA, 1999, P NATL ACAD SCI USA, V96, P9333, DOI 10.1073/pnas.96.16.9333
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025
   Llinas M, 2006, NUCLEIC ACIDS RES, V34, P1166, DOI 10.1093/nar/gkj517
   Lu X, 2004, NUCLEIC ACIDS RES, V32, P447, DOI 10.1093/nar/gkh205
   PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87
   PAUL F, 1981, LANCET, V2, P70
   POLITIS DN, 1994, ANN STAT, V22, P2031, DOI 10.1214/aos/1176325770
   Politis D.N., 1999, SUBSAMPLING
   SCHOLZ M, 2008, PLASMODIUM FALCIPARU, V9, pR88
   Siau A, 2007, J INFECT DIS, V196, P1603, DOI 10.1086/522012
   Simpson JA, 2002, PARASITOLOGY, V124, P247, DOI 10.1017/S0031182001001202
   Rossi A, 2016, APPL GENET MOL BIOL, V2, DOI DOI 10.2202/1544-6115.1027
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Young JA, 2005, MOL BIOCHEM PARASIT, V143, P67, DOI 10.1016/j.molbiopara.2005.05.007
NR 29
TC 37
Z9 37
U1 0
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 5
PY 2009
VL 106
IS 18
BP 7559
EP 7564
DI 10.1073/pnas.0811829106
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 441QI
UT WOS:000265783600054
PM 19376968
OA No
DA 2017-08-15
ER

PT J
AU Finney, OC
   Nwakanma, D
   Conway, DJ
   Walther, M
   Riley, EM
AF Finney, Olivia C.
   Nwakanma, Davis
   Conway, David J.
   Walther, Michael
   Riley, Eleanor M.
TI Homeostatic regulation of T effector to Treg ratios in an area of
   seasonal malaria transmission
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Human; Malaria; Regulation; T cells
ID PLASMODIUM-FALCIPARUM MALARIA; MEROZOITE SURFACE PROTEIN; CEREBRAL
   MALARIA; CYTOKINE PRODUCTION; TGF-BETA; IN-VIVO; PERIPHERAL-BLOOD;
   GAMBIAN CHILDREN; IMMUNE-RESPONSES; INTERFERON-GAMMA
AB An important aspect of clinical immunity to malaria is the ability to down-regulate inflammatory responses, once parasitaemia is under control, in order to avoid immune-mediated pathology. The role of classical (CD4(+)CD25(+)CD127(lo/-)FOXP3(+)) Treg in this process, however, remains controversial. Thus, we have characterized the frequency, phenotype and function of Treg populations, over time, in healthy individuals in The Gambia. We observed that both the percentage and the absolute number of CD4(+)FOXP3(+)CD127(lo/-) T cells were higher among individuals living in a rural village with highly seasonal malaria transmission than among individuals living in an urban area where malaria rarely occurs. These CD4(+)FOXP3(+)CD127(lo/-) T cells exhibited an effector memory and apoptosis-prone phenotype and suppressed cytokine production in response to malaria antigen. Cells from individuals exposed to malaria expressed significantly higher levels of mRNA for forkhead box P3 and T-box 21 (T-BET) at the end of the malaria transmission season than at the end of the non-transmission season. Importantly, the ratio of T-BET to forkhead box P3 was remarkably consistent between populations and over time, indicating that in healthy individuals, a transient increase in Th1 responses during the malaria transmission season is balanced by a commensurate Treg response, ensuring that immune homeostasis is maintained.
C1 [Finney, Olivia C.; Nwakanma, Davis; Conway, David J.; Walther, Michael] MRC Labs, Malaria Programme, Banjul, Gambia.
   [Finney, Olivia C.; Conway, David J.; Riley, Eleanor M.] London Sch Hyg & Trop Med, Immunol Unit, Dept Infect & Trop Dis, London WC1, England.
RP Riley, EM (reprint author), Room 236,Keppel St, London WC1E 7HT, England.
EM eleanor.riley@lshtm.ac.uk
RI Riley, Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570; Conway, David/0000-0002-8711-3037
FU UK Medical Research Council; MRC postgraduate training scholarship
FX We would like to thank all the field workers, nurses and laboratory
   technicians involved in the study for their invaluable support. Special
   thanks are due to Natalia Gomez-Escobar, Martin Holland and Sarah Burl
   for helping set up RT-PCR assays, Irfan Zaidi for assistance with flow
   cytometry, Patrick Corran for his help with analysis of antimalarial
   antibody responses and Idrissa Sambou for kindly preparing malaria
   antigens for the study. We are grateful to Professor Sarah Rowland-Jones
   for her support and advice throughout the study. This work was supported
   by the UK Medical Research Council. O.C.F. was supported by an MRC
   postgraduate training scholarship.
CR Akbar AN, 2007, NAT REV IMMUNOL, V7, P231, DOI 10.1038/nri2037
   Amante FH, 2007, AM J PATHOL, V171, P548, DOI 10.2353/ajpath.2007.061033
   Anderson CF, 2005, J IMMUNOL, V174, P2934
   Artavanis-Tsakonas K, 2003, CLIN EXP IMMUNOL, V133, P145, DOI 10.1046/j.1365-2249.2003.02174.x
   Baecher-Allan C, 2001, J IMMUNOL, V167, P1245
   Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152
   Belkaid Y, 2006, IMMUNOL REV, V212, P287, DOI 10.1111/j.0105-2896.2006.00409.x
   Brandenburg S, 2008, EUR J IMMUNOL, V38, P1643, DOI 10.1002/eji.200737791
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   BURGHAUS PA, 1994, MOL BIOCHEM PARASIT, V64, P165, DOI 10.1016/0166-6851(94)90144-9
   Cambos M, 2008, INT J PARASITOL, V38, P229, DOI 10.1016/j.ijpara.2007.07.006
   Campbell JJ, 2001, J IMMUNOL, V166, P877
   Chaiyaroj SC, 2004, ACTA TROP, V89, P319, DOI 10.1016/j.actatropica.2003.10.010
   Chen RF, 2005, FEMS IMMUNOL MED MIC, V44, P43, DOI 10.1016/j.femsim.2004.11.012
   CHIZZOLINI C, 1990, CLIN EXP IMMUNOL, V79, P95
   Coombes JL, 2005, IMMUNOL REV, V204, P184, DOI 10.1111/j.0105-2896.2005.00250.x
   Couper KN, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000004
   Couper KN, 2008, J IMMUNOL, V180, P5771
   DALESSANDRO U, 1996, EPIDEMIOLOGICAL EVAL, P291
   Day NPJ, 1999, J INFECT DIS, V180, P1288, DOI 10.1086/315016
   De Rosa V, 2007, IMMUNITY, V26, P241, DOI 10.1016/j.immuni.2007.01.011
   de Souza JB, 2002, MICROBES INFECT, V4, P291, DOI 10.1016/S1286-4579(02)01541-1
   Dodoo D, 2002, J INFECT DIS, V185, P971, DOI 10.1086/339408
   Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102
   Faal N, 2006, PLOS MED, V3, P1292, DOI 10.1371/journal.pmed.0030266
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   Good MF, 1999, CURR OPIN IMMUNOL, V11, P412, DOI 10.1016/S0952-7915(99)80069-7
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   HICKS EJ, 1973, CLIN CHEM, V19, P533
   Hisaeda H, 2004, NAT MED, V10, P29, DOI 10.1038/nm975
   Jawara M, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-156
   Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285
   KARP CL, 1993, J CLIN INVEST, V91, P1644, DOI 10.1172/JCI116372
   Katona P, 2008, CLIN INFECT DIS, V46, P1582, DOI 10.1086/587658
   Krause W., 1994, Applied Parasitology, V35, P70
   Kursar M, 2007, J IMMUNOL, V178, P2661
   Kurtzhals JAL, 1998, LANCET, V351, P1768, DOI 10.1016/S0140-6736(97)09439-7
   LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553
   Long TTA, 2003, INT J PARASITOL, V33, P175, DOI 10.1016/S0020-7519(02)00261-8
   Maizels RM, 2005, CURR OPIN IMMUNOL, V17, P656, DOI 10.1016/j.coi.2005.09.001
   Moore SE, 2002, ARCH DIS CHILD, V87, P192, DOI 10.1136/adc.87.3.192
   Nie CQ, 2007, INFECT IMMUN, V75, P2275, DOI 10.1128/IAI.01783-06
   Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x
   Okech BA, 2004, INFECT IMMUN, V72, P1557, DOI 10.1128/IAI.72.3.1557-1567.2004
   Okiro EA, 2008, TROP MED INT HEALTH, V13, P914, DOI 10.1111/j.1365-3156.2008.02092.x
   Omer FM, 2000, PARASITOL TODAY, V16, P18, DOI 10.1016/S0169-4758(99)01562-8
   Omer FM, 2003, J IMMUNOL, V171, P5430
   Othoro C, 1999, J INFECT DIS, V179, P279, DOI 10.1086/314548
   Perkins DJ, 2000, J INFECT DIS, V182, P988, DOI 10.1086/315762
   Rhee MSM, 2001, CLIN EXP IMMUNOL, V126, P503, DOI 10.1046/j.1365-2249.2001.01681.x
   RILEY EM, 1993, CLIN EXP IMMUNOL, V94, P64
   RILEY EM, 1993, PARASITE IMMUNOL, V15, P513, DOI 10.1111/j.1365-3024.1993.tb00639.x
   ROWLAND S G J G, 1985, Journal of Diarrhoeal Diseases Research, V3, P7
   Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   Taams LS, 2001, EUR J IMMUNOL, V31, P1122, DOI 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P
   Taylor MD, 2005, J IMMUNOL, V174, P4924
   Todryk SM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002027
   Torcia MG, 2008, P NATL ACAD SCI USA, V105, P646, DOI 10.1073/pnas.0709969105
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Vigario AM, 2007, INT J PARASITOL, V37, P963, DOI 10.1016/j.ijpara.2007.01.004
   von Seidlein L, 2002, B WORLD HEALTH ORGAN, V80, P790
   Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941
   Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006
   Walther M, 2006, J IMMUNOL, V177, P5736
   WENISCH C, 1995, J CLIN IMMUNOL, V15, P69, DOI 10.1007/BF01541734
NR 69
TC 36
Z9 37
U1 0
U2 0
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD MAY
PY 2009
VL 39
IS 5
BP 1288
EP 1300
DI 10.1002/eji.200839112
PG 13
WC Immunology
SC Immunology
GA 446RB
UT WOS:000266137700011
PM 19338000
OA No
DA 2017-08-15
ER

PT J
AU Hill, SE
   Njie, O
   Sanneh, M
   Jallow, M
   Peel, D
   Njie, M
   Weber, M
   Hill, PC
   Adegbola, RA
   Howie, SRC
AF Hill, S. E.
   Njie, O.
   Sanneh, M.
   Jallow, M.
   Peel, D.
   Njie, M.
   Weber, M.
   Hill, P. C.
   Adegbola, R. A.
   Howie, S. R. C.
TI Oxygen for treatment of severe pneumonia in The Gambia, West Africa: a
   situational analysis
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE oxygen; pneumonia; Gambia; Africa; children; health service
ID PAPUA-NEW-GUINEA; CONCENTRATOR; CHILDREN; HYPOXEMIA
AB SETTING: Health facilities in The Gambia, West Africa. OBJECTIVES: Oxygen treatment Is vital in pneumonia, the leading cause of death in children globally. There are shortages of oxygen in developing countries, but little information is available on the extent of the problem. We assessed national oxygen availability and use in The Gambia, a sub-Saharan African country.
   METHODS: A government-led team visited 12 health facilities in The Gambia. A modified World Health Organization assessment tool was used to determine oxygen requirements, current provision and capacity to support effective oxygen use.
   RESULTS: Eleven of the 12 facilities managed severe pneumonia. Oxygen was reliable in three facilities. Requirement and supply were often mismatched. Both oxygen concentrators and oxygen cylinders were used. Suboptimal electricity and maintenance made using concentrators difficult, while logistical problems and cost hampered cylinder use. Children were usually triaged by trained nurses who reported lack of training in oxygen use. Oxygen was given typically by nasal prongs; pulse oximetry was available in two facilities.
   CONCLUSIONS: National data showed that oxygen availability did not meet needs in most Gambian health facilities. Remedial options must be carefully assessed for real costs, reliability and site-by-site usability. Training is needed to support oxygen use and equipment maintenance.
C1 [Sanneh, M.; Hill, P. C.; Adegbola, R. A.; Howie, S. R. C.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Hill, S. E.] Univ Otago, Dept Publ Hlth, Wellington, New Zealand.
   [Njie, O.] Dept State Hlth & Social Welf, Integrated Management Childhood Illness Programme, Banjul, Gambia.
   [Weber, M.] WHO, Dept Child & Adolescent Hlth, CH-1211 Geneva, Switzerland.
   [Hill, P. C.] Univ Otago, Ctr Int Hlth, Dunedin, New Zealand.
RP Howie, SRC (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM showie@mrc.gm
FU Medical Research Council UK
FX The authors sincerely thank the staff of the health facilities and
   Divisional Health teams that assisted in the completion of this work.
   This work was funded by the Medical Research Council UK. MW is a staff
   member of the WHO; however, the views expressed in this publication do
   not necessarily represent the decisions or the policies of the WHO.
CR Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8
   Dobson M, 1996, LANCET, V347, P1597, DOI 10.1016/S0140-6736(96)91080-6
   DOBSON MB, 1992, TROP DOCT, V22, P56
   Duke T, 2001, INT J TUBERC LUNG D, V5, P511
   Enarson P, 2008, B WORLD HEALTH ORGAN, V86, P344, DOI 10.2471/BLT.07.048017
   *GAMB CENTR STAT D, 2003, CENS B
   GRANT M, 2003, DESCRIPTION HLTH CAR
   Howie SR, 2008, B WORLD HEALTH ORGAN, V86, P52, DOI 10.2471/BLT.07.042994
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Junge S, 2006, TROP MED INT HEALTH, V11, P367, DOI 10.1111/j.1365-3156.2006.01570.x
   Litch JA, 2000, WILD ENVIRON MED, V11, P189, DOI 10.1580/1080-6032(2000)011[0189:OCFTDO]2.3.CO;2
   Mokuolu OA, 2002, ANN TROP PAEDIATR, V22, P209, DOI 10.1179/027249302125001499
   PEEL D, 2002, IDENTIFICATION OXYGE
   Perrelet A, 2004, INT J TUBERC LUNG D, V8, P1138
   Schneider G, 2001, INT J TUBERC LUNG D, V5, P524
   Shrestha BM, 2002, CAN J ANAESTH, V49, P8
   Wandi F, 2006, ANN TROP PAEDIATR, V26, P277, DOI 10.1179/146532806X152791
   Weber MW, 1998, LANCET, V351, P1589, DOI 10.1016/S0140-6736(05)61160-9
   World Health Organization, 2000, WHOFCHCAH001
   *WHO, 2003, DRAFT REP WHO INF CO
   *WHO, 1993, OXYG THER AC RESP IN
   World Health Organization, 2005, REV GLOB BURD DIS GB
   *WHO, 2003, WHOFCHCAH039
   WOOD PB, 1985, TROP DOCT, V15, P26
NR 24
TC 13
Z9 13
U1 1
U2 2
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD MAY
PY 2009
VL 13
IS 5
BP 587
EP 593
PG 7
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 436OY
UT WOS:000265424900011
PM 19383191
OA No
DA 2017-08-15
ER

PT J
AU Njie, M
   Dilger, E
   Lindsay, SW
   Kirby, MJ
AF Njie, Mbye
   Dilger, Erin
   Lindsay, Steven W.
   Kirby, Matthew J.
TI Importance of Eaves to House Entry by Anopheline, But Not Culicine,
   Mosquitoes
SO JOURNAL OF MEDICAL ENTOMOLOGY
LA English
DT Article
DE Anopheles gambiae s.l.; eaves; house screening; house entry
ID VERTICAL-DISTRIBUTION; GAMBIAE COMPLEX; MALARIA VECTORS; WEST-AFRICA;
   DIPTERA; BEHAVIOR; HUTS; AREA; IDENTIFICATION; DELTAMETHRIN
AB Screening homes is an effective way of reducing house entry by mosquitoes. Here, we assess how important blocking the eaves is for reducing house entry by anopheline and culicine mosquitoes that have screened doors and no windows. Twelve houses, with two screened doors and no windows, in which a single adult male slept, were included in a simple crossover design. in the first period, six houses were randomly; selected and had the eaves blocked using a mixture of rubble and mortar, the other six were left with open eaves Mosquitoes were sampled using CDC light traps from each house twice it week for 4 wk. Mosquito control activities and the number and type of domestic animals within the compound was recorded oil each sampling occasion. Before beginning the second sampling period, homes with blocked eaves had them opened, awl those with open eaves had them closed. Mosquitoes were theo sampled from each house for it further 4 wk. When houses had their eaves closed, a three-fold reduction in Anopheles gambiae, s.l. Giles caught indoors was observed. However, there was no reduction in total colicine that the eaves are the major route by which An. gambiae enters houses. By contrast. culicine mosquitoes enter largely through doors and windows. Sealing the eave gape is all important method for reducing malaria transmission in homes where doors and windows are screened
C1 [Njie, Mbye; Lindsay, Steven W.; Kirby, Matthew J.] Univ Durham, Sci Labs, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
   [Njie, Mbye] Natl Malaria Control Programme, Banjul, Gambia.
RP Kirby, MJ (reprint author), Univ Durham, Sci Labs, Sch Biol & Biomed Sci, South Rd, Durham DH1 3LE, England.
EM m.j.kirby@durham.ac.uk
FU Medical Research Council [G0400031]
CR BERTRAM D. S., 1956, Bulletin of Entomological Research, V47, P669
   BRYAN JH, 1979, T ROY SOC TROP MED H, V73, P463, DOI 10.1016/0035-9203(79)90179-2
   Charlwood JD, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-45
   Costantini C, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P209
   Diallo M, 2005, MED VET ENTOMOL, V19, P119, DOI 10.1111/j.0269-283X.2005.00564.x
   GILLIES MT, 1976, B ENTOMOL RES, V66, P5
   GILLIES MT, 2001, MALARIA, P453
   Gillies M. T., 1968, ANOPHELINAE AFRICA S
   Grieco JP, 2000, J VECTOR ECOL, V25, P62
   Howell PI, 2007, J VECTOR ECOL, V32, P69, DOI 10.3376/1081-1710(2007)32[69:TIOHCO]2.0.CO;2
   JANAKARA BR, 1995, J TROP MED HYG, V98, P73
   Kirby MJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-2
   KOHNERT A, 1991, BAYREUTHER MATH SCHR, V38, P1
   LINDSAY SW, 1995, MED VET ENTOMOL, V9, P50, DOI 10.1111/j.1365-2915.1995.tb00116.x
   Lindsay SW, 2003, TROP MED INT HEALTH, V8, P512, DOI 10.1046/j.1365-3156.2003.01059.x
   Lindsay SW, 2002, TRENDS PARASITOL, V18, P510, DOI 10.1016/S1471-4922(02)02382-6
   LINDSAY SW, 1988, T ROY SOC TROP MED H, V82, P645, DOI 10.1016/0035-9203(88)90546-9
   LINDSAY SWP, 1987, T R SOC TROP MED S2, V87, P19
   Mackinnon MJ, 2005, PLOS MED, V2, P1253, DOI 10.1371/journa;.pmed.0020340
   NUTSATHAPANA S, 1986, B ENTOMOL RES, V76, P303
   ROBERTS DR, 1987, J AM MOSQUITO CONTR, V3, P433
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   Service M.W., 1976, MOSQUITO ECOLOGY FIE
   Sharma S. N., 1993, Indian Journal of Malariology, V30, P155
   SMITH A, 1972, B ENTOMOL RES, V61, P415
   SNOW WF, 1987, MED VET ENTOMOL, V1, P9, DOI 10.1111/j.1365-2915.1987.tb00318.x
   SNOW WF, 1979, B ENTOMOL RES, V69, P561
   SNOW WF, 1975, B ENTOMOL RES, V65, P269
   TRPIS M, 1978, B ENTOMOL RES, V68, P521
   Van Bortel W, 1999, TROP MED INT HEALTH, V4, P257
   WHITTAKER VP, 1969, STRUCTURE FUNCTION N, V3, P1
NR 31
TC 32
Z9 33
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-2585
EI 1938-2928
J9 J MED ENTOMOL
JI J. Med. Entomol.
PD MAY
PY 2009
VL 46
IS 3
BP 505
EP 510
DI 10.1603/033.046.0314
PG 6
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA 441XM
UT WOS:000265803800014
PM 19496420
OA No
DA 2017-08-15
ER

PT J
AU Chessa, B
   Pereira, F
   Arnaud, F
   Amorim, A
   Goyache, F
   Mainland, I
   Kao, RR
   Pemberton, JM
   Beraldi, D
   Stear, MJ
   Alberti, A
   Pittau, M
   Iannuzzi, L
   Banabazi, MH
   Kazwala, RR
   Zhang, YP
   Arranz, JJ
   Ali, BA
   Wang, ZL
   Uzun, M
   Dione, MM
   Olsaker, I
   Holm, LE
   Saarma, U
   Ahmad, S
   Marzanov, N
   Eythorsdottir, E
   Holland, MJ
   Ajmone-Marsan, P
   Bruford, MW
   Kantanen, J
   Spencer, TE
   Palmarini, M
AF Chessa, Bernardo
   Pereira, Filipe
   Arnaud, Frederick
   Amorim, Antonio
   Goyache, Felix
   Mainland, Ingrid
   Kao, Rowland R.
   Pemberton, Josephine M.
   Beraldi, Dario
   Stear, Michael J.
   Alberti, Alberto
   Pittau, Marco
   Iannuzzi, Leopoldo
   Banabazi, Mohammad H.
   Kazwala, Rudovick R.
   Zhang, Ya-ping
   Arranz, Juan J.
   Ali, Bahy A.
   Wang, Zhiliang
   Uzun, Metehan
   Dione, Michel M.
   Olsaker, Ingrid
   Holm, Lars-Erik
   Saarma, Urmas
   Ahmad, Sohail
   Marzanov, Nurbiy
   Eythorsdottir, Emma
   Holland, Martin J.
   Ajmone-Marsan, Paolo
   Bruford, Michael W.
   Kantanen, Juha
   Spencer, Thomas E.
   Palmarini, Massimo
TI Revealing the History of Sheep Domestication Using Retrovirus
   Integrations
SO SCIENCE
LA English
DT Article
ID NEAR-EAST; MITOCHONDRIAL; LINEAGES; ORIGIN; WILD
AB The domestication of livestock represented a crucial step in human history. By using endogenous retroviruses as genetic markers, we found that sheep differentiated on the basis of their "retrotype" and morphological traits dispersed across Eurasia and Africa via separate migratory episodes. Relicts of the first migrations include the Mouflon, as well as breeds previously recognized as "primitive" on the basis of their morphology, such as the Orkney, Soay, and the Nordic short-tailed sheep now confined to the periphery of northwest Europe. A later migratory episode, involving sheep with improved production traits, shaped the great majority of present-day breeds. The ability to differentiate genetically primitive sheep from more modern breeds provides valuable insights into the history of sheep domestication.
C1 [Chessa, Bernardo; Arnaud, Frederick; Kao, Rowland R.; Stear, Michael J.; Palmarini, Massimo] Univ Glasgow, Fac Vet Med, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland.
   [Chessa, Bernardo; Alberti, Alberto; Pittau, Marco] Univ Sassari, Dipartimento Patol & Clin Vet, I-07100 Sassari, Italy.
   [Pereira, Filipe; Amorim, Antonio] Univ Porto, Inst Patol & Imunol Mol, Fac Ciencias, P-4200465 Oporto, Portugal.
   [Goyache, Felix] SERIDA Somio, Area Genet & Reprod Anim, E-33203 Gijon, Spain.
   [Mainland, Ingrid] Univ Bradford, Div Archael Geog & Environm Sci, Bradford BD7 1DP, W Yorkshire, England.
   [Pemberton, Josephine M.; Beraldi, Dario] Univ Edinburgh, Sch Biol Sci, Inst Evolutionary Biol, Edinburgh EH9 3JT, Midlothian, Scotland.
   [Iannuzzi, Leopoldo] ISPAAM, CNR, Natl Res Council, I-80147 Naples, Italy.
   [Banabazi, Mohammad H.] Anim Sci Res Inst Iran, Dept Biotechnol, Karaj 3146618361, Iran.
   [Kazwala, Rudovick R.] Sokoine Univ Agr, Dept Vet Med & Publ Hlth, Morogoro, Tanzania.
   [Zhang, Ya-ping] Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Kunming 650223, Peoples R China.
   [Arranz, Juan J.] Univ Leon, Fac Vet, Dept Anim Prod, E-24071 Leon, Spain.
   [Ali, Bahy A.] Mubarak City Sci Res & Technol Applicat, Genet Engn & Biotechnol Res Inst, Alexandria 21934, Egypt.
   [Wang, Zhiliang] China Anim Hlth & Epidemiol Ctr, Natl Diagnost Ctr Exot Anim Dis, Qingdao 266032, Peoples R China.
   [Uzun, Metehan] Canakkale Onsekiz Mart Univ, Sch Hlth Sci, TR-17100 Canakkale, Turkey.
   [Dione, Michel M.] Int Trypanotolerance Ctr, Banjul, Gambia.
   [Olsaker, Ingrid] Norwegian Sch Vet Sci, Dept Basic Sci & Aquat Med, N-0033 Oslo, Norway.
   [Holm, Lars-Erik] Univ Aarhus, Fac Agr Sci, Dept Genet & Biotechnol, DK-8830 Tjele, Denmark.
   [Saarma, Urmas] Univ Tartu, Inst Ecol & Earth Sci, Dept Zool, EE-51014 Tartu, Estonia.
   [Ahmad, Sohail] NW Frontier Prov Agr Univ, Peshwar, Pakistan.
   [Marzanov, Nurbiy] Russian Acad Agr Sci, All Russian Res Inst Anim Husbandry, Dubrovitsy 142132, Russia.
   [Eythorsdottir, Emma] Agr Univ Iceland, IS-311 Hvanneyri, Borgarnes, Iceland.
   [Holland, Martin J.] MRC Labs, Banjul, Gambia.
   [Holland, Martin J.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Ajmone-Marsan, Paolo] Univ Cattolica Sacro Cuore, Ist Zootecn, I-29100 Piacenza, Italy.
   [Bruford, Michael W.] Cardiff Univ, Sch Biosci, Cardiff CF10 3AX, S Glam, Wales.
   [Kantanen, Juha] MTT Agrifood Res Finland, Biotechnol & Food Res, Jokioinen 31600, Finland.
   [Spencer, Thomas E.] Texas A&M Univ, Ctr Anim Biotechnol & Genom, College Stn, TX 77843 USA.
RP Palmarini, M (reprint author), Univ Glasgow, Fac Vet Med, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland.
EM m.palmarini@vet.gla.ac.uk
RI Pereira, Filipe/F-6391-2010; City for Scientific , and
   Research/E-6802-2017; Bruford, Michael/D-3750-2009; Pemberton,
   Josephine/F-3100-2010; Palmarini, Massimo/H-5982-2011; Holm,
   Lars-Erik/A-4678-2013; Amorim, Antonio/A-7938-2008; Goyache,
   Felix/B-7764-2009; Arranz, Juan Jose/H-1225-2015; Saarma,
   Urmas/J-6448-2015; Banabazi, Mohammad Hossein/S-2335-2016; Genetic
   Engineering & Biotechnology, Research Institute /E-7221-2017
OI Pereira, Filipe/0000-0001-8950-1036; Bruford,
   Michael/0000-0001-6357-6080; Holm, Lars-Erik/0000-0002-5312-3579;
   Amorim, Antonio/0000-0002-7518-6247; Goyache, Felix/0000-0002-6872-1045;
   Arranz, Juan Jose/0000-0001-9058-131X; Saarma,
   Urmas/0000-0002-3222-571X; Alberti, Alberto/0000-0002-1708-9473;
   Iannuzzi, Leopoldo/0000-0002-5445-883X; Banabazi, Mohammad
   Hossein/0000-0002-7873-8123; Spencer, Thomas/0000-0003-2815-766X; Kao,
   Rowland/0000-0003-0919-6401
FU Biotechnology and Biological Sciences Research Council [, BB/F014643/1];
   NICHD NIH HHS [HD05274, R01 HD052745]; Wellcome Trust [, 076522, 081696]
CR Arnaud F, 2008, CELL MOL LIFE SCI, V65, P3422, DOI 10.1007/s00018-008-8500-9
   Arnaud F, 2007, PLOS PATHOG, V3, P1716, DOI 10.1371/journal.ppat.0030170
   Barker G., 2002, EXAMINING FARMING LA, P151
   Boeke J. D., 1997, P343
   Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN
   CLUTTONBROCK J, 1999, NATURAL HIST DOMESTR
   Colledge S., 2005, EUROPEAN J ARCHAEOLO, V8, P137, DOI DOI 10.1177/1461957105066937
   Excoffier L, 2005, EVOL BIOINFORM, V1, P47
   HARRIS D. R., 1996, ORIGINS SPREAD AGR P, P370
   Helmer Daniel, 2007, Anthropozoologica, V42, P41
   Hernandez S, 2005, WIT TRANS BUILT ENV, V80, P269
   Hiendleder S, 2002, P ROY SOC B-BIOL SCI, V269, P893, DOI 10.1098/rspb.2002.1975
   MCGOVERN TH, 1990, ANNU REV ANTHROPOL, V19, P331
   Meadows JRS, 2007, GENETICS, V175, P1371, DOI 10.1534/genetics.106.068353
   Naderi S, 2008, P NATL ACAD SCI USA, V105, P17659, DOI 10.1073/pnas.0804782105
   Palmarini M, 1999, J VIROL, V73, P6964
   Pedrosa S, 2005, P ROY SOC B-BIOL SCI, V272, P2211, DOI 10.1098/rspb.2005.3204
   Pedrosa S, 2007, GENET SEL EVOL, V39, P91, DOI 10.1051/gse:2006034
   Pereira F, 2006, MOL BIOL EVOL, V23, P1420, DOI 10.1093/molbev/msl007
   POPLIN F, 1979, ANN GENET SEL ANIM, V11, P133, DOI 10.1186/1297-9686-11-2-133
   Price T., 2000, EUROPES 1 FARMERS
   Ryder M. A., 1983, SHEEP MAN
   Sherratt A., 1981, PATTERN PAST STUDIES, P261
   Tapio M, 2006, MOL BIOL EVOL, V23, P1776, DOI 10.1093/molbev/mls043
   Vigne Jean-Denis, 1999, P295
   Zeder MA, 2008, P NATL ACAD SCI USA, V105, P11597, DOI 10.1073/pnas.0801317105
   Zohary D, 1998, J ZOOL, V245, P129
NR 27
TC 125
Z9 133
U1 4
U2 59
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD APR 24
PY 2009
VL 324
IS 5926
BP 532
EP 536
DI 10.1126/science.1170587
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 436JU
UT WOS:000265411200052
PM 19390051
OA No
DA 2017-08-15
ER

PT J
AU Doumbia, M
   Jarju, A
   Sene, M
   Traore, K
   Yost, R
   Kablan, R
   Brannan, K
   Berthe, A
   Yamoah, C
   Querido, A
   Traore, PCS
   Ballo, A
AF Doumbia, Mamadou
   Jarju, Ansumana
   Sene, Modou
   Traore, Kalifa
   Yost, Russell
   Kablan, Richard
   Brannan, Kevin
   Berthe, Abou
   Yamoah, Charles
   Querido, Antonio
   Traore, Pierre C. S.
   Ballo, Abdou
TI Sequestration of organic carbon in West African soils by Amenagement en
   Courbes de Niveau
SO AGRONOMY FOR SUSTAINABLE DEVELOPMENT
LA English
DT Article
DE ACN; Amenagement en courbes de niveau; ridge-tillage; Mali; Senegal; The
   Gambia; soil organic carbon; reductions in carbon dioxide; carbon
   sequestration; climate change
ID AGRICULTURE; MANAGEMENT; RAINFALL; MALI
AB A recent Intergovernmental Panel on Climate Change (IPPC) report concludes that global warming, while already a global crisis, is likely to become even more devastating. The scientific consensus is that global warming is caused by increases in greenhouse gases including carbon dioxide. The Sahel of West Africa seems to be more adversely affected by such climate changes, leading to reduced and more sporadic rainfall. In addition, food security in the region is tenuous and fragile, due to adverse climate change, but also due to the historical mining of nutrients and carbon. With the adoption of the Kyoto accords, at least by some countries, sequestered carbon (C) has become a tradable commodity. This provides a double incentive to increase soil organic carbon in the C-depleted and degraded soils of West Africa-return C to improve soil quality and assist in removing CO2 from the atmosphere to assist in mitigating climate change. A challenge, however, remains to determine which agricultural systems can actually sequester C. The technology called Amenagement en courbes de niveau (ACN), which can be roughly translated as 'Ridge-tillage', has given crop yield increases of 30 to 50%. To date, there has only been anecdotal evidence suggesting that Amenagement en courbes de niveau leads to increased soil organic C. The objectives of the study reported here were to determine whether the technology has the potential to sequester C in West African soils, and, if so, how much. In this study, soil organic C was measured by combustion methods in soils sampled at 0-20 and 20-40 cm depths in a series of experiments in Mali, Senegal and The Gambia. Soil organic C was measured in three very different types of experiments, all including Amenagement en courbes de niveau technology, resulting in three methods of measuring C sequestration. Our results indicate that the Amenagement en courbes de niveau technology significantly increased maize yields by 24% by weight in the Gambia experiment while soil organic C was increased by 26% in The Gambia, by 12% in Siguidolo, Mali, and by 14% in peanut systems of Nioro, Senegal. These increases in soil organic C are likely due to three factors: (1) reduced erosion and movement of soil, (2) increased crop growth resulting from the greater capture of rainfall, and (3) increased growth and density of shrubs and trees resulting from the increased subsoil water, resulting in turn from the increased capture of rainfall, and reduced runoff. Measuring soil C on fields that were successively placed under Amenagement en courbes de niveau management and the use of replicated experimental plots appear to be the best methods to quantify the C sequestration potential of the practice. These results indicate that this soil and water conservation technology not only harvests water and increases food production, but also increases soil organic carbon. This technology thus is a successful technique to sequester C in soils and if carried out in a large region may both offset CO2 emissions and help mitigate climate change.
C1 [Yost, Russell; Kablan, Richard; Yamoah, Charles; Querido, Antonio] Univ Hawaii, Honolulu, HI 96822 USA.
   [Traore, Pierre C. S.] Lab Sol Eau Plante, Int Crops Res Inst Semi Arid Trop, Bamako, Mali.
   [Doumbia, Mamadou; Traore, Kalifa; Berthe, Abou; Ballo, Abdou] Inst Econ Rurale, Bamako, Mali.
   [Jarju, Ansumana] Natl Agr Res Inst, Serrekunda, Gambia.
   [Sene, Modou] Ctr Etud Reg Ameliorat Adaptat Secheresse, Thies, Senegal.
   [Brannan, Kevin] Virginia Polytech & State Univ, Blacksburg, VA 24061 USA.
RP Yost, R (reprint author), Univ Hawaii, 3190 Maile Way, Honolulu, HI 96822 USA.
EM rsyost@hawaii.edu
CR ANTLE JM, 2002, SPECIAL PUBLICATION, P111
   Bationo A, 2001, NUTR CYCL AGROECOSYS, V61, P131, DOI 10.1023/A:1013355822946
   Brady NC, 2002, NATURE PROPERTIES SO
   Casenave A., 1989, ETATS SURFACE ZONE S
   Chivenge PP, 2007, SOIL TILL RES, V94, P328, DOI 10.1016/j.still.2006.08.006
   Doraiswamy PC, 2007, AGR SYST, V94, P63, DOI 10.1016/j.agsy.2005.09.011
   Doumbia MD, 1998, ARID SOIL RES REHAB, V12, P179
   GIGOU J, 2006, CAH AGR, V15
   GIGOU J, 1999, B RESEAU EROSION, V19, P391
   GIGOU J, 1997, RAPPORT ANAL PROJET
   HOOGMOED WB, 1984, SOIL TILL RES, V4, P5, DOI 10.1016/0167-1987(84)90013-8
   Kablan R, 2008, ARID LAND RES MANAG, V22, P62, DOI 10.1080/15324980701784191
   KEELING CO, 2008, ATMOSPHERIC CARBON D
   KELLY VA, 2000, MEASURING IMPACTS NA
   Lal R, 2008, AGRON SUSTAIN DEV, V28, P57, DOI 10.1051/agro:2007025
   Littell R.C., 2002, SAS LINEAR MODELS
   Pieri C. J. M. G., 1992, FERTILITY SOILS FUTU
   QUERIDO A, 2008, THESIS U HAWAII MANO
   REIJ C, 1996, SUSTAINING SOIL
   ROBERTS M, 2007, SUQUESTERING CARBON
   Soil Survey Staff, 1975, SOIL TAX BAS SYST SO
   Traore K, 2003, THESIS ECOLE NATL SU
   TRAORE KB, 2002, C INT GEST BIOM RUIS
   Traore Seydou B., 2000, Secheresse (Montrouge), V11, P227
NR 24
TC 9
Z9 9
U1 1
U2 17
PU SPRINGER FRANCE
PI PARIS
PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE
SN 1774-0746
J9 AGRON SUSTAIN DEV
JI Agron. Sustain. Dev.
PD APR-JUN
PY 2009
VL 29
IS 2
BP 267
EP 275
DI 10.1051/agro:2008041
PG 9
WC Agronomy; GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY
SC Agriculture; Science & Technology - Other Topics
GA 434MT
UT WOS:000265279500004
OA No
DA 2017-08-15
ER

PT J
AU Bojang, K
   Milligan, P
   Pinder, M
   Doherty, T
   Leach, A
   Ofori-Anyinam, O
   Lievens, M
   Kester, K
   Schaecher, K
   Ballou, WR
   Cohen, J
AF Bojang, Kalifa
   Milligan, Paul
   Pinder, Margaret
   Doherty, Tom
   Leach, Amanda
   Ofori-Anyinam, Opokua
   Lievens, Marc
   Kester, Kent
   Schaecher, Kurt
   Ballou, W. Ripley
   Cohen, Joe
TI Five-year safety and immunogenicity of GlaxoSmithKline's candidate
   malaria vaccine RTS,S/AS02 following administration to semi-immune adult
   men living in a malaria-endemic region of The Gambia
SO HUMAN VACCINES
LA English
DT Article
DE malaria vaccine; RTS,S; five-year follow-up; long term persistence of
   anti-HBs; AS02 adjuvant system
ID PLASMODIUM-FALCIPARUM INFECTION; RANDOMIZED CONTROLLED-TRIAL;
   HEPATITIS-B-VACCINE; PROTECTION; EFFICACY; CHILDREN; DISEASE
AB RTS,S is a pre-erythrocytic malaria vaccine candidate antigen based on the circumsporozoite surface protein of Plasmodium falciparum fused to HBsAg, incorporating a novel Adjuvant System (AS02). The first field efficacy of RTS,S/AS02 against infection was demonstrated in a trial initiated in The Gambia in 1998. This paper presents the five-year safety and immunogenicity follow up of the 306 men who were enrolled in the original trial.
   In the primary study men aged 18 to 45 years were randomized to receive either RTS, S/AS02 or rabies vaccine at 0, 1, 5 months followed by a booster dose at month 19. The subjects were observed for long term safety and immunogenicity continuously until month 58.
   Of the 153 subjects in each group at enrollment, 80 (52%) subjects in the RTS,S/AS02 group and 83 (54%) subjects in the rabies group returned for the final long-term follow-up visit at month 58. The main reason for non-attendance at month 58 was migration (76% of all drop-outs). Nine subjects in the RTS, S/AS02 group and seven in the rabies group experienced serious adverse events (SAEs) over the 58 month surveillance period, of which seven had a fatal outcome (five RTS, S/AS02 and two rabies group). None of the SAEs with fatal outcome were attributed to the study vaccine. Anti-CS antibody persistence compared to control was observed for five years, although titres had waned from post-booster levels; similar responses in anti-HBs antibody persistence were observed in initially HBsAg seronegative subjects.
   This study provides the first indication of the long-term safety and persistence of anti-CS and anti-HBs antibodies of the RTS, S vaccine candidate in combination with the novel AS02 Adjuvant System.
C1 [Bojang, Kalifa; Pinder, Margaret] MRC Labs, Banjul, Gambia.
   [Milligan, Paul; Doherty, Tom] London Sch Hyg & Trop Med, London WC1, England.
   [Leach, Amanda; Ofori-Anyinam, Opokua; Lievens, Marc; Cohen, Joe] GlaxoSmithKline Biol, Rixensart, Belgium.
   [Kester, Kent; Schaecher, Kurt] Walter Reed Army Inst Res, Div Malaria Vaccine Dev, Silver Spring, MD USA.
   [Ballou, W. Ripley] Bill & Melinda Gates Fdn, Seattle, WA USA.
RP Bojang, K (reprint author), MRC Labs, Atlantic Blvd, Banjul, Gambia.
EM kbojang@mrc.gm
RI Kester, Kent/A-2114-2011; Milligan, Paul/D-8985-2017
OI Kester, Kent/0000-0002-5056-0802; Milligan, Paul/0000-0003-3430-3395
FU Medical Research Council [G0700837]
CR Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6
   Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   Aponte JJ, 2007, LANCET, V370, P1543, DOI 10.1016/S0140-6736(07)61542-6
   Assad S, 1999, VACCINE, V18, P57, DOI 10.1016/S0264-410X(99)00179-6
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Breman JG, 2001, AM J TROP MED HYG, V64, P1
   *CDCP, COMPR IMM STRAT EL 2
   Garcon Nathalie, 2003, Expert Rev Vaccines, V2, P231, DOI 10.1586/14760584.2.2.231
   GESEMANN M, 1995, VACCINE, V13, P443, DOI 10.1016/0264-410X(94)00010-K
   GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q
   JILG W, 1984, LANCET, V2, P458
   RATCLIFFE AA, 2002, POPULATION HLTH DEV
   WESTMORELAND D, 1990, EPIDEMIOL INFECT, V104, P499
NR 13
TC 22
Z9 24
U1 0
U2 1
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, TX 78701 USA
SN 1554-8619
J9 HUM VACCINES
JI Hum. Vaccines
PD APR
PY 2009
VL 5
IS 4
BP 242
EP 247
PG 6
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA 453BS
UT WOS:000266585600008
PM 19276646
OA No
DA 2017-08-15
ER

PT J
AU Ritchie, LMP
   Howie, SRC
   Arenovich, T
   Cheung, YB
   Weber, M
   Moore, S
   Adegbola, RA
AF Ritchie, L. M. Puchalski
   Howie, S. R. C.
   Arenovich, T.
   Cheung, Y. B.
   Weber, M.
   Moore, S.
   Adegbola, R. A.
TI Long-term morbidity from severe pneumonia in early childhood in The
   Gambia, West Africa: a follow-up study
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE childhood pneumonia; follow-up; chronic lung disease
ID RESPIRATORY-TRACT INFECTION; CHILDREN; ASTHMA; SPIROMETRY; INFANCY;
   BRONCHIOLITIS; DIAGNOSIS; MORTALITY
AB OBJECTIVE: To assess long-term outcomes in severe early childhood pneumonia in The Gambia.
   DESIGN: Observational cohort study of children hospitalised with severe pneumonia between 1992 and 1 04 compared to age, sex, and neigh bourhood-marched controls on measures of current general and pulmonary health.
   RESULTS: Of 83 children successfully traced, 68 of the 69 alive at follow-up agreed to participate. Thirteen per Cent of cases and 4% of controls had lung disease clinically or on spirometry. Another 16 (13%) participants had abnormal spirometry but did not meet the American Thoracic Society technical criteria (formally 'inconclusive'). Odds ratios of lung disease among childhood pneumonia cases were 2.93 (95 %CI 0.69-12.48, P = 0.1468) with incon-clusives omitted; 2.53 (95 %CI 0.61-10.59, P = 0.2033) with inconclusives included as normal; and 2.83 (95%CI 1.09-7.36, P = 0.0334) with inconclusives included as lung disease. Among deceased cases, most deaths were reported within weeks of discharge, suggesting a possible connection between admission and subsequent death.
   CONCLUSION: These African data, while not conclusive, add to previous data suggesting a link between severe early, childhood pneumonia and later chronic lung disease. While larger-scale research is needed, increased awareness of possible long-term morbidity in children with severe pneumonia is warranted to limit its impact and optimise long-term health.
C1 [Ritchie, L. M. Puchalski] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada.
   [Ritchie, L. M. Puchalski; Howie, S. R. C.; Adegbola, R. A.] MRC Labs, Bacterial Dis Programme, Fajara, Gambia.
   [Arenovich, T.] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada.
   [Cheung, Y. B.] London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England.
   [Weber, M.] World Hlth Org, Dept Child & Adolescent Hlth, Geneva, Switzerland.
   [Moore, S.] MRC Labs, Nutr Programme, Fajara, Gambia.
RP Ritchie, LMP (reprint author), Univ Hlth Network, Toronto Gen Hosp, 200 Elizabeth St,RFE GS-488, Toronto, ON M5C 2C4, Canada.
EM lisa.puchalskiritchie@utoronto.ca
CR Adegbola RA, 2000, ANN TROP MED PARASIT, V94, P197
   Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0
   BENABRAHAM R, 2002, MED SCI MONITOR, V8, P153
   EMMONS EE, 2007, E MED BRONCHIECTASIS
   Enright PL, 2000, CHEST, V118, P665, DOI 10.1378/chest.118.3.665
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   Korppi M, 2004, PEDIATR PULM, V38, P155, DOI 10.1002/ppul.20058
   KORPPI M, 1994, ARCH PEDIAT ADOL MED, V148, P1079
   Kycler Z, 2001, Pneumonol Alergol Pol, V69, P167
   LEEDER SR, 1976, BRIT J PREV SOC MED, V30, P219
   MAJIAS A, 2005, CURR OPIN INFECT DIS, V18, P199
   Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805
   Milligan G, 2005, J MOL NEUROSCI, V26, P161, DOI 10.1385/JMN/26:02:161
   MOK JYQ, 1984, ARCH DIS CHILD, V59, P306
   Piippo-Savolainen E, 2004, ARCH PEDIAT ADOL MED, V158, P1070, DOI 10.1001/archpedi.158.11.1070
   Quadrelli S, 2007, MEDICINA-BUENOS AIRE, V67, P685
   Ratageri VH, 2001, J TROP PEDIATRICS, V47, P57, DOI 10.1093/tropej/47.1.57
   Tsao Pei-Chen, 2002, Acta Paediatrica Taiwanica, V43, P271
   Weber MW, 1997, ARCH DIS CHILD, V76, P310
   WESLEY AG, 1991, S AFR MED J, V79, P73
   West TE, 1999, B WORLD HEALTH ORGAN, V77, P144
   World Health Organization. World Health Statistics, 2008, CHRON RESP DIS
   WHO, 2008, WHO STAT INF SYST CO
   *WHO, 2008, AC RESP INF CHILDR
NR 24
TC 9
Z9 10
U1 0
U2 3
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD APR
PY 2009
VL 13
IS 4
BP 527
EP 532
PG 6
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 420QX
UT WOS:000264305400018
OA No
DA 2017-08-15
ER

PT J
AU de Jong, BC
   Antonio, M
   Awine, T
   Ogungbemi, K
   de Jong, YP
   Gagneux, S
   DeRiemer, K
   Zozio, T
   Rastogi, N
   Borgdorff, M
   Hill, PC
   Adegbola, RA
AF de Jong, Bouke C.
   Antonio, Martin
   Awine, Timothy
   Ogungbemi, Kunle
   de Jong, Ype P.
   Gagneux, Sebastien
   DeRiemer, Kathryn
   Zozio, Thierry
   Rastogi, Nalin
   Borgdorff, Martien
   Hill, Philip C.
   Adegbola, Richard A.
TI Use of Spoligotyping and Large Sequence Polymorphisms To Study the
   Population Structure of the Mycobacterium tuberculosis Complex in a
   Cohort Study of Consecutive Smear-Positive Tuberculosis Cases in The
   Gambia
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID GENOMIC DELETIONS; AFRICANUM; STRAINS; EPIDEMIOLOGY; DIVERSITY;
   PATHOGEN; CAMEROON; FAMILY
AB Mycobacterium africanum, first described in Senegal in 1968, causes up to half of the smear-positive pulmonary tuberculosis cases in West Africa, but it has not been found in other geographical areas except among recent West African migrants. The reasons for the geographic restriction of M. africanum are unknown. We used molecular tools to determine the population structure of the Mycobacterium tuberculosis complex in a cohort study of consecutive smear-positive tuberculosis cases in The Gambia. We collected and genotyped 386 clinical isolates using spoligotype analysis and PCRs for large sequence polymorphisms (LSPs) and compared the genotype patterns to the patterns in an international database. The results of spoligotyping and LSP analysis for the study population were also compared to determine the correlation between them. The main lineages within the Mycobacterium tuberculosis complex identified in The Gambia included M. africanum type I (38.4%), characterized by an LSP in region of difference 702 (RD702; West African type 2). Among the M. tuberculosis sensu stricto isolates, lineages characterized by RD182 and by RD174 were the most common. We also detected a gradient in the prevalence of M. africanum that extended from neighboring Guinea-Bissau. The genotypic diversity of the spoligotype patterns was greater among the isolates of M. africanum than among the isolates of M. tuberculosis. We postulate that M. africanum became endemic in West Africa first, before the introduction of different lineages within M. tuberculosis sensu stricto.
C1 [de Jong, Bouke C.; Antonio, Martin; Awine, Timothy; Ogungbemi, Kunle; de Jong, Ype P.; Hill, Philip C.; Adegbola, Richard A.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [de Jong, Bouke C.] NYU, New York, NY USA.
   [Gagneux, Sebastien] Natl Inst Med Res, MRC, London NW7 1AA, England.
   [DeRiemer, Kathryn] Univ Calif Davis, Sch Med, Davis, CA 95616 USA.
   [Zozio, Thierry; Rastogi, Nalin] Inst Pasteur Guadeloupe, Abymes, Guadeloupe.
   [Borgdorff, Martien] Univ Amsterdam, Amsterdam, Netherlands.
   [Borgdorff, Martien] KNCV, The Hague, Netherlands.
RP de Jong, BC (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM bdejong@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675; DeRiemer,
   Kathryn/0000-0002-8375-7505; Gagneux, Sebastien/0000-0001-7783-9048
FU MRC core funds; NIH [TW006083]; European Commission (ERDF/FEDER)
   [A34-05]
FX We thank the participants and TB diagnostics staff, in particular, Neneh
   Sallah and Ebou Mbowe. We also thank colleagues at the Institut Pasteur
   de Guadeloupe for various aspects regarding genotyping analysis,
   Christophe Sola for an initial comparison of preliminary results using
   the SpolDB4 database, and Christophe Demay for the entry of new data
   from the updated data set into the SITVIT2 database.
CR Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299
   Brudey K, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-23
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   de Jong BC, 2007, INT J TUBERC LUNG D, V11, P450
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977
   de Jong BC, 2005, AIDS, V19, P1714, DOI 10.1097/01.aids.0000185991.54595.41
   Desmond E, 2004, EMERG INFECT DIS, V10, P921
   Diop S, 1976, Bull Soc Med Afr Noire Lang Fr, V21, P50
   Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103
   Gagneux S, 2007, LANCET INFECT DIS, V7, P328, DOI 10.1016/S1473-3099(07)70108-1
   Hershberg R, 2008, PLOS BIOL, V6, P2658, DOI 10.1371/journal.pbio.0060311
   Huard RC, 2003, J CLIN MICROBIOL, V41, P1637, DOI 10.1128/JCM.41.4.1637-1650.2003
   HUNTER PR, 1988, J CLIN MICROBIOL, V26, P2465
   Kallenius G, 1999, J CLIN MICROBIOL, V37, P3872
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907
   Marmiesse M, 2004, MICROBIOL-SGM, V150, P483, DOI 10.1099/mic.0.26662-0
   Mostowy S, 2004, J CLIN MICROBIOL, V42, P3594, DOI 10.1128/jcm.42.8.3594-3599.2004
   Niobe-Eyangoh SN, 2004, J CLIN MICROBIOL, V42, P5029, DOI 10.1128/JCM.42.11.5029-5035.2004
   Niobe-Eyangoh SN, 2003, J CLIN MICROBIOL, V41, P2547, DOI 10.1128/JCM.41.6.2547-2553.2003
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402
   Sola C, 2003, J CLIN MICROBIOL, V41, P1345, DOI 10.1128/JCM.41.3.1345-1348.2003
   Tanaka MM, 2006, P NATL ACAD SCI USA, V103, P15266, DOI 10.1073/pnas.0603130103
   Tsolaki AG, 2004, P NATL ACAD SCI USA, V101, P4865, DOI 10.1073/pnas.0305634101
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406
   Verver S, 2004, LANCET, V363, P212, DOI 10.1016/S0140-6736(03)15332-9
   Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205
   Zink AR, 2003, J CLIN MICROBIOL, V41, P359, DOI 10.1128/JCM.41.1.359-367.2003
   2004, NATL LEPROSY TUBERCU
NR 28
TC 34
Z9 35
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD APR
PY 2009
VL 47
IS 4
BP 994
EP 1001
DI 10.1128/JCM.01216-08
PG 8
WC Microbiology
SC Microbiology
GA 427RS
UT WOS:000264797000019
PM 19193842
OA No
DA 2017-08-15
ER

PT J
AU Walther, M
   Jeffries, D
   Finney, OC
   Njie, M
   Ebonyi, A
   Deininger, S
   Lawrence, E
   Ngwa-Amambua, A
   Jayasooriya, S
   Cheeseman, IH
   Gomez-Escobar, N
   Okebe, J
   Conway, DJ
   Riley, EM
AF Walther, Michael
   Jeffries, David
   Finney, Olivia C.
   Njie, Madi
   Ebonyi, Augustine
   Deininger, Susanne
   Lawrence, Emma
   Ngwa-Amambua, Alfred
   Jayasooriya, Shamanthi
   Cheeseman, Ian H.
   Gomez-Escobar, Natalia
   Okebe, Joseph
   Conway, David J.
   Riley, Eleanor M.
TI Distinct Roles for FOXP3(+) and FOXP3(-) CD4(+) T Cells in Regulating
   Cellular Immunity to Uncomplicated and Severe Plasmodium falciparum
   Malaria
SO PLOS PATHOGENS
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; EXPERIMENTAL CEREBRAL MALARIA; FACTOR-ALPHA;
   RHEUMATOID-ARTHRITIS; CYTOKINE PRODUCTION; CLINICAL IMMUNITY;
   INTERFERON-GAMMA; SERUM LEVELS; TGF-BETA; INFECTION
AB Failure to establish an appropriate balance between pro- and anti-inflammatory immune responses is believed to contribute to pathogenesis of severe malaria. To determine whether this balance is maintained by classical regulatory T cells (CD4(+) FOXP3(+) CD127(-/low); Tregs) we compared cellular responses between Gambian children (n=124) with severe Plasmodium falciparum malaria or uncomplicated malaria infections. Although no significant differences in Treg numbers or function were observed between the groups, Treg activity during acute disease was inversely correlated with malaria-specific memory responses detectable 28 days later. Thus, while Tregs may not regulate acute malarial inflammation, they may limit memory responses to levels that subsequently facilitate parasite clearance without causing immunopathology. Importantly, we identified a population of FOXP3(-), CD45RO(+) CD4(+) T cells which coproduce IL-10 and IFN-gamma. These cells are more prevalent in children with uncomplicated malaria than in those with severe disease, suggesting that they may be the regulators of acute malarial inflammation.
C1 [Walther, Michael; Jeffries, David; Finney, Olivia C.; Njie, Madi; Ebonyi, Augustine; Deininger, Susanne; Lawrence, Emma; Ngwa-Amambua, Alfred; Jayasooriya, Shamanthi; Cheeseman, Ian H.; Gomez-Escobar, Natalia; Okebe, Joseph; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Finney, Olivia C.; Cheeseman, Ian H.; Conway, David J.; Riley, Eleanor M.] London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1, England.
   [Deininger, Susanne] Univ Clin Bonn, Inst Med Microbiol Immunol & Parasitol, Bonn, Germany.
RP Walther, M (reprint author), MRC Labs, Banjul, Gambia.
EM mwalther@mrc.gm
RI Riley, Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570; cheeseman, ian/0000-0003-4426-4027
FU MRC laboratories; Fajara Malaria Programme
FX The project was fully financed by the core budget allocated to the MRC
   laboratories, Fajara Malaria Programme. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Akbar AN, 2007, NAT REV IMMUNOL, V7, P231, DOI 10.1038/nri2037
   Amante FH, 2007, AM J PATHOL, V171, P548, DOI 10.2353/ajpath.2007.061033
   Anderson CF, 2007, J EXP MED, V204, P285, DOI 10.1084/jem.20061886
   Artavanis-Tsakonas K, 2003, CLIN EXP IMMUNOL, V133, P145, DOI 10.1046/j.1365-2249.2003.02174.x
   Artavanis-Tsakonas K, 2002, J IMMUNOL, V169, P2956
   Baecher-Allan C, 2002, J IMMUNOL, V169, P6210
   BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
   Brustoski K, 2006, J INFECT DIS, V193, P146, DOI 10.1086/498578
   Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358
   Cambos M, 2008, INT J PARASITOL, V38, P229, DOI 10.1016/j.ijpara.2007.07.006
   Chaiyaroj SC, 2004, ACTA TROP, V89, P319, DOI 10.1016/j.actatropica.2003.10.010
   Chen RF, 2005, FEMS IMMUNOL MED MIC, V44, P43, DOI 10.1016/j.femsim.2004.11.012
   Chen X, 2007, J IMMUNOL, V179, P154
   CONWAY DJ, 1991, PARASITOLOGY, V103, P1
   Couper KN, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000004
   Couper KN, 2007, J IMMUNOL, V178, P4136
   Day NPJ, 1999, J INFECT DIS, V180, P1288, DOI 10.1086/315016
   Dodoo D, 2002, J INFECT DIS, V185, P971, DOI 10.1086/339408
   Dondorp AM, 2005, PLOS MED, V2, P788, DOI 10.1371/journal.pmed.0020204
   Ehrenstein MR, 2004, J EXP MED, V200, P277, DOI 10.1084/jem.20040165
   ELHASSAN IM, 1994, AM J TROP MED HYG, V51, P372
   Faal N, 2006, PLOS MED, V3, P1292, DOI 10.1371/journal.pmed.0030266
   FINNEY OC, 2009, EUR J IMMUN IN PRESS
   Good MF, 1999, CURR OPIN IMMUNOL, V11, P412, DOI 10.1016/S0952-7915(99)80069-7
   GRAU GE, 1989, INT ARCH ALLER A IMM, V88, P34
   GRAU GE, 1989, IMMUNOL REV, V112, P49, DOI 10.1111/j.1600-065X.1989.tb00552.x
   GRAU GE, 1989, P NATL ACAD SCI USA, V86, P5572, DOI 10.1073/pnas.86.14.5572
   GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918
   Gupta S, 1999, NAT MED, V5, P340, DOI 10.1038/6560
   Gwer S, 2007, AM J TROP MED HYG, V77, P6
   HICKS EJ, 1973, CLIN CHEM, V19, P533
   Hisaeda H, 2004, NAT MED, V10, P29, DOI 10.1038/nm975
   Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1
   Hviid L, 2000, INFECT IMMUN, V68, P6087, DOI 10.1128/IAI.68.10.6087-6089.2000
   Hviid L, 1997, INFECT IMMUN, V65, P4090
   Isomaki P, 2007, RHEUMATOLOGY, V46, P1538, DOI 10.1093/rheumatology/kem198
   Jankovic D, 2007, J EXP MED, V204, P273, DOI 10.1084/jem.20062175
   Keating SM, 2005, J IMMUNOL, V175, P5675
   KERN P, 1989, AM J MED, V87, P139
   KREMSNER PG, 1995, AM J TROP MED HYG, V53, P532
   Kursar M, 2002, J EXP MED, V196, P1585, DOI 10.1084/jem.20011347
   Kurtzhals JAL, 1998, LANCET, V351, P1768, DOI 10.1016/S0140-6736(97)09439-7
   KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5
   Kwiatkowski Dominic P., 2006, Parassitologia (Rome), V48, P450
   Langhorne J, 2008, NAT IMMUNOL, V9, P725, DOI 10.1038/ni.f.205
   Li C, 2003, INFECT IMMUN, V71, P4850, DOI 10.1128/IAI.71.9.4850-4856.2003
   Lim HW, 2006, J IMMUNOL, V177, P840
   LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553
   LISSE IM, 1994, T ROY SOC TROP MED H, V88, P709, DOI 10.1016/0035-9203(94)90242-9
   Long TTA, 2003, INT J PARASITOL, V33, P175, DOI 10.1016/S0020-7519(02)00261-8
   Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a
   Moore AC, 2005, J IMMUNOL, V175, P7264
   Nie CQ, 2007, INFECT IMMUN, V75, P2275, DOI 10.1128/IAI.01783-06
   Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141
   O'Garra A, 2007, NAT REV IMMUNOL, V7, P425, DOI 10.1038/nri2097
   Omer FM, 2003, J IMMUNOL, V171, P5430
   Othoro C, 1999, J INFECT DIS, V179, P279, DOI 10.1086/314548
   Perkins DJ, 2000, J INFECT DIS, V182, P988, DOI 10.1086/315762
   Perry JA, 2005, J IMMUNOL, V174, P5921
   Pombo DJ, 2002, LANCET, V360, P610, DOI 10.1016/S0140-6736(02)09784-2
   Riley EM, 2006, PARASITE IMMUNOL, V28, P35, DOI 10.1111/j.1365-3024.2006.00775.x
   Rudin W, 1997, EUR J IMMUNOL, V27, P810, DOI 10.1002/eji.1830270403
   Schofield L, 2006, CURR MOL MED, V6, P205, DOI 10.2174/156652406776055221
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2
   Sponaas AM, 2006, J EXP MED, V203, P1427, DOI 10.1084/jem.20052450
   Sugimoto N, 2006, INT IMMUNOL, V18, P1197, DOI 10.1093/intimm/dx1060
   Torcia MG, 2008, P NATL ACAD SCI USA, V105, P646, DOI 10.1073/pnas.0709969105
   Valencia X, 2006, BLOOD, V108, P253, DOI 10.1182/blood-2005-11-4567
   Vigario AM, 2007, INT J PARASITOL, V37, P963, DOI 10.1016/j.ijpara.2007.01.004
   Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941
   Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006
   Walther M, 2006, J IMMUNOL, V177, P5736
   Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
   WELLS RA, 1979, CLIN EXP IMMUNOL, V35, P202
   WENISCH C, 1995, J CLIN IMMUNOL, V15, P69, DOI 10.1007/BF01541734
   World Health Organization, 2000, T R SOC TROP MED HYG, V94
   Wu Y, 2007, EXP PARASITOL, V115, P301, DOI 10.1016/j.exppara.2006.09.015
NR 78
TC 113
Z9 120
U1 2
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7366
J9 PLOS PATHOG
JI PLoS Pathog.
PD APR
PY 2009
VL 5
IS 4
AR e1000364
DI 10.1371/journal.ppat.1000364
PG 14
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 447UC
UT WOS:000266216300008
PM 19343213
OA gold
DA 2017-08-15
ER

PT J
AU Okoko, BJ
   Idoko, OT
   Adegbola, RA
AF Okoko, Brown J.
   Idoko, Olubukola T.
   Adegbola, Richard A.
TI Prospects and challenges with introduction of a mono-valent
   meningococcal conjugate vaccine in Africa
SO VACCINE
LA English
DT Review
DE Meningococcal meningitis; Conjugate vaccine; N. meningitidis serogroup A
ID NEISSERIA-MENINGITIDIS; BACTERIAL-MENINGITIS; POLYSACCHARIDE VACCINE;
   UNITED-KINGDOM; HUMAN IMMUNITY; CHILDREN; DISEASE; EFFICACY; ENGLAND;
   EPIDEMIOLOGY
AB Epidemic meningococcal meningitis is a priority disease for prevention and control in Africa. The current World Health Organization (WHO) approach to the control of meningitis epidemics is based on early detection of cases and emergency vaccination of the Population at risk with meningococcal polysaccharide (PS) vaccines. But this is a tall order for the developing nations of Africa where experts operate from an ineffective health system. Although the widespread use of meningococal polysaccharide vaccines has had a major and much appreciated public health impact on the disease it has not prevented epidemics of this dreaded infection. The Current partnership between WHO and the PATH aims to develop, evaluate and introduce an appropriate and affordable meningococcal conjugate vaccine that Could potentially provide for a means of preventing epidemic meningitis caused by N. meningitidis group A. In this paper, we review the prospects and challenges facing the introduction of the mono-valent conjugate vaccine in Africa. (C) 2009 Published by Elsevier Ltd.
C1 [Okoko, Brown J.; Idoko, Olubukola T.; Adegbola, Richard A.] MRC Labs, Banjul, Gambia.
RP Adegbola, RA (reprint author), MRC Labs, Atlantic Rd,Fajara Box 237, Banjul, Gambia.
EM radegbola@mrc.gm
CR Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   AlMazrou Y, 2005, INFECT IMMUN, V73, P2932, DOI 10.1128/IAI.73.5.2932-2939.2005
   Andrews N, 2003, CLIN DIAGN LAB IMMUN, V10, P780, DOI 10.1128/CDLI.10.5.780-786.2003
   ARMAND J, 1982, J BIOL STAND, V10, P335, DOI 10.1016/S0092-1157(82)80010-3
   Auckland C, 2006, J INFECT DIS, V194, P1745, DOI 10.1086/509619
   Balmer P, 2002, J MED MICROBIOL, V51, P717
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Boisier P, 2005, TROP MED INT HEALTH, V10, P435, DOI 10.1111/j.1365-3156.2005.01394.x
   Boisier P, 2007, VACCINE, V25, pA24, DOI 10.1016/j.vaccine.2007.04.036
   Boisier P, 2007, CLIN INFECT DIS, V44, P657, DOI 10.1086/511646
   Borrow R, 2005, VACCINE, V23, P2222, DOI 10.1016/j.vaccine.2005.01.051
   Borrow R, 2001, INFECT IMMUN, V69, P1568, DOI 10.1128/IAI.69.3.1568-1573.2001
   Borrow R, 2006, HDB MENINGOCOCCAL DI, P323, DOI 10.1002/3527608508.ch16
   Caugant DA, 2008, INFECT GENET EVOL, V8, P558, DOI 10.1016/j.meegid.2008.04.002
   de Chabalier F, 2000, T ROY SOC TROP MED H, V94, P664, DOI 10.1016/S0035-9203(00)90224-4
   Forgor AA, 2005, TROP MED INT HEALTH, V10, P1229, DOI 10.1111/j.1365-3156.2005.01520.x
   Girard MP, 2006, VACCINE, V24, P4692, DOI 10.1016/j.vaccine.2006.03.034
   GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307
   GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327
   Gray SJ, 2006, J MED MICROBIOL, V55, P887, DOI 10.1099/jmm.0.46288-0
   Greenwood B, 1999, T ROY SOC TROP MED H, V93, P341, DOI 10.1016/S0035-9203(99)90106-2
   Greenwood BM, 1987, BACTERIAL MENINGITIS, P61
   Hamlin J, 2008, CURR OPIN PEDIATR, V20, P483, DOI 10.1097/MOP.0b013e328306ebd1
   HASSANKING MKA, 1988, J INFECTION, V16, P55, DOI 10.1016/S0163-4453(88)96117-8
   Hodgson A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002159
   Iversen BG, 1996, SCAND J INFECT DIS, V28, P253, DOI 10.3109/00365549609027167
   Jodar L, 2002, LANCET, V359, P1499, DOI 10.1016/S0140-6736(02)08416-7
   Kshirsagar N, 2007, VACCINE, V25, pA101, DOI 10.1016/j.vaccine.2007.04.050
   LaForce FM, 2007, VACCINE, V25, pA97, DOI 10.1016/j.vaccine.2007.04.049
   Lapeyssonnie L., 1963, B WHO              S, V28, P3
   LEPOW ML, 1977, PEDIATRICS, V60, P673
   MacLennan J, 1999, VACCINE, V17, P3086, DOI 10.1016/S0264-410X(99)00139-5
   Maiden MCJ, 2002, LANCET, V359, P1829, DOI 10.1016/S0140-6736(02)08679-8
   Mohammed I, 2000, T ROY SOC TROP MED H, V94, P265, DOI 10.1016/S0035-9203(00)90316-X
   MOORE PS, 1992, INT J EPIDEMIOL, V21, P155, DOI 10.1093/ije/21.1.155
   MOORE PS, 1988, JAMA-J AM MED ASSOC, V260, P2686, DOI 10.1001/jama.260.18.2686
   Moura AS, 2003, EMERG INFECT DIS, V9, P355
   Nicolas P, 1996, Med Trop (Mars), V56, P203
   Njanpop-Lafourcade BM, 2005, MICROBES INFECT, V7, P645, DOI 10.1016/j.micinf.2005.01.003
   O'Brien KL, 2003, LANCET, V362, P355, DOI 10.1016/S0140-6736(03)14022-6
   PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302
   Pichichero M, 2005, PEDIATR INFECT DIS J, V24, P57, DOI 10.1097/01.inf.0000148928.10057.86
   Ramsay ME, 2003, BRIT MED J, V326, P365, DOI 10.1136/bmj.326.7385.365
   Ramsay ME, 2001, LANCET, V357, P195, DOI 10.1016/S0140-6736(00)03594-7
   Rappuoli R, 2001, VACCINE, V19, P2319, DOI 10.1016/S0264-410X(00)00552-1
   REINGOLD AL, 1985, LANCET, V2, P114
   Richmond P, 2001, J INFECT DIS, V183, P160, DOI 10.1086/317646
   SELL SH, 1983, PEDIATR INFECT DIS J, V2, P90, DOI 10.1097/00006454-198303000-00003
   SMITH AW, 1988, T ROY SOC TROP MED H, V82, P312, DOI 10.1016/0035-9203(88)90459-2
   Soriano-Gabarro M, 2004, J HEALTH POPUL NUTR, V22, P275
   Soriano-Gabarro M, 2002, Semin Pediatr Infect Dis, V13, P182, DOI 10.1053/spid.2002.125861
   Stephens DS, 2007, LANCET, V369, P2196, DOI 10.1016/S0140-6736(07)61016-2
   Stephens DS, 2007, FEMS MICROBIOL REV, V31, P3, DOI 10.1111/j.1574-6976.2006.00051.x
   Teyssou R, 2007, VACCINE, V25, pA3, DOI 10.1016/j.vaccine.2007.04.032
   Trotter C, 2003, VACCINE, V21, P1094, DOI 10.1016/S0264-410X(02)00630-8
   Vergnano Stefania, 2003, Expert Rev Vaccines, V2, P571, DOI 10.1586/14760584.2.4.571
   WALS PD, 2004, PEDIAT INFECT DI S12, V23, pS280
   WALS PD, 2004, VACCINE, V22, P1233
   *WHO, 1998, 1WHOEMCBA98, V3, P1
   *WHO, 2006, FACT SHEET MEN MEN O
   *WHO, 2003, WHOCDSCSRGAR200314
   World Health Organization, 2005, WKLY EPIDEMIOL REC, V80, P313
   World Health Organization, 2005, WKLY EPIDEMIOL REC, V80, P113
   *WHO, 2007, WKLY EPIDMEIOL REC, V82, P222
   Wuorimaa T, 2001, J INFECT DIS, V184, P1211, DOI 10.1086/323648
NR 65
TC 13
Z9 13
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2009
VL 27
IS 14
BP 2023
EP 2029
DI 10.1016/j.vaccine.2008.11.092
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 426AV
UT WOS:000264680700006
PM 19095025
OA No
DA 2017-08-15
ER

PT J
AU Campino, S
   Forton, J
   Auburn, S
   Fry, A
   Diakite, M
   Richardson, A
   Hull, J
   Jallow, M
   Sisay-Joof, F
   Pinder, M
   Molyneux, ME
   Taylor, TE
   Rockett, K
   Clark, TG
   Kwiatkowski, DP
AF Campino, Susana
   Forton, Julian
   Auburn, Sarah
   Fry, Andrew
   Diakite, Mahamadou
   Richardson, Anna
   Hull, Jeremy
   Jallow, Muminatou
   Sisay-Joof, Fatou
   Pinder, Margaret
   Molyneux, Malcolm E.
   Taylor, Terrie E.
   Rockett, Kirk
   Clark, Taane G.
   Kwiatkowski, Dominic P.
TI TLR9 polymorphisms in African populations: no association with severe
   malaria, but evidence of cis-variants acting on gene expression
SO MALARIA JOURNAL
LA English
DT Article
ID REGULATORY T-CELLS; GENOME; TOLL-LIKE-RECEPTOR-9; AMPLIFICATION;
   HEMOZOIN; PCR
AB Background: During malaria infection the Toll-like receptor 9 (TLR9) is activated through induction with plasmodium DNA or another malaria motif not yet identified. Although TLR9 activation by malaria parasites is well reported, the implication to the susceptibility to severe malaria is not clear. The aim of this study was to assess the contribution of genetic variation at TLR9 to severe malaria.
   Methods: This study explores the contribution of TLR9 genetic variants to severe malaria using two approaches. First, an association study of four common single nucleotide polymorphisms was performed on both family-and population-based studies from Malawian and Gambian populations (n>6000 individual). Subsequently, it was assessed whether TLR9 expression is affected by cis-acting variants and if these variants could be mapped. For this work, an allele specific expression (ASE) assay on a panel of HapMap cell lines was carried out.
   Results: No convincing association was found with polymorphisms in TLR9 for malaria severity, in either Gambian or Malawian populations, using both case-control and family based study designs. Using an allele specific expression assay it was observed that TLR9 expression is affected by cis-acting variants, these results were replicated in a second experiment using biological replicates.
   Conclusion: By using the largest cohorts analysed to date, as well as a standardized phenotype definition and study design, no association of TLR9 genetic variants with severe malaria was found. This analysis considered all common variants in the region, but it is remains possible that there are
C1 [Campino, Susana; Forton, Julian; Auburn, Sarah; Fry, Andrew; Diakite, Mahamadou; Richardson, Anna; Rockett, Kirk; Clark, Taane G.; Kwiatkowski, Dominic P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Campino, Susana; Auburn, Sarah; Clark, Taane G.; Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
   [Hull, Jeremy] John Radcliffe Hosp, Univ Dept Paediat, Oxford OX3 9DU, England.
   [Jallow, Muminatou; Sisay-Joof, Fatou; Pinder, Margaret] MRC Labs, Banjul, Gambia.
   [Molyneux, Malcolm E.] Coll Med, Malawi Liverpool Wellcome Programme Clin Trop Res, Blantyre 30096, Malawi.
   [Taylor, Terrie E.] Coll Med, Blantyre Malaria Project, Blantyre 30096, Malawi.
RP Campino, S (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
EM sc11@sanger.ac.uk; Julian.Forton@paediatrics.ox.ac.uk; sa3@sanger.ac.uk;
   afry@well.ox.ac.uk; m.diakite@well.ox.ac.uk;
   anna.richardson@well.ox.ac.uk; Jeremy.hull@paediatrics.ox.ac.uk;
   muminatou@yahoo.com; fjoof@hotmail.com; mpinder@mrc.gm;
   mmolyneux@malawi.net; taylort@msu.edu; Kirk.Rockett@well.ox.ac.uk;
   tc5@sanger.ac.uk; Dominic@well.ox.ac.uk
OI Kwiatkowski, Dominic/0000-0002-5023-0176; Auburn,
   Sarah/0000-0002-4638-536X
FU Wellcome Trust; Medical Research Council UK; Marie-Curie intra-European
   fellowship [FP6]; Bill and Melinda Gates Foundation
FX This work was in part funded by the Wellcome Trust and Medical Research
   Council UK. SC was funded by a Marie-Curie intra-European fellowship
   (FP6). JF and AF were funded by a Wellcome Trust Training Fellowship.
   TGC, SA, KR and DPK are in part funded by the Bill and Melinda Gates
   Foundation, Wellcome Trust, and Medical Research Council UK.
CR Amante FH, 2007, AM J PATHOL, V171, P548, DOI 10.2353/ajpath.2007.061033
   Bernasconi NL, 2003, BLOOD, V101, P4500, DOI 10.1182/blood-2002-11-3569
   CAMPINO S, 2008, PLOS ONE, V3
   Cheung VG, 2005, NATURE, V437, P1365, DOI 10.1038/nature04244
   Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836
   Cordell HJ, 2004, GENET EPIDEMIOL, V26, P186, DOI 10.1002/gepi.10306
   Elvidge GP, 2005, ANAL BIOCHEM, V339, P231, DOI 10.1016/j.ab.2005.01.040
   Forton JT, 2007, GENOME RES, V17, P82, DOI 10.1101/gr.5663007
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Goring HHH, 2007, NAT GENET, V39, P1208, DOI 10.1038/ng2119
   Gonzalez JM, 2005, ENVIRON MICROBIOL, V7, P1024, DOI 10.1111/j.1462-2920.2005.00779.x
   Hisaeda H, 2008, J IMMUNOL, V180, P2496
   Hull J, 2007, PLOS GENET, V3, P1009, DOI 10.1371/journal.pgen.0030099
   Knight JC, 2004, NAT GENET, V36, P394, DOI 10.1038/ng1331
   LEORATTI FM, 2008, J INFECT DIS
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Mockenhaupt F P, 2006, J Commun Dis, V38, P230
   Mockenhaupt FP, 2006, J INFECT DIS, V194, P184, DOI 10.1086/505152
   Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797
   Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104
   Pastinen T, 2005, HUM MOL GENET, V14, P3963, DOI 10.1093/hmg/ddi420
   Pastinen T, 2004, SCIENCE, V306, P647, DOI 10.1126/science.1101659
   Pichyangkul S, 2004, J IMMUNOL, V172, P4926
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142
   Stranger BE, 2005, PLOS GENET, V1, P695, DOI 10.1371/journal.pgen.0010078
   Teare MD, 2006, AM J HUM GENET, V79, P539, DOI 10.1086/506968
   TEO YYF, 2008, HUM HEREDITY
   ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847
NR 29
TC 16
Z9 18
U1 1
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T
   4LB, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD MAR 13
PY 2009
VL 8
AR 44
DI 10.1186/1475-2875-8-44
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 424SJ
UT WOS:000264588000002
PM 19284650
OA gold
DA 2017-08-15
ER

PT J
AU Hennig, BJ
   Fulford, AJ
   Sirugo, G
   Rayco-Solon, P
   Hattersley, AT
   Frayling, TM
   Prentice, AM
AF Hennig, Branwen J.
   Fulford, Anthony J.
   Sirugo, Giorgio
   Rayco-Solon, Pura
   Hattersley, Andrew T.
   Frayling, Timothy M.
   Prentice, Andrew M.
TI FTO gene variation and measures of body mass in an African population
SO BMC MEDICAL GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; INTRAUTERINE GROWTH RESTRICTION; FAT MASS;
   ADULT OBESITY; VARIANTS; RS9939609; CHILDREN; CHINESE; BMI;
   POLYMORPHISMS
AB Background: Variation in the fat mass and obesity associated (FTO) gene has been reproducibly associated with body mass index (BMI) and obesity in populations of White European origin. Data from Asians and African-Americans is less conclusive.
   Methods: We assessed the effect of 16 FTO polymorphisms on body mass in a large population of predominantly lean Gambians (N(max) 2208) participating in a long-term surveillance program providing contemporary and early-life anthropometric measurements.
   Results: Sixteen FTO tagSNPs screened here, including several associated with BMI in Europeans, were not associated with birth weight (BWT), early weight gain in 1-2 year olds, BMI in adults (>= 18 y), or weight-for-height (WFH) z-score across all ages. No association was seen between genotype and WFH z-score or other measures of body mass. The confidence limits indicate that the effect size for WFH z-score never exceeded 0.17 units per allele copy for any SNP (excluding the three SNPs with allele < 15%). with much the lowest allele frequency. The confidence interval of the effect size for rs9939609 did not overlap that reported previously in Europeans.
   Conclusion: To our knowledge this is the first study of FTO gene variation in a well-characterised African population. Our results suggest that FTO gene variation does not influence measures of body mass in Gambians living a traditional lifestyle, or has a smaller effect than that detected in Europeans. These findings are not directly comparable to results from previous studies in African-Americans due to differences in study design and analysis. It is also possible that any effect of FTO genotype on body mass is of limited relevance in a lean population where little excess food is available, compared to similar ethnic populations where food supply is plentiful.
C1 [Hennig, Branwen J.; Fulford, Anthony J.; Rayco-Solon, Pura; Prentice, Andrew M.] Univ London London Sch Hyg & Trop Med, NPHIRU, EPH, MRC Int Nutr Grp, London WC1E 7HT, England.
   [Sirugo, Giorgio] Osped S Pietro FBF, Med Genet Unit, I-00189 Rome, Italy.
   [Rayco-Solon, Pura] MRC Labs, MRC Keneba, Banjul, Gambia.
   [Hattersley, Andrew T.; Frayling, Timothy M.] Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter EX1 2LU, Devon, England.
RP Hennig, BJ (reprint author), Univ London London Sch Hyg & Trop Med, NPHIRU, EPH, MRC Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM branwen.hennig@lshtm.ac.uk; tony.fulford@lshtm.ac.uk; gsirugo@gmail.com;
   psolon@NCP.org.ph; andrew.hattersley@pms.ac.uk; tim.frayling@pms.ac.uk;
   andrew.prentice@lshtm.ac.uk
RI Hennig, Branwen/M-6444-2014
FU Medical Research Council
FX We are grateful to the population of the West-Kiang region in The Gambia
   for participation in the original study on "Nutrient-gene regulation of
   birth size and post-natal growth in a rural African setting" (manuscript
   in preparation). We also thank all fieldworkers, drivers, data and
   laboratory staff in The Gambia. Further thanks go to Emily Lyons, Andrew
   Morris and Denise Brocklebank for sharing WTCCC information on genotype
   frequencies in Gambian controls and advising on the analysis. Funding:
   Medical Research Council.
CR Al-Attar SA, 2008, CARDIOVASC DIABETOL, V7, DOI 10.1186/1475-2840-7-5
   Baltagi B. H, 2001, ECONOMETRIC ANAL PAN
   Cha SW, 2008, OBESITY, V16, P2185, DOI 10.1038/oby.2008.314
   Chang YC, 2008, DIABETES, V57, P2245, DOI 10.2337/db08-0377
   COLE TJ, 1995, ARCH DIS CHILD, V73, P25
   Collinson A, 2005, AM J CLIN NUTR, V81, P488
   DIGGLE JP, 2002, ANAL LONGITUDINAL, P70
   Dina C, 2007, NAT GENET, V39, P724, DOI 10.1038/ng2048
   Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634
   Fulford AJC, 2006, PAEDIATR PERINAT EP, V20, P251, DOI 10.1111/j.1365-3016.2006.00714.x
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gerken T, 2007, SCIENCE, V318, P1469, DOI 10.1126/science.1151710
   Gonzalez-Sanchez JL, 2009, CLIN ENDOCRINOL, V70, P390, DOI 10.1111/j.1365-2265.2008.03335.x
   Grant SFA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001746
   Haupt A, 2008, OBESITY, V16, P1969, DOI 10.1038/oby.2008.283
   Hinney A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001361
   Horikoshi M, 2007, DIABETOLOGIA, V50, P2461, DOI 10.1007/s00125-007-0827-5
   Ioannidis JPA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000841
   Jacobsson JA, 2008, BIOCHEM BIOPH RES CO, V368, P476, DOI 10.1016/j.bbrc.2008.01.087
   Jess T, 2008, INT J OBESITY, V32, P1388, DOI 10.1038/ijo.2008.110
   Li HX, 2008, DIABETES, V57, P264
   Lopez-Bermejo A, 2008, J CLIN ENDOCR METAB, V93, P1501, DOI 10.1210/jc.2007-2343
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Ng MCY, 2008, DIABETES, V57, P2226, DOI [10.2337/db07-1583, 10.2337/007-1583]
   Ohashi J, 2007, J HUM GENET, V52, P1031, DOI 10.1007/s10038-007-0198-2
   Omori S., 2008, Diabetes (New York), V57, P791, DOI 10.2337/db07-0979
   Prentice AM, 2005, MECH AGEING DEV, V126, P976, DOI 10.1016/j.mad.2005.03.018
   Qi L, 2008, DIABETES, V57, P3145, DOI 10.2337/db08-0006
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
   Saunders CL, 2007, OBESITY, V15, P2263, DOI 10.1038/oby.2007.269
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   Scuteri A, 2007, PLOS GENET, V3, P1200, DOI 10.1371/journal.pgen.0030115
   Tan JT, 2008, DIABETES, V57, P2851, DOI 10.2337/db08-0214
   Wardle J, 2009, INT J OBESITY, V33, P42, DOI 10.1038/ijo.2008.174
   Wardle J, 2008, J CLIN ENDOCR METAB, V93, P3640, DOI 10.1210/jc.2008-0472
NR 35
TC 63
Z9 69
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD MAR 5
PY 2009
VL 10
AR 21
DI 10.1186/1471-2350-10-21
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 430XI
UT WOS:000265025500001
PM 19265514
OA gold
DA 2017-08-15
ER

PT J
AU Chisti, MJ
   Saha, S
   Roy, CN
   Ahmed, T
   Faruque, ASG
   Salam, MA
   Islam, S
AF Chisti, M. J.
   Saha, S.
   Roy, C. N.
   Ahmed, T.
   Faruque, A. S. G.
   Salam, M. A.
   Islam, S.
TI Predictors of mortality in infants with sclerema presenting to the
   Centre for Diarrhoeal Disease, Dhaka
SO ANNALS OF TROPICAL PAEDIATRICS
LA English
DT Article
ID NEONATORUM; HYPERAMMONEMIA; MALNUTRITION; MANAGEMENT; SEPTICEMIA;
   NEWBORN; PROTEIN; CHILD
AB Background: Sclerema is an uncommon, life-threatening condition, usually of newborns, with a case-fatality rate ranging from 50 to 100%. Very little is known about factors influencing outcome.
   Aim: To identify clinical and biochemical predictors associated with fatal outcome of sclerema in infants with diarrhoea.
   Methods: Thirty infants with sclerema admitted to the Special Care Unit of the Dhaka Hospital of ICDDR, B with diarrhoea from May 2005 to end April 2006 were studied prospectively. Nine infants who died (30%) were considered to be cases while the 21 who survived constituted the comparison group. Hypothermia, severe malnutrition, septic shock, serum ammonia and CRP levels were considered to be predictors of death. Differences in proportions were compared by the chi(2) test and mean differences were compared using Student's t-test or the Mann-Whitney test, as appropriate.
   Results: The mean age of the 30 infants was 2.1 months ( range 12 d to 8 m). Fatal cases were more likely than survivors to be associated with severe underweight, a positive blood culture and higher serum ammonia and serum CRP levels. After adjusting for possible confounders in logistic regression analysis, the likelihood of death was higher in infants admitted with septic shock or who developed it soon after admission (OR 17.96, 95% CI 1.5-220.4, p=0.024).
   Conclusions: Sclerema is associated with a high fatality rate and scleremic infants with diarrhoea who present with septic shock are at a greater risk of death.
C1 [Chisti, M. J.; Roy, C. N.; Ahmed, T.; Faruque, A. S. G.; Salam, M. A.] Int Ctr Diarrhoeal Dis Res Bangladesh ICDDR B, Div Clin Sci, Dhaka 1212, Bangladesh.
   [Islam, S.] East West Univ, Dept Pharm, Dhaka, Bangladesh.
   [Saha, S.] MRC, Banjul, Gambia.
RP Chisti, MJ (reprint author), Int Ctr Diarrhoeal Dis Res Bangladesh ICDDR B, Div Clin Sci, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.
EM chisti@icddrb.org
RI Roy, Chandra Nath/E-8710-2010
OI Roy, Chandra Nath/0000-0001-6667-1550
FU ICDDR,B; Australian Agency for International Development (AusAID);
   Government of the People's Republic of Bangladesh; Canadian
   International Development Agency (CIDA); Embassy of the Kingdom of the
   Netherlands Development (EKN); Swedish International Development
   Cooperation Agency (Sida); Swiss Agency for Development and Cooperation
   (SDC); Department for International Development, UK (DFID)
FX The research was funded by ICDDR,B and its donors who provide
   unrestricted support to the centre for its operations and research.
   Current donors include: Australian Agency for International Development
   (AusAID), Government of the People's Republic of Bangladesh, Canadian
   International Development Agency (CIDA), Embassy of the Kingdom of the
   Netherlands Development (EKN), Swedish International Development
   Cooperation Agency (Sida), Swiss Agency for Development and Cooperation
   (SDC) and Department for International Development, UK (DFID). The
   sponsors of the study collaborated on study design and data collection
   and analysis. We gratefully acknowledge their support and commitment to
   the centre's research. Sincere thanks to Dr Julian Kelly, Dr P. K.
   Bardhan, Ashish Kumar Chowdhury and Dr Debasish Saha for invaluable
   comments and suggestions. There are no competing interests.
CR Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6
   BALLARD RA, 1978, NEW ENGL J MED, V299, P920, DOI 10.1056/NEJM197810262991704
   Battin M, 2002, J PAEDIATR CHILD H, V38, P533, DOI 10.1046/j.1440-1754.2002.00532.x
   BHAKOO ON, 1974, INDIAN PEDIATR, V11, P519
   Bwibo N O, 1970, East Afr Med J, V47, P50
   Carcillo Joseph A, 2005, Pediatr Crit Care Med, V6, pS157, DOI 10.1097/01.PCC.0000161574.36857.CA
   Clay AS, 2007, CHEST, V132, P1368, DOI 10.1378/chest.06-2940
   Dasgupta A, 1993, Indian J Pathol Microbiol, V36, P45
   DEONIS M, 1993, B WORLD HEALTH ORGAN, V71, P703
   Ehl S, 1997, PEDIATRICS, V99, P216, DOI 10.1542/peds.99.2.216
   Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2, DOI 10.1097/01.PCC.0000149131.72248.E6
   HORSFIELD GI, 1965, J INVEST DERMATOL, V44, P326
   ISLAM MA, 1994, EUR J CLIN NUTR, V48, P416
   JARDINE D, 1990, EUR J PEDIATR, V150, P125, DOI 10.1007/BF02072054
   LINDENBERG JA, 1987, J PEDIATR GASTR NUTR, V6, P474, DOI 10.1097/00005176-198705000-00028
   Milunsky A, 1966, S Afr Med J, V40, P638
   Narayanan I, 1982, Indian J Pediatr, V49, P519, DOI 10.1007/BF02834557
   Navarini-Meury Susanne, 2007, Arch Dis Child Fetal Neonatal Ed, V92, pF307, DOI 10.1136/adc.2006.103978
   PASYK K, 1980, VIRCHOWS ARCH A, V388, P87, DOI 10.1007/BF00430679
   PRODHOM LS, 1974, PEDIATRICS, V53, P170
   Sadana S, 1997, Indian Pediatr, V34, P20
   Sarwono E, 1973, Paediatr Indones, V13, P120
   SATO T, 1977, ACTA PATHOL JAPON, V27, P917
   SHARMA S, SEPTIC SHOCK
   URBATSCH AJ, SCLEREMA NEONATORUM
   VAIN NE, 1980, PEDIATRICS, V66, P693
   World Health Organization, 1999, MAN SEV MALN MAN PHY
   Zeb A, 2008, J PERINATOL, V28, P453, DOI 10.1038/jp.2008.33
NR 28
TC 6
Z9 6
U1 0
U2 0
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 0272-4936
EI 1465-3281
J9 ANN TROP PAEDIATR
JI Ann. Trop. Paediatr.
PD MAR
PY 2009
VL 29
IS 1
BP 45
EP 50
DI 10.1179/146532809X402024
PG 6
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 416XH
UT WOS:000264038300007
PM 19222934
OA No
DA 2017-08-15
ER

PT J
AU Rutherford, ME
   Dockerty, JD
   Jasseh, M
   Howie, SRC
   Herbison, P
   Jeffries, DJ
   Leach, M
   Stevens, W
   Mulholland, K
   Adegbola, RA
   Hill, PC
AF Rutherford, Merrin E.
   Dockerty, John D.
   Jasseh, Momodou
   Howie, Stephen R. C.
   Herbison, Peter
   Jeffries, David J.
   Leach, Melissa
   Stevens, Warren
   Mulholland, Kim
   Adegbola, Richard A.
   Hill, Philip C.
TI Access to health care and mortality of children under 5 years of age in
   the Gambia: a case-control study
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID RISK-FACTORS; UNDER-5 MORTALITY; AFRICAN COMMUNITY; SEEKING BEHAVIOR;
   YOUNG-CHILDREN; NORTHERN GHANA; CHILDHOOD; MORBIDITY; DEATHS; IMPACT
AB Objective To assess whether traditional measures of access to health care (distance and travel time to a facility) and non-traditional measures (social and financial support indicators) are associated with mortality among children under 5 years of age in the Gambia.
   Methods We conducted a case-control study in a population under demographic surveillance. Cases (n = 140) were children under 5 years of age who died between 31 December 2003 and 30 April 2006. Each case was matched in age and sex to five controls (n = 700). Information was gathered by interviewing primary caregivers. The data were analysed using conditional logistic regression.
   Findings Of traditional measures of access, only rural versus urban/periurban residence was important: children from rural areas were more likely to die (OR: 4.9; 95% confidence interval, CI: 1.2-20.2). For non-traditional measures, children were more likely to die if their primary caregivers; lacked help with meal preparation (OR: 2.3; 95% CI: 1.2-4.1), had no one to relax with (OR: 1.8; 95% CI: 1.1-2.9), had no one who could offer good advice (OR: 23.1; 95% CI: 4.3-123.4), had little say over how earned money was spent (OR: 12.7; 95% CI: 1.3-127.6), were unable to cut spending for health care (OR: 2.5; 95% CI: 1.5-4.2) or had to carry out odd jobs to pay for the care (OR:.3.4; 95% CI: 2.1-5.5). A protective effect was observed when the caregiver had other children to care for (OR: 0.2; 95% CI: 0.1-0.5).
   Conclusion Improving access to health-care for children in the Gambia and similar settings is not simply a matter of reducing travel time and distance to a health facility, but requires improvements in caregivers' support networks and their access to the financial resources they need.
C1 [Jasseh, Momodou; Howie, Stephen R. C.; Jeffries, David J.; Stevens, Warren; Adegbola, Richard A.; Hill, Philip C.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Rutherford, Merrin E.; Dockerty, John D.; Herbison, Peter] Univ Otago, Ctr Int Hlth, Dunedin, New Zealand.
   [Leach, Melissa] Univ Sussex, Inst Dev Studies, Brighton, E Sussex, England.
   [Mulholland, Kim] London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England.
RP Hill, PC (reprint author), MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
EM philip.hill@otago.ac.nz
FU Medical Research Council of the United Kingdom; University of Otago, New
   Zealand
FX This study was funded by The Medical Research Council of the United
   Kingdom and the University of Otago, New Zealand.
CR Baume C, 2000, SOC SCI MED, V51, P1491, DOI 10.1016/S0277-9536(00)00049-6
   Becher H, 2004, B WORLD HEALTH ORGAN, V82, P265
   Begin F, 1999, J NUTR, V129, P680
   BINKA FN, 1995, INT J EPIDEMIOL, V24, P127, DOI 10.1093/ije/24.1.127
   Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8
   Cassell JA, 2006, HEALTH POLICY PLANN, V21, P373, DOI 10.1093/heapol/czl020
   Ensor T, 1996, INT J HEALTH PLAN M, V11, P69
   Fantahun M, 2007, ACTA PAEDIATR, V96, P582, DOI 10.1111/j.1651-2227.2007.00147.x
   *FAR MED RES COUNC, 2004, FAR DEM SURV SYST RE
   FOSU GB, 1994, SOC SCI MED, V38, P1209, DOI 10.1016/0277-9536(94)90186-4
   GORDON AJ, 2005, C LOC FIELD ETHN MED
   GREENWOOD BM, 1990, J TROP MED HYG, V93, P87
   GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91
   Hampshire K, 2002, SOC SCI MED, V54, P1025, DOI 10.1016/S0277-9536(01)00078-8
   Hill RC, 2005, INT J TUBERC LUNG D, V9, P1349
   Hill Z, 2003, TROP MED INT HEALTH, V8, P668, DOI 10.1046/j.1365-3156.2003.01058.x
   Holtz TH, 2003, T ROY SOC TROP MED H, V97, P491, DOI 10.1016/S0035-9203(03)80003-2
   HOUSEHOLDS UKM, 1999, EC POL WKLY MUMBAI, V34, P10
   James C, 2005, BRIT MED J, V331, P747, DOI 10.1136/bmj.331.7519.747
   Magnani RJ, 1996, INT J EPIDEMIOL, V25, P568, DOI 10.1093/ije/25.3.568
   MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923
   MTANGO FDE, 1992, TROP MED PARASITOL, V43, P229
   Murray CJL, 2007, LANCET, V370, P1040, DOI 10.1016/S0140-6736(07)61478-0
   PICKERING H, 1986, T ROY SOC TROP MED H, V80, P311, DOI 10.1016/0035-9203(86)90045-3
   PISON G, 1993, INT J EPIDEMIOL, V22, P72, DOI 10.1093/ije/22.1.72
   Pronyk PM, 2007, JAMA-J AM MED ASSOC, V298, P1925, DOI 10.1001/jama.298.16.1925
   Reyes H, 1997, HEALTH POLICY PLANN, V12, P214, DOI 10.1093/heapol/12.3.214
   Schellenberg JRMA, 2002, TROP MED INT HEALTH, V7, P506, DOI 10.1046/j.1365-3156.2002.00888.x
   SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B
   Shier RP, 1996, TROP MED INT HEALTH, V1, P334, DOI 10.1046/j.1365-3156.1996.d01-55.x
   Sodemann M, 1997, B WORLD HEALTH ORGAN, V75, P205
   Tsay C, 1985, Jing Ji Lun Wen, V13, P145
   VandenBroeck J, 1996, INT J EPIDEMIOL, V25, P998
   VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474
   STANDARDIZED VA QUES
NR 35
TC 37
Z9 38
U1 3
U2 6
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD MAR
PY 2009
VL 87
IS 3
BP 216
EP 224
DI 10.2471/BLT.08.052175
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 413SS
UT WOS:000263813400016
PM 19377718
OA No
DA 2017-08-15
ER

PT J
AU Falade, AG
   Lagunju, IA
   Bakare, RA
   Odekanmi, AA
   Adegbola, RA
AF Falade, A. G.
   Lagunju, I. A.
   Bakare, R. A.
   Odekanmi, A. A.
   Adegbola, R. A.
TI Invasive Pneumococcal Disease in Children Aged < 5 Years Admitted to 3
   Urban Hospitals in Ibadan, Nigeria
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID STREPTOCOCCUS-PNEUMONIAE; BACTERIAL-MENINGITIS; GAMBIAN CHILDREN;
   ETIOLOGY; EPIDEMIOLOGY; INFECTIONS
AB Background. Streptococcus pneumoniae remains a major cause of childhood morbidity and mortality in the world. The introduction of pneumococcal conjugate vaccine in developing countries will be facilitated by a clearer understanding of the disease burden for bacterial causes of pneumonia and meningitis and the prevalent serotypes of S. pneumoniae.
   Methods. We conducted a prospective, hospital-based surveillance for a 2-year period involving children aged 2-59 months at 3 urban hospitals in Ibadan, Nigeria, using standard microbiological methods with confirmation and further testing of isolates at the Medical Research Council Laboratories in The Gambia.
   Results. There were 1210 cases overall: 481 (39.8%) were meningitis, 399 (33.0%) were pneumonia, and 330 (27.2%) were bacteremia clinical syndromes. There were 24 cases of definite meningitis, of which 9 were caused by S. pneumoniae, 11 by Haemophilus influenzae type b, and 4 by Klebsiella species. Of the 90 culture-positive pneumonia cases, 9 were caused by S. pneumoniae, 2 by H. influenzae type b, and 79 by other species. Among cases of bacteremia, the pathogen isolation rate was 28.8% (95 of 330); the isolated species included S. pneumoniae (3 isolates), Staphylococcus aureus (20 isolates), Klebsiella species (13 isolates), Salmonella species (15 isolates), and Escherichia coli (6 isolates). Of the 23 S. pneumoniae isolates, 11 were serotyped; the serotypes found were 5 (5 isolates), 19F (3 isolates), and 4 (3 isolates), and 1 isolate was nontypeable. These isolates were all susceptible to penicillin. Eight of 9 patients with definite pneumococcal meningitis died, whereas all patients with pneumococcal pneumonia and septicemia survived.
   Conclusions. Of the pneumococcal serotypes identified, 55% were covered by the licensed 7-valent pneumococcal conjugate vaccine, whereas all are covered by the 10- and 13-valent vaccines.
C1 [Falade, A. G.; Lagunju, I. A.] Univ Ibadan, Univ Coll Hosp, Dept Pediat, Ibadan, Nigeria.
   [Bakare, R. A.; Odekanmi, A. A.] Univ Ibadan, Univ Coll Hosp, Dept Med Microbiol, Ibadan, Nigeria.
   [Bakare, R. A.; Odekanmi, A. A.] Univ Ibadan, Coll Med, Ibadan, Nigeria.
   [Adegbola, R. A.] MRC Labs, Fajara, Gambia.
RP Falade, AG (reprint author), Univ Ibadan, Univ Coll Hosp, Dept Pediat, Ibadan, Nigeria.
EM afalade33@hotmail.com
FU GAVI Alliance; Vaccine Fund
FX Financial support. PneumoADIP (PneumoADIP is funded by the GAVI Alliance
   and the Vaccine Fund).
CR ADEDOYIN M A, 1987, Nigerian Journal of Paediatrics, V14, P37
   ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Aderele W I, 1994, West Afr J Med, V13, P7
   Aderele W. I., 1992, NIG J PAEDIAT, V19, P80
   Ayoola O O, 2005, West Afr J Med, V24, P175
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Campbell JD, 2004, PEDIATR INFECT DIS J, V23, P642, DOI 10.1097/01.inf.0000130951.85974.79
   Clinical and Laboratory Standards Institute (CLSI), 2008, M100S18 CLSI S
   DIAKPAROMRE M, 1981, Nigerian Journal of Paediatrics, V8, P61
   du Chatelet IP, 2005, CLIN INFECT DIS, V40, P17
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   Greenwood B, 1999, PHILOS T ROY SOC B, V354, P777, DOI 10.1098/rstb.1999.0430
   Husain E, 2006, CLIN INVEST MED, V29, P131
   Leimkugel J, 2005, J INFECT DIS, V192, P192, DOI 10.1086/431151
   Madhi SA, 2000, PEDIATR INFECT DIS J, V19, P1141, DOI 10.1097/00006454-200012000-00004
   Noorani N, 2005, East Afr Med J, V82, P343
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   PELODY RG, 2006, EURO SURVEILL, V11, P171
   *POP REF BUR, 2007 WORLD POP DAT S
   Roca A, 2006, TROP MED INT HEALTH, V11, P1422, DOI 10.1111/j.1365-3156.2006.01697.x
   Saha SK, 2005, PEDIATR INFECT DIS J, V24, P1093, DOI 10.1097/01.inf.0000190030.75892.78
   Shabani IS, 2006, MED PRIN PRACT, V15, P431, DOI 10.1159/000095489
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
   World Health Organization, 2003, WKLY EPIDEMIOL REC, V14, P110
NR 26
TC 20
Z9 21
U1 1
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAR 1
PY 2009
VL 48
BP S190
EP S196
DI 10.1086/596500
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 403DF
UT WOS:000263061800021
PM 19191615
OA No
DA 2017-08-15
ER

PT J
AU Sutherland, JS
   Adetifa, IM
   Hill, PC
   Adegbola, RA
   Ota, MOC
AF Sutherland, Jayne S.
   Adetifa, Ifedayo M.
   Hill, Philip C.
   Adegbola, Richard A.
   Ota, Martin O. C.
TI Pattern and diversity of cytokine production differentiates between
   Mycobacterium tuberculosis infection and disease
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Cytokines; Mycobacterium tuberculosis infection; T cells; Tuberculosis
   disease
ID T-CELL RESPONSES; INTERFERON-GAMMA; IMMUNE-RESPONSE; CD4(+); MEMORY;
   ESTABLISHMENT; POPULATIONS; VACCINATION; PROTECTION; PULMONARY
AB Tuberculosis (TB) remains a global health problem. The solution involves development of an effective vaccine, but has been limited by incomplete understanding of what constitutes protective immunity during natural infection with Mycobacterium tuberculosis. in this study, M. tuberculosis-specific responses following an overnight whole-blood assay were assessed by intracellular cytokine staining and luminex, and compared between TB cases and exposed household contacts. TB cases had significantly higher levels of IFN-gamma(+)TNF-alpha(+) IL-2(+)CD4(+)T cells compared with contacts. TB cases also had a significantly higher proportion of cells single-positive for TNF-alpha, but lower proportion of cells producing IL-2 alone and these differences were seen for both CD4(+) and CD8(+) T cells. Cytokine profiles from culture supernatants were significantly biased toward a Th1 phenotype (IFN-gamma and IL-12(p40)) together with a complete abrogation of IL-17 secretion in TB cases. Our data indicate that despite a robust response to TB antigens in active TB disease, changes in the pattern of cytokine production between TB infection and disease clearly contribute to disease progression.
C1 [Sutherland, Jayne S.; Adetifa, Ifedayo M.; Hill, Philip C.; Adegbola, Richard A.; Ota, Martin O. C.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
RP Sutherland, JS (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM jsutherland@mrc.gm
OI Sutherland, Jayne/0000-0002-7083-4997
FU Bill and Melinda Gates Foundation; Medical Research Council (UK); The
   Gambia
FX We thank all study participants, Mr. Simon Donkor for data management,
   field workers for sample collection, the TB Immunology laboratory staff,
   and the Gambian National Tuberculosis and Leprosy Control programme for
   continuing collaboration. We are grateful to Professor Sarah
   Rowland-Jones for critical review of the paper. This work was funded by
   the Bill and Melinda Gates Foundation and the Medical Research Council
   (UK), The Gambia.
CR Balcewicz-Sablinska MK, 1998, J IMMUNOL, V161, P2636
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Beveridge NER, 2007, EUR J IMMUNOL, V37, P3089, DOI 10.1002/eji.2007375041
   Chakravarty SD, 2008, INFECT IMMUN, V76, P916, DOI 10.1128/IAI.01011-07
   Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
   Day CL, 2008, J INFECT DIS, V197, P990, DOI 10.1086/529048
   Dockrell H, 2007, MICROBIOLOGY TOD NOV, P172
   Dooms H, 2004, J IMMUNOL, V172, P5973
   Duvall MG, 2008, EUR J IMMUNOL, V38, P350, DOI 10.1002/eji.200737768
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2
   Goldsack L, 2007, TUBERCULOSIS, V87, P465, DOI 10.1016/j.tube.2007.07.001
   Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203
   Hawkridge T, 2008, J INFECT DIS, V198, P544, DOI 10.1086/590185
   Jamil B, 2007, TUBERCULOSIS, V87, P279, DOI 10.1016/j.tube.2007.03.004
   Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449
   Khader SA, 2006, J EXP MED, V203, P1805, DOI 10.1084/jem.20052545
   Leal IS, 2001, IMMUNOLOGY, V104, P157, DOI 10.1046/j.1365-2567.2001.01305.x
   Mueller H, 2008, CYTOKINE, V43, P143, DOI 10.1016/j.cyto.2008.05.002
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   Pfeffer K, 2003, CYTOKINE GROWTH F R, V14, P185, DOI 10.1016/S1359-6101(03)00022-4
   Scriba TJ, 2008, J IMMUNOL, V180, P1962
   Smith SM, 2000, INFECT IMMUN, V68, P7144, DOI 10.1128/IAI.68.12.7144-7148.2000
   Soares AP, 2008, J IMMUNOL, V180, P3569
   World Health Organization, 2007, WHOHTMTB2007376
   Wu B, 2007, J IMMUNOL, V178, P3688
   Yamada G, 2000, AM J RESP CRIT CARE, V161, P1786
   Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598
NR 28
TC 134
Z9 138
U1 0
U2 4
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD MAR
PY 2009
VL 39
IS 3
BP 723
EP 729
DI 10.1002/eji.200838693
PG 7
WC Immunology
SC Immunology
GA 426BW
UT WOS:000264683500021
PM 19224636
OA No
DA 2017-08-15
ER

PT J
AU Antonio, M
   Hakeem, I
   Sankareh, K
   Cheung, YB
   Adegbola, RA
AF Antonio, Martin
   Hakeem, Ishrat
   Sankareh, Kawsu
   Cheung, Yin Bun
   Adegbola, Richard A.
TI Evaluation of sequential multiplex PCR for direct detection of multiple
   serotypes of Streptococcus pneumoniae from nasopharyngeal secretions
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; DETERMINING CAPSULAR SEROTYPES;
   DEVELOPING-WORLD; GAMBIAN CHILDREN; OTITIS-MEDIA; CARRIAGE; DISEASE;
   INFANTS; IMPACT; IMMUNOGENICITY
AB Sequential multiplex PCR was evaluated for detection of multiple Streptococcus pneumoniae serotypes directly from nasopharyngeal secretions. A total of 279 nasopharyngeal swab samples were tested blindly. When limited to the 29 serotypes identifiable by the molecular method, the mean number of serotypes identified by the conventional latex/Quellung method was 0.85, which was significantly lower than that by the molecular method (P < 0.0001). The multiplex PCR method identified significantly more serotypes than the latex/Quellung method if limited to the 29 serotypes (P = 0.001 and P = 0.014, respectively).
C1 [Antonio, Martin; Hakeem, Ishrat; Sankareh, Kawsu; Adegbola, Richard A.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Cheung, Yin Bun] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Antonio, M (reprint author), MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
EM mantonio@mrc.gm
FU MRC (UK)
FX We would like to acknowledge Ebou Mbowe and Lamin Juwara for technical
   assistance and the MRC (UK) for funding this project.
CR Antonio M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-81
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   BERMAN S, 1995, NEW ENGL J MED, V332, P1560, DOI 10.1056/NEJM199506083322307
   Dagan R, 2003, PEDIATR INFECT DIS J, V22, P532, DOI 10.1097/00006454-200306000-00009
   Dias CA, 2007, J MED MICROBIOL, V56, P1185, DOI 10.1099/jmm.0.47347-0
   Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5
   FREDERIKSEN B, 1988, J TROP PEDIATRICS, V34, P114
   Ghaffar F, 2004, CLIN INFECT DIS, V39, P930, DOI 10.1086/423379
   GRATTEN M, 1986, BIOL NEONATE, V50, P114
   GRAY BM, 1980, J INFECT DIS, V142, P923
   Greenwood B, 1999, PHILOS T ROY SOC B, V354, P777, DOI 10.1098/rstb.1999.0430
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Jones N, 1998, AIDS, V12, P2177, DOI 10.1097/00002030-199816000-00013
   Klugman K P, 2001, Lancet Infect Dis, V1, P85, DOI 10.1016/S1473-3099(01)00063-9
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   Madhi SA, 2000, PEDIATR INFECT DIS J, V19, P1141, DOI 10.1097/00006454-200012000-00004
   Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009
   Morais L, 2007, J MED MICROBIOL, V56, P1181, DOI 10.1099/jmm.0.47346-0
   O'Brien KL, 2003, LANCET, V362, P355, DOI 10.1016/S0140-6736(03)14022-6
   O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI 10.1097/00006454-200302000-00009
   Obaro SK, 2000, PEDIATR INFECT DIS J, V19, P463, DOI 10.1097/00006454-200005000-00014
   OBARO SK, 1996, LANCET, V348, P272
   Pai R, 2006, J CLIN MICROBIOL, V44, P124, DOI 10.1128/JCM.44.1.124-131.2006
   Park IH, 2007, J CLIN MICROBIOL, V45, P1225, DOI 10.1128/JCM.02199-06
   Scott JAG, 2007, VACCINE, V25, P2398, DOI 10.1016/j.vaccine.2006.09.008
   Scott JAG, 2008, J CLIN INVEST, V118, P1291, DOI 10.1172/JCI33947
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   Syrjanen RK, 2005, PEDIATR INFECT DIS J, V24, P801, DOI 10.1007/01.inf.0000178072.83531.4f
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
NR 31
TC 16
Z9 16
U1 0
U2 1
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 0022-2615
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PD MAR
PY 2009
VL 58
IS 3
BP 296
EP 302
DI 10.1099/jmm.0.006031-0
PG 7
WC Microbiology
SC Microbiology
GA 415GF
UT WOS:000263921600003
PM 19208877
OA No
DA 2017-08-15
ER

PT J
AU Nuhu, A
   Samateh, A
AF Nuhu, A.
   Samateh, A.
TI DAY CASE HAEMORRHOIDECTOMY IN A DEVELOPING COUNTRY
SO NIGERIAN JOURNAL OF CLINICAL PRACTICE
LA English
DT Article
DE Haemorrhoidectomy; Day case; Outcome
ID TRIAL
AB Background: Ligation excision haemorrhoidectomies are usually done on inpatient basis. Over the years howover, there has been an increase in the numbers done on outpatient basis. This retrospective review was conducted to evaluate the results of day case haemorrhoidectomy in a developing country.
   Materials and Methods: Forty three consecutive patients, who met the criteria for day case surgery, had ligation excision haemorrhoidectomy, between January 2004 and September 2005 at the Royal Victoria Teaching Hospital (RVTH) Banjul with the intention of same-day discharge from hospital. For each patient, data collected included age, sex, duration of symptoms, degree of haemorrhoids, and duration of rest after the procedure in minutes or hours, whether the patient was discharged same day or needed admission for complications. Local anaesthesia, 1% lignocaine was used for all the patients.
   Results: Forty three patients comprising 28 males (65.1%) and 15 females (34.9%), with a male female ratio of 1.87:1 underwent planned day case haemorrhoidectomy. Their mean age was 36.27 +/- 10.26 years and range, was 25 to 56 years. Forty patients (93%) were discharged on the same day of surgery after a rest period in the as. day care theatre ranging between 25 minutes and 60 minutes with a mean of 41.2 +/- 11.08 minutes. Three (7%) of the patients required admission, two for acute urinary retention and control of excessive pain and the other:5 days postoperative on account of secondary haemorrhage. Pain control was achieved by oral non steroidal anti-inflammatory agents. There were no deaths and majority of the patients were satisfied with the procedure.
   Conclusion: Ligation excision (Milligan-Morgan) haemorrhoidectomy is safe and can be performed successfully on out patient basis, saving inpatient health care costs. This is suitable for developing country.
C1 [Nuhu, A.] Univ Maiduguri, Teaching Hosp, Dept Surg, Maiduguri, Niger.
   [Samateh, A.] Royal Victoria Teaching Hosp, Banjul, Gambia.
RP Nuhu, A (reprint author), Univ Maiduguri, Teaching Hosp, Dept Surg, Maiduguri, Niger.
EM nuhualinvwa@yahoo.com
CR Arroyo A, 2004, INT J COLORECTAL DIS, V19, P370, DOI 10.1007/s00384-003-0573-1
   CHERSTER JF, 1990, DIS COLON RECTUM, V33, P487
   DENNISON AR, 1988, SURG CLIN N AM, V68, P1401
   HESTER YSC, 2004, ANN COLL SURG HONG K, V8, P35
   Ho YH, 1998, AUST NZ J SURG, V68, P334, DOI 10.1111/j.1445-2197.1998.tb04766.x
   Hunt L, 1999, BRIT J SURG, V86, P255
   Jayne DG, 2002, BRIT J SURG, V89, P428, DOI 10.1046/j.0007-1323.2002.02056.x
   JOHNSON CD, 1987, DIS COLON RECTUM, V30, P780, DOI 10.1007/BF02554626
   Labas P, 2002, EUR J SURG, V168, P619, DOI 10.1080/11024150201680008
   Lam TYD, 2001, ANZ J SURG, V71, P652, DOI 10.1046/j.1445-1433.2001.02235.x
   LEWIS AAM, 1983, BRIT J SURG, V70, P54, DOI 10.1002/bjs.1800700121
   Marsh G D, 1993, J R Coll Surg Edinb, V38, P41
   Milligan ETC, 1937, LANCET, V2, P1119
   MURIE JA, 1982, BRIT J SURG, V69, P563
   Orlay George, 2003, Aust Fam Physician, V32, P523
NR 15
TC 2
Z9 2
U1 0
U2 0
PU MEDICAL & DENTAL CONSULTANTS ASSOC NIGERIA
PI NNEWI
PA UNIV TEACHING HOSP, DEPT SURGERY, NNAMDI AZIKIWE. PMB 5025, NNEWI,
   00000, NIGERIA
SN 1119-3077
J9 NIGER J CLIN PRACT
JI Niger. J. Clin. Pract.
PD MAR
PY 2009
VL 12
IS 1
BP 51
EP 53
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 435SV
UT WOS:000265364500012
PM 19562922
OA No
DA 2017-08-15
ER

PT J
AU Geerts, S
   Osaer, S
   Goossens, B
   Faye, D
AF Geerts, Stanny
   Osaer, Sabine
   Goossens, Bart
   Faye, Dethie
TI Trypanotolerance in small ruminants of sub-Saharan Africa
SO TRENDS IN PARASITOLOGY
LA English
DT Review
ID TRYPANOSOMA-CONGOLENSE INFECTION; GASTROINTESTINAL NEMATODE PARASITES;
   MANAGED DJALLONKE SHEEP; DWARF GOATS; HAEMONCHUS-CONTORTUS; SUBHUMID
   TROPICS; HEMATOLOGICAL-CHANGES; GENETIC-RESISTANCE; MILK-PRODUCTION; RED
   MAASAI
AB Although a lot of information is currently available on trypanotolerance in cattle, until recently the trypanotolerant nature of small ruminants was not well known. Trypanotolerance in small ruminants is less pronounced than in cattle and should be considered as resilience rather than resistance. West African Dwarf (WAD) goats seem to be less trypanotolerant than Djallonke sheep. However, recent studies have shown that there is an important introgression of genes of trypanosusceptible breeds into WAD goat populations, which possibly explains the loss of trypanotolerance in these animals. Measures need to be taken to safeguard and upgrade the genetic purity of trypanotolerant goat and sheep breeds in Africa.
C1 [Geerts, Stanny] Inst Trop Med, Dept Anim Hlth, B-2000 Antwerp, Belgium.
   [Geerts, Stanny] Int Trypanotolerance Ctr, Banjul, Gambia.
   [Goossens, Bart] Endem Livestock Project, UNOPS, Baku, Gambia.
RP Geerts, S (reprint author), Inst Trop Med, Dept Anim Hlth, Natl Str 155, B-2000 Antwerp, Belgium.
EM sgeerts@itg.be
FU Belgian Directorate General for Development Cooperation (Brussels)
FX The authors want to thank the Belgian Directorate General for
   Development Cooperation (Brussels) for its financial support of the
   research project on trypanotolerant small ruminants at the International
   Trypanotolerance Centre, Banjul. The authors are also grateful to P.H.
   Holmes, L. Dempfle and M. Murray for their critical review of the
   manuscript.
CR ADAH MI, 1993, VET PARASITOL, V47, P177, DOI 10.1016/0304-4017(93)90020-N
   AGYEMANG K, 1990, LIVEST PROD SCI, V26, P39, DOI 10.1016/0301-6226(90)90054-A
   Agyemang K., 2005, PAAT TECHN SCI SER, V7, P1
   Agyemang K, 1997, VILLAGE NDAMA CATTLE
   AUTHIE E, 1994, PARASITOL TODAY, V10, P360, DOI 10.1016/0169-4758(94)90252-6
   Baker RL, 1999, ANIM SCI, V69, P335
   Baker RL, 2003, ANIM SCI, V76, P119
   Baker RL, 1998, VET PARASITOL, V79, P53, DOI 10.1016/S0304-4017(98)00151-4
   Bakert RL, 2001, ANIM SCI, V73, P61
   Behnke JM, 2006, VET PARASITOL, V141, P107, DOI 10.1016/j.vetpar.2006.04.017
   Bengaly Z, 1993, Rev Elev Med Vet Pays Trop, V46, P563
   Bengaly Z, 2002, VET PARASITOL, V108, P1, DOI 10.1016/S0304-4017(02)00164-4
   Bisset SA, 2001, NEW ZEAL VET J, V49, P236, DOI 10.1080/00480169.2001.36238
   Bosso NA, 2007, SMALL RUMINANT RES, V67, P271, DOI 10.1016/j.smallrumres.2005.11.001
   BUNGENER W, 1976, TROPENMED PARASITOL, V27, P405
   Chiejina SN, 2005, VET PARASITOL, V128, P29, DOI 10.1016/j.vetpar.2004.11.005
   Chiejina SN, 2002, VET PARASITOL, V104, P229, DOI 10.1016/S0304-4017(01)00636-7
   d'Ieteren GDM, 1998, REV SCI TECH OIE, V17, P154
   Dhollander S, 2005, VET PARASITOL, V130, P1, DOI 10.1016/j.vetpar.2004.11.012
   Fakae BB, 2004, VET PARASITOL, V122, P51, DOI 10.1016/j.vetpar.2004.02.005
   *FAO, 1991, 88 FAO AN PROD HLTH, P231
   Faye D, 2005, ACTA TROP, V93, P247, DOI 10.1016/j.actatropica.2004.10.008
   Faye D, 2002, VET PARASITOL, V108, P117, DOI 10.1016/S0304-4017(02)00184-X
   Goossens B, 1997, INT J PARASITOL, V27, P1579, DOI 10.1016/S0020-7519(97)00094-5
   Goossens B, 1999, VET PARASITOL, V85, P25, DOI 10.1016/S0304-4017(99)00087-4
   Goossens B, 1998, VET PARASITOL, V79, P283, DOI 10.1016/S0304-4017(98)00171-X
   Goossens B, 1997, RES VET SCI, V63, P169, DOI 10.1016/S0034-5288(97)90013-8
   GRIFFIN L, 1979, TROP ANIM HEALTH PRO, V11, P133, DOI 10.1007/BF02237789
   GRIFFIN L, 1979, VET PARASITOL, V5, P97, DOI 10.1016/0304-4017(79)90001-3
   *ILCA, 1979, TRYP LIV W CENTR AFR, V1
   Jaitner J, 2006, TROP ANIM HEALTH PRO, V38, P261, DOI 10.1007/s11250-006-4364-x
   KAAYA G P, 1977, Bulletin of Animal Health and Production in Africa, V25, P397
   Kanyari P. W. N., 1986, Bulletin of Animal Health and Production in Africa, V34, P93
   KATUNGUKARWAKISHAYA E, 1993, VET PARASITOL, V47, P189, DOI 10.1016/0304-4017(93)90021-E
   KatungukaRwakishaya E, 1997, TROP ANIM HEALTH PRO, V29, P7, DOI 10.1007/BF02632337
   Masumu J, 2006, INT J PARASITOL, V36, P497, DOI 10.1016/j.ijpara.2006.01.003
   MATTIOLI RC, 1993, VET PARASITOL, V47, P139, DOI 10.1016/0304-4017(93)90184-O
   Monirei J. M., 1982, Trypanotolerance and animal production. Proceedings of the Workshop 10-14 May 1982, Lome et Avetonou, Togo. (Schriftenreihe der GTZ No.116)., P33
   Morris C. A., 2004, Proceedings of the New Zealand Society of Animal Production, V64, P300
   Morris C. A., 2001, Proceedings of the New Zealand Society of Animal Production, V61, P92
   MURRAY M, 1982, ADV PARASIT, V21, P1, DOI 10.1016/S0065-308X(08)60274-2
   MUTAYOBA BM, 1989, VET PARASITOL, V31, P95, DOI 10.1016/0304-4017(89)90024-1
   Naessens J, 2003, VET PARASITOL, V111, P125, DOI 10.1016/S0304-4017(02)00360-6
   Naessens J, 2002, VET IMMUNOL IMMUNOP, V87, P187, DOI 10.1016/S0165-2427(02)00070-3
   Odo BI, 2003, SMALL RUMINANT RES, V50, P203, DOI 10.1016/S0921-4488(03)00101-9
   Ogunsanmi A O, 1994, Rev Elev Med Vet Pays Trop, V47, P195
   Osaer S, 1999, VET PARASITOL, V82, P101, DOI 10.1016/S0304-4017(99)00011-4
   Osaer S, 2000, ACTA TROP, V74, P13, DOI 10.1016/S0001-706X(99)00042-X
   OSAER S, 1994, VET PARASITOL, V51, P191, DOI 10.1016/0304-4017(94)90156-2
   Osaer S, 1998, RES VET SCI, V65, P65, DOI 10.1016/S0034-5288(98)90029-7
   PALING RW, 1991, PARASITE IMMUNOL, V13, P413, DOI 10.1111/j.1365-3024.1991.tb00294.x
   PRESTON JM, 1978, VET REC, V103, P509
   PRESTON JM, 1979, RES VET SCI, V26, P134
   Snow WF, 1996, VET PARASITOL, V66, P1, DOI 10.1016/S0304-4017(96)01003-5
   VALE GA, 1977, B ENTOMOL RES, V67, P635
   WHITELAW DD, 1985, TROP ANIM HEALTH PRO, V17, P155, DOI 10.1007/BF02355876
   Woolaston RR, 1996, INT J PARASITOL, V26, P845, DOI 10.1016/S0020-7519(96)80054-3
NR 57
TC 16
Z9 16
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4922
J9 TRENDS PARASITOL
JI Trends Parasitol.
PD MAR
PY 2009
VL 25
IS 3
BP 132
EP 138
DI 10.1016/j.pt.2008.12.004
PG 7
WC Parasitology
SC Parasitology
GA 420GV
UT WOS:000264278000008
PM 19200783
OA No
DA 2017-08-15
ER

PT J
AU Mackenzie, GA
   Carapetis, JR
   Leach, AJ
   Morris, PS
AF Mackenzie, Grant Austin
   Carapetis, Jonathan Rhys
   Leach, Amanda Jane
   Morris, Peter Stanley
TI Pneumococcal vaccination and otitis media in Australian Aboriginal
   infants: comparison of two birth cohorts before and after introduction
   of vaccination
SO BMC PEDIATRICS
LA English
DT Article
ID CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; CHILDREN; EFFICACY;
   IMMUNOGENICITY; IMMUNIZATION; EMERGENCE; SEROTYPES; DECLINE; DISEASE
AB Background: Aboriginal children in remote Australia have high rates of complicated middle ear disease associated with Streptococcus pneumoniae and other pathogens. We assessed the effectiveness of pneumococcal vaccination for prevention of otitis media in this setting.
   Methods: We compared two birth cohorts, one enrolled before (1996-2001), and the second enrolled after introduction of 7-valent pneumococcal conjugate and booster 23-valent polysaccharide vaccine (2001-2004). Source populations were the same for both cohorts. Detailed examinations including tympanometry, video-recorded pneumatic otoscopy and collection of discharge from tympanic membrane perforations, were performed as soon as possible after birth and then at regular intervals until 24 months of life. Analyses ( survival, point prevalence and incidence) were adjusted for confounding factors and repeated measures with sensitivity analyses of differential follow-up.
   Results: Ninety-seven vaccinees and 51 comparison participants were enrolled. By age 6 months, 96% (81/84) of vaccinees and 100% (41/41) of comparison subjects experienced otitis media with effusion (OME), and by 12 months 89% and 88% experienced acute otitis media (AOM), 34% and 35% experienced tympanic membrane perforation (TMP) and 14% and 23% experienced chronic suppurative otitis media (CSOM). Age at the first episode of OME, AOM, TMP and CSOM was not significantly different between the two groups. Adjusted incidence of AOM ( incidence rate ratio: 0.88 [95% confidence interval (CI): 0.69-1.13]) and TMP ( incidence rate ratio: 0.63 [0.36-1.11]) was not significantly reduced in vaccinees. Vaccinees experienced less recurrent TMP, 9% (8/95) versus 22% (11/51), ( odds ratio: 0.33 [0.11-1.00]).
   Conclusion: Results of this study should be interpreted with caution due to potential bias and confounding. It appears that introduction of pneumococcal vaccination among Aboriginal infants was not associated with significant changes in prevalence or age of onset of different OM outcomes or the incidence of AOM or TMP. Vaccinees appeared to experience reduced recurrence of TMP. Ongoing high rates of complicated OM necessitate additional strategies to prevent ear disease in this population.
C1 [Mackenzie, Grant Austin] Med Res Council UK, Bacterial Dis Program, Fajara, Gambia.
   [Mackenzie, Grant Austin; Carapetis, Jonathan Rhys; Leach, Amanda Jane; Morris, Peter Stanley] Menzies Sch Hlth Res, Child Hlth Div, Darwin, NT, Australia.
   [Mackenzie, Grant Austin; Carapetis, Jonathan Rhys; Leach, Amanda Jane; Morris, Peter Stanley] Charles Darwin Univ, Inst Adv Studies, Darwin, NT 0909, Australia.
   [Mackenzie, Grant Austin] Flinders Univ S Australia, Sch Med, Adelaide, SA, Australia.
   [Morris, Peter Stanley] Flinders Univ S Australia, NT Clin Sch, Darwin, NT, Australia.
RP Mackenzie, GA (reprint author), Med Res Council UK, Bacterial Dis Program, Fajara, Gambia.
EM gmackenzie@mrc.gm; jonathan.carapetis@menzies.edu.au;
   amanda.leach@menzies.edu.au; peter.morris@menzies.edu.au
FU National Health and Medical Research Council of Australia and Wyeth
   Australia
FX This work is attributed to the Child Health Division, Menzies School of
   Health Research.
CR Amusa Y B, 2005, West Afr J Med, V24, P227
   *AUSTR BUR STAT, 2002, 71010 AUSTR BUR STAT
   *AUSTR BUR STAT, 1997, 710100609 AUSTR BUR
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Block SL, 2004, PEDIATR INFECT DIS J, V23, P829, DOI 10.1097/01.inf.0000136868.91756.80
   Casey JR, 2004, PEDIATR INFECT DIS J, V23, P824, DOI 10.1097/01.inf.0000136871.51792.19
   Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602
   Fireman B, 2003, PEDIATR INFECT DIS J, V22, P10, DOI 10.1097/00006454-200301000-00006
   FLETCHER MA, 2006, VACCINE, V25, P2507
   Grijalvaj CG, 2007, LANCET, V369, P1179, DOI 10.1016/S0140-6736(07)60564-9
   Kamal N, 2004, Bangladesh Med Res Counc Bull, V30, P95
   LEACH AJ, 1994, PEDIATR INFECT DIS J, V13, P983, DOI 10.1097/00006454-199411000-00009
   LEACH AJ, 2006, STREPTOCOCCI NEW INS, P89
   LEACH AJ, 1996, THESIS U SYDNEY
   Leach AJ, 2008, VACCINE, V26, P3885, DOI 10.1016/j.vaccine.2008.05.012
   Leach AJ, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-23
   Matanda RN, 2005, B-ENT, V1, P57
   McEllistrem MC, 2005, CLIN INFECT DIS, V40, P1738, DOI 10.1086/429908
   Minja B M, 2006, East Afr Med J, V83, P322
   Morris Peter S, 2005, BMC Pediatr, V5, P27, DOI 10.1186/1471-2431-5-27
   O'Brien KL, 2008, PEDIATR INFECT DIS J, V27, P71, DOI 10.1097/INF.0b013e318159228f
   O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI 10.1097/00006454-200302000-00009
   OGRADY KA, 2008, REYKJAVIK
   Palmu AAI, 2004, PEDIATR INFECT DIS J, V23, P732, DOI 10.1097/01.inf.0000133049.30299.5d
   Pelton SI, 2007, PEDIATR INFECT DIS J, V26, P468, DOI 10.1097/TNF.0b013e31803df9ca
   Pichichero ME, 2007, JAMA-J AM MED ASSOC, V298, P1772, DOI 10.1001/jama.298.15.1772
   Poehling KA, 2007, PEDIATRICS, V119, P707, DOI 10.1542/peds.2006-2138
   Prymula R, 2006, LANCET, V367, P740, DOI 10.1016/S0140-6736(06)68304-9
   Rothstein J, 2007, MED J AUSTRALIA, V186, P519
   Singleton RJ, 2007, JAMA-J AM MED ASSOC, V297, P1784, DOI 10.1001/jama.297.16.1784
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   *WHO, 1996, WHOMAL961075, P19
   *WYETH, WYETH PROD PIP
NR 33
TC 29
Z9 29
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2431
J9 BMC PEDIATR
JI BMC Pediatr.
PD FEB 19
PY 2009
VL 9
AR 14
DI 10.1186/1471-2431-9-14
PG 11
WC Pediatrics
SC Pediatrics
GA 421HZ
UT WOS:000264351300001
PM 19228431
OA gold
DA 2017-08-15
ER

PT J
AU Clark, TG
   Diakite, M
   Auburn, S
   Campino, S
   Fry, AE
   Green, A
   Richardson, A
   Small, K
   Teo, YY
   Wilson, J
   Jallow, M
   Sisay-Joof, F
   Pinder, M
   Griffiths, MJ
   Peshu, N
   Williams, TN
   Marsh, K
   Molyneux, ME
   Taylor, TE
   Rockett, KA
   Kwiatkowski, DP
AF Clark, Taane G.
   Diakite, Mahamadou
   Auburn, Sarah
   Campino, Susana
   Fry, Andrew E.
   Green, Angela
   Richardson, Anna
   Small, Kerrin
   Teo, Yik Y.
   Wilson, Jonathan
   Jallow, Muminatou
   Sisay-Joof, Fatou
   Pinder, Margaret
   Griffiths, Michael J.
   Peshu, Norbert
   Williams, Thomas N.
   Marsh, Kevin
   Molyneux, Malcolm E.
   Taylor, Terrie E.
   Rockett, Kirk A.
   Kwiatkowski, Dominic P.
TI Tumor Necrosis Factor and Lymphotoxin-alpha Polymorphisms and Severe
   Malaria in African Populations
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; CEREBRAL MALARIA; PROMOTER REGION;
   LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISMS; DISEASE SEVERITY; MILD
   MALARIA; MHC REGION; TNF; ASSOCIATION
AB The tumor necrosis factor gene (TNF) and lymphotoxin-alpha gene (LTA) have long attracted attention as candidate genes for susceptibility traits for malaria, and several of their polymorphisms have been found to be associated with severe malaria (SM) phenotypes. In a large study involving > 10,000 individuals and encompassing 3 African populations, we found evidence to support the reported associations between the TNF - 238 polymorphism and SM in The Gambia. However, no TNF/LTA polymorphisms were found to be associated with SM in cohorts in Kenya and Malawi. It has been suggested that the causal polymorphisms regulating the TNF and LTA responses may be located some distance from the genes. Therefore, more-detailed mapping of variants across TNF/LTA genes and their flanking regions in the Gambian and allied populations may need to be undertaken to find any causal polymorphisms.
C1 [Clark, Taane G.; Diakite, Mahamadou; Fry, Andrew E.; Green, Angela; Richardson, Anna; Small, Kerrin; Teo, Yik Y.; Wilson, Jonathan; Rockett, Kirk A.; Kwiatkowski, Dominic P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Williams, Thomas N.] John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.
   [Clark, Taane G.; Campino, Susana; Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Cambridge, England.
   [Marsh, Kevin; Molyneux, Malcolm E.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   [Jallow, Muminatou; Sisay-Joof, Fatou; Pinder, Margaret] MRC Labs, Banjul, Fajara, Gambia.
   [Griffiths, Michael J.; Peshu, Norbert; Williams, Thomas N.] Wellcome Trust Collaborat Programme, Kilifi Kenya Med Res Inst, Kilifi, Kenya.
   [Molyneux, Malcolm E.] Malawi Liverpool Wellcome Trust Programme Clin Tr, Blantyre, Malawi.
   [Taylor, Terrie E.] Coll Med, Blantyre Malaria Project, Blantyre, Malawi.
   [Taylor, Terrie E.] Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA.
RP Clark, TG (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
EM tgc@well.ox.ac.uk
OI Kwiatkowski, Dominic/0000-0002-5023-0176; Auburn,
   Sarah/0000-0002-4638-536X
FU Bill and Melinda Gates Foundation; Wellcome Trust; Medical Research
   Council United Kingdom; Fundacao para a Ciencia e Tecnologia, Ministerio
   da Ciencia e Tecnologia; Wellcome Trust Clinical Research Training
   Fellowship; MalariaGEN; European Union Network 6 BioMalPar Consortium;
   International Atomic Energy Agency
FX Financial support: The Bill and Melinda Gates Foundation; Wellcome
   Trust; Medical Research Council United Kingdom; Fundacao para a Ciencia
   e Tecnologia, Ministerio da Ciencia e Tecnologia (Portuguese Post-Doc
   fellowship to S. C.); Wellcome Trust Clinical Research Training
   Fellowship (to A. E. F.); Wellcome Trust, MalariaGEN, and European Union
   Network 6 BioMalPar Consortium (funding to T. N. W.); International
   Atomic Energy Agency (training fellowship to M. D.).
CR Ackerman HC, 2003, GENES IMMUN, V4, P476, DOI 10.1038/sj.gene.6364008
   Aidoo M, 2001, GENET EPIDEMIOL, V21, P201, DOI 10.1002/gepi.1029
   Alcais A, 2007, NAT GENET, V39, P517, DOI 10.1038/ng2000
   Bayley JP, 2004, GENES IMMUN, V5, P315, DOI 10.1038/sj.gene.6364055
   Cabantous S, 2006, INFECT IMMUN, V74, P7040, DOI 10.1128/IAI.01581-05
   Campino S, 2006, SEMIN IMMUNOL, V18, P411, DOI 10.1016/j.smim.2006.07.011
   Clark IA, 2004, CLIN MICROBIOL REV, V17, P509, DOI 10.1128/CMR.17.3.509-539.2004
   CLARK TG, EUR J HUM G IN PRESS
   Clarke R, 2006, PLOS GENET, V2, P990, DOI 10.1371/journal.pgen.0020107
   Division of Control of Tropical Diseases, 1990, T R SOC TROP MED S2, V84, P1
   Engwerda CR, 2002, J EXP MED, V195, P1371, DOI 10.1084/jem.20020128
   Flori L, 2005, GENES IMMUN, V6, P472, DOI 10.1038/sj.gene.6364231
   Gonzalez JM, 2005, ENVIRON MICROBIOL, V7, P1024, DOI 10.1111/j.1462-2920.2005.00779.x
   GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404
   Hananantachai H, 2007, TISSUE ANTIGENS, V69, P277, DOI 10.1111/j.1399-0039.2006.00756.x
   Hananantachai H, 2001, AM J MED GENET, V102, P391, DOI 10.1002/ajmg.1486
   Knight JC, 2004, NAT GENET, V36, P394, DOI 10.1038/ng1331
   Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649
   Knight JC, 2005, J MOL MED-JMM, V83, P97, DOI 10.1007/s00109-004-0603-7
   KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5
   Kwiatkowski DP, 2005, AM J HUM GENET, V77, P171, DOI 10.1086/432519
   Lake SL, 2003, HUM HERED, V55, P56, DOI 10.1159/000071811
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   McGuire W, 1999, J INFECT DIS, V179, P287, DOI 10.1086/314533
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   Migita O, 2005, CLIN EXP ALLERGY, V35, P790, DOI 10.1111/j.1365-2222.2005.02265.x
   Migot-Nabias F, 2000, GENES IMMUN, V1, P435, DOI 10.1038/sj.gene.6363703
   Mombo LE, 2003, AM J TROP MED HYG, V68, P186
   Newton JL, 2004, ARTHRITIS RHEUM, V50, P2122, DOI 10.1002/art.20358
   Parikh S, 2004, AM J TROP MED HYG, V71, P750
   R-Project, R PROJECT STAT COMPU
   Roach DR, 2001, J EXP MED, V193, P239, DOI 10.1084/jem.193.2.239
   Ross P, 1998, NAT BIOTECHNOL, V16, P1347, DOI 10.1038/4328
   Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Stenzel A, 2004, HUM GENET, V114, P377, DOI 10.1007/s00439-003-1075-5
   Stirnadel HA, 1999, TROP MED INT HEALTH, V4, P187, DOI 10.1046/j.1365-3156.1999.43381.x
   Teo YY, 2009, HUM HERED, V67, P26, DOI 10.1159/000164396
   Wattavidanage J, 1999, CLIN EXP IMMUNOL, V115, P350, DOI 10.1046/j.1365-2249.1999.00804.x
   Wilson JN, 2005, GENES IMMUN, V6, P462, DOI 10.1038/sj.gene.6364227
   ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847
NR 41
TC 27
Z9 27
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD FEB 15
PY 2009
VL 199
IS 4
BP 569
EP 575
DI 10.1086/596320
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 399LU
UT WOS:000262802200015
PM 19281305
OA No
DA 2017-08-15
ER

PT J
AU Gomes, MF
   Faiz, MA
   Gyapong, JO
   Warsame, M
   Agbenyega, T
   Babiker, A
   Baiden, F
   Yunus, EB
   Binka, F
   Clerk, C
   Folb, P
   Hassan, R
   Hossain, MA
   Kimbute, O
   Kitua, A
   Krishna, S
   Makasi, C
   Mensah, N
   Mrango, Z
   Olliaro, P
   Peto, R
   Peto, TJ
   Rahman, MR
   Ribeiro, I
   Samad, R
   White, NJ
AF Gomes, M. F.
   Faiz, M. A.
   Gyapong, J. O.
   Warsame, M.
   Agbenyega, T.
   Babiker, A.
   Baiden, F.
   Yunus, E. B.
   Binka, F.
   Clerk, C.
   Folb, P.
   Hassan, R.
   Hossain, M. A.
   Kimbute, O.
   Kitua, A.
   Krishna, S.
   Makasi, C.
   Mensah, N.
   Mrango, Z.
   Olliaro, P.
   Peto, R.
   Peto, T. J.
   Rahman, M. R.
   Ribeiro, I.
   Samad, R.
   White, N. J.
CA Study 13 Res Grp
TI Pre-referral rectal artesunate to prevent death and disability in severe
   malaria: a placebo-controlled trial
SO LANCET
LA English
DT Article
ID SEVERE FALCIPARUM-MALARIA; ANTIMALARIAL-DRUG RESISTANCE; CEREBRAL
   MALARIA; CHILDREN; EFFICACY; QUININE
AB Background Most malaria deaths occur in rural areas. Rapid progression from illness to death can be interrupted by prompt, effective medication. Antimalarial treatment cannot rescue terminally ill patients but could be effective if given earlier. If patients who cannot be treated orally are several hours from facilities for injections, rectal artesunate can be given before referral and acts rapidly on parasites. We investigated whether this intervention reduced mortality and permanent disability.
   Methods In Bangladesh, Ghana, and Tanzania, patients with suspected severe malaria who could not be treated orally were allocated randomly to a single artesunate (n=8954) or placebo (n=8872) suppository by taking the next numbered box, then referred to clinics at which injections could be given. Those with antimalarial injections or negative blood smears before randomisation were excluded, leaving 12068 patients (6072 artesunate, 5996 placebo) for analysis. Primary endpoints were mortality, assessed 7-30 days later, and permanent disability, reassessed periodically. All investigators were masked to group assignment. Analysis was by intention to treat. This study is registered in all three countries, numbers ISRCTN83979018, 46343627, and 76987662.
   Results Mortality was 154 of 6072 artesunate versus 177 of 5996 placebo (2.5% vs 3 . 0%, p=0 . 1). Two versus 13 (0 . 03% vs 0 . 22%, p=0 . 0020) were permanently disabled; total dead or disabled: 156 versus 190 (2 . 6% vs 3.2%, p=0 . 0484). There was no reduction in early mortality (56 vs 51 deaths within 6 h; median 2 h). In patients reaching clinic within 6 h (median 3 h), pre-referral artesunate had no significant effect on death after 6 h or permanent disability (71/4450 [1.6%] vs 82/4426 [1.9%], risk ratio 0.86 [95% Cl 0.63-1.18], p=0.35). In patients still not in clinic after more than 6 h, however, half were still not there after more than 15 h, and pre-referral rectal artesurate significantly reduced death or permanent disability (29/1566 [1.9%] vs 57/1519 [3.8%], risk ratio 0.49 [95% CI 0.32-0.77], p=0 . 0013).
   Interpretation If patients with severe malaria cannot be treated orally and access to injections will take several hours, a single inexpensive artesunate suppository at the time of referral substantially reduces the risk of death or permanent disability.
   Funding UNICEF/UNDP/World Bank Special Programme for Research and Training in Tropical Diseases (WHO/TDR); WHO Global Malaria Programme (WHO/GMP); Sall Family Poundation; the European Union (QLRT-2000-01430); the UK Medical Research Council; USAID; Irish Aid; the Karolinska Institute; and the University of Oxford Clinical Trial Service Unit (CTSU).
C1 [Gomes, M. F.; Olliaro, P.] WHO, UNICEF UNDP World Bank, Special Programme Res & Training Trop Dis, CH-1211 Geneva 27, Switzerland.
   [Faiz, M. A.] Govt Peoples Repub Bangladesh, Minist Hlth & Family Welf, Dhaka, Bangladesh.
   [Gyapong, J. O.] Ghana Hlth Serv, Hlth Res Unit, Accra, Ghana.
   [Warsame, M.] WHO, Global Malaria Programme, CH-1211 Geneva, Switzerland.
   [Agbenyega, T.] Kwame Nkrumah Univ Sci & Technol, Sch Med Sci, Kumasi, Ghana.
   [Babiker, A.] MRC, HIV Clin Trials Ctr, London, England.
   [Baiden, F.] WHO, Representat Off, Dar Es Salaam, Tanzania.
   [Yunus, E. B.; Hassan, R.; Hossain, M. A.; Samad, R.] Chittagong Med Coll, Malaria Res Grp, Chittagong, Bangladesh.
   [Binka, F.] Univ Ghana, Sch Publ Hlth, Accra, Ghana.
   [Clerk, C.] Dodowa Hlth Res Ctr, Dodowa, Ghana.
   [Folb, P.] MRC, Cape Town, South Africa.
   [Kimbute, O.; Kitua, A.; Makasi, C.; Mrango, Z.] Natl Inst Med Res, Dar Es Salaam, Tanzania.
   [Krishna, S.] Univ London St Georges Hosp, Sch Med, London SW17 0RE, England.
   [Mensah, N.] Navrongo Hlth Res Ctr, Navrongo, Ghana.
   [Peto, R.] Univ Oxford, Clin Trial Serv Unit, Oxford, England.
   [Peto, T. J.] MRC Labs, Banjul, Gambia.
   [Rahman, M. R.] Begum Khaleda Zia Med Coll, Dhaka, Bangladesh.
   [Ribeiro, I.] DNDi, Rio De Janeiro, Brazil.
   [White, N. J.] Mahidol Univ, Fac Trop Med, Bangkok 10700, Thailand.
RP Gomes, MF (reprint author), WHO, UNICEF UNDP World Bank, Special Programme Res & Training Trop Dis, 1211 Ave Appia, CH-1211 Geneva 27, Switzerland.
EM gomesm@who.int
RI White, Nicholas/I-4629-2012
OI Krishna, Sanjeev/0000-0003-0066-0634; Kimbute, Omari/0000-0002-0067-5783
FU UNICEF/UNDP/World Bank Special Programme for Research and Training in
   Tropical Diseases (WHO/TDR); Global Malaria Programme (WHO/GMP); Sall
   Family Foundation, the European Union [QLRT-2000-01430]; UK Medical
   Research Council; USAID; Irish Aid; Karolinska Institute; University of
   Oxford Clinical Trial Service Unit (CTSU); NJW is Wellcome Trust
   Principal Fellow
FX We thank the hundreds of villages and thousands of parents or guardians
   who agreed to take part in this trial; the 417 village recruiters and 74
   field supervisors; the local clinics and hospitals in Bangladesh, Ghana,
   and Tanzania; and the facilities of the Bangladesh Institute of Tropical
   and Infectious Diseases, the Ghanaian Ministry of Health, and the
   Tanzanian National Institute of Medical Research. The study was
   supported financially by the UNICEF/UNDP/World Bank Special Programme
   for Research and Training in Tropical Diseases (WHO/TDR), the Global
   Malaria Programme (WHO/GMP), the Sall Family Foundation, the European
   Union (QLRT-2000-01430), the UK Medical Research Council, USAID, Irish
   Aid, the Karolinska Institute, and the University of Oxford Clinical
   Trial Service Unit (CTSU). NJW is Wellcome Trust Principal Fellow.
CR Al Fadil SM, 2003, B WORLD HEALTH ORGAN, V81, P708
   ARROW KJ, 2004, SAVING LIVES BUYTING
   Barnes KI, 2004, LANCET, V363, P1598, DOI 10.1016/S0140-6736(04)16203-X
   Brewer T G, 1994, Trans R Soc Trop Med Hyg, V88 Suppl 1, pS33
   Carter JA, 2005, J NEUROL NEUROSUR PS, V76, P476, DOI 10.1136/jnnp.2004.043893
   Chowdhury EK, 2008, LANCET, V372, P822, DOI 10.1016/S0140-6736(08)61166-6
   Faiz MA, 2005, LANCET, V366, P717
   Krishna S, 2001, ANTIMICROB AGENTS CH, V45, P509, DOI 10.1128/AAC.45.2.509-516.2001
   Lopez AD, 2006, DIS CONTROL PRIORITI
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4
   Ngoungou EB, 2006, EPILEPSIA, V47, P873, DOI 10.1111/j.1528-1167.2006.00524.x
   Peterson S, 2004, LANCET, V363, P1955, DOI 10.1016/S0140-6736(04)16411-8
   Simpson JA, 2006, PLOS MED, V3, P2113, DOI 10.1371/journal.pmed.0030444
   White N, 1999, TROP MED INT HEALTH, V4, P469, DOI 10.1046/j.1365-3156.1999.00435.x
   White NJ, 2004, J CLIN INVEST, V113, P1084, DOI 10.1172/JCI200421682
   White NJ, 1997, ANTIMICROB AGENTS CH, V41, P1413
   YUNUS EB, 2004, J BANG COLL PHYS SUR, V22, P83
NR 18
TC 83
Z9 86
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD FEB 14
PY 2009
VL 373
IS 9663
BP 557
EP 566
DI 10.1016/S0140-6736(08)61734-1
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 406ZO
UT WOS:000263333600034
PM 19059639
OA No
DA 2017-08-15
ER

PT J
AU Brabin, L
   Stokes, E
   Dumbaya, I
   Owens, S
AF Brabin, Loretta
   Stokes, Elizabeth
   Dumbaya, Isatou
   Owens, Stephen
TI Gambian women's reliance on health workers to deliver
   sulphadoxine-pyrimethamine as recommended intermittent preventive
   treatment for malaria in pregnancy
SO MALARIA JOURNAL
LA English
DT Article
ID ANTENATAL CARE; WESTERN KENYA; TANZANIA; DISTRICT; UGANDA; MALAWI; TRIAL
AB Background: The use of most anti-malarial medications is restricted during pregnancy, but two doses of sulphadoxine-pyrimethamine are recommended after the first trimester as intermittent preventive treatment in pregnancy (IPTp). In The Gambia, only 32% of women receive two doses and very little research has been conducted on women's awareness of drug safety during pregnancy. The objective of this paper was to assess whether rural Gambian women were aware of the importance of the timing of the two-dose IPT dose schedule and its relevance to drug safety.
   Methods: This was a qualitative study in which 41 interviews and 16 focus group discussions with women, adolescents, men and traditional birth attendants were conducted. A generic qualitative approach was used to generate a theory as to why women might not participate in IPTp as recommended.
   Results: Although most women used calendar months to count their stage of pregnancy, these months did not correlate with their concept of foetal development. Foetal growth was described following Islamic tradition as water, clot, piece of meat and human being, although there was little consensus about the order or timing in which these stages occurred. Common signs and conditions of malaria were known. Women were anxious about miscarriage and recognized that some medicines should not be taken in the first trimester, but were urged by men and traditional birth attendants to attend for antenatal care in the first trimester to "start treatment." General knowledge about the purpose of pregnancy medications and when they should be taken was poor among both men and women. One important result was that women relied entirely on health workers to provide safe drugs, at the correct time.
   Conclusion: Women did not have relevant information to judge the safety and appropriate timing of pregnancy drugs, which made them over-reliant on health workers. They should be encouraged to date their own pregnancies in culturally relevant terms and to anticipate when and which medications they should receive.
C1 [Brabin, Loretta; Stokes, Elizabeth] Univ Manchester, Acad Unit Obstet & Gynaecol, Manchester M13 0JH, Lancs, England.
   [Dumbaya, Isatou; Owens, Stephen] MRC, Keneba Field Stn, Keneba, Gambia.
RP Brabin, L (reprint author), Univ Manchester, Acad Unit Obstet & Gynaecol, Manchester M13 0JH, Lancs, England.
EM loretta.brabin@manchester.ac.uk; lizstokes74@hotmail.com;
   lizstokes74@hotmail.com; sowens3@mac.com
FU Sir Halley Stewart Trust; Max Elstein Foundation
FX We thank Dr. Sophie Moore, Head of Station, MRC Keneba for her support
   and encouragement, and Mr. Bekai Touray for his diligent and sensitive
   efforts in the field. The funding source was the Sir Halley Stewart
   Trust, and this covered fieldworker costs for E. Stokes and I. Dumbaya.
   Dr Owens was an MRC Research Fellow conducting nutritional research in
   Keneba. Dr. Brabin is supported by the Max Elstein Foundation. The
   funder played no role in any part of the research.
CR ANYA SE, 2009, BMC PREGNANCY CHILDB, V8, P9
   Bonnet D., 1988, CORPS BIOL CORPS SOC
   Caelli K., 2003, INT J QUAL METH, V2, P1
   Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2
   Dellicour S, 2008, PLOS MED, V5, P1310, DOI 10.1371/journal.pmed.0050187
   Filler SJ, 2006, J INFECT DIS, V194, P286, DOI 10.1086/505080
   GBoS, 2007, GAMB MULT IND CLUST
   Gies S, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-180
   Kiwuwa MS, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-44
   Kocturk T, 2003, ACTA PAEDIATR, V92, P617, DOI 10.1080/0803532031000518
   Launiala A, 2007, T ROY SOC TROP MED H, V101, P980, DOI 10.1016/j.trstmh.2007.04.005
   Mbonye AK, 2006, HEALTH POLICY, V77, P279, DOI 10.1016/j.healthpol.2005.07.020
   Mubyazi G, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-31
   Mubyazi GM, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-135
   Nosten Francois, 2006, Curr Drug Saf, V1, P1, DOI 10.2174/157488606775252584
   Ouma PO, 2007, TROP MED INT HEALTH, V12, P953, DOI 10.1111/j.1365-3156.2007.01876.x
   Peters PJ, 2007, DRUG SAFETY, V30, P481, DOI 10.2165/00002018-200730060-00003
   Renne EP, 1996, SOC SCI MED, V42, P483, DOI 10.1016/0277-9536(95)00171-9
   Shaikh S., 2003, SACRED RIGHTS CASE C, P105
   Stokes E, 2008, BJOG-INT J OBSTET GY, V115, P1641, DOI 10.1111/j.1471-0528.2008.01950.x
   van Eijk AM, 2004, TROP MED INT HEALTH, V9, P630, DOI 10.1111/j.1365-3156.2004.01242.x
   *WHO, 2008, TECHN EXP GROUP M IN
NR 22
TC 13
Z9 13
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD FEB 12
PY 2009
VL 8
AR 25
DI 10.1186/1475-2875-8-25
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 424OU
UT WOS:000264576800001
PM 19216759
OA gold
DA 2017-08-15
ER

PT J
AU Diakite, M
   Clark, TG
   Auburn, S
   Campino, S
   Fry, AE
   Green, A
   Morris, AP
   Richardson, A
   Jallow, M
   Sisay-Joof, F
   Pinder, M
   Kwiatkowski, DP
   Rockett, KA
AF Diakite, Mahamadou
   Clark, Taane G.
   Auburn, Sarah
   Campino, Susana
   Fry, Andrew E.
   Green, Angela
   Morris, Andrew P.
   Richardson, Anna
   Jallow, Muminatou
   Sisay-Joof, Fatou
   Pinder, Margaret
   Kwiatkowski, Dominic P.
   Rockett, Kirk A.
TI A genetic association study in the Gambia using tagging polymorphisms in
   the major histocompatibility complex class III region implicates a HLA-B
   associated transcript 2 polymorphism in severe malaria susceptibility
SO HUMAN GENETICS
LA English
DT Article
AB The tumour necrosis factor (TNF) gene and other genes flanking it in the major histocompatibility complex (MHC) class III region are potentially important mediators of both immunity and pathogenesis of malaria. We investigated the association of severe malaria with 11 haplotype tagging-polymorphisms for 11 MHC class III candidate genes, including TNF, lymphotoxin alpha (LTA), allograft inflammatory factor 1 (AIF1), and HLA-B associated transcript 2 (BAT2). An analysis of 2,162 case-controls demonstrated the first evidence of association between a BAT2 polymorphism (rs1046089) and severe malaria.
C1 [Diakite, Mahamadou; Clark, Taane G.; Fry, Andrew E.; Green, Angela; Morris, Andrew P.; Richardson, Anna; Kwiatkowski, Dominic P.; Rockett, Kirk A.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Jallow, Muminatou; Sisay-Joof, Fatou; Pinder, Margaret] MRC Labs, Banjul, Gambia.
   [Diakite, Mahamadou] Univ Bamako, Fac Med Pharm & Odontostomatol, Malaria Res & Training Ctr, Bamako, Mali.
RP Clark, TG (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
EM tgc@well.ox.ac.uk
OI Kwiatkowski, Dominic/0000-0002-5023-0176; Auburn,
   Sarah/0000-0002-4638-536X
FU UK Medical Research Council; Wellcome Trust; Bill and Melinda Gates
   Foundation; International Atomic Energy Agency
FX We thank the patients from the Gambian study population, as well as the
   many investigators involved in the original study for their
   contributions. We thank Bronwyn MacInnis and Daniel Alcock for providing
   useful comments on an earlier version of this manuscript. This work was
   funded by the UK Medical Research Council, Wellcome Trust, Bill and
   Melinda Gates Foundation and Grand Challenges in Global Health and a PhD
   training fellowship from the International Atomic Energy Agency ( MD).
CR Ackerman HC, 2003, GENES IMMUN, V4, P476, DOI 10.1038/sj.gene.6364008
   Beck S, 1999, NATURE, V401, P921
   CLARK TG, 2009, J INFECT DI IN PRESS
   Harney SMJ, 2008, RHEUMATOLOGY, V47, P1761, DOI 10.1093/rheumatology/ken376
   Hashimoto M, 1999, HUM GENET, V105, P197, DOI 10.1007/s004390051089
   Knight JC, 2004, NAT GENET, V36, P394, DOI 10.1038/ng1331
   Kwiatkowski DP, 2005, AM J HUM GENET, V77, P171, DOI 10.1086/432519
   Langhorne J, 2008, NAT IMMUNOL, V9, P725, DOI 10.1038/ni.f.205
   *MALARIAGEN WTCC, 2008, NAT GENET IN PRESS
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Teo YY, 2007, ANN HUM GENET, V71, P701, DOI 10.1111/j.1469-1809.2007.00356.x
NR 11
TC 14
Z9 14
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
J9 HUM GENET
JI Hum. Genet.
PD FEB
PY 2009
VL 125
IS 1
BP 105
EP 109
DI 10.1007/s00439-008-0597-2
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA 396BO
UT WOS:000262567400010
PM 19039607
OA No
DA 2017-08-15
ER

PT J
AU Hawkesworth, S
   Prentice, AM
   Fulford, AJC
   Moore, SE
AF Hawkesworth, Sophie
   Prentice, Andrew M.
   Fulford, Anthony J. C.
   Moore, Sophie E.
TI Maternal protein-energy supplementation does not affect adolescent blood
   pressure in The Gambia
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Blood pressure; maternal supplementation; The Gambia; DOHaD
ID INTRAUTERINE GROWTH RESTRICTION; RANDOMIZED CONTROLLED-TRIAL;
   BIRTH-WEIGHT; DIETARY SUPPLEMENTATION; DUTCH FAMINE; RURAL GAMBIA;
   EXPOSURE; SIZE; AGE; HYPERTENSION
AB Background Birthweight, and by inference maternal nutrition during pregnancy, is thought to be an important determinant of offspring blood pressure but the evidence base for this in humans is lacking data from randomized controlled trials.
   Methods The offspring from a maternal prenatal protein-energy supplementation trial were enrolled into a follow-up study of chronic disease risk factors including blood pressure. Subjects were 11-17 years of age and blood pressure was measured in triplicate using an automated monitor (Omron 705IT). One-thousand two-hundred sixty seven individuals (71% of potential participants) were included in the analysis.
   Results There was no difference in blood pressure between those whose mothers had consumed protein-energy biscuits during pregnancy and those whose mothers had consumed the same supplement post-partum. For systolic blood pressure the intention-to-treat regression coefficient was 0.46 (95% CI: -1.12, 2.04). Mean systolic blood pressure for control children was 110.2 (SD +/- 9.3) mmHg and for intervention children was 110.8 (SD +/- 8.8) mmHg. Mean diastolic blood pressure for control children was 64.7 (SD +/- 7.7) mmHg and for intervention children was 64.6 (SD +/- 7.6) mmHg.
   Conclusions We have found no association between maternal prenatal protein-energy supplementation and offspring blood pressure in adolescence amongst rural Gambians. We found some evidence to suggest that offspring body composition may interact with the effect of maternal supplementation on blood pressure.
C1 [Hawkesworth, Sophie] London Sch Hyg & Trop Med, MRC Int Nutr Grp, Nutr & Publ Hlth Intervent Res Unit, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   [Prentice, Andrew M.; Fulford, Anthony J. C.; Moore, Sophie E.] MRC Labs, MRC Keneba, Fajara, Gambia.
RP Hawkesworth, S (reprint author), London Sch Hyg & Trop Med, MRC Int Nutr Grp, Nutr & Publ Hlth Intervent Res Unit, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM sophie.hawkesworth@lshtm.ac.uk
RI Sandall, Jane/D-4146-2009
OI Sandall, Jane/0000-0003-2000-743X; Hawkesworth,
   Sophie/0000-0002-3554-242X
FU Medical Research Council
CR Adair L, 2005, ANNU REV NUTR, V25, P407, DOI 10.1146/annurev.nutr.25.050304.092538
   ADAIR LS, 1985, AM J CLIN NUTR, V41, P948
   Adair LS, 2001, CIRCULATION, V104, P1034, DOI 10.1161/hc3401.095037
   Barker DJP, 2005, J AM SOC NEPHROL, V16, P2537, DOI 10.1681/ASN.2005020160
   Barker DJP, 1998, MOTHERS BABIES HLTH
   Campbell MK, 2004, BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   COLE TJ, 1990, EUR J CLIN NUTR, V44, P45
   Fulford AJC, 2006, PAEDIATR PERINAT EP, V20, P251, DOI 10.1111/j.1365-3016.2006.00714.x
   Gluckman PD, 2004, TRENDS ENDOCRIN MET, V15, P183, DOI 10.1016/j.tem.2004.03.002
   Huxley R, 2002, LANCET, V360, P659, DOI 10.1016/S0140-6736(02)09834-3
   Huxley RR, 2000, J HYPERTENS, V18, P815, DOI 10.1097/00004872-200018070-00002
   Kuzawa CW, 2007, EARLY HUM DEV, V83, pS44, DOI 10.1016/S0378-3782(07)70048-8
   Langley-Evans S. C., 2003, Archives of Physiology and Biochemistry, V111, P8, DOI 10.1076/apab.111.1.8.15136
   Langley-Evans SC, 1999, LIFE SCI, V64, P965, DOI 10.1016/S0024-3205(99)00022-3
   Law CM, 1996, J HYPERTENS, V14, P935
   Leary SD, 2005, ARCH DIS CHILD, V90, P492, DOI 10.1136/adc.2004.070698
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Moore SE, 2001, DIABETIC MED, V18, P646, DOI 10.1046/j.1464-5491.2001.00565.x
   Painter RC, 2005, REPROD TOXICOL, V20, P345, DOI 10.1016/j.reprotox.2005.04.005
   PARKIN JM, 1976, ARCH DIS CHILD, V51, P259
   Pickering TG, 2005, CIRCULATION, V111, P697, DOI 10.1161/01.CIR.0000154900.76284.F6
   PRENTICE AM, 1983, HUM NUTR-CLIN NUTR, V37, P65
   PRENTICE AM, 1983, HUM NUTR-CLIN NUTR, V37, P53
   Prins M, 2008, EUR J CLIN NUTR, V62, P1065, DOI 10.1038/sj.ejcn.1602830
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
   Stein AD, 2006, EUR J EPIDEMIOL, V21, P759, DOI 10.1007/s10654-006-9065-2
   Vaidya A, 2008, LANCET, V371, P492, DOI 10.1016/S0140-6736(08)60172-5
   Vehaskari VM, 2005, J AM SOC NEPHROL, V16, P2545, DOI 10.1681/ASN.2005030300
   Webb AL, 2005, INT J EPIDEMIOL, V34, P898, DOI 10.1093/ije/dyi097
   [Anonymous], 1996, PEDIATRICS, V98, P649
NR 31
TC 18
Z9 19
U1 1
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD FEB
PY 2009
VL 38
IS 1
BP 119
EP 127
DI 10.1093/ije/dyn156
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 404PB
UT WOS:000263164400016
PM 18676982
OA No
DA 2017-08-15
ER

PT J
AU Nturibi, EM
   Kolawole, AA
   McCurdy, SA
AF Nturibi, E. M.
   Kolawole, A. A.
   McCurdy, S. A.
TI Smoking prevalence and tobacco control measures in Kenya, Uganda, the
   Gambia and Liberia: a review
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE tobacco; prevalence; control; Kenya; Uganda; Liberia; the Gambia
AB BACKGROUND: Smoking prevalence is increasing in developing countries. These resource-poor countries will have to battle tobacco-related diseases before they have eliminated common communicable diseases.
   METHODS: We conducted a computerised search of PubMed to identify published estimates of smoking prevalence in Kenya, the Gambia, Uganda and Liberia. We also reviewed tobacco control measures in each country using information provided by the respective health departments.
   RESULTS: We noted a high prevalence of smoking in Kenya, Uganda and the Gambia. There were no published data on tobacco use prevalence for Liberia. Tobacco control measures were inadequate.
   CONCLUSION: Standardised prevalence studies involving general populations should be conducted. Tobacco control efforts need to be reinforced.
C1 [Nturibi, E. M.] Kenya Assoc Prevent TB & Lung Dis, Nairobi, Kenya.
   [Kolawole, A. A.] MRC Labs, Basse, Gambia.
   [McCurdy, S. A.] Univ Calif Davis, Dept Publ Hlth Sci, Div Environm & Occupat Hlth, Davis, CA 95616 USA.
RP Nturibi, EM (reprint author), Kenya Assoc Prevent TB & Lung Dis, POB 29774-00202-27789-00506, Nairobi, Kenya.
EM mugambi@kma.co.ke
CR *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P324
   CHAPMAN S, 1994, BRIT MED J, V308, P189
   *GYTS, 2008, UG GLOB YOUTH TOB SU
   *GYTS, 2002, REP RES GLOB YOUTH T
   Haub C., 2007, 2007 WORLD POPULATIO
   Kwamanga D H, 2001, East Afr Med J, V78, P119
   LORE W, 1988, E AFR MED J, V65, P71
   Maassen ITHM, 2004, HEALTH EDUC RES, V19, P551, DOI 10.1093/her/cyg077
   Mpabulungi L, 2004, CROAT MED J, V45, P80
   Mpabulungi Lillian, 2006, Rural Remote Health, V6, P609
   Muller Mike, 1978, TOBACCO 3 WORLD TOMO
   ODEKOGUNDE M, 2001, E AFR MED J, V78, P119
   Ortiz Alma, 2003, P R Health Sci J, V22, P173
   Othieno CJ, 2000, E AFR MED J, V77, P592
   *PAN AM HLTH ORG, 2004, PAN AM TOB INF ONL S
   Patel Preeti, 2007, Tob Control, V16, pe1, DOI 10.1136/tc.2006.016071
   Shafey O, 2003, TOBACCO CONTROL COUN
   Walraven GEL, 2001, CLIN EXP ALLERGY, V31, P1679, DOI 10.1046/j.1365-2222.2001.01094.x
   *WHO, 2007, WHO MEMB STAT REG AR
   *WHO AFRO, 2008, MESS WHO REG DIR LG
   *WHO REG OFF EUR, 2007, CROSS COUNTR PROF
   *WHO W PAC REG, 2008, GLOB INF SYST TOB CO
   *WORLD BANK, 2006, 2006 WORLD DEV IND T
   2007, KENYA GAZETTE S, V95, P133
NR 24
TC 7
Z9 7
U1 0
U2 1
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD FEB
PY 2009
VL 13
IS 2
BP 165
EP 170
PG 6
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 396EE
UT WOS:000262574200003
PM 19146742
OA No
DA 2017-08-15
ER

PT J
AU Hawkesworth, S
AF Hawkesworth, Sophie
TI Exploiting dietary supplementation trials to assess the impact of the
   prenatal environment on CVD risk
SO PROCEEDINGS OF THE NUTRITION SOCIETY
LA English
DT Article; Proceedings Paper
CT Summer Meeting of the Nutrition-Society
CY JUN 30-JUL 03, 2008
CL Univ Nottingham, Nottingham, ENGLAND
SP Nutr Soc
HO Univ Nottingham
DE Developmental origins of health and disease; Maternal supplementation
   trials; CVD risk
ID RANDOMIZED CONTROLLED-TRIAL; GROWTH-FACTOR-I; MULTIPLE MICRONUTRIENT
   SUPPLEMENTATION; OFFSPRING BLOOD-PRESSURE; YOUNG GUATEMALAN ADULTS;
   ISCHEMIC-HEART-DISEASE; REDUCED FETAL-GROWTH; CALCIUM SUPPLEMENTATION;
   FOLLOW-UP; BIRTH-WEIGHT
AB Animal studies have demonstrated that altering the maternal diet during pregnancy affects offspring disease risk. Data from human subjects on the early-life determinants of disease have been derived primarily from birth-weight associations; studies of the impact of the maternal diet are scarce and inconsistent. Investigating CVD risk factors in the offspring of women who have participated in maternal supplementation trials provides a useful resource in this research field, by virtue of employing an experimental design (as compared with observational studies). To date, follow-up studies have been published only for a small number of trials; these trials include the impact of maternal protein-energy, multiple-micronutrient and Ca supplementation on offspring disease risk. In Nepal maternal micronutrient supplementation has been shown to be associated with lower offspring systolic blood pressure at 2 years of age. Data from Guatemala on a pre- and postnatal protein-energy community intervention have suggested long-term improvements in fasting glucose and body composition but not in blood pressure. In The Gambia no association has been found between prenatal protein-energy supplementation and markers of CVD risk including body composition, blood pressure and fasting glucose and insulin in childhood and adolescence. Little evidence of an effect of maternal Ca supplementation on offspring blood pressure has been demonstrated in four trials, although the risk of high systolic blood pressure was found to be reduced in one trial. The present paper reviews the current evidence relating maternal nutritional supplementation during pregnancy to offspring CVD risk and explores the potential explanations for the lack of association.
C1 [Hawkesworth, Sophie] Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
   [Hawkesworth, Sophie] MRC Labs, MRC Keneba, Fajara, Gambia.
RP Hawkesworth, S (reprint author), Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
EM sophie.hawkesworth@lshtm.ac.uk
OI Hawkesworth, Sophie/0000-0002-3554-242X
FU Medical Research Council
CR Adair L, 2005, ANNU REV NUTR, V25, P407, DOI 10.1146/annurev.nutr.25.050304.092538
   Barker D. J., 1986, LANCET, V327, P1077, DOI [10.1016/S0140-6736(86)91340-1, DOI 10.1016/S0140-6736(86)91340-1]
   BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095
   Barker DJP, 2002, TRENDS ENDOCRIN MET, V13, P364, DOI 10.1016/S1043-2760(02)00689-6
   Barker DJP, 1998, MOTHERS BABIES HLTH
   Belizan JM, 1997, BRIT MED J, V315, P281
   BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002
   Ben-Shlomo Y, 2005, CANCER EPIDEM BIOMAR, V14, P1336, DOI 10.1158/1055-9965.EPI-04-0908
   Ben-Shlomo Y, 2003, CLIN ENDOCRINOL, V59, P366, DOI 10.1046/j.1365-2265.2003.01857.x
   Bhutta ZA, 2008, LANCET, V371, P417, DOI 10.1016/S0140-6736(07)61693-6
   Brion MJA, 2008, PEDIATR RES, V63, P593, DOI 10.1203/PDR.0b013e31816fdbd3
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   Christian P, 2003, BRIT MED J, V326, P571, DOI 10.1136/bmj.326.7389.571
   Conlisk AJ, 2004, J NUTR, V134, P890
   Crowther CA, 1999, AUST NZ J OBSTET GYN, V39, P12
   Falkner B, 1996, PEDIATRICS, V98, P649
   Fernandez-Twinn DS, 2006, PHYSIOL BEHAV, V88, P234, DOI 10.1016/j.physbeh.2006.05.039
   Fewtrell MS, 2008, ARCH DIS CHILD, V93, P458, DOI 10.1136/adc.2007.127316
   FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91
   Gambling L, 2003, J PHYSIOL-LONDON, V552, P603, DOI 10.1113/jphysiol.2003.051383
   Gluckman PD, 2004, TRENDS ENDOCRIN MET, V15, P183, DOI 10.1016/j.tem.2004.03.002
   Gonzalez-Cossio T, 1998, J NUTR, V128, P1692
   Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5
   Hatton DC, 2003, AM J HYPERTENS, V16, P801, DOI 10.1016/S0895-7061(03)01027-6
   HAWKESWORTH S, 2008, J NUTR IN PRESS
   HAWKESWORTH S, 2008, INT J EPIDEMIOL, DOI DOI 10.1093/IJE/DYNL56
   Hiller JE, 2007, AUST NZ J OBSTET GYN, V47, P115, DOI 10.1111/j.1479-828X.2007.00696.x
   Hofmeyr GJ, 2007, BJOG-INT J OBSTET GY, V114, P933, DOI 10.1111/j.1471-0528.2007.01389.x
   Huxley R, 2002, LANCET, V360, P659, DOI 10.1016/S0140-6736(02)09834-3
   Huxley RR, 2000, J HYPERTENS, V18, P815, DOI 10.1097/00004872-200018070-00002
   Hypponen E, 2004, PAEDIATR PERINAT EP, V18, P168, DOI 10.1111/j.1365-3016.2004.00556.x
   Jarjou LM, 2006, AM J CLIN NUTR, V83, P657
   Juul A, 2002, CIRCULATION, V106, P939, DOI 10.1161/01.CIR.0000027563.44593.CC
   Kajantie E, 2005, INT J EPIDEMIOL, V34, P655
   Langley-Evans SC, 2006, P NUTR SOC, V65, P97, DOI 10.1079/PNS2005478
   Langley-Evans SC, 1999, LIFE SCI, V64, P965, DOI 10.1016/S0024-3205(99)00022-3
   Lawlor DA, 2007, CIRCULATION, V115, P562, DOI 10.1161/CIRCULATIONAHA.106.646661
   Leary SD, 2005, ARCH DIS CHILD, V90, P492, DOI 10.1136/adc.2004.070698
   Leon DA, 1998, BRIT MED J, V317, P241
   Levine RJ, 1997, NEW ENGL J MED, V337, P69, DOI 10.1056/NEJM199707103370201
   Lucas A, 1999, BRIT MED J, V319, P245
   MARTORELL R, 1995, J NUTR, V125, pS1027
   MARTORELL R, 1995, J NUTR, V125, pS1127
   MASTORCI F, 2008, NEUROSCI BIOBEHAV RE
   McArdle HJ, 2006, PLACENTA, V27, pS56, DOI 10.1016/j.placenta.2006.01.014
   MCGARVEY ST, 1991, HYPERTENSION, V17, P218
   Osrin D, 2005, LANCET, V365, P955, DOI 10.1016/S0140-6736(05)71084-9
   Prentice AM, 2005, ARCH DIS CHILD, V90, P429, DOI 10.1136/adc.2004.059030
   PRENTICE AM, 1983, HUM NUTR-CLIN NUTR, V37, P53
   Prentice AM, 2000, AM J CLIN NUTR, V71, P1226
   Prins M, 2007, EUR J CLIN NUTR, V62, P1065
   RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701
   RIVERA JA, 1995, J NUTR, V125, pS1068
   Roseboom T, 2006, EARLY HUM DEV, V82, P485, DOI 10.1016/j.earlhumdev.2006.07.001
   Salafia CM, 2006, CLIN OBSTET GYNECOL, V49, P236, DOI 10.1097/00003081-200606000-00007
   Sandhu MS, 2002, LANCET, V359, P1740, DOI 10.1016/S0140-6736(02)08655-5
   Simmons RA, 2001, DIABETES, V50, P2279, DOI 10.2337/diabetes.50.10.2279
   Singhal A, 2004, CIRCULATION, V109, P1108, DOI 10.1161/01.CIR.0000118500.23649.DF
   Singhal A, 2003, LANCET, V361, P1089, DOI 10.1016/S0140-6736(03)12895-4
   Singhal A, 2001, LANCET, V357, P413, DOI 10.1016/S0140-6736(00)04004-6
   Stein AD, 2006, EUR J EPIDEMIOL, V21, P759, DOI 10.1007/s10654-006-9065-2
   Tofail F, 2008, AM J CLIN NUTR, V87, P704
   Vaidya A, 2008, LANCET, V371, P492, DOI 10.1016/S0140-6736(08)60172-5
   Vickers MH, 2000, AM J PHYSIOL-ENDOC M, V279, pE83
   Villar J, 2006, AM J OBSTET GYNECOL, V194, P639, DOI 10.1016/j.ajog.2006.01.068
   Webb AL, 2005, INT J EPIDEMIOL, V34, P898, DOI 10.1093/ije/dyi097
   Yajnik CS, 2004, P NUTR SOC, V63, P387, DOI 10.1079/PNS2004365
NR 67
TC 14
Z9 14
U1 1
U2 2
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0029-6651
J9 P NUTR SOC
JI Proc. Nutr. Soc.
PD FEB
PY 2009
VL 68
IS 1
BP 78
EP 88
DI 10.1017/S0029665108008781
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 432MW
UT WOS:000265139400010
PM 19012806
OA No
DA 2017-08-15
ER

PT J
AU Rutherford, ME
   Dockerty, JD
   Jasseh, M
   Howie, SRC
   Herbison, P
   Jeffries, DJ
   Mulholland, K
   Adegbola, RA
   Hill, PC
AF Rutherford, Merrin E.
   Dockerty, John D.
   Jasseh, Momodou
   Howie, Stephen R. C.
   Herbison, Peter
   Jeffries, David J.
   Mulholland, Kim
   Adegbola, Richard A.
   Hill, Philip C.
TI Preventive measures in infancy to reduce under-five mortality: a
   case-control study in The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE child mortality; immunization; sub-Saharan Africa; prevention; primary
   breastfeeding
ID VITAMIN-A SUPPLEMENTATION; PRIMARY-HEALTH-CARE; CHILD-MORTALITY;
   RISK-FACTORS; MORBIDITY; IMPACT; DEFICIENCY; COMMUNITY; NEPAL; GHANA
AB To investigate the relationship between child mortality and common preventive interventions: vaccination, trained birthing attendants, tetanus toxoid during pregnancy, breastfeeding and vitamin A supplementation.
   Case-control study in a population under demographic surveillance. Cases (n = 141) were children under five who died. Each was age and sex-matched to five controls (n = 705). Information was gathered by interviewing primary caregivers.
   All but one of the interventions - whether the mother had received tetanus toxoid during pregnancy - were protective against child mortality after multivariate analysis. Having a trained person assisting at child birth (OR 0.2 95% CI 0.1-0.4), receiving all vaccinations by 9 months of age (OR 0.1; 95% CI 0.01-0.3), being breastfed for more than 12 months (Children breastfed between 13 and 24 months OR 0.1 95% CI 0.03-0.3, more than 25 months OR 0.1 95% CI 0.01-0.5) and receiving vitamin A supplementation at or after 6 months of age (OR 0.05; 95% CI 0.01-0.2) were protective against child death.
   This study confirms the value of at least four available interventions in the prevention of under-five death in The Gambia. It is now important to identify those who are not receiving them and why, and to intervene to improve coverage across the population.
C1 [Rutherford, Merrin E.; Dockerty, John D.; Herbison, Peter; Hill, Philip C.] Univ Otago, Ctr Int Hlth Prevent & Social Med, Dunedin, Otago, New Zealand.
   [Jasseh, Momodou; Howie, Stephen R. C.; Jeffries, David J.; Adegbola, Richard A.; Hill, Philip C.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Mulholland, Kim] London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England.
RP Rutherford, ME (reprint author), Univ Otago, Ctr Int Hlth Prevent & Social Med, Dunedin, Otago, New Zealand.
EM merrin.rutherford@gmail.com
FU Medical Research Council [MC_UP_A900_1123, MC_U190081970, MC_U190081992]
CR Aguayo Victor M., 2005, Food and Nutrition Bulletin, V26, P348
   Benn CS, 2005, BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55
   BINKA FN, 1995, INT J EPIDEMIOL, V24, P127, DOI 10.1093/ije/24.1.127
   Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8
   CHAHNAZARIAN A, 1993, INT J EPIDEMIOL, V22, pS32
   Darboe MK, 2007, LANCET, V369, P2088, DOI 10.1016/S0140-6736(07)60981-7
   GREENWOOD AM, 1990, J TROP MED HYG, V93, P58
   Huffman SL, 2001, MIDWIFERY, V17, P80, DOI 10.1054/midw.2001.0253
   Huhn GD, 2006, VACCINE, V24, P730, DOI 10.1016/j.vaccine.2005.08.077
   HUMPHREY JH, 1992, B WORLD HEALTH ORGAN, V70, P225
   Hussein Asia K, 2005, Afr J Reprod Health, V9, P113
   Ip S, 2007, EVID REP TECHNOL ASS, V153, P1, DOI DOI 10.1542/GR.18-2-15
   Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1
   MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923
   *MRC, 2004, PROF FAR DSS
   Murray CJL, 2007, LANCET, V370, P1040, DOI 10.1016/S0140-6736(07)61478-0
   RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401
   Reyes H, 1997, HEALTH POLICY PLANN, V12, P214, DOI 10.1093/heapol/12.3.214
   ROSS DA, 1995, AM J PUBLIC HEALTH, V85, P1246, DOI 10.2105/AJPH.85.9.1246
   Saadeh M Randa, 2003, Forum Nutr, V56, P236
   Schellenberg JRMA, 2002, TROP MED INT HEALTH, V7, P506, DOI 10.1046/j.1365-3156.2002.00888.x
   Semega-Janneh IJ, 2001, HEALTH POLICY PLANN, V16, P199, DOI 10.1093/heapol/16.2.199
   SOMMER A, 1986, LANCET, V1, P1169
   Sommer A, 2002, J NUTR, V132, p2845S
   Thapa S, 2005, TROP MED INT HEALTH, V10, P782, DOI 10.1111/j.1365-3156.2005.01448.x
   VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474
   VIJAYARAGHAVAN K, 1990, LANCET, V336, P1342, DOI 10.1016/0140-6736(90)92895-O
   WEST KP, 1991, LANCET, V338, P67, DOI 10.1016/0140-6736(91)90070-6
   World Health Organization, 1995, WKLY EPIDEMIOL REC, V70, P117
NR 29
TC 3
Z9 3
U1 0
U2 3
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD FEB
PY 2009
VL 14
IS 2
BP 149
EP 155
DI 10.1111/j.1365-3156.2008.02204.x
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 409HL
UT WOS:000263496700005
PM 19171012
OA No
DA 2017-08-15
ER

PT J
AU Mangano, VD
   Clark, TG
   Auburn, S
   Campino, S
   Diakite, M
   Fry, AE
   Green, A
   Richardson, A
   Jallow, M
   Sisay-Joof, F
   Pinder, M
   Griffiths, MJ
   Newton, C
   Peshu, N
   Williams, TN
   Marsh, K
   Molyneux, ME
   Taylor, TE
   Modiano, D
   Kwiatkowski, DP
   Rockett, KA
AF Mangano, Valentina D.
   Clark, Taane G.
   Auburn, Sarah
   Campino, Susana
   Diakite, Mahamadou
   Fry, Andrew E.
   Green, Angela
   Richardson, Anna
   Jallow, Muminatou
   Sisay-Joof, Fatou
   Pinder, Margaret
   Griffiths, Michael J.
   Newton, Charles
   Peshu, Norbert
   Williams, Thomas N.
   Marsh, Kevin
   Molyneux, Malcolm E.
   Taylor, Terrie E.
   Modiano, David
   Kwiatkowski, Dominic P.
   Rockett, Kirk A.
TI Lack of Association of Interferon Regulatory Factor 1 with Severe
   Malaria in Affected Child-Parental Trio Studies across Three African
   Populations
SO PLOS ONE
LA English
DT Article
AB Interferon Regulatory Factor 1 (IRF-1) is a member of the IRF family of transcription factors, which have key and diverse roles in the gene-regulatory networks of the immune system. IRF-1 has been described as a critical mediator of IFN-gamma signalling and as the major player in driving TH1 type responses. It is therefore likely to be crucial in both innate and adaptive responses against intracellular pathogens such as Plasmodium falciparum. Polymorphisms at the human IRF1 locus have been previously found to be associated with the ability to control P. falciparum infection in populations naturally exposed to malaria. In order to test whether genetic variation at the IRF1 locus also affects the risk of developing severe malaria, we performed a family-based test of association for 18 Single Nucleotide Polymorphisms (SNPs) across the gene in three African populations, using genotype data from 961 trios consisting of one affected child and his/her two parents (555 from The Gambia, 204 from Kenya and 202 from Malawi). No significant association with severe malaria or severe malaria subphenotypes (cerebral malaria and severe malaria anaemia) was observed for any of the SNPs/haplotypes tested in any of the study populations. Our results offer no evidence that the molecular pathways regulated by the transcription factor IRF-1 are involved in the immune-based pathogenesis of severe malaria.
C1 [Mangano, Valentina D.; Clark, Taane G.; Auburn, Sarah; Campino, Susana; Diakite, Mahamadou; Fry, Andrew E.; Green, Angela; Richardson, Anna; Kwiatkowski, Dominic P.; Rockett, Kirk A.] Wellcome Trust Ctr Human Genet, Childhood Infect Grp, Oxford, England.
   [Mangano, Valentina D.; Modiano, David] Univ Roma La Sapienza, Dept Publ Hlth Sci, Sect Parasitol, Rome, Italy.
   [Clark, Taane G.; Auburn, Sarah; Campino, Susana; Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Hinxton, England.
   [Jallow, Muminatou; Sisay-Joof, Fatou; Pinder, Margaret] MRC, Fajara, Gambia.
   [Griffiths, Michael J.; Newton, Charles; Peshu, Norbert; Williams, Thomas N.; Marsh, Kevin] Ctr Geograph Med Res, Kenya Med Res Inst, Kilifi, Kenya.
   [Williams, Thomas N.; Marsh, Kevin] John Radcliffe Hosp, Nuffield Dept Med, Oxford, England.
   [Molyneux, Malcolm E.; Taylor, Terrie E.] Malawi Liverpool Wellcome Trust Progr Clin Trop, Coll Med, Blantyre Malaria Project, Blantyre, Malawi.
   [Molyneux, Malcolm E.] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England.
   [Taylor, Terrie E.] Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA.
RP Mangano, VD (reprint author), Wellcome Trust Ctr Human Genet, Childhood Infect Grp, Oxford, England.
EM vmangano@well.ox.ac.uk
RI mangano, valentina/I-2456-2012; Newton, 21/B-7578-2014
OI Newton, 21/0000-0002-6999-5507; Mangano, Valentina
   D/0000-0002-2021-6162; Kwiatkowski, Dominic/0000-0002-5023-0176; Auburn,
   Sarah/0000-0002-4638-536X
FU Priority 1 Life Sciences, Genomics and Biotechnology for Health in the
   6th Framework Programme [LSHP-CT-2004-503578]; BioMalPar PhD Fellowship;
   UK Medical Research Council; Wellcome Trust; Bill and Melinda Gates
   Foundation; National Institutes of Health
FX This work is part of the activities of the BioMalPar European Network of
   Excellence supported by a European grant (LSHP-CT-2004-503578) from the
   Priority 1 Life Sciences, Genomics and Biotechnology for Health in the
   6th Framework Programme, and Mangano VD was funded by a BioMalPar PhD
   Fellowship. The sample collections and resources used in this study
   received funding from the UK Medical Research Council, the Wellcome
   Trust, the Bill and Melinda Gates Foundation, and the National
   Institutes of Health. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ackerman H, 2005, ANN HUM GENET, V69, P559, DOI 10.1111/j.1529-8817.2005.00180.x
   Agarwal A, 2000, BLOOD, V96, P2358
   Artavanis-Tsakonas K, 2003, CLIN EXP IMMUNOL, V133, P145, DOI 10.1046/j.1365-2249.2003.02174.x
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   CLARK T, 2008, J INFECT DI IN PRESS
   Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577
   Dodoo D, 2002, J INFECT DIS, V185, P971, DOI 10.1086/339408
   Evans DM, 2006, BEHAV GENET, V36, P947, DOI 10.1007/s10519-006-9087-2
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gonzalez JM, 2005, ENVIRON MICROBIOL, V7, P1024, DOI 10.1111/j.1462-2920.2005.00779.x
   Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a
   Honda K, 2006, IUBMB LIFE, V58, P290, DOI 10.1080/15216540600702206
   Kwiatkowski DP, 2005, AM J HUM GENET, V77, P171, DOI 10.1086/432519
   Lohoff M, 2005, NAT REV IMMUNOL, V5, P125, DOI 10.1038/nri1552
   Luty AJF, 1999, J INFECT DIS, V179, P980, DOI 10.1086/314689
   Mackinnon MJ, 2005, PLOS MED, V2, P1253, DOI 10.1371/journa;.pmed.0020340
   Mackintosh CL, 2004, TRENDS PARASITOL, V20, P597, DOI 10.1016/j.pt.2004.09.006
   Mangano VD, 2008, GENES IMMUN, V9, P122, DOI 10.1038/sj.gene.6364456
   Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Modiano D, 2008, HUM MOL GENET, V17, P789, DOI 10.1093/hmg/ddm350
   Ozato K, 2007, J BIOL CHEM, V282, P20065, DOI 10.1074/jbc.R700003200
   Plebanski M, 2000, CURR OPIN IMMUNOL, V12, P437, DOI 10.1016/S0952-7915(00)00117-5
   Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918
   Ross P, 1998, NAT BIOTECHNOL, V16, P1347, DOI 10.1038/4328
   Sakuntabhai A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002000
   Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Teo YY, 2007, ANN HUM GENET, V71, P701, DOI 10.1111/j.1469-1809.2007.00356.x
   TEO YY, 2008, HUM HEREDIT IN PRESS
   Tishkoff SA, 2002, NAT REV GENET, V3, P611, DOI 10.1038/nrg865
   Wigginton JE, 2005, BIOINFORMATICS, V21, P3445, DOI 10.1093/bioinformatics/bti529
   ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847
NR 34
TC 7
Z9 7
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 15
PY 2009
VL 4
IS 1
AR e4206
DI 10.1371/journal.pone.0004206
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 437IG
UT WOS:000265479800012
PM 19145247
OA gold
DA 2017-08-15
ER

PT J
AU Cham, M
   Sundby, J
   Vangen, S
AF Cham, Mamady
   Sundby, Johanne
   Vangen, Siri
TI Fetal outcome in severe maternal morbidity: Too many stillbirths
SO ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
LA English
DT Article
DE Severe acute maternal morbidity; stillbirths; cesarean section; The
   Gambia
ID OBSTETRIC CARE; WEST-AFRICA; PERINATAL-MORTALITY; NEONATAL DEATHS;
   GAMBIA; COUNTRIES; RATES; INTRAPARTUM; SERVICES; NIGERIA
AB Objective. We determined the stillbirth rates among singleton births in Gambian hospitals. Contribution of severe obstetric complications was given special attention. Design. A multi-center retrospective review. Setting. Three obstetric referral hospitals. Sample. Fetal outcomes in 826 women with severe maternal morbidity out of 3,280 singleton deliveries. Methods. All women with severe maternal morbidity reported in the investigated hospitals between January and June 2006 were identified and their cases reviewed. For each case, information about fetal outcome and the mother's age, parity, obstetric complications and delivery mode was abstracted from maternity records. Main outcome measures. Stillbirth rates and the impact of health service factors. Results. There were excessively high stillbirth rates with an eight-fold increased risk among women with severe obstetric complications (310/1,000 births), compared to women without complications (51/1,000 births). Hemorrhage, anemia, sepsis and hypertensive pregnancy disorders were associated with higher stillbirth rates. Dystocia cases had a relatively lower stillbirth rate. In women with severe obstetric complications, vaginal delivery was associated with a four-fold increased risk of stillbirth compared to cesarean section. Conclusion. Severe maternal morbidity has significant impact on stillbirth rates. Better access to emergency obstetric care and improved intrapartum care will significantly reduce stillbirth rates in poor settings of the world, such as The Gambia.
C1 [Cham, Mamady; Sundby, Johanne] Univ Oslo, Fac Med, Sect Int Hlth, Inst Gen Practice & Community Med, NO-0317 Oslo, Norway.
   [Cham, Mamady] Dept State Hlth, Banjul, Gambia.
   [Vangen, Siri] Univ Oslo, Rikshosp, Med Ctr, Dept Obstet & Gynecol,Natl Resource Ctr Womens Hl, N-0027 Oslo, Norway.
RP Cham, M (reprint author), Univ Oslo, Fac Med, Sect Int Hlth, Inst Gen Practice & Community Med, Post Box 1130, NO-0317 Oslo, Norway.
EM cham.mamady@medisin.uio.no
FU Institute of General Practice and Community Medicine, University of
   Oslo, Norway
FX We would like to thank our research assistants: Ousman Ceesay, Kaddy
   Kujabi, Ebrima Jaiteh (Royal Victoria Teaching Hospital); Rachel Mendy,
   Anna Jatta (Armed Forces Provisional Ruling Council), Sanna Keita and
   Modou Darboe (Bansang Hospital). We are indebted to Riders for Health
   and the defunctWorld Bank- supported Participatory Health, Population
   and Nutrition Project, which facilitated transportation during data
   collection. This project was financed by the Institute of General
   Practice and Community Medicine, University of Oslo, Norway.
CR Anya SE, 2004, AM J TROP MED HYG, V70, P510
   BARROS FC, 1987, B WORLD HEALTH ORGAN, V65, P95
   Cham M, 2007, Glob Public Health, V2, P359, DOI 10.1080/17441690600918188
   *DEP STAT HLTH, 2002, REP NAT SURV MAT PER
   Fauveau V, 2007, INT J GYNECOL OBSTET, V96, P233, DOI 10.1016/j.ijgo.2006.12.004
   FERRAZ EM, 1991, INT J GYNECOL OBSTET, V34, P13, DOI 10.1016/0020-7292(91)90532-A
   *GAMB GOV, 2005, STAND DRUG TREATM MA
   *GAMB GOV, 2005, GAMB ROAD MAP ACC RE
   Goldenberg R L, 2004, J Matern Fetal Neonatal Med, V16, P79
   Goldenberg RL, 2007, ACTA OBSTET GYN SCAN, V86, P1303, DOI 10.1080/00016340701644876
   Hoestermann CFL, 1996, TROP MED INT HEALTH, V1, P710
   Kusiako T, 2000, B WORLD HEALTH ORGAN, V78, P621
   Lavender T, 2007, TROP DOCT, V37, P191, DOI 10.1258/004947507781524647
   Lawn J, 2005, B WORLD HEALTH ORGAN, V83, P409
   Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5
   McClure EM, 2007, INT J GYNECOL OBSTET, V96, P139, DOI 10.1016/j.ijgo.2006.10.010
   NJIE I, 2004, EVALUATION AVAILABIL
   Oladapo OT, 2007, AUST NZ J OBSTET GYN, V47, P110, DOI 10.1111/j.1479-828X.2007.00695.x
   Ozumba BC, 2002, INT J GYNECOL OBSTET, V76, P307, DOI 10.1016/S0020-7292(01)00501-X
   Paxton A, 2006, INT J GYNECOL OBSTET, V93, P300, DOI 10.1016/j.ijgo.2006.01.030
   Prual A, 2000, B WORLD HEALTH ORGAN, V78, P593
   Ronsmans C, 2003, TROP MED INT HEALTH, V8, P940, DOI 10.1046/j.1365-3156.2003.01111.x
   Stanton C, 2006, LANCET, V367, P1487, DOI 10.1016/S0140-6736(06)68586-3
   Walraven G, 2000, B WORLD HEALTH ORGAN, V78, P603
   WALRAVEN G, 2003, AUDIT REPORT MATERNA
   WATTS T, 1982, B WORLD HEALTH ORGAN, V60, P971
   World Health Organization, 2004, MAK PREGN SAF CRIT R
   World Bank, 1999, SAF MOTH WORLD BANK
NR 28
TC 10
Z9 10
U1 1
U2 2
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 0001-6349
J9 ACTA OBSTET GYN SCAN
JI Acta Obstet. Gynecol. Scand.
PY 2009
VL 88
IS 3
BP 343
EP 349
AR PII 908190579
DI 10.1080/00016340902730318
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 412DR
UT WOS:000263704300017
PM 19172420
OA No
DA 2017-08-15
ER

PT J
AU Mboto, CI
   Davies-Russell, A
   Fielder, M
   Jewell, AP
AF Mboto, C., I
   Davies-Russell, A.
   Fielder, M.
   Jewell, A. P.
TI CD4+lymphocyte values and trends in individuals infected with Human
   Immunodeficiency Virus and/or co-infected with Hepatitis C Virus in The
   Gambia
SO AFRICAN HEALTH SCIENCES
LA English
DT Article
DE HIV; HCV; co-infection; CD4+lymphocyte; West Africa
ID CD4 CELL COUNTS; SUB-SAHARAN AFRICA; HIV; TRANSMISSION; AIDS;
   COINFECTION; HIV/AIDS; THERAPY; GENDER; ADULTS
AB Objectives: This study was undertaken to monitor the CD4+ lymphocyte count in individuals infected with Human Immunodeficiency Virus (HIV) and/or co-infected with Hepatitis C Virus (HCV) and to compare this with the counts in normal individuals in The Gambia.
   Methods: Blood samples were taken from 1500 individuals referred for HIV serology at the Royal Victoria Teaching Hospital (RVTH) following informed consent. Samples were tested for antibodies to HIV by the Murex ELISA, antibodies to HCV by the Ortho ELISA, and CD4 counts determined by the Dynalimmunomagnetic cell isolation method
   Results: Of the 1500 patients screened for HIV and HCV antibodies, 6.7% (101/1500) were infected with HIV, 0.6% (9/1500) were co-infected with HCV and 1.5%(22/1500) were infected with HCV alone. Almost half (44.6%; 25/56) of HIV1 infected patients had a CD4+ lymphocyte count at diagnosis of 200 cells/mu l or less as compared to 41.7%(10/24) of HIV-2 and 75% (6/8) of HIV-D infected patients. The rate of CD4 decline was higher among HIV/HCV co-infected persons than individuals infected with HIV or HCV. The rate of decline was higher among men than women. These differences did not reach statistical significance due in large part to the small number of participants who completed the programme. The CD4+ lymphocyte count of apparently healthy Gambian male and females was 489 cells/mu l and 496 cells/mu l respectively. This rate is lower than that reported for Caucasians, but in agreement with the global range.
   Conclusion: A significant progressive decline in CD4+ lymphocyte count was observed among the female control group who were negative for HIV and HCV. This finding is unclear and calls for a longitudinal study involving a cohort of women in this region.
   Short title: CD4+ counts in HIV/HCV co-infection
C1 [Jewell, A. P.] Kingston Univ, Fac Hlth & Social Care Sci, London SW17 0RE, England.
   [Jewell, A. P.] St Georges Univ London, London, England.
   [Mboto, C., I] Royal Victoria Hosp, Banjul, Gambia.
   [Davies-Russell, A.; Fielder, M.] Kingston Univ, Sch Life Sci, London SW17 0RE, England.
RP Jewell, AP (reprint author), Kingston Univ, Fac Hlth & Social Care Sci, London SW17 0RE, England.
EM a.jewell@kingston.ac.uk
FU University of Calabar, Calabar-Nigeria; Community Health Organization
FX CM is particularly grateful to Dr Sam Omar, Director of Medical Services
   Department of State for health for approval of this work, the head of
   the Pathology department Mr. Jaye for permitting the use of laboratory
   facilities, Messer Emmanuel Ogenekun, Batchilly, Faal, Jobarteh, Daniel
   Eyam, who gave generously their time and Dr Mark Egbe for some reagents
   and material support. This work was partly supported by the University
   of Calabar, Calabar-Nigeria research grant, and Community Health
   Organization financial aid. In addition, CM is grateful to the
   University of Calabar for the release to undertake this study.
CR Abuye C, 2005, J CLIN IMMUNOL, V25, P127, DOI 10.1007/s10875-005-2818-y
   Alary M, 2004, AIDS, V18, P945, DOI 10.1097/01.aids.0000111473.61782.1f
   Amatya R, 2004, CLIN IMMUNOL, V112, P290, DOI 10.1016/j.clim.2004.04.008
   Ateka GK, 2001, B WORLD HEALTH ORGAN, V79, P1168
   Carter Michael, 2004, IAPAC Mon, V10, P433
   Easterbrook PJ, 2000, AIDS, V14, P561, DOI 10.1097/00002030-200003310-00012
   Easterbrook PJ, 1996, AIDS, V10, P1147
   Eckels DD, 2000, IMMUNOL REV, V174, P90, DOI 10.1034/j.1600-0528.2002.017403.x
   Evans-Gilbert T, 2004, W INDIAN MED J, V53, P322
   Hershow RC, 2005, CLIN INFECT DIS, V40, P859, DOI 10.1086/428121
   Kilaru KR, 2004, REV PANAM SALUD PUBL, V16, P302
   KOBLAVIDEME S, J CLIN MICROBIOL, V39, P1808
   Levine AM, 2000, BLOOD, V96, P4084
   MIDDLEBERG MI, 2003, STD AIDS, V14, P570
   Nag VL, 2002, INDIAN J MED RES, V116, P45
   Prins M, 1999, AIDS, V13, P2361, DOI 10.1097/00002030-199912030-00007
   Shirshev SV, 2003, BIOCHEMISTRY-MOSCOW+, V68, P470, DOI 10.1023/A:1023664316723
   STEIN DS, 1992, J INFECT DIS, V165, P352
   Tedaldi EM, 2003, CLIN INFECT DIS, V36, P363, DOI 10.1086/345953
   van Benthem BHB, 2002, AIDS, V16, P919, DOI 10.1097/00002030-200204120-00012
   Webster H. Kyle, 1996, Southeast Asian Journal of Tropical Medicine and Public Health, V27, P418
NR 21
TC 0
Z9 0
U1 0
U2 1
PU MAKERERE UNIV, FAC MED
PI KAMPALA
PA PO BOX 7072, KAMPALA, 00000, UGANDA
SN 1680-6905
J9 AFR HEALTH SCI
JI Afr. Health Sci.
PY 2009
VL 9
IS 3
BP 130
EP 136
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 541VW
UT WOS:000273450100001
PM 20589139
OA No
DA 2017-08-15
ER

PT J
AU Reiches, MW
   Sharrock, K
   Moore, S
   Prentice, AM
   Ellison, PT
AF Reiches, M. W.
   Sharrock, K.
   Moore, S.
   Prentice, A. M.
   Ellison, P. T.
TI Comparison of heart rate monitor and accelerometer for measuring energy
   expenditure under field conditions.
SO AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY
LA English
DT Meeting Abstract
CT 78th Annual Meeting of the
   American-Association-of-Physical-Anthropologists
CY MAR 31-APR 03, 2009
CL Chicago, IL
SP Amer Assoc Phys Anthropol
C1 [Reiches, M. W.; Sharrock, K.; Ellison, P. T.] Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA.
   [Moore, S.] MRC Keneba, MRC Labs, Keneba, Gambia.
   [Prentice, A. M.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0002-9483
J9 AM J PHYS ANTHROPOL
JI Am. J. Phys. Anthropol.
PY 2009
BP 219
EP 219
PG 1
WC Anthropology; Evolutionary Biology
SC Anthropology; Evolutionary Biology
GA 408NW
UT WOS:000263442701200
OA No
DA 2017-08-15
ER

PT J
AU Hippenstiel, S
   Brell, B
   Dohna, CZ
   Dorenberg, M
   Hocke, AC
   Martens, H
   Suttorp, N
   Temmesfeld-Wollbruck, B
AF Hippenstiel, S.
   Brell, B.
   Dohna, C. Zu
   Dorenberg, M.
   Hocke, A. C.
   Martens, H.
   Suttorp, N.
   Temmesfeld-Wollbruck, B.
TI Adrenomedullin Reduces Sepsis-Related Intestinal Epithelial Permeability
   In Vivo and In Vitro
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Hippenstiel, S.; Brell, B.; Dohna, C. Zu; Dorenberg, M.; Hocke, A. C.; Suttorp, N.; Temmesfeld-Wollbruck, B.] Charite, Dept Internal Med Infect Dis & Resp Med, D-13353 Berlin, Germany.
   [Martens, H.] Free Univ Berlin, Dept Vet Physiol, Berlin, Gambia.
EM stefan.hippenstiel@charite.de
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2009
VL 179
MA A1162
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V29FA
UT WOS:000208733100163
OA No
DA 2017-08-15
ER

PT J
AU Peterson, I
   Borrell, LN
   El-Sadr, W
   Teklehaimanot, A
AF Peterson, Ingrid
   Borrell, Luisa N.
   El-Sadr, Wafaa
   Teklehaimanot, Awash
TI Individual and Household Level Factors Associated with Malaria Incidence
   in a Highland Region of Ethiopia: A Multilevel Analysis
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID ENTOMOLOGICAL RISK-FACTORS; SPATIAL-DISTRIBUTION; GAMBIAN CHILDREN;
   CLINICAL MALARIA; PERIURBAN AREA; VECTOR DENSITY; URBAN MALARIA;
   SRI-LANKA; INTERVENTIONS; PREVALENCE
AB Multilevel analysis Was used to identify individual and household level factors associated with malaria risk in 1.367 individuals in a peri-urban area of highland Ethiopia. Living within 450 in of a major vector-breeding site accounted for 38.78%, and 78.49% of between-household Variance ill Malaria incidence in adults and Children. respectively. In adults. other individual level factors associated with malaria risk were regular or recent travel to rural areas (incidence rate ratio [IRR] = 12.96;95% confidence interval [CI] 4.05, 41.48) and having all indoor job (IRR = 0.37; 95%) CI = 0.16, 0.87). Household level factors associated with adult malaria risk were low vegetation level in compound (IRR = 0.27: 95%, CI =0.10, 0.78), tidy compound (IRR 0.29 95% CI = 0.12. 0.71), household use of preventive measures (IRR = 0.31: 95% CI = 0.13, 0.74), and the number of 5- to 9-year-old children in the household (IRR = 1.66: 95%) CI = 1.08, 2.53). Aside from distance to the vector-breeding site, few other malaria risk factors were identified in children. Malaria interventions in highland African communities should address household level factors associated with malaria clustering.
C1 [Peterson, Ingrid] MRC Labs, Banjul, Gambia.
   CUNY, Dept Hlth Sci, Lehman Coll, New York, NY 10021 USA.
   Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   [El-Sadr, Wafaa] Columbia Univ, Mailman Sch Publ Hlth, Int Ctr AIDS Care & Treatment Program ICAP, New York, NY 10032 USA.
RP Peterson, I (reprint author), MRC Labs, Atlantic Rd,POB 273, Banjul, Gambia.
EM idpet2@gmail.com
CR ADIAMAH JH, 1993, ANN TROP MED PARASIT, V87, P491
   BASHFORD G, 1992, PAPUA NEW GUINEA MED, V35, P306
   Binka FN, 1998, AM J TROP MED HYG, V59, P80
   BURKOT TR, 1989, AM J TROP MED HYG, V40, P229
   Cameron A, 1998, REGRESSION ANAL COUN, P59, DOI 10.1017/CCOL0521632013.003
   Carter R, 2000, B WORLD HEALTH ORGAN, V78, P1401
   Clarke SE, 2002, T ROY SOC TROP MED H, V96, P499, DOI 10.1016/S0035-9203(02)90419-0
   Creasey A, 2004, PARASITOLOGY, V129, P263, DOI 10.1017/S0031182004005724
   Deressa W, 2004, ETHIOPIAN MED J, V42, P237
   GAMAGEMENDIS AC, 1991, AM J TROP MED HYG, V45, P77
   Ghebreyesus TA, 1999, BRIT MED J, V319, P663
   Ghebreyesus TA, 2000, T ROY SOC TROP MED H, V94, P17, DOI 10.1016/S0035-9203(00)90424-3
   Gu WD, 2005, AM J TROP MED HYG, V73, P546
   Gunawardena DM, 1998, AM J TROP MED HYG, V58, P533
   Guthmann JP, 2002, TROP MED INT HEALTH, V7, P518, DOI 10.1046/j.1365-3156.2002.00883.x
   Guthmann JP, 2001, T ROY SOC TROP MED H, V95, P577, DOI 10.1016/S0035-9203(01)90084-7
   KORAM KA, 1995, T ROY SOC TROP MED H, V89, P146, DOI 10.1016/0035-9203(95)90471-9
   LENZ R, 1988, SOC SCI MED, V26, P641, DOI 10.1016/0277-9536(88)90029-9
   Lindsay SW, 1998, B WORLD HEALTH ORGAN, V76, P33
   Lindsay SW, 2002, TRENDS PARASITOL, V18, P510, DOI 10.1016/S1471-4922(02)02382-6
   LINDSAY SW, 1988, T ROY SOC TROP MED H, V82, P645, DOI 10.1016/0035-9203(88)90546-9
   Mahande A, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-100
   Mauny F, 2004, INT J EPIDEMIOL, V33, P1337, DOI 10.1093/ije/dyh274
   Mendez F, 2000, T ROY SOC TROP MED H, V94, P367, DOI 10.1016/S0035-9203(00)90106-8
   Ribeiro JMC, 1996, B WORLD HEALTH ORGAN, V74, P299
   Robert V, 2003, AM J TROP MED HYG, V68, P169
   SEVILLACASAS E, 1993, SOC SCI MED, V37, P1155, DOI 10.1016/0277-9536(93)90255-3
   Sintasath DM, 2005, AM J TROP MED HYG, V72, P682
   Snow RW, 1998, T ROY SOC TROP MED H, V92, P381, DOI 10.1016/S0035-9203(98)91056-2
   Thomas CJ, 2000, T ROY SOC TROP MED H, V94, P159, DOI 10.1016/S0035-9203(00)90257-8
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   TRAPE JF, 1992, AM J TROP MED HYG, V47, P181
   van der Hoek W, 1998, T ROY SOC TROP MED H, V92, P265, DOI 10.1016/S0035-9203(98)91003-3
   Willis S, 2004, ACTA TROP, V91, P167
   Wolff CG, 2001, BRIT MED J, V322, P1209, DOI 10.1136/bmj.322.7296.1209
   Yohannes M, 1996, ETHIOPIAN MED J, V34, P83
NR 36
TC 36
Z9 36
U1 1
U2 4
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JAN
PY 2009
VL 80
IS 1
BP 103
EP 111
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 393RY
UT WOS:000262391700020
PM 19141847
OA No
DA 2017-08-15
ER

PT J
AU Darboe, MK
   Moore, SE
   Fulford, T
   Siegrist, CA
   Prentice, AM
AF Darboe, Momodou K.
   Moore, Sophie E.
   Fulford, Tony
   Siegrist, Claire-Anne
   Prentice, Andrew M.
TI VITAMIN A SUPPLEMENTATION (VAS) GIVEN WITH INFANT IMMUNISATION DEPRESSES
   ANTIBODY RESPONSE AND INCREASES VACCINE FAILURES
SO ANNALS OF NUTRITION AND METABOLISM
LA English
DT Meeting Abstract
C1 [Siegrist, Claire-Anne] Ctr Vaccinat & Neonatal Immunol CMU, Geneva 4, Switzerland.
   [Darboe, Momodou K.; Moore, Sophie E.; Fulford, Tony; Prentice, Andrew M.] MRC Int Nutr Grp, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-6807
J9 ANN NUTR METAB
JI Ann. Nutr. Metab.
PY 2009
VL 55
SU 1
BP 115
EP 115
PG 1
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 507CF
UT WOS:000270827200429
OA No
DA 2017-08-15
ER

PT J
AU Adetifa, I
   Okomo, U
AF Adetifa, Ifedayo
   Okomo, Uduak
TI Iron supplementation for reducing morbidity and mortality in children
   with HIV
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII-PNEUMONIA; DEFICIENCY
   ANEMIA; HEMATOLOGIC MANIFESTATIONS; SECONDARY PROPHYLAXIS; TRANSFERRIN
   RECEPTOR; INFECTED CHILDREN; PROGENITOR CELLS; CONTROLLED-TRIAL; SERUM
   FERRITIN
AB Background
   The most prevalent haematologic disturbance associated with HIV in children (apart from CD4 lymphocytopenia) is anaemia. Anaemia associated with HIV arises from multiple mechanisms, including the direct inhibitory effect of HIV on red cell precursors, other locally prevalent and/or opportunistic infections, micronutrient deficiency, anaemia of chronic disease, and as a consequence of medicines given for HIV and/or other concurrent illnesses. Iron deficiency is the most common cause of nutritional anaemia globally. There is significant geographical overlap of areas of the world where iron deficiency anaemia (IDA) and paediatric HIV are distributed. Given the high prevalence of IDA, it is likely that many HIV-infected children also are iron deficient. The contribution of iron deficiency to anaemia in HIV-infected children has been described but is incompletely understood. Currently, iron supplementation for anaemic infants and children is routinely practiced without any obvious effect in most developing countries, which bear most of the burden of global paediatric HIV infections.
   Because iron deficiency and IDA are common in HIV-infected children in high-prevalence areas and because there are concerns about possible deleterious effects of iron, this review aims to assess the evidence for iron supplementation for reducing morbidity and mortality in HIV-infected children.
   Objectives
   To determine whether iron supplementation improves clinical, immunologic, and virologic outcomes in children infected with HIV
   Search strategy
   We used the comprehensive search strategy developed specifically by the Cochrane HIV/AIDS Review Group to identify HIV/AIDS randomised controlled trials, and searched the following electronic databases: MEDLINE (searched November 2007); Embase (searched December 2007); and CENTRAL (December 2007). This search was supplemented with a search of AIDSearch (searched December 2007) and NLM Gateway (searched December 2007) to identify relevant conference abstracts, as well as a search of the reference lists of all eligible articles. The search was not limited by language or publication status.
   Selection criteria
   Randomised controlled trials (RCTs) of iron supplementation in any form and dose in HIV-infected children aged 12 years and younger.
   Data collection and analysis
   We independently screened the results of the search to select potentially relevant studies and to retrieve the full articles. We independently applied the inclusion criteria to the potentially relevant studies.
   No studies were identified that fulfilled the selection criteria.
   Main results
   No RCTs of iron supplementation in HIV-infected children were found.
   Authors' conclusions
   Implications for clinical practice:
   The current clinical practice of iron supplementation in HIV-infected children is based on weak evidence comprising observational studies and expert opinions.
   Implications for clinical practice:
   High-quality RCTs of iron supplementation are urgently required, especially in areas with significant overlap of high prevalence of HIV, iron deficiency anaemia, and malaria. Policy makers should prioritise funding for these trials.
C1 [Adetifa, Ifedayo] MRC Labs, TB Off, Banjul, Gambia.
   [Okomo, Uduak] MRC Labs, Clin Serv, Fajara, Gambia.
RP Adetifa, I (reprint author), MRC Labs, TB Off, Atlantic Blvd,POB 276, Banjul, Gambia.
EM iadetifa@mrc.gm
CR Adetifa IMO, 2006, ANN TROP PAEDIATR, V26, P121, DOI 10.1179/146532806X107467
   Adewuyi J. O., 1994, Central African Journal of Medicine, V40, P333
   Afacan YE, 2002, J NATL MED ASSOC, V94, P73
   Allen UD, 1998, AIDS, V12, P1785, DOI 10.1097/00002030-199814000-00010
   Berhane K, 2004, JAIDS-J ACQ IMM DEF, V37, P1245, DOI 10.1097/01.qai.0000134759.01684.27
   Boelaert JR, 1996, INFECT AGENT DIS, V5, P36
   BUTLER KM, 1991, NEW ENGL J MED, V324, P137, DOI 10.1056/NEJM199101173240301
   Carr JM, 1998, J GEN VIROL, V79, P71
   Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P1
   Clark TD, 2002, ANN TROP PAEDIATR, V22, P11, DOI 10.1170/027249302125000102
   Clark TD, 2001, MED HYPOTHESES, V57, P476, DOI 10.1054/mehy.2001.1368
   COSTAGLIOLA DG, 1994, BRIT J HAEMATOL, V87, P849, DOI 10.1111/j.1365-2141.1994.tb06750.x
   Coyle TE, 1997, MED CLIN N AM, V81, P449, DOI 10.1016/S0025-7125(05)70526-5
   de Monye C, 1999, AIDS, V13, P375, DOI 10.1097/00002030-199902250-00010
   Delanghe JR, 1998, AIDS, V12, P1027, DOI 10.1097/00002030-199809000-00009
   ELEY BS, 2002, BMC INFECT DIS, V2
   ELLAURIE M, 1990, AM J PEDIAT HEMATOL, V12, P449
   Feelders RA, 1999, CLIN CHEM LAB MED, V37, P1, DOI 10.1515/CCLM.1999.001
   Forsyth BWC, 1996, J PEDIATR-US, V129, P648, DOI 10.1016/S0022-3476(96)70144-0
   FRASER A, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005977
   Friis H., 2005, MICRONUTRIENTS HIV I, P1
   GEISE RJ, 1991, BIOSENS BIOELECTRON, V6, P151, DOI 10.1016/0956-5663(91)87039-E
   Gordeuk VR, 2006, HAEMATOL-HEMATOL J, V91, P739
   Gordeuk VR, 2001, J CLIN VIROL, V20, P111, DOI 10.1016/S1386-6532(00)00134-7
   Iannotti LL, 2006, AM J CLIN NUTR, V84, P1261
   Jacobus DP, 1996, J INFECT DIS, V173, P1044
   Kupka R, 2007, J NUTR, V137, P2317
   MARTINS S, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003016
   McDermid JM, 2007, JAIDS-J ACQ IMM DEF, V46, P498
   Moore RD, 1999, CLIN INFECT DIS, V29, P44, DOI 10.1086/520178
   Moses AV, 1996, BLOOD, V87, P919
   Ojukwu JU, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006589
   Olsen A, 2006, ANN TROP MED PARASIT, V100, P251, DOI 10.1179/136485906X91486
   Olsen A, 2004, JAIDS-J ACQ IMM DEF, V36, P637, DOI 10.1097/00126334-200405010-00013
   PIZZO PA, 1988, NEW ENGL J MED, V319, P889, DOI 10.1056/NEJM198810063191401
   RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402
   Sahli Y, 1998, J ACQ IMMUN DEF SYND, V18, P473
   SALMONCERON D, 1995, J INFECT DIS, V172, P656
   Savarino A, 1999, CELL BIOCHEM FUNCT, V17, P279, DOI 10.1002/(SICI)1099-0844(199912)17:4<279::AID-CBF833>3.0.CO;2-J
   SCHWARTZ GN, 1994, EXP HEMATOL, V22, P1288
   Semba RD, 2003, CLIN INFECT DIS, V37, pS105, DOI 10.1086/375892
   Semba RD, 2000, EUR J CLIN NUTR, V54, P872, DOI 10.1038/sj.ejcn.1601106
   Semba RD, 2001, J INVEST MED, V49, P225, DOI 10.2310/6650.2001.33967
   Semba RD, 2007, JAIDS-J ACQ IMM DEF, V45, P298
   Totin D, 2002, J NUTR, V132, P423
   [UNU WHO MI UNICEF], 1998, PREV IR DEF WOM CHIL
   *UNICEF WHO UNU, 2001, IR DEF AN ASS PREV C
   Volberding P, 2000, CLIN THER, V22, P1004, DOI 10.1016/S0149-2918(00)80081-8
   Vorster HH, 2004, PUBLIC HEALTH NUTR, V7, P1055, DOI 10.1079/PHN2004643
   Weinberg GA, 1996, J INFECT DIS, V174, P241
   Weinberg GA, 2001, CLIN INFECT DIS, V33, P2098, DOI 10.1086/324363
   World Health Organization, 2006, ANT THER HIV INF INF
   Xiaoxi Z, 2007, COCHRANE DB SYST REV
   ZAULI G, 1994, BLOOD, V84, P1896
   Zauli G, 1996, J EXP MED, V183, P99, DOI 10.1084/jem.183.1.99
   ZON LI, 1988, SEMIN HEMATOL, V25, P208
NR 56
TC 11
Z9 11
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1469-493X
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2009
IS 1
AR CD006736
DI 10.1002/14651858.CD006736.pub2
PG 25
WC Medicine, General & Internal
SC General & Internal Medicine
GA 396KZ
UT WOS:000262591900081
PM 19160298
OA No
DA 2017-08-15
ER

PT J
AU Odey, F
   Okomo, U
   Oyo-Ita, A
AF Odey, Friday
   Okomo, Uduak
   Oyo-Ita, Angela
TI Vaccines for preventing invasive salmonella infections in people with
   sickle cell disease
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID TYPHOID-FEVER; OSTEOMYELITIS; METAANALYSIS; SEPTICEMIA; MORTALITY;
   ANEMIA
AB Background
   Salmonella infections are a common bacterial cause of invasive disease in people with sickle cell disease especially children, and are associated with high morbidity and mortality rates. Although available in some centres, people with sickle cell anaemia are not routinely immunized with salmonella vaccines.
   Objectives
   To determine whether routine administration of salmonella vaccines to people with sickle cell disease reduces the morbidity and mortality associated with infection.
   Search strategy
   We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We also conducted a search of the LILACS database. Date of most recent search of the Group's Haemoglobinopathies Trials Register: 17 June 2009.
   Selection criteria
   We planned to select all randomized controlled trials that compared the use of either the inactivated vaccine or an oral attenuated vaccine with a placebo among people with sickle cell disease. Equally, studies that compared the efficacy of one vaccine type over another were to be selected for the review.
   Data collection and analysis
   No trials of salmonella vaccines in people with sickle cell disease were found.
   Main results
   There is an absence of randomized controlled trial evidence relating to the scope of this review.
   Authors' conclusions
   It is expected that salmonella vaccines may be useful in people with sickle cell disease, especially in resource-poor settings where the majority of those who suffer from the condition are found. Unfortunately, there are no randomized controlled trials on the efficacy and safety of the different types of salmonella vaccines in people with sickle cell disease. We conclude that there is a need for a well-designed, adequately-powered, randomized controlled trial to assess the benefits and risks of the different types of salmonella vaccines as a means of improving survival and decreasing mortality from salmonella infections in people with sickle cell disease.
C1 [Odey, Friday] Univ Calabar, Dept Paediat, Teaching Hosp, Calabar, Cross River Sta, Nigeria.
   [Okomo, Uduak] MRC Labs, Clin Serv, Fajara, Gambia.
   [Oyo-Ita, Angela] Univ Calabar, Dept Community Hlth, Teaching Hosp, Calabar, Cross River Sta, Nigeria.
RP Odey, F (reprint author), Univ Calabar, Dept Paediat, Teaching Hosp, PMB 1115, Calabar, Cross River Sta, Nigeria.
EM awhobe@yahoo.com
FU Nigeria branch of the South African Cochrane Centre; Institute of
   Tropical Diseases Research and Prevention, University of Calabar
   Teaching Hospital, Nigeria; DFID, UK
FX Effective Health Care Alliance Programme (supported by DFID), UK.
CR ADEYOKUNNU AA, 1980, ARCH DIS CHILD, V55, P175
   Aidoo M, 2002, LANCET, V359, P1311, DOI 10.1016/S0140-6736(02)08273-9
   Ashcroft M T, 1967, Lancet, V2, P1056
   BENNETT OM, 1990, J BONE JOINT SURG BR, V72, P494
   BENNISH ML, 1995, INFECT DIS CLIN PRAC, V4, P114, DOI 10.1097/00019048-199503000-00011
   Burnett MW, 1998, PEDIATRICS, V101, P297
   CATES C, 2003, VISUAL RX ONLINE NNT
   CDC, 1990, MMWR-MORBID MORTAL W, V39, P1
   CONSTANT.A, 1973, AM J DIS CHILD, V125, P663
   DAVIES EG, 2004, COCHRANE DB SYST REV
   Davies SC, 1997, BRIT MED J, V315, P656
   DeRoeck D, 2004, UPDATE POLICY ISSUES
   EBONG WW, 1986, ANN RHEUM DIS, V45, P911, DOI 10.1136/ard.45.11.911
   Egger M, 1997, BRIT MED J, V315, P629
   Elbashier AM, 2003, ANN SAUDI MED, V23, P358
   Engels EA, 1998, BRIT MED J, V316, P110
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA
   Magnus SA, 1999, ARCH DIS CHILD, V80, P537
   The Nordic Cochrane Centre, 2008, REV MAN REVMAN 5 0
   Ochiai RL, 2008, B WORLD HEALTH ORGAN, V86, P260, DOI 10.2471/BLT.06.039818
   OVERTURF GD, 1977, AM J DIS CHILD, V131, P784
   Serjeant GR, 1994, RECENT ADV PAEDIAT, V12, P141
   Tarr PE, 1999, AM J TROP MED HYG, V61, P163
   VICHINSKY E, 1988, PEDIATRICS, V81, P749
   WHO, 2008, WKLY EPIDEMIOL REC, V83, P49
   Wierenga KJJ, 2001, ARCH DIS CHILD, V84, P156, DOI 10.1136/adc.84.2.156
   Wright J, 1997, J PEDIATR-US, V130, P394, DOI 10.1016/S0022-3476(97)70201-4
   Yugoslav Typhoid Commission, 1964, B WORLD HEALTH ORGAN, V30, P623
NR 29
TC 3
Z9 3
U1 0
U2 2
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1469-493X
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2009
IS 4
AR CD006975
DI 10.1002/14651858.CD006975.pub2
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 505IR
UT WOS:000270687000008
PM 19821392
OA No
DA 2017-08-15
ER

PT J
AU Ojukwu, JU
   Okebe, JU
   Yahav, D
   Paul, M
AF Ojukwu, J. U.
   Okebe, J. U.
   Yahav, D.
   Paul, M.
TI Oral iron supplementation for preventing or treating anaemia among
   children in malaria-endemic areas
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; FOLIC-ACID
   SUPPLEMENTATION; BREAST-FED INFANTS; PAPUA-NEW-GUINEA; VITAMIN-A STATUS;
   ROUTINE PROPHYLACTIC SUPPLEMENTATION; WEEKLY MICRONUTRIENT
   SUPPLEMENTATION; PLASMODIUM-FALCIPARUM MALARIA; INDONESIAN
   PRESCHOOL-CHILDREN
AB Background
   Iron-deficiency anaemia is common during childhood. Iron supplementation has been claimed to increase the risk of malaria.
   Objectives
   To assess the effect of iron on malaria and deaths.
   Search strategy
   We searched The Cochrane Library (2009, issue 1); MEDLINE; EMBASE; LILACS and metaRegister of Controlled Trials, all up to March 2009. We scanned references of included trials.
   Selection criteria
   Individually and cluster-randomized controlled trials conducted in hypoendemic to holoendemic malaria regions and including children < 18 years. We included trials comparing orally administered iron with or without folic acid vs. placebo or no treatment. Iron fortification was excluded. Antimalarials and/or antiparasitics could be administered to either group. Additional micronutrients could only be administered equally to both groups.
   Data collection and analysis
   The primary outcomes were malaria-related events and deaths. Secondary outcomes included haemoglobin, anaemia, other infections, growth, hospitalizations, and clinic visits. We assessed risk of bias using domain-based evaluation. Two authors independently selected studies and extracted data. We contacted authors for missing data. We assessed heterogeneity. We performed fixed-effect meta-analysis and presented random-effects results when heterogeneity was present. We present pooled risk ratios (RR) with 95% confidence intervals (CIs). We used adjusted analyses for cluster-randomized trials.
   Main results
   Sixty-eight trials (42,981 children) fulfilled the inclusion criteria. Iron supplementation did not increase the risk of clinical malaria (RR 1.00, 95% CI 0.88 to 1.13; 22,724 children, 14 trials, random-effects model). The risk was similar among children who were non-anaemic at baseline (RR 0.96, 95% CI 0.85 to 1.09). An increased risk of malaria with iron was observed in trials that did not provide malaria surveillance and treatment. The risk of malaria parasitaemia was higher with iron (RR 1.13, 95% CI 1.01 to 1.26), but there was no difference in adequately concealed trials. Iron + antimalarial was protective for malaria (four trials). Iron did not increase the risk of parasitological failure when given during malaria (three trials). There was no increased risk of death across all trials comparing iron versus placebo (RR 1.11, 95% CI 0.91 to 1.36; 21,272 children, 12 trials). Iron supplementation increased haemoglobin, with significant heterogeneity, and malaria endemicity did not affect this effect. Growth and other infections were mostly not affected by iron supplementation.
   Authors' conclusions
   Iron does not increase the risk of clinical malaria or death, when regular malaria surveillance and treatment services are provided. There is no need to screen for anaemia prior to iron supplementation.
C1 [Ojukwu, J. U.] Ebonyi State Univ, Dept Paediat, Abakaliki, Ebonyi, Nigeria.
   [Okebe, J. U.] MRC, UK Labs, Malaria Programme, Banjul, Gambia.
   [Yahav, D.; Paul, M.] Rabin Med Ctr, Dept Med E, Petah Tiqwa, Israel.
   [Paul, M.] Rabin Med Ctr, Infect Dis Unit, Petah Tiqwa, Israel.
RP Ojukwu, JU (reprint author), Ebonyi State Univ, Dept Paediat, PMB 077, Abakaliki, Ebonyi, Nigeria.
EM julieojk@yahoo.com
FU Nuffield Foundation; UK Department for International Development (DFID)
FX The editorial base for the Cochrane Infectious Diseases Group is funded
   by the UK Department for International Development (DFID) for the
   benefit of developing countries. Dafna Yahav received funding from the
   editorial base.
CR ABDALLA SH, 1990, ANN TROP PAEDIATR, V10, P265
   Abdelrazik N, 2007, INDIAN J PEDIATR, V74, P739, DOI 10.1007/s12098-007-0130-y
   Adam C, 1997, THESIS LONDON SCH TR
   Adu-Afarwuah S, 2008, AM J CLIN NUTR, V87, P929
   Agarwal K N, 2003, Indian Pediatr, V40, P296
   Aguayo VM, 2000, EUR J NUTR, V39, P263, DOI 10.1007/s003940070005
   Ahmed F, 2001, AM J CLIN NUTR, V74, P108
   AKENZUA GI, 1985, J TROP PEDIATRICS, V31, P59
   Allen LH, 2000, AM J CLIN NUTR, V71, P1485
   Anand K, 2007, INDIAN PEDIATR, V44, P823
   ANGELES IT, 1993, AM J CLIN NUTR, V58, P339
   AngelesAgdeppa I, 1997, AM J CLIN NUTR, V66, P177
   Arcanjo FPN, 2008, J TROP PEDIATRICS, V54, P243, DOI 10.1093/tropej/fmm113
   Archer RP, 2002, ASSESSMENT, V9, P3, DOI 10.1177/1073191102091001
   Asibey-Berko E, 2007, East Afr Med J, V84, P473
   ATUKORALA S, 2001, INT NUTR AN CONS GRO
   AUKETT MA, 1986, ARCH DIS CHILD, V61, P849
   Baird JK, 1997, LANCET, V350, P1855, DOI 10.1016/S0140-6736(05)63676-8
   Baqui AH, 2005, J NUTR, V135, P2187
   Baqui AH, 2003, J NUTR, V133, P4150
   BARCLAY SM, 1991, PEDIATR RES, V29, P297, DOI 10.1203/00006450-199103000-00015
   BATES CJ, 1987, T ROY SOC TROP MED H, V81, P286, DOI 10.1016/0035-9203(87)90244-6
   Beard JL, 2001, J NUTR, V131, P568
   Beasley NMR, 2000, TROP MED INT HEALTH, V5, P794, DOI 10.1046/j.1365-3156.2000.00641.x
   Beck H P, 1999, Trans R Soc Trop Med Hyg, V93 Suppl 1, P41, DOI 10.1016/S0035-9203(99)90326-7
   BENDERGOTZE C, 1980, FORTSCHR MED, V98, P590
   Berger J, 1997, EUR J CLIN NUTR, V51, P381, DOI 10.1038/sj.ejcn.1600418
   Berger J, 2006, EUR J CLIN NUTR, V60, P443, DOI 10.1038/sj.ejcn.1602336
   Berger J, 2000, EUR J CLIN NUTR, V54, P29, DOI 10.1038/sj.ejcn.1600888
   BERGER JR, 1992, SEMIN NEUROL, V12, P1, DOI 10.1055/s-2008-1041151
   Bhatia D, 1993, Indian Pediatr, V30, P195
   Biemba G, 2000, TROP MED INT HEALTH, V5, P9, DOI 10.1046/j.1365-3156.2000.00506.x
   Black MM, 2004, AM J CLIN NUTR, V80, P903
   Bloland PB, 1999, AM J TROP MED HYG, V60, P635
   BOIVIN MJ, 1993, J PEDIATR PSYCHOL, V18, P249, DOI 10.1093/jpepsy/18.2.249
   Bojang KA, 1997, T ROY SOC TROP MED H, V91, P557, DOI 10.1016/S0035-9203(97)90025-0
   BRADFIELD RB, 1968, AM J CLIN NUTR, V21, P57
   BRADFIELD RB, 1968, AM J CLIN NUTR, V21, P68
   Breman JG, 2001, AM J TROP MED HYG, V64, P1
   Browne E, 2005, 4 MIM MAL C YAOUND C
   Bruner AB, 1996, LANCET, V348, P992, DOI 10.1016/S0140-6736(96)02341-0
   BRUNSER O, 1993, EUR J CLIN NUTR, V47, P317
   Carter JY, 2005, AM J TROP MED HYG, V73, P166
   Chandramohan D, 2005, BRIT MED J, V331, P727, DOI 10.1136/bmj.331.7519.727
   CHAROENLARP P, 1973, Southeast Asian Journal of Tropical Medicine and Public Health, V4, P588
   CHIPPAUX JP, 1991, B SOC PATHOL EXOT, V84, P54
   CHWANG LC, 1988, AM J CLIN NUTR, V47, P496
   Crawley J, 2004, AM J TROP MED HYG, V71, P25
   Cusick SE, 2005, AM J CLIN NUTR, V82, P406
   de Silva A, 2003, AM J CLIN NUTR, V77, P234
   Deeksha Kapur, 2002, Indian Pediatrics, V39, P136
   DEINARD AS, 1986, J PEDIATR-US, V108, P681, DOI 10.1016/S0022-3476(86)81041-1
   DENNO D, 2006, PREVENTING ANAEMIA C
   Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X
   Desai MR, 2004, J NUTR, V134, P1167
   Desai MR, 2003, J INFECT DIS, V187, P658, DOI 10.1086/367986
   Devaki PB, 2007, ARZNEIMITTEL-FORSCH, V57, P417
   Dewey KG, 2002, J NUTR, V132, P3249
   Dijkhuizen MA, 2001, J NUTR, V131, P2860
   DIOUF S, 2002, INTEGRATED TREATMENT
   Domellof M, 2001, J PEDIATR-US, V138, P679, DOI 10.1067/mpd.2001.112895
   Dossa RAM, 2001, J NUTR, V131, P2874
   Dossa RAM, 2001, EUR J CLIN NUTR, V55, P223, DOI 10.1038/sj.ejcn.1601126
   Ekvall H, 2000, TROP MED INT HEALTH, V5, P696, DOI 10.1046/j.1365-3156.2000.00626.x
   Ekvall H, 2003, CURR OPIN HEMATOL, V10, P108, DOI 10.1097/00062752-200303000-00002
   Engstrom Elyne Montenegro, 2008, Rev Saude Publica, V42, P786, DOI [10.1590/S0034-89102008005000043, 10.1590/s0034-89102008000500002]
   Fahmida U, 2007, ASIA PAC J CLIN NUTR, V16, P301
   Assuncao MCF, 2007, REV SAUDE PUBL, V41, P539, DOI 10.1590/s0034-89102006005000031
   Assuncao MCF, 2007, REV SAUDE PUBL, V41, P328, DOI [10.1590/S0034-89102007000300002, 10.1590/s0034-89102007000300002]
   FUERTH JH, 1972, J PEDIATR-US, V80, P974, DOI 10.1016/S0022-3476(72)80010-6
   Gebreselassie H., 1996, THESIS MCGILL U MONT
   Gera T, 2002, BRIT MED J, V325, P1142, DOI 10.1136/bmj.325.7373.1142
   Gera T, 2007, J PEDIATR GASTR NUTR, V44, P468, DOI 10.1097/01.mpg.0000243440.85452.38
   GEWA CA, 2008, BRIT J NUTR     0930, P1
   Giovannini M, 2006, J PEDIATR GASTR NUTR, V42, P306, DOI 10.1097/01.mpg.0000189363.07040.4b
   Gomber S, 1998, INDIAN J MED RES, V107, P269
   GOMES, 2001, INTERMITTENT MALARIA
   GOMES M, 2000, PREVENTION MALARIA
   GOPALDAS T, 1985, Indian Pediatrics, V22, P745
   GOPALDAS T, 1985, Indian Pediatrics, V22, P731
   GOPALDAS T, 1985, Indian Pediatrics, V22, P737
   GOPALDAS T, 1983, NUTR RES, V3, P831, DOI 10.1016/S0271-5317(83)80036-0
   Grantham-McGregor S, 2001, J NUTR, V131, P649
   GREISEN G, 1986, ACTA PAEDIATR SCAND, V75, P662, DOI 10.1111/j.1651-2227.1986.tb10268.x
   Gulliford MC, 1999, AM J EPIDEMIOL, V149, P876
   Hall A, 2002, PUBLIC HEALTH NUTR, V5, P413, DOI 10.1079/PHN2001327
   HARVEY PWJ, 1989, AM J TROP MED HYG, V40, P12
   HATHIRAT P, 1992, BRIT J NUTR, V68, P245, DOI 10.1079/BJN19920081
   HAY SI, 2004, M5037019
   Hess SY, 2002, AM J CLIN NUTR, V75, P743
   Hettiarachchi M, 2008, EUR J CLIN NUTR, V62, P856, DOI 10.1038/sj.ejcn.1602791
   HEYWOOD A, 1989, AM J CLIN NUTR, V50, P630
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA
   Hirve S, 2007, INDIAN PEDIATR, V44, P91
   Honig AS, 1978, INFANT BEHAV DEV, V1, P168, DOI 10.1016/S0163-6383(78)80027-7
   Hop LT, 2005, J NUTR, V135, p660S
   HUSSEN MA, 1985, 13 INT C NUTR BRIGNT
   Hyder SMZ, 2007, J NUTR, V137, P2147
   Iannotti LL, 2006, AM J CLIN NUTR, V84, P1261
   IDJRADINATA P, 1993, LANCET, V341, P1, DOI 10.1016/0140-6736(93)92477-B
   IDJRADINATA P, 1994, LANCET, V343, P1252, DOI 10.1016/S0140-6736(94)92151-2
   IFEDIBA TC, 1985, BLOOD, V65, P452
   International Nutritional Anemia Consultative Group (INACG), 1999, INACG CONS STAT SAF
   Ip H, 2009, EUR J CLIN NUTR, V63, P165, DOI 10.1038/sj.ejcn.1602917
   Isager H, 1974, Scand J Haematol Suppl, V21, P1
   JACOBI H, 1972, Medizinische Welt, V23, P228
   Joint FAO/WHOExpert Consultation on Human Vitamin Mineral Requirements. Iron, 2005, VIT MIN REQ HUM NUTR, P246
   Juni P, 2001, BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42
   Kahigwa E, 2002, TROP MED INT HEALTH, V7, P823, DOI 10.1046/j.1365-3156.2002.00938.x
   Kaiser R, 2006, DISASTERS, V30, P199, DOI 10.1111/j.0361-3666.2006.00315.x
   Kanani SJ, 2000, J NUTR, V130, p452S
   Kapur D, 2005, INDIAN PEDIATR, V42, P351
   Kapur D, 2003, Indian Pediatr, V40, P1131
   KASHYAP P, 1987, NUTR RES, V7, P1127, DOI 10.1016/S0271-5317(87)80038-6
   Kazembe PN, 1995, AM J TROPICAL MED S2, V53, P91
   Kianfar H, 2000, INT J VITAM NUTR RES, V70, P172, DOI 10.1024/0300-9831.70.4.172
   Kleinschmidt H, 1985, MUNCHEN MED WOCHEN, V107, P1835
   Kochan I, 1973, Curr Top Microbiol Immunol, V60, P1
   Kordas K, 2005, J PEDIATR-US, V147, P632, DOI 10.1016/j.jpeds.2005.06.037
   Kurz KM, 1985, THESIS CORNELL U ITH
   LATHAM MC, 1990, NUTRITION, V6, P159
   LAWLESS JW, 1994, J NUTR, V124, P645
   le Cessie S., 2002, Archives of Disease in Childhood, V86, pF182, DOI 10.1136/fn.86.3.F182
   Le Huong Thi, 2007, Br J Nutr, V97, P955
   Leenstra T, 2009, EUR J CLIN NUTR, V63, P173, DOI 10.1038/sj.ejcn.1602919
   LENGELER C, 2004, COCHRANE DATABASE SY, DOI 10.1002/14651858.CD000363
   Lima Ana C V M S, 2006, J Pediatr (Rio J), V82, P452, DOI 10.1590/S0021-75572006000800010
   Lind T, 2004, AM J CLIN NUTR, V80, P729
   Lind T, 2003, AM J CLIN NUTR, V77, P883
   Lind T, 2008, ACTA PAEDIATR, V97, P770, DOI 10.1111/j.1651-2227.2008.00773.x
   Liu X N, 1996, Biomed Environ Sci, V9, P341
   Liu Xu-Nian, 1995, Food and Nutrition Bulletin, V16, P139
   Maldonado Lozano J., 2007, AN PEDIATR, V66, P591, DOI 10.1157/13107394
   Lozoff B, 2003, PEDIATRICS, V112, P846
   LOZOFF B, 1987, PEDIATRICS, V79, P981
   Lozoff B, 1996, J PEDIATR-US, V129, P382, DOI 10.1016/S0022-3476(96)70070-7
   LOZOFF B, 1982, J PEDIATR-US, V100, P351, DOI 10.1016/S0022-3476(82)80428-9
   Lutter CK, 2008, J NUTR, V138, P379, DOI 10.3945/jn.108.095406
   LUZZI GA, 1990, BRIT J HAEMATOL, V74, P519, DOI 10.1111/j.1365-2141.1990.tb06344.x
   Majumdar I, 2003, J TROP PEDIATRICS, V49, P84, DOI 10.1093/tropej/49.2.84
   Mamiro P R, 2001, Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet, V66, P291
   Martin S, 2001, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001444
   Massaga JJ, 2003, LANCET, V361, P1853, DOI 10.1016/S0140-6736(03)13504-0
   Mebrahtu T, 2004, J NUTR, V134, P3037
   MEJIA LA, 1988, AM J CLIN NUTR, V48, P595
   Menendez C, 2000, PARASITOL TODAY, V16, P469, DOI 10.1016/S0169-4758(00)01774-9
   Menendez C, 2004, AM J TROP MED HYG, V71, P434
   Menendez C, 2002, PEDIATR INFECT DIS J, V21, P249, DOI 10.1097/00006454-200203000-00016
   Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3
   Meremikwu MM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003756.pub3
   Migasena P, 1972, Southeast Asian J Trop Med Public Health, V3, P255
   Mitra AK, 1997, J NUTR, V127, P1451
   Morales J, 2008, J FOOD SCI, V73, pS1, DOI 10.1111/j.1750-3841.2007.00581.x
   Morley R, 1999, ARCH DIS CHILD, V81, P247
   Munoz EC, 2000, AM J CLIN NUTR, V71, P789
   MURRAY MJ, 1978, BRIT MED J, V2, P1113
   Mwanri L, 2000, J NUTR, V130, P2691
   Naghii MR, 2007, BIOFACTORS, V30, P19
   Nagpal J, 2004, J HEALTH POPUL NUTR, V22, P203
   Newton CRJC, 1997, TROP MED INT HEALTH, V2, P165, DOI 10.1046/j.1365-3156.1997.d01-238.x
   Ngnie-Teta I, 2008, FOOD NUTR BULL, V28, P76
   Nguyen Xuan Ninh, 2002, Sante, V12, P31
   The Nordic Cochrane Centre, 2008, REV MAN REVMAN 5 0
   Nwanyanwu OC, 1996, ANN TROP MED PARASIT, V90, P589
   Nyakeriga AM, 2004, J INFECT DIS, V190, P439, DOI 10.1086/422331
   Olney DK, 2006, J NUTR, V136, P2427
   Olsen A, 2006, ANN TROP MED PARASIT, V100, P251, DOI 10.1179/136485906X91486
   OPPENHEIMER SJ, 1987, T ROY SOC TROP MED H, V81, P322, DOI 10.1016/0035-9203(87)90253-7
   OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P603, DOI 10.1016/0035-9203(86)90154-9
   OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P596, DOI 10.1016/0035-9203(86)90153-7
   OPPENHEIMER SJ, 1984, LANCET, V4, P389
   Oppenheimer SJ, 2001, J NUTR, V131, p616S
   OSKI FA, 1983, PEDIATRICS, V71, P877
   OSKI FA, 1978, J PEDIATR-US, V92, P21, DOI 10.1016/S0022-3476(78)80063-8
   Palupi L, 1997, AM J CLIN NUTR, V65, P1057
   PARKS YA, 1989, ARCH DIS CHILD, V64, P400
   PEREIRA SM, 1978, BRIT J NUTR, V39, P493, DOI 10.1079/BJN19780065
   Perrone L, 1999, J TRACE ELEM MED BIO, V13, P51
   POLLITT E, 1989, AM J CLIN NUTR, V50, P687
   POLLITT E, 1993, ANNU REV NUTR, V13, P521, DOI 10.1146/annurev.nutr.13.1.521
   POWERS HJ, 1983, HUM NUTR-CLIN NUTR, V37, P413
   Rahimy MC, 2007, PEDIATR BLOOD CANCER, V48, P544, DOI 10.1002/pbc.21103
   Rahman MM, 1999, J NUTR, V129, P1319
   Ramakrishnan U, 2004, J NUTR, V134, P2592
   Richard SA, 2006, AM J TROP MED HYG, V75, P126
   Rico JA, 2006, PEDIATRICS, V117, pE518, DOI 10.1542/peds.2005-1172
   Rosado JL, 1997, AM J CLIN NUTR, V65, P13
   Roschnik N, 2004, TROP MED INT HEALTH, V9, P904, DOI 10.1111/j.1365-3156.2004.01279.x
   Roschnik N., 2003, IMPACT WEEKLY SCH BA
   Sachdev HPS, 2006, PUBLIC HEALTH NUTR, V9, P904, DOI 10.1017/PHN2005918
   Sachdev HPS, 2005, PUBLIC HEALTH NUTR, V8, P117, DOI 10.1079/PHN2004677
   Sarma KVR, 2006, NUTRITION, V22, pS8, DOI 10.1016/j.nut.2005.07.011
   SARMA KVR, 1977, INDIAN J MED RES, V65, P839
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Schellenberg D, 1999, AM J TROP MED HYG, V61, P431
   Schellenberg D, 2004, AM J TROP MED HYG, V71, P428
   Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2
   Schneider D, 1995, Bull Soc Pathol Exot, V88, P260
   Schumann K, 2009, EUR J CLIN NUTR, V63, P355, DOI 10.1038/sj.ejcn.1602930
   SCHULTINK W, 1995, AM J CLIN NUTR, V61, P111
   SESHADRI S, 1984, Indian Pediatrics, V21, P529
   SESHADRI S, 1984, INDIAN J MED RES, V80, P164
   SESHADRI S, 1989, AM J CLIN NUTR, V50, P675
   SESHADRI S, 1982, BRIT J NUTR, V48, P233, DOI 10.1079/BJN19820109
   Shah BK, 2002, ARCH PEDIAT ADOL MED, V156, P131
   Sharma A, 2000, Indian Pediatr, V37, P261
   Siegel E, 2004, THESIS J HOPKINS U
   SINGLA PN, 1982, J TROP PEDIATRICS, V28, P77
   SLUTSKER L, 1994, T ROY SOC TROP MED H, V88, P548, DOI 10.1016/0035-9203(94)90157-0
   SMITH AW, 1989, ANN TROP PAEDIATR, V9, P6
   SMITH JT, 1989, J PEDIATR ORTHOPED, V9, P1
   Smuts CM, 2005, J NUTR, V135, p631S
   Soekarjo DD, 2004, EUR J CLIN NUTR, V58, P927, DOI 10.1038/sj.ejcn.1601914
   SOEMANTRI AG, 1989, AM J CLIN NUTR, V50, P698
   SOEMANTRI AG, 1985, AM J CLIN NUTR, V42, P1221
   SOEWONDO S, 1989, AM J CLIN NUTR, V50, P667
   Stoltzfus RJ, 2004, J NUTR, V134, P348
   Stoltzfus RJ, 2001, BRIT MED J, V323, P1389, DOI 10.1136/bmj.323.7326.1389
   Stoltzfus RJ, 1997, NUTR REV, V55, P223
   Stoltzfus RJ, 1998, GUIDELINES USE IRON
   Sungthong R, 2002, J NUTR, V132, P418
   Taylor M, 2001, T ROY SOC TROP MED H, V95, P211, DOI 10.1016/S0035-9203(01)90171-3
   Tee ES, 1999, AM J CLIN NUTR, V69, P1249
   Terlouw DJ, 2004, AM J CLIN NUTR, V79, P466
   THIBAULT H, 1993, EUR J PEDIATR, V152, P120, DOI 10.1007/BF02072487
   Thu BD, 1999, AM J CLIN NUTR, V69, P80
   Tielsch JM, 2006, LANCET, V367, P144, DOI 10.1016/S0140-6736(06)67963-4
   Tomashek KM, 2001, AM J TROP MED HYG, V64, P164
   UNICEF, 1998, STAT WORLDS CHIDR 19, P78
   van Stuijvenberg ME, 2008, J NUTR, V138, P782
   vandenHombergh J, 1996, J TROP PEDIATRICS, V42, P220, DOI 10.1093/tropej/42.4.220
   vanHensbroek MB, 1995, T ROY SOC TROP MED H, V89, P672, DOI 10.1016/0035-9203(95)90438-7
   VAUGHAN JP, 1977, TROP GEOGR MED, V29, P369
   Verhoef H, 2002, BLOOD, V100, P3489, DOI 10.1182/blood-2001-12-0228
   Verhoef H, 2002, LANCET, V360, P908, DOI 10.1016/S0140-6736(02)11027-0
   Walker CLF, 2009, EUR J CLIN NUTR, V63, P87, DOI 10.1038/sj.ejcn.1602905
   WALTER T, 1986, AM J CLIN NUTR, V44, P877
   WALTER T, 1989, PEDIATRICS, V84, P7
   WALTER T, 1989, AM J CLIN NUTR, V50, P655
   Walter T, 1989, AM J CLIN NUTR S, V50
   Wasantwisut E, 2006, J NUTR, V136, P2405
   Wegmuller R, 2006, J NUTR, V136, P1814
   [Anonymous], 2004, COMP QUANT HLTH RISK, V1
   WHO, 2007, FOOD NUTR BULL, V28, pS621
   World Health Organization, 2003, WHOCDSMAL20031093
   World Health Organization (WHO), 2008, WORLD MAL REP
   WHO, 2001, WHONHD013
   *WHO, 2008, WORLDW PREV AN REP 1
   Wijaya-Erhardt M, 2007, AM J CLIN NUTR, V86, P1680
   Williams J, 1999, BRIT MED J, V318, P693
   Yalcin SS, 2000, PEDIATR INT, V42, P625, DOI 10.1046/j.1442-200x.2000.01299.x
   Yang Qingjun, 2004, Wei Sheng Yan Jiu, V33, P205
   Zavaleta N, 2000, J NUTR, V130, p462S
   Zavaleta N, 1997, 16 INT C NUTR CAN, VPW5, P62
   ZIMMERMANN M, 2007, IRON FORTIFICATION P
   Zimmermann MB, 2005, AM J CLIN NUTR, V81, P615
   Zlotkin S, 2003, B WORLD HEALTH ORGAN, V81, P108
   ZLOTKIN SH, 2005, USIGN IRON SUPPLEMEN
   [Anonymous], 2006, PRESCRIRE INT, V15, P233
NR 259
TC 32
Z9 32
U1 1
U2 9
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1469-493X
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2009
IS 3
AR CD006589
DI 10.1002/14651858.CD006589.pub2
PG 222
WC Medicine, General & Internal
SC General & Internal Medicine
GA 471EE
UT WOS:000268037500007
PM 19588399
OA No
DA 2017-08-15
ER

PT J
AU Lugos, MD
   Adetifa, IMO
   Donkor, S
   Hill, PC
   Adegbola, RA
   Ota, MOC
AF Lugos, Moses D.
   Adetifa, Ifedayo M. O.
   Donkor, Simon
   Hill, Philip C.
   Adegbola, Richard A.
   Ota, Martin O. C.
TI Evaluation of the Contribution of Major T Cell Subsets to IFN-gamma
   Production in TB Infection by ELISPOT
SO IMMUNOLOGICAL INVESTIGATIONS
LA English
DT Article
DE T lymphocyte subsets; Tuberculosis; IFN-gamma; ELISPOT
ID MYCOBACTERIUM-TUBERCULOSIS INFECTION; INTERFERON-GAMMA; GAMBIA; ESAT-6;
   RESPONSES; HIV
AB Interferon gamma remains a key effector molecule that is still widely used as the most informative biomarker for screening human immune responses against tuberculosis, particularly in ELISPOT assays. We investigated the participation of CD4(+) and CD8(+) T lymphocytes in the PBMC responses to Mycobacterium tuberculosis (Mtb) specific antigens in 33 TB cases and 49 contacts. Responses to ESAT-6 were higher than CFP-10. There was no significant difference in responses to both Mtb antigens between cases and contacts. PBMCs response to ESAT-6 but not CFP-10 in cases was significantly reduced by depletion of CD4(+) cells whereas CD8(+) cell depletion had no impact. In conclusion, ESAT-6 is a more recognized antigen in this population, and CD4(+) lymphocytes are the main participants in IFN-gamma response by ELISPOT. Thus, a decline of CD4(+) T lymphocytes below a critical level might affect the sensitivity of IFN-g release assays for detecting Mtb infection.
C1 [Lugos, Moses D.; Adetifa, Ifedayo M. O.; Donkor, Simon; Hill, Philip C.; Adegbola, Richard A.; Ota, Martin O. C.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Lugos, Moses D.] Natl Inst Vet Res, Fed Coll Vet, Vom, Plateau, Nigeria.
   [Lugos, Moses D.] Natl Inst Vet Res, Med Lab Technol, Vom, Plateau, Nigeria.
   [Hill, Philip C.] Univ Otago, Sch Med, Dept Prevent & Social Med, Ctr Int Hlth, Dunedin, New Zealand.
RP Ota, MOC (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM mota@mrc.gm
FU Medical Research Council Fajara
FX We thank the National TB control programme for their ongoing
   collaboration and our field and laboratory assistants for their hard
   work. We are grateful to the subjects who took part in this study. The
   study was motivated by the Training Committee and funded by the Medical
   Research Council Fajara.
CR Berthet FX, 1998, MICROBIOL-UK, V144, P3195
   Cardoso FLL, 2002, INFECT IMMUN, V70, P6707, DOI 10.1128/IAI.70.12.6707-6714.2002
   Corbett EL, 2003, J INFECT DIS, V188, P1156, DOI 10.1086/378519
   Corbett EL, 2003, INT J TUBERC LUNG D, V7, P709
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   Flynn JL, 2004, TUBERCULOSIS, V84, P93, DOI 10.1016/j.tube.2003.08.010
   Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030
   Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824
   Lalvani A, 2008, J INFECT DIS, V197, P941, DOI 10.1086/529049
   Lalvani A, 2007, CHEST, V131, P1898, DOI 10.1378/chest.06-2471
   Lin MY, 2008, BIOL CHEM, V389, P497, DOI 10.1515/BC.2008.057
   Menzies D, 2007, ANN INTERN MED, V146, P340
   Newport MJ, 2003, SCAND J IMMUNOL, V58, P383, DOI 10.1046/j.1365-3083.2003.01328.x
   Ottenhoff THM, 2005, TUBERCULOSIS, V85, P53, DOI 10.1016/j.tube.2004.09.011
   Roberts T, 2007, J INFECT DIS, V195, P870, DOI 10.1086/511277
   Smith SM, 2000, INFECT IMMUN, V68, P7144, DOI 10.1128/IAI.68.12.7144-7148.2000
   Smith SM, 2000, IMMUNOL CELL BIOL, V78, P325, DOI 10.1046/j.1440-1711.2000.00936.x
   van Pinxteren LAH, 2000, EUR J IMMUNOL, V30, P3689, DOI 10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4
   Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001
NR 19
TC 4
Z9 5
U1 1
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0882-0139
J9 IMMUNOL INVEST
JI Immunol. Invest.
PY 2009
VL 38
IS 5
BP 341
EP 349
DI 10.1080/08820130902748744
PG 9
WC Immunology
SC Immunology
GA 479NU
UT WOS:000268667700001
PM 19811412
OA No
DA 2017-08-15
ER

PT J
AU Njie, R
   Bell, AI
   Jia, H
   Croom-Carter, D
   Chaganti, S
   Hislop, AD
   Whittle, H
   Rickinson, AB
AF Njie, Ramou
   Bell, Andrew I.
   Jia, Hui
   Croom-Carter, Debbie
   Chaganti, Sridhar
   Hislop, Andrew D.
   Whittle, Hilton
   Rickinson, Alan B.
TI The Effects of Acute Malaria on Epstein-Barr Virus (EBV) Load and
   EBV-Specific T Cell Immunity in Gambian Children
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; B-CELLS; BURKITTS-LYMPHOMA; AFRICAN
   CHILDREN; HIV-INFECTION; HIGH-RISK; REACTIVATION; RESPONSES; ACTIVATION;
   FREQUENCY
AB Background. To investigate how intense Plasmodium falciparum infection predisposes to Epstein-Barr virus (EBV)-positive Burkitt lymphoma (BL), we analyzed the effect of acute malaria on existing EBV-host balance.
   Methods. EBV genome loads in peripheral blood mononuclear cells were assayed by quantitative polymerase chain reaction, and EBV-specific CD8(+) T cell responses were assayed by interferon-gamma enzyme-linked immunospot assay.
   Results. Gambian children, from whom samples were obtained during an acute malaria attack and again up to 6 weeks later, had extremely high viral loads, reaching levels that in the United Kingdom are seen only in patients with infectious mononucleosis. Gambian control subjects ( children and adults with no recent history of malaria) had lower median viral loads, although they were still > 10-fold above the median for healthy UK adults. Limited experiments with EBV epitope peptides (restricted through the HLA-B*3501 and HLA-B*5301 alleles) also suggested an impairment of virus-specific CD8(+) T cell function in children with malaria, but only during acute disease.
   Conclusions. Acute malaria is associated with sustained increase in EBV load and, possibly, a transient decrease in EBV-specific T cell surveillance. We infer that the unusually high set point of virus carriage in P. falciparum challenged populations, allied with the parasite's capacity to act as a chronic B cell stimulus, probably contributes to the pathogenesis of endemic BL.
C1 [Njie, Ramou; Bell, Andrew I.; Jia, Hui; Croom-Carter, Debbie; Chaganti, Sridhar; Hislop, Andrew D.; Rickinson, Alan B.] Univ Birmingham, Sch Med, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.
   [Njie, Ramou; Whittle, Hilton] MRC Labs, Banjul, Fajara, Gambia.
RP Rickinson, AB (reprint author), Univ Birmingham, Sch Med, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.
EM a.b.rickinson@bham.ac.uk
OI Bell, Andrew/0000-0001-9520-4417
FU UK Medical Research Council (MRC), London; Cancer Research UK; MRC
   Clinical Training Fellowship; MRC New Investigator Award.
FX Financial support: UK Medical Research Council (MRC), London, and Cancer
   Research UK (support to this work). R. N. was the recipient of an MRC
   Clinical Training Fellowship. A. D. H. is the recipient of an MRC New
   Investigator Award.
CR Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6
   BIGGAR RJ, 1978, INT J CANCER, V22, P239, DOI 10.1002/ijc.2910220304
   Biggar RJ, 2007, J NATL CANCER I, V99, P962, DOI 10.1093/jnci/djm010
   Blake N, 2000, J IMMUNOL, V165, P7078
   Brooks JM, 2000, J VIROL, V74, P1801, DOI 10.1128/JVI.74.4.1801-1809.2000
   Chene A, 2007, PLOS PATHOG, V3, P826, DOI 10.1371/journal.ppat.0030080
   DALLDORF G, 1962, JAMA-J AM MED ASSOC, V181, P1026
   De Milito A, 2004, CURR HIV RES, V2, P11, DOI 10.2174/1570162043485068
   Donati D, 2006, J INFECT DIS, V193, P971, DOI 10.1086/500839
   Donati D, 2006, J IMMUNOL, V177, P3035
   Duraiswamy J, 2003, J VIROL, V77, P7401, DOI 10.1128/JVI.77.13.7401-7410.2003
   GESER A, 1980, REV EPIDEMIOL SANTE, V28, P307
   Gottschalk S, 2005, ANNU REV MED, V56, P29, DOI 10.1146/annurev.med.56.082103.104727
   Gudgeon NH, 2005, J VIROL, V79, P5477, DOI 10.1128/JVI.79.9.5477-5488.2005
   Hislop AD, 2007, ANNU REV IMMUNOL, V25, P587, DOI 10.1146/annurev.immunol.25.022106.141553
   IOACHIM HL, 1990, AM J CLIN PATHOL, V93, P208
   Junying Jia, 2003, Virology, V306, P236, DOI 10.1016/S0042-6822(02)00027-2
   Kuppers R, 2005, NAT REV CANCER, V5, P251, DOI 10.1038/nrc1589
   LAM KMC, 1991, LANCET, V337, P876, DOI 10.1016/0140-6736(91)90203-2
   LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803
   Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4
   Meij P, 2003, BLOOD, V101, P4290, DOI 10.1182/blood-2002-10-3001
   Midgley RS, 2003, J VIROL, V77, P11517, DOI 10.1128/JVI.77.21.11517-11530.2003
   Moormann AM, 2005, J INFECT DIS, V191, P1233, DOI 10.1086/428910
   Moormann AM, 2007, J INFECT DIS, V195, P799, DOI 10.1086/511984
   MOSS DJ, 1983, INT J CANCER, V31, P727, DOI 10.1002/ijc.2910310609
   Piriou ER, 2004, J IMMUNOL, V172, P6931
   Rasti N, 2005, SCAND J IMMUNOL, V61, P461, DOI 10.1111/j.1365-3083.2005.01589.x
   RICKINSON AB, 1974, INT J CANCER, V14, P704, DOI 10.1002/ijc.2910140603
   Rickinson A. B., 2006, FIELDS VIROLOGY, V2, P2655
   Rochford R, 2005, NAT REV MICROBIOL, V3, P182, DOI 10.1038/nrmicro1089
   SAMPLE J, 1990, J VIROL, V64, P4084
   Shannon-Lowe CD, 2006, P NATL ACAD SCI USA, V103, P7065, DOI 10.1073/pnas.0510512103
   Tan LC, 1999, J IMMUNOL, V162, P1827
   Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584
   WHITTLE HC, 1984, NATURE, V312, P449, DOI 10.1038/312449a0
   WHITTLE HC, 1990, CLIN EXP IMMUNOL, V80, P213
   Yone CLRP, 2006, T ROY SOC TROP MED H, V100, P669, DOI 10.1016/j.trstmh.2005.08.009
   Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452
NR 39
TC 40
Z9 41
U1 1
U2 6
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 1
PY 2009
VL 199
IS 1
BP 31
EP 38
DI 10.1086/594373
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 384OP
UT WOS:000261754400006
PM 19032105
OA No
DA 2017-08-15
ER

PT J
AU Kremsner, PG
   Valim, C
   Missinou, MA
   Olola, C
   Krishna, S
   Issifou, S
   Kombila, M
   Bwanaisa, L
   Mithwani, S
   Newton, CR
   Agbenyega, T
   Pinder, M
   Bojang, K
   Wypij, D
   Taylor, T
AF Kremsner, Peter Gottfried
   Valim, Clarissa
   Missinou, Michel A.
   Olola, Christopher
   Krishna, Sanjeev
   Issifou, Saadou
   Kombila, Maryvonne
   Bwanaisa, Lloyd
   Mithwani, Sadik
   Newton, Charles R.
   Agbenyega, Tsiri
   Pinder, Margaret
   Bojang, Kalifa
   Wypij, David
   Taylor, Terrie
TI Prognostic Value of Circulating Pigmented Cells in African Children with
   Malaria
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; TUMOR-NECROSIS-FACTOR; HEMOZOIN; ANEMIA;
   ERYTHROPOIESIS; ASSOCIATION; SUPPRESSION; SEVERITY; PARASITE
AB Background. Plasmodium falciparum malaria is a common cause of morbidity in African children, but identifying those who are likely to die is problematic. Previous studies suggested that circulating malarial pigment might be a useful predictor of severity, but none were large enough to detect any association with mortality.
   Methods. We used thick blood smears performed on admission for 26,296 children hospitalized with P. falciparum at 1 of 6 hospitals in the Severe Malaria in African Children network to assess the prognostic value of pigment-containing granulocytes, monocytes, and parasites.
   Results. Although at all but one of the study sites the risk of mortality for subjects presenting with >5 pigmented granulocytes per 200 white blood cells was higher than in subjects with no pigmented granulocytes, adjusted odds ratios estimated through logistic regression, which included other established markers of severe malaria, suggested that associations between pigmented cells and mortality were moderate to nonexistent in most sites. The predictive ability of pigmented cells was low, as measured by the change in the area under the receiver operating characteristic curve of logistic regression models.
   Conclusions. Although high levels of pigmented cells were associated with a fatal outcome in some study sites, they were not useful predictors of outcome across Africa.
C1 [Taylor, Terrie] Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48424 USA.
   Univ Hlth Sci Libreville, Fac Med, Dept Parasitol Mycol & Trop Med, Libreville, Gabon, France.
   [Kremsner, Peter Gottfried; Missinou, Michel A.; Issifou, Saadou] Univ Tubingen, Inst Trop Med, Dept Parasitol, Tubingen, Germany.
   [Valim, Clarissa] Harvard Univ, Sch Med, Div Biostat Clin Res Program, Childrens Hosp Boston, Boston, MA USA.
   [Valim, Clarissa] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
   [Wypij, David] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
   [Wypij, David] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Olola, Christopher; Mithwani, Sadik; Newton, Charles R.] Kenya Med Res Inst Geog Med, Kilifi, Kenya.
   [Krishna, Sanjeev; Kombila, Maryvonne] St Georges Univ London, Div Cellular & Mol Med, Ctr Infect, London, England.
   [Bwanaisa, Lloyd; Taylor, Terrie] Univ Malawi, Coll Med, Blantyre Malaria Project, Blantyre, Malawi.
   [Agbenyega, Tsiri] Univ Sci & Technol Kumasi, Sch Med Sci, Kumasi, Ghana.
   [Pinder, Margaret; Bojang, Kalifa] MRC Labs, Banjul, Gambia.
RP Taylor, T (reprint author), Michigan State Univ, Coll Osteopath Med, Dept Internal Med, B309-B W Fee Hall, E Lansing, MI 48424 USA.
EM taylort@msu.edu
RI Newton, Charles/C-6222-2009; Newton, 21/B-7578-2014
OI Newton, 21/0000-0002-6999-5507; Krishna, Sanjeev/0000-0003-0066-0634;
   Bojang, Kalifa/0000-0001-7506-0938
FU Institute of Allergy and Infectious Diseases; National Institutes of
   Health [AI45955]
FX Financial support: Institute of Allergy and Infectious Diseases,
   National Institutes of Health (grant AI45955). The funder had no role in
   the design and conduct of the study; the collection, management,
   analysis, and interpretation of the data; and the preparation, review,
   or approval of the manuscript.
CR Amodu OK, 1998, T ROY SOC TROP MED H, V92, P54, DOI 10.1016/S0035-9203(98)90952-X
   Casals-Pascual C, 2006, BLOOD, V108, P2569, DOI 10.1182/blood-2006-05-018697
   Giribaldi G, 2004, HAEMATOLOGICA, V89, P492
   Grobusch MP, 2003, CYTOM PART B-CLIN CY, V55B, P46, DOI 10.1002/cyto.b.10039
   Keller CC, 2006, J INFECT DIS, V193, P1384, DOI 10.1086/503047
   Lell B, 2005, AM J TROP MED HYG, V73, P588
   Luty AJF, 2000, INFECT IMMUN, V68, P3909, DOI 10.1128/IAI.68.7.3909-3915.2000
   Lyke KE, 2003, AM J TROP MED HYG, V69, P253
   Metzger WG, 1995, T ROY SOC TROP MED H, V89, P637, DOI 10.1016/0035-9203(95)90423-9
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Newton CRJC, 2005, CLIN INFECT DIS, V41, P948, DOI 10.1086/432941
   Olola CHO, 2006, METHOD INFORM MED, V45, P483
   PHU NH, 1995, T ROY SOC TROP MED H, V89, P200
   Poser C M, 1999, ILLUSTRATED HIST MAL
   PRADA J, 1995, EUR CYTOKINE NETW, V6, P109
   SCHWARZER E, 1992, J EXP MED, V176, P1033, DOI 10.1084/jem.176.4.1033
   Skorokhod OA, 2004, J IMMUNOL, V173, P4066
   Taylor T, 2006, T ROY SOC TROP MED H, V100, P615, DOI 10.1016/j.trstmh.2005.09.021
   Tripathi AK, 2002, BIOCHEM BIOPH RES CO, V290, P595, DOI 10.1006/bbrc.2001.6231
NR 19
TC 31
Z9 31
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 1
PY 2009
VL 199
IS 1
BP 142
EP 150
DI 10.1086/595295
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 384OP
UT WOS:000261754400019
PM 19086817
OA No
DA 2017-08-15
ER

PT J
AU Cooper, S
   van der Loeff, MS
   McConkey, S
   Cooper, M
   Sarge-Njie, R
   Kaye, S
   Whittle, H
AF Cooper, S.
   van der Loeff, M. Schim
   McConkey, S.
   Cooper, M.
   Sarge-Njie, R.
   Kaye, S.
   Whittle, H.
TI Neurological morbidity among human T-lymphotropic-virus-type-1-infected
   individuals in a rural West African population
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID VIRUS TYPE-I; MYELOPATHY/TROPICAL SPASTIC PARAPARESIS; HTLV-I;
   GUINEA-BISSAU; RISK-FACTORS; 1-ASSOCIATED MYELOPATHY; INFECTION;
   EPIDEMIOLOGY; PREVALENCE; DISEASE
AB Background: Community-based neurological data about human T lymphotropic virus type 1 (HTLV-1) morbidity in sub-Saharan Africa are scarce.
   Objectives: To ascertain the prevalence of neurological morbidity, in particular tropical spastic paraparesis (TSP), among HTLV-1-infected subjects and to compare TSP prevalence in HTLV-1-infected with that in non-infected subjects in a rural West African population.
   Methods: A cross-sectional study of HTLV-1-infected cases and controls (ratio 4: 1) from a rural community (population approximately 10 000, HTLV-1 prevalence 7.7%). One neurologist masked to HTLV-1 serological status assessed all subjects. Clinical criteria were employed to diagnose TSP.
   Results: From 205 eligible cases and controls, 139 were recruited with a mean age of 56 years, and 113 (81%) were HTLV-1-infected. 108/139 (78%) were female, and 8/113 HTLV-1 infected cases (7.1%) had a definite or probable TSP (all females; mean age 67 years) compared with 0/26 controls. Two with TSP were co-infected with HIV-2. Complaints of back pain and leg weakness were more common in HTLV-1-infected individuals (p = 0.03, p = 0.02), but no single symptom distinguished between subjects with and without TSP.
   Conclusion: We report a prevalence of TSP among HTLV-1-infected persons in this rural West African setting of 7.1%. There are difficulties excluding other potential aetiologies here.
C1 [Cooper, S.] So Gen Hosp, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland.
   [van der Loeff, M. Schim] GGD Hlth Serv Amsterdam, Amsterdam, Netherlands.
   [McConkey, S.] Royal Coll Surgeons Ireland, Dublin 2, Ireland.
   [Cooper, M.] Univ Glasgow, Dept Gen Practice, Glasgow, Lanark, Scotland.
   [Sarge-Njie, R.; Whittle, H.] MRC Labs, Fajara, Gambia.
   [Kaye, S.] Univ London Imperial Coll Sci Technol & Med, London, England.
RP Cooper, S (reprint author), So Gen Hosp, Inst Neurol Sci, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.
EM sarah.cooper@doctors.org.uk
RI McConkey, Samuel/E-7307-2012
CR Araujo AQC, 2006, LANCET NEUROL, V5, P1068, DOI 10.1016/S1474-4422(06)70628-7
   BHIGJEE AI, 1990, BRAIN, V113, P1307, DOI 10.1093/brain/113.5.1307
   Cabre P, 2000, J NEUROL NEUROSUR PS, V68, P550, DOI 10.1136/jnnp.68.5.550
   Casseb J, 2008, J MED VIROL, V80, P392, DOI 10.1002/jmv.21111
   DETHE G, 1993, AIDS RES HUM RETROV, V9, P381, DOI 10.1089/aid.1993.9.381
   GESSAIN A, 1985, LANCET, V2, P407
   Gessain A, 2000, B SOC PATHOL EXOT, V93, P163
   Holmgren B, 2002, J ACQ IMMUN DEF SYND, V30, P342, DOI 10.1097/01.QAI.0000013943.86473.3E
   KRAMER A, 1995, AM J EPIDEMIOL, V142, P1212
   Kumar SP, 2000, NEUROL INDIA, V48, P314
   Larsen O, 2000, J ACQ IMMUN DEF SYND, V25, P157, DOI 10.1097/00126334-200010010-00010
   Melbye M, 1998, INT J CANCER, V76, P293, DOI 10.1002/(SICI)1097-0215(19980504)76:3<293::AID-IJC1>3.0.CO;2-Q
   MONTEFORT S, 1993, RESP MED, V87, P9, DOI 10.1016/S0954-6111(06)80346-X
   Olindo S, 2006, ARCH NEUROL-CHICAGO, V63, P1560, DOI 10.1001/archneur.63.11.1560
   Orland JR, 2003, NEUROLOGY, V61, P1588
   Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968
   RODGERSJOHNSON P, 1988, ANN NEUROL, V23, pS121, DOI 10.1002/ana.410230729
   Sabouri AH, 2005, J GEN VIROL, V86, P773, DOI 10.1099/vir.0.80509-0
   Takenouchi N, 2003, J NEUROVIROL, V9, P29, DOI 10.1080/13550280390173418
   Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6
   VERNANT JC, 1987, ANN NEUROL, V21, P123, DOI 10.1002/ana.410210204
   Webb S, 1998, BRAIN, V121, P923, DOI 10.1093/brain/121.5.923
   World Health Organization, 1989, WEEKLY EPIDEMIOLOGIC, V49, P377
NR 23
TC 4
Z9 4
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD JAN
PY 2009
VL 80
IS 1
BP 66
EP 68
DI 10.1136/jnnp.2008.152819
PG 3
WC Clinical Neurology; Psychiatry; Surgery
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 384RM
UT WOS:000261761900019
PM 18977823
OA No
DA 2017-08-15
ER

PT J
AU Ozor, FU
AF Ozor, Frederick Ugwu
TI Electoral Process, Democracy and Governance in Africa: Search for an
   Alternative Democratic Model
SO POLITIKON
LA English
DT Article
AB In search for answers to what is wrong and where to locate what is wrong with African democracy, this paper attempts to establish the validity of the nexus between elections, democracy and governance in Africa. The paper further argues that the feasibility of recreating aspects of Africa's past to develop an African democracy variant necessitates the need to move away from philosophy to concrete suggestions. Strengthening representative democracy will require institutional changes that draw upon the spirituality and traditions of Africa's past, which nevertheless take into account present day African politico-cultural imperatives arising from changing socio-politico-economic relations, perceptions, values, and attitudes.
C1 Univ Gambia, Dept Social Sci, Serekunda, Gambia.
RP Ozor, FU (reprint author), Univ Gambia, Dept Social Sci, POB 3530, Serekunda, Gambia.
EM fred_oz_or@yahoo.co.uk
CR Ake C., 1996, DEMOCRACY DEV AFRICA
   Amartya S., 1999, DEV FREEDOM
   Asiegbu Johnson U. J., 1984, NIGERIA ITS BRIT INV
   Bayart J.- F., 1993, STATE AFRICA POLITIC
   Birch A. H., 2001, CONCEPTS THEORIES MO
   Bratton M., 1997, DEMOCRATIC EXPT AFRI
   BRZEZINSKI Z, 1967, SOVIET BLOC
   Burke Edmund, 2001, REFLECTIONS REVOLUTI
   Collier Ruth B., 1982, REGIMES TROPICAL AFR
   Dahl R. A., 1967, PLURALIST DEMOCRACY
   DUIGNAN P, 1986, POLITICS GOVT AFRICA
   FRANCIS D. J., 2008, PEACE CONFLICT AFRIC
   GLOPPEN S, 2003, RESPONSIVENESS POOR
   Good K., 2002, LIBERAL MODEL AFRICA
   Grossman GE, 2001, SPECIAL INTEREST POL
   HENSLEY TR, 2001, BOUNDARIES FREEDOM E
   KAMAL S, 2000, INT IDEA 2000 DEM FO
   Kante Babacar, 1994, J DEMOCR, V5, P96
   KANTE B, 1994, AFRICA CONFIDENTIAL, V35
   KAYODE F, 1999, GOVERNANCE POLITY NI
   Kiros T, 2001, EXPLORATIONS AFRICAN
   KREIS S, 2008, HIST GUIDE
   Linberg S, 2006, DEMOCRACY ELECTIONS
   MAIER K, 2000, BRINGING DOWN HOUSE
   MARX K, 1887, CAPITAL PROCESS PROD, V1
   Marx K., 1969, SELECTED WORKS, V1, P98
   MAZRUI AA, 2008, WHO KILLED DEMOCRACY
   MCKEON R, 1951, DEMOCRACY WORLD TENS, P522
   OBAYELU AE, 2007, EFFECTS CORRUP UNPUB
   ORIZU NAA, 1944, WITHOUT BITTERNESS
   OSABUKLE DT, 2000, COMPATIBLE CULTURAL, P97
   Oyediran O., 1999, NIGERIA POLITICS TRA
   Persson T., 2000, POLITICAL EC EXPLAIN
   Pomper Gerald M., 1968, ELECTIONS AM
   Saine A, 2008, ARMED FORCES SOC, V34, P450, DOI 10.1177/0095327X07312081
   SCHIMITTER P, 2004, DEMOCRATIZATION, V11, P59
   SOYIBO A, 1999, NIGERIA POLITICS TRA, P175
   Stromberg R. N, 1996, DEMOCRACY SHORT ANAL
   Crouch C, 2006, DIVERSITY OF DEMOCRACY: CORPORATISM, SOCIAL ORDER AND POLITICAL CONFLICT, P1
NR 39
TC 1
Z9 1
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0258-9346
J9 POLITIKON-UK
JI Politikon
PY 2009
VL 36
IS 2
BP 315
EP 336
AR PII 917840937
DI 10.1080/02589340903240302
PG 22
WC Political Science
SC Government & Law
GA 533TI
UT WOS:000272847800007
OA No
DA 2017-08-15
ER

PT J
AU Casals-Pascual, C
   Idro, R
   Picot, S
   Roberts, DJ
   Newton, CRJC
AF Casals-Pascual, Climent
   Idro, Richard
   Picot, Stephane
   Roberts, David J.
   Newton, Charles R. J. C.
TI Can erythropoietin be used to prevent brain damage in cerebral malaria?
SO TRENDS IN PARASITOLOGY
LA English
DT Review
ID PLASMODIUM-FALCIPARUM MALARIA; TRANSCRIPTIONAL REGULATORY ELEMENTS;
   TISSUE-PROTECTIVE CYTOKINE; HYPOXIA-INDUCIBLE FACTOR; ENCODING GENE
   CONTAINS; CARBAMYLATED ERYTHROPOIETIN; NEURONAL APOPTOSIS; FLANKING
   REGION; SEVERE ANEMIA; BONE-MARROW
AB Erythropoietin (Epo) modulates the survival of developing erythroid cells and the production of new erythrocytes in the bone marrow and is a key molecule in the adaptation to hypoxia and anaemia. Epo receptors have been found to be widely expressed on nonhaematopoietic cells, and Epo has been shown to have diverse actions (in particular, preventing ischaemic damage to tissues of the central nervous system). Recently, Epo has been shown to improve the outcome in a murine model of malaria, and high plasma levels of Epo in children with cerebral malaria were associated with a better outcome. Here, we review the biological importance of Epo, its mechanisms of action and the rationale for the proposed use of Epo as an adjunct treatment in cerebral malaria.
C1 [Casals-Pascual, Climent] MRC Labs, Fajara, Gambia.
   [Idro, Richard; Newton, Charles R. J. C.] Kenya Govt Med Res Ctr, Ctr Geog Med Coast, Kilifi, Kenya.
   [Idro, Richard] Makerere Univ, Mulago Hosp, Dept Paediat, Kampala, Uganda.
   [Picot, Stephane] Univ Lyon 1, EA4170, Malaria Res Unit, F-69365 Lyon, France.
   [Roberts, David J.] John Radcliffe Hosp, Nuffield Dept, Clin Sci Lab, Oxford OX3 9BQ, England.
   [Roberts, David J.] John Radcliffe Hosp, Natl Blood Serv, Oxford Ctr, Oxford OX3 9BQ, England.
   [Newton, Charles R. J. C.] UCL, Inst Child Hlth, Neurosci Unit, London, England.
   [Newton, Charles R. J. C.] London Sch Hyg & Trop Med, Clin Res Unit, London WC1, England.
RP Casals-Pascual, C (reprint author), MRC Labs, POB 273, Fajara, Gambia.
EM ccasals@mrc.gm
RI picot, stephane/F-5973-2014; Newton, 21/B-7578-2014
OI picot, stephane/0000-0002-5735-6759; Newton, 21/0000-0002-6999-5507;
   Casals-Pascual, Climent/0000-0002-0867-8954
FU Medical Research Council, UK; Medical Research Council, UK and the
   Oxford Tropical Network.; Howard Hughes Medical Institute; National
   Blood Service; HS RD funding; Biomedical Research Centre; John Radcliffe
   Hospital; EU; Wellcome Trust, UK [070114]
FX C,C.P. is supported by the Medical Research Council, UK and the Oxford
   Tropical Network. D.J.R. is supported by the Howard Hughes Medical
   Institute and the National Blood Service, and this work benefits from
   NHS R&D funding, NIHR funding from the Biomedical Research Centre, John
   Radcliffe Hospital and the EU Framework VI NoE BioMaIPar. C.R.J.C.N. is
   funded by the Wellcome Trust, UK (070114). We would like to thank
   Anne-Lise Bienvenu (Malaria Research Unit, Lyon, France) for critical
   review of the manuscript and sharing data on current trials with Epo in
   patients.
CR ABDALLA SH, 1988, CLIN LAB HAEMATOL, V10, P33
   Adembri C, 2008, CRIT CARE MED, V36, P975, DOI [10.1097/CCM.0B013E3181644343, 10.1097/CCM.0B013E:3181644343]
   Amani V, 1998, INFECT IMMUN, V66, P4093
   Arcasoy MO, 2008, BRIT J HAEMATOL, V141, P14, DOI 10.1111/j.1365-2141.2008.07014.x
   Banks WA, 2004, EUR J PHARMACOL, V505, P93, DOI 10.1016/j.ejphar.2004.10.035
   Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393
   Bienvenu AL, 2008, ACTA TROP, V106, P104, DOI 10.1016/j.actatropica.2008.02.001
   Brines M, 2006, KIDNEY INT, V70, P246, DOI 10.1038/sj.kl.5001546
   Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687
   Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.040691101
   Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526
   Burgmann H, 1996, AM J TROP MED HYG, V54, P280
   Casals-Pascual C, 2008, P NATL ACAD SCI USA, V105, P2634, DOI 10.1073/pnas.0709715105
   Casals-Pascual C, 2006, BLOOD, V108, P2569, DOI 10.1182/blood-2006-05-018697
   Cazzola M, 1998, BLOOD, V91, P2139
   Chong ZZ, 2002, J HEMATOTH STEM CELL, V11, P863, DOI 10.1089/152581602321080529
   Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503
   Coleman TR, 2006, P NATL ACAD SCI USA, V103, P5965, DOI 10.1073/pnas.0601377103
   DANDREA AD, 1990, J CLIN INVEST, V86, P681, DOI 10.1172/JCI114763
   Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074
   DORDAL MS, 1985, ENDOCRINOLOGY, V116, P2293
   ElHassan AMA, 1997, EUR J HAEMATOL, V59, P299
   Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100
   FUKUDA MN, 1989, BLOOD, V73, P84
   Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450
   Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187
   Idro R, 2005, LANCET NEUROL, V4, P827, DOI 10.1016/S1474-4422(05)70247-7
   Imagawa S, 1997, BLOOD, V89, P1430
   Jelkmann W, 2007, METHOD ENZYMOL, V435, P179, DOI 10.1016/S0076-6879(07)35010-6
   Kaiser K, 2006, J INFECT DIS, V193, P987, DOI 10.1086/500844
   King VR, 2007, EUR J NEUROSCI, V26, P90, DOI 10.1111/j.1460-9568.2007.05635.x
   Kumar KA, 2002, NEUROSCI LETT, V329, P319, DOI 10.1016/S0304-3940(02)00470-6
   Kurtzhals JAL, 1997, BRIT J HAEMATOL, V97, P169, DOI 10.1046/j.1365-2141.1997.82654.x
   LEEHUANG S, 1993, GENE, V128, P227, DOI 10.1016/0378-1119(93)90567-M
   LEEHUANG S, 1993, GENE, V137, P203
   LEEHUANG S, 1984, P NATL ACAD SCI-BIOL, V81, P2708, DOI 10.1073/pnas.81.9.2708
   Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313
   Liu J, 2005, STROKE, V36, P1264, DOI 10.1161/01.STR.0000166180.91042.02
   Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001
   Macdougall Iain C, 2002, Kidney Int Suppl, P55
   Maiese K, 2005, JAMA-J AM MED ASSOC, V293, P90, DOI 10.1001/jama.293.1.90
   MASUDA S, 1993, J BIOL CHEM, V268, P11208
   MILLER CB, 1990, NEW ENGL J MED, V322, P1689, DOI 10.1056/NEJM199006143222401
   MIYAKE T, 1977, J BIOL CHEM, V252, P5558
   Mori M, 2003, J CELL PHYSIOL, V195, P290, DOI 10.1002/jcp.10245
   Nagai A, 2001, J NEUROPATH EXP NEUR, V60, P386
   Newton CRJC, 1997, TROP MED INT HEALTH, V2, P165, DOI 10.1046/j.1365-3156.1997.d01-238.x
   O'Donnell A, 2007, P NATL ACAD SCI USA, V104, P9440, DOI 10.1073/pnas.0703424104
   PALLARD C, 1995, J BIOL CHEM, V270, P15942
   Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200
   Prass K, 2003, STROKE, V34, P1981, DOI 10.1161/01.STR.0000080381.76409.B2
   Sanni Latifu A, 2002, Methods Mol Med, V72, P57, DOI 10.1385/1-59259-271-6:57
   SASAKI H, 1987, J BIOL CHEM, V262, P12059
   Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004
   Seydel KB, 2006, J INFECT DIS, V194, P208, DOI 10.1086/505078
   Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598
   Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2
   Villa P, 2007, J CEREBR BLOOD F MET, V27, P552, DOI 10.1038/sj.jcbfm.9600370
   Widness JA, 2007, CLIN PHARMACOL THER, V81, P873, DOI 10.1038/sj.clpt.6100165
   Wiese L, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-3
   Wiese L, 2006, EXP NEUROL, V200, P216, DOI 10.1016/j.expneurol.2006.02.011
   WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L
NR 62
TC 35
Z9 37
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4922
J9 TRENDS PARASITOL
JI Trends Parasitol.
PD JAN
PY 2009
VL 25
IS 1
BP 30
EP 36
DI 10.1016/j.pt.2008.10.002
PG 7
WC Parasitology
SC Parasitology
GA 400VT
UT WOS:000262898200008
PM 19008152
OA No
DA 2017-08-15
ER

PT J
AU Stabell, C
   Fisker, AB
   Rodrigues, A
   Ravn, H
   Sartono, E
   Whittle, H
   Yazdanbakhsh, M
   Aaby, P
AF Stabell, Christine
   Fisker, Ane Baerent
   Rodrigues, Amabelia
   Ravn, Henrik
   Sartono, Erliyani
   Whittle, Hilton
   Yazdanbakhsh, Maria
   Aaby, Peter
TI Sex-Differential Effect on Infant Mortality of Oral Polio Vaccine
   Administered with BCG at Birth in Guinea-Bissau. A Natural Experiment
SO PLOS ONE
LA English
DT Article
AB Background: The policy to provide oral polio vaccine (OPV) at birth was introduced in low-income countries to increase coverage. The effect of OPV at birth on overall child mortality was never studied. During a trial of vitamin A supplementation (VAS) at birth in Guinea-Bissau, OPV was not available during several periods. We took advantage of this "natural experiment" to test the effect on mortality of receiving OPV at birth.
   Methodology: Between 2002 and 2004, the VAS trial randomised normal-birth-weight infants to 50,000 IU VAS or placebo administered with BCG. Provision of OPV at birth was not part of the trial, but we noted whether the infants received OPV or not. OPV was missing during several periods in 2004. We used Cox proportional hazards models to compute mortality rate ratios (MRR) of children who had received or not received OPV at birth.
   Principal Findings: A total of 962 (22.1%) of the 4345 enrolled children did not receive OPV at birth; 179 children died within the first year of life. Missing OPV at birth was associated with a tendency for decreased mortality (adjusted MRR=0.69 (95% CI = 0.46-1.03)), the effect being similar among recipients of VAS and placebo. There was a highly significant interaction between OPV at birth and sex (p = 0.006). Not receiving OPV at birth was associated with a weak tendency for increased mortality in girls (1.14 (0.70-1.89)) but significantly decreased mortality in boys (0.35 (0.18-0.71)).
   Conclusions: In our study OPV at birth had a sex-differential effect on mortality. Poliovirus is almost eradicated and OPV at birth contributes little to herd immunity. A randomised study of the effect of OPV at birth on overall mortality in both sexes is warranted.
C1 [Ravn, Henrik] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen, Denmark.
   [Fisker, Ane Baerent; Rodrigues, Amabelia; Aaby, Peter] Indepth Network, Bandim Hlth Project, Bissau, Guinea Bissau.
   [Sartono, Erliyani; Yazdanbakhsh, Maria] Leiden Univ, Med Ctr, Dept Immunoparasitol, NL-2300 RA Leiden, Netherlands.
   [Whittle, Hilton] MRC Labs, Fajara, Gambia.
RP Stabell, C (reprint author), Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen, Denmark.
EM cb@ssi.dk
OI Fisker, Ane/0000-0002-8521-0992
FU EU [ICA4-CT-2002-10053]; Danish Medical Research Council; University of
   Copenhagen; March of Dimes; Ville Heise Foundation; DANIDA; Danish
   National Research Foundation; Novo Nordisk Foundation [research
   professorship]
FX The vitamin A trial was funded by the EU (ICA4-CT-2002-10053), The
   Danish Medical Research Council, University of Copenhagen, March of
   Dimes, and the Ville Heise Foundation. The Bandim Health Project
   received support from DANIDA and the Danish National Research
   Foundation. PA holds a research professorship grant from the Novo
   Nordisk Foundation. The sponsors had no role in the study design, data
   collection, data analysis, data interpretation, or the writing of the
   report.
CR Aaby P, 2005, VACCINE, V23, P1746, DOI 10.1016/j.vaccine.2004.02.054
   Aaby P, 2004, VACCINE, V22, P3014, DOI 10.1016/j.vaccine.2004.02.009
   Aaby P, 2004, INT J EPIDEMIOL, V33, P374, DOI 10.1093/ije/dyh005
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 2002, VACCINE, V21, P15, DOI 10.1016/S0264-410X(02)00441-3
   ANKER M, 1999, WHOCDSIRS994
   Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Benn CS, 2008, BRIT MED J, V336, P1416, DOI 10.1136/bmj.39542.509444.AE
   Cox D. R., 1984, ANAL SURVIVAL DATA
   DASILVA ZJ, AIDS IN PRESS
   *EXP PROGR IMM, 1985, WKLY EPIDEMIOL REC, V60, P13
   Hull HF, 2001, AM J EPIDEMIOL, V153, P215, DOI 10.1093/aje/153.3.215
   Khare Shashi, 1993, Indian Journal of Pediatrics, V60, P275, DOI 10.1007/BF02822191
   Roth A, 2006, EXPERT REV VACCINES, V5, P277, DOI 10.1586/14760584-5.2.277
   WECKX LY, 1992, B WORLD HEALTH ORGAN, V70, P85
   World Health Organization, IMM POL GLOB PROGR V
NR 16
TC 0
Z9 0
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 29
PY 2008
VL 3
IS 12
AR e4056
DI 10.1371/journal.pone.0004056
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 437DI
UT WOS:000265466000016
OA gold
DA 2017-08-15
ER

PT J
AU Yukich, JO
   Lengeler, C
   Tediosi, F
   Brown, N
   Mulligan, JA
   Chavasse, D
   Stevens, W
   Justino, J
   Conteh, L
   Maharaj, R
   Erskine, M
   Mueller, DH
   Wiseman, V
   Ghebremeskel, T
   Zerom, M
   Goodman, C
   McGuire, D
   Urrutia, JM
   Sakho, F
   Hanson, K
   Sharp, B
AF Yukich, Joshua O.
   Lengeler, Christian
   Tediosi, Fabrizio
   Brown, Nick
   Mulligan, Jo-Ann
   Chavasse, Des
   Stevens, Warren
   Justino, John
   Conteh, Lesong
   Maharaj, Rajendra
   Erskine, Marcy
   Mueller, Dirk H.
   Wiseman, Virginia
   Ghebremeskel, Tewolde
   Zerom, Mehari
   Goodman, Catherine
   McGuire, David
   Urrutia, Juan Manuel
   Sakho, Fana
   Hanson, Kara
   Sharp, Brian
TI Costs and consequences of large-scale vector control for malaria
SO MALARIA JOURNAL
LA English
DT Article
ID INSECTICIDE-TREATED NETS; COVERAGE; BEDNETS; AFRICA; PROGRAM; MORBIDITY;
   MORTALITY; ERITREA; KENYA
AB Background: Five large insecticide-treated net (ITN) programmes and two indoor residual spraying (IRS) programmes were compared using a standardized costing methodology.
   Methods: Costs were measured locally or derived from existing studies and focused on the provider perspective, but included the direct costs of net purchases by users, and are reported in 2005 USD. Effectiveness was estimated by combining programme outputs with standard impact indicators.
   Findings: Conventional ITNs: The cost per treated net-year of protection ranged from USD 1.21 in Eritrea to USD 6.05 in Senegal. The cost per child death averted ranged from USD 438 to USD 2,199 when targeting to children was successful.
   Long-lasting insecticidal nets (LLIN) of five years duration: The cost per treated-net year of protection ranged from USD 1.38 in Eritrea to USD 1.90 in Togo. The cost per child death averted ranged from USD 502 to USD 692.
   IRS: The costs per person-year of protection for all ages were USD 3.27 in KwaZulu Natal and USD 3.90 in Mozambique. If only children under five years of age were included in the denominator the cost per person-year of protection was higher: USD 23.96 and USD 21.63. As a result, the cost per child death averted was higher than for ITNs: USD 3,933-4,357.
   Conclusion: Both ITNs and IRS are highly cost-effective vector control strategies. Integrated ITN free distribution campaigns appeared to be the most efficient way to rapidly increase ITN coverage. Other approaches were as or more cost-effective, and appeared better suited to "keep-up" coverage levels. ITNs are more cost-effective than IRS for highly endemic settings, especially if high ITN coverage can be achieved with some demographic targeting.
C1 [Yukich, Joshua O.; Lengeler, Christian; Tediosi, Fabrizio; Brown, Nick; Conteh, Lesong] Swiss Trop Inst, Dept Epidemiol & Publ Hlth, CH-4002 Basel, Switzerland.
   [Tediosi, Fabrizio] Univ Boconi, Ctr Res Hlth & Social Care Management, Milan, Italy.
   [Brown, Nick] Minist Hlth, Natl Malaria Control Programme, ITN Cell, Dar Es Salaam, Tanzania.
   [Mulligan, Jo-Ann; Conteh, Lesong; Mueller, Dirk H.; Wiseman, Virginia; Goodman, Catherine; Hanson, Kara] London Sch Hyg & Trop Med, Hlth Econ & Financing Programme, London WC1E 7HT, England.
   [Chavasse, Des] Populat Serv Int, Nairobi, Kenya.
   [Stevens, Warren] MRC Labs, Banjul, Gambia.
   [Justino, John] Populat Serv Int, Blantyre, Malawi.
   [Maharaj, Rajendra] Med Res Council S Afr, Malaria Lead Programme, Durban, KwaZulu Natal, South Africa.
   [Erskine, Marcy] Canadian Red Cross, Ottawa, ON, Canada.
   [Ghebremeskel, Tewolde; Zerom, Mehari] Minist Hlth, Natl Malaria Control Programme, Asmera, Eritrea.
   [Goodman, Catherine] KEMRI Wellcome Trust Programme, Nairobi, Kenya.
   [McGuire, David] ABT Associates Inc, Bethesda, MD USA.
   [Urrutia, Juan Manuel] Acad Educ Dev, Johannesburg, South Africa.
   [Sakho, Fana] Acad Educ Dev, Dakar, Senegal.
RP Lengeler, C (reprint author), Swiss Trop Inst, Dept Epidemiol & Publ Hlth, CH-4002 Basel, Switzerland.
EM joshua.yukich@unibas.ch; christian.lengeler@unibas.ch;
   fabrizio.tediosi@unibas.ch; nick.brown@natnets.org;
   jo.mulligan@lshtm.ac.uk; chavasse@psikenya.org;
   warren.stevens@lshtm.ac.uk; jjustino@PSIMalawi.org;
   lesong.conteh@unibas.ch; rajendra.maharaj@mrc.ac.za;
   marcy.erskine@gmail.com; dirk.mueller@lshtm.ac.uk;
   virginia.wiseman@lshtm.ac.uk; tewoldeg2003@yahoo.com;
   meharizerom@yahoo.com; cgoodman@nairobi.kemri-wellcome.org;
   david_mcguire@abtassoc.com; jurrutia@aed.org; fsakho@aed.org;
   kara.hanson@lshtm.ac.uk; sharpb@mrc.ac.za
RI Agyemang, Samuel/H-8377-2014
OI Tediosi, Fabrizio/0000-0001-8671-9400
CR *AC ED DEV, 2005, NETMARK CAS STUD SUS
   Aikins MK, 1998, SOC SCI MED, V46, P181, DOI 10.1016/S0277-9536(97)00145-7
   Baume CA, 2007, AM J TROP MED HYG, V77, P963
   Breman JG, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P413
   CHAVASSE D, 2001, ESSENTIAL DRUGS MONI, V30
   Conteh L, 2004, TROP MED INT HEALTH, V9, P125, DOI 10.1046/j.1365-3156.2003.01150.x
   Curtis C, 2003, LANCET INFECT DIS, V3, P304, DOI 10.1016/S1473-3099(03)00612-1
   Curtis C, 2001, B WORLD HEALTH ORGAN, V79, P687
   Curtis CF, 2000, B WORLD HEALTH ORGAN, V78, P1389
   Curtis CF, 1998, TROP MED INT HEALTH, V3, P619
   Goodman CA, 1999, LANCET, V354, P378, DOI 10.1016/S0140-6736(99)02141-8
   Goodman CA, 2001, TROP MED INT HEALTH, V6, P280, DOI 10.1046/j.1365-3156.2001.00700.x
   Grabowsky M, 2005, B WORLD HEALTH ORGAN, V83, P195
   Grabowsky M, 2007, TROP MED INT HEALTH, V12, P815, DOI 10.1111/j.1365-3156.2007.01862.x
   Guyatt HL, 2002, HEALTH POLICY PLANN, V17, P144, DOI 10.1093/heapol/17.2.144
   Hawley WA, 2003, AM J TROP MED HYG, V68, P121
   Killeen GF, 2007, PLOS MED, V4, P1246, DOI 10.1371/journal.pmed.0040229
   Kolaczinski J, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-37
   Lalloo DG, 2006, LANCET INFECT DIS, V6, P780, DOI 10.1016/S1473-3099(06)70655-7
   Lengeler C, 2001, B WORLD HEALTH ORGAN, V79, P77
   LENGELER C, 2004, COCHRANE DATABASE SY, DOI 10.1002/14651858.CD000363
   Lengeler C., 2003, REDUCING MALARIAS BU, P17
   Lengeler C, 2007, AM J TROP MED HYG, V77, P222
   Lengeler C, 2007, LANCET, V370, P1009, DOI 10.1016/S0140-6736(07)61454-8
   Lines J, 2003, LANCET INFECT DIS, V3, P465, DOI 10.1016/S1473-3099(03)00717-5
   Macintyre K, 2006, TROP MED INT HEALTH, V11, P824, DOI 10.1111/j.1365-3156.2006.01637.x
   Magesa SM, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-34
   Mnzava AEP, 1998, S AFR MED J, V88, P1024
   Mueller DH, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-73
   Mulligan JA, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-32
   N'Guessan R, 2001, MED VET ENTOMOL, V15, P97, DOI 10.1046/j.1365-2915.2001.00284.x
   Noor AM, 2007, PLOS MED, V4, P1341, DOI 10.1371/journal.pmed.0040255
   Nyarango PM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-33
   *PRES MAL IN, PRES MAL IN IND RES
   Roll Back Malaria, 2005, GLOB STRAT PLAN ROLL
   Stevens W, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-22
   Tami A, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-19
   TANSER FC, 2007, COCHRANE DATABASE SY
   Teklehaimanot A, 2007, LANCET, V369, P2143, DOI [10.1016/S0140-6736(07)60951-9, 10.1016/S01406736(07)60951-9]
   *UN SECR, WORLD POP PROSP 2004
   *US BUR EC AN, US IMPL PRIC DEFL GR
   *US CDCP, 2005, MMWR-MORBID MORTAL W, V54, P994
   Webster J, 2007, HEALTH POLICY PLANN, V22, P277, DOI 10.1093/heapol/czm021
   *WHO, CHOOS INT WHICH AR C
   World Health Organization, WORLD HLTH REP 2006
   World Health Organisation, 2004, SOURC PRIC SEL PROD
   World Health Organization [webpage on the Internet], DIS ADJ LIF YEARS DA
   WHO, 2007, INS TREAT MOSQ NETS
   Worrall E, 2007, TROP MED INT HEALTH, V12, P75, DOI 10.1111/j.1365-3156.2006.01772.x
   YUKICH J, 2005, OPERATIONS COSTS COS
   MAPPING MALARIA RISK
NR 51
TC 78
Z9 78
U1 1
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD DEC 17
PY 2008
VL 7
AR 258
DI 10.1186/1475-2875-7-258
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 409ZF
UT WOS:000263543600001
PM 19091114
OA gold
DA 2017-08-15
ER

PT J
AU Arrive, E
   Marquis, B
   Timwesigye, N
   Brinkhof, MWG
   Fassinou, P
   Cotton, M
   Wemin, L
   Boulle, A
   Holland, M
   Renner, L
   Kariyo, P
   Aveika, A
   Azondekon, A
   Carter, R
   Kieffer, MP
   Namale, L
   Newell, ML
   Mbori-Ngacha, D
   Dabis, F
AF Arrive, Elise
   Marquis, Benoit
   Timwesigye, Nathan
   Brinkhof, Martin W. G.
   Fassinou, Patricia
   Cotton, Mark
   Wemin, Louise
   Boulle, Andrew
   Holland, Margaret
   Renner, Lorna
   Kariyo, Pierre
   Aveika, Akum
   Azondekon, Alain
   Carter, Rosalind
   Kieffer, Maiy-Pat
   Namale, Leticia
   Newell, Marie-Louise
   Mbori-Ngacha, Dorothy
   Dabis, Francois
CA KIDS-ART-LINC Collaborat
TI Low Risk of Death, but Substantial Program Attrition, in Pediatric HIV
   Treatment Cohorts in Sub-Saharan Africa
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE antiretroviral treatment; children; death; HIV; loss to follow-up;
   sub-Saharan Africa
ID ACTIVE ANTIRETROVIRAL THERAPY; RESOURCE-LIMITED SETTINGS; HIV-1-INFECTED
   CHILDREN; INFECTED CHILDREN; INCOME COUNTRIES; FOLLOW-UP; SURVIVAL;
   OUTCOMES; MORTALITY; MALAWI
AB Background: To date, an estimated 10% of children eligible for antiretroviral treatment (ART.) receive it, and the frequency Of retention in programs is unknown. We evaluated the 2-year risks of death and loss to follow-up (LTFU) of children after ART initiation in a Multicenter Study in sub-Saharan Africa.
   Methods: Pooled analysis of routine individual data from 16 participating clinics produced overall Kaplan-Meier estimates of the probabilities of death or LTFU after ART initiation. Risk factors analysis used Weibull regression, accounting for between-cohort heterogeneity.
   Results: The median age of 2405 children at ART initiation was 4.9 years (12%, younger than 12 months), 52% were male, 70% had severe immunodeficiency, and 59% started ART with a nonnucleoside reverse transcriptase inhibitor. The 2-year risk of death after ART initiation was 6.9% (95% confidence interval [CI]: 5.9 to 8.1), independently associated with baseline severe anemia (adjusted hazard ratio [aHR]: 4.10 [CI: 2.36 to 7.13]), immunodeficiency (adjusted aHR: 2.95 [CI: 1.49 to 5.82]), and severe clinical status (adjusted aHR: 3.64 [CI: 1.95 to 6.81]); the 2-year risk of LTFU was 10.3% (CI: 8.9 to 11.9), higher in children with severe clinical Status.
   Conclusions: Once on treatment, the 2-year risk of death is low but the LTFU risk is substantial. ART is still mainly initiated at advanced disease stage in African children, reinforcing the need for early HIV diagnosis, early initiation of ART, and procedures to increase program retention.
C1 [Marquis, Benoit] Inst Sante Publ & Dev ISPED, INSERM, U897, Bordeaux, France.
   [Timwesigye, Nathan] African Network Care Children Affected AIDS, Kampala, Uganda.
   [Brinkhof, Martin W. G.] Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland.
   [Fassinou, Patricia] Univ Yopougon, Ctr Hosp, Abidjan, Cote Ivoire.
   [Cotton, Mark] Tygerberg Childrens Hosp, Cape Town, South Africa.
   [Wemin, Louise] ACONDA, Ctr Prise Charge Rech & Format CEPREF Enfants, Abidjan, Cote Ivoire.
   [Boulle, Andrew] Khayelitsha Hosp, Cape Town, South Africa.
   [Holland, Margaret] Connaught Clin, Harare, Zimbabwe.
   [Renner, Lorna] Korle Bu Hosp, Accra, Ghana.
   [Kariyo, Pierre] ANSS, Bujumbura, Burundi.
   [Aveika, Akum] MRC, Fajara, Gambia.
   [Azondekon, Alain] UPEIV, Hop Intruct Armees, Cotonou, Benin.
   [Carter, Rosalind] Columbia Univ, MTCT Plus Network, New York, NY USA.
   [Kieffer, Maiy-Pat] USAID, Nairobi, Kenya.
   [Namale, Leticia] ANECCA, Kampala, Uganda.
   [Mbori-Ngacha, Dorothy] Univ Nairobi, Nairobi, Kenya.
RP Dabis, F (reprint author), Univ Bordeaux 2, Inst Sante Publ, INSERM, Epidemiol & Dev Case 11,ISPED,U897, F-33076 Bordeaux, France.
EM francois.dabis@isped.u-bordeaux2.fr
RI Leroy, Valeriane/F-8129-2013
OI Leroy, Valeriane/0000-0003-3542-8616; Prozesky,
   Hans/0000-0001-9715-3449; Newell, Marie-Louise/0000-0002-1074-7699;
   Weigel, Ralf/0000-0001-9034-2634
FU US National Institutes of Health/Office of AIDS Research; United States
   Agency for International Development East Africa; French Agence
   Nationale de Recherche sur le Sida et les hepatitis virates [12147]; The
   International epidemiological Databases to Evaluate AIDS; National
   Institutes of Health/National Institute of Allergy and Infectious
   Diseases; KIDS-ART-LINC Collaboration
FX Supported by US National Institutes of Health/Office of AIDS Research
   and United States Agency for International Development East Africa
   (2005-2007) and French Agence Nationale de Recherche sur le Sida et les
   hepatitis virates Grant 12147 (2007). The International epidemiological
   Databases to Evaluate AIDS project of the National Institutes of
   Health/National Institute of Allergy and Infectious Diseases provided
   additional support to the KIDS-ART-LINC Collaboration in 2006-2007.
CR Anglaret X, 2004, JAIDS-J ACQ IMM DEF, V35, P320, DOI 10.1097/00126334-200403010-00015
   ARRIVE E, 2007, INT J EPIDEMIOL, V37, P474
   Bolton-Moore C, 2007, JAMA-J AM MED ASSOC, V298, P1888, DOI 10.1001/jama.298.16.1888
   Bong CN, 2007, AIDS, V21, P1805, DOI 10.1097/QAD.0b013e3282c3a9e4
   Braitstein P, 2006, LANCET, V367, P817
   Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248
   Chintu C, 2004, LANCET, V364, P1865, DOI 10.1016/S0140-6736(04)17442-4
   Division of AIDS (DAIDS), TABL GRAD SEV AD PED
   Diack MB, 2005, ARCH PEDIATR, V12, P404
   Eley B, 2006, SAMJ S AFR MED J, V96, P988
   Fassinou P, 2004, AIDS, V18, P1905, DOI 10.1097/00002030-200409240-00006
   George E, 2007, J INFECT DIS, V195, P1411, DOI 10.1086/514823
   Giordano TP, 2007, CLIN INFECT DIS, V44, P1493, DOI 10.1086/516778
   Hesseling AC, 2005, ARCH DIS CHILD, V90, P1171, DOI 10.1136/adc.2004.070466
   Jones SA, 2005, AIDS CARE, V17, P466, DOI 10.1080/09540120412331319723
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   KARIYO P, 2006, 16 INT AIDS C AUG 13
   Lockman S, 2007, NEW ENGL J MED, V356, P135, DOI 10.1056/NEJMoa062876
   Manzi M, 2005, TROP MED INT HEALTH, V10, P1242, DOI 10.1111/j.1365-3156.2005.01526.x
   MBEWE M, 2006, 16 INT AIDS C AUG 13
   MBORINGACHA D, 2006, 16 INT AIDS C AUG 13
   Nardi A, 2003, STAT MED, V22, P3597, DOI 10.1002/sim.1592
   Niekerk NKMV, 2006, J TROP PEDIATRICS, V52, P3, DOI 10.1093/tropej/fmi047
   Nyandiko WM, 2006, JAIDS-J ACQ IMM DEF, V43, P418, DOI 10.1097/01.qai.0000243122.52282.89
   O'Brien DP, 2007, CLIN INFECT DIS, V44, P1245, DOI 10.1086/513433
   O'Brien DP, 2006, AIDS, V20, P1955, DOI 10.1097/01.aids.0000247117.66585.ce
   Puthanakit T, 2005, CLIN INFECT DIS, V41, P100, DOI 10.1086/430714
   Reddi Anand, 2007, BMC Pediatr, V7, P13, DOI 10.1186/1471-2431-7-13
   Rouet F, 2006, AIDS, V20, P2315, DOI 10.1097/QAD.0b013e328010943b
   Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301
   UNAIDS, 2007, AIDS EP UPD
   Violari A, 2007, 4 IAS C HIV PATH TRE
   *WHO, CHILDR AIDS STOCKT R
   World Health Organization, ANT THER HIV INF INF
   *WHO, UN ACC SCAL PRIOR HI
NR 35
TC 10
Z9 10
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 15
PY 2008
VL 49
IS 5
BP 523
EP 531
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 376YN
UT WOS:000261219000010
OA No
DA 2017-08-15
ER

PT J
AU Idoko, OT
   Okoko, BJ
   Sow, S
   Tapia, M
   Preziosi, MP
   Marchetti, E
   Haidara, FC
   Martellet, L
   Chaumont, J
   Parulekar, V
   Plikaytis, B
   Borrow, R
   Carlone, G
   Adegbola, R
   Preaud, JM
   Kulkarni, P
   Kapre, S
   Jadhav, S
   Hassan-King, M
   LaForce, M
   Viviani, S
   Findlow, H
   Elie, C
AF Idoko, Olubukola T.
   Okoko, Brown J.
   Sow, Samba
   Tapia, Milagritos
   Preziosi, Marie-Pierre
   Marchetti, Elisa
   Haidara, Fadima C.
   Martellet, Lionel
   Chaumont, Julie
   Parulekar, Varsha
   Plikaytis, Brian
   Borrow, Ray
   Carlone, George
   Adegbola, Richard
   Preaud, Jean-Marie
   Kulkarni, Prasad
   Kapre, Subhash
   Jadhav, Suresh
   Hassan-King, Musa
   LaForce, Marc
   Viviani, Simonetta
   Findlow, Helen
   Elie, Cheryl
TI A PHASE II, OBSERVER BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE
   SAFETY, IMMUNOGENICITY AND IMMUNOLOGICAL MEMORY OF A BOOSTER DOSE OF A
   NEW GROUP A MENINGOCOCCAL CONJUGATE VACCINE (MENAFRIVAC (TM)) IN HEALTHY
   AFRICAN CHILDREN PREVIOUSLY PRIMED AT 12-23 MONTHS OF AGE
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [Idoko, Olubukola T.; Okoko, Brown J.; Adegbola, Richard] MRC, Banjul, Gambia.
   [Sow, Samba; Tapia, Milagritos; Haidara, Fadima C.] CVD Mali, Bamako, Mali.
   [Preziosi, Marie-Pierre] WHO, Initiat Vaccine Res, Meningitis Vaccine Project, CH-1211 Geneva, Switzerland.
   [Marchetti, Elisa; Martellet, Lionel; Chaumont, Julie; Preaud, Jean-Marie; Hassan-King, Musa; LaForce, Marc; Viviani, Simonetta] PATH, Meningitis Vaccine Project, Ferney Voltaire, France.
   [Parulekar, Varsha] iGATE Clin Res Unit, Bombay, Maharashtra, India.
   [Plikaytis, Brian; Carlone, George; Elie, Cheryl] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Borrow, Ray; Findlow, Helen] Hlth Protect Agcy, Vaccine Evaluat Unit, Manchester, Lancs, England.
   [Kulkarni, Prasad; Kapre, Subhash; Jadhav, Suresh] SIIL, Pune, Maharashtra, India.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
MA 264
BP 77
EP 77
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644600265
OA No
DA 2017-08-15
ER

PT J
AU Bojaing, KA
   Akor, F
   Conway, D
   Milligan, P
   Bittaye, O
   Greenwood, B
AF Bojaing, Kalifa A.
   Akor, Francis
   Conway, David
   Milligan, Paul
   Bittaye, Ousman
   Greenwood, Brian
TI A RANDOMISED TRIAL TO COMPARE THE SAFETY, TOLERABILITY AND EFFICACY OF
   THREE POTENTIAL DRUG COMBINATIONS FOR INTERMITTENT PREVENTIVE TREATMENT
   IN CHILDREN AGED ONE TO FIVE YEARS IN AN AREA OF SEASONAL MALARIA
   TRANSMISSION IN UPPER RIVER REGION, THE GAMBIA
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [Bojaing, Kalifa A.; Akor, Francis; Conway, David; Bittaye, Ousman] MRC Labs, Banjul, Gambia.
   [Milligan, Paul; Greenwood, Brian] London Sch Hyg & Trop Med, London WC1, England.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
MA 726
BP 214
EP 214
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644601091
OA No
DA 2017-08-15
ER

PT J
AU Kirby, MJ
   Milligan, PJ
   Jasseh, M
   Conway, DJ
   Lindsay, SW
AF Kirby, Matthew J.
   Milligan, Paul J.
   Jasseh, Momodou
   Conway, David J.
   Lindsay, Steve W.
TI SCREENING HOMES TO PREVENT MALARIA: A RANDOMISED CONTROLLED TRIAL
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [Kirby, Matthew J.; Lindsay, Steve W.] Univ Durham, Durham, England.
   [Milligan, Paul J.; Conway, David J.] London Sch Hyg & Trop Med, London WC1, England.
   [Jasseh, Momodou] MRC Labs, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
MA 735
BP 217
EP 217
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644601100
OA No
DA 2017-08-15
ER

PT J
AU Cheeseman, IH
   Gomez-Escobar, N
   Carret, C
   Ivens, A
   Tetteh, KK
   Stewart, L
   Walther, M
   Kwiatkowski, D
   Conway, D
AF Cheeseman, Ian H.
   Gomez-Escobar, Natalia
   Carret, Celine
   Ivens, Alasdair
   Tetteh, Kevin K.
   Stewart, Lindsay
   Walther, Micheal
   Kwiatkowski, Dominic
   Conway, David
TI GENOME-WIDE SURVEY OF GENE COPY NUMBER VARIATION IN THE MALARIA PARASITE
   PLASMODIUM FALCIPARUM
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [Cheeseman, Ian H.; Gomez-Escobar, Natalia; Walther, Micheal; Conway, David] MRC Gambia, Banjul, Gambia.
   [Carret, Celine; Ivens, Alasdair; Kwiatkowski, Dominic] Wellcome Trust Sanger Inst, Cambridge, England.
   [Tetteh, Kevin K.; Stewart, Lindsay] London Sch Hyg & Trop Med, London WC1, England.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
MA 773
BP 228
EP 228
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644601138
OA No
DA 2017-08-15
ER

PT J
AU Pinder, M
   Majambere, S
   Ameh, D
   Jeffries, D
   Jawara, M
   Kelly, A
   Green, C
   Hutchinson, R
   Conway, D
   Lindsay, S
AF Pinder, Margaret
   Majambere, Silas
   Ameh, David
   Jeffries, David
   Jawara, Musa
   Kelly, Ann
   Green, Clare
   Hutchinson, Robert
   Conway, David
   Lindsay, Steve
TI IMPACT OF LARVICIDING ON MALARIA IN THE GAMBIA
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [Pinder, Margaret; Majambere, Silas; Hutchinson, Robert; Lindsay, Steve] Univ Durham, Durham, England.
   [Ameh, David; Jeffries, David; Jawara, Musa; Conway, David] MRC Labs, Banjul, Gambia.
   [Kelly, Ann] London Sch Hyg & Trop Med, London WC1, England.
   [Green, Clare] Ctr Infect Dis & Int Hlth, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
MA 793
BP 234
EP 234
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644601158
OA No
DA 2017-08-15
ER

PT J
AU Haidara, FC
   Sow, SO
   Brown, O
   Dia, A
   Iosi, MPP
   Marcheti, E
   Chaumont, J
   Tapia, M
   Agdebola, R
   Idoko, I
   Arduin, P
   Borrow, R
   Carlone, G
   Akinsola, A
   Parulekar, V
   Plikyatis, B
   Findlow, J
   Elie, C
   Laforce, M
   Kulkarni, P
   Viviani, S
AF Haidara, Fadima Cheick
   Sow, Samba O.
   Brown, Okoko
   Dia, Aldjouma
   Iosi, Marie Pierre Prez
   Marcheti, Elisa
   Chaumont, Julie
   Tapia, Milagritos
   Agdebola, Richard
   Idoko, Ilubukola
   Arduin, Pascal
   Borrow, Ray
   Carlone, Georges
   Akinsola, Adebayo
   Parulekar, Varsha
   Plikyatis, Brian
   Findlow, Jamie
   Elie, Cheryl
   Laforce, Marc
   Kulkarni, Prasad
   Viviani, Simonetta
TI SAFETY AND IMMUNOGENICITY OF A NEW MENINGOCOCCAL A CONJUGATE VACCINE IN
   A HEALTHY AFRICAN POPULATION AGED 2-29 YEARS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [Haidara, Fadima Cheick; Sow, Samba O.] Ctr Vaccine Dev Mali, Bamako, Mali.
   [Brown, Okoko] MRC Gambia, Banjul, Gambia.
   [Dia, Aldjouma; Arduin, Pascal] IRD Dakar, Dakar, Senegal.
   [Iosi, Marie Pierre Prez] WHO, MVP, CH-1211 Geneva, Switzerland.
   [Marcheti, Elisa; Chaumont, Julie; Laforce, Marc; Viviani, Simonetta] MVP France, Ferney, France.
   [Tapia, Milagritos] Ctr Vaccine Dev Mali, Baltimore, MD USA.
   [Agdebola, Richard; Idoko, Ilubukola; Akinsola, Adebayo] MRC Gambia, Fajara, Gambia.
   [Borrow, Ray; Findlow, Jamie] HPA, Manchester, Lancs, England.
   [Carlone, Georges; Plikyatis, Brian; Elie, Cheryl] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Parulekar, Varsha] IGATE, Bombay, Maharashtra, India.
   [Kulkarni, Prasad] SIIL, Pune, Maharashtra, India.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
MA 883
BP 260
EP 260
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644601248
OA No
DA 2017-08-15
ER

PT J
AU Gomez-Escobar, N
   Ngwa, A
   Walther, M
   Okebe, J
   Ebonyi, A
   Conway, D
AF Gomez-Escobar, Natalia
   Ngwa, Alfred
   Walther, Michael
   Okebe, Joseph
   Ebonyi, Augustine
   Conway, David
TI ERYTHROCYTE INVASION AND VARIATION IN MEROZOITE LIGAND GENE EXPRESSION
   IN PLASMODIUM FALCIPARUM
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [Gomez-Escobar, Natalia; Ngwa, Alfred; Walther, Michael; Okebe, Joseph; Ebonyi, Augustine; Conway, David] MRC Labs, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
MA 930
BP 273
EP 274
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644601295
OA No
DA 2017-08-15
ER

PT J
AU Ngwa, AA
   Conway, DJ
AF Ngwa, Alfred A.
   Conway, David J.
TI DIVERSITY OF PLASMODIUM FALCIPARUM PLASTOME IN GAMBIAN ISOLATES
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [Ngwa, Alfred A.; Conway, David J.] Med Res Council UK Labs, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
MA 933
BP 274
EP 274
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644601298
OA No
DA 2017-08-15
ER

PT J
AU Satoguina, JS
   Oriero, EC
   Nwakanma, D
   Ebonyi, A
   Okebe, J
   Vincent, T
   Gomez-Escobar, N
   Corran, P
   Riley, E
   Conway, D
   Walther, M
AF Satoguina, Judith S.
   Oriero, Eniyou C.
   Nwakanma, Davis
   Ebonyi, Augustine
   Okebe, Joseph
   Vincent, Tim
   Gomez-Escobar, Natalia
   Corran, Patrick
   Riley, Eleanor
   Conway, David
   Walther, Michael
TI ALTERED MALARIA ENDEMICITY IN RURAL COMMUNITIES IN THE GAMBIA AND IN
   GUINEA BISSAU
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [Satoguina, Judith S.; Oriero, Eniyou C.; Nwakanma, Davis; Ebonyi, Augustine; Okebe, Joseph; Vincent, Tim; Gomez-Escobar, Natalia; Conway, David; Walther, Michael] MRC, Banjul, Gambia.
   [Corran, Patrick; Riley, Eleanor] London Sch Hyg & Trop Med, London WC1, England.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
MA 1016
BP 299
EP 299
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644601380
OA No
DA 2017-08-15
ER

PT J
AU della Torre, A
   Santolamazza, F
   Caputo, B
   Mancini, E
   Palsson, K
   Nwakanama, D
   Jawara, M
   Conway, D
   Tu, ZJ
   Petrarca, V
   Pinto, J
AF della Torre, Alessandra
   Santolamazza, Federica
   Caputo, Beniamino
   Mancini, Emiliano
   Palsson, Katinka
   Nwakanama, Davis
   Jawara, Musa
   Conway, David
   Tu, Zhijian
   Petrarca, Vincenzo
   Pinto, Joao
TI HIGH HYBRIDIZATION RATE BETWEEN ANOPHELES GAMBIAE MOLECULAR FORMS AT THE
   WESTERN EXTREME OF THEIR RANGE HIGHLIGHTS POSSIBLE GENE-FLOW IN THE
   X-CHROMOSOME "SPECIATION ISLAND"
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [della Torre, Alessandra; Santolamazza, Federica; Caputo, Beniamino; Mancini, Emiliano] Univ Roma La Sapienza, Dip Sci Sanita Pubbl, Rome, Italy.
   [Palsson, Katinka] Uppsala Univ, Evolutionary Biol Ctr, Dept Systemat Zool, Norbyvagen, Sweden.
   [Nwakanama, Davis; Jawara, Musa; Conway, David] MRC, Fajara, Gambia.
   [Tu, Zhijian] Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA.
   [Petrarca, Vincenzo] Univ Roma La Sapienza, Dip Genet & Biol Mol, Rome, Italy.
   [Pinto, Joao] Univ Nova Lisboa, Inst Higiene & Med Trop, Ctr Malaria & Outras Doencas Trop, P-1200 Lisbon, Portugal.
RI Mancini, Emiliano/G-4771-2012; Caputo, Beniamino/I-2880-2015
OI Caputo, Beniamino/0000-0002-5650-8773
NR 0
TC 0
Z9 0
U1 0
U2 4
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
MA 1168
BP 343
EP 343
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644601531
OA No
DA 2017-08-15
ER

PT J
AU Helbok, R
   Kendjo, E
   Issifou, S
   Lackner, P
   Newton, CR
   Kombila, M
   Agbenyega, T
   Dietz, K
   Bojang, K
   Schmutzhard, E
   Kremsner, PG
AF Helbok, Raimund
   Kendjo, Eric
   Issifou, Saadou
   Lackner, Peter
   Newton, Charles R.
   Kombila, Maryvonne
   Agbenyega, Tsiri
   Dietz, Klaus
   Bojang, Kalifa
   Schmutzhard, Erich
   Kremsner, Peter G.
TI THE LAMBARENE-ORGAN-DYSFUNCTION SCORE (LODS) IS A SIMPLE CLINICAL
   PREDICTOR FOR FATAL MALARIA IN AFRICAN CHILDREN
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [Helbok, Raimund; Kendjo, Eric; Issifou, Saadou; Kremsner, Peter G.] Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon.
   [Helbok, Raimund] Innsbruck Med Univ, Dept Clin Neurol, Innsbruck, Austria.
   [Kendjo, Eric; Issifou, Saadou; Kremsner, Peter G.] Univ Tubingen, Inst Trop Med, Dept Parasitol, Tubingen, Germany.
   [Lackner, Peter; Schmutzhard, Erich] Innsbruck Med Univ, Dept Clin Neurol, Innsbruck, Austria.
   [Newton, Charles R.] Kenya Govt Med Res Ctr, Ctr Geog Med, Kilifi, Kenya.
   [Newton, Charles R.] UCL, Neurosci Unit, Inst Child Hlth, London, England.
   [Kombila, Maryvonne] Univ Hlth Sci Libreville, Fac Med, Dept Parasitol Mycol & Trop Med, Libreville, Gabon, Gabon.
   [Agbenyega, Tsiri] Univ Sci & Technol Kumasi, Sch Med Sci, Kumasi, Ghana.
   [Dietz, Klaus] Univ Tubingen, Dept Med Biometry, Tubingen, Germany.
   [Bojang, Kalifa] MRC Labs, Banjul, Gambia.
RI Newton, Charles/C-6222-2009
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
SU S
MA 1190
BP 350
EP 350
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644601553
OA No
DA 2017-08-15
ER

PT J
AU Harding-Esch, E
   Holland, MJ
   Sillah, A
   Molina, S
   Aguirre-Andreasen, A
   Snell, P
   Edwards, T
   Bailey, RL
   Mabey, DC
AF Harding-Esch, Emma
   Holland, Martin J.
   Sillah, Ansumana
   Molina, Sandra
   Aguirre-Andreasen, Aura
   Snell, Paul
   Edwards, Tansy
   Bailey, Robin L.
   Mabey, David C.
TI IMPACT OF MASS AZITHROMYCIN TREATMENT ON THE PREVALENCE OF ACTIVE
   TRACHOMA AND OCULAR CHLAMYDIA TRACHOMATIS IN THE GAMBIA
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [Harding-Esch, Emma; Holland, Martin J.; Molina, Sandra; Aguirre-Andreasen, Aura; Edwards, Tansy; Bailey, Robin L.; Mabey, David C.] London Sch Hyg & Trop Med, London WC1, England.
   [Sillah, Ansumana] Natl Eye Care Programme, Banjul, Gambia.
   [Snell, Paul] MRC Labs, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
MA 1225
BP 360
EP 360
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644601588
OA No
DA 2017-08-15
ER

PT J
AU Finney, O
   Lawrence, E
   Satoguina, J
   Conway, D
   Riley, E
   Walther, M
AF Finney, Olivia
   Lawrence, Emma
   Satoguina, Judith
   Conway, David
   Riley, Eleanor
   Walther, Michael
TI CO-CULTURE WITH PLASMODIUM FALCIPARUM-INFECTED RED BLOOD CELLS INDUCES
   DIFFERENTIATION OF FUNCTIONALLY COMPETENT REGULATORY T CELLS FROM
   LYMPHOCYTES OF MALARIA-NAIVE DONORS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY DEC 07-11, 2008
CL New Orleans, LA
SP Amer Soc Trop Med & Hyg
C1 [Finney, Olivia; Riley, Eleanor] LSHTM, London, England.
   [Lawrence, Emma] Univ Manchester, Manchester, Lancs, England.
   [Satoguina, Judith; Conway, David; Walther, Michael] MRC, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD DEC
PY 2008
VL 79
IS 6
MA 1229
BP 361
EP 361
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 382ZT
UT WOS:000261644601592
OA No
DA 2017-08-15
ER

PT J
AU Stokes, E
   Dumbaya, I
   Owens, S
   Brabin, L
AF Stokes, E.
   Dumbaya, I.
   Owens, S.
   Brabin, L.
TI The right to remain silent: a qualitative study of the medical and
   social ramifications of pregnancy disclosure for Gambian women
SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Article
DE Antenatal care; drugs; Gambia; informed decision-making; pregnancy
ID INTERMITTENT PREVENTIVE TREATMENT; MALARIA; CARE; CHALLENGES; COMMUNITY;
   EXPOSURE; GOSSIP
AB Control of infectious diseases in developing countries often requires using drugs that are contraindicated during pregnancy. Avoiding inadvertent exposure to drugs involves women (a) recognising pregnancy early, (b) disclosing the pregnancy to health workers and (c) using medicines in an informed manner. We explored these factors to inform and improve the process by which health workers provide care and treatment to pregnant women.
   Qualitative study.
   The Gambia.
   Rural women and men.
   We conducted 41 interviews and 16 focus group discussions with women, adolescents, men and traditional birth attendants (TBAs).
   Pregnancy disclosure.
   Most women recognised early signs and symptoms of pregnancy and believed other people could easily do so. To avoid gossip, women hid their pregnancies and delayed antenatal care, even though husbands and TBAs insisted on attendance. Women acutely ill in early pregnancy hoped health workers would recognise pregnancy without explicit disclosure. Women said that they knew, and sought to avoid, some contraindicated drugs, but their knowledge was rudimentary. Health workers stressed the benefits, not the risks of prescribed drugs.
   Despite public health and clinical benefits of preventing and treating pregnancy infections, women were ill informed and pressurised into taking drugs. These ethical issues should be more widely addressed.
C1 [Stokes, E.; Brabin, L.] Univ Manchester, Acad Unit Obstet & Gynaecol, Manchester, Lancs, England.
   [Dumbaya, I.; Owens, S.] MRC, Keneba Field Stn, Keneba, Gambia.
RP Brabin, L (reprint author), St Marys Hosp, Acad Unit Obstet & Gynaecol, Res floor,Hathersage Rd, Manchester M13 OJH, Lancs, England.
EM loretta.brabin@manchester.ac.uk
FU Immpact (DFID, Bill and Melinda Gates Foundation, USAID)
FX The author's work is funded by Immpact (DFID, Bill and Melinda Gates
   Foundation, USAID) and the University of Aberdeen.
CR Anya Samuel E, 2008, BMC Pregnancy Childbirth, V8, P9, DOI 10.1186/1471-2393-8-9
   Caelli K., 2003, INT J QUAL METH, V2, P1
   CAMPBELL JD, 1996, APPL BEHAV SCI REV, V4, P81, DOI 10.1016/S1068-8595(96)80018-3
   Chapman RR, 2003, SOC SCI MED, V57, P355, DOI 10.1016/S0277-9536(02)00363-5
   Crawley J, 2007, LANCET INFECT DIS, V7, P145, DOI 10.1016/S1473-3099(07)70026-9
   De Martin S, 2001, TROP MED INT HEALTH, V6, P442, DOI 10.1046/j.1365-3156.2001.00723.x
   DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277-9536(92)90206-6
   Fenwick A, 2006, CURR OPIN INFECT DIS, V19, P577, DOI 10.1097/01.qco.0000247591.13671.6a
   GILMORE D, 1978, ETHNOLOGY, V17, P89, DOI 10.2307/3773282
   GLUCKMAN M, 1963, CURR ANTHROPOL, V4, P307, DOI 10.1086/200378
   Gyapong JO, 2003, TROP MED INT HEALTH, V8, P1093, DOI 10.1046/j.1360-2276.2003.01142.x
   HOMEDES N, 1993, HEALTH POLICY PLANN, V8, P291, DOI 10.1093/heapol/8.4.291
   Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142
   Lang T, 2006, LANCET INFECT DIS, V6, P46, DOI 10.1016/S1473-3099(05)70326-1
   LEVY M, 1991, AM J PERINAT, V8, P174, DOI 10.1055/s-2007-999371
   Maduka CU, 2004, ANN TROP MED PARASIT, V98, P697, DOI 10.1179/000349804225021497
   Malm H, 2004, DRUG SAFETY, V27, P899, DOI 10.2165/00002018-200427120-00006
   MEHTA D, 2008, BRIT NATL FORMULARY
   Mubyazi G, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-31
   Muula AS, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-97
   Ouma PO, 2007, TROP MED INT HEALTH, V12, P953, DOI 10.1111/j.1365-3156.2007.01876.x
   Peacock N R, 2001, Matern Child Health J, V5, P109
   *REP GAMB DEP STAT, 2001, STAND DRUG TREATM GU
   Schirm E, 2004, EUR J OBSTET GYN R B, V114, P182, DOI 10.1016/j.ejogrb.2003.10.024
   Tagbor HK, 2007, EXPERT OPIN DRUG SAF, V6, P631, DOI 10.1517/14740338.6.6.631
NR 25
TC 16
Z9 16
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1470-0328
J9 BJOG-INT J OBSTET GY
JI BJOG
PD DEC
PY 2008
VL 115
IS 13
BP 1641
EP 1647
DI 10.1111/j.1471-0528.2008.01950.x
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 370FO
UT WOS:000260748300009
PM 19035940
OA No
DA 2017-08-15
ER

PT J
AU Ondondo, BO
   Rowland-Jones, SL
   Dorrell, L
   Peterson, K
   Cotten, M
   Whittle, H
   Jaye, A
AF Ondondo, Beatrice O.
   Rowland-Jones, Sarah L.
   Dorrell, Lucy
   Peterson, Kevin
   Cotten, Matthew
   Whittle, Hilton
   Jaye, Assan
TI Comprehensive analysis of HIV Gag-specific IFN-gamma response in
   HIV-1-and HIV-2-infected asymptomatic patients from a clinical cohort in
   The Gambia
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Cellular immunology; HIV; Interferon-gamma; T cells
ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; TYPE-2 HIV-2; VIRAL
   LOAD; DISTINCT RECOGNITION; WEST-AFRICA; INFECTION; CD8(+); INDIVIDUALS;
   RECOMBINANT
AB Majority of HIV-2-infected individuals meet the criteria of long-term non-progressors. This has been linked to superior qualitative HIV-2-specific cellular immune responses that correlate with viral control. However, it is unknown whether this is due to frequent targeting of immunodominant Gag epitopes in HIV-2 than HIV-1 infection. We describe a comprehensive comparison of the magnitude, breadth and frequency of Gag responses and the degree of cross-recognition of frequently targeted, immunodominant Gag peptides in a cross-sectional study of asymptomatic HIV-1- and HIV-2-infected individuals. Fresh PBMC from 20 HIV-1- and 20 HIV-2-infected patients with similar CD4(+) T-cell counts (p = 0.36) were stimulated with pools of HIV-1 and/or HIV-2 Gag peptides in an IFN-gamma ELISPOT assay. We found no difference in the cumulative magnitude of IFN-gamma responses (p = 0.75) despite significantly lower plasma viral loads in HIV-2-infected people (p<0.0001). However, Gag211-290 was targeted with significantly higher magnitude in HIV-2-infected subjects (p = 0.03) although this did not correlate with viral control. There was no difference in frequently targeted Gag peptides, the breadth, immunodominance or cross-recognition of Gag peptide pools between the two infections. This suggests that other factors may control viral replication in HIV-2 infection.
C1 [Ondondo, Beatrice O.; Rowland-Jones, Sarah L.; Dorrell, Lucy] John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford OX3 9DU, England.
   [Ondondo, Beatrice O.; Rowland-Jones, Sarah L.; Peterson, Kevin; Cotten, Matthew; Whittle, Hilton; Jaye, Assan] MRC Labs, Banjul, Gambia.
RP Ondondo, BO (reprint author), Univ Bristol, Dept Cellular & Mol Med, Univ Walk, Bristol BS8 1TD, Avon, England.
EM Beatrice.Ondondo@bristol.ac.uk
FU Medical Research Council; International AIDS Vaccine Initiative;
   Universities UK
FX We would like to thank the patients for volunteering to participate in
   the study. We thank Bakary Sanneh, Mamadi Njie and Abdoulie Jabang for
   technical assistance, Jainaba Njie-Jobe for the cell counts, Abraham
   Alabi for HIV viral loads, Ramu Sarge-Njie for HIV serology, Louis-Marie
   Yindom for HLA-ryping, Akum Aveika for help with patient recruitment,
   the Genitourinary Medicine clinic staff for provision of blood samples
   and Jerreh Sanyang for administrative issues. This work was supported by
   funding from the Medical Research Council (MRC) allocated to the MRC
   Gambia Unit. B.O.O. acknowledges the International AIDS Vaccine
   Initiative for a research studentship and Universities UK for an ORS
   award.
CR Alatrakchi N, 2006, AIDS, V20, P29, DOI 10.1097/01.aids.0000198077.30421.bf
   Andersson S, 1999, VIROLOGY, V262, P312, DOI 10.1006/viro.1999.9867
   BARIN F, 1985, LANCET, V2, P1387
   Berry N, 1998, J Hum Virol, V1, P457
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   Bertoletti A, 1998, J VIROL, V72, P2439
   Brander C, 1998, J CLIN INVEST, V101, P2559, DOI 10.1172/JCI2405
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   CLAVEL F, 1986, NATURE, V324, P691, DOI 10.1038/324691a0
   CLAVERIE JM, 1988, EUR J IMMUNOL, V18, P1547, DOI 10.1002/eji.1830181012
   Dorrell L, 2006, J VIROL, V80, P4705, DOI 10.1128/JVI.80.10.4705-4716.2006
   Dorrell L, 1999, J VIROL, V73, P1708
   Dorrell L, 2001, EUR J IMMUNOL, V31, P1747, DOI 10.1002/1521-4141(200106)31:6<1747::AID-IMMU1747>3.0.CO;2-L
   Duvall MG, 2008, EUR J IMMUNOL, V38, P350, DOI 10.1002/eji.200737768
   Duvall MG, 2006, J IMMUNOL, V176, P6973
   Edwards BH, 2002, J VIROL, V76, P2298, DOI 10.1128/JVI.76.5.2298-2305.2002
   Frahm N, 2004, J VIROL, V78, P2187, DOI 10.1128/JVI.78.5.2187-2200.2004
   Gillespie GMA, 2005, EUR J IMMUNOL, V35, P1445, DOI 10.1002/eji.200526007
   GOTCH F, 1993, J IMMUNOL, V151, P3361
   Hanson A, 2005, AIDS RES HUM RETROV, V21, P791, DOI 10.1089/aid.2005.21.791
   Jaffar S, 1997, J ACQ IMMUN DEF SYND, V16, P327
   Jaye A, 2004, J INFECT DIS, V189, P498, DOI 10.1086/381185
   Kaufmann DE, 2004, J VIROL, V78, P4463, DOI 10.1128/JVI.78.9.4463-4477.2004
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365
   Kostense S, 2001, EUR J IMMUNOL, V31, P677, DOI 10.1002/1521-4141(200103)31:3<677::AID-IMMU677>3.0.CO;2-M
   Kurle S, 2004, AIDS RES HUM RETROV, V20, P1113, DOI 10.1089/aid.2004.20.1113
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Lopes AR, 2003, J IMMUNOL, V171, P307
   Malhotra U, 2001, J CLIN INVEST, V107, P505, DOI 10.1172/JCI11275
   Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004
   Masemola AM, 2004, J IMMUNOL, V173, P4607
   Mwau M, 2004, J GEN VIROL, V85, P911, DOI 10.1099/vir.0.19701-0
   Nuvor SV, 2006, J VIROL, V80, P2529, DOI 10.1128/JVI.80.5.2529-2538.2006
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   Ondondo BO, 2006, EUR J IMMUNOL, V36, P2585, DOI 10.1002/eji.200636508
   PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0
   Ramduth D, 2005, J INFECT DIS, V192, P1588, DOI 10.1086/496894
   RIVIERE Y, 1995, AIDS RES HUM RETROV, V11, P903, DOI 10.1089/aid.1995.11.903
   Rowland-Jones S, 1998, AIDS, V12, P1391, DOI 10.1097/00002030-199811000-00023
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   Schramm B, 2000, J VIROL, V74, P9594, DOI 10.1128/JVI.74.20.9594-9600.2000
   Zheng NN, 2004, J VIROL, V78, P13934, DOI 10.1128/JVI.78.24.13934-13942.2004
NR 43
TC 8
Z9 8
U1 0
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD DEC
PY 2008
VL 38
IS 12
BP 3549
EP 3560
DI 10.1002/eji.200838759
PG 12
WC Immunology
SC Immunology
GA 387GY
UT WOS:000261940900029
PM 19016530
OA No
DA 2017-08-15
ER

PT J
AU Bojang, KA
AF Bojang, Kalifia A.
TI Novel therapies for the prevention of malaria
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Review
DE artemisinin-based combination therapy; chemotherapy; home-based
   management of malaria; intermittent preventive treatment; malaria; mass
   drug administration
ID PLACEBO-CONTROLLED TRIAL; INTERMITTENT SULFADOXINE-PYRIMETHAMINE;
   PLASMODIUM-FALCIPARUM MALARIA; DOUBLE-BLIND; ANTIMALARIAL-DRUGS;
   RANDOMIZED-TRIAL; WESTERN KENYA; MEFLOQUINE COMBINATION; ROUTINE
   VACCINATIONS; SENEGALESE CHILDREN
AB Background: Malaria continues to exact a huge toll on the health of residents of endemic countries. Thus, new approaches to prevention and treatment are needed. Objective: To provide an update on novel therapies for the prevention of malaria. Methods: Systematic MEDLINE search from 1956 to 2008 using the search term 'malaria' (with the subheadings 'intermittent preventive treatment', 'mass drug administration', 'chemotherapy', 'artemisinin-based combination therapy' and 'home-based management of malaria'). Conclusions: Chemoprophylaxis is used as a short-term protective measure for non-immune visitors to malaria-endemic countries. However, in malaria-endemic areas, chemoprophylaxis has not been implemented widely because of concerns related to sustainability, cost-effectiveness, appropriate delivery systems and development of drug resistance. Intermittent preventive treatment, a novel approach to malaria control, has the potential to provide some of the benefits of sustained chemoprophylaxis without some of its drawbacks.
C1 Med Res Council UK, Gambia MRC Labs, Banjul, Gambia.
RP Bojang, KA (reprint author), Med Res Council UK, Gambia MRC Labs, POB 273, Banjul, Gambia.
EM kbojang@mrc.gm
OI Bojang, Kalifa/0000-0001-7506-0938
CR ALLEN SJ, 1990, J TROP MED HYG, V93, P313
   Baird JK, 2005, NEW ENGL J MED, V352, P1565, DOI 10.1056/NEJMra043207
   Barnes KI, 2005, PLOS MED, V2, P1123, DOI 10.1371/journal.pmed.0020330
   Chandramohan D, 2005, BRIT MED J, V331, P727, DOI 10.1136/bmj.331.7519.727
   Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0
   Clarke SE, 2008, LANCET, V372, P127, DOI 10.1016/S0140-6736(08)61034-X
   Denis MB, 2006, TROP MED INT HEALTH, V11, P1360, DOI 10.1111/j.1365-3156.2006.01690.x
   Desai MR, 2003, J INFECT DIS, V187, P658, DOI 10.1086/367986
   Dicko A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-123
   Faiz MA, 2005, LANCET, V366, P717
   GARFIELD RM, 1983, LANCET, V2, P500
   GARNER P, 2000, COCHRANE DB SYST REV, V2, P169
   Geerligs PDP, 2003, B WORLD HEALTH ORGAN, V81, P205
   Gomes M, 2008, BMC INFECT DIS, V28, P39
   Greenwood B, 2004, AM J TROP MED HYG, V70, P1
   Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3
   GREENWOOD BM, 1988, LANCET, V1, P1121
   GREENWOOD BM, 1991, WAITING VACCINE, P83
   Greenwood Brian, 2008, Travel Med Infect Dis, V6, P173, DOI 10.1016/j.tmaid.2007.11.003
   Greenwood B, 2007, CLIN INFECT DIS, V45, P26, DOI 10.1086/518574
   Greenwood B, 2006, TROP MED INT HEALTH, V11, P983, DOI 10.1111/j.1365-3156.2006.01657.x
   Grobusch MP, 2007, J INFECT DIS, V196, P1595, DOI 10.1086/522160
   Guyatt HL, 2001, T ROY SOC TROP MED H, V95, P569, DOI 10.1016/S0035-9203(01)90082-3
   Hamer DH, 2007, J INFECT DIS, V196, P1585, DOI 10.1086/522142
   *IOM, 2008, ASS ROL INT PREV TRE
   Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0
   Kobbe Robin, 2007, Clin Infect Dis, V45, P16, DOI 10.1086/518575
   Macete E, 2006, J INFECT DIS, V194, P276, DOI 10.1086/505431
   Massaga JJ, 2003, LANCET, V361, P1853, DOI 10.1016/S0140-6736(03)13504-0
   MCGREGOR IA, 1956, BRIT MED J, V2, P686
   Mockenhaupt FP, 2007, ANTIMICROB AGENTS CH, V51, P3273, DOI 10.1128/AAC.00513-07
   Molineaux L, 1980, GARKI PROJECT
   National Institutes of Health USA, 2006, INT PREV TREATM PREG
   *NIH, 2006, EFF INT SULF PYR SUL
   *NIH, 2006, LUNG ANT INT STUD SI
   Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8
   Ro DK, 2006, NATURE, V440, P940, DOI 10.1038/nature04640
   Rogerson SJ, 2000, T ROY SOC TROP MED H, V94, P549, DOI 10.1016/S0035-9203(00)90083-X
   Sabatinelli G, 2001, Euro Surveill, V6, P61
   Schellenberg D, 2005, LANCET, V365, P1481, DOI 10.1016/S0140-6736(05)66418-5
   Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2
   Schellenberg D, 2006, TRENDS PARASITOL, V22, P296, DOI 10.1016/j.pt.2006.05.006
   SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515
   Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8
   Sirima SB, 2003, TROP MED INT HEALTH, V8, P133, DOI 10.1046/j.1365-3156.2003.00997.x
   Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Sokhna C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001471
   Sunstrum J, 2001, AM J TROP MED HYG, V65, P949
   ter Kuile FO, 2007, JAMA-J AM MED ASSOC, V297, P2603, DOI 10.1001/jama.297.23.2603
   ter Kuile FO, 2003, AM J TROP MED HYG, V68, P68
   van Eijk AM, 2004, TROP MED INT HEALTH, V9, P351, DOI 10.1111/j.1365-3156.2004.01196.x
   Verhoef H, 2002, LANCET, V360, P908, DOI 10.1016/S0140-6736(02)11027-0
   von Seidlein L, 2003, T ROY SOC TROP MED H, V97, P217
   von Seidlein L, 2003, TRENDS PARASITOL, V19, P452, DOI 10.1016/j.pt.2003.08.003
   White NJ, 2005, PLOS MED, V2, P28, DOI 10.1371/journal.pmed.0020003
   WHO, 2005, ROLL BACK MAL STRAT
   World Health Organization, WHOHTMMAL20061108
   WHO, 2004, AFRMAL0401 WHO
   WHO, 2004, SCAL HOM BAS MAN MAL
   *WHO, 1956, INT ORGAN, V10, P642
NR 61
TC 0
Z9 0
U1 1
U2 2
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1354-3784
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD DEC
PY 2008
VL 17
IS 12
BP 1839
EP 1847
DI 10.1517/13543780802514039
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 379MF
UT WOS:000261399700007
PM 19012500
OA No
DA 2017-08-15
ER

PT J
AU Auburn, S
   Diakite, M
   Fry, AE
   Ghansah, A
   Campino, S
   Richardson, A
   Jallow, M
   Sisay-Joof, F
   Pinder, M
   Griffiths, MJ
   Peshu, N
   Williams, TN
   Marsh, K
   Molyneux, ME
   Taylor, TE
   Koram, KA
   Oduro, AR
   Rogers, WO
   Rockett, KA
   Haldar, K
   Kwiatkowski, DP
AF Auburn, Sarah
   Diakite, Mahamadou
   Fry, Andrew E.
   Ghansah, Anita
   Campino, Susana
   Richardson, Anna
   Jallow, Muminatou
   Sisay-Joof, Fatou
   Pinder, Margaret
   Griffiths, Michael J.
   Peshu, Norbert
   Williams, Thomas N.
   Marsh, Kevin
   Molyneux, Malcolm E.
   Taylor, Terrie E.
   Koram, Kwadwo A.
   Oduro, Abraham R.
   Rogers, William O.
   Rockett, Kirk A.
   Haldar, Kasturi
   Kwiatkowski, Dominic P.
TI Association of the GNAS locus with severe malaria
SO HUMAN GENETICS
LA English
DT Article
ID PLASMODIUM-FALCIPARUM; INFECTION; PROTEINS; AMPLIFICATION; CHOLESTEROL;
   LINKAGE; GENE; CELL
AB Functional studies have demonstrated an interaction between the stimulatory G protein alpha subunit (G-alpha-s) and the malaria parasite at a cellular level. Obstruction of signal transduction via the erythrocyte G-alpha-s subunit reduced invasion by Plasmodium falciparum parasites. We sought to determine whether this signal pathway had an impact at the disease level by testing polymorphisms in the gene encoding G-alpha-s (GNAS) for association with severe malaria in a large multi-centre study encompassing family and case-control studies from The Gambia, Kenya and Malawi, and a case-control study from Ghana. We gained power to detect association using meta-analysis across the seven studies, with an overall sample size approximating 4,000 cases and 4,000 controls. Out of 12 SNPs investigated in the 19 kb GNAS region, four presented signals of association (P < 0.05) with severe malaria. The strongest single-locus association demonstrated an odds ratio of 1.13 (1.05-1.21), P = 0.001. Three of the loci presenting significant associations were clustered at the 5-prime end of the GNAS gene. Accordingly, haplotypes constructed from these loci demonstrated significant associations with severe malaria [OR = 0.88 (0.81-0.96), P = 0.005 and OR = 1.12 (1.03-1.20), P = 0.005]. The evidence presented here indicates that the influence of G-alpha-s on erythrocyte invasion efficacy may, indeed, alter individual susceptibility to disease.
C1 [Auburn, Sarah; Campino, Susana; Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
   [Auburn, Sarah; Diakite, Mahamadou; Fry, Andrew E.; Ghansah, Anita; Campino, Susana; Richardson, Anna; Rockett, Kirk A.; Kwiatkowski, Dominic P.] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Ghansah, Anita; Koram, Kwadwo A.] Noguchi Mem Inst Med Res, Legon, Accra, Ghana.
   [Jallow, Muminatou; Sisay-Joof, Fatou; Pinder, Margaret] MRC, Banjul, Gambia.
   [Griffiths, Michael J.; Peshu, Norbert; Williams, Thomas N.; Marsh, Kevin] Ctr Geog Med Res Coast, Kenya Med Res Inst, Kilifi, Kenya.
   [Williams, Thomas N.; Marsh, Kevin] John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DS, England.
   [Molyneux, Malcolm E.] Malawi Liverpool Wellcome Trust Programme Clin Tr, Blantyre, Malawi.
   [Taylor, Terrie E.] Coll Med, Blantyre Malaria Project, Blantyre, Malawi.
   [Molyneux, Malcolm E.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   [Taylor, Terrie E.] Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA.
   [Oduro, Abraham R.] Navrongo Hlth Res Ctr, Navrongo, Ghana.
   [Rogers, William O.] USN, Med Res Ctr, Malaria Program, Silver Spring, MD USA.
   [Haldar, Kasturi] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Haldar, Kasturi] Northwestern Univ, Dept Immunol Microbiol, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Auburn, S (reprint author), Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
EM sa3@sanger.ac.uk
RI Haldar, Kasturi/C-6685-2014
OI Kwiatkowski, Dominic/0000-0002-5023-0176; Auburn,
   Sarah/0000-0002-4638-536X
FU Medical Research council, UK; International Atomic Energy Agency;
   Wellcome Trust Training Fellowships; Marie-Curie IntraEuropean
   Fellowship; Professor Dominic Kwiatkowski and a National Institute of
   Health
FX We wish to thank Dr. Taane Clark, Dr. YY Teo and Dr. Andrew Morris for
   their statistical advice. SA was supported by a PhD studentship from the
   Medical Research council, UK. MD was supported by a training fellowship
   from the International Atomic Energy Agency. AEF and MJG were funded by
   Wellcome Trust Training Fellowships. SC was funded by a Marie-Curie
   IntraEuropean Fellowship (FP6). TNW and KM were funded by a Wellcome
   Trust grant. The genetic component of this research was funded by a
   Medical Research Council (UK) grant to Professor Dominic Kwiatkowski and
   a National Institute of Health (USA) grant to Professor Kasturi Haldar.
   This study is part of the European Union Network of Excellence on the
   biology of malaria parasites. This manuscript is published with the
   permission of the director of the Kenya Medical Research Institute.
CR Adams JH, 2001, TRENDS PARASITOL, V17, P297, DOI 10.1016/S1471-4922(01)01948-1
   Aidoo M, 2002, LANCET, V359, P1311, DOI 10.1016/S0140-6736(02)08273-9
   Cowman AF, 2006, CELL, V124, P755, DOI 10.1016/j.cell.2006.02.006
   Gonzalez JM, 2005, ENVIRON MICROBIOL, V7, P1024, DOI 10.1111/j.1462-2920.2005.00779.x
   Harrison T, 2003, SCIENCE, V301, P1734, DOI 10.1126/science.1089324
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Ihaka R., 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.1080/10618600.1996.10474713, DOI 10.2307/1390807]
   Ioannidis JPA, 2003, TRENDS MOL MED, V9, P135, DOI 10.1016/S1471-4914(03)00030-3
   KAVVOURA FK, 2007, HUM GENET, V123, P1
   Kazeem GR, 2005, ANN HUM GENET, V69, P329, DOI 10.1046/j.1529-8817.2005.00156.x
   Lauer S, 2000, EMBO J, V19, P3556, DOI 10.1093/emboj/19.14.3556
   LEWONTIN RC, 1960, EVOLUTION, V14, P458, DOI 10.2307/2405995
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Murphy SC, 2004, BLOOD, V103, P1920, DOI 10.1182/blood-2003-9-3165
   Oldham WM, 2008, NAT REV MOL CELL BIO, V9, P60, DOI 10.1038/nrm2299
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Samuel BU, 2001, J BIOL CHEM, V276, P29319, DOI 10.1074/jbc.M101268200
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   TEO YY, 2008, HUM HERED, V67, P26
   Thompson Miles D., 2008, V448, P77, DOI 10.1007/978-1-59745-205-2_6
   Weinstein LS, 2006, TRENDS PHARMACOL SCI, V27, P260, DOI 10.1016/j.tips.2006.03.005
   ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847
NR 23
TC 10
Z9 10
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD DEC
PY 2008
VL 124
IS 5
BP 499
EP 506
DI 10.1007/s00439-008-0575-8
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 376JC
UT WOS:000261178900007
PM 18951142
OA No
DA 2017-08-15
ER

PT J
AU Todryk, SM
   Bejon, P
   Keating, S
   Hutchings, C
   Berthoud, T
   Porter, D
   Thompson, F
   Flanagan, K
   Hill, AVS
AF Todryk, S. M.
   Bejon, P.
   Keating, S.
   Hutchings, C.
   Berthoud, T.
   Porter, D.
   Thompson, F.
   Flanagan, K.
   Hill, A. V. S.
TI Measuring malaria memory
SO IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Congress of the British-Society-of-Immunology
CY NOV 17-21, 2008
CL Glasgow, SCOTLAND
SP British Soc Immunol
C1 [Todryk, S. M.; Bejon, P.; Keating, S.; Hutchings, C.; Berthoud, T.; Porter, D.; Thompson, F.; Hill, A. V. S.] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [Todryk, S. M.] Northumbria Univ, Sch Appl Sci, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England.
   [Bejon, P.; Flanagan, K.] KEMRI Wellcome, Kilifi, Kenya.
   [Flanagan, K.] MRC Labs, Banjul, Gambia.
   [Hill, A. V. S.] Univ Oxford, Jenner Inst, Oxford, England.
RI Keating, Sheila/B-1652-2013
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD DEC
PY 2008
VL 125
BP 79
EP 80
PG 2
WC Immunology
SC Immunology
GA 398XL
UT WOS:000262764800256
OA No
DA 2017-08-15
ER

PT J
AU Ahmed, S
   Khan, WA
   Saha, D
   Salam, MA
   Bennish, ML
   Rahman, M
AF Ahmed, S.
   Khan, W. A.
   Saha, D.
   Salam, M. A.
   Bennish, M. L.
   Rahman, M.
TI Mutation in DNA Gyrase and Topoisomerase IV of V. cholerae Causing
   Diminished Susceptibility to Ciprofloxacin
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Ahmed, S.; Khan, W. A.; Salam, M. A.] ICDDR B, Dhaka, Bangladesh.
   [Saha, D.] Med Res Council UK, Basse, Gambia.
   [Bennish, M. L.] Mpilonhle, Mtubatuba, South Africa.
   [Rahman, M.] Family Hlth Int, Bangkok, Thailand.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD DEC
PY 2008
VL 12
SU 1
BP E113
EP E114
DI 10.1016/j.ijid.2008.05.284
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 406II
UT WOS:000263287800283
OA gold
DA 2017-08-15
ER

PT J
AU Oriero, CE
   Nwakanma, D
   Sesay, S
   Conway, D
AF Oriero, C. E.
   Nwakanma, D.
   Sesay, S.
   Conway, D.
TI Determination of Parasite Clearance Time in Antimalarial Drug Trials
   Using Real-Time Quantitative PCR (PCR)
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Oriero, C. E.; Nwakanma, D.; Sesay, S.; Conway, D.] MRC Labs, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD DEC
PY 2008
VL 12
BP E311
EP E311
DI 10.1016/j.ijid.2008.05.833
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA 406II
UT WOS:000263287800778
OA gold
DA 2017-08-15
ER

PT J
AU Hawkesworth, S
   Prentice, AM
   Fulford, AJC
   Moore, SE
AF Hawkesworth, Sophie
   Prentice, Andrew M.
   Fulford, Anthony J. C.
   Moore, Sophie E.
TI Dietary Supplementation of Rural Gambian Women during Pregnancy Does Not
   Affect Body Composition in Offspring at 11-17 Years of Age
SO JOURNAL OF NUTRITION
LA English
DT Article
ID FOR-GESTATIONAL-AGE; BIRTH-WEIGHT; EARLY GROWTH; FAT MASS; OBESITY;
   CHILDREN; FAMINE; ADOLESCENTS; CHILDHOOD; EXPOSURE
AB Fetal nutrition is thought to be an important determinant of later disease risk, although evidence from randomized-controlled trials in humans is lacking. We followed children born during a protein-energy supplementation trial to investigate to what extent this maternal supplement, which improved birth weight, influenced offspring body composition in adolescence. Subjects were 1270 Gambian children (659 boys, 611 girls) aged 11-17 y whose mothers had participated in the original cluster-randomized trial and had received the supplement during pregnancy (intervention) or postpartum (control). Basic anthropometry was measured using standard techniques and fatness was assessed by bioelectrical impedance analysis and population-specific prediction equations. For boys, mean body fat was 12.6% for both intervention and control groups. Mean trunk fat was 11.9% in the intervention group and 12.0% in the control. Intervention girls had a mean body fat of 19.5% and trunk fat of 15.2%; for control girls, it was 19.3 and 14.8%, respectively. BMI, body fat, trunk fat, fat mass index, and fat-free mass index did not differ for either sex when analyzed with generalized estimating equations adjusted for age, maternal height, maternal parity, location, season of birth, and menarche in females. Neither infant-attained size nor the onset of menarche were affected by maternal supplementation. These findings suggest that protein-energy supplements to pregnant women, compared with lactating women, do not affect offspring body composition during adolescence. J. Nutr. 138: 2468-2473, 2008.
C1 [Hawkesworth, Sophie; Prentice, Andrew M.; Fulford, Anthony J. C.] Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   [Prentice, Andrew M.; Fulford, Anthony J. C.; Moore, Sophie E.] Med Res Council Keneba, Med Res Council Labs, Fajara, Gambia.
RP Hawkesworth, S (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM sophie.hawkesworth@lshtm.ac.uk
OI Hawkesworth, Sophie/0000-0002-3554-242X
FU European Union Community Early Nutrition Programming
   [FOOD-CT-2005-007036]; UK Medical Research Council
FX Supported by the European Union Sixth Framework Programme for Research
   and Technical Development of the European Union Community Early
   Nutrition Programming Project (FOOD-CT-2005-007036) and the UK Medical
   Research Council.
CR Barker DJP, 1998, MOTHERS BABIES HLTH
   Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
   Cole TJ, 2000, BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240
   Cole TJ, 1998, STAT MED, V17, P407, DOI 10.1002/(SICI)1097-0258(19980228)17:4<407::AID-SIM742>3.0.CO;2-L
   Eriksson JG, 2006, INT J OBESITY, V30, pS18, DOI 10.1038/sj.ijo.0803515
   Fernandez-Twinn DS, 2006, PHYSIOL BEHAV, V88, P234, DOI 10.1016/j.physbeh.2006.05.039
   Hediger ML, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.5.e60
   Hediger ML, 1999, PEDIATRICS, V104, part. no., DOI 10.1542/peds.104.3.e33
   Kinra S, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a605
   Langley-Evans SC, 2005, MATERN CHILD NUTR, V1, P142, DOI 10.1111/j.1740-8709.2005.00015.x
   Law CM, 1996, J HYPERTENS, V14, P935
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   MARTORELL R, 1995, J NUTR, V125, pS1027
   Oken E, 2003, OBES RES, V11, P496, DOI 10.1038/oby.2003.69
   PARKIN JM, 1976, ARCH DIS CHILD, V51, P259
   PRENTICE AM, 1983, HUM NUTR-CLIN NUTR, V37, P65
   PRENTICE AM, 1983, HUM NUTR-CLIN NUTR, V37, P53
   Prins M, 2008, EUR J CLIN NUTR, V62, P1065, DOI 10.1038/sj.ejcn.1602830
   Ravelli ACJ, 1999, AM J CLIN NUTR, V70, P811
   RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701
   RIVERA JA, 1995, J NUTR, V125, pS1068
   Rogers I, 2003, INT J OBESITY, V27, P755, DOI 10.1038/sj.ijo.0802316
   Rogers IS, 2006, AM J CLIN NUTR, V84, P739
   Singhal A, 2003, AM J CLIN NUTR, V77, P726
   Stein AD, 2007, AM J CLIN NUTR, V85, P869
   Wells JCK, 2002, INT J OBESITY, V26, P947, DOI 10.1038/sj.ijo.0802027
   Wells JCK, 2005, INT J OBESITY, V29, P1192, DOI 10.1038/sj.ijo.0803054
NR 27
TC 16
Z9 17
U1 0
U2 2
PU AMER SOC NUTRITIONAL SCIENCE
PI BETHESDA
PA 9650 ROCKVILLE PIKE, RM L-2407A, BETHESDA, MD 20814 USA
SN 0022-3166
J9 J NUTR
JI J. Nutr.
PD DEC
PY 2008
VL 138
IS 12
BP 2468
EP 2473
DI 10.3945/jn.108.098665
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 374IZ
UT WOS:000261038300028
PM 19022974
OA No
DA 2017-08-15
ER

PT J
AU Harding-Esch, EM
   Edwards, T
   Sillah, A
   Sarr-Sissoho, I
   Aryee, EA
   Snell, P
   Holland, MJ
   Mabey, DC
   Bailey, RL
AF Harding-Esch, E. M.
   Edwards, T.
   Sillah, A.
   Sarr-Sissoho, I.
   Aryee, E. A.
   Snell, P.
   Holland, M. J.
   Mabey, D. C.
   Bailey, R. L.
TI Risk factors for active trachoma in The Gambia
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE Trachoma; Chlamydia trachomatis; Prevalence; Risk factors; Control; The
   Gambia
ID FLY MUSCA-SORBENS; INFECTION; VILLAGE; TANZANIA; AZITHROMYCIN;
   PREVALENCE; COMMUNITY; ETHIOPIA; LATRINES; PROGRAM
AB Trachoma has been endemic in The Gambia for decades but national surveys indicate that the prevalence is failing. Risk factor data can help guide trachoma control efforts. This study investigated risk factors for active trachoma and ocular Chlamydia trachomatis infection in children aged below 10 years in two Gambian regions. The overall prevalence of C. trachomatis infection was only 0.3% (3/950) compared with 10.4% (311/2990) for active trachoma, therefore analyses were only performed for active trachoma. After adjustment, increased risk of trachoma was associated with being aged 1-2 years (odds ratio (OR) 2.20, 95% Cl 1.07-4.52) and 3-5 years (OR 3.62, 95% Cl 1.80-7.25) compared with < 1 year, nasal discharge (OR 2.07, 95% Cl 1.53-2.81), ocular discharge (OR 2.68, 95% Cl 1.76-4.09) and there being at least one other child in the household with active trachoma (OR 11.28, 95% Cl 8.31-15.31). Compared with other occupations, children of traders had reduced risk (OR 0.53, 95% Cl 0.30-0.94). At the household level, only the presence of another child in the household with active trachoma was associated with increased risk of active trachoma, suggesting that current trachoma control interventions are effective at this level. In contrast, child-level factors were associated with increased risk after adjustment, indicating a need to increase control efforts at the child level. Crown Copyright (c) 2008 Published by Elsevier Ltd on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved.
C1 [Harding-Esch, E. M.; Edwards, T.; Holland, M. J.; Mabey, D. C.; Bailey, R. L.] London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Sillah, A.] Minist Hlth, Natl Eye Care Programme, Banjul, Gambia.
   [Sarr-Sissoho, I.; Aryee, E. A.; Snell, P.; Holland, M. J.] MRC Labs, Banjul, Gambia.
RP Harding-Esch, EM (reprint author), London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM emma.harding-esch@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276
FU Wellcome Trust, London, UK [078460/Z/05/Z]
FX Wellcome Trust, London, UK (reference: 078460/Z/05/Z).
CR Abdou A, 2007, BRIT J OPHTHALMOL, V91, P13, DOI 10.1136/bjo.2006.099507
   Baggaley RF, 2006, TROP MED INT HEALTH, V11, P220, DOI 10.1111/j.1365-3156.2005.01553.x
   Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076
   BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944
   BAILEY R, 1991, T ROY SOC TROP MED H, V85, P824, DOI 10.1016/0035-9203(91)90470-J
   BAILEY RL, 1994, BRIT J OPHTHALMOL, V78, P813, DOI 10.1136/bjo.78.11.813
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   Dolin PJ, 1997, LANCET, V349, P1511, DOI 10.1016/S0140-6736(97)01355-X
   Edwards T, 2006, OPHTHALMOLOGY, V113, P548, DOI 10.1016/j.ophtha.2006.01.008
   Edwards T, 2008, TROP MED INT HEALTH, V13, P556, DOI 10.1111/j.1365-3156.2008.02034.x
   Emerson PM, 2005, TROP MED INT HEALTH, V10, P706, DOI 10.1111/j.1365-3156.2005.01432.x
   Emerson PM, 2000, T ROY SOC TROP MED H, V94, P28, DOI 10.1016/S0035-9203(00)90427-9
   Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1
   Emerson PM, 2001, MED VET ENTOMOL, V15, P314, DOI 10.1046/j.0269-283x.2001.00318.x
   Emerson PM, 2000, TROP MED INT HEALTH, V5, P515, DOI 10.1046/j.1365-3156.2000.00603.x
   Faal H, 2000, BRIT J OPHTHALMOL, V84, P948, DOI 10.1136/bjo.84.9.948
   Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1
   MABEY DCW, 1992, EPIDEMIOL INFECT, V108, P343
   Ngondi J, 2007, AM J TROP MED HYG, V77, P126
   Rabe-Heskteh SSA, 2002, STATA J, V2, P1
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schemann JF, 2002, INT J EPIDEMIOL, V31, P194, DOI 10.1093/ije/31.1.194
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   Gower EW, 2006, INVEST OPHTH VIS SCI, V47, P4767, DOI 10.1167/iovs.05-1599
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   West SK, 1996, AM J EPIDEMIOL, V143, P73
   World Health Organization, 1997, WHOPBL9760
NR 30
TC 21
Z9 21
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD DEC
PY 2008
VL 102
IS 12
BP 1255
EP 1262
DI 10.1016/j.trstmh.2008.04.022
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 377XK
UT WOS:000261285500014
PM 18502459
OA No
DA 2017-08-15
ER

PT J
AU de Silva, TI
   Cotten, M
   Rowland-Jones, SL
AF de Silva, Thushan I.
   Cotten, Matthew
   Rowland-Jones, Sarah L.
TI HIV-2: the forgotten AIDS virus
SO TRENDS IN MICROBIOLOGY
LA English
DT Review
ID T-CELL RESPONSES; PLASMA VIRAL LOAD; REVERSE-TRANSCRIPTASE INHIBITORS;
   SINGLE AMINO-ACID; IN-VITRO; TYPE-2 HIV-2; WEST-AFRICA; GUINEA-BISSAU;
   HIV-2-INFECTED PATIENTS; IMMUNE ACTIVATION
AB HIV type 2 (HIV-2), a closely related retrovirus discovered a few years after HIV type 1, causes AIDS in only a minority of infected individuals. Determining why HIV-2 causes asymptomatic infection in most patients could further our understanding of HIV immunopathogenesis. Studies to date have suggested that both enhanced immune responses and lower viral replication could play a role. We summarize the important findings to date and highlight areas that warrant further exploration.
C1 [de Silva, Thushan I.; Cotten, Matthew; Rowland-Jones, Sarah L.] MRC Labs, Fajara, Gambia.
   [Rowland-Jones, Sarah L.] John Radcliffe Hosp, Weatherall Inst Mol Med, Med Res Council Human Immunol Unit, Oxford OX3 9DS, England.
RP de Silva, TI (reprint author), MRC Labs, Atlantic Rd,POB 273, Fajara, Gambia.
EM tdesilva@mrc.gm
FU British Infection Society
FX T.I.dS. is supported by a British Infection Society Research Fellowship.
CR Aaby P, 1996, AIDS, V10, P1585
   Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   Alatrakchi N, 2006, AIDS, V20, P29, DOI 10.1097/01.aids.0000198077.30421.bf
   Albuquerque AS, 2007, J IMMUNOL, V178, P3252
   Andersson S, 2000, ARCH INTERN MED, V160, P3286, DOI 10.1001/archinte.160.21.3286
   Apetrei C, 2005, J VIROL, V79, P2631, DOI 10.1128/JVI.79.4.2631-2636.2005
   Arien KK, 2005, J VIROL, V79, P8979, DOI 10.1128/JVI.79.14.8979-8990.2005
   Ariyoshi K, 1998, J Hum Virol, V1, P193
   Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006
   Arya SK, 1996, P NATL ACAD SCI USA, V93, P4486, DOI 10.1073/pnas.93.9.4486
   BARIN F, 1985, LANCET, V2, P1387
   Barker E, 1998, BLOOD, V92, P3105
   Berry N, 1998, J Hum Virol, V1, P457
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   BJORLING E, 1993, VIROLOGY, V193, P528, DOI 10.1006/viro.1993.1160
   Blaak H, 2006, VIROLOGY, V353, P144, DOI 10.1016/j.virol.2006.05.029
   BOERI E, 1992, J VIROL, V66, P4546
   Boyer PL, 2006, PLOS PATHOG, V2, P101, DOI 10.1371/journal.ppat0020010
   Braaten D, 1996, J VIROL, V70, P4220
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Chen ZW, 1996, J VIROL, V70, P3617
   Colson P, 2005, J MED VIROL, V75, P381, DOI 10.1002/jmv.20296
   da Silva ZJ, 2008, AIDS, V22, P1195, DOI 10.1097/QAD.0b013e328300a33d
   Damond F, 2004, AIDS RES HUM RETROV, V20, P666, DOI 10.1089/0889222041217392
   Damond F, 2001, VIROLOGY, V280, P19, DOI 10.1006/viro.2000.0685
   Damond F, 2008, AIDS, V22, P665, DOI 10.1097/QAD.0b013e3282f51203
   Decker JM, 2005, J EXP MED, V201, P1407, DOI 10.1084/jem.20042510
   Dern K, 2001, AIDS RES HUM RETROV, V17, P295, DOI 10.1089/08892220150503672
   Desbois D, 2008, ANTIMICROB AGENTS CH, V52, P1545, DOI 10.1128/AAC.01284-07
   Diouf K, 2002, J HUMAN VIROL, V5, P1, DOI 10.1097/01.QHV.0000021465.39141.02
   Drylewicz J, 2008, AIDS, V22, P457, DOI 10.1097/QAD.0b013e3282f4ddfc
   Duvall MG, 2008, EUR J IMMUNOL, V38, P350, DOI 10.1002/eji.200737768
   Duvall MG, 2006, J IMMUNOL, V176, P6973
   Foxall RB, 2008, J VIROL, V82, P9795, DOI 10.1128/JVI.01217-08
   GAO F, 1994, J VIROL, V68, P7433
   Gautier D, 2007, J VIROL, V81, P12685, DOI 10.1128/JVI.01131-07
   Gillespie GMA, 2005, EUR J IMMUNOL, V35, P1445, DOI 10.1002/eji.200526007
   Gottlieb GS, 2006, AIDS, V20, P895, DOI 10.1097/01.aids.0000218554.59531.80
   Gottlieb GS, 2002, J INFECT DIS, V185, P905, DOI 10.1086/339295
   Greenberg AE, 2001, AIDS, V15, P2319, DOI 10.1097/00002030-200111230-00015
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   Hahn BH, 2000, SCIENCE, V287, P607, DOI 10.1126/science.287.5453.607
   Hamel DJ, 2007, AIDS RES HUM RETROV, V23, P1189, DOI 10.1089/aid.2007.0037
   Hansmann A, 2005, JAIDS-J ACQ IMM DEF, V38, P335
   Hanson A, 2005, AIDS RES HUM RETROV, V21, P791, DOI 10.1089/aid.2005.21.791
   Holmes RK, 2007, TRENDS BIOCHEM SCI, V32, P118, DOI 10.1016/j.tibs.2007.01.004
   Isaka Y, 2001, ARCH VIROL, V146, P743, DOI 10.1007/s007050170143
   Jaffar S, 2004, B WORLD HEALTH ORGAN, V82, P462
   Jaffar S, 2005, AIDS RES HUM RETROV, V21, P560, DOI 10.1089/aid.2005.21.560
   JALECO AC, 1994, CLIN EXP IMMUNOL, V98, P185
   Javanbakht H, 2006, VIROLOGY, V354, P15, DOI 10.1016/j.virol.2006.06.031
   Jaye A, 2004, J INFECT DIS, V189, P498, DOI 10.1086/381185
   Kokkotou EG, 2000, P NATL ACAD SCI USA, V97, P6797, DOI 10.1073/pnas.97.12.6797
   Kootstra NA, 2007, AIDS, V21, P2015
   Leligdowicz A, 2008, EXPERT REV VACCINES, V7, P319, DOI 10.1586/14760584.7.3.319
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100
   Machuca A, 2004, AIDS RES HUM RETROV, V20, P507, DOI 10.1089/088922204323087750
   MacNeil A, 2007, J VIROL, V81, P5325, DOI 10.1128/JVI.02625-06
   MacNeil A, 2007, J INFECT DIS, V195, P726, DOI 10.1086/511308
   MacNeil A, 2006, J VIROL, V80, P7316, DOI 10.1128/JVI.00604-06
   Masse S, 2007, ANTIMICROB AGENTS CH, V51, P3075, DOI 10.1128/AAC.00146-07
   Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501
   Michel P, 2000, J INFECT DIS, V181, P64, DOI 10.1086/315170
   Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248
   Nkengasong JN, 2000, AIDS RES HUM RETROV, V16, P1371, DOI 10.1089/08892220050140919
   Ntemgwa M, 2007, ANTIMICROB AGENTS CH, V51, P604, DOI 10.1128/AAC.00870-06
   Nuvor SV, 2006, J VIROL, V80, P2529, DOI 10.1128/JVI.80.5.2529-2538.2006
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Otten RA, 2004, AIDS, V18, P1127, DOI 10.1097/01.aids.0000125947.88690.17
   Pandrea IV, 2007, J IMMUNOL, V179, P3035
   Pepin J, 2006, AIDS, V20, P1303
   Popper SJ, 2000, J VIROL, V74, P1554, DOI 10.1128/JVI.74.3.1554-1557.2000
   Popper SJ, 1999, J INFECT DIS, V180, P1116, DOI 10.1086/315010
   POULSEN AG, 1993, J ACQ IMMUN DEF SYND, V6, P941
   Poulsen AG, 2000, SCAND J INFECT DIS, V32, P169
   Reeves JD, 2002, J GEN VIROL, V83, P1253, DOI 10.1099/vir.O.18253-O
   Reid P, 2005, VIROLOGY, V336, P251, DOI 10.1016/j.virol.2005.03.030
   Ribeiro AC, 2005, J VIROL, V79, P823, DOI 10.1128/JVI.79.2.823-833.2005
   Rodriguez SK, 2007, J VIROL, V81, P5331, DOI 10.1128/JVI.02789-06
   Rowland-Jones S, 2006, FUTURE MICROBIOL, V1, P427, DOI 10.2217/17460913.1.4.427
   Santiago ML, 2005, J VIROL, V79, P12515, DOI 10.1128/JVI.79.19.12515-12527.2005
   Sawyer SL, 2006, CURR BIOL, V16, P95, DOI 10.1016/j.club.2005.11.045
   Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033
   Schmitz C, 2004, J VIROL, V78, P2006, DOI 10.1128/JVI.78.4.2006-2016.2004
   SCHULZ TF, 1990, J VIROL, V64, P5177
   Shi Y, 2005, J GEN VIROL, V86, P3385, DOI 10.1099/vir.0.81259-0
   Song H, 2007, J VIROL, V81, P7280, DOI 10.1128/JVI.00406-07
   Sousa AE, 2002, J IMMUNOL, V169, P3400
   Speelmon EC, 2006, J VIROL, V80, P2463, DOI 10.1128/JVI.80.5.2463-2471.2006
   Thomas ER, 2003, AIDS, V17, P291, DOI 10.1097/01.aids.0000050804.28043.58
   van der Loeff MFS, 2002, AIDS, V16, P1775
   WEISS RA, 1988, AIDS, V2, P95, DOI 10.1097/00002030-198804000-00004
   Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246
   Wilson SJ, 2008, P NATL ACAD SCI USA, V105, P3557, DOI 10.1073/pnas.0709003105
   Witvrouw M, 2004, ANTIVIR THER, V9, P57
   Witvrouw M, 1999, AIDS, V13, P1477, DOI 10.1097/00002030-199908200-00006
   Ylinen LMJ, 2005, J VIROL, V79, P11580, DOI 10.1128/JVI.79.18.11580-11587.2005
   Zheng NN, 2007, J VIROL, V81, P9061, DOI 10.1128/JVI.00117-07
   Zheng NN, 2004, J VIROL, V78, P13934, DOI 10.1128/JVI.78.24.13934-13942.2004
NR 100
TC 89
Z9 91
U1 1
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0966-842X
EI 1878-4380
J9 TRENDS MICROBIOL
JI Trends Microbiol.
PD DEC
PY 2008
VL 16
IS 12
SI SI
BP 588
EP 595
DI 10.1016/j.tim.2008.09.003
PG 8
WC Biochemistry & Molecular Biology; Microbiology
SC Biochemistry & Molecular Biology; Microbiology
GA 386RL
UT WOS:000261900200007
PM 18964021
OA No
DA 2017-08-15
ER

PT J
AU Antonio, M
   Hakeem, I
   Awine, T
   Secka, O
   Sankareh, K
   Nsekpong, D
   Lahai, G
   Akisanya, A
   Egere, U
   Enwere, G
   Zaman, SMA
   Hill, PC
   Corrah, T
   Cutts, F
   Greenwood, BM
   Adegbola, RA
AF Antonio, Martin
   Hakeem, Ishrat
   Awine, Timothy
   Secka, Ousman
   Sankareh, Kawsu
   Nsekpong, David
   Lahai, George
   Akisanya, Abiodun
   Egere, Uzochukwu
   Enwere, Godwin
   Zaman, Syed M. A.
   Hill, Philip C.
   Corrah, Tumani
   Cutts, Felicity
   Greenwood, Brian M.
   Adegbola, Richard A.
TI Seasonality and outbreak of a predominant Streptococcus pneumoniae
   serotype 1 clone from The Gambia: Expansion of ST217 hypervirulent
   clonal complex in West Africa
SO BMC MICROBIOLOGY
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; NASOPHARYNGEAL CARRIAGE; INVASIVE
   DISEASE; MENINGITIS; CHILDREN; INFANTS; TRIAL
AB Background: Streptococcus pneumoniae serotype 1 causes > 20% of invasive disease, among all age groups combined, in The Gambia. In contrast, it is rarely detected in carriage studies. This study compares the molecular epidemiology of S. pneumoniae serotype 1 causing invasive disease in The Gambia between 1996 and 2005 to those carried in the nasopharynx between 2004 and 2006.
   Results: A total of 127 invasive and 36 nasopharyngeal carriage serotype 1 isolates were recovered from individuals of all age groups and were analyzed by serotyping, antibiotic susceptibility testing and MLST. MLST analysis revealed 23 different sequence types (STs), 18 of which were novel. The most prevalent clone among the 163 isolates was ST618 (70.5%), followed by ST3575 (7.4%), ST2084 (2.5%) and ST612 (2.5%). A single ST (ST618), previously shown to belong to the ST217 hypervirulent clonal complex, was frequent among carriage (61.1%) and invasive (72.7%) serotype 1 isolates. ST618 causing both paediatric and adult disease peaked annually in the hot dry season and caused outbreak in 1997 and 2002.
   Conclusion: For over a decade, isolates of ST618 have been the dominant lineage among serotype 1 carriage and disease isolates circulating in the Gambia. This lineage shows similar epidemiological features to those of the meningococcus in the African meningitis belt being able to cause outbreaks of disease
C1 [Antonio, Martin; Hakeem, Ishrat; Awine, Timothy; Secka, Ousman; Sankareh, Kawsu; Nsekpong, David; Lahai, George; Akisanya, Abiodun; Egere, Uzochukwu; Enwere, Godwin; Zaman, Syed M. A.; Hill, Philip C.; Corrah, Tumani; Cutts, Felicity; Adegbola, Richard A.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Greenwood, Brian M.] London Sch Hyg & Trop Med, London WC1, England.
RP Antonio, M (reprint author), MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
EM mantonio@mrc.gm; ishrathakeem@yahoo.com; tawine@navrongo.mimcom.net;
   osecka@mrc.gm; ksankareh@mrc.gm; snsekpong@mrc.gm; glahai@mrc.gm;
   aakisanya@mrc.gm; uegere@mrc.gm; genwere4@yahoo.co.uk;
   azama228@yahoo.com; philip.hill@otago.ac.nz; tcorrah@mrc.gm;
   felicity.cutts@lshtm.ac.uk; brian.greenwood@lshtm.ac.uk;
   radegbola@mrc.gm
FU MRC (UK)
FX We would like to acknowledge Ebou Mbowe, Lamin Juwara and Pauline Sambou
   for technical assistance and MRC (UK) for funding this project. We also
   acknowledge the use of the Core Sequencing Facility at MRC Fajara, The
   Gambia and the S. pneumoniae MLST database [16,17] which is housed at
   Imperial College, London, UK.
CR Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Antonio M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-81
   Bernatoniene J, 2005, DRUGS, V65, P229, DOI 10.2165/00003495-200565020-00005
   Brueggemann AB, 2003, J CLIN MICROBIOL, V41, P4966, DOI 10.1128/JCM.41.11.4966-4970.2003
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dagan R, 2000, CLIN INFECT DIS, V30, P319, DOI 10.1086/313645
   DEMARIA A, 1980, JAMA-J AM MED ASSOC, V244, P1446, DOI 10.1001/jama.244.13.1446
   Enright MC, 1998, MICROBIOL-UK, V144, P3049
   GREENWOOD B, 2006, TROP MET INT HLTH, P773
   Hill PC, 2008, CLIN INFECT DIS, V46, P807, DOI 10.1086/528688
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   Klugman KP, 2008, PNEUMOCOCCAL VACCINES: THE IMPACT OF CONJUGATE VACCINE, P317
   Leimkugel J, 2005, J INFECT DIS, V192, P192, DOI 10.1086/431151
   MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147
   Yaro S, 2006, CLIN INFECT DIS, V43, P693, DOI 10.1086/506940
   [Anonymous], 2008, COMMUNICATION
NR 17
TC 34
Z9 34
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2180
J9 BMC MICROBIOL
JI BMC Microbiol.
PD NOV 17
PY 2008
VL 8
AR 198
DI 10.1186/1471-2180-8-198
PG 7
WC Microbiology
SC Microbiology
GA 378LJ
UT WOS:000261322000001
PM 19014613
OA gold
DA 2017-08-15
ER

PT J
AU Atkinson, SH
   Rockett, KA
   Morgan, G
   Bejon, PA
   Sirugo, G
   O'Connell, MA
   Hanchard, N
   Kwiatkowski, DP
   Prentice, AM
AF Atkinson, Sarah H.
   Rockett, Kirk A.
   Morgan, Gareth
   Bejon, Philip A.
   Sirugo, Giorgio
   O'Connell, Maria A.
   Hanchard, Neil
   Kwiatkowski, Dominic P.
   Prentice, Andrew M.
TI Tumor necrosis factor SNP haplotypes are associated with iron deficiency
   anemia in West African children
SO BLOOD
LA English
DT Article
ID FACTOR-ALPHA PROMOTER; TNF-ALPHA; HEREDITARY HEMOCHROMATOSIS;
   TRANSCRIPTIONAL ACTIVATION; PHENOTYPIC-EXPRESSION; CEREBRAL MALARIA;
   SERUM FERRITIN; KAPPA-B; POLYMORPHISM; GENE
AB Plasma levels of tumor necrosis factor-alpha (TNF-alpha) are significantly raised in malaria infection and TNF-alpha is thought to inhibit intestinal iron absorption and macrophage iron release. This study investigated putative functional single nucleotide polymorphisms (SNPs) and haplotypes across the major histocompatibility complex (MHC) class III region, including TNF and its immediate neighbors nuclear factor of kappa light polypeptide gene enhancer in B cells (l kappa BL), inhibitor-like 1 and lymphotoxin alpha (LTA), in relation to nutritional iron status and anemia, in a cohort of 780 children across a malaria season. The prevalence of iron deficiency anemia (IDA) increased over the malaria season (P <.001). The TNF(-308) AA genotype was associated with an increased risk of iron deficiency (adjusted OR 8.1; P <.001) and IDA (adjusted OR 5.1; P=.01) at the end of the malaria season. No genotypes were associated with IDA before the malaria season. Thus, TNF appears to be a risk factor for iron deficiency and IDA in children in a malaria-endemic environment and this is likely to be due to a TNF-alpha-induced block in iron absorption. (Blood. 2008; 112: 4276-4283)
C1 [Atkinson, Sarah H.; Kwiatkowski, Dominic P.] Univ Oxford, Dept Paediat, Childrens Hosp John Radcliffe, Oxford, England.
   [Atkinson, Sarah H.; Morgan, Gareth; Sirugo, Giorgio; Prentice, Andrew M.] MRC, Keneba & MRC Labs, Banjul, Gambia.
   [Atkinson, Sarah H.; Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
   [Atkinson, Sarah H.; Rockett, Kirk A.; Bejon, Philip A.; Hanchard, Neil; Kwiatkowski, Dominic P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [O'Connell, Maria A.] MRC Human Nutr Res, Cambridge, England.
   [Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Hinxton, England.
RP Atkinson, SH (reprint author), Univ Oxford, Dept Paediat, Childrens Hosp John Radcliffe, Oxford, England.
EM sarah.atkinson@paediatrics.ox.ac.uk
OI Kwiatkowski, Dominic/0000-0002-5023-0176
FU United Kingdom Medical Research Council (London)
FX This work was supported by the United Kingdom Medical Research Council
   (London).
CR Aidoo M, 2001, GENET EPIDEMIOL, V21, P201, DOI 10.1002/gepi.1029
   ALBERTELLA MR, 1994, HUM MOL GENET, V3, P793, DOI 10.1093/hmg/3.5.793
   ALVAREZHERNANDEZ X, 1989, LAB INVEST, V61, P319
   Asobayire FS, 2001, AM J CLIN NUTR, V74, P776
   Atkinson SH, 2006, PLOS MED, V3, P652, DOI 10.1371/journal.pmed.0030172
   Beutler E, 2002, BLOOD, V100, P2268, DOI 10.1182/blood-2002-05-1520
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   CLARK IA, 1988, BRIT J HAEMATOL, V70, P99, DOI 10.1111/j.1365-2141.1988.tb02440.x
   COOK JD, 1974, AM J CLIN NUTR, V27, P681
   *COUNC MMR NANA NA, 2001, NAT SURV PREV VIT A
   Crawley J, 2004, AM J TROP MED HYG, V71, P25
   DALFONSO S, 1994, IMMUNOGENETICS, V39, P150
   Distante S, 2003, SCAND J GASTROENTERO, V38, P871, DOI 10.1080/00365520310003444
   Doherty CP, 2007, J NUTR, V137, P1341
   DROUET C, 1991, J IMMUNOL, V147, P1694
   Fargion S, 2001, BLOOD, V97, P3707, DOI 10.1182/blood.V97.12.3707
   Feelders RA, 1998, EUR J CLIN INVEST, V28, P520
   Gonzalez S, 2003, AM J GASTROENTEROL, V98, P1101, DOI 10.1016/S0002-9270(03)00134-5
   Griffin TJ, 2000, TRENDS BIOTECHNOL, V18, P77, DOI 10.1016/S0167-7799(99)01401-8
   Hanchard N, 2006, IMMUNOGENETICS, V58, P465, DOI 10.1007/s00251-006-0118-1
   Johnson D, 2004, FEBS LETT, V573, P195, DOI 10.1016/j.febslet.2004.07.081
   Kaluza W, 2000, J INVEST DERMATOL, V114, P1180, DOI 10.1046/j.1523-1747.2000.00001.x
   Krayenbuehl PA, 2006, CLIN CHEM, V52, P1552, DOI 10.1373/clinchem.2005.065417
   Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7
   Kurtzhals JAL, 1999, T ROY SOC TROP MED H, V93, P623, DOI 10.1016/S0035-9203(99)90073-1
   KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5
   Laftah AH, 2006, BIOCHEM J, V397, P61, DOI 10.1042/BJ20060215
   May J, 2000, J INFECT DIS, V182, P1570, DOI 10.1086/315857
   McGuire W, 1999, J INFECT DIS, V179, P287, DOI 10.1086/314533
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   MOLDAWER LL, 1989, FASEB J, V3, P1637
   MOLVIG J, 1988, SCAND J IMMUNOL, V27, P705, DOI 10.1111/j.1365-3083.1988.tb02404.x
   Natividad A, 2007, GENES IMMUN, V8, P288, DOI 10.1038/sj.gene.6364384
   Othoro C, 1999, J INFECT DIS, V179, P279, DOI 10.1086/314548
   Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047
   POCIOT F, 1995, SCAND J IMMUNOL, V42, P501, DOI 10.1111/j.1365-3083.1995.tb03686.x
   Rees DC, 1998, BRIT J HAEMATOL, V103, P365
   ROODMAN GD, 1987, EXP HEMATOL, V15, P928
   Scaccabarozzi A, 2000, BRIT J HAEMATOL, V110, P978, DOI 10.1046/j.1365-2141.2000.02280.x
   Sharma N, 2005, BIOCHEM J, V390, P437, DOI 10.1042/BJ20050256
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Stoltzfus RJ, 1997, J NUTR, V127, P293
   TORTI SV, 1988, J BIOL CHEM, V263, P12638
   Udalova IA, 2000, INFECT IMMUN, V68, P5447, DOI 10.1128/IAI.68.9.5447-5449.2000
   ULICH TR, 1990, EXP HEMATOL, V18, P311
   Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809
   Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6
   Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
   ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847
NR 52
TC 19
Z9 20
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD NOV 15
PY 2008
VL 112
IS 10
BP 4276
EP 4283
DI 10.1182/blood-2008-06-162008
PG 8
WC Hematology
SC Hematology
GA 369JU
UT WOS:000260691300050
PM 18716131
OA No
DA 2017-08-15
ER

PT J
AU Viviani, S
   Carrieri, P
   Bah, E
   Hall, AJ
   Kirk, GD
   Mendy, M
   Montesano, R
   Plymoth, A
   Sam, O
   Van der Sande, M
   Whittle, H
   Hainaut, P
AF Viviani, Simonetta
   Carrieri, Patrizia
   Bah, Ebrima
   Hall, Andrew J.
   Kirk, Gregory D.
   Mendy, Maimuna
   Montesano, Ruggero
   Plymoth, Amelie
   Sam, Omar
   Van der Sande, Marianne
   Whittle, Hilton
   Hainaut, Pierre
CA Gambia Hepatitis Intervention Stud
TI 20 Years into the Gambia Hepatitis Intervention Study: Assessment of
   Initial Hypotheses and Prospects for Evaluation of Protective
   Effectiveness Against Liver Cancer
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID B VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; WEST-AFRICA; EXPANDED
   PROGRAM; VACCINATION; CHILDREN; IMMUNIZATION; AFLATOXIN; EFFICACY;
   INFANCY
AB Primary hepatocellular carcinoma is the commonest cancer in The Gambia. The Gambia Hepatitis Intervention Study (GHIS) was established in 1986 to evaluate the protective effectiveness of infant hepatitis B immunization in the prevention of chronic liver disease, particularly, hepatocellular carcinoma and cirrhosis later in adult life. This program was designed based on a series of assumptions. Here, we used data from observational and epidemiologic studies developed since 1986 to examine the validity of these assumptions. We found that (a) hepatitis B vaccine coverage was 15% more than originally assumed, (b) protection against hepatitis B virus (HBV) infection was not dependent on the number of vaccine doses received, (C) perinatal infection with HBV was of negligible importance, and (d) the HBV attributable risk of hepatocellular carcinoma at age <50 was 70% to 80%, lower than initially assumed. Based on these data, the final outcome of the GHIS should be measurable from 2017, sooner than originally assumed. The GHIS strategy takes into account-specific patterns of virus epidemiology and natural history of hepatocellular carcinoma in Africa and provides a model for integrating and evaluating new vaccines into the Expanded Programme of Immunization of sub-Saharan African countries. (Cancer Epidemiol Biomarkers Prev 2008;17(11):3216-23)
C1 [Viviani, Simonetta; Bah, Ebrima; Plymoth, Amelie; Hainaut, Pierre] Int Agcy Res Canc, F-69372 Lyon 08, France.
   [Carrieri, Patrizia] INSERM, U379, Marseille, France.
   [Viviani, Simonetta; Bah, Ebrima; Mendy, Maimuna] Gambia Hepatitis Intervent Study, Fajara, Gambia.
   [Mendy, Maimuna; Van der Sande, Marianne; Whittle, Hilton] MRC Labs, Fajara, Gambia.
   [Hall, Andrew J.] London Sch Hyg & Trop Med, London WC1, England.
   [Kirk, Gregory D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Sam, Omar] Dept State Hlth & Social Serv, Banjul, Gambia.
RP Hainaut, P (reprint author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.
EM hainaut@iarc.fr
RI Kirk, Gregory/A-8484-2009; Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610; Inskip, Hazel/0000-0001-8897-1749
FU IARC; Medical Research Council of the United Kingdom; Government of the
   Republic of the Gambia; Direzione Generale per la Cooperazione alto
   Sviluppo of the Ministry of Foreign Affairs of Italy (1985-1990);
   Regione Autonorna Valle d' Aosta of Italy (1991-1997); Swedish Medical
   Research Council (1991-1997)
FX The Gambia Hepatitis Intervention Study is a joint undertaking of the
   IARC, the Medical Research Council of the United Kingdom, and the
   Government of the Republic of the Gambia. This programme was funded by
   the Direzione Generale per la Cooperazione alto Sviluppo of the Ministry
   of Foreign Affairs of Italy (1985-1990), the Regione Autonorna Valle d'
   Aosta of Italy (1991-1997), and the Swedish Medical Research Council
   (1991-1997).
CR Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   BAH E, 1990, BRIT J CANCER, V62, P647, DOI 10.1038/bjc.1990.347
   Brechot C, 2004, GASTROENTEROLOGY, V127, pS56, DOI 10.1053/j.gastro.2004.09.016
   *CENTR STAT DEP, 1996, NAT MIGR AN
   Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602
   CHOTARD J, 1992, J INFECT DIS, V166, P764
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   HALL A J, 1987, Cancer Research, V47, P5782
   HALL AJ, 1989, LANCET, V1, P1057
   INSKIP HM, 1991, INT J EPIDEMIOL, V20, P770, DOI 10.1093/ije/20.3.770
   INSKIP HM, 1991, INT J EPIDEMIOL, V20, P764, DOI 10.1093/ije/20.3.764
   Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
   Kao JH, 2002, LANCET INFECT DIS, V2, P395, DOI 10.1016/S1473-3099(02)00315-8
   Kew MC, 2003, LIVER INT, V23, P405, DOI 10.1111/j.1478-3231.2003.00869.x
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kirk GD, 2006, CARCINOGENESIS, V27, P2070, DOI 10.1093/carcin/bgl060
   Koulibaly M, 1997, INT J CANCER, V70, P39, DOI 10.1002/(SICI)1097-0215(19970106)70:1<39::AID-IJC6>3.0.CO;2-7
   Montesano R, 1997, J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844
   PARKIN DM, 2002, CA CANC J CLIN, V55, P74
   RYDER RW, 1992, AM J EPIDEMIOL, V136, P1122
   SUN ZT, 1991, CANCER DETECT PREV, V15, P313
   Szymanska K, 2004, INT J CANCER, V110, P374, DOI 10.1002/ijc.20103
   TORTEY E, 1985, LANCET, V1, P514
   Turner PC, 2005, LANCET, V365, P1950, DOI 10.1016/S0140-6736(05)66661-5
   VANDERSANDE MA, 2007, PLOS ONE, V2, pE753
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   Whittle H, 2002, BRIT MED J, V325, P569, DOI 10.1136/bmj.325.7364.569
   WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6
   WILD CP, 1993, CANCER EPIDEM BIOMAR, V2, P555
   WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229
   WILD CP, 1992, TOXICOL LETT, P64
NR 31
TC 36
Z9 36
U1 2
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD NOV
PY 2008
VL 17
IS 11
BP 3216
EP 3223
DI 10.1158/1055-9965.EPI-08-0303
PG 8
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 372IY
UT WOS:000260896500042
PM 18990765
OA No
DA 2017-08-15
ER

PT J
AU Kuniholm, MH
   Lesi, OA
   Mendy, M
   Akano, AO
   Sam, O
   Hall, AJ
   Whittle, H
   Bah, E
   Goederts, JJ
   Hainaut, P
   Kirk, GD
AF Kuniholm, Mark H.
   Lesi, Olufunmilayo A.
   Mendy, Maimuna
   Akano, Aliu O.
   Sam, Omar
   Hall, Andrew J.
   Whittle, Hilton
   Bah, Ebrima
   Goederts, James J.
   Hainaut, Pierre
   Kirk, Gregory D.
TI Aflatoxin Exposure and Viral Hepatitis in the Etiology of Liver
   Cirrhosis in The Gambia, West Africa
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article
DE aflatoxin; Africa; hepatitis B virus; liver cirrhosis; p53; The Gambia;
   ultrasound
ID HEPATOCELLULAR-CARCINOMA PATIENTS; B-VIRUS-INFECTION; C VIRUS; P53
   MUTATIONS; PLASMA DNA; DEVELOPING-COUNTRIES; ALCOHOL INTAKE; TP53
   MUTATION; RISK-FACTORS; CANCER
AB BACKGROUND: Cirrhosis of the liver is thought to be a major cause of morbidity and mortality in sub-Saharan Africa, but few controlled studies on the etiology of cirrhosis have been conducted in this region.
   OBJECTIVES: We aimed to elucidate the association between environmental and infectious exposures and cirrhosis in The Gambia.
   METHODS: Ninety-seven individuals were diagnosed with cirrhosis using a validated ultrasound scoring system and were compared with 397 controls. Participants reported demographic and food frequency information. Blood samples were tested for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis C virus (HCV) antibody, HCV RNA, and the aflatoxin-associated 249(ser) TP53 mutation.
   RESULTS: HBsAg seropositivity was associated with a significant increase in risk of cirrhosis [odds ratio (OR) = 8.0; 95% confidence interval (Cl), 4.4-14.7] as was the presence of HBeAg (OR = 10.3; 95% CI, 2.0-53.9) and HCV infection (OR = 3.3; 95% CI, 1.2-9.5). We present novel data that exposure to aflatoxin, as assessed both by high lifetime groundnut (peanut) intake and by the presence of the 249(ser) TP53 mutation in plasma, is associated with a significant increase in the risk for cirrhosis (OR = 2.8; 95% CI, 1.1-7.7 and OR = 3.8; 95% CI, 1.5-9.6, respectively). Additionally, aflatoxin and hepatitis B virus exposure appeared to interact synergistically to substantially increase the risk of cirrhosis, although this was not statistically significant.
   CONCLUSIONS: Our results suggest that the spectrum of morbidity associated with aflatoxin exposure could include cirrhosis.
C1 [Kuniholm, Mark H.; Kirk, Gregory D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Program Infect Dis, Baltimore, MD USA.
   [Lesi, Olufunmilayo A.; Bah, Ebrima] Gambia Hepatitis Intervent Study, Int Agcy Res Canc, Banjul, Gambia.
   [Lesi, Olufunmilayo A.] Univ Lagos, Teaching Hosp, Dept Med, Lagos, Nigeria.
   [Mendy, Maimuna; Whittle, Hilton] MRC Labs, Banjul, Gambia.
   [Akano, Aliu O.; Sam, Omar] Royal Victoria Teaching Hosp, Dept Med Serv, Banjul, Gambia.
   [Akano, Aliu O.] Natl Hosp, Dept Radiodiag, Abuja, Nigeria.
   [Hall, Andrew J.] London Sch Hyg & Trop Med, London WC1, England.
   [Goederts, James J.] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, Dept Hlth & Human Serv,NIH, Bethesda, MD 20892 USA.
   [Hainaut, Pierre] Gambia Hepatitis Intervent Study, Int Agcy Res Canc, Lyon, France.
RP Kirk, GD (reprint author), 615 N Wolfe St,E-6533, Baltimore, MD 21205 USA.
EM gkirk@jhsph.edu
RI Kirk, Gregory/A-8484-2009; Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
FU National Cancer Institute; National Institutes of Health [N02-CP40521]
FX This work was supported by the National Cancer Institute, National
   Institutes of Health, contract N02-CP40521.
CR AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586
   AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   Bosch F Xavier, 2005, Clin Liver Dis, V9, P191, DOI 10.1016/j.cld.2004.12.009
   Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65
   Corrao G, 1998, EUR J EPIDEMIOL, V14, P447, DOI 10.1023/A:1007411423766
   Gershwin ME, 2005, HEPATOLOGY, V42, P1194, DOI 10.1002/hep.20907
   Gong YY, 2004, ENVIRON HEALTH PERSP, V112, P1334, DOI 10.1289/ehp.6954
   Groopman JD, 2008, ANNU REV PUBL HEALTH, V29, P187, DOI [10.1146/annurev.publhealth.29.020907.090859, 10.1146/annurev.publhealth.29.020907.09089]
   Hall A.J., 1994, TOXICOLOGY AFLATOXIN, P233
   Hung CH, 2003, J GASTROENTEROL, V38, P153, DOI 10.1007/s005350300025
   Hutin Y, 2004, J CLIN PHARMACOL, V44, P20, DOI 10.1177/0091270003258669
   International Agency for Research on Cancer, 1993, IARC MON EV CARC RIS, V56, P245
   Iloeje UH, 2006, GASTROENTEROLOGY, V130, P678, DOI 10.1053/j.gastro.2005.11.016
   Jackson PE, 2003, CARCINOGENESIS, V24, P1657, DOI 10.1093/carcin/bgg101
   Kew MC, 2003, LIVER INT, V23, P405, DOI 10.1111/j.1478-3231.2003.00869.x
   Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kirk GD, 2000, J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148
   Kirk GD, 2006, CARCINOGENESIS, V27, P2070, DOI 10.1093/carcin/bgl060
   Lesi OA, 2002, NIG Q J HOSP MED, V12, P1
   Lewis L, 2005, ENVIRON HEALTH PERSP, V113, P1763, DOI 10.1289/ehp.7998
   LIN DY, 1993, J CLIN ULTRASOUND, V21, P303, DOI 10.1002/jcu.1870210502
   Lin XM, 2005, J GASTROEN HEPATOL, V20, P833, DOI 10.1111/j.1400-1746.2005.03813.x
   Lleonart ME, 2005, CANCER EPIDEM BIOMAR, V14, P2956, DOI 10.1158/1055-9965.EPI-05-0612
   Mace K, 1997, CARCINOGENESIS, V18, P1291, DOI 10.1093/carcin/18.7.1291
   Mastrangelo G, 2004, ENVIRON HEALTH PERSP, V112, P1188, DOI 10.1289/ehp.6972
   McMahon BJ, 2005, SEMIN LIVER DIS, V25, P3, DOI 10.1055/s-2005-915644
   Ortatatli M, 2005, RES VET SCI, V78, P61, DOI 10.1016/j.rvsc.2004.06.006
   Poonawala A, 2000, HEPATOLOGY, V32, P689, DOI 10.1053/jhep.2000.17894
   QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3
   Schneider ARJ, 2005, LIVER INT, V25, P1150, DOI 10.1111/j.1478-3231.2005.01164.x
   Seffner W, 1997, TOXICOL LETT, V92, P161, DOI 10.1016/S0378-4274(97)00052-0
   Shen L, 2006, WORLD J GASTROENTERO, V12, P1292
   Sohn S, 2000, MUTAT RES-DNA REPAIR, V460, P17, DOI 10.1016/S0921-8777(00)00010-0
   Strosnider H, 2006, ENVIRON HEALTH PERSP, V114, P1898, DOI 10.1289/ehp.9302
   Szymanska K, 2004, INT J CANCER, V110, P374, DOI 10.1002/ijc.20103
   TAKANO S, 1995, HEPATOLOGY, V21, P650
   Tong WM, 2006, INT J CANCER, V119, P745, DOI 10.1002/ijc.21890
   TSAI JF, 1994, LIVER, V14, P98
   Tsai JF, 2003, MEDICINE, V82, P365, DOI 10.1097/01.md.0000090401.56130.59
   Turner PC, 2005, LANCET, V365, P1950, DOI 10.1016/S0140-6736(05)66661-5
   Turner PC, 2003, ENVIRON HEALTH PERSP, V111, P217, DOI 10.1289/ehp.5753
   World Health Organization, 2003, WORLD HLTH REP SHAP
   WILD CP, 1993, CANCER EPIDEM BIOMAR, V2, P555
   Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1<1::AID-IJC1>3.0.CO;2-I
   Wild CP, 2002, MUTAGENESIS, V17, P471, DOI 10.1093/mutage/17.6.471
   Yamada H, 2006, J HEPATOL, V44, P68, DOI 10.1016/j.jhep.2005.08.009
   Zhang MD, 2006, BLOOD, V107, P892, DOI 10.1182/blood-2005-07-2781
NR 49
TC 26
Z9 26
U1 0
U2 4
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD NOV
PY 2008
VL 116
IS 11
BP 1553
EP 1557
DI 10.1289/ehp.11661
PG 5
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA 366ZG
UT WOS:000260521500031
PM 19057710
OA gold
DA 2017-08-15
ER

PT J
AU Ceesay, SJ
   Casals-Pascual, C
   Erskine, J
   Anya, SE
   Duah, NO
   Fulford, AJC
   Sesay, SSS
   Abubakar, I
   Dunyo, S
   Sey, O
   Palmer, A
   Fofana, M
   Corrah, T
   Bojang, KA
   Whittle, HC
   Greenwood, BM
   Conway, DJ
AF Ceesay, Serign J.
   Casals-Pascual, Climent
   Erskine, Jamie
   Anya, Samuel E.
   Duah, Nancy O.
   Fulford, Anthony J. C.
   Sesay, Sanie S. S.
   Abubakar, Ismaela
   Dunyo, Samuel
   Sey, Omar
   Palmer, Ayo
   Fofana, Malang
   Corrah, Tumani
   Bojang, Kalifa A.
   Whittle, Hilton C.
   Greenwood, Brian M.
   Conway, David J.
TI Changes in malaria indices between 1999 and 2007 in The Gambia: a
   retrospective analysis
SO LANCET
LA English
DT Article
ID TREATED BED NETS; RESISTANT PLASMODIUM-FALCIPARUM; MOSQUITO NETS;
   WEST-AFRICA; RURAL AREA; FOLLOW-UP; MORTALITY; CHILDREN; MORBIDITY;
   TRIAL
AB Background Malaria is a major cause of morbidity and mortality in Africa. International effort and funding for control has been stepped up, with substantial increases from 2003 in the delivery of malaria interventions to pregnant women and children younger than 5 years in The Gambia. We investigated the changes in malaria indices in this country, and the causes and public-health significance of these changes.
   Methods We undertook a retrospective analysis of original records to establish numbers and proportions of malaria inpatients, deaths, and blood-slide examinations at one hospital over 9 years (January, 1999-December, 2007), and at four health facilities in three different administrative regions over 7 years (January, 2001-December, 2007). We obtained additional data from single sites for haernoglobin concentrations in paediatric admissions and for age distribution of malaria admissions.
   Findings From 2003 to 2007, at four sites with complete slide examination records, the proportions of malaria-positive slides decreased by 82% (3397/10861 in 2003 to 337/6142 in 2007), 85% (137/1259 to 6/368), 73% (3664/16932 to 666/11333), and 50% (1206/3304 to 336/1853). At three sites with complete admission records, the proportions of malaria admissions fell by 74% (435/2530 to 69/1531), 69% (797/2824 to 89/1032), and 27% (2204/4056 to 496/1251.). Proportions of deaths attributed to malaria in two hospitals decreased by 100% (seven of 115 in 2003 to none of 117 in 2007) and 90% (22/122 in 2003 to one of 58 in 2007). Since 2004, mean haemoglobin concentrations for all-cause admissions increased by 12 g/L (85 g/L in 2000-04 to 97 g/L in 2005-07), and mean age of paediatric malaria admissions increased from 3.9 years (95% CI 3.7-4 . 0) to 5.6 years (5.0-6.2).
   Interpretation A large proportion of the malaria burden has been alleviated in The Gambia. Our results encourage consideration of a policy to eliminate malaria as a public-health problem, while emphasising the importance of accurate and continuous surveillance.
   Funding UK Medical Research Council,
C1 [Ceesay, Serign J.; Casals-Pascual, Climent; Duah, Nancy O.; Fulford, Anthony J. C.; Sesay, Sanie S. S.; Abubakar, Ismaela; Dunyo, Samuel; Corrah, Tumani; Bojang, Kalifa A.; Whittle, Hilton C.; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Erskine, Jamie] WEC Mission Hosp, Sibanor, Western Region, Gambia.
   [Anya, Samuel E.] Univ Gambia, Sch Med & Allied Hlth Sci, Kanifing, Gambia.
   [Anya, Samuel E.; Palmer, Ayo] CIAM Publ Hlth Res & Dev Ctr, Kanifing, Gambia.
   [Fulford, Anthony J. C.; Greenwood, Brian M.; Conway, David J.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Sey, Omar] AFPRC Farafenni Hosp, N Bank Region, Gambia.
   [Fofana, Malang] NMCP, Banjul, Gambia.
RP Conway, DJ (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM dconway@mrc.gm
OI Duah, Nancy/0000-0001-8819-1793; Conway, David/0000-0002-8711-3037
FU UK Medical Research Council
FX Financial support for the research was provided by the UK Medical
   Research Council (MRC). We thank Jula Jaiteh. and Lamin Sanyang (Senior
   Nursing Officers at Government health facilities) for providing hospital
   records and helping to extract data; Gibril Bah, Lamin Manneh, Bernard
   Ndaye, Lamin Gibba. Fabakary Sanyang, Hawa Manneh. Demba B T Sainbou,
   and Yorro Bah (MRC staff) for data extraction of the haematology
   laboratory) and ward records: Aja Abbie Khan (Head of Regional Health
   Team for Western Division) for support in implementing the project at
   the Government health facilities: Andrew Prentice (Head of MRC Nutrition
   Research Programme) for supporting the Keneba laboratory record database
   management: Pamela Collier Njie and Muminatou Jallow for help with the
   provision of clinical data front the MRC ward in Fajara; and many other
   colleagues and partner organisations who have encouraged this work.
CR ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   Anya SE, 2004, AM J TROP MED HYG, V70, P510
   Bhattarai A, 2007, PLOS MED, V4, P1784, DOI 10.1371/journal.pmed.0040309
   Binka FN, 2002, T ROY SOC TROP MED H, V96, P597, DOI 10.1016/S0035-9203(02)90321-4
   BRUCECHWATT LJ, 1973, LANCET, V2, P547
   Butler D, 2007, NATURE, V450, P144, DOI 10.1038/450144b
   Caputo B, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-182
   Cavanagh DR, 1998, J IMMUNOL, V161, P347
   Chambers RG, 2008, LANCET, V371, P1399, DOI 10.1016/S0140-6736(08)60609-1
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   Diallo DA, 2004, B WORLD HEALTH ORGAN, V82, P85
   Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102
   Dunyo S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010014
   Fegan GW, 2007, LANCET, V370, P1035, DOI 10.1016/S0140-6736(07)61477-9
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   GREENWOOD BM, 1988, LANCET, V1, P1121
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   KOYATE B, 2007, PLOS MED, V4, pE127
   MARSDEN P. D., 1964, TRANS ROY SOC TROP MED HYG, V58, P455, DOI 10.1016/0035-9203(64)90101-4
   MCGREGOR IA, 1956, BRIT MED J, V2, P686
   Meerman L, 2005, J INFECT DIS, V192, P1651, DOI 10.1086/496887
   MENON A, 1990, T ROY SOC TROP MED H, V84, P768, DOI 10.1016/0035-9203(90)90071-L
   MENON A, 1990, T ROY SOC TROP MED H, V84, P638, DOI 10.1016/0035-9203(90)90130-7
   *MICS, 2002, GAMB MULT IND CLUST, P1
   *MICS, 2007, GAMB MULT IND CLUST, P1
   Nyarango PM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-33
   OKIRO EA, 2007, MALARIA J, V6, pE151
   Polley SD, 2004, VACCINE, V23, P718, DOI 10.1016/j.vaccine.2004.05.031
   Shanks GD, 2008, LANCET INFECT DIS, V8, P564, DOI [10.1016/S1473-3099(08)70130-0, 10.1016/S473-3099(08)70130-0]
   Sharp BL, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-52
   Sharp BL, 2007, AM J TROP MED HYG, V76, P42
   Snow RW, 2008, PLOS MED, V5, P1068, DOI 10.1371/journal.pmed.0050142
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9
   Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   *UNICEF, 2007, MAL CHILDR PROGR INT, P1
   *WHO, 2008, IMP LONG LAST INS NE
   Williams Christopher J, 2007, Travel Med Infect Dis, V5, P295, DOI 10.1016/j.tmaid.2007.05.001
   [Anonymous], 2007, LANCET, V370, P1459
NR 41
TC 242
Z9 246
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD NOV 1
PY 2008
VL 372
IS 9649
BP 1545
EP 1554
DI 10.1016/S0140-6736(08)61654-2
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 367ZG
UT WOS:000260590500026
PM 18984187
OA No
HC Y
HP N
DA 2017-08-15
ER

PT J
AU Greenwood, B
   Bojang, K
   Chandramohan, D
   Cisse, B
   Kweku, M
   Milligan, P
AF Greenwood, Brian
   Bojang, Kalifa
   Chandramohan, Daniel
   Cisse, Badara
   Kweku, Margaret
   Milligan, Paul
TI Response to Buffet et al: Intermittent preventive anti-malarial
   treatment to children (IPTc): firebreak or fire trap?
SO TRENDS IN PARASITOLOGY
LA English
DT Editorial Material
ID SENEGALESE CHILDREN; MALARIA; TRIAL
AB Buffet and colleagues have reviewed some of the potential benefits and drawbacks of intermittent preventive antimalarial treatment in children (IPTc). They acknowledge its efficacy but raise concerns about the feasibility of implementing this intervention, its safety, its impact on drug resistance, the possibility that IPTc might impair the development of naturally acquired immunity and its role in a changing environment. We believe that we can address some, although not all, of their concerns.
C1 [Greenwood, Brian; Chandramohan, Daniel; Milligan, Paul] Univ London London Sch Hyg & Trop Med, Dept Infect Dis, London WC1E 7HT, England.
   [Greenwood, Brian; Chandramohan, Daniel; Milligan, Paul] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   [Bojang, Kalifa] MRC Labs, Banjul, Gambia.
   [Cisse, Badara] Univ Dakar, Fac Med, Dept Parasitol, Dakar, Senegal.
   [Kweku, Margaret] Onchocerciasis Chemotherapy Res Ctr, Hohoe, Volta Region, Ghana.
RP Greenwood, B (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect Dis, Keppel St, London WC1E 7HT, England.
EM brain.greenwood@lshtm.ac.uk
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Aponte JJ, 2007, PLOS MED, V4, P1259, DOI 10.1371/journal.pmed.0040242
   Cisse B, 2007, TROP MED INT HEALTH, V12, P46
   Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0
   Committee on the Perspectives on the Role of Intermittent Preventive Treatment for Malaria in Infants, 2008, ASS ROL INT PREV TRE
   DICKO A, 2008, MALARIA J, V7, pE123
   Greenwood BM, 1995, T ROY SOC TROP MED H, V89, P629, DOI 10.1016/0035-9203(95)90419-0
   Olliaro P, 1996, LANCET, V348, P1196, DOI 10.1016/S0140-6736(96)06217-4
   Sokhna C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001471
NR 8
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4922
J9 TRENDS PARASITOL
JI Trends Parasitol.
PD NOV
PY 2008
VL 24
IS 11
BP 485
EP 486
DI 10.1016/j.pt.2008.08.003
PG 2
WC Parasitology
SC Parasitology
GA 376CF
UT WOS:000261159900003
OA No
DA 2017-08-15
ER

PT J
AU Finan, C
   Ota, MOC
   Marchant, A
   Newport, MJ
AF Finan, Chris
   Ota, Martin O. C.
   Marchant, Arnaud
   Newport, Melanie J.
TI Natural Variation in Immune Responses to Neonatal Mycobacterium bovis
   Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian
   Infants
SO PLOS ONE
LA English
DT Article
AB Background: There is a need for new vaccines for tuberculosis ( TB) that protect against adult pulmonary disease in regions where BCG is not effective. However, BCG could remain integral to TB control programmes because neonatal BCG protects against disseminated forms of childhood TB and many new vaccines rely on BCG to prime immunity or are recombinant strains of BCG. Interferon-gamma (IFN-gamma) is required for immunity to mycobacteria and used as a marker of immunity when new vaccines are tested. Although BCG is widely given to neonates IFN-gamma responses to BCG in this age group are poorly described. Characterisation of IFN-gamma responses to BCG is required for interpretation of vaccine immunogenicity study data where BCG is part of the vaccination strategy.
   Methodology/Principal Findings: 236 healthy Gambian babies were vaccinated with M. bovis BCG at birth. IFN-gamma, interleukin (IL)-5 and IL-13 responses to purified protein derivative (PPD), killed Mycobacterium tuberculosis (KMTB), M. tuberculosis short term culture filtrate (STCF) and M. bovis BCG antigen 85 complex (Ag85) were measured in a whole blood assay two months after vaccination. Cytokine responses varied up to 10 log-fold within this population. The majority of infants (89-98% depending on the antigen) made IFN-gamma responses and there was significant correlation between IFN-gamma responses to the different mycobacterial antigens (Spearman's coefficient ranged from 0.340 to 0.675, p = 10(-6)-10(-22)). IL-13 and IL-5 responses were generally low and there were more non-responders (33-75%) for these cytokines. Nonetheless, significant correlations were observed for IL-13 and IL-5 responses to different mycobacterial antigens
   Conclusions/Significance: Cytokine responses to mycobacterial antigens in BCG-vaccinated infants are heterogeneous and there is significant inter-individual variation. Further studies in large populations of infants are required to identify the factors that determine variation in IFN-gamma responses.
C1 [Finan, Chris; Newport, Melanie J.] Brighton & Sussex Med Sch, Dept Med, Falmer, Sussex, England.
   [Ota, Martin O. C.] MRC Labs, Fajara, Gambia.
   [Marchant, Arnaud] Free Univ Brussels, Inst Med Immunol, B-1050 Brussels, Belgium.
RP Finan, C (reprint author), Brighton & Sussex Med Sch, Dept Med, Falmer, Sussex, England.
EM m.j.newport@bsms.ac.uk
FU MRC UK; British Lung Foundation; The Wellcome Trust [061147]
FX MRC UK, British Lung Foundation (CF), The Wellcome Trust (MN, grant
   number 061147). The study sponsors had no role in study design;
   collection, analysis, and interpretation of data; writing of the paper;
   or decision to submit it for publication.
CR Behr MA, 2002, LANCET INFECT DIS, V2, P86, DOI 10.1016/S1473-3099(02)00182-2
   BENNETT S, 1992, J IMMUNOL METHODS, V146, P229, DOI 10.1016/0022-1759(92)90232-I
   Beveridge NER, 2007, EUR J IMMUNOL, V37, P3089, DOI 10.1002/eji.2007375041
   Black GF, 2001, J INFECT DIS, V184, P322, DOI 10.1086/322042
   Black GF, 2001, INT J TUBERC LUNG D, V5, P664
   Bonecini-Almeida MG, 1998, J IMMUNOL, V160, P4490
   Brookes RH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002921
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243
   Dai G, 1998, FRONT BIOSCI, V3, P110
   Davids V, 2006, J INFECT DIS, V193, P531, DOI 10.1086/499825
   Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901
   Dupuis S, 2000, IMMUNOL REV, V178, P129, DOI 10.1034/j.1600-065X.2000.17810.x
   Ellner JJ, 2000, CLIN INFECT DIS, V30, pS279, DOI 10.1086/313874
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Fletcher Helen, 2006, Expert Opin Emerg Drugs, V11, P207, DOI 10.1517/14728214.11.2.207
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Hill AVS, 2006, ANNU REV GENET, V40, P469, DOI 10.1146/annurev.genet.40.110405.090546
   Hill PC, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-156
   Horwitz MA, 2003, INFECT IMMUN, V71, P1672, DOI 10.1128/IAI.71.4.1672-1679.2003
   Jouanguy E, 1997, J CLIN INVEST, V100, P2658, DOI 10.1172/JCI119810
   Lalvani A, 2007, CHEST, V131, P1898, DOI 10.1378/chest.06-2471
   Mahomed H, 2006, INT J TUBERC LUNG D, V10, P310
   Malhotra I, 1999, J IMMUNOL, V162, P6843
   Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135
   Marchant A, 1999, J IMMUNOL, V163, P2249
   Newport MJ, 2004, GENES IMMUN, V5, P122, DOI 10.1038/sj.gene.6364051
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Ota MOC, 2006, J TROP PEDIATRICS, V52, P136, DOI 10.1093/tropej/fmi087
   Ota MOC, 2002, J IMMUNOL, V168, P919
   Poland Gregory A., 1998, Current Opinion in Pediatrics, V10, P208, DOI 10.1097/00008480-199804000-00017
   Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859
   REICHMAN LB, 1979, CHEST S6, V76, pS764
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154
   Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149
   Sirugo G, 2008, HUM GENET, V123, P557, DOI 10.1007/s00439-008-0511-y
   Soares AP, 2008, J IMMUNOL, V180, P3569
   Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1
   Weir RE, 2006, CLIN EXP IMMUNOL, V146, P390, DOI 10.1111/j.1365-2249.2006.03222.x
   WEIR RE, 1994, J IMMUNOL METHODS, V176, P93, DOI 10.1016/0022-1759(94)90353-0
   World Health Organization, 2006, WHOHTMSTB200635
   World Health Organization (WHO), 2004, WHOHTMTB2004331
   Wu B, 2007, INFECT IMMUN, V75, P3658, DOI 10.1128/IAI.00244-07
NR 46
TC 16
Z9 17
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 22
PY 2008
VL 3
IS 10
AR e3485
DI 10.1371/journal.pone.0003485
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 432IG
UT WOS:000265126100016
PM 18941532
OA gold
DA 2017-08-15
ER

PT J
AU Kirby, MJ
   West, P
   Green, C
   Jasseh, M
   Lindsay, SW
AF Kirby, Matthew J.
   West, Philippa
   Green, Clare
   Jasseh, Momodou
   Lindsay, Steve W.
TI Risk factors for house-entry by culicine mosquitoes in a rural town and
   satellite villages in The Gambia
SO PARASITES & VECTORS
LA English
DT Article
ID AEGYPTI L DIPTERA; CULEX-QUINQUEFASCIATUS; WEST-AFRICA; AEDES-AEGYPTI;
   MALARIA TRANSMISSION; SOUTH-INDIA; BEHAVIOR; VECTORS; TANZANIA; AREA
AB Background: Screening doors, windows and eaves of houses should reduce house entry by eusynanthropic insects, including the common African house mosquito Culex pipiens quinquefasciatus and other culicines. In the pre-intervention year of a randomized controlled trial investigating the protective effects of house screening against mosquito house entry, a multi-factorial risk factor analysis study was used to identify factors influencing house entry by culicines of nuisance biting and medical importance. These factors were house location, architecture, human occupancy and their mosquito control activities, and the number and type of domestic animals within the compound.
   Results: 40,407 culicines were caught; the dominant species were Culex thalassius, Cx. pipiens s.l., Mansonia africanus, M. uniformis and Aedes aegypti. There were four times more Cx. pipiens s.l. in Farafenni town (geometric mean/trap/night = 8.1, 95% confidence intervals, CIs = 7.2-9.1) than in surrounding villages (2.1, 1.9-2.3), but over five times more other culicines in the villages (25.1, 22.1-28.7) than in town (4.6, 4.2-5.2). The presence of Cx. pipiens s.l. was reduced in both settings if the house had closed eaves (odds ratios, OR town = 0.62, 95% CIs = 0.49-0.77; OR village = 0.49, 0.33-0.73), but increased per additional person in the trapping room (OR town = 1.16, 1.09-1.24; OR village = 1.10, 1.02-1.18). In the town only, Cx. pipiens s.l. numbers were reduced if houses had a thatched roof (OR = 0.70, 0.51-0.96), for each additional cow tethered near the house (OR = 0.73, 0.65-0.82) and with increasing distance from a pit latrine (OR = 0.97, 0.95-0.99). In the villages a reduction in Cx. pipiens s.l. numbers correlated with increased horses in the compound (OR = 0.90, 0.82-0.99). The presence of all other culicines was reduced in houses with closed eaves (both locations), with horses tethered outside (village only) and with increasing room height (town only), but increased with additional people in the trapping room and where cows were tethered outside (both locations).
   Conclusion: The findings of this study advocate eave closure and pit latrine treatment in all locations, and zooprophylaxis using horses in rural areas, as simple control measures that could reduce the number of culicines found indoors.
C1 [Kirby, Matthew J.; Lindsay, Steve W.] Univ Durham, Sch Biol & Biomed Sci, Sci Labs, Durham DH1 3LE, England.
   [West, Philippa] Essex Hlth Protect Unit, Witham CM8 2TT, Essex, England.
   [Green, Clare] UCL, Windeyer Inst Med Res, Ctr Infect Dis & Int Hlth, London W1T 4JF, England.
   [Jasseh, Momodou] MRC Labs, Fajara, Gambia.
RP Lindsay, SW (reprint author), Univ Durham, Sch Biol & Biomed Sci, Sci Labs, South Rd, Durham DH1 3LE, England.
EM j.kirby@durham.ac.uk; pippa.west@hotmail.co.uk; clare.green@ucl.ac.uk;
   mjasseh@mrc.gm; s.w.lindsay@durham.ac.uk
FU Medical Research Council, UK [G0400031]
FX This study was funded by the Medical Research Council, UK, grant number
   G0400031.
CR BEIER JC, 1990, J AM MOSQUITO CONTR, V6, P207
   BERTRAM D. S., 1956, Bulletin of Entomological Research, V47, P669
   Bogh C, 2003, B ENTOMOL RES, V93, P279, DOI 10.1079/BER2003239
   Bogh C, 2007, AM J TROP MED HYG, V76, P875
   CHARLWOOD JD, 1994, T ROY SOC TROP MED H, V88, P380, DOI 10.1016/0035-9203(94)90390-5
   CHAVASSE DC, 1995, MED VET ENTOMOL, V9, P141
   CLARKE S, 2001, THESIS U COPENHAGEN
   Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X
   Costantini C, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P209
   Diallo M, 2005, MED VET ENTOMOL, V19, P119, DOI 10.1111/j.0269-283X.2005.00564.x
   Diarrassouba S, 1997, B SOC PATHOL EXOT, V90, P361
   Edwards F. W., 1941, MOSQUITOES ETHIOPIAN, VIII
   *FAO EIO WHO, 1997, AN HLTH YB 1997
   FORATTINI OP, 1993, REV SAUDE PUBL, V27, P398
   GILLIES MT, 1976, B ENTOMOL RES, V66, P5
   Gillies M. T., 1968, ANOPHELINAE AFRICA S
   Gowda N. Ninge, 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P152
   Howell PI, 2007, J VECTOR ECOL, V32, P69, DOI 10.3376/1081-1710(2007)32[69:TIOHCO]2.0.CO;2
   KIRBY MJ, 2008, MALAR J, V7
   Kumar N. Pradeep, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P324
   LAURENCE B. R., 1959, Proceedings of the Royal Entomological Society of London, A, V34, P161
   Lindsay S, 2000, LANCET, V355, P1972, DOI 10.1016/S0140-6736(00)02334-5
   LINDSAY SW, 1988, T ROY SOC TROP MED H, V82, P645, DOI 10.1016/0035-9203(88)90546-9
   Lounibos LP, 2003, WAG UR FRON, V2, P33
   Mahande AM, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-109
   MCLAUGHLIN RE, 1989, J AM MOSQUITO CONTR, V5, P60
   Muturi EJ, 2008, PARASITOL RES, V102, P1329, DOI 10.1007/s00436-008-0914-7
   NJIE M, J MED ENTOM IN PRESS
   Oduola A. O., 2006, Journal of Vector Borne Diseases, V43, P16
   POOPATHI S, 1995, MED VET ENTOMOL, V9, P169, DOI 10.1111/j.1365-2915.1995.tb00174.x
   Rwegoshora RT, 2007, ANN TROP MED PARASIT, V101, P51, DOI 10.1179/136485907X154610
   Samuel PP, 2004, J MED ENTOMOL, V41, P442, DOI 10.1603/0022-2585-41.3.442
   SIMONSEN PE, 2003, MANSONS TROPICAL DIS, P1489
   Smith JL, 2004, AM J TROP MED HYG, V70, P339
   SNOW WF, 1987, MED VET ENTOMOL, V1, P9, DOI 10.1111/j.1365-2915.1987.tb00318.x
   SNOW WF, 1983, J TROP MED HYG, V86, P237
   Takken W, 1999, ANNU REV ENTOMOL, V44, P131, DOI 10.1146/annurev.ento.44.1.131
   THEOBALD FV, 2003, MONOGRAPH CULICIDAE
   Thomas CJ, 2000, T ROY SOC TROP MED H, V94, P159, DOI 10.1016/S0035-9203(00)90257-8
   TRAPE JF, 1987, T ROY SOC TROP MED H, V81, P19, DOI 10.1016/0035-9203(87)90473-1
   TRPIS M, 1978, B ENTOMOL RES, V68, P521
   TRPIS M, 1975, B ENTOMOL RES, V65, P199
   Vatandoost H, 2004, IRAN J ENVIRON HEALT, V1, P42
   Vinogradova EB, 2000, CULEX PIPIENS PIPIEN, P46
   White GB, 1969, ANN REPORT E AFRICAN, P37
   WHITE GB, 1996, MANSONS TROPICAL DIS, P1674
NR 46
TC 13
Z9 14
U1 1
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-3305
J9 PARASITE VECTOR
JI Parasites Vectors
PD OCT 21
PY 2008
VL 1
AR 41
DI 10.1186/1756-3305-1-41
PG 7
WC Parasitology
SC Parasitology
GA 380GE
UT WOS:000261453400001
PM 18939969
OA gold
DA 2017-08-15
ER

PT J
AU Gottlieb, GS
   Eholie, SP
   Nkengasong, JN
   Jallow, S
   Rowland-Jones, S
   Whittle, HC
   Sow, PS
AF Gottlieb, Geoffrey S.
   Eholie, Serge-Paul
   Nkengasong, John N.
   Jallow, Sabelle
   Rowland-Jones, Sarah
   Whittle, Hilton C.
   Sow, Papa Salif
TI A call for randomized controlled trials of antiretroviral therapy for
   HIV-2 infection in West Africa
SO AIDS
LA English
DT Editorial Material
DE Africa; antiretroviral; controlled trial; HIV-2; resource limited
ID PLASMA VIRAL LOAD; IMMUNODEFICIENCY-VIRUS TYPE-2; DRUG-RESISTANCE
   MUTATIONS; VITRO PHENOTYPIC SUSCEPTIBILITY; T-CELL DECLINE;
   HIV-2-INFECTED PATIENTS; PROTEASE INHIBITORS; IN-VITRO; IMMUNOLOGICAL
   RESPONSE; INTEGRASE INHIBITORS
C1 [Gottlieb, Geoffrey S.] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA.
   [Eholie, Serge-Paul] CHU Treichville, Serv Malad Infect & Trop, Abidjan, Cote Ivoire.
   [Nkengasong, John N.] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Jallow, Sabelle; Rowland-Jones, Sarah; Whittle, Hilton C.] MRC Labs, Fajara, Gambia.
   [Sow, Papa Salif] Univ Cheikh Anta Diop Dakar, CHU Fann, Clin Malad Infect Ibrahima Diop Mar, Dakar, Senegal.
   [Jallow, Sabelle] Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium.
RP Gottlieb, GS (reprint author), Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA.
EM gottlieb@u.washington.edu
FU Medical Research Council [G0801751]; NIAID NIH HHS [K08 AI049755-05, K08
   AI049755, R01 AI060466, R01 AI060466-04]
CR Adje-Toure CA, 2003, AIDS, V17, pS49
   Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   Andersson S, 2000, ARCH INTERN MED, V160, P3286, DOI 10.1001/archinte.160.21.3286
   ANDREASSON PA, 1993, AIDS, V7, P989
   Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006
   Boyer PL, 2006, PLOS PATHOG, V2, P101, DOI 10.1371/journal.ppat0020010
   Brandin E, 2003, AIDS RES HUM RETROV, V19, P543, DOI 10.1089/088922203322230905
   Brower ET, 2008, CHEM BIOL DRUG DES, V71, P298, DOI [10.1111/j.1747-0285.2008.00647.x, 10.1111/j.1747.0285.2008.00647.x]
   Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962
   Clark NM, 1998, AIDS, V12, P2506
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602
   Colson P, 2004, J CLIN MICROBIOL, V42, P570, DOI 10.1128/JCM.42.2.570-577.2004
   Damond F, 2005, J CLIN MICROBIOL, V43, P484, DOI 10.1128/JCM.43.1.484-487.2005
   DAMOND F, 2007, P 14 C RETR OPP INF
   Damond F, 2008, AIDS, V22, P665, DOI 10.1097/QAD.0b013e3282f51203
   DECOCK KM, 1990, AIDS, V4, P443, DOI 10.1097/00002030-199005000-00010
   DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083
   Desbois D, 2008, ANTIMICROB AGENTS CH, V52, P1545, DOI 10.1128/AAC.01284-07
   DESCAMPS D, 2003, P 2 IAS C HIV PATH T
   Desclaux A, 2003, AIDS, V17, pS95, DOI 10.1097/00002030-200317003-00013
   Drylewicz J, 2008, AIDS, V22, P457, DOI 10.1097/QAD.0b013e3282f4ddfc
   Eholie S, 2006, INT J EPIDEMIOL, V35, P1329, DOI 10.1093/ije/dyl156
   EVANS LA, 1988, LANCET, V2, P1389
   Gilbert PB, 2003, STAT MED, V22, P573, DOI 10.1002/sim.1342
   Gottlieb GS, 2006, AIDS, V20, P895, DOI 10.1097/01.aids.0000218554.59531.80
   Gottlieb GS, 2002, J INFECT DIS, V185, P905, DOI 10.1086/339295
   Hamel DJ, 2007, AIDS RES HUM RETROV, V23, P1189, DOI 10.1089/aid.2007.0037
   Jallow S, 2006, AIDS, V20, P1455, DOI 10.1097/01.aids.0000233582.64467.8e
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   Maniar JK, 2006, INT J STD AIDS, V17, P781, DOI 10.1258/095646206778691059
   MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332204
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Matheron S, 2006, AIDS, V20, P459, DOI 10.1097/01.aids.0000199829.57112.2f
   Matheron S, 2003, AIDS, V17, P2593, DOI 10.1097/01.aids.0000096907.73209.b9
   Mullins C, 2004, CLIN INFECT DIS, V38, P1771, DOI 10.1086/421390
   Ndour CT, 2006, MED MALADIES INFECT, V36, P111, DOI 10.1016/j.medmal.2005.11.012
   Nkengasong JN, 2000, AIDS RES HUM RETROV, V16, P1371, DOI 10.1089/08892220050140919
   ODEHOURI K, 1989, AIDS, V3, P509, DOI 10.1097/00002030-198908000-00004
   Pieniazek D, 2004, AIDS, V18, P495, DOI 10.1097/01.aids.0000111412.02002.fc
   Popper SJ, 1999, J INFECT DIS, V180, P1116, DOI 10.1086/315010
   Poveda E, 2004, AIDS RES HUM RETROV, V20, P347, DOI 10.1089/088922204322996590
   Ren J, 2002, P NATL ACAD SCI USA, V99, P14410, DOI 10.1073/pnas.222366699
   Rodes B, 2006, J ANTIMICROB CHEMOTH, V57, P709, DOI 10.1093/jac/dkl034
   Rodes B, 2006, AIDS, V20, P127
   Rodes B, 2000, J CLIN MICROBIOL, V38, P1370
   Roquebert B, 2007, ANTIVIR THER, V12, pS92
   Ruelle J, 2007, AIDS RES HUM RETROV, V23, P955, DOI 10.1089/aid.2007.0034
   Schutten M, 2000, NEW ENGL J MED, V342, P1758, DOI 10.1056/NEJM200006083422317
   SIMON F, 1993, AIDS, V7, P1411, DOI 10.1097/00002030-199311000-00002
   Smith NA, 2001, J INFECTION, V42, P126, DOI 10.1053/jinf.2001.0792
   Smith RA, 2008, ANTIMICROB AGENTS CH, V52, P329, DOI 10.1128/AAC.01004-07
   Soriano V, 2000, J MED VIROL, V61, P111, DOI 10.1002/(SICI)1096-9071(200005)61:1<111::AID-JMV18>3.0.CO;2-W
   *UNAIDS WHO, 2006, UNAIDS AIDS EP UPD 2, P1
   van der Ende ME, 2003, AIDS, V17, pS55, DOI 10.1097/00002030-200317003-00008
   van der Loeff MFS, 2006, INT J EPIDEMIOL, V35, P1322, DOI 10.1093/ije/dy1037
   Van Der Sande MAB, 2004, ANN TROP PAEDIATR, V24, P277, DOI 10.1179/027249304225019073
   WHO, 2006, ANT DRUGS TREAT PREG
   World Health Organization, 2002, SCAL ANT THER RES LT
   WHO, 2006, ANT THER HIV INF AD
   Willey S, 2005, ANTIVIR RES, V68, P96, DOI 10.1016/j.antiviral.2005.07.006
   Witvrouw M, 2004, ANTIVIR THER, V9, P57
NR 62
TC 36
Z9 38
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD OCT 18
PY 2008
VL 22
IS 16
BP 2069
EP 2072
DI 10.1097/QAD.0b013e32830edd44
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 365VH
UT WOS:000260436600003
PM 18832869
OA No
DA 2017-08-15
ER

PT J
AU de Jong, BC
   Hill, PC
   Aiken, A
   Awine, T
   Antonio, M
   Adetifa, IM
   Jackson-Sillah, DJ
   Fox, A
   DeRiemer, K
   Gagneux, S
   Borgdorff, MW
   McAdam, KPWJ
   Corrah, T
   Small, PM
   Adegbola, RA
AF de Jong, Bouke C.
   Hill, Philip C.
   Aiken, Alex
   Awine, Timothy
   Antonio, Martin
   Adetifa, Ifedayo M.
   Jackson-Sillah, Dolly J.
   Fox, Annette
   DeRiemer, Kathryn
   Gagneux, Sebastien
   Borgdorff, Martien W.
   McAdam, Keith P. W. J.
   Corrah, Tumani
   Small, Peter M.
   Adegbola, Richard A.
TI Progression to active tuberculosis, but not transmission, varies by
   Mycobacterium tuberculosis lineage in the Gambia
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT Keystone Symposium on Tuberculosis - From Lab Research to Field Trials
CY MAR 20-25, 2007
CL Vancouver, CENT AFR REPUBL
ID IMMUNE-RESPONSE; STRAINS; VIRULENCE; EPIDEMIOLOGY; PARASITES; DISEASE;
   HOSTS
AB Background. There is considerable variability in the outcome of Mycobacterium tuberculosis infection. We hypothesized that Mycobacterium africanum was less likely than M. tuberculosis to transmit and progress to tuberculosis disease.
   Methods. In a cohort study of patients with tuberculosis and their household contacts in The Gambia, we categorized 1808 HIV-negative tuberculosis contacts according to exposure to M. tuberculosis or M. africanum. Positive skin test results indicated transmission, and development of tuberculosis during 2 years of follow-up indicated progression to disease.
   Results. Transmission rates were similar, but rates of progression to disease were significantly lower in contacts exposed to M. africanum than in those exposed to M. tuberculosis (1.0% vs. 2.9%; hazard ratio [HR], 3.1 [95% confidence interval {CI}, 1.1 - 8.7]). Within M. tuberculosis sensu stricto, contacts exposed to a Beijing family strain were most likely to progress to disease (5.6%; HR relative to M. africanum, 6.7 [95% CI, 2.0 - 22]).
   Conclusions. M. africanum and M. tuberculosis transmit equally well to household contacts, but contacts exposed to M. africanum are less likely to progress to tuberculosis disease than those exposed to M. tuberculosis. The variable rate of progression by lineage suggests that tuberculosis variability matters in clinical settings and should be accounted for in studies evaluating tuberculosis vaccines and treatment regimens for latent tuberculosis infection.
C1 [de Jong, Bouke C.; Hill, Philip C.; Aiken, Alex; Awine, Timothy; Antonio, Martin; Adetifa, Ifedayo M.; Jackson-Sillah, Dolly J.; Fox, Annette; McAdam, Keith P. W. J.; Corrah, Tumani; Adegbola, Richard A.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [de Jong, Bouke C.] Stanford Univ, Stanford, CA 94305 USA.
   [DeRiemer, Kathryn] Univ Calif Davis, Davis, CA 95616 USA.
   [Gagneux, Sebastien; Small, Peter M.] Inst Syst Biol, Seattle, WA USA.
   [Borgdorff, Martien W.] Univ Amsterdam, Amsterdam, Netherlands.
   [Borgdorff, Martien W.] Royal Netherlands TB Assoc, The Hague, Netherlands.
RP de Jong, BC (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM bdejong@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675; DeRiemer,
   Kathryn/0000-0002-8375-7505; Gagneux, Sebastien/0000-0001-7783-9048
FU FIC NIH HHS [K01 TW006083, K01 TW006083-06, TW006083]; Medical Research
   Council [MC_U190071468, MC_U190081982]
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403
   ANDERSON RM, 1982, PARASITOLOGY, V85, P411
   Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6
   Blaser MJ, 2007, NATURE, V449, P843, DOI 10.1038/nature06198
   Brodin P, 2004, TRENDS MICROBIOL, V12, P500, DOI 10.1016/j.tim.2004.09.007
   Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977
   Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103
   Gagneux S, 2007, LANCET INFECT DIS, V7, P328, DOI 10.1016/S1473-3099(07)70108-1
   Gao LY, 2004, MOL MICROBIOL, V53, P1677, DOI 10.1111/j.1365-2958.2004.04261.x
   Grange JM, 2001, TUBERCULOSIS, V81, P71, DOI 10.1054/tube.2000.0263
   GRIGG ERN, 1958, AM REV TUBERC PULM, V78, P151
   Gustafson P, 2007, EPIDEMIOLOGY, V18, P340, DOI 10.1097/01.ede.0000259987.46912.2b
   Hill PC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001379
   Hill PC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000183
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907
   LENSKI RE, 1994, J THEOR BIOL, V169, P253, DOI 10.1006/jtbi.1994.1146
   Lopez B, 2003, CLIN EXP IMMUNOL, V133, P30, DOI 10.1046/j.1365-2249.2003.02171.x
   Malik AN, 2005, LANCET INFECT DIS, V5, P174, DOI 10.1016/S1473-3099(05)01310-1
   Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859
   Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402
   Tsolaki AG, 2004, P NATL ACAD SCI USA, V101, P4865, DOI 10.1073/pnas.0305634101
   Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001
   Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205
   World Health Organization, 2007, 2007 TUB FACTS
NR 28
TC 148
Z9 148
U1 0
U2 5
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 1
PY 2008
VL 198
IS 7
BP 1037
EP 1043
DI 10.1086/591504
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 345EO
UT WOS:000258979100013
PM 18702608
OA No
DA 2017-08-15
ER

PT J
AU Prentice, A
AF Prentice, Ann
TI Vitamin D deficiency: a global perspective
SO NUTRITION REVIEWS
LA English
DT Article; Proceedings Paper
CT 22nd Marabou Symposium on the Changing Faces of Vitamin D
CY JUN 01-03, 2007
CL Stockholm, SWEDEN
DE 25-hydroxyvitamin D; calcium; parathyroid hormone; rickets; vitamin D
ID LOW-CALCIUM INTAKE; PARATHYROID-HORMONE; NUTRITIONAL RICKETS;
   HYPOVITAMINOSIS-D; HIGH PREVALENCE; SERUM 25-HYDROXYVITAMIN-D; D
   INSUFFICIENCY; GAMBIAN CHILDREN; PREGNANT-WOMEN; UNITED-STATES
AB The prevalence of clinical vitamin D deficiency (rickets and osteomalacia) is high in many parts of the world, and there is a resurgence of rickets among children of ethnic minority groups in Europe and Australasia. Plasma 25-hydroxyvitamin D concentration (25OHD) is a useful risk marker of clinical vitamin D deficiency. This review summarizes the factors that contribute to differences in 25OHD among populations and provides an overview of the prevalence of low vitamin D status worldwide. It discusses the controversies that surround the interpretation of 25OHD, other proposed indices of vitamin D adequacy and dietary reference values for vitamin D, and describes the emerging evidence that a very low calcium intake may contribute to the etiology of rickets in Africa and Asia. There is an urgent need for action to address the global burden of rickets and osteomalacia. (C) 2008 International Life Sciences Institute.
C1 [Prentice, Ann] Elsie Widdowson Lab, MRC Human Nutr Res, Cambridge CB1 9NL, England.
   [Prentice, Ann] Med Res Council Keneba, Keneba, Gambia.
RP Prentice, A (reprint author), Elsie Widdowson Lab, MRC Human Nutr Res, Cambridge CB1 9NL, England.
EM ann.prentice@mrc-hnr.cam.ac.uk
FU Medical Research Council [MC_U105960371]
CR Abrams SA, 2005, J CLIN ENDOCR METAB, V90, P5576, DOI 10.1210/jc.2005-1021
   Agarwal KS, 2002, ARCH DIS CHILD, V87, P111, DOI 10.1136/adc.87.2.111
   Allgrove J, 2004, ARCH DIS CHILD, V89, P699, DOI 10.1136/adc.2003.036780
   ARNAUD SB, 1976, PEDIATRICS, V57, P221
   Ashraf S, 2002, ARCH DIS CHILD, V87, P263, DOI 10.1136/adc.87.3.263-a
   Aspray TJ, 2005, BONE, V36, P710, DOI 10.1016/j.bone.2005.01.002
   Awumey EMK, 1998, J CLIN ENDOCR METAB, V83, P169, DOI 10.1210/jc.83.1.169
   Barger-Lux MJ, 2002, J CLIN ENDOCR METAB, V87, P4952, DOI 10.1210/jc.2002-020636
   Bates CJ, 2003, OSTEOPOROSIS INT, V14, P152, DOI 10.1007/s00198-002-1338-3
   Binkley N, 2004, J CLIN ENDOCR METAB, V89, P3152, DOI 10.1210/jc.2003-031979
   Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18
   Bodnar LM, 2007, J NUTR, V137, P447
   Calvo MS, 2005, J NUTR, V135, P310
   Calvo MS, 2004, AM J CLIN NUTR, V80, P1710
   Carter GD, 2004, J STEROID BIOCHEM, V89-90, P467, DOI 10.1016/j.jsbmb.2004.03.055
   Carter GD, 2004, CLIN CHEM, V50, P2195, DOI 10.1373/clinchem.2004.040683
   Chapuy MC, 1997, OSTEOPOROSIS INT, V7, P439, DOI 10.1007/s001980050030
   CLEMENTS MR, 1987, NATURE, V325, P62, DOI 10.1038/325062a0
   Commission of the European Communities, 1993, NUTR EN INT EUR COMM
   DAGNELIE PC, 1990, AM J CLIN NUTR, V51, P202
   Datt S, 2002, BJOG-INT J OBSTET GY, V109, P905, DOI 10.1016/S1470-0328(02)01171-0
   Davies PSW, 1999, EUR J CLIN NUTR, V53, P584
   Davies PSW, 1999, EUR J CLIN NUTR, V53, P195, DOI 10.1038/sj.ejcn.1600697
   DeLuca Hector F, 2004, Am J Clin Nutr, V80, p1689S
   Department of Health, 1991, DIET REF VAL FOOD EN
   Department of Health, 1998, NUTR BON HLTH PART R
   Dibba B, 2000, AM J CLIN NUTR, V71, P544
   Dijkstra SH, 2007, ARCH DIS CHILD, V92, P750, DOI 10.1136/adc.2006.105577
   Finch S., 1998, NATL DIET NUTR SURVE, V1
   Fraser DR, 2004, J STEROID BIOCHEM, V89-90, P491, DOI 10.1016/j.jsbmb.2004.03.057
   Gannage-Yared MH, 2000, J BONE MINER RES, V15, P1856, DOI 10.1359/jbmr.2000.15.9.1856
   Gregory J., 2000, NATL DIET NUTR SURVE
   Gregory JR, 1995, NATL DIET NUTR SURVE
   Grover SR, 2001, MED J AUSTRALIA, V175, P251
   Guillemant J, 1996, EUR J CLIN NUTR, V50, P469
   Harris SS, 2006, J NUTR, V136, P1126
   Hathcock JN, 2007, AM J CLIN NUTR, V85, P6
   Henderson L, 2003, NATL DIET NUTR SURVE, V4
   Hill TR, 2004, EUR J CLIN NUTR, V58, P1509, DOI 10.1038/sj.ejcn.1602001
   HOLICK MF, 1992, NEW ENGL J MED, V326, P1178, DOI 10.1056/NEJM199204303261802
   Holick MF, 2005, SEMIN DIALYSIS, V18, P266, DOI 10.1111/j.1525-139X.2005.18402.x
   HOLICK MF, 1994, AM J CLIN NUTR, V60, P619
   Holick Michael F, 2004, Am J Clin Nutr, V80, p1678S
   Hollis BW, 2007, J STEROID BIOCHEM, V103, P473, DOI 10.1016/j.jsbmb.2006.11.004
   Hollis BW, 2006, AM J CLIN NUTR, V84, P272
   Hypponen E, 2007, AM J CLIN NUTR, V85, P860
   Institute of Medicine Food and Nutrition Board, 1997, DIET REF INT CALC PH
   JARJOU LMA, 2004, CALCIUM NUTR RURAL P
   Judkins Annie, 2006, N Z Med J, V119, pU2144
   Kolek OI, 2005, AM J PHYSIOL-GASTR L, V289, pG1036, DOI 10.1152/ajpgi.00243.2005
   Laing CJ, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P117
   Lappe JM, 2006, J AM COLL NUTR, V25, P395
   Lawson M, 1999, BRIT MED J, V318, P28
   Lips P, 2001, J CLIN ENDOCR METAB, V86, P1212, DOI 10.1210/jc.86.3.1212
   Lips P, 2006, J INTERN MED, V260, P245, DOI 10.1111/j.1365-2796.2006.01685.x
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   Lips P, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P1019
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
   Looker AC, 2002, BONE, V30, P771, DOI 10.1016/S8756-3282(02)00692-0
   Malabanan A, 1998, LANCET, V351, P805, DOI 10.1016/S0140-6736(05)78933-9
   MAWER EB, 1972, CLIN SCI, V43, P413
   Munns C, 2006, MED J AUSTRALIA, V185, P268
   Nesby-O'Dell S, 2002, AM J CLIN NUTR, V76, P187
   Norman AW, 2007, J STEROID BIOCHEM, V103, P204, DOI 10.1016/j.jsbmb.2006.12.071
   Norman AW, 1998, AM J CLIN NUTR, V67, P1108
   Odeka E, 2005, ARCH DIS CHILD, V90, P1203
   Ovesen L, 2003, ANN NUTR METAB, V47, P107, DOI 10.1159/000070031
   Patel S, 2007, CALCIFIED TISSUE INT, V80, P221, DOI 10.1007/s00223-007-9001-9
   Pedersen P, 2003, ACTA PAEDIATR, V92, P87
   PETTIFOR JM, 2003, PEDIAT BONE BIOL DIS
   Prentice A, 2004, BRIT J NUTR, V92, pS83, DOI 10.1079/BJN20041159
   Prentice A, 1997, ACTA PAEDIATR, V86, P1006, DOI 10.1111/j.1651-2227.1997.tb15189.x
   Prentice A, 2002, CALCIFIED TISSUE INT, V70, P83, DOI 10.1007/s00223-001-0035-0
   Prentice A, 1998, J CLIN ENDOCR METAB, V83, P1059, DOI 10.1210/jc.83.4.1059
   Prentice A., 2003, PEDIAT BONE BIOL DIS, P249, DOI 10.1016/B978-012286551-0/50012-9
   Prentice A, 2007, P NUTR SOC, V66, P512, DOI 10.1017/S0029665107005836
   Prentice A, 2008, BONE, V42, P788, DOI 10.1016/j.bone.2007.11.014
   Prentice A, 2006, P NUTR SOC, V65, P348, DOI 10.1079/PNS2006519
   Robinson PD, 2006, ARCH DIS CHILD, V91, P564, DOI 10.1136/adc.2004.069575
   Ruston D, 2003, NATL DIET NUTR SURVE
   Schroth Robert J, 2005, Int J Circumpolar Health, V64, P112
   Scientific Advisory Committee on Nutrition, 2007, UPD VIT D
   Shaw NJ, 2002, ARCH DIS CHILD, V86, P147, DOI 10.1136/adc.86.3.147
   Shenoy SD, 2005, ARCH DIS CHILD, V90, P437, DOI 10.1136/adc.2004.065268
   Snijder MB, 2005, J CLIN ENDOCR METAB, V90, P4119, DOI 10.1210/jc.2005-0216
   SPECKER BL, 1994, AM J CLIN NUTR S, V59, P484
   Thacher TD, 1999, NEW ENGL J MED, V341, P563, DOI 10.1056/NEJM199908193410803
   UNDERWOOD P, 1987, SOC SCI MED, V24, P37, DOI 10.1016/0277-9536(87)90136-5
   van der Meer IM, 2006, AM J CLIN NUTR, V84, P350
   VANDERWIELEN RPJ, 1995, LANCET, V346, P207, DOI 10.1016/S0140-6736(95)91266-5
   Vieth R, 1999, AM J CLIN NUTR, V69, P842
   Vieth R, 2003, J CLIN ENDOCR METAB, V88, P185, DOI 10.1210/jc.2002-021064
   Vieth R, 2007, AM J CLIN NUTR, V85, P649
   WILLETT A, 2004, P NUTR SOC, V64, P195
   Williams AF, 2007, ARCH DIS CHILD, V92, P740, DOI 10.1136/adc.2007.120774
   Worstman J, 2000, AM J CLIN NUTR, V72, P690
   Yan L, 2003, BONE, V33, P620, DOI 10.1016/S8756-3282(03)00216-3
   YAN L, 1994, EFFECT 25 HYDROXYVIT
NR 98
TC 190
Z9 203
U1 0
U2 21
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0029-6643
J9 NUTR REV
JI Nutr. Rev.
PD OCT
PY 2008
VL 66
IS 10
SU 2
BP S153
EP S164
DI 10.1111/j.1753-4887.2008.00100.x
PG 12
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 353GJ
UT WOS:000259553800010
PM 18844843
OA No
HC Y
HP N
DA 2017-08-15
ER

PT J
AU Caputo, B
   Nwakanma, D
   Jawara, M
   Adiamoh, M
   Dia, I
   Konate, L
   Petrarca, V
   Conway, DJ
   della Torre, A
AF Caputo, Beniamino
   Nwakanma, Davis
   Jawara, Musa
   Adiamoh, Majidah
   Dia, Ibrahima
   Konate, Lassana
   Petrarca, Vincenzo
   Conway, David J.
   della Torre, Alessandra
TI Anopheles gambiae complex along The Gambia river, with particular
   reference to the molecular forms of An. gambiae s.s
SO MALARIA JOURNAL
LA English
DT Article
ID MALARIA TRANSMISSION; WEST-AFRICA; INVERSION POLYMORPHISM; INCIPIENT
   SPECIATION; SENEGAL; ARABIENSIS; AREA; CULICIDAE; VILLAGES; DIPTERA
AB Background: The geographic and temporal distribution of M and S molecular forms of the major Afrotropical malaria vector species Anopheles gambiae s.s. at the western extreme of their range of distribution has never been investigated in detail.
   Materials and methods: Collections of indoor-resting An. gambiae s.l. females were carried out along a ca. 400 km west to east transect following the River Gambia from the western coastal region of The Gambia to south-eastern Senegal during 2005 end of rainy season/early dry season and the 2006 rainy season. Specimens were identified to species and molecular forms by PCR-RFLP and the origin of blood-meal of fed females was determined by ELISA test.
   Results: Over 4,000 An. gambiae s.l. adult females were collected and identified, 1,041 and 3,038 in 2005 and 2006, respectively. M-form was mainly found in sympatry with Anopheles melas and S-form in the western part of the transect, and with Anopheles arabiensis in the central part. S-form was found to prevail in rural Sudan-Guinean savannah areas of Eastern Senegal, in sympatry with An. arabiensis. Anopheles melas and An. arabiensis relative frequencies were generally lower in the rainy season samples, when An. gambiae s.s. was prevailing. No large seasonal fluctuations were observed for M and S-forms. In areas where both M and S were recorded, the frequency of hybrids between them ranged from to 0.6% to 7%.
   Discussion: The observed pattern of taxa distribution supports the hypothesis of a better adaptation of M- form to areas characterized by water-retaining alluvial deposits along the Gambia River, characterized by marshy vegetation, mangrove woods and rice cultivations. In contrast, the S-form seems to be better adapted to free-draining soil, covered with open woodland savannah or farmland, rich in temporary larval breeding sites characterizing mainly the eastern part of the transect, where the environmental impact of the Gambia River is much less profound and agricultural activities are mainly rain-dependent. Very interestingly, the observed frequency of hybridization between the molecular forms along the whole transect was much higher than has been reported so far for other areas.
   Conclusion: The results support a bionomic divergence between the M and S-forms, and suggest that the western extreme of An. gambiae s.s. geographical distribution may represent an area of higher-than-expected hybridization between the two molecular forms.
C1 [Nwakanma, Davis; Jawara, Musa; Adiamoh, Majidah; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Caputo, Beniamino; della Torre, Alessandra] Univ Roma La Sapienza, Dipartimento Sci Sanita Pubbl, Sez Parassitol, Ist Pasteur,Fdn Cenci Bolognetti, I-00185 Rome, Italy.
   [Dia, Ibrahima] Inst Pasteur, Dakar, Senegal.
   [Konate, Lassana] Univ Dakar, Dakar, Senegal.
   [Petrarca, Vincenzo] Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy.
RP Conway, DJ (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM beniamino.caputo@uniroma1.it; dnwakanma@mrc.gm; mjawara@mrc.gm;
   madiamoh@mrc.gm; dia@pasteur.sn; konatela@yahoo.fr;
   vincenzo.petrarca@uniroma1.it; dconway@mrc.gm;
   ale.dellatorre@uniroma1.it
RI Caputo, Beniamino/I-2880-2015
OI Caputo, Beniamino/0000-0002-5650-8773; Conway, David/0000-0002-8711-3037
FU University of Rome "La Sapienza" (Italy); National Institutes of Health
   [A142121]; EDCTP
FX Field collections and laboratory analysis in The Gambia was supported by
   the Medical Research Council of the UK, with helpful facilitation from
   the Gambian National Malaria Control Programme. We thank Abdoulie Jallow
   and Mbye Njie for their help with entomological collections, and Demba
   Sanneh for laboratory support with species and molecular form typing. BC
   was supported by PhD programme in "Pasteurian Sciences" from University
   of Rome "La Sapienza" (Italy). BC field activities was partly supported
   by grant A142121 from the National Institutes of Health. DN was
   supported by EDCTP fellowship award. We thank Prof. Mario Coluzzi for
   advice and support.
CR Beck LR, 1997, AM J TROP MED HYG, V56, P99
   BECK LR, 1994, AM J TROP MED HYG, V51, P271
   Bogh C, 2003, B ENTOMOL RES, V93, P279, DOI 10.1079/BER2003239
   Bogh C, 2001, J MED ENTOMOL, V38, P822
   BRYAN GT, 1983, PATHOLOGY BLADDER CA, V1, P1
   Bryan J.H., 1987, Parassitologia (Rome), V29, P221
   BRYAN JH, 1982, GENETICA, V59, P167, DOI 10.1007/BF00056539
   BURKOT TR, 1981, AM J TROP MED HYG, V30, P1336
   Calzetta M, 2008, AM J TROP MED HYG, V78, P169
   COLUZZI M, 1973, MOSQ NEWS, V33, P249
   Costantini C, 1996, MED VET ENTOMOL, V10, P220, DOI 10.1111/j.1365-2915.1996.tb00734.x
   Costantini C., 2003, American Journal of Tropical Medicine and Hygiene, V69, P210
   COSTANTINI C, 2002, AM J TROP MED HYG, V67, P350
   della Torre A, 2001, INSECT MOL BIOL, V10, P9, DOI 10.1046/j.1365-2583.2001.00235.x
   della Torre A, 2002, SCIENCE, V298, P115, DOI 10.1126/science.1078170
   della Torre A, 2005, INSECT BIOCHEM MOLEC, V35, P755, DOI 10.1016/j.ibmb.2005.02.006
   Dia I, 2000, PARASITE, V7, P179
   Diabate A, 2005, J MED ENTOMOL, V42, P548, DOI 10.1603/0022-2585(2005)042[0548:LDOTMF]2.0.CO;2
   Diabate A, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-5
   Diatta M, 1998, T ROY SOC TROP MED H, V92, P270, DOI 10.1016/S0035-9203(98)91005-7
   Fanello C, 2002, MED VET ENTOMOL, V16, P461, DOI 10.1046/j.1365-2915.2002.00393.x
   Fontenille D, 1997, T ROY SOC TROP MED H, V91, P647, DOI 10.1016/S0035-9203(97)90506-X
   Fontenille D, 1997, AM J TROP MED HYG, V56, P247
   Gillies MT, 1987, PUBL S AFR I MED RES, V55, P1
   Gillies MT, 1968, PUBLICATIONS S AFRIC, V54, P1
   Hogg JC, 1996, MED VET ENTOMOL, V10, P385, DOI 10.1111/j.1365-2915.1996.tb00761.x
   Kirby MJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-2
   Lemasson JJ, 1997, J MED ENTOMOL, V34, P396
   LINDSAY SW, 1991, J TROP MED HYG, V94, P313
   Oyewole I. O., 2007, Journal of Vector Borne Diseases, V44, P56
   Petrarca V, 2000, MED VET ENTOMOL, V14, P149, DOI 10.1046/j.1365-2915.2000.00231.x
   Santolamazza F, 2004, AM J TROP MED HYG, V70, P604
   Santolamazza F, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-163
   Santolamazza F, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-74
   Thomson M, 1996, SOC SCI MED, V43, P101, DOI 10.1016/0277-9536(95)00346-0
   Toure Y. T., 1998, Parassitologia (Rome), V40, P477
   Toure Y T, 1986, Ann Ist Super Sanita, V22, P215
   Tripet F, 2001, MOL ECOL, V10, P1725, DOI 10.1046/j.0962-1083.2001.01301.x
   TROLLDALEN JM, 1991, FRINGE SYSTEMS APPRO, V10
   Turner TL, 2005, PLOS BIOL, V3, P1572, DOI 10.1371/journal.pbio.0030285
   WHITE GB, 1974, T ROY SOC TROP MED H, V68, P278, DOI 10.1016/0035-9203(74)90035-2
   Wiseman V, 2006, TROP MED INT HEALTH, V11, P419, DOI 10.1111/j.1365-3156.2006.01586.x
   Wondji C, 2005, J MED ENTOMOL, V42, P998, DOI 10.1603/0022-2585(2005)042[0998:SAPOTA]2.0.CO;2
NR 43
TC 51
Z9 51
U1 2
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD SEP 22
PY 2008
VL 7
AR 182
DI 10.1186/1475-2875-7-182
PG 17
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 365FL
UT WOS:000260391200001
PM 18803885
OA gold
DA 2017-08-15
ER

PT J
AU Jeffries, D
   Zaidi, I
   de Jong, B
   Holland, MJ
   Miles, DJC
AF Jeffries, David
   Zaidi, Irfan
   de Jong, Bouke
   Holland, Martin J.
   Miles, David J. C.
TI Analysis of flow cytometry data using an automatic processing tool
SO CYTOMETRY PART A
LA English
DT Article
DE immunophenotyping; clustering; population; T-cell
ID DISTRIBUTION DIFFERENCES/; VACCINES; BLOOD
AB In spite of recent advances in flow cytometry technology, most cytometry data is still analyzed manually which is labor-intensive for large datasets and prone to bias and inconsistency. We designed an automatic processing tool (APT) to rapidly and consistently define and describe cell populations across large datasets. Image processing, smoothing, and clustering algorithms were used to generate an expert system that automatically reproduces the functionality of commercial manual cytometry processing tools. The algorithms were developed using a dataset collected from CMV-infected infants and combined within a graphical user interface, to create the APT. The APT was used to identify regulatory T-cells in HIV-infected adults, based on expression of FOXP3. Results from the APT were compared directly with the manual analyses of five immunologists and showed close agreement, with a concordance correlation coefficient of 0.96 (95% CI 0.91-0.98). The APT was well accepted by users and able to process around 100 data files per hour. By applying consistent criteria to all data generated by a study, the APT can provide a level of objectivity that is difficult to match using conventional manual analysis. (C) 2008 International Society for Advancement of Cytometry.
C1 [Jeffries, David; Zaidi, Irfan; de Jong, Bouke; Holland, Martin J.] MRC, Banjul, Gambia.
   [Miles, David J. C.] Clin Res Program, Malawi Liverpool Wellcome Trust, Blantyre, Malawi.
   [Holland, Martin J.] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
RP Jeffries, D (reprint author), MRC, POB 273, Banjul, Gambia.
EM djeffries@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU Medical Research Council [MC_U190081975, MC_U190081978]
CR Baumgarth N, 2000, J IMMUNOL METHODS, V243, P77, DOI 10.1016/S0022-1759(00)00229-5
   Boedigheimer MJ, 2008, CYTOM PART A, V73A, P421, DOI 10.1002/cyto.a.20553
   Costa ES, 2006, LEUKEMIA, V20, P1221, DOI 10.1038/sj.leu.2404241
   Dunn J. C., 1973, Journal of Cybernetics, V3, P32
   Eilers PHC, 1996, STAT SCI, V11, P89, DOI 10.1214/ss/1038425655
   Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016
   GATH I, 1989, IEEE T PATTERN ANAL, V11, P773, DOI 10.1109/34.192473
   Herzenberg LA, 2006, NAT IMMUNOL, V7, P681, DOI 10.1038/ni0706-681
   HULETT HR, 1969, SCIENCE, V166, P747, DOI 10.1126/science.166.3906.747
   JAHNE B, 2002, DIGITAL IMAGE PROCES, P585
   Keilhoz U, 2006, CLIN CANCER RES, V12, p2346S, DOI 10.1158/1078-0432.CCR-05-2540
   Leif RC, 2005, P SOC PHOTO-OPT INS, V5699, P325, DOI 10.1117/12.589960
   LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051
   Lo K, 2008, CYTOM PART A, V73A, P321, DOI 10.1002/cyto.a.20531
   Manly B. F. J., 1997, RANDOMIZATION BOOTST
   The Mathworks Inc, 2001, MATL LANG TECHN COMP
   McMichael AJ, 2003, NAT MED, V9, P874, DOI 10.1038/nm0703-874
   Miles DJC, 2007, J VIROL, V81, P5766, DOI 10.1128/JVI.00052-07
   *NVDIA, 2007, ACC MATLAB CUDA US M
   Parks DR, 2006, CYTOM PART A, V69A, P541, DOI 10.1002/cyto.20258
   Paulson D. S., 2006, HDB REGRESSION MODEL
   PERFETTO S, 2004, NAT REV IMMUNOL, P648
   Roederer M, 2001, CYTOMETRY, V45, P47, DOI 10.1002/1097-0320(20010901)45:1<47::AID-CYTO1143>3.0.CO;2-A
   Roederer M, 2001, CYTOMETRY, V45, P37, DOI 10.1002/1097-0320(20010901)45:1<37::AID-CYTO1142>3.0.CO;2-E
   Roederer M, 2001, CYTOMETRY, V45, P56, DOI 10.1002/1097-0320(20010901)45:1<56::AID-CYTO1144>3.0.CO;2-9
   Suni MA, 1998, J IMMUNOL METHODS, V212, P89, DOI 10.1016/S0022-1759(98)00004-0
   Todryk SM, 2007, NAT REV MICROBIOL, V5, P487, DOI 10.1038/nrmicro1712
   Toedling J, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-282
   VANLIER RA, 2003, NAT REV IMMUNOL, V3, P1
NR 29
TC 11
Z9 13
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1552-4922
J9 CYTOM PART A
JI Cytom. Part A
PD SEP
PY 2008
VL 73A
IS 9
BP 857
EP 867
DI 10.1002/cyto.a.20611
PG 11
WC Biochemical Research Methods; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 343XV
UT WOS:000258890500011
PM 18613039
OA No
DA 2017-08-15
ER

PT J
AU Sirugo, G
   Hennig, BJ
   Adeyemo, AA
   Matimba, A
   Newport, MJ
   Ibrahim, ME
   Ryckman, KK
   Tacconelli, A
   Mariani-Costantini, R
   Novelli, G
   Soodyall, H
   Rotimi, CN
   Ramesar, RS
   Tishkoff, SA
   Williams, SM
AF Sirugo, Giorgio
   Hennig, Branwen J.
   Adeyemo, Adebowale A.
   Matimba, Alice
   Newport, Melanie J.
   Ibrahim, Muntaser E.
   Ryckman, Kelli K.
   Tacconelli, Alessandra
   Mariani-Costantini, Renato
   Novelli, Giuseppe
   Soodyall, Himla
   Rotimi, Charles N.
   Ramesar, Raj S.
   Tishkoff, Sarah A.
   Williams, Scott M.
TI Genetic studies of African populations: an overview on disease
   susceptibility and response to vaccines and therapeutics (vol 123, pg
   557, 2008)
SO HUMAN GENETICS
LA English
DT Correction
C1 [Sirugo, Giorgio] MRC Labs, Fajara, Gambia.
   [Sirugo, Giorgio; Tacconelli, Alessandra; Novelli, Giuseppe] Osped S Pietro FBF, Med Genet Unit, Rome, Italy.
   [Sirugo, Giorgio; Tacconelli, Alessandra; Novelli, Giuseppe] Univ Roma Tor Vergata, Sch Med, Dept Biopathol & Diagnost Imaging, Rome, Italy.
   [Hennig, Branwen J.] London Sch Hyg & Trop Med, London WC1, England.
   [Adeyemo, Adebowale A.; Rotimi, Charles N.] Howard Univ, Coll Med, Natl Human Genome Ctr, Washington, DC USA.
   [Matimba, Alice] AiBST, Mol Sci Unit, Harare, Zimbabwe.
   [Newport, Melanie J.] Univ Sussex, Dept Med, Brighton & Sussex Med Sch, Brighton, E Sussex, England.
   [Ibrahim, Muntaser E.] Univ Khartoum, Inst Endem Dis, Dept Mol Biol, Khartoum, Sudan.
   [Ryckman, Kelli K.; Williams, Scott M.] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37212 USA.
   [Mariani-Costantini, Renato] Univ Gabriele Annunzio, Dept Oncol, Chieti, Italy.
   [Mariani-Costantini, Renato] Univ Gabriele Annunzio, Neurosci & Ageing Res Ctr, Chieti, Italy.
   [Soodyall, Himla] Univ Witwatersrand, Human Genom Divers & Dis Res Unit, Johannesburg, South Africa.
   [Ramesar, Raj S.] Univ Cape Town, Inst Infect Dis & Mol Med, Div Human Genet, ZA-7925 Cape Town, South Africa.
   [Tishkoff, Sarah A.] Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.
RP Sirugo, G (reprint author), MRC Labs, Fajara, Gambia.
EM sirugo.giorgio@fbfrm.it; smwilliams@chgr.mc.vanderbilt.edu
RI Hennig, Branwen/M-6444-2014; Ramesar, Raj/I-6941-2015
OI Ramesar, Raj/0000-0001-5688-1634
CR Sirugo G, 2008, HUM GENET, V123, P557, DOI 10.1007/s00439-008-0511-y
NR 1
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
J9 HUM GENET
JI Hum. Genet.
PD SEP
PY 2008
VL 124
IS 2
BP 195
EP 195
DI 10.1007/s00439-008-0534-4
PG 1
WC Genetics & Heredity
SC Genetics & Heredity
GA 342BJ
UT WOS:000258759300010
OA No
DA 2017-08-15
ER

PT J
AU de Bono, S
   Schoenmakers, I
   Ceesay, M
   Mendy, M
   Laskey, M
   Cole, T
   Prentice, A
AF de Bono, S.
   Schoenmakers, I.
   Ceesay, M.
   Mendy, M.
   Laskey, M.
   Cole, T.
   Prentice, A.
TI Birth Weight Predicts Bone Size, Adult Weight Predicts BMC and BMD In
   Young Gambian Adults.
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Meeting Abstract
CT 30th Annual Meeting of the
   American-Society-for-Bone-and-Mineral-Research
CY SEP 12-16, 2008
CL Montreal, CANADA
SP Amer Soc Bone & Mineral Res
C1 [de Bono, S.; Schoenmakers, I.; Laskey, M.; Prentice, A.] MRC Human Nutr Res, Cambridge, England.
   [Ceesay, M.; Mendy, M.] MRC, Keneba, Gambia.
   [Cole, T.] MRC Ctr Epidemiol Child Hlth, UCL Inst Child Hlth, London, England.
RI Cole, Tim/B-7883-2008
OI Cole, Tim/0000-0001-5711-8200
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC BONE & MINERAL RES
PI WASHINGTON
PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD SEP
PY 2008
VL 23
BP S502
EP S502
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 351FX
UT WOS:000259411002631
OA No
DA 2017-08-15
ER

PT J
AU Mendy, M
   D'Mello, F
   Kanellos, T
   Oliver, S
   Whittle, H
   Howard, CR
AF Mendy, Maimuna
   D'Mello, Felicity
   Kanellos, Theophanis
   Oliver, Stefan
   Whittle, Hilton
   Howard, Colin R.
TI Envelope protein variability among HBV-Infected asymptomatic carriers
   and immunized children with breakthrough infections
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE breakthrough infections; hepatocellular carcinoma; hepatitis B surface
   mutants
ID HEPATITIS-B-VIRUS; GAMBIAN EXPANDED PROGRAM; SURFACE GENE VARIANTS;
   T-CELL EPITOPE; NUCLEOTIDE-SEQUENCE; GENOTYPE-E;
   HEPATOCELLULAR-CARCINOMA; ANTIBODY-RESPONSE; ESCAPE MUTANT; WEST-AFRICA
AB A detailed study of hepatitis B virus (HBV) surface variants and their role in breakthrough infections has been conducted in The Gambia, West Africa. Samples from 1856 vaccinated subjects were tested for hepatitis B surface antigen (HBsAg). Evidence of infection was found in 11% (22/192) of subjects with breakthrough infections and 18 (81.8%) were also positive for HBV DNA following PCR analysis. A cohort of 58 unvaccinated carriers which also included 11 patients with hepatocellular carcinoma was also investigated in order to establish the prevalence of surface variants in the unvaccinated population. Analysis of the S gene from HBV PCR-positive subjects (n = 64) revealed little variation in the S gene of these subjects. Twenty-four S protein sequences (37.5%) were identical and a further 22 sequences differed by only a single amino acid. The K141E variant found in previous work was not detected and little variation was observed in the immunodominant "a" determinant; a single change was found in one vaccinated patient (Q129H) and nine changes detected among six unvaccinated carriers. This study showed that breakthrough HBV infection in vaccinated Gambians is mainly caused by the wild type genoytype E strain and that immune escape mutants are uncommon. However, HBV mutants may play a role in establishing infection later in life when anti-HBs antibodies have begun to decline. Further investigation is required to determine the cause of these breakthrough infections and whether they contribute to the establishment of the carrier state.
C1 [D'Mello, Felicity; Kanellos, Theophanis; Oliver, Stefan; Howard, Colin R.] Univ London Royal Vet Coll, Dept Pathol & Infect Dis, London NW1 0TU, England.
   [Mendy, Maimuna; Whittle, Hilton] MRC, Banjul, Gambia.
RP Howard, CR (reprint author), Univ London Royal Vet Coll, Dept Pathol & Infect Dis, Royal Coll St, London NW1 0TU, England.
EM choward@rvc.ac.uk
FU Medical Research Council [, MC_U190071425]
CR CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A
   Chen CJ, 2000, J GASTROEN HEPATOL, V15, pE3, DOI 10.1046/j.1440-1746.2000.02124.x
   Chen WN, 1999, BIOCHEM BIOPH RES CO, V262, P757, DOI 10.1006/bbrc.1999.1267
   Chen YCJ, 1996, P NATL ACAD SCI USA, V93, P1997, DOI 10.1073/pnas.93.5.1997
   CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29
   CHOTARD J, 1992, J INFECT DIS, V166, P764
   Das K, 2001, J VIROL, V75, P4771, DOI 10.1128/JVI.75.10.4771-4779.2001
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   FORTUIN M, 1994, J INFECT DIS, V169, P1374
   Hou JL, 2001, HEPATOLOGY, V34, P1027, DOI 10.1053/jhep.2001.28708
   Hsu HY, 1999, HEPATOLOGY, V30, P1312, DOI 10.1002/hep.510300511
   Hsu HY, 1997, HEPATOLOGY, V26, P786, DOI 10.1002/hep.510260336
   Huy TTT, 2006, J MED VIROL, V78, P178, DOI 10.1002/jmv.20525
   INSKIP HM, 1991, INT J EPIDEMIOL, V20, P764, DOI 10.1093/ije/20.3.764
   Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
   Kalinina T, 2003, HEPATOLOGY, V38, P1274, DOI 10.1053/jhep.2003.50484
   KARTHIGESU VD, 1994, J GEN VIROL, V75, P443, DOI 10.1099/0022-1317-75-2-443
   KIDDLJUNGGREN K, 1995, J MED VIROL, V47, P454, DOI 10.1002/jmv.1890470427
   Kramvis A, 2005, J MED VIROL, V77, P47, DOI 10.1002/jmv.20412
   Lee PI, 1997, J INFECT DIS, V176, P427
   Liu CJ, 2002, J MED VIROL, V68, P50, DOI 10.1002/jmv.10169
   MCMAHON G, 1992, HEPATOLOGY, V15, P757, DOI 10.1002/hep.1840150503
   Mulders MN, 2004, J INFECT DIS, V190, P400, DOI 10.1086/421502
   NAIMAN OV, 2002, J MED VIROL, V68, P319
   NORDER H, 1994, VIROLOGY, V198, P489, DOI 10.1006/viro.1994.1060
   Ogura Y, 1999, J INFECT DIS, V180, P1444, DOI 10.1086/315094
   OON CJ, 1995, VACCINE, V13, P699, DOI 10.1016/0264-410X(94)00080-7
   Oon CJ, 2002, J GASTROEN HEPATOL, V17, pS491
   Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357
   PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0
   Protzer-Knolle U, 1998, HEPATOLOGY, V27, P254, DOI 10.1002/hep.510270138
   RHO HM, 1989, NUCLEIC ACIDS RES, V17, P2124, DOI 10.1093/nar/17.5.2124
   Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502
   STEWARD MW, 1993, VACCINE, V11, P1405, DOI 10.1016/0264-410X(93)90169-X
   STIRK HJ, 1992, INTERVIROLOGY, V33, P148
   Tai PC, 1997, J VIROL, V71, P4852
   THANAVALA YM, 1986, J EXP MED, V164, P227, DOI 10.1084/jem.164.1.227
   Torresi J, 2002, VIROLOGY, V293, P305, DOI 10.1006/viro.2001.1246
   VALENZUELA P, 1979, NATURE, V280, P815, DOI 10.1038/280815a0
   VANDERSANDE MA, 2007, PLOS ONE, V2, pE753
   VAUDIN M, 1988, J GEN VIROL, V69, P1383, DOI 10.1099/0022-1317-69-6-1383
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   WATERS JA, 1992, VIRUS RES, V22, P1, DOI 10.1016/0168-1702(92)90085-N
   Whittle H, 2002, BRIT MED J, V325, P569, DOI 10.1136/bmj.325.7364.569
   WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4
   WHITTLE HC, 1983, LANCET, V1, P1203
   Wilson JN, 1999, VACCINE, V17, P973, DOI 10.1016/S0264-410X(98)00313-2
   Wilson JN, 1998, J VIRAL HEPATITIS, V5, P25, DOI 10.1046/j.1365-2893.1998.0050s2025.x
   Yeh CT, 2003, J GASTROEN HEPATOL, V18, P1129, DOI 10.1046/j.1440-1746.2003.03146.x
   Zuckerman AJ, 2000, LANCET, V355, P1382, DOI 10.1016/S0140-6736(00)02132-2
NR 50
TC 12
Z9 12
U1 0
U2 1
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2008
VL 80
IS 9
BP 1537
EP 1546
DI 10.1002/jmv.21221
PG 10
WC Virology
SC Virology
GA 331KQ
UT WOS:000258011500005
PM 18649345
OA No
DA 2017-08-15
ER

PT J
AU Bradley, AJ
   Kovacs, IJ
   Gatherer, D
   Dargan, DJ
   Alkharsah, KR
   Chan, PKS
   Carman, WF
   Dedicoat, M
   Emery, VC
   Geddes, CC
   Gerna, G
   Ben-Ismaeil, B
   Kaye, S
   McGregor, A
   Moss, PA
   Pusztai, R
   Rawlinson, WD
   Scott, GM
   Wilkinson, GWG
   Schulz, TF
   Davison, AJ
AF Bradley, Amanda J.
   Kovacs, Ida J.
   Gatherer, Derek
   Dargan, Derrick J.
   Alkharsah, Khaled R.
   Chan, Paul K. S.
   Carman, William F.
   Dedicoat, Martin
   Emery, Vincent C.
   Geddes, Colin C.
   Gerna, Giuseppe
   Ben-Ismaeil, Bassam
   Kaye, Steve
   McGregor, Alistair
   Moss, Paul A.
   Pusztai, Rozalia
   Rawlinson, William D.
   Scott, Gillian M.
   Wilkinson, Gavin W. G.
   Schulz, Thomas F.
   Davison, Andrew J.
TI Genotypic analysis of two hypervariable human cytomegalovirus genes
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE herpesvirus; variation; genotype; chemokine; glycoprotein
ID MULTIPLE SEQUENCE ALIGNMENT; TRANSPLANT RECIPIENTS; CLINICAL STRAINS;
   GENOMIC VARIANTS; ALPHA-CHEMOKINE; VARIABILITY; UL146; CD24; STABILITY;
   EMERGENCE
AB Most human cytomegalovirus (HCMV) genes are highly conserved in sequence among strains, but some exhibit a substantial degree of variation. Two of these genes are UL146, which encodes a CXC chemokine, and UL139,which is predicted to encode a membrane glycoprotein. The sequences of these genes were determined from a collection of 184 HCMV samples obtained from Africa, Australia, Asia, Europe, and North America. UL146 is hypervariable throughout, whereas variation in UL139 is concentrated in a sequence encoding a potentially highly glycosylated region. The UL146 sequences fell into 14 genotypes, as did all previously reported sequences. The UL139 sequences grouped into 8 genotypes, and all previously reported sequences fell into a subset of these. There were minor differences among continents in genotypic frequencies for UL146 and UL139, but no clear geographical separation, and identical nucleotide sequences were represented among communities distant from each other. The frequent detection of multiple genotypes indicated that mixed infections are common. For both genes, the degree of divergence was sufficient to preclude reliable sequence alignments between genotypes in the most variable regions, and the mode of evolution involved in generating the genotypes could not be discerned. Within genotypes, constraint appears to have been the predominant mode, and positive selection was detected marginally at best. No evidence was found for linkage disequilibrium. The emerging scenario is that the HCMV genotypes developed in early human populations (or even earlier), becoming established via founder or bottleneck effects, and have spread, recombined and mixed worldwide in more recent times.
C1 [Bradley, Amanda J.; Gatherer, Derek; Dargan, Derrick J.; Davison, Andrew J.] Univ Glasgow, Inst Virol, MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland.
   [Kovacs, Ida J.; Pusztai, Rozalia] Univ Szeged, Dept Med Microbiol & Immunol, Szeged, Hungary.
   [Alkharsah, Khaled R.; Schulz, Thomas F.] Hannover Med Sch, Inst Virol, Hannover, Germany.
   [Chan, Paul K. S.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Microbiol, Shatin, Hong Kong, Peoples R China.
   [Carman, William F.; Ben-Ismaeil, Bassam] Gartnavel Royal Hosp, W Scotland Specialist Virol Ctr, Glasgow, Lanark, Scotland.
   [Dedicoat, Martin] Ngwelezane Hosp, Kwa Zulu, South Africa.
   [Emery, Vincent C.] UCL Royal Free & Univ Coll Med Sch, Ctr Virol, Div Infect & Immun, London WC1E 6BT, England.
   [Geddes, Colin C.] Univ Glasgow, Western Infirm, Renal Unit, Glasgow G11 6NT, Lanark, Scotland.
   [Gerna, Giuseppe] Policlin San Matteo, Fdn IRCCS, Serv Virol, I-27100 Pavia, Italy.
   [Kaye, Steve] MRC Labs, Viral Dis Programme, Banjul, Gambia.
   [McGregor, Alistair] Univ Minnesota, Dept Pediat, Ctr Infect Dis & Microbiol Translat Res, McGuire Translat Res Facil,Div Infect Dis, Minneapolis, MN 55455 USA.
   [Moss, Paul A.] Univ Birmingham, Inst Canc Studies, Canc Res UK, Birmingham, W Midlands, England.
   [Rawlinson, William D.; Scott, Gillian M.] Prince Wales Hosp, Dept Microbiol, Div Virol, Randwick, NSW 2031, Australia.
   [Wilkinson, Gavin W. G.] Cardiff Univ, Wales Sch Med, Dept Med Microbiol, Cardiff, S Glam, Wales.
RP Davison, AJ (reprint author), Univ Glasgow, Inst Virol, MRC, Virol Unit, Church St, Glasgow G11 5JR, Lanark, Scotland.
EM a.davison@mrcvu.gla.ac.uk
RI Chan, Paul/J-9360-2013; Alkharsah, Khaled/A-6726-2012; Wilkinson,
   Gavin/J-6388-2015; Alkharsah, Khaled/O-9087-2016
OI Chan, Paul/0000-0002-6360-4608; Alkharsah, Khaled/0000-0002-4641-2604;
   Wilkinson, Gavin/0000-0002-5623-0126; Alkharsah,
   Khaled/0000-0002-4641-2604; Rawlinson, William/0000-0003-0988-7827;
   Gatherer, Derek/0000-0002-7385-5734; Emery, Vincent/0000-0001-5893-9756
FU Medical Research Council [MC_U130184136, MC_UU_12014/3, G0700142]
CR Arav-Boger R, 2006, J INFECT DIS, V193, P788, DOI 10.1086/500508
   Arav-Boger R, 2005, VIRUS GENES, V31, P65, DOI 10.1007/s11262-005-2201-3
   Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675
   Beyari MM, 2005, J MED VIROL, V75, P575, DOI 10.1002/jmv.20312
   Cha TA, 1996, J VIROL, V70, P78
   CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128
   Davison AJ, 2003, J GEN VIROL, V84, P17, DOI 10.1099/vir.0.18606-0
   Dedicoat M, 2004, J INFECT DIS, V190, P1068, DOI 10.1086/423326
   Dolan A, 2004, J GEN VIROL, V85, P1301, DOI 10.1099/vir.0.79888-0
   Hassan-Walker AF, 2004, J MED VIROL, V74, P573, DOI 10.1002/jmv.20210
   He R, 2006, INTERVIROLOGY, V49, P215, DOI 10.1159/000091468
   Iwasenko JM, 2007, J CLIN VIROL, V40, P152, DOI 10.1016/j.jcv.2007.07.003
   Kall L, 2004, J MOL BIOL, V338, P1027, DOI 10.1016/j.jmb.2004.03.016
   Katoh K, 2005, NUCLEIC ACIDS RES, V33, P511, DOI 10.1093/nar/gki198
   Lurain NS, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-4
   Mattick C, 2004, VIROLOGY, V318, P582, DOI 10.1016/j.virol.2003.09.036
   McGeoch DJ, 2006, VIRUS RES, V117, P90, DOI 10.1016/j.virusres.2006.01.002
   Murphy E, 2003, P NATL ACAD SCI USA, V100, P14976, DOI 10.1073/pnas.2136652100
   Penfold MET, 1999, P NATL ACAD SCI USA, V96, P9839, DOI 10.1073/pnas.96.17.9839
   Pignatelli S, 2004, REV MED VIROL, V14, P383, DOI 10.1002/rmv.438
   Pignatelli S, 2003, J GEN VIROL, V84, P647, DOI 10.1099/vir.0.18704-0
   Pignatelli S, 2001, J GEN VIROL, V82, P2777
   Poncet C, 1996, ACTA NEUROPATHOL, V91, P400
   Prichard MN, 2001, REV MED VIROL, V11, P191, DOI 10.1002/rmv.315
   PRIDE DT, 2004, SWAAP 1 2 1 TOOL ANA
   Puchhammer-Stockl E, 2006, TRANSPLANTATION, V81, P187, DOI 10.1097/01.tp.0000194858.50812.cb
   Puchhammer-Stockl E, 2006, J CLIN VIROL, V36, P239, DOI 10.1016/j.jcv.2006.03.004
   Qi Y, 2006, J MED VIROL, V78, P517, DOI 10.1002/jmv.20571
   Rasmussen L, 2003, J INFECT DIS, V187, P809, DOI 10.1086/367900
   Rasmussen L, 2002, J VIROL, V76, P10841, DOI 10.1128/JVI.76.21.10841-10848.2002
   Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359
   Schabath H, 2006, J CELL SCI, V119, P314, DOI 10.1242/jcs.02741
   Smith SC, 2006, CANCER RES, V66, P1917, DOI 10.1158/0008-5472.CAN-05-3855
   Staden R, 2000, Methods Mol Biol, V132, P115
   Stanton R, 2005, J MED VIROL, V75, P42, DOI 10.1002/jmv.20235
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555
NR 38
TC 33
Z9 36
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD SEP
PY 2008
VL 80
IS 9
BP 1615
EP 1623
DI 10.1002/jmv.21241
PG 9
WC Virology
SC Virology
GA 331KQ
UT WOS:000258011500015
PM 18649324
OA No
DA 2017-08-15
ER

PT J
AU Andreasen, AA
   Burton, MJ
   Holland, MJ
   Polley, S
   Faal, N
   Mabey, DCW
   Bailey, RL
AF Andreasen, Aura A.
   Burton, Matthew J.
   Holland, Martin J.
   Polley, Spencer
   Faal, Nkoyo
   Mabey, David C. W.
   Bailey, Robin L.
TI Chlamydia trachomatis ompA Variants in Trachoma: What Do They Tell Us?
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID OUTER-MEMBRANE PROTEIN; ANTIBIOTIC-TREATMENT; GAMBIAN COMMUNITY; DNA
   POLYMORPHISM; GLOBAL DATA; INFECTION; GENE; DIVERSITY; VILLAGES; STRAINS
AB Background: Trachoma, caused by Chlamydia trachomatis (Ct), is the leading infectious cause of blindness. Sequence-based analysis of the multiple strains typically present in endemic communities may be informative for epidemiology, transmission, response to treatment, and understanding the host response.
   Methods: Conjunctival and nasal samples from a Gambian community were evaluated before and 2 months after mass azithromycin treatment. Samples were tested for Ct by Amplicor, with infection load determined by quantitative PCR (qPCR). ompA sequences were determined and their diversity analysed using frequency-based tests of neutrality.
   Results: Ninety-five of 1,319 (7.2%) individuals from 14 villages were infected with Ct at baseline. Two genovars (A and B) and 10 distinct ompA genotypes were detected. Two genovar A variants (A1 and A2) accounted for most infections. There was an excess of rare ompA mutations, not sustained in the population. Post-treatment, 76 (5.7%) individuals had Ct infection with only three ompA genotypes present. In 12 of 14 villages, infection had cleared, while in two it increased, probably due to mass migration. Infection qPCR loads associated with infection were significantly greater for A1 than for A2. Seven individuals had concurrent ocular and nasal infection, with divergent genotypes in five.
   Conclusions: The number of strains was substantially reduced after mass treatment. One common strain was associated with higher infection loads. Discordant genotypes in concurrent infection may indicate distinct infections at ocular and nasal sites. Population genetic analysis suggests the fleeting appearance of rare multiple ompA variants represents purifying selection rather than escape variants from immune pressure. Genotyping systems accessing extra-ompA variation may be more informative.
C1 [Andreasen, Aura A.; Burton, Matthew J.; Holland, Martin J.; Polley, Spencer; Mabey, David C. W.; Bailey, Robin L.] London Sch Hyg & Trop Med, London WC1, England.
   [Burton, Matthew J.; Holland, Martin J.; Faal, Nkoyo; Bailey, Robin L.] MRC Labs, Fajara, Gambia.
RP Andreasen, AA (reprint author), London Sch Hyg & Trop Med, London WC1, England.
EM robin.bailey@lshtm.ac.uk
RI Polley, Spencer/F-7766-2013
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169
FU Medical Research Council (UK); Wellcome Trust/Burroughs Wellcome Fund
FX This work was supported by grants from the Medical Research Council (UK)
   and the Wellcome Trust/Burroughs Wellcome Fund. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bain DL, 2001, J INFECT DIS, V184, P1581, DOI 10.1086/324661
   Brunelle BW, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-r42
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   CALDWELL HD, 1982, INFECT IMMUN, V38, P745
   Carlson JH, 2005, INFECT IMMUN, V73, P6407, DOI 10.1128/IAI.73.10.6407-6418.2005
   Chapman HA, 2006, CURR OPIN IMMUNOL, V18, P78, DOI 10.1016/j.coi.2005.11.011
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   DEAN D, 1992, J INFECT DIS, V166, P383
   FU YX, 1993, GENETICS, V133, P693
   Geisler WM, 2003, SEX TRANSM DIS, V30, P160, DOI 10.1097/00007435-200302000-00013
   Hanisch FG, 2005, BIOCHEM SOC T, V33, P705
   HAYES LJ, 1995, J INFECT DIS, V172, P268
   HAYES LJ, 1992, J INFECT DIS, V166, P1173
   Hsieh YH, 2001, MICROBES INFECT, V3, P447, DOI 10.1016/S1286-4579(01)01400-9
   Kari L, 2008, J INFECT DIS, V197, P449, DOI 10.1086/525285
   Millman K, 2006, MICROBES INFECT, V8, P604, DOI 10.1016/j.micinf.2005.08.012
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359
   Smith A, 2001, Ophthalmic Epidemiol, V8, P127, DOI 10.1076/opep.8.2.127.4164
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   TAJIMA F, 1989, GENETICS, V123, P585
   Takourt B, 2001, MICROBES INFECT, V3, P459, DOI 10.1016/S1286-4579(01)01401-0
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   WEST S, 1993, INVEST OPHTH VIS SCI, V34, P3194
   Zhang JZ, 2004, PEDIATR INFECT DIS J, V23, P217, DOI 10.1097/01.inf.0000115501.60397.a6
NR 27
TC 12
Z9 12
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD SEP
PY 2008
VL 2
IS 9
AR e306
DI 10.1371/journal.pntd.0000306
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 385II
UT WOS:000261807500008
PM 18820750
OA gold
DA 2017-08-15
ER

PT J
AU Geissler, PW
   Kelly, A
   Imoukhuede, B
   Pool, R
AF Geissler, P. Wenzel
   Kelly, Ann
   Imoukhuede, Babatunde
   Pool, Robert
TI 'He is now like a brother, I can even give him some blood' - Relational
   ethics and material exchanges in a malaria vaccine 'trial community' in
   The Gambia
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE Africa; The Gambia; research ethics; benefits; vaccinations;
   ethnography; malaria
ID MEDICAL-RESEARCH; AFRICA
AB This paper explores social relations within the 'trial community' (staff and volunteers) of a Malaria Vaccine Trial (MVT), implemented by the Medical Research Council (MRC) in The Gambia between 2001 and 2004. It situates ethical concerns with medical research within the everyday life of scientific fieldwork. Based upon discussions with volunteers and staff, we explore processes of mediation between scientific project and study population, and between formal ethics, local ethical debates and everyday practice. We observe that material contact and substantial transactions, notably of blood and medicine, are central to the construction of the MVT. These transactions are guided by a concrete and relational form of ethics, which contrasts with the abstract and vertical formal ethical principles underwriting the scientific study protocol. The success of the MVT owed much to these kinshiplike ethics. One possible conclusion from these observations is that research ethics should be understood, not just as a quasi-legal frame but also as an open, searching movement, much in the same way that kinship is not merely a juridical institution and a prescriptive frame of rules. but a network made through relational work. However, this conclusion raises new problems: by contrasting formal, abstract principles to intimate, immediate relations, and economic justice to personal morality, we accept that the order of medical research is moved further out of the public and political, and into the domains of either quasi-legal claims or of private morality. Irrespective of the undeniable importance of clear-cut rules and of good face-to-face relations, a third essential foundation of medical research ethics is the democratically constituted public sphere, including equitable health services, and transparent institutions to facilitate open debate and regulate particular interests. Ultimately, the ethics of global science call rely neither on principles nor trust but requires citizenship and democratic government. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Geissler, P. Wenzel; Kelly, Ann; Pool, Robert] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Imoukhuede, Babatunde] MRC Labs, European Malaria Vaccine Initiat, Fajara, Gambia.
   [Pool, Robert] Barcelona Sch Hyg, Barcelona 08036, Spain.
RP Geissler, PW (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM wenzel.geissler@lshtm.ac.uk; ann.kelly@lshun.ac.uk;
   ebimoukhuede@hotmail.co.uk; robert.pool@lshtm.ac.uk
CR Bauman Zygmunt, 1993, POSTMODERN ETHICS
   Benatar SR, 2000, BRIT MED J, V321, P824, DOI 10.1136/bmj.321.7264.824
   [Anonymous], 2002, INT ETH GUID BIOM RE
   Emanuel EJ, 2004, J INFECT DIS, V189, P930, DOI 10.1086/381709
   Fairhead J, 2006, SOC SCI MED, V63, P1109, DOI 10.1016/j.socscimed.2006.02.018
   *FDSS, 2004, PROF FAR DSS
   Ferguson J, 2006, GLOBAL SHADOWS AFRIC
   FOUCAULT M, 1973, BIRTH CLIN ENCY MED
   Geissler PW, 2006, TROP MED INT HEALTH, V11, P975, DOI 10.1111/j.1365-3156.2006.01682.x
   Geissler PW, 2005, AFRICA, V75, P173
   HEALY K, 2006, LAST BEST GIFTS ALTU
   Kleinman Arthur, 1995, WRITING MARGIN DISCO
   Logstrup KE, 1997, ETHICAL DEMAND
   Molyneux CS, 2005, SOC SCI MED, V61, P1463, DOI 10.1016/j.socscimed.2004.11.073
   Moorthy VS, 2004, PLOS MED, V1, P128, DOI 10.1371/journal.pmed.0010033
   Nyanzi S, 2005, CULT HEALTH SEX, V7, P557, DOI 10.1080/136910500245687
   Whyte S.R., 1997, QUESTIONING MISFORTU
   Zelizer VA, 2005, PURCHASE OF INTIMACY, P1
NR 18
TC 50
Z9 52
U1 1
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD SEP
PY 2008
VL 67
IS 5
BP 696
EP 707
DI 10.1016/.j.socscimed.2008.02.004
PG 12
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 347TO
UT WOS:000259164200002
PM 18455854
OA No
DA 2017-08-15
ER

PT J
AU Jawara, M
   Pinder, M
   Drakeley, CJ
   Nwakanma, DC
   Jallow, E
   Bogh, C
   Lindsay, SW
   Conway, DJ
AF Jawara, Musa
   Pinder, Margaret
   Drakeley, Chris J.
   Nwakanma, Davis C.
   Jallow, Ebrima
   Bogh, Claus
   Lindsay, Steve W.
   Conway, David J.
TI Dry season ecology of Anopheles gambiae complex mosquitoes in The Gambia
SO MALARIA JOURNAL
LA English
DT Article
ID WEST-AFRICA; MALARIA TRANSMISSION; MOLECULAR-FORMS; SENEGAL; AREA;
   ARABIENSIS; CULICIDAE; GILES; IDENTIFICATION; PERSISTENCE
AB Background: Malaria in The Gambia is highly seasonal, with transmission occurring as Anopheles gambiae s.l. populations expand during and immediately after a single annual rainy season that lasts from June to October. There has been very limited investigation of the ecology of vectors during the dry season, when numbers are very limited and distributions may be restricted.
   Methods: Weekly adult mosquito collections (pyrethrum spray, light trap, and search collections from rooms, as well as light trap collections from animal shelters, abandoned wells and grain stores), and artificial sentinel breeding site surveys were performed in four villages near the upper tidal and partially saline part of the Gambia River in the last four months of an annual dry season (March to June). Mosquito species were identified by morphological and DNA analysis, and ELISA assays were performed to test for Plasmodium falciparum sporozoites and human blood meal components.
   Results: Adults of An. gambiae s.l. were collected throughout the period, numbers increasing towards the end of the dry season when humidity was increasing. Adult collections were dominated by An. melas (86%), with An. gambiae s.s. (10%) and An. arabiensis (3%) also present throughout. Most females collected in room search and spray collections contained blood meals, but most from light traps were unfed. None of the females tested (n = 1709) contained sporozoites. Larvae (mostly An. gambiae s. s.) were recovered from artificial sentinel breeding sites in the two villages that had freshwater pools. These two villages had the highest proportions of An. gambiae s. s. adults, and experienced the most substantial increase in proportions of An. gambiae s. s. after the onset of rains.
   Conclusion: During the dry season population minimum, An. melas was the predominant vector species, but differences among villages in availability of fresh-water breeding sites correlate with egg laying activity and relative numbers of An. gambiae s. s. adults, and with the increase in this species immediately after the beginning of the rains. Local variation in dry season vector persistence is thus likely to influence spatial heterogeneity of transmission intensity in the early part of the rainy season.
C1 [Jawara, Musa; Pinder, Margaret; Nwakanma, Davis C.; Jallow, Ebrima; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Drakeley, Chris J.; Conway, David J.] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   [Bogh, Claus] Sumba Fdn, Kuta 80361, Bali, Indonesia.
   [Lindsay, Steve W.] Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
RP Conway, DJ (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM mjawara@mrc.gm; mpinder@mrc.gm; chris.drakeley@lshtm.ac.uk;
   dnwakanma@mrc.gm; mjawara@mrc.gm; cbogh@cbn.net.id;
   s.w.lindsay@durham.ac.uk; dconway@mrc.gm
OI Conway, David/0000-0002-8711-3037
FU Medical Research Council
CR Awolola TS, 2002, ANN TROP MED PARASIT, V96, P75, DOI 10.1179/000349802125000538
   BEIER JC, 1990, J AM MOSQUITO CONTR, V6, P105
   Bogh C, 2003, B ENTOMOL RES, V93, P279, DOI 10.1079/BER2003239
   Bogh C, 2007, AM J TROP MED HYG, V76, P875
   Bryan J.H., 1987, Parassitologia (Rome), V29, P221
   BRYAN JH, 1983, ANN TROP MED PARASIT, V77, P1
   BURKOT TR, 1981, AM J TROP MED HYG, V30, P1336
   della Torre A, 2005, INSECT BIOCHEM MOLEC, V35, P755, DOI 10.1016/j.ibmb.2005.02.006
   Fanello C, 2002, MED VET ENTOMOL, V16, P461, DOI 10.1046/j.1365-2915.2002.00393.x
   Fontenille D, 1997, T ROY SOC TROP MED H, V91, P647, DOI 10.1016/S0035-9203(97)90506-X
   Fontenille D, 1997, AM J TROP MED HYG, V56, P247
   GIGLIOLI M E, 1964, Riv Malariol, V43, P245
   GIGLIOLI M. E. C., 1965, ANN ENTOMOL SOC AMER, V58, P885
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3
   Lemasson JJ, 1997, J MED ENTOMOL, V34, P396
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P253, DOI 10.1111/j.1365-2915.1989.tb00225.x
   LINDSAY SW, 1991, J TROP MED HYG, V94, P313
   ODETOYINBO JA, 1969, B WORLD HEALTH ORGAN, V40, P547
   OMER SM, 1968, NATURE, V217, P879, DOI 10.1038/217879b0
   OMER SM, 1970, B WORLD HEALTH ORGAN, V42, P319
   Simard F, 2000, INSECT MOL BIOL, V9, P467, DOI 10.1046/j.1365-2583.2000.00210.x
   TAYLOR CE, 1993, MED VET ENTOMOL, V7, P351, DOI 10.1111/j.1365-2915.1993.tb00704.x
   THOMSON MC, 1995, MED VET ENTOMOL, V9, P413, DOI 10.1111/j.1365-2915.1995.tb00015.x
   von Seidlein L, 2003, T ROY SOC TROP MED H, V97, P217
   WHITE GB, 1973, B ENTOMOL RES, V62, P613
   WIRTZ RA, 1989, B WORLD HEALTH ORGAN, V67, P535
NR 27
TC 18
Z9 18
U1 1
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 18
PY 2008
VL 7
AR 156
DI 10.1186/1475-2875-7-156
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 351MW
UT WOS:000259429400001
PM 18710559
OA gold
DA 2017-08-15
ER

PT J
AU Brookes, RH
   Hill, PC
   Owiafe, PK
   Ibanga, HB
   Jeffries, DJ
   Donkor, SA
   Fletcher, HA
   Hammond, AS
   Lienhardt, C
   Adegbola, RA
   McShane, H
   Hill, AVS
AF Brookes, Roger H.
   Hill, Philip C.
   Owiafe, Patrick K.
   Ibanga, Hannah B.
   Jeffries, David J.
   Donkor, Simon A.
   Fletcher, Helen A.
   Hammond, Abdulrahman S.
   Lienhardt, Christian
   Adegbola, Richard A.
   McShane, Helen
   Hill, Adrian V. S.
TI Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A
   in West Africa
SO PLOS ONE
LA English
DT Article
AB Background: Vaccination with a recombinant modified vaccinia Ankara expressing antigen 85A from Mycobacterium tuberculosis, MVA85A, induces high levels of cellular immune responses in UK volunteers. We assessed the safety and immunogenicity of this new vaccine in West African volunteers.
   Methods and Findings: We vaccinated 21 healthy adult male subjects (11 BCG scar negative and 10 BCG scar positive) with MVA85A after screening for evidence of prior exposure to mycobacteria. We monitored them over six months, observing for clinical, haematological and biochemical adverse events, together with assessment of the vaccine induced cellular immune response using ELISPOT and flow cytometry. MVA85A was well tolerated with no significant adverse events. Mild local and systemic adverse events were consistent with previous UK trials. Marked immunogenicity was found whether individuals had a previous BCG scar or not. There was not enhanced immunogenicity in those with a BCG scar, and induced T cell responses were better maintained in apparently BCG-naive Gambians than previously studied BCG-naive UK vaccinees. Although responses were predominantly attributable to CD4+ T cells, we also identified antigen specific CD8+ T cell responses, in subjects who were HLA B-35 and in whom enough blood was available for more detailed immunological analysis.
   Conclusions: These data on the safety and immunogenicity of MVA85A in West Africa support its accelerated development as a promising booster vaccine for tuberculosis.
C1 [Brookes, Roger H.; Hill, Philip C.; Owiafe, Patrick K.; Ibanga, Hannah B.; Jeffries, David J.; Donkor, Simon A.; Hammond, Abdulrahman S.; Adegbola, Richard A.] MRC Labs, TB Div, Bacterial Dis Programme, Banjul, Gambia.
   [Fletcher, Helen A.; McShane, Helen; Hill, Adrian V. S.] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [Lienhardt, Christian] Inst Rech Dev, Paris, France.
   [Hill, Adrian V. S.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
RP Brookes, RH (reprint author), MRC Labs, TB Div, Bacterial Dis Programme, Banjul, Gambia.
EM helen.mcshane@ndm.ox.ac.uk
RI Fletcher, Helen/D-1470-2011; Hammond, Abdulrahman/F-1541-2011
OI Fletcher, Helen/0000-0002-0435-1006; Kwasi Owiafe,
   Patrick/0000-0002-4287-3577
FU Medical Research Council (UK); European Commission
   [AFTBVAC-ICA4-CT-2002-10052]
FX The study was funded by the Medical Research Council (UK) and the
   European Commission (AFTBVAC-ICA4-CT-2002-10052). Neither funder had any
   role in the design of the study or the preparation of the manuscript.
CR Ahmed RKS, 2005, SCAND J IMMUNOL, V61, P63, DOI 10.1111/j.0300-9475.2005.01530.x
   ANDERSEN P, 1995, J IMMUNOL, V154, P3359
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   Brandt L, 2002, INFECT IMMUN, V70, P672, DOI 10.1128/IAI.70.2.672-678.2002
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767
   Floyd S, 2000, INT J TUBERC LUNG D, V4, P1133
   FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013
   Goonetilleke NP, 2003, J IMMUNOL, V171, P1602
   Hallander HO, 2002, VACCINE, V21, P138, DOI 10.1016/S0264-410X(02)00348-1
   Hanke T, 1999, J VIROL, V73, P7524
   Hill PC, 2006, PEDIATRICS, V117, P1542, DOI 10.1542/peds.2005-2095
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Hill PC, 2007, PLOS MED, V4, P1061, DOI 10.1371/journal.pmed.0040192
   Hill PC, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000068
   Ibango HB, 2006, LANCET INFECT DIS, V6, P522, DOI 10.1016/S1473-3099(06)70552-7
   Klein MR, 2001, J INFECT DIS, V183, P928, DOI 10.1086/319267
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   LEE SP, 1995, EUR J IMMUNOL, V25, P102, DOI 10.1002/eji.1830250119
   Levine MM, 2006, VACCINE, V24, P3865, DOI 10.1016/j.vaccine.2006.03.039
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   McShane H, 2005, TUBERCULOSIS, V85, P47, DOI 10.1016/j.tube.2004.09.015
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128
   Moorthy VS, 2004, J INFECT DIS, V189, P2213, DOI 10.1086/421118
   Mwau M, 2004, J GEN VIROL, V85, P911, DOI 10.1099/vir.0.19701-0
   Pathan A. A., 2007, PLOS ONE, V2, pe1052
   Pinder M, 2004, CLIN EXP IMMUNOL, V135, P286, DOI 10.1111/j.1365-2249.2004.02371.x
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   Sousa AO, 2000, P NATL ACAD SCI USA, V97, P4204, DOI 10.1073/pnas.97.8.4204
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3
   van Pinxteren LAH, 2000, EUR J IMMUNOL, V30, P3689, DOI 10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4
   Williams A, 2005, INFECT IMMUN, V73, P3814, DOI 10.1128/IAI.73.6.3814-3816.2005
   YOUNG TK, 1992, TUBERCLE LUNG DIS, V73, P94, DOI 10.1016/0962-8479(92)90062-O
NR 34
TC 41
Z9 41
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 13
PY 2008
VL 3
IS 8
AR e2921
DI 10.1371/journal.pone.0002921
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 422FK
UT WOS:000264412600007
PM 18698342
OA gold
DA 2017-08-15
ER

PT J
AU Martins, CL
   Garly, ML
   Bale, C
   Rodrigues, A
   Ravn, H
   Whittle, HC
   Lisse, IM
   Aaby, P
AF Martins, Cesario L.
   Garly, May-Lill
   Bale, Carlito
   Rodrigues, Amabelia
   Ravn, Henrik
   Whittle, Hilton C.
   Lisse, Ida M.
   Aaby, Peter
TI Protective efficacy of standard Edmonston-Zagreb measles vaccination in
   infants aged 4.5 months: interim analysis of a randomised clinical trial
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID GUINEA-BISSAU; MORTALITY RATIO; UNVACCINATED CHILDREN; PEDIATRIC WARD;
   RURAL SENEGAL; FEMALE; IMMUNIZATION; COMMUNITY; RESPONSES; COVERAGE
AB Objective To examine the protective efficacy of measles vaccination in infants in a low income country before 9 months of age.
   Design Randomised clinical trial.
   Participants 1333 infants aged 4.5 months: 441 in treatment group and 892 in control group.
   Setting Urban area in Guinea-Bissau.
   Intervention Measles vaccination using standard titre Edmonston-Zagreb vaccine at 4.5 months of age.
   Main outcome measures Vaccine efficacy against measles infection, admission to hospital for measles, and measles mortality before standard vaccination at 9 months of age.
   Results 28% of the children tested at 4.5 months of age had protective levels of maternal antibodies against measles at enrolment. After early vaccination against measles 92% had measles antibodies at 9 months of age. A measles outbreak offered a unique situation for testing the efficacy of early measles vaccination. During the outbreak, 96 children developed measles; 19% of unvaccinated children had measles before 9 months of age. The monthly incidence of measles among the 441 children enrolled in the treatment arm was 0.7% and among the 892 enrolled in the control arm was 3.1%. Early vaccination with the Edmonston-Zagreb measles vaccine prevented infection; vaccine efficacy for children with serologically confirmed measles and definite clinical measles was 94% (95% confidence interval 77% to 99%), for admissions to hospital for measles was 100% (46% to 100%), and for measles mortality was 100% (-42% to 100%). The number needed to treat to prevent one case of measles between ages 4.5 months and 9 months during the epidemic was 7.2 (6.8 to 9.2). The treatment group tended to have lower overall mortality (mortality rate ratio 0.18, 0.02 to 1.36) although this was not significant.
   Conclusions In low income countries, maternal antibody levels against measles may be low and severe outbreaks of measles can occur in infants before the recommended age of vaccination at 9 months. Outbreaks of measles may be curtailed by measles vaccination using the Edmonston-Zagreb vaccine as early as 4.5 months of age.
   Trial registration Clinical Trials NCT00168558 [ClinicalTrials.gov].
C1 [Martins, Cesario L.; Garly, May-Lill; Bale, Carlito; Rodrigues, Amabelia; Ravn, Henrik; Aaby, Peter] Bandim Hlth Project, Indepth Network, Bissau, Guinea Bissau.
   [Garly, May-Lill; Ravn, Henrik; Aaby, Peter] Statens Serum Inst, Danish Epidemiol Sci Ctr, Bandim Hlth Project, DK-2300 Copenhagen S, Denmark.
   [Whittle, Hilton C.] MRC Labs, Fajara, Gambia.
   [Lisse, Ida M.] Herlev Univ Hosp, Dept Pathol, DK-2730 Herlev, Denmark.
RP Aaby, P (reprint author), Bandim Hlth Project, Indepth Network, Bissau, Guinea Bissau.
EM p.aaby@bandim.org
FU DANIDA; Fonden tit Laegevidenskabens Fremme; Danish National Research
   Foundation; Novo Nordisk Foundation
FX The research on maternal antibodies that inspired the present trial was
   funded by the Thrasher Foundation. The present study was mostly funded
   by DANIDA and Fonden tit Laegevidenskabens Fremme. The Bandim Health
   Project received support from DANIDA and the Danish National Research
   Foundation. PA holds a research professorship grant from the Novo
   Nordisk Foundation. The funding institutions had no role in the
   implementation and interpretation of the study.
CR AABY P, 1986, J PEDIATR-US, V109, P40, DOI 10.1016/S0022-3476(86)80569-8
   Aaby P, 2006, VACCINE, V24, P4701, DOI 10.1016/j.vaccine.2006.03.038
   Aaby P, 2006, VACCINE, V24, P2764, DOI 10.1016/j.vaccine.2006.01.004
   Aaby P, 2004, VACCINE, V22, P3014, DOI 10.1016/j.vaccine.2004.02.009
   AABY P, 1986, J INFECT DIS, V154, P858
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 2003, PEDIATR INFECT DIS J, V22, P798, DOI 10.1097/01.inf.0000083821.33187.b5
   Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3
   Aaby P, 1998, LANCET, V352, P1229, DOI 10.1016/S0140-6736(05)60575-2
   AABY P, 1984, J INFECTION, V8, P13, DOI 10.1016/S0163-4453(84)93192-X
   Aaby P., 1997, PROSPECTIVE COMMUNIT, P276
   Aaby P, 2007, PEDIATR INFECT DIS J, V26, P247, DOI 10.1097/01.inf.0000256735.05098.01
   Aaby P, 2006, PEDIATR INFECT DIS J, V25, P721, DOI 10.1097/01.inf.0000227829.64686.ae
   Cisse B, 2001, THESIS LONDON SCH HY
   de Quadros CA, 2004, J INFECT DIS, V189, pS227, DOI 10.1086/377741
   deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224
   DULOU AD, 1995, AM J EPIDEMIOL, V142, P643
   Expanded Programme on Immunization, 1982, WEEKLY EPIDEMIOL REC, V57, P89
   Expanded Programme on Immunization, 1992, WKLY EPIDEMIOL REC, V67, P357
   Gans HA, 1998, JAMA-J AM MED ASSOC, V280, P527, DOI 10.1001/jama.280.6.527
   Garly ML, 1999, INT J EPIDEMIOL, V28, P347, DOI 10.1093/ije/28.2.347
   Garly ML, 2001, VACCINE, V19, P1951, DOI 10.1016/S0264-410X(00)00431-X
   Grais RF, 2006, EPIDEMIOL INFECT, V134, P845, DOI 10.1017/S0950268805005716
   HALL AJ, 1990, INT J EPIDEMIOL, V19, P777, DOI 10.1093/ije/19.4.777
   HOSKINS EW, 1993, THESIS U OXFORD
   JENSEN TG, 1994, VACCINE, V12, P1026, DOI 10.1016/0264-410X(94)90340-9
   Leuridan E, 2007, VACCINE, V25, P6296, DOI 10.1016/j.vaccine.2007.06.020
   MARKOWITZ LE, 1990, NEW ENGL J MED, V322, P580, DOI 10.1056/NEJM199003013220903
   MARTINS CL, 2002, O CRUZ
   ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055
   Otten M, 2005, LANCET, V366, P832, DOI 10.1016/S0140-6736(05)67216-9
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007
   Sniadack DH, 1999, B WORLD HEALTH ORGAN, V77, P545
   Veirum JE, 2005, VACCINE, V23, P1197, DOI 10.1016/j.vaccine.2004.02.053
   WHITTLE H, 1988, LANCET, V2, P811
   Whittle H, 1990, LANCET, V336, P1048
   WHO, 1977, B WORLD HEALTH ORGAN, V55, P21
NR 37
TC 41
Z9 41
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-535X
J9 BRIT MED J
JI Br. Med. J.
PD AUG 9
PY 2008
VL 337
IS 7665
AR a661
DI 10.1136/bmj.a661
PG 21
WC Medicine, General & Internal
SC General & Internal Medicine
GA 339EO
UT WOS:000258561100033
PM 18653640
OA No
DA 2017-08-15
ER

PT J
AU Miles, DJC
   van der Sande, M
   Jeffries, D
   Kaye, S
   Ojuola, O
   Sanneh, M
   Cox, M
   Palmero, MS
   Touray, ES
   Waight, P
   Rowland-Jones, S
   Whittle, H
   Marchant, A
AF Miles, David J. C.
   van der Sande, Marianne
   Jeffries, David
   Kaye, Steve
   Ojuola, Olubukola
   Sanneh, Mariama
   Cox, Momodou
   Palmero, Melba S.
   Touray, Ebrima S.
   Waight, Pauline
   Rowland-Jones, Sarah
   Whittle, Hilton
   Marchant, Arnaud
TI Maintenance of Large Subpopulations of Differentiated CD8 T-Cells Two
   Years after Cytomegalovirus Infection in Gambian Infants
SO PLOS ONE
LA English
DT Article
AB Background: In a previously published study, we found that large differentiated subpopulations of CD8 T-cells emerged rapidly after CMV infection in young infants and persisted throughout the following year. Here we describe a follow-up study conducted on the same infants to establish whether the differentiated subpopulations continued through the second year post-infection.
   Methodology/Principal Findings: CMV-specific cells identified using tetramers remained more activated and differentiated than the overall CD8 population. The large subpopulation of differentiated cytotoxic (CD28(-)CD62L(-)Bcl-2(low)CD95(+)perforin(+)) cells that emerged rapidly after infection remained stable after two years. No similar subpopulation was found in CMV-uninfected infants indicating that two years after infection, CMV remained a major factor in driving CD8 T-cell differentiation. Although markers of activation (CD45R0 and HLA-D) declined throughout the first year, HLA-D expression continued to decline during the second year and CD45R0 expression increased slightly. The age-related increase in IFN gamma response observed during the first year continued but was non-significant during the second year, indicating that the rate of functional improvement had slowed substantially.
   Conclusions/Significance: The large differentiated subpopulations of CD8 T-cells that had emerged immediately after CMV infection persisted through the second year post-infection, while levels of activation and functional capacity remained fairly constant.
C1 [Miles, David J. C.; Jeffries, David; Sanneh, Mariama; Cox, Momodou; Palmero, Melba S.; Touray, Ebrima S.; Rowland-Jones, Sarah; Whittle, Hilton] MRC Labs Gambia, Banjul, Gambia.
   [van der Sande, Marianne] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands.
   [Kaye, Steve] Imperial Coll London, Jefferiss Trust Lab, London, England.
   [Ojuola, Olubukola] Bronx Lebanon Hosp Ctr, Dept Pediat, Bronx, NY USA.
   [Waight, Pauline] Hlth Protect Agcy Ctr Infect, Immunisat Dept, London, England.
   [Marchant, Arnaud] Free Univ Brussels, Inst Med Immunol, Charleroi, Belgium.
RP Miles, DJC (reprint author), MRC Labs Gambia, Banjul, Gambia.
EM djcm1@liverpool.ac.uk
FU GSK Biologicals; Medical Research Council; Fonds National de la
   Recherche Scientifique, Belgium
FX The study was funded by GSK Biologicals and the Medical Research
   Council. Arnaud Marchant is a senior research associate at the Fonds
   National de la Recherche Scientifique, Belgium. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR AKBAR AN, 1993, J EXP MED, V178, P427, DOI 10.1084/jem.178.2.427
   Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   BARNABA V, 1994, EUR J IMMUNOL, V24, P71, DOI 10.1002/eji.1830240112
   BELLO C, 1991, J CLIN PATHOL, V44, P366, DOI 10.1136/jcp.44.5.366
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   Chen SF, 2004, J INFECT DIS, V189, P1619, DOI 10.1086/383249
   de Vries E, 2000, PEDIATR RES, V47, P528, DOI 10.1203/00006450-200004000-00019
   Gamadia LE, 2003, BLOOD, V101, P2686, DOI 10.1182/blood-2002-08-2502
   GAVIN MA, 1993, J IMMUNOL, V151, P3971
   GERDES J, 1984, J IMMUNOL, V133, P1710
   Gillespie GMA, 2000, J VIROL, V74, P8140, DOI 10.1128/JVI.74.17.8140-8150.2000
   GRATAMA JW, 1987, BLOOD, V70, P516
   Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407
   Hamann D, 1999, IMMUNOL TODAY, V20, P177, DOI 10.1016/S0167-5699(99)01444-9
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Jaimes MC, 2002, J VIROL, V76, P4741, DOI 10.1128/JVI.76.10.4741-4749.2002
   JEFFRIES D, CYTOMETRY IN PRESS
   Kaech S., 2002, NAT REV IMMUNOL, P251
   KAYE S, 2008, J INFECT DIS, P197
   Kern F, 1999, J VIROL, V73, P8179
   Khan N, 2007, J IMMUNOL, V178, P4455
   Komatsu Haruki, 2006, Immun Ageing, V3, P11, DOI 10.1186/1742-4933-3-11
   Kuijpers TW, 2003, J IMMUNOL, V170, P4342
   Lohman BL, 2005, J VIROL, V79, P8121, DOI 10.1128/JVI.79.13.8121-8130.2005
   Looney RJ, 1999, CLIN IMMUNOL, V90, P213, DOI 10.1006/clim.1998.4638
   Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI200317470
   Miles DJC, 2007, J VIROL, V81, P5766, DOI 10.1128/JVI.00052-07
   Olsson J, 2000, MECH AGEING DEV, V121, P187
   PASS RF, 1985, J INFECT DIS, V152, P243
   Retiere C, 2000, J VIROL, V74, P3948, DOI 10.1128/JVI.74.9.3948-3952.2000
   Sandberg JK, 2003, J IMMUNOL, V170, P4403
   Saurwein-Teissl M, 2002, J IMMUNOL, V168, P5893
   Seder RA, 2003, NAT IMMUNOL, V4, P835, DOI 10.1038/ni969
   Solache A, 1999, J IMMUNOL, V163, P5512
   Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882
   Tomiyama H, 2004, EUR J IMMUNOL, V34, P999, DOI 10.1002/eji.200324478
   Tomiyama H, 2002, J IMMUNOL, V168, P5538
   Trzonkowski P, 2003, VACCINE, V21, P3826, DOI 10.1016/S0264-410X(03)00309-8
   UTZ U, 1992, J IMMUNOL, V149, P214
   van Leeuwen EMM, 2006, J IMMUNOL, V177, P4998
   VANLIER RA, 2003, NAT REV IMMUNOL, V3, P1
   WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603
   Weekes MP, 1999, J VIROL, V73, P2099
   Wikby A, 2002, EXP GERONTOL, V37, P445, DOI 10.1016/S0531-5565(01)00212-1
   Wills MR, 1996, J VIROL, V70, P7569
NR 45
TC 26
Z9 26
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 6
PY 2008
VL 3
IS 8
AR e2905
DI 10.1371/journal.pone.0002905
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 421NW
UT WOS:000264366600061
PM 18682836
OA gold
DA 2017-08-15
ER

PT J
AU Prentice, A
   Goldberg, GR
   Schoenmakers, I
AF Prentice, Ann
   Goldberg, Gail R.
   Schoenmakers, Inez
TI Vitamin D across the lifecycle: physiology and biomarkers
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID SURROGATE END-POINTS; BONE-MINERAL STATUS; PARATHYROID-HORMONE;
   D-DEFICIENCY; D INSUFFICIENCY; POSTMENOPAUSAL WOMEN; NUTRITIONAL
   RICKETS; HIGH PREVALENCE; PREGNANT-WOMEN; 25-HYDROXYVITAMIN-D
AB The field of vitamin D public health research has a pressing need to define sensitive and specific predictors of vitamin D status that can be used to determine whether an individual or population has a supply of vitamin D that is sufficient to meet requirements. The aim of this review is to highlight the considerations needed when evaluating evidence of the relations between vitamin D biomarkers and functional or health outcomes across the life cycle. It draws attention to the importance of distinguishing between biomarkers of supply, function, and outcome and of considering the many factors that could influence interpretation, such as life stage, ethnicity, body mass index, liver and kidney function, and dietary calcium and phosphorus intake. The vitamin D biomarkers that have shown the most utility to date are the plasma concentration of 25-hydroxy vitamin D (supply), the plasma concentration of parathyroid hormone (function), and the presence or absence of rickets (outcome). However, a single biomarker of vitamin D status or threshold value is unlikely to be valid in all situations. The field therefore needs research to refine existing biomarkers or establish new indicators that take the many factors into account and to identify useful functional biomarkers of vitamin D status for infants, children, women of reproductive age, and specific ethnic groups. However, evidence using the biomarkers currently available shows that frank vitamin D deficiency is a major public health problem in many parts of the world that requires urgent attention.
C1 [Prentice, Ann] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   [Prentice, Ann] Med Res Council Keneba, Keneba, Gambia.
RP Prentice, A (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Fulbourn Rd, Cambridge CB1 9NL, England.
EM ann.prentice@mrc-hnr.cam.ac.uk
FU Medical Research Council [MC_U105960371]
CR Abrams SA, 2005, J CLIN ENDOCR METAB, V90, P5576, DOI 10.1210/jc.2005-1021
   Al-oanzi ZH, 2006, CLIN CHEM, V52, P248, DOI 10.1373/clinchem.2005.059568
   Ashraf S, 2002, ARCH DIS CHILD, V87, P263, DOI 10.1136/adc.87.3.263-a
   Aspray TJ, 2005, BONE, V36, P710, DOI 10.1016/j.bone.2005.01.002
   Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989
   Bates CJ, 2003, OSTEOPOROSIS INT, V14, P152, DOI 10.1007/s00198-002-1338-3
   Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18
   Bodnar LM, 2007, J CLIN ENDOCR METAB, V92, P3517, DOI 10.1210/jc.2007-0718
   Bodnar LM, 2007, J NUTR, V137, P447
   Bolland MJ, 2007, AM J CLIN NUTR, V86, P959
   Brandi L, 2002, NEPHROL DIAL TRANSPL, V17, P829, DOI 10.1093/ndt/17.5.829
   Calvo MS, 2005, J NUTR, V135, P310
   Chapuy MC, 1997, OSTEOPOROSIS INT, V7, P439, DOI 10.1007/s001980050030
   Chen TC, 2007, ARCH BIOCHEM BIOPHYS, V460, P213, DOI 10.1016/j.abb.2006.12.017
   CLEMENS TL, 1986, J CLIN ENDOCR METAB, V63, P656
   Datt S, 2002, BJOG-INT J OBSTET GY, V109, P905, DOI 10.1016/S1470-0328(02)01171-0
   Dawson-Hughes B, 2005, OSTEOPOROSIS INT, V16, P713, DOI 10.1007/s00198-005-1867-7
   De Gruttola VG, 2001, CONTROL CLIN TRIALS, V22, P485, DOI 10.1016/S0197-2456(01)00153-2
   DeLuca Hector F, 2004, Am J Clin Nutr, V80, p1689S
   Department of Health, 1998, NUTR BON HLTH PART R
   Diplock AT, 1999, BRIT J NUTR, V81, pS1
   DUELAND S, 1983, AM J PHYSIOL, V245, pE463
   Finch S, 1998, NATL DIET NUTR SURV, V1
   Fischer PR, 1999, J TROP PEDIATRICS, V45, P291, DOI 10.1093/tropej/45.5.291
   Fraser DR, 2004, J STEROID BIOCHEM, V89-90, P491, DOI 10.1016/j.jsbmb.2004.03.057
   Fraser WD, 2004, CURR OPIN NEPHROL HY, V13, P437, DOI 10.1097/01.mnh.0000133985.29880.34
   Gannage-Yared MH, 2000, J BONE MINER RES, V15, P1856, DOI 10.1359/jbmr.2000.15.9.1856
   Gascon-Barre M, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P47
   Grover SR, 2001, MED J AUSTRALIA, V175, P251
   Guillemant J, 1999, OSTEOPOROSIS INT, V10, P222, DOI 10.1007/s001980050219
   Heaney RP, 2005, J STEROID BIOCHEM, V97, P13, DOI 10.1016/j.jsbmb.2005.06.020
   Henry HL, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P69
   Hodsman A. B., 2002, PRINCIPLES BONE BIOL, P1305, DOI 10.1016/B978-012098652-1.50177-3
   Holick MF, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P37
   Holick Michael F, 2004, Am J Clin Nutr, V80, p1678S
   Hollis BW, 2008, AM J CLIN NUTR, V88, p507S
   Hollis BW, 2007, J STEROID BIOCHEM, V103, P631, DOI 10.1016/j.jsbmb.2006.12.066
   Hollis BW, 2005, J NUTR, V135, P317
   Hollis BW, 2005, NEW ENGL J MED, V352, P515
   Horst RL, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P15
   Institute of Medicine Food and Nutrition Board, 1997, DIET REF INT CALC PH
   Kovacs CS, 2008, AM J CLIN NUTR, V88, p520S
   KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602
   Lappe JM, 2007, AM J CLIN NUTR, V85, P1586
   Lappe JM, 2006, J AM COLL NUTR, V25, P395
   Lensmeyer GL, 2006, DYNAMICS BONE CARTIL, P513, DOI [10.1016/B978-012088562-6/50032-7, DOI 10.1016/B978-012088562-6/50032-7]
   Liang CJ, 2005, VITAMIN D, V2nd, P117
   Lips P, 2006, J INTERN MED, V260, P245, DOI 10.1111/j.1365-2796.2006.01685.x
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   Lips P, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P1019
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
   LUND B, 1980, J CLIN ENDOCR METAB, V51, P606
   Malabanan A, 1998, LANCET, V351, P805, DOI 10.1016/S0140-6736(05)78933-9
   Need AG, 2000, AM J CLIN NUTR, V71, P1577
   Norman AW, 2008, AM J CLIN NUTR, V88, p491S
   Omdahl J, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P85
   OOMS ME, 1995, J CLIN ENDOCR METAB, V80, P1052, DOI 10.1210/jc.80.4.1052
   ORWOLL ES, 1986, J CLIN ENDOCR METAB, V63, P1262
   Ovesen L, 2003, ANN NUTR METAB, V47, P107, DOI 10.1159/000070031
   Patel S, 2007, CALCIFIED TISSUE INT, V80, P221, DOI 10.1007/s00223-007-9001-9
   PETTIFOR JM, 2003, PEDIAT BONE BIOL DIS
   Pike JW, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P167
   PRENTICE A, NUTR REV IN PRESS
   Prentice A., 2003, PEDIAT BONE BIOL DIS, P249, DOI 10.1016/B978-012286551-0/50012-9
   Prentice A, 2007, P NUTR SOC, V66, P512, DOI 10.1017/S0029665107005836
   Schroth Robert J, 2005, Int J Circumpolar Health, V64, P112
   Scientific Advisory Committee on Nutrition, 2007, UPD VIT D
   SITRIN MD, 1982, AM J PHYSIOL, V242, pG326
   SLOVIK DM, 1981, NEW ENGL J MED, V305, P372, DOI 10.1056/NEJM198108133050704
   Souberbielle JC, 2001, J CLIN ENDOCR METAB, V86, P3086, DOI 10.1210/jc.86.7.3086
   Thacher TD, 1999, NEW ENGL J MED, V341, P563, DOI 10.1056/NEJM199908193410803
   Tylavsky FA, 2005, J NUTR, V135, p2735S
   van der Meer IM, 2006, AM J CLIN NUTR, V84, P350
   van Hoof HJC, 2001, EUR J ENDOCRINOL, V144, P391, DOI 10.1530/eje.0.1440391
   van Leeuwen JPTM, 2001, STEROIDS, V66, P375, DOI 10.1016/S0039-128X(00)00155-0
   VANDERWIEL HE, 1991, BONE MINER, V13, P123, DOI 10.1016/0169-6009(91)90079-F
   Vieth R, 2003, J CLIN ENDOCR METAB, V88, P185, DOI 10.1210/jc.2002-021064
   Vieth R, 2007, AM J CLIN NUTR, V85, P649
   Webb AR, 2006, PROG BIOPHYS MOL BIO, V92, P17, DOI 10.1016/j.pbiomolbio.2006.02.004
   Willett AM, 2005, P NUTR SOC, V64, P193, DOI 10.1079/PNS2005420
   Yan L, 2003, BONE, V33, P620, DOI 10.1016/S8756-3282(03)00216-3
NR 81
TC 95
Z9 100
U1 0
U2 15
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD AUG 1
PY 2008
VL 88
IS 2
SU S
BP 500S
EP 506S
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 346GK
UT WOS:000259056600003
PM 18689390
OA No
DA 2017-08-15
ER

PT J
AU Dionisio, KL
   Howie, S
   Fornace, KM
   Chimah, O
   Adegbola, RA
   Ezzati, M
AF Dionisio, K. L.
   Howie, S.
   Fornace, K. M.
   Chimah, O.
   Adegbola, R. A.
   Ezzati, M.
TI Measuring the exposure of infants and children to indoor air pollution
   from biomass fuels in The Gambia
SO INDOOR AIR
LA English
DT Article
DE indoor air pollution; biomass fuel; pneumonia; acute lower respiratory
   infection; global health; particulate matter; carbon monoxide
ID LOWER RESPIRATORY-INFECTIONS; PARTICULATE MATTER; MEASUREMENT ERROR;
   COMBUSTION; POLLUTANTS; EMISSIONS; HOUSEHOLDS; PATTERNS; AFRICA; CHINA
AB Indoor air pollution (IAP) from biomass fuels contains high concentrations of health damaging pollutants and is associated with an increased risk of childhood pneumonia. We aimed to design an exposure measurement component for a matched case-control study of IAP as a risk factor for pneumonia and severe pneumonia in infants and children in The Gambia. We conducted co-located simultaneous area measurement of carbon monoxide (CO) and particles with aerodynamic diameter < 2.5 mu m (PM(2.5)) in 13 households for 48 h each. CO was measured using a passive integrated monitor and PM(2.5) using a continuous monitor. In three of the 13 households, we also measured continuous PM(2.5) concentration for 2 weeks in the cooking, sleeping, and playing areas. We used gravimetric PM(2.5) samples as the reference to correct the continuous PM(2.5) for instrument measurement error. Forty-eight hour CO and PM(2.5) concentrations in the cooking area had a correlation coefficient of 0.80. Average 48-h CO and PM(2.5) concentrations in the cooking area were 3.8 +/- 3.9 ppm and 361 +/- 312 mu g/m(3), respectively. The average 48-h CO exposure was 1.5 +/- 1.6 ppm for children and 2.4 +/- 1.9 ppm for mothers. PM(2.5) exposure was an estimated 219 mu g/m(3) for children and 275 mu g/m(3) for their mothers. The continuous PM(2.5) concentration had peaks in all households representing the morning, midday, and evening cooking periods, with the largest peak corresponding to midday. The results are used to provide specific recommendations for measuring the exposure of infants and children in an epidemiological study.
C1 [Dionisio, K. L.; Ezzati, M.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Dionisio, K. L.; Fornace, K. M.; Ezzati, M.] Harvard Univ, Initiat Global Hlth, Cambridge, MA 02138 USA.
   [Howie, S.; Chimah, O.; Adegbola, R. A.] MRC Labs, Fajara, Gambia.
RP Ezzati, M (reprint author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave,SPH 1,1107, Boston, MA 02115 USA.
EM majid_ezzati@harvard.edu
OI Fornace, Kimberly/0000-0002-5484-241X
FU Medical Research Council [MC_U190088484]
CR ARMSTRONG JRM, 1991, INT J EPIDEMIOL, V20, P424, DOI 10.1093/ije/20.2.424
   Bailis R, 2005, SCIENCE, V308, P98, DOI 10.1126/science.1106881
   Balakrishnan K, 2002, ENVIRON HEALTH PERSP, V110, P1069
   BALAKRISHNAN K, 2004, INDIA J EXPO ANAL S1, V14, pS14
   BBRUCE N, 2004, J EXPO ANAL ENV E S1, V14, pS26
   Berkley JA, 2005, BRIT MED J, V330, P995, DOI 10.1136/bmj.38408.471991.8F
   Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8
   Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8
   CARROLL RJ, 1994, STAT MED, V13, P1265, DOI 10.1002/sim.4780131208
   Cohen A., 2004, COMP QUANTIFICATION, P1353
   Ezzati M, 2000, ENVIRON HEALTH PERSP, V108, P833, DOI 10.2307/3434990
   Ezzati M, 2005, J EPIDEMIOL COMMUN H, V59, P15, DOI 10.1136/jech.2003019741
   Ezzati M, 2001, LANCET, V358, P619, DOI 10.1016/S0140-6736(01)05777-4
   Gupta P, 2006, ATMOS ENVIRON, V40, P5880, DOI 10.1016/j.atmosenv.2006.03.016
   He GL, 2005, ENVIRON SCI TECHNOL, V39, P991, DOI 10.1021/es049731f
   Jin YL, 2005, ENVIRON SCI TECHNOL, V39, P9431, DOI 10.1021/es0507517
   Liu WL, 2003, ENVIRON HEALTH PERSP, V111, P1454, DOI 10.1289/ehp.6286
   Naeher LP, 2001, ENVIRON SCI TECHNOL, V35, P575, DOI 10.1021/es991225g
   ODempsey TJD, 1996, INT J EPIDEMIOL, V25, P885, DOI 10.1093/ije/25.4.885
   Pepin J, 2001, T ROY SOC TROP MED H, V95, P410, DOI 10.1016/S0035-9203(01)90199-3
   Rehfuess E, 2006, ENVIRON HEALTH PERSP, V114, P373, DOI 10.1289/ehp.8603
   ROSNER B, 1992, AM J EPIDEMIOL, V136, P1400
   Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895
   SAKSENA S, 1992, ATMOS ENVIRON A-GEN, V26, P2125, DOI 10.1016/0960-1686(92)90096-4
   Smith K.R., 2004, COMP QUANTIFICATION, P1435
   Wang B, 2007, SCI TOTAL ENVIRON, V377, P52, DOI 10.1016/j.scitotenv.2007.01.099
   Zheng M, 2005, ATMOS ENVIRON, V39, P3967, DOI 10.1016/j.atmosenv.2005.03.036
NR 27
TC 35
Z9 35
U1 0
U2 13
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0905-6947
J9 INDOOR AIR
JI Indoor Air
PD AUG
PY 2008
VL 18
IS 4
BP 317
EP 327
DI 10.1111/j.1600-0668.2008.00533.x
PG 11
WC Construction & Building Technology; Engineering, Environmental; Public,
   Environmental & Occupational Health
SC Construction & Building Technology; Engineering; Public, Environmental &
   Occupational Health
GA 328DY
UT WOS:000257779200007
PM 18422570
OA No
DA 2017-08-15
ER

PT J
AU Voelter, V
   Rufer, N
   Reynard, S
   Greub, G
   Brookes, R
   Guillaume, P
   Grosjean, F
   Fagerberg, T
   Michelin, O
   Rowland-Jones, S
   Pinilla, C
   Leyvraz, S
   Romero, P
   Appay, V
AF Voelter, Verena
   Rufer, Nathalie
   Reynard, Severine
   Greub, Gilbert
   Brookes, Roger
   Guillaume, Philippe
   Grosjean, Frederic
   Fagerberg, Theres
   Michelin, Olivier
   Rowland-Jones, Sarah
   Pinilla, Clemencia
   Leyvraz, Serge
   Romero, Pedro
   Appay, Victor
TI Characterization of Melan-A reactive memory CD8+T cells in a healthy
   donor
SO INTERNATIONAL IMMUNOLOGY
LA English
DT Article
DE cross-reactivity; melanoma; Mycobacterium; T lymphocytes; tumor immunity
ID CD8(+) T-CELLS; MYCOBACTERIUM-TUBERCULOSIS INFECTION; COMBINATORIAL
   PEPTIDE LIBRARIES; MHC CLASS-I; CROSS-REACTIVITY; ANTIGEN RECOGNITION;
   IMMUNE-RESPONSES; IDENTIFICATION; LIGANDS; LYMPHOCYTES
AB Melan-A specific CD8+ T cells are thought to play an important role against the development of melanoma. Their in vivo expansion is often observed with advanced disease. In recent years, low levels of Melan-A reactive CD8+ T cells have also been found in HLA-A2 healthy donors, but these cells harbor naive characteristics and are thought to be mostly cross-reactive for the Melan-A antigen. Here, we report on a large population of CD8+ T cells reactive for the Melan-A antigen, identified in one donor with no evidence of melanoma. Interestingly, this population is oligoclonal and displays a clear memory phenotype. However, a detailed study of these cells indicated that they are unlikely to be directly specific for melanoma, so that their in vivo expansion may have been driven by an exogenous antigen. Screening of a Melan-A cross-reactive peptide library suggested that these cells may be specific for an epitope derived from a Mycobacterium protein, which would provide a further example of CD8+ T cell cross-reactivity between a pathogen antigen and a tumor antigen. Finally, we discuss potential perspectives regarding the role of such cells in heterologous immunity, by influencing the balance between protective immunity and pathology, e.g. in the case of melanoma development.
C1 [Voelter, Verena; Rufer, Nathalie; Reynard, Severine; Michelin, Olivier; Leyvraz, Serge; Appay, Victor] CHUV, Multidisciplinary Oncol Ctr, Lausanne, Switzerland.
   [Greub, Gilbert] CHUV, Inst Microbiol, Ctr Res Intracellular Bacteria, Lausanne, Switzerland.
   [Greub, Gilbert] Univ Lausanne, Lausanne, Switzerland.
   [Brookes, Roger; Rowland-Jones, Sarah] MRC Labs, Banjul, Gambia.
   [Guillaume, Philippe; Grosjean, Frederic; Romero, Pedro] Ludwig Inst Canc Res, Lausanne Branch, Div Clin Oncoimmunol, Lausanne, Switzerland.
   [Fagerberg, Theres; Michelin, Olivier] Swiss Inst Bioinformat, Lausanne, Switzerland.
   [Pinilla, Clemencia] Torrey Pines Inst Mol Studies, San Diego, CA USA.
   [Appay, Victor] Univ Paris 06, INSERM, Cellular Immunol Lab, Hop La Pitie Salpetriere,Avenir Grp,U543, Paris, France.
RP Appay, V (reprint author), CHUV, Multidisciplinary Oncol Ctr, Lausanne, Switzerland.
EM victor.appay@chups.jussieu.fr
OI Greub, Gilbert/0000-0001-9529-3317
FU Medical Research Council [MC_U137884180]
CR Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94
   Appay V, 2002, J IMMUNOL METHODS, V268, P9, DOI 10.1016/S0022-1759(02)00195-3
   Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Appay V, 2006, EUR J IMMUNOL, V36, P1805, DOI 10.1002/eji.200535805
   Appay V, 2006, J IMMUNOL, V177, P1670
   BHARDWAJ V, 1993, J IMMUNOL, V151, P5000
   Boom WH, 2003, TUBERCULOSIS, V83, P98, DOI 10.1016/S1472-9792(02)00054-9
   Brehm MA, 2002, NAT IMMUNOL, V3, P627, DOI 10.1038/ni806
   Derre L, 2007, J IMMUNOL, V179, P7635
   DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H
   Dunbar PR, 2000, J IMMUNOL, V165, P6644
   Dutoit V, 2002, J EXP MED, V196, P207, DOI 10.1084/jem.20020242
   EICHLER J, 1994, PEPTIDE RES, V7, P300
   EVAVOLD BD, 1995, IMMUNITY, V2, P655, DOI 10.1016/1074-7613(95)90010-1
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9
   Fagerberg T, 2006, J MOL BIOL, V356, P521, DOI 10.1016/j.jmb.2005.11.059
   Grogan JL, 1999, J IMMUNOL, V163, P3764
   HAGERTY DT, 1995, J IMMUNOL, V155, P2993
   Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651
   KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347
   Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1
   Loftus DJ, 1996, J EXP MED, V184, P647, DOI 10.1084/jem.184.2.647
   Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7
   Misko IS, 1999, P NATL ACAD SCI USA, V96, P2279, DOI 10.1073/pnas.96.5.2279
   Montes M, 2005, CLIN EXP IMMUNOL, V142, P292, DOI 10.1111/j.1365-2249.2005.02914.x
   Pinilla C, 1999, CURR OPIN IMMUNOL, V11, P193, DOI 10.1016/S0952-7915(99)80033-8
   Pinilla C, 2001, CANCER RES, V61, P5153
   Pittet MJ, 1999, J EXP MED, V190, P705, DOI 10.1084/jem.190.5.705
   Romero P, 1998, J EXP MED, V188, P1641, DOI 10.1084/jem.188.9.1641
   Romero P, 2002, IMMUNOL REV, V188, P81, DOI 10.1034/j.1600-065X.2002.18808.x
   Rubio-Godoy V, 2002, EUR J IMMUNOL, V32, P2292, DOI 10.1002/1521-4141(200208)32:8<2292::AID-IMMU2292>3.0.CO;2-K
   Rubio-Godoy V, 2002, J IMMUNOL, V169, P5696
   Rufer N, 2005, CURR OPIN IMMUNOL, V17, P441, DOI 10.1016/j.coi.2005.06.003
   Selin LK, 2004, SEMIN IMMUNOL, V16, P335, DOI 10.1016/j.smim.2004.08.014
   Selin LK, 2004, IMMUNITY, V20, P5, DOI 10.1016/S1074-7613(03)00356-X
   Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373
   Tumenjargal S, 2003, EUR J IMMUNOL, V33, P3175, DOI 10.1002/eji.200324244
   Wilson DB, 2004, MOL IMMUNOL, V40, P1047, DOI 10.1016/j.molimm.2003.11.022
   Zhao YD, 2001, J IMMUNOL, V167, P2130
   Zippelius A, 2002, J EXP MED, V195, P485, DOI 10.1084/jem.20011658
NR 40
TC 10
Z9 10
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0953-8178
J9 INT IMMUNOL
JI Int. Immunol.
PD AUG
PY 2008
VL 20
IS 8
BP 1087
EP 1096
DI 10.1093/intimm/dxn066
PG 10
WC Immunology
SC Immunology
GA 330SS
UT WOS:000257963700013
PM 18573812
OA No
DA 2017-08-15
ER

PT J
AU Mendy, ME
   Kaye, S
   Le Roux, E
   Kirk, GD
   Jeng-Barry, A
   McConkey, S
   Cotten, M
   Kuniholm, MH
   Leligdowicz, A
   Hainaut, P
   Rowland-Jones, S
   Whittle, H
AF Mendy, M. E.
   Kaye, S.
   Le Roux, E.
   Kirk, G. D.
   Jeng-Barry, A.
   McConkey, S.
   Cotten, M.
   Kuniholm, M. H.
   Leligdowicz, A.
   Hainaut, P.
   Rowland-Jones, S.
   Whittle, H.
TI Application of a novel, rapid, and sensitive oligonucleotide ligation
   assay for detection of cancer-predicting mutations in the precore and
   basal core promoter of hepatitis B virus
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA; E-ANTIGEN; ALPHA-FETOPROTEIN; CHRONIC
   CARRIERS; POL GENE; INFECTION; MUTANTS; FULMINANT; GAMBIA; LIVER
AB Hepatocellular carcinoma (HCC) and cirrhosis are important causes of mortality worldwide. Persistent hepatitis B virus (HBV) infection is a major cause of these diseases. Double mutations in the basal core promoter (BCP) (A1762T and G1764A) and precore (pre-C) (G1896A) regions of the virus are associated with progression to HCC. The current study is aimed at developing a simple method for screening and detecting BCP and pre-C mutations in HBV carriers. We have developed and validated an oligonucleotide ligation assay (OLA) to detect point mutations in the HBV core gene. We have applied OLA methods to samples from HBV-infected carriers recruited from the Gambia Liver Cancer Study (GLCS) comprising asymptomatic HBsAg carriers, patients with cirrhosis, and patients with HCC. We observed an 89.3% and 95.8% concordance between the OLA and DNA sequencing for BCP and pre-C mutations, respectively. OLA detected the mutations in single-strain infections and in infections with mixtures of wild-type and mutant viruses under conditions where sequencing detected only the single dominant strains. BCP mutations were detected in 75.7% of patients with advanced liver disease (cirrhosis/HCC) compared to 47.6% of asymptomatic carriers, while pre-C mutations were detected in 34.5% of advanced liver disease patients and in 47.6% of asymptomatic HBsAg carriers. There was a significant association between the presence of BCP mutations and advanced liver disease. In conclusion, OLA is a simple, economical, and reliable assay for detection of pre-C and BCP mutations. Its application can lead to improvement in diagnosis and clinical care in regions where HBV is endemic.
C1 [Mendy, M. E.; Kaye, S.; Jeng-Barry, A.; McConkey, S.; Cotten, M.; Leligdowicz, A.; Rowland-Jones, S.; Whittle, H.] MRC, Viral Dis Programme, Banjul, Gambia.
   [Le Roux, E.; Hainaut, P.] Int Agcy Res Canc, Mol Carcinogenesis, F-69372 Lyon, France.
   [Kirk, G. D.; Kuniholm, M. H.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
RP Mendy, ME (reprint author), MRC, Viral Dis Programme, Atlantic Blvd,POB 273, Banjul, Gambia.
EM mmendy@mrc.gm
RI Kirk, Gregory/A-8484-2009; McConkey, Samuel/E-7307-2012; Hainaut, Pierre
   /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610; McConkey,
   Samuel/0000-0001-9085-7793; Leligdowicz, Aleksandra/0000-0001-6055-4644
FU Medical Research Council (United Kingdom); International Agency for
   Research on Cancer, Lyon, France; National Cancer Institute; NIH; DHHS
FX Sincere thanks go to Fumi Lesi for clinical support in recruiting HCC
   patients and asymptomatic HBsAg carriers, Alasana Bah for laboratory
   assistance, and Yusupha Bah and Ebrima Bah for invaluable assistance in
   the collection of field and cancer registry data.; This work was
   supported by the Medical Research Council (United Kingdom); the
   International Agency for Research on Cancer, Lyon, France; and the
   National Cancer Institute, NIH, DHHS, Bethesda, MD.
CR Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   Ballard AL, 1997, J VIROL METHODS, V67, P143, DOI 10.1016/S0166-0934(97)00089-X
   Baptista M, 1999, HEPATOLOGY, V29, P946, DOI 10.1002/hep.510290336
   BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J
   Beck Ingrid A, 2002, J Clin Microbiol, V40, P1413, DOI 10.1128/JCM.40.4.1413-1419.2002
   Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557
   Brunetto MR, 1999, INTERVIROLOGY, V42, P69, DOI 10.1159/000024968
   Buckwold VE, 1996, J VIROL, V70, P5845
   Cameron-Wilson CL, 2003, J VIROL METHODS, V114, P97, DOI 10.1016/j.jviromet.2003.09.014
   CARMAN WF, 1989, LANCET, V2, P588
   Dumpis U, 2001, J MED VIROL, V65, P664, DOI 10.1002/jmv.2088
   Edelstein RE, 1998, J CLIN MICROBIOL, V36, P569
   Ellis GM, 2004, J CLIN MICROBIOL, V42, P3670, DOI 10.1128/jcm.42.8.3670-3674.2004
   Fang ZL, 2002, J MED VIROL, V68, P33, DOI 10.1002/jmv.10167
   Grandjacques C, 2000, J HEPATOL, V33, P430, DOI 10.1016/S0168-8278(00)80279-2
   HAWKINS AE, 1994, J MED VIROL, V44, P13, DOI 10.1002/jmv.1890440105
   Jallow S, 2007, J CLIN MICROBIOL, V45, P1565, DOI 10.1128/JCM.02220-06
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kramvis A, 1999, J VIRAL HEPATITIS, V6, P415, DOI 10.1046/j.1365-2893.1999.00189.x
   LASKUS T, 1995, GASTROENTEROLOGY, V109, P1618, DOI 10.1016/0016-5085(95)90651-7
   Laskus T, 1998, BIOCHEM BIOPH RES CO, V244, P812, DOI 10.1006/bbrc.1998.8249
   Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406
   LIN DY, 1993, J CLIN ULTRASOUND, V21, P303, DOI 10.1002/jcu.1870210502
   Liu CJ, 2006, J INFECT DIS, V193, P1258, DOI 10.1086/502978
   Locarnini S, 2004, SEMIN LIVER DIS, V24, P3, DOI 10.1055/s-2004-828672
   Mendy ME, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-23
   Moriyama K, 1996, VIROLOGY, V226, P269, DOI 10.1006/viro.1996.0655
   NORDER H, 1994, VIROLOGY, V198, P489, DOI 10.1006/viro.1994.1060
   OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404
   Pang A, 2004, J HEPATOL, V40, P1008, DOI 10.1016/j.jhep.2004.02.024
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Soresi M, 2003, ANTICANCER RES, V23, P1747
   Tobe VO, 1996, NUCLEIC ACIDS RES, V24, P3728, DOI 10.1093/nar/24.19.3728
   Tong MJ, 2001, J GASTROEN HEPATOL, V16, P553, DOI 10.1046/j.1440-1746.2001.02470.x
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   Wong IHN, 2000, CANCER LETT, V156, P141, DOI 10.1016/S0304-3835(00)00473-0
   Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20
   Yim HJ, 2006, HEPATOLOGY, V43, pS173, DOI 10.1002/hep.20956
NR 38
TC 5
Z9 5
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD AUG
PY 2008
VL 46
IS 8
BP 2723
EP 2730
DI 10.1128/JCM.01622-07
PG 8
WC Microbiology
SC Microbiology
GA 344EI
UT WOS:000258908700034
PM 18508941
OA No
DA 2017-08-15
ER

PT J
AU Wiseman, V
   Scott, A
   Conteh, L
   McElroy, B
   Stevens, W
AF Wiseman, Virginia
   Scott, Anthony
   Conteh, Lesong
   McElroy, Brendan
   Stevens, Warren
TI Determinants of provider choice for malaria treatment: Experiences from
   The Gambia
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE malaria; treatment-seeking demand; provider choice; The Gambia
ID WILLINGNESS-TO-PAY; TREATMENT SEEKING; RURAL GAMBIA; HEALTH; CHILDREN;
   MANAGEMENT; PERCEPTION; AFRICA; UGANDA; GHANA
AB Malaria is responsible for an estimated one million deaths per year, the vast majority in sub-Saharan Africa. Many of these deaths are attributed to delays in seeking treatment and poor adherence to drug regimes. While there are a growing number of studies describing the factors influencing treatment seeking for malaria, far less is known about the relative weight given to these factors in different settings. This study estimates two models of demand for malaria treatment in the Farafenni region of The Gambia. The first examines the determinants of seeking malaria treatment outside the home versus no treatment or self-care while the second identifies the determinants of provider choice conditional on having decided to seek malaria treatment outside the home. Providers included hospital: health centre; and 'other' which included pharmacies, kiosks: petty traders; neighbours; and traditional healers. Results show that older people were more likely to opt for self-care, or no treatment. The longer the time spent ill or the more severe the fever, the more likely a treatment was sought outside the home. Time of the year and availability of community infrastructure played a key role in both models. Poorer households and those from the Fula ethnic group were much more likely to visit an 'other' provider than a hospital. The policy and methodological implications of these findings are discussed. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Wiseman, Virginia; Conteh, Lesong] London Sch Hugiene & Trop Med, Hlth Econ & Financing Programme, London WC1E 7HT, England.
   [Scott, Anthony] Univ Melbourne, Melbourne Inst Appl Econ & Social Res, Melbourne, Vic, Australia.
   [McElroy, Brendan] Natl Univ Ireland Univ Coll Cork, Dept Econ, Cork, Ireland.
   [Stevens, Warren] MRC, Fajara, Gambia.
RP Wiseman, V (reprint author), London Sch Hugiene & Trop Med, Hlth Econ & Financing Programme, Keppel St, London WC1E 7HT, England.
EM virginia.wiseman@lshtm.ac.uk
RI Scott, Anthony/E-6636-2010
OI Scott, Anthony/0000-0002-2851-5378
CR AKIN JS, 1995, SOC SCI MED, V40, P1527, DOI 10.1016/0277-9536(94)00274-W
   Asenso-Okyere WK, 1997, HEALTH POLICY, V42, P223, DOI 10.1016/S0168-8510(97)00069-9
   Clarke SE, 2003, TROP MED INT HEALTH, V8, P884, DOI 10.1046/j.1365-3156.2003.01095.x
   DEATON A, 2000, CONSUMPTION, P91
   Deaton A. S., 1997, ANAL HOUSEHOLD SURVE
   *DIFID, 2002, MEAS HLTH POV REV AP
   Dor A, 1993, HLTH EC RES DEV COUN, P193
   Dzator J, 2004, HEALTH POLICY, V69, P389, DOI 10.1016/j.healthpol.2004.01.005
   Grosh M., 2000, DESIGNING HOUSEHOLD
   GUIGUEMDE TR, 1994, T ROY SOC TROP MED H, V88, P285, DOI 10.1016/0035-9203(94)90079-5
   Guyatt HL, 2004, T ROY SOC TROP MED H, V98, P111, DOI 10.1016/S0035-9203(03)00016-6
   Hossain S. M. Moazzem, 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P707
   Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359
   KENGEYAKAYONDO JF, 1994, ACTA TROP, V58, P267, DOI 10.1016/0001-706X(94)90020-5
   Killingsworth M. R., 1983, LABOUR SUPPLY
   Kofoed PE, 2004, ACTA TROP, V90, P17, DOI 10.1016/j.actatropica.2003.09.011
   McCombie SC, 1996, SOC SCI MED, V43, P933, DOI 10.1016/0277-9536(95)00446-7
   McKenzie D, 2003, MEASURING INEQUALITY
   MENSAH AO, 2000, THESIS LONDON SCH HY
   Morey ER, 2003, SOC SCI MED, V57, P155, DOI 10.1016/S0277-9536(02)00338-6
   MUELLER O, 2004, MALARIA J, V20, P36
   Nuwaha F, 2002, TROP MED INT HEALTH, V7, P462, DOI 10.1046/j.1365-3156.2002.00877.x
   Nyamongo IK, 1999, TROP MED INT HEALTH, V4, P736, DOI 10.1046/j.1365-3156.1999.00484.x
   OFSTEDAL MB, 2003, SELF ASSESSED HLTH E
   RARCLIFFE A, 2004, POPULATON HLTH DEV C, P201
   Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55
   Saeed I E, 2003, East Mediterr Health J, V9, P593
   *UNICEF, 2007, REP PROC SUPPL CHILD
   von Seidlein L, 2002, B WORLD HEALTH ORGAN, V80, P790
   Walraven GEL, 2001, CLIN EXP ALLERGY, V31, P1679, DOI 10.1046/j.1365-2222.2001.01094.x
   Weesie J., 1999, STATA TECH B, V52, P34
   *WHO, 2007, 94 WHO
   Williams HA, 2004, SOC SCI MED, V59, P501, DOI 10.1016/j.socscimed.2003.11.010
   Zimmer Z, 2000, J HEALTH SOC BEHAV, V41, P465, DOI 10.2307/2676298
NR 34
TC 22
Z9 22
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD AUG
PY 2008
VL 67
IS 4
BP 487
EP 496
DI 10.1016/j.socscimed.2008.04.007
PG 10
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 346HY
UT WOS:000259060600001
PM 18538458
OA No
DA 2017-08-15
ER

PT J
AU Walton, RT
   Rowland-Jones, SL
AF Walton, Robert T.
   Rowland-Jones, Sarah L.
TI HIV and chemokine binding to red blood cells - DARC matters
SO CELL HOST & MICROBE
LA English
DT Editorial Material
ID RECEPTORS; ANTIGEN
AB A mutation in the Duffy antigen (DARC) that abrogates receptor expression and gives profound protection against some malaria species has become almost universal in African populations. He et al. (2008) show that this polymorphism also leads to significantly increased susceptibility to HIV-1 infection but, paradoxically, to prolonged survival in HIV-1-infected subjects.
C1 [Walton, Robert T.; Rowland-Jones, Sarah L.] MRC Labs, Banjul, Gambia.
   [Walton, Robert T.] Univ Oxford, Dept Clin Pharmacol, Oxford OX3 7DQ, England.
   [Rowland-Jones, Sarah L.] John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford OX3 9DS, England.
RP Rowland-Jones, SL (reprint author), MRC Labs, Atlantic Rd,POB 273, Banjul, Gambia.
EM sarah.rowland-jones@ndm.ox.ac.uk
OI Walton, Robert/0000-0001-7700-1907
FU Medical Research Council [MC_U190092710]
CR Arenzana-Seisdedos F, 2006, SEMIN IMMUNOL, V18, P387, DOI 10.1016/j.smim.2006.07.007
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8
   Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767
   Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160
   Hadley TJ, 1997, BLOOD, V89, P3077
   He WJ, 2008, CELL HOST MICROBE, V4, P52, DOI 10.1016/j.chom.2008.06.002
   Mayr FB, 2008, CRIT CARE MED, V36, P159, DOI 10.1097/01.CCM.0000297875.55969.DB
   Pruenster M, 2006, BIOCHEM SOC T, V34, P1005
NR 10
TC 10
Z9 11
U1 0
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1931-3128
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD JUL 17
PY 2008
VL 4
IS 1
BP 3
EP 5
DI 10.1016/j.chom.2008.06.006
PG 3
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 329ZF
UT WOS:000257908400002
PM 18621004
OA No
DA 2017-08-15
ER

PT J
AU Cooke, GS
   Campbell, SJ
   Bennett, S
   Lienhardt, C
   McAdam, KPWJ
   Sirugo, G
   Sow, O
   Gustafson, P
   Mwangulu, F
   van Helden, P
   Fine, P
   Hoal, EG
   Hill, AVS
AF Cooke, Graham S.
   Campbell, Sarah J.
   Bennett, Steve
   Lienhardt, Christian
   McAdam, Keith P. W. J.
   Sirugo, Giorgio
   Sow, Oumou
   Gustafson, Per
   Mwangulu, Frank
   van Helden, Paul
   Fine, Paul
   Hoal, Eileen G.
   Hill, Adrian V. S.
TI Mapping of a novel susceptibility locus suggests a role for MC3R and
   CTSZ in human tuberculosis
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE tuberculosis; host genetics; MC3R; Africa
ID INTERFERON-GAMMA GENE; PULMONARY TUBERCULOSIS; LINKAGE ANALYSIS;
   CATHEPSIN-Z; LEPROSY; POLYMORPHISM; ASSOCIATION; AFRICA; NRAMP1;
   INTERLEUKIN-10
AB Rationale: Tuberculosis remains a major cause of morbidity and mortality in the developing world. A better understanding of the mechanisms of disease protection could allow novel strategies to disease management and control.
   Objectives: To identify human genomic loci with evidence of linkage to tuberculosis susceptibility and, within these loci, to identify individual genes influencing tuberculosis susceptibility.
   Methods: Affected sibling pair analysis in South African and Malawian populations. Independent case-control study in West Africa.
   Measurements and Main Results: Two novel putative loci for tuberculosis susceptibility are identified: chromosome 6p21-q23 and chromosome 20q 13.31-33-the latter with the strongest evidence for any locus reported to date in human tuberculosis (single point LOD score of 3.1, P = 10(-4), with a maximum likelihood score [MLS] of 2.8). An independent, multistage genetic association study in West African populations mapped this latter region in detail, finding evidence that variation in the melanocortin 3 receptor (MC3R) and cathepsin Z (CTSZ) genes play a role in the pathogenesis of tuberculosis.
   Conclusions: These results demonstrate how a genomewide approach to the complex phenotype of human tuberculosis can identify novel targets for further research.
C1 [Cooke, Graham S.] Univ KwaZulu Natal, Africa Ctr Hlth & Populat Studies, ZA-3935 Somkhele, Kwazulu Natal, South Africa.
   [Cooke, Graham S.; Campbell, Sarah J.; Hill, Adrian V. S.] Univ Oxford, Churchill Hosp, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Cooke, Graham S.] Univ London Imperial Coll Sci Technol & Med, London, England.
   [Bennett, Steve] London Sch Hyg & Trop Med, London WC1, England.
   [Lienhardt, Christian] Natl TB Leprosy Control Programme, Banjul, Gambia.
   [McAdam, Keith P. W. J.; Sirugo, Giorgio] MRC Labs, Fajara, Gambia.
   [Sow, Oumou] CHU Ignace Deen, Conakry, Guinea.
   [Gustafson, Per] Danish Epidemiol Sci Ctr, Bissau, Guinea Bissau.
   [Mwangulu, Frank; Fine, Paul] Karonga Prevent Study, Chilumba, Malawi.
   [van Helden, Paul; Hoal, Eileen G.] Univ Stellenbosch, MRC, Ctr Cellular & Mol Biol, ZA-7600 Stellenbosch, South Africa.
RP Cooke, GS (reprint author), Univ KwaZulu Natal, Africa Ctr Hlth & Populat Studies, POB 198, ZA-3935 Somkhele, Kwazulu Natal, South Africa.
EM gcooke@africacentre.ac.za
RI HILL, Adrian/C-1306-2008
OI Hoal, Eileen/0000-0002-6444-5688
FU Medical Research Council [G0000690]; Wellcome Trust [079828,
   IC18CT980375]
CR Abdel-Malek ZA, 2001, CELL MOL LIFE SCI, V58, P434, DOI 10.1007/PL00000868
   Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   Awomoyi AA, 2002, J INFECT DIS, V186, P1808, DOI 10.1086/345920
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897
   Bennett S, 2002, AM J EPIDEMIOL, V155, P1074, DOI 10.1093/aje/155.11.1074
   BRAHMAJOTHI V, 1991, TUBERCLE, V72, P123, DOI 10.1016/0041-3879(91)90039-U
   Campbell SJ, 2003, IMMUNOGENETICS, V55, P502, DOI 10.1007/s00251-003-0602-9
   Ceriani Giuliana, 1994, Neuroimmunomodulation, V1, P28, DOI 10.1159/000097087
   Cervino ACL, 2002, HUM MOL GENET, V11, P1599, DOI 10.1093/hmg/11.14.1599
   Cooke GS, 2006, AM J RESP CRIT CARE, V174, P339, DOI 10.1164/rccm.200601-088OC
   Delgado JC, 2002, J INFECT DIS, V186, P1463, DOI 10.1086/344891
   Falcone FH, 2000, EXP PARASITOL, V94, P201, DOI 10.1006/expr.2000.4489
   Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165
   Getting SJ, 1999, J IMMUNOL, V162, P7446
   Getting SJ, 2001, J LEUKOCYTE BIOL, V69, P98
   GETTING SJ, 2003, J PHARM EXP THER
   Getting SJ, 2006, FASEB J, V20, P2234, DOI 10.1096/fj.06-6339com
   Hoal EG, 2004, INT J TUBERC LUNG D, V8, P1464
   HOLMANS P, 1993, AM J HUM GENET, V52, P362
   Jamieson SE, 2004, GENES IMMUN, V5, P46, DOI 10.1038/sj.gene.6364029
   Khor CC, 2007, NAT GENET, V39, P523, DOI 10.1038/ng1976
   KRUGLYAK L, 1995, AM J HUM GENET, V57, P439
   Lennon-Dumenil AM, 2002, J EXP MED, V196, P529, DOI 10.1084/jem.20020327
   Lio D, 2002, EUR J IMMUNOGENET, V29, P371, DOI 10.1046/j.1365-2370.2002.00327.x
   Lopez-Maderuelo D, 2003, AM J RESP CRIT CARE, V167, P970, DOI 10.1164/rccm.200205-438BC
   Ma X, 2002, INT J TUBERC LUNG D, V6, P818
   Miller EN, 2004, GENES IMMUN, V5, P63, DOI 10.1038/sj.gene.6364031
   Mira MT, 2003, NAT GENET, V33, P412, DOI 10.1038/ng1096
   Mira MT, 2004, NATURE, V427, P636, DOI 10.1038/nature02326
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   Ravikumar M., 1999, Tubercle and Lung Disease, V79, P309, DOI 10.1054/tuld.1999.0213
   RICHARDS DB, 1984, PEPTIDES, V5, P815, DOI 10.1016/0196-9781(84)90027-5
   Rossouw M, 2003, LANCET, V361, P1871, DOI 10.1016/S0140-6736(03)13491-5
   Santamaria I, 1998, J BIOL CHEM, V273, P16816, DOI 10.1074/jbc.273.27.16816
   Satsangi J, 1996, NAT GENET, V14, P199, DOI 10.1038/ng1096-199
   Shi GP, 2000, J EXP MED, V191, P1177, DOI 10.1084/jem.191.7.1177
   Siddiqui MR, 2001, NAT GENET, V27, P439, DOI 10.1038/86958
   SINGH SPN, 1983, J INFECT DIS, V148, P676
   Tosh K, 2002, J INFECT DIS, V186, P1190, DOI 10.1086/343806
NR 40
TC 48
Z9 54
U1 1
U2 5
PU AMER THORACIC SOC
PI NEW YORK
PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD JUL 15
PY 2008
VL 178
IS 2
BP 203
EP 207
DI 10.1164/rccm.200710-1554OC
PG 5
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 327MY
UT WOS:000257734400013
PM 18420963
OA No
DA 2017-08-15
ER

PT J
AU Howie, S
   Mueller, J
   Whittle, H
AF Howie, Stephen
   Mueller, Jenny
   Whittle, Hilton
TI Assuring trial safety for children
SO LANCET
LA English
DT Letter
C1 [Howie, Stephen; Mueller, Jenny; Whittle, Hilton] MRC Labs, Banjul, Gambia.
RP Howie, S (reprint author), MRC Labs, Banjul, Gambia.
EM showie@mrc.gm
CR Committee for Medicinal Products for Human Use, 2005, GUID DAT MON COMM
   *NIH, 2000, GUID DAT SAF MON PHA
   NIH, 1998, NIH POL DAT SAF MON
   Sammons HM, 2008, ACTA PAEDIATR, V97, P474, DOI 10.1111/j.1651-2227.2008.00676.x
   2008, LANCET, V371, P1046
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD JUL 5
PY 2008
VL 372
IS 9632
BP 30
EP 30
DI 10.1016/S0140-6736(08)60988-5
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 321XN
UT WOS:000257339900026
PM 18603156
OA No
DA 2017-08-15
ER

PT J
AU Saaka, M
   Okoko, BJ
   Kohberger, RC
   Jaffar, S
   Enwere, G
   Biney, EE
   Oluwalana, C
   Vaughan, A
   Zaman, SMA
   Asthon, L
   Goldblatt, D
   Greenwood, BM
   Cutts, FT
   Adegbola, RA
AF Saaka, M.
   Okoko, B. J.
   Kohberger, R. C.
   Jaffar, S.
   Enwere, G.
   Biney, E. E.
   Oluwalana, C.
   Vaughan, A.
   Zaman, S. M. A.
   Asthon, L.
   Goldblatt, D.
   Greenwood, B. M.
   Cutts, F. T.
   Adegbola, R. A.
TI Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal
   conjugate vaccine (PCV-9) determined during an efficacy trial in The
   Gambia
SO VACCINE
LA English
DT Article
DE pneumococcal conjugate vaccine; immunogenicity; efficacy; Gambia;
   pneumococcus
ID STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE; SENTINEL
   SURVEILLANCE; INVASIVE DISEASE; UNITED-STATES; CHILDREN; INFANTS;
   SAFETY; DIPHTHERIA; TETANUS
AB This study aimed to determine the immunogenicity of a 9-valent pneumococcal conjugate vaccine (PCV-9) in a subgroup of Gambian children enrolled in a large vaccine efficacy trial. To place the antibody results in context, in this paper we also report previously unpublished data on serotype-specific clinical vaccine efficacy from the main trial. In the sub-study, a single 2-4 ml venous blood specimen was collected from 212 Gambian children 4-6 weeks after the administration of a third dose of PCV-9 or placebo. IgG antibodies to pneumococcal serotype 1, 4,5,613, 9V, 14,18C, 19F and 23F polysaccharides were measured by ELISA. The proportions of infants with antibody concentrations above 0.2, 0.35 and 1.0 mu g/ml, and the geometric mean concentrations (GMCs) of anti-pneumococcal polysaccharide antibodies were substantially higher for each serotype in children who received three doses of PCV-9 than those in the placebo group. Among PCV-9 recipients, GMCs ranged between 2.61 and 11.09 mu g/ml with the highest being against serotype 14 and the lowest against 9V polysaccharide. The estimated overall protective antibody level for all nine serotypes, based on the vaccine efficacy against vaccine-type invasive pneumococcal disease (IPD) of 77% (95% CI: 51,90) observed in the trial, was 2.3 mu g/ml (95% CI: 1.0, 5,0). The PCV-9 studied was immunogenic in a Gambian population where it was also found to be efficacious. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Kohberger, R. C.] Blair & Co, Greenwich, CT 06831 USA.
   [Jaffar, S.; Greenwood, B. M.; Cutts, F. T.] London Sch Hyg & Trop Med, London, England.
   [Asthon, L.; Goldblatt, D.] UCL Inst Child Hlth, WHO Reference Lab Pneumococcal ELISAs, London, England.
RP Okoko, BJ (reprint author), MRC Labs, Box 273, Banjul, Gambia.
EM bokoko@mrc.gm
RI Goldblatt, David/C-5972-2008
OI Goldblatt, David/0000-0002-0769-5242
FU Medical Research Council [G0700837]; NIAID NIH HHS [N01-AI-25477]
CR ADEGBOLA RA, 1994, PEDIAT INFECT DIS, V13, P75
   Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Advisory Committee of Immunization Practices. Prevention of pneumococcal disease: Recommendations of the Advisory Committee of Immunization Practices (ACIP), 1997, MMWR-MORBID MORTAL W, V46, P1
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Bricks Lucia Ferro, 2006, J Pediatr (Rio J), V82, pS67, DOI 10.1590/S0021-75572006000400008
   Butler JC, 1996, J INFECT DIS, V174, P986
   Capeding MZR, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-17
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5
   Goldblatt D, 2006, PEDIATR INFECT DIS J, V25, P312, DOI 10.1097/01.inf.0000207483.60267.e7
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608
   Huebner RE, 2002, PEDIATR INFECT DIS J, V21, P1004, DOI 10.1097/01.inf.0000036012.37665.fe
   Jefferson T, 2006, LANCET INFECT DIS, V6, P405, DOI 10.1016/S1473-3099(06)70520-5
   Jodar L, 2003, VACCINE, V21, P3265, DOI 10.1016/S0264-410X(03)00230-5
   Kadioglu A, 2004, INFECT IMMUN, V72, P2689, DOI 10.1128/IAI.72.5.2689-2697.2004
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Klugman KP, 2005, EMERG INFECT DIS, V11, P802
   Madhi SA, 2007, VACCINE, V25, P2451, DOI 10.1016/j.vaccine.2006.09.019
   Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009
   Miernyk KM, 2000, CLIN INFECT DIS, V31, P34, DOI 10.1086/313907
   Millar EV, 2006, CLIN INFECT DIS, V43, P8, DOI 10.1086/504802
   Moore SE, 2003, ACTA PAEDIATR, V92, P170
   MOORE SE, 2006, TROP MED INT HEALTH, V11, P529
   Nurkka A, 2004, PEDIATR INFECT DIS J, V23, P1008, DOI 10.1097/01.inf.0000143640.03214.18
   O'Brien KL, 2003, LANCET, V362, P355, DOI 10.1016/S0140-6736(03)14022-6
   Obaro SK, 2000, PEDIATR INFECT DIS J, V19, P463, DOI 10.1097/00006454-200005000-00014
   Obaro SK, 2002, PEDIATR INFECT DIS J, V21, P940, DOI 10.1097/01.inf.0000034245.88174.3c
   OBARO SK, 2006, LANCET INFECT DIS, V6, P50
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   Ouml;rtqvist A, 2005, SEMIN RESP CRIT CARE, V26, P563, DOI 10.1055/s-2005-925523
   Palmer A, 1999, J TROP PEDIATRICS, V45, P51, DOI 10.1093/tropej/45.1.51
   Rennels MB, 1998, PEDIATRICS, V101, P604, DOI 10.1542/peds.101.4.604
   SCHUCHAT A, 2004, PEDIAT INFECT DIS, V15, P181
   Siber GR, 2007, VACCINE, V25, P3816, DOI 10.1016/j.vaccine.2007.01.119
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   Wernette CM, 2003, CLIN DIAGN LAB IMMUN, V10, P514, DOI 10.1128/CDLI.10.4.514-519.2003
   WHO, 2005, WHO TECH REP SER, V927, P64
NR 38
TC 27
Z9 28
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUL 4
PY 2008
VL 26
IS 29-30
BP 3719
EP 3726
DI 10.1016/j.vaccine.2008.04.066
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 326HK
UT WOS:000257649000023
PM 18514974
OA No
DA 2017-08-15
ER

PT J
AU DeRiemer, K
   De Jong, BC
AF DeRiemer, Kathryn
   De Jong, Bouke C.
TI Catch them while you can!
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Editorial Material
ID MYCOBACTERIUM-TUBERCULOSIS; MOLECULAR EPIDEMIOLOGY; RESISTANT
   TUBERCULOSIS; SOUTH-AFRICA; COMBINATION; STRAINS
C1 [DeRiemer, Kathryn] Univ Calif Davis, Davis, CA 95616 USA.
   [De Jong, Bouke C.] NYU, New York, NY USA.
   [De Jong, Bouke C.] MRC Labs, Banjul, Gambia.
RP DeRiemer, K (reprint author), Univ Calif Davis, Davis, CA 95616 USA.
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675; DeRiemer,
   Kathryn/0000-0002-8375-7505
CR Ahmed N, 2008, NAT REV MICROBIOL, V6, P387, DOI 10.1038/nrmicro1889
   Alonso-Rodriguez N, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-34
   Barnard M, 2008, AM J RESP CRIT CARE, V177, P787, DOI 10.1164/rccm.200709-1436OC
   Barnes PF, 2003, NEW ENGL J MED, V349, P1149, DOI 10.1056/NEJMra021964
   DeRiemer K, 2007, AM J RESP CRIT CARE, V176, P936, DOI 10.1164/rccm.200603-440OC
   Evans JT, 2004, J CLIN MICROBIOL, V42, P4175, DOI 10.1128/JCM.42.9.4175-4180.2004
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1
   Golub JE, 2005, INT J TUBERC LUNG D, V9, P1183
   Keeler Emmett, 2006, Nature, V444 Suppl 1, P49, DOI 10.1038/nature05446
   Kik SV, 2008, AM J RESP CRIT CARE, V178, P96, DOI 10.1164/rccm.200708-1256OC
   Koenig R, 2008, SCIENCE, V319, P894, DOI 10.1126/science.319.5865.894
   World Health Organization, 2008, PUBL WHO, VWHO/IVP/08.07
   Zhang L, 2008, FEMS MICROBIOL LETT, V282, P22, DOI 10.1111/j.1574-6968.2008.01081.x
NR 13
TC 0
Z9 0
U1 0
U2 1
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD JUL 1
PY 2008
VL 178
IS 1
BP 5
EP 6
DI 10.1164/rccm.200804-589ED
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 319YB
UT WOS:000257199800004
PM 18565961
OA No
DA 2017-08-15
ER

PT J
AU Majambere, S
   Fillinger, U
   Sayer, DR
   Green, C
   Lindsay, SW
AF Majambere, Silas
   Fillinger, Ulrike
   Sayer, David R.
   Green, Clare
   Lindsay, Steven W.
TI Spatial distribution of mosquito larvae and the potential for targeted
   larval control in the Gambia
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID CONTROLLING AQUATIC STAGES; DAR-ES-SALAAM; ANOPHELES-GAMBIAE; MALARIA
   CONTROL; WESTERN KENYA; HABITAT CHARACTERIZATION; MICROBIAL LARVICIDES;
   RICE CULTIVATION; URBAN MALARIA; AFRICA
AB We examined the distribution of aquatic stages of malaria vectors in a 400-km(2) area in rural Gambia to assess the practicality of targeting larval control. During the rainy season, the peak period of malaria transmission, breeding sites were 70% more likely to have anopheline larvae in the floodplain of the Gambia River than upland sites (P < 0.001). However, mosquitoes were found in some examples of all habitats apart from moving water. Habitats most often colonized by anopheline larvae were the largest water bodies, situated near the landward edge of the floodplain, where culicine larvae were present. In the wet season, 49% of sites had anophelines versus 19% in the dry season (P < 0.001). Larval control targeted at specific habitats is unlikely to be successful in this setting. Nonetheless, larval control initiated at the end of the dry season and run throughout the rainy season could help reduce transmission.
C1 [Lindsay, Steven W.] Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
   MRC Labs, Fajara, Gambia.
RP Lindsay, SW (reprint author), Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
EM S.W.Lindsay@durham.ac.uk
OI Fillinger, Ulrike/0000-0002-4037-431X
FU NIAID NIH HHS [1 UO1 AI058250-01]
CR BARBER M. A., 1931, ANN TROP MED AND PARASITOL, V25, P461
   BERTRAM D. S., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P135, DOI 10.1016/0035-9203(58)90035-X
   Bogh C, 2003, B ENTOMOL RES, V93, P279, DOI 10.1079/BER2003239
   Bogh C, 2007, AM J TROP MED HYG, V76, P875
   Boyd MF., 1949, MALARIOLOGY COMPREHE
   Briet OJT, 2003, TROP MED INT HEALTH, V8, P439, DOI 10.1046/j.1365-3156.2003.01054.x
   CHAWATT LJ, 1945, AM J TROP MED HYG, V48, P22
   Clarke SE, 2002, T ROY SOC TROP MED H, V96, P499, DOI 10.1016/S0035-9203(02)90419-0
   DUNSMORE JR, 1976, AGR DEV GAMBIA AGR E
   Fillinger U, 2004, TROP MED INT HEALTH, V9, P1274, DOI 10.1111/j.1365-3156.2004.01335.x
   Fillinger U, 2003, TROP MED INT HEALTH, V8, P37, DOI 10.1046/j.1365-3156.2003.00979.x
   Fillinger U, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-20
   Fillinger U, 2006, TROP MED INT HEALTH, V11, P1629, DOI 10.1111/j.1365-3156.2006.01733.x
   GELFAND H. M., 1955, TRANS ROY SOC TROP MED AND HYG, V49, P508, DOI 10.1016/0035-9203(55)90023-7
   GIGLIOLI M E, 1964, Riv Malariol, V43, P245
   GIGLIOLI M. E. C., 1965, ANN ENTOMOL SOC AMER, V58, P885
   GIGLIOLL MARCO E. C., 1965, J APPL ECOL, V2, P81, DOI 10.2307/2401695
   Gillies M. T., 1968, ANOPHELINAE AFRICA S
   Gimnig JE, 2001, J MED ENTOMOL, V38, P282, DOI 10.1603/0022-2585-38.2.282
   Gu WD, 2005, AM J TROP MED HYG, V73, P546
   Holstein M, 1954, BIOL ANOPHELES GAMBI
   Ijumba JN, 2001, MED VET ENTOMOL, V15, P1, DOI 10.1046/j.1365-2915.2001.00279.x
   Killeen Gerry F, 2002, Malar J, V1, P8, DOI 10.1186/1475-2875-1-8
   Killeen GF, 2006, AM J TROP MED HYG, V74, P517
   Killeen GF, 2002, LANCET INFECT DIS, V2, P618, DOI 10.1016/S1473-3099(02)00397-3
   Klinkenberg E, 2005, EMERG INFECT DIS, V11, P1290
   LINDSAY SW, 1991, J TROP MED HYG, V94, P313
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90171-L
   Majambere S, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-76
   Minakawa N, 2004, MED VET ENTOMOL, V18, P301, DOI 10.1111/j.0269-283X.2004.00503.x
   Minakawa N, 1999, AM J TROP MED HYG, V61, P1010
   Muirhead-Thomson R C, 1951, MOSQUITO BEHAV RELAT
   Mutuku FM, 2006, AM J TROP MED HYG, V74, P44
   Mwangangi J, 2006, J VECTOR ECOL, V31, P245, DOI 10.3376/1081-1710(2006)31[245:DOISOA]2.0.CO;2
   Mwangangi Joseph M., 2007, Journal of Vector Borne Diseases, V44, P44
   Najera JA, 2002, MALARIA VECTOR CONTR
   Robert Vincent, 2002, Malar J, V1, P4, DOI 10.1186/1475-2875-1-4
   Sattler MA, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-4
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   SERVICE MW, 1971, B WORLD HEALTH ORGAN, V45, P169
   Service MW, 1997, J MED ENTOMOL, V34, P579
   SERVICE MW, 1989, PARASITOL TODAY, V5, P162, DOI 10.1016/0169-4758(89)90083-5
   Shililu J, 2007, AM J TROP MED HYG, V76, P103
   SNOW WF, 1983, J TROP MED HYG, V86, P237
   Sogoba N, 2007, AM J TROP MED HYG, V77, P82
   Soper F., 1943, ANOPHELES GAMBIAE BR
   Thomas CJ, 2000, T ROY SOC TROP MED H, V94, P159, DOI 10.1016/S0035-9203(00)90257-8
   Toure Y. T., 1998, Parassitologia (Rome), V40, P477
   TRAPE JF, 1992, AM J TROP MED HYG, V47, P181
   Utzinger J, 2002, TROP MED INT HEALTH, V7, P657, DOI 10.1046/j.1365-3156.2002.00916.x
   Utzinger J, 2001, TROP MED INT HEALTH, V6, P677, DOI 10.1046/j.1365-3156.2001.00769.x
NR 51
TC 37
Z9 37
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD JUL
PY 2008
VL 79
IS 1
BP 19
EP 27
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 322XD
UT WOS:000257407700006
PM 18606759
OA No
DA 2017-08-15
ER

PT J
AU Du, L
   Yan, L
   Schoenmakers, I
   Zhou, B
   Jarjou, LM
   Nigdikar, S
   Goldberg, GR
   Prentice, A
AF Du, L.
   Yan, L.
   Schoenmakers, I.
   Zhou, B.
   Jarjou, L. M.
   Nigdikar, S.
   Goldberg, G. R.
   Prentice, A.
TI Ethnic differences in fibroblast growth factor 23 and phosphate
   excretion in response to phosphate loading
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Meeting Abstract
C1 [Du, L.; Yan, L.; Schoenmakers, I.; Nigdikar, S.; Goldberg, G. R.; Prentice, A.] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge, England.
   [Zhou, B.] Shenyang Med Coll, Dept Prevent Med, Shenyang, Peoples R China.
   [Jarjou, L. M.; Goldberg, G. R.; Prentice, A.] MRC, Keneba, Gambia.
CR YAN L, 2007, OSTEOPOROSIS INT, V18, pS277
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171-967X
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JUL
PY 2008
VL 83
IS 1
BP 11
EP 12
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 339YP
UT WOS:000258613500030
OA No
DA 2017-08-15
ER

PT J
AU Fry, AE
   Auburn, S
   Diakite, M
   Green, A
   Richardson, A
   Wilson, J
   Jallow, M
   Sisay-Joof, F
   Pinder, M
   Griffiths, MJ
   Peshu, N
   Williams, TN
   Marsh, K
   Molyneux, ME
   Taylor, TE
   Rockett, KA
   Kwiatkowski, DP
AF Fry, A. E.
   Auburn, S.
   Diakite, M.
   Green, A.
   Richardson, A.
   Wilson, J.
   Jallow, M.
   Sisay-Joof, F.
   Pinder, M.
   Griffiths, M. J.
   Peshu, N.
   Williams, T. N.
   Marsh, K.
   Molyneux, M. E.
   Taylor, T. E.
   Rockett, K. A.
   Kwiatkowski, D. P.
TI Variation in the ICAM1 gene is not associated with severe malaria
   phenotypes
SO GENES AND IMMUNITY
LA English
DT Article
DE ICAM-1; Plasmodium falciparum; genetic association study
ID INTERCELLULAR-ADHESION MOLECULE-1; PLASMODIUM-FALCIPARUM MALARIA;
   FAMILY-BASED TESTS; N-TERMINAL DOMAIN; CEREBRAL MALARIA; INFECTED
   ERYTHROCYTES; NATURAL-SELECTION; BINDING-SITES; CHILDREN; RECEPTOR
AB Evidence from autopsy and in vitro binding studies suggests that adhesion of erythrocytes infected with Plasmodium falciparum to the human host intercellular adhesion molecule (ICAM)-1 receptor is important in the pathogenesis of severe malaria. Previous association studies between polymorphisms in the ICAM1 gene and susceptibility to severe malarial phenotypes have been inconclusive and often contradictory. We performed genetic association studies with 15 single nucleotide polymorphisms (SNPs) around the ICAM1 locus. All SNPs were screened in a family study of 1071 trios from The Gambia, Malawi and Kenya. Two key non-synonymous SNPs with previously reported associations, rs5491 (K56M or 'ICAM-1(Kilifi)') and rs5498 (K469E), were tested in an additional 708 Gambian trios and a case-control study of 4058 individuals. None of the polymorphisms were associated with severe malaria phenotypes. Pooled results across our studies for ICAM-1(Kilifi) were, in severe malaria, odds ratio (OR) 1.02, 95% confidence interval (CI) 0.96-1.09, P = 0.54, and cerebral malaria OR 1.07, CI 0.97-1.17, P = 0.17. We assess the available epidemiological, population genetic and functional evidence that links ICAM-1(Kilifi) to severe malaria susceptibility.
C1 [Fry, A. E.; Auburn, S.; Diakite, M.; Green, A.; Richardson, A.; Wilson, J.; Griffiths, M. J.; Rockett, K. A.; Kwiatkowski, D. P.] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Griffiths, M. J.; Peshu, N.; Williams, T. N.; Marsh, K.] Kenya Med Res Inst Ctr Geog Med Res, Kilifi, Kenya.
   [Jallow, M.; Sisay-Joof, F.; Pinder, M.] MRC, Banjul, Gambia.
   [Williams, T. N.; Marsh, K.] John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England.
   [Molyneux, M. E.] Malawi Liverpool Wellcome Trust Programme Clin Tr, Blantyre, Malawi.
   [Molyneux, M. E.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   [Taylor, T. E.] Blantyre Malaria Project, Coll Med, Blantyre, Malawi.
   [Taylor, T. E.] Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA.
   [Kwiatkowski, D. P.] Wellcome Trust Genome Campus, Cambridge, England.
RP Fry, AE (reprint author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
EM afry@well.ox.ac.uk
OI Kwiatkowski, Dominic/0000-0002-5023-0176; Auburn,
   Sarah/0000-0002-4638-536X
FU Medical Research Council [G0600230, , G0600230(77610)]; Wellcome Trust
   [, 074586, 076934]
CR Adams S, 2000, INFECT IMMUN, V68, P264
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Amodu OK, 2005, ACTA TROP, V95, P248, DOI 10.1016/j.actatropica.2005.05.011
   Armah H, 2005, ANN TROP MED PARASIT, V99, P629, DOI 10.1179/136485905X51508
   Ayodo G, 2007, AM J HUM GENET, V81, P234, DOI 10.1086/519221
   Baratin M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000228
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bellamy R, 1998, T ROY SOC TROP MED H, V92, P312, DOI 10.1016/S0035-9203(98)91026-4
   BERENDT AR, 1994, PARASITOL TODAY, V10, P412, DOI 10.1016/0169-4758(94)90238-0
   Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134
   Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a
   Chen QJ, 2000, CLIN MICROBIOL REV, V13, P439, DOI 10.1128/CMR.13.3.439-450.2000
   Cordell HJ, 2004, GENET EPIDEMIOL, V26, P167, DOI 10.1002/gepi.10307
   Craig A, 2000, HUM MOL GENET, V9, P525, DOI 10.1093/hmg/9.4.525
   DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129
   Dietrich JB, 2002, J NEUROIMMUNOL, V128, P58, DOI 10.1016/S0165-5728(02)00114-5
   Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108
   FernandezReyes D, 1997, HUM MOL GENET, V6, P1357, DOI 10.1093/hmg/6.8.1357
   Fry AE, 2008, HUM MOL GENET, V17, P567, DOI 10.1093/hmg/ddm331
   Gonzalez JM, 2005, ENVIRON MICROBIOL, V7, P1024, DOI 10.1111/j.1462-2920.2005.00779.x
   Heddini A, 2001, INFECT IMMUN, V69, P5849, DOI 10.1128/IAI.69.9.5849-5856.2001
   Horvath S, 2004, GENET EPIDEMIOL, V26, P61, DOI 10.1002/gepi.10295
   Jenkins NE, 2005, CLIN INFECT DIS, V41, P1817, DOI 10.1086/498156
   Kun JFJ, 1999, AM J TROP MED HYG, V61, P776
   Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.0.CO;2-M
   LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y
   Ma J, 2007, J DIABETES COMPLICAT, V21, P28, DOI 10.1016/j.jdiacomp.2006.03.002
   MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Ndiaye R, 2005, TISSUE ANTIGENS, V65, P474, DOI 10.1111/j.1399-0039.2005.00388.x
   Newbold C, 1999, INT J PARASITOL, V29, P927, DOI 10.1016/S0020-7519(99)00049-1
   Newbold C, 1997, AM J TROP MED HYG, V57, P389
   OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R
   Ohashi J, 2001, JPN J INFECT DIS, V54, P114
   PORTA J, 1993, CLIN NEUROPATHOL, V12, P142
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   REGISTER RB, 1991, J VIROL, V65, P6589
   Register TC, 2004, CLIN CHEM, V50, P2185, DOI 10.1373/clinchem.2004.036806
   Rogerson SJ, 1999, AM J TROP MED HYG, V61, P467
   Ross P, 1998, NAT BIOTECHNOL, V16, P1347, DOI 10.1038/4328
   Silamut K, 1999, AM J PATHOL, V155, P395, DOI 10.1016/S0002-9440(10)65136-X
   Smith JD, 2000, P NATL ACAD SCI USA, V97, P1766, DOI 10.1073/pnas.040545897
   STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2
   STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O
   Tse MT, 2004, MOL MICROBIOL, V51, P1039, DOI 10.1046/j.1365-2958.2003.03895.x
   TURNER GDH, 1994, AM J PATHOL, V145, P1057
   van der Heyde HC, 2006, TRENDS PARASITOL, V22, P503, DOI 10.1016/j.pt.2006.09.002
   Voight BF, 2006, PLOS BIOL, V4, P446, DOI 10.1371/journal.pbio.0040072
   Walsh EC, 2006, HUM GENET, V119, P92, DOI 10.1007/s00439-005-0090-0
   Wildman DE, 2003, P NATL ACAD SCI USA, V100, P7181, DOI 10.1073/pnas.1232172100
   Xiao C, 2004, J VIROL, V78, P10034, DOI 10.1128/JVI.78.18.10034-10044.2004
   ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847
   [Anonymous], 1990, T R SOC TROP MED S2, V84, P1
NR 53
TC 22
Z9 23
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUL
PY 2008
VL 9
IS 5
BP 462
EP 469
DI 10.1038/gene.2008.38
PG 8
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 329PT
UT WOS:000257881500009
PM 18528404
OA No
DA 2017-08-15
ER

PT J
AU Sirugo, G
   Hennig, BJ
   Adeyemo, AA
   Matimba, A
   Newport, MJ
   Ibrahim, ME
   Ryckman, KK
   Tacconelli, A
   Mariani-Costantini, R
   Novelli, G
   Soodyall, H
   Rotimi, CN
   Ramesar, RS
   Tishkoff, SA
   Williams, SM
AF Sirugo, Giorgio
   Hennig, Branwen J.
   Adeyemo, Adebowale A.
   Matimba, Alice
   Newport, Melanie J.
   Ibrahim, Muntaser E.
   Ryckman, Kelli K.
   Tacconelli, Alessandra
   Mariani-Costantini, Renato
   Novelli, Giuseppe
   Soodyall, Himla
   Rotimi, Charles N.
   Ramesar, Raj S.
   Tishkoff, Sarah A.
   Williams, Scott M.
TI Genetic studies of African populations: an overview on disease
   susceptibility and response to vaccines and therapeutics
SO HUMAN GENETICS
LA English
DT Review
ID PLASMODIUM-FALCIPARUM MALARIA; HLA CLASS-I; PROSTATE-CANCER RISK;
   HEPATITIS-B-VIRUS; INFLUENZAE TYPE-B; NITRIC-OXIDE PRODUCTION; IIA CD32
   POLYMORPHISM; MAJOR HISTOCOMPATIBILITY COMPLEX; SLC11A1 FORMERLY NRAMP1;
   SQUAMOUS-CELL CARCINOMA
AB Africa is the ultimate source of modern humans and as such harbors more genetic variation than any other continent. For this reason, studies of the patterns of genetic variation in African populations are crucial to understanding how genes affect phenotypic variation, including disease predisposition. In addition, the patterns of extant genetic variation in Africa are important for understanding how genetic variation affects infectious diseases that are a major problem in Africa, such as malaria, tuberculosis, schistosomiasis, and HIV/AIDS. Therefore, elucidating the role that genetic susceptibility to infectious diseases plays is critical to improving the health of people in Africa. It is also of note that recent and ongoing social and cultural changes in sub-Saharan Africa have increased the prevalence of non-communicable diseases that will also require genetic analyses to improve disease prevention and treatment. In this review we give special attention to many of the past and ongoing studies, emphasizing those in Sub-Saharan Africans that address the role of genetic variation in human disease.
C1 [Sirugo, Giorgio] MRC Labs, Fajara, Gambia.
   [Sirugo, Giorgio; Tacconelli, Alessandra; Novelli, Giuseppe] Osped S Pietro FBF, Med Gent Unit, Rome, Italy.
   [Sirugo, Giorgio; Tacconelli, Alessandra; Novelli, Giuseppe] Univ Roma Tor Vergata, Sch Med, Dept Biopathol & Diagnost Imaging, Rome, Italy.
   [Hennig, Branwen J.] London Sch Hyg & Trop Med, London WC1, England.
   [Adeyemo, Adebowale A.; Rotimi, Charles N.] Howard Univ, Coll Med, Natl Human Genome Ctr, Washington, DC USA.
   [Matimba, Alice] AiBST, Mol Sci Unit, Harare, Zimbabwe.
   [Newport, Melanie J.] Univ Sussex, Brighton & Sussex Med Sch, Dept Med, Brighton, E Sussex, England.
   [Ibrahim, Muntaser E.] Univ Khartoum, Inst Endem Dis, Dept Mol Biol, Khartoum, Sudan.
   [Ryckman, Kelli K.; Williams, Scott M.] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37212 USA.
   [Mariani-Costantini, Renato] Univ Gabriele Annunzio, Dept Oncol & Neurosci, Chieti, Italy.
   [Mariani-Costantini, Renato] Univ Gabriele Annunzio, Ageing Res Ctr, Chieti, Italy.
   [Soodyall, Himla] Univ Witwatersrand, Human Genome Divers & Dis Res Unit, Johannesburg, South Africa.
   [Ramesar, Raj S.] Univ Cape Town, Inst Infect Dis & Mol Med, Div Human Genet, Cape Town, South Africa.
   [Tishkoff, Sarah A.] Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.
RP Sirugo, G (reprint author), MRC Labs, Fajara, Gambia.
EM sirugo.giorgio@fbfrm.it; smwilliams@chgr.mc.vanderbilt.edu
RI Hennig, Branwen/M-6444-2014; Ramesar, Raj/I-6941-2015
OI Ramesar, Raj/0000-0001-5688-1634; Novelli, Giuseppe/0000-0002-7781-602X;
   Adeyemo, Adebowale/0000-0002-3105-3231
CR ABDELSALAM E, 1986, TISSUE ANTIGENS, V27, P142
   ABUBAKARI AR, 2008, OBES REV IN PRESS
   Adebamowo C A, 2000, Afr J Med Med Sci, V29, P71
   ADEBAMOWO CA, 2008, BREAST CANC IN PRESS
   Adeyemo AA, 2005, ATHEROSCLEROSIS, V181, P389, DOI 10.1016/j.atherosclerosis.2004.12.049
   Adeyemo AA, 2002, J HYPERTENS, V20, P859, DOI 10.1097/00004872-200205000-00019
   Adje CA, 2001, J MED VIROL, V64, P398, DOI 10.1002/jmv.1064
   Agarwal A, 2000, BLOOD, V96, P2358
   Aklillu E, 2002, PHARMACOGENETICS, V12, P375, DOI 10.1097/00008571-200207000-00005
   AKLILLU E, 2007, PHARMACOGENOMICS ADM
   Alberts M, 2005, EUR J CARDIOV PREV R, V12, P347, DOI 10.1097/01.hjr.0000174792.24188.8e
   Ali S, 2000, J INFECT DIS, V181, P737, DOI 10.1086/315234
   Allabi AC, 2005, PHARMACOGENET GENOM, V15, P779, DOI 10.1097/01.fpc.0000174787.92861.91
   Allabi AC, 2004, CLIN PHARMACOL THER, V76, P113, DOI 10.1016/j.clpt.2004.04.001
   Alm JS, 2002, GENES IMMUN, V3, P71, DOI 10.1038/sj/gene/6363834
   ALPER CA, 1995, EXP CLIN IMMUNOGENET, V12, P171
   ALTER A, 2008, HUM GENET IN PRESS
   Alves S, 2004, ANN HUM GENET, V68, P313, DOI 10.1046/j.1529-8817.2004.00104.x
   AMBROSINO DM, 1985, J CLIN INVEST, V75, P1935, DOI 10.1172/JCI111909
   Ameyaw MM, 2001, PHARMACOGENETICS, V11, P217, DOI 10.1097/00008571-200104000-00005
   Amodu OK, 2005, ACTA TROP, V95, P248, DOI 10.1016/j.actatropica.2005.05.011
   Amodu OK, 2005, ACTA TROP, V95, P226, DOI 10.1016/j.actatropica.2005.06.017
   Anderson DW, 2007, COLORECTAL DIS, V9, P509, DOI 10.1111/j.1463-1318.2006.01172.x
   Arya R, 2002, DIABETES, V51, P841, DOI 10.2337/diabetes.51.3.841
   Atkinson SH, 2007, CLIN INFECT DIS, V44, P802, DOI 10.1086/511868
   Aucan C, 2004, J MED GENET, V41, P21, DOI 10.1136/jmg.2003.011981
   Aucan C, 2003, GENES IMMUN, V4, P275, DOI 10.1038/sj.gene.6363962
   Aucan C, 2002, T ROY SOC TROP MED H, V96, P327, DOI 10.1016/S0035-9203(02)90114-8
   Awadelkarim KD, 2008, HISTOPATHOLOGY, V52, P445, DOI 10.1111/j.1365-2559.2008.02966.x
   Awadelkarim KD, 2007, BREAST CANCER RES TR, V102, P189, DOI 10.1007/s10549-006-9303-z
   Awomoyi AA, 2005, J ENDOTOXIN RES, V11, P281, DOI 10.1179/096805105X58706
   Awomoyi AA, 2004, THORAX, V59, P291, DOI 10.1136/thx.2003.013029
   Awomoyi AA, 2002, J INFECT DIS, V186, P1808, DOI 10.1086/345920
   Babb C, 2007, TUBERCULOSIS, V87, P295, DOI 10.1016/j.tube.2007.03.001
   Ball TB, 2007, AIDS, V21, P1091, DOI 10.1097/QAD.0b013e3280ef6ae1
   Banus S, 2007, CLIN VACCINE IMMUNOL, V14, P1377, DOI 10.1128/CVI.00175-07
   Barlassina C, 2000, AM J HYPERTENS, V13, P719, DOI 10.1016/S0895-7061(00)01187-0
   Barreiro LB, 2006, PLOS MED, V3, P230, DOI 10.1371/journal.pmed.0030020
   Barreiro LB, 2008, NAT GENET, V40, P340, DOI 10.1038/ng.78
   Bathum L, 1999, BRIT J CLIN PHARMACO, V48, P395, DOI 10.1046/j.1365-2125.1999.00019.x
   Baum J, 2003, INFECT IMMUN, V71, P1856, DOI 10.1128/IAI.71.4.1856-1863.2003
   Baynam G, 2007, J ALLERGY CLIN IMMUN, V119, P366, DOI 10.1016/j.jaci.2006.09.018
   Bellamy R., 1998, Tubercle and Lung Disease, V79, P83, DOI 10.1054/tuld.1998.0009
   Bellamy R, 1998, QJM-MON J ASSOC PHYS, V91, P13, DOI 10.1093/qjmed/91.1.13
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Bellamy R, 1998, T ROY SOC TROP MED H, V92, P312, DOI 10.1016/S0035-9203(98)91026-4
   Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897
   Ben-Ali M, 2004, CLIN DIAGN LAB IMMUN, V11, P625, DOI 10.1128/CDLI.11.3.625-626.2004
   Ben-Ali M, 2007, HUM IMMUNOL, V68, P908, DOI 10.1016/j.humimm.2007.09.003
   Bendjemana K, 2006, B CANCER, V93, P297
   BENNETT S, 1993, T ROY SOC TROP MED H, V87, P286, DOI 10.1016/0035-9203(93)90130-I
   Bertilsson L, 2002, BRIT J CLIN PHARMACO, V53, P111, DOI 10.1046/j.0306-5251.2001.01548.x
   Bienzle U, 2005, TROP MED INT HEALTH, V10, P668, DOI 10.1111/j.1365-3156.2005.01444.x
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   Blanton RE, 2005, EUR J HUM GENET, V13, P660, DOI 10.1038/sj.ejhg.5201388
   Boldt ABW, 2006, GENES IMMUN, V7, P393, DOI 10.1038/sj.gene.6364312
   Bonilla C, 2006, INT J OBESITY, V30, P715, DOI 10.1038/sj.ijo.0803047
   Bornman L, 2004, J INFECT DIS, V190, P1631, DOI 10.1086/424462
   Bouzekri N, 2004, EUR J HUM GENET, V12, P460, DOI 10.1038/sj.ejhg.5201166
   Brawley O W, 1998, Semin Urol Oncol, V16, P184
   Bucheton B, 2003, AM J HUM GENET, V73, P1052, DOI 10.1086/379084
   Bucheton B, 2003, GENES IMMUN, V4, P104, DOI 10.1038/sj.gene.6363927
   Bunker Clareann H, 2002, Ethn Dis, V12, pS3
   Burgner D, 2003, HUM GENET, V112, P379, DOI 10.1007/s00439-002-0882-4
   Burton MJ, 2007, INVEST OPHTH VIS SCI, V48, P4440, DOI 10.1167/iovs.07-0315
   Cabantous S, 2005, J INFECT DIS, V192, P854, DOI 10.1086/432484
   Campbell SJ, 2003, IMMUNOGENETICS, V55, P502, DOI 10.1007/s00251-003-0602-9
   Campino S, 2006, SEMIN IMMUNOL, V18, P411, DOI 10.1016/j.smim.2006.07.011
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Carter R, 2002, CLIN MICROBIOL REV, V15, P564, DOI 10.1128/CMR.15.4.564-594.2002
   Casals-Pascual C, 2001, AM J TROP MED HYG, V65, P736
   Cervino ACL, 2002, HUM MOL GENET, V11, P1599, DOI 10.1093/hmg/11.14.1599
   Cervino ACL, 2000, ANN HUM GENET, V64, P507, DOI 10.1046/j.1469-1809.2000.6460507.x
   Chen G, 2005, INT J OBESITY, V29, P255, DOI 10.1038/sj.ijo.0802873
   Chen Guanjie, 2007, Diabetes Res Clin Pract, V78, pe1, DOI 10.1016/j.diabres.2007.04.010
   Chen GJ, 2007, AM J KIDNEY DIS, V49, P394, DOI 10.1053/j.ajkd.2006.12.011
   Chen YS, 2000, AM J HUM GENET, V66, P1362, DOI 10.1086/302848
   Chen YX, 2007, MOL VIS, V13, P2142
   Chen YX, 2005, ANN EPIDEMIOL, V15, P153, DOI 10.1016/j.annepidem.2004.05.014
   Chevillard C, 2003, J IMMUNOL, V171, P5596
   Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4
   Cholera R, 2008, P NATL ACAD SCI USA, V105, P991, DOI 10.1073/pnas.0711401105
   Chuang WCM, 2007, J MED VIROL, V79, P724, DOI 10.1002/jmv.20848
   Comuzzie AG, 1997, NAT GENET, V15, P273, DOI 10.1038/ng0397-273
   Cooke GS, 2006, AM J RESP CRIT CARE, V174, P339, DOI 10.1164/rccm.200601-088OC
   Cooke GS, 2006, J INFECT DIS, V194, P666, DOI 10.1086/505875
   Cooke GS, 2004, J INFECT DIS, V189, P1545, DOI 10.1086/382489
   Cooke GS, 2003, AM J TROP MED HYG, V69, P565
   COOKE GS, 2008, AM J RESP C IN PRESS
   Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160
   Cooper RS, 2002, HYPERTENSION, V40, P629, DOI 10.1161/01.HYP.0000035708.02789.39
   Cooper RS, 2000, HYPERTENSION, V35, P1141
   Cox SE, 2008, TROP MED INT HEALTH, V13, P76, DOI 10.1111/j.1365-3156.2007.01976.x
   Cox SE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000362
   Cramer JP, 2004, TROP MED INT HEALTH, V9, P1074, DOI 10.1111/j.1365-3156.2004.01312.x
   CREININ M, 1989, J REPROD MED, V34, P379
   Dandara C, 2006, CARCINOGENESIS, V27, P791, DOI 10.1093/carcin/bgi257
   Dandara C, 2003, PHARMACOGENETICS, V13, P55, DOI 10.1097/00008571-200301000-00008
   Dardari R, 2001, INT J CANCER, V92, P294, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1177>3.0.CO;2-9
   Davey G, 2007, T ROY SOC TROP MED H, V101, P1175, DOI 10.1016/j.trstmh.2007.08.013
   Davey G, 2007, T ROY SOC TROP MED H, V101, P91, DOI 10.1016/j.trstmh.2006.05.002
   DAVIES EG, 2004, COCHRANE DATABASE SY, V1
   DE SA, 2001, GENES IMMUN, V2, P367
   DELAHAYE NF, 2007, CURR PROB CANCER, V9, P160
   Delongchamps Nicolas B, 2007, Curr Probl Cancer, V31, P226, DOI 10.1016/j.currproblcancer.2007.01.004
   DEMOTZ S, 1993, EUR J IMMUNOL, V23, P425, DOI 10.1002/eji.1830230219
   Dessein AJ, 1999, AM J HUM GENET, V65, P709, DOI 10.1086/302526
   Destas K, 2003, TROP DOCT, V33, P217
   Dhiman N, 2003, EUR J IMMUNOGENET, V30, P195, DOI 10.1046/j.1365-2370.2003.00382.x
   Dhiman N, 2007, J ALLERGY CLIN IMMUN, V120, P666, DOI 10.1016/j.jaci.2007.04.036
   Dhiman N, 2007, J INFECT DIS, V195, P21, DOI 10.1086/510596
   Diouf K, 2002, J HUMAN VIROL, V5, P1, DOI 10.1097/01.QHV.0000021465.39141.02
   Donaldson IJ, 2002, IMMUNOGENETICS, V53, P894, DOI 10.1007/s00251-001-0407-7
   Dong YB, 2001, J HUM HYPERTENS, V15, P425, DOI 10.1038/sj.jhh.1001182
   Duggan D, 2007, J NATL CANCER I, V99, P1836, DOI 10.1093/jnci/djm250
   El Baghdadi J, 2006, J EXP MED, V203, P1679
   El-Safi S, 2006, CR BIOL, V329, P863, DOI 10.1016/j.crvi.2006.07.007
   El-Safi SH, 2002, MICROBES INFECT, V4, P1439, DOI 10.1016/S1286-4579(02)00026-6
   Elloumi-Zghal H, 2002, J INFECT DIS, V185, P1468, DOI 10.1086/340510
   Emonts M, 2007, PEDIATRICS, V120, P814, DOI 10.1542/peds.2007-0524
   Enattah NS, 2002, NAT GENET, V30, P233, DOI 10.1038/ng826
   ENEVOLD A, 2008, TANZANIA AM J TROP M, V78, P714
   Esteban E, 2006, J HUM GENET, V51, P129, DOI 10.1007/s10038-005-0336-7
   Estefania E, 2007, TISSUE ANTIGENS, V70, P34, DOI 10.1111/j.1399-0039.2007.00844.x
   Ezzikouri S, 2008, ARCH MED RES, V39, P236, DOI 10.1016/j.arcmed.2007.09.006
   Faal N, 2006, PLOS MED, V3, P1292, DOI 10.1371/journal.pmed.0030266
   Fackenthal JD, 2005, J MED GENET, V42, P276, DOI 10.1136/jmg.2004.020446
   Fairhurst RM, 2005, NATURE, V435, P1117, DOI 10.1038/nature03631
   Fejerman L, 2006, J HUM HYPERTENS, V20, P882, DOI 10.1038/sj.jhh.1002077
   Felix R, 2006, MUTAT RES-FUND MOL M, V602, P175, DOI 10.1016/h.mrfmmm.2006.09.004
   Ferlay J, 2004, GLOBOCAN 2002 CANC I
   Fitness J, 2004, AM J TROP MED HYG, V71, P341
   Flori L, 2003, HUM MOL GENET, V12, P375, DOI 10.1093/hmg/ddg033
   Flori L, 2005, GENES IMMUN, V6, P472, DOI 10.1038/sj.gene.6364231
   Flori L, 2003, GENES IMMUN, V4, P265, DOI 10.1038/sj.gene.6363960
   FOOTE SJ, 2005, GENETICS, V4, P270
   Freedman ML, 2006, P NATL ACAD SCI USA, V103, P14068, DOI 10.1073/pnas.0605832103
   Fry AE, 2008, HUM MOL GENET, V17, P567, DOI 10.1093/hmg/ddm331
   Gaedigk A, 2007, CLIN PHARMACOL THER, V81, P242, DOI 10.1038/sj.clpt.6100033
   Gaedigk A, 2005, PHARMACOGENOMICS J, V5, P173, DOI 10.1038/sj.tpj.6500305
   Gao Q, 2000, HUM GENET, V107, P192, DOI 10.1007/s004390000342
   Garcia A, 1998, AM J TROP MED HYG, V58, P705
   Garner CP, 2008, HUM GENET, V123, P247, DOI 10.1007/s00439-008-0468-x
   Ghosh S, 1999, P NATL ACAD SCI USA, V96, P2198, DOI 10.1073/pnas.96.5.2198
   Gonder MK, 2007, MOL BIOL EVOL, V24, P757, DOI 10.1093/molbev/msl209
   Govan VA, 2007, INT J IMMUNOGENET, V34, P213, DOI 10.1111/j.1744-313X.2007.00678.x
   Govan VA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-24
   GRANOFF DM, 1985, J PEDIATR-US, V107, P330, DOI 10.1016/S0022-3476(85)80502-3
   GRANOFF DM, 1992, J INFECT DIS, V165, pS66
   Gudmundsson J, 2007, NAT GENET, V39, P977, DOI 10.1038/ng2062
   Guindo A, 2007, PLOS MED, V4, P516, DOI 10.1371/journal.pmed.0040066
   Gyan BA, 2004, CLIN EXP IMMUNOL, V138, P145, DOI 10.1111/j.1365-2249.2004.02590.x
   Hacker UT, 2001, CLIN EXP IMMUNOL, V125, P465, DOI 10.1046/j.1365-2249.2001.01621.x
   HADHRI G, 2007, CANCER GENET CYTOGEN, V178, P89
   Haile-Selassie Y, 2004, AM J PHYS ANTHROPOL, V123, P1, DOI 10.1002/ajpa.10330
   Haiman CA, 2007, NAT GENET, V39, P638, DOI 10.1038/ng2015
   Hainaut P, 2008, LANCET, V371, P367, DOI 10.1016/S0140-6736(08)60181-6
   Haldane JBS, 1949, HEREDITAS S, V35, P267, DOI DOI 10.1111/J.1601-5223.1949.TB03339.X)
   Hamblin MT, 2000, AM J HUM GENET, V66, P1669, DOI 10.1086/302879
   Hamblin MT, 2002, AM J HUM GENET, V70, P369, DOI 10.1086/338628
   Hammer MF, 2001, MOL BIOL EVOL, V18, P1189
   Hansen DS, 2007, CURR OPIN IMMUNOL, V19, P416, DOI 10.1016/j.coi.2007.07.011
   Harrath AB, 2006, PATHOL ONCOL RES, V12, P79
   Hassen E, 2007, CANCER GENET CYTOGEN, V175, P41, DOI 10.1016/j.cancergencyto.2007.01.009
   Hayney MS, 1997, VACCINE, V15, P3, DOI 10.1016/S0264-410X(96)00133-8
   Hayney MS, 1996, J INVEST MED, V44, P261
   He H, 2008, GENES IMMUN, V9, P195, DOI 10.1038/gene.2008.2
   Heath PT, 1998, PEDIATR INFECT DIS J, V17, pS117, DOI 10.1097/00006454-199809001-00005
   Helgadottir A, 2006, NAT GENET, V38, P68, DOI 10.1038/ng1692
   Helgason A, 2007, NAT GENET, V39, P218, DOI 10.1038/ng1960
   Hennig BJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001898
   Henri S, 2002, J IMMUNOL, V169, P929
   Herb F, 2008, HUM MOL GENET, V17, P1052, DOI 10.1093/hmg/ddm378
   Hill AVS, 2006, ANNU REV GENET, V40, P469, DOI 10.1146/annurev.genet.40.110405.090546
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Hoal EG, 2004, INT J TUBERC LUNG D, V8, P1464
   Hobbs MR, 2002, LANCET, V360, P1468, DOI 10.1016/S0140-6736(02)11474-7
   Hohler T, 2005, HEPATOLOGY, V42, P72, DOI 10.1002/hep.20740
   Hohler T, 2002, LANCET, V360, P991, DOI 10.1016/S0140-6736(02)11083-X
   Horikawa Y, 2000, NAT GENET, V26, P163
   Ibrahim ME, 1999, AM J TROP MED HYG, V61, P941
   Ingelman-Sundberg M, 2007, PHARMACOL THERAPEUT, V116, P496, DOI 10.1016/j.pharmthera.2007.09.004
   Jacobson RM, 2004, ACTA PAEDIATR, V93, P43, DOI 10.0180/08035320310021246
   Jennes W, 2006, J IMMUNOL, V177, P6588
   Jepson A, 1997, BRIT MED J, V315, P96
   Jepson A, 2001, INFECT IMMUN, V69, P3989, DOI 10.1128/IAI.69.6.3989-3994.2001
   Ji LN, 1997, DIABETES, V46, P876, DOI 10.2337/diabetes.46.5.876
   Jrad BBH, 2007, EUR J HAEMATOL, V78, P117, DOI 10.1111/j.1600-0609.2006.00784.x
   Khakoo SI, 2004, SCIENCE, V305, P872, DOI 10.1126/science.1097670
   Khedhaier A, 2003, BRIT J CANCER, V89, P1502, DOI 10.1038/sj.bjc.6601292
   Khor CC, 2007, GENES IMMUN, V8, P570, DOI 10.1038/sj.gene.6364417
   Khor CC, 2007, NAT GENET, V39, P523, DOI 10.1038/ng1976
   Kimani J, 2008, AIDS, V22, P131
   Kimman TG, 2007, COMMUNITY GENET, V10, P201, DOI 10.1159/000106559
   Kirchheiner J, 2001, ACTA PSYCHIAT SCAND, V104, P173, DOI 10.1034/j.1600-0447.2001.00299.x
   Kirk GD, 2005, CANCER EPIDEM BIOMAR, V14, P373, DOI 10.1158/1055-9965.EPI-04-0161
   Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732
   Kirk GD, 2000, J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148
   Kirk GD, 2006, CARCINOGENESIS, V27, P2070, DOI 10.1093/carcin/bgl060
   Kittles RA, 2002, HUM GENET, V110, P553, DOI 10.1007/s00439-002-0731-5
   Kittles RA, 2001, HUM GENET, V109, P253, DOI 10.1007/s004390100576
   Klein K, 2005, PHARMACOGENET GENOM, V15, P861, DOI 10.1097/01213011-200512000-00004
   Klupa T, 2000, DIABETES, V49, P2212, DOI 10.2337/diabetes.49.12.2212
   Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649
   Koch O, 2002, J INFECT DIS, V185, P1684, DOI 10.1086/340516
   Kohle C, 2003, BIOCHEM PHARMACOL, V65, P1521, DOI 10.1016/S0006-2952(03)00074-1
   KONRADSEN HB, 1993, CLIN EXP IMMUNOL, V92, P532
   KONRADSEN HB, 1994, SCAND J IMMUNOL, V40, P251, DOI 10.1111/j.1365-3083.1994.tb03458.x
   Koram KA, 2007, AM J TROP MED HYG, V77, P1
   Kouriba B, 2005, J IMMUNOL, V174, P6274
   Kruger A, 2005, CLIN EXP IMMUNOL, V140, P325, DOI 10.1111/j.1365-2249.2005.02765.x
   Kuhn L, 2007, AIDS, V21, P1753, DOI 10.1097/QAD.0b013e3282ba553a
   Kun JF, 2001, J INFECT DIS, V184, P330, DOI 10.1086/322037
   Kwiatkowski DP, 2005, AM J HUM GENET, V77, P171, DOI 10.1086/432519
   Lahr MM, 1998, YEARB PHYS ANTHROPOL, V41, P137
   Lama J, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-52
   Lee YC, 2006, VACCINE, V24, P5335, DOI 10.1016/j.vaccine.2006.04.021
   Lessells RJ, 2008, LANCET, V371, P1504, DOI 10.1016/S0140-6736(08)60652-2
   Levesque MC, 1999, J INFECT DIS, V180, P1994, DOI 10.1086/315140
   Lewallen S, 2001, BRIT J OPHTHALMOL, V85, P897, DOI 10.1136/bjo.85.8.897
   Li CM, 2002, J INFECT DIS, V186, P1458, DOI 10.1086/344351
   Li DP, 2005, CLIN CHEM LAB MED, V43, P370, DOI 10.1515/CCLM.2005.067
   Li J, 2007, PSYCHOSOM MED, V69, P551, DOI 10.1097/PSY.0b013e3180cc2c61
   Li X, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-22
   Lin P, 2001, CANCER EPIDEM BIOMAR, V10, P1037
   LIN TM, 1989, ANTICANCER RES, V9, P737
   Lindemann M, 2002, VIROLOGY, V297, P245, DOI 10.1006/viro.2002.1467
   Liu H, 2006, AM J HUM GENET, V79, P230, DOI 10.1086/505436
   LIVINGSTONE FB, 1984, HUM BIOL, V56, P413
   Lombard Z, 2006, HUM IMMUNOL, V67, P643, DOI 10.1016/j.humimm.2006.04.008
   Loock M, 2006, ETHNIC DIS, V16, P872
   Lopez-Vazquez A, 2005, HUM IMMUNOL, V66, P285, DOI 10.1016/j.humimm.2005.01.001
   LOUAGIE H, 1993, VACCINE, V11, P1188, DOI 10.1016/0264-410X(93)90041-U
   Lucas A, 2007, J ANTIMICROB CHEMOTH, V59, P591, DOI 10.1093/jac/dkl557
   Luoni G, 2001, GENES IMMUN, V2, P411, DOI 10.1038/sj.gene.6363797
   Ma LY, 2005, JAIDS-J ACQ IMM DEF, V40, P89, DOI 10.1097/01.qai.0000157008.66584.d6
   MacDonald KS, 2000, J INFECT DIS, V181, P1581, DOI 10.1086/315472
   Mackinnon MJ, 2005, PLOS MED, V2, P1253, DOI 10.1371/journa;.pmed.0020340
   Magoha G A O, 2007, East Afr Med J, V84, pS3
   Malik S, 2006, HUM GENET, V118, P752, DOI 10.1007/s00439-005-0092-y
   MANGANO VD, 2008, GENES IMMUN IN PRESS
   Marchant A, 2006, J INFECT DIS, V193, P1598, DOI 10.1086/503775
   Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181
   MARQUET S, HUM MOL GEN IN PRESS
   Martin MP, 2005, CURR OPIN IMMUNOL, V17, P510, DOI 10.1016/j.coi.2005.07.012
   Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934
   MASIMIREMBWA C, 1995, CLIN PHARMACOL THER, V57, P656, DOI 10.1016/0009-9236(95)90228-7
   Masimirembwa C, 1996, BRIT J CLIN PHARMACO, V42, P713, DOI 10.1046/j.1365-2125.1996.00489.x
   Masimirembwa CM, 1997, BRAIN RES BULL, V44, P561, DOI 10.1016/S0361-9230(97)00307-9
   MATIMBA A, 2008, EUR J HUM G IN PRESS
   Matte C, 2004, AIDS, V18, P427, DOI 10.1097/00002030-200402200-00008
   McDougall I, 2005, NATURE, V433, P733, DOI 10.1038/nature03258
   MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0
   Meisner SJ, 2001, AM J TROP MED HYG, V65, P733
   Meyer CG, 2002, TISSUE ANTIGENS, V59, P287, DOI 10.1034/j.1399-0039.2002.590406.x
   Migot-Nabias F, 2000, GENES IMMUN, V1, P435, DOI 10.1038/sj.gene.6363703
   Migot-Nabias F, 2006, MICROBES INFECT, V8, P2352, DOI 10.1016/j.micinf.2006.03.021
   Milich DR, 2003, AUTOIMMUN REV, V2, P248, DOI 10.1016/S1568-9972(03)00031-4
   Miller EN, 2007, PLOS GENET, V3, P679, DOI 10.1371/journal.pgen.0030071
   MLLER M, 1997, AM J HUM GENET, V61, P452
   Mockenhaupt F P, 2006, J Commun Dis, V38, P230
   Modiano D, 2001, T ROY SOC TROP MED H, V95, P149, DOI 10.1016/S0035-9203(01)90141-5
   Modiano D, 2001, NATURE, V414, P305, DOI 10.1038/35104556
   MODIANO D, 1996, P NATL ACAD SCI USA, V93, P13026
   MODIANO D, 2008, HUM MOL GEN IN PRESS
   Moller M, 2007, MICROBES INFECT, V9, P522, DOI 10.1016/j.micinf.2007.01.011
   Mohamed HS, 2004, EUR J HUM GENET, V12, P66, DOI 10.1038/sj.ejhg.5201089
   Mohamed HS, 2003, GENES IMMUN, V4, P351, DOI 10.1038/sj.gene.6363977
   Mokni-Baizig N, 2001, ONCOLOGY-BASEL, V61, P55, DOI 10.1159/000055353
   Moller M, 2007, MOL CELL PROBE, V21, P148, DOI 10.1016/j.mcp.2006.10.001
   Mombo LE, 2003, AM J TROP MED HYG, V68, P186
   Mombo LE, 2003, GENES IMMUN, V4, P362, DOI 10.1038/sj.gene.6363979
   Monemi S, 2005, HUM MOL GENET, V14, P725, DOI 10.1093/hmg/ddi068
   Monot M, 2005, SCIENCE, V308, P1040, DOI 10.1126/science.1109759
   Montesano R, 1997, J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844
   Morahan G, 2002, GENES IMMUN, V3, P414, DOI 10.1038/sj.gene.6363909
   Mori Y, 2002, DIABETES, V51, P1247, DOI 10.2337/diabetes.51.4.1247
   Mostafa MH, 1999, CLIN MICROBIOL REV, V12, P97
   Motala AA, 2002, DIABETES METAB RES, V18, pS14, DOI 10.1002/dmrr.284
   Musher DM, 2000, VACCINE, V19, P623, DOI 10.1016/S0264-410X(00)00250-4
   Musher DM, 1997, J INVEST MED, V45, P57
   Mutapi F, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-139
   Nadel B, 1998, J IMMUNOL, V161, P6068
   Nasr A, 2007, SCAND J IMMUNOL, V66, P87, DOI 10.1111/j.1365-3083.2007.01947.x
   Natividad A, 2007, GENES IMMUN, V8, P288, DOI 10.1038/sj.gene.6364384
   Natividad A, 2005, GENES IMMUN, V6, P332, DOI 10.1038/sj.gene.6364182
   Natividad A, 2008, HUM MOL GENET, V17, P323, DOI 10.1093/hmg/ddm310
   Natividad A, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-40
   Ndiaye R, 2005, TISSUE ANTIGENS, V65, P474, DOI 10.1111/j.1399-0039.2005.00388.x
   Ndung'u T, 2005, CLIN DIAGN LAB IMMUN, V12, P1020, DOI 10.1128/CDLI.12.9.1020-1028.2005
   NEEL JV, 1953, AM J HUM GENET, V5, P154
   Nejentsev S, 2008, NAT GENET, V40, P261, DOI 10.1038/ng0308-261
   Newport MJ, 2005, EXPERT REV VACCINES, V4, P739, DOI 10.1586/14760584.4.5.739
   Newport MJ, 2004, TUBERCULOSIS, V84, P347, DOI 10.1016/j.tube.2004.02.001
   Newport MJ, 2004, GENES IMMUN, V5, P122, DOI 10.1038/sj.gene.6364051
   Niesporek S, 2005, INT J IMMUNOGENET, V32, P7, DOI 10.1111/j.1744-313X.2005.00484.x
   Nkeh B, 2003, AM J HYPERTENS, V16, P847, DOI 10.1016/S0895-7061(03)01016-1
   Novitsky V, 2001, HUM IMMUNOL, V62, P146, DOI 10.1016/S0198-8859(00)00236-6
   Ntoumi F, 2007, AM J TROP MED HYG, V77, P270
   NYAKUTIRA C, 2008, HIV AIDS, V64, P357
   Olesen R, 2007, GENES IMMUN, V8, P456, DOI 10.1038/sj.gene.6364410
   Opie LH, 2005, CIRCULATION, V112, P3562, DOI 10.1161/CIRCULATIONAHA.105.539569
   Osafo-Addo AD, 2008, AM J TROP MED HYG, V78, P251
   OTTENHOFF THM, 1986, LANCET, V2, P310
   Ouahchi K, 2006, PHARMACOGENOMICS, V7, P25, DOI 10.2217/14622416.7.1.25
   Ouerhani Slah, 2008, Bull Cancer, V95, pE1, DOI 10.1684/bdc.2008.0583
   Ouerhani S, 2007, CANCER GENET CYTOGEN, V176, P48, DOI 10.1016/j.cancergencyto.2007.03.007
   Ouerhani S, 2006, ANN HUM BIOL, V33, P529, DOI 10.1080/03014460600907517
   Ouma C, 2006, AM J TROP MED HYG, V74, P573
   Ovsyannikova IG, 2006, J INFECT DIS, V193, P655, DOI 10.1086/500144
   Ovsyannikova IG, 2006, VACCINE, V24, P5381, DOI 10.1016/j.vaccine.2006.04.034
   Ovsyannikova IG, 2005, IMMUNOGENETICS, V57, P828, DOI 10.1007/s00251-005-0061-6
   Ovsyannikova IG, 2005, J INFECT DIS, V191, P515, DOI 10.1086/427558
   Ovsyannikova IG, 2005, IMMUNOGENETICS, V56, P798, DOI 10.1007/s00251-004-0756-0
   Ovsyannikova IG, 2004, VACCINE, V22, P1914, DOI 10.1016/j.vaccine.2003.11.016
   Ovsyannikova IG, 2004, PHARMACOGENOMICS, V5, P417, DOI 10.1517/14622416.5.4.417
   Ovsyannikova IG, 2004, HUM IMMUNOL, V65, P209, DOI 10.1016/j.humimm.2003.12.002
   Ovsyannikova IG, 2004, J VIROL, V78, P42, DOI 10.1128/JVI.78.1.42-51.2004
   Ovsyannikova IG, 2007, VACCINE, V25, P3090, DOI 10.1016/j.vaccine.2007.01.020
   Ovsyannikova IG, 2007, VIROLOGY, V364, P87, DOI 10.1016/j.virol.2007.02.028
   Ovsyannikova IG, 2006, EXPERT REV VACCINES, V5, P33, DOI 10.1586/14760584.5.1.33
   Pain A, 2001, LANCET, V357, P1502, DOI 10.1016/S0140-6736(00)04662-6
   Parikh S, 2004, AM J TROP MED HYG, V71, P750
   Parkin DM, 2003, CANC AFRICA EPIDEMIO
   Passarino G, 1998, AM J HUM GENET, V62, P420, DOI 10.1086/301702
   Pasvol G, 2006, PLOS MED, V3, P591, DOI 10.1371/journal.pmed.0030235
   Patel M, 2002, CLIN LAB HAEMATOL, V24, P215, DOI 10.1046/j.1365-2257.2002.00448.x
   Pearce EJ, 2004, IMMUNOL REV, V201, P117, DOI 10.1111/j.0105-2896.2004.00187.x
   Petersen DC, 2005, JAIDS-J ACQ IMM DEF, V40, P521, DOI 10.1097/01.qai.0000186360.42834.28
   Poland GA, 2007, CLIN PHARMACOL THER, V82, P653, DOI 10.1038/sj.clpt.6100415
   Poland GA, 2001, HUM IMMUNOL, V62, P197, DOI 10.1016/S0198-8859(00)00238-X
   Poland GA, 1998, AM J HUM GENET, V62, P215, DOI 10.1086/301736
   Poland GA, 1999, VACCINE, V17, P1525, DOI 10.1016/S0264-410X(98)00362-4
   Poland GA, 2001, VACCINE, V20, P430, DOI 10.1016/S0264-410X(01)00346-2
   Poland Gregory A., 1998, Current Opinion in Pediatrics, V10, P208, DOI 10.1097/00008480-199804000-00017
   Porter P, 2008, NEW ENGL J MED, V358, P213, DOI 10.1056/NEJMp0708307
   PRICE EW, 1990, PODOCONIOSIS NONFLAR
   Puumalainen T, 2003, PEDIATR INFECT DIS J, V22, P141, DOI 10.1097/01.inf.0000050459.74134.d5
   QUINTANA M, 2007, NAT IMMUNOL, V8, P1165
   Quintana-Murci L, 1999, NAT GENET, V23, P437
   Rager-Zisman B, 2004, CLIN DIAGN LAB IMMUN, V11, P913, DOI 10.1128/CDLI.11.5.913-918.2004
   Ramaley PA, 2002, NATURE, V417, P140, DOI 10.1038/417140a
   Ranque B, 2008, M S-MED SCI, V24, P491, DOI 10.1051/medsci/2008245491
   Ranque B, 2007, J INFECT DIS, V196, P1248, DOI 10.1086/521684
   Rayner BL, 2003, J HYPERTENS, V21, P921, DOI 10.1097/01.hjh.0000059009.82022.9b
   Reed FA, 2006, CURR OPIN GENET DEV, V16, P597, DOI 10.1016/j.gde.2006.10.008
   Remus N, 2004, J INFECT DIS, V190, P580, DOI 10.1086/422534
   Rennert H, 2005, CANCER EPIDEM BIOMAR, V14, P949, DOI 10.1158/1055-9965.EPI-04-0637
   Rihet P, 2004, HUM MOL GENET, V13, P1, DOI 10.1093/hmg/ddh002
   Rihet P, 1998, AM J HUM GENET, V63, P498, DOI 10.1086/301967
   Robbins C, 2007, GENOME RES, V17, P1717, DOI 10.1101/gr.6782707
   Robinson M, 2004, J HUM HYPERTENS, V18, P865, DOI 10.1038/sj.jhh.1001768
   Rossouw M, 2003, LANCET, V361, P1871, DOI 10.1016/S0140-6736(03)13491-5
   Rotger M, 2007, PHARMACOGENET GENOM, V17, P885, DOI 10.1097/FPC.0b013e3282ef5cd1
   Rotger Margalida, 2005, Pharmacogenet Genomics, V15, P1
   Rotimi CN, 2006, INVEST OPHTH VIS SCI, V47, P3262, DOI 10.1167/iovs.05-1537
   Rotimi CN, 2004, NAT GENET, V36, P544, DOI 10.1038/ng0604-544
   Rotimi CN, 2004, DIABETES, V53, P838, DOI 10.2337/diabetes.53.3.838
   Rotimi CN, 2001, ANN EPIDEMIOL, V11, P51, DOI 10.1016/S1047-2797(00)00180-0
   Rotimi CN, 1999, HYPERTENSION, V33, P874
   Rowe JA, 2002, GENES IMMUN, V3, P497, DOI 10.1038/sj.gene.6363899
   RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0
   Ryan JR, 2006, AM J TROP MED HYG, V75, P575
   Saad AA, 2005, INT J BIOL MARKER, V20, P69
   Sabeti P, 2002, GENES IMMUN, V3, P286, DOI 10.1038/sj.gene.636877
   Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140
   SABETI PC, 2007, NATURE, V18, P913
   Sakuntabhai A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002000
   Salih MA, 2007, GENES IMMUN, V8, P75, DOI 10.1038/sj.gene.6364353
   Sarma AV, 2008, PROSTATE, V68, P296, DOI 10.1002/pros.20696
   Saunders MA, 2002, GENETICS, V162, P1849
   SCHIM V, 2007, GLOBAL HIV AIDS MED
   Schumacher FR, 2007, CANCER RES, V67, P2951, DOI 10.1158/0008-5472.CAN-06-3591
   Scozzari R, 1999, AM J HUM GENET, V65, P829, DOI 10.1086/302538
   Sgaier SK, 2007, SCIENCE, V318, P1074, DOI 10.1126/science.1149157
   Shand RL, 2006, CURR OPIN UROL, V16, P123, DOI 10.1097/01.mou.0000193384.39351.64
   Shi YP, 2001, J INFECT DIS, V184, P107, DOI 10.1086/320999
   Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0
   SIBER GR, 1990, NEW ENGL J MED, V323, P1387, DOI 10.1056/NEJM199011153232005
   Sile S, 2007, AM J HYPERTENS, V20, P1176, DOI 10.1016/j.amjhyper.2007.07.003
   Single RM, 2007, NAT GENET, V39, P1114, DOI 10.1038/ng2077
   Sirugo G, 2004, NAT GENET, V36, P785, DOI 10.1038/ng0804-785
   Sistonen J, 2007, PHARMACOGENET GENOM, V17, P93
   Sleijffers A, 2003, J IMMUNOL, V170, P3423
   Snoussi K, 2006, HUM IMMUNOL, V67, P13, DOI 10.1016/j.humimm.2006.03.018
   Soborg C, 2007, MOL IMMUNOL, V44, P2213, DOI 10.1016/j.molimm.2006.11.002
   St Sauver JL, 2005, HUM IMMUNOL, V66, P788, DOI 10.1016/j.humimm.2005.03.008
   St Sauver JL, 2002, J INFECT DIS, V185, P1545, DOI 10.1086/340573
   Stanton T, 2004, IMMUNOGENETICS, V56, P107, DOI 10.1007/s00251-004-0668-z
   Stein CM, 2007, HUM GENET, V121, P663, DOI 10.1007/s00439-007-0357-8
   Steyn K, 2005, CIRCULATION, V112, P3554, DOI 10.1161/CIRCULATIONAHA.105.563452
   Tanara G, 2003, INT J BIOL MARKER, V18, P280
   Tang JM, 2004, J INFECT DIS, V189, P1696, DOI 10.1086/383280
   Tang JM, 2004, AIDS RES HUM RETROV, V20, P19, DOI 10.1089/088922204322749468
   Tang JM, 2002, J VIROL, V76, P8276, DOI 10.1128/JVI.76.16.8276-8284.2002
   Thathy V, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-54
   Thursz M, 2001, QJM-MON J ASSOC PHYS, V94, P287, DOI 10.1093/qjmed/94.6.287
   THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604
   Thye T, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.037960
   Tiago AD, 2003, AM J HYPERTENS, V16, P1006, DOI 10.1016/j.amjhyper.2003.07.010
   TIBAZARWA K, 2008, INT J CARDI IN PRESS
   Timmann C, 2007, PLOS GENET, V3, P393, DOI 10.1371/journal.pgen.0030048
   Tishkoff SA, 2000, AM J HUM GENET, V67, P901, DOI 10.1086/303068
   Tishkoff SA, 2003, CURR OPIN GENET DEV, V13, P569, DOI 10.1016/j.gde.2003.10.010
   Tishkoff SA, 2004, NAT GENET, V36, pS21, DOI 10.1038/ng1438
   Tishkoff SA, 1998, AM J HUM GENET, V62, P1389, DOI 10.1086/301861
   Tishkoff SA, 2002, NAT REV GENET, V3, P611, DOI 10.1038/nrg865
   Tishkoff SA, 1996, SCIENCE, V271, P1380, DOI 10.1126/science.271.5254.1380
   Tishkoff SA, 2003, ANNU REV GENOM HUM G, V4, P293, DOI 10.1146/annurev.genom.4.070802.110226
   Tishkoff SA, 2001, SCIENCE, V293, P455, DOI 10.1126/science.1061573
   Tishkoff SA, 2007, MOL BIOL EVOL, V24, P2180, DOI 10.1093/molbev/msm155
   Tishkoff SA, 2007, NAT GENET, V39, P31, DOI 10.1038/ng1946
   TISHKOV SA, 2003, GENETIC HIST LINGUIS
   Torcia MG, 2008, P NATL ACAD SCI USA, V105, P646, DOI 10.1073/pnas.0709969105
   Tornesello ML, 2005, CANCER DETECT PREV, V29, P501, DOI 10.1016/j.cdp.2005.08.003
   Tosh K, 2006, P NATL ACAD SCI USA, V103, P10364, DOI 10.1073/pnas.0603340103
   TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224
   Troudi W, 2007, J HUM GENET, V52, P915, DOI 10.1007/s10038-007-0195-5
   Ukaejiofo E O, 2006, West Afr J Med, V25, P61
   Uko GP, 1999, CLIN EXP IMMUNOL, V118, P56
   Unwin N, 2001, B WORLD HEALTH ORGAN, V79, P947
   VAFA M, 2007, FULANI MALI MICROBES, V9, P1043
   van der Sande MAB, 2001, AM J PUBLIC HEALTH, V91, P1641, DOI 10.2105/AJPH.91.10.1641
   van der Werf MJ, 2003, ACTA TROP, V86, P125, DOI 10.1016/S0001-706X(03)00029-9
   Van Loveren H, 2001, ENVIRON HEALTH PERSP, V109, P757
   VANEDEN W, 1983, CLIN EXP IMMUNOL, V52, P287
   Vannberg FO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001388
   Verra F, 2004, ACTA TROP, V90, P205, DOI 10.1016/j.actatropica.2003.11.014
   Verrelli BC, 2002, AM J HUM GENET, V71, P1112, DOI 10.1086/344345
   WADELIUS M, 2006, PHARMACOGENOMICS J, V7, P99
   Wagner TMU, 1999, HUM MOL GENET, V8, P413, DOI 10.1093/hmg/8.3.413
   Wallace C, 2004, GENES IMMUN, V5, P221, DOI 10.1038/sj.gene.6364062
   Wallace TA, 2008, CANCER RES, V68, P927, DOI 10.1158/0008-5472.CAN-07-2608
   Walley AJ, 2004, EUR J HUM GENET, V12, P132, DOI 10.1038/sj.ejhg.5201084
   Wambua S, 2006, PLOS MED, V3, P643, DOI 10.1371/journal.pmed.0030158
   Wang CB, 2004, HEPATOLOGY, V39, P978, DOI 10.1002/hep.20142
   Webb J. L. A., 2005, J WORLD HIST, V16, P270, DOI 10.1353/jwh.2006.0011
   Wennerholm A, 2001, PHARMACOGENETICS, V11, P417, DOI 10.1097/00008571-200107000-00005
   White TD, 2003, NATURE, V423, P742, DOI 10.1038/nature01669
   Wiertsema SP, 2007, VACCINE, V25, P306, DOI 10.1016/j.vaccine.2006.07.024
   Wiertsema SP, 2006, VACCINE, V24, P792, DOI 10.1016/j.vaccine.2005.08.029
   WILLCOX M, 1983, ANN TROP MED PARASIT, V77, P335
   Williams SM, 2007, ETHNIC DIS, V17, P492
   Williams SM, 2000, HYPERTENSION, V36, P2
   Williams SM, 2004, HUM HERED, V57, P28, DOI 10.1159/000077387
   Williams TN, 2005, BLOOD, V106, P368, DOI 10.1182/blood-2005-01-0313
   Williams TN, 2005, NAT GENET, V37, P1253, DOI 10.1038/ng1660
   Williams TN, 1996, NATURE, V383, P522, DOI 10.1038/383522a0
   Woodiwiss AJ, 2006, J HYPERTENS, V24, P1057, DOI 10.1097/01.hjh.0000226195.59428.57
   Yasar U, 2002, EUR J CLIN PHARMACOL, V58, P555, DOI 10.1007/s00228-002-0518-6
   Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022
   Yee AMF, 2000, CLIN INFECT DIS, V30, P25, DOI 10.1086/313588
   Yucesoy B, 2002, VACCINE, V20, P3193, DOI 10.1016/S0264-410X(02)00267-0
   Zaahl MG, 2005, CANCER GENET CYTOGEN, V159, P48, DOI 10.1016/j.cancergencyto.2004.09.017
   Zabaleta J, 2008, CARCINOGENESIS, V29, P573, DOI 10.1093/carcin/bgm277
   Zeigler-Johnson CM, 2002, HUM HERED, V54, P13, DOI 10.1159/000066695
   Zheng SL, 2008, NEW ENGL J MED, V358, P910, DOI 10.1056/NEJMoa075819
   Zijenah LS, 2002, HUM IMMUNOL, V63, P1026, DOI 10.1016/S0198-8859(02)00684-5
   Zimmerman PA, 2003, GENES IMMUN, V4, P368, DOI 10.1038/sj.gene.6363980
   Zouali H, 1997, HUM MOL GENET, V6, P1401, DOI 10.1093/hmg/6.9.1401
NR 461
TC 51
Z9 53
U1 2
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
J9 HUM GENET
JI Hum. Genet.
PD JUL
PY 2008
VL 123
IS 6
BP 557
EP 598
DI 10.1007/s00439-008-0511-y
PG 42
WC Genetics & Heredity
SC Genetics & Heredity
GA 312HF
UT WOS:000256659100001
PM 18512079
OA No
DA 2017-08-15
ER

PT J
AU Miles, DJC
   Sanneh, M
   Holder, B
   Crozier, S
   Nyamweya, S
   Touray, ES
   Palmero, MS
   Zaman, SMA
   Rowland-Jones, S
   van der Sande, M
   Whittle, H
AF Miles, David J. C.
   Sanneh, Mariama
   Holder, Beth
   Crozier, Sarah
   Nyamweya, Samuel
   Touray, Ebrima S.
   Palmero, Melba S.
   Zaman, Syed M. A.
   Rowland-Jones, Sarah
   van der Sande, Marianne
   Whittle, Hilton
TI Cytomegalovirus infection induces T-cell differentiation without
   impairing antigen-specific responses in Gambian infants
SO IMMUNOLOGY
LA English
DT Article
DE cytomegalovirus; infant; measles; SEB; T cell
ID VACCINE EFFICACY; LYMPHOCYTE SUBPOPULATIONS; ELDERLY INDIVIDUALS;
   REPLICATIVE SENESCENCE; HEALTHY-CHILDREN; OLD-AGE; CD8(+); MEMORY;
   MEASLES; VIRUS
AB Cytomegalovirus (CMV) infection induces profound differentiation of T cells, and is associated with impaired responses to other immune challenges. We therefore considered whether CMV infection and the consequent T-cell differentiation in Gambian infants was associated with impaired specific responses to measles vaccination or polyclonal responses to the superantigen staphylococcal enterotoxin B (SEB). While the concentration of undifferentiated (CD27(+) CD28(+) CCR7(+)) T-cells in peripheral blood was unaffected by CMV, there was a large increase in differentiated (CD28(-) CD57(+)) CD8 T-cells and a smaller increase in differentiated CD4 cells. One week post-vaccination, the CD4 cell interferon-gamma (IFN-gamma) response to measles was lower among CMV-infected infants, but there were no other differences between the cytokine responses, or between the cytokine or proliferative responses 4 months post-vaccination. However, the CD8 T cells of CMV-infected infants proliferated more in response to SEB and the antibody response to measles correlated with the IFN-gamma response to CMV, indicating that CMV infection actually enhances some immune responses in infancy.
C1 [Miles, David J. C.; Sanneh, Mariama; Holder, Beth; Crozier, Sarah; Nyamweya, Samuel; Touray, Ebrima S.; Zaman, Syed M. A.; Rowland-Jones, Sarah; Whittle, Hilton] MRC, Labs Gambia, Banjul, Gambia.
   [van der Sande, Marianne] Natl Inst Publ Hlth & Environm, RIVM, NL-3720 BA Bilthoven, Netherlands.
RP Miles, DJC (reprint author), MRC, Labs Gambia, POB 273, Banjul, Gambia.
EM djcm1@liverpool.ac.uk
OI Crozier, Sarah/0000-0002-9524-1127
FU Medical Research Council [MC_U190081978]
CR AABY P, 1990, J INFECT DIS, V162, P1043
   Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Barton ES, 2007, NATURE, V447, P326, DOI 10.1038/nature05762
   Boucher N, 1998, EXP GERONTOL, V33, P267, DOI 10.1016/S0531-5565(97)00132-0
   Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103
   Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118
   Chen SF, 2004, J INFECT DIS, V189, P1619, DOI 10.1086/383249
   Cisse B, 1999, AM J EPIDEMIOL, V149, P295
   de Vries E, 2000, PEDIATR RES, V47, P528, DOI 10.1203/00006450-200004000-00019
   Effros RB, 2007, VACCINE, V25, P599, DOI 10.1016/j.vaccine.2006.08.032
   EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25
   Fletcher JM, 2005, J IMMUNOL, V175, P8218
   Goronzy JJ, 2001, J VIROL, V75, P12182, DOI 10.1128/JVI.75.24.12182-12187.2001
   GRATAMA JW, 1987, BLOOD, V70, P516
   Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407
   Hamann D, 1999, INT IMMUNOL, V11, P1027, DOI 10.1093/intimm/11.7.1027
   HAYES K, 1987, J INFECT DIS, V156, P615
   HENAORESTREPO A, 2001, J INFECT DIS S1, V187, pS15
   Janaszek W, 2003, VACCINE, V21, P473, DOI 10.1016/S0264-410X(02)00482-6
   Jaye A, 1998, J INFECT DIS, V177, P1282
   KAYHTY H, 1994, BIOLOGICALS, V22, P397, DOI 10.1006/biol.1994.1062
   Khan N, 2004, J IMMUNOL, V173, P7481
   Khan N, 2002, J IMMUNOL, V169, P1984
   Kovaiou RD, 2005, INT IMMUNOL, V17, P1359, DOI 10.1093/intimm/dxh314
   Kuijpers TW, 2003, J IMMUNOL, V170, P4342
   Li HM, 1998, IMMUNITY, V9, P807, DOI 10.1016/S1074-7613(00)80646-9
   Looney RJ, 1999, CLIN IMMUNOL, V90, P213, DOI 10.1006/clim.1998.4638
   Lynn TV, 2004, J INFECT DIS, V189, pS86, DOI 10.1086/377699
   MALFAIT P, 1994, PEDIATR INFECT DIS J, V13, P38, DOI 10.1097/00006454-199401000-00009
   Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI200317470
   McCloskey TW, 2004, CLIN DIAGN LAB IMMUN, V11, P957, DOI 10.1128/CDLI.11.5.957-962.2004
   MELVILLESMITH ME, 1983, J BIOL STAND, V11, P137, DOI 10.1016/S0092-1157(83)80038-9
   Miles DJC, 2007, J VIROL, V81, P5766, DOI 10.1128/JVI.00052-07
   Nociari MM, 1999, J IMMUNOL, V162, P3327
   NORRBY E, 1972, INFECT IMMUN, V6, P240
   Olsson J, 2000, MECH AGEING DEV, V121, P187
   PASS RF, 1985, J INFECT DIS, V152, P243
   Pawelec G, 2004, TRENDS IMMUNOL, V25, P406, DOI 10.1016/j.it.2004.05.006
   Pawelec G, 2001, MECH AGEING DEV, V122, P132, DOI 10.1016/S0047-6374(00)00240-2
   Pawelec G, 2006, AGING CLIN EXP RES, V18, P171
   Permar SR, 2004, J INFECT DIS, V190, P998, DOI 10.1086/422846
   Preiser W, 2001, J CLIN VIROL, V20, P59, DOI 10.1016/S1386-6532(00)00156-6
   Rizzardini G, 1998, AIDS, V12, P2387, DOI 10.1097/00002030-199818000-00007
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Saurwein-Teissl M, 2002, J IMMUNOL, V168, P5893
   Schauer U, 2003, CLIN DIAGN LAB IMMUN, V10, P202, DOI 10.1128/CDLI.10.2.202-207.2003
   Seder RA, 2003, NAT IMMUNOL, V4, P835, DOI 10.1038/ni969
   Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1067/mai.2003.1778
   SIMONSEN O, 1986, J BIOL STAND, V14, P231, DOI 10.1016/0092-1157(86)90008-9
   Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882
   Trzonkowski P, 2003, VACCINE, V21, P3826, DOI 10.1016/S0264-410X(03)00309-8
   Tsegaye A, 2003, CLIN IMMUNOL, V109, P338, DOI 10.1016/j.clim.2003.08.008
   van Leeuwen EMM, 2006, J IMMUNOL, V177, P4998
   VANLIER RA, 2003, NAT REV IMMUNOL, V3, P1
   Vitek CR, 1999, PEDIATR INFECT DIS J, V18, P620, DOI 10.1097/00006454-199907000-00010
   Weekes MP, 1999, J VIROL, V73, P2099
   Weinberger B, 2007, HUM IMMUNOL, V68, P86, DOI 10.1016/j.humimm.2006.10.019
   WHITTLE H, 1988, LANCET, V331, P963, DOI 10.1016/S0140-6736(88)91780-1
   Wikby A, 2002, EXP GERONTOL, V37, P445, DOI 10.1016/S0531-5565(01)00212-1
   Wills MR, 2002, J IMMUNOL, V168, P5455
NR 60
TC 19
Z9 19
U1 1
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD JUL
PY 2008
VL 124
IS 3
BP 388
EP 400
DI 10.1111/j.1365-2567.2007.02787.x
PG 13
WC Immunology
SC Immunology
GA 309XO
UT WOS:000256493700011
PM 18194268
OA No
DA 2017-08-15
ER

PT J
AU Benn, CS
   Diness, BR
   Roth, A
   Nante, E
   Fisker, AB
   Lisse, IM
   Yazdanbakhsh, M
   Whittle, H
   Rodrigues, A
   Aaby, P
AF Benn, Christine Stabell
   Diness, Birgitte Rode
   Roth, Adam
   Nante, Ernesto
   Fisker, Ane Baerent
   Lisse, Ida Maria
   Yazdanbakhsh, Maria
   Whittle, Hilton
   Rodrigues, Amabelia
   Aaby, Peter
TI Effect of 50 000 IU vitamin A given with BCG vaccine on mortality in
   infants in Guinea-Bissau: randomised placebo controlled trial
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID CHILDHOOD MORTALITY; BIRTH-WEIGHT; SUPPLEMENTATION; CHILDREN; IMPACT;
   MORBIDITY; RESPONSES; GROWTH; SEX; AGE
AB Objective To investigate the effect of high dose vitamin A supplementation given with BCG vaccine at birth in an African setting with high infant mortality.
   Design Randomised placebo controlled trial.
   Setting Bandim Health Project's demographic surveillance system in Guinea-Bissau, covering approximately 90 000 inhabitants.
   Participants 4345 infants due to receive BCG. Intervention Infants were randomised to 50 000 IU vitamin A or placebo and followed until age 12 months.
   Main outcome measure Mortality rate ratios.
   Results 174 children died during follow-up (mortality=47/ 1000 person-years). Vitamin A supplementation was not significantly associated with mortality; the mortality rate ratio was 1.07 (95% confidence interval 0.79 to 1.44). The effect was 1.00 (0.65 to 1.56) during the first four months and 1.13 (0.75 to 1.68) from 4 to 12 months of age. The mortality rate ratio in boys was 0.84 (0.55 to 1.27) compared with 1.39 (0.90 to 2.14) in girls (P for interaction=0.10). An explorative analysis revealed a strong interaction between vitamin A and season of administration.
   Conclusions Vitamin A supplementation given with BCG vaccine at birth had no significant benefit in this African setting. Although little doubt exists that vitamin A supplementation reduces mortality in older children, a global recommendation of supplementation for all newborn infants may not contribute to better survival.
   Registration Clinical trials NCT00168597.
C1 [Benn, Christine Stabell; Diness, Birgitte Rode; Roth, Adam] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen, Denmark.
   [Roth, Adam] Lund Univ, Dept Med Microbiol, S-20502 Malmo, Sweden.
   [Nante, Ernesto; Fisker, Ane Baerent; Rodrigues, Amabelia; Aaby, Peter] Indepth Network, Bandim Hlth Project, Bissau, Guinea Bissau.
   [Lisse, Ida Maria] Herlev Univ Hosp, Dept Pathol, DK-2730 Herlev, Denmark.
   [Yazdanbakhsh, Maria] Leiden Univ, Med Ctr, Dept Immunoparasitol, NL-2333 AZ Leiden, Netherlands.
   [Whittle, Hilton] MRC Labs, Fajara, Gambia.
RP Benn, CS (reprint author), Statens Serum Inst, Bandim Hlth Project, Artillerivej 5, DK-2300 Copenhagen, Denmark.
EM cb@ssi.dk
OI Fisker, Ane/0000-0002-8521-0992
CR ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462
   Aguayo Victor M., 2005, Food and Nutrition Bulletin, V26, P348
   Anker M, 1999, STANDARD VERBAL AUTO
   Bahl R, 1997, EUR J CLIN NUTR, V51, P26, DOI 10.1038/sj.ejcn.1600352
   Benn CS, 2007, VACCINE, V25, P777, DOI 10.1016/j.vaccine.2006.09.044
   Benn CS, 2005, BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55
   Benn CS, 1997, LANCET, V350, P101, DOI 10.1016/S0140-6736(96)12019-5
   Benn CS, 2003, INT J EPIDEMIOL, V32, P822, DOI 10.1093/ije/dyg208
   BENN CS, 2006, J INFECT DIS, V194, P721, DOI 10.1086/506457
   Bhutta ZA, 2008, LANCET, V371, P417, DOI 10.1016/S0140-6736(07)61693-6
   Coutsoudis A, 1996, S Afr Med J, V86, P1337
   Cox D. R., 1984, ANAL SURVIVAL DATA
   Diness BR, 2007, AM J CLIN NUTR, V86, P1152
   FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898
   Fisker AB, 2007, AM J CLIN NUTR, V86, P1032
   Hadi H, 2004, EUR J CLIN NUTR, V58, P990, DOI 10.1038/sj.ejcn.1601920
   Humphrey Jean H, 2006, J Infect Dis, V193, P860, DOI 10.1086/500366
   Humphrey JH, 1996, J PEDIATR-US, V128, P489, DOI 10.1016/S0022-3476(96)70359-1
   INDEPTH-Network, 2003, STAND VERB AUT QUEST
   KJOLHEDE CL, 1995, INT J EPIDEMIOL, V24, P399, DOI 10.1093/ije/24.2.399
   KLEMM R, 2008, 1 MICR FOR M IST TUR
   Malaba LC, 2005, AM J CLIN NUTR, V81, P454
   Moore SE, 2006, TROP MED INT HEALTH, V11, P1529, DOI 10.1111/j.1365-3156.2006.01700.x
   Nante JE, 2007, EUR J CLIN NUTR
   Rahmathullah L, 2003, BRIT MED J, V327, P254, DOI 10.1136/bmj.327.7409.254
   Rondo PHC, 2001, J TROP PEDIATRICS, V47, P307, DOI 10.1093/tropej/47.5.307
   ROSS DA, 1995, AM J PUBLIC HEALTH, V85, P1246, DOI 10.2105/AJPH.85.9.1246
   SOMMER A, 1986, LANCET, V1, P1169
   Tolba AM, 1998, J TROP PEDIATRICS, V44, P174, DOI 10.1093/tropej/44.3.174
   *UNICEF, 2004, VIT MIN DEF
   Villamor E, 2005, CLIN MICROBIOL REV, V18, P446, DOI 10.1128/CNR.18.3.446-464.2005
   West Jr K, 2007, 1 MICR FOR M IST TUR
   West KP, 1997, J NUTR, V127, P1957
   *WHO UNICEF IVACG, 1997, VIT A SUPPL GUID THE
   YASSAI MB, 1989, J TROP PEDIATRICS, V35, P247
NR 35
TC 76
Z9 77
U1 0
U2 5
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-535X
J9 BRIT MED J
JI Br. Med. J.
PD JUN 21
PY 2008
VL 336
IS 7658
BP 1416
EP +
DI 10.1136/bmj.39542.509444.AE
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 318WJ
UT WOS:000257123200032
PM 18558641
OA No
DA 2017-08-15
ER

PT J
AU Gessner, BD
   Adegbola, RA
AF Gessner, Bradford D.
   Adegbola, Richard A.
TI The impact of vaccines on pneumonia: Key lessons from Haemophilus
   influenzae type b conjugate vaccines
SO VACCINE
LA English
DT Article; Proceedings Paper
CT 1st International Pneumonia Vaccines Workshop
CY DEC   15, 2007
CL Seoul, SOUTH KOREA
DE pneumonia; Haemophilus influenzae type b (Hib); vaccine
ID DAY-CARE-CENTERS; OROPHARYNGEAL CARRIAGE; PHARYNGEAL CARRIAGE;
   HEMOPHILUS-INFLUENZAE; INVASIVE DISEASE; HIGH-RISK; CHILDREN;
   IMMUNIZATION; COLONIZATION; VACCINATION
AB This article explores key lessons learned from vaccination with Haemophilus influenzae type b (Hib) conjugate vaccine and how these lessons may provide insight into the impact of emergent pneumococcal vaccines against pneumonia. The worldwide value of Hib vaccination for reducing Hib disease burden and carriage is reviewed. Using comparisons of data for pneumococcus versus Hib, the article concludes that epidemiological and biological differences between these pathogens will complicate efforts to use results from the Hib vaccine experience to predict outcomes following pneumococcal conjugate vaccine introduction. (c) 2008 Elsevier Ltd. All rights reserved.
C1 [Gessner, Bradford D.] Inst Pasteur, Agcy Med Prevent, F-75724 Paris, France.
   [Adegbola, Richard A.] MRC Labs, Banjul, Gambia.
RP Gessner, BD (reprint author), Inst Pasteur, Agcy Med Prevent, 25 Rue Doctor Roux, F-75724 Paris, France.
EM BradGessner@compuserve.com; radegbola@mrc.gm
CR Adegbola RA, 1998, J INFECT DIS, V177, P1758, DOI 10.1086/517440
   Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   Atkinson W, 2008, EPIDEMIOLOGY PREVENT
   Bakir M, 2002, PEDIATR INT, V44, P381, DOI 10.1046/j.1442-200X.2002.01581.x
   Baqui AH, 2007, PEDIATR INFECT DIS J, V26, P565, DOI 10.1097/INF.0b013e31806166a0
   BARBOUR ML, 1995, J INFECT DIS, V171, P93
   BENNETT JV, 2002, VACCINES BIOL
   Bisgard KM, 1998, EMERG INFECT DIS, V4, P229
   Castillo-Febres Olga, 2005, Invest Clin, V46, P15
   Cowgill KD, 2006, JAMA-J AM MED ASSOC, V296, P671, DOI 10.1001/jama.296.6.671
   Dabernat H, 2003, J CLIN MICROBIOL, V41, P1664, DOI 10.1128/JCM.41.4.1664-1672.2003
   Daza P, 2006, VACCINE, V24, P6232, DOI 10.1016/j.vaccine.2006.05.076
   de Andrade ALSS, 2004, INT J EPIDEMIOL, V33, P173, DOI 10.1093/ije/dyh025
   Factor SH, 2005, EMERG INFECT DIS, V11, P1476
   Forleo-Neto E, 1999, J INFECT DIS, V180, P1153, DOI 10.1086/315018
   Galil K, 1999, J INFECT DIS, V179, P101, DOI 10.1086/314569
   Gessner BD, 2002, EUR J CLIN MICROBIOL, V21, P569, DOI 10.1007/s10096-002-0787-0
   Gessner BD, 2005, LANCET, V365, P43, DOI 10.1016/S0140-6736(04)17664-2
   GESSNER BD, 1998, INDONESIA PEDIAT I S, V17, pS179
   Gratten Mike, 1994, Southeast Asian Journal of Tropical Medicine and Public Health, V25, P123
   HALL DB, 1987, AM J EPIDEMIOL, V126, P1190
   HUSSEY GD, 1994, S AFR MED J, V84, P135
   Kuroki H, 1997, ACTA PAEDIATR JAPON, V39, P541
   Lai Guoxiang, 2002, Zhonghua Liu Xing Bing Xue Za Zhi, V23, P108
   Lau YL, 1998, PEDIATR INFECT DIS J, V17, pS165, DOI 10.1097/00006454-199809001-00014
   Levine OS, 1999, PEDIATR INFECT DIS J, V18, P1060, DOI 10.1097/00006454-199912000-00006
   LEWIS RF, B WHO IN PRESS
   Martin M, 2004, PEDIATR INFECT DIS J, V23, P842, DOI 10.1097/01.inf.0000137575.82874.0c
   McVernon J, 2004, EPIDEMIOL INFECT, V132, P765, DOI 10.1017/S0950268804002122
   MONTGOMERY JM, 1990, REV INFECT DIS, V12, pS1006
   Muganga N, 2007, VACCINE, V25, P7001, DOI 10.1016/j.vaccine.2007.06.032
   Mulholland K, 1997, LANCET, V350, P524
   Peltola H, 2000, CLIN MICROBIOL REV, V13, P302, DOI 10.1128/CMR.13.2.302-317.2000
   Singleton R, 2000, J PEDIATR-US, V137, P313, DOI 10.1067/mpd.2000.107843
   SINGLETON RJ, 1994, PEDIATR INFECT DIS J, V13, P362, DOI 10.1097/00006454-199405000-00006
   STEPHENSON WP, 1985, AM J EPIDEMIOL, V122, P868
   TAKALA AK, 1991, J INFECT DIS, V164, P982
   TAKALA AK, 1993, PEDIATR INFECT DIS J, V12, P589
   Torun MM, 2007, CHEMOTHERAPY, V53, P114, DOI 10.1159/000099982
   WARD JI, 1981, LANCET, V1, P1281
NR 40
TC 23
Z9 26
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUN 16
PY 2008
VL 26
SU 2
BP B3
EP B8
DI 10.1016/j.vaccine.2008.04.013
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 331VQ
UT WOS:000258041100002
PM 18793604
OA No
DA 2017-08-15
ER

PT J
AU Antonio, M
   Dada-Adegbola, H
   Biney, E
   Awine, T
   O'Callaghan, J
   Pfluger, V
   Enwere, G
   Okoko, B
   Oluwalana, C
   Vaughan, A
   Zaman, SMA
   Pluschke, G
   Greenwood, BM
   Cutts, F
   Adegbola, RA
AF Antonio, Martin
   Dada-Adegbola, Hannah
   Biney, Ekow
   Awine, Tim
   O'Callaghan, John
   Pfluger, Valentin
   Enwere, Godwin
   Okoko, Brown
   Oluwalana, Claire
   Vaughan, Adeola
   Zaman, Syed M. A.
   Pluschke, Gerd
   Greenwood, Brian M.
   Cutts, Felicity
   Adegbola, Richard A.
TI Molecular epidemiology of pneumococci obtained from Gambian children
   aged 2-29 months with invasive pneumococcal disease during a trial of a
   9-valent pneumococcal conjugate vaccine
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID STREPTOCOCCUS-PNEUMONIAE; DEVELOPING-WORLD; ETIOLOGY; MENINGITIS;
   INFECTIONS; BACTEREMIA; SEROTYPE; STRAINS; IMPACT; ADULTS
AB Background: The study describes the molecular epidemiology of Streptococcus pneumoniae causing invasive disease in Gambian children
   Methods: One hundred and thirty-two S. pneumoniae isolates were recovered from children aged 2-29 months during the course of a pneumococcal conjugate vaccine trial conducted in The Gambia of which 131 were characterized by serotyping, antibiotic susceptibility, BOX-PCR and MLST.
   Results: Twenty-nine different serotypes were identified; serotypes 14, 19A, 12F, 5, 23F, and 1 were common and accounted for 58.3% of all serotypes overall. MLST analysis showed 72 sequence types (STs) of which 46 are novel. eBURST analysis using the stringent 6/7 identical loci definition, grouped the isolates into 17 clonal complexes and 32 singletons. The population structure of the 8 serotype 1 isolates obtained from 4 vaccinated and 2 unvaccinated children were the same (ST 618) except that one (ST3336) of the isolates from an unvaccinated child had a novel ST which is a single locus variant of ST 618.
   Conclusion: We provide the first background data on the genetic structure of S. pneumoniae causing IPD prior to PC7V use in The Gambia. This data will be important for assessing the impact of PC7V in post-vaccine surveillance from The Gambia.
C1 [Antonio, Martin; Dada-Adegbola, Hannah; Biney, Ekow; Awine, Tim; O'Callaghan, John; Enwere, Godwin; Okoko, Brown; Oluwalana, Claire; Vaughan, Adeola; Zaman, Syed M. A.; Cutts, Felicity; Adegbola, Richard A.] MRC Labs, Banjul, Gambia.
   [Pfluger, Valentin; Pluschke, Gerd] Swiss Trop Inst, CH-4002 Basel, Switzerland.
   [Greenwood, Brian M.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Antonio, M (reprint author), MRC Labs, Banjul, Gambia.
EM mantonio@mrc.gm; dadaadegbola@yahoo.com; ekowbee746@yahoo.com;
   TAwine@navrongo.mimcom.net; ocallaghan.john@gmail.com;
   V.Pflueger@stud.unibas.ch; genwere@mrc.gm; bokoko@mrc.gm;
   colulana@mrc.gm; ade_vaughan@hotmail.com; azaman228@yahoo.com;
   gerd.pluschke@unibas.ch; Brian.Greenwood@lshtm.ac.uk;
   Felicity.Cutts@lshtm.ac.uk; radegbola@mrc.gm
FU Medical Research Council [, MC_U190074190, MC_U190081991]; NIAID NIH HHS
   [N01-AI-25477]
CR Aanensen DM, 2005, NUCLEIC ACIDS RES, V33, pW728, DOI 10.1093/nar/gki415
   ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   BERMAN S, 1995, NEW ENGL J MED, V332, P1560, DOI 10.1056/NEJM199506083322307
   Brueggemann AB, 2004, J INFECT DIS, V190, P1203, DOI 10.1086/423820
   COFFEY TJ, 1991, MOL MICROBIOL, V5, P2255, DOI 10.1111/j.1365-2958.1991.tb02155.x
   Coffey TJ, 1998, MOL MICROBIOL, V27, P73, DOI 10.1046/j.1365-2958.1998.00658.x
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   Gertz RE, 2003, J CLIN MICROBIOL, V41, P4194, DOI 10.1128/JCM.41.9.4194-4216.2003
   Greenwood B, 1999, PHILOS T ROY SOC B, V354, P777, DOI 10.1098/rstb.1999.0430
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608
   Jones N, 1998, AIDS, V12, P2177, DOI 10.1097/00002030-199816000-00013
   Kyaw MH, 2006, NEW ENGL J MED, V354, P1455, DOI 10.1056/NEJMoa051642
   Leimkugel J, 2005, J INFECT DIS, V192, P192, DOI 10.1086/431151
   Madhi SA, 2000, PEDIATR INFECT DIS J, V19, P1141, DOI 10.1097/00006454-200012000-00004
   Medina MJ, 2005, MICROB DRUG RESIST, V11, P9, DOI 10.1089/mdr.2005.11.9
   MUNOZ R, 1991, J INFECT DIS, V164, P302
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   Park IH, 2007, J CLIN MICROBIOL, V45, P1225, DOI 10.1128/JCM.02199-06
   Scott JAG, 2007, VACCINE, V25, P2398, DOI 10.1016/j.vaccine.2006.09.008
   SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006
   vanBelkum A, 1996, J CLIN MICROBIOL, V34, P1176
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
   Yaro S, 2006, CLIN INFECT DIS, V43, P693, DOI 10.1086/506940
NR 28
TC 25
Z9 26
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUN 11
PY 2008
VL 8
AR 81
DI 10.1186/1471-2334-8-81
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA 322TX
UT WOS:000257399300001
PM 18547404
OA gold
DA 2017-08-15
ER

PT J
AU Kirby, MJ
   Milligan, PJ
   Conway, DJ
   Lindsay, SW
AF Kirby, Matthew J.
   Milligan, Paul J.
   Conway, David J.
   Lindsay, Steve W.
TI Study protocol for a three-armed randomized controlled trial to assess
   whether house screening can reduce exposure to malaria vectors and
   reduce malaria transmission in The Gambia
SO TRIALS
LA English
DT Article
ID NETS MOSQUITO NETS; ANOPHELES-GAMBIAE; RESISTANCE; CHILDREN; AFRICA
AB Background: Mosquito-proofing homes was one of the principal methods of environmental management in the early 1900s. House screening provides protection against malaria by reducing exposure to malaria parasites and has the added benefit of protecting everyone sleeping in the house, avoiding issues of inequity within the household. The aim of this study is to determine whether house screening protects people against malaria in Africa. It is hoped that this study will mark the beginning of a series of trials assessing a range of environmental interventions for malaria control in Africa.
   Design: A 3-armed randomised-controlled trial will be conducted in and around Farafenni town in The Gambia, West Africa, to assess whether screening windows, doors and closing eaves or installing netting ceilings in local houses can substantially reduce malaria transmission and anaemia compared to homes with no screening. Eligible houses will be sorted and stratified by location and the number of children in each house, then randomly allocated to the interventions in blocks of 5 houses (2 with full screening, 2 with screened ceilings and 1 control house without screening). Risk of malaria transmission will be assessed in each house by routine collections of mosquitoes using light traps and an anaemia prevalence study in children at the end of the main transmission period.
   Discussion: Practical issues concerning intervention implementation, as well as the potential benefits and risks of the study, are discussed.
   Trial Registration: ISRCTN51184253 - Screening-homes to prevent malaria.
C1 [Kirby, Matthew J.; Lindsay, Steve W.] Univ Durham, Sci Labs, Durham DH1 3LE, England.
   [Kirby, Matthew J.; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Milligan, Paul J.; Conway, David J.] London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Lindsay, SW (reprint author), Univ Durham, Sci Labs, South Rd, Durham DH1 3LE, England.
EM m.j.kirby@durham.ac.uk; paul.milligan@lshtm.ac.uk; dconway@mrc.gm;
   s.w.lindsay@durham.ac.uk
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Conway, David/0000-0002-8711-3037
FU Medical Research Council [G0700837]
CR Atkinson SH, 2006, PLOS MED, V3, P652, DOI 10.1371/journal.pmed.0030172
   Celli A, 1901, COLLECTED PAPERS MAL, p[1899, 1]
   Clarke SE, 2003, TROP MED INT HEALTH, V8, P884, DOI 10.1046/j.1365-3156.2003.01095.x
   Hemingway J, 2002, SCIENCE, V298, P96, DOI 10.1126/science.1078052
   Killeen GF, 2002, LANCET INFECT DIS, V2, P618, DOI 10.1016/S1473-3099(02)00397-3
   KIRBY MJ, 2008, MALAR J, V7
   Koram KA, 2000, AM J TROP MED HYG, V62, P670
   Lindsay SW, 2003, TROP MED INT HEALTH, V8, P512, DOI 10.1046/j.1365-3156.2003.01059.x
   Lindsay SW, 2002, TRENDS PARASITOL, V18, P510, DOI 10.1016/S1471-4922(02)02382-6
   MORNER J, 2002, INTERORGANIZATION PR, P88
   N'Guessan R, 2003, MED VET ENTOMOL, V17, P19, DOI 10.1046/j.1365-2915.2003.00406.x
   Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P212, DOI 10.1016/0035-9203(88)90414-2
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9
   Spielman A., 2001, MOSQUITO NATURAL HIS
   Takken W., 1990, ENV MEASURES MALARIA
   *WHO, 2005, ATL INS RES MAL VECT, P27
   WHO, 2000, WHO EXP COMM MAL
   Winstanley PA, 2002, MICROBES INFECT, V4, P157, DOI 10.1016/S1286-4579(01)01523-4
   Zaim M, 2002, TRENDS PARASITOL, V18, P161, DOI 10.1016/S1471-4922(01)02220-6
NR 20
TC 13
Z9 13
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD JUN 6
PY 2008
VL 9
AR 33
DI 10.1186/1745-6215-9-33
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 313ZR
UT WOS:000256779000001
PM 18538004
OA gold
DA 2017-08-15
ER

PT J
AU Viviani, S
   Bah, E
   Carrieri, P
   Hall, AJ
   Kirk, G
   Mendy, M
   Montesano, R
   VanderSande, M
   Whittle, H
   Hainaut, P
AF Viviani, S.
   Bah, E.
   Carrieri, P.
   Hall, A. J.
   Kirk, G.
   Mendy, M.
   Montesano, R.
   VanderSande, M.
   Whittle, H.
   Hainaut, P.
TI Assessment of the initial assumptions of the gambia hepatitis
   intervention study (GHIS) after twenty years of operation
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Meeting Abstract
CT 41st Annual Meeting of the Society-for-Epidemiologic-Research
CY JUN 24-27, 2008
CL Chicago, IL
SP Soc Epidemiol Res
C1 [Viviani, S.; Bah, E.; Carrieri, P.; Hall, A. J.; Kirk, G.; Mendy, M.; Montesano, R.; VanderSande, M.; Whittle, H.; Hainaut, P.] MRC, IARC, GHIS, Banjul, Gambia.
RI Kirk, Gregory/A-8484-2009; Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 1
PY 2008
VL 167
IS 11
SU S
BP S111
EP S111
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 307HO
UT WOS:000256310200443
OA No
DA 2017-08-15
ER

PT J
AU Erskine, J
AF Erskine, James
TI Sick children
SO BRITISH JOURNAL OF GENERAL PRACTICE
LA English
DT Letter
C1 Sibanor Rural Hlth Ctr, Banjul, Gambia.
RP Erskine, J (reprint author), Sibanor Rural Hlth Ctr, POB 86, Banjul, Gambia.
EM erskinesjd@yahoo.co.uk
CR Cave JAH, 2008, BRIT J GEN PRACT, V58, P228, DOI 10.3399/bjgp08X279706
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ROYAL COLL GENERAL PRACTITIONERS
PI LONDON
PA 14 PRINCES GATE, HYDE PARK, LONDON SW7 1PU, ENGLAND
SN 0960-1643
J9 BRIT J GEN PRACT
JI Br. J. Gen. Pract.
PD JUN
PY 2008
VL 58
IS 551
BP 435
EP 435
DI 10.3399/bjgp08X302718
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 340GR
UT WOS:000258634600011
PM 18505623
OA No
DA 2017-08-15
ER

PT J
AU Schoenmakers, I
   Goldberg, GR
   Prentice, A
AF Schoenmakers, Inez
   Goldberg, Gail R.
   Prentice, Ann
TI Abundant sunshine and vitamin D deficiency
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Editorial Material
ID PARATHYROID-HORMONE; D INSUFFICIENCY; 25-HYDROXYVITAMIN-D; NUTRITION;
   POPULATION; PEOPLE; CHINA; WOMEN; DIET; ASIA
C1 [Schoenmakers, Inez; Goldberg, Gail R.; Prentice, Ann] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   MRC, Keneba, Gambia.
RP Schoenmakers, I (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Fulbourn Rd, Cambridge CB1 9NL, England.
EM inez.schoenmakers@mrc-hnr.cam.ac.uk
FU Medical Research Council [U.1059.00.017(60371), MC_U105960371]
CR Aspray TJ, 2005, BONE, V36, P710, DOI 10.1016/j.bone.2005.01.002
   Bates CJ, 2003, OSTEOPOROSIS INT, V14, P152, DOI 10.1007/s00198-002-1338-3
   Binkley N, 2006, CLIN CHEM, V52, P2124, DOI 10.1373/clinchem.2006.074922
   Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18
   Chapuy MC, 1997, OSTEOPOROSIS INT, V7, P439, DOI 10.1007/s001980050030
   Cooper C, 2005, J NUTR, V135, p2728S
   Department of Health, 1998, NUTR BON HLTH PART R
   Diffey BL, 2002, METHODS, V28, P4, DOI 10.1016/S1046-2023(02)00204-9
   Fraser DR, 2004, J STEROID BIOCHEM, V89-90, P491, DOI 10.1016/j.jsbmb.2004.03.057
   Hodsman A. B., 2002, PRINCIPLES BONE BIOL, P1305, DOI 10.1016/B978-012098652-1.50177-3
   Horst RL, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P15
   Institute of Medicine Food and Nutrition Board, 1997, DIET REF INT CALC PH
   Islam MZ, 2008, BRIT J NUTR, V99, P1322, DOI 10.1017/S0007114508894445
   Javaid MK, 2006, LANCET, V367, P36, DOI 10.1016/S0140-6736(06)67922-1
   Lips P, 2007, J STEROID BIOCHEM, V103, P620, DOI 10.1016/j.jsbmb.2006.12.076
   Malabanan A, 1998, LANCET, V351, P805, DOI 10.1016/S0140-6736(05)78933-9
   Norman AW, 2007, J STEROID BIOCHEM, V103, P204, DOI 10.1016/j.jsbmb.2006.12.071
   Prentice A, 2004, PUBLIC HEALTH NUTR, V7, P227, DOI 10.1079/PHN2003590
   PRENTICE A, 2008, IN PRESS AM J CLIN N
   PRENTICE A, 2008, IN PRESS NUTR REV
   Scientific Advisory Committee on Nutrition, 2007, UPD VIT D
   Souberbielle JC, 2001, J CLIN ENDOCR METAB, V86, P3086, DOI 10.1210/jc.86.7.3086
   Vieth R, 2003, J CLIN ENDOCR METAB, V88, P185, DOI 10.1210/jc.2002-021064
   Woo J, 2008, BRIT J NUTR, V99, P1330, DOI 10.1017/S0007114507844382
   Yan L, 2003, BONE, V33, P620, DOI 10.1016/S8756-3282(03)00216-3
   Yan L, 2000, EUR J CLIN NUTR, V54, P68, DOI 10.1038/sj.ejcn.1600895
NR 26
TC 15
Z9 15
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD JUN
PY 2008
VL 99
IS 6
BP 1171
EP 1173
DI 10.1017/S0007114508898662
PG 3
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 302FZ
UT WOS:000255955500002
PM 18234141
OA No
DA 2017-08-15
ER

PT J
AU Miles, DJC
   van der Sande, M
   Crozier, S
   Ojuola, O
   Palmero, MS
   Sanneh, M
   Touray, ES
   Rowland-Jones, S
   Whittle, H
   Ota, M
   Marchant, A
AF Miles, David J. C.
   van der Sande, Marianne
   Crozier, Sarah
   Ojuola, Olubukola
   Palmero, Melba S.
   Sanneh, Mariama
   Touray, Ebrima S.
   Rowland-Jones, Sarah
   Whittle, Hilton
   Ota, Martin
   Marchant, Arnaud
TI Effects of antenatal and postnatal environments on CD4 T-cell responses
   to Mycobacterium bovis BCG in healthy infants in the Gambia
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID MULTIDRUG-RESISTANT TUBERCULOSIS; INTERFERON-GAMMA-RECEPTOR; PRENATAL
   UNDERNUTRITION; PULMONARY TUBERCULOSIS; LIGAND EXPRESSION;
   IMMUNE-RESPONSES; EARLY-LIFE; IFN-GAMMA; VACCINATION; INFECTION
AB The Mycobacterium bovis BCG vaccine has a poor record of efficacy in low-income tropical settings. Against this background, we evaluated the immune response of infants to mycobacterial antigens over the 2 years following BCG vaccination at birth by measuring the gamma interferon (IFN-gamma), interleukin-2 (IL-2), and CD154 responses of CD4 T cells. Similar numbers of cells expressed IFN-gamma in infants, 4-to 5-year-old children, and adults, while CD154 was not expressed at comparable levels until the second year of infancy. The IL-2 response remained relatively low in infants, children, and adults but correlated negatively with mother's body mass index and was highest among infants born to Mandinka mothers. Similarly, infants born in the wet season had a stronger CD154 response than those born in the dry season throughout the 2 years of the study. We conclude that the prenatal and perinatal environments have a lasting effect on the response of infants to the BCG vaccine.
C1 [Miles, David J. C.; Crozier, Sarah; Palmero, Melba S.; Sanneh, Mariama; Touray, Ebrima S.; Rowland-Jones, Sarah; Whittle, Hilton; Ota, Martin] MRC Labs, Banjul, Gambia.
   [van der Sande, Marianne] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands.
   [Ojuola, Olubukola] Bronx Lebanon Hosp Ctr, Dept Pediat, Bronx, NY 10457 USA.
   [Marchant, Arnaud] Univ Libre Bruxelles, Inst Med Immunol, Charleroi, Belgium.
RP Miles, DJC (reprint author), MLW Clin Res Programme, POB 30096, Blantyre 3, Chichiri, Malawi.
EM djcm1@liverpool.ac.uk
OI Crozier, Sarah/0000-0002-9524-1127
FU MRC; GSK Biologics
FX A.M. is a senior research associate at the Fonds National de la
   Recherche Scientifique, Belgium. The study was funded by MRC and GSK
   Biologics.
CR Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   Brosch R, 2007, P NATL ACAD SCI USA, V104, P5596, DOI 10.1073/pnas.0700869104
   Casazza JP, 2006, J EXP MED, V203, P2865, DOI 10.1081/jem.20052246
   Chattopadhyay PK, 2005, NAT MED, V11, P1113, DOI 10.1038/nm1293
   COLDITZ GA, 1995, PEDIATRICS, V96, P29
   Collinson AC, 2003, ACTA PAEDIATR, V92, P1014, DOI 10.1080/08035250310004379
   Dorman SE, 1998, J CLIN INVEST, V101, P2364, DOI 10.1172/JCI2901
   DURANDY A, 1995, J IMMUNOL, V154, P1560
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677
   Ellner JJ, 1997, J INFECT DIS, V176, P1351
   Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292
   Hayashi T, 1999, INFECT IMMUN, V67, P3558
   Hill PC, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-156
   Hogan LH, 2001, INFECT IMMUN, V69, P2596, DOI 10.1128/IAI.69.4.2596-2603.2001
   Hughes AJ, 2005, CLIN EXP IMMUNOL, V142, P132, DOI 10.1111/j.1365-2249.2005.02884.x
   Johnson BJ, 1997, TUBERCLE LUNG DIS, V78, P195, DOI 10.1016/S0962-8479(97)90026-5
   Johnson BJ, 1998, INFECT IMMUN, V66, P2426
   Johnson JL, 2003, AM J RESP CRIT CARE, V168, P185, DOI 10.1164/rccm.200211-1359OC
   Kampmann B, 2005, J CLIN INVEST, V115, P2480, DOI 10.1172/JCI19316
   Kampmann B, 2000, J INFECT DIS, V182, P895, DOI 10.1086/315766
   Malhotra I, 1999, J IMMUNOL, V162, P6843
   Marchand A, 1999, J CHEM SOC PERK T 1, P2249, DOI 10.1039/a904380b
   McDade TW, 2001, J NUTR, V131, P1225
   McDade TW, 2001, AM J CLIN NUTR, V74, P543
   Miles DJC, 2008, J INFECT DIS, V197, P658, DOI 10.1086/527418
   Miles DJC, 2007, J VIROL, V81, P5766, DOI 10.1128/JVI.00052-07
   Moore SE, 2004, AM J CLIN NUTR, V80, P453
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   Moore SE, 2006, TROP MED INT HEALTH, V11, P1529, DOI 10.1111/j.1365-3156.2006.01700.x
   Narayanan P R, 2006, Indian J Med Res, V123, P119
   Newport MJ, 2004, GENES IMMUN, V5, P122, DOI 10.1038/sj.gene.6364051
   Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602
   NONOYAMA S, 1995, J CLIN INVEST, V95, P66, DOI 10.1172/JCI117677
   OLERUP O, 1991, P NATL ACAD SCI USA, V88, P8480, DOI 10.1073/pnas.88.19.8480
   Pathan AA, 2001, J IMMUNOL, V167, P5217
   PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   Rayco-Solon P, 2005, AM J CLIN NUTR, V81, P134
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154
   Roth A, 2005, VACCINE, V23, P3991, DOI 10.1016/j.vaccine.2004.10.022
   Samten B, 2000, INFECT IMMUN, V68, P3002, DOI 10.1128/IAI.68.5.3002-3006.2000
   Stubbe M, 2006, J IMMUNOL, V177, P8185
   Tena GN, 2003, J INFECT DIS, V187, P1544, DOI 10.1086/374799
   Vekemans J, 2004, INFECT IMMUN, V72, P381, DOI 10.1128/IAI.72.1.381-388.2004
   Vincenti D, 2003, MOL MED, V9, P105
   Wallis RS, 2005, CLIN INFECT DIS, V41, P201, DOI 10.1086/430914
   World Health Organization, 2007, WORLD HLTH STAT 2007
   WHO/UNICEF, 2004, REV NAT IMM COV 1980
NR 49
TC 12
Z9 12
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD JUN
PY 2008
VL 15
IS 6
BP 995
EP 1002
DI 10.1128/CVI.00037-08
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 340TD
UT WOS:000258667000014
PM 18400973
OA No
DA 2017-08-15
ER

PT J
AU Damond, F
   Benard, A
   Ruelle, J
   Alabi, A
   Kupfer, B
   Gomes, P
   Rodes, B
   Albert, J
   Boni, J
   Garson, J
   Ferns, B
   Matheron, S
   Chene, G
   Vezinet, FB
AF Damond, Florence
   Benard, Antoine
   Ruelle, Jean
   Alabi, Abraham
   Kupfer, Bernd
   Gomes, Perpetua
   Rodes, Berta
   Albert, Jan
   Boeni, Juerg
   Garson, Jeremy
   Ferns, Bridget
   Matheron, Sophie
   Chene, Genevieve
   Vezinet, Francoise Brun
CA ACHIEV2E Collaboration HIV 2 Infe
TI Quality control assessment of human immunodeficiency virus type 2
   (HIV-2) viral load quantification assays: Results from an international
   collaboration on HIV-2 infection in 2006
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID RT-PCR; PLASMA; RNA; SUBTYPE; SPREAD
AB Human immunodeficiency virus type 2 (HIV-2) RNA quantification assays used in nine laboratories of the ACHIEV2E (A Collaboration on HIV-2 Infection) study group were evaluated. In a blinded experimental design, laboratories quantified three series of aliquots of an HIV-2 subtype A strain, each at a different theoretical viral load. Quantification varied between laboratories, and international standardization of quantification assays is strongly needed.
C1 [Damond, Florence; Vezinet, Francoise Brun] Hop Bichat Claude Bernard, Virol Lab, APHP, F-75018 Paris, France.
   [Benard, Antoine; Chene, Genevieve] Univ Bordeaux 2, INSERM, U897, ISPED, F-33076 Bordeaux, France.
   [Ruelle, Jean] Univ Catholique Louvain, AIDS Reference Lab, B-1348 Louvain, Belgium.
   [Alabi, Abraham] MRC Labs, Banjul, Gambia.
   [Kupfer, Bernd] Inst Virol, Bonn, Germany.
   [Rodes, Berta] Hosp Carlos III, Dept Infect Dis, Madrid, Spain.
   [Gomes, Perpetua] CHLO Hosp Egas Moniz, Mol Biol Lab, Lisbon, Portugal.
   [Albert, Jan] Swedish Inst Infect Dis Control, Dept Virol, Solna, Sweden.
   [Albert, Jan] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.
   [Boeni, Juerg] Swiss HIV Cohort Study, Zurich, Switzerland.
   [Garson, Jeremy; Ferns, Bridget] UCL Royal Free & Univ Coll Med Sch, Ctr Virol, London WC1E 6BT, England.
   [Matheron, Sophie] Hop Bichat Claude Bernard, Serv Malad Infect & Trop, APHP, F-75877 Paris 18, France.
RP Damond, F (reprint author), Hop Bichat Claude Bernard, Virol Lab, APHP, F-75018 Paris, France.
RI Garson, Jeremy/C-5357-2008; Gomes, Perpetua/I-5652-2012; SHCS,
   all/G-4072-2011; SHCS, int. coll. A/G-4083-2011; chene,
   genevieve/H-8665-2014; Camacho, Ricardo/I-7629-2012; Benard,
   Antoine/N-4738-2015
OI Gomes, Perpetua/0000-0003-3271-8255; Camacho,
   Ricardo/0000-0002-9129-3237; Benard, Antoine/0000-0003-2289-8096; Cavaco
   Silva, Perpetua/0000-0001-8429-1316; Matheron,
   Sophie/0000-0001-7879-6553
FU Agence Nationale de Recherche sur le SIDA (ANRS)
FX This work was supported by the Agence Nationale de Recherche sur le SIDA
   (ANRS).; The members of the ACHI<INF>E</INF>V<INF>2E</INF> study group
   in Belgium are Patrick Goubau and Jean Ruelle (AIDS Reference
   Laboratory, Universite Catholique de Louvain). Those in France are
   Francoise Brun-Vezinet, Pauline Campa, Florence Damond, Diane Descamps,
   Sophie Matheron (Bichat-Claude Bernard Hospital, Paris), Francois Simon
   (Saint-Louis Hospital, Paris), Antoine Benard, Genevieve Chene, Audrey
   Taieb (INSERM U897, Bordeaux2 University, Bordeaux), and Brigitte Autran
   (Pitie-Salpetriere Hospital, Paris). Those in Gambia are Abraham Alabi,
   Matt Cotten, Assan Jaye, Kevin Peterson, and Sarah Rowland-Jones
   (Medical Research Council Laboratories). Those in Germany are Bernd
   Kupfer (Institute of Virology, Bonn), Jurgen Rockstroh, and Carolynne
   Schwarze-Zander (Department of Internal Medicine I, University of Bonn,
   Bonn). Those in The Netherlands are Frank De Wolf, Ard Van Sighem
   (National AIDS Therapy Evaluation Center, AMC, Amsterdam), Peter Reiss,
   Maarten Schim Van Der Loeff (AMC-CPCD, Amsterdam; MRC, Gambia), and
   Martin Schutten (Department of Virology, Erasmus MC, Rotterdam). Those
   in Portugal are Ricardo Camacho, Perpetua Gomes, Kamal Mansinho (Egas
   Moniz Hospital, Lisbon), Francisco Antunes, Luis Franca, and Emilia
   Valadas (Clinica Universitaria de Doenc, as Infecciosas, Lisbon). Those
   in Spain are Berta Rodes, Carlos Toro, and Vicente Soriano (Department
   of Infectious Diseases, Hospital Carlos III, Madrid). Those in Sweden
   are Jan Albert (Department of Virology, Swedish Institute for Infectious
   Disease Control, Solna), Katarina Gyllensten, Anders Sonnerborg
   (Divisions of Clinical Virology and Infectious Diseases, Huddinge
   University Hospital, Karolinska Institute, Stockholm), Aylin Yilmaz, and
   Magnus Gisslen (Department of Infectious Diseases, Sahlgrenska
   University Hospital, Goteborg). Those in Switzerland are Jurg Boni,
   Alexandra Calmy, and Martin Rickenbach (Swiss HIV Cohort Study). Those
   in the United Kingdom are Deenan Pillay, Bridget Ferns, Jeremy Garson
   (Centre for Virology, Royal Free & University College London Medical
   School, London), Jennifer Tosswill (Centre for Infections, Health
   Protection Agency, London), Jane Anderson (Centre for the Study of
   Sexual Health and HIV, Homerton University Hospital, London), and David
   Chadwick (James Cook University Hospital, Middlesbrough).
CR Damond F, 2005, J CLIN MICROBIOL, V43, P4234, DOI 10.1128/JCM.43.8.4234-4236.2005
   Ferns RB, 2006, J VIROL METHODS, V135, P102, DOI 10.1016/j.jviromet.2006.02.005
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   Matheron S, 2003, AIDS, V17, P2593, DOI 10.1097/01.aids.0000096907.73209.b9
   Muyldermans G, 2000, CLIN MICROBIOL INFEC, V6, P213, DOI 10.1046/j.1469-0691.2000.00048.x
   Rodes B, 2007, J CLIN MICROBIOL, V45, P88, DOI 10.1128/JCM.01613-06
   Ruelle J, 2004, J VIROL METHODS, V117, P67, DOI 10.1016/j.jviromet.2003.12.006
   Schutten M, 2000, J VIROL METHODS, V88, P81, DOI 10.1016/S0166-0934(00)00177-4
   SMALLMANRAYNOR M, 1991, INT J EPIDEMIOL, V20, P480, DOI 10.1093/ije/20.2.480
   Soriano V, 2000, J MED VIROL, V61, P111, DOI 10.1002/(SICI)1096-9071(200005)61:1<111::AID-JMV18>3.0.CO;2-W
   Toro Carlos, 2002, HIV Clin Trials, V3, P397
   van den Bogert Antonie J, 2003, Biomed Eng Online, V2, P17, DOI 10.1186/1475-925X-2-17
   1994, ACCURACY TRUENESS 2
NR 13
TC 23
Z9 23
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUN
PY 2008
VL 46
IS 6
BP 2088
EP 2091
DI 10.1128/JCM.00126-08
PG 4
WC Microbiology
SC Microbiology
GA 341DX
UT WOS:000258695500035
PM 18434556
OA No
DA 2017-08-15
ER

PT J
AU Otu, J
   Antonio, M
   Cheung, YB
   Donkor, S
   De Jong, BC
   Corrah, T
   Adegbola, RA
AF Otu, Jacob
   Antonio, Martin
   Cheung, Yin Bun
   Donkor, Simon
   De Jong, Bouke C.
   Corrah, Tumani
   Adegbola, Richard A.
TI Comparative evaluation of BACTEC MGIT 960 with BACTEC 9000 MB and LJ for
   isolation of mycobacteria in The Gambia
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE Mycobacterium tuberculosis complex; BACTEC 9000 MB; BACTEC MGIT 960; TB
   clinical diagnosis
AB Background: The BACTEC MGIT 960 was evaluated and compared with BACTEC 9000 MB and Lowenstein-Jensen medium for recovery rate of mycobacteria, time to detection, and contamination rate.
   Methodology: 147 sputum samples obtained from patients with suspicion of tuberculosis were processed and inoculated into BACTEC MGIT 960, BACTEC 9000 MB and Lowenstein-Jensen medium using standardized procedures.
   Results: BACTEC MGIT 960 detected 57.1%; BACTEC 9000 MB detected 57.8%; and LJ medium detected 43.5% specimens with Mycobacterium tuberculosis complex (MTBC). BACTEC MGIT 960 had the shortest mean number of days (10.3) to detection, followed by BACTEC 9000 MB (13.2) and LJ medium (26.1). Sign rank test showed all three methods had significant difference in days to detection (each P<0.0001). About 39% of detection by BACTEC MGIT 960 took place within the first week, compared to 27.0% and 0.0% by BACTEC 9000 MB and LJ medium respectively. The best yield was obtained with BACTEC 9000 MB, but when compared with the BACTEC MGIT 960, it was not statistically significant. Performances were the same when the combination of a liquid plus a LJ medium were measured (P=0.05). Contamination rates were significantly higher in BACTEC MGIT 960 (12%) than in BACTEC 9000 MB (7%) (P=0.041) and LJ (4%) medium (P=0.022). BACTEC 9000 MB and LJ medium have lower contamination rates (P=0.607).
   Conclusions: BACTEC MGIT 960 had a shorter time to detection of MTBC than BACTEC 9000 MB and L J medium. Despite a higher contamination rate, its performance did not appear to be inferior.
C1 [Antonio, Martin] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Cheung, Yin Bun] London Sch Hyg & Trop Med, London WC1, England.
RP Antonio, M (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM mantonio@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU MRC (UK)
FX We thank Francis Mendy, Oumie Secka, Andrew Rives and Muhamed Dukuray
   for technical assistance. MRC (UK) supported this work.
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   Benjamin WH, 1998, J CLIN MICROBIOL, V36, P3234
   Casal M, 1997, INT J TUBERC LUNG D, V1, P81
   Dye C, 2006, INT J TUBERC LUNG D, V10, P460
   Fisher L.D., 1993, BIOSTATISTICS
   Hanna BA, 1999, J CLIN MICROBIOL, V37, P748
   Heifets L, 2000, J CLIN MICROBIOL, V38, P1227
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Kent PT, 1985, PUBLIC HLTH MYCOBACT
   National Leprosy and Tuberculosis Programme, 2004, NAT LEPR TUB PROGR A
   Maher D, 2007, B WORLD HEALTH ORGAN, V85, P341, DOI 10.2471/BLT.06.037820
   Middleton AM, 1997, EUR J CLIN MICROBIOL, V16, P166, DOI 10.1007/BF01709480
   Nolte S, 1995, MANUAL CLIN MICROBIO, P400
   Pfyffer GE, 1997, J CLIN MICROBIOL, V35, P364
   Pfyffer GE, 1997, J CLIN MICROBIOL, V35, P2229
   Piersimoni C, 2003, MONALDI ARCH CHEST D, V57, P306
   Rivera AB, 1997, INT J TUBERC LUNG D, V5, P454
   Rohner P, 1997, J CLIN MICROBIOL, V35, P3127
   SEWELL DL, 1993, J CLIN MICROBIOL, V31, P2689
   Tortoli E, 1999, J CLIN MICROBIOL, V37, P3578
   Tortoli E, 1998, J CLIN MICROBIOL, V36, P1378
   World Health Organization, 2007, US LIQ MED CULT DST
   WHO, 2006, WHOHTMTB2006362
   Williams-Bouyer N, 2000, J CLIN MICROBIOL, V38, P4167
   WILSON ML, 1995, J CLIN MICROBIOL, V33, P2516
   Woods GL, 1997, J CLIN MICROBIOL, V35, P121
   Zhou AT, 1996, CLIN DIAGN LAB IMMUN, V3, P337
NR 27
TC 9
Z9 9
U1 0
U2 1
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD JUN
PY 2008
VL 2
IS 3
BP 200
EP 205
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA V22BF
UT WOS:000208250000006
PM 19738351
OA No
DA 2017-08-15
ER

PT J
AU Weedall, GD
   Polley, SD
   Conway, DJ
AF Weedall, Gareth D.
   Polley, Spencer D.
   Conway, David J.
TI Gene-Specific Signatures of Elevated Non-Synonymous Substitution Rates
   Correlate Poorly across the Plasmodium Genus
SO PLOS ONE
LA English
DT Article
AB Background: Comparative genome analyses of parasites allow large scale investigation of selective pressures shaping their evolution. An acute limitation to such analysis of Plasmodium falciparum is that there is only very partial low-coverage genome sequence of the most closely related species, the chimpanzee parasite P. reichenowi. However, if orthologous genes have been under similar selective pressures throughout the Plasmodium genus then positive selection on the P. falciparum lineage might be predicted to some extent by analysis of other lineages.
   Principal Findings: Here, three independent pairs of closely related species in different sub-generic clades (P. falciparum and P. reichenowi; P. vivax and P. knowlesi; P. yoelii and P. berghei) were compared for a set of 43 candidate ligand genes considered likely to be under positive directional selection and a set of 102 control genes for which there was no selective hypothesis. The ratios of non-synonymous to synonymous substitutions (dN/dS) were significantly elevated in the candidate ligand genes compared to control genes in each of the three clades. However, the rank order correlation of dN/dS ratios for individual candidate genes was very low, less than the correlation for the control genes.
   Significance: The inability to predict positive selection on a gene in one lineage by identifying elevated dN/dS ratios in the orthologue within another lineage needs to be noted, as it reflects that adaptive mutations are generally rare events that lead to fixation in individual lineages. Thus it is essential to complete the genome sequences of particular species of phylogenetic importance, such as P. reichenowi.
C1 [Weedall, Gareth D.; Polley, Spencer D.; Conway, David J.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   [Conway, David J.] MRC Labs, Banjul, Gambia.
RP Weedall, GD (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
EM gweedall@hotmail.com
RI Polley, Spencer/F-7766-2013
OI Conway, David/0000-0002-8711-3037
FU UK Medical Research Council PhD studentship; Wellcome Trust
   [074695/Z/04/B]
FX This work was supported in part by a UK Medical Research Council PhD
   studentship for GDW, and Wellcome Trust programme grant 074695/Z/04/B to
   DJC.
CR Arisue N, 2007, J MOL EVOL, V65, P82, DOI 10.1007/s00239-006-0253-1
   Black CG, 2003, MOL BIOCHEM PARASIT, V127, P59, DOI 10.1016/S0166-6851(02)00308-0
   BORRE MB, 1991, MOL BIOCHEM PARASIT, V49, P119, DOI 10.1016/0166-6851(91)90135-S
   Burns JM, 1999, INFECT IMMUN, V67, P675
   Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099
   CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7
   Chattopadhyay R, 2003, J BIOL CHEM, V278, P25977, DOI 10.1074/jbc.M300865200
   Clark AG, 2007, NATURE, V450, P203, DOI 10.1038/nature06341
   Cowman AF, 2000, FEBS LETT, V476, P84, DOI 10.1016/S0014-5793(00)01703-8
   Dessens JT, 2001, INFECT IMMUN, V69, P4041, DOI 10.1128/IAI.69.6.4041-4047.2001
   Dessens JT, 1999, EMBO J, V18, P6221, DOI 10.1093/emboj/18.22.6221
   Dessens JT, 2003, MOL MICROBIOL, V49, P319, DOI 10.1046/j.1365-2958.2003.03566.x
   Eksi S, 2006, MOL MICROBIOL, V61, P991, DOI 10.1111/j.1365-2958.2006.0528.x
   ESCALANTE AA, 1994, P NATL ACAD SCI USA, V91, P11373, DOI 10.1073/pnas.91.24.11373
   FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Gaur D, 2007, P NATL ACAD SCI USA, V104, P17789, DOI 10.1073/pnas.0708772104
   Ghai M, 2002, MOL BIOCHEM PARASIT, V123, P35, DOI 10.1016/S0166-6851(02)00123-8
   Gilberger TW, 2003, J BIOL CHEM, V278, P14480, DOI 10.1074/jbc.M211446200
   Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717
   Hisaeda H, 2000, INFECT IMMUN, V68, P6618, DOI 10.1128/IAI.68.12.6618-6623.2000
   HOWARD RF, 1990, EXP PARASITOL, V71, P330, DOI 10.1016/0014-4894(90)90038-E
   Hughes AL, 2005, MOL BIOCHEM PARASIT, V142, P170, DOI 10.1016/j.molbiopara.2005.02.014
   Ishino T, 2006, MOL MICROBIOL, V59, P1175, DOI 10.1111/j.1365-2958.2005.05014.x
   Ishino T, 2005, MOL MICROBIOL, V58, P1264, DOI 10.1111/j.1365-2958.2005.04801.x
   Jeffares DC, 2007, NAT GENET, V39, P120, DOI 10.1038/ng1931
   Kadota K, 2004, P NATL ACAD SCI USA, V101, P16310, DOI 10.1073/pnas.0406187101
   Kaneko O, 2005, MOL BIOCHEM PARASIT, V143, P20, DOI 10.1016/j.molbiopara.2005.05.003
   Kaneko O, 2002, MOL BIOCHEM PARASIT, V121, P275, DOI 10.1016/S0166-6851(02)00042-7
   Kariu T, 2006, MOL MICROBIOL, V59, P1369, DOI 10.1111/j.1365-2958.2958.2005.05024.x
   Kariu T, 2002, J EXP MED, V195, P1317, DOI 10.1084/jem.20011876
   Kato K, 2005, P NATL ACAD SCI USA, V102, P5552, DOI 10.1073/pnas.0501594102
   Kushwaha A, 2002, MOL BIOCHEM PARASIT, V122, P45, DOI 10.1016/S0166-6851(02)00077-4
   Li XR, 2004, J BIOL CHEM, V279, P5765, DOI 10.1074/jbc.M308716200
   Ling IT, 2004, MOL MICROBIOL, V52, P107, DOI 10.1111/j.1365-2958.2003.03969.x
   Ling IT, 2003, MOL BIOCHEM PARASIT, V127, P47, DOI 10.1016/S0166-6851(02)00302-X
   LUSTIGMAN S, 1988, MOL BIOCHEM PARASIT, V30, P217, DOI 10.1016/0166-6851(88)90090-4
   Maier AG, 2003, NAT MED, V9, P87, DOI 10.1038/nm807
   Marshall VM, 1997, INFECT IMMUN, V65, P4460
   Marshall VM, 1998, MOL BIOCHEM PARASIT, V94, P13, DOI 10.1016/S0166-6851(98)00045-0
   McCormick CJ, 1999, MOL BIOCHEM PARASIT, V100, P111, DOI 10.1016/S0166-6851(99)00052-3
   Mu JB, 2002, NATURE, V418, P323, DOI 10.1038/nature00836
   Mu JB, 2007, NAT GENET, V39, P126, DOI 10.1038/ng1924
   MULLER HM, 1993, EMBO J, V12, P2881
   Narum DL, 2002, MOL BIOCHEM PARASIT, V119, P159, DOI 10.1016/S0166-6851(01)00428-5
   Nielsen R, 2001, HEREDITY, V86, P641, DOI 10.1046/j.1365-2540.2001.00895.x
   Pearce JA, 2005, MOL BIOCHEM PARASIT, V139, P141, DOI 10.1016/j.molbiopara.2004.09.012
   Perkins SL, 2002, J PARASITOL, V88, P972, DOI 10.1645/0022-3395(2002)088[0972:AMPOMP]2.0.CO;2
   Preiser P, 2004, INFECT IMMUN, V72, P3604, DOI 10.1128/IAI.72.6.3604-3608.2004
   QUAKYI IA, 1987, J IMMUNOL, V139, P4213
   Rich SM, 2003, ADV PARASIT, V54, P255, DOI 10.1016/S0065-308X(03)54005-2
   RIDLEY RG, 1991, MOL BIOCHEM PARASIT, V47, P245, DOI 10.1016/0166-6851(91)90184-8
   Sanders PR, 2006, INFECT IMMUN, V74, P4330, DOI 10.1128/IAI.00054-06
   Sanders PR, 2005, J BIOL CHEM, V280, P40169, DOI 10.1074/jbc.M509631200
   Shi QF, 2006, MOL BIOCHEM PARASIT, V149, P231, DOI 10.1016/j.molbiopara.2006.06.002
   Siden-Kiamos I, 2006, MOL MICROBIOL, V60, P1355, DOI 10.1111/j.1365-2958.2006.05189.x
   Sidjanski SP, 1997, MOL BIOCHEM PARASIT, V90, P33, DOI 10.1016/S0166-6851(97)00124-2
   Silvie O, 2004, J BIOL CHEM, V279, P9490, DOI 10.1074/jbc.M311331200
   Sterkers Y, 2007, J INFECT DIS, V196, P617, DOI 10.1086/519685
   Stoeckert CJ, 2006, TRENDS PARASITOL, V22, P543, DOI 10.1016/j.pt.2006.09.005
   Stubbs J, 2005, SCIENCE, V309, P1384, DOI 10.1126/science.1115257
   Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5
   Suyama M, 2006, NUCLEIC ACIDS RES, V34, pW609, DOI 10.1093/nar/gkl315
   Thompson J, 2004, MOL BIOCHEM PARASIT, V134, P225, DOI 10.1016/j.molbiopara.2003.12.003
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Thompson JK, 2001, MOL MICROBIOL, V41, P47, DOI 10.1046/j.1365-2958.2001.02484.x
   Tomas AM, 2001, EMBO J, V20, P3975, DOI 10.1093/emboj/20.15.3975
   Topolska AE, 2004, J BIOL CHEM, V279, P4648, DOI 10.1074/jbc.M307859200
   Trenholme KR, 2000, P NATL ACAD SCI USA, V97, P4029, DOI 10.1073/pnas.040561197
   Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x
   Tsai YL, 2001, INFECT IMMUN, V69, P4048, DOI 10.1128/IAI.69.6.4048-4054.2001
   van Dijk MR, 2001, CELL, V104, P153, DOI 10.1016/S0092-8674(01)00199-4
   van Schaijk BCL, 2006, MOL BIOCHEM PARASIT, V149, P216, DOI 10.1016/j.molbiopara.2006.05.015
   Volkman SK, 2007, NAT GENET, V39, P113, DOI 10.1038/ng1930
   Yang ZH, 2000, MOL BIOL EVOL, V17, P32
   Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555
   Yuda M, 1999, J EXP MED, V190, P1711, DOI 10.1084/jem.190.11.1711
   Yuda M, 2001, MOL BIOCHEM PARASIT, V116, P65, DOI 10.1016/S0166-6851(01)00304-8
NR 78
TC 9
Z9 9
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 28
PY 2008
VL 3
IS 5
AR e2281
DI 10.1371/journal.pone.0002281
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 391XW
UT WOS:000262268500025
PM 18509456
OA gold
DA 2017-08-15
ER

PT J
AU Collinson, AC
   Ngom, PT
   Moore, SE
   Morgan, G
   Prentice, AM
AF Collinson, Andrew C.
   Ngom, Pa Tamba
   Moore, Sophie E.
   Morgan, Gareth
   Prentice, Andrew M.
TI Birth season and environmental influences on blood leucocyte and
   lymphocyte subpopulations in rural Gambian infants
SO BMC IMMUNOLOGY
LA English
DT Article
ID GROWTH RETARDATION; THYMIC FUNCTION; CHILDREN; MALNUTRITION; SUBSETS;
   AGE; ADULTHOOD; RESPONSES; MALARIA; AFRICA
AB Background: In rural Gambia, birth season predicts infection-related adult mortality, providing evidence that seasonal factors in early life may programme immune development. This study tested whether lymphocyte subpopulations assessed by automated full blood count and flow cytometry in cord blood and at 8, 16 and 52 weeks in rural Gambian infants ( N = 138) are affected by birth season ( DRY = Jan-Jun, harvest season, few infections; WET = Jul-Dec, hungry season, many infections), birth size or micronutrient status.
   Results: Geometric mean cord and postnatal counts were higher in births occurring in the WET season with both season of birth and season of sampling effects. Absolute CD3+, CD8+, and CD56+ counts, were higher in WET season births, but absolute CD4+ counts were unaffected and percentage CD4+ counts were therefore lower. CD19+ counts showed no association with birth season but were associated with concurrent plasma zinc status. There were no other associations between subpopulation counts and micronutrient or anthropometric status.
   Conclusion: These results demonstrate a seasonal influence on cell counts with a disproportionate effect on CD8+ and CD56+ relative to CD4+ cells. This seasonal difference was seen in cord blood ( indicating an effect in utero) and subsequent samples, and is not explained by nutritional status. These findings are consistent with the hypothesis than an early environmental exposure can programme human immune development.
C1 [Collinson, Andrew C.; Ngom, Pa Tamba; Moore, Sophie E.; Prentice, Andrew M.] MRC Labs, Nutr Program, Banjul, Gambia.
   [Collinson, Andrew C.] Royal Devon & Exeter Hosp, Directorate Child & Womens Hlth, Exeter EX2 5DW, Devon, England.
   [Morgan, Gareth] Univ Coll Swansea, Swansea, W Glam, Wales.
   [Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1, England.
RP Prentice, AM (reprint author), MRC Labs, Nutr Program, Banjul, Gambia.
EM andrew.collinson@rdehc-tr.swest.nhs.uk; tngom@mrc.gm;
   sophie.moore@lshtm.ac.uk; gareth.morgan@swansea.ac.uk;
   andrew.prentice@lshtm.ac.uk
FU Medical Research Council [, MC_U123292699, MC_U123292701]
CR AREF GH, 1982, J TROP MED HYG, V85, P109
   Chevalier Philipe, 1994, Journal of Nutritional Immunology, V3, P27, DOI 10.1300/J053v03n01_04
   COLLINSON AC, 2002, EARLY NUTR ENV INFLU
   Dourov N, 1986, HUMAN THYMUS HISTOPH, P127
   Dubowitz L M, 1980, Brain Dev, V2, P3
   ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5
   FERGUSON AC, 1974, J PEDIATR-US, V85, P717, DOI 10.1016/S0022-3476(74)80527-5
   FERGUSON AC, 1978, J PEDIATR-US, V93, P52, DOI 10.1016/S0022-3476(78)80599-X
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   Ghattas H, 2007, AM J CLIN NUTR, V85, P480
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   Janeway C, 1999, IMMUNOBIOLOGY IMMUNE
   Lee BW, 1996, CYTOMETRY, V26, P8, DOI 10.1002/(SICI)1097-0320(19960315)26:1<8::AID-CYTO2>3.0.CO;2-E
   LINDER J, 1987, ARCH PATHOL LAB MED, V111, P1118
   LISSE IM, 1994, T ROY SOC TROP MED H, V88, P709, DOI 10.1016/0035-9203(94)90242-9
   Lisse IM, 1997, J PEDIATR-US, V130, P77, DOI 10.1016/S0022-3476(97)70313-5
   Low T L, 1989, Nutrition, V5, P429
   McCune JM, 2000, J CLIN INVEST, V105, pR1, DOI 10.1172/JCI8647
   Moore SE, 2004, AM J CLIN NUTR, V80, P453
   Moore SE, 2003, ACTA PAEDIATR, V92, P170
   Moore SE, 2001, AM J CLIN NUTR, V74, P840
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   Morgan G, 1997, LANCET, V349, P1693, DOI 10.1016/S0140-6736(96)12038-9
   NAEYE RL, 1971, PEDIATR RES, V5, P17, DOI 10.1203/00006450-197101000-00004
   NEUMANN CG, 1975, AM J CLIN NUTR, V28, P89
   Ngom PT, 2004, AM J CLIN NUTR, V80, P722
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Owens JA, 1989, ADV FETAL PHYSL, P263
   Panaro A, 1991, Allergol Immunopathol (Madr), V19, P109
   Poulin JF, 1999, J EXP MED, V190, P479, DOI 10.1084/jem.190.4.479
   Prentice AM, 1999, BRIT J NUTR, V81, P345
   Prentice AM, 1999, FETAL PROGRAMMING IN, P399
   REMY N, 1991, EUR J PEDIATR, V150, P230, DOI 10.1007/BF01955518
   ROWLAND M G M, 1985, Annals of Tropical Paediatrics, V5, P23
NR 34
TC 22
Z9 22
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2172
J9 BMC IMMUNOL
JI BMC Immunol.
PD MAY 7
PY 2008
VL 9
AR 18
DI 10.1186/1471-2172-9-18
PG 10
WC Immunology
SC Immunology
GA 308EK
UT WOS:000256370900001
PM 18462487
OA gold
DA 2017-08-15
ER

PT J
AU Doherty, CP
   Cox, SE
   Fulford, AJ
   Austin, S
   Hilmers, DC
   Abrams, SA
   Prentice, AM
AF Doherty, Conor P.
   Cox, Sharon E.
   Fulford, Antony J.
   Austin, Steven
   Hilmers, David C.
   Abrams, Steven A.
   Prentice, Andrew M.
TI Iron Incorporation and Post-Malaria Anaemia
SO PLOS ONE
LA English
DT Article
AB Background: Iron supplementation is employed to treat post-malarial anaemia in environments where iron deficiency is common. Malaria induces an intense inflammatory reaction that stalls reticulo-endothelial macrophagal iron recycling from haemolysed red blood cells and inhibits oral iron absorption, but the magnitude and duration of these effects are unclear.
   Methodology/Principal Findings: We examined the red blood cell incorporation of oral administered stable isotopes of iron and compared incorporation between age matched 18 to 36 months old children with either anaemia post-malaria (n = 37) or presumed iron deficiency anaemia alone (n = 36). All children were supplemented for 30 days with 2 mg/kg elemental iron as liquid iron sulphate and administered (57)Fe and (58)Fe on days 1 and 15 of supplementation respectively. (57)Fe and (58)Fe incorporation were significantly reduced (8% vs. 28%: p<0.001 and 14% vs. 26%: p=0.045) in the malaria vs. non-malaria groups. There was a significantly greater haemoglobin response in the malaria group at both day 15 (p = 0.001) and 30 (p<0.000) with a regression analysis estimated greater change in haemoglobin of 7.2 g/l (s.e. 2.0) and 10.1 g/l (s.e. 2.5) respectively.
   Conclusion/Significance: Post-malaria anaemia is associated with a better haemoglobin recovery despite a significant depressant effect on oral iron incorporation which may indicate that early erythropoetic iron need is met by iron recycling rather than oral iron. Supplemental iron administration is of questionable utility within 2 weeks of clinical malaria in children with mild or moderate anaemia.
C1 [Doherty, Conor P.] MRC, Nutr Program, Keneba Field Stn, Fajara, Gambia.
   [Cox, Sharon E.; Fulford, Antony J.; Prentice, Andrew M.] London Sch Hyg & Trop Med, Nutr & Publ Hlth Intervent Res Unit, Med Res Council Int Nutr Grp, London, England.
   [Austin, Steven] Elsie Widdowson Lab, Med Res Council Human Nutr Res, Cambridge, England.
   [Hilmers, David C.; Abrams, Steven A.] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Houston, TX USA.
RP Doherty, CP (reprint author), MRC, Nutr Program, Keneba Field Stn, Fajara, Gambia.
EM conor.doherty@yorkhill.scot.nhs.uk
OI Cox, Sharon/0000-0002-9908-2936; Abrams, Steven/0000-0003-4972-9233
FU Medical Research Council
FX Medical Research Council
CR Abrams S. A., 2002, Food and Nutrition Bulletin, V23, P158
   Ames SK, 1999, AM J CLIN NUTR, V70, P44
   Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607
   Asobayire FS, 2001, AM J CLIN NUTR, V74, P776
   Beesley R, 2000, T ROY SOC TROP MED H, V94, P295, DOI 10.1016/S0035-9203(00)90329-8
   Brock JH, 2000, P NUTR SOC, V59, P537, DOI 10.1017/S002966510000077X
   Chen ZS, 2005, J NUTR, V135, P1790
   COOK JD, 1993, ANNU REV MED, V44, P63, DOI 10.1146/annurev.med.44.1.63
   Das BS, 1997, BRIT J NUTR, V78, P751, DOI 10.1079/BJN19970192
   Das BS, 1999, T ROY SOC TROP MED H, V93, P58, DOI 10.1016/S0035-9203(99)90180-3
   Ekvall H, 2003, CURR OPIN HEMATOL, V10, P108, DOI 10.1097/00062752-200303000-00002
   Ganz T, 2003, BLOOD, V102, P783, DOI 10.1182/blood-2003-03-0672
   Garibay EV, 2001, J AM COLL NUTR, V20, P286
   Griffiths MJ, 2001, BRIT J HAEMATOL, V113, P486, DOI 10.1046/j.1365-2141.2001.02758.x
   GUBLER CJ, 1950, J BIOL CHEM, V184, P563
   Kurtzhals JAL, 1997, BRIT J HAEMATOL, V97, P169, DOI 10.1046/j.1365-2141.1997.82654.x
   Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102
   MASSA E, 1978, J PEDIATR-US, V93, P1045
   Menendez C, 2004, AM J TROP MED HYG, V71, P434
   *NAT NUTR AG, 2001, GAMB
   Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235
   PHILLIPS RE, 1986, Q J MED, V58, P305
   vanHensbroek MB, 1995, T ROY SOC TROP MED H, V89, P672, DOI 10.1016/0035-9203(95)90438-7
   World Health Organization, 1999, MAN SEV MALN MAN PHY
   [Anonymous], 2001, IR DEF AN ASS PREV C
   Williams TN, 1999, AM J TROP MED HYG, V60, P875
NR 26
TC 33
Z9 33
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 7
PY 2008
VL 3
IS 5
AR e2133
DI 10.1371/journal.pone.0002133
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 382YX
UT WOS:000261642400054
PM 18461143
OA gold
DA 2017-08-15
ER

PT J
AU Jacquet, S
   Nishino, Y
   Kumphune, S
   Sicard, P
   Clark, JE
   Kobayashi, KS
   Flavell, RA
   Eickhoff, J
   Cotten, M
   Marber, MS
AF Jacquet, Sebastien
   Nishino, Yasuhiro
   Kumphune, Sarawut
   Sicard, Pierre
   Clark, James E.
   Kobayashi, Koichi S.
   Flavell, Richard A.
   Eickhoff, Jan
   Cotten, Matt
   Marber, Michael S.
TI The role of RIP2 in p38 MAPK activation in the stressed heart
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PROTEIN-KINASE ACTIVATION; INDEPENDENT ACTIVATION; MYOCARDIAL-ISCHEMIA;
   SIMULATED ISCHEMIA; CELL-DEATH; INHIBITION; P38-ALPHA; PATHWAY;
   MECHANISMS; BINDING
AB The activation of p38 MAPK by dual phosphorylation aggravates myocardial ischemic injury and depresses cardiac contractile function. SB203580, an ATP-competitive inhibitor of p38 MAPK and other kinases, prevents this dual phosphorylation during ischemia. Studies in non-cardiac tissue have shown receptor-interacting protein 2 (RIP2) lies upstream of p38 MAPK, is SB203580-sensitive and ischemia-responsive, and aggravates ischemic injury. We therefore examined the RIP2-p38 MAPK signaling axis in the heart. Adenovirus-driven expression of wild-type RIP2 in adult rat ventricular myocytes caused robust, SB203580-sensitive dual phosphorylation of p38 MAPK associated with activation of p38 MAPK kinases MKK3, MKK4, and MKK6. The effect of SB203580 was recapitulated by unrelated inhibitors of RIP2 or the downstream MAPK kinase kinase, TAK1. However, overexpression of wild-type, kinase-dead, caspase recruitment domain-deleted, or kinase-dead and caspase recruitment domain-deleted forms of RIP2 had no effect on the activating dual phosphorylation of p38 MAPK during simulated ischemia. Similarly, p38 MAPK activation and myocardial infarction size in response to true ischemia did not differ between hearts from wild-type and RIP2 null mice. However, both p38 MAPK activation and the contractile depression caused by the endotoxin component muramyl dipeptide were attenuated by SB203580 and in RIP2 null hearts. Although RIP2 can cause myocardial p38 MAPK dual phosphorylation in the heart under some circumstances, it is not responsible for the SB203580-sensitive pattern of activation during ischemia.
C1 [Jacquet, Sebastien; Nishino, Yasuhiro; Kumphune, Sarawut; Sicard, Pierre; Clark, James E.; Marber, Michael S.] Kings Coll London, Rayne Inst, St Thomas Hosp, Div Cardiovasc, London SE1 7EH, England.
   [Kobayashi, Koichi S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
   [Flavell, Richard A.] Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Immunobiol, New Haven, CT 06520 USA.
   [Eickhoff, Jan] GBC Biotech, D-82152 Munich, Germany.
   [Cotten, Matt] MRC Labs, Banjul, Gambia.
RP Marber, MS (reprint author), Kings Coll London, Rayne Inst, St Thomas Hosp, Div Cardiovasc, London SE1 7EH, England.
EM mike.marber@kcl.ac.uk
RI Sicard, Pierre/B-1637-2010
OI Sicard, Pierre/0000-0001-8100-9792; Sicard, Pierre/0000-0001-5837-3916
FU British Heart Foundation [07/073/23432]; NIDDK NIH HHS [R01 DK074738,
   R01 DK074738-05]; Wellcome Trust [074653]
CR Aleshin A, 2004, EUR J CARDIO-THORAC, V26, P974, DOI 10.1016/j.ejcts.2004.06.021
   Argast GM, 2005, MOL CELL BIOCHEM, V268, P129, DOI 10.1007/s11010-005-3701-0
   Armstrong SC, 2004, CARDIOVASC RES, V61, P427, DOI 10.1016/j.cardiores.2003.09.031
   Bellahcene M, 2006, J AM COLL CARDIOL, V48, P545, DOI 10.1016/j.jacc.2006.02.072
   Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7
   Capano M, 2006, BIOCHEM J, V395, P57, DOI 10.1042/BJ20051654
   Clanachan AS, 2003, TRANSPLANTATION, V75, P173, DOI 10.1097/01.TP.0000040429.40245.3A
   Clark JE, 2007, PHARMACOL THERAPEUT, V116, P192, DOI 10.1016/j.pharmthera.2007.06.013
   Dorsch M, 2006, CELL SIGNAL, V18, P2223, DOI 10.1016/j.cellsig.2006.05.005
   Eickhoff J, 2004, J BIOL CHEM, V279, P9642, DOI 10.1074/jbc.M312893200
   Fiedler B, 2006, J BIOL CHEM, V281, P32831, DOI 10.1074/jbc.M603416200
   Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289
   Ge BX, 2003, J BIOL CHEM, V278, P2286, DOI 10.1074/jbc.M210918200
   Godl K, 2003, P NATL ACAD SCI USA, V100, P15434, DOI 10.1073/pnas.2535024100
   Gorog DA, 2004, CARDIOVASC RES, V61, P123, DOI 10.1016/j.cardiores.2003.09.034
   Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605
   HASEGAWA M, 2007, EMBO J, V27, P373
   House SL, 2005, AM J PHYSIOL-HEART C, V289, pH2167, DOI 10.1152/ajpheart.00392.2005
   Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426
   Iwanaga Y, 2003, INFLAMM RES, V52, P272, DOI 10.1007/s00011-003-1170-z
   Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008
   Kang YJ, 2006, J BIOL CHEM, V281, P26225, DOI 10.1074/jbc.M606800200
   Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a
   Lau JMC, 2007, MOL CELL BIOL, V27, P1455, DOI 10.1128/MCB.01369-06
   Li J, 2005, CIRC RES, V97, P872, DOI 10.1161/01.RES.0000187458.77026.10
   Lu CF, 2005, J BIOL CHEM, V280, P16278, DOI 10.1074/jbc.M410114200
   Marber MS, 2000, CIRC RES, V86, P926
   Maulik N, 1998, AM J PHYSIOL, V275, P1857
   McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968
   MURCH O, 2008, IN PRESS SHOCK
   Ninomiya-Tsuji J, 2003, J BIOL CHEM, V278, P18485, DOI 10.1074/jbc.M207453200
   Punn A, 2000, BIOCHEM J, V350, P891, DOI 10.1042/0264-6021:3500891
   Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392
   Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1
   Tanno M, 2003, CIRC RES, V93, P254, DOI 10.1161/01.RES.0000083490.43943.85
   Vahebi S, 2007, CIRC RES, V100, P408, DOI 10.1161/01.RES.0000258116.60404.ad
   Wang MJ, 2005, ANN THORAC SURG, V80, P2235, DOI 10.1016/j.athoracsur.2005.05.070
   Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002
   Wilson KP, 1996, J BIOL CHEM, V271, P27696
   Windheim M, 2007, BIOCHEM J, V404, P179, DOI 10.1042/BJ20061704
   Yada M, 2004, J THORAC CARDIOV SUR, V128, P588, DOI 10.1016/j.jtcvs.2004.02.007
   Yang YB, 2007, J BIOL CHEM, V282, P36223, DOI 10.1074/jbc.M703079200
   Zhang JY, 2007, TRENDS PHARMACOL SCI, V28, P286, DOI 10.1016/j.tips.2007.04.008
   Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100
NR 44
TC 17
Z9 18
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 2
PY 2008
VL 283
IS 18
BP 11964
EP 11971
DI 10.1074/jbc.M707750200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 293MS
UT WOS:000255340000012
PM 18310079
OA No
DA 2017-08-15
ER

PT J
AU Osier, FHA
   Fegan, G
   Polley, SD
   Murungi, L
   Verra, F
   Tetteh, KKA
   Lowe, B
   Mwangi, T
   Bull, PC
   Thornas, AW
   Cavanagh, DR
   McBride, JS
   Lanar, DE
   Mackinnon, MJ
   Conway, DJ
   Marsh, K
AF Osier, Faith H. A.
   Fegan, Gregory
   Polley, Spencer D.
   Murungi, Linda
   Verra, Federica
   Tetteh, Kevin K. A.
   Lowe, Brett
   Mwangi, Tabitha
   Bull, Peter C.
   Thornas, Alan W.
   Cavanagh, David R.
   McBride, Jana S.
   Lanar, David E.
   Mackinnon, Margaret J.
   Conway, David J.
   Marsh, Kevin
TI Breadth and magnitude of antibody responses to multiple Plasmodium
   falciparum merozoite antigens are associated with protection from
   clinical malaria
SO INFECTION AND IMMUNITY
LA English
DT Article
ID APICAL MEMBRANE ANTIGEN-1; ERYTHROCYTE-BINDING ANTIGEN-175;
   INVASION-INHIBITORY ANTIBODIES; NATURALLY ACQUIRED-IMMUNITY; NEW-GUINEAN
   CHILDREN; SURFACE PROTEIN-1; SERUM ANTIBODIES; MONOCLONAL-ANTIBODIES;
   TERMINAL FRAGMENT; ESCHERICHIA-COLI
AB Individuals living in areas where malaria is endemic are repeatedly exposed to many different malaria parasite antigens. Studies on naturally acquired antibody-mediated immunity to clinical malaria have largely focused on the presence of responses to individual antigens and their associations with decreased morbidity. We hypothesized that the breadth (number of important targets to which antibodies were made) and magnitude (antibody level measured in a random serum sample) of the antibody response were important predictors of protection from clinical malaria. We analyzed naturally acquired antibodies to five leading Plasmodium falciparum merozoite-stage vaccine candidate antigens, and schizont extract, in Kenyan children monitored for uncomplicated malaria for 6 months (n = 119). Serum antibody levels to apical membrane antigen 1 (AMA1) and merozoite surface protein antigens (MSP-1 block 2, MSP-2, and MSP-3) were inversely related to the probability of developing malaria, but levels to MSP-1(19) and erythrocyte binding antigen (EBA-175) were not. The risk of malaria was also inversely associated with increasing breadth of antibody specificities, with none of the children who simultaneously had high antibody levels to five or more antigens experiencing a clinical episode (17/119; 15%; P = 0.0006). Particular combinations of antibodies (AMA1, MSP-2, and MSP-3) were more strongly predictive of protection than others. The results were validated in a larger, separate case-control study whose end point was malaria severe enough to warrant hospital admission (n = 387). These findings suggest that under natural exposure, immunity to malaria may result from high titers antibodies to multiple antigenic targets and support the idea of testing combination blood-stage vaccines optimized to induce similar antibody profiles.
C1 [Osier, Faith H. A.; Fegan, Gregory; Murungi, Linda; Lowe, Brett; Mwangi, Tabitha; Bull, Peter C.; Mackinnon, Margaret J.; Marsh, Kevin] CGMRC, KEMRI, Kilifi, Kenya.
   [Osier, Faith H. A.; Fegan, Gregory; Polley, Spencer D.; Verra, Federica; Tetteh, Kevin K. A.; Conway, David J.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Mackinnon, Margaret J.] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England.
   [Verra, Federica] Univ Roma La Sapienza, Dipartimento Sci Sanita Pubblica, Sez Parassitol, I-00185 Rome, Italy.
   [Thornas, Alan W.] BPRC, Dept Parasitol, NL-2280 GH Rijswijk, Netherlands.
   [Cavanagh, David R.; McBride, Jana S.] Univ Edinburgh, Sch Biomed Sci, Inst Immunol & Infect Res, Edinburgh EH9 3JT, Midlothian, Scotland.
   [Lanar, David E.] Walter Reed Army Inst Res, Dept Immunol, Silver Spring, MD 20910 USA.
   [Conway, David J.] MRC Labs, Banjul, Gambia.
RP Osier, FHA (reprint author), CGMRC, KEMRI, POB 230-80108, Kilifi, Kenya.
EM fosier@kilifi.kemri-wellcome.org
RI Lanar, David/B-3560-2011; Cavanagh, David/A-1828-2008; Polley,
   Spencer/F-7766-2013; Mackinnon, Margaret/L-3155-2013
OI Mackinnon, Margaret/0000-0003-1279-9625; Osier,
   Faith/0000-0001-7133-5375; Bull, Peter/0000-0002-7674-6752; Fegan,
   Greg/0000-0002-2663-2765; Conway, David/0000-0002-8711-3037
FU Medical Research Council [MC_U190081993]; Wellcome Trust [073591]
CR ALYAMAN F, 1995, PARASITE IMMUNOL, V17, P493, DOI 10.1111/j.1365-3024.1995.tb00920.x
   AlYaman F, 1996, AM J TROP MED HYG, V54, P443
   BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379
   BLAND JM, 1995, BRIT MED J, V310, P170
   Branch OH, 1998, AM J TROP MED HYG, V58, P211
   Bull PC, 2002, J INFECT DIS, V185, P1688, DOI 10.1086/340420
   Bull PC, 2002, TRENDS MICROBIOL, V10, P55, DOI 10.1016/S0966-842X(01)02278-8
   Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358
   BURGHAUS PA, 1994, MOL BIOCHEM PARASIT, V64, P165, DOI 10.1016/0166-6851(94)90144-9
   Cavanagh DR, 1997, MOL BIOCHEM PARASIT, V85, P197, DOI 10.1016/S0166-6851(96)02826-5
   Cavanagh DR, 2004, INFECT IMMUN, V72, P6492, DOI 10.1128/IAI.72.11.6492.6502.2004
   Cavanagh DR, 1998, J IMMUNOL, V161, P347
   CLARK JT, 1989, MOL BIOCHEM PARASIT, V32, P15, DOI 10.1016/0166-6851(89)90125-4
   COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0
   Conway DJ, 2000, NAT MED, V6, P689, DOI 10.1038/76272
   Conway DJ, 2002, PARASITOLOGY, V125, pS3, DOI 10.1017/S0031182002002214
   Corran PH, 2004, INFECT IMMUN, V72, P6185, DOI 10.1128/IAI.72.10.6185-6189.2004
   Cowman AF, 2006, CELL, V124, P755, DOI 10.1016/j.cell.2006.02.006
   Daugherty JR, 1997, INFECT IMMUN, V65, P3631
   DEANS JA, 1982, CLIN EXP IMMUNOL, V49, P297
   Dodoo D, 1999, INFECT IMMUN, V67, P2131
   Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102
   Dutta S, 2002, INFECT IMMUN, V70, P3101, DOI 10.1128/IAI.70.6.3101-3110.2002
   Egan AF, 1996, J INFECT DIS, V173, P765
   EPPING RJ, 1988, MOL BIOCHEM PARASIT, V28, P1, DOI 10.1016/0166-6851(88)90173-9
   Fluck C, 2004, INFECT IMMUN, V72, P6300, DOI 10.1128/IAI.72.11.6300-6305.2004
   Fouda GG, 2006, CLIN VACCINE IMMUNOL, V13, P1307, DOI 10.1128/CVI.00183-06
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Gray JC, 2007, CLIN CHEM, V53, P1244, DOI 10.1373/clinchem.2006.081695
   Hay SI, 2006, PLOS MED, V3, P2204, DOI 10.1371/journal.pmed.0030473
   HOGH B, 1995, INFECT IMMUN, V63, P4034
   John CC, 2005, AM J TROP MED HYG, V73, P222
   John CC, 2004, J IMMUNOL, V173, P666
   Kimbi HK, 2004, T ROY SOC TROP MED H, V98, P284, DOI 10.1016/S0035-9203(03)00068-3
   Kocken CHM, 2002, INFECT IMMUN, V70, P4471, DOI 10.1128/IAI.70.8.4471-4476.2002
   Locher CP, 1996, EXP PARASITOL, V84, P74, DOI 10.1006/expr.1996.0091
   MARSH K, 1992, PARASITOLOGY, V104, pS53
   Mbogo CM, 2003, AM J TROP MED HYG, V68, P734
   MBOGO CNM, 1993, AM J TROP MED HYG, V49, P245
   McGREGOR I. A., 1963, TRANS ROY SOC TROP MED AND HYG, V57, P170, DOI 10.1016/0035-9203(63)90058-0
   Meraldi V, 2004, PARASITE IMMUNOL, V26, P265, DOI 10.1111/j.0141-9838.2004.00705.x
   Metzger WG, 2003, PARASITE IMMUNOL, V25, P307, DOI 10.1046/j.1365-3024.2003.00636.x
   Mitchell MN, 2005, STATA J, V5, P64
   Mwangi TW, 2005, J INFECT DIS, V191, P1932, DOI 10.1086/430006
   Ndungu FM, 2002, PARASITE IMMUNOL, V24, P77, DOI 10.1046/j.0141-9838.2001.00440.x
   OEUVRAY C, 1994, BLOOD, V84, P1594
   Ohas EA, 2004, INFECT IMMUN, V72, P735, DOI 10.1128/IAI.72.2.735-741.2004
   Okech BA, 2004, INFECT IMMUN, V72, P1557, DOI 10.1128/IAI.72.3.1557-1567.2004
   Okenu DMN, 2000, INFECT IMMUN, V68, P5559, DOI 10.1128/IAI.68.10.5559-5566.2000
   Osier FHA, 2007, PARASITE IMMUNOL, V29, P387, DOI 10.1111/j.1365-3024.2007.00951.x
   Pandey KC, 2002, MOL BIOCHEM PARASIT, V123, P23, DOI 10.1016/S0166-6851(02)00122-6
   Perraut R, 2005, J INFECT DIS, V191, P264, DOI 10.1086/426398
   Polley SD, 2006, VACCINE, V24, P4233, DOI 10.1016/j.vaccine.2005.06.030
   Polley SD, 2004, VACCINE, V23, P718, DOI 10.1016/j.vaccine.2004.05.031
   Polley SD, 2003, INFECT IMMUN, V71, P1833, DOI 10.1128/IAI.71.4.1833-1842.2003
   Polley SD, 2007, J INFECT DIS, V195, P279, DOI 10.1086/509806
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   Roussilhon C, 2007, PLOS MED, V4, P1791, DOI 10.1371/journal.pmed.0040320
   Rowe AK, 2006, INT J EPIDEMIOL, V35, P691, DOI 10.1093/ije/dy1027
   SIM BKL, 1990, J CELL BIOL, V111, P1877, DOI 10.1083/jcb.111.5.1877
   Singh S, 2004, J INFECT DIS, V190, P1010, DOI 10.1086/423208
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Soe S, 2004, INFECT IMMUN, V72, P247, DOI 10.1128/IAI.72.1.247-252.2004
   Sundaresh S, 2006, BIOINFORMATICS, V22, P1760, DOI 10.1093/bioinformatics/btl162
   TAYLOR RR, 1995, INFECT IMMUN, V63, P4382
   Taylor RR, 1998, AM J TROP MED HYG, V58, P406
   Tongren JE, 2006, INFECT IMMUN, V74, P257, DOI 10.1128/IAI.74.1.257-264.2006
   Toure FS, 2006, CLIN MED RES, V4, P175, DOI [10.3121/cmr.4.3.175, 10.3121/cmr.4.1.1]
   Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090
NR 69
TC 183
Z9 185
U1 0
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD MAY
PY 2008
VL 76
IS 5
BP 2240
EP 2248
DI 10.1128/IAI.01585-07
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 292LJ
UT WOS:000255267200050
PM 18316390
OA No
DA 2017-08-15
ER

PT J
AU Millar, J
   Boyd, R
   Surherland, J
AF Millar, Jeremy
   Boyd, Richard
   Surherland, Jayne
TI An update of the phase III trial comparing whole pelvic to prostate only
   radiotherapy and neoadjuvant to adjuvant total androgen suppression:
   Updated analysis of RTOG 94-13, with emphasis on unexpected
   hormone/radiation interactions: In regard to Lawton et al.
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Letter
C1 [Millar, Jeremy] Bayside Hlth, Melbourne, Vic, Australia.
   [Millar, Jeremy] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia.
   [Millar, Jeremy] Monash Univ, Dept Epidemiol Prevent Med, Melbourne, Vic 3004, Australia.
   [Boyd, Richard] Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia.
   [Surherland, Jayne] MRC Labs, Banjul, Gambia.
RP Millar, J (reprint author), Bayside Hlth, Melbourne, Vic, Australia.
OI Millar, Jeremy/0000-0001-8202-8602
FU Medical Research Council [MC_U190071468]
CR Lawton CA, 2007, INT J RADIAT ONCOL, V69, P646, DOI 10.1016/j.ijrobp.2007.04.003
   Sutherland JS, 2005, J IMMUNOL, V175, P2741
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAY 1
PY 2008
VL 71
IS 1
BP 316
EP 316
DI 10.1016/j.ijrobp.2008.01.009
PG 1
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 290UV
UT WOS:000255149000045
PM 18406900
OA No
DA 2017-08-15
ER

PT J
AU Kaye, S
   Miles, D
   Antoine, P
   Burny, W
   Ojuola, B
   Kaye, P
   Rowland-Jones, S
   Whittle, H
   van der Sande, M
   Marchant, A
AF Kaye, Steve
   Miles, David
   Antoine, Pierre
   Burny, Wivine
   Ojuola, Bukky
   Kaye, Pauline
   Rowland-Jones, Sarah
   Whittle, Hilton
   van der Sande, Marianne
   Marchant, Arnaud
TI Virological and immunological correlates of mother-to-child transmission
   of cytomegalovirus in the Gambia
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID MATERNAL INFECTION; HUMAN-PREGNANCY; BREAST-MILK; EXCRETION; IMMUNITY;
   CELLS; WOMEN; EPIDEMIOLOGY; REACTIVATION; PHENOTYPE
AB Background. Cytomegalovirus (CMV) is the most common congenital infection and can follow primary and recurrent maternal infection. We studied correlates of vertical transmission of CMV in The Gambia, where most children acquire CMV during the first year of life.
   Methods. A cohort of 281 mothers and infants was recruited at birth. Infants were prospectively followed up for CMV infection during the first year of life. Excretion of CMV and antiviral immune response were studied at birth in mothers of children infected in utero, early during infancy, or late during infancy or not infected at 1 year of age.
   Results. Congenital infection was diagnosed in 3.9% of newborns, and 85% of children were infected by 1 year. Excretion of CMV in colostrum or in the genital tract was more common in mothers of congenitally (100%) or early infected children (48%) than in mothers of late-infected (20%) or uninfected children (27%). Higher rates of viral excretion were associated with significantly higher levels of serum anti-CMV immunoglobulin G and higher frequencies of CMV-specific CD4(+) T cells.
   Conclusion. In the context of recurrent maternal infection, transmission of CMV in utero and during early postnatal life is associated with excretion of the virus in colostrum and the genital tract.
C1 [Antoine, Pierre; Burny, Wivine; Marchant, Arnaud] Inst Med Immunol, B-6041 Charleroi, Belgium.
   [Kaye, Steve; Miles, David; Ojuola, Bukky; Kaye, Pauline; Rowland-Jones, Sarah; Whittle, Hilton; van der Sande, Marianne; Marchant, Arnaud] MRC Labs, Fajara, Gambia.
RP Marchant, A (reprint author), Inst Med Immunol, Rue Adrienne Bolland 8, B-6041 Charleroi, Belgium.
EM arnaud.marchant@ulb.ac.be
FU Medical Research Council [MC_U190081978, MC_U190085854]
CR Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   Boppana SB, 2001, NEW ENGL J MED, V344, P1366, DOI 10.1056/NEJM200105033441804
   DWORSKY M, 1983, PEDIATRICS, V72, P295
   Fowler KB, 2003, JAMA-J AM MED ASSOC, V289, P1008, DOI 10.1001/jama.289.8.1008
   Hamprecht K, 2001, LANCET, V357, P513, DOI 10.1016/S0140-6736(00)04043-5
   Lazzarotto T, 2004, HUM IMMUNOL, V65, P410, DOI 10.1016/j.humimm.2004.02.006
   Ljungman P, 2002, J INFECT DIS, V186, pS99, DOI 10.1086/342962
   Mikyas Y, 1997, J REPROD IMMUNOL, V33, P157, DOI 10.1016/S0165-0378(97)00018-1
   Mincheva-Nilsson L, 2006, J IMMUNOL, V176, P3585
   PASS RF, 1985, J INFECT DIS, V152, P243
   PASS RF, 1982, J INFECT DIS, V146, P1
   Pass R. F., 2001, FIELDS VIROLOGY, P2675
   Pereira L, 2005, TRENDS MICROBIOL, V13, P164, DOI 10.1016/j.tim.2005.02.009
   Plotkin SA, 1999, PEDIATR INFECT DIS J, V18, P313, DOI 10.1097/00006454-199904000-00002
   Preiser W, 2001, J CLIN VIROL, V20, P59, DOI 10.1016/S1386-6532(00)00156-6
   Revello MG, 1998, J INFECT DIS, V177, P1170
   REYNOLDS DW, 1973, NEW ENGL J MED, V289, P1, DOI 10.1056/NEJM197307052890101
   Ross SA, 2006, J PEDIATR-US, V148, P332, DOI 10.1016/j.jpeds.2005.09.030
   Sargent IL, 2006, TRENDS IMMUNOL, V27, P399, DOI 10.1016/j.it.2006.06.009
   Sinclair J, 2006, J GEN VIROL, V87, P1763, DOI 10.1099/vir.0.81891-0
   Soderberg-Naucler C, 2001, J VIROL, V75, P7543, DOI 10.1128/JVI.75.16.7543-7554.2001
   STAGNO S, 1975, J INFECT DIS, V131, P522
   STAGNO S, 1973, PEDIATRICS, V52, P788
   STAGNO S, 1982, NEW ENGL J MED, V306, P945, DOI 10.1056/NEJM198204223061601
   STAGNO S, 1980, NEW ENGL J MED, V302, P1073, DOI 10.1056/NEJM198005083021908
   STAGNO S, 2001, PHILAPELPHIA, P389
   STERN H, 1973, BRIT MED J, V2, P268
   Taylor DD, 2006, J IMMUNOL, V176, P1534
   van der Sande MAB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000492
NR 29
TC 48
Z9 48
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 1
PY 2008
VL 197
IS 9
BP 1307
EP 1314
DI 10.1086/586715
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 290KC
UT WOS:000255120700013
PM 18422443
OA No
DA 2017-08-15
ER

PT J
AU Rowland-Jones, S
   de Silva, T
AF Rowland-Jones, Sarah
   de Silva, Thushan
TI Resisting immune exhaustion in HIV-1 infection
SO PLOS MEDICINE
LA English
DT Article
ID VIRUS TYPE-1 INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; T-CELL
   PROLIFERATION; VIRAL CONTROL; VACCINATION; DISEASE; DISCONTINUATION;
   PROGRESSION; EXPRESSION; VIREMIA
C1 [Rowland-Jones, Sarah; de Silva, Thushan] MRC Labs, Banjul, Gambia.
RP Rowland-Jones, S (reprint author), MRC Labs, Banjul, Gambia.
EM sarah.rowland-jones@ndm.ox.ac.uk
CR ALLEN TM, 2000, NATURE, V407, P313
   Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Berrey MM, 2001, J INFECT DIS, V183, P1466, DOI 10.1086/320189
   Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874
   CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404
   DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   Ha SJ, 2008, J EXP MED, V205, P543, DOI 10.1084/jem.20071949
   Hecht FM, 2006, J INFECT DIS, V194, P725, DOI 10.1086/506616
   Kaufmann DE, 2004, PLOS MED, V1, P137, DOI 10.1371/journal.pmed.0010036
   Kinloch-de Loes S, 2005, J INFECT DIS, V192, P607, DOI 10.1086/432002
   Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270
   Markowitz M, 2002, J INFECT DIS, V186, P634, DOI 10.1086/342559
   Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501
   McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658
   MEHANDRU S, 2007, PLOS MED, V3, pE484, DOI DOI 10.1371/J0URNAL.PMED.0030484
   Mehandru S, 2007, J VIROL, V81, P11016, DOI 10.1128/JVI.01340-07
   MELLORS JW, 1995, ANN INTERN MED, V122, P573
   Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845
   Oxenius A, 2002, P NATL ACAD SCI USA, V99, P13747, DOI 10.1073/pnas.202372199
   PRAZUCK T, 2008, 15 C RETR OPP INF 3
   Rehr M, 2008, J VIROL, V82, P3391, DOI 10.1128/JVI.02383-07
   RINALDO CR, 1999, J INFECT DIS, V179, P336
   Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103
   Streeck H, 2008, PLOS MED, V5, P790, DOI 10.1371/journal.pmed.0050100
   Streeck H, 2006, J INFECT DIS, V194, P734, DOI 10.1086/503811
   Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482
   Yang HB, 2007, J IMMUNOL, V179, P597
NR 29
TC 4
Z9 4
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD MAY
PY 2008
VL 5
IS 5
BP 721
EP 724
AR e103
DI 10.1371/journal.pmed.0050103
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 315AL
UT WOS:000256850200012
PM 18462014
OA gold
DA 2017-08-15
ER

PT J
AU Cheung, YB
   Zaman, SMA
   Ruopuro, ML
   Enwere, G
   Adegbola, RA
   Greenwood, B
   Cutts, FT
AF Cheung, Yin-Bun
   Zaman, Syed M. A.
   Ruopuro, Marja-Leena
   Enwere, Godwin
   Adegbola, Richard A.
   Greenwood, Brian
   Cutts, Felicity T.
TI C-reactive protein and procalcitonin in the evaluation of the efficacy
   of a pneumococcal conjugate vaccine in Gambian children
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE pneumonia; conjugate vaccines; pneumococcus; diagnosis; C-reactive
   protein; procalcitonin
ID STANDARDIZED INTERPRETATION; CHEST RADIOGRAPHS; PNEUMONIA; WORLD;
   INFECTION; TRIAL; EPIDEMIOLOGY; PREVENTION; SAFETY
AB OBJECTIVE To determine the value of C-reactive protein (CRP) and procalcitonin in the evaluation of the efficacy of a pneumococcal conjugate vaccine in Gambian children.
   METHODS The investigation was done as a substudy of a phase III pneumococcal conjugate vaccine trial. A pilot study (n = 120) to compare CRP and procalcitonin concentrations in children with pneumonia was undertaken, followed by a larger study of CRP concentrations (n = 1868) obtained from a subsample of children with clinical pneumonia seen during the trial.
   RESULTS In the pilot study, CRP had a higher sensitivity and specificity for the detection of primary endpoint (radiographic) pneumonia than procalcitonin. In the subsequent study of 1868 episodes of clinical pneumonia, CRP showed moderate sensitivity but poor positive predictive value in identifying primary endpoint pneumonia or pneumococcal bacteraemia. Addition of CRP thresholds of 40, 60 or 120 mg/l to the diagnosis of clinical pneumonia did not give higher estimates of vaccine efficacy or vaccine attributable reduction in incidence than primary endpoint pneumonia.
   CONCLUSION A combination of a raised CRP concentration with a clinical diagnosis of pneumonia is a more specific endpoint than clinical pneumonia alone but less appropriate than primary endpoint pneumonia as a measure of the impact of a pneumococcal vaccine in a Gambian setting.
C1 [Cheung, Yin-Bun; Greenwood, Brian; Cutts, Felicity T.] London Sch Hyg & Trop Med, London WC1, England.
   [Zaman, Syed M. A.; Enwere, Godwin; Adegbola, Richard A.; Cutts, Felicity T.] MRC Labs, Fajara, Gambia.
   [Ruopuro, Marja-Leena] Ctr Hosp Cent Finland, Jyvaskyla, Finland.
RP Cheung, YB (reprint author), CTERU, 226 Outram Rd,Blk A 03-02, Singapore 169039, Singapore.
EM yinbun@cteru.com.sg
FU NIAID NIH HHS [N01-AI-5477]
CR Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Cutts FT, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010016
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Enwere G, 2007, TROP MED INT HEALTH, V12, P1377, DOI 10.1111/j.1365-3156.2007.01922.x
   Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7
   Greenwood B, 1999, PHILOS T ROY SOC B, V354, P777, DOI 10.1098/rstb.1999.0430
   Hansen J, 2006, PEDIATR INFECT DIS J, V25, P779, DOI 10.1097/01.inf.0000232706.35674.2f
   HURT N, 1994, CLIN DIAGN LAB IMMUN, V1, P437
   JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Madhi SA, 2006, PEDIATR INFECT DIS J, V25, P30, DOI 10.1097/01.inf.0000195787.99199.4a
   Madhi SA, 2005, PLOS MED, V2, P147, DOI 10.1371/journal.pmed.0020038
   Madhi SA, 2007, VACCINE, V25, P2413, DOI 10.1016/j.vaccine.2006.09.010
   O'Brien KL, 2003, LANCET, V362, P355, DOI 10.1016/S0140-6736(03)14022-6
   ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212
   Reichenheim ME, 2002, STATA J, V2, P351
   Simon L, 2004, CLIN INFECT DIS, V39, P206, DOI 10.1086/421997
   van der Meer V, 2005, BRIT MED J, V331, P26, DOI 10.1136/bmj.38483.478183.EB
   Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0
NR 21
TC 14
Z9 16
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAY
PY 2008
VL 13
IS 5
BP 603
EP 611
DI 10.1111/j.1365-3156.2008.02050.x
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 289NW
UT WOS:000255062200002
PM 18331385
OA No
DA 2017-08-15
ER

PT J
AU Todryk, SM
   Bejon, P
   Mwangi, T
   Plebanski, M
   Urban, B
   Marsh, K
   Hill, AVS
   Flanagan, KL
AF Todryk, Stephen M.
   Bejon, Philip
   Mwangi, Tabitha
   Plebanski, Magdalena
   Urban, Britta
   Marsh, Kevin
   Hill, Adrian V. S.
   Flanagan, Katie L.
TI Correlation of Memory T Cell Responses against TRAP with Protection from
   Clinical Malaria, and CD4(+) CD25(high) T Cells with Susceptibility in
   Kenyans
SO PLOS ONE
LA English
DT Article
AB Background: Immunity to malaria develops naturally in endemic regions, but the protective immune mechanisms are poorly understood. Many vaccination strategies aim to induce T cells against diverse pre-erythrocytic antigens, but correlates of protection in the field have been limited. The objective of this study was to investigate cell-mediated immune correlates of protection in natural malaria. Memory T cells reactive against thrombospondin-related adhesive protein (TRAP) and circumsporozoite (CS) protein, major vaccine candidate antigens, were measured, as were frequencies of CD4(+) CD25(high) T cells, which may suppress immunity, and CD56(+) NK cells and gamma delta T cells, which may be effectors or may modulate immunity.
   Methodology and Principal Findings: 112 healthy volunteers living in rural Kenya were entered in the study. Memory T cells reactive against TRAP and CS were measured using a cultured IFN gamma ELISPOT approach, whilst CD4(+) CD25(high) T cells, CD56(+) NK cells, and gamma delta T cells were measured by flow cytometry. We found that T cell responses against TRAP were established early in life (< 5 years) in contrast to CS, and cultured ELISPOT memory T cell responses did not correlate with ex-vivo IFN gamma ELISPOT effector responses. Data was examined for associations with risk of clinical malaria for a period of 300 days. Multivariate logistic analysis incorporating age and CS response showed that cultured memory T cell responses against TRAP were associated with a significantly reduced incidence of malaria (p = 0.028). This was not seen for CS responses. Higher numbers of CD4(+) CD25(high) T cells, potentially regulatory T cells, were associated with a significantly increased risk of clinical malaria (p = 0.039).
   Conclusions: These data demonstrate a role for central memory T cells in natural malarial immunity and support current vaccination strategies aimed at inducing durable protective T cell responses against the TRAP antigen. They also suggest that CD4(+) CD25(high) T cells may negatively affect naturally acquired malarial immunity.
C1 [Todryk, Stephen M.; Bejon, Philip; Urban, Britta; Hill, Adrian V. S.] Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [Todryk, Stephen M.; Bejon, Philip; Mwangi, Tabitha; Urban, Britta; Marsh, Kevin; Flanagan, Katie L.] Kenya Med Res Inst KEMRI, Ctr Geograph Med Res Coast, Wellcome Trust Collaborat Res Programme, Kilifi, Kenya.
   [Hill, Adrian V. S.] Wellcome Trust Ctr Human Genet, Oxford, England.
   [Plebanski, Magdalena] Monash Univ, Dept Immunol, Clayton, Vic, Australia.
   [Flanagan, Katie L.] Med Res Council MRC Lab, Fajara, Gambia.
   [Todryk, Stephen M.] Northumbria Univ, Sch Appl Sci, Newcastle Upon Tyne, Tyne & Wear, England.
RP Todryk, SM (reprint author), Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford, England.
EM stephen.todryk@unn.ac.uk
OI Urban, Britta/0000-0002-4197-8393
FU Wellcome Trust [fellowship]; Medical Research council
FX We acknowledge funding support from the Wellcome Trust and the Medical
   Research council. KF was supported by a Wellcome Trust fellowship in
   Clinical Tropical Medicine. AVSH is a Wellcome Trust Principal Research
   Fellow. Funders had no role in any aspect of this project.
CR Bejon P, 2006, CLIN INFECT DIS, V42, P1102, DOI 10.1086/501459
   Bejon P, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010029
   Doolan DL, 2000, J IMMUNOL, V165, P1453
   FERREIRA A, 1986, SCIENCE, V232, P881, DOI 10.1126/science.3085218
   Flanagan KL, 1999, EUR J IMMUNOL, V29, P1943, DOI 10.1002/(SICI)1521-4141(199906)29:06<1943::AID-IMMU1943>3.3.CO;2-T
   Flanagan KL, 2003, AM J TROP MED HYG, V68, P421
   Flanagan KL, 2001, J IMMUNOL, V167, P4729
   Godkin AJ, 2002, J IMMUNOL, V169, P2210
   Hill AVS, 2006, NAT REV IMMUNOL, V6, P21, DOI 10.1038/nri1746
   Hisaeda H, 2004, NAT MED, V10, P29, DOI 10.1038/nm975
   Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409
   Keating SM, 2005, J IMMUNOL, V175, P5675
   Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772
   Luty AJF, 1999, J INFECT DIS, V179, P980, DOI 10.1086/314689
   Mbogo CM, 2003, AM J TROP MED HYG, V68, P734
   Mwangi TW, 2005, J INFECT DIS, V191, P1932, DOI 10.1086/430006
   Reece WHH, 2004, NAT MED, V10, P406, DOI 10.1038/nm1009
   RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y
   Roetynck S, 2006, IMMUNOL REV, V214, P251, DOI 10.1111/j.1600-065X.2006.00446.x
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702
   Taniguchi T, 2007, IMMUNOLOGY, V122, P514, DOI 10.1111/j.1365-2567.2007.02661.x
   Vuola JM, 2005, J IMMUNOL, V174, P449
   Walther M, 2006, INFECT IMMUN, V74, P2706, DOI 10.1128/IAI.74.5.2706-2716.2006
   Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006
   Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102
   Weedall GD, 2007, INT J PARASITOL, V37, P77, DOI 10.1016/j.ijpara.2006.09.001
   White KL, 1996, J IMMUNOL, V156, P3374
NR 28
TC 62
Z9 62
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 30
PY 2008
VL 3
IS 4
AR e2027
DI 10.1371/journal.pone.0002027
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 381YR
UT WOS:000261572300001
PM 18446217
OA gold
DA 2017-08-15
ER

PT J
AU Mendy, ME
   McConkey, SJ
   van der Sande, MAB
   Crozier, S
   Kaye, S
   Jeffries, D
   Hall, AJ
   Whittle, HC
AF Mendy, Maimuna E.
   McConkey, Samuel J.
   van der Sande, Marianne A. B.
   Crozier, Sarah
   Kaye, Steve
   Jeffries, David
   Hall, Andrew J.
   Whittle, Hilton C.
TI Changes in viral load and HBsAg and HBeAg status with age in HBV chronic
   carriers in The Gambia
SO VIROLOGY JOURNAL
LA English
DT Article
ID HEPATITIS-B-VIRUS; HEPATOCELLULAR-CARCINOMA; E-ANTIGEN; SURFACE-ANTIGEN;
   NATURAL-HISTORY; PLASMA DNA; INFECTION; RISK; VACCINATION; CARRIAGE
AB Background: Little is known about changes in hepatitis B viral load (HBV DNA) in relation to age in Africa. The aim of this study is to determine the natural course of HBV chronic infection, particularly in relation to sequential changes in serum HBV DNA levels and hepatitis B surface (HBsAg) antigen/hepatitis e antigen (HBeAg) status by age.
   Methods: The study was conducted on 190 HBV chronic carriers, aged 1-19 years who were followed for 19 years. 160, 99 and 123 were traced at 5, 9 and 19 years later. All available samples were tested for HBsAg and HBeAg, whilst 170, 61, 63 and 81 were tested for HBV DNA at the baseline, and at 5, 9 and 19 years following recruitment.
   Results: In general HBeAg which correlated with high levels of HBV DNA was lost at a much faster rate than HBsAg. 86% of the carriers who were recruited at the age of 1-4 yrs lost HBeAg by the age of 19 years compared to 30% who lost HBsAg. HBeAg negative carriers had serum HBV DNA levels of < 10(5) copies per mL, HBV DNA positivity declined from 100% in 1-4 yrs old carriers at recruitment to 62.5%, 60% and 88% at 5, 9 and 19 years respectively following recruitment.
   Conclusion: After 19 years of follow up, the majority of HBV surface antigen carriers had lost HBeAg positivity and had low levels of viral replication. However small proportions (10-20%) retained HBeAg and continue to have high levels of viral replication.
C1 [Mendy, Maimuna E.; McConkey, Samuel J.; van der Sande, Marianne A. B.; Crozier, Sarah; Kaye, Steve; Jeffries, David; Whittle, Hilton C.] MRC Labs, Banjul, Gambia.
   [McConkey, Samuel J.] Royal Coll Surgeons Ireland, Dublin 2, Ireland.
   [van der Sande, Marianne A. B.] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands.
   [Crozier, Sarah] Univ Southampton, Epidemiol Resource Ctr, MRC, Southampton, Hants, England.
   [Kaye, Steve] Univ London Imperial Coll Sci Technol & Med, London, England.
   [Hall, Andrew J.] London Sch Hyg & Trop Med, London WC1, England.
RP Mendy, ME (reprint author), MRC Labs, Atlantic Blvd,POB 273, Banjul, Gambia.
EM m.mendy@mrc.gm; sammcconkey@rcsi.ie; Marianne.van.der.Sande@rivm.nl;
   src@mrc.soton.ac.uk; steve.kaye@imperial.ac.uk; djeffries@mrc.gm;
   Andy.Hall@lshtm.ac.uk; hwhittle@mrc.gm
RI McConkey, Samuel/E-7307-2012
OI McConkey, Samuel/0000-0001-9085-7793; Crozier, Sarah/0000-0002-9524-1127
FU Medical Research Council [, MC_U190071516]
CR ALTER HJ, 1976, NEW ENGL J MED, V295, P909, DOI 10.1056/NEJM197610212951701
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   BEASLEY RP, 1977, AM J EPIDEMIOL, V105, P94
   Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65
   Chen CJ, 2000, J GASTROEN HEPATOL, V15, pE3, DOI 10.1046/j.1440-1746.2000.02124.x
   Cougot D, 2005, J CLIN VIROL, V34, pS75, DOI 10.1016/S1386-6532(05)80014-9
   Dumpis U, 2001, J MED VIROL, V65, P664, DOI 10.1002/jmv.2088
   FATTOVICH G, 1986, GASTROENTEROLOGY, V91, P692
   Hui CK, 2007, HEPATOLOGY, V46, P395, DOI 10.1002/hep.21724
   Hui CK, 2006, SEMIN LIVER DIS, V26, P192, DOI 10.1055/s-2006-939757
   Ikeda K, 2006, J HEPATOL, V44, P1089, DOI 10.1016/j.jhep.2006.02.008
   Kirk GD, 2005, CANCER EPIDEM BIOMAR, V14, P373, DOI 10.1158/1055-9965.EPI-04-0161
   Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kirk GD, 2000, J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148
   Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406
   LIAW YF, 1983, AM J TROP MED HYG, V32, P1401
   Manno M, 2004, GASTROENTEROLOGY, V127, P756, DOI 10.1053/j.gastro.2004.06.021
   Mendy ME, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-23
   Mendy ME, 1999, BRIT J BIOMED SCI, V56, P34
   MOYER LA, 1994, AM J PREV MED, V10, P45
   Schim van der Loeff Maarten F., 2003, AIDS (Hagerstown), V17, P1841
   Seitz HK, 2006, BIOL CHEM, V387, P349, DOI 10.1515/BC.2006.047
   van der Sande MAB, 2006, J INFECT DIS, V193, P1528
   VILLENEUVE JP, 1994, GASTROENTEROLOGY, V106, P1000
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WHITTLE HC, 1983, LANCET, V2, P733
   WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4
   WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6
   WHITTLE HC, 1983, LANCET, V1, P1203
   Yang HI, 2002, NEW ENGL J MED, V347, P168, DOI 10.1056/NEJMoa013215
   You SL, 2004, ANN MED, V36, P215, DOI 10.1080/07853890310021580
NR 32
TC 11
Z9 14
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD APR 16
PY 2008
VL 5
AR 49
DI 10.1186/1743-422X-5-49
PG 8
WC Virology
SC Virology
GA 295LT
UT WOS:000255476700001
PM 18416832
OA gold
DA 2017-08-15
ER

PT J
AU Nweneka, CV
AF Nweneka, Chidi Victor
TI Delayed recognition of HIV infection in malnourished children is
   associated with poor clinical outcome in low HIV prevalence settings -
   Preliminary observations
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Letter
ID SEVERE MALNUTRITION
C1 MRC Labs, Keneba Field Stn, Banjul, Gambia.
RP Nweneka, CV (reprint author), MRC Labs, Keneba Field Stn, Banjul, Gambia.
CR Bachou Hanifa, 2006, BMC Pediatr, V6, P7, DOI 10.1186/1471-2431-6-7
   Bavdekar SB, 2005, INDIAN PEDIATR, V42, P1191
   Gernaat HBPE, 1998, J TROP PEDIATRICS, V44, P211, DOI 10.1093/tropej/44.4.211
   Kessler L, 2000, ANN TROP PAEDIATR, V20, P50, DOI 10.1080/02724930092075
   Matee MIN, 1995, E AFR MED J, V72, P694
   Merchant R H, 2001, Indian Pediatr, V38, P239
   PRAZUCK T, 1993, AIDS, V7, P103, DOI 10.1097/00002030-199301000-00016
   Ticklay IMH, 1997, E AFR MED J, V74, P217
   van Gend CL, 2003, J TROP PEDIATRICS, V49, P143, DOI 10.1093/tropej/49.3.143
   Vergeront J M, 1998, WMJ, V97, P52
   World Health Organization, 1999, MAN SEV MALN MAN PHY
   Yeung S, 2000, J TROP PEDIATRICS, V46, P107, DOI 10.1093/tropej/46.2.107
NR 12
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD APR 15
PY 2008
VL 47
IS 5
BP 645
EP 647
DI 10.1097/QAI.0b013e31815e723f
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 280SE
UT WOS:000254445700019
PM 18362697
OA No
DA 2017-08-15
ER

PT J
AU Prentice, A
   Ceesay, M
   Nigdikar, S
   Allen, SJ
   Pettifor, JM
AF Prentice, Ann
   Ceesay, Mustapha
   Nigdikar, Shadja
   Allen, Stephen J.
   Pettifor, John M.
TI FGF23 is elevated in Gambian children with rickets
SO BONE
LA English
DT Article
DE Africa; calcium-deficiency; FGF23; phosphate; rickets
ID VITAMIN-D DEFICIENCY; NIGERIAN CHILDREN; NUTRITIONAL RICKETS;
   D-RECEPTOR; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; HYPOPHOSPHATEMIC RICKETS;
   CALCIUM SUPPLEMENTATION; SERUM CONCENTRATION; DIETARY CALCIUM;
   BONE-FORMATION
AB Objectives: Fibroblast growth factor 23 (FGF23) is a phosphaturic factor that is elevated in several diseases associated with hypophosphatemia and rickets. Rickets in the absence of vitamin D deficiency has been reported in African and Asian populations with a low calcium intake but the definition of risk factors has proved elusive. The aim of the study was to characterize the biochemical profile and measure FGF23 in a series of Gambian children who had presented with rickets of unknown etiology and a plasma 25-hydroxyvitamin D (250HD) above the range typical of vitamin D-deficiency rickets.
   Methods: The 46 patients (30 males, 16 females) had bone deformities typical of rickets and were 1.1-16.4 years old (geometric mean, 3.4 years). Active rickets (on radiographs and/or elevated plasma alkaline phosphatase) was present in 28%. Plasma 25-hydroxyvitamin D was above 20 nmol/l in all patients. Concentrations of plasma FGF23, phosphate and other relevant biochemical analytes were measured in stored samples of fasting, early morning plasma and compared with those measured in samples collected from local children and stored under similar conditions.
   Results: The rickets patients had lower plasma phosphate, lower 25-hydroxyvitamin D, higher 1,25-dihydroxyvitamin D and elevated total alkaline phosphatase than local children. Those with active rickets had raised parathyroid hormone concentration. The patients had significantly higher FGF23 concentration than local children (geometric mean (-1SID, + 1SD, range) RU/ml: 367 (87, 1552, 46-7052, n = 39) vs 51 (23, 112, 3-130, n = 30), p <= 0.001). At presentation, the majority (74%) had an FGF23 concentration that was above the range seen in local children, some grossly so (up to 50-fold). There was no significant difference in FGF23 concentration between those with active rickets and the other patients. Plasma phosphate was significantly and inversely correlated with FGF23 concentration. Some clinical improvements were noted after 612 months, during which time calcium and vitamin D had been prescribed, but FGF23 remained elevated in many patients.
   Conclusions: These data suggest that perturbations of phosphate and FGF23 regulation may be implicated in the pathogenesis, is of calcium-deficiency rickets in Africa and Asia. (c) 2007 Elsevier Inc. All rights reserved.
C1 [Prentice, Ann; Nigdikar, Shadja] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   [Allen, Stephen J.] Gambia, MRC Labs, Fajara, Gambia.
   [Pettifor, John M.] Univ Witwatersrand, Dept Paediat, MRC, Mineral Metab Res Unit, Johannesburg, South Africa.
   [Pettifor, John M.] Chris Hani Baragwanath Hosp, Johannesburg, South Africa.
EM ann.prentice@mrc-hnr.cam.ac.uk; chrissise@hotmail.com;
   shailja.nigdikar@mrc-hnr.cam.ac.uk; S.J.Allen@swansea.ac.uk;
   John.Pettifor@wits.ac.za
RI Pettifor, John/D-5943-2012
OI Pettifor, John/0000-0003-1155-0334
FU Medical Research Council [MC_U105960371]
CR ARNAUD SB, 1976, PEDIATRICS, V57, P221
   Aspray TJ, 2005, BONE, V36, P710, DOI 10.1016/j.bone.2005.01.002
   Barth JH, 1996, ANN CLIN BIOCHEM, V33, P55
   BERNDT T, 2005, BONEKEY OSTEOVISION, V2, P5
   CLEMENTS MR, 1987, NATURE, V325, P62, DOI 10.1038/325062a0
   Dibba B, 2000, AM J CLIN NUTR, V71, P544
   Ferrari SL, 2005, J CLIN ENDOCR METAB, V90, P1519, DOI 10.1210/jc.2004-1039
   Fischer PR, 2000, J BONE MINER RES, V15, P2206, DOI 10.1359/jbmr.2000.15.11.2206
   Fischer PR, 1999, J TROP PEDIATRICS, V45, P291, DOI 10.1093/tropej/45.5.291
   FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17
   Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325
   Imel EA, 2007, J BONE MINER RES, V22, P520, DOI 10.1359/JBMR.070107
   Ito N, 2005, J BONE MINER METAB, V23, P435, DOI 10.1007/s00774-005-0625-4
   Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881
   Kolek OI, 2005, AM J PHYSIOL-GASTR L, V289, pG1036, DOI 10.1152/ajpgi.00243.2005
   Larsson T, 2003, KIDNEY INT, V64, P2272, DOI 10.1046/j.1523-1755.2003.00328.x
   Sava L, 2005, BONE, V20, P158
   Oginni LM, 1996, J PEDIATR-US, V128, P692, DOI 10.1016/S0022-3476(96)80137-5
   Oginni LM, 1999, LANCET, V353, P296, DOI 10.1016/S0140-6736(05)74931-X
   OKONOFUA F, 1991, METABOLISM, V40, P209, DOI 10.1016/0026-0495(91)90177-X
   PETTIFOR JM, 1978, J PEDIATR-US, V92, P320, DOI 10.1016/S0022-3476(78)80035-3
   PETTIFOR JM, 1981, METAB BONE DIS RELAT, V2, P301, DOI 10.1016/0221-8747(81)90013-8
   PETTIFOR JM, 2003, PEDIAT BONE BIOL DIS
   Pfitzner MA, 1998, J PEDIATR-US, V133, P740, DOI 10.1016/S0022-3476(98)70143-X
   PORTALE AA, 1986, J CLIN INVEST, V77, P7, DOI 10.1172/JCI112304
   PORTALE AA, 1989, J CLIN INVEST, V83, P1494, DOI 10.1172/JCI114043
   PRENTICE A, 2002, NUTR RICKETS NIGERIA, V15
   Prentice Ann, 1993, Nutrition Research Reviews, V6, P51, DOI 10.1079/NRR19930006
   Riminucci M, 2003, J CLIN INVEST, V112, P683, DOI 10.1172/JC120031899
   Saito H, 2003, J BIOL CHEM, V278, P2206, DOI 10.1074/jbc.M207872200
   Saito H, 2005, J BIOL CHEM, V280, P2543, DOI 10.1074/jbc.M408903200
   Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081
   Shimada T, 2004, BIOCHEM BIOPH RES CO, V314, P409, DOI 10.1016/j.bbrc.2003.12.102
   Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   SHIMADA T, 2002, ENDOCRINOLOGY, V143, P2179
   Silve C, 2002, NEPHROL DIAL TRANSPL, V17, P958, DOI 10.1093/ndt/17.6.958
   Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14
   STREWLER GJ, 2005, BONEKEY OSTEOVISION, V2, P29
   Thacher TD, 2000, J TROP PEDIATRICS, V46, P132, DOI 10.1093/tropej/46.3.132
   Thacher TD, 1999, NEW ENGL J MED, V341, P563, DOI 10.1056/NEJM199908193410803
   Thacher TD, 2006, J PEDIATR-US, V149, P840, DOI 10.1016/j.jpeds.2006.08.070
   Weber TJ, 2003, J BONE MINER RES, V18, P1227, DOI 10.1359/jbmr.2003.18.7.1227
   Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002-021105
   YOSHIDA T, 2006, ENDOCRINOL, V143
   Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391
NR 46
TC 29
Z9 29
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD APR
PY 2008
VL 42
IS 4
BP 788
EP 797
DI 10.1016/j.bone.2007.11.014
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 283NQ
UT WOS:000254643500021
PM 18234575
OA No
DA 2017-08-15
ER

PT J
AU Schmidt, WP
   Van der Loeff, MS
   Aaby, P
   Whittle, H
   Bakker, R
   Buckner, M
   Dias, F
   White, RG
AF Schmidt, W. P.
   Van der Loeff, M. Schim
   Aaby, P.
   Whittle, H.
   Bakker, R.
   Buckner, M.
   Dias, F.
   White, R. G.
TI Behaviour change and competitive exclusion can explain the diverging
   HIV-1 and HIV-2 prevalence trends in Guinea-Bissau
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PLASMA VIRAL LOAD; WEST-AFRICA;
   HIV-2-ASSOCIATED MORTALITY; RURAL AREA; INFECTION; COHORT; TRANSMISSION;
   COMMUNITY; POPULATION
AB The aim of this study was to determine whether a temporary rise in sexual risk behaviour during war in Guinea-Bissau could explain the observed trends in HIV-1 and HIV-2 prevalence, and to explore the possible contribution of competitive elimination of HIV-2 by HIV-1 A simulation model of the heterosexual transmission of sexually transmitted infections was parameterized using demographic, behavioural and epidemiological data from rural Guinea-Bissau, and fitted to the observed HIV-1 and HIV-2 trends with and without a historic rise in risk behaviour. The observed trends could only be simulated by assuming a temporary rise in risk behaviour. Around 30% of the projected decline in HIV-2 prevalence from a peak of 8 center dot 7% to 4 center dot 3% in 2010 was due to competitive elimination by HIV-1. Importantly for public health, HIV-1 prevalence was predicted to continue increasing and to become the dominant HIV type by 2010. Data collection is required to validate this prediction.
C1 [Schmidt, W. P.; Van der Loeff, M. Schim] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Dis Control & Vector Biol Unit, London WC1E 7HT, England.
   [Van der Loeff, M. Schim; Whittle, H.] MRC Labs, Fajara, Gambia.
   [Aaby, P.] Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen, Denmark.
   [Bakker, R.] Erasmus MC Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.
   [Buckner, M.] Missouri State Univ, Dept Sociol Anthropol & Criminol, Springfield, MO USA.
   [Dias, F.] Minist Hlth, Bissau, Guinea Bissau.
   [White, R. G.] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Publ Hlth, London WC1E 7HT, England.
RP Schmidt, WP (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Dis Control & Vector Biol Unit, Keppel St, London WC1E 7HT, England.
EM Wolf-Peter.Schmidt@lshtm.ac.uk
RI White, Richard/D-5407-2009
OI White, Richard/0000-0003-4410-6635
CR Aaby P, 1996, AIDS, V10, P1585
   ALMEIDA MJM, 1989, 5 INT C AIDS MONTR
   Anderson RM, 1996, AIDS, V10, P1663
   Andersson S, 2000, ARCH INTERN MED, V160, P3286, DOI 10.1001/archinte.160.21.3286
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   BUCKNER M, 1999, EXPERIENCING UNDERST, P391
   Buve A, 2001, AIDS, V15, pS117, DOI 10.1097/00002030-200108004-00013
   DONNELLY C, 1993, B MATH BIOL, V55, P731, DOI 10.1007/BF02460671
   FULTZ PN, 1988, AIDS, V2, P129, DOI 10.1097/00002030-198804000-00010
   Gilbert PB, 2003, STAT MED, V22, P573, DOI 10.1002/sim.1342
   Greenberg AE, 2001, AIDS, V15, P2319, DOI 10.1097/00002030-200111230-00015
   Holmgren B, 1999, SCAND J INFECT DIS, V31, P459
   Kanki P J, 1989, AIDS Clin Rev, P95
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   KAWAMURA M, 1989, LANCET, V1, P385
   Koblavi-Deme S, 2004, AIDS, V18, P413, DOI 10.1097/01.aids.0000104327.15729.cb
   Korenromp EL, 2000, AIDS, V14, P573, DOI 10.1097/00002030-200003310-00013
   Korenromp EL, 2000, MATH POPUL STUD, V8, P135, DOI DOI 10.1080/08898480009525479
   Lagarde E, 2003, INT J EPIDEMIOL, V32, P744, DOI 10.1093/ije/dyg111
   Larsen O, 1998, AIDS, V12, P1707, DOI 10.1097/00002030-199813000-00020
   LERNEY P, 2003, P NATL ACAD SCI USA, V100, P6588
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Matheron S, 1997, AIDS, V11, P934
   Morgan D, 2002, AIDS, V16, P597, DOI 10.1097/00002030-200203080-00011
   Nnko S, 2004, SOC SCI MED, V59, P299, DOI 10.1016/j.socscimed.2003.10.031
   Norrgren H, 1999, AIDS, V13, P701, DOI 10.1097/00002030-199904160-00011
   Norrgren H, 2003, SCAND J INFECT DIS, V35, P265, DOI 10.1080/00365540310000210
   NORRGREN H, 1995, J ACQ IMMUN DEF SYND, V9, P422, DOI 10.1097/00042560-199508000-00014
   ORROTH KK, SEXUALLY TRANSMITTED
   Peeters M, 1998, AIDS RES HUM RETROV, V14, P51, DOI 10.1089/aid.1998.14.51
   PEPIN J, 1991, AIDS, V5, P69
   Pepin J, 2006, AIDS, V20, P1303
   Popper SJ, 1999, J INFECT DIS, V180, P1116, DOI 10.1086/315010
   POULSEN AG, 1989, LANCET, V1, P827
   POULSEN AG, 1993, J ACQ IMMUN DEF SYND, V6, P941
   Poulsen AG, 2000, SCAND J INFECT DIS, V32, P169
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   ROMIEU I, 1990, J ACQ IMMUN DEF SYND, V3, P220
   Sarr AD, 1999, J HUMAN VIROL, V2, P45
   *UNAIDS WHO, 2006, UNAIDS WHO EP FACT S
   UNAIDS/WHO, 2006, REP GLOB AIDS EP
   van der Loeff MFS, 2006, INT J EPIDEMIOL, V35, P1322, DOI 10.1093/ije/dy1037
   van der Loeff MFS, 1999, AIDS, V13, pS69
   van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012
   White RG, 2004, JAIDS-J ACQ IMM DEF, V37, P1500, DOI 10.1097/01.qai.0000127062.94627.31
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   *WHO, 2003, COR HLTH IND COUNTR
   Wiktor SZ, 1999, AIDS, V13, P695, DOI 10.1097/00002030-199904160-00010
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 50
TC 14
Z9 14
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD APR
PY 2008
VL 136
IS 4
BP 551
EP 561
DI 10.1017/S0950268807008758
PG 11
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 350FE
UT WOS:000259337200018
PM 17559692
OA No
DA 2017-08-15
ER

PT J
AU Leligdowicz, A
   Rowland-Jones, S
AF Leligdowicz, Aleksandra
   Rowland-Jones, Sarah
TI Tenets of protection from progression to AIDS: lessons from the immune
   responses to HIV-2 infection
SO EXPERT REVIEW OF VACCINES
LA English
DT Review
DE cellular immunity; HIV-2; immune activation; long-term nonprogression; T
   cell; West Africa
ID IMMUNODEFICIENCY-VIRUS TYPE-2; T-CELL RESPONSES; PLASMA VIRAL LOAD;
   GUINEA-BISSAU; WEST-AFRICA; LYMPHOCYTE ACTIVITY; CORECEPTOR USAGE;
   GAMBIAN PATIENTS; SOOTY MANGABEYS; SIV INFECTION
AB In the past 25 years, life survival curves of many countries have been remodeled owing to HIV infection. Both HIV-1 and HIV-2 can cause AIDS, yet patients infected with HIV-2 fare much better clinically and most will never experience detrimental effects of the infection. Despite over two decades of comprehensive research into vaccine development, a prophylactic vaccine is not yet realized. An essential missing link in the innovation of a successful vaccine strategy is the description of a favorable immune response that abolishes virus replication. Lessons learned from studying the role of the immune system in the long-term nonprogression characteristic of HIV-2 infection will offer insight into how a balanced immune response can protect from the destruction of the immune system associated with chronic HIV-1 infection.
C1 [Leligdowicz, Aleksandra; Rowland-Jones, Sarah] MRC, John Radcliffe Hosp, Weatherall Inst Mol Med, Human Immunol Unit, Oxford OX3 9DS, England.
   [Leligdowicz, Aleksandra; Rowland-Jones, Sarah] MRC Labs, Banjul, Gambia.
RP Leligdowicz, A (reprint author), MRC, John Radcliffe Hosp, Weatherall Inst Mol Med, Human Immunol Unit, Oxford OX3 9DS, England.
EM aleligdowicz@mrc.gm; srowland-jones@mrc.gm
OI Leligdowicz, Aleksandra/0000-0001-6055-4644
CR Aaby P, 1996, AIDS, V10, P1585
   Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003
   ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462
   Alabi AS, 2003, AIDS, V17, P1513, DOI 10.1097/01.aids.0000060410.18106.46
   Alatrakchi N, 2006, AIDS, V20, P29, DOI 10.1097/01.aids.0000198077.30421.bf
   Albuquerque AS, 2007, J IMMUNOL, V178, P3252
   Andersson S, 2000, ARCH INTERN MED, V160, P3286, DOI 10.1001/archinte.160.21.3286
   Andersson S, 2005, CLIN EXP IMMUNOL, V139, P483, DOI 10.1111/j.1365-2249.2005.02723.x
   Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Berry N, 1998, J Hum Virol, V1, P457
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Bertoletti A, 1998, J VIROL, V72, P2439
   Betts MR, 2004, J IMMUNOL, V172, P6407
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   BJORLING E, 1993, VIROLOGY, V193, P528, DOI 10.1006/viro.1993.1160
   Blaak H, 2004, JAIDS-J ACQ IMM DEF, V36, P777, DOI 10.1097/00126334-200407010-00003
   BORROW P, 1994, J VIROL, V68, P6103
   Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316
   Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874
   Bron R, 1997, J VIROL, V71, P8405
   Broussard SR, 2001, J VIROL, V75, P2262, DOI 10.1128/JVI.75.5.2262-2275.2001
   Cao JH, 2003, J VIROL, V77, P6867, DOI 10.1128/JVI.77.12.6867-6878.2003
   Chen ZW, 1996, J VIROL, V70, P3617
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   Colson P, 2004, J CLIN MICROBIOL, V42, P570, DOI 10.1128/JCM.42.2.570-577.2004
   DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083
   Diouf K, 2002, J HUMAN VIROL, V5, P1, DOI 10.1097/01.QHV.0000021465.39141.02
   Dong T, 2004, J EXP MED, V200, P1547, DOI 10.1084/jem.20032044
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Duvall MG, 2008, EUR J IMMUNOL, V38, P350, DOI 10.1002/eji.200737768
   Duvall MG, 2007, J VIROL, V81, P13486, DOI 10.1128/JVI.00976-07
   Duvall MG, 2006, J IMMUNOL, V176, P6973
   Edwards BH, 2002, J VIROL, V76, P2298, DOI 10.1128/JVI.76.5.2298-2305.2002
   EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0
   Fauci AS, 2005, NAT REV IMMUNOL, V5, P835, DOI 10.1038/nri1711
   Fenyo EM, 1996, IMMUNOL LETT, V51, P95, DOI 10.1016/0165-2478(96)02561-8
   Gillespie GMA, 2005, EUR J IMMUNOL, V35, P1445, DOI 10.1002/eji.200526007
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Gordon SN, 2007, J IMMUNOL, V179, P3026
   GOTCH F, 1993, J IMMUNOL, V151, P3361
   Goulder PJR, 2000, J VIROL, V74, P5679, DOI 10.1128/JVI.74.12.5679-5690.2000
   Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212
   Grassly NC, 1998, J VIROL, V72, P7895
   Guillon C, 1998, J VIROL, V72, P6260
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   Hamilton SE, 2006, NAT IMMUNOL, V7, P475, DOI 10.1038/ni1326
   HANNIBAL MC, 1993, J VIROL, V67, P5035
   Hansmann A, 2005, JAIDS-J ACQ IMM DEF, V38, P335
   Hanson A, 2005, AIDS RES HUM RETROV, V21, P791, DOI 10.1089/aid.2005.21.791
   Harari A, 2005, J IMMUNOL, V174, P1037
   Jaffar S, 1997, J ACQ IMMUN DEF SYND, V16, P327
   Jaffar S, 2005, AIDS RES HUM RETROV, V21, P560, DOI 10.1089/aid.2005.21.560
   Jallow S, 2006, AIDS, V20, P1455, DOI 10.1097/01.aids.0000233582.64467.8e
   Jaye A, 2004, J INFECT DIS, V189, P498, DOI 10.1086/381185
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   John M, 2005, NAT IMMUNOL, V6, P232, DOI 10.1038/ni0305-232
   Kalams SA, 1999, J VIROL, V73, P6715
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   Kaufmann DE, 2004, J VIROL, V78, P4463, DOI 10.1128/JVI.78.9.4463-4477.2004
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Klenerman P, 2005, NAT IMMUNOL, V6, P873, DOI 10.1038/ni1241
   Kostense S, 2001, EUR J IMMUNOL, V31, P677, DOI 10.1002/1521-4141(200103)31:3<677::AID-IMMU677>3.0.CO;2-M
   KOUP RA, 1994, J VIROL, V68, P4650
   Larsen O, 1998, AIDS, V12, P1707, DOI 10.1097/00002030-199813000-00020
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100
   Lichterfeld M, 2004, AIDS, V18, P1383, DOI 10.1097/01.aids.0000131329.51633.a3
   Lopes AR, 2003, J IMMUNOL, V171, P307
   Luban J, 2007, J VIROL, V81, P1054, DOI 10.1128/JVI.01519-06
   MacNeil A, 2007, J VIROL, V81, P5325, DOI 10.1128/JVI.02625-06
   MacNeil A, 2007, J INFECT DIS, V195, P726, DOI 10.1086/511308
   MARKOVITZ DM, 1990, P NATL ACAD SCI USA, V87, P9098, DOI 10.1073/pnas.87.23.9098
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Martinez-Picado J, 2006, J VIROL, V80, P3617, DOI 10.1128/JVI.80.7.3617-3623.2006
   Martinez-Steele E, 2007, AIDS, V21, P317, DOI 10.1097/QAD.0b013e328011d7ab
   Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004
   MATLOUBIAN M, 1994, J VIROL, V68, P8056
   Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501
   McKnight A, 1998, J VIROL, V72, P4065
   McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658
   Melamed D, 2004, J VIROL, V78, P9675, DOI 10.1128/JVI.78.18.9675-9688.2004
   Meyer-Olson D, 2006, BLOOD, V107, P2373, DOI 10.1182/blood-2005-04-1636
   Michel P, 2000, J INFECT DIS, V181, P64, DOI 10.1086/315170
   Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660
   Morner A, 1999, J VIROL, V73, P2343
   Mullins C, 2004, CLIN INFECT DIS, V38, P1771, DOI 10.1086/421390
   Munch J, 2005, J VIROL, V79, P10547, DOI 10.1128/JVI.79.16.10547-10560.2005
   Norrgren H, 1999, AIDS, V13, P701, DOI 10.1097/00002030-199904160-00011
   Novitsky V, 2002, J VIROL, V76, P10155, DOI 10.1128/JVI.76.20.10155-10168.2002
   Novitsky V, 2003, J VIROL, V77, P882, DOI 10.1128/JVI.77.2.882-890.2003
   Nuvor SV, 2006, J VIROL, V80, P2529, DOI 10.1128/JVI.80.5.2529-2538.2006
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Ogg GS, 1999, J VIROL, V73, P9153
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   Owen SM, 1998, J VIROL, V72, P5425
   Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020
   PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0
   Picker LJ, 2005, NAT IMMUNOL, V6, P430, DOI 10.1038/ni0505-430
   Popper SJ, 2000, J VIROL, V74, P1554, DOI 10.1128/JVI.74.3.1554-1557.2000
   POULSEN AG, 1993, J ACQ IMMUN DEF SYND, V6, P941
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25
   QUINN TC, 1994, P NATL ACAD SCI USA, V91, P2407, DOI 10.1073/pnas.91.7.2407
   Ramduth D, 2005, J INFECT DIS, V192, P1588, DOI 10.1086/496894
   Reeves JD, 1999, J VIROL, V73, P7795
   Reeves JD, 2002, J GEN VIROL, V83, P1253, DOI 10.1099/vir.O.18253-O
   RINALDO C, 1995, J VIROL, V69, P5838
   Rowland-Jones SL, 2007, NAT IMMUNOL, V8, P329, DOI 10.1038/ni0407-329
   Rowland-Jones SL, 1999, IMMUNOL LETT, V66, P9, DOI 10.1016/S0165-2478(98)00179-5
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   Santiago ML, 2005, J VIROL, V79, P12515, DOI 10.1128/JVI.79.19.12515-12527.2005
   Sarr AD, 2001, AIDS RES HUM RETROV, V17, P1257, DOI 10.1089/088922201750461311
   Schindler M, 2006, CELL, V125, P1055, DOI 10.1016/j.cell.2006.04.033
   Schramm B, 2000, J VIROL, V74, P9594, DOI 10.1128/JVI.74.20.9594-9600.2000
   Shi Y, 2005, J GEN VIROL, V86, P3385, DOI 10.1099/vir.0.81259-0
   Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8
   Silvestri G, 2007, J CLIN INVEST, V117, P3148, DOI 10.1172/JCI33034
   Song H, 2007, J VIROL, V81, P7280, DOI 10.1128/JVI.00406-07
   Sousa AE, 2002, J IMMUNOL, V169, P3400
   Sousa AE, 2001, J INFECT DIS, V184, P552, DOI 10.1086/322804
   Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343
   Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317
   TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936
   UNAIDS, 2006, AIDS EP UPD SPEC REP
   van der Loeff MFS, 2006, INT J EPIDEMIOL, V35, P1322, DOI 10.1093/ije/dy1037
   van der Loeff MFS, 1999, AIDS, V13, pS69
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   van der Loeff MFS, 2002, AIDS, V16, P1775
   van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012
   WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   Whittle HC, 1998, CURR OPIN IMMUNOL, V10, P382, DOI 10.1016/S0952-7915(98)80108-8
   Wiktor SZ, 1999, AIDS, V13, P695, DOI 10.1097/00002030-199904160-00010
   Witvrouw M, 1999, AIDS, V13, P1477, DOI 10.1097/00002030-199908200-00006
   Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960
   Ylinen LMJ, 2005, J VIROL, V79, P11580, DOI 10.1128/JVI.79.18.11580-11587.2005
   Yu XG, 2002, J VIROL, V76, P8690, DOI 10.1128/JVI.76.17.8690-8701.2002
   Zheng NN, 2004, J VIROL, V78, P13934, DOI 10.1128/JVI.78.24.13934-13942.2004
NR 141
TC 16
Z9 16
U1 0
U2 1
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND
SN 1476-0584
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD APR
PY 2008
VL 7
IS 3
BP 319
EP 331
DI 10.1586/14760584.7.3.319
PG 13
WC Immunology
SC Immunology
GA 360HG
UT WOS:000260048000013
PM 18393602
OA No
DA 2017-08-15
ER

PT J
AU Nweneka, CV
   Sharma, A
   Doherty, CP
   Darboe, MK
   Cummings, DE
   Prentice, AM
AF Nweneka, Chidi Victor
   Sharma, Amita
   Doherty, Conor P.
   Darboe, Momodou K.
   Cummings, David E.
   Prentice, Andrew M.
TI Ghrelin response in malnourished African children undergoing nutritional
   rehabilitation
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Nweneka, Chidi Victor; Sharma, Amita; Darboe, Momodou K.; Prentice, Andrew M.] MRC Labs, Nutr Programme Keneba, Banjul, Gambia.
   [Doherty, Conor P.] Univ Glasgow, RHSC, Dept Child Hlth, Glasgow, Lanark, Scotland.
   [Prentice, Andrew M.] LSHTM, MRC, Int Nut Grp, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2008
VL 22
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA V25GZ
UT WOS:000208467805686
OA No
DA 2017-08-15
ER

PT J
AU Savy, M
   Nyan, O
   Browning, LM
   Chatfield, M
   Prentice, AM
AF Savy, Mathilde
   Nyan, Ousman
   Browning, Lucy M.
   Chatfield, Mark
   Prentice, Andrew M.
TI Dietary Modulation of Plasma and Adipose Tissue n-3:n-6 PUPA Ratio has
   no Effect on Insulin Resistance and Inflammation in Obese Gambian Women
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Savy, Mathilde; Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
   [Nyan, Ousman] MRC Labs, Fajara, Gambia.
   [Browning, Lucy M.; Chatfield, Mark] MRC Human Nutr Res, Cambridge, England.
RI Chatfield, Mark/N-2278-2013
OI Chatfield, Mark/0000-0002-0004-6274
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2008
VL 22
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA V25GZ
UT WOS:000208467803681
OA No
DA 2017-08-15
ER

PT J
AU Akpogheneta, OJ
   Duah, NO
   Tetteh, KKA
   Dunyo, S
   Lanar, DE
   Pinder, M
   Conway, DJ
AF Akpogheneta, Onome J.
   Duah, Nancy O.
   Tetteh, Kevin K. A.
   Dunyo, Samuel
   Lanar, David E.
   Pinder, Margaret
   Conway, David J.
TI Duration of naturally acquired antibody responses to blood-stage
   Plasmodium falciparum is age dependent and antigen specific
SO INFECTION AND IMMUNITY
LA English
DT Article
ID MEROZOITE SURFACE PROTEIN-1; SERUM ANTIBODIES; ESCHERICHIA-COLI;
   EARLY-LIFE; MALARIA; IGG; EXPOSURE; CHILDREN; SUBCLASS; PROTECTION
AB Naturally acquired antibody responses provide partial protection from clinical malaria, and blood-stage parasite vaccines under development aim to prime such responses. To investigate the determinants of antibody response longevity, immunoglobulin G (IgG) antibodies to several blood-stage vaccine candidate antigens in the sera of two cohorts of children of up to 6 years of age during the dry seasons of 2003 and 2004 in The Gambia were examined. The first cohort showed that most antibodies were lost within less than 4 months of the first sampling if a persistent infection was not present,, so the study of the second-year cohort involved collecting samples from individuals every 2 weeks over a 3-month period. Antibody responses in the second cohort were also influenced by persistent malaria infection, so analysis focused particularly on children in whom parasites were not detected after the first time point. Antibodies to most antigens declined more slowly in children in the oldest age group (>5 years old) and more rapidly in children in the youngest group (<3 years old). However, antibodies to merozoite surface protein 2 were shorter lived than antibodies to other antigens and were not more persistent in older children. The age-specific and antigen-specific differences were not explained by different IgG subclass response profiles, indicating the probable importance of differential longevities of plasma. cell populations rather than antibody molecules. It is likely that young children mostly have short-lived plasma cells and thus experience rapid declines in antibody levels but that older children have longer-lasting antibody responses that depend on long-lived plasma cells.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   [Lanar, David E.] Walter Reed Army Inst Res, Dept Immunol, Silver Spring, MD 20910 USA.
   [Akpogheneta, Onome J.; Duah, Nancy O.; Dunyo, Samuel; Pinder, Margaret; Conway, David J.] MRC Labs, Fajara, Gambia.
RP Conway, DJ (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM dconway@mrc.gm
RI Lanar, David/B-3560-2011
OI Duah, Nancy/0000-0001-8819-1793; Conway, David/0000-0002-8711-3037
FU Medical Research Council [MC_U190074193]
CR Boutlis CS, 2003, J INFECT DIS, V187, P862, DOI 10.1086/367897
   Branch OH, 1998, AM J TROP MED HYG, V58, P211
   Branch OH, 2000, J INFECT DIS, V181, P1746, DOI 10.1086/315424
   BRUCECHWATT LJ, 1972, LANCET, V1, P512
   BURGHAUS PA, 1994, MOL BIOCHEM PARASIT, V64, P165, DOI 10.1016/0166-6851(94)90144-9
   Cavanagh DR, 2001, INFECT IMMUN, V69, P1207, DOI 10.1128/IAI.69.2.1207-1211.2001
   Cavanagh DR, 1998, J IMMUNOL, V161, P347
   CLERICI M, 1993, J CLIN INVEST, V91, P2829, DOI 10.1172/JCI116526
   COLLINS WE, 1968, AM J EPIDEMIOL, V87, P592
   Daugherty JR, 1997, INFECT IMMUN, V65, P3631
   Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102
   Dutta S, 2002, INFECT IMMUN, V70, P3101, DOI 10.1128/IAI.70.6.3101-3110.2002
   FORTHAL DN, 1995, J INFECT DIS, V172, P1587
   Franks S, 2003, INFECT IMMUN, V71, P3485, DOI 10.1128/IAI.71.6.3485-3495.2003
   Gray JC, 2007, CLIN CHEM, V53, P1244, DOI 10.1373/clinchem.2006.081695
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   KAYHTY H, 1980, J INFECT DIS, V142, P861
   Kinyanjui SM, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-82
   Kinyanjui SM, 2003, J INFECT DIS, V187, P667, DOI 10.1086/373994
   Manz RA, 2005, ANNU REV IMMUNOL, V23, P367, DOI 10.1146/annurev.immunol.23.021704.115723
   MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1
   MORELL A, 1970, J CLIN INVEST, V49, P673, DOI 10.1172/JCI106279
   Ofori MF, 2002, INFECT IMMUN, V70, P2982, DOI 10.1128/IAI.70.6.2982-2988.2002
   Okenu DMN, 2000, INFECT IMMUN, V68, P5559, DOI 10.1128/IAI.68.10.5559-5566.2000
   Pihlgren M, 2006, J IMMUNOL, V176, P165
   Pihlgren M, 2001, EUR J IMMUNOL, V31, P939, DOI 10.1002/1521-4141(200103)31:3<939::AID-IMMU939>3.0.CO;2-I
   Polley SD, 2006, VACCINE, V24, P4233, DOI 10.1016/j.vaccine.2005.06.030
   Polley SD, 2004, VACCINE, V23, P718, DOI 10.1016/j.vaccine.2004.05.031
   RICHIE T, 2007, PARASITOLOGY, V133, pS113
   Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5
   Struik SS, 2004, IMMUNOL REV, V201, P268, DOI 10.1111/j.0105-2896.2004.00181.x
   Taylor RR, 1998, AM J TROP MED HYG, V58, P406
   Taylor RR, 1996, INT IMMUNOL, V8, P905, DOI 10.1093/intimm/8.6.905
   Todryk SM, 2007, NAT REV MICROBIOL, V5, P487, DOI 10.1038/nrmicro1712
   Tongren JE, 2006, INFECT IMMUN, V74, P257, DOI 10.1128/IAI.74.1.257-264.2006
NR 35
TC 86
Z9 86
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD APR
PY 2008
VL 76
IS 4
BP 1748
EP 1755
DI 10.1128/IAI.01333-07
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 284SI
UT WOS:000254725700044
PM 18212081
OA No
DA 2017-08-15
ER

PT J
AU Prentice, AM
   Gershwin, ME
   Schaible, UE
   Keusch, GT
   Victora, CG
   Gordon, JI
AF Prentice, Andrew M.
   Gershwin, M. Eric
   Schaible, Ulrich E.
   Keusch, Gerald T.
   Victora, Cesar G.
   Gordon, Jeffrey I.
TI New challenges in studying nutrition-disease interactions in the
   developing world
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Review
ID VITAMIN-A SUPPLEMENTATION; PLACEBO-CONTROLLED TRIAL; ROUTINE
   PROPHYLACTIC SUPPLEMENTATION; CHILD-MORTALITY; PULMONARY TUBERCULOSIS;
   ZINC SUPPLEMENTATION; SOUTHERN NEPAL; FOLIC-ACID; IRON; DEFICIENCY
AB Latest estimates indicate that nutritional deficiencies account for 3 million child deaths each year in less-developed countries. Targeted nutritional interventions could therefore save millions of lives. However, such interventions require careful optimization to maximize benefit and avoid harm. Progress toward designing effective life-saving interventions is currently hampered by some serious gaps in our understanding of nutrient metabolism in humans. In this Personal Perspective, we highlight some of these gaps and make some proposals as to how improved research methods and technologies can be brought to bear on the problems of undernourished children in the developing world.
C1 [Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   [Prentice, Andrew M.] MRC Keneba, Keneba, Gambia.
   [Gershwin, M. Eric] Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Genome & Biomed Sci Facil, Davis, CA 95616 USA.
   [Schaible, Ulrich E.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Immunol Unit, London WC1E 7HT, England.
   [Keusch, Gerald T.] Boston Univ, Med Campus & Sch Publ Hlth, Boston, MA 02215 USA.
   [Victora, Cesar G.] Univ Fed Pelotas, Pelotas, Brazil.
   [Gordon, Jeffrey I.] Washington Univ, Sch Med, Ctr Genome Sci, St Louis, MO USA.
RP Prentice, AM (reprint author), London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM andrew.prentice@lshtm.ac.uk
RI Schaible, Ulrich/C-7837-2011; Epidemiologicas, Centro de pesquisas
   /D-4561-2013; Victora, Cesar/D-4476-2013
OI Victora, Cesar/0000-0002-2465-2180; Keusch, Gerald/0000-0001-5724-2965
CR ABDELJABER MH, 1991, AM J PUBLIC HEALTH, V81, P1654, DOI 10.2105/AJPH.81.12.1654
   Beck MA, 2007, J NUTR, V137, P1338
   Benn CS, 2007, VACCINE, V25, P777, DOI 10.1016/j.vaccine.2006.09.044
   Benn CS, 2005, BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55
   Black RE, 2003, J NUTR, V133, p1485S
   Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0
   BOGDEN JD, 1978, HEALTH LAB SCI, V15, P38
   Borregaard N, 2006, BIOMETALS, V19, P211, DOI 10.1007/s10534-005-3251-7
   BYRD TF, 1989, J CLIN INVEST, V83, P1457, DOI 10.1172/JCI114038
   Caldwell HD, 2003, J CLIN INVEST, V111, P1757, DOI 10.1172/JCI200317993
   Cegielski JP, 2004, INT J TUBERC LUNG D, V8, P286
   Committee on Metagenomics, 2007, NEW SCI MET REV SECR
   Darboe MK, 2007, LANCET, V369, P2088, DOI 10.1016/S0140-6736(07)60981-7
   Denic S, 2007, NUTRITION, V23, P603, DOI 10.1016/j.nut.2007.05.002
   Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591
   Eckmann L, 2000, J IMMUNOL, V164, P1478
   FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898
   Fawzi WW, 2002, AIDS, V16, P1935, DOI 10.1097/00002030-200209270-00011
   *GLOB FOR HLTH RES, 2004, 1090 GLOB FOR HLTH R
   Golden MH, 1995, SCN NEWS, V12, P10
   HERRERA MG, 1992, LANCET, V340, P267, DOI 10.1016/0140-6736(92)92357-L
   Humphrey Jean H, 2006, J Infect Dis, V193, P860, DOI 10.1086/500366
   Iannotti LL, 2006, AM J CLIN NUTR, V84, P1261
   Kakishima K, 2007, BIOCHEM BIOPH RES CO, V355, P587, DOI 10.1016/j.bbrc.2007.02.017
   KEUSCH GT, 1990, NEW ENGL J MED, V323, P985, DOI 10.1056/NEJM199010043231408
   Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017
   Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/nature4441022a
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
   Liuzzi JP, 2004, ANNU REV NUTR, V24, P151, DOI 10.1146/annurev.nutr.24.012003.132402
   MacKenzie CR, 2007, CURR DRUG METAB, V8, P237, DOI 10.2174/138920007780362518
   Man WDC, 1998, TROP MED INT HEALTH, V3, P678
   MURRAY MJ, 1978, BRIT MED J, V2, P1113
   Prentice AM, 2005, ARCH DIS CHILD, V90, P429, DOI 10.1136/adc.2004.059030
   RAHMATHULLAH L, 1991, AM J CLIN NUTR, V54, P568
   Rawls JF, 2006, CELL, V127, P423, DOI 10.1016/j.cell.2006.08.043
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Sazawal S, 2007, LANCET, V369, P927, DOI 10.1016/S0140-6736(07)60452-8
   Schaible UE, 2005, TRENDS MICROBIOL, V13, P373, DOI 10.1016/j.tim.2005.06.009
   Schaible UE, 2002, J EXP MED, V196, P1507, DOI 10.1084/jem.20020897
   Schaible UE, 2007, PLOS MED, V4, P806, DOI 10.1371/journal.pmed.0040115
   Schaible Ulrich E., 2004, Nature Reviews Microbiology, V2, P946, DOI 10.1038/nrmicro1046
   Singh PK, 2002, NATURE, V417, P552, DOI 10.1038/417552a
   SOMMER A, 1986, LANCET, V1, P1169
   SOMMER A, 1983, LANCET, V2, P585
   Sommer A, 2002, J NUTR, V132, p2845S
   Stevanin TM, 2005, INFECT IMMUN, V73, P3322, DOI 10.1128/IAI.73.6.3322-3329.2005
   Tielsch JM, 2007, LANCET, V370, P1230, DOI 10.1016/S0140-6736(07)61539-6
   Tielsch JM, 2006, LANCET, V367, P144, DOI 10.1016/S0140-6736(06)67963-4
   U.N, 2007, MILL DEV GOALS REP 2
   UNICEF, 2007, STAT WORLDS CHILDR
   van Lettow M, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-61
   van Lettow M, 2003, NUTR REV, V61, P81, DOI 10.1301/nr.2003.marr.81-90
   Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809
   *WHO, 1995, VIT DEF ITS CONS FIE
   WHO, 1987, WKLY EPIDEMIOL REC, V62, P133
   Wilmore D, 2004, J NUTR, V134, p2863S
   [Anonymous], 2006, REP NUTR CENTR DEV S
   Zhu Y, 2007, INFECT IMMUN, V75, P4219, DOI 10.1128/IAI.00509-07
NR 58
TC 23
Z9 26
U1 0
U2 6
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD APR
PY 2008
VL 118
IS 4
BP 1322
EP 1329
DI 10.1172/JCI34034
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 282SX
UT WOS:000254588600024
PM 18382744
OA No
DA 2017-08-15
ER

PT J
AU David, SP
   Munafo, MR
   Murphy, MFG
   Proctor, M
   Walton, RT
   Johnstone, EC
AF David, S. P.
   Munafo, M. R.
   Murphy, M. F. G.
   Proctor, M.
   Walton, R. T.
   Johnstone, E. C.
TI Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking
   cessation: follow-up of a randomised clinical trial of transdermal
   nicotine patch
SO PHARMACOGENOMICS JOURNAL
LA English
DT Article
DE DRD4; VNTR; C-521T; smoking cessation; nicotine replacement therapy
ID DEFICIT HYPERACTIVITY DISORDER; HUMAN PERSONALITY-TRAIT; EXON-III
   POLYMORPHISM; NOVELTY SEEKING; PROMOTER REGION; INCENTIVE-SENSITIZATION;
   REPEAT POLYMORPHISM; ASSOCIATION; ATTENTION; METAANALYSIS
AB Smokers of European ancestry (n 720) who participated in a double-blind, randomised, placebo-controlled trial of transdermal nicotine replacement therapy, were genotyped for two functional polymorphisms ( variable number of tandem repeats ( VNTR) and a C to T transition at position -521 (C-521T)) in the dopamine D4 receptor gene (DRD4) gene. Logistic regression models of abstinence at 12- and 26-week follow- ups were carried out separately for each polymorphism. For the DRD4 VNTR models, the main effect of treatment was significant at both 12-week ( P = 0.001)and 26-week (P = 0.006) follow- ups, indicating an increased likelihood of successful cessation on active nicotine replacement therapy transdermal patch relative to placebo. The main effect of DRD4 VNTR genotype was associated with abstinence at 12- week follow-up (P = 0.034), with possession of one or more copies of the long allele associated with reduced likelihood of cessation ( 17 vs 23%), but this effect was not observed at 26-week follow-up. For the DRD4 C-521T models, no main effect or interaction terms involving genotype were retained in the models at either 12- or 26-week follow-up. These data are consistent with observations from studies of the DRD2 gene that genetic variants related to relatively decreased dopaminergic tone in the mesocorticolimbic system are associated with increased risk for relapse to smoking following a cessation attempt.
C1 [David, S. P.] Brown Univ, Mem Hosp Rhode Isl, Brown Med Sch, Pawtucket, RI 02860 USA.
   [Munafo, M. R.] Univ Bristol, Dept Expt Psychol, Bristol, Avon, England.
   [Murphy, M. F. G.] Univ Oxford, Childhood Canc Res Grp, Oxford, England.
   [Proctor, M.; Walton, R. T.; Johnstone, E. C.] Univ Oxford, Dept Clin Pharmacol, Oxford, England.
   [Walton, R. T.] MRC Labs, Fajara, Gambia.
RP David, SP (reprint author), Brown Med Sch, Ctr Primary Care & Prevent, 111 Brewster St, Pawtucket, RI 02860 USA.
EM Sean_David@Brown.Edu
OI David, Sean/0000-0002-4922-2603; Munafo, Marcus/0000-0002-4049-993X
FU Cancer Research UK; NIDA NIH HHS [K08 DA014276-04, 1K08 DA14276-04, K08
   DA014276, K08 DA014276-01A2, K08 DA014276-02, K08 DA014276-03, K08
   DA014276-05]
CR ASGHARI V, 1994, MOL PHARMACOL, V46, P364
   ASGHARI V, 1995, J NEUROCHEM, V65, P1157
   Balfour David J. K., 2002, Current Drug Targets - CNS and Neurological Disorders, V1, P413, DOI 10.2174/1568007023339076
   Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81
   BENWELL MEM, 1992, BRIT J PHARMACOL, V105, P849
   Brody AL, 2004, AM J PSYCHIAT, V161, P1211, DOI 10.1176/appi.ajp.161.7.1211
   BURKE P, 1994, BRIT MED J, V308, P1476
   BURKE P, 1993, BRIT MED J, V306, P1304
   Comings DE, 1999, AM J MED GENET, V88, P358, DOI 10.1002/(SICI)1096-8628(19990820)88:4<358::AID-AJMG13>3.0.CO;2-G
   Comings DE, 2000, PROG BRAIN RES, V126, P325
   CORRIGALL WA, 1994, BRAIN RES, V653, P278, DOI 10.1016/0006-8993(94)90401-4
   David SP, 2005, BIOL PSYCHIAT, V58, P488, DOI 10.1016/j.biopsych.2005.04.028
   DAVID SP, 2007, IN PRESS NICOTINE TO, V9
   Di Chiara G, 2000, EUR J PHARMACOL, V393, P295, DOI 10.1016/S0014-2999(00)00122-9
   Durston S, 2005, MOL PSYCHIATR, V10, P678, DOI 10.1038/sj.mp.4001649
   Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78
   Ebstein RP, 1997, AM J MED GENET, V74, P65, DOI 10.1002/(SICI)1096-8628(19970221)74:1<65::AID-AJMG15>3.0.CO;2-P
   Epping-Jordan MP, 1998, NATURE, V393, P76
   Fan J, 2003, P NATL ACAD SCI USA, V100, P7406, DOI 10.1073/pnas.0732088100
   Faraone SV, 2001, AM J PSYCHIAT, V158, P1052, DOI 10.1176/appi.ajp.158.7.1052
   GELERNTER J, 1992, GENOMICS, V13, P208, DOI 10.1016/0888-7543(92)90222-E
   Gelernter J, 1997, AM J HUM GENET, V61, P1144, DOI 10.1086/301595
   Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642
   Heath A C, 1993, J Subst Abuse, V5, P221, DOI 10.1016/0899-3289(93)90065-J
   Hutchison KE, 2002, J ABNORM PSYCHOL, V111, P134, DOI 10.1037//0021-843X.111.1.134
   Hutchison KE, 2002, HEALTH PSYCHOL, V21, P139, DOI 10.1037//0278-6133.21.2.139
   Johnstone EC, 2004, PHARMACOGENETICS, V14, P83, DOI 10.1097/01.fpc.0000054154.92680.6d
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   LaHoste GJ, 1996, MOL PSYCHIATR, V1, P121
   Lerman C, 2003, HEALTH PSYCHOL, V22, P541, DOI 10.1037/0278-6133.22.5.541
   Lerman C, 2006, NEUROPSYCHOPHARMACOL, V31, P231
   Lerman C, 1998, HEALTH PSYCHOL, V17, P56, DOI 10.1037/0278-6133.17.1.56
   Lerman C, 2002, ONCOGENE, V21, P7412, DOI 10.1038/sj.onc.1205801
   Li MD, 2003, ADDICTION, V98, P23, DOI 10.1046/j.1360-0443.2003.00295.x
   LICHTER JB, 1993, HUM MOL GENET, V2, P767, DOI 10.1093/hmg/2.6.767
   Madden PAF, 1999, BEHAV GENET, V29, P423, DOI 10.1023/A:1021674804714
   Malhotra AK, 1996, MOL PSYCHIATR, V1, P388
   McClernon FJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1940, DOI 10.1038/sj.npp.1300780
   Mill JS, 2002, MOL PSYCHIATR, V7, P383, DOI 10.1038/sj/mp/4000984
   Mitsuyasu H, 2001, J HUM GENET, V46, P26, DOI 10.1007/s100380170120
   MITSUYASU H, 2006, J PSYCHIAT RES
   Muglia P, 2000, AM J MED GENET, V96, P273, DOI 10.1002/1096-8628(20000612)96:3<273::AID-AJMG7>3.0.CO;2-Z
   Munafo MR, 2003, MOL PSYCHIATR, V8, P471, DOI 10.1038/sj.mp.4001326
   Munafo MR, 2004, NICOTINE TOB RES, V6, P583, DOI 10.1080/14622200410001734030
   Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039
   Okuyama Y, 1999, BIOCHEM BIOPH RES CO, V258, P292, DOI 10.1006/bbrc.1999.0630
   Ono Y, 1997, AM J MED GENET, V74, P501, DOI 10.1002/(SICI)1096-8628(19970919)74:5<501::AID-AJMG9>3.3.CO;2-Y
   Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323
   Peto R, 1996, BRIT MED BULL, V52, P12
   Rivera A, 2002, J NEUROCHEM, V80, P219, DOI 10.1046/j.0022-3042.2001.00702.x
   Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Ronai Z, 2001, ELECTROPHORESIS, V22, P1102, DOI 10.1002/1522-2683()22:6<1102::AID-ELPS1102>3.0.CO;2-3
   Ronai Z, 2001, MOL PSYCHIATR, V6, P35, DOI 10.1038/sj.mp.4000832
   Rowe DC, 1998, MOL PSYCHIATR, V3, P419, DOI 10.1038/sj.mp.4000432
   Sander T, 1997, AM J MED GENET, V74, P483, DOI 10.1002/(SICI)1096-8628(19970919)74:5<483::AID-AJMG5>3.0.CO;2-P
   Shao CH, 2006, PSYCHOPHARMACOLOGY, V186, P185, DOI 10.1007/s00213-006-0375-6
   Shields PG, 1998, CANCER EPIDEM BIOMAR, V7, P453
   Sobik L, 2005, APPETITE, V44, P253, DOI 10.1016/j.appet.2004.12.001
   Swan GE, 2005, PHARMACOGENOMICS J, V5, P21, DOI 10.1038/sj.tpj.6500281
   Swanson JM, 1998, MOL PSYCHIATR, V3, P38, DOI 10.1038/sj.mp.4000354
   True WR, 1997, ADDICTION, V92, P1277, DOI 10.1111/j.1360-0443.1997.tb02847.x
   VANTOL HHM, 1992, NATURE, V358, P149
   VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0
   Yudkin P, 2004, BRIT MED J, V328, P989, DOI 10.1136/bmj.38050.674826.AE
   Yudkin P, 2003, BRIT MED J, V327, P28, DOI 10.1136/bmj.327.7405.28
NR 66
TC 45
Z9 46
U1 2
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1470-269X
J9 PHARMACOGENOMICS J
JI Pharmacogenomics J.
PD APR
PY 2008
VL 8
IS 2
BP 122
EP 128
DI 10.1038/sj.tpj.6500447
PG 7
WC Genetics & Heredity; Pharmacology & Pharmacy
SC Genetics & Heredity; Pharmacology & Pharmacy
GA 276EK
UT WOS:000254123900006
PM 17387332
OA No
DA 2017-08-15
ER

PT J
AU Garton, NJ
   Waddell, SJ
   Sherratt, AL
   Lee, SM
   Smith, RJ
   Senner, C
   Hinds, J
   Rajakumar, K
   Adegbola, RA
   Besra, GS
   Butcher, PD
   Barer, MR
AF Garton, Natalie J.
   Waddell, Simon J.
   Sherratt, Anna L.
   Lee, Su-Min
   Smith, Rebecca J.
   Senner, Claire
   Hinds, Jason
   Rajakumar, Kumar
   Adegbola, Richard A.
   Besra, Gurdyal S.
   Butcher, Philip D.
   Barer, Michael R.
TI Cytological and transcript analyses reveal fat and lazy persister-like
   bacilli in tuberculous sputum
SO PLOS MEDICINE
LA English
DT Article
ID CHRONICALLY INFECTED MICE; COMPLETE GENOME SEQUENCE;
   MYCOBACTERIUM-TUBERCULOSIS; GENE-EXPRESSION; STATIONARY-PHASE;
   MICROARRAY ANALYSIS; IN-VITRO; NONREPLICATING PERSISTENCE; DIFFERENTIAL
   EXPRESSION; MESSENGER-RNA
AB Background
   Tuberculous sputum provides a sample of bacilli that must be eliminated by chemotherapy and that may go on to transmit infection. A preliminary observation that Mycobacterium tuberculosis cells contain triacylglycerol lipid bodies in sputum, but not when growing in vitro, led us to investigate the extent of this phenomenon and its physiological basis.
   Methods and Findings
   Microscopy-positive sputum samples from the UK and The Gambia were investigated for their content of lipid body-positive mycobacteria by combined Nile red and auramine staining. All samples contained a lipid body-positive population varying from 3% to 86% of the acid-fast bacilli present. The recent finding that triacylglycerol synthase is expressed by mycobacteria when they enter in vitro nonreplicating persistence led us to investigate whether this state was also associated with lipid body formation. We found that, when placed in laboratory conditions inducing nonreplicating persistence, two M. tuberculosis strains had lipid body levels comparable to those found in sputum. We investigated these physiological findings further by comparing the M. tuberculosis transcriptome of growing and nonreplicating persistence cultures with that obtained directly from sputum samples. Although sputum has traditionally been thought to contain actively growing tubercle bacilli, our transcript analyses refute the hypothesis that these cells predominate. Rather, they reinforce the results of the lipid body analyses by revealing transcriptional signatures that can be clearly attributed to slowly replicating or nonreplicating mycobacteria. Finally, the lipid body count was highly correlated (R(2) = 0.64, p < 0.03) with time to positivity in diagnostic liquid cultures, thereby establishing a direct link between this cytological feature and the size of a potential nonreplicating population.
   Conclusion
   As nonreplicating tubercle bacilli are tolerant to the cidal action of antibiotics and resistant to multiple stresses, identification of this persister-like population of tubercle bacilli in sputum presents exciting and tractable new opportunities to investigate both responses to chemotherapy and the transmission of tuberculosis.
C1 [Waddell, Simon J.; Senner, Claire; Hinds, Jason; Butcher, Philip D.] St Georges Univ London, Div Cellular & Mol Med, London, England.
   [Garton, Natalie J.; Sherratt, Anna L.; Lee, Su-Min; Smith, Rebecca J.; Rajakumar, Kumar; Barer, Michael R.] Univ Leicester, Sch Med, Dept Infect Immun & Inflammat, Leicester, Leics, England.
   [Rajakumar, Kumar; Barer, Michael R.] Univ Hosp Leicester Natl Hlth Serv Trust, Dept Clin Microbiol, Leicester, Leics, England.
   [Adegbola, Richard A.] MRC Labs, Banjul, Gambia.
   [Besra, Gurdyal S.] Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England.
RP Butcher, PD (reprint author), St Georges Univ London, Div Cellular & Mol Med, London, England.
EM butcherp@sgul.ac.uk; mrb19@le.ac.uk
RI Waddell, Simon/A-9170-2013
OI Waddell, Simon/0000-0002-3684-9116; Besra, Gurdyal/0000-0002-5605-0395;
   Lee, Su-Min/0000-0002-2687-7826
FU Medical Research Council [, G0200510, G0501435]; NIAID NIH HHS
   [HHSN266200400091C, N01AI40091]; Wellcome Trust [, 080039]
CR Alvarez HM, 2004, FEMS MICROBIOL ECOL, V50, P75, DOI 10.1016/j.femsec.2004.06.002
   Bacon J, 2004, TUBERCULOSIS, V84, P205, DOI 10.1016/j.tube.2003.12.011
   Beste DJV, 2007, J BACTERIOL, V189, P3969, DOI 10.1128/JB.01787-06
   Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x
   Canetti G., 1955, TUBERCLE BACILLUS, P29
   Cole ST, 1998, NATURE, V393, P537
   Connolly LE, 2007, PLOS MED, V4, P435, DOI 10.1371/journal.pmed.0040120
   Conway T, 2003, MOL MICROBIOL, V47, P879, DOI 10.1046/j.1365-2958.2003.03338.x
   Daniel J, 2004, J BACTERIOL, V186, P5017, DOI 10.1128/jb.186.15.5017-5030.2004
   Daugelat S, 2003, MICROBES INFECT, V5, P1082, DOI 10.1016/S1286-4579(03)00205-3
   Desjardin LE, 1999, AM J RESP CRIT CARE, V160, P203
   Dhar N, 2007, CURR OPIN MICROBIOL, V10, P30, DOI 10.1016/j.mib.2006.12.007
   Dubnau E, 2002, INFECT IMMUN, V70, P2787, DOI 10.1128/IAI.70.6.2787-2795.2002
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Fenhalls G, 2002, INFECT IMMUN, V70, P6330, DOI 10.1128/IAI.70.11.6330-6338.2002
   Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002
   Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100
   Garton NJ, 2002, MICROBIOL-SGM, V148, P2951
   Gomez JE, 2004, TUBERCULOSIS, V84, P29, DOI 10.1016/j.tube.2003.08.003
   Kalscheuer R, 2003, J BIOL CHEM, V278, P8075, DOI 10.1047/jbc.M210533200
   Karakousis PC, 2004, J EXP MED, V200, P647, DOI 10.1084/jem.20040646
   Kendall SL, 2007, MOL MICROBIOL, V65, P684, DOI 10.1111/j.1365-2958.2007.05827.x
   KOLTER R, 1993, ANNU REV MICROBIOL, V47, P855, DOI 10.1146/annurev.micro.47.1.855
   Kumar A, 2007, P NATL ACAD SCI USA, V104, P11568, DOI 10.1073/pnas.0705054104
   LARSEN MH, 2000, MOL GENETICS MYCOBAC, P216
   Levin BR, 2006, NAT REV MICROBIOL, V4, P556, DOI 10.1038/nrmicro1445
   Mangan JA, 2002, METHOD MICROBIOL, V33, P137
   Manganelli R, 1999, MOL MICROBIOL, V31, P715, DOI 10.1046/j.1365-2958.1999.01212.x
   McKinney JD, 2000, NATURE, V406, P735, DOI 10.1038/35021074
   MITCHISON DA, 1979, CHEST, V76, P771, DOI 10.1378/chest.76.6_Supplement.771
   Mitchison DA, 2004, FRONT BIOSCI, V9, P1059, DOI 10.2741/1293
   MONAHAN IM, 2001, MYCOBACTERIUM TUBERC, P31
   Mukamolova GV, 2002, MOL MICROBIOL, V46, P623, DOI 10.1046/j.1365-2958.2002.03184.x
   Munoz-Elias EJ, 2005, INFECT IMMUN, V73, P546, DOI 10.1128/IAI.73.1.546-551.2005
   Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3
   Muttucumaru DGN, 2004, TUBERCULOSIS, V84, P239, DOI 10.1016/j.tube.2003.12.006
   NAKAGAWA H, 1976, J BIOCHEM-TOKYO, V80, P923
   Neyrolles O, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000043
   Paramasivan CN, 2005, ANTIMICROB AGENTS CH, V49, P627, DOI 10.1128/AAC.49.2.627-631.2005
   Park HD, 2003, MOL MICROBIOL, V48, P833, DOI 10.1046/j.1365-2958.2003.03474.x
   Rachman H, 2006, INFECT IMMUN, V74, P1233, DOI 10.1128/IAI.74.2.1223-1242.2006
   Rajakumar K, 2004, J CLIN MICROBIOL, V42, P1890, DOI 10.1128/JCM.42.5.1890-1896.2004
   Reed MB, 2007, J BACTERIOL, V189, P2583, DOI 10.1128/JB.01670-06
   Rohde KH, 2007, CELL HOST MICROBE, V2, P352, DOI 10.1016/j.chom.2007.09.006
   Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846
   Shi LB, 2005, P NATL ACAD SCI USA, V102, P15629, DOI 10.1073/pnas.0507850102
   SIEGELE DA, 1992, J BACTERIOL, V174, P345
   Sirakova TD, 2006, MICROBIOL-SGM, V152, P2717, DOI 10.1099/mic.0.28993-0
   Smeulders MJ, 1999, J BACTERIOL, V181, P270
   Sommers HM, 1985, MANUAL CLIN MICROBIO, P216
   Stewart GR, 2002, MICROBIOL-SGM, V148, P3129
   Talaat AM, 2007, J BACTERIOL, V189, P4265, DOI 10.1128/JB.00011-07
   Talaat AM, 2004, P NATL ACAD SCI USA, V101, P4602, DOI 10.1073/pnas.0306023101
   Timm J, 2003, P NATL ACAD SCI USA, V100, P14321, DOI 10.1073/pnas.2436197100
   Van der Geize R, 2007, P NATL ACAD SCI USA, V104, P1947, DOI 10.1073/pnas.0605728104
   Voskuil MI, 2004, TUBERCULOSIS, V84, P218, DOI 10.1016/j.tube.2004.02.003
   Waddell SJ, 2007, CURR MOL MED, V7, P287, DOI 10.2174/156652407780598548
   Waddell SJ, 2004, TUBERCULOSIS, V84, P263, DOI 10.1016/j.tube.2003.12.005
   WADDELL SJ, 2008, BMC GENOMICS, V9, P3528
   Waltermann M, 2005, J BACTERIOL, V187, P3607, DOI 10.1128/JB.187.11.3607-3619.2005
   Wayne LG, 1996, INFECT IMMUN, V64, P2062
   Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139
   Weichart DH, 2001, MICROBIOL-SGM, V147, P1875
   World Health Organization, 2007, GLOB TUB CONTR SURV
   Wilkinson RJ, 2001, MOL MICROBIOL, V39, P813, DOI 10.1046/j.1365-2958.2001.02280.x
   YOUNG DB, 1995, ANNU REV MICROBIOL, V49, P641
NR 66
TC 187
Z9 188
U1 4
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD APR
PY 2008
VL 5
IS 4
BP 634
EP 645
AR e75
DI 10.1371/journal.pmed.0050075
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 293XX
UT WOS:000255369800018
PM 18384229
OA gold
DA 2017-08-15
ER

PT J
AU Hennig, BJ
   Fielding, K
   Broxholme, J
   Diatta, M
   Mendy, M
   Moore, C
   Pollard, AJ
   Rayco-Solon, P
   Sirugo, G
   van der Sande, MA
   Waight, P
   Whittle, HC
   Zaman, SM
   Hill, AV
   Hall, AJ
AF Hennig, Branwen J.
   Fielding, Katherine
   Broxholme, John
   Diatta, Mathurin
   Mendy, Maimuna
   Moore, Catrin
   Pollard, Andrew J.
   Rayco-Solon, Pura
   Sirugo, Giorgio
   van der Sande, Marianne A.
   Waight, Pauline
   Whittle, Hilton C.
   Zaman, Syed M.
   Hill, Adrian V.
   Hall, Andrew J.
TI Host Genetic Factors and Vaccine-Induced Immunity to Hepatitis B Virus
   Infection
SO PLOS ONE
LA English
DT Article
AB Background: Vaccination against hepatitis B virus infection (HBV) is safe and effective; however, vaccine-induced antibody level wanes over time. Peak vaccine-induced anti-HBs level is directly related to antibody decay, as well as risk of infection and persistent carriage despite vaccination. We investigated the role of host genetic factors in long-term immunity against HBV infection based on peak anti-HBs level and seroconversion to anti-HBc.
   Methods: We analyzed 715 SNP across 133 candidate genes in 662 infant vaccinees from The Gambia, assessing peak vaccine-induced anti-HBs level and core antibody (anti-HBc) status, whilst adjusting for covariates. A replication study comprised 43 SNPs in a further 393 individuals.
   Results: In our initial screen we found variation in IFNG, MAPK8, and IL10RA to affect peak anti-HBs level (GMTratio of <0.6 or >1.5 and P <= 0.001) and lesser associations in other genes. Odds of core-conversion was associated with variation in CD163. A coding change in ITGAL (R719V) with likely functional relevance showed evidence of association with increased peak anti-HBs level in both screens (1st screen: s595_22 GMTratio 1.71, P = 0.013; 2nd screen: s595_22 GMTratio 2.15, P = 0.011).
   Conclusion: This is to our knowledge the largest study to date assessing genetic determinants of HBV vaccine-induced immunity. We report on associations with anti-HBs level, which is directly related to durability of antibody level and predictive of vaccine efficacy long-term. A coding change in ITGAL, which plays a central role in immune cell interaction, was shown to exert beneficial effects on induction of peak antibody level in response to HBV vaccination. Variation in this gene does not appear to have been studied in relation to immune responses to viral or vaccine challenges previously. Our findings suggest that genetic variation in loci other than the HLA region affect immunity induced by HBV vaccination.
C1 [Hennig, Branwen J.; Fielding, Katherine; Rayco-Solon, Pura; Hall, Andrew J.] London Sch Hyg & Trop Med, London WC1, England.
   [Hennig, Branwen J.; Broxholme, John; Hill, Adrian V.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Diatta, Mathurin; Mendy, Maimuna; Rayco-Solon, Pura; Sirugo, Giorgio; van der Sande, Marianne A.; Waight, Pauline; Whittle, Hilton C.; Zaman, Syed M.; Hall, Andrew J.] MRC Labs, Banjul, Gambia.
   [Moore, Catrin; Pollard, Andrew J.] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England.
RP Hennig, BJ (reprint author), London Sch Hyg & Trop Med, London WC1, England.
EM branwen.hennig@lshtm.ac.uk
RI Hennig, Branwen/M-6444-2014
FU Wellcome Trust Advanced Training Fellowship
FX B.J.H. was supported by a Wellcome Trust Advanced Training Fellowship.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR ALPER CA, 1995, EXP CLIN IMMUNOGENET, V12, P171
   Arbour N, 2002, J EXP MED, V195, P801, DOI 10.1084/jem.20011481
   CHOTARD J, 1992, J INFECT DIS, V166, P764
   De Silvestri A, 2001, GENES IMMUN, V2, P367, DOI 10.1038/sj.gene.6363792
   DESOMBERE I, 1995, J IMMUNOL, V154, P520
   Desombere I, 2005, CLIN EXP IMMUNOL, V140, P126, DOI 10.1111/j.1365-2249.2005.02749.x
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   FORTUIN M, 1994, J INFECT DIS, V169, P1374
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   HATAE K, 1992, EUR J IMMUNOL, V22, P1899, DOI 10.1002/eji.1830220733
   Hiraoka A, 2005, PATHOL RES PRACT, V201, P379, DOI 10.1016/j.prp.2004.10.006
   Hohler T, 2005, HEPATOLOGY, V42, P72, DOI 10.1002/hep.20740
   Hohler T, 2002, J HEPATOL, V37, P387, DOI 10.1016/S0168-8278(02)00205-2
   Hohler T, 2002, LANCET, V360, P991, DOI 10.1016/S0140-6736(02)11083-X
   Hohler T, 1998, HUM IMMUNOL, V59, P212, DOI 10.1016/S0198-8859(98)00014-7
   INSKIP HM, 1991, INT J EPIDEMIOL, V20, P764, DOI 10.1093/ije/20.3.764
   Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
   Kimman TG, 2007, COMMUNITY GENET, V10, P201, DOI 10.1159/000106559
   Kruger A, 2005, CLIN EXP IMMUNOL, V140, P325, DOI 10.1111/j.1365-2249.2005.02765.x
   LIN TM, 1989, ANTICANCER RES, V9, P737
   Lindemann M, 2002, VIROLOGY, V297, P245, DOI 10.1006/viro.2002.1467
   Lindemann M, 2001, FEBS LETT, V495, P82, DOI 10.1016/S0014-5793(01)02339-0
   LOUAGIE H, 1993, VACCINE, V11, P1188, DOI 10.1016/0264-410X(93)90041-U
   Martinetti M, 2000, CLIN IMMUNOL, V97, P234, DOI 10.1006/clim.2000.4933
   McDermott AB, 1997, TISSUE ANTIGENS, V50, P8, DOI 10.1111/j.1399-0039.1997.tb02827.x
   Milich DR, 2003, AUTOIMMUN REV, V2, P248, DOI 10.1016/S1568-9972(03)00031-4
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Newport MJ, 2004, GENES IMMUN, V5, P122, DOI 10.1038/sj.gene.6364051
   Ovsyannikova IG, 2004, PHARMACOGENOMICS, V5, P417, DOI 10.1517/14622416.5.4.417
   Sleijffers A, 2003, J IMMUNOL, V170, P3423
   Sullivan JS, 1999, J PAEDIATR CHILD H, V35, P412
   SUN ZT, 1991, CANCER DETECT PREV, V15, P313
   Tabor HK, 2002, NAT REV GENET, V3, P391, DOI 10.1038/nrg796
   Thursz M, 2001, QJM-MON J ASSOC PHYS, V94, P287, DOI 10.1093/qjmed/94.6.287
   van der Sande MAB, 2006, J INFECT DIS, V193, P1528
   van der Sande MAB, 2007, PLOS ONE, V2, pe753
   Vanlandschoot P, 2002, BIOCHEM BIOPH RES CO, V297, P486, DOI 10.1016/S0006-291X(02)02243-X
   Vidan-Jeras B, 2000, PFLUG ARCH EUR J PHY, V440, pR188, DOI 10.1007/s004240000059
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   Wang CB, 2004, HEPATOLOGY, V39, P978, DOI 10.1002/hep.20142
   Weaver LK, 2007, J LEUKOCYTE BIOL, V81, P663, DOI 10.1189/jlb.0706428
   Whittle H, 2002, BRIT MED J, V325, P569, DOI 10.1136/bmj.325.7364.569
   WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4
   WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6
   WHITTLE HC, 1983, LANCET, V1, P1203
   WHO, 2000, HEP B FACT SHEET
   Yang SH, 2006, GENE THER, V13, P1110, DOI 10.1038/sj.gt.3302751
   Yucesoy B, 2002, VACCINE, V20, P3193, DOI 10.1016/S0264-410X(02)00267-0
NR 48
TC 46
Z9 48
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 26
PY 2008
VL 3
IS 3
AR e1898
DI 10.1371/journal.pone.0001898
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 370KZ
UT WOS:000260762400036
PM 18365030
OA gold
DA 2017-08-15
ER

PT J
AU Hill, PC
   Cheung, YB
   Akisanya, A
   Sankareh, K
   Lahai, G
   Greenwood, BM
   Adegbola, RA
AF Hill, Philip C.
   Cheung, Yin Bun
   Akisanya, Abiodun
   Sankareh, Kawsu
   Lahai, George
   Greenwood, Brian M.
   Adegbola, Richard A.
TI Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants:
   A longitudinal study
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; 1ST 2 YEARS; INVASIVE DISEASE;
   UNITED-STATES; CHILDREN; EPIDEMIOLOGY; EFFICACY; TRIAL; LIFE;
   ACQUISITION
AB Background. To prepare for national introduction of a pneumococcal conjugate vaccine of restricted valency, we studied nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants.
   Methods. We studied 236 infants in 21 villages. We collected nasopharyngeal swab samples at birth, twice per month for 6 months, and every second month until 1 year of age. We studied time to acquisition and duration of pneumococcal carriage according to serotype.
   Results. All infants carried S. pneumoniae at some point. Sixty-five serotypes were found, and the 5 most common serotypes (6B, 19F, 6A, 14, and 23F) accounted for 51% of isolates. The mean age at first acquisition of carriage was 33 days (95% confidence interval, 29 -36 days). There were no significant differences in acquisition rates between the 6 most common serotypes (P = .067) or between vaccine serotypes, vaccine-related serotypes, or nonvaccine serotypes (P = .317). However, the duration of carriage differed significantly between the 6 most common serotypes (P = .004). The rate of reacquisition of carriage and the duration of carriage did not differ significantly between the 6 most common serotypes (P = .229 and P = .699 respectively). However, nonvaccine types were acquired faster (P = .004) and were carried for a shorter duration (P < .001) than were vaccine serotypes. A previous episode of serotype 14 carriage was associated with delayed reacquisition of this serotype (P = .005) and longer duration of carriage (P = .017).
   Conclusions. The data provided in this study regarding time to acquisition and duration of pneumococcal carriage in Gambian infants provide an important baseline for evaluating the impact of the introduction of a pneumococcal conjugate vaccine in The Gambia and elsewhere in Africa.
C1 [Hill, Philip C.; Akisanya, Abiodun; Sankareh, Kawsu; Lahai, George; Adegbola, Richard A.] MRC Labs, Bacterial Dis Program, Banjul, Gambia.
   [Cheung, Yin Bun; Greenwood, Brian M.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Hill, PC (reprint author), MRC Labs, Bacterial Dis Program, Box 273, Banjul, Gambia.
EM pandmhill@hotmail.com
CR Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Albrich WC, 2007, CLIN INFECT DIS, V44, P1569, DOI 10.1086/517149
   Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003
   Byington CL, 2005, CLIN INFECT DIS, V41, P21, DOI 10.1086/430604
   Cheung YB, 2003, J CLIN EPIDEMIOL, V56, P38, DOI 10.1016/S0895-4356(02)00536-X
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Ekdahl K, 1997, CLIN INFECT DIS, V25, P1113, DOI 10.1086/516103
   Ghaffar F, 2004, CLIN INFECT DIS, V39, P930, DOI 10.1086/423379
   Gonzalez BE, 2006, PEDIATR INFECT DIS J, V25, P301, DOI 10.1097/01.inf.0000207484.52850.38
   Granat SM, 2007, PEDIATR INFECT DIS J, V26, P319, DOI 10.1097/01.inf.0000257425.24492.11
   GRAY BM, 1980, J INFECT DIS, V142, P923
   Hausdorff WP, 2000, CLIN INFECT DIS, V30, P122, DOI 10.1086/313609
   Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941
   KALEIDA PH, 1993, J CLIN MICROBIOL, V31, P2674
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Leino T, 2001, PEDIATR INFECT DIS J, V20, P1022, DOI 10.1097/00006454-200111000-00004
   Leowski J, 1986, World Health Stat Q, V39, P138
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   MONTGOMERY JM, 1990, REV INFECT DIS, V12, pS1006
   O'Brien KL, 2003, LANCET, V362, P355, DOI 10.1016/S0140-6736(03)14022-6
   O'Brien K, 2003, PEDIATR INFECT DIS J, V22, P1
   Pelton SI, 2007, PEDIATR INFECT DIS J, V26, P468, DOI 10.1097/TNF.0b013e31803df9ca
   Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729
   Scott JAG, 1996, CLIN INFECT DIS, V22, P973
   Singleton RJ, 2007, JAMA-J AM MED ASSOC, V297, P1784, DOI 10.1001/jama.297.16.1784
   Sleeman KL, 2006, J INFECT DIS, V194, P682, DOI 10.1086/505710
   Sleeman KL, 2005, PEDIATR INFECT DIS J, V24, P121, DOI 10.1097/01.inf.0000151030.10159.b1
   Syrjanen RK, 2001, J INFECT DIS, V184, P451, DOI 10.1086/322048
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
NR 30
TC 92
Z9 93
U1 0
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD MAR 15
PY 2008
VL 46
IS 6
BP 807
EP 814
DI 10.1086/528688
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 266RD
UT WOS:000253453800004
PM 18279039
OA No
DA 2017-08-15
ER

PT J
AU Morris, GAJ
   Ikumapayi, UN
   Antonio, M
   Howie, SRC
   Adegbola, RA
AF Morris, Gerard A. J.
   Ikumapayi, Usman N.
   Antonio, Martin
   Howie, Stephen R. C.
   Adegbola, Richard A.
TI A Novel Campylobacter jejuni Sequence Type from a Culture-Negative
   Patient in The Gambia
SO PLOS ONE
LA English
DT Article
AB The introduction of molecular diagnostic methods is crucial for improved understanding of the aetiology and epidemiology of bacterial infections in communities in resource poor settings. A blood sample from a 7 month old patient diagnosed with malaria in 2001 in a Gambian outpatient clinic was reported as culture negative after it was subjected to traditional bacterial culture protocols. We re-addressed the analysis of the blood sample from this case more recently (after 6.5 years in archival storage) in pilot work establishing 16S rRNA PCR in our molecular laboratory. Initial 16S rRNA PCR results confirmed the presence of bacterial DNA in the sample. 16S rRNA sequence analysis identified the organism as Campylobacter spp. In light of the molecular evidence we successfully grew the organism using appropriate culture conditions and subsequently biochemically confirmed that the isolate was Campylobacter jejuni. PCR and DNA sequencing of a set of seven C. jejuni housekeeping genes and in silico Multilocus Sequence Typing (MLST) analysis revealed that the isolate exhibits a novel sequence type (ST) of C. jejuni (ST 2928) and belongs to ST-443 clonal complex. This study demonstrates the potential for molecular tools to enhance the diagnosis of bacterial infections, which remain a major killer globally, not least in children in the developing world. Improvements in diagnostics are needed, and will be important not only for sick individuals but also for populations, where better measures of disease burden will contribute significantly to the improvement of public health policy.
C1 [Morris, Gerard A. J.; Ikumapayi, Usman N.; Antonio, Martin; Howie, Stephen R. C.; Adegbola, Richard A.] MRC Labs, Bacterial Dis Programme, Fajara, Gambia.
RP Morris, GAJ (reprint author), MRC Labs, Bacterial Dis Programme, Fajara, Gambia.
EM gmorris@mrc.gm
FU Medical Research Council United Kingdom
FX The study was mainly supported by funding from Medical Research Council
   United Kingdom. The MRC UK was not directly involved in the design and
   conduct of the study, in the collection, analysis, and interpretation of
   the data, nor in the preparation, review, or approval of the manuscript.
CR BLASER MJ, 1995, MANDELL DOUGLAS BENN
   Butzler JP, 2004, CLIN MICROBIOL INFEC, V10, P868, DOI 10.1111/j.1469-0691.2004.00983.x
   Clarridge JE, 2004, CLIN MICROBIOL REV, V17, P840, DOI 10.1128/CMR.17.4.840-862.2004
   Coker AO, 2002, EMERG INFECT DIS, V8, P237
   Colles FM, 2003, APPL ENVIRON MICROB, V69, P7409, DOI 10.1128/AEM.69.12.7409-7413.2003
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dingle KE, 2001, J CLIN MICROBIOL, V39, P14, DOI 10.1128/JCM.39.1.14-23.2001
   Dingle KE, 2002, EMERG INFECT DIS, V8, P949
   Duim B, 2003, J CLIN MICROBIOL, V41, P5593, DOI 10.1128/JCM.41.12.5593-5597.2003
   Fenollar F, 2007, INT J ANTIMICROB AG, V30, pS7, DOI 10.1016/j.ijantimicag.2007.06.024
   Manning G, 2003, APPL ENVIRON MICROB, V69, P6370, DOI 10.1128/AEM.69.11.6370-6379.2003
   McLaughlin RW, 2002, J CLIN MICROBIOL, V40, P4771, DOI 10.1128/JCM.40.12.4771-4775.2002
   Miller RL, 2007, AM J EVAL, V28, P7, DOI 10.1177/1098214006298057
   MULHOLLAND EK, 2005, NEW ENGL J MED, V352, P39
   Nachamkin I, 1998, CLIN MICROBIOL REV, V11, P555
   Nadkarni MA, 2002, MICROBIOL-SGM, V148, P257
   Nikkari S, 2001, J CLIN MICROBIOL, V39, P1956, DOI 10.1128/JCM.39.5.1956-1959.2001
   ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y
   Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088
   Peters RPH, 2004, LANCET INFECT DIS, V4, P751, DOI 10.1016/S1473-3099(04)01205-8
   Petti CA, 2007, CLIN INFECT DIS, V44, P1108, DOI 10.1086/512818
   Rao MR, 2001, AM J EPIDEMIOL, V154, P166, DOI 10.1093/aje/154.2.166
   Scott JAG, 1999, CHEST, V116, P1716, DOI 10.1378/chest.116.6.1716
   Wassenaar TM, 2000, APPL ENVIRON MICROB, V66, P1
   Young KT, 2007, NAT REV MICROBIOL, V5, P665, DOI 10.1038/nrmicro1718
NR 25
TC 4
Z9 4
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 12
PY 2008
VL 3
IS 3
AR e1773
DI 10.1371/journal.pone.0001773
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 369VW
UT WOS:000260723000026
PM 18335047
OA gold
DA 2017-08-15
ER

PT J
AU Wootton, DG
   Opara, H
   Biagini, GA
   Kanjala, MK
   Duparc, S
   Kirby, PL
   Woessner, M
   Neate, C
   Nyirenda, M
   Blencowe, H
   Dube-Mbeye, Q
   Kanyok, T
   Ward, S
   Molyneux, M
   Dunyo, S
   Winstanley, PA
AF Wootton, Daniel G.
   Opara, Hyginus
   Biagini, Giancarlo A.
   Kanjala, Maxwell K.
   Duparc, Stephan
   Kirby, Paula L.
   Woessner, Mary
   Neate, Colin
   Nyirenda, Maggie
   Blencowe, Hannah
   Dube-Mbeye, Queen
   Kanyok, Thomas
   Ward, Stephen
   Molyneux, Malcolm
   Dunyo, Sam
   Winstanley, Peter A.
TI Open-Label Comparative Clinical Study of Chlorproguanil-Dapsone Fixed
   Dose Combination (Lapdap (TM)) Alone or with Three Different Doses of
   Artesunate for Uncomplicated Plasmodium falciparum Malaria
SO PLOS ONE
LA English
DT Article
AB The objective of this study was to determine the appropriate dose of artesunate for use in a fixed dose combination therapy with chlorproguanil-dapsone (CPG-DDS) for the treatment of uncomplicated falciparum malaria. Methods: Open-label clinical trial comparing CPG-DDS alone or with artesunate 4, 2, or 1 mg/kg at medical centers in Blantyre, Malawi and Farafenni, The Gambia. The trial was conducted between June 2002 and February 2005, including 116 adults (median age 27 years) and 107 children (median age 38 months) with acute uncomplicated Plasmodium falciparum malaria. Subjects were randomized into 4 groups to receive CPG-DDS alone or plus 4, 2 or 1 mg/kg of artesunate once daily for 3 days. Assessments took place on Days 023 in hospital and follow-up on Days 7 and 14 as out-patients. Efficacy was evaluated in the Day 3 per-protocol (PP) population using mean time to reduce baseline parasitemia by 90% (PC90). A number of secondary outcomes were also included. Appropriate artesunate dose was determined using a pre-defined decision matrix based on primary and secondary outcomes. Treatment emergent adverse events were recorded from clinical assessments and blood parameters. Safety was evaluated in the intent to treat (ITT) population.
   Results: In the Day 3 PP population for the adult group (N = 85), mean time to PC90 was 19.1 h in the CPG-DDS group, significantly longer than for the + artesunate 1 mg/kg (12.5 h; treatment difference -6.6 h [95% CI -11.8, -1.5]), 2 mg/kg (10.7 h; -8.4 h [95% CI -13.6, -3.2]) and 4 mg/kg (10.3 h; -8.7 h [95% CI -14.1, -3.2]) groups. For children in the Day 3 PP population (N = 92), mean time to PC90 was 21.1 h in the CPG-DDS group, similar to the + artesunate 1 mg/kg group (17.7 h; -3.3 h [95% CI -8.6, 2.0]), though the + artesunate 2 mg/kg and 4 mg/kg groups had significantly shorter mean times to PC90 versus CPG-DDS; 14.4 h (treatment difference 26.4 h [95% CI -11.7, -1.0]) and 12.8 h (-7.4 h [ 95% CI -12.9, -1.8]), respectively. An analysis of mean time to PC90 for the Day 14 PP and ITT populations was consistent with the primary analysis. Treatment emergent, drug-related adverse events were experienced in 35.3% (41/116) of adults and 70.1% (75/107) of children; mostly hematological and gastroenterological. The nature and incidence of adverse events was similar between the groups. No dose-related changes in laboratory parameters were observed. Nine serious adverse events due to any cause occurred in five subjects including two cases of hemolysis believed to be associated with drug treatment (one adult, one child). One adult died of anaphylactic shock, not associated with investigational therapy.
   Conclusions: CP-DDS plus artesunate demonstrated advantages over CPG-DDS alone for the primary efficacy endpoint (mean time to PC90) except in children for the 1 mg/kg artesunate dose. Based on a pre-defined decision matrix, the primary endpoint in the child group supported an artesunate dose of 4 mg/kg. Secondary endpoints also supported a 4 mg/kg artesunate dose to take forward into the remainder of the development program.
C1 [Wootton, Daniel G.; Winstanley, Peter A.] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England.
   [Wootton, Daniel G.; Kanjala, Maxwell K.; Molyneux, Malcolm] Coll Med, Malawi Liverpool Wellcome Trust, Major Overseas Programme, Blantyre, Malawi.
   [Opara, Hyginus; Dunyo, Sam] MRC Labs, Banjul, Gambia.
   [Biagini, Giancarlo A.; Ward, Stephen; Molyneux, Malcolm] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England.
   [Duparc, Stephan; Kirby, Paula L.; Woessner, Mary; Neate, Colin] GlaxoSmithKline Inc, Greenford, Middx, England.
   [Nyirenda, Maggie; Blencowe, Hannah; Dube-Mbeye, Queen] Coll Med, Dept Paediat, Blantyre, Malawi.
   [Kanyok, Thomas] Bill & Melinda Gates Fdn, Global Hlth Infect Dis, Seattle, WA USA.
RP Wootton, DG (reprint author), Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England.
EM p.a.winstanley@liverpool.ac.uk
RI Blencowe, Hannah/K-7415-2012; Biagini, Giancarlo/F-3449-2011; Ward,
   Steve/G-6003-2015
OI Biagini, Giancarlo/0000-0001-6356-6595; Ward, Steve/0000-0003-2331-3192
FU UK government Department for International Development; Liverpool School
   of Tropical Medicine, Liverpool University; London School of Hygiene and
   Tropical Medicine
FX The development of chlorproguanil-dapsone-artesunate fixed dose
   combination is by public-private partnership and was commissioned by the
   Medicines for Malaria Venture. A development agreement was made between
   the UNICEF-United Nations Development Programme-World Bank-World Health
   Organization Special Programme for Research and Training in Tropical
   Medicine and GlaxoSmithKline PLC. The UK government Department for
   International Development supplied some initial funding to the project.
   Liverpool School of Tropical Medicine, Liverpool University, and the
   London School of Hygiene and Tropical Medicine joined the joint
   development team as academic partners. A committee comprising
   representatives from all development partners developed the protocol.
CR ALIN MH, 1994, AM J TROP MED HYG, V50, P771
   Alloueche A, 2004, LANCET, V363, P1843, DOI 10.1016/S0140-6736(04)16350-2
   Angus BJ, 2002, ANTIMICROB AGENTS CH, V46, P778, DOI 10.1128/AAC.46.3.778-782.2002
   Barnes KI, 2005, PLOS MED, V2, P1123, DOI 10.1371/journal.pmed.0020330
   Borrmann S, 2003, ANTIMICROB AGENTS CH, V47, P901, DOI 10.1128/AAC.47.3.901-904.2003
   Bousema JT, 2006, J INFECT DIS, V193, P1151, DOI 10.1086/503051
   Cattamanchi A, 2003, AM J TROP MED HYG, V68, P133
   DEGOWIN RL, 1966, B WORLD HEALTH ORGAN, V35, P165
   DUTTA GP, 1989, CHEMOTHERAPY, V35, P200
   Hallett RL, 2004, ANTIMICROB AGENTS CH, V48, P3940, DOI 10.1128/AAC.48.10.3940-3943.2004
   Hyde JE, 2005, TRENDS PARASITOL, V21, P494, DOI 10.1016/j.pt.2005.08.020
   *JOINT UN PROGR HI, 2006, REP GLOB AIDS EP 200
   Laufer MK, 2006, J INFECT DIS, V193, P872, DOI 10.1086/500245
   MURPHY S, 1995, AM J TROP MED HYG, V53, P303
   Nzila AM, 2000, J INFECT DIS, V181, P2023, DOI 10.1086/315520
   Price R, 1999, AM J TROP MED HYG, V60, P547
   Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9
   Price RN, 1997, T ROY SOC TROP MED H, V91, P574, DOI 10.1016/S0035-9203(97)90032-8
   Schwarz NG, 2005, AM J TROP MED HYG, V73, P705
   Sulo J, 2002, LANCET, V360, P1136, DOI 10.1016/S0140-6736(02)11198-6
   van Vugt M, 2000, T ROY SOC TROP MED H, V94, P545, DOI 10.1016/S0035-9203(00)90082-8
   *WHO, 2005, WORLD MAL REP WHO
   WHO, 2003, ASS MON ANT DRUG EFF
   WHO, 2002, MON ANT DRUG RES REP
   WHO, 2004, POS PAP WHO ROLL BAC
   World Health Organization, 2004, REV SAF CHLORPR DAPS
   Winstanley P, 2001, TROP MED INT HEALTH, V6, P952, DOI 10.1046/j.1365-3156.2001.00751.x
NR 27
TC 15
Z9 15
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 5
PY 2008
VL 3
IS 3
AR e1779
DI 10.1371/journal.pone.0001779
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 367XT
UT WOS:000260586600042
PM 18320064
OA gold
DA 2017-08-15
ER

PT J
AU Miles, DJC
   van der Sande, M
   Kaye, S
   Crozier, S
   Ojuola, O
   Palmero, MS
   Sanneh, M
   Touray, ES
   Waight, P
   Rowland-Jones, S
   Whittle, H
   Marchant, A
AF Miles, David J. C.
   van der Sande, Marianne
   Kaye, Steve
   Crozier, Sarah
   Ojuola, Olubukola
   Palmero, Melba S.
   Sanneh, Mariama
   Touray, Ebrima S.
   Waight, Pauline
   Rowland-Jones, Sarah
   Whittle, Hilton
   Marchant, Arnaud
TI CD4(+) T cell responses to cytomegalovirus in early life: A prospective
   birth cohort study
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID INFECTION; DIFFERENTIATION; ACQUISITION; EXPRESSION; IMMUNITY; MEMORY;
   VIRUS; CMV
AB We compared cytomegalovirus (CMV)-specific interferon-gamma (IFN-gamma), interleukin 2 (IL-2), and CD154 CD4(+) T cell responses of infants to those from chronically infected adults and from children aged 4-5 years. Magnitudes of the responses were similar, although coexpression of IFN-gamma plus CD154 occurred more than coexpression of IFN-gamma plus IL-2 or IL-2 plus CD154. Responses remained constant during infancy, although the proportion of IFN-gamma-producing cells increased from infancy to adulthood. Most responding cells in infants were undifferentiated (i.e., CD27(+)CD28(+)), although IFN-gamma-producing cells were disproportionately CD27(-). By 12 months after diagnosis, viremia was rarely detectable, indicating that CMV was controlled despite the slow development of CMV-specific CD4(+) T cell responses.
C1 [Miles, David J. C.; Crozier, Sarah; Palmero, Melba S.; Sanneh, Mariama; Touray, Ebrima S.; Rowland-Jones, Sarah; Whittle, Hilton] MRC Labs Gambia, Banjul, Gambia.
   [van der Sande, Marianne] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands.
   [Kaye, Steve] Univ London Imperial Coll Sci Technol & Med, Jefferiss Trust Lab, London, England.
   [Waight, Pauline] Hlth Protect Agcy Ctr Infect, Immunisat Dept, London, England.
   [Ojuola, Olubukola] Bronx Lebanon Hosp Ctr, Dept Pediat, Bronx, NY 10456 USA.
   [Marchant, Arnaud] Univ Libre Bruxelles, Inst Med Immunol, Charleroi, Belgium.
RP Miles, DJC (reprint author), MLW Clin Res Programme, POB 30096, Blantyre 3, Malawi.
EM djcm1@liverpool.ac.uk
OI Crozier, Sarah/0000-0002-9524-1127
FU Medical Research Council [MC_U190081978, MC_U190085854]
CR Amyes E, 2005, J IMMUNOL, V175, P5765
   Casazza JP, 2006, J EXP MED, V203, P2865, DOI 10.1081/jem.20052246
   EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25
   Gamadia LE, 2003, BLOOD, V101, P2686, DOI 10.1182/blood-2002-08-2502
   HAYES K, 1987, J INFECT DIS, V156, P615
   Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI200317470
   Miles DJC, 2007, J VIROL, V81, P5766, DOI 10.1128/JVI.00052-07
   NONOYAMA S, 1995, J CLIN INVEST, V95, P66, DOI 10.1172/JCI117677
   PASS RF, 1985, J INFECT DIS, V152, P243
   Pourgheysari B, 2007, J VIROL, V81, P7759, DOI 10.1128/JVI.01262-06
   Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882
   Tu WW, 2004, J IMMUNOL, V172, P3260
   van Leeuwen EMM, 2004, J IMMUNOL, V173, P1834
   Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338
   WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603
NR 15
TC 18
Z9 21
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR 1
PY 2008
VL 197
IS 5
BP 658
EP 662
DI 10.1086/527418
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 271FD
UT WOS:000253773400007
PM 18279047
OA No
DA 2017-08-15
ER

PT J
AU Pinchbeck, GL
   Morrison, LJ
   Tait, A
   Langford, J
   Meehan, L
   Jallow, S
   Jallow, J
   Jallow, A
   Christley, RM
AF Pinchbeck, Gina L.
   Morrison, Liam J.
   Tait, Andy
   Langford, Joanna
   Meehan, Lucinda
   Jallow, Saloum
   Jallow, Jibril
   Jallow, Amadou
   Christley, Robert M.
TI Trypanosomosis in The Gambia: prevalence in working horses and donkeys
   detected by whole genome amplification and PCR, and evidence for
   interactions between trypanosome species
SO BMC VETERINARY RESEARCH
LA English
DT Article
ID TSETSE; CATTLE; VIVAX; ESTABLISHMENT; INTERFERENCE; CONGOLENSE;
   SUPERINFECTIONS; IDENTIFICATION; TRANSMISSION; SAMPLES
AB Background: The Gambia has an increasing population of equidae largely used for agriculture and transportation. A review of cases at The Gambian Horse and Donkey Trust (GHDT) indicated that a common reason for presentation is a poorly defined medical condition often attributed to trypanosomosis. There are few reports describing the prevalence or the range of clinical signs associated with infection with different species of trypanosomes in horses and donkeys, but given the importance of these animals, the role of trypanosomosis requires investigation.
   Results: In total 241 animals from the Central River Division in The Gambia (183 horses and 58 donkeys) were screened using Whole Genome Amplification (WGA) followed by trypanosome species identification using polymerase chain reaction (PCR). The results indicated overall trypanosome prevalence of 91%; with an infection rate of 31% for Trypanosoma congolense Savannah, 87% for Trypanosoma vivax and 18% for Trypanosoma brucei sp. Multiple species were present in 43% of infections. Microscopy had a good specificity (100%) and positive predictive value (100%) for trypanosome detection, but the sensitivity (20%) and negative predictive value (10.5%) were low relative to PCR-based diagnosis.
   Infection with T congolense showed the greatest negative effect on packed cell volume (PCV), while infection with T. brucei sp also had a significant, although lesser, negative effect on PCV. In addition, cases positive by microscopy were associated with significantly lower PCV. However, concurrent infection with T. vivax appeared to cause less effect on PCV, compared to animals infected with T. congolense alone.
   Conclusion: The prevalence of Trypanosomosis was high in both horses and donkeys. Infection with T. congolense appeared to have the greatest clinical significance, while T. vivax infection may be of limited clinical significance in this population. Indeed, there is evidence of T. vivax co-infection ameliorating the pathology caused by T. congolense. WGA and PCR allowed a more comprehensive analysis of field infections with the detection of infections below the threshold of microscopy, and provided indications of interactions between parasite species that would otherwise remain undetected. The study raises important questions about the epidemiology of trypanosome infection in relation to disease that require a full scale longitudinal analysis.
C1 [Pinchbeck, Gina L.; Langford, Joanna; Meehan, Lucinda; Christley, Robert M.] Univ Liverpool, Fac Vet Sci, Leahurt CH64 7TE, Neston, England.
   [Morrison, Liam J.; Tait, Andy] Univ Glasgow, Glasgow Biomed Res Ctr, Welcome Ctr Mol Parasitol, Glasgow G12 8TA, Lanark, Scotland.
   [Jallow, Saloum; Jallow, Jibril; Jallow, Amadou] Gambia Horse & Donkey Trust, Sambel Kunda, Gambia.
RP Pinchbeck, GL (reprint author), Univ Liverpool, Fac Vet Sci, Leahurt CH64 7TE, Neston, England.
EM ginap@liv.ac.uk; lm78y@udcf.gla.ac.uk; gvwa01@udcf.gla.ac.uk;
   jolangford16@yahoo.co.uk; ljmeehan@hotmail.co.uk;
   gambiahorseanddonkeytrust@hotmail.com;
   gambiahorseanddonkeytrust@hotmail.com;
   gambiahorseanddonkeytrust@hotmail.com; robc@liverpool.ac.uk
OI Christley, Robert/0000-0001-9250-3032
FU Wellcome Trust
CR CONNOR RJ, 1994, AFRICAN ANIMAL TRYPA
   Cox A, 2005, EXP PARASITOL, V111, P24, DOI 10.1016/j.exppara.2005.03.014
   Desquesnes M, 2003, EXP PARASITOL, V103, P35, DOI 10.1016/S0014-4894(03)00067-5
   Desquesnes M, 2002, VET PARASITOL, V109, P213, DOI 10.1016/S0304-4017(02)00270-4
   Dhollander S, 2006, PREV VET MED, V75, P152, DOI 10.1016/j.prevetmed.2005.11.009
   DWINGER RH, 1989, VET PARASITOL, V30, P177, DOI 10.1016/0304-4017(89)90013-7
   DWINGER RH, 1986, PARASITE IMMUNOL, V8, P293
   Faye D, 2001, VET PARASITOL, V101, P101, DOI 10.1016/S0304-4017(01)00503-9
   Lasken RS, 2003, TRENDS BIOTECHNOL, V21, P531, DOI 10.1016/j.tibtech.2003.09.010
   MacLennan K. J. R., 1970, P751
   MacLeod A, 2005, NUCLEIC ACIDS RES, V33, P6688, DOI 10.1093/nar/gki980
   MASIGA DK, 1992, INT J PARASITOL, V22, P909, DOI 10.1016/0020-7519(92)90047-O
   MATTILI RC, 1994, TROP ANIM HEALTH PRO, V26, P102, DOI 10.1007/BF02239909
   Morlais I, 2001, ACTA TROP, V80, P207, DOI 10.1016/S0001-706X(01)00160-7
   Morrison LJ, 2007, AM J TROP MED HYG, V76, P1132
   MORRISON WI, 1982, J PARASITOL, V68, P755, DOI 10.2307/3280980
   MURRAY M, 1977, T ROY SOC TROP MED H, V71, P325, DOI 10.1016/0035-9203(77)90110-9
   Njiru ZK, 2005, PARASITOL RES, V95, P186, DOI 10.1007/s00436-004-1267-5
   Pritchard JC, 2006, EQUINE VET J, V38, P433, DOI 10.2746/042516406778400646
   Snow WF, 1996, VET PARASITOL, V66, P1, DOI 10.1016/S0304-4017(96)01003-5
   Stephen L. E., 1970, P774
   Stephen L. E., 1959, Veterinary Record, V71, P527
   WELLDE BT, 1983, TROP ANIM HEALTH PRO, V15, P95, DOI 10.1007/BF02239803
   2002, ANNEX C D EQUINE IND
NR 24
TC 16
Z9 16
U1 1
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-6148
J9 BMC VET RES
JI BMC Vet. Res.
PD FEB 20
PY 2008
VL 4
AR 7
DI 10.1186/1746-6148-4-7
PG 7
WC Veterinary Sciences
SC Veterinary Sciences
GA 301IE
UT WOS:000255888800001
PM 18289378
OA gold
DA 2017-08-15
ER

PT J
AU Casals-Pascual, C
   Idro, R
   Gicheru, N
   Gwer, S
   Kitsao, B
   Gitau, E
   Mwakesi, R
   Roberts, DJ
   Newton, CRJC
AF Casals-Pascual, Climent
   Idro, Richard
   Gicheru, Nimmo
   Gwer, Samson
   Kitsao, Barnes
   Gitau, Evelyn
   Mwakesi, Robert
   Roberts, David J.
   Newton, Charles R. J. C.
TI High levels of erythropoietin are associated with protection against
   neurological sequelae in African children with cerebral malaria
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE anemia; Plasmodium falciparum; severe malaria; vascular endothelial
   growth factor
ID SEVERE FALCIPARUM-MALARIA; ENDOTHELIAL GROWTH-FACTOR;
   TUMOR-NECROSIS-FACTOR; BLOOD-BRAIN-BARRIER;
   RECOMBINANT-HUMAN-ERYTHROPOIETIN; NEURONAL APOPTOSIS; FACTOR-ALPHA;
   CLINICAL-FEATURES; NERVOUS-SYSTEM; ISCHEMIC BRAIN
AB Cerebral malaria (CM) in children is associated with a high mortality and long-term neurocognitive sequelae. Both erythropoietin (Epo) and vascular endothelial growth factor (VEGF) have been shown to be neuroprotective. We hypothesized that high plasma and cerebrospinal fluid (CSF) levels of these cytokines would prevent neurological sequelae in children with CM. We measured Epo, VEGF, and tumor necrosis factor in paired samples of plasma and CSF of Kenyan children admitted with CM. Logistic regression models were used to identify risk and protective factors associated with the development of neurological sequelae. Children with CM (n = 124) were categorized into three groups: 76 without sequelae, 32 with sequelae, and 16 who died. Conditional logistic regression analysis matching the 32 patients with CM and neurological sequelae to 64 patients with CM without sequelae stratified for hemoglobin level estimated that plasma Epo (>200 units/liter) was associated with >80% reduction in the risk of developing neurological sequelae [adjusted odds ratio (OR) 0.18; 95% C.I. 0.05-0.93; P = 0.041]. Admission with profound coma (adjusted OR 5.47; 95% C.I. 1.45-20.67; P = 0.012) and convulsions after admission (adjusted OR 16.35; 95% C.I. 2.94-90.79; P = 0.001) were also independently associated with neurological sequelae. High levels of Epo were associated with reduced risk of neurological sequelae in children with CM. The age-dependent Epo response to anemia and the age-dependent protective effect may influence the clinical epidemiology of CM. These data support further study of Epo as an adjuvant therapy in CM.
C1 [Casals-Pascual, Climent; Roberts, David J.] Univ Oxford, Nuffield Dept Clin, Lab Sci, Oxford OX3 9BQ, England.
   [Casals-Pascual, Climent; Roberts, David J.] John Radcliffe Hosp, Natl Blood Serv, Oxford OX3 9BQ, England.
   [Casals-Pascual, Climent] MRC Labs, Fajara, Gambia.
   [Idro, Richard; Gicheru, Nimmo; Gwer, Samson; Kitsao, Barnes; Gitau, Evelyn; Mwakesi, Robert; Newton, Charles R. J. C.] Kenya Govt Med Res Ctr, Ctr Geog Med Coast, Kilifi, Kenya.
   [Idro, Richard] Makerere Univ, Dept Pediat, Mulago Hosp, Kampala, Uganda.
   [Newton, Charles R. J. C.] UCL, Inst Child Hlth, Wolfson Ctr, Neurosci Unit, London WC1N 2AP, England.
RP Casals-Pascual, C (reprint author), Univ Oxford, Nuffield Dept Clin, Lab Sci, Oxford OX3 9BQ, England.
EM ccasals@mrc.gm
RI Newton, 21/B-7578-2014
OI Newton, 21/0000-0002-6999-5507; Gitau, Evelyn /0000-0002-5270-7492;
   Casals-Pascual, Climent/0000-0002-0867-8954
FU Wellcome Trust
CR Barone FC, 1997, STROKE, V28, P1233
   Berkley JA, 2001, LANCET, V357, P1753, DOI 10.1016/S0140-6736(00)04897-2
   BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7
   Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687
   Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526
   Carnot P, 1906, CR HEBD ACAD SCI, V143, P384
   Carter JA, 2005, J NEUROL NEUROSUR PS, V76, P476, DOI 10.1136/jnnp.2004.043893
   Carter JA, 2005, TROP MED INT HEALTH, V10, P3, DOI 10.1111/j.1365-3156.2004.01345.x
   Carter JA, 2004, EPILEPSIA, V45, P978, DOI 10.1111/j.0013-9580.2004.65103.x
   Casals-Pascual C, 2006, BLOOD, V108, P2569, DOI 10.1182/blood-2006-05-018697
   Chi OZ, 2005, NEUROL RES, V27, P864, DOI 10.1179/016164405X49418
   Croll SD, 2004, ADV EXP MED BIOL, V548, P57
   Deininger MH, 2003, J NEUROIMMUNOL, V142, P101, DOI 10.1016/S0165-5728(03)00250-9
   Ehrenreich H, 2002, MOL MED, V8, P495
   Fandrey J, 1997, KIDNEY INT, V51, P492, DOI 10.1038/ki.1997.68
   GORDEUK V, 1992, NEW ENGL J MED, V327, P1473, DOI 10.1056/NEJM199211193272101
   Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299
   GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404
   Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481
   Idro R, 2006, ARCH DIS CHILD, V91, P142, DOI 10.1136/adc.2005.077784
   Idro R, 2005, LANCET NEUROL, V4, P827, DOI 10.1016/S1474-4422(05)70247-7
   IDRO R, 2004, UGANDA AFR HLTH, V4, P50
   Intiso D, 2004, NEUROL SCI, V24, P390, DOI 10.1007/s10072-003-0194-z
   Kaiser K, 2006, J INFECT DIS, V193, P987, DOI 10.1086/500844
   Kurtzhals JAL, 1997, BRIT J HAEMATOL, V97, P169, DOI 10.1046/j.1365-2141.1997.82654.x
   KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5
   Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313
   Levy AP, 1996, J BIOL CHEM, V271, P2746
   Liu RQ, 2006, J NEUROCHEM, V96, P1101, DOI 10.1111/j.1471-4159.2005.03597.x
   Marti HH, 2004, J EXP BIOL, V207, P3233, DOI 10.1242/jeb.01049
   MASUDA S, 1994, J BIOL CHEM, V269, P19488
   MOLYNEUX ME, 1989, Q J MED, V71, P441
   Nagai A, 2001, J NEUROPATH EXP NEUR, V60, P386
   Namiuchi S, 2005, J AM COLL CARDIOL, V45, P1406, DOI 10.1016/j.jacc.2005.01.043
   Newton CRJC, 1997, TROP MED INT HEALTH, V2, P165, DOI 10.1046/j.1365-3156.1997.d01-238.x
   Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4
   NEWTON CRJC, 1991, LANCET, V337, P573, DOI 10.1016/0140-6736(91)91638-B
   Ngoungou EB, 2006, EPILEPSIA, V47, P873, DOI 10.1111/j.1528-1167.2006.00524.x
   Njuguna P, 2004, J Postgrad Med, V50, P45
   O'Donnell A, 2007, P NATL ACAD SCI USA, V104, P9440, DOI 10.1073/pnas.0703424104
   Ryuto M, 1996, J BIOL CHEM, V271, P28220
   Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635
   Siddiq A, 2005, J BIOL CHEM, V280, P41732, DOI 10.1074/jbc.M504963200
   Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598
   SMITH HJ, 2003, COCHRANE DATABASE SY
   Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2
   Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067
   Wang YM, 2006, BRAIN RES, V1115, P186, DOI 10.1016/j.brainres.2006.07.060
   Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166
   Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev
   *WHO, 2000, 20 REP
   Wiese L, 2006, EXP NEUROL, V200, P216, DOI 10.1016/j.expneurol.2006.02.011
   Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369
NR 53
TC 62
Z9 64
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 19
PY 2008
VL 105
IS 7
BP 2634
EP 2639
DI 10.1073/pnas.0709715105
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 266XB
UT WOS:000253469900069
PM 18263734
OA No
DA 2017-08-15
ER

PT J
AU Fry, AE
   Griffiths, MJ
   Auburn, S
   Diakite, M
   Forton, JT
   Green, A
   Richardson, A
   Wilson, J
   Jallow, M
   Sisay-Joof, F
   Pinder, M
   Peshu, N
   Williams, TN
   Marsh, K
   Molyneux, ME
   Taylor, TE
   Rockett, KA
   Kwiatkowski, DP
AF Fry, Andrew E.
   Griffiths, Michael J.
   Auburn, Sarah
   Diakite, Mahamadou
   Forton, Julian T.
   Green, Angela
   Richardson, Anna
   Wilson, Jonathan
   Jallow, Muminatou
   Sisay-Joof, Fatou
   Pinder, Margaret
   Peshu, Norbert
   Williams, Thomas N.
   Marsh, Kevin
   Molyneux, Malcolm E.
   Taylor, Terrie E.
   Rockett, Kirk A.
   Kwiatkowski, Dominic P.
TI Common variation in the ABO glycosyltransferase is associated with
   susceptibility to severe Plasmodium falciparum malaria
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID BLOOD-GROUP ANTIGENS; HAPLOTYPE RECONSTRUCTION; NATURAL-SELECTION;
   CEREBRAL MALARIA; HUMAN GENOME; VAR GENES; GROUP-A; SYSTEM; CELL;
   RESISTANCE
AB There is growing epidemiological and molecular evidence that ABO blood group affects host susceptibility to severe Plasmodium falciparum infection. The high frequency of common ABO alleles means that even modest differences in susceptibility could have a significant impact on the health of people living in malaria endemic regions. We performed an association study, the first to utilize key molecular genetic variation underlying the ABO system, genotyping > 9000 individuals across three African populations. Using population- and family-based tests, we demonstrated that alleles producing functional ABO enzymes are associated with greater risk of severe malaria phenotypes (particularly malarial anemia) in comparison with the frameshift deletion underlying blood group O: case-control allelic odds ratio (OR), 1.2; 95% confidence interval (CI), 1.09-1.32; P = 0.0003; family-studies allelic OR, 1.19; 95% CI, 1.08-1.32; P = 0.001; pooled across all studies allelic OR, 1.18; 95% CI, 1.11-1.26; P = 2 x 10(-7). We found suggestive evidence of a parent-of-origin effect at the ABO locus by analyzing the family trios. Non-O haplotypes inherited from mothers, but not fathers, are significantly associated with severe malaria (likelihood ratio test of Weinberg, P = 0.046). Finally, we used HapMap data to demonstrate a region of low F-ST (-0.001) between the three main HapMap population groups across the ABO locus, an outlier in the empirical distribution of F-ST across chromosome 9 (similar to 99.5-99.9th centile). This low F-ST region may be a signal of long-standing balancing selection at the ABO locus, caused by multiple infectious pathogens including P. falciparum.
C1 [Fry, Andrew E.; Griffiths, Michael J.; Auburn, Sarah; Diakite, Mahamadou; Forton, Julian T.; Green, Angela; Richardson, Anna; Wilson, Jonathan; Rockett, Kirk A.; Kwiatkowski, Dominic P.] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Griffiths, Michael J.; Peshu, Norbert; Williams, Thomas N.; Marsh, Kevin] Inst Ctr Geog Med Res Coast, Kenya Med Res, Kilifi, Kenya.
   [Jallow, Muminatou; Sisay-Joof, Fatou; Pinder, Margaret] MRC, Banjul, Gambia.
   [Williams, Thomas N.; Marsh, Kevin] John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DS, England.
   [Molyneux, Malcolm E.] Malawi Liverpool Wellcome Trust Programme Clin Tr, Blantyre, Malawi.
   [Taylor, Terrie E.] Coll Med, Blantyre Malaria Project, Blantyre, Malawi.
   [Molyneux, Malcolm E.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   [Taylor, Terrie E.] Michigan State Univ, Coll Osteopath Med, Dept Internal Med, E Lansing, MI 48824 USA.
   [Kwiatkowski, Dominic P.] Wellcome Trust Sanger Inst, Hinxton CB10 1SA, England.
RP Fry, AE (reprint author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
EM afry@well.ox.ac.uk
OI Kwiatkowski, Dominic/0000-0002-5023-0176; Auburn,
   Sarah/0000-0002-4638-536X
FU Medical Research Council [G0600230(77610), G0600230, G19/9]; Wellcome
   Trust [, 074586, 076934]
CR Ackerman H, 2005, ANN HUM GENET, V69, P559, DOI 10.1111/j.1529-8817.2005.00180.x
   ADALSTEINSSON S, 1985, ANN HUM GENET, V49, P275, DOI 10.1111/j.1469-1809.1985.tb01703.x
   Akey JM, 2004, PLOS BIOL, V2, P1591, DOI 10.1371/journal.pbio.0020286
   AKINBOYE DO, 1987, T ROY SOC TROP MED H, V81, P398, DOI 10.1016/0035-9203(87)90147-7
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Barragan A, 2000, INFECT IMMUN, V68, P2971, DOI 10.1128/IAI.68.5.2971-2975.2000
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Baruch DI, 1997, BLOOD, V90, P3766
   BAYOUMI RA, 1986, AM J TROP MED HYG, V35, P45
   Beiguelman B, 2003, MEM I OSWALDO CRUZ, V98, P455, DOI 10.1590/S0074-02762003000400004
   Blackwell CC, 2002, J INFECT DIS, V185, P393, DOI 10.1086/338343
   BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146
   Bull PC, 2002, TRENDS MICROBIOL, V10, P55, DOI 10.1016/S0966-842X(01)02278-8
   CARLSON J, 1992, J EXP MED, V176, P1311, DOI 10.1084/jem.176.5.1311
   CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N
   Cavalli-Sforza LL, 1996, HIST GEOGRAPHY HUMAN
   Chen QJ, 2000, J EXP MED, V192, P1, DOI 10.1084/jem.192.1.1
   Cordell HJ, 2004, GENET EPIDEMIOL, V26, P167, DOI 10.1002/gepi.10307
   Cserti CM, 2007, BLOOD, V110, P2250, DOI 10.1182/blood-2007-03-077602
   DOBROVIC A, 1993, BLOOD, V82, P1684
   DOUGHTY BR, 1977, MED LAB SCI, V34, P351
   Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252
   DUDBRIDGE F, 2006, 20065 MRC BIOST UN
   Fischer PR, 1998, AM J TROP MED HYG, V58, P122
   Flick K, 2004, MOL BIOCHEM PARASIT, V134, P3, DOI 10.1016/j.molbiopara.2003.09.010
   FRANCO RF, 1995, VOX SANG, V69, P50
   Gao S, 2004, INT J CANCER, V109, P230, DOI 10.1002/ijc.11592
   Gonzalez JM, 2005, ENVIRON MICROBIOL, V7, P1024, DOI 10.1111/j.1462-2920.2005.00779.x
   Hamblin MT, 2000, AM J HUM GENET, V66, P1669, DOI 10.1086/302879
   Heddini A, 2001, INFECT IMMUN, V69, P5849, DOI 10.1128/IAI.69.9.5849-5856.2001
   KASSIM OO, 1982, ACTA TROP, V39, P179
   Kermarrec N, 1999, IMMUNOGENETICS, V49, P517, DOI 10.1007/s002510050529
   Kominato Y, 1999, J BIOL CHEM, V274, P37240, DOI 10.1074/jbc.274.52.37240
   Lell B, 1999, CLIN INFECT DIS, V28, P794, DOI 10.1086/515193
   Lindesmith L, 2003, NAT MED, V9, P548, DOI 10.1038/nm860
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   MARTIN SK, 1979, T ROY SOC TROP MED H, V73, P216, DOI 10.1016/0035-9203(79)90217-7
   Migot-Nabias F, 2000, GENES IMMUN, V1, P435, DOI 10.1038/sj.gene.6363703
   Montoya Fabiola, 1994, Revista do Instituto de Medicina Tropical de Sao Paulo, V36, P33
   Newbold C, 1997, AM J TROP MED HYG, V57, P389
   Pant C. S., 1992, Indian Journal of Malariology, V29, P235
   Pathirana SL, 2005, ANN TROP MED PARASIT, V99, P119, DOI 10.1179/136485905X19946
   Poujol-Robert A, 2006, DIGEST DIS SCI, V51, P1633, DOI 10.1007/s10620-006-9121-5
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   RAZA MW, 1991, BRIT MED J, V303, P815
   Ross P, 1998, NAT BIOTECHNOL, V16, P1347, DOI 10.1038/4328
   ROWE A, 1995, INFECT IMMUN, V63, P2323
   Rowe JA, 2007, P NATL ACAD SCI USA, V104, P17471, DOI 10.1073/pnas.0705390104
   Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888
   Sabeti PC, 2006, SCIENCE, V312, P1614, DOI 10.1126/science.1124309
   Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140
   Singh Neeru, 1995, Indian Journal of Malariology, V32, P59
   SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X
   Smith JD, 2000, P NATL ACAD SCI USA, V97, P1766, DOI 10.1073/pnas.040545897
   Spielman RS, 1996, AM J HUM GENET, V59, P983
   Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Thakur A., 1992, Indian Journal of Malariology, V29, P241
   UDOMSANGPETCH R, 1993, AM J TROP MED HYG, V48, P149
   Uneke CJ, 2007, PARASITOL RES, V100, P759, DOI 10.1007/s00436-006-0342-5
   Weinberg CR, 1998, AM J HUM GENET, V62, P969, DOI 10.1086/301802
   World Health Organization, 1990, T R SOC TROP MED S2, V84, P1
   YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257
   YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0
   Yip SP, 2002, ANN HUM GENET, V66, P1, DOI 10.1017/S0003480001008995
   ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847
NR 66
TC 77
Z9 79
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD FEB 14
PY 2008
VL 17
IS 4
BP 567
EP 576
DI 10.1093/hmg/ddm331
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 258YL
UT WOS:000252906200008
PM 18003641
OA No
DA 2017-08-15
ER

PT J
AU Duvall, MG
   Precopio, ML
   Ambrozak, DA
   Jaye, A
   McMichael, AJ
   Whittle, HC
   Roederer, M
   Rowland-Jones, SL
   Koup, RA
AF Duvall, Melody G.
   Precopio, Melissa L.
   Ambrozak, David A.
   Jaye, Assan
   McMichael, Andrew J.
   Whittle, Hilton C.
   Roederer, Mario
   Rowland-Jones, Sarah L.
   Koup, Richard A.
TI Polyfunctional T cell responses are a hallmark of HIV-2 infection
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE chemokines; cytokines; HIV; T cells
ID IMMUNODEFICIENCY-VIRUS TYPE-1; POLYMERASE CHAIN-REACTION; WEST-AFRICA;
   HIV-2-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; HUMAN CYTOMEGALOVIRUS;
   HEALTHY-INDIVIDUALS; EFFECTOR FUNCTIONS; PROVIRAL LOAD; CYTO-TOXICITY
AB HIV-2 is distinguished clinically and immunologically from HIV-1 infection by delayed disease progression and maintenance of HIV-specific CD4(+) T cell help in most infected subjects. Thus, HIV-2 provides a unique natural human model in which to investigate correlates of immune protection against HIV disease progression. Here, we report a detailed assessment of the HIV-2-specific CD4(+) and CD8(+) T cell response compared to HIV-1, using polychromatic flow cytometry to assess the quality of the HIV-specific T cell response by measuring IFN-gamma, IL-2, TNF-alpha, MIP-1 beta, and CD107a mobilization (degranulation) simultaneously following Gag peptide stimulation. We find that HIV-2-specific CD4(+) and CD8(+) T cells are more polyfunctional that those specific for HIV-1 and that polyfunctional HIV-2-specific Tcells produce more IFN-gamma and TNF-alpha on a per-cell basis than monofunctional T cells. Polyfunctional HIV-2-specific CD4(+) T cells were generally more differentiated and expressed CD57, while there was no association between function and phenotype in the CD8(+) T cell fraction. Polyfunctional HIV-specific T cell responses are a hallmark of non-progressive HIV-2 infection and may be related to good clinical outcome in this setting.
C1 [Duvall, Melody G.; Precopio, Melissa L.; Ambrozak, David A.; Koup, Richard A.] NIAID, Immunol Lab, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   [Duvall, Melody G.; McMichael, Andrew J.; Rowland-Jones, Sarah L.] Univ Oxford, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford, England.
   [Roederer, Mario] NIAID, Immunol Technol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   [Jaye, Assan; Whittle, Hilton C.; Rowland-Jones, Sarah L.] MRC Labs Fajara, Banjul, Gambia.
RP Koup, RA (reprint author), NIAID, Immunol Lab, Vaccine Res Ctr, NIH, 40 Convent Dr,MSC 3022,Bldg 40,Room 3502, Bethesda, MD 20892 USA.
EM rkoup@mail.nih.gov
RI Roederer, Mario/G-1887-2011
FU Intramural NIH HHS [Z99 AI999999]; Medical Research Council [,
   MC_U137884180, MC_U190081958]
CR Andersson S, 1999, VIROLOGY, V262, P312, DOI 10.1006/viro.1999.9867
   Appay V, 2002, J IMMUNOL, V168, P5954
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006
   Berry N, 1998, J Hum Virol, V1, P457
   BERRY N, 1994, AIDS RES HUM RETROV, V10, P1031, DOI 10.1089/aid.1994.10.1031
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Bertoletti A, 1998, J VIROL, V72, P2439
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5
   Betts MR, 2005, P NATL ACAD SCI USA, V102, P4512, DOI 10.1073/pnas.0408773102
   Beveridge NER, 2007, EUR J IMMUNOL, V37, P3089, DOI 10.1002/eji.2007375041
   Boaz MJ, 2002, J IMMUNOL, V169, P6376
   Casazza JP, 2006, J EXP MED, V203, P2865, DOI 10.1081/jem.20052246
   Cham F, 2000, AIDS RES HUM RETROV, V16, P1915, DOI 10.1089/08892220050195874
   CHATTOPADHYAY PK, 2006, NAT MED, V12, P912
   CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376
   Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
   De Rosa SC, 2004, J IMMUNOL, V173, P5372
   Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Duvall MG, 2006, J IMMUNOL, V176, P6973
   Emu B, 2005, J VIROL, V79, P14169, DOI 10.1128/JVI.79.22.14169-14178.2005
   Gillespie GMA, 2005, EUR J IMMUNOL, V35, P1445, DOI 10.1002/eji.200526007
   GOTCH F, 1993, J IMMUNOL, V151, P3361
   Harari A, 2005, J IMMUNOL, V174, P1037
   Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203
   HENKART P, 1985, ADV EXP MED BIOL, V184, P121
   HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31
   Iyasere C, 2003, J VIROL, V77, P10900, DOI 10.1128/JVI.77.20.10900-10909.2003
   Jaye A, 2004, J INFECT DIS, V189, P498, DOI 10.1086/381185
   Miles DJC, 2007, J VIROL, V81, P5766, DOI 10.1128/JVI.00052-07
   Musey LK, 1999, J INFECT DIS, V180, P278, DOI 10.1086/314868
   Perfetto SP, 2006, J IMMUNOL METHODS, V313, P199, DOI 10.1016/j.jim.2006.04.007
   PINTO LA, 1995, J MED VIROL, V47, P139, DOI 10.1002/jmv.1890470206
   PINTO LA, 1993, AIDS, V7, P1389, DOI 10.1097/00002030-199310000-00016
   Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   Precopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363
   Rubio V, 2003, NAT MED, V9, P1377, DOI 10.1038/nm942
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Sarr AD, 1999, J HUMAN VIROL, V2, P45
   Sousa AE, 2001, J INFECT DIS, V184, P552, DOI 10.1086/322804
   van der Loeff MFS, 2002, AIDS, V16, P1775
   WANG ECY, 1993, CLIN EXP IMMUNOL, V94, P297
   WANG ECY, 1995, J IMMUNOL, V155, P5046
   Whittle HC, 1998, CURR OPIN IMMUNOL, V10, P382, DOI 10.1016/S0952-7915(98)80108-8
   Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598
   Zaunders JJ, 2004, BLOOD, V103, P2238, DOI 10.1182/blood-2003-08-2765
   Zheng NN, 2004, J VIROL, V78, P13934, DOI 10.1128/JVI.78.24.13934-13942.2004
   Zimmerli SC, 2005, P NATL ACAD SCI USA, V102, P7239, DOI 10.1073/pnas.0502393102
NR 51
TC 139
Z9 143
U1 0
U2 3
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD FEB
PY 2008
VL 38
IS 2
BP 350
EP 363
DI 10.1002/eji.200737768
PG 14
WC Immunology
SC Immunology
GA 264YK
UT WOS:000253326100005
PM 18200635
OA No
DA 2017-08-15
ER

PT J
AU Nwakanma, D
   Kheir, A
   Sowa, M
   Dunyo, S
   Jawara, M
   Pinder, M
   Milligan, P
   Walliker, D
   Babiker, HA
AF Nwakanma, Davis
   Kheir, Amani
   Sowa, Mercy
   Dunyo, Sam
   Jawara, Musa
   Pinder, Margaret
   Milligan, Paul
   Walliker, David
   Babiker, Hamza A.
TI High gametocyte complexity and mosquito infectivity of Plasmodium
   falciparum in the Gambia
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Article
DE Plasmodium falciparum; gametocytes; RT-PCR; Anopheles mosquito
   infectivity
ID POLYMERASE-CHAIN-REACTION; MALARIA PARASITES; ANOPHELES-GAMBIAE; EASTERN
   SUDAN; TRANSMISSION; ARTESUNATE; AREA; DRY; PYRIMETHAMINE; EPIDEMIOLOGY
AB The purpose of this work was to determine the infectivity to mosquitoes of genetically diverse Plasmodium falciparum clones seen in natural infections in the Gambia. Two principal questions were addressed: (i) how infectious are gametocytes of sub-patent infections, particularly at the end of the dry season; and (ii) are all clones in multiclonal infections equally capable of infecting mosquitoes? The work was carried out with two cohorts of infected individuals. Firstly, a group of 31 P. falciparum-infected people were recruited in the middle of the dry season (May, 2003), then examined for P. falciparum at the beginning (August 2003) and middle (October, 2003) of the transmission season. Oil each occasion, we examined the genotypes of asexual forms and gametocytes by PCR and RT-PCR, as well as their infectivity to Anopheles gambiae using membrane feeds. One individual gave rise to infected mosquitoes in May, and two in August. Different gametocyte genotypes co-existed in the same infection and fluctuated over time. The mean multiplicity of infection was 1.4, 1.7 and 1.5 clones in May, August and October, respectively. Second, a group of patients undergoing drug-treatment during August 2003 was tested for asexual and gametocyte genotypes and their infectivity to mosquitoes. Forty-three out of 100 feeds produced infections. The genetic complexity of the parasites in mosquitoes was sometimes greater than that detectable in the blood on which the mosquitoes had fed. This suggested that gametocytes of clones existing in the blood below PCR detection limits at the time of the feed were at least as infectious to the mosquitoes as the more abundant clones. These findings emphasise the crucial role of gametocyte complexity and infectivity in generating the remarkable diversity of P. falciparum genotypes seen in infected people, even in an area of seasonal transmission. (c) 2007 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Nwakanma, Davis; Dunyo, Sam; Jawara, Musa; Pinder, Margaret; Milligan, Paul] Sultan Qaboos Univ, Fac Med, Dept Biochem, Muscat, Oman.
   [Kheir, Amani; Sowa, Mercy; Walliker, David; Babiker, Hamza A.] MRC Labs, Banjul, Gambia.
   [Babiker, Hamza A.] Univ Edinburgh, Sch Biol Sci, Edinburgh EH8 9YL, Midlothian, Scotland.
RP Babiker, HA (reprint author), Sultan Qaboos Univ, Fac Med, Dept Biochem, PO Box 35, Muscat, Oman.
EM H.babiker@ed.ac.uk
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
CR Abdel-Wahab A, 2002, J INFECT DIS, V185, P1838, DOI 10.1086/340638
   Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4
   Alano P, 1995, MOL BIOCHEM PARASIT, V74, P143, DOI 10.1016/0166-6851(95)02491-3
   Alves J, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-32
   Babiker HA, 1998, AM J TROP MED HYG, V59, P582
   Babiker HA, 1999, MOL BIOCHEM PARASIT, V99, P143, DOI 10.1016/S0166-6851(98)00175-3
   BEIER JC, 1993, PARASITOL TODAY, V9, P210, DOI 10.1016/0169-4758(93)90010-D
   Bousema JT, 2006, J INFECT DIS, V193, P1151, DOI 10.1086/503051
   Buckling A, 1999, PARASITOLOGY, V118, P339, DOI 10.1017/S0031182099003960
   Carter R, 1979, Bull World Health Organ, V57 Suppl 1, P37
   Coleman RE, 2004, J MED ENTOMOL, V41, P201, DOI 10.1603/0022-2585-41.2.201
   CONWAY DJ, 1991, PARASITOLOGY, V103, P1
   Di Girolamo Francesco, 2005, Annali dell'Istituto Superiore di Sanita, V41, P469
   Drakeley CJ, 1999, TROP MED INT HEALTH, V4, P131, DOI 10.1046/j.1365-3156.1999.00361.x
   DUNYO S, 2006, PLOS CLIN TRIALS, V1
   GRAVES PM, 1984, AM J TROP MED HYG, V33, P1045
   GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q
   Hamad AA, 2002, ACTA TROP, V83, P71, DOI 10.1016/S0001-706X(02)00059-1
   HILL WG, 1995, GENET RES, V65, P53
   Hill WG, 1995, P ROY SOC B-BIOL SCI, V262, P249, DOI 10.1098/rspb.1995.0203
   INCARDONA S, 2007, MALARIA J, P37
   KRAJDEN S, 1991, T ROY SOC TROP MED H, V85, P731, DOI 10.1016/0035-9203(91)90434-Z
   LINDSAY SW, 1991, J TROP MED HYG, V94, P313
   Menegon M, 2000, MOL BIOCHEM PARASIT, V111, P153, DOI 10.1016/S0166-6851(00)00314-5
   MUIRHEADTHOMSON RC, 1954, T ROY SOC TROP MED H, V48, P208, DOI 10.1016/0035-9203(54)90067-X
   Nassir E, 2005, INT J PARASITOL, V35, P49, DOI 10.1016/j.ijpara.2004.10.014
   Ouedraogo AL, 2007, AM J TROP MED HYG, V76, P626
   PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897
   PLOWE CV, 1995, AM J TROP MED HYG, V52, P565
   Price R, 1999, AM J TROP MED HYG, V60, P1019
   RANFORDCARTWRIGHT LC, 1991, MOL BIOCHEM PARASIT, V49, P239, DOI 10.1016/0166-6851(91)90067-G
   Robert F, 1996, T ROY SOC TROP MED H, V90, P704, DOI 10.1016/S0035-9203(96)90446-0
   Schneider P, 2007, AM J TROP MED HYG, V76, P470
   Schneider P, 2006, INT J PARASITOL, V36, P403, DOI 10.1016/j.ijpara.2006.01.002
   Smith T, 1999, Trans R Soc Trop Med Hyg, V93 Suppl 1, P59, DOI 10.1016/S0035-9203(99)90329-2
   Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351
   Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689
   Taylor LH, 1997, PARASITOL TODAY, V13, P135, DOI 10.1016/S0169-4758(97)89810-9
   TRAGER W, 1992, J PROTOZOOL, V39, P429, DOI 10.1111/j.1550-7408.1992.tb01476.x
   Wargo AR, 2006, EXP PARASITOL, V112, P13, DOI 10.1016/j.exppara.2005.08.013
   Zwetyenga J, 1998, AM J TROP MED HYG, V59, P726
NR 41
TC 37
Z9 37
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0020-7519
J9 INT J PARASITOL
JI Int. J. Parasit.
PD FEB
PY 2008
VL 38
IS 2
BP 219
EP 227
DI 10.1016/j.ijpara.2007.07.003
PG 9
WC Parasitology
SC Parasitology
GA 260TS
UT WOS:000253033900010
PM 17709108
OA No
DA 2017-08-15
ER

PT J
AU Kari, L
   Whitmire, WM
   Carlson, JH
   Crane, DD
   Reveneau, N
   Nelson, DE
   Mabey, DCW
   Bailey, RL
   Holland, MJ
   McClarty, G
   Caldwell, HD
AF Kari, Laszlo
   Whitmire, William M.
   Carlson, John H.
   Crane, Deborah D.
   Reveneau, Nathalie
   Nelson, David E.
   Mabey, David C. W.
   Bailey, Robin L.
   Holland, Martin J.
   McClarty, Grant
   Caldwell, Harlan D.
TI Pathogenic diversity among Chlamydia trachomatis ocular strains in
   nonhuman primates is affected by subtle genomic variations
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT Meeting of the Chlamydia-Basic-Research-Society
CY MAR, 2007
CL Louisville, KY
SP Chlamydia Basic Res Soc
ID GAMMA-INTERFERON; TRYPTOPHAN SYNTHASE; MEMBRANE-PROTEINS; TISSUE
   TROPISM; ANIMAL-MODEL; AMINO-ACID; POLYMORPHISMS; RISK; INFECTIONS;
   RESISTANCE
AB Chlamydia trachomatis is the etiological agent of trachoma, the leading cause of preventable blindness. Trachoma presents distinct clinical syndromes ranging from mild and self-limiting to severe inflammatory disease. The underlying host and pathogen factors responsible for these diverse clinical outcomes are unclear. To assess the role played by pathogen variation in disease outcome, we analyzed the genomes of 4 trachoma strains representative of the 3 major trachoma serotypes, using microarray-based comparative genome sequencing. Outside of ompA, trachoma strains differed primarily in a very small subset of genes (n = 22). These subtle genetic variations were manifested in profound differences in virulence as measured by in vitro growth rate, burst size, plaque morphology, and interferon-gamma sensitivity but most importantly in virulence as shown by ocular infection of non-human primates. Our findings are the first to identify genes that correlate with differences in pathogenicity among trachoma strains.
C1 [Kari, Laszlo; Whitmire, William M.; Carlson, John H.; Crane, Deborah D.; Reveneau, Nathalie; Caldwell, Harlan D.] NIAID, Rocky Mt Labs, Intracellular Parasites Lab, Hamilton, MT 59840 USA.
   [Nelson, David E.] Indiana Univ, Dept Biol, Bloomington, IN USA.
   [Mabey, David C. W.; Bailey, Robin L.; Holland, Martin J.] London Sch Hyg & Trop Med, Infect Trop Dis Dept, Clin Res Unit, London WC1, England.
   [Holland, Martin J.] MRC Labs, Viral Dis Programme, Banjul, Gambia.
   [McClarty, Grant] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada.
RP Caldwell, HD (reprint author), NIAID, Rocky Mt Labs, Intracellular Parasites Lab, 903 S 4th St, Hamilton, MT 59840 USA.
EM hcaldwell@niaid.nih.gov
OI Mabey, David/0000-0002-0031-8276
FU Intramural NIH HHS; Medical Research Council [MC_U190081961]
CR Albert TJ, 2005, NAT METHODS, V2, P951, DOI 10.1038/NMETH805
   BAILEY RL, 1994, BRIT J OPHTHALMOL, V78, P813, DOI 10.1136/bjo.78.11.813
   BEATTY WL, 1994, INFECT IMMUN, V62, P3705
   Belland RJ, 2003, P NATL ACAD SCI USA, V100, P8478, DOI 10.1073/pnas.1331135100
   Bowman RJC, 2001, OPHTHALMOLOGY, V108, P2219, DOI 10.1016/S0161-6420(01)00645-5
   BRICKMAN TJ, 1993, J BACTERIOL, V175, P4274
   Caldwell HD, 2003, J CLIN INVEST, V111, P1757, DOI 10.1172/JCI200317993
   CALDWELL HD, 1981, INFECT IMMUN, V31, P1161
   Carlson JH, 2005, INFECT IMMUN, V73, P6407, DOI 10.1128/IAI.73.10.6407-6418.2005
   Carlson JH, 2004, INFECT IMMUN, V72, P7063, DOI 10.1128/IAI.72.12.7063-7072.2004
   Clifton DR, 2004, P NATL ACAD SCI USA, V101, P10166, DOI 10.1073/pnas.0402829101
   *COMM CAR US LAB A, 1996, GUID CAR US LAB AN
   Conway DJ, 1996, J INFECT DIS, V174, P643
   Fehlner-Gardiner C, 2002, J BIOL CHEM, V277, P26893, DOI 10.1074/jbc.M203937200
   Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8
   Gomes JP, 2006, J BACTERIOL, V188, P275, DOI 10.1128/JB.188.1.275-286.2006
   Holland MJ, 1996, CLIN EXP IMMUNOL, V105, P429, DOI 10.1046/j.1365-2249.1996.d01-792.x
   HWANG YW, 1989, J BIOL CHEM, V264, P8304
   Jewett TJ, 2006, P NATL ACAD SCI USA, V103, P15599, DOI 10.1073/pnas.0603044103
   Klint M, 2007, J CLIN MICROBIOL, V45, P1410, DOI 10.1128/JCM.02301-06
   Matsumoto A, 1998, J CLIN MICROBIOL, V36, P3013
   Millman K, 2006, MICROBES INFECT, V8, P604, DOI 10.1016/j.micinf.2005.08.012
   Morrison RP, 2000, INFECT IMMUN, V68, P6038, DOI 10.1128/IAI.68.10.6038-6040.2000
   Natividad A, 2007, GENES IMMUN, V8, P288, DOI 10.1038/sj.gene.6364384
   Natividad A, 2005, GENES IMMUN, V6, P332, DOI 10.1038/sj.gene.6364182
   Natividad A, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-40
   Nelson DE, 2006, INFECT IMMUN, V74, P73, DOI 10.1128/IAI.74.1.73-80.2006
   NICHOLS RL, 1971, TRACHOMA RELATED DIS, P337
   Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x
   Perry LL, 1997, J IMMUNOL, V158, P3344
   Raulston JE, 1997, INFECT IMMUN, V65, P4539
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SCHACHTER J, 1978, NEW ENGL J MED, V298, P540, DOI 10.1056/NEJM197803092981005
   SCHACHTER J, 1978, NEW ENGL J MED, V298, P428, DOI 10.1056/NEJM197802232980805
   Shtrichman R, 2001, CURR OPIN MICROBIOL, V4, P251, DOI 10.1016/S1369-5274(00)00199-5
   Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754
   Takemoto K K, 1966, Prog Med Virol, V8, P314
   TAYLOR HR, 1982, INVEST OPHTH VIS SCI, V23, P507
   TAYLOR HR, 1981, INVEST OPHTH VIS SCI, V21, P422
   Vogel G, 2006, SCIENCE, V311, P592
   WANG SP, 1991, J CLIN MICROBIOL, V29, P1295
   West S K, 2001, Ophthalmic Epidemiol, V8, P137, DOI 10.1076/opep.8.2.137.4158
   White AG, 1997, BRIT J OPHTHALMOL, V81, P431, DOI 10.1136/bjo.81.6.431
   YUAN Y, 1989, INFECT IMMUN, V57, P1040
   Zhang JZ, 2004, PEDIATR INFECT DIS J, V23, P217, DOI 10.1097/01.inf.0000115501.60397.a6
   Zhang YX, 1997, ARCH BIOCHEM BIOPHYS, V344, P43, DOI 10.1006/abbi.1997.0178
NR 46
TC 64
Z9 65
U1 0
U2 4
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD FEB 1
PY 2008
VL 197
IS 3
BP 449
EP 456
DI 10.1086/525285
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 262EK
UT WOS:000253131600018
PM 18199030
OA No
DA 2017-08-15
ER

PT J
AU Sere, Y
   Sorho, F
   Onasanya, A
   Jobe, L
   Darboe, S
   Bojang, Y
   Touray, ML
   Pinel-Galzi, A
   Fargette, D
AF Sere, Y.
   Sorho, F.
   Onasanya, A.
   Jobe, L.
   Darboe, S.
   Bojang, Y.
   Touray, M. L.
   Pinel-Galzi, A.
   Fargette, D.
TI First report of rice yellow mottle virus in rice in the Gambia
SO PLANT DISEASE
LA English
DT News Item
C1 [Sere, Y.; Sorho, F.; Onasanya, A.] Africa Rice Ctr WARDA, Cotonou, Benin.
   [Jobe, L.; Darboe, S.; Bojang, Y.; Touray, M. L.] Natl Agr Res Inst, PMB 526, Brikama, Gambia.
   [Pinel-Galzi, A.; Fargette, D.] IRD, F-34394 Montpellier 5, France.
RP Sere, Y (reprint author), Africa Rice Ctr WARDA, 01 BP 2031, Cotonou, Benin.
CR Kouassi NK, 2005, PLANT DIS, V89, P124, DOI 10.1094/PD-89-0124
   Pinel A, 2000, ARCH VIROL, V145, P1621, DOI 10.1007/s007050070080
NR 2
TC 3
Z9 3
U1 1
U2 3
PU AMER PHYTOPATHOLOGICAL SOC
PI ST PAUL
PA 3340 PILOT KNOB ROAD, ST PAUL, MN 55121 USA
SN 0191-2917
J9 PLANT DIS
JI PLANT DIS.
PD FEB
PY 2008
VL 92
IS 2
BP 316
EP 316
DI 10.1094/PDIS-92-2-0316B
PG 1
WC Plant Sciences
SC Plant Sciences
GA 253GP
UT WOS:000252507000032
OA No
DA 2017-08-15
ER

PT J
AU Owens, S
   Fall, CHD
AF Owens, Stephen
   Fall, Caroline H. D.
TI Consequences of poor maternal micronutrition before and during early
   pregnancy
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Review
DE micronutrients; vitamins; pregnancy; fetus; peri-conceptional;
   pre-conceptional
ID SUPPLEMENTATION
AB In developing countries, micronutrient deficiencies are common and associated with poor pregnancy outcomes, which may in turn have longer-term effects on human health. The peri-conceptional period represents a particularly sensitive window of feto-placental development, during which suboptimal maternal micronutrition may have far-reaching consequences. The effects of targeted interventions during this period have been little studied in humans. (c) 2007 Royal Society of Tropical. Medicine and Hygiene. Published by Elsevier Ltd. All. rights reserved.
C1 [Owens, Stephen] MRC Keneba, MRC Labs, Banjul, Gambia.
   [Owens, Stephen] Univ Liverpool, Liverpool Sch Trop Med, Child Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England.
   [Fall, Caroline H. D.] Univ Southampton, Southampton Gen Hosp, MRC, Epidemiol Resource Ctr, Southampton SO16 6YD, Hants, England.
RP Owens, S (reprint author), MRC Keneba, MRC Labs, POB 273, Banjul, Gambia.
EM sowens@mrc.gm
FU Medical Research Council [G0400519, G0400519(71108), MC_U147585821,
   U.1475.00.004.00005.01 (85821)]
CR BLOOMFIELD FH, 2006, ARCH DIS CHILD-FETAL, V91, P299
   Catov JM, 2007, AM J EPIDEMIOL, V166, P296, DOI 10.1093/aje/kwm071
   Godfrey KM, 2007, PEDIATR RES, V61, p5R, DOI 10.1203/pdr.0b013e318045bedb
   Goh YI, 2007, CLIN PHARMACOL THER, V81, P685, DOI 10.1038/sj.clpt.6100100
   Haider BA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004905
NR 5
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD FEB
PY 2008
VL 102
IS 2
BP 103
EP 104
DI 10.1016/j.trstmh.2007.09.018
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 269LK
UT WOS:000253650300001
PM 17996910
OA No
DA 2017-08-15
ER

PT J
AU Cheung, YB
   Jeffries, D
   Thomson, A
   Milligan, P
AF Cheung, Yin Bun
   Jeffries, David
   Thomson, Andrew
   Milligan, Paul
TI A simple approach to test for interaction between intervention and an
   individual-level variable in community randomized trials
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE randomized controlled trials; community randomization; interaction;
   sample size; significance test
ID T-TEST; DESIGN; MALARIA
AB OBJECTIVE To develop a simple and robust approach for the test of interaction between community intervention and an individual-level variable suitable for use in typical situations of community randomized trials (CRTs), i.e. small number of communities but large number of subjects per community.
   METHODS We propose a method based on taking the difference between summary statistics from groups of individuals with and without an attribute within each community, then applying a two-sample t-test or Wilcoxon test to compare the distribution of within-community differences between trial arms. The method is evaluated using simulations and illustrated using data from a CRT of a health education intervention. Approximate sample size formulas are derived.
   RESULTS Analyses based on the t-test give power very close to expected level in a variety of situations, including when the summary statistics are not symmetrically distributed across communities, the covariate is not distributed as planned, and the number of communities per intervention arm ranges from 8 to 20. Even in the situation with as few as four communities per arm, the power is only slightly lower than expected. Type I error rates always closely follow 5% as required, whether the distributional assumption is correct or not. The application of the Wilcoxon test appears too conservative.
   CONCLUSIONS The proposed approach to test for interaction is valid and easy to use. The application of the t-test in this setting is robust.
C1 [Cheung, Yin Bun] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Publ Hlth, MRC, Trop Epidemiol Grp, London WC1E 7HT, England.
   [Jeffries, David] MRC Labs, Fajara, Gambia.
RP Cheung, YB (reprint author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Publ Hlth, MRC, Trop Epidemiol Grp, Keppel St, London WC1E 7HT, England.
EM yinbun.cheung@lshtm.ac.uk
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395
FU Medical Research Council [G0700837]
CR Bennett S, 2002, INT J EPIDEMIOL, V31, P839, DOI 10.1093/ije/31.4.839
   Chandramohan D, 2005, BRIT MED J, V331, P727, DOI 10.1136/bmj.331.7519.727
   DIEHR P, 1995, STAT MED, V14, P1491, DOI 10.1002/sim.4780141309
   Donner A., 2000, DESIGN ANAL CLUSTER
   Feng ZD, 2001, ANNU REV PUBL HEALTH, V22, P167, DOI 10.1146/annurev.publhealth.22.1.167
   Fisher LD, 1993, BIOSTATISTICS METHOD
   Gail MH, 1996, STAT MED, V15, P1069, DOI 10.1002/(SICI)1097-0258(19960615)15:11<1069::AID-SIM220>3.0.CO;2-Q
   GAIL MH, 1992, CONTROL CLIN TRIALS, V13, P6, DOI 10.1016/0197-2456(92)90026-V
   Gulmezoglu A Metin, 2004, BMC Med Res Methodol, V4, P2, DOI 10.1186/1471-2288-4-2
   Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319
   HEEREN T, 1987, STAT MED, V6, P79, DOI 10.1002/sim.4780060110
   Kerry SM, 1998, BRIT MED J, V316, P54
   Klar N, 1997, STAT MED, V16, P1753, DOI 10.1002/(SICI)1097-0258(19970815)16:15<1753::AID-SIM597>3.3.CO;2-5
   Marbiah NT, 1998, AM J TROP MED HYG, V58, P1
   Murray DM, 2004, AM J PUBLIC HEALTH, V94, P423, DOI 10.2105/AJPH.94.3.423
   Murray D. M., 1998, DESIGN ANAL GROUP RA
   Omar RZ, 2000, STAT MED, V19, P2675, DOI 10.1002/1097-0258(20001015)19:19<2675::AID-SIM556>3.3.CO;2-1
   Peters TJ, 2003, INT J EPIDEMIOL, V32, P840, DOI 10.1093/ije/dyg228
   Snedecor G. W., 1967, STAT METHODS
   Wang D, 2006, CLIN TRIALS PRACTICA
NR 20
TC 11
Z9 11
U1 0
U2 3
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD FEB
PY 2008
VL 13
IS 2
BP 247
EP 255
DI 10.1111/j.1365-3156.2007.01997.x
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 281GM
UT WOS:000254484900015
PM 18304272
OA No
DA 2017-08-15
ER

PT J
AU Thompson, FM
   Porter, DW
   Okitsu, SL
   Westerfeld, N
   Vogel, D
   Todryk, S
   Poulton, I
   Correa, S
   Hutchings, C
   Berthoud, T
   Dunachie, S
   Andrews, L
   Williams, JL
   Sinden, R
   Gilbert, SC
   Pluschke, G
   Zurbriggen, R
   Hill, AVS
AF Thompson, Fiona M.
   Porter, David W.
   Okitsu, Shinji L.
   Westerfeld, Nicole
   Vogel, Denise
   Todryk, Stephen
   Poulton, Ian
   Correa, Simon
   Hutchings, Claire
   Berthoud, Tamara
   Dunachie, Susanna
   Andrews, Laura
   Williams, Jack L.
   Sinden, Robert
   Gilbert, Sarah C.
   Pluschke, Gerd
   Zurbriggen, Rinaldo
   Hill, Adrian V. S.
TI Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a
   Phase IIa Clinical Trial
SO PLOS ONE
LA English
DT Article
AB Background. Previous research indicates that a combination vaccine targeting different stages of the malaria life cycle is likely to provide the most effective malaria vaccine. This trial was the first to combine two existing vaccination strategies to produce a vaccine that induces immune responses to both the pre-erythrocytic and blood stages of the P. falciparum life cycle. Methods. This was a Phase I/IIa study of a new combination malaria vaccine FFM ME-TRAP+PEV3A. PEV3A includes peptides from both the pre-erythrocytic circumsporozoite protein and the blood-stage antigen AMA-1. This study was conducted at the Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK. The participants were healthy, malaria naive volunteers, from Oxford. The interventions were vaccination with PEV3A alone, or PEV3A+FFM ME-TRAP. The main outcome measure was protection from malaria in a sporozoite challenge model. Other outcomes included measures of parasite specific immune responses induced by either vaccine; and safety, assessed by collection of adverse event data. Results. We observed evidence of blood stage immunity in PEV3A vaccinated volunteers, but no volunteers were completely protected from malaria. PEV3A induced high antibody titres, and antibodies bound parasites in immunofluorescence assays. Moreover, we observed boosting of the vaccine-induced immune response by sporozoite challenge. Immune responses induced by FFM ME-TRAP were unexpectedly low. The vaccines were safe, with comparable side effect profiles to previous trials. Although there was no sterile protection two major observations support an effect of the vaccine-induced response on blood stage parasites: (i) Lower rates of parasite growth were observed in volunteers vaccinated with PEV3A compared to unvaccinated controls (p = 0.012), and this was reflected in the PCR results from PEV3A vaccinated volunteers. These showed early control of parasitaemia by some volunteers in this group. One volunteer, who received PEV3A alone, was diagnosed very late, on day 20 compared to an average of 11.8 days in unvaccinated controls. (ii). Morphologically abnormal parasites were present in the blood of all (n = 24) PEV3A vaccinated volunteers, and in only 2/6 controls (p = 0.001). We describe evidence of vaccine-induced blood stage efficacy for the first time in a sporozoite challenge study. Trial Registration. ClinicalTrials.Gov NCT00408668
C1 [Thompson, Fiona M.; Porter, David W.; Todryk, Stephen; Poulton, Ian; Hutchings, Claire; Berthoud, Tamara; Dunachie, Susanna; Andrews, Laura; Gilbert, Sarah C.; Hill, Adrian V. S.] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [Okitsu, Shinji L.; Vogel, Denise; Pluschke, Gerd] Swiss Trop Inst, Basel, Switzerland.
   [Westerfeld, Nicole; Zurbriggen, Rinaldo] Pevion Biotech Ltd, Bern, Switzerland.
   [Correa, Simon] Medical Research Council MRC, Res Lab, Fajara, Gambia.
   [Williams, Jack L.] Walter Reed Army Inst Res, Div Commun Dis & Immunol, Silver Spring, MD USA.
   [Sinden, Robert] Imperial Coll London, Biol Dept, Infect & Immun Sect, London, England.
RP Thompson, FM (reprint author), Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England.
EM fiona.thompson@ndm.ox.ac.uk
OI Gilbert, Sarah/0000-0002-6823-9750
FU UK Medical Research Council
FX This trial was funded by a grant from the UK Medical Research Council.
CR Andrews L, 2005, AM J TROP MED HYG, V73, P191
   Bejon P, 2005, J INFECT DIS, V191, P619, DOI 10.1086/427243
   Bejon P, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010029
   CHULAY JD, 1986, AM J TROP MED HYG, V35, P66
   CLARK IA, 1981, INFECT IMMUN, V32, P1058
   Dunachie SJ, 2006, INFECT IMMUN, V74, P5933, DOI 10.1128/IAI.00590-06
   Dunachie SJ, 2006, VACCINE, V24, P2850, DOI 10.1016/j.vaccine.2005.12.041
   FERREIRA MU, 1995, J IMMUNOL METHODS, V187, P297, DOI 10.1016/0022-1759(95)00186-4
   Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107
   Genton B, 2007, PLOS ONE, V2, pe1018
   GLUCK R, 1992, J CLIN INVEST, V90, P2491, DOI 10.1172/JCI116141
   Hermsen CC, 2004, AM J TROP MED HYG, V71, P196
   Hutchings CL, 2007, INFECT IMMUN, V75, P5819, DOI 10.1128/IAI.00828-07
   JENSEN JB, 1982, SCIENCE, V216, P1230, DOI 10.1126/science.7043736
   KARUNAWEERA ND, 1992, CLIN EXP IMMUNOL, V88, P499
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   KLOTZ FW, 1987, J EXP MED, V165, P359, DOI 10.1084/jem.165.2.359
   Malkin EM, 2005, INFECT IMMUN, V73, P3677, DOI 10.1128/IAI.73.6.3677-3685.2005
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   MILLER LH, 1986, SCIENCE, V234, P1349, DOI 10.1126/science.2431481
   Moorthy VS, 2004, J INFECT DIS, V189, P2213, DOI 10.1086/421118
   Mueller MS, 2003, INFECT IMMUN, V71, P4749, DOI 10.1128/IAI.71.8.4749-4758.2003
   Okitsu SL, 2007, CHEM BIOL, V14, P577, DOI 10.1016/j.chembiol.2007.04.008
   Pombo DJ, 2002, LANCET, V360, P610, DOI 10.1016/S0140-6736(02)09784-2
   Richie TL, 2002, NATURE, V415, P694, DOI 10.1038/415694a
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   Taliaferro WH, 1944, J INFECT DIS, V75, P1, DOI 10.1093/infdis/75.1.1
   Vuola JM, 2005, J IMMUNOL, V174, P449
   Walther M, 2006, INFECT IMMUN, V74, P2706, DOI 10.1128/IAI.74.5.2706-2716.2006
   Wang RB, 1996, IMMUNOL LETT, V53, P83, DOI 10.1016/S0165-2478(96)02610-7
   Webster DP, 2006, VACCINE, V24, P3026, DOI 10.1016/j.vaccine.2005.10.058
   Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102
NR 33
TC 54
Z9 55
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 30
PY 2008
VL 3
IS 1
AR e1493
DI 10.1371/journal.pone.0001493
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 366SR
UT WOS:000260504200006
PM 18231580
OA gold
DA 2017-08-15
ER

PT J
AU Ndugwa, RP
   Ramroth, H
   Muller, O
   Jasseh, M
   Sie, A
   Kouyate, B
   Greenwood, B
   Becher, H
AF Ndugwa, Robert P.
   Ramroth, Heribert
   Mueller, Olaf
   Jasseh, Momodou
   Sie, Ali
   Kouyate, Bocar
   Greenwood, Brian
   Becher, Heiko
TI Comparison of all-cause and malaria-specific mortality from two West
   African countries with different malaria transmission patterns
SO MALARIA JOURNAL
LA English
DT Review
ID TREATED BED NETS; PRIMARY-HEALTH-CARE; UPPER RIVER DIVISION; SUB-SAHARAN
   AFRICA; RURAL BURKINA-FASO; GAMBIAN CHILDREN; PLASMODIUM-FALCIPARUM;
   CHILDHOOD MORTALITY; TARGETED CHEMOPROPHYLAXIS; COST-EFFECTIVENESS
AB Background: Malaria is a leading cause of death in children below five years of age in sub-Saharan Africa. All-cause and malaria-specific mortality rates for children under-five years old in a mesoendemic malaria area (The Gambia) were compared with those from a hyper/holoendemic area (Burkina Faso).
   Methods: Information on observed person-years (PY), deaths and cause of death was extracted from online search, using key words: "Africa, The Gambia, Burkina Faso, malaria, Plasmodium falciparum, mortality, child survival, morbidity". Missing person-years were estimated and all-cause and malaria-specific mortality were calculated as rates per 1,000 PY. Studies were classified as longitudinal/clinical studies or surveys/censuses. Linear regression was used to investigate mortality trends.
   Results: Overall, 39 and 18 longitudinal/clinical studies plus 10 and 15 surveys and censuses were identified for The Gambia and Burkina Faso respectively (1960-2004). Model-based estimates for under-five all-cause mortality rates show a decline from 1960 to 2000 in both countries (Burkina Faso: from 71.8 to 39.0), but more markedly in The Gambia (from 104.5 to 28.4). The weighted-average malaria-specific mortality rate per 1000 person-years for Burkina Faso (15.4, 95% CI: 13.0-18.3) was higher than that in The Gambia (9.5, 95% CI: 9.1-10.1). Malaria mortality rates did not decline over time in either country.
   Conclusion: Child mortality in both countries declined significantly in the period 1960 to 2004, possibly due to socio-economic development, improved health services and specific intervention projects. However, there was little decline in malaria mortality suggesting that there had been no major impact of malaria control programmes during this period. The difference in malaria mortality rates across countries points to significant differences in national disease control policies and/or disease transmission patterns.
C1 [Ndugwa, Robert P.; Ramroth, Heribert; Mueller, Olaf; Becher, Heiko] Univ Heidelberg, Dept Trop Hyg & Publ Hlth, D-69120 Heidelberg, Germany.
   [Jasseh, Momodou] MRC Labs, Farafenni, Gambia.
   [Sie, Ali] Ctr Rech & Sante Nouna, Nouna, Burkina Faso.
   [Kouyate, Bocar] Ctr Natl Rech Format Paludisme, Ouagadougou, Burkina Faso.
   [Greenwood, Brian] London Sch Hyg & Trop Med, London WC1, England.
RP Becher, H (reprint author), Univ Heidelberg, Dept Trop Hyg & Publ Hlth, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.
EM robert.ndugwa@urz.uni-heidelberg.de; hramroth@urz.uni-heidelberg.de;
   olaf.mueller@urz.uni-heidelberg.de; mjasseh@mrc.gm; sieali@yahoo.fr;
   bocar.crsn@fasonet.bf; Brian.Greenwood@lshtm.ac.uk;
   heiko.becher@urz.uniheidelberg.de
OI SIE, Ali/0000-0002-3959-2520
FU Medical Research Council [MC_UP_A900_1123]
CR Aaby P, 2006, VACCINE, V24, P4701, DOI 10.1016/j.vaccine.2006.03.038
   Adjuik M, 2006, B WORLD HEALTH ORGAN, V84, P181, DOI 10.2471/BLT.05.026492
   Aikins MK, 1998, SOC SCI MED, V46, P181, DOI 10.1016/S0277-9536(97)00145-7
   ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E
   ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O
   ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P13, DOI 10.1016/0035-9203(93)90170-U
   Becher H, 2008, AM J TROP MED HYG, V78, P106
   BICEGO GT, 1996, INFANT CHILD MORTALI, P36
   BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219
   Bojang KA, 1997, ANN TROP PAEDIATR, V17, P355
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8
   *CENTR STAT DEP, 1996, POP HOUS CENS 1993 B
   DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0
   Deen JL, 2002, J TROP PEDIATRICS, V48, P78, DOI 10.1093/tropej/48.2.78
   DEFRANCISCO A, 1994, J TROP MED HYG, V97, P69
   Department of State for Health and Social Welfare, 2002, REP NAT SURV MAT PER
   Diallo DA, 2004, B WORLD HEALTH ORGAN, V82, P85
   Esteve J, 1994, IARC SCI PUBL, V128, P1
   FASO B, 1997, DEMOGRAPHIE 2 GEN PO
   GAMBLE D P, 1952, J Trop Med Hyg, V55, P145
   GAZIN P, 1990, THESIS U MONTPELIER
   Gemperli A, 2004, AM J EPIDEMIOL, V159, P64, DOI 10.1093/aje/kwh001
   GREENWOOD AM, 1992, T ROY SOC TROP MED H, V86, P483, DOI 10.1016/0035-9203(92)90078-Q
   Greenwood BM, 1995, T ROY SOC TROP MED H, V89, P629, DOI 10.1016/0035-9203(95)90419-0
   GREENWOOD BM, 1989, T ROY SOC TROP MED H, V83, P589, DOI 10.1016/0035-9203(89)90362-3
   GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2
   GREENWOOD BM, 1990, J TROP MED HYG, V93, P87
   GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91
   Habluetzel A, 1997, TROP MED INT HEALTH, V2, P855, DOI 10.1046/j.1365-3156.1997.d01-413.x
   Hay SI, 2005, NAT REV MICROBIOL, V3, P81, DOI 10.1038/nrmicro1069
   Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3
   Hill AG, 2000, TROP MED INT HEALTH, V5, P107, DOI 10.1046/j.1365-3156.2000.00528.x
   *INDEPTH NETW, 2002, POP HLTH SURV INDEPT, V1, P356
   Jaffar S, 1997, AM J TROP MED HYG, V57, P20
   Jaffar S, 2000, TROP MED INT HEALTH, V5, P628, DOI 10.1046/j.1365-3156.2000.00610.x
   Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x
   KORAM KA, 1995, T ROY SOC TROP MED H, V89, P146, DOI 10.1016/0035-9203(95)90471-9
   Korenromp EL, 2004, INT J EPIDEMIOL, V33, P1293, DOI 10.1093/ije/dyh182
   Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218
   Maxwell CA, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-28
   Mbacke C, 1988, Pop Sahel, P14
   MENON A, 1990, T ROY SOC TROP MED H, V84, P768, DOI 10.1016/0035-9203(90)90071-L
   MENON A, 1987, LANCET, V1, P1029
   *MICS, CHILD SURV HLTH
   MILLS A, 1994, J TROP MED HYG, V97, P325
   Modiano D, 1998, AM J TROP MED HYG, V59, P539
   Muller O, 2003, TROP MED INT HEALTH, V8, P290, DOI 10.1046/j.1365-3156.2003.01030.x
   Muller O, 1999, LANCET, V353, P673, DOI 10.1016/S0140-6736(05)75469-6
   Muller O, 1997, SOC SCI MED, V44, P1903, DOI 10.1016/S0277-9536(96)00299-7
   MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P447
   Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4
   Omumbo JA, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-17
   PACQUEMARGOLIS S, 1993, GAMBIAN CONTRACEPTIV
   Pelletier DL, 2003, J NUTR, V133, P107
   Rayco-Solon P, 2004, TROP MED INT HEALTH, V9, P1151, DOI 10.1111/j.1365-3156.2004.01325.x
   ROBERTSON RL, 1985, J TROP MED HYG, V88, P343
   Rowe AK, 2006, INT J EPIDEMIOL, V35, P691, DOI 10.1093/ije/dy1027
   Sankoh OA, 2001, INT J EPIDEMIOL, V30, P485, DOI 10.1093/ije/30.3.485
   Smith T, 2004, AM J TROP MED HYG, V71, P80
   Smith TA, 2001, TRENDS PARASITOL, V17, P145, DOI 10.1016/S1471-4922(00)01814-6
   SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1
   Snow RW, 2001, TRENDS PARASITOL, V17, P593, DOI 10.1016/S1471-4922(01)02031-1
   SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4
   Snow RW, 2002, ADV PARASIT, V52, P235, DOI 10.1016/S0065-308X(02)52013-3
   Snow RW, 1998, J INFECT DIS, V177, P819
   SNOW RW, 1987, LANCET, V1, P1493
   Soleman N, 2006, B WORLD HEALTH ORGAN, V84, P239, DOI 10.2471/BLT.05.027003
   Traore C, 2003, THESIS U HEIDELBERG
   vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201
   Vaugelade J, 2004, BRIT MED J, V329, P1309, DOI 10.1136/bmj.38261.496366.82
   von Seidlein L, 2003, T ROY SOC TROP MED H, V97, P217
NR 72
TC 15
Z9 15
U1 1
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JAN 18
PY 2008
VL 7
AR 15
DI 10.1186/1475-2875-7-15
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 267UD
UT WOS:000253533800001
PM 18205915
OA gold
DA 2017-08-15
ER

PT J
AU Hammond, AS
   McConkey, SJ
   Hill, PC
   Crozier, S
   Klein, MR
   Adegbola, RA
   Rowland-Jones, S
   Brookes, RH
   Whittle, H
   Jaye, A
AF Hammond, Abdulrahman S.
   McConkey, Samuel J.
   Hill, Philip C.
   Crozier, Sarah
   Klein, Michel R.
   Adegbola, Richard A.
   Rowland-Jones, Sarah
   Brookes, Roger H.
   Whittle, Hilton
   Jaye, Assan
TI Mycobacterial T cell responses in HIV-infected patients with advanced
   immunosuppression
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 2nd Meeting on Measuring Antigen-Specific Immune Responses
CY JUN 14-17, 2006
CL Santorini, GREECE
ID TUBERCULOSIS INFECTION; PULMONARY TUBERCULOSIS; FUSION PROTEIN;
   ANTIGENS; PROTECTION; DIAGNOSIS; CONTACT; GAMBIA; ESAT-6; ASSAY
AB Antimycobacterial T cell reactivity at different stages of HIV infection was investigated. Subjects were screened with purified protein derivative (PPD), early secreted antigenic target (ESAT) -6, and culture filtrate protein (CFP) -10 antigens for interferon (IFN)-gamma-producing effector T cell responses by direct ex vivo enzyme-linked immunospot (ELISpot) assay. The proportion of responders to PPD tuberculin decreased with a reduction in CD4 T cell count, whereas the proportion of responder to ESAT-6 and CFP-10 did not. The main sources of IFN-gamma secretion were CD4 cells, and the relative responses to ESAT-6 and CFP-10 significantly increased in HIV-infected patients with decreasing CD4 cell count. This may reflect early signs of reactivation, reinfection, or a restricted, inefficient immune response to Mycobacterium tuberculosis.
C1 [Hammond, Abdulrahman S.; McConkey, Samuel J.; Hill, Philip C.; Crozier, Sarah; Klein, Michel R.; Adegbola, Richard A.; Rowland-Jones, Sarah; Brookes, Roger H.; Whittle, Hilton; Jaye, Assan] MRC Labs, Bacterial & Viral Dis Programme, Fajara, Gambia.
RP Hammond, AS (reprint author), MRC Labs, Bacterial Dis Program, Atlantic Blvd,Fajara,POB 273, Banjul, Gambia.
EM ahammond@mrc.gm
RI Hammond, Abdulrahman/F-1541-2011; McConkey, Samuel/E-7307-2012
OI McConkey, Samuel/0000-0001-9085-7793; Crozier, Sarah/0000-0002-9524-1127
FU Medical Research Council [MC_U190071468, MC_U190085847, MC_U190085854]
CR Arend SM, 2001, CLIN DIAGN LAB IMMUN, V8, P1089, DOI 10.1128/CDLI.8.6.1089-1096.2001
   Bates I, 2004, LANCET INFECT DIS, V4, P267, DOI 10.1016/S1473-3099(04)01002-3
   Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008
   DiPerri G, 1996, TUBERCLE LUNG DIS, V77, P244, DOI 10.1016/S0962-8479(96)90008-8
   DUNCAN LE, 1995, T ROY SOC TROP MED H, V89, P37, DOI 10.1016/0035-9203(95)90649-5
   Hervas-Stubbs S, 2006, INFECT IMMUN, V74, P3396, DOI 10.1128/IAI.02086-05
   Hill PC, 2005, J CLIN MICROBIOL, V43, P2070, DOI 10.1128/JCM.43.5.2070-2074.2005
   Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030
   Karakousis PC, 2004, LANCET INFECT DIS, V4, P557, DOI 10.1016/S1473-3099(04)01130-2
   Kaufmann SHE, 2005, NAT MED, V11, pS33, DOI 10.1038/nm1221
   Langermans JAM, 2005, VACCINE, V23, P2740, DOI 10.1016/j.vaccine.2004.11.051
   Silveira H, 1997, CLIN EXP IMMUNOL, V110, P26, DOI 10.1111/j.1365-2249.1997.509-ce1407.x
   van der Loeff MFS, 2002, AIDS, V16, P1775
   van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000
   van Pinxteren LAH, 2000, EUR J IMMUNOL, V30, P3689, DOI 10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4
NR 15
TC 20
Z9 20
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 15
PY 2008
VL 197
IS 2
BP 295
EP 299
DI 10.1086/524685
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 251TX
UT WOS:000252399200019
PM 18194089
OA No
DA 2017-08-15
ER

PT J
AU Moore, SE
   Jalil, F
   Szu, SC
   Hahn-Zoric, M
   Prentice, AM
   Hanson, LA
AF Moore, Sophie E.
   Jalil, Fehmida
   Szu, Shousun Chen
   Hahn-Zoric, Mirjana
   Prentice, Andrew M.
   Hanson, Lars A.
TI Revaccination does not improve an observed deficit in antibody responses
   in Pakistani adults born of a lower birth weight
SO VACCINE
LA English
DT Article
DE vaccine responses; immune; programming; birth weight
ID B CONJUGATE VACCINES; CAPSULAR POLYSACCHARIDE; BREAST-MILK; AVIDITY;
   VACCINATION; CHILDREN; DISEASE; IMMUNIZATION; INFANTS; ORIGINS
AB We have previously shown that the generation of antibodies to a polysaccharide vaccine (Typhim Vi) is compromised in Pakistani adults born of a lower birth weight. To assess whether this represents a true B-cell-dependent deficit, we revaccinated subjects with a second dose of the same vaccine and with a polysaccharide-protein conjugate vaccine to a different polysaccharide antigen (conjugated Haemophilus influenzae type b (Nib) vaccine). Anti-Vi IgG levels remained positively correlated with birth weight (p = 0.0284) but no associations were observed between anti-Hib IgG levels and size at birth. These findings indicate that small size at birth results in a poor antibody response to vaccination with a polysaccharide antigen vaccine in adulthood, even following a second dose of the vaccine. No such association was observed in response to a polysaccharide-protein conjugate vaccine indicating an early-life programming effect on the generation of antibodies during a B-cell-dependent immune response. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Moore, Sophie E.] MRC Labs, MRC Keneba, Banjul, Gambia.
   [Moore, Sophie E.; Prentice, Andrew M.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
   [Jalil, Fehmida] King Edward Med Coll, Dept Social & Prevent Paediat, Lahore, Pakistan.
   [Jalil, Fehmida] Mayo Hosp, Lahore, Pakistan.
   [Szu, Shousun Chen] Natl Inst Hlth, Bethesda, MD 20892 USA.
   [Hahn-Zoric, Mirjana; Hanson, Lars A.] Univ Gothenburg, Dept Clin Immunol, Gothenburg, Sweden.
RP Moore, SE (reprint author), MRC Labs, MRC Keneba, POB 273, Banjul, Gambia.
EM Sophie.Moore@lshtm.ac.uk
CR Ada G, 2003, CLIN MICROBIOL INFEC, V9, P79, DOI 10.1046/j.1469-0691.2003.00530.x
   Byrne CD, 2000, J CLIN PATHOL, V53, P822, DOI 10.1136/jcp.53.11.822
   CLAESSON BA, 1990, J PEDIATR-US, V116, P929, DOI 10.1016/S0022-3476(05)80655-9
   Collinson AC, 2003, ACTA PAEDIATR, V92, P1014, DOI 10.1080/08035250310004379
   Goldblatt D, 1998, J INFECT DIS, V177, P1112
   HANSON LA, 2006, P NUTR SOC, V66, P384
   Holt P, 2004, CHEM IMMUNOL, V84, P102
   Jalil F, 1989, Acta Paediatr Scand Suppl, V350, P44
   KEITEL WA, 1994, VACCINE, V12, P195, DOI 10.1016/0264-410X(94)90194-5
   Kossaczka Z, 1999, INFECT IMMUN, V67, P5806
   Lane P, 1996, CLIN EXP IMMUNOL, V105, P10, DOI 10.1046/j.1365-2249.1996.d01-743.x
   Lin FYC, 2001, NEW ENGL J MED, V344, P1263, DOI 10.1056/NEJM200104263441701
   McDade TW, 2001, AM J CLIN NUTR, V74, P543
   MELLANDER L, 1993, ACTA PAEDIATR, V82, P552, DOI 10.1111/j.1651-2227.1993.tb12752.x
   Moore SE, 2004, AM J CLIN NUTR, V80, P453
   Moore SE, 2006, P NUTR SOC, V65, P311, DOI 10.1079/PNS2006503
   Moore SE, 2006, TROP MED INT HEALTH, V11, P1529, DOI 10.1111/j.1365-3156.2006.01700.x
   Ngom PT, 2004, AM J CLIN NUTR, V80, P722
   PULLEN GR, 1986, J IMMUNOL METHODS, V86, P83, DOI 10.1016/0022-1759(86)90268-1
   ROBERTON DM, 1988, SCAND J IMMUNOL, V28, P783, DOI 10.1111/j.1365-3083.1988.tb01512.x
   SCHLESINGER Y, 1992, JAMA-J AM MED ASSOC, V267, P1489, DOI 10.1001/jama.267.11.1489
   Singhal A, 2004, LANCET, V363, P1642, DOI 10.1016/S0140-6736(04)16210-7
   SUTTON A, 1985, J IMMUNOL METHODS, V82, P215, DOI 10.1016/0022-1759(85)90353-9
   Weller S, 2005, TRENDS IMMUNOL, V26, P85, DOI 10.1016/j.it.2004.11.004
   WHO, 1983, MEAS CHANG NUTR STAT
NR 25
TC 12
Z9 12
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JAN 10
PY 2008
VL 26
IS 2
BP 158
EP 165
DI 10.1016/j.vaccine.2007.11.007
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 261DT
UT WOS:000253060000004
PM 18068877
OA No
DA 2017-08-15
ER

PT J
AU Kirby, MJ
   Green, C
   Milligan, PM
   Sismanidis, C
   Jasseh, M
   Conway, DJ
   Lindsay, SW
AF Kirby, Matthew J.
   Green, Clare
   Milligan, Paul M.
   Sismanidis, Charalambos
   Jasseh, Momadou
   Conway, David J.
   Lindsay, Steven W.
TI Risk factors for house-entry by malaria vectors in a rural town and
   satellite villages in The Gambia
SO MALARIA JOURNAL
LA English
DT Article
ID ANOPHELES-GAMBIAE; WEST-AFRICA; USAMBARA MOUNTAINS; UNTREATED BEDNETS;
   TRANSMISSION; MOSQUITOS; COMPLEX; AREA; CULICIDAE; INFECTION
AB Background: In the pre-intervention year of a randomized controlled trial investigating the protective effects of house screening against malaria-transmitting vectors, a multi-factorial risk factor analysis study was used to identify factors that influence mosquito house entry.
   Methods: Mosquitoes were sampled using CDC light traps in 976 houses, each on one night, in Farafenni town and surrounding villages during the malaria-transmission season in The Gambia. Catches from individual houses were both (a) left unadjusted and (b) adjusted relative to the number of mosquitoes caught in four sentinel houses that were operated nightly throughout the period, to allow for night-tonight variation. Houses were characterized by location, architecture, human occupancy and their mosquito control activities, and the number and type of domestic animals within the compound.
   Results: 106,536 mosquitoes were caught, of which 55% were Anopheles gambiae sensu lato, the major malaria vectors in the region. There were seven fold higher numbers of An. gambiae s.l. in the villages (geometric mean per trap night = 43.7, 95% confidence intervals, CIs = 39.5-48.4) than in Farafenni town (6.3, 5.7-7.2) and significant variation between residential blocks (p < 0.001). A negative binomial multivariate model performed equally well using unadjusted or adjusted trap data. Using the unadjusted data the presence of nuisance mosquitoes was reduced if the house was located in the town (odds ratio, OR = 0.11, 95% CIs = 0.09-0.13), the eaves were closed (OR = 0.71, 0.60-0.85), a horse was tethered near the house (OR = 0.77, 0.73-0.82), and churai, a local incense, was burned in the room at night (OR = 0.56, 0.47-0.66). Mosquito numbers increased per additional person in the house (OR = 1.04, 1.02-1.06) or trapping room (OR = 1.19, 1.13-1.25) and when the walls were made of mud blocks compared with concrete (OR = 1.44, 1.10-1.87).
   Conclusion: This study demonstrates that the risk of malaria transmission is greatest in rural areas, where large numbers of people sleep in houses made of mud blocks, where the eaves are open, horses are not tethered nearby and where churai is not burnt at night. These factors need to be considered in the design and analysis of intervention studies designed to reduce malaria transmission in The Gambia and other parts of sub-Saharan Africa.
C1 [Kirby, Matthew J.; Green, Clare; Lindsay, Steven W.] Univ Durham, Sci Labs, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
   [Milligan, Paul M.; Sismanidis, Charalambos] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Jasseh, Momadou; Conway, David J.] MRC Labs, Fajara 273, Gambia.
RP Lindsay, SW (reprint author), Univ Durham, Sci Labs, Sch Biol & Biomed Sci, S Rd, Durham DH1 3LE, England.
EM m.j.kirby@durham.ac.uk; clare.green@durham.ac.uk;
   paul.milligan@lshtm.ac.uk; charalambos.sismanidis@lshtm.ac.uk;
   mjasseh@mrc.gm; dconway@mrc.gm; S.W.Lindsay@durham.ac.uk
RI Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Conway, David/0000-0002-8711-3037
FU Medical Research Council [, G0700837, MC_UP_A900_1123]
CR Balls MJ, 2004, T ROY SOC TROP MED H, V98, P400, DOI 10.1016/j.trstmh.2003.11.005
   Bodker R, 2003, J MED ENTOMOL, V40, P706, DOI 10.1603/0022-2585-40.5.706
   Bogh C, 2003, B ENTOMOL RES, V93, P279, DOI 10.1079/BER2003239
   Bogh C, 2001, J MED ENTOMOL, V38, P822
   Bogh C, 2007, AM J TROP MED HYG, V76, P875
   BRYAN JH, 1983, ANN TROP MED PARASIT, V77, P1
   BRYAN JH, 1979, T ROY SOC TROP MED H, V73, P463, DOI 10.1016/0035-9203(79)90179-2
   Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X
   COLUZZI M, 1984, B WORLD HEALTH ORGAN, V62, P107
   Costantini C, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P209
   Ernst KC, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-78
   *FAO EIO WHO, 1997, AN HLTH YB
   Fontenille D, 1997, T ROY SOC TROP MED H, V91, P647, DOI 10.1016/S0035-9203(97)90506-X
   GAMAGEMENDIS AC, 1991, AM J TROP MED HYG, V45, P77
   Keating J, 2005, J BIOSOC SCI, V37, P761, DOI 10.1017/S0021932004007182
   Knols BGJ, 1995, T ROY SOC TROP MED H, V89, P604, DOI 10.1016/0035-9203(95)90406-9
   Lemasson JJ, 1997, J MED ENTOMOL, V34, P396
   LINDSAY SW, 1995, MED VET ENTOMOL, V9, P50, DOI 10.1111/j.1365-2915.1995.tb00116.x
   LINDSAY SW, 1993, J MED ENTOMOL, V30, P368
   Lindsay SW, 2003, TROP MED INT HEALTH, V8, P512, DOI 10.1046/j.1365-3156.2003.01059.x
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P253, DOI 10.1111/j.1365-2915.1989.tb00225.x
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P97, DOI 10.1111/j.1365-2915.1989.tb00481.x
   Lindsay SW, 2002, TRENDS PARASITOL, V18, P510, DOI 10.1016/S1471-4922(02)02382-6
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P263, DOI 10.1111/j.1365-2915.1989.tb00226.x
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90171-L
   LINDSAY SW, 1988, T ROY SOC TROP MED H, V82, P645, DOI 10.1016/0035-9203(88)90546-9
   LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553
   Mackinnon MJ, 2005, PLOS MED, V2, P1253, DOI 10.1371/journa;.pmed.0020340
   Matthys B, 2006, AM J TROP MED HYG, V75, P1223
   Mbogo CNM, 1999, AM J TROP MED HYG, V60, P781
   PORT GR, 1982, B ENTOMOL RES, V69, P43
   Robert V, 1998, TROP MED INT HEALTH, V3, P667
   SAMANI FZ, 1987, J TROP MED HYG, V90, P69
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   Sintasath DM, 2005, AM J TROP MED HYG, V72, P682
   SNOW R, 1989, ANN TROP MED PARASIT, V81, P449
   SNOW WF, 1987, MED VET ENTOMOL, V1, P9, DOI 10.1111/j.1365-2915.1987.tb00318.x
   SUBRAMANIAN S, 1991, INDIAN J MALARIOL, V37, P28
   Takken W, 1999, ANNU REV ENTOMOL, V44, P131, DOI 10.1146/annurev.ento.44.1.131
   TAKKEN W, 2003, ECOLOGICAL ASPECTS A, P2075
   Thomas CJ, 2000, T ROY SOC TROP MED H, V94, P159, DOI 10.1016/S0035-9203(00)90257-8
   WHITE GB, 1972, T ROY SOC TROP MED H, V66, P572, DOI 10.1016/0035-9203(72)90302-1
   *WHO, 1982, WORLD HLTH ORG
   Ye Y, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-8
NR 44
TC 59
Z9 60
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JAN 7
PY 2008
VL 7
AR 2
DI 10.1186/1475-2875-7-2
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 280WP
UT WOS:000254457700001
PM 18179686
OA gold
DA 2017-08-15
ER

PT J
AU Hill, PC
   Jackson-Sillah, DJ
   Fox, A
   Brookes, RH
   de Jong, BC
   Lugos, MD
   Adetifa, IM
   Donkor, SA
   Aiken, AM
   Howie, SR
   Corrah, T
   McAdam, KP
   Adegbola, RA
AF Hill, Philip C.
   Jackson-Sillah, Dolly J.
   Fox, Annette
   Brookes, Roger H.
   de Jong, Bouke C.
   Lugos, Moses D.
   Adetifa, Ifedayo M.
   Donkor, Simon A.
   Aiken, Alex M.
   Howie, Stephen R.
   Corrah, Tumani
   McAdam, Keith P.
   Adegbola, Richard A.
TI Incidence of Tuberculosis and the Predictive Value of ELISPOT and
   Mantoux Tests in Gambian Case Contacts
SO PLOS ONE
LA English
DT Article
ID INTERFERON-GAMMA ASSAY; LINKED IMMUNOSPOT ASSAY; HEALTH-CARE WORKERS;
   MYCOBACTERIUM-TUBERCULOSIS; SKIN-TEST; HOUSEHOLD CONTACTS; PULMONARY
   TUBERCULOSIS; RISK-FACTORS; INFECTION; DIAGNOSIS
AB Background. Studies of Tuberculosis (TB) case contacts are increasingly being utilised for understanding the relationship between M. tuberculosis and the human host and for assessing new interventions and diagnostic tests. We aimed to identify the incidence rate of new TB cases among TB contacts and to relate this to their initial Mantoux and ELISPOT test results. Methods and Findings. After initial Mantoux and ELISPOT tests and exclusion of co-prevalent TB cases, we followed 2348 household contacts of sputum smear positive TB cases. We visited them at 3 months, 6 months, 12 months, 18 months and 24 months, and investigated those with symptoms consistent with TB. Those who were diagnosed separately at a government clinic had a chest x-ray. Twenty six contacts were diagnosed with definite TB over 4312 person years of follow-up (Incidence rate 603/100,000 person years; 95% Confidence Interval, 370-830). Nine index and secondary case pairs had cultured isolates available for genotyping. Of these, 6 pairs were concordant and 3 were discordant. 2.5% of non-progressors were HIV positive compared to 12% of progressors (HR 6.2; 95% CI 1.7-22.5; p = 0.010). 25 secondary cases had initial Mantoux results, 14 (56%) were positive; 21 had initial ELISPOT results, 11 (52%) were positive; 15 (71%) of 21 tested were positive by one or the other test. Of the 6 contacts who had concordant isolates with their respective index case, 4 (67%) were Mantoux positive at recruitment, 3 (50%) were ELISPOT positive; 5 (83%) were positive by one or other of the two tests. ELISPOT positive contacts, and those with discordant results, had a similar rate of progression to those who were Mantoux positive. Those negative on either or both tests had the lowest rate of progression. Conclusions. The incidence rate of TB disease in Gambian TB case contacts, after screening for co-prevalent cases, was 603/100,000 person years. Since initial ELISPOT test and Mantoux tests were each positive in only just over half of cases, but 71% were positive by one or other test, positivity by either might be the best indication for preventive treatment. These data do not support the replacement of the Mantoux test by an ELISPOT test in The Gambia or similar settings.
C1 [Hill, Philip C.; Jackson-Sillah, Dolly J.; Fox, Annette; Brookes, Roger H.; de Jong, Bouke C.; Lugos, Moses D.; Adetifa, Ifedayo M.; Donkor, Simon A.; Aiken, Alex M.; Howie, Stephen R.; Corrah, Tumani; McAdam, Keith P.; Adegbola, Richard A.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
RP Hill, PC (reprint author), MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
EM pandmhill@hotmail.com
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU Medical Research Council (UK); European Commission
FX This study was funded by the Medical Research Council (UK) and the
   European Commission. Neither funder had any role in conducting the study
   or preparing the manuscript.
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   EGSMOSE T, 1965, B WORLD HEALTH ORGAN, V33, P419
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9
   Ewer K, 2006, AM J RESP CRIT CARE, V174, P831, DOI 10.1164/rccm.200511-1783OC
   Ferebee S H, 1970, Bibl Tuberc, V26, P28
   FEREBEE SH, 1962, AM REV RESPIR DIS, V85, P490
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6
   Guwatudde D, 2003, AM J EPIDEMIOL, V158, P887, DOI 10.1093/aje/kwg227
   Hill PC, 2006, PEDIATRICS, V117, P1542, DOI 10.1542/peds.2005-2095
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Hill PC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000183
   Hill PC, 2007, PLOS MED, V4, P1061, DOI 10.1371/journal.pmed.0040192
   Hill PC, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-156
   Jackson-Sillah D, 2007, T ROY SOC TROP MED H, V101, P594, DOI 10.1016/j.trstmh.2007.02.001
   Jeffries DJ, 2006, INT J TUBERC LUNG D, V10, P192
   Jeffries DJ, 2004, INT J TUBERC LUNG D, V8, P1095
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907
   Kaufmann SHE, 2007, NAT MED, V13, P299, DOI 10.1038/nm0307-299
   Lienhardt C, 2005, INT J EPIDEMIOL, V34, P914, DOI 10.1093/ije/dyi100
   Mazurek GH, 2001, JAMA-J AM MED ASSOC, V286, P1740, DOI 10.1001/jama.286.14.1740
   *NIH CLIN EXC, 2006, CLIN GUID, V33
   Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746
   Pai M, 2006, AM J RESP CRIT CARE, V174, P349, DOI 10.1164/rccm.200604-472OC
   PUFFER RR, 1952, AM REV TUBERC PULM, V65, P111
   TAYLOR RE, 2007, ARCH DIS CH IN PRESS
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406
   Verver S, 2004, LANCET, V363, P212, DOI 10.1016/S0140-6736(03)15332-9
   [Anonymous], 2005, MMWR RECOMM REP, V54, P1
NR 29
TC 87
Z9 90
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 2
PY 2008
VL 3
IS 1
AR e1379
DI 10.1371/journal.pone.0001379
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 366GP
UT WOS:000260468900008
PM 18167540
OA gold
DA 2017-08-15
ER

PT J
AU Vannberg, FO
   Chapman, SJ
   Khor, CC
   Tosh, K
   Floyd, S
   Jackson-Sillah, D
   Crampin, A
   Sichali, L
   Bah, B
   Gustafson, P
   Aaby, P
   McAdam, KPWJ
   Bah-Sow, O
   Lienhardt, C
   Sirugo, G
   Fine, P
   Hill, AVS
AF Vannberg, Fredrik O.
   Chapman, Stephen J.
   Khor, Chiea C.
   Tosh, Kerrie
   Floyd, Sian
   Jackson-Sillah, Dolly
   Crampin, Amelia
   Sichali, Lifted
   Bah, Boubacar
   Gustafson, Per
   Aaby, Peter
   McAdam, Keith P. W. J.
   Bah-Sow, Oumou
   Lienhardt, Christian
   Sirugo, Giorgio
   Fine, Paul
   Hill, Adrian V. S.
TI CD209 Genetic Polymorphism and Tuberculosis Disease
SO PLOS ONE
LA English
DT Article
ID PATTERN-RECOGNITION RECEPTORS; HUMAN DENDRITIC CELLS; LECTINS DC-SIGN;
   MYCOBACTERIUM-TUBERCULOSIS; IMMUNE-RESPONSES; TRANS-INFECTION; CUTTING
   EDGE; RISK-FACTORS; T-CELLS; VIRUS
AB Background. Tuberculosis causes significant morbidity and mortality worldwide, especially in sub-Saharan Africa. DC-SIGN, encoded by CD209, is a receptor capable of binding and internalizing Mycobacterium tuberculosis. Previous studies have reported that the CD209 promoter single nucleotide polymorphism (SNP)-336A/G exerts an effect on CD209 expression and is associated with human susceptibility to dengue, HIV-1 and tuberculosis in humans. The present study investigates the role of the CD209-336A/G variant in susceptibility to tuberculosis in a large sample of individuals from sub-Saharan Africa. Methods and Findings. A total of 2,176 individuals enrolled in tuberculosis case-control studies from four sub-Saharan Africa countries were genotyped for the CD209-336A/G SNP (rs4804803). Significant overall protection against pulmonary tuberculosis was observed with the -336G allele when the study groups were combined (n = 914 controls vs. 1262 cases, Mantel-Haenszel 2x2 chi(2) = 7.47, P = 0.006, odds ratio = 0.86, 95% CI 0.77-0.96). In addition, the patients with -336GG were associated with a decreased risk of cavitory tuberculosis, a severe form of tuberculosis disease (n = 557, Pearson's 262 chi(2) = 17.34, P = 0.00003, odds ratio = 0.42, 95% CI 0.27-0.65). This direction of association is opposite to a previously observed result in a smaller study of susceptibility to tuberculosis in a South African Coloured population, but entirely in keeping with the previously observed protective effect of the -336G allele. Conclusion. This study finds that the CD209-336G variant allele is associated with significant protection against tuberculosis in individuals from sub-Saharan Africa and, furthermore, cases with -336GG were significantly less likely to develop tuberculosis-induced lung cavitation. Previous in vitro work demonstrated that the promoter variant -336G allele causes down-regulation of CD209 mRNA expression. Our present work suggests that decreased levels of the DC-SIGN receptor may therefore be protective against both clinical tuberculosis in general and cavitory tuberculosis disease in particular. This is consistent with evidence that Mycobacteria can utilize DC-SIGN binding to suppress the protective pro-inflammatory immune response.
C1 [Vannberg, Fredrik O.; Chapman, Stephen J.; Khor, Chiea C.; Tosh, Kerrie; Hill, Adrian V. S.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   [Floyd, Sian; Crampin, Amelia; Fine, Paul] London Sch Hyg & Trop Med, London, England.
   [Jackson-Sillah, Dolly; McAdam, Keith P. W. J.; Lienhardt, Christian; Sirugo, Giorgio] MRC Labs, Fajara, Gambia.
   [Crampin, Amelia; Sichali, Lifted] Karonga Prevent Study, Chilumba, Malawi.
   [Bah, Boubacar; Bah-Sow, Oumou] Univ Ignace Deen, Conakry, Guinea.
   [Gustafson, Per; Aaby, Peter] Bandim Hlth Project, Bissau, Guinea Bissau.
   [Lienhardt, Christian] Inst Rech Dev IRD, UMR 145, Dakar, Senegal.
RP Vannberg, FO (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
EM fredrik.vannberg@well.ox.ac.uk
OI Khor, Chiea Chuen/0000-0002-1128-4729
FU EU GenoSept; UK Overseas Research Student Scheme; Wellcome Trust
   [Clinical Research Fellow, Principal Fellow, IC18CT980375]; Agency for
   Science, Technology and Research (A-STAR), Singapore; EU
FX FOV is supported by the EU GenoSept Grant and the UK Overseas Research
   Student Scheme. SJC is a Wellcome Trust Clinical Research Fellow; AVSH
   is a Wellcome Trust Principal Fellow. CCK is a scholar of the Agency for
   Science, Technology and Research (A-STAR), Singapore and member of the
   MBBS-PhD programme, Faculty of Medicine, National University of
   Singapore. The tuberculosis samples were collected as part of an
   EU-funded project (contract number IC18CT980375). This work was funded
   by the Wellcome Trust.
CR Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002
   Appelmelk BJ, 2003, J IMMUNOL, V170, P1635
   Barreiro LB, 2006, PLOS MED, V3, P230, DOI 10.1371/journal.pmed.0030020
   Barreiro LB, 2006, HUM IMMUNOL, V67, P102, DOI 10.1016/j.humimm.2006.02.028
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002
   Bennett S, 2002, AM J EPIDEMIOL, V155, P1074, DOI 10.1093/aje/155.11.1074
   Bergman MP, 2004, J EXP MED, V200, P979, DOI 10.1084/jem.20041061
   Colmenares M, 2002, J BIOL CHEM, V277, P36766, DOI 10.1074/jbc.M205270200
   COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621
   Condos R, 1998, AM J RESP CRIT CARE, V157, P729
   Cooke GS, 2001, NAT REV GENET, V2, P967, DOI 10.1038/35103577
   Doffinger R, 2002, MOL IMMUNOL, V38, P903, DOI 10.1016/S0161-5890(02)00017-2
   Fitness J, 2004, AM J TROP MED HYG, V71, P341
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4
   Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5
   Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815
   Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1
   Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8
   Koppel EA, 2004, IMMUNOBIOLOGY, V209, P117, DOI 10.1016/j.imbio.2004.03.003
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Lozach PY, 2004, J BIOL CHEM, V279, P32035, DOI 10.1074/jbc.M402296200
   Martin MP, 2004, J VIROL, V78, P14053, DOI 10.1128/JVI.78.24.14053-14056.2004
   Mazzarella G, 2003, CLIN EXP IMMUNOL, V132, P283, DOI 10.1046/j.1365-2249.2003.02121.x
   Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003
   Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398
   Sakuntabhai A, 2005, NAT GENET, V37, P507, DOI 10.1038/ng1550
   Soilleux EJ, 2006, J PATHOL, V209, P182, DOI 10.1002/path.1972
   Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445
   Soilleux EJ, 2000, J IMMUNOL, V165, P2937
   STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702
   Storm Niels, 2003, Methods Mol Biol, V212, P241
   Tailleux L, 2005, PLOS MED, V2, P1269, DOI 10.1371/journal.pmed.0020381
   Tailleux L, 2003, TRENDS MICROBIOL, V11, P259, DOI 10.1016/S0966-842X(03)00102-1
   Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468
   Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840
   Torrelles JB, 2006, J IMMUNOL, V177, P1805
   van Crevel R, 2000, J INFECT DIS, V181, P1194, DOI 10.1086/315325
   van Kooyk Y, 2004, CURR OPIN IMMUNOL, V16, P488, DOI 10.1016/j.coi.2004.05.010
   van Kooyk Y, 2003, TRENDS MOL MED, V9, P153, DOI 10.1016/S1471-4914(03)00027-3
   van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182
   [Anonymous], 2003, WKLY EPIDEMIOL REC, V78, P122
NR 44
TC 64
Z9 70
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 2
PY 2008
VL 3
IS 1
AR e1388
DI 10.1371/journal.pone.0001388
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 366GP
UT WOS:000260468900016
PM 18167547
OA gold
DA 2017-08-15
ER

PT J
AU Nahid, P
   De Jong, BC
   Daley, CL
AF Nahid, Payam
   De Jong, Bouke C.
   Daley, Charles L.
TI On treatment outcomes of patients with HIV and tuberculosis
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Letter
C1 [Nahid, Payam] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94143 USA.
   [De Jong, Bouke C.] MRC Labs, Banjul, Gambia.
   [Daley, Charles L.] Natl Jewish Med & Res Ctr, Denver, CO USA.
RP Nahid, P (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA 94143 USA.
CR Breen RAM, 2006, J INFECT DIS, V193, P1437, DOI 10.1086/503437
   Nahid P, 2007, AM J RESP CRIT CARE, V175, P1199, DOI 10.1164/rccm.200509-1529OC
NR 2
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD JAN 1
PY 2008
VL 177
IS 1
BP 121
EP 122
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 246BN
UT WOS:000251982600018
OA No
DA 2017-08-15
ER

PT J
AU Chukualim, B
   Peters, N
   Fowler, CH
   Berriman, M
AF Chukualim, Bridget
   Peters, Nick
   Fowler, Christiane Hertz
   Berriman, Matthew
TI TrypanoCyc - a metabolic pathway database for Trypanosoma brucei
SO BMC BIOINFORMATICS
LA English
DT Article; Proceedings Paper
CT 4th International-Society-for-Computational-Biology Student Council
   Symposium held at the 16th Annual International Conference on
   Intelligent Systems for Molecular Biology
CY JUL 18, 2008
CL Toronto, CANADA
SP Int Soc Computat Biol
C1 [Chukualim, Bridget] Int Trypanotolerance Ctr, Banjul, Gambia.
   [Peters, Nick; Fowler, Christiane Hertz; Berriman, Matthew] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
RP Chukualim, B (reprint author), Int Trypanotolerance Ctr, Banjul, Gambia.
EM bchukualim@yahoo.com
RI Berriman, Matthew/A-7618-2011
CR Karp Peter D, 2002, Bioinformatics, V18 Suppl 1, pS225
NR 1
TC 10
Z9 10
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PY 2008
VL 9
SU 10
AR P5
DI 10.1186/1471-2105-9-S10-P5
PG 2
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA 366MY
UT WOS:000260487400014
OA gold
DA 2017-08-15
ER

PT J
AU Howie, SR
   Hill, SE
   Peel, D
   Sanneh, M
   Njie, M
   Hill, PC
   Mulholland, K
   Aclegbola, RA
AF Howie, Stephen Rc
   Hill, Sarah E.
   Peel, David
   Sanneh, Momodou
   Njie, Malick
   Hill, Philip C.
   Mulholland, Kim
   Aclegbola, Richard A.
TI Beyond good intentions: lessons on equipment donation from an African
   hospital
SO BULLETIN OF THE WORLD HEALTH ORGANIZATION
LA English
DT Article
ID CARE
AB Objective In 2000, a referral hospital in the Gambia accepted a donation of oxygen concentrators to help maintain oxygen supplies. The concentrators broke down and were put into storage. A case study was done to find the reasons for the problem and to draw lessons to help improve both oxygen supplies and the success of future equipment donations.
   Methods A technical assessment of the concentrators was carried out by a biomedical engineer with relevant expertise. Semi-structured interviews were undertaken with key informants, and content analysis and inductive approaches were applied to construct the history of the episode and the reasons for the failure.
   Findings Interviews confirmed the importance of technical problems with the equipment. They also revealed that the donation process was flawed, and that the hospital did not have the expertise to assess or maintain the equipment. Technical assessment showed that all units had the wrong voltage and frequency, leading to overheating and breakdown. Subsequently a hospital donations committee was established to oversee the donations process. On-site biomedical engineering expertise was arranged with a nongovernmental organization (NGO) partner.
   Conclusion Appropriate donations of medical equipment, including oxygen concentrators, can be of benefit to hospitals in resource-poor settings, but recipients and donors need to actively manage donations to ensure that the donations are beneficial. Success requires planning, technical expertise and local participation. Partners with relevant skills and resources may also be needed. In 2002, WHO produced guidelines for medical equipment donations, which address problems that might be encountered. These guidelines should be publicized and used.
C1 [Howie, Stephen Rc; Sanneh, Momodou; Hill, Philip C.; Aclegbola, Richard A.] MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   [Hill, Sarah E.] Univ Otago, Dept Publ Hlth, Wellington, New Zealand.
   [Peel, David] Ashdown Consultants, Hartfield, England.
   [Njie, Malick] Royal Victorial Hosp, Banjul, Gambia.
   [Mulholland, Kim] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London, England.
RP Howie, SR (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM showie@mrc.gm
FU Medical Research Council [MC_U190081957]
CR Dobson M, 1996, LANCET, V347, P1597, DOI 10.1016/S0140-6736(96)91080-6
   Duke T, 2003, ARCH DIS CHILD, V88, P563, DOI 10.1136/adc.88.7.563
   Free MJ, 2004, INT J GYNECOL OBSTET, V85, pS3, DOI 10.1016/j.ijgo.2004.01.009
   Patton MQ, 2002, QUALITATIVE RES EVAL
   PEEL D, 2002, IDENTIFICATION OXYGE
   Perrelet A, 2004, INT J TUBERC LUNG D, V8, P1138
   Rollins G, 2004, HOSP HEALTH NETWORK, V78, P52
   Schneider G, 2001, INT J TUBERC LUNG D, V5, P524
   Strauss A. L., 1990, BASICS QUALITATIVE R
   Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0
   *WHO, WHOA5513
   World Health Organization, 2000, WHOARA973
   *WHO FCH CAH, 2003, WHOFCHCAH039
NR 13
TC 18
Z9 18
U1 1
U2 3
PU WORLD HEALTH ORGANIZATION
PI GENEVA 27
PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND
SN 0042-9686
J9 B WORLD HEALTH ORGAN
JI Bull. World Health Organ.
PD JAN
PY 2008
VL 86
IS 1
BP 52
EP 56
DI 10.2471/BLT.07.042994
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 250XT
UT WOS:000252335300013
PM 18235890
OA No
DA 2017-08-15
ER

PT J
AU Durieux, P
   Trinquart, L
   Colombet, I
   Nies, J
   Walton, RT
   Rajeswaran, A
   Walther, MR
   Harvey, E
   Burnand, B
AF Durieux, Pierre
   Trinquart, Ludovic
   Colombet, Isabelle
   Nies, Julie
   Walton, R. T.
   Rajeswaran, Anand
   Walther, Myriam Rege
   Harvey, Emma
   Burnand, Bernard
TI Computerized advice on drug dosage to improve prescribing practice
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID DECISION-SUPPORT-SYSTEM; ORAL ANTICOAGULATION MANAGEMENT; RANDOMIZED
   CONTROLLED TRIAL; PHYSICIAN ORDER ENTRY; PRIMARY-CARE; WARFARIN THERAPY;
   CLINICAL-APPLICATION; COST-BENEFIT; DESIGN; AMINOGLYCOSIDES
AB Background
   Maintaining therapeutic concentrations of drugs with a narrow therapeutic window is a complex task. Several computer systems have been designed to help doctors determine optimum drug dosage. Significant improvements in health care could be achieved if computer advice improved health outcomes and could be implemented in routine practice in a cost effective fashion. This is an updated version of an earlier Cochrane systematic review, by Walton et al, published in 2001.
   Objectives
   To assess whether computerised advice on drug dosage has beneficial effects on the process or outcome of health care. Search strategy We searched the Cochrane Effective Practice and Organisation of Care Group specialized register (June 1996 to December 2006), MEDLINE (1966 to December 2006), EMBASE (1980 to December 2006), hand searched the journal Therapeutic Drug Monitoring (1979 to March 2007) and the Journal of the American Medical Informatics Association (1996 to March 2007) as well as reference lists from primary articles.
   Selection criteria
   Randomized controlled trials, controlled trials, controlled before and after studies and interrupted time series analyses of computerized advice on drug dosage were included. The participants were health professionals responsible for patient care. The outcomes were: any objectively measured change in the behaviour of the health care provider (such as changes in the dose of drug used); any change in the health of patients resulting from computerized advice (such as adverse reactions to drugs).
   Data collection and analysis
   Two reviewers independently extracted data and assessed study quality.
   Main results
   Twenty-six comparisons (23 articles) were included (as compared to fifteen comparisons in the original review) including a wide range of drugs in inpatient and outpatient settings. Interventions usually targeted doctors although some studies attempted to influence prescriptions by pharmacists and nurses. Although all studies used reliable outcome measures, their quality was generally low.
   Computerized advice for drug dosage gave significant benefits by:
   1. increasing the initial dose (standardised mean difference 1.12, 95% CI 0.33 to 1.92)
   2. increasing serum concentrations (standradised mean difference 1.12, 95% CI 0.43 to 1.82)
   3. reducing the time to therapeutic stabilisation (standardised mean difference -0.55, 95% CI -1.03 to -0.08)
   4. reducing the risk of toxic drug level (rate ratio 0.45, 95% CI 0.30 to 0.70)
   5. reducing the length of hospital stay (standardised mean difference -0.35, 95% CI -0.52 to -0.17).
   Authors' conclusions
   This review suggests that computerized advice for drug dosage has some benefits: it increased the initial dose of drug, increased serum drug concentrations and led to a more rapid therapeutic control. It also reduced the risk of toxic drug levels and the length of time spent in the hospital. However, it had no effect on adverse reactions. In addition, there was no evidence to suggest that some decision support technical features (such as its integration into a computer physician order entry system) or aspects of organization of care (such as the setting) could optimise the effect of computerised advice.
C1 [Durieux, Pierre] Hop Cochin, Serv Sante Publ, F-75014 Paris, France.
   [Trinquart, Ludovic] Univ Paris 05, Georges Pompidou European Hosp, INSERM, Epidemiol & Clin Res Unit,CIE4, Paris, France.
   [Colombet, Isabelle] Univ Paris 05, Georges Pompidou European Hosp, INSERM, Dept Med Informat,U729, Paris, France.
   [Walton, R. T.] Med Res Labs, Banjul, Gambia.
   [Rajeswaran, Anand; Burnand, Bernard] Univ Inst Social & Prevent Med, Hlth Care Evaluat Unit, Lausanne, Switzerland.
   [Harvey, Emma] SaltaSustainable, Leeds, W Yorkshire, England.
RP Durieux, P (reprint author), Hop Cochin, Serv Sante Publ, 27 Rue Faubourg St Jacques, F-75014 Paris, France.
EM pierre.durieux@cch.ap-hop-paris.fr
RI Colombet, Isabelle/J-8186-2017
OI Colombet, Isabelle/0000-0002-8721-1526; Trinquart,
   Ludovic/0000-0002-3028-4900
CR ABBRECHT PH, 1982, CLIN PHARMACOL THER, V32, P129
   Ageno W, 1998, THROMB RES, V91, P237, DOI 10.1016/S0049-3848(98)00092-9
   ALVIS JM, 1985, ANESTHESIOLOGY, V63, P41, DOI 10.1097/00000542-198507000-00006
   BALDWIN L, 1995, BRIT MED J, V310, P1154
   BEGG EJ, 1989, BRIT J CLIN PHARMACO, V28, P137
   BURTON ME, 1991, CLIN PHARMACOL THER, V49, P685
   Bury J, 2005, BRIT J HAEMATOL, V129, P746, DOI 10.1111/j.1365-2141.2005.05541.x
   CARTER BL, 1987, CLIN PHARMACY, V6, P37
   CASNER PR, 1993, CLIN PHARMACOL THER, V53, P684
   Chertow GM, 2001, JAMA-J AM MED ASSOC, V286, P2839, DOI 10.1001/jama.286.22.2839
   CHIARELLI F, 1990, DIABETES CARE, V13, P1080, DOI 10.2337/diacare.13.10.1080
   Collins CD, 2004, AM J HEALTH-SYST PH, V61, P1395
   DESTACHE CJ, 1990, THER DRUG MONIT, V12, P419, DOI 10.1097/00007691-199009000-00003
   Durieux P, 2005, NEW ENGL J MED, V352, P1034, DOI 10.1056/NEJMe058016
   FIHN SD, 1994, J GEN INTERN MED, V9, P131, DOI 10.1007/BF02600026
   Fitzmaurice DA, 2000, ARCH INTERN MED, V160, P2343, DOI 10.1001/archinte.160.15.2343
   Fitzmaurice DA, 1998, FAM PRACT, V15, P144, DOI 10.1093/fampra/15.2.144
   Fitzmaurice DA, 1996, BRIT J GEN PRACT, V46, P533
   GARCIA JM, 2002, COCHRANE DB SYST REV
   Garg AX, 2005, JAMA-J AM MED ASSOC, V293, P1223, DOI 10.1001/jama.293.10.1223
   GONZALEZ ER, 1989, AM J EMERG MED, V7, P395, DOI 10.1016/0735-6757(89)90046-6
   HICKLING K, 1989, INTENS CARE MED, V15, P233, DOI 10.1007/BF00271057
   Hobbs FDR, 1996, FAM PRACT, V13, P133, DOI 10.1093/fampra/13.2.133
   Horn W, 2002, ARTIF INTELL MED, V24, P217, DOI 10.1016/S0933-3657(01)00105-1
   HURLEY SF, 1986, AM REV RESPIR DIS, V134, P1219
   Hwang HG, 2004, MED INFORM INTERNET, V29, P239, DOI 10.1080/14639230400009158
   Kaushal R, 2006, J AM MED INFORM ASSN, V13, P261, DOI 10.1197/jamia.M1984
   Kawamoto K, 2005, BRIT MED J, V330, P765, DOI 10.1136/bmj.38398.500764.8F
   Kroese WLG, 2005, J CLIN PHARM THER, V30, P279, DOI 10.1111/j.1365-2710.2005.00650.x
   Kuperman GJ, 2003, ANN INTERN MED, V139, P31
   Lesourd F, 2002, FERTIL STERIL, V77, P456, DOI 10.1016/S0015-0282(01)03231-9
   Manotti C, 2001, HAEMATOLOGICA, V86, P1060
   MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405
   MCDONALD CJ, 1980, JAMA-J AM MED ASSOC, V244, P1579, DOI 10.1001/jama.244.14.1579
   MCMICHAEL J, 1993, J CLIN PHARMACOL, V33, P599
   MUNGALL DR, 1994, CLIN PHARMACOL THER, V55, P591
   Murchie C J, 1989, J Cardiothorac Anesth, V3, P16
   Nies Julie, 2006, AMIA Annu Symp Proc, P594
   Nightingale PG, 2000, BRIT MED J, V320, P750, DOI 10.1136/bmj.320.7237.750
   PECK CC, 1973, NEW ENGL J MED, V289, P441, DOI 10.1056/NEJM197308302890902
   Peters A, 1996, BIOMED TECH, V41, P2, DOI 10.1515/bmte.1996.41.1-2.2
   PETERSON CM, 1986, AM J MED, V81, P69, DOI 10.1016/0002-9343(86)90184-1
   Peterson JF, 2005, ARCH INTERN MED, V165, P802, DOI 10.1001/archinte.165.7.802
   POLLER L, 1993, J CLIN PATHOL, V46, P299, DOI 10.1136/jcp.46.4.299
   Poller L, 1998, LANCET, V352, P1505, DOI 10.1016/S0140-6736(98)04147-6
   RODMAN JH, 1984, ARCH INTERN MED, V144, P703, DOI 10.1001/archinte.144.4.703
   ROLFE S, 1995, BRIT MED J, V310, P1173
   Rood E, 2005, J AM MED INFORM ASSN, V12, P172, DOI 10.1197/jamia.M1598
   Rotman BL, 1996, J AM MED INFORM ASSN, V3, P340
   Ruiz Ricardo, 1993, Biomedical Instrumentation and Technology, V27, P244
   RYFFDELECHE A, 1992, DIABETES RES CLIN EX, V19, P97
   Strack T, 1985, Life Support Syst, V3 Suppl 1, P568
   Tamblyn R, 2003, CAN MED ASSOC J, V169, P549
   Theil D R, 1993, J Cardiothorac Vasc Anesth, V7, P300, DOI 10.1016/1053-0770(93)90009-A
   Vadher B, 1997, BRIT MED J, V314, P1252
   Vadher BD, 1997, CLIN LAB HAEMATOL, V19, P203
   VANDENNIEUWENHUYZEN MCO, 1995, ANESTH ANALG, V81, P671, DOI 10.1097/00000539-199510000-00003
   VERNER D, 1992, EUR J CLIN PHARMACOL, V43, P29, DOI 10.1007/BF02280750
   Walton RT., 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002894, DOI 10.1002/14651858.CD002894]
   WHITE KS, 1984, J AM COLL CARDIOL, V4, P571
   WHITE RH, 1987, J GEN INTERN MED, V2, P141, DOI 10.1007/BF02596140
   WHITE RH, 1991, THER DRUG MONIT, V13, P46, DOI 10.1097/00007691-199101000-00006
   WILLCOURT RJ, 1994, AM J OBSTET GYNECOL, V170, P603
   [Anonymous], 2002, J ALLERGY CLIN IMMUN, V110, pS141
NR 64
TC 39
Z9 39
U1 1
U2 8
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1469-493X
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2008
IS 3
AR CD002894
DI 10.1002/14651858.CD002894.pub2
PG 51
WC Medicine, General & Internal
SC General & Internal Medicine
GA 328PS
UT WOS:000257810900008
PM 18646085
OA No
DA 2017-08-15
ER

PT J
AU Nwachukwu, CE
   Okebe, JU
AF Nwachukwu, Chukwuemeka E.
   Okebe, Joseph U.
TI Antimotility agents for chronic diarrhoea in people with HIV/AIDS
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; PERSISTENT
   DIARRHEA; HIV-1 INFECTION; MANIFESTATIONS; PROPHYLAXIS; NELFINAVIR;
   MANAGEMENT; POTENT; ADULTS
AB Background
   AIDS-related diarrhoea is a common cause of morbidity and mortality in HIV positive individuals, especially in the sub-Saharan Africa where 70% of deaths from HIV occur. It often compromises quality of life both in those receiving antiretroviral therapy ( ART) and the ART naive. Empirical antidiarrhoeal treatment may be required in about 50% of cases which are non-pathogenic or idiopathic and in cases resulting from antiretroviral therapy. Antimotility agents ( Loperamide, Diphenoxylate, Codeine) and adsorbents ( Bismuth Subsalicylate, Kaolin/Pectin, Attapulgite) are readily available, and have been found to be useful in this condition and so, are often used. Antimotilitics are opioids, decreasing stool output by reducing bowel activity thereby increasing fecal transit time in the gut, promoting fluid and electrolyte retention while adsorbents act by binding to fluids, toxins and other substances to improve stool consistency and eliminate the toxins. Due to its potential impact on the management of chronic diarrhoea in persons with HIV/AIDS, we reviewed the effectiveness of antimotility agents in controlling chronic diarrhoea in immunocompromised states caused by HIV/AIDS.
   Objectives
   To assess the effectiveness of antimotility agents in controlling chronic diarrhoea in people with HIV/AIDS.
   Search strategy
   We searched Medline, EMBASE, the Cochrane Controlled Trials Register, the Cochrane HIV/AIDS Register and AIDSearch databases in November 2006. We also contacted WHO, CDC, pharmaceutical companies and experts in the field for information on previous or on-going trials and checked reference list from retrieved studies, irrespective of language and publication status.
   Selection criteria
   Randomised controlled trials comparing an antimotility agent or an adsorbent with another antimotility agent, placebo, an adsorbent or no treatment in children and adults diagnosed with HIV and presenting with diarrhoea of three or more weeks duration.
   Data collection and analysis
   Two authors independently undertook study selection and examined full articles of potentially eligible studies.
   Main results
   One trial was found assessing the use of an adsorbent ( attapulgite) compared to a placebo for chronic diarrhoea in people with HIV/AIDS. It included 91 adults ( Aged 18 to 60), diagnosed with AIDS and experiencing diarrhoea for at least 7 days. There was no evidence that attapulgite is superior to placebo in controlling diarrhoea by reducing stool frequency and normalising stool consistency on days 1 (0.34 (95% CI 0.01 - 8.15)), 3 (1.35 ( 95% CI 0.51 - 3.62)) and 5 (1.74 ( 95% CI 0.89 - 3.38)). This was a small trial and may not have had enough power to show evidence of effects. Five deaths were reported which was not classified according to the arms of the study.
   Studies assessing the use of antimotility agents were not found.
   Authors' conclusions
   This review highlights the absence of evidence for the use of antimotility agents and adsorbents in controlling diarrhoea in people with HIV/AIDS. While no trials assessing the use of Antimotilitics were found, the retrieved study showed that attapulgite was not better than placebo in controlling diarrhoea in HIV/AIDS patients. For optimum patient care, these agents can still be used, with greater emphasis placed on adjunct therapies like massive fluid replacement while evidence for practice is awaited from further studies and reviews.
C1 [Nwachukwu, Chukwuemeka E.] Univ Calabar, Teaching Hosp, Inst Trop Dis Res & Prevent, EHCAP Nigeria, Calabar 540001, Cross River Sta, Nigeria.
   [Okebe, Joseph U.] MRC Labs, Malaria Programme, Banjul, Gambia.
RP Nwachukwu, CE (reprint author), Univ Calabar, Teaching Hosp, Inst Trop Dis Res & Prevent, EHCAP Nigeria, Moore Rd, Calabar 540001, Cross River Sta, Nigeria.
EM dremeka31@yahoo.com
FU The Nuffield Foundation
FX Chukwuemeka Nwachukwu was awarded a Reviews for Africa Programme
   Fellowship; (www.mrc.ac.za/cochrane/rap.htm), funded by a grant from the
   Nuffield; Commonwealth Programme, through The Nuffield Foundation.;
   Staff members of South African Cochrane Centre (SACC) and the Nigerian
   Branch of the South African Cochrane Centre (NBof-SACC).; Thanks to
   Richmal Oates-Whitehead who initiated the mentorship to this review and
   to Kate Grimwalde who completed it.
CR Abubakar I, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004932.pub2
   ADELMAN RD, 1996, NELSON TXB PAEDIAT, V15
   Anastasi JK, 2000, AM J INFECT CONTROL, V28, P262, DOI 10.1067/mic.2000.107585
   Anastasi Joyce K, 2003, J Assoc Nurses AIDS Care, V14, P28, DOI 10.1177/1055329003014003003
   Armon K, 2001, ARCH DIS CHILD, V85, P132, DOI 10.1136/adc.85.2.132
   BRAWNERCALUAG J, 1993, PHILIPINES J INTERNA, V31, P273
   Carcamo C, 2005, J INFECT DIS, V191, P11, DOI 10.1086/426508
   Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3
   COHEN MR, 1999, INTEGRATIVE MED, V2, P79
   COMPEAN DG, 1994, AIDS, V8, P1563, DOI 10.1097/00002030-199411000-00007
   Deschamps MM, 2000, AIDS, V14, P2515, DOI 10.1097/00002030-200011100-00014
   DRYDEN MS, 1988, J INFECTION, V17, P107, DOI 10.1016/S0163-4453(88)91515-0
   Dumitrascu D L, 2004, Rom J Intern Med, V42, P191
   DUPONT HL, 1992, CLIN INFECT DIS, V15, pS228
   DUPONT HL, 1993, T ROY SOC TROP MED H, V87, P31, DOI 10.1016/0035-9203(93)90534-W
   EDWARDS P, 1990, AUST NZ J MED, V20, P141, DOI 10.1111/j.1445-5994.1990.tb01291.x
   Foudraine NA, 1998, AIDS, V12, P35, DOI 10.1097/00002030-199801000-00005
   Gassama A, 2001, Int J Infect Dis, V5, P192, DOI 10.1016/S1201-9712(01)90069-4
   Greenwood-Van Meerveld B, 2004, NEUROGASTROENT MOTIL, V16, P46, DOI 10.1111/j.1743-3150.2004.00555.x
   Guarino Alfredo, 2004, Paediatr Drugs, V6, P347, DOI 10.2165/00148581-200406060-00003
   Guest JL, 2004, PHARMACOTHERAPY, V24, P727, DOI 10.1592/phco.24.8.727.36071
   Ilboudo D, 1997, MED AFRIQUE NOIRE, V44, P307
   JAMJIAN MC, MANAGING ADVERSE EFF, V6
   Joint United Nations Programme on HIV/AIDS, 2004, 2004 REP GLOB AIDS E
   Kadappu K K, 2002, J Postgrad Med, V48, P179
   Kaplan Jonathan E, 2004, Top HIV Med, V12, P136
   Katabira E T, 1999, Int J Infect Dis, V3, P164, DOI 10.1016/S1201-9712(99)90040-1
   Krain Alysa, 2005, Curr HIV/AIDS Rep, V2, P98, DOI 10.1007/s11904-005-0025-3
   Liu JP, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003937.pub2
   LOGIE DE, RURAL REMOTE HLTH, V4
   LUTGE E, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005175.pub2
   MCQUAID KR, 2004, BASIC CLIN PHARM, P1034
   Moyle GJ, 1998, J CLIN PHARMACOL, V38, P736
   Mwachari C, 1998, J INFECTION, V37, P48, DOI 10.1016/S0163-4453(98)90561-8
   O'Brien ME, 2003, JAIDS-J ACQ IMM DEF, V34, P407, DOI 10.1097/00126334-200312010-00008
   ODELL MW, 1995, J ACQ IMMUN DEF SYND, V10, P350
   PAPE JW, 1994, ANN INTERN MED, V121, P654
   SCHILLER LR, 1982, J CLIN INVEST, V70, P999, DOI 10.1172/JCI110711
   Schumacher M.A., 2004, BASIC CLIN PHARM, P497
   Sherman DS, 2000, CLIN INFECT DIS, V30, P908, DOI 10.1086/313826
   Silverberg MJ, 2004, CLIN INFECT DIS, V39, P717, DOI 10.1086/423181
   Turner MJ, 2004, HIV CLIN TRIALS, V5, P19
   *UNAIDS, 2006, 2006 REP GLOB AIDS E, P16
   WALTERSMITH JA, 1993, T ROYAL SOC TROPI S3, V87, P13
   Wang HH, 2005, WORLD J GASTROENTERO, V11, P1540
   World Health Organization, 2008, WORLD HLTH STAT, P13
   *WHO GPA, 1991, GUID CLIN MAN HIV IN
   *WHO HIV, 2005, WHOHIV200502
NR 48
TC 8
Z9 8
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2008
IS 4
AR CD005644
DI 10.1002/14651858.CD005644.pub2
PG 18
WC Medicine, General & Internal
SC General & Internal Medicine
GA 358CU
UT WOS:000259895000037
PM 18843696
OA No
DA 2017-08-15
ER

PT J
AU Rowland-Jones, S
AF Rowland-Jones, Sarah
TI A winding road towards an HIV vaccine
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT News Item
ID T-CELL RESPONSES; ASSOCIATIONS
C1 [Rowland-Jones, Sarah] MRC Labs, Fajara, Gambia.
   [Rowland-Jones, Sarah] Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford, England.
RP Rowland-Jones, S (reprint author), MRC Labs, Fajara, Gambia.
EM sarah.rowland-jones@ndm.ox.ac.uk
CR Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784
   Altfeld M, 2006, PLOS MED, V3, P1851, DOI 10.1371/journal.pmed.0030403
   Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818
   Bhattacharya T, 2007, SCIENCE, V315, P1583, DOI 10.1126/science.1131528
   Brumme ZL, 2007, PLOS PATHOG, V3, P913, DOI 10.1371/journal.ppat.0030094
   DUVALL MG, EUR J IMMUNOL, V38
   Fischer W, 2007, NAT MED, V13, P100, DOI 10.1038/nm1461
   Frater AJ, 2007, J VIROL, V81, P6742, DOI 10.1128/JVI.00022-07
   Gao F, 2007, CURR HIV RES, V5, P572, DOI 10.2174/157016207782418498
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Leligdowicz A, 2007, J CLIN INVEST, V117, P3067, DOI 10.1172/JCI32380
   Letourneau S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000984
   Sacha JB, 2007, J IMMUNOL, V178, P2746
NR 14
TC 4
Z9 4
U1 0
U2 0
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD JAN
PY 2008
VL 38
IS 1
BP 13
EP 14
PG 2
WC Immunology
SC Immunology
GA 256KA
UT WOS:000252726300005
PM 18286707
OA No
DA 2017-08-15
ER

PT J
AU Natividad, A
   Holland, MJ
   Rockett, KA
   Forton, J
   Faal, N
   Joof, HM
   Mabey, DCW
   Bailey, RL
   Kwiatkowski, DP
AF Natividad, Angels
   Holland, Martin J.
   Rockett, Kirk A.
   Forton, Julian
   Faal, Nkoyo
   Joof, Hassan M.
   Mabey, David C. W.
   Bailey, Robin L.
   Kwiatkowski, Dominic P.
TI Susceptibility to sequelae of human ocular chlamydial infection
   associated with allelic variation in IL10 cis-regulation
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; TRACHOMATIS INFECTION; GENE-EXPRESSION;
   INTERLEUKIN-10 PRODUCTION; SCARRING TRACHOMA; INTERFERON-GAMMA; IL-10;
   RISK; POLYMORPHISM; PROMOTER
AB Trachoma, an infectious disease of the conjunctiva caused by Chlamydia trachomatis, causes scarring and blindness in some infected individuals but not others. In an African community where trachoma is endemic, we have previously identified an IL10 haplotype that is associated with increased risk of scarring complications. Here we examine the hypothesis that the risk haplotype (H-RISK) affects levels of IL10 expression in the conjunctiva during active trachoma infection. To overcome potential genetic and environmental confounders we used the method of allele-specific quantification, which involved identifying subjects in the community who had active trachoma and were also heterozygous for the H-RISK. We find that there is allelic variation in cis-regulation of IL10 in the conjunctiva during active trachoma, with the H-RISK generating relatively more IL10 transcripts than other haplotypes in this population (average difference in IL10 allelic transcripts in the conjunctiva of heterozygous individuals infected with C. trachomatis of 23% (95% confidence interval: 14-32%, P < 0.0001). These findings provide a plausible functional explanation for the observed genetic association, and support the hypothesis that an excessive IL10 response to C. trachomatis infection is a risk factor for scarring and blindness.
C1 [Natividad, Angels; Holland, Martin J.; Mabey, David C. W.; Bailey, Robin L.] Univ London London Sch Hyg & Trop Med, Clin Res Unit, Infect Trop Dis Dept, London WC1E 7HT, England.
   [Natividad, Angels; Rockett, Kirk A.; Forton, Julian; Kwiatkowski, Dominic P.] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Holland, Martin J.; Faal, Nkoyo; Joof, Hassan M.] MRC Labs, Dept Virol, Fajara, Gambia.
RP Natividad, A (reprint author), Univ London London Sch Hyg & Trop Med, Clin Res Unit, Infect Trop Dis Dept, Keppel St,Room 246, London WC1E 7HT, England.
EM angels.natividad-sancho@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Kwiatkowski,
   Dominic/0000-0002-5023-0176
FU Medical Research Council [G19/9, G0600230, MC_U190081961]; Wellcome
   Trust
CR Barbarin V, 2005, AM J PHYSIOL-LUNG C, V288, pL841, DOI 10.1152/ajplung.00329.2004
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Cohen CR, 2005, J INFECT DIS, V192, P591, DOI 10.1086/432070
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Cowles CR, 2002, NAT GENET, V32, P432, DOI 10.1038/ng992
   Crawley E, 1999, ARTHRITIS RHEUM-US, V42, P590, DOI 10.1002/1529-0131(199904)42:3<590::AID-ANR37>3.0.CO;2-9
   Faal N, 2005, CLIN EXP IMMUNOL, V142, P347, DOI 10.1111/j.1365-2249.2005.02917.x
   Fenton KA, 2004, SEX TRANSM INFECT, V80, P255, DOI 10.1136/sti.2004.009415
   Gibson AW, 2001, J IMMUNOL, V166, P3915
   Igietseme JU, 2000, J IMMUNOL, V164, P4212
   Kane MM, 2001, J IMMUNOL, V166, P1141
   Kinnunen AH, 2002, HUM REPROD, V17, P2073, DOI 10.1093/humrep/17.8.2073
   Knight JC, 2003, NAT GENET, V33, P469, DOI 10.1038/ng1124
   Lazarus M, 1997, J RHEUMATOL, V24, P2314
   Lee CG, 2002, J BIOL CHEM, V277, P35466, DOI 10.1074/jbc.M206395200
   Lim S, 1998, LANCET, V352, P113, DOI 10.1016/S0140-6736(98)85018-6
   Llorente L, 1997, ARTHRITIS RHEUM, V40, P1429, DOI 10.1002/art.1780400810
   Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112
   Mabey DCW, 2003, LANCET, V362, P223, DOI 10.1016/S0140-6736(03)13914-1
   Mariotti SP, 2004, NEW ENGL J MED, V351, P2004, DOI 10.1056/NEJMe048205
   McMahon-Pratt D, 2004, IMMUNOL REV, V201, P206, DOI 10.1111/j.0105-2896.2004.00190.x
   Mozzato-Chamay N, 2001, GENES IMMUN, V2, P153, DOI 10.1038/sj.gene.6363753
   Mozzato-Chamay N, 2000, J INFECT DIS, V182, P1545, DOI 10.1086/315891
   Natividad A, 2007, GENES IMMUN, V8, P288, DOI 10.1038/sj.gene.6364384
   Natividad A, 2005, GENES IMMUN, V6, P332, DOI 10.1038/sj.gene.6364182
   Natividad A, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-40
   Ohman H, 2006, GENES IMMUN, V7, P243, DOI 10.1038/sj.gene.6364293
   Pastinen T, 2004, SCIENCE, V306, P647, DOI 10.1126/science.1101659
   Redpath S, 2001, TRENDS MICROBIOL, V9, P86, DOI 10.1016/S0966-842X(00)01919-3
   Wang CB, 2005, J INFECT DIS, V191, P1084, DOI 10.1086/428592
   Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6
   Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545
   Yang X, 1999, J IMMUNOL, V162, P1010
   Yang X, 1996, J IMMUNOL, V156, P4338
NR 34
TC 28
Z9 31
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JAN
PY 2008
VL 17
IS 2
BP 323
EP 329
DI 10.1093/hmg/ddm310
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 248BG
UT WOS:000252125700015
PM 17947295
OA No
DA 2017-08-15
ER

PT J
AU Cheeseman, I
   Gomez-Escobar, N
   Carret, C
   Ivens, A
   Tetteh, K
   Stewart, L
   Conway, D
AF Cheeseman, Ian
   Gomez-Escobar, Natalia
   Carret, Celine
   Ivens, Alistair
   Tetteh, Kevin
   Stewart, Lindsay
   Conway, David
TI A genome-wide survey of gene amplifications and deletions in laboratory
   and field isolates of Plasmodium falciparam.
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Meeting Abstract
CT 3rd Molecular Approaches to Malaria Meeting (MAM 2008)
CY FEB 03-07, 2008
CL Lorne, AUSTRALIA
SP BioMalPar, Boehringer Ingelheim Foods, Burroughs Wellcome Fund, Fdn Natl Inst Hlth, PATH Malaria Vaccine Initiative, Walter & Eliza Hall Inst Med Res, Wellcome Trust, ARC/NHMRC Net Parasitol, Australian Soc Biochem & Molecular Biol, Lorne Protein Conf, GlaxoSmithKline
C1 [Cheeseman, Ian; Tetteh, Kevin; Stewart, Lindsay; Conway, David] London Sch Hyg & Trop Med, Pathogen Mol Biol Unit, London WC1, England.
   [Cheeseman, Ian; Gomez-Escobar, Natalia; Conway, David] MRC, Banjul, Gambia.
   [Carret, Celine; Ivens, Alistair] Sanger Inst, Pathogen Microarray Unit, Cambridge, England.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0020-7519
J9 INT J PARASITOL
JI Int. J. Parasit.
PD JAN
PY 2008
VL 38
SU 1
BP S69
EP S70
PG 2
WC Parasitology
SC Parasitology
GA 262CW
UT WOS:000253127600187
OA No
DA 2017-08-15
ER

PT J
AU Gomez-Escobar, N
   Walther, M
   Ngwa, A
   Okebe, J
   Conway, D
AF Gomez-Escobar, Natalia
   Walther, Michael
   Ngwa, Alfred
   Okebe, Joseph
   Conway, David
TI Erythrocyte invasion and malaria severity in Plasmodium falciparum
   clinical isolates from The Gambia.
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Meeting Abstract
CT 3rd Molecular Approaches to Malaria Meeting (MAM 2008)
CY FEB 03-07, 2008
CL Lorne, AUSTRALIA
SP BioMalPar, Boehringer Ingelheim Foods, Burroughs Wellcome Fund, Fdn Natl Inst Hlth, PATH Malaria Vaccine Initiative, Walter & Eliza Hall Inst Med Res, Wellcome Trust, ARC/NHMRC Net Parasitol, Australian Soc Biochem & Molecular Biol, Lorne Protein Conf, GlaxoSmithKline
C1 [Gomez-Escobar, Natalia; Walther, Michael; Ngwa, Alfred; Okebe, Joseph; Conway, David] MRC Labs, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0020-7519
J9 INT J PARASITOL
JI Int. J. Parasit.
PD JAN
PY 2008
VL 38
SU 1
BP S38
EP S38
PG 1
WC Parasitology
SC Parasitology
GA 262CW
UT WOS:000253127600073
OA No
DA 2017-08-15
ER

PT J
AU Tetteh, K
   Ochola, L
   Stewart, L
   Ngwa, A
   Marsh, K
   Conway, D
AF Tetteh, Kevin
   Ochola, Lynette
   Stewart, Lindsay
   Ngwa, Alfred
   Marsh, Kevin
   Conway, David
TI Studies of natural selection on malaria parasite merozoites in relation
   to invasion and immunity.
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Meeting Abstract
CT 3rd Molecular Approaches to Malaria Meeting (MAM 2008)
CY FEB 03-07, 2008
CL Lorne, AUSTRALIA
SP BioMalPar, Boehringer Ingelheim Foods, Burroughs Wellcome Fund, Fdn Natl Inst Hlth, PATH Malaria Vaccine Initiative, Walter & Eliza Hall Inst Med Res, Wellcome Trust, ARC/NHMRC Net Parasitol, Australian Soc Biochem & Molecular Biol, Lorne Protein Conf, GlaxoSmithKline
C1 [Tetteh, Kevin; Stewart, Lindsay; Conway, David] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   [Ngwa, Alfred; Conway, David] MRC Labs, Banjul, Gambia.
   [Ochola, Lynette; Marsh, Kevin] Kenya Govt Med Res Ctr, Ctr Geograph Med Res Coast, Kilifi, Kenya.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0020-7519
J9 INT J PARASITOL
JI Int. J. Parasit.
PD JAN
PY 2008
VL 38
SU 1
BP S63
EP S63
PG 1
WC Parasitology
SC Parasitology
GA 262CW
UT WOS:000253127600162
OA No
DA 2017-08-15
ER

PT J
AU Stoate, C
   Jarju, AK
AF Stoate, C.
   Jarju, A. K.
TI A participatory investigation into multifunctional benefits of
   indigenous trees in West African savanna farmland
SO INTERNATIONAL JOURNAL OF AGRICULTURAL SUSTAINABILITY
LA English
DT Article
DE agro-forestry; cultural values; farmer experimentation; food security;
   Natural Resource Management; Participatory Action Research; soil organic
   matter; tree use values
ID SEMIARID SENEGAL; NATIVE SHRUB; MANAGEMENT; SYSTEMS; MILLET; NIGER
AB Loss of trees has contributed to soil erosion and depletion of soil organic matter and nutrient status across sub-Saharan Africa, enhanced by a period of dependence on subsidized inorganic fertilizer. This paper is based on an eight-year study with farmers on the northern Gambia/Senegal border. It documents farmers' perceptions of past and present farming systems and their attitudes to farmland trees, communicates results of a literature review to them, and facilitates farmer experimentation into the potential of tree leaf mulches for groundnut production. Trees have many use values but little value was initially perceived for farming. Information provided on the use of trees in cropping systems elsewhere in the region was not thought to be relevant locally. The exception was for Faidherbia albida which was initially encouraged for cultural reasons, and tree density increased from one to 17 trees per hectare over the subsequent six years in response to protection by farmers. Farmer experimentation with tree mulches identified Guiera senegalensis as a beneficial species when used in combination with low rate inorganic fertilizer and this species is now valued by some farmers, rather than being perceived as a weed. Such protection of indigenous trees is likely to maintain the natural resource base, benefiting local people and wildlife species associated with the trees, as well as providing ecosystem services that benefit the wider community.
C1 [Stoate, C.] Allerton Project, Game & Wildlife Conservat Trust, Loddington LE7 9XE, Leics, England.
   [Jarju, A. K.] Natl Agr Res Inst, Serekunda, Gambia.
RP Stoate, C (reprint author), Allerton Project, Game & Wildlife Conservat Trust, Loddington LE7 9XE, Leics, England.
EM cstoate@gct.org.uk
CR BADIANE C, 2001, TED CASE STUDIES, V646
   Boffa J. M, 1999, AGROFORESTRY PARKLAN
   CISSE MI, 1992, FAIDHERBIA ALBIDA W, P29
   Diack M, 2000, ARID SOIL RES REHAB, V14, P205, DOI 10.1080/089030600406626
   Diack M., 1998, PILIOSTIGMA RETICULA
   DUPUY N, 1992, FAIDHERBIA ALBIDA W, P145
   Elberling B, 2003, AGR ECOSYST ENVIRON, V96, P37, DOI [10.1016/S0167-8809(03)00010-0, 10.1016/S0167-8809(02)00166-4]
   FELLER C, 2001, P 3 INT C LAND DEGR
   Garrity DP, 2004, AGROFOREST SYST, V61-2, P5, DOI 10.1023/B:AGFO.0000028986.37502.7c
   Hagmann J, 2002, AGR SYST, V73, P23, DOI 10.1016/S0308-521X(01)00098-1
   HERVOUET JP, 1992, FAIDHERBIA ALBIDA W, P165
   Kizito F, 2007, AGR WATER MANAGE, V90, P137, DOI 10.1016/j.agwat.2007.02.015
   KNUTSEN PG, 2002, 17 S INT FARM SYST A
   Liniger H.P., 2007, LAND GREENER CASE ST
   LYKKE AM, 1996, THESIS U AARHUS DENM
   Mahamane L, 2005, AGR ECOSYST ENVIRON, V105, P267, DOI 10.1016/j.agee.2004.03.004
   Mandibaya W, 1999, ANIM FEED SCI TECH, V78, P287, DOI 10.1016/S0377-8401(98)00280-6
   MCGAHUEY M, 1992, FAIDH ALB W AFR SEM, P159
   Pandey DN, 2002, CURR SCI INDIA, V83, P593
   Pelissier P., 1966, PAYSANS SENEGAL
   PRETTY J, 1994, IDS BULL-I DEV STUD, V25, P37
   Reed J. D., 1992, FAIDH ALB W AFR SEM, P43
   Reij C, 2001, FARMER INNOVATION AF
   REIJ C, 2006, MORE SUCCESS STORIES
   SALL PN, 1998, ETUDE IMPACT REGENER
   SALL PN, 1992, FAIDHERBIA ALBIDA W, P103
   SCHOONMAKERFREU.M, 1993, FIELDS FALLOWS FLEXI
   SIRE D, 2007, THESIS OREGON STATE
   Soderstrom B, 2003, AGR ECOSYST ENVIRON, V99, P113, DOI 10.1016/S0167-8809(03)00144-0
   Stoate C, 1998, BIRD STUDY, V45, P251
   Tottrup C, 2004, AGR ECOSYST ENVIRON, V103, P545, DOI 10.1016/j.agee.2003.11.009
   Wezel A, 1999, SOIL TILL RES, V50, P341, DOI 10.1016/S0167-1987(99)00008-2
   Wood PJ, 1989, FAIDHERBIA ALBIDA MO
NR 33
TC 4
Z9 4
U1 0
U2 14
PU EARTHSCAN
PI COLCHESTER
PA C/O PORTLAND CUSTOMER SERV, COMMERCE WAY, COLCHESTER, CO2 8HP, ENGLAND
SN 1473-5903
J9 INT J AGR SUSTAIN
JI Int. J. Agric. Sustain.
PY 2008
VL 6
IS 2
BP 122
EP 132
DI 10.3763/ijas.2008.0299
PG 11
WC Agriculture, Multidisciplinary; GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY
SC Agriculture; Science & Technology - Other Topics
GA 437LI
UT WOS:000265488600002
OA No
DA 2017-08-15
ER

PT J
AU Seale, AC
   de Jong, BC
   Zaidi, I
   Duvall, M
   Whittle, H
   Rowland-Jones, S
   Jaye, A
AF Seale, Anna C.
   de Jong, Bouke C.
   Zaidi, Irfan
   Duvall, Melody
   Whittle, Hilton
   Rowland-Jones, Sarah
   Jaye, Assan
TI Effects of cryopreservation on CD4+CD25+T cells of HIV-1 infected
   individuals
SO JOURNAL OF CLINICAL LABORATORY ANALYSIS
LA English
DT Article
DE freezing; preservation; lymphocytes; T regulatory cells
ID REGULATORY T-CELLS; HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD
   MONONUCLEAR-CELLS; PERIPHERAL-BLOOD; IMMUNE-RESPONSES; CD4(+)
AB The role of T regulatory cells (Tregs) in human immunodeficiency virus (HIV)-1 infection, although not entirely clear, has recently been highlighted. Despite their lack of specificity, fluorochrome-labeled CD4 and CD25 antibodies are common flow cytometric reagents used to identify these cells with immunosuppressive potential. Cryopreservation has previously been shown to alter the proportions of lymphocytes with certain phenotypes expressed in peripheral blood mononuclear cells (PBMCs). The aim of this study was to assess the effect of cryopreservation on CD4+ CD25+ T cells in PBMCs from HIV-1+ individuals to guide the design of future studies on Tregs. We recruited 30 HIV-1+ individuals and nine healthy controls. CD25 expression in CD4+ T cells was compared between fresh and frozen/thawed PBMC samples from the same time point. In this study, cryopreservation significantly decreased the proportion of CD4+ CD25+ T cells in PBMC samples from HIV-1 infected subjects. This finding suggests that studies of CD4+ CD25+ T cells should be carried out on fresh samples to avoid bias introduced by cryopreservation.
C1 [de Jong, Bouke C.; Zaidi, Irfan; Duvall, Melody; Whittle, Hilton; Rowland-Jones, Sarah; Jaye, Assan] MRC Labs, Viral Dis Programme, Fajara, Gambia.
   [Seale, Anna C.; Rowland-Jones, Sarah] Univ Oxford, Nuffield Dept Med, Oxford, England.
RP de Jong, BC (reprint author), MRC Labs, Viral Dis Programme, POB 273 Banjul, Fajara, Gambia.
EM bdejong@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU FIC NIH HHS [TW 006083]; Medical Research Council [MC_U190085855,
   MC_U190081975]
CR Aandahl EM, 2004, J VIROL, V78, P2454, DOI 10.1128/JVI.78.5.2454.2459.2004
   Baecher-Allan C, 2001, J IMMUNOL, V167, P1245
   Castro KG, 1992, MMWR-MORBID MORTAL W, V41, pRR
   Costantini A, 2003, J IMMUNOL METHODS, V278, P145, DOI 10.1016/S0022-1759(03)00202-3
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   Fritzsching B, 2005, J IMMUNOL, V175, P32
   Kinter AL, 2004, J EXP MED, V200, P331, DOI 10.1084/jem.20032069
   Kleeberger CA, 1999, CLIN DIAGN LAB IMMUN, V6, P14
   Smith JG, 2001, CLIN DIAGN LAB IMMUN, V8, P871, DOI 10.1128/CDLI.8.5.871-879.2001
   TOLLERUD DJ, 1991, J CLIN LAB ANAL, V5, P255
   Weiss L, 2004, BLOOD, V104, P3249, DOI 10.1182/blood-2004-01-0365
   Wickelgren I, 2004, SCIENCE, V306, P596, DOI 10.1126/science.306.5696.596
NR 12
TC 14
Z9 14
U1 1
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0887-8013
J9 J CLIN LAB ANAL
JI J. Clin. Lab. Anal.
PY 2008
VL 22
IS 3
BP 153
EP 158
DI 10.1002/jcla.20234
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 312CN
UT WOS:000256646800001
PM 18484654
OA No
DA 2017-08-15
ER

PT J
AU Onabolu, OO
   Otulana, TO
   Awodein, OG
AF Onabolu, O. O.
   Otulana, T. O.
   Awodein, O. G.
TI Assessing the visual status of truck drivers in a developing country
SO TROPICAL DOCTOR
LA English
DT Article
ID DRIVING PERFORMANCE; OLDER DRIVERS; RISK-FACTORS
AB We undertook an interventional prospective study of truck drivers from a cement factory in Nigeria to assess their visual status after licensing. Out of 149 drivers, 122 (81.9%) were visually eligible to drive and 27 (18.1%)were not. Causes for failing the vision test included refractive error, cataracts, glaucoma, corneal leucoma and pterygia.
C1 [Onabolu, O. O.; Otulana, T. O.; Awodein, O. G.] Olabisi Onabanjo Univ Teaching Hosp, Dept Ophthalmol, Shagamu, Ogun State, Nigeria.
RP Onabolu, OO (reprint author), Royal Victoria Teaching Hosp, Dept Ophthalmol, Banjul, Gambia.
CR Babizhayev MA, 2003, OPHTHALMIC RES, V35, P19, DOI 10.1159/000068199
   Currie Z, 2000, BRIT MED J, V321, P990, DOI 10.1136/bmj.321.7267.990
   Mantyjarvi M, 1998, INT ARCH OCC ENV HEA, V71, P357, DOI 10.1007/s004200050293
   McGwin G, 2000, ACCIDENT ANAL PREV, V32, P735, DOI 10.1016/S0001-4575(99)00123-2
   MCKNIGHT AJ, 1991, ACCIDENT ANAL PREV, V23, P225, DOI 10.1016/0001-4575(91)90002-M
   Owsley C, 2001, ARCH OPHTHALMOL-CHIC, V119, P881
   Wood JM, 2001, OPTOMETRY VISION SCI, V78, P343, DOI 10.1097/00006324-200105000-00018
NR 7
TC 1
Z9 1
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0049-4755
J9 TROP DOCT
JI Trop. Dr.
PD JAN
PY 2008
VL 38
IS 1
BP 54
EP 55
DI 10.1258/td.2007.060207
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 269HF
UT WOS:000253639400027
PM 18302873
OA No
DA 2017-08-15
ER

PT J
AU Cox, SE
   Doherty, CP
   Atkinson, SH
   Nweneka, CV
   Fulford, AJC
   Sirugo, G
   Rockett, KA
   Kwiatkowski, DP
   Prentice, AM
AF Cox, Sharon E.
   Doherty, Conor P.
   Atkinson, Sarah H.
   Nweneka, Chidi V.
   Fulford, Anthony J. C.
   Sirugo, Giorgio
   Rockett, Kirk A.
   Kwiatkowski, Dominic P.
   Prentice, Andrew M.
TI Haptoglobin genotype, anaemia and malaria in Gambian children
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE malaria; haptoglobin genotype; anaemia; seasonal; cross-sectional
   survey; The Gambia
ID PLASMODIUM-FALCIPARUM MALARIA; HEMOGLOBIN SCAVENGER RECEPTOR; IRON
   STATUS; IN-VITRO; POLYMORPHISM; INFECTION; PHENOTYPE; SUPPLEMENTATION;
   ASSOCIATION; METABOLISM
AB OBJECTIVE To retest our previous finding that the haptoglobin (Hp) 22 genotype is associated with seasonal anaemia, and to investigate the role of malaria in this effect.
   METHODS Haemoglobin (Hb) and peripheral parasitaemia were assessed at pre- and post-malarial season cross-sectional surveys in rural Gambian children aged 10-72 months. Between the surveys, active longitudinal surveillance was conducted to detect febrile episodes.
   RESULTS Unlike previously, no overall reduction in Hb was observed (Hb = 106.1 vs. 107.2 g/l, P = 0.13, n = 545). However, multi-variable linear regression revealed differences in Hb over the season by Hp and Hb-sickle (HbS) genotype (-2.20 g/l per copy of the Hp2 allele, P = 0.043; HbAS vs. HbAA + 3.13 g/l, P = 0.11, n = 536). There was no effect of malarial episodes during follow-up; this suggests that when effective treatment is given, Hb levels recover. The A61-C Hp promoter SNP, associated with the Hp2 allele, had no effect.
   CONCLUSION The effect of the Hp2 allele appears to be independent of effects on malaria incidence but may affect Hb levels through increased oxidant stress and red cell turnover. This may be supported by our previous observations that the effect of Hp22 was independent of markers of iron status and zinc protoporphyrin measured at the cross-sectional surveys and therefore also of iron availability for erythropoiesis.
C1 [Cox, Sharon E.; Atkinson, Sarah H.; Fulford, Anthony J. C.; Prentice, Andrew M.] Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   [Doherty, Conor P.; Atkinson, Sarah H.; Nweneka, Chidi V.] MRC Labs, MRC Keneba, Keneba, Gambia.
   [Sirugo, Giorgio] MRC Labs, MRC Fajara, Fajara, Gambia.
   [Rockett, Kirk A.; Kwiatkowski, Dominic P.] Wellcome Trust Ctr Human Genet, Oxford, England.
RP Cox, SE (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM sharon.cox@lshtm.ac.uk
OI Cox, Sharon/0000-0002-9908-2936; Kwiatkowski,
   Dominic/0000-0002-5023-0176
FU Medical Research Council [G0600230, G19/9, MC_U123292699, MC_U123292700]
CR Andrews NC, 2000, NAT REV GENET, V1, P208, DOI 10.1038/35042073
   Arredouani M, 2003, IMMUNOLOGY, V108, P144, DOI 10.1046/j.1365-2567.2003.01569.x
   Asleh R, 2005, CIRC RES, V96, P435, DOI 10.1161/01.RES.0000156653.05853.b9
   Atkinson SH, 2006, PLOS MED, V3, P652, DOI 10.1371/journal.pmed.0030172
   Atkinson SH, 2007, CLIN INFECT DIS, V44, P802, DOI 10.1086/511868
   Aucan C, 2002, T ROY SOC TROP MED H, V96, P327, DOI 10.1016/S0035-9203(02)90114-8
   Bienzle U, 2005, TROP MED INT HEALTH, V10, P668, DOI 10.1111/j.1365-3156.2005.01444.x
   Carter K, 2003, BRIT J HAEMATOL, V122, P326, DOI 10.1046/j.1365-2141.2003.04436.x
   Cordell HJ, 2005, LANCET, V366, P1121, DOI 10.1016/S0140-6736(05)67424-7
   Cox SE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000362
   Delanghe JR, 1998, AIDS, V12, P1027, DOI 10.1097/00002030-199809000-00009
   Elagib AA, 1998, T ROY SOC TROP MED H, V92, P309, DOI 10.1016/S0035-9203(98)91025-2
   Graversen JH, 2002, INT J BIOCHEM CELL B, V34, P309, DOI 10.1016/S1357-2725(01)00144-3
   Guetta J, 2007, ATHEROSCLEROSIS, V191, P48, DOI 10.1016/j.atherosclerosis.2006.04.032
   Kasvosve I, 2002, CLIN CHEM LAB MED, V40, P810, DOI 10.1515/CCLM.2002.140
   Koch W, 2003, CLIN CHEM, V49, P1937, DOI 10.1373/clinchem.2003.022442
   Koch W, 2002, CLIN CHEM, V48, P1377
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   Langlois MR, 2000, CLIN CHEM, V46, P1619
   Langlois MR, 1997, AM J CLIN NUTR, V66, P606
   Langlois MR, 1996, CLIN CHEM, V42, P1589
   Mahalanabis D, 2005, BRIT J NUTR, V94, P969, DOI 10.1079/JBN.20051586
   McDermid JM, 2006, CLIN SCI, V110, P503, DOI 10.1042/CS20050273
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Minang JT, 2004, ACTA TROP, V90, P107, DOI 10.1016/j.actatropica.2003.10.016
   Okazaki T, 1997, CLIN CHEM, V43, P2012
   Okazaki T, 1997, CLIN CHIM ACTA, V258, P137, DOI 10.1016/S0009-8981(96)06468-6
   Olsen A, 2006, ANN TROP MED PARASIT, V100, P251, DOI 10.1179/136485906X91486
   Philippidis P, 2004, CIRC RES, V94, P119, DOI 10.1161/01.RES.0000109414.78907.F9
   Quaye I, 2003, T ROY SOC TROP MED H, V97, P121, DOI 10.1016/S0035-9203(03)90045-9
   Quaye IKE, 2000, T ROY SOC TROP MED H, V94, P216, DOI 10.1016/S0035-9203(00)90281-5
   Roberts DJ, 2005, CURR TOP MICROBIOL, V295, P137
   SINGH IP, 1986, HUM HERED, V36, P31, DOI 10.1159/000153596
   TAKIZAWA T, 1987, Genomics, V1, P228, DOI 10.1016/0888-7543(87)90048-6
   vanStuijvenberg ME, 1997, INT J FOOD SCI NUTR, V48, P41, DOI 10.3109/09637489709006962
NR 35
TC 8
Z9 8
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JAN
PY 2008
VL 13
IS 1
BP 76
EP 82
DI 10.1111/j.1365-3156.2007.01976.x
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 281GL
UT WOS:000254484800011
PM 18291005
OA No
DA 2017-08-15
ER

PT J
AU Faburay, B
   Jongejan, F
   Taoufik, A
   Ceesay, A
   Geysen, D
AF Faburay, Bonto
   Jongejan, Frans
   Taoufik, Amar
   Ceesay, Ansumana
   Geysen, Dirk
TI Genetic diversity of Ehrlichia ruminantium in Amblyomma variegatum ticks
   and small ruminants in The Gambia determined by restriction fragment
   profile analysis
SO VETERINARY MICROBIOLOGY
LA English
DT Article
DE Ehrlichia ruminantium; map1; restriction fragment length polymorphism;
   genetic diversity; genotypes; The Gambia
ID POLYMERASE CHAIN-REACTION; COWDRIA-RUMINANTIUM; CROSS-IMMUNITY;
   HEARTWATER; INFECTION; PROTEIN; MICE; PCR; SEROPREVALENCE; STOCKS
AB Understanding genetic diversity of Ehrlichia ruminantium in host and vector populations is an important prerequisite to controlling heartwater by vaccination in traditional livestock systems in sub-Saharan Africa. We carried out a study in two phases: (i) evaluating the usefulness of the PCR-RFLP assay based on the map1 coding sequence of E. ruminantium as a discriminatory tool to characterise genetic diversity, (ii) applying the technique to field samples from Amblyomma variegatum ticks and small ruminants to characterise genotypic diversity of the organism in three main agroecological zones of The Gambia, Sudano-Guinean (SG), Western Sudano-Sahelian (WSS) and Eastern Sudano-Sahelian (ESS). Restriction fragment length polymorphisms were observed among different strains of E. ruminantium supporting the usefulness of the PCR-RFLP technique for studying genetic diversity of the organism. Restriction enzyme map1 profile analysis indicated the presence in The Gambia of multiple genotypes (at least: 11) of E. ruminantium with sites in the WSS and SG zones showing comparatively high number of diverse genotypes. Profiles similar to the Kerr Seringe genotype (DQ333230) showed the highest distribution frequency, being present at sites in all three agroecological zones, thereby making the strain a suitable candidate for further characterisation in cross-protection studies. An additional three genotypes showed relatively high distribution frequency and were present in all three zones making them equally important for isolation and subsequent characterisation. The study demonstrated the occurrence of mixed infections with E. ruminantium genotypes in ruminants and ticks. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Faburay, Bonto; Jongejan, Frans; Taoufik, Amar] Univ Utrecht, Fac Vet Med, Utrecht Ctr Tick Borne Dis, NL-3584 CL Utrecht, Netherlands.
   [Faburay, Bonto; Ceesay, Ansumana] Int Trypanotolerance Ctr, Banjul, Gambia.
   [Geysen, Dirk] Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
   [Jongejan, Frans] Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0110 Onderstepoort, South Africa.
RP Faburay, B (reprint author), Univ Utrecht, Fac Vet Med, Utrecht Ctr Tick Borne Dis, Yalelann 1, NL-3584 CL Utrecht, Netherlands.
EM b.fabureh1@vet.uu.nl
CR Allsopp MTEP, 1997, VET PARASITOL, V71, P283, DOI 10.1016/S0304-4017(97)00012-5
   Allsopp MTEP, 1999, EPIDEMIOL INFECT, V122, P323, DOI 10.1017/S0950268899002101
   Allsopp MTEP, 2001, J CLIN MICROBIOL, V39, P4200, DOI 10.1128/JCM.39.11.4200-4203.2001
   BARBET AF, 1994, CLIN DIAGN LAB IMMUN, V1, P744
   Bekker CPJ, 2001, CLIN DIAGN LAB IMMUN, V8, P843, DOI 10.1128/CDLI.8.4.843-846.2001
   Bell-Sakyi L, 2004, VET MICROBIOL, V100, P175, DOI 10.1016/j.vetmic.2004.02.010
   Bell-Sakyi L., 1997, P 22 ANN C GHAN VET, P46
   BRINDLEY PJ, 1993, AM J TROP MED HYG, V48, P447
   de Villiers EP, 2000, J CLIN MICROBIOL, V38, P1967
   du Plessis J L, 1971, J S Afr Vet Med Assoc, V42, P217
   Dumler JS, 2001, INT J SYST EVOL MICR, V51, P2145
   DUPLESSIS JL, 1985, ONDERSTEPOORT J VET, V52, P55
   DUPLESSIS JL, 1989, ONDERSTEPOORT J VET, V56, P195
   Faburay B, 2005, CLIN DIAGN LAB IMMUN, V12, P508, DOI 10.1128/CDLI.12.4.508-512.2005
   FABURAY B, 2007, EXP APPL ACAROL
   GASSER RB, 1994, INT J PARASITOL, V24, P291, DOI 10.1016/0020-7519(94)90041-8
   Geysen D, 2003, VET PARASITOL, V110, P171, DOI 10.1016/S0304-4017(02)00313-8
   GRIFFAIS R, 1991, NUCLEIC ACIDS RES, V19, P3887
   ILEMOBADE AA, 1978, TROP ANIM HEALTH PRO, V10, P39, DOI 10.1007/BF02235302
   JONGEJAN F, 1991, RES VET SCI, V51, P24, DOI 10.1016/0034-5288(91)90025-J
   JONGEJAN F, 1984, VET RES COMMUN, V8, P141, DOI 10.1007/BF02214705
   JONGEJAN F, 1988, RES VET SCI, V44, P186
   JONGEJAN F, 1999, RICKETTSIAE RICKETTS, P373
   KOCAN KM, 1987, AM J VET RES, V48, P356
   MACKENZIE PK, 1981, P INT C TICK BIOL CO, P47
   MACKENZIE PKI, 1984, PREV VET MED, V2, P227, DOI 10.1016/0167-5877(84)90066-7
   Martinez D, 2004, ANN NY ACAD SCI, V1026, P106, DOI 10.1196/annals.1307.014
   NEEFS JM, 1993, NUCLEIC ACIDS RES, V21, P3025, DOI 10.1093/nar/21.13.3025
   PERE JM, 1997, FEMS MICROBIOL LETT, V1, P73
   Postigo M, 2007, VET MICROBIOL, V122, P298, DOI 10.1016/j.vetmic.2007.01.019
   REDDY GR, 1996, CLIN DIAGN LAB IMMUN, V154, P73
   UILENBERG G, 1983, ADV VET SCI COMP MED, V27, P427
   UILENBERG G, 1985, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V38, P34
   UILENBERG G, 1982, VET QUART, V4, P106
   VANVLIET AHM, 1994, INFECT IMMUN, V62, P1451
   WALKER JB, 1987, ONDERSTEPOORT J VET, V54, P353
NR 36
TC 10
Z9 10
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1135
J9 VET MICROBIOL
JI Vet. Microbiol.
PD JAN 1
PY 2008
VL 126
IS 1-3
BP 189
EP 199
DI 10.1016/j.vetmic.2007.06.010
PG 11
WC Microbiology; Veterinary Sciences
SC Microbiology; Veterinary Sciences
GA 245HC
UT WOS:000251924700020
PM 17646061
OA No
DA 2017-08-15
ER

PT J
AU Ota, MOC
   Brookes, RH
   Hill, PC
   Owiafe, PK
   Ibanga, HB
   Donkor, S
   Awine, T
   McShane, H
   Adegbola, RA
AF Ota, Martin O. C.
   Brookes, Roger H.
   Hill, Philip C.
   Owiafe, Patrick K.
   Ibanga, Hannah B.
   Donkor, Simon
   Awine, Timothy
   McShane, Helen
   Adegbola, Richard A.
TI The effect of tuberculin skin test and BCG vaccination on the expansion
   of PPD-specific IFN-gamma producing cells ex vivo
SO VACCINE
LA English
DT Article
DE BCG; tuberculin skin test; immune response
ID CALMETTE-GUERIN VACCINATION; ENVIRONMENTAL MYCOBACTERIA;
   INTERFERON-GAMMA; NORTHERN MALAWI; PUBLISHED LITERATURE; PROTECTIVE
   IMMUNITY; T-CELLS; EFFICACY; RESPONSES; PREVENTION
AB Understanding the immunogenicity of BCG in a population where it has failed will facilitate the design of new TB vaccines. We assessed the immunogenicity of M. bovis BCG over 12 months by ELISPOT assay. Forty-one adolescents and young Gambian male adults received a tuberculin skin test (TST) which was followed one week later by BCG vaccination, but the 23 control subjects received neither of these. TST alone significantly induced PPD-specific IFN-gamma producing cells. Twenty-three percent of subjects did not respond to BCG, which was associated with higher pre-existing ex vivo response to PPD. Paradoxically, amongst BCG responders there was a correlation between preexisting response and subsequent response to BCG. We conclude that BCG is immunogenic, but this effector response is short-lived and can be limited in higher pre-existing anti-mycobacterial immunity, suggesting a possible threshold beyond which BCG immumogenicity is inhibited. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Ota, Martin O. C.; Brookes, Roger H.; Hill, Philip C.; Owiafe, Patrick K.; Ibanga, Hannah B.; Donkor, Simon; Awine, Timothy; Adegbola, Richard A.] MRC, Bacterial Dis Programme, Banjul, Gambia.
   [McShane, Helen] Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford OX3 7LJ, England.
RP Ota, MOC (reprint author), MRC, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM mota@mrc.gm
FU Medical Research Council [MC_U190071468]; Wellcome Trust [076943]
CR ALKASSIMI FA, 1995, AM J RESP CRIT CARE, V152, P1575
   Barbosa T, 2003, VACCINE, V21, P2152, DOI 10.1016/S0264-410X(02)00721-1
   Bierrenbach AL, 2001, INT J TUBERC LUNG D, V5, P656
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   Black GF, 2001, J INFECT DIS, V184, P322, DOI 10.1086/322042
   Brandt L, 2002, INFECT IMMUN, V70, P672, DOI 10.1128/IAI.70.2.672-678.2002
   Buddle BM, 2002, VACCINE, V20, P1126, DOI 10.1016/S0264-410X(01)00436-4
   COLDITZ GA, 1995, PEDIATRICS, V96, P29
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Dantas OMS, 2006, INT J TUBERC LUNG D, V10, P536
   Fine PEM, 1996, LANCET, V348, P17
   FINE PEM, 1994, LANCET, V344, P1245, DOI 10.1016/S0140-6736(94)90748-X
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   FINE PEM, 1989, REV INFECT DIS S2, V2, P353
   Johnson PDR, 1999, CLIN DIAGN LAB IMMUN, V6, P934
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   LEYTEN EM, 2007, EUR RESP J
   Moreno S, 2001, ARCH INTERN MED, V161, P1760, DOI 10.1001/archinte.161.14.1760
   MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0
   OTA MO, 2006, J TROP PEDIATRICS, V52, P36
   Palmer MV, 2006, CLIN VACCINE IMMUNOL, V13, P387, DOI 10.1128/CVI.13.3.387-394.2006
   Pantaleo G, 1997, P NATL ACAD SCI USA, V94, P9848, DOI 10.1073/pnas.94.18.9848
   PITULLE C, 1992, INT J SYST BACTERIOL, V42, P337
   PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4
   REICHMAN LB, 1979, CHEST, V76, P764, DOI 10.1378/chest.76.6.764
   Richeldi L, 2006, THORAX, V61, P180, DOI 10.1136/thx.2005.049759
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154
   Salles CG, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-38
   Soysal A, 2005, LANCET, V366, P1443, DOI 10.1016/S0140-6736(05)67534-4
   STANFORD JL, 1981, TUBERCLE, V62, P55, DOI 10.1016/0041-3879(81)90037-4
   SUTHERLAND I, 1987, TUBERCLE, V68, P81, DOI 10.1016/0041-3879(87)90023-7
   ten Dam H G, 1984, Adv Tuberc Res, V21, P79
   Weir RE, 2006, CLIN EXP IMMUNOL, V146, P390, DOI 10.1111/j.1365-2249.2006.03222.x
   Weir RE, 2003, CLIN EXP IMMUNOL, V134, P285, DOI 10.1046/j.1365-2249.2003.02272.x
NR 34
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD DEC 17
PY 2007
VL 25
IS 52
BP 8861
EP 8867
DI 10.1016/j.vaccine.2007.10.025
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 253DC
UT WOS:000252497900022
PM 18023944
OA No
DA 2017-08-15
ER

PT J
AU Walther, B
   Walther, M
AF Walther, B.
   Walther, M.
TI What does it take to control malaria?
SO ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY
LA English
DT Review
ID INTERMITTENT PREVENTIVE TREATMENT; PLACEBO-CONTROLLED TRIAL;
   PLASMODIUM-FALCIPARUM MALARIA; RANDOMIZED CONTROLLED-TRIAL;
   INSECTICIDE-TREATED NETS; PAPUA-NEW-GUINEA; SULFADOXINE-PYRIMETHAMINE;
   FOLLOW-UP; ROUTINE VACCINATIONS; ACQUIRED-IMMUNITY
AB More than 125 years after the discovery of the causative parasites, human malaria remains a major global-health problem. Despite many important discoveries in the epidemiology and pathogenesis of the disease, and the availability of effective treatment and control measures, there was no decline in global malarial mortality from 1954 to 1997. The economic prospects of the countries in which malaria is endemic arc closely related to the burden of the disease, a situation that calls for an enhanced, concerted effort from the global community in the fight against the disease.
   This review explains the effects and limitations of the available control tools, summarises the extent to which they are currently employed, describes how their use could be improved, and discusses the particular importance of a vaccine in controlling the disease.
C1 MRC Labs, Banjul, Gambia.
RP Walther, M (reprint author), MRC Labs, PO Box 273, Banjul, Gambia.
EM mwalther@mrc.gm
CR Aceng JR, 2005, BRIT MED J, V330, P334, DOI 10.1136/bmj.330.7487.334
   Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6
   Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   Artavanis-Tsakonas K, 2003, CLIN EXP IMMUNOL, V133, P145, DOI 10.1046/j.1365-2249.2003.02174.x
   BAIRD JK, 1995, PARASITOL TODAY, V11, P105, DOI 10.1016/0169-4758(95)80167-7
   Barnes KI, 2004, LANCET, V363, P1598, DOI 10.1016/S0140-6736(04)16203-X
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Binka FN, 2002, T ROY SOC TROP MED H, V96, P597, DOI 10.1016/S0035-9203(02)90321-4
   BLACK RH, 1968, MANUAL EPIDEMIOLOGIC
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Bojang KA, 2005, VACCINE, V23, P4148, DOI 10.1016/j.vaccine.2005.03.019
   Breman JG, 2001, AM J TROP MED HYG, V64, P1
   Brent AJ, 2006, PEDIATR INFECT DIS J, V25, P230, DOI 10.1097/01.inf.0000202066.02212.ff
   Brent AJ, 2006, LANCET, V367, P482, DOI 10.1016/S0140-6736(06)68180-4
   Brooke BD, 2001, B ENTOMOL RES, V91, P265, DOI 10.1079/BER2001108
   Brown V, 1998, LANCET, V352, P1356, DOI 10.1016/S0140-6736(05)60747-7
   Chandramohan D, 2005, BRIT MED J, V331, P727, DOI 10.1136/bmj.331.7519.727
   Chandre F, 1999, B WORLD HEALTH ORGAN, V77, P230
   CHAVASSE D, 2006, MOSQUITO NET COVERAG
   Chen A, 2003, EMERG INFECT DIS, V9, P960
   Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660
   Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0
   CLYDE DF, 1975, AM J TROP MED HYG, V24, P397
   COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0
   Curtis C, 2003, LANCET INFECT DIS, V3, P304, DOI 10.1016/S1473-3099(03)00612-1
   Desai MR, 2003, J INFECT DIS, V187, P658, DOI 10.1086/367986
   Diallo DA, 2004, B WORLD HEALTH ORGAN, V82, P85
   Egan AF, 2002, BLOOD, V99, P3863, DOI 10.1182/blood.V99.10.3863
   Faiz MA, 2005, LANCET, V366, P717
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Ghebreyesus TA, 1999, BRIT MED J, V319, P663
   Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a
   Greenwood B, 2006, TROP MED INT HEALTH, V11, P983, DOI 10.1111/j.1365-3156.2006.01657.x
   GUILLET P, 2004, 5 UPDATE LONG LASTIN
   Gupta S, 1999, NAT MED, V5, P340, DOI 10.1038/6560
   Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6
   Hill J, 2006, TROP MED INT HEALTH, V11, P409, DOI 10.1111/j.1365-3156.2006.01585.x
   Hisaeda Hajime, 2002, Journal of Medical Investigation, V49, P118
   Holding PA, 2001, AM J TROP MED HYG, V64, P68
   Karunajeewa HA, 2006, ANTIMICROB AGENTS CH, V50, P968, DOI 10.1128/AAC.50.3.968-974.2006
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0
   Korenromp EL, 2003, LANCET INFECT DIS, V3, P349, DOI 10.1016/S1473-3099(03)00657-1
   Korenromp E. L., 2004, MALARIA INCIDENCE ES
   Krishna S, 2001, ANTIMICROB AGENTS CH, V45, P509, DOI 10.1128/AAC.45.2.509-516.2001
   Lang T, 2006, LANCET INFECT DIS, V6, P46, DOI 10.1016/S1473-3099(05)70326-1
   Lengeler C, 2004, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000363.PUB2
   Macdonald G., 1957, EPIDEMIOLOGY CONTROL
   Macete E, 2006, J INFECT DIS, V194, P276, DOI 10.1086/505431
   Makani J, 2003, QJM-INT J MED, V96, P355, DOI 10.1093/qjmed/hcg059
   Makobongo MO, 2003, P NATL ACAD SCI USA, V100, P2628, DOI 10.1073/pnas.0337659100
   Marsh VM, 1999, TROP MED INT HEALTH, V4, P383, DOI 10.1046/j.1365-3156.1999.00403.x
   Molineaux L, 1997, ANN TROP MED PARASIT, V91, P811
   Nicoll A, 2000, T ROY SOC TROP MED H, V94, P9, DOI 10.1016/S0035-9203(00)90418-8
   NUSSENZWEIG RS, 1967, NATURE, V216, P160, DOI 10.1038/216160a0
   Pombo DJ, 2002, LANCET, V360, P610, DOI 10.1016/S0140-6736(02)09784-2
   Reyburn H, 2004, BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55
   Ridley RG, 2002, NATURE, V415, P686, DOI 10.1038/415686a
   ROWE AK, 2006, INT J EPIDEMIOL, V35, P704
   SABCHAREON A, 1991, AM J TROP MED HYG, V45, P297
   Sachs JD, 2005, LANCET, V365, P347, DOI 10.1016/S0140-6736(05)17791-5
   Sachs JD, 2001, MACROECONOMICS HLTH
   Schellenberg D, 2005, LANCET, V365, P1481, DOI 10.1016/S0140-6736(05)66418-5
   Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2
   Schellenberg JRMA, 2001, LANCET, V357, P1241, DOI 10.1016/S0140-6736(00)04404-4
   Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8
   The National Academies Press, 2004, SAVING LIVES BUYING
   Trouiller P, 1998, Int J Infect Dis, V3, P61, DOI 10.1016/S1201-9712(99)90010-3
   Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900
   Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006
   Walther M, 2006, EXPERT REV VACCINES, V5, P81, DOI 10.1586/14760584.5.1.81
   White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X
   WHO. World Health Organization (WHO), 2006, WHOHTMMAL20061108
   World Health Organization, 2003, WORLD HLTH REP 2003
   WHO, 2006, WHOHTMMAL20061112
   World Health Organization, 2003, WHOCDSMAL20031093
   World Health Organization, 2005, WHOHTMMAL20051102
   Worrall E, 2004, AM J TROP MED HYG, V71, P136
   Yates A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-52
   Zaim M, 2002, TRENDS PARASITOL, V18, P161, DOI 10.1016/S1471-4922(01)02220-6
   2005, PROGR CHILDREN REPOR
   2002, REDUCING ELIMINATING
   2007, IMMUNIZATION SUMMARY
NR 83
TC 9
Z9 9
U1 0
U2 2
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 0003-4983
J9 ANN TROP MED PARASIT
JI Ann. Trop. Med. Parasitol.
PD DEC
PY 2007
VL 101
IS 8
BP 657
EP 672
DI 10.1179/136485907X229013
PG 16
WC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
   Medicine
GA 238QW
UT WOS:000251463600001
PM 18028727
OA No
DA 2017-08-15
ER

PT J
AU Nweneka, CV
AF Nweneka, C. V.
TI Rethinking iron supplementation recommendations in health care
SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Letter
ID CONTROLLED-TRIAL; HEMOGLOBIN
C1 Med Res Labs, Keneba Field Stn, Banjul, Gambia.
RP Nweneka, CV (reprint author), Med Res Labs, Keneba Field Stn, Banjul, Gambia.
CR Knutson M, 2003, CRIT REV BIOCHEM MOL, V38, P61, DOI 10.1080/713609210
   Olsen A, 2006, ANN TROP MED PARASIT, V100, P251, DOI 10.1179/136485906X91486
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   Ziaei S, 2007, BJOG-INT J OBSTET GY, V114, P684, DOI 10.1111/j.1471-0528.2007-01325.x
NR 4
TC 2
Z9 2
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1470-0328
J9 BJOG-INT J OBSTET GY
JI BJOG
PD DEC
PY 2007
VL 114
IS 12
BP 1581
EP 1581
DI 10.1111/j.1471-0528.2007.01532.x
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 229ID
UT WOS:000250795600020
PM 17995501
OA No
DA 2017-08-15
ER

PT J
AU David, SP
   Munafo, MR
   Johansen-Berg, H
   MacKillop, J
   Sweet, LH
   Cohen, RA
   Niaura, R
   Rogers, RD
   Matthews, PM
   Walton, RT
AF David, Sean P.
   Munafo, Marcus R.
   Johansen-Berg, Heidi
   MacKillop, James
   Sweet, Lawrence H.
   Cohen, Ronald A.
   Niaura, Raymond
   Rogers, Robert D.
   Matthews, Paul M.
   Walton, Robert T.
TI Effects of Acute Nicotine Abstinence on Cue-elicited Ventral
   Striatum/Nucleus Accumbens Activation in Female Cigarette Smokers: A
   Functional Magnetic Resonance Imaging Study
SO BRAIN IMAGING AND BEHAVIOR
LA English
DT Article
DE fMRI; Smoking; Tobacco; Cue reactivity; Ventral striatum; Nucleus
   accumbens
AB To achieve greater understanding of the brain mechanisms underlying nicotine craving in female smokers, we examined the influence of nicotine non-abstinence vs. acute nicotine abstinence on cue-elicited activation of the ventral striatum. Eight female smokers underwent an event-related functional magnetic resonance imaging (fMRI) paradigm presenting randomized sequences of smoking-related and non-smoking related pictures. Participants were asked to indicate by a key press the gender of individuals in smoking-related and non-smoking related pictures (gender discrimination task), to maintain and evaluate attention to the pictures. There was a significant effect of smoking condition on reaction times (RT) for a gender discrimination task intended to assess and maintain attention to the photographs-suggesting a deprivation effect of acute nicotine abstinence and a statistical trend indicating greater RTs for smoking cues than neutral cues. BOLD contrast (smoking vs. non-smoking cues) was greater in the non-abstinent vs. acutely abstinent conditions in the ventral striatum including the nucleus accumbens (VS/NAc). Moreover, a significant positive correlation was observed between baseline cigarette craving prior to scanning and VS/NAc activation (r = 0.84, p = 0.009), but only in the non-abstinent condition. These results may either be explained by ceiling effects of nicotine withdrawal in the abstinent condition or, may indicate reduced relative activation (smoking vs. neutral contrast) in the VS/NAc in the abstinent vs. non-abstinent conditions in this group of female smokers.
C1 [David, Sean P.] Brown Univ, Warren Alpert Med Sch, Ctr Primary Care & Prevent, Pawtucket, RI 02860 USA.
   [David, Sean P.] Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England.
   [Munafo, Marcus R.] Univ Bristol, Dept Expt Psychol, Bristol, Avon, England.
   [Johansen-Berg, Heidi] Univ Oxford, John Radcliffe Hosp, Dept Clin Neurol, Oxford OX3 9DU, England.
   [MacKillop, James] Brown Univ, Warren Alpert Med Sch, Ctr Alcohol & Addict Studies, Pawtucket, RI 02860 USA.
   [Sweet, Lawrence H.; Cohen, Ronald A.] Brown Univ, Warren Alpert Med Sch, Ctr Behav & Prevent Med, Pawtucket, RI 02860 USA.
   [Niaura, Raymond] Brown Univ, Warren Alpert Med Sch, Dept Psychiat & Human Behav, Pawtucket, RI 02860 USA.
   [Rogers, Robert D.] Univ Oxford, Dept Psychiat, Oxford, England.
   [Matthews, Paul M.] GlaxoSmithKline Clin Imaging Ctr, London, England.
   [Walton, Robert T.] MRC Labs, Fajara, Gambia.
RP David, SP (reprint author), Brown Univ, Warren Alpert Med Sch, Ctr Primary Care & Prevent, 111 Brewster St, Pawtucket, RI 02860 USA.
EM Sean_David@Brown.Edu
OI Johansen-Berg, Heidi/0000-0002-4134-9730; David,
   Sean/0000-0002-4922-2603; Walton, Robert/0000-0001-7700-1907; Matthews,
   Paul M/0000-0002-1619-8328; Munafo, Marcus/0000-0002-4049-993X
FU Public Health Service, National Institute on Drug Abuse/National
   Institutes of Health [K08 DA14276]; Cancer Research UK; Centre for
   Functional Neuroimaging of the Brain (FMRIB), Medical Research Council
FX This research was funded by Public Health Service grant K08 DA14276 from
   the National Institute on Drug Abuse/National Institutes of Health, and
   by Cancer Research UK. Work in the Centre for Functional Neuroimaging of
   the Brain (FMRIB) and personal support to PMM come from the Medical
   Research Council. We would like to acknowledge Peter Hobden for
   assistance in protocol development and scanner operation.
CR Balfour David J. K., 2002, Current Drug Targets - CNS and Neurological Disorders, V1, P413, DOI 10.2174/1568007023339076
   Balfour DJK, 1998, PHARMACOL BIOCHEM BE, V59, P1021, DOI 10.1016/S0091-3057(97)00537-6
   Beckmann CF, 2003, NEUROIMAGE, V20, P1052, DOI 10.1016/S1053-8119(03)00435-X
   BENWELL MEM, 1995, BRIT J PHARMACOL, V114, P454
   Bortolozzi A, 2003, NEUROTOXICOLOGY, V24, P149, DOI 10.1016/S0161-813X(02)00156-0
   Breiter HC, 1999, ANN NY ACAD SCI, V877, P523, DOI 10.1111/j.1749-6632.1999.tb09287.x
   Brody AL, 2004, AM J PSYCHIAT, V161, P1211, DOI 10.1176/appi.ajp.161.7.1211
   Brody AL, 2002, ARCH GEN PSYCHIAT, V59, P1162, DOI 10.1001/archpsyc.59.12.1162
   Caggiula AR, 2001, PHARMACOL BIOCHEM BE, V70, P515, DOI 10.1016/S0091-3057(01)00676-1
   Carpenter MJ, 2006, NICOTINE TOB RES, V8, P627, DOI 10.1080/14622200600910793
   Carter BL, 1999, ADDICTION, V94, P327, DOI 10.1046/j.1360-0443.1999.9433273.x
   David SP, 2005, BIOL PSYCHIAT, V58, P488, DOI 10.1016/j.biopsych.2005.04.028
   Due DL, 2002, AM J PSYCHIAT, V159, P954, DOI 10.1176/appi.ajp.159.6.954
   Duvernoy H., 1999, HUMAN BRAIN
   Etter JF, 2006, ADDICTION, V101, P362, DOI 10.1111/j.1360-0443.2005.01289.x
   Fudge JL, 2002, J NEUROSCI, V22, P10078
   Garreffa G, 2004, MAGN RESON IMAGING, V22, P1445, DOI 10.1016/j.mri.2004.10.013
   Gilbert DG, 1999, INT SMOKING IMAGES S
   GROSS TM, 1993, PSYCHOPHARMACOLOGY, V110, P333, DOI 10.1007/BF02251289
   Havermans RC, 2003, PSYCHOL ADDICT BEHAV, V17, P336, DOI 10.1037/0893-164X.17.4.336
   HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119
   Heiervang E, 2006, NEUROIMAGE, V33, P867, DOI 10.1016/j.neuroimage.2006.07.037
   Heinz A, 2004, AM J PSYCHIAT, V161, P1783, DOI 10.1176/appi.ajp.161.10.1783
   HUGHES JR, 1986, ADDICT BEHAV, V11, P115, DOI 10.1016/0306-4603(86)90035-3
   HUGHES JR, 1986, ARCH GEN PSYCHIAT, V43, P289
   Hutchison KE, 2003, NEUROPSYCHOPHARMACOL, V28, P1882, DOI 10.1038/sj.npp.1300264
   Hutchison KE, 2000, PSYCHOPHARMACOLOGY, V150, P244, DOI 10.1007/s002130000399
   Hutchison KE, 1999, EXP CLIN PSYCHOPHARM, V7, P250, DOI 10.1037/1064-1297.7.3.250
   *ICRF, 1993, BUILDERS MERCHANTS J, V306, P1304
   Ishai A, 1999, P NATL ACAD SCI USA, V96, P9379, DOI 10.1073/pnas.96.16.9379
   Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132
   Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6
   Johansen-Berg H, 2002, BRAIN, V125, P2731, DOI 10.1093/brain/awf282
   Katner SN, 1996, BEHAV PHARMACOL, V7, P669
   Katner SN, 1999, ALCOHOL CLIN EXP RES, V23, P1751, DOI 10.1097/00000374-199911000-00007
   Kenny PJ, 2001, PHARMACOL BIOCHEM BE, V70, P531, DOI 10.1016/S0091-3057(01)00651-7
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Mawlawi O, 2001, J CEREBR BLOOD F MET, V21, P1034
   McClernon FJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1940, DOI 10.1038/sj.npp.1300780
   Melendez RI, 2002, ALCOHOL CLIN EXP RES, V26, P318
   Munafo M, 2003, J PSYCHOPHARMACOL, V17, P310, DOI 10.1177/02698811030173013
   Niaura R, 1998, ADDICT BEHAV, V23, P209, DOI 10.1016/S0306-4603(97)00043-9
   NIAURA RS, 1988, J ABNORM PSYCHOL, V97, P133, DOI 10.1037/0021-843X.97.2.133
   Palfai TP, 2000, J ABNORM PSYCHOL, V109, P96, DOI 10.1037//0021-843X.109.1.96
   Robinson TE, 2000, ADDICTION, V95, pS91
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   ROHSENOW D J, 1990, International Journal of the Addictions, V25, P957
   Rose JE, 2000, PHARMACOL BIOCHEM BE, V67, P71, DOI 10.1016/S0091-3057(00)00301-4
   Rose JE, 2003, PHARMACOL BIOCHEM BE, V76, P243, DOI 10.1016/j.pbb.2003.07.002
   SCHNEIDER LH, 1982, NEUROSCI LETT, V33, P281, DOI 10.1016/0304-3940(82)90385-8
   SHIFFMAN SM, 1998, 4 ANN SCI C SOC RES
   Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062
   Smolka MN, 2006, PSYCHOPHARMACOLOGY, V184, P577, DOI 10.1007/s00213-005-0080-x
   Stein EA, 1998, AM J PSYCHIAT, V155, P1009
   STEWART J, 1983, PROG NEURO-PSYCHOPH, V7, P591, DOI 10.1016/0278-5846(83)90030-1
   STEWART J, 1984, PSYCHOL REV, V91, P251, DOI 10.1037/0033-295X.91.2.251
   STEWART J, 1984, PHARMACOL BIOCHEM BE, V20, P917, DOI 10.1016/0091-3057(84)90017-0
   Teneggi V, 2005, PSYCHOPHARMACOLOGY, V183, P1, DOI 10.1007/s00213-005-0145-x
   Teneggi V, 2002, PSYCHOPHARMACOLOGY, V164, P177, DOI 10.1007/s00213-002-1176-1
   Tidey JW, 2005, NICOTINE TOB RES, V7, P421, DOI 10.1080/14622200500125724
   TIFFANY ST, 1991, BRIT J ADDICT, V86, P1467
   Trimmel M, 2004, PHARMACOL BIOCHEM BE, V78, P639, DOI 10.1016/j.pbb.2004.04.030
   Volkow ND, 2003, J CLIN INVEST, V111, P1444, DOI 10.1172/JCI200318533
   Warfield SK, 2004, IEEE T MED IMAGING, V23, P903, DOI 10.1109/TMI.2004.828354
   Waters AJ, 2000, PSYCHOL ADDICT BEHAV, V14, P111, DOI 10.1037/0893-164X.14.2.111
   Waters AJ, 2004, J CONSULT CLIN PSYCH, V72, P1136, DOI 10.1037/0022-006X.72.6.1136
   WEISS F, 1993, J PHARMACOL EXP THER, V267, P250
   WILLNER P, 1995, PSYCHOPHARMACOLOGY, V118, P171, DOI 10.1007/BF02245836
   Wilson SJ, 2005, NICOTINE TOB RES, V7, P637, DOI 10.1080/14622200500185520
   Woolrich MW, 2004, NEUROIMAGE, V21, P1732, DOI 10.1016/j.neuroimage.2003.12.023
   Woolrich MW, 2001, NEUROIMAGE, V14, P1370, DOI 10.1006/nimg.2001.0931
   WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900
   Yudkin P, 2004, BRIT MED J, V328, P989, DOI 10.1136/bmj.38050.674826.AE
NR 73
TC 39
Z9 41
U1 3
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1931-7557
J9 BRAIN IMAGING BEHAV
JI Brain Imaging Behav.
PD DEC
PY 2007
VL 1
IS 3-4
BP 43
EP 57
DI 10.1007/s11682-007-9004-1
PG 15
WC Neuroimaging
SC Neurosciences & Neurology
GA V07KY
UT WOS:000207261300001
PM 18458752
OA No
DA 2017-08-15
ER

PT J
AU Eriksson, M
   Sartono, E
   Martins, CL
   Bale, C
   Garly, ML
   Whittle, H
   Aaby, P
   Pedersen, BK
   Yazdanbakhsh, M
   Erikstrup, C
   Benn, CS
AF Eriksson, M.
   Sartono, E.
   Martins, C. L.
   Bale, C.
   Garly, M. -L.
   Whittle, H.
   Aaby, P.
   Pedersen, B. K.
   Yazdanbakhsh, M.
   Erikstrup, C.
   Benn, C. S.
TI A comparison of ex vivo cytokine production in venous and capillary
   blood
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE capillary; cytokines; sex differences; venous; whole blood cultures
ID WHOLE-BLOOD; HEMATOLOGICAL PARAMETERS; MORTALITY; CULTURES; CHILDREN;
   MEASLES; COUNTS; GENDER; PLASMA
AB We performed a randomized study of the immunological effects of an early measles vaccine given at 4.5 months of age and aimed to obtain venous samples from the infants at baseline and 6 weeks later. If this was not feasible, a capillary sample was obtained. We analysed baseline samples from the first 50 children enrolled in the study to investigate the potential differences in ex vivo cytokine production between venous blood and capillary blood. We also obtained paired venous and capillary blood samples from 11 adult volunteers. Whole blood was stimulated with lipopolysaccharide (LPS) [a Toll-like receptor (TLR)-4 ligand], (S)-(2, 3-bis (palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys4-OH, trihydrochloride (PAM3Cys) (a TLR-2 ligand), phytohaemagglutinin (PHA) or purified protein derivative (PPD). Cytokine concentrations in the supernatants were assessed by a multiplexed assay and were compared between venous and capillary samples in both infants and adults. The production of both the pro- and the anti-inflammatory cytokines, tumour necrosis factor (TNF)-alpha and interleukin (IL)-10, was higher in cultures of capillary blood compared with venous blood. This was found in non-stimulated control samples as well as in blood stimulated with PAM3Cys and PPD. Adults produced more IL-5 in venous blood than in capillary blood upon PHA stimulation. We found no other difference in the levels of IL-5 or IFN-gamma between venous and capillary blood. In capillary blood we found sex differences in response to PHA but this was not the case in venous blood. We found significant differences in the production of cytokines between venous and capillary blood. Such differences should be taken into account when setting up immuno-epidemiological studies.
C1 Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen, Denmark.
   INDEPTH Network, Projecto Saude Bandim, Bissau, Guinea Bissau.
   Rigshosp, Dept Infect Dis, Ctr Inflammat & Metab, DK-2100 Copenhagen, Denmark.
   Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands.
   MRC Labs, Fajara, Gambia.
RP Eriksson, M (reprint author), Statens Serum Inst, Bandim Hlth Project, Artillerivej 5, DK-2300 Copenhagen, Denmark.
EM miaerixon@gmail.com
OI Sondergaard, Mia Johanna/0000-0002-9382-3748; Pedersen, Bente
   Klarlund/0000-0001-6508-6288
CR Aaby P, 2002, VACCINE, V21, P15, DOI 10.1016/S0264-410X(02)00441-3
   AABY P, 1994, B WORLD HEALTH ORGAN, V72, P761
   Colagiuri S, 2003, DIABETIC MED, V20, P953, DOI 10.1046/j.1464-5491.2003.01048.x
   DAAE LNW, 1988, SCAND J CLIN LAB INV, V48, P723, DOI 10.3109/00365518809085796
   DAAE LNW, 1991, SCAND J CLIN LAB INV, V51, P651, DOI 10.3109/00365519109104576
   DEGROOTE D, 1992, CYTOKINE, V4, P239, DOI 10.1016/1043-4666(92)90062-V
   ELSASSERBEILE U, 1991, J IMMUNOL METHODS, V139, P191, DOI 10.1016/0022-1759(91)90188-L
   Kayiran SM, 2003, CLIN LAB HAEMATOL, V25, P9, DOI 10.1046/j.1365-2257.2003.00484.x
   Kuwa K, 2001, CLIN CHIM ACTA, V307, P187, DOI 10.1016/S0009-8981(01)00426-0
   Matthiesen G, 2002, SCAND J CLIN LAB INV, V62, P565, DOI 10.1080/003655102764654295
   Pinsky NA, 2003, SCAND J INFECT DIS, V35, P107, DOI 10.1080/0036554021000027008
   Roth A, 2006, EPIDEMIOLOGY, V17, P562, DOI 10.1097/01.ede.0000231546.14749.ab
   Trotter A, 2001, CRIT CARE, V5, P343, DOI 10.1186/cc1067
   Uekert SJ, 2006, J ALLERGY CLIN IMMUN, V118, P1375, DOI 10.1016/j.jaci.2006.09.008
   Yang ZW, 2001, CLIN LAB HAEMATOL, V23, P155, DOI 10.1046/j.1365-2257.2001.00388.x
   Yaqoob P, 1999, CYTOKINE, V11, P600, DOI 10.1006/cyto.1998.0471
NR 16
TC 13
Z9 15
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD DEC
PY 2007
VL 150
IS 3
BP 469
EP 476
DI 10.1111/j.1365-2249.2007.03515.x
PG 8
WC Immunology
SC Immunology
GA 229PH
UT WOS:000250816000010
PM 17924971
OA No
DA 2017-08-15
ER

PT J
AU Couillard, V
AF Couillard, Valerie
TI The Nairobi Declaration: Redefining Reparations for Women Victims of
   Sexual Violence
SO INTERNATIONAL JOURNAL OF TRANSITIONAL JUSTICE
LA English
DT Article
AB This paper explores the contribution of the 'Nairobi Declaration on the Right of Women and Girls to a Remedy and Reparation' to the problem of delivering justice through reparation programmes for women victims of sexual violence in conflict situations. It highlights that this civil society initiative is particularly significant because it gives voice to women and girls who are survivors of sexual violence. Placed in the context of the recent adoption by the United Nations General Assembly of the Basic Principles and Guidelines on the Right to a Remedy and Reparation for Victims of Gross Violations of International Human Rights Law and Serious Violations of International Humanitarian Law, the Nairobi Declaration redefines reparation and guides policy-making for implementing this right specifically for victims of sexual violence. The concept of reparation as a transformative and participative process put forward in the Nairobi Declaration constitutes its most innovative and inspiring contribution.
C1 African Commiss Human & Peoples Rights, Banjul, Gambia.
RP Couillard, V (reprint author), African Commiss Human & Peoples Rights, Banjul, Gambia.
EM valeriecou@hotmail.com
CR *COAL WOM HUM RIGH, BACKGR PAP WOM RIGHT
   MINOW M, 1998, AE HIRSCH LECT SER N
   Minow M., 1998, VENGEANCE FORGIVENES
   Ruth Rubio-Marin, 2006, WHAT HAPPENED WOMEN
NR 4
TC 7
Z9 7
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1752-7716
J9 INT J TRANSIT JUST
JI Int. J. Transitional Justice
PD DEC
PY 2007
VL 1
IS 3
SI SI
BP 444
EP 453
DI 10.1093/ijtj/ijm030
PG 10
WC International Relations; Law; Political Science
SC International Relations; Government & Law
GA V14KN
UT WOS:000207733400009
OA No
DA 2017-08-15
ER

PT J
AU McDermid, JM
   Jaye, A
   van der Loeff, MFS
   Todd, J
   Bates, C
   Austin, S
   Jeffries, D
   Awasana, AA
   Whittle, HC
   Prentice, AM
AF McDermid, Joann M.
   Jaye, Assan
   van der Loeff, Maarten F. Schim
   Todd, Jim
   Bates, Chris
   Austin, Steve
   Jeffries, David
   Awasana, Akum A.
   Whittle, Hilton C.
   Prentice, Andrew M.
TI Elevated iron status strongly predicts mortality in West African adults
   with HIV infection
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article; Proceedings Paper
CT 15th International AIDS Conference
CY JUL 11-17, 2004
CL Bangkok, THAILAND
DE Africa; cohort; iron; mortality; nutrition
ID SERUM TRANSFERRIN RECEPTOR; IMMUNODEFICIENCY-VIRUS-INFECTION;
   INJECTION-DRUG USERS; KAPOSIS-SARCOMA; SURVIVAL; ANEMIA; FERRITIN;
   DEFICIENCY; DIAGNOSIS; OVERLOAD
AB Objective: To comprehensively assess iron status and determine whether elevated iron status, like anemia, predicts mortality.
   Methods: We followed 1362 Gambian adults (53% female) in an HIV-seroprevalent clinic-based cohort over 11.5 years to ascertain all-cause mortality. Baseline iron status (iron, soluble transferrin receptor [sTfR], transferrin, ferritin, transferrin saturation, log [transferrin receptor: ferritin]), age, gender, ethnicity, hemoglobin, body mass index, HIV type, absolute CD4 count, malaria status, and alpha-(1)-antichymotrypsin were measured.
   Results: The mortality rate was 25.9/100 person-years. Elevated iron universally predicted greater mortality compared to normal iron status for all iron status indices, with the exception of sTfR in unadjusted models. In fully adjusted models, transferrin (elevated vs. normal, hazard ratio [HR]: 1.77; 95% confidence interval [Cl]: 1.30 to 2.42; P < 0.001), ferritin (elevated vs. normal, HR: 1.40; 95% CI: 1.07 to 1.83; P = 0.014), and the combined iron status index (highly elevated vs. normal, HR: 2.20; 95% CI: 1.16 to 4.18-1 P = 0.016) remained significant predictors. As expected, hemoglobin (Hb) concentration and absolute CD4 counts were each inversely associated with mortality.
   Conclusions: Elevated iron status predicts mortality in HIV infection, even after adjustment for immunosuppression and other confounders. This finding has implications in the clinical monitoring of disease progression and for iron-supplementation practices in areas of high HIV prevalence.
C1 London Sch Hyg & Trop Med, Med Res Council Int Nutr Grp, Nutr & Publ Hlth Int Res Unit, London, ON WC1E 7HT, Canada.
   The Gambia, Med Res Council Lab, Fajara, Gambia.
   London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, Trop Epidemiol Grp, London, England.
   Micronutrient Status Res Sect, Med Res Council Human Nutr Res, Cambridge, England.
RP McDermid, JM (reprint author), London Sch Hyg & Trop Med, Med Res Council Int Nutr Grp, Nutr & Publ Hlth Int Res Unit, Keppel St, London, ON WC1E 7HT, Canada.
EM joann.mcdermid@gmail.com
FU Medical Research Council [MC_U105960399]
CR Allen J, 1998, CLIN CHEM, V44, P35
   Balakrishnan P, 2005, INDIAN J MED RES, V121, P345
   Beck MA, 2001, FASEB J, V15, P1481, DOI 10.1096/fj.00-0721fje
   Beguin Y, 2003, CLIN CHIM ACTA, V329, P9, DOI 10.1016/S0009-8981(03)00005-6
   Cook JD, 1999, AM J MED SCI, V318, P269, DOI 10.1097/00000441-199910000-00006
   de Monye C, 1999, AIDS, V13, P375, DOI 10.1097/00002030-199902250-00010
   DOUVAS GS, 1993, J INFECT DIS, V167, P857
   FIELDSGARDNER C, 1997, CLIN GUIDE NUTR HIV
   Gibson R., 1990, PRINCIPLES NUTR ASSE
   Gomo E, 2003, EUR J OBSTET GYN R B, V107, P156, DOI 10.1016/S0301-2115(02)00346-9
   Gordeuk VR, 2006, HAEMATOL-HEMATOL J, V91, P739
   Gordeuk VR, 2001, J CLIN VIROL, V20, P111, DOI 10.1016/S1386-6532(00)00134-7
   Halonen P, 2003, PEDIATRICS, V111, P91, DOI 10.1542/peds.111.1.91
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Khumalo H, 1998, CLIN CHEM, V44, P40
   Lounis N, 2001, J CLIN VIROL, V20, P123, DOI 10.1016/S1386-6532(00)00136-0
   Mainous AG, 2004, ANN FAM MED, V2, P139, DOI 10.1370/afm.82
   Mainous AG, 2004, ANN FAM MED, V2, P133, DOI 10.1370/afm.25
   Malope BI, 2001, BRIT J HAEMATOL, V115, P84, DOI 10.1046/j.1365-2141.2001.03063.x
   McDermid JM, 2006, CLIN SCI, V110, P503, DOI 10.1042/CS20050273
   MILMAN N, 1990, SCAND J CLIN LAB INV, V50, P559, DOI 10.3109/00365519009089171
   Mocroft A, 1999, AIDS, V13, P943, DOI 10.1097/00002030-199905280-00010
   Moore RD, 1998, J ACQ IMMUN DEF SYND, V19, P29
   Moore RD, 1999, CLIN INFECT DIS, V29, P44, DOI 10.1086/520178
   Offermann MK, 1996, J ACQ IMMUN DEF SYND, V13, P1
   Olsen A, 2004, JAIDS-J ACQ IMM DEF, V36, P637, DOI 10.1097/00126334-200405010-00013
   Punnonen K, 1997, BLOOD, V89, P1052
   Salhi Y, 1998, J ACQ IMMUN DEF SYND, V18, P473
   SALMONCERON D, 1995, J INFECT DIS, V172, P656
   Semba RD, 2002, J ACQ IMMUN DEF SYND, V29, P142
   Semba RD, 2007, JAIDS-J ACQ IMM DEF, V45, P298
   Simonart T, 1998, INT J CANCER, V78, P720, DOI 10.1002/(SICI)1097-0215(19981209)78:6<720::AID-IJC9>3.0.CO;2-F
   Stephenson J, 2002, JAMA-J AM MED ASSOC, V288, P151, DOI 10.1001/jama.288.2.151
   Sullivan P, 2002, J INFECT DIS, V185, pS138, DOI 10.1086/340203
   Sullivan PS, 1998, BLOOD, V91, P301
   Traore HN, 2004, J CLIN VIROL, V31, pS92, DOI 10.1016/j.jcv.2004.09.011
   Tucker T, 2001, S AFR MED J, V91, P615
   van der Loeff MFS, 2002, AIDS, V16, P1775
   van der Sande MAB, 2004, JAIDS-J ACQ IMM DEF, V37, P1288, DOI 10.1097/01.qai.0000122708.59121.03
   Worwood M, 2002, ANN CLIN BIOCHEM, V39, P221, DOI 10.1258/0004563021902152
NR 40
TC 52
Z9 53
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 1
PY 2007
VL 46
IS 4
BP 498
EP 507
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 231ZH
UT WOS:000250987200018
PM 18077841
OA No
DA 2017-08-15
ER

PT J
AU Ord, R
   Alexander, N
   Dunyo, S
   Hallett, R
   Jawara, M
   Targett, G
   Drakeley, CJ
   Sutherland, CJ
AF Ord, Rosalynn
   Alexander, Neal
   Dunyo, Sam
   Hallett, Rachel
   Jawara, Musa
   Targett, Geoffrey
   Drakeley, Christopher J.
   Sutherland, Colin J.
TI Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium
   falciparum imply reduced fitness of chloroquine-resistant parasites
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID CHLOROQUINE/SULPHADOXINE-PYRIMETHAMINE; UNCOMPLICATED MALARIA;
   RANDOMIZED-TRIAL; CHILDREN; TRANSMISSION; ARTESUNATE; MOSQUITOS;
   GAMETOCYTAEMIA; SULFADOXINE; INFECTION
AB Background. Observations in natural Plasmodium falciparum populations after removal of failing drugs suggest that there is a fitness cost of drug resistance.
   Methods. To examine the effect of transient removal of drug pressure, we analyzed seasonal changes in the prevalence of chloroquine (CQ)-resistant parasite genotypes in The Gambia. Parasite isolates from 441 children presenting with uncomplicated falciparum malaria over 5 seasons (1998-2002) were linked to weekly rainfall data.
   Results. The prevalence of CQ-resistant parasites increased slightly over 5 years, with the 76T allele of pfcrt (odds ratio [OR] per year, 1.16; P = .03) and the 86Y allele of pfmdr1 (OR per year, 1.18; P = .02) becoming significantly more common. However, intraseasonal analysis showed that these alleles decreased in prevalence each dry season. Wild-type parasites with respect to both loci predominated as transmission began each year, with resistant parasites becoming more common as drug use increased. This pattern was seen for both pfcrt-76T (OR per week, 1.09; P = .001) and pfmdr1-86Y (OR per week, 1.07; P = .001) and could not be explained by seasonal changes in the clonal complexity of infections.
   Conclusions. The fitness cost of CQ resistance works against the persistence of resistant parasites through the dry season.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect Dis, London WC1E 7HT, England.
   MRC Labs, Banjul, Gambia.
   Joint Malaria Programme, Moshi, Tanzania.
RP Sutherland, CJ (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect Dis, Keppel St, London WC1E 7HT, England.
EM colin.sutherland@lshtm.ac.uk
FU Medical Research Council [G0700837]; Wellcome Trust [061910]
CR Abdel-Muhsin AMA, 2004, J INFECT DIS, V189, P1239, DOI 10.1086/382509
   Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   Brown D., 1993, MODELS BIOL MATH STA
   Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0
   CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112
   Drakeley CJ, 2000, T ROY SOC TROP MED H, V94, P472, DOI 10.1016/S0035-9203(00)90056-7
   Drakeley CJ, 2004, TROP MED INT HEALTH, V9, P53, DOI 10.1046/j.1365-3156.2003.01169.x
   Duffy PE, 2006, LANCET, V367, P2037, DOI 10.1016/S0140-6736(06)68900-9
   Dunyo S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010020
   Dunyo S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010014
   Enosse S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010005
   Hallett RL, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010015
   Hallett RL, 2004, ANTIMICROB AGENTS CH, V48, P3940, DOI 10.1128/AAC.48.10.3940-3943.2004
   Kublin JG, 2003, J INFECT DIS, V187, P1870, DOI 10.1086/375419
   Laufer MK, 2006, NEW ENGL J MED, V355, P1959, DOI 10.1056/NEJMoa062032
   Meerman L, 2005, J INFECT DIS, V192, P1651, DOI 10.1086/496887
   MENON A, 1990, T ROY SOC TROP MED H, V84, P638, DOI 10.1016/0035-9203(90)90130-7
   Muller O, 1996, TROP MED INT HEALTH, V1, P124, DOI 10.1046/j.1365-3156.1996.d01-13.x
   Schellenberg D, 2005, LANCET, V365, P1481, DOI 10.1016/S0140-6736(05)66418-5
   Sutherland CJ, 2005, PLOS MED, V2, P338, DOI 10.1371/journal.pmed.0020092
   Sutherland CJ, 2003, AM J TROP MED HYG, V69, P19
   Sutherland CJ, 2002, AM J TROP MED HYG, V67, P578
   Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689
   Trapani J. A., 2001, GENOME BIOL, V2
   von Seidlein L, 2001, TROP MED INT HEALTH, V6, P92, DOI 10.1046/j.1365-3156.2001.00683.x
NR 25
TC 56
Z9 56
U1 1
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD DEC 1
PY 2007
VL 196
IS 11
BP 1613
EP 1619
DI 10.1086/522154
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 231RE
UT WOS:000250965900007
PM 18008244
OA No
DA 2017-08-15
ER

PT J
AU Duvall, MG
   Lore, K
   Blaak, H
   Ambrozak, DA
   Adams, WC
   Santos, K
   Geldmacher, C
   Mascola, JR
   McMichael, AJ
   Jaye, A
   Whittle, HC
   Rowland-Jones, SL
   Koup, RA
AF Duvall, Melody G.
   Lore, Karin
   Blaak, Hetty
   Ambrozak, David A.
   Adams, William C.
   Santos, Kathlyn
   Geldmacher, Christof
   Mascola, John R.
   McMichael, Andrew J.
   Jaye, Assan
   Whittle, Hilton C.
   Rowland-Jones, Sarah L.
   Koup, Richard A.
TI Dendritic cells are less susceptible to human immunodeficiency virus
   type 2 (HIV-2) infection than to HIV-1 infection
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID CD4(+) T-CELLS; POLYCHROMATIC FLOW-CYTOMETRY; DC-SIGN; INTRAVAGINAL
   INOCULATION; 1-INFECTED INDIVIDUALS; PRODUCTIVE INFECTION; REVERSE
   TRANSCRIPTS; LANGERHANS CELLS; TRANS-INFECTION; PLASMA VIREMIA
AB Human immunodeficiency virus type 1 (HIV-1) infection of dendritic cells (DCs) has been documented in vivo and may be an important contributor to HIV-1 transmission and pathogenesis. HIV-1-specific CD4(+) T cells respond to HIV antigens presented by HIV-1-infected DCs and in this process become infected, thereby providing a mechanism through which HIV-1-specific CD4(+) T cells could become preferentially infected in vivo. HIV-2 disease is attenuated with respect to HIV-1 disease, and host immune responses are thought to be contributory. Here we investigated the susceptibility of primary myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) to infection by HIV-2. We found that neither CCR5-tropic primary HIV-2 isolates nor a lab-adapted CXCR4-tropic HIV-2 strain could efficiently infect mDCs or pDCs, though these viruses could infect primary CD4(+) T cells in vitro. HIV-2-exposed mDCs were also incapable of transferring virus to autologous CD4(+) T cells. Despite this, we found that HIV-2-specific CD4(+) T cells contained more viral DNA than memory CD4(+) T cells of other specificities in vivo. These data suggest that either infection of DCs is not an important contributor to infection of HIV-2-specific CD4(+) T cells in vivo or that infection of DCs by HIV-2 occurs at a level that is undetectable in vitro. The frequent carriage of HIV-2 DNA within HIV-2-specific CD4(+) T cells, however, does not appear to be incompatible with preserved numbers and functionality of HIV-2-specific CD4(+) T cells in vivo, suggesting that additional mechanisms contribute to maintenance of HIV-2-specific CD4(+) T-cell help in vivo.
C1 [Duvall, Melody G.; Lore, Karin; Ambrozak, David A.; Adams, William C.; Santos, Kathlyn; Geldmacher, Christof; Koup, Richard A.] NIAID, Immunol Lab, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   [Duvall, Melody G.; McMichael, Andrew J.; Rowland-Jones, Sarah L.] Univ Oxford, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England.
   [Lore, Karin; Adams, William C.] Karolinska Inst, Dept Med, Ctr Infect Med, Stockholm, Sweden.
   [Blaak, Hetty] Erasmus MC, Dept Virol, Rotterdam, Netherlands.
   [Mascola, John R.] NIAID, Core Virol Lab BSL 3, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
   [Jaye, Assan; Whittle, Hilton C.; Rowland-Jones, Sarah L.] MRC Labs Fajara, Banjul, Gambia.
RP Koup, RA (reprint author), NIAID, Immunol Lab, Vaccine Res Ctr, NIH, 40 Convent Dr,MSC 3022,Bldg 40,Room 3502, Bethesda, MD 20892 USA.
EM rkoup@mail.nih.gov
FU Medical Research Council [MC_U137884180, MC_U190081958]
CR Arrighi JF, 2004, J EXP MED, V200, P1279, DOI 10.1084/jem.20041356
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Baribaud F, 2002, J VIROL, V76, P9135, DOI 10.1128/JVI.76.18.9135-9142.2002
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Blaak H, 2005, J VIROL, V79, P1686, DOI 10.1128/JVI.79.3.1686-1700.2005
   Blaak H, 2004, JAIDS-J ACQ IMM DEF, V36, P777, DOI 10.1097/00126334-200407010-00003
   Blaak H, 2006, VIROLOGY, V353, P144, DOI 10.1016/j.virol.2006.05.029
   Brenchley J M, 2002, Clin Exp Immunol, V130, P432, DOI 10.1046/j.1365-2249.2002.02015.x
   Brenchley JM, 2006, J VIROL, V80, P6801, DOI 10.1128/JVI.00070-06
   Brenchley JM, 2004, J VIROL, V78, P1160, DOI 10.1128/JVI.78.3.1160-1168.2004
   Burleigh L, 2006, J VIROL, V80, P2949, DOI 10.1128/JVI.80.6.2949-2957.2006
   CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913
   Chattopadhyay PK, 2006, NAT MED, V12, P972, DOI 10.1038/nm1371
   Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493
   Clark EA, 1996, CURR BIOL, V6, P655, DOI 10.1016/S0960-9822(09)00441-2
   Donaghy H, 2003, BLOOD, V101, P4505, DOI 10.1182/blood-2002-10-3189
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Douek DC, 2000, LANCET, V355, P1875, DOI 10.1016/S0140-6736(00)02293-5
   Duvall MG, 2006, J IMMUNOL, V176, P6973
   FOLKS T, 1986, J IMMUNOL, V136, P4049
   Fong L, 2002, J VIROL, V76, P11033, DOI 10.1128/JVI.76.21.11033-11041.2002
   Fonteneau JF, 2004, J VIROL, V78, P5223, DOI 10.1128/JVI.78.10.5223-5232.2004
   Frank I, 1999, J VIROL, V73, P3449
   Frankel SS, 1997, AM J PATHOL, V151, P89
   Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5
   Granelli-Piperno A, 2005, J IMMUNOL, V175, P4265
   Granelli-Piperno A, 1999, CURR BIOL, V9, P21, DOI 10.1016/S0960-9822(99)80043-8
   Gummuluru S, 2003, J VIROL, V77, P12865, DOI 10.1128/JVI.77.23.12865-12874.2003
   Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9
   Hladik F, 2007, IMMUNITY, V26, P257, DOI 10.1016/j.immuni.2007.01.007
   Hu JJ, 2000, J VIROL, V74, P6087, DOI 10.1128/JVI.74.13.6087-6095.2000
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   Kawamura T, 2003, P NATL ACAD SCI USA, V100, P8401, DOI 10.1073/pnas.1432450100
   Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338
   Lore K, 2005, J EXP MED, V201, P2023, DOI 10.1084/jem.20042413
   Lore K, 2003, J IMMUNOL, V171, P4320
   Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709
   MARCELLA R, 2001, NEW REV INFORMATION, V2, P87
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   MARLINK RG, 1988, AIDS RES HUM RETROV, V4, P137, DOI 10.1089/aid.1988.4.137
   Mascola JR, 1996, AIDS RES HUM RETROV, V12, P1319, DOI 10.1089/aid.1996.12.1319
   Mattapallil JJ, 2006, J EXP MED, V203, P1533, DOI 10.1084/jem.20060657
   McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238
   Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904
   Nobile C, 2005, J VIROL, V79, P5386, DOI 10.1128/JVI.79.9.5386-5399.2005
   Patterson S, 2001, J VIROL, V75, P6710, DOI 10.1128/JVI.75.14.6710-6713.2001
   Perfetto SP, 2006, J IMMUNOL METHODS, V313, P199, DOI 10.1016/j.jim.2006.04.007
   Pope M, 1997, AIDS RES HUM RETROV, V13, P819, DOI 10.1089/aid.1997.13.819
   POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045
   Pope M, 1997, J VIROL, V71, P8001
   POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   Sanchez G, 1997, J VIROL, V71, P2233
   SCHULZ TF, 1990, J VIROL, V64, P5177
   Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00969
   SHEEHY AM, 2003, VIF NAT MED, V9, P1404
   Smed-Sorensen A, 2004, BLOOD, V104, P2810, DOI 10.1182/blood-2003-07-2314
   Smed-Sorensen A, 2005, J VIROL, V79, P8861, DOI 10.1128/JVI.79.14.8861-8869.2005
   Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215
   Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8
   Stremlau M, 2006, P NATL ACAD SCI USA, V103, P5514, DOI 10.1073/pnas.0509996103
   Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343
   Trumpfheller C, 2003, INT IMMUNOL, V15, P289, DOI 10.1093/intimm/dxg030
   Turville SG, 2004, BLOOD, V103, P2170, DOI 10.1182/blood-2003-09-3129
   Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246
   Wiley RD, 2006, P NATL ACAD SCI USA, V103, P738, DOI 10.1073/pnas.0507995103
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
   Wu L, 2002, P NATL ACAD SCI USA, V99, P1568, DOI 10.1073/pnas.032654399
   Wu L, 2002, J VIROL, V76, P5905, DOI 10.1128/JVI.76.12.5905-5914-2002
   Ylinen LMJ, 2005, J VIROL, V79, P11580, DOI 10.1128/JVI.79.18.11580-11587.2005
   Yonezawa A, 2003, J VIROL, V77, P3777, DOI 10.1128/JVI.77.6.3777-3784.2003
   Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591
   Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204
   ZACK JA, 1988, SCIENCE, V240, P1026, DOI 10.1126/science.2835813
   ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L
   ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502
   Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369
   Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707
   ZHANG H, 1994, J VIROL, V68, P7591
NR 81
TC 26
Z9 26
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD DEC
PY 2007
VL 81
IS 24
BP 13486
EP 13498
DI 10.1128/JVI.00976-07
PG 13
WC Virology
SC Virology
GA 239XR
UT WOS:000251552100021
PM 17913821
OA No
DA 2017-08-15
ER

PT J
AU Faburay, B
   Geysen, D
   Ceesay, A
   Marcelino, I
   Alves, PM
   Taoufik, A
   Postigo, M
   Bell-Sakyi, L
   Jongejan, F
AF Faburay, Bonto
   Geysen, Dirk
   Ceesay, Ansurnana
   Marcelino, Isabel
   Alves, Paula M.
   Taoufik, Amar
   Postigo, Milagros
   Bell-Sakyi, Lesley
   Jongejan, Frans
TI Immunisation of sheep against heartwater in The Gambia using inactivated
   and attenuated Ehrlichia ruminantium vaccines
SO VACCINE
LA English
DT Article
DE heartwater; sheep; inactivated vaccine; attenuated vaccine; The Gambia
ID AMBLYOMMA-VARIEGATUM TICKS; COWDRIA-RUMINANTIUM; CHALLENGE MATERIAL;
   CROSS-IMMUNITY; DNA-PROBE; INFECTION; PROTEIN; STRAINS; GOATS; ASSAY
AB Heartwater (cowdriosis) is a disease of ruminants caused by a rickettsial pathogen Ehrlichia ruminantium and transmitted by ticks of the genus Amblyomma. The purpose of this work was to evaluate the protective efficacies of inactivated and attenuated vaccines to protect sheep against heartwater in The Gambia. An inactivated vaccine, prepared from E. ruminantium (Gardel stock), and a live attenuated vaccine from E. ruminantium (Senegal stock), were evaluated in two independent on-station trials. A local stock of E. ruminantium (Kerr Seringe) was used as challenge material. Inactivated and live attenuated vaccines provided 43% and 100% protection, respectively, against virulent needle challenge. In a subsequent field trial, the attenuated vaccine protected 75% of sheep against virulent tick challenge, which was fatal for all control sheep. Quantification by real-time PCR showed that an immunising dose of approximately 23,000 attenuated E. ruminantium organisms was sufficient. Moreover, restriction fragment length polymorphism (RFLP) analysis indicated that the local Kerr Seringe genotype caused mortality amongst control sheep, whereas fatalities in the vaccinated group could be attributed to a different genotype. (C) 2007 Elsevier Ltd. All rights reserved.
C1 Univ Utrecht, Fac Vet Med, Utrecht Ctr Tick Borne Dis, Dept Immunol & Infect Dis, NL-3584 CL Utrecht, Netherlands.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
   Inst Biol & Expt Technol ITQB, P-2780901 Oeiras, Portugal.
   Univ Edinburgh, Royal Dick Sch Vet Studies, Ctr Trop Vet Med, Roslin EH25 9RG, Midlothian, Scotland.
   Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0110 Onderstepoort, South Africa.
RP Faburay, B (reprint author), Univ Utrecht, Fac Vet Med, Utrecht Ctr Tick Borne Dis, Dept Immunol & Infect Dis, Yalelaan 1, NL-3584 CL Utrecht, Netherlands.
EM b.fabureh1@vet.uu.nl
RI Alves, Paula/C-1070-2008; Marcelino, Isabel/D-6503-2017
OI Alves, Paula/0000-0003-1445-3556; Marcelino, Isabel/0000-0001-5454-8811
CR Allsopp MTEP, 1999, EPIDEMIOL INFECT, V122, P323, DOI 10.1017/S0950268899002101
   Allsopp MTEP, 2001, J CLIN MICROBIOL, V39, P4200, DOI 10.1128/JCM.39.11.4200-4203.2001
   BARBET AF, 1994, CLIN DIAGN LAB IMMUN, V1, P744
   Bell-Sakyi L, 2004, VET MICROBIOL, V100, P175, DOI 10.1016/j.vetmic.2004.02.010
   Brayton KA, 2003, VET PARASITOL, V112, P63, DOI 10.1016/S0304-4017(02)00421-1
   BURRIDGE MJ, 1985, PARASITOL TODAY, V1, P1
   Collins N E, 2003, Dev Biol (Basel), V114, P121
   Collins NE, 2005, P NATL ACAD SCI USA, V102, P838, DOI 10.1073/pnas.0406633102
   Faburay B, 2007, EXP APPL ACAROL, V42, P61, DOI 10.1007/s10493-007-9073-2
   Faburay B, 2005, CLIN DIAGN LAB IMMUN, V12, P508, DOI 10.1128/CDLI.12.4.508-512.2005
   FABURAY B, 2007, VET MICROBIOL
   Gueye A., 1989, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V42, P497
   Gueye A, 1994, Rev Elev Med Vet Pays Trop, V47, P401
   JONGEJAN F, 1991, RES VET SCI, V51, P24, DOI 10.1016/0034-5288(91)90025-J
   Jongejan F, 2004, PARASITOLOGY, V129, pS3, DOI 10.1017/S0031182004005967
   JONGEJAN F, 1991, INFECT IMMUN, V59, P729
   Jongejan F, 1993, Rev Elev Med Vet Pays Trop, V46, P223
   Mahan S M, 2003, Dev Biol (Basel), V114, P137
   MAHAN SM, 1992, J CLIN MICROBIOL, V30, P981
   Mahan SM, 1998, VACCINE, V16, P1203, DOI 10.1016/S0264-410X(98)80120-5
   Mahan SM, 2001, VET PARASITOL, V97, P295, DOI 10.1016/S0304-4017(01)00437-X
   Martinez D, 2004, ANN NY ACAD SCI, V1026, P106, DOI 10.1196/annals.1307.014
   MARTINEZ D, 1994, VET IMMUNOL IMMUNOP, V41, P153, DOI 10.1016/0165-2427(94)90064-7
   Martinez D, 1996, VET PARASITOL, V67, P175, DOI 10.1016/S0304-4017(96)01043-6
   Martinez D., 1997, THESIS UTRECHT U UTR
   Mattioli RC, 2000, EXP APPL ACAROL, V24, P957, DOI 10.1023/A:1010645927535
   Mboloi MM, 1999, CLIN DIAGN LAB IMMUN, V6, P66
   Peixoto CC, 2005, VET MICROBIOL, V107, P273, DOI 10.1016/j.vetmic.2005.02.001
   PERREAU P, 1980, REV ELEV MED VET PAY, V33, P21
   PETER TF, 1995, J CLIN MICROBIOL, V33, P166
   Postigo M, 2007, VET MICROBIOL, V122, P298, DOI 10.1016/j.vetmic.2007.01.019
   PURCHASE H. S., 1945, Veterinary Record, V57, P414
   REDDY GR, 1996, CLIN DIAGN LAB IMMUN, V154, P73
   UILENBERG G, 1983, ADV VET SCI COMP MED, V27, P427
   UILENBERG G, 1985, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V38, P34
   UILENBERG G, 1990, VET QUART, V12, P39
   Vachiery N, 2006, VACCINE, V24, P4747, DOI 10.1016/j.vaccine.2006.03.031
   VANVLIET AHM, 1995, J CLIN MICROBIOL, V33, P2405
   VANVLIET AHM, 1994, INFECT IMMUN, V62, P1451
   VANWINKELHOFF AJ, 1981, TROP ANIM HEALTH PRO, V13, P160
   YU XJ, 2006, VET PARASITOL, V143, P337
   Zweygarth E, 2005, VACCINE, V23, P1695, DOI 10.1016/j.vaccine.2004.09.030
NR 42
TC 14
Z9 15
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD NOV 14
PY 2007
VL 25
IS 46
BP 7939
EP 7947
DI 10.1016/j.vaccine.2007.09.002
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 233PW
UT WOS:000251103800009
PM 17920167
OA No
DA 2017-08-15
ER

PT J
AU Walther, M
   Gomez-Escobar, N
   Deininger, S
   Okebe, J
   Finney, O
   Nwakanma, D
   Riley, E
   Conway, D
AF Walther, Michael
   Gomez-Escobar, Natalia
   Deininger, Susanne
   Okebe, Joseph
   Finney, Olivia
   Nwakanma, Davis
   Riley, Eleanor
   Conway, David
TI Immunoregulation in mild and severe Plasmodium falciparum malaria
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY NOV 04-08, 2007
CL Philadelphia, PA
SP Amer Soc Trop Med & Hyg
C1 [Walther, Michael; Gomez-Escobar, Natalia; Deininger, Susanne; Okebe, Joseph; Finney, Olivia; Nwakanma, Davis; Conway, David] MRC Labs Fajara, Banjul, Gambia.
   [Riley, Eleanor] London Sch Hyg & Trop Med, London WC1, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2007
VL 77
IS 5
SU S
MA 197
BP 57
EP 57
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 228UN
UT WOS:000250758200197
OA No
DA 2017-08-15
ER

PT J
AU Gomez-Escobar, N
   Walther, M
   Ngwa, AA
   Okebe, J
   Nwakanma, D
   Conway, D
AF Gomez-Escobar, Natalia
   Walther, Michael
   Ngwa, Alfred A.
   Okebe, Joseph
   Nwakanma, Davis
   Conway, David
TI Invasion phenotypes and transcript profiles in Gambian Plasmodium
   falciparum clinical isolates
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY NOV 04-08, 2007
CL Philadelphia, PA
SP Amer Soc Trop Med & Hyg
C1 [Gomez-Escobar, Natalia; Walther, Michael; Ngwa, Alfred A.; Okebe, Joseph; Nwakanma, Davis; Conway, David] MRC Labs, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2007
VL 77
IS 5
SU S
MA 210
BP 61
EP 61
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 228UN
UT WOS:000250758200210
OA No
DA 2017-08-15
ER

PT J
AU Duah, NO
   Tetteh, K
   Akpogheneta, O
   Polley, S
   Corran, P
   Whittle, H
   Conway, DJ
AF Duah, Nancy O.
   Tetteh, Kevin
   Akpogheneta, Onome
   Polley, Spencer
   Corran, Patrick
   Whittle, Hilton
   Conway, David J.
TI The rate of acquisition of human antibody isotype profiles to Plasmodium
   falciparium blood stage antigens in Gambian infants
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY NOV 04-08, 2007
CL Philadelphia, PA
SP Amer Soc Trop Med & Hyg
C1 [Duah, Nancy O.; Tetteh, Kevin; Akpogheneta, Onome; Polley, Spencer; Corran, Patrick] London Sch Hyg & Trop Med, London WC1, England.
   [Whittle, Hilton; Conway, David J.] Med Res Council The Gambia, Banjul, Gambia.
RI Polley, Spencer/F-7766-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2007
VL 77
IS 5
SU S
MA 302
BP 85
EP 86
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 228UN
UT WOS:000250758200301
OA No
DA 2017-08-15
ER

PT J
AU Sow, SO
   Okoko, B
   Preziosi, MP
   Marchetti, E
   Tapia, MD
   Haidara, FC
   Adegbola, R
   Borrow, R
   Carlone, G
   Akinsola, A
   Diakite, S
   Parulekar, V
   Plikaytis, B
   Findlow, H
   Elie, C
   Preaud, JM
   Kapre, S
   Jadav, S
   LaForce, M
   Kulkarni, P
   Viviani, S
AF Sow, Samba O.
   Okoko, Brown
   Preziosi, Marie-Pierre
   Marchetti, Elisa
   Tapia, Milagritos D.
   Haidara, Faclima C.
   Adegbola, Richard
   Borrow, Ray
   Carlone, George
   Akinsola, Adebayo
   Diakite, Souleymane
   Parulekar, Varsha
   Plikaytis, Brian
   Findlow, Helen
   Elie, Cheryl
   Preaud, Jean-Marie
   Kapre, Subash
   Jadav, Suresh
   LaForce, Marc
   Kulkarni, Prasad
   Viviani, Simonetta
TI A phase II vaccine trial of meningococcal a conjugate vaccine (PsATT) in
   African toddlers
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY NOV 04-08, 2007
CL Philadelphia, PA
SP Amer Soc Trop Med & Hyg
C1 [Sow, Samba O.; Haidara, Faclima C.; Diakite, Souleymane] Ctr Vaccine Dev, Bamako, Mali.
   [Okoko, Brown; Adegbola, Richard; Akinsola, Adebayo] MRC, Basse, Gambia.
   [Preziosi, Marie-Pierre; LaForce, Marc; Viviani, Simonetta] Meningitis Vaccine Project, Initiative Vaccine Res, WHO, Geneva, Switzerland.
   [Marchetti, Elisa; Preaud, Jean-Marie; LaForce, Marc] Meningitis Vaccine Project, PATH, Ferney Voltaire, France.
   [Tapia, Milagritos D.] Univ Maryland, Sch Med, Baltimore, MD USA.
   [Borrow, Ray; Findlow, Helen] Hlth Protect Agcy, Manchester, Lancs, England.
   [Carlone, George; Plikaytis, Brian; Elie, Cheryl] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Parulekar, Varsha] Gate Clin Res Int, Bombay, Maharashtra, India.
   [Jadav, Suresh; Kulkarni, Prasad] Serum Inst India Ltd, Pune, Maharashtra, India.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2007
VL 77
IS 5
SU S
MA 384
BP 111
EP 111
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 228UN
UT WOS:000250758200383
OA No
DA 2017-08-15
ER

PT J
AU Finney, O
   Walther, M
   Corran, P
   Conway, D
   Riley, E
AF Finney, Olivia
   Walther, Michael
   Corran, Patrick
   Conway, David
   Riley, Eleanor
TI The role of immunoregulatory cells in natural immunity to Plasmodium
   falciparum
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY NOV 04-08, 2007
CL Philadelphia, PA
SP Amer Soc Trop Med & Hyg
C1 [Finney, Olivia; Walther, Michael; Conway, David] MRC, Banjul, Gambia.
   [Corran, Patrick; Riley, Eleanor] London Sch Hyg & Trop Med, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2007
VL 77
IS 5
SU S
MA 696
BP 199
EP 199
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 228UN
UT WOS:000250758201157
OA No
DA 2017-08-15
ER

PT J
AU Nwakanma, D
   Gomez-Escobar, N
   Walther, M
   Crozier, S
   Malkin, E
   Locke, E
   Conway, D
AF Nwakanma, Davis
   Gomez-Escobar, Natalia
   Walther, Michael
   Crozier, Sarah
   Malkin, Elissa
   Locke, Emily
   Conway, David
TI Estimation of malaria parasite density in urine and saliva samples using
   real-time quantitative PCR (QPCR) methods
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY NOV 04-08, 2007
CL Philadelphia, PA
SP Amer Soc Trop Med & Hyg
C1 [Nwakanma, Davis; Gomez-Escobar, Natalia; Walther, Michael; Crozier, Sarah; Conway, David] MRC Labs, Banjul, Gambia.
   [Malkin, Elissa; Locke, Emily] PATH, Malaria Vaccine Initiat, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2007
VL 77
IS 5
SU S
MA 812
BP 233
EP 233
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 228UN
UT WOS:000250758201271
OA No
DA 2017-08-15
ER

PT J
AU Looareesuwan, S
   Gaye, O
   Tjitra, E
   Bojang, K
   Socheat, D
   Pioia, P
AF Looareesuwan, Sornchai
   Gaye, Oumar
   Tjitra, Emiliana
   Bojang, Kalifa
   Socheat, Duong
   Pioia, Patrice
TI Results of a randomised, multicentre, phase II, dose-ranging clinical
   study to assess the safety and efficacy of fixed dose, orally
   administered pyronaridine and artesunate in adult patients with acute
   uncomplicated Plasmodium falciparum malaria
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 56th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY NOV 04-08, 2007
CL Philadelphia, PA
SP Amer Soc Trop Med & Hyg
C1 [Looareesuwan, Sornchai] Mahidol Univ, Bangkok Hosp Trop Dis, Fac Trop Med, Bangkok 10700, Thailand.
   [Gaye, Oumar] Univ Cheikh Anta Diop, Fac Med, Dept Parasitol, Dakar, Senegal.
   [Tjitra, Emiliana] Bethesda Hosp, Tomohon, Indonesia.
   [Bojang, Kalifa] MRC, Fajara, Gambia.
   [Socheat, Duong] Natl Malaria Ctr, Phnom Penh, Cambodia.
   [Pioia, Patrice] MSF Epictr, Mbarara, Uganda.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2007
VL 77
IS 5
SU S
MA 1004
BP 287
EP 287
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 228UN
UT WOS:000250758201462
OA No
DA 2017-08-15
ER

PT J
AU Qiu, YT
   Smallegange, RC
   Ter Braak, CJF
   Spitzen, J
   Van Loon, JJA
   Jawara, M
   Milligan, P
   Galimard, AM
   Van Beek, TA
   Knols, BGJ
   Takken, W
AF Qiu, Yu Tong
   Smallegange, Renate C.
   Ter Braak, Cajo J. F.
   Spitzen, Jeroen
   Van Loon, Joop J. A.
   Jawara, Musa
   Milligan, Paul
   Galimard, Agnes M.
   Van Beek, Teris A.
   Knols, Bart G. J.
   Takken, Willem
TI Attractiveness of MM-X traps baited with human or synthetic odor to
   mosquitoes (Diptera : Culicidae) in the Gambia
SO JOURNAL OF MEDICAL ENTOMOLOGY
LA English
DT Article
DE mosquito sampling; odor baits; carbon dioxide; human odor
ID VECTOR ANOPHELES-GAMBIAE; YELLOW-FEVER MOSQUITO; AEDES-AEGYPTI DIPTERA;
   HOST-SEEKING BEHAVIOR; HUMAN SKIN EMANATIONS; L-LACTIC ACID;
   CARBON-DIOXIDE; MALARIA MOSQUITO; CARBOXYLIC-ACIDS; HUMAN SWEAT
AB Chemical cues play an important role in the host-seeking behavior of blood-feeding mosquitoes (Diptera : Culicidae). A field study was carried out in The Gambia to investigate the effects of human odor or synthetic odor blends on the attraction of mosquitoes. MM-X traps baited with 16 odor blends to which carbon dioxide (CO,) was added were tested in four sets of experiments. In a second series of experiments, MM-X traps with 14 odor blends without CO2 were tested. A blend of ammonia and L-lactic acid with or without CO2 was used as control odor in series I and 2, respectively. Centers for Disease Control and Prevention (CDC) traps were placed in a traditional house and an experimental house to monitor mosquito densities during the experiments. The MM-X traps caught a total number of 196,756 mosquitoes, with the most abundant species belonging to the genera Mansonia (70.6%), Anopheles (17.5%), and Culex (11.5%). The most abundant mosquito species caught by the CDC traps (56,290 in total) belonged to the genera Mansonia (59.4%), Anopheles (16.0% An. gambiae s.l. Giles, and 11.3% An. ziemanni Grunberg), and Culex (11.6%). MM-X traps baited with synthetic blends were in many cases more attractive than MM-X traps baited with human odors. Addition of CO2 to synthetic odors substantially increased the catch of all mosquito species in the MM-X traps. A blend of ammonia + L-lactic acid + CO2 + 3-methylbutanoic acid was the most attractive odor for most mosquito species. The candidate odor blend shows the potential to enhance trap collections so that traps will provide better surveillance and possible control.
C1 Wageningen Univ, Entomol Lab, NL-6700 EH Wageningen, Netherlands.
   Univ Wageningen & Res Ctr, NL-6700 AC Wageningen, Netherlands.
   MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
   Wageningen Univ, Nat Prod Chem Grp, Organ Chem Lab, NL-6700 EG Wageningen, Netherlands.
RP Takken, W (reprint author), Wageningen Univ, Entomol Lab, POB 8031, NL-6700 EH Wageningen, Netherlands.
EM willem.takken@wur.nl
RI Spitzen, Jeroen/B-3098-2012; ter Braak, Cajo/G-7006-2011; van Loon, Joop
   /B-3744-2009; Knols, Bart/C-5765-2017; Milligan, Paul/D-8985-2017
OI Spitzen, Jeroen/0000-0003-0455-7511; ter Braak,
   Cajo/0000-0002-0414-8745; van Loon, Joop /0000-0002-4260-0501; Milligan,
   Paul/0000-0003-3430-3395
FU Medical Research Council [G0700837]
CR Bernier UR, 2002, J AM MOSQUITO CONTR, V18, P186
   Bernier UR, 2000, ANAL CHEM, V72, P747, DOI 10.1021/ac990963k
   Brady J, 1997, ANN TROP MED PARASIT, V91, pS121
   Braks MAH, 2001, PHYSIOL ENTOMOL, V26, P142, DOI 10.1046/j.1365-3032.2001.00227.x
   COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1
   Cork A, 1996, MED VET ENTOMOL, V10, P269, DOI 10.1111/j.1365-2915.1996.tb00742.x
   Cosse AA, 1996, J AGR ENTOMOL, V13, P301
   Costantini C., 1993, Parassitologia (Rome), V35, P5
   Costantini C, 1998, AM J TROP MED HYG, V58, P56
   Costantini C, 1996, MED VET ENTOMOL, V10, P220, DOI 10.1111/j.1365-2915.1996.tb00734.x
   Costantini C, 2001, MED VET ENTOMOL, V15, P259, DOI 10.1046/j.0269-283x.2001.00297.x
   DAVIS EE, 1984, J INSECT PHYSIOL, V30, P211, DOI 10.1016/0022-1910(84)90005-2
   Dekker T, 2005, J EXP BIOL, V208, P2963, DOI 10.1242/jeb.01736
   Dekker T, 2002, MED VET ENTOMOL, V16, P91, DOI 10.1046/j.0269-283x.2002.00345.x
   Dekker T, 1998, MED VET ENTOMOL, V12, P136, DOI 10.1046/j.1365-2915.1998.00073.x
   Diallo M, 2005, MED VET ENTOMOL, V19, P119, DOI 10.1111/j.0269-283X.2005.00564.x
   EIRAS AE, 1991, B ENTOMOL RES, V81, P151
   Garrett-Jones C., 1964, Bulletin of the World Health Organization, V30, P241
   Geier M, 1999, CHEM SENSES, V24, P647, DOI 10.1093/chemse/24.6.647
   *GENSTAT COMM, 2003, GENSTAT REL 7 1 GUID
   GILLIES MT, 1972, B ENTOMOL RES, V61, P389
   GILLIES MT, 1969, B ENTOMOL RES, V59, P441
   Gillies MT, 1987, SUPPLEMENT ANOPHELIN
   Hastie T.J., 1990, GEN ADDITIVE MODELS
   HEALY TP, 1995, MED VET ENTOMOL, V9, P331, DOI 10.1111/j.1365-2915.1995.tb00143.x
   Healy TP, 2002, MED VET ENTOMOL, V16, P126, DOI 10.1046/j.1365-2915.2002.00353.x
   Jongman R. H., 1995, DATA ANAL COMMUNITY
   Kline DL, 1999, J AM MOSQUITO CONTR, V15, P276
   KLINE DL, 1991, J MED ENTOMOL, V28, P254
   Knols BGJ, 1997, B ENTOMOL RES, V87, P151
   KRAMER WL, 1980, J CHEM ECOL, V6, P415, DOI 10.1007/BF01402918
   Larsson MC, 2003, J CHEM ECOL, V29, P1253, DOI 10.1023/A:1023893926038
   Lindsay SW, 2003, TROP MED INT HEALTH, V8, P512, DOI 10.1046/j.1365-3156.2003.01059.x
   LINDSAY SW, 1991, J TROP MED HYG, V94, P313
   Lindsay SW, 1993, J MED ENTOMOL, V30, P308
   Mboera LEG, 2000, MED VET ENTOMOL, V14, P257, DOI 10.1046/j.1365-2915.2000.00239.x
   Mboera LEG, 1997, B ENTOMOL RES, V87, P173
   Mboera LEG, 2000, B ENTOMOL RES, V90, P155
   Mboera L.E.G., 1997, REV MED VET ENTOMOLO, V85, P355
   McCullagh P, 1989, GEN LINEAR MODELS
   Meijerink J, 1999, J INSECT PHYSIOL, V45, P365, DOI 10.1016/S0022-1910(98)00135-8
   Meijerink J, 2001, J INSECT PHYSIOL, V47, P455, DOI 10.1016/S0022-1910(00)00136-0
   Meijerink J, 2000, J CHEM ECOL, V26, P1367, DOI 10.1023/A:1005475422978
   MUKABABA WR, 2002, DIFFERENTIAL ATTRACT
   Mukabana WR, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-1
   Njiru Basilio N., 2006, Malaria Journal, V5, P1
   Qiu YT, 2006, MED VET ENTOMOL, V20, P280, DOI 10.1111/j.1365-2915.2006.00627.x
   QIU YT, 2005, SENSORY BEHAV RESPON, P208
   Qiu YT, 2006, CHEM SENSES, V31, P845, DOI 10.1093/chemse/bjl027
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   Smallegange RC, 2005, CHEM SENSES, V30, P145, DOI 10.1093/chemse/bji010
   Smith DL, 2005, NATURE, V438, P492, DOI 10.1038/nature04024
   SNOW WF, 1970, B ENTOMOL RES, V60, P43
   SPITZEN J, 2007, IN PRESS PHYSL ENTOM
   SUDIA WILLIAM D., 1962, MOSQUITO NEWS, V22, P126
   Takken W, 1999, ANNU REV ENTOMOL, V44, P131, DOI 10.1146/annurev.ento.44.1.131
   Takken W, 1996, Ciba Found Symp, V200, P302
   Takken W, 1997, J INSECT BEHAV, V10, P395, DOI 10.1007/BF02765606
   ter Braak CJF, 2002, CANOCO REFERENCE MAN
   van den Broek IVF, 1999, J INSECT PHYSIOL, V45, P1001, DOI 10.1016/S0022-1910(99)00081-5
   van den Broek IVF, 2000, ENTOMOL EXP APPL, V96, P167, DOI 10.1046/j.1570-7458.2000.00692.x
NR 61
TC 46
Z9 46
U1 1
U2 8
PU ENTOMOLOGICAL SOC AMER
PI LANHAM
PA 10001 DEREKWOOD LANE, STE 100, LANHAM, MD 20706-4876 USA
SN 0022-2585
EI 1938-2928
J9 J MED ENTOMOL
JI J. Med. Entomol.
PD NOV
PY 2007
VL 44
IS 6
BP 970
EP 983
DI 10.1603/0022-2585(2007)44[970:AOMTBW]2.0.CO;2
PG 14
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA 232QM
UT WOS:000251034200009
PM 18047195
OA No
DA 2017-08-15
ER

PT J
AU Ikumapayi, UN
   Antonio, M
   Sonne-Hansen, J
   Biney, E
   Enwere, G
   Okoko, B
   Oluwalana, C
   Vaughan, A
   Zaman, SMA
   Greenwood, BM
   Cutts, FT
   Adegbola, RA
AF Ikumapayi, Usman N.
   Antonio, Martin
   Sonne-Hansen, Jacob
   Biney, Ekow
   Enwere, Godwin
   Okoko, Brown
   Oluwalana, Claire
   Vaughan, Adeola
   Zaman, Syed M. A.
   Greenwood, Brian M.
   Cutts, Felicity T.
   Adegbola, Richard A.
TI Molecular epidemiology of community-acquired invasive non-typhoidal
   Salmonella among children aged 2-29 months in rural Gambia and discovery
   of a new serovar, Salmonella enterica Dingiri
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
ID WEST-AFRICA; ANTIMICROBIAL RESISTANCE; BACTERIAL-INFECTIONS; MALAWIAN
   CHILDREN; BACTEREMIA; KENYA; SURVEILLANCE; PNEUMONIA; FEATURES; MALARIA
AB Sixty-two invasive non-typhoidal Salmonella (NTS) isolates from children aged 2-29 months in rural Gambia were examined for serovar prevalence and antimicrobial susceptibility, and characterized using multilocus sequence typing (MLST) of seven genes, aroC, dnaN, hemD, hisD), purE, sucA and thrA. Salmonella enterica serovar Enteritidis was the most common serovar (80.6 %), followed by S. enterica serovar Typhimurium (8.0 %). Thirty-three per cent of the isolates were resistant to all eight antimicrobials tested, including ampicillin (74.2 %), cotrimoxazole (64.5 %) and tetracycline (63 %). A total of 40.3 % of the NTS cases had an initial clinical diagnosis of malaria, whilst 27.3 % had a diagnosis of clinical pneumonia and 18 % had a diagnosis of septicaemia. MLST of NTS resulted in ten different sequence types (STs), of which five were novel, representing five different NTS serovars. In general, STs were restricted to the same serovar. One type (ST1 1) encompassed 80.6 % of the NTSs. A new NTS serovar named S. enterica serovar Dingiri was discovered. S. Dingiri was isolated from a 6-month-old male with an initial clinical diagnosis of malaria but a final clinical diagnosis of anaemia. and septicaemia. S. Dingiri, which possesses an antigenic formula of 1 7:z:1,6, was sensitive to ampicillin, cefotaxime, chloramphenicol, ciprofloxacin, cotrimoxazole and tetracycline but resistant to gentamicin, and was ST338.
C1 State Serum Inst, Danish Salmonella Ctr, Copenhagen, Denmark.
   London Sch Hyg & Trop Med, London, England.
RP Antonio, M (reprint author), MRC Labs, Banjul, Gambia.
EM mantonio@mrc.gm
FU Medical Research Council [MC_U190074190, MC_U190081991]; NIAID NIH HHS
   [1AI 25477]
CR Aanensen DM, 2005, NUCLEIC ACIDS RES, V33, pW728, DOI 10.1093/nar/gki415
   Berkley J, 1999, T ROY SOC TROP MED H, V93, P283, DOI 10.1016/S0035-9203(99)90024-X
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   Commey Joo, 1994, Central African Journal of Medicine, V40, P257
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5
   Galanis E, 2006, EMERG INFECT DIS, V12, P381
   Gebreyes WA, 2005, ANTIMICROB AGENTS CH, V49, P503, DOI 10.1128/AAC.49.2.503-511.2005
   GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z
   Graham SM, 2000, T ROY SOC TROP MED H, V94, P310, DOI 10.1016/S0035-9203(00)90337-7
   Graham SM, 2000, PEDIATR INFECT DIS J, V19, P1189, DOI 10.1097/00006454-200012000-00016
   HADFIELD TL, 1985, J INFECT DIS, V151, P790
   Hill PC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-2
   Kariuki S, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-101
   Kotetishvili M, 2002, J CLIN MICROBIOL, V40, P1626, DOI 10.1128/JCM.40.5.1626-1635.2002
   Lee WS, 2003, J TROP PEDIATRICS, V49, P37, DOI 10.1093/tropej/49.1.37
   LEPAGE P, 1984, J ANTIMICROB CHEMOTH, V14, P153
   MABEY DCW, 1987, J INFECT DIS, V155, P1319
   Mulholland EK, 2005, NEW ENGL J MED, V352, P75, DOI 10.1056/NEJMe048306
   Nathoo KJ, 1996, PEDIATR INFECT DIS J, V15, P1092, DOI 10.1097/00006454-199612000-00007
   *NCCLS, 2004, PERF STAND ANT SUSC
   ODEMPSEY TJD, 1994, PEDIATR INFECT DIS J, V13, P122, DOI 10.1097/00006454-199402000-00009
   Rongkavilit C, 2000, PEDIATR INFECT DIS J, V19, P122, DOI 10.1097/00006454-200002000-00009
   Soler P, 2006, J ANTIMICROB CHEMOTH, V58, P310, DOI 10.1093/jac/dkl223
   Sukhnanand S, 2005, J CLIN MICROBIOL, V43, P3688, DOI 10.1128/JCM.43.8.3688-3698.2005
   Torpdahl M, 2005, J MICROBIOL METH, V63, P173, DOI 10.1016/j.mimet.2005.03.006
   Urwin R, 2003, TRENDS MICROBIOL, V11, P479, DOI 10.1016/j.tim.2003.08.006
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   Walsh AL, 2000, PEDIATR INFECT DIS J, V19, P312, DOI 10.1097/00006454-200004000-00010
NR 29
TC 34
Z9 34
U1 0
U2 4
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 0022-2615
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PD NOV
PY 2007
VL 56
IS 11
BP 1479
EP 1484
DI 10.1099/jmm.0.47416-0
PG 6
WC Microbiology
SC Microbiology
GA 234RC
UT WOS:000251180400010
PM 17965348
OA No
DA 2017-08-15
ER

PT J
AU Newport, M
   Sirugo, G
   Lyons, E
   Vannberg, F
   Hill, AVS
   Bradbury, LA
   Farrar, C
   Pointon, JJ
   Wordsworth, P
   Brown, MA
   Franklyn, JA
   Heward, JM
   Simmonds, MJ
   Gough, SC
   Seal, S
   Stratton, MR
   Rahman, N
   Ban, M
   Goris, A
   Sawcer, SJ
   Compston, A
   Conway, D
   Jallow, M
   Newport, M
   Sirugo, G
   Rockett, KA
   Kwiatkowski, DP
   Bumpstead, SJ
   Chaney, A
   Downes, K
   Ghori, MJ
   Gwilliam, R
   Hunt, SE
   Inouye, M
   Keniry, A
   King, E
   McGinnis, R
   Potter, S
   Ravindrarajah, R
   Whittaker, P
   Widden, C
   Withers, D
   Deloukas, P
   Leung, HT
   Nutland, S
   Stevens, HE
   Walker, NM
   Todd, JA
   Easton, D
   Clayton, DG
   Burton, PR
   Tobin, MD
   Barrett, JC
   Evans, DM
   Morris, AP
   Cardon, LR
   Cardin, NJ
   Davison, D
   Ferreira, T
   Pereira-Gale, J
   Hallgrimsdottir, IB
   Howie, BN
   Marchini, JL
   Spencer, CC
   Su, Z
   Teo, YY
   Vukcevic, D
   Donnelly, P
   Bentley, D
   Brown, MA
   Cardon, LR
   Caulfield, M
   Clayton, DG
   Compston, A
   Craddock, N
   Deloukas, P
   Donnelly, P
   Farrall, M
   Barton, A
   Bruce, IN
   Donovan, H
   Eyre, S
   Gilbert, PD
   Hilder, SL
   Hinks, AM
   John, SL
   Potter, C
   Silman, AJ
   Symmons, DPM
   Thomson, W
   Worthington, J
   Gough, SC
   Hall, AS
   Hattersley, AT
   Hill, AVS
   Kwiatkowski, DP
   Matthew, CG
   McCarthy, MI
   Ouwehand, WH
   Parkes, M
   Pembrey, M
   Rahman, N
   Samani, NJ
   Stratton, MR
   Todd, JA
   Worthington, J
   Mitchell, SL
   Newby, PR
   Brand, OJ
   Carr-Smith, J
   Pearce, SHS
   Gough, SCL
   McGinnis, R
   Keniry, A
   Deloukas, P
   Reveille, JD
   Zhou, X
   Bradbury, LA
   Sims, AM
   Dowling, A
   Taylor, J
   Doan, T
   Cardon, LR
   Davis, JC
   Pointon, JJ
   Savage, L
   Ward, MM
   Learch, TL
   Weisman, MH
   Wordsworth, P
   Brown, MA
AF Newport, Melanie
   Sirugo, Giorgio
   Lyons, Emily
   Vannberg, Fredrik
   Hill, Adrian V. S.
   Bradbury, Linda A.
   Farrar, Claire
   Pointon, Jennifer J.
   Wordsworth, Paul
   Brown, Matthew A.
   Franklyn, Jayne A.
   Heward, Joanne M.
   Simmonds, Matthew J.
   Gough, Stephen C. L.
   Seal, Sheila
   Stratton, Michael R.
   Rahman, Nazneen
   Ban, Maria
   Goris, An
   Sawcer, Stephen J.
   Compston, Alastair
   Conway, David
   Jallow, Muminatou
   Newport, Melanie
   Sirugo, Giorgio
   Rockett, Kirk A.
   Kwiatkowski, Dominic P.
   Bumpstead, Suzannah J.
   Chaney, Amy
   Downes, Kate
   Ghori, Mohammed J. R.
   Gwilliam, Rhian
   Hunt, Sarah E.
   Inouye, Michael
   Keniry, Andrew
   King, Emma
   McGinnis, Ralph
   Potter, Simon
   Ravindrarajah, Rathi
   Whittaker, Pamela
   Widden, Claire
   Withers, David
   Deloukas, Panos
   Leung, Hin-Tak
   Nutland, Sarah
   Stevens, Helen E.
   Walker, Neil M.
   Todd, John A.
   Easton, Doug
   Clayton, David G.
   Burton, Paul R.
   Tobin, Martin D.
   Barrett, Jeffrey C.
   Evans, David M.
   Morris, Andrew P.
   Cardon, Lon R.
   Cardin, Niall J.
   Davison, Dan
   Ferreira, Teresa
   Pereira-Gale, Joanne
   Hallgrimsdottir, Ingeleif B.
   Howie, Bryan N.
   Marchini, Jonathan L.
   Spencer, Chris C. A.
   Su, Zhan
   Teo, Yik Ying
   Vukcevic, Damjan
   Donnelly, Peter
   Bentley, David
   Brown, Matthew A.
   Cardon, Lon R.
   Caulfield, Mark
   Clayton, David G.
   Compston, Alastair
   Craddock, Nick
   Deloukas, Panos
   Donnelly, Peter
   Farrall, Martin
   Barton, Anne
   Bruce, Ian N.
   Donovan, Hannah
   Eyre, Steve
   Gilbert, Paul D.
   Hilder, Samantha L.
   Hinks, Anne M.
   John, Sally L.
   Potter, Catherine
   Silman, Alan J.
   Symmons, Deborah P. M.
   Thomson, Wendy
   Worthington, Jane
   Gough, Stephen C. L.
   Hall, Alistair S.
   Hattersley, Andrew T.
   Hill, Adrian V. S.
   Kwiatkowski, Dominic P.
   Matthew, Christopher G.
   McCarthy, Mark I.
   Ouwehand, Willem H.
   Parkes, Miles
   Pembrey, Marcus
   Rahman, Nazneen
   Samani, Nilesh J.
   Stratton, Michael R.
   Todd, John A.
   Worthington, Jane
   Mitchell, Sarah L.
   Newby, Paul R.
   Brand, Oliver J.
   Carr-Smith, Jackie
   Pearce, Simon H. S.
   Gough, Stephen C. L.
   McGinnis, R.
   Keniry, A.
   Deloukas, P.
   Reveille, John D.
   Zhou, Xiaodong
   Bradbury, Linda A.
   Sims, Anne-Marie
   Dowling, Alison
   Taylor, Jacqueline
   Doan, Tracy
   Cardon, Lon R.
   Davis, John C.
   Pointon, Jennifer J.
   Savage, Laurie
   Ward, Michael M.
   Learch, Thomas L.
   Weisman, Michael H.
   Wordsworth, Paul
   Brown, Matthew A.
TI Association scan of 14,500 nonsynonymous SNPs in four diseases
   identifies autoimmunity variants
SO NATURE GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SINGLE-NUCLEOTIDE POLYMORPHISMS;
   GRAVES-DISEASE; CROHN-DISEASE; ANKYLOSING-SPONDYLITIS;
   POPULATION-STRUCTURE; GENETIC ASSOCIATION; SUSCEPTIBILITY LOCI;
   AMINOPEPTIDASE; RISK
AB We have genotyped 14,436 nonsynonymous SNPs (nsSNPs) and 897 major histocompatibility complex (MHC) tag SNPs from 1,000 independent cases of ankylosing spondylitis ( AS), autoimmune thyroid disease (AITD), multiple sclerosis ( MS) and breast cancer ( BC). Comparing these data against a common control dataset derived from 1,500 randomly selected healthy British individuals, we report initial association and independent replication in a North American sample of two new loci related to ankylosing spondylitis, ARTS1 and IL23R, and confirmation of the previously reported association of AITD with TSHR and FCRL3. These findings, enabled in part by increased statistical power resulting from the expansion of the control reference group to include individuals from the other disease groups, highlight notable new possibilities for autoimmune regulation and suggest that IL23R may be a common susceptibility factor for the major `seronegative' diseases.
C1 Univ Leicester, Dept Hlth Sci, Genet Epidemiol Grp, Leicester LE1 7RH, Leics, England.
   Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Juvenile Diabet Res Fdn Wellcome Trust Diabet & I, Cambridge CB2 0XY, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Cardiff Univ, Sch Med, Dept Psychol Med, Cardiff CF14 4XN, Wales.
   Wellcome Trust Res Labs, London NW1 2BE, England.
   Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
   Univ Oxford, Churchill Hosp, Oxford Ctr Diabet Endocrinol & Med, Oxford OX3 7LJ, England.
   Univ Cambridge, Dept Haematol, Cambridge CB2 2PT, England.
   Cambridge Ctr, Natl Hlth Serv Blood & Transplant, Cambridge CB2 2PT, England.
   Univ Leicester, Dept Cardiovasc Sci, Glenfield Hosp, Leicester LE3 9QP, Leics, England.
   Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
   Strangeways Res Lab, Canc Res UK Genet Epidemiol Unit, Cambridge CB1 8RN, England.
   Natl Hlth Serv Blood & Transplant, Sheffield Ctr, Sheffield S5 7JN, S Yorkshire, England.
   Natl Hlth Serv Blood & Transplant, Brentwood Ctr, Brentwood CM15 8DP, Essex, England.
   Scottish Natl Blood Transfus Serv, Edinburgh CB17 7QT, Midlothian, Scotland.
   Natl Hlth Serv Blood & Transplant, Southampton Ctr, Southampton SO16 5AF, Hants, England.
   Univ Bristol, Avon Longitudinal Study Parents & Children, Bristol BS8 1TQ, Avon, England.
   St Georges Univ London, Div Community Hlth Serv, London SW17 0RE, England.
   UCL, Inst Child Hlth, London WC1N 1EH, England.
   Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.
   Univ Birmingham, Div Neurosci, Dept Psychiat, Birmingham B15 2QZ, W Midlands, England.
   Cardiff Univ, Sch Med, Dept Med Psychol, Cardiff CF14 4XN, Wales.
   Kings Coll London, Inst Psychiat, SGDP, London SE5 8AF, England.
   Royal Victoria Infirm, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   Univ Leeds, Fac Med & Hlth, LIGHT & LIMM Res Inst, Leeds LS1 3EX, W Yorkshire, England.
   Univ Cambridge, Addenbrookes Hosp, IBD Res Grp, Cambridge CB2 2QQ, England.
   Univ Edinburgh, Western Gen Hosp, Sch Mol & Clin Med, Gastrointestinal Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   Kings Coll London, Sch Med, Guys Hosp, Dept Med & Mol Genet, London SE1 9RT, England.
   UCL, Hosp Trust, Inst Digest Dis, London NW1 2BU, England.
   Guys & St Thomas NHS Fdn Trust, Dept Gastroenterol, London SE1 7EH, England.
   Newcastle Univ, Royal Victoria Infirm, Dept Gastroenterol & Hepatol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   Univ Oxford, Radcliffe Infirm, Gastroenterol Unit, Oxford OX2 6HE, England.
   Aberdeen Royal Infirm, Aberdeen AB9 2ZB, Scotland.
   Univ Cambridge, Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 2QQ, England.
   Univ Cambridge, Addenbrookes Hosp, Diabet & Inflammat Lab, Cambridge CB2 2QQ, England.
   Ctr Natl Genotypage, F-91057 Paris, France.
   Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland.
   Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, Clin Pharmacol & Barts & London Genome Ctr, London EC1M 6BQ, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Univ Manchester, Arc Epidemiol Res Unit, Manchester M13 9PT, Lancs, England.
   Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England.
   Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter EX1 2LU, Devon, England.
   Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter EX2 5DU, Devon, England.
   Barts & London Royal London Hosp, Ctr Diabet & Metab Med, London E1 1BB, England.
   Univ Newcastle, Sch Clin Med Sci, Diabet Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Univ Bristol, MRC Ctr Causal Anal Translat Epidemiol, Bristol BS2 8PR, Avon, England.
   MRC Labs, Fajara, Gambia.
   Univ Queensland, Princess Alexandra Hosp, Diamantina Inst Canc Immunol & Metab Med, Woolloongabba, Qld 4102, Australia.
   Univ Oxford, Botnar Res Ctr, Oxford OX3 7BN, England.
   Univ Birmingham, Biomed Res Inst, Div Med Sci, Dept Med, Birmingham B15 2TT, W Midlands, England.
   Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England.
   Wellcome Trust Sanger Inst, Canc Genome Project, Cambridge CB10 1SA, England.
   Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 2QQ, England.
   Illumina Cambridge, Saffron Walden CB10 1XL, Essex, England.
   Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
   Univ Newcastle, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   Univ Texas, Houston Med Sch, Houston, TX 77030 USA.
   Univ Queensland, Diamantina Inst Canc Immunol & Metab Med, St Lucia, Qld 4072, Australia.
   Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Univ Calif San Francisco, Dept Rheumatol, San Francisco, CA 94143 USA.
   Spondylitis Assoc Amer, Sherman Oaks, CA 91403 USA.
   Univ Oxford, Botnar Res Ctr, Oxford OX3 7BN, England.
   NIAMSD, Natl Inst Hlth, Bethesda, MD 20892 USA.
   Cedars Sinai Med Ctr, Dept Radiol, Los Angeles, CA 90048 USA.
   Cedars Sinai Med Ctr, Dept Rheumatol Med, Los Angeles, CA 90048 USA.
RP Newport, M (reprint author), Univ Leicester, Dept Hlth Sci, Genet Epidemiol Grp, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.
RI ; Fox, Laura /C-6249-2016; eyre, stephen/K-3776-2017; HILL,
   Adrian/C-1306-2008; Todd, John/A-3542-2010; turton, miranda/F-4682-2011;
   Deloukas, Panos/B-2922-2013; Evans, David/H-6325-2013; Rahman,
   Nazneen/B-8890-2012; Worthington, Jane/M-9770-2014; Barton,
   Anne/N-2053-2014; Goris, An/F-2943-2010; Hinks, Anne/E-1853-2015;
   Burton, Paul/H-7527-2016; Newhouse, Stephen/C-9330-2011; Rahman,
   Nazneen/D-2802-2013
OI Wallace, Chris/0000-0001-9755-1703; Bruce, Ian/0000-0003-3047-500X;
   Prescott, Natalie/0000-0002-5901-7371; Kwiatkowski,
   Dominic/0000-0002-5023-0176; O'Donovan, Michael/0000-0001-7073-2379;
   Lindgren, Cecilia/0000-0002-4903-9374; Thomson,
   Wendy/0000-0002-9022-5179; Kirov, George/0000-0002-3427-3950; dobson,
   richard/0000-0003-4224-9245; Walker, Neil/0000-0001-9796-7688; Grozeva,
   Detelina/0000-0003-3239-8415; King, Emma/0000-0003-3611-9647; Timpson,
   Nicholas/0000-0002-7141-9189; Evans, David/0000-0003-0663-4621;
   Dominiczak, Anna/0000-0003-4913-3608; Bishop, Tim/0000-0002-8752-8785;
   eyre, stephen/0000-0002-1251-6974; Todd, John/0000-0003-2740-8148;
   Deloukas, Panos/0000-0001-9251-070X; Worthington,
   Jane/0000-0003-0544-042X; Barton, Anne/0000-0003-3316-2527; Goris,
   An/0000-0002-1276-6682; Hinks, Anne/0000-0001-8843-3967; Newhouse,
   Stephen/0000-0002-1843-9842; Lango Allen, Hana/0000-0002-7803-8688;
   Rahman, Nazneen/0000-0003-4376-0440; Potter, Simon/0000-0003-4208-4102;
   Simmonds, Matt/0000-0003-3154-3510; Hunt, Sarah/0000-0002-8350-1235;
   Brown, Matthew A/0000-0003-0538-8211; Zeggini,
   Eleftheria/0000-0003-4238-659X; Dunger, Professor
   David/0000-0002-2566-9304; Symmons, Deborah/0000-0002-8625-1200; Pearce,
   Simon/0000-0001-8384-8063
CR Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775
   Brown MA, 1996, ANN RHEUM DIS, V55, P268, DOI 10.1136/ard.55.4.268
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Capon F, 2001, J INVEST DERMATOL, V116, P728, DOI 10.1046/j.1523-1747.2001.01311.x
   Cargill M, 2007, AM J HUM GENET, V80, P273, DOI 10.1086/511051
   Chang SC, 2005, P NATL ACAD SCI USA, V102, P17107, DOI 10.1073/pnas.0500721102
   Clayton DG, 2005, NAT GENET, V37, P1243, DOI 10.1038/ng1653
   Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870
   Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355
   Cui XL, 2003, J BIOL CHEM, V278, P28677, DOI 10.1074/jbc.M300456200
   Cui XL, 2002, J CLIN INVEST, V110, P515, DOI 10.1172/JCI200213847
   Cui XL, 2003, J IMMUNOL, V171, P6814
   Dai KZ, 2001, GENES IMMUN, V2, P263, DOI 10.1038/sj.gene.6363774
   Dechairo BM, 2005, EUR J HUM GENET, V13, P1223, DOI 10.1038/sj.ejhg.5201485
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   DUERR RH, 2006, SCIENCE
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Gudmundsson J, 2007, NAT GENET, V39, P977, DOI 10.1038/ng2062
   Haiman CA, 2007, NAT GENET, V39, P638, DOI 10.1038/ng2015
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Hiratani H, 2005, J CLIN ENDOCR METAB, V90, P2898, DOI 10.1210/jc.2004-2148
   Hue S, 2006, J EXP MED, V203, P2473, DOI 10.1084/jem.20061099
   Jiang HR, 2006, J IMMUNOL, V177, P2258
   Jorgenson E, 2006, AM J HUM GENET, V78, P884, DOI 10.1086/503751
   Kochi Y, 2005, NAT GENET, V37, P478, DOI 10.1038/ng1540
   Libioulle C, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030058
   Mannon PJ, 2004, NEW ENGL J MED, V351, P2069, DOI 10.1056/NEJMoa033402
   Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337
   McGinnis R, 2002, BEHAV GENET, V32, P135, DOI 10.1023/A:1015205924326
   MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325
   Miretti MM, 2005, AM J HUM GENET, V76, P634, DOI 10.1086/429393
   Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014
   Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Purcell S, 2007, BIOINFORMATICS, V23, P255, DOI 10.1093/bioinformatics/btl580
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Saveanu L, 2005, NAT IMMUNOL, V6, P689, DOI 10.1038/ni1208
   Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   Simmonds MJ, 2006, J CLIN ENDOCR METAB, V91, P1056, DOI 10.1210/jc.2005-1634
   Sims AM, 2007, GENES IMMUN, V8, P115, DOI 10.1038/sj.gene.6364362
   Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616
   Smyth DJ, 2006, NAT GENET, V38, P617, DOI 10.1038/ng1800
   Thomas DC, 2004, J NATL CANCER I, V96, P421, DOI 10.1093/jnci/djh094
   Tremelling M, 2007, GASTROENTEROLOGY, V132, P1657, DOI 10.1053/j.gastro.2007.02.051
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089
   ZEGGINI E, 2007, SCIENCE, V316, P470
NR 49
TC 794
Z9 805
U1 5
U2 64
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD NOV
PY 2007
VL 39
IS 11
BP 1329
EP 1337
DI 10.1038/ng.2007.17
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 226GM
UT WOS:000250575900017
OA No
HC Y
HP N
DA 2017-08-15
ER

PT J
AU Prentice, A
AF Prentice, Ann
TI Symposium on 'Nutrition in early life: new horizons in a new century' -
   Elsie Widdowson Lecture 2006 - Mining the depths: metabolic insights
   into mineral nutrition
SO PROCEEDINGS OF THE NUTRITION SOCIETY
LA English
DT Article; Proceedings Paper
CT International Conference of the Nutrition-Society
CY DEC 11-13, 2006
CL Churchill Coll, Cambridge, ENGLAND
SP Nutr Soc, Royal Soc Med
HO Churchill Coll
DE calcium; Elsie Widdowson; mineral metabolism; phosphorus; vitamin D
ID VITAMIN-D; CALCIUM SUPPLEMENTATION; PARATHYROID-HORMONE; GAMBIAN WOMEN;
   BONE-GROWTH; IN-VIVO; KLOTHO; PHOSPHATE; RECEPTOR; CHILDREN
AB 2006 marked the centenary of the birth of Dr Elsie Widdowson, a pioneer of nutrition science. One of the hallmarks of Elsie Widdowson's research was an integrative approach that recognised the importance of investigating the mechanisms underpinning a public health or clinical issue at all levels, looking into the physiology, comparative biology, intermediate metabolism and basic science. The theme of the present lecture, given in celebration of the work of Dr Widdowson, is mineral nutrition, with a particular focus on Ca, P and vitamin D. The contributions of Dr Widdowson to the early understanding of mineral nutrition are reviewed and the latest scientific findings in this rapidly-expanding field of research are presented.
C1 [Prentice, Ann] MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   [Prentice, Ann] MRC Keneba, Keneba, Gambia.
RP Prentice, A (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
EM ann.prentice@mrc-hnr.cam.ac.uk
FU Medical Research Council [MC_U105960371, U.1059.00.017(60371)]
CR American Society for Bone and Mineral Research, 2006, PRIM MET BON DIS DIS
   Aspray TJ, 2005, BONE, V36, P710, DOI 10.1016/j.bone.2005.01.002
   Awumey E.M., 2006, CALCIUM HUMAN HLTH, P13, DOI 10.1007/978-1-59259-961-5_3
   Bailey DA, 1999, J BONE MINER RES, V14, P1672, DOI 10.1359/jbmr.1999.14.10.1672
   Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614
   BERNDT T, 2005, BONEKEY OSTEOVISION, V2, P5
   Brown EM, 2000, ANNU REV NUTR, V20, P507, DOI 10.1146/annurev.nutr.20.1.507
   Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.11114245
   *COMM PRIV COUNC M, 1948, REP MED RES COUNC YE
   Department of Health, 1998, NUTR BON HLTH PART R
   Department of Health and Social Security, 1969, REC INT NUTR UK
   *DEP HLTH SOC SEC, 1980, RICK OST
   Ferrari S, 2006, BONEKEY OSTEOVISION, V3, P11
   Fleet J. C., 2006, CALCIUM HUMAN HLTH, P163, DOI 10.1007/978-1-59259-961-5_11
   Food Standards Agency, 2002, MCCANC WIDD COMP FOO
   Gomez-Morilla I, 2006, NUCL INSTRUM METH B, V249, P665, DOI 10.1016/j.nimb.2006.03.076
   HEGSTED DM, 1986, J NUTR, V116, P2316
   Hegsted DM, 2000, ANNU REV NUTR, V20, P1, DOI 10.1146/annurev.nutr.20.1.1
   Institute of Medicine Food and Nutrition Board, 1997, DIET REF INT CALC PH
   Jarjou LM, 2006, AM J CLIN NUTR, V83, P657
   KANIS JA, 1989, BRIT MED J, V298, P137
   Ketteler M, 2006, NEPHROL DIAL TRANSPL, V21, P33, DOI 10.1093/ndt/gfi270
   Kolek OI, 2005, AM J PHYSIOL-GASTR L, V289, pG1036, DOI 10.1152/ajpgi.00243.2005
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200
   Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
   MALM OLE J., 1958, SCAND JOUR CLIN AND LAB INVERT, V10, P1
   McCance RA, 1939, BIOCHEM J, V33, P523
   McCance RA, 1943, J PHYSIOL-LONDON, V102, P42
   McCance RA, 1942, J PHYSIOL-LONDON, V101, P44
   McCance RA, 1937, BRIT MED J, V1937, P311
   MCCANCE RA, 1942, CHEM COMPOSITION FOO
   MCCANCE RA, 1946, EXPT STUDY RATIONING
   Negri AL, 2005, J NEPHROL, V18, P654
   Paul AA, 1978, MCCANCE WIDDOWSONS C
   Pele L, 2005, FALK SYMP, V140, P123
   PETTIFOR JM, 2003, TXB NUTR METABOLISM, P247
   Pettifor J. M., 2003, PEDIAT BONE BIOL DIS, P541, DOI 10.1016/B978-012286551-0/50024-5
   PRENTICE A, 1995, AM J CLIN NUTR, V62, P58
   Prentice A, 2003, EUR J NUTR, V42, P28, DOI 10.1007/s00394-003-1103-1
   Prentice A, 2004, BRIT J NUTR, V92, pS83, DOI 10.1079/BJN20041159
   Prentice A, 2004, PUBLIC HEALTH NUTR, V7, P227, DOI 10.1079/PHN2003590
   Prentice A, 2001, P NUTR SOC, V60, P45, DOI 10.1079/PNS200072
   Prentice A, 2001, BONE, V28, pS253
   Prentice A., 1999, NUTR BONE DEV, P127
   Prentice A., 2007, INT C SERIES, V1297, P15, DOI 10.1016/j.ics.2006.08.011
   Prentice A, 2006, P NUTR SOC, V65, P348, DOI 10.1079/PNS2006519
   Prentice Ann, 1993, Nutrition Research Reviews, V6, P51, DOI 10.1079/NRR19930006
   Saito H, 2005, J BIOL CHEM, V280, P2543, DOI 10.1074/jbc.M408903200
   SPECTOR TD, 1995, BRIT MED J, V310, P1357
   Tallini YN, 2006, P NATL ACAD SCI USA, V103, P4753, DOI 10.1073/pnas.0509378103
   TEEGARDEN D, 2006, CALCIUM HUMAN HLTH, P327, DOI 10.1007/978-1-59259-961-5_21
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   White KE, 2006, ENDOCR REV, V27, P221, DOI 10.1219/er.2005-0019
   WIDDOWSON E M, 1951, Spec Rep Ser Med Res Counc (G B), V275, P296
   WIDDOWSON EM, 1962, P NUTR SOC, V21, P121, DOI 10.1079/PNS19620023
   Widdowson EM, 1964, MINER METABOL, P1
   WIDDOWSON EM, 1963, J COLL GEN PRACT S2, V19, P10
   Yan L, 2003, BONE, V33, P620, DOI 10.1016/S8756-3282(03)00216-3
NR 60
TC 6
Z9 6
U1 0
U2 7
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0029-6651
EI 1475-2719
J9 P NUTR SOC
JI Proc. Nutr. Soc.
PD NOV
PY 2007
VL 66
IS 4
BP 512
EP 521
DI 10.1017/S0029665107005836
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 253QV
UT WOS:000252533600006
PM 17961272
OA No
DA 2017-08-15
ER

PT J
AU Enwere, G
   Cheung, YB
   Zaman, SMA
   Akano, A
   Oluwalana, C
   Brown, O
   Vaughan, A
   Adegbola, R
   Greenwood, B
   Cutts, F
AF Enwere, Godwin
   Cheung, Yin Bun
   Zaman, Syed M. A.
   Akano, Alieu
   Oluwalana, Claire
   Brown, Okoko
   Vaughan, Adeola
   Adegbola, Richard
   Greenwood, Brian
   Cutts, Felicity
TI Epidemiology and clinical features of pneumonia according to
   radiographic findings in Gambian children
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE pneumonia; epidemiology; clinical features; radiographic findings
ID PNEUMOCOCCAL CONJUGATE VACCINE; RESPIRATORY-TRACT INFECTIONS; INTEGRATED
   MANAGEMENT; CHILDHOOD ILLNESS; BACTERIAL; DISEASE; DIAGNOSIS; BURDEN;
   TRIAL; LUNG
AB OBJECTIVE To assess the effect of vaccines against pneumonia in Gambian children.
   METHODS Data from a randomized, controlled trial of a 9-valent pneumococcal conjugate vaccine (PCV) were used. Radiographic findings, interpreted using WHO definitions, were classified as primary end point pneumonia, 'other infiltrates/abnormalities' pneumonia and pneumonia with no abnormality. We calculated the incidence of the different types of radiological pneumonia, and compared clinical and laboratory features between these groups.
   RESULTS Among children who did not receive PCV, the incidence of pneumonia with no radiographic abnormality was about twice that of 'other infiltrates' pneumonia and three times that of primary endpoint pneumonia. Most respiratory symptoms, reduced feeding and vomiting occurred most frequently in children with primary endpoint pneumonia. These children were more likely to be malnourished, to have bronchial breath sounds or invasive bacterial diseases, and to die within 28 days of consultation than children in the other groups. Conversely, a history of convulsion, diarrhoea or fast breathing, malaria parasitaemia and isolation of salmonellae were commoner in children with pneumonia with no radiographic abnormality. Lower chest wall indrawing and rhonchi on auscultation were seen most frequently in children with 'other infiltrates/abnormalities' pneumonia.
   CONCLUSION Primary endpoint pneumonia is strongly associated with bacterial aetiology and severe pneumonia'. Since this category of pneumonia is significantly reduced after vaccination with Hib and pneumococcal vaccines, the risk-benefit of antimicrobial prescription for clinical pneumonia for children with increased respiratory rate may warrant re-examination once these vaccines are in widespread use.
C1 [Enwere, Godwin; Zaman, Syed M. A.; Oluwalana, Claire; Brown, Okoko; Vaughan, Adeola; Adegbola, Richard; Cutts, Felicity] MRC Labs, Fajara, Gambia.
   [Cheung, Yin Bun; Greenwood, Brian] London Sch Hyg & Trop Med, London WC1, England.
   [Akano, Alieu] Natl Hosp, Abuja, Nigeria.
RP Enwere, G (reprint author), WHO, Dept Immunizat Vaccines & Biol, Geneva, Switzerland.
EM enwereg@who.int
FU Medical Research Council [G0700837]; NIAID NIH HHS [N01-AI-25477]
CR Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   BOBADILLA JL, 1994, B WORLD HEALTH ORGAN, V72, P653
   Bryce J, 2006, LANCET, V368, P1067, DOI 10.1016/S0140-6736(06)69339-2
   Centers for Disease Control and Prevention, 2005, MMWR-MORBID MORTAL W, V54, P893
   Cherian T, 2005, B WORLD HEALTH ORGAN, V83, P353
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5
   Falade AG, 1997, ANN TROP PAEDIATR, V17, P315
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009
   FORGIE IM, 1992, PEDIATR INFECT DIS J, V11, P466, DOI 10.1097/00006454-199206000-00009
   Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7
   Hazir T, 2006, BRIT MED J, V333, P629, DOI 10.1136/bmj.38915.673322.80
   Lucero MG, 2005, LANCET, V365, P1113, DOI 10.1016/S0140-6736(05)71853-5
   Madhi SA, 2005, CLIN INFECT DIS, V40, P1511, DOI 10.1086/429828
   Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077
   Magree HC, 2005, B WORLD HEALTH ORGAN, V83, P427
   MIMICA I, 1971, AM J DIS CHILD, V122, P278
   Mulholland K, 2003, PEDIATR PULM, V36, P469, DOI 10.1002/ppul.10344
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y
   Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895
   SILVERMAN M, 1977, ARCH DIS CHILD, V52, P925
   Virkki R, 2002, THORAX, V57, P438, DOI 10.1136/thorax.57.5.438
   Wardlaw T, 2006, LANCET, V368, P1048, DOI 10.1016/S0140-6736(06)69334-3
   Weber MW, 1997, B WORLD HEALTH ORGAN, V75, P25
   *WHO, 2001, STAND CHEST RAD DIAG
   Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0
NR 29
TC 27
Z9 28
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD NOV
PY 2007
VL 12
IS 11
BP 1377
EP 1385
DI 10.1111/j.1365-3156.2007.01922.x
PG 9
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 242HT
UT WOS:000251716900015
PM 18045264
OA No
DA 2017-08-15
ER

PT J
AU Adetifa, IMO
   Lugos, MD
   Hammond, A
   Jeffries, D
   Donkor, S
   Adegbola, RA
   Hill, PC
AF Adetifa, Ifedayo M. O.
   Lugos, Moses D.
   Hammond, Abdulrahman
   Jeffries, David
   Donkor, Simon
   Adegbola, Richard A.
   Hill, Philip C.
TI Comparison of two interferon gamma release assays in the diagnosis of
   Mycobacterium tuberculosis infection and disease in The Gambia
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID LINKED IMMUNOSPOT ASSAY; CALMETTE-GUERIN VACCINATION; HEALTH-CARE
   WORKERS; SKIN-TEST; ACTIVE TUBERCULOSIS; ELISPOT TEST; RURAL INDIA;
   CHILDREN; CONTACT; TESTS
AB Background: IFN-gamma Release Assays (IGRAs) have been licensed for the diagnosis of latent Mycobacterium tuberculosis infection (LTBI). Their performance may depend on assay format and may vary across populations and settings. We compared the diagnostic performance of an in-house T-cell and commercial whole blood-based IGRAs for the diagnosis of LTBI and TB disease in The Gambia.
   Methods: Newly diagnosed sputum smear positive cases and their household contacts were recruited. Cases and contacts were bled for IGRA and contacts had a Mantoux skin test. We assessed agreement and discordance between the tests and categorized a contact's level of M. tuberculosis exposure according to where s/he slept relative to a case: the same room, same house or a different house. We assessed the relationship between exposure and test results by multiple logistic regression.
   Results: In 80 newly diagnosed TB cases, the sensitivity of ELISPOT was 78.7% and for QFT-GIT was 64.0% (p = 0.047). Of 194 household contacts 57.1% and 58.8% were positive for ELISPOT and QFT-GIT respectively. The overall agreement between both IGRAs for LTBI in contacts was 71.4% and there was no significant discordance (p = 0.29). There was significant discordance between the IGRAs and TST. Neither IGRA nor TST had evidence of false positive results because of Bacille Calmette Guerin (BCG) vaccination. However, agreement between QFT-GIT and TST as well as discordance between both IGRAs and TST were associated with BCG vaccination. Both IGRAs responded to the M. tuberculosis exposure gradient and were positively associated with increasing TST induration (p = 0.003 for ELISPOT and p = 0.001 for QFT-GIT).
   Conclusion: The ELISPOT test is more sensitive than the QFT-GIT for diagnosing TB disease. The two tests perform similarly in the diagnosis of LTBI in TB contacts. Significant discordance between the two IGRAs and between each and the TST remain largely unexplained.
C1 [Adetifa, Ifedayo M. O.; Lugos, Moses D.; Hammond, Abdulrahman; Jeffries, David; Donkor, Simon; Adegbola, Richard A.; Hill, Philip C.] MRC Labs, Bacterial Dis Programme, Fajara, Gambia.
RP Adetifa, IMO (reprint author), MRC Labs, Bacterial Dis Programme, Fajara, Gambia.
EM iadetifa@mrc.gm; mlugos2003@yahoo.com; ahammond@mrc.gm;
   djeffries@mrc.gm; sdonkor@mrc.gm; radegbola@mrc.gm; phill@mrc.gm
RI Hammond, Abdulrahman/F-1541-2011
FU Medical Research Council [MC_U190071468, MC_U190081968]
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   Aiken AM, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-66
   Almeida LMD, 2001, PEDIATR INFECT DIS J, V20, P1061, DOI 10.1097/00006454-200111000-00011
   Arend SM, 2007, AM J RESP CRIT CARE, V175, P618, DOI 10.1164/rccm.200608-1099OC
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   Detjen AK, 2007, CLIN INFECT DIS, V45, P322, DOI 10.1086/519266
   Dewan PK, 2007, CLIN INFECT DIS, V44, P69, DOI 10.1086/509928
   Diel R, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-77
   Dinnes J, 2007, HEALTH TECHNOL ASSES, V11, P1
   Dogra S, 2007, J INFECTION, V54, P267, DOI 10.1016/j.jinf.2006.04.007
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6
   Goletti D, 2006, CLIN MICROBIOL INFEC, V12, P544, DOI 10.1111/j.1469-0691.2006.01391.x
   Harada N, 2006, INFECT CONT HOSP EP, V27, P442, DOI 10.1086/504358
   Heifets Leonid B., 1994, P85
   Hill PC, 2006, PEDIATRICS, V117, P1542, DOI 10.1542/peds.2005-2095
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Hill PC, 2007, PLOS MED, V4, P1061, DOI 10.1371/journal.pmed.0040192
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968
   Igari H, 2007, INT J TUBERC LUNG D, V11, P788
   Jasmer RM, 2002, NEW ENGL J MED, V347, P1860, DOI 10.1056/NEJMcp021045
   Jeffries DJ, 2006, INT J TUBERC LUNG D, V10, P192
   Kang YA, 2005, JAMA-J AM MED ASSOC, V293, P2756, DOI 10.1001/jama.293.22.2756
   Kang YA, 2007, CHEST, V132, P959, DOI 10.1378/chest.06-2805
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lee JY, 2006, EUR RESPIR J, V28, P24, DOI 10.1183/09031936.06.00016906
   Leyten EMS, 2007, EUR RESPIR J, V29, P1212, DOI 10.1183/09031936.00117506
   Lienhardt C, 2003, AM J RESP CRIT CARE, V168, P448, DOI 10.1164/rccm.200212-1483OC
   Menzies D, 2007, ANN INTERN MED, V146, P340
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC
   Mudido PM, 1999, INT J TUBERC LUNG D, V3, P891
   Naseer A, 2007, EUR RESPIR J, V29, P1282, DOI 10.1183/09031936.0017807
   Oxford Immunotec, 2006, T SPOT TB AID DIAGN
   Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X
   Pai M, 2007, AM J RESP CRIT CARE, V175, P529, DOI 10.1164/rccm.200701-024ED
   Pitman R, 2002, INT J TUBERC LUNG D, V6, P485
   Tsiouris SJ, 2006, J CLIN MICROBIOL, V44, P2844, DOI 10.1128/JCM.02411-05
   Wang L, 2002, THORAX, V57, P804, DOI 10.1136/thorax.57.9.804
   World Health Organization, TUB
NR 39
TC 50
Z9 55
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD OCT 25
PY 2007
VL 7
AR 122
DI 10.1186/1471-2334-7-122
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 256PE
UT WOS:000252741300002
PM 17961228
OA gold
DA 2017-08-15
ER

PT J
AU Verra, F
   Simpore, J
   Warimwe, GM
   Tetteh, KK
   Howard, T
   Osier, FHA
   Bancone, G
   Avellino, P
   Blot, I
   Fegan, G
   Bull, PC
   Williams, TN
   Conway, DJ
   Marsh, K
   Modiano, D
AF Verra, Federica
   Simpore, Jacques
   Warimwe, George M.
   Tetteh, Kevin K.
   Howard, Tevis
   Osier, Faith H. A.
   Bancone, Germana
   Avellino, Pamela
   Blot, Isa
   Fegan, Greg
   Bull, Peter C.
   Williams, Thomas N.
   Conway, David J.
   Marsh, Kevin
   Modiano, David
TI Haemoglobin C and S Role in Acquired Immunity against Plasmodium
   falciparum Malaria
SO PLOS ONE
LA English
DT Article
AB A recently proposed mechanism of protection for haemoglobin C (HbC; beta 6Glu -> Lys) links an abnormal display of PfEMP1, an antigen involved in malaria pathogenesis, on the surface of HbC infected erythrocytes together with the observation of reduced cytoadhesion of parasitized erythrocytes and impaired rosetting in vitro. We investigated the impact of this hypothesis on the development of acquired immunity against Plasmodium falciparum variant surface antigens (VSA) encoding PfEMP1 in HbC in comparison with HbA and HbS carriers of Burkina Faso. We measured: i) total IgG against a single VSA, A4U, and against a panel of VSA from severe malaria cases in human sera from urban and rural areas of Burkina Faso of different haemoglobin genotypes (CC, AC, AS, SC, SS); ii) total IgG against recombinant proteins of P. falciparum asexual sporozoite, blood stage antigens, and parasite schizont extract; iii) total IgG against tetanus toxoid. Results showed that the reported abnormal cell-surface display of PfEMP1 on HbC infected erythrocytes observed in vitro is not associated to lower anti-PfEMP1 response in vivo. Higher immune response against the VSA panel and malaria antigens were observed in all adaptive genotypes containing at least one allelic variant HbC or HbS in the low transmission urban area whereas no differences were detected in the high transmission rural area. In both contexts the response against tetanus toxoid was not influenced by the beta-globin genotype. These findings suggest that both HbC and HbS affect the early development of naturally acquired immunity against malaria. The enhanced immune reactivity in both HbC and HbS carriers supports the hypothesis that the protection against malaria of these adaptive genotypes might be at least partially mediated by acquired immunity against malaria.
C1 [Verra, Federica; Bancone, Germana; Avellino, Pamela; Modiano, David] Univ Roma La Sapienza, Dipartimento Sci Sanita Pubbl, Sez Parassitol, Rome, Italy.
   [Verra, Federica; Tetteh, Kevin K.; Osier, Faith H. A.; Fegan, Greg; Conway, David J.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   [Simpore, Jacques] Ctr Med St Camille, Ouagadougou, Burkina Faso.
   [Warimwe, George M.; Howard, Tevis; Osier, Faith H. A.; Fegan, Greg; Bull, Peter C.; Williams, Thomas N.; Marsh, Kevin] Kilifi Dist Hosp, Ctr Geog Med Res, Wellcome Trust Programme, Kenya Med Res Inst, Kilifi, Kenya.
   [Blot, Isa] Ctr Natl Transfus Sanguine, Ouagadougou, Burkina Faso.
   [Conway, David J.] MRC Labs, Banjul, Gambia.
RP Verra, F (reprint author), Univ Roma La Sapienza, Dipartimento Sci Sanita Pubbl, Sez Parassitol, Rome, Italy.
EM federica.verra@uniroma1.it
OI Osier, Faith/0000-0001-7133-5375; Bull, Peter/0000-0002-7674-6752;
   SIMPORE, Jacques/0000-0002-0415-9161; Bancone,
   Germana/0000-0003-4550-0431; Fegan, Greg/0000-0002-2663-2765; Conway,
   David/0000-0002-8711-3037
FU Wellcome Trust [071626]; European, Priority 1 Life Sciences, Genomics
   and Biotechnology for Health [LSH-CT-2004-503578]; malaria Network;
   Compagnia di San Paolo, Turin, Italy
FX This project was supported by the Wellcome Trust grant no 071626
   (Advanced Training Fellowship in Tropical Medicine to FV). This work is
   also part of the activities of the BioMalPar European Network of
   Excellence supported by a European grant (LSH-CT-2004-503578) from the
   Priority 1 Life Sciences, Genomics and Biotechnology for Health in the
   6th Framework Programme. FV is currently funded by the malaria Network
   sponsored by the Compagnia di San Paolo, Turin, Italy. The above
   mentioned funders had no role in the design and conduct of the study, in
   the collection, analysis, and interpretation, review, or approval of the
   manuscript.
CR Agarwal A, 2000, BLOOD, V96, P2358
   ALLISON AC, 1954, T ROY SOC TROP MED H, V48, P312, DOI 10.1016/0035-9203(54)90101-7
   Ayi K, 2004, BLOOD, V104, P3364, DOI 10.1182/blood-2003-11-3820
   Bull PC, 2002, J INFECT DIS, V185, P1688, DOI 10.1086/340420
   Cabrera G, 2005, J INFECT DIS, V191, P1631, DOI 10.1086/429832
   Cavanagh DR, 1997, MOL BIOCHEM PARASIT, V85, P197, DOI 10.1016/S0166-6851(96)02826-5
   Cavanagh DR, 1998, J IMMUNOL, V161, P347
   Fairhurst RM, 2005, NATURE, V435, P1117, DOI 10.1038/nature03631
   Fairhurst RM, 2003, BLOOD, V101, P3309, DOI 10.1182/blood-2002-10-3105
   Giha HA, 1999, INFECT IMMUN, V67, P4092
   Haldane J. B. S., 1949, Ricerca Scientifica Suppl, P68
   Kinyanjui SM, 2004, J INFECT DIS, V190, P1527, DOI 10.1086/424675
   MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1
   Mockenhaupt FP, 2004, J INFECT DIS, V190, P1006, DOI 10.1086/422847
   Modiano D, 2001, NATURE, V414, P305, DOI 10.1038/35104556
   SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X
   VIRIYAKOSOL S, 1995, B WORLD HEALTH ORGAN, V73, P85
   Weatherall DJ, 2001, NAT REV GENET, V2, P245, DOI 10.1038/35066048
   Williams TN, 2005, PLOS MED, V2, P441, DOI 10.1371/journal.pmed.0020128
   Williams TN, 2003, CYTOM PART A, V56A, P96, DOI 10.1002/cyto.a.10088
NR 20
TC 34
Z9 35
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 3
PY 2007
VL 2
IS 10
AR e978
DI 10.1371/journal.pone.0000978
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10HU
UT WOS:000207455900014
PM 17912355
OA gold
DA 2017-08-15
ER

PT J
AU Diness, BR
   Fisker, AB
   Roth, A
   Yazdanbakhsh, M
   Sartono, E
   Whittle, H
   Nante, JE
   Lisse, IM
   Ravn, H
   Rodrigues, A
   Aaby, P
   Benn, CS
AF Diness, Birgitte R.
   Fisker, Ane B.
   Roth, Adam
   Yazdanbakhsh, Maria
   Sartono, Erliyani
   Whittle, Hilton
   Nante, Jose E.
   Lisse, Ida M.
   Ravn, Henrik
   Rodrigues, Amabelia
   Aaby, Peter
   Benn, Christine S.
TI Effect of high-dose vitamin A supplementation on the immune response to
   Bacille Calmette-Guerin vaccines
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE Bacille Calmette-Guerin; BCG vaccination; vitamin A; PPD response;
   purified protein derivative of Mycobacterium tuberculosis response;
   randomized trial; sex-differential effects
ID DELAYED-TYPE HYPERSENSITIVITY; TUBERCULIN REACTION; INFANT-MORTALITY;
   RANDOMIZED-TRIAL; NORTHERN MALAWI; BCG VACCINATION; GUINEA-BISSAU;
   COMMUNITY; IMPACT; SENSITIVITY
AB Background: Vitamin A supplementation (VAS) at birth has been associated with decreased mortality in Asia. Bacille Calmette-Guerin (BCG) vaccine is given at birth in tuberculosis-endemic countries. Previous studies suggest that VAS may influence the immune response to vaccines.
   Objective: Our objective was to examine whether VAS influences the immune response to simultaneously administered BCG vaccine.
   Design: Within a randomized trial of 50 000 IU vitamin A or placebo Given with BCG vaccine at birth in Guinea-Bissau, 27 10 infants were examined for BCG scar formation and delayed-type hypersensitivity (DTH) to purified protein derivative of Mycobacterium tuberculosis (PPD) at 2 and 6 mo of age. The ex vivo cytokine response to PPD was measured in 607 infants.
   Results: At 2 mo of age, 39% (43% of the boys and 34% of the girls) responded to PPD. The prevalence ratio of a measurable PPD reaction for VAS compared with placebo recipients was 0.90 (95% CI: 0.80, 1.02) for all infants. 0.81 (95% CI: 0.69, 0.95) for boys, and 1.04 (95% CI: 0.86, 1.26) for girls. At 6 mo of age, 42% of the infants responded to PPD. No difference was observed between VAS and placebo recipients. The prevalence of BCG scar was not affected by VAS. The ex vivo interferon-gamma response to PPD was increased by VAS (means ratio: 1.40: 95% CI: 1.03, 1.91).
   Conclusions: VAS with BCG vaccination does not appear to interfere with the long-term immune response to BCG. However, VAS temporarily altered the DTH reaction to PPD in boys at 2 mo of age, suggesting sex differences in the immunologic response to VAS Given with BCG. This trial was registered at www.clinicaltrials.gov as #NCT00168597.
C1 Statens Serum Inst, Bandim Hlth Project, DK-2300 Copenhagen, Denmark.
   INDEPTH Network, Bandim Hlth Project, Bissau, Guinea Bissau.
   Leiden Univ, Dept Parasitol, Leiden, Netherlands.
   MRC, Fajara, Gambia.
   Herlev Univ Hosp, Dept Pathol, Copenhagen, Denmark.
   Lund Univ, Malmo, Sweden.
RP Diness, BR (reprint author), Statens Serum Inst, Bandim Hlth Project, Artillerivej 5, DK-2300 Copenhagen, Denmark.
EM birgitte@diness.dk
CR ALKASSIMI FA, 1995, AM J RESP CRIT CARE, V152, P1575
   Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Benn CS, 2005, BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55
   Benn CS, 1997, LANCET, V350, P101, DOI 10.1016/S0140-6736(96)12019-5
   BENN CS, 2006, J INFECT DIS, V194, P721, DOI 10.1086/506457
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   BOUROS D, 1991, CHEST, V99, P416, DOI 10.1378/chest.99.2.416
   Fine P E, 1986, Lepr Rev, V57 Suppl 2, P275
   Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962
   Fjallbrant H, 2001, EUR RESPIR J, V18, P376, DOI 10.1183/09031936.01.00086901
   Floyd S, 2002, J INFECT DIS, V186, P807, DOI 10.1086/342416
   Floyd S, 2000, INT J TUBERC LUNG D, V4, P1133
   Garly ML, 2001, VACCINE, V20, P468, DOI 10.1016/S0264-410X(01)00339-5
   Gustafson P, 2004, INT J EPIDEMIOL, V33, P163, DOI 10.1093/ije/dyh026
   Hoft DF, 2002, J INFECT DIS, V186, P1448, DOI 10.1086/344359
   Hoft DF, 2000, CLIN INFECT DIS, V30, pS217, DOI 10.1086/313864
   Humphrey JH, 1996, J PEDIATR-US, V128, P489, DOI 10.1016/S0022-3476(96)70359-1
   KELLER MA, 1987, PEDIATR RES, V22, P277, DOI 10.1203/00006450-198709000-00008
   KRAMER TR, 1993, AM J CLIN NUTR, V58, P566
   Malaba LC, 2005, AM J CLIN NUTR, V81, P454
   MARTINS CL, IN PRESS PLOS MED
   OTA MO, 2005, J TROP PEDIATRICS, V52, P136, DOI 10.1093/tropej/fmi087
   Rahmathullah L, 2003, BRIT MED J, V327, P254, DOI 10.1136/bmj.327.7409.254
   Roth A, 2005, VACCINE, V23, P3991, DOI 10.1016/j.vaccine.2004.10.022
   Roth A, 2006, EPIDEMIOLOGY, V17, P562, DOI 10.1097/01.ede.0000231546.14749.ab
   SEMBA RD, 1995, LANCET, V345, P1330
   SOMMER A, 1986, LANCET, V1, P1169
   Villamor E, 2005, CLIN MICROBIOL REV, V18, P446, DOI 10.1128/CNR.18.3.446-464.2005
   *WHO TUB RES OFF, 1955, B WORLD HEALTH ORGAN, V12, P123
NR 29
TC 30
Z9 30
U1 0
U2 0
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD OCT
PY 2007
VL 86
IS 4
BP 1152
EP 1159
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 220CN
UT WOS:000250134600036
PM 17921396
OA No
DA 2017-08-15
ER

PT J
AU Hawkesworth, S
   Futford, AJC
   Prentice, AM
   Moore, SE
AF Hawkesworth, S.
   Futford, A. J. C.
   Prentice, A. M.
   Moore, S. E.
TI Maternal prenatal protein-energy supplementation is not associated with
   offspring blood pressure at 11-16 years of age in rural Gambia
SO EARLY HUMAN DEVELOPMENT
LA English
DT Meeting Abstract
C1 [Hawkesworth, S.; Futford, A. J. C.; Prentice, A. M.] London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
   [Hawkesworth, S.; Futford, A. J. C.; Prentice, A. M.; Moore, S. E.] MRC Labs, MRC Keneba, Fajara, Gambia.
EM sophie.hawkesworth@tshtm.ac.uk
CR Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786
NR 1
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-3782
J9 EARLY HUM DEV
JI Early Hum. Dev.
PD OCT
PY 2007
VL 83
SU 1
BP S53
EP S53
DI 10.1016/S0378-3782(07)70073-7
PG 1
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA 232YS
UT WOS:000251058200074
OA No
DA 2017-08-15
ER

PT J
AU Khor, CC
   Vannberg, FO
   Chapman, SJ
   Walley, A
   Aucan, C
   Loke, H
   White, NJ
   Peto, T
   Khor, LK
   Kwiatkowski, D
   Day, N
   Scott, A
   Berkley, JA
   Marsh, K
   Peshu, N
   Maitland, K
   Williams, TN
   Hill, AVS
AF Khor, C. C.
   Vannberg, F. O.
   Chapman, S. J.
   Walley, A.
   Aucan, C.
   Loke, H.
   White, N. J.
   Peto, T.
   Khor, L. K.
   Kwiatkowski, D.
   Day, N.
   Scott, A.
   Berkley, J. A.
   Marsh, K.
   Peshu, N.
   Maitland, K.
   Williams, T. N.
   Hill, A. V. S.
TI Positive replication and linkage disequilibrium mapping of the
   chromosome 21q22.1 malaria susceptibility locus
SO GENES AND IMMUNITY
LA English
DT Article
DE association; IFNAR1; severe malaria
ID PLASMODIUM-FALCIPARUM MALARIA; INTERFERON-GAMMA RESPONSES; HEMOGLOBIN E
   TRAIT; CEREBRAL MALARIA; NATURAL-SELECTION; AFRICAN CHILDREN; T-CELL;
   PROTECTION; ALPHA; GENOME
AB Four cytokine receptor genes are located on Chr21q22.11, encoding the a and beta subunits of the interferon-alpha receptor (IFNAR1 and IFNAR2), the beta subunit of the interleukin 10 receptor ( IL10RB) and the second subunit of the interferon-g receptor (IFNGR2). We previously reported that two variants in IFNAR1 were associated with susceptibility to malaria in Gambians. We now present an extensive fine-scale mapping of the associated region utilizing 45 additional genetic markers obtained from public databases and by sequencing a 44 kb region in and around the IFNAR1 gene in 24 Gambian children (12 cases/12controls). Within the IFNAR1 gene, a newly studied C-G single-nucleotide polymorphism (IFNAR1 272354c-g) at position -576 relative to the transcription start was found to be more strongly associated with susceptibility to severe malaria. Association was observed in three populations: in Gambian (P = 0.002), Kenyan (P = 0.022) and Vietnamese (P = 0.005) case-control studies. When all three studies were combined, using the Mantel-Haenszel test, the presence of IFNAR1 -576G was associated with a substantially elevated risk of severe malaria (N = 2444, OR = 1.38, 95% CI: 1.17-1.64; P = 1.7 x 10(-4)). This study builds on previous work to further highlight the importance of the type-I interferon pathway in malaria susceptibility and illustrates the utility of typing SNPs within regions of high linkage disequilibrium in multiple populations to confirm initial positive associations.
C1 Hammersmith Hosp, Imperial Coll London, Sect Genom Med, London, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   Mahidol Univ, Fac Trop Med, Bangkok, Thailand.
   Univ Oxford, Dept Clin Med, Oxford, England.
   Natl Univ Singapore Hosp, Dept Diagnost Imaging, Singapore, Singapore.
   MRC Labs, Banjul, Gambia.
   Cho Quan Hosp, Ctr Trop Dis, Ho Chi Minh City, Vietnam.
   Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   Kilifi Dist Hosp, Ctr Geog Med Res, Wellcome Trust Programme, KEMRI, Kilifi, Kenya.
   Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford, England.
RP Khor, CC (reprint author), Agcy Sci Technol & Res, Ctr Mol Med, Sect Genet Med, 30 Med Dr, Singapore 117609, Singapore.
EM khor_chiea_chuen@sics.a-star.edu.sg
RI HILL, Adrian/C-1306-2008
OI Walley, Andrew/0000-0001-7707-7549; Berkley, James/0000-0002-1236-849X;
   Khor, Chiea Chuen/0000-0002-1128-4729; Kwiatkowski,
   Dominic/0000-0002-5023-0176; Maitland, Kathryn/0000-0002-0007-0645
FU Medical Research Council [G0600230, G19/9]; Wellcome Trust [077092, ,
   061089, 076934, 081835]
CR Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182
   ALLISON AC, 1964, COLD SPRING HARB SYM, V29, P137
   Aucan C, 2003, GENES IMMUN, V4, P275, DOI 10.1038/sj.gene.6363962
   Cousens LP, 1999, J EXP MED, V189, P1315, DOI 10.1084/jem.189.8.1315
   Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739
   Ewing B, 1998, GENOME RES, V8, P186
   Ewing B, 1998, GENOME RES, V8, P175
   FLINT J, 1986, NATURE, V321, P744, DOI 10.1038/321744a0
   Frodsham AJ, 2006, P NATL ACAD SCI USA, V103, P9148, DOI 10.1073/pnas.0602800103
   Frodsham AJ, 2004, HUM MOL GENET, V13, pR187, DOI 10.1093/hmg/ddh225
   Gordon D, 1998, GENOME RES, V8, P195
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464
   Hugosson E, 2004, PARASITE IMMUNOL, V26, P111, DOI 10.1111/j.0141-9838.2004.00678.x
   Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1
   Hutagalung R, 1999, J INFECT DIS, V179, P283, DOI 10.1086/314561
   Hutagalung R, 2000, J INFECT DIS, V181, P1513, DOI 10.1086/315373
   Jeffares DC, 2007, NAT GENET, V39, P120, DOI 10.1038/ng1931
   John CC, 2004, INFECT IMMUN, V72, P5135, DOI 10.1128/IAI.72.9.5135-5142.2004
   Jurinke Christian, 2002, Adv Biochem Eng Biotechnol, V77, P57
   Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649
   Koch O, 2002, J INFECT DIS, V185, P1684, DOI 10.1086/340516
   Luty AJF, 1999, J INFECT DIS, V179, P980, DOI 10.1086/314689
   Lyke KE, 2004, INFECT IMMUN, V72, P5630, DOI 10.1128/IAI.72.10.5630-5637.2004
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   McGuire W, 1999, J INFECT DIS, V179, P287, DOI 10.1086/314533
   Mu JB, 2007, NAT GENET, V39, P126, DOI 10.1038/ng1924
   Pichyangkul S, 2004, J IMMUNOL, V172, P4926
   RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357
   Vigario AM, 2001, BLOOD, V97, P3966, DOI 10.1182/blood.V97.12.3966
   Volkman SK, 2007, NAT GENET, V39, P113, DOI 10.1038/ng1930
NR 34
TC 10
Z9 11
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
EI 1476-5470
J9 GENES IMMUN
JI Genes Immun.
PD OCT
PY 2007
VL 8
IS 7
BP 570
EP 576
DI 10.1038/sj.gene.6364417
PG 7
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 223OV
UT WOS:000250382200006
PM 17703179
OA No
DA 2017-08-15
ER

PT J
AU Turner, PC
   Collinson, AC
   Cheung, YB
   Gong, YY
   Hall, AJ
   Prentice, AM
   Wild, CP
AF Turner, Paul C.
   Collinson, Andrew C.
   Cheung, Yin Bun
   Gong, YunYun
   Hall, Andrew J.
   Prentice, Andrew M.
   Wild, Christopher P.
TI Aflatoxin exposure in utero causes growth faltering in Gambian infants
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE aflatoxin; biomarker; The Gambia; growth faltering; in utero
ID SIMULTANEOUS PRENATAL EXPOSURE; WEST-AFRICA; DIETARY AFLATOXIN;
   YOUNG-CHILDREN; PUBLIC-HEALTH; OCHRATOXIN-A; INFECTION; BENIN; ZINC; B-1
AB Background Growth faltering in West African children has previously been associated with dietary exposure to aflatoxins, particularly upon weaning. However, in animal studies in utero exposure to low levels of aflatoxin also results in growth faltering.
   Objective This study investigated the effect of in utero aflatoxin exposure on infant growth in the first year of life in The Gambia.
   Methods Height and weight were measured for 138 infants at birth and at regular monthly intervals for one year. Aflatoxin-albumin (AF-alb) adduct level was measured in maternal blood during pregnancy, in cord blood and in infants at age 16 weeks.
   Results The geometric mean AF-alb levels were 40.4pg/mg (range 4.82-60.8pg/mg), 10.1pg/mg (range 5.01-89.6pg/mg) and 8.7pg/mg (range 5.0-30.2pg/mg) in maternal, cord and infant blood, respectively. AF-alb in maternal blood was a strong predictor of both weight (P = 0.012) and height (P = 0.044) gain, with lower gain in those with higher exposure. A reduction of maternal AF-alb from 110pg/mg to 10pg/mg would lead to a 0.8kg increase in weight and 2cm increase in height within the first year of life.
   Conclusions This study shows a strong effect of maternal aflatoxin exposure during pregnancy on growth in the first year of life and thus extends earlier observations of an association between aflatoxin exposure during infancy and growth faltering. The findings imply value in targeting intervention strategies at early life exposures.
C1 Univ Leeds, Fac Med & Hlth, Leeds Inst Genet Hlth & Therapeut, Ctr Biostat & Epidemiol,Mol Epidemiol Unit, Leeds, W Yorkshire, England.
   London Sch Hyg & Trop Med, Publ Hlth Nutr Unit, MRC Int Nutr Grp, London WC1, England.
   MRC Labs, MRC Keneba, Fajara, Gambia.
   Univ London, London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London, England.
RP Wild, CP (reprint author), Univ Leeds, Fac Med & Hlth, Leeds Inst Genet Hlth & Therapeut, Ctr Biostat & Epidemiol,Mol Epidemiol Unit, Leeds, W Yorkshire, England.
EM c.p.wild@leeds.ac.uk
RI Turner, Paul/A-6152-2011; Turner, Paul/B-8131-2013; Gong,
   Yun/L-7094-2016
OI Gong, Yun/0000-0003-4927-5526
FU Medical Research Council [G0700837]; NIEHS NIH HHS [ES06052]
CR Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8
   Campbell DI, 2003, J NUTR, V133, P1332
   Caulfield LE, 2004, AM J TROP MED HYG, V71, P55
   Caulfield LE, 2004, AM J CLIN NUTR, V80, P193
   CHAPOT B, 1991, TECHNIQUES DIAGNOSTI, P35
   Collinson AC, 2003, ACTA PAEDIATR, V92, P1014, DOI 10.1080/08035250310004379
   Coulombe R. A., 1994, TOXICOLOGY AFLATOXIN, P89
   de Wildt SN, 1999, CLIN PHARMACOKINET, V37, P485, DOI 10.2165/00003088-199937060-00004
   DENNING DW, 1990, CARCINOGENESIS, V11, P1033, DOI 10.1093/carcin/11.6.1033
   Doi AM, 2002, TOXICOL APPL PHARM, V181, P48, DOI 10.1006/taap.2002.9399
   DUBOWITZ LM, 1980, BRAIN DEV, V2, P2
   Gong YY, 2004, ENVIRON HEALTH PERSP, V112, P1334, DOI 10.1289/ehp.6954
   Gong YY, 2003, INT J EPIDEMIOL, V32, P556, DOI 10.1093/ije/dyg109
   Gong YY, 2002, BRIT MED J, V325, P20, DOI 10.1136/bmj.325.7354.20
   Hudson Geoffrey J., 1992, Natural Toxins, V1, P100, DOI 10.1002/nt.2620010208
   IARC International Agency for Research on Cancer Aflatoxins, 2002, IARC MON EV CARC RIS, V82, P171
   Lunn PG, 2000, P NUTR SOC, V59, P147, DOI 10.1017/S0029665100000173
   Machin D, 2004, J INTERN MED, V255, P521, DOI 10.1111/j.1365-2796.2004.01319.x
   Maxwell SM, 1998, ANN TROP PAEDIATR, V18, pS41
   Miller D.M., 1994, TOXICOLOGY AFLATOXIN, P347
   Mocchegiani E, 1998, VET IMMUNOL IMMUNOP, V62, P245, DOI 10.1016/S0165-2427(98)00073-7
   Montesano R, 1997, J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844
   Royston P, 1998, ULTRASOUND OBST GYN, V11, P30, DOI 10.1046/j.1469-0705.1998.11010030.x
   Sazawal S, 2001, PEDIATRICS, V108, P1280, DOI 10.1542/peds.108.6.1280
   Thorn M, 2005, BRIT J CLIN PHARMACO, V60, P54, DOI 10.1111/j.1365-2125.2005.02389.x
   Turner PC, 2005, LANCET, V365, P1950, DOI 10.1016/S0140-6736(05)66661-5
   Turner PC, 2003, ENVIRON HEALTH PERSP, V111, P217, DOI 10.1289/ehp.5753
   Turner PC, 2000, TROP MED INT HEALTH, V5, P837, DOI 10.1046/j.1365-3156.2000.00664.x
   Walker CF, 2004, ANNU REV NUTR, V24, P255, DOI 10.1146/annurev.nutr.23.011702.073054
   Wangikar PB, 2004, BIRTH DEFECTS RES B, V71, P343, DOI 10.1002/bdrb.20021
   Wangikar PB, 2004, BIRTH DEFECTS RES B, V71, P352, DOI 10.1002/bdrb.20022
   WILD CP, 1993, CANCER EPIDEM BIOMAR, V2, P555
   Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1<1::AID-IJC1>3.0.CO;2-I
   Wild CP, 2002, MUTAGENESIS, V17, P471, DOI 10.1093/mutage/17.6.471
   WILD CP, 1991, LANCET, V337, P1602, DOI 10.1016/0140-6736(91)93295-K
   Williams JH, 2004, AM J CLIN NUTR, V80, P1106
   Wright EM, 1999, STAT METHODS MED RES, V8, P93, DOI 10.1191/096228099672225506
   YU FL, 1988, CARCINOGENESIS, V9, P527, DOI 10.1093/carcin/9.4.527
   ZARBA A, 1992, CARCINOGENESIS, V13, P891, DOI 10.1093/carcin/13.5.891
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 40
TC 84
Z9 87
U1 4
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD OCT
PY 2007
VL 36
IS 5
BP 1119
EP 1125
DI 10.1093/ije/dym122
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 227TO
UT WOS:000250680900030
PM 17576701
OA No
DA 2017-08-15
ER

PT J
AU Burton, MJ
   Adegbola, RA
   Kinteh, F
   Ikumapayi, UN
   Foster, A
   Mabey, DCW
   Bailey, RL
AF Burton, Matthew J.
   Adegbola, Richard A.
   Kinteh, Fabakary
   Ikumapayi, Usman N.
   Foster, Allen
   Mabey, David C. W.
   Bailey, Robin L.
TI Bacterial infection and trachoma in the gambia: A case-control study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID NATURAL-HISTORY; TRICHIASIS; CONJUNCTIVITIS; SURGERY
AB PURPOSE. Trachoma is the leading infectious cause of blindness worldwide. Conjunctival scarring is initiated by recurrent Chlamydia trachomatis infection. However, disease progression to trichiasis occurs even in regions where chlamydial prevalence is currently low, which suggests that other factors, for example other bacterial infection, may also drive inflammation and scarring, particularly in the late stages of trachoma. This study was undertaken to investigate whether trachomatous trichiasis or conjunctival scarring are associated with increased prevalence of bacterial infection.
   METHODS. Within a case-control study design, individuals with trichiasis or conjunctival scarring (without trichiasis) were compared with normal matched control subjects. Subjects were examined for signs of trachoma. Conjunctival swab samples were collected for bacteriologic culture and C. trachomatis PCR.
   RESULTS. Recruited for the study were 121 trichiasis case control pairs and 117 conjunctival scarring case-control pairs. Eyes with trichiasis were more frequently infected with bacteria (37%) than were normal control eyes (7%) (OR: 8.2; P < 0.001; 95% CI: 3.24-20.8). Bacterial infection was more common with increased trichiasis severity. In the conjunctival scarring case-control group, scarred eyes had slightly more bacterial infection (11%) than did normal control eyes ( 6%), although this was not significantly different (OR: 2.2; P = 0.144; 95% CI: 0.79-6.33).
   CONCLUSIONS. Trichiasis is associated with increased risk of bacterial infection, and there may be a similar trend in eyes with conjunctival scarring. Bacterial infection of the conjunctiva is associated with inflammation, which may result in progressive scarring. Prospective studies are needed to determine the contribution of bacterial infection to disease progression. Bacterial infection probably also contributes to the development of corneal opacification.
C1 Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
   Minist Hlth, Natl Eye Care Programme, Banjul, Gambia.
RP Burton, MJ (reprint author), Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.
EM matthew.burton@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169
FU Medical Research Council [MC_U190081961]; Wellcome Trust [059134]
CR Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   AOUCHICHE M, 1969, Revue Internationale du Trachome et de Pathologie Oculaire Tropicale et Subtropicale, V46, P157
   Bowman RJC, 2002, BRIT J OPHTHALMOL, V86, P339, DOI 10.1136/bjo.86.3.339
   Bowman RJC, 2001, OPHTHALMOLOGY, V108, P2219, DOI 10.1016/S0161-6420(01)00645-5
   Burton MJ, 2006, INVEST OPHTH VIS SCI, V47, P847, DOI 10.1167/iovs.05-0714
   Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P1282, DOI 10.1136/bjo.2004.062489
   Burton MJ, 2005, BRIT J OPHTHALMOL, V89, P575, DOI 10.1136/bjo.2004.055996
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Darougar S., 1977, NONGONOCOCCAL URETHR, P186
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930
   Faal H, 2000, BRIT J OPHTHALMOL, V84, P948, DOI 10.1136/bjo.84.9.948
   FAAL H, 1989, BRIT J OPHTHALMOL, V73, P82, DOI 10.1136/bjo.73.2.82
   HARRISON RW, 1936, AM J OPTHALMOL, V19, P119
   HOWCROFT MJ, 1978, CAN J OPHTHALMOL, V13, P39
   Nabli B, 1974, Rev Int Trach, V51, P93
   REINHARD.J, 1968, B WORLD HEALTH ORGAN, V39, P497
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   TAYLOR HR, 1984, INFECT IMMUN, V44, P614
   VASTINE DW, 1974, BRIT J OPHTHALMOL, V58, P833, DOI 10.1136/bjo.58.10.833
   WOOLRIDGE RL, 1962, B WORLD HEALTH ORGAN, V26, P789
NR 21
TC 23
Z9 24
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2007
VL 48
IS 10
BP 4440
EP 4444
DI 10.1167/iovs.07-0315
PG 5
WC Ophthalmology
SC Ophthalmology
GA 214SE
UT WOS:000249757600010
PM 17898263
OA No
DA 2017-08-15
ER

PT J
AU Leligdowicz, A
   Yindom, LM
   Onyango, C
   Sarge-Njie, R
   Alabi, A
   Cotten, M
   Vincent, T
   da Costa, C
   Aaby, P
   Jaye, A
   Dong, T
   McMichael, A
   Whittle, H
   Rowland-Jones, S
AF Leligdowicz, Aleksandra
   Yindom, Louis-Marie
   Onyango, Clayton
   Sarge-Njie, Ramu
   Alabi, Abraham
   Cotten, Matthew
   Vincent, Tim
   da Costa, Carlos
   Aaby, Peter
   Jaye, Assan
   Dong, Tao
   McMichael, Andrew
   Whittle, Hilton
   Rowland-Jones, Sarah
TI Robust gag-specific T cell responses characterize viremia control in
   HIV-2 infection
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; MAJOR HOMOLOGY REGION; VIRAL LOAD;
   LYMPHOCYTE ACTIVITY; WEST-AFRICA; GAMBIAN PATIENTS; PROVIRAL LOAD;
   GUINEA-BISSAU; SUBTYPE-C; CD8(+)
AB HIV-2 infection in the majority of infected subjects follows an attenuated disease course that distinguishes it from infection with HIV-1. Antigen-specific T cells are pivotal in the management of chronic viral infections but are not sufficient to control viral replication in HIV-1-positive subjects, and their function in HIV-2 infection is not fully established. In a community-based cohort of HIV-2 long-term nonprogressors in rural Guinea-Bissau, we performed what we believe is the first comprehensive analysis of HIV-2-specific immune responses. We demonstrate that Gag is the most immunogenic protein. The magnitude of the IFN-gamma immune response to the HIV-2 proteome was inversely correlated with HIV-2 viremia, and this relationship was specifically due to the targeting of Gag. Furthermore, patients with undetectable viremia had greater Gag-specific responses compared with patients with high viral replication. The most frequently recognized peptides clustered within a defined region of Gag, and responses to a single peptide in this region were associated with low viral burden. The consistent relationship between Gag-specific immune responses and viremia control suggests that T cell responses are vital in determining the superior outcome of HIV-2 infection. A better understanding of how HIV-2 infection is controlled may identify correlates of effective protective immunity essential for the design of HIV vaccines.
C1 John Radcliffe Hosp, MRC Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
   MRC Labs, Fajara, Gambia.
   Projecto Saude Bandim, Bissau, Guinea Bissau.
RP Leligdowicz, A (reprint author), John Radcliffe Hosp, MRC Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
EM aleksandra.leligdowicz@balliol.ox.ac.uk
OI Leligdowicz, Aleksandra/0000-0001-6055-4644
FU Medical Research Council [G0600520, MC_U137884180, MC_U190085856]
CR Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003
   Andersson S, 2000, ARCH INTERN MED, V160, P3286, DOI 10.1001/archinte.160.21.3286
   ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004
   Ariyoshi K, 2000, AIDS, V14, P339, DOI 10.1097/00002030-200003100-00006
   Berry N, 1998, J Hum Virol, V1, P457
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Bertoletti A, 1998, J VIROL, V72, P2439
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   BORROW P, 1994, J VIROL, V68, P6103
   Cao JH, 2003, J VIROL, V77, P6867, DOI 10.1128/JVI.77.12.6867-6878.2003
   Chertova E, 2006, J VIROL, V80, P9039, DOI 10.1128/JVI.01013-06
   Currier JR, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-8
   Duvall MG, 2006, J IMMUNOL, V176, P6973
   Edwards BH, 2002, J VIROL, V76, P2298, DOI 10.1128/JVI.76.5.2298-2305.2002
   Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849
   Gillespie GMA, 2005, EUR J IMMUNOL, V35, P1445, DOI 10.1002/eji.200526007
   GOTCH F, 1993, J IMMUNOL, V151, P3361
   Goulder PJR, 2000, J VIROL, V74, P5679, DOI 10.1128/JVI.74.12.5679-5690.2000
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   Jaye A, 2004, J INFECT DIS, V189, P498, DOI 10.1086/381185
   Kalams SA, 1999, J VIROL, V73, P6715
   Kaufman Jay S, 2004, Epidemiol Perspect Innov, V1, P4, DOI 10.1186/1742-5573-1-4
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Lopes AR, 2003, J IMMUNOL, V171, P307
   Malhotra U, 2001, J CLIN INVEST, V107, P505, DOI 10.1172/JCI11275
   MAMMANO F, 1994, J VIROL, V68, P4927
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   Martinez-Picado J, 2006, J VIROL, V80, P3617, DOI 10.1128/JVI.80.7.3617-3623.2006
   Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004
   Melamed D, 2004, J VIROL, V78, P9675, DOI 10.1128/JVI.78.18.9675-9688.2004
   Novitsky V, 2002, J VIROL, V76, P10155, DOI 10.1128/JVI.76.20.10155-10168.2002
   Ogg GS, 1998, AIDS, V12, P1561, DOI 10.1097/00002030-199812000-00026
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   Popper SJ, 2000, J VIROL, V74, P1554, DOI 10.1128/JVI.74.3.1554-1557.2000
   POULSEN AG, 1993, J ACQ IMMUN DEF SYND, V6, P941
   Provitera P, 2001, BIOCHEMISTRY-US, V40, P5565, DOI 10.1021/bi002040l
   Ramduth D, 2005, J INFECT DIS, V192, P1588, DOI 10.1086/496894
   RINALDO C, 1995, J VIROL, V69, P5838
   Roederer M, 2003, J IMMUNOL METHODS, V274, P221, DOI 10.1016/S0022-1759(02)00423-4
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   Sacha JB, 2007, J IMMUNOL, V178, P2746
   Sarr AD, 2001, AIDS RES HUM RETROV, V17, P1257, DOI 10.1089/088922201750461311
   TSOMIDES TJ, 1994, J EXP MED, V180, P1283, DOI 10.1084/jem.180.4.1283
   WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
   Yu XG, 2002, J VIROL, V76, P8690, DOI 10.1128/JVI.76.17.8690-8701.2002
   Zheng NN, 2004, J VIROL, V78, P13934, DOI 10.1128/JVI.78.24.13934-13942.2004
NR 48
TC 51
Z9 55
U1 0
U2 1
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD OCT
PY 2007
VL 117
IS 10
BP 3067
EP 3074
DI 10.1172/JCI32380
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 216QP
UT WOS:000249894400037
PM 17823657
OA No
DA 2017-08-15
ER

PT J
AU Coulibaly, MB
   Pombi, M
   Caputo, B
   Nwakanma, D
   Jawara, M
   Konate, L
   Dia, I
   Fofana, A
   Kern, M
   Simard, F
   Conway, DJ
   Petrarca, V
   della Torre, A
   Traore, S
   Besansky, NJ
AF Coulibaly, Mamadou B.
   Pombi, Marco
   Caputo, Beniamino
   Nwakanma, Davis
   Jawara, Musa
   Konate, Lassana
   Dia, Ibrahima
   Fofana, Abdrahamane
   Kern, Marcia
   Simard, Frederic
   Conway, David J.
   Petrarca, Vincenzo
   della Torre, Alessandra
   Traore, Sekou
   Besansky, Nora J.
TI PCR-based karyotyping of Anopheles gambiae inversion 2Rj identifies the
   BAMAKO chromosomal form
SO MALARIA JOURNAL
LA English
DT Article
ID INCIPIENT SPECIATION; MOLECULAR-FORMS; GENETIC DIFFERENTIATION; COMPLEX;
   S.S.
AB Background: The malaria vector Anopheles gambiae is polymorphic for chromosomal inversions on the right arm of chromosome 2 that segregate nonrandomly between assortatively mating populations in West Africa. One such inversion, 2Rj, is associated with the BAMAKO chromosomal form endemic to southern Mali and northern Guinea Conakry near the Niger River. Although it exploits a unique ecology and both molecular and chromosomal data suggest reduced gene flow between BAMAKO and other A. gambiae populations, no molecular markers exist to identify this form.
   Methods: To facilitate study of the BAMAKO form, a PCR assay for molecular karyotyping of 2Rj was developed based on sequences at the breakpoint junctions. The assay was extensively validated using more than 700 field specimens whose karyotypes were determined in parallel by cytogenetic and molecular methods. As inversion 2Rj also occurs in SAVANNA populations outside the geographic range of BAMAKO, samples were tested from Senegal, Cameroon and western Guinea Conakry as well as from Mali.
   Results: In southern Mali, where 2Rj polymorphism in SAVANNA populations was very low and most of the 2Rj homozygotes were found in BAMAKO karyotypes, the molecular and cytogenetic methods were almost perfectly congruent. Elsewhere agreement between the methods was much poorer, as the molecular assay frequently misclassified 2Rj heterozygotes as 2R(+j) standard homozygotes.
   Conclusion: Molecular karyotyping of 2Rj is robust and accurate on 2R(+j) standard and 2Rj inverted homozygotes. Therefore, the proposed approach overcomes the lack of a rapid tool for identifying the BAMAKO form across developmental stages and sexes, and opens new perspectives for the study of BAMAKO ecology and behaviour. On the other hand, the method should not be applied for molecular karyotyping of j-carriers within the SAVANNA chromosomal form.
C1 [Coulibaly, Mamadou B.; Kern, Marcia; Besansky, Nora J.] Univ Notre Dame, Dept Biol Sci, Ctr Global Hlth & Infect Dis, Notre Dame, IN 46556 USA.
   [Coulibaly, Mamadou B.; Fofana, Abdrahamane; Traore, Sekou] Univ Bamako, Malaria Res & Training Ctr, Bamako, Mali.
   [Pombi, Marco; Caputo, Beniamino; Petrarca, Vincenzo; della Torre, Alessandra] Univ Roma La Sapienza, Ist Pasteur Fdn Cenci Bolognetti, Rome, Italy.
   [Coulibaly, Mamadou B.; Fofana, Abdrahamane; Traore, Sekou] Univ Roma La Sapienza, Dipartimento Sci Sanita Pubbl, Rome, Italy.
   [Nwakanma, Davis; Jawara, Musa; Conway, David J.] MRC Labs, Banjul, Gambia.
   [Konate, Lassana] Univ Dakar, Fac Tech Sci, Dept Biol Anim, Dakar, Senegal.
   [Dia, Ibrahima] Inst Pasteur, Med Entomol Unit, Dakar, Senegal.
   [Simard, Frederic] Org Coordinat Lutte Endemies Afr Cent, Yaounde, Cameroon.
   [Simard, Frederic] Inst Rech Dev, Unite Rech 016, Yaounde, Cameroon.
   [Petrarca, Vincenzo] Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, I-00185 Rome, Italy.
RP Besansky, NJ (reprint author), Univ Notre Dame, Dept Biol Sci, Ctr Global Hlth & Infect Dis, Notre Dame, IN 46556 USA.
EM coulibaly7@gmail.com; marco.pombi@uniroma1.it;
   beniamino.caputo@uniroma1.it; dnwakanma@mrc.gm; mjawara@mrc.gm;
   konatela@yahoo.fr; dia@pasteur.sn; afofana@mrtcbko.org; mkern@nd.edu;
   Frederic.Simard@ird.fr; dconway@mrc.gm; vincenzo.petrarca@uniroma1.it;
   alessandra.dellatorre@uniroma1.it; cheick@mrtcbko.org; nbesansk@nd.edu
RI Caputo, Beniamino/I-2880-2015; SIMARD, Frederic/J-9489-2016
OI Caputo, Beniamino/0000-0002-5650-8773; SIMARD,
   Frederic/0000-0002-2871-5329; Pombi, Marco/0000-0002-4382-9922; Conway,
   David/0000-0002-8711-3037
FU NIAID NIH HHS [R01 AI63508, R01 AI063508]
CR CAPUTO B, POPULATIONS ANOPHELS
   COLUZZI M, 1985, B ZOOL, V52, P45
   Coluzzi M, 2002, SCIENCE, V298, P1415, DOI 10.1126/science.1077769
   COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1
   Coulibaly MB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000849
   della Torre A, 2001, INSECT MOL BIOL, V10, P9, DOI 10.1046/j.1365-2583.2001.00235.x
   della Torre A, 2002, SCIENCE, V298, P115, DOI 10.1126/science.1078170
   della Torre A, 2005, INSECT BIOCHEM MOLEC, V35, P755, DOI 10.1016/j.ibmb.2005.02.006
   Fanello C, 2003, INSECT MOL BIOL, V12, P241, DOI 10.1046/j.1365-2583.2003.00407.x
   Fanello C, 2002, MED VET ENTOMOL, V16, P461, DOI 10.1046/j.1365-2915.2002.00393.x
   Favia G, 1997, INSECT MOL BIOL, V6, P377, DOI 10.1046/j.1365-2583.1997.00189.x
   Lehmann T, 1996, GENETICS, V144, P1155
   PETRARCA V, 1983, Parassitologia (Rome), V25, P29
   POMBI M, MACROGEOGRAPHIC PATT
   Rozeu S., 2000, BIOINFORMATICS METHO, P365, DOI DOI 10.1385/1-59259-192-2:365
   Santolamazza F, 2004, AM J TROP MED HYG, V70, P604
   Slotman MA, 2006, AM J TROP MED HYG, V74, P641
   Stump AD, 2005, GENETICS, V169, P1509, DOI 10.1534/genctics.104.035303
   Torre A. della, 1997, The molecular biology of insect disease vectors: a methods manual., P329
   Toure Y. T., 1998, Parassitologia (Rome), V40, P477
   TOURE YT, 1985, THESIS U DROIT MARSE
NR 21
TC 11
Z9 11
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD OCT 1
PY 2007
VL 6
AR 133
DI 10.1186/1475-2875-6-133
PG 8
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 243SM
UT WOS:000251817600001
PM 17908310
OA gold
DA 2017-08-15
ER

PT J
AU Munafo, MR
   Elliot, KM
   Murphy, MFG
   Walton, RT
   Johnstone, EC
AF Munafo, M. R.
   Elliot, K. M.
   Murphy, M. F. G.
   Walton, R. T.
   Johnstone, E. C.
TI Association of the mu-opioid receptor gene with smoking cessation
SO PHARMACOGENOMICS JOURNAL
LA English
DT Article
DE smoking cessation; genotype; OPRM1; sex differences; weight gain; body
   mass index
ID NICOTINE REPLACEMENT THERAPY; BETA-ENDORPHIN; WEIGHT-GAIN;
   SEX-DIFFERENCES; WITHDRAWAL SYMPTOMS; APPETITE REGULATION;
   GENDER-DIFFERENCES; RANDOMIZED-TRIAL; DEFICIENT MICE; CLINICAL-TRIAL
AB We investigated the association of the OPRM1 genotype with long-term smoking cessation and change in body mass index (BMI) following a smoking cessation attempt among smokers who attempted to quit using the nicotine replacement therapy (NRT) patch or placebo in a randomized controlled trial, and were followed-up over an 8-year period following their initial cessation attempt. We also investigated possible sex differences in these relationships, given evidence for sex differences in smoking cessation and central opioid mechanisms, as well as some evidence for sex differences in response to NRT. Our results indicate that OPRM1 genotype may moderate the effect of transdermal nicotine patch compared to placebo during active treatment, with a benefit of active NRT treatment evident in the OPRM1 AA genotype group only and those carrying one or more copies of the G allele demonstrating no benefit of active NRT versus placebo patch. Our results also indicate a sex difference in change in BMI at 8-year follow-up following a smoking cessation attempt, with ex-smokers demonstrating an increase in BMI, and this increase being greater in female subjects than in male subjects. We did not observe any association of OPRM1 genotype with change in BMI, although there was a trend for genotype to influence the observed sex difference in change in BMI over time. Future studies should attempt to replicate these findings, and investigate the relationship between both short-and long-term weight gain and smoking cessation and investigate possible mechanisms that may underlie these processes. Future studies should also investigate the role of OPRM1 genotype and smoking cessation on other appetitive and reward behaviours such as alcohol consumption.
C1 Univ Bristol, Dept Expt Psychol, Bristol BS8 1TU, Avon, England.
   Univ Oxford, Dept Clin Pharmacol, Oxford, England.
   Univ Oxford, Childrens Canc Res Grp, Oxford, England.
   MRC Labs, Banjul, Gambia.
RP Munafo, MR (reprint author), Univ Bristol, Dept Expt Psychol, 12 A Priory Rd, Bristol BS8 1TU, Avon, England.
EM marcus.munafo@bristol.ac.uk
OI Munafo, Marcus/0000-0002-4049-993X
CR Appleyard SM, 2003, ENDOCRINOLOGY, V144, P1753, DOI 10.1210/en.2002-221096
   Becker A, 2002, N-S ARCH PHARMACOL, V365, P296, DOI 10.1007/s00210-002-0533-2
   Befort K, 2001, J BIOL CHEM, V276, P3130, DOI 10.1074/jbc.M006352200
   Berrendero F, 2002, J NEUROSCI, V22, P10935
   Beyer A, 2004, J NEUROCHEM, V89, P553, DOI 10.1111/j.1471-4159.2004.02340.x
   Bohadana A, 2003, NICOTINE TOB RES, V5, P111, DOI 10.1080/1462220021000060482
   Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608
   Boyadjieva NI, 1997, LIFE SCI, V61, pPL59
   BURKE P, 1993, BRIT MED J, V306, P1304
   Cicero TJ, 2003, PHARMACOL BIOCHEM BE, V74, P541, DOI 10.1016/S0091-3057(02)01039-0
   Clark MM, 2006, ADDICT BEHAV, V31, P1144, DOI 10.1016/j.addbeh.2005.08.011
   Contarino A, 2002, EUR J PHARMACOL, V446, P103, DOI 10.1016/S0014-2999(02)01812-5
   Craft RM, 1996, BEHAV PHARMACOL, V7, P764
   DAVENPORT KE, 1990, NEUROSCI LETT, V113, P40, DOI 10.1016/0304-3940(90)90491-Q
   DILTS RP, 1989, BRAIN RES, V488, P311, DOI 10.1016/0006-8993(89)90723-3
   Doll R, 2004, BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE
   Filozof C, 2004, Obes Rev, V5, P95, DOI 10.1111/j.1467-789X.2004.00131.x
   Fox CS, 2004, DIABETES, V53, P1399, DOI 10.2337/diabetes.53.5.1399
   Gianoulakis C, 2001, J PSYCHIATR NEUROSCI, V26, P304
   GRUNBERG NE, 1986, PSYCHOPHARMACOLOGY, V90, P101
   GRUNBERG NE, 1986, PSYCHOPHARMACOL BULL, V22, P875
   Hall FS, 2004, MOL BRAIN RES, V121, P123, DOI 10.1016/j.molbrainres.2003.10.024
   Hall FS, 2001, PSYCHOPHARMACOLOGY, V154, P43, DOI 10.1007/s002130000622
   Hall S M, 1986, NIDA Res Monogr, V72, P118
   HATSUKAMI DK, 1984, PSYCHOPHARMACOLOGY, V84, P231, DOI 10.1007/BF00427451
   Hughes JR, 2003, J GEN INTERN MED, V18, P1053, DOI 10.1111/j.1525-1497.2003.20640.x
   John U, 2006, AM J ADDICTION, V15, P192, DOI 10.1080/10550490500528738
   JOHNSON SW, 1992, J NEUROSCI, V12, P483
   Johnstone EC, 2004, PHARMACOGENETICS, V14, P83, DOI 10.1097/01.fpc.0000054154.92680.6d
   KELLEY AE, 1980, BEHAV BRAIN RES, V1, P3, DOI 10.1016/S0166-4328(80)80047-7
   Lee FJS, 2005, J MOL NEUROSCI, V26, P245, DOI 10.1385/JMN/26:02:245
   Lerman C, 2004, PHARMACOGENOMICS J, V4, P184, DOI 10.1038/sj.tpj.6500238
   Lerman C, 2006, NEUROPSYCHOPHARMACOL, V31, P231
   Low MJ, 2003, ANN NY ACAD SCI, V994, P192
   Lynch WJ, 1999, PSYCHOPHARMACOLOGY, V144, P77, DOI 10.1007/s002130050979
   MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8
   Mayer P, 2006, PHARMACOGENET GENOM, V16, P1
   Micevych PE, 2003, J NEUROSCI RES, V71, P802, DOI 10.1002/jnr.10526
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mills RH, 2004, J NEUROSCI, V24, P947, DOI 10.1523/JNEUROSCI.1366-03.2004
   Miyata G, 1999, SURGERY, V126, P255, DOI 10.1016/S0039-6060(99)70163-7
   Munafo M, 2004, NICOTINE TOB RES, V6, P769, DOI 10.1080/1462200410001696556
   Munafo MR, 2006, AM J MED GENET B, V141B, P398, DOI 10.1002/ajmg.b.30289
   Munafo MR, 2006, CANCER EPIDEM BIOMAR, V15, P398, DOI 10.1158/1055-9965.EPI-05-0648
   Munafo MR, 2005, CURR OPIN MOL THER, V7, P202
   Munafo MR, 2005, PHARMACOGENOMICS, V6, P211, DOI 10.1517/14622416.6.3.211
   Munafo MR, 2004, NICOTINE TOB RES, V6, P583, DOI 10.1080/14622200410001734030
   PASTOR R, 2005, NEUROPSYCHOPHARMACOL, V31, P1489
   Perkins K A, 1999, Nicotine Tob Res, V1, P301, DOI 10.1080/14622299050011431
   Perkins K A, 1990, J Subst Abuse, V2, P287
   Ray LA, 2004, ALCOHOL CLIN EXP RES, V28, P1789, DOI 10.1097/01.ALC.0000148114/34000.B9
   Ray R, 2006, PSYCHOPHARMACOLOGY, V188, P355, DOI 10.1007/s00213-006-0504-2
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   SAMET JM, 1990, AM REV RESPIR DIS, V142, P993
   SPRING B, 1991, HEALTH PSYCHOL, V10, P216, DOI 10.1037/0278-6133.10.3.216
   Sullivan PF, 2004, AM J MED GENET B, V126B, P23, DOI 10.1002/ajmg.b.20138
   SWAN GE, 1995, AM J PUBLIC HEALTH, V85, P73, DOI 10.2105/AJPH.85.1.73
   Wewers ME, 1999, BRAIN RES, V822, P107, DOI 10.1016/S0006-8993(99)01095-1
   WILLIAMSON DF, 1991, NEW ENGL J MED, V324, P739, DOI 10.1056/NEJM199103143241106
   Xi ZX, 2002, ALCOHOL ALCOHOLISM, V37, P485, DOI 10.1093/alcalc/37.5.485
   Yudkin P, 2004, BRIT MED J, V328, P989, DOI 10.1136/bmj.38050.674826.AE
   Zhang HP, 2006, HUM MOL GENET, V15, P807, DOI 10.1093/hmg/ddl024
   Zhang Lan, 2006, Behav Brain Funct, V2, P28, DOI 10.1186/1744-9081-2-28
   Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200
   Zubieta JK, 1999, AM J PSYCHIAT, V156, P842
NR 65
TC 48
Z9 48
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1470-269X
J9 PHARMACOGENOMICS J
JI Pharmacogenomics J.
PD OCT
PY 2007
VL 7
IS 5
BP 353
EP 361
DI 10.1038/sj.tpj.6500432
PG 9
WC Genetics & Heredity; Pharmacology & Pharmacy
SC Genetics & Heredity; Pharmacology & Pharmacy
GA 216GN
UT WOS:000249866600010
PM 17224915
OA No
DA 2017-08-15
ER

PT J
AU Darboe, MK
   Fulford, TJ
   Doherty, CP
   Morgan, G
   Prentice, AM
AF Darboe, Momodou K.
   Fulford, Tony J.
   Doherty, Conor P.
   Morgan, Gareth
   Prentice, Andrew M.
TI Early supplementation with high-dose vitamin A in The Gambia - Reply
SO LANCET
LA English
DT Letter
C1 MRC, Keneba, Gambia.
   Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   Univ Glasgow, Glasgow, Lanark, Scotland.
   Univ Coll Swansea, Sch Med, Swansea, W Glam, Wales.
RP Prentice, AM (reprint author), MRC, Keneba, Gambia.
EM andrew.prentice@lshtm.ac.uk
CR Benn CS, 2007, VACCINE, V25, P777, DOI 10.1016/j.vaccine.2006.09.044
   Benn CS, 2003, INT J EPIDEMIOL, V32, P822, DOI 10.1093/ije/dyg208
NR 2
TC 0
Z9 0
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD SEP 22
PY 2007
VL 370
IS 9592
BP 1030
EP 1031
DI 10.1016/S0140-6736(07)61469-X
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 214HJ
UT WOS:000249727900019
OA No
DA 2017-08-15
ER

PT J
AU Olesen, R
   Wejse, C
   Velez, DR
   Bisseye, C
   Sodemann, M
   Aaby, P
   Rabna, P
   Worwui, A
   Chapman, H
   Diatta, M
   Adegbola, R
   Hill, P
   Ostergaard, L
   Williams, SM
   Sirugo, G
AF Olesen, R.
   Wejse, C.
   Velez, D. R.
   Bisseye, C.
   Sodemann, M.
   Aaby, P.
   Rabna, P.
   Worwui, A.
   Chapman, H.
   Diatta, M.
   Adegbola, Ra
   Hill, Pc
   Ostergaard, L.
   Williams, S. M.
   Sirugo, G.
TI DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants
   associate with pulmonary tuberculosis risk in West Africans
SO GENES AND IMMUNITY
LA English
DT Article
DE tuberculosis; genetic susceptibility; DC-SIGN; pentraxin 3; vitamin D
   receptor; epistasis
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; TOLL-LIKE RECEPTORS; WALL COMPONENT
   LIPOARABINOMANNAN; HUMAN DENDRITIC CELLS; MYCOBACTERIUM-TUBERCULOSIS;
   SUSCEPTIBILITY; DISEASE; EXPRESSION; HYPERTENSION; INFLAMMATION
AB We investigated the role of DC-SIGN ( CD209), long pentraxin 3 ( PTX3) and vitamin D receptor ( VDR) gene single nucleotide polymorphisms ( SNPs) in susceptibility to pulmonary tuberculosis ( TB) in 321 TB cases and 347 healthy controls from Guinea-Bissau. Five additional, functionally relevant SNPs within toll-like receptors ( TLRs) 2, 4 and 9 were typed but found, when polymorphic, not to affect host vulnerability to pulmonary TB. We did not replicate an association between SNPs in the DC-SIGN promoter and TB. However, we found that two polymorphisms, one in DC-SIGN and one in VDR, were associated in a nonadditive model with disease risk when analyzed in combination with ethnicity ( P = 0.03 for DC- SIGN and P = 0.003 for VDR). In addition, PTX3 haplotype frequencies significantly differed in cases compared to controls and a protective effect was found in association with a specific haplotype ( OR 0.78, 95% Cl 0.63-0.98). Our findings support previous data showing that VDR SNPs modulate the risk for TB in West Africans and suggest that variation within DC- SIGN and PTX3 also affect the disease outcome.
C1 MRC Labs, Banjul, Gambia.
   Aarhus Univ Hosp, Dept Infect Dis, Skejby, Denmark.
   Danish Epidemiol Sci Ctr, Bandin Hlth Project, Bissau, Guinea Bissau.
   State Serum Inst, Bissau, Guinea Bissau.
   Vanderbilt Univ, Dept Cardiovasc Med, Ctr Human Genet Res, Nashville, TN USA.
RP Sirugo, G (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM gsirugo@mrc.gm
RI Williams, Scott/B-9491-2012; Velez Edwards, Digna/C-1090-2012; Wejse,
   Christian/C-8468-2014
OI Wejse, Christian/0000-0002-2534-2942; Olesen, Rikke/0000-0002-5157-080X
FU Medical Research Council [MC_U190071468]
CR AABY P, 1983, J INFECT DIS, V147, P693
   Abel B, 2002, J IMMUNOL, V169, P3155
   Arbour NC, 2000, NAT GENET, V25, P187
   Azzurri A, 2005, MICROBES INFECT, V7, P1, DOI 10.1016/j.micinf.2004.09.004
   Bafica A, 2005, J EXP MED, V202, P1715, DOI 10.1081/jem.20051782
   BARREIRO LB, 2006, PLOS MED, V3, DOI UNSP 0230-0235
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Ben-Ali M, 2004, CLIN DIAGN LAB IMMUN, V11, P625, DOI 10.1128/CDLI.11.3.625-626.2004
   Bornman L, 2004, J INFECT DIS, V190, P1631, DOI 10.1086/424462
   Brassat D, 2006, GENES IMMUN, V7, P310, DOI 10.1038/sj.gene.6364299
   Cho YM, 2004, DIABETOLOGIA, V47, P549, DOI 10.1007/s00125-003-1321-3
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009
   Ducati RG, 2006, MEM I OSWALDO CRUZ, V101, P697, DOI 10.1590/S0074-02762006000700001
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756
   Gomez LM, 2006, HUM IMMUNOL, V67, P808, DOI 10.1016/j.humimm.2006.07.003
   Gustafson P, 2004, INT J EPIDEMIOL, V33, P163, DOI 10.1093/ije/dyh026
   Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869
   HARRIES A, 2004, TB HIV CLIN MANUAL, P105
   Hill AVS, 2006, ANNU REV GENET, V40, P469, DOI 10.1146/annurev.genet.40.110405.090546
   JAKULIN A, 2003, 7 EUR C PRINC PRACT, P229
   JAKULIN A, 2003, 9 C ART INT MED EUR, P229
   Lazarus R, 2003, GENOMICS, V81, P85, DOI 10.1016/S0888-7543(02)00022-8
   Liu KJ, 2005, BIOINFORMATICS, V21, P2128, DOI 10.1093/bioinformatics/bti282
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
   Means TK, 1999, J IMMUNOL, V163, P3920
   Means TK, 2001, J IMMUNOL, V166, P4074
   Moore JH, 2006, J THEOR BIOL, V241, P252, DOI 10.1016/j.jtbi.2005.11.036
   Newport MJ, 2004, TUBERCULOSIS, V84, P347, DOI 10.1016/j.tube.2004.02.001
   Ogus AC, 2004, EUR RESPIR J, V23, P219, DOI 10.1183/09031936.03.00061703
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Sakuntabhai A, 2005, NAT GENET, V37, P507, DOI 10.1038/ng1550
   Sanada H, 2006, CLIN CHEM, V52, P352, DOI 10.1373/clinchem.2005.059139
   Schroder NW, 2005, LANCET INFECT DIS, V5, P156, DOI 10.1016/S1473-3099(05)70023-2
   Sirugo G, 2004, NAT GENET, V36, P785, DOI 10.1038/ng0804-785
   Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468
   Tsai CT, 2004, CIRCULATION, V109, P1640, DOI 10.1161/01.CIR.0000124487.36586.26
   Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000
   Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459
   Vouret-Craviari V, 1997, CYTOKINE, V9, P992, DOI 10.1006/cyto.1997.0242
   VouretCraviari V, 1997, INFECT IMMUN, V65, P1345
   Williams SM, 2004, HUM HERED, V57, P28, DOI 10.1159/000077387
   Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986
NR 44
TC 108
Z9 112
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD SEP
PY 2007
VL 8
IS 6
BP 456
EP 467
DI 10.1038/sj.gene.6364410
PG 12
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 207UT
UT WOS:000249277300002
PM 17611589
OA No
DA 2017-08-15
ER

PT J
AU Howie, SRC
   Antonio, M
   Akisanya, A
   Sambou, S
   Hakeem, I
   Secka, O
   Adegbola, RA
AF Howie, Stephen R. C.
   Antonio, Martin
   Akisanya, Abiodun
   Sambou, Sana
   Hakeem, Ishrat
   Secka, Ousman
   Adegbola, Richard A.
TI Re-emergence of Haemophilus influenzae type b (Hib) disease in The
   Gambia following successful elimination with conjugate Hib vaccine
SO VACCINE
LA English
DT Article
DE Hib vaccination; Hib disease; surveillance
ID FIELD GEL-ELECTROPHORESIS
AB Invasive Hib disease, which remains a major cause of childhood mortality and morbidity in most of the developing world, was eliminated in The Gambia by 2002 following the introduction of conjugate Hib vaccine in 1997. Formal disease surveillance was stopped in 2002 but five cases (including three of meningitis) were detected non-systematically between July 2005 and April 2006. This equates to an incidence of 3 per 100,000 annually for meningitis, a likely underestimate. The age distribution of cases (median 15 months, range 0-36 months) was older than previously seen and there were examples of apparent vaccine failure, but the cause for this re-emergence is not clear. No evidence was found of the emergence of a hypervirulent strain. The re-establishment of continuing surveillance is required to answer the questions raised by this report, and is particularly important in settings like The Gambia, where a booster dose is not given, to determine long-term effects of national immunisation with Hib vaccine. (c) 2007 Elsevier Ltd. All rights reserved.
C1 MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   Dept State Hlth & Social Welfare, Banjul, Gambia.
RP Howie, SRC (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM showie@mrc.gm; radegbola@mrc.gm
FU Medical Research Council [MC_U190074190, MC_U190081991, MC_U190088478]
CR Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   FALLA TJ, 1994, J CLIN MICROBIOL, V32, P2382
   Meats E, 2003, J CLIN MICROBIOL, V41, P1623, DOI 10.1128/JCM.41.4.1623-1636.2003
   Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7
   Peltola H, 2000, CLIN MICROBIOL REV, V13, P302, DOI 10.1128/CMR.13.2.302-317.2000
   Ramsay ME, 2003, J INFECT DIS, V188, P481, DOI 10.1086/376997
   Rijkers GT, 2003, LANCET, V361, P1563, DOI 10.1016/S0140-6736(03)13201-1
   Saito M, 1999, J CLIN MICROBIOL, V37, P2142
   SWINGLER G, COCHRANE DB SYST REV, DOI DOI 10.1002/114651858.CD0011729
   TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233
   Trotter C L, 2003, Commun Dis Public Health, V6, P55
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   World Health Organization, 2006, WKLY EPIDEMIOL REC, V81, P445
NR 13
TC 26
Z9 26
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 21
PY 2007
VL 25
IS 34
BP 6305
EP 6309
DI 10.1016/j.vaccine.2007.06.023
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 203DJ
UT WOS:000248955000003
PM 17630053
OA No
DA 2017-08-15
ER

PT J
AU Howie, S
AF Howie, Stephen
TI Conduct of clinical trials in developing countries
SO LANCET
LA English
DT Letter
C1 MRC Labs, Banjul, Gambia.
RP Howie, S (reprint author), MRC Labs, Banjul, Gambia.
EM showie@mrc.gm
CR Epstein M, 2007, LANCET, V369, P1859, DOI 10.1016/S0140-6736(07)60846-0
   Hoey R, 2007, LANCET, V369, P1777, DOI 10.1016/S0140-6736(07)60797-1
   Lancet, 2007, LANCET, V369, P1233
NR 3
TC 0
Z9 0
U1 0
U2 0
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD AUG 18
PY 2007
VL 370
IS 9587
BP 562
EP 562
DI 10.1016/S0140-6736(07)61284-7
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 201HA
UT WOS:000248820900018
PM 17707742
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   Waight, PA
   Mendy, M
   Zaman, S
   Kaye, S
   Sam, O
   Kahn, A
   Jeffries, D
   Akum, AA
   Hall, AJ
   Bah, E
   McConkey, SJ
   Hainaut, P
   Whittle, HC
AF van der Sande, Marianne A. B.
   Waight, Pauline A.
   Mendy, Maimuna
   Zaman, Syed
   Kaye, Steve
   Sam, Omar
   Kahn, Abi
   Jeffries, David
   Akum, Aveika A.
   Hall, Andrew J.
   Bah, Ebrima
   McConkey, Samuel J.
   Hainaut, Pierre
   Whittle, Hilton C.
TI Long-term protection against HBV chronic carriage of Gambian adolescents
   vaccinated in infancy and immune response in HBV booster trial in
   adolescence
SO PLOS CLINICAL TRIALS
LA English
DT Article
ID HEPATITIS-B-VACCINE; YOUNG-ADULTS; RECOMBINANT; ANTIBODY;
   IMMUNOGENICITY; REGIMEN; MEMORY; 2-DOSE; CHILDREN
AB Background. Chronic infection with hepatitis B virus (HBV) arising in childhood is associated with hepatocellular carcinoma in adult life. Between 1986 and 1990, approximately 120,000 Gambian newborns were enrolled in a randomised controlled trial to assess the effectiveness of infant HBV vaccination on the prevention of hepatocellular carcinoma in adulthood. These children are now in adolescence and approaching adulthood, when the onset of sexual activity may challenge their hepatitis B immunity. Thus a booster dose in adolescence could be important to maintain long-term protection. Methods. Fifteen years after the start of the HBV infant vaccination study, 492 vaccinated and 424 unvaccinated children were identified to determine vaccine efficacy against infection and carriage in adolescence. At the same time, 297 of the 492 infant-vaccinated subjects were randomly offered a booster dose of HBV vaccine. Anti-HBs was measured before the booster, and two weeks and 1 year afterwards (ISRCTN71271385). Results. Vaccine efficacy 15 years after vaccination was 67.0% against infection as manifest by anti-HBc positivity (95% CI 58.2-74.6%), and 96.6% against HBsAg carriage (95% CI 91.5-100%). 31.2% of participants had detectable anti-HBs with a GMC of 32 IU/l. For 168 boosted participants GMC anti-HBs responses were 38 IU/l prior to vaccination, 524 IU/l two weeks after boosting, and 101 IU/l after 1 year. Conclusions. HBV vaccination in infants confers very good protection against carriage up to 15 years of age, although a large proportion of vaccinated subjects did not have detectable anti-HBs at this age. The response to boosting persisted for at least a year. Trial Registration. Controlled-Trials.com ISRCTN71271385.
C1 [van der Sande, Marianne A. B.; Waight, Pauline A.; Mendy, Maimuna; Zaman, Syed; Kaye, Steve; Jeffries, David; Akum, Aveika A.; McConkey, Samuel J.; Whittle, Hilton C.] MRC Labs, Fajara, Gambia.
   [Mendy, Maimuna; Bah, Ebrima; Hainaut, Pierre] Int Agcy Res Canc, Gambia Hepatitis Intervent Study, F-69372 Lyon, France.
   [Kahn, Abi] Dept Stat Hlth, Banjul, Gambia.
   [Hall, Andrew J.] London Sch Hyg & Trop Med, London WC1, England.
RP van der Sande, MAB (reprint author), Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands.
EM Marianne.van.der.sande@rivm.nl
RI McConkey, Samuel/E-7307-2012; Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
CR Akram DS, 2005, VACCINE, V23, P5792, DOI 10.1016/j.vaccine.2005.06.013
   Banatvala J, 2000, LANCET, V355, P561
   Banatvala J, 2000, VACCINE, V19, P877, DOI 10.1016/S0264-410X(00)00224-3
   Bulkow LR, 1998, CLIN INFECT DIS, V26, P933, DOI 10.1086/513939
   Cassidy WM, 2001, PEDIATRICS, V107, P626, DOI 10.1542/peds.107.4.626
   COURSAGET P, 1994, J HEPATOL, V21, P20
   Gambia Hepatitis Study Group, 1987, CANCER RES, V47, P5782
   Gellin BG, 1997, J INFECT DIS, V175, P1494
   Heron LG, 2002, VACCINE, V20, P3472, DOI 10.1016/S0264-410X(02)00346-8
   Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
   JILG W, 1988, J MED VIROL, V24, P377, DOI 10.1002/jmv.1890240404
   Lavanchy D, 2005, J CLIN VIROL, V34, pS1, DOI 10.1016/S1386-6532(05)00384-7
   Levie K, 2002, SCAND J INFECT DIS, V34, P610, DOI 10.1080/00365540110080881
   Liao SS, 1999, VACCINE, V17, P2661, DOI 10.1016/S0264-410X(99)00031-6
   Marsano LS, 1998, VACCINE, V16, P624, DOI 10.1016/S0264-410X(97)00233-8
   van der Sande MAB, 2006, J INFECT DIS, V193, P1528
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4
   WHITTLE HC, 2004, BMJ-BRIT MED J, V325, P569
   Williams IT, 2003, PEDIATR INFECT DIS J, V22, P157
   Wistrom J, 1999, VACCINE, V17, P2162, DOI 10.1016/S0264-410X(99)00012-2
NR 21
TC 4
Z9 4
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1555-5887
J9 PLOS CLIN TRIALS
JI PLos Clin. Trials
PD AUG 15
PY 2007
VL 2
IS 8
AR e753
DI 10.1371/journal.pone.0000753
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 248EL
UT WOS:000252134600001
OA gold
DA 2017-08-15
ER

PT J
AU Hanchard, N
   Elzein, A
   Trafford, C
   Rockett, K
   Pinder, M
   Jallow, M
   Harding, R
   Kwiatkowski, D
   McKenzie, C
AF Hanchard, Neil
   Elzein, Abier
   Trafford, Clare
   Rockett, Kirk
   Pinder, Margaret
   Jallow, Muminatou
   Harding, Rosalind
   Kwiatkowski, Dominic
   McKenzie, Colin
TI Classical sickle beta-globin haplotypes exhibit a high degree of
   long-range haplotype similarity in African and Afro-Caribbean
   populations
SO BMC GENETICS
LA English
DT Article
ID GENE-CLUSTER; CELL-ANEMIA; HUMAN GENOME; ORIGIN; MALARIA;
   RECONSTRUCTION; SELECTION; MUTATION; DISEASE; LOCUS
AB Background: The sickle (beta(s)) mutation in the beta- globin gene ( HBB) occurs on five " classical" beta(s) haplotype backgrounds in ethnic groups of African ancestry. Strong selection in favour of the beta(s) allele - a consequence of protection from severe malarial infection afforded by heterozygotes - has been associated with a high degree of extended haplotype similarity. The relationship between classical beta(s) haplotypes and long- range haplotype similarity may have both anthropological and clinical implications, but to date has not been explored. Here we evaluate the haplotype similarity of classical beta(s) haplotypes over 400 kb in population samples from Jamaica, The Gambia, and among the Yoruba of Nigeria ( Hapmap YRI).
   Results: The most common beta(s) sub- haplotype among Jamaicans and the Yoruba was the Benin haplotype, while in The Gambia the Senegal haplotype was observed most commonly. Both subtypes exhibited a high degree of long- range haplotype similarity extending across approximately 400 kb in all three populations. This long- range similarity was significantly greater than that seen for other haplotypes sampled in these populations ( P < 0.001), and was independent of marker choice and marker density. Among the Yoruba, Benin haplotypes were highly conserved, with very strong linkage disequilibrium ( LD) extending a megabase across the beta(s) mutation.
   Conclusion: Two different classical beta(s) haplotypes, sampled from different populations, exhibit comparable and extensive long- range haplotype similarity and strong LD. This LD extends across the adjacent recombination hotspot, and is discernable at distances in excess of 400 kb. Although the multicentric geographic distribution of beta(s) haplotypes indicates strong subdivision among early Holocene subSaharan populations, we find no evidence that selective pressures imposed by falciparum malaria varied in intensity or timing between these subpopulations. Our observations also suggest that cis- acting loci, which may influence outcomes in sickle cell disease, could lie considerable distances away from beta globin.
C1 Univ W Indies, Res Inst Trop Med, Trop Metab Res Unit, Kingston 7, Jamaica.
   MRC Labs, Fajara, Gambia.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   Univ Oxford, Dept Zool, Oxford OX1 3PS, England.
   Univ Oxford, Dept Stat, Oxford OX1 3PS, England.
   Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA.
RP Hanchard, N (reprint author), Univ W Indies, Res Inst Trop Med, Trop Metab Res Unit, Kingston 7, Jamaica.
EM neil.hanchard@green-oxford.com; abeere@well.ox.ac.uk;
   clare.trafford@well.ox.ac.uk; Kirk.Rockett@paediatrics.oxford.ac.uk;
   mpinder@mrc.gm; muminatou@yahoo.com;
   rosalind.harding@zoology.oxford.ac.uk; dominic@well.ox.ac.uk;
   colin.mckenzie02@uwimona.edu.jm
OI Kwiatkowski, Dominic/0000-0002-5023-0176
FU Medical Research Council [G0600230, G19/9]
CR Ackerman H, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r24
   Aidoo M, 2002, LANCET, V359, P1311, DOI 10.1016/S0140-6736(02)08273-9
   ALLISON AC, 1954, T ROY SOC TROP MED H, V48, P312, DOI 10.1016/0035-9203(54)90101-7
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P853, DOI 10.1073/pnas.81.3.853
   BERSAGLIERI T, 2004, AM J HUM GENET, V74
   BOYD MARK F., 1929, AMER JOUR TROP MED, V9, P309
   CHANDLER D, 1972, THESIS, P308
   Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160
   Currat M, 2002, AM J HUM GENET, V70, P207, DOI 10.1086/338304
   Flint J, 1998, BAILLIERE CLIN HAEM, V11, P1, DOI 10.1016/S0950-3536(98)80069-3
   FULLERTON SM, 1994, P NATL ACAD SCI USA, V91, P1805, DOI 10.1073/pnas.91.5.1805
   Griffin TJ, 2000, TRENDS BIOTECHNOL, V18, P77, DOI 10.1016/S0167-7799(99)01401-8
   Hanchard NA, 2006, AM J HUM GENET, V78, P153, DOI 10.1086/499252
   Hanchard NA, 2005, BRIT J HAEMATOL, V130, P939, DOI 10.1111/j.1365-2141.2005.05704.x
   Harding RM, 1997, AM J HUM GENET, V60, P772
   Haverfield EV, 2005, BLOOD, V105, P968, DOI 10.1182/blood-2004-02-0521
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   JELLIFFE DB, 1952, BRIT MED J, V1, P405
   Kirkwood B, 2003, ESSENTIAL MED STAT, P501
   NAGEL RL, 1985, NEW ENGL J MED, V312, P880, DOI 10.1056/NEJM198504043121403
   OHASHI J, 2004, AM J HUM GENET, V74
   ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0
   PAGNIER J, 1984, P NATL ACAD SCI-BIOL, V81, P1771, DOI 10.1073/pnas.81.6.1771
   POWARS D, 1993, AM J DIS CHILD, V147, P1197
   POWARS DR, 1990, AM J PEDIAT HEMATOL, V12, P367
   POWARS DR, 1989, ANN NY ACAD SCI, V565, P262, DOI 10.1111/j.1749-6632.1989.tb24174.x
   Rich SM, 1998, P NATL ACAD SCI USA, V95, P4425, DOI 10.1073/pnas.95.8.4425
   Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140
   Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Voight BF, 2006, PLOS BIOL, V4, P446, DOI 10.1371/journal.pbio.0040072
   Wainscoat J S, 1983, Mol Biol Med, V1, P191
   Webster MT, 2003, HUM GENET, V113, P123, DOI 10.1007/s00439-003-0954-0
   *WHO, AFR MAL REP
   Wood ET, 2005, AM J HUM GENET, V77, P637, DOI 10.1086/491748
   ENSEMBL DATABASE
   CST GENOMIC DNA PURI
NR 38
TC 26
Z9 26
U1 2
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1471-2156
J9 BMC GENET
JI BMC Genet.
PD AUG 10
PY 2007
VL 8
AR 52
DI 10.1186/1471-2156-8-52
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 216TK
UT WOS:000249901700001
PM 17688704
OA gold
DA 2017-08-15
ER

PT J
AU Williams, EA
   Elia, M
   Lunn, PG
AF Williams, Elizabeth A.
   Elia, Marinos
   Lunn, Peter G.
TI A double-blind, placebo-controlled, glutamine-supplementation trial in
   growth-faltering Gambian infants
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE glutamine; growth; intestinal permeability; infants; malnutrition;
   immune response; randomized control trial; The Gambia
ID INTESTINAL BARRIER FUNCTION; CHRONIC DIARRHEA; CROHNS-DISEASE;
   AMINO-ACID; PERMEABILITY; NUTRITION; MALNUTRITION; INFECTION; CHILDREN;
   LACTOSE
AB Background: Growth faltering during infancy is a characteristic of life in developing countries. Previous studies have shown that small-intestine mucosal enteropathy, accompanied by endotoxemia and a persistent systemic inflammatory response, accounts for up to 64% of the growth faltering in Gambian infants.
   Objective: The objective was to test whether glutamine, with its putative trophic effects on enterocytes, immune cells, and intestinal integrity, can accelerate the repair of the intestine, lower immunostimulation, and reduce growth faltering.
   Design: Ninety-three infants aged 4-10 mo from the West Kiang region of The Gambia were studied in a double-blind, double-placebo, controlled trial. Glutamine (0.25 mg/kg body wt) or a placebo that contained an isonitrogenous, isoenergetic mix of nonessential amino acids was orally administered twice daily throughout the 5-mo rainy season. Anthropometric measurements were made monthly during the supplementation period and for 6 mo after supplementation. Intestinal permeability was measured monthly (by determining the ratio of lactulose to mannitol), and finger-prick blood samples were collected for the analysis of plasma proteins on 3 occasions.
   Results: Gambian infants showed a seasonal deterioration in growth and persistently elevated acute phase protein concentrations and intestinal permeability. Oral supplementation with glutamine did not improve growth (x +/- SE: weight gain, 60 +/- 19 and 69 +/- 20 g/mo; length gain, 1.01 +/- 0.05 and 0.95 +/- 0.03 cm/mo) or intestinal permeability [lactulose:mannitol ratio: 0.29 (95% CI: 0.23, 0.35) and 0.26 (95% CI: 0.21, 0.32)] in the glutamine and placebo groups, respectively. It also had no effect on infant morbidity or on plasma concentrations of immunoglobulins or acute phase proteins.
   Conclusion: Glutamine supplementation failed to improve growth or intestinal status in malnourished Gambian infants.
C1 Univ Sheffield, Royal Hallamshire Hosp, Human Nutr Unit, Sheffield S10 2JF, S Yorkshire, England.
   MRC, Keneba, Gambia.
   Univ Southampton, Inst Human Nutr, Southampton, Hants, England.
   Southmead Gen Hosp, Southampton, Hants, England.
   Univ Cambridge, Dept Biol Anthropol, Cambridge, England.
RP Lunn, PG (reprint author), Univ Cambridge, Dept Biol Anthropol, Downing St, Cambridge CB2 3DZ, England.
EM pgl21@cam.ac.uk
CR Akobeng AK, 2000, J PEDIATR GASTR NUTR, V30, P78, DOI 10.1097/00005176-200001000-00022
   Alpers DH, 2006, GASTROENTEROLOGY, V130, pS106, DOI 10.1053/j.gastro.2005.11.049
   Alverdy J., 1990, JPEN S, V14, P109
   ARDAWI MSM, 1983, BIOCHEM J, V212, P835
   Avenell A, 2006, P NUTR SOC, V65, P236, DOI 10.1079/PNS2006498
   BERGSTROM J, 1974, J APPL PHYSIOL, V36, P693
   Calder PC, 1999, AMINO ACIDS, V17, P227, DOI 10.1007/BF01366922
   Campbell DI, 2003, J NUTR, V133, P1332
   Coeffier M, 2001, CYTOKINE, V13, P148, DOI 10.1006/cyto.2000.0813
   COLE TJ, 1993, SOC ST HUM, V35, P89, DOI 10.1017/CBO9780511600517.008
   Den Hond E, 1999, JPEN-PARENTER ENTER, V23, P7, DOI 10.1177/014860719902300107
   Duggan C, 2002, AM J CLIN NUTR, V75, P789
   ELIA M, 1996, RECENT DEV INFANT NU, P318
   FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17
   GIANOTTI L, 1995, JPEN-PARENTER ENTER, V19, P69, DOI 10.1177/014860719501900169
   Kelly D, 2003, CURR OPIN CLIN NUTR, V6, P217, DOI 10.1097/01.mco.0000058593.27240.dc
   KLIMBERG VS, 1990, ARCH SURG-CHICAGO, V125, P1040
   Labow BI, 2000, WORLD J SURG, V24, P1503, DOI 10.1007/s002680010269
   LACEY JM, 1990, NUTR REV, V48, P297
   Lima AAM, 2005, J PEDIATR GASTR NUTR, V40, P28, DOI 10.1097/00005176-200501000-00006
   Lunn P. G., 1998, Proceedings of the Nutrition Society, V57, p106A
   LUNN PG, 1992, CLIN CHIM ACTA, V205, P151, DOI 10.1016/S0009-8981(05)80011-7
   Lunn PG, 2000, P NUTR SOC, V59, P147, DOI 10.1017/S0029665100000173
   LUNN PG, 1991, T ROY SOC TROP MED H, V85, P8, DOI 10.1016/0035-9203(91)90137-N
   LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M
   Meites S., 1989, PEDIAT CLIN CHEM REF
   NEILLY PJD, 1995, CLIN NUTR, V14, P283, DOI 10.1016/S0261-5614(95)80065-4
   Neu J, 1997, J PEDIATR-US, V131, P691, DOI 10.1016/S0022-3476(97)70095-7
   NORTHROP CA, 1990, CLIN CHIM ACTA, V187, P79, DOI 10.1016/0009-8981(90)90333-N
   NorthropClewes CA, 1997, J PEDIATR GASTR NUTR, V24, P257, DOI 10.1097/00005176-199703000-00005
   ODWYER ST, 1989, JPEN-PARENTER ENTER, V13, P579, DOI 10.1177/0148607189013006579
   Prentice A., 1993, S AFR J CLIN NUTR, V6, P33
   Quan ZF, 2004, WORLD J GASTROENTERO, V10, P1992
   ROWLAND MGM, 1977, BRIT J NUTR, V37, P441, DOI 10.1079/BJN19770047
   Shinozaki M, 1997, DIS COLON RECTUM, V40, pS59, DOI 10.1007/BF02062022
   SULLIVAN PB, 1991, J PEDIATR GASTR NUTR, V12, P195, DOI 10.1097/00005176-199102000-00010
   TRAVIS S, 1992, CLIN SCI, V82, P471
   Van der Julst RRWJ, 1993, LANCET, V334, P1363
   WINDMUELLER HG, 1982, ADV ENZYMOL RAMB, V53, P201
   Ziegler T R, 2000, Curr Opin Clin Nutr Metab Care, V3, P355, DOI 10.1097/00075197-200009000-00005
   Ziegler TR, 2003, ANNU REV NUTR, V23, P229, DOI 10.1146/annurev.nutr.23.011702.073036
NR 41
TC 12
Z9 12
U1 0
U2 1
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD AUG
PY 2007
VL 86
IS 2
BP 421
EP 427
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 198LN
UT WOS:000248629700021
PM 17684214
OA No
DA 2017-08-15
ER

PT J
AU Osier, FHA
   Polley, SD
   Mwangi, T
   Lowe, B
   Conway, DJ
   Marsh, K
AF Osier, F. H. A.
   Polley, S. D.
   Mwangi, T.
   Lowe, B.
   Conway, D. J.
   Marsh, K.
TI Naturally acquired antibodies to polyrnorphic and conserved epitopes of
   Plasmodium falciparum merozoite surface protein 3
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE allele-specific; antibodies; immunity; MSP3; Plasmodium falciparum
ID GLUTAMATE-RICH PROTEIN; CLINICAL MALARIA; ANTIGEN MSA2; PROTECTION;
   RESPONSES; VACCINE; HUMANS; AREA; TRANSMISSION; IMMUNIZATION
AB Many studies on the role of merozoite surface protein 3 (MSP3) in immunity against malaria have focused on a conserved section of MSP3. New evidence suggests that polymorphic sequences within MSP3 are under immune selection. We report a detailed analysis of naturally-acquired antibodies to allele-specific and conserved parts of MSP3 in a Kenyan cohort. Indirect and competition ELISA to heterologous recombinant MSP3 proteins were used for antibody assays, and parasites were genotyped for msp3 alleles. Antibody reactivity to allele-specific and conserved epitopes of MSP3 was heterogenous between individuals. Overall, the prevalence of allele-specific antibody reactivity was significantly higher (3D7-specific 54%, K1-specific 4%) than that to a recombinant protein representing a conserved portion of C-terminal MSP3 (24%, P < 0 center dot 01). The most abundant IgG subclass was IgG3, followed by IgG1. Allele-specific reactivity to the KI-type of MSP3 was associated with a lower risk of clinical malaria episodes during a 6-month follow-up in individuals who were parasitized at the start of the malaria transmission season (Relative risk 0 center dot 41 with 95% confidence interval 0 center dot 20-0 center dot 81, P = 0 center dot 011). The potential importance of allele-specific immunity to MSP3 should be considered in addition to immunity to conserved epitopes, in the development of an MSP3 malaria vaccine.
C1 KEMRI, Ctr Geog Med Res Coast, Kilifi, Kenya.
   London Sch Hyg & Trop Med, London WC1E 7HT, England.
   MRC Labs, Fajara, Gambia.
RP Osier, FHA (reprint author), KEMRI, Ctr Geog Med Res Coast, POB 230, Kilifi, Kenya.
EM fosier@kilifi.kemri-wellcome.org
RI Polley, Spencer/F-7766-2013
FU Medical Research Council [MC_U190081993]
CR Audran R, 2005, INFECT IMMUN, V73, P8017, DOI 10.1128/IAI.73.12.8017-8026.2005
   Badell E, 2000, J EXP MED, V192, P1653, DOI 10.1084/jem.192.11.1653
   Binks RH, 1999, MOL BIOCHEM PARASIT, V103, P123, DOI 10.1016/S0166-6851(99)00115-2
   BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633
   Bull PC, 2002, J INFECT DIS, V185, P1688, DOI 10.1086/340420
   Carvalho LJM, 2005, CLIN DIAGN LAB IMMUN, V12, P242, DOI 10.1128/CDLI.12.2.242-248.2005
   Cavanagh DR, 1998, J IMMUNOL, V161, P347
   COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0
   Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506
   Druilhe P, 2005, PLOS MED, V2, P1135, DOI 10.1371/journal.pmed.0020344
   Ekala MT, 2002, ACTA TROP, V81, P33, DOI 10.1016/S0001-706X(01)00188-7
   Fluck C, 2004, INFECT IMMUN, V72, P6300, DOI 10.1128/IAI.72.11.6300-6305.2004
   Hisaeda H, 2002, J INFECT DIS, V185, P657, DOI 10.1086/339187
   Huber W, 1997, MOL BIOCHEM PARASIT, V87, P231, DOI 10.1016/S0166-6851(97)00067-4
   Jouin H, 2001, EUR J IMMUNOL, V31, P539, DOI 10.1002/1521-4141(200102)31:2<539::AID-IMMU539>3.0.CO;2-1
   Kimbi HK, 2004, T ROY SOC TROP MED H, V98, P284, DOI 10.1016/S0035-9203(03)00068-3
   Lawrence G, 2000, VACCINE, V18, P1925, DOI 10.1016/S0264-410X(99)00444-2
   MARSH K, 1992, PARASITOLOGY, V104, P53
   Mbogo CM, 2003, AM J TROP MED HYG, V68, P734
   MCCOLL DJ, 1994, MOL BIOCHEM PARASIT, V68, P53, DOI 10.1016/0166-6851(94)00149-9
   Meraldi V, 2004, PARASITE IMMUNOL, V26, P265, DOI 10.1111/j.0141-9838.2004.00705.x
   Metzger WG, 2003, PARASITE IMMUNOL, V25, P307, DOI 10.1046/j.1365-3024.2003.00636.x
   Mills KE, 2002, MOL MICROBIOL, V43, P1401, DOI 10.1046/j.1365-2958.2002.02834.x
   Mwangi TW, 2005, J INFECT DIS, V191, P1932, DOI 10.1086/430006
   OEUVRAY C, 1994, BLOOD, V84, P1594
   Polley SD, 2006, VACCINE, V24, P4233, DOI 10.1016/j.vaccine.2005.06.030
   Polley SD, 2004, VACCINE, V23, P718, DOI 10.1016/j.vaccine.2004.05.031
   Polley SD, 2007, J INFECT DIS, V195, P279, DOI 10.1086/509806
   SAUL A, 1992, J IMMUNOL, V148, P208
   Singh S, 2004, J INFECT DIS, V190, P1010, DOI 10.1086/423208
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Soe S, 2004, INFECT IMMUN, V72, P247, DOI 10.1128/IAI.72.1.247-252.2004
   TAYLOR RR, 1995, INFECT IMMUN, V63, P4382
   THOMAS AW, 1990, MOL BIOCHEM PARASIT, V43, P211, DOI 10.1016/0166-6851(90)90146-D
   Tongren JE, 2004, TRENDS PARASITOL, V20, P604, DOI 10.1016/j.pt.2004.09.005
   Weisman S, 2001, INFECT IMMUN, V69, P959, DOI 10.1128/IAI.69.2.959-967.2001
NR 36
TC 35
Z9 35
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD AUG
PY 2007
VL 29
IS 8
BP 387
EP 394
DI 10.1111/j.1365-3024.2007.00951.x
PG 8
WC Immunology; Parasitology
SC Immunology; Parasitology
GA 197GR
UT WOS:000248543100001
PM 17650180
OA No
DA 2017-08-15
ER

PT J
AU Ruggeberg, JU
   Gold, MS
   Bayas, JM
   Blum, MD
   Bonhoeffer, J
   Friedlander, S
   Brito, GD
   Heininger, U
   Imoukhuede, B
   Khamesipour, A
   Erlewyn-Lajeunesse, M
   Martin, S
   Makela, M
   Nell, P
   Pool, V
   Simpson, N
AF Rueggeberg, Jens U.
   Gold, Michael S.
   Bayas, Jose-Maria
   Blum, Michael D.
   Bonhoeffer, Jan
   Friedlander, Sheila
   Brito, Glacus de Souza
   Heininger, Ulrich
   Imoukhuede, Babatunde
   Khamesipour, Ali
   Erlewyn-Lajeunesse, Michel
   Martin, Susana
   Makela, Mika
   Nell, Patricia
   Pool, Vitali
   Simpson, Nick
CA Brighton Collaboration Anaphylaxis
TI Anaphylaxis: Case definition and guidelines for data collection,
   analysis, and presentation of immunization safety data
SO VACCINE
LA English
DT Article
DE anaphylaxis; adverse event; immunization; guidelines; case definition
ID MUMPS-RUBELLA VACCINATION; MAST-CELL TRYPTASE; REVISED NOMENCLATURE;
   ALLERGIC REACTIONS; ADVERSE REACTIONS; CHILDREN; STATEMENT; MANAGEMENT;
   DIAGNOSIS; FEATURES
C1 Univ Childrens Hosp, Basel, Switzerland.
   Univ Kinder Klin, Dusseldorf, Germany.
   Univ London St Georges Hosp, Sch Med, London, England.
   Univ Adelaide, S Australian Immunisat Coordinat Unit, Adelaide, SA 5005, Australia.
   Hosp Clin Barcelona, Barcelona, Spain.
   Wyeth Res, Collegeville, PA USA.
   Univ Calif San Diego, Med Ctr, La Jolla, CA 92093 USA.
   Sao Paulo State Univ, Sao Paulo, Brazil.
   MRC Fajara, Banjul, Gambia.
   Univ Tehran Med Sci, Tehran, Iran.
   Univ Bristol, Bristol, Avon, England.
   EAP Santa Hortensia, Area 2, Madrid, Spain.
   Univ Cent Hosp Helsinki, Helsinki, Finland.
   USAF, Sturgeon Bay, WI USA.
   Ctr Dis Control & Prevent, Atlanta, GA USA.
   John Curtin Sch Med Res, Canberra, ACT, Australia.
RP Heininger, U (reprint author), Univ Childrens Hosp, Basel, Switzerland.
EM secretariat@brightoncollaboration.org
RI Bonhoeffer, Jan/E-5903-2014
CR *AAP, 2003, RED BOOK 2003 REP CO
   Bohlke K, 2003, PEDIATRICS, V112, P815, DOI 10.1542/peds.112.4.815
   Council for International Organizations of Medical Sciences (CIOMS), REP INT REP ADV DRUG
   *COUNC INT ORG MED, 1999, DEF BAS REQ US TERMS, P217
   Crockett RE, 2001, IMMUNOL ALLERGY CLIN, V21, P707
   DOUGLAS DM, 1994, J ALLERGY CLIN IMMUN, V93, P977, DOI 10.1016/S0091-6749(94)70044-3
   Duclos P, 1991, Can Dis Wkly Rep, V17, P147
   Ewan PW, 1998, BRIT MED J, V316, P1442
   Fredette MJ, 2003, CLIN INFECT DIS, V37, P1136, DOI 10.1086/378294
   *ICH, GUID CLIN SAF ASS
   JACOBS RL, 1982, JAMA-J AM MED ASSOC, V247, P40, DOI 10.1001/jama.247.1.40
   JAMES JM, 1995, NEW ENGL J MED, V332, P1262, DOI 10.1056/NEJM199505113321904
   Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x
   Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591
   Kelso JM, 1999, J ALLERGY CLIN IMMUN, V103, P698, DOI 10.1016/S0091-6749(99)70245-9
   Kohl KS, 2007, VACCINE, V25, P5671, DOI 10.1016/j.vaccine.2007.02.063
   Lee JM, 2000, PEDIATRICS, V106, P762, DOI 10.1542/peds.106.4.762
   Madaan A, 2003, IMMUNOL ALLERGY CLIN, V23, P555, DOI 10.1016/S0889-8561(03)00099-7
   MILSTIEN JB, 1987, PEDIATRICS, V80, P270
   Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987
   Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5
   Novembre E, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.4.e8
   Patja A, 2000, PEDIATR INFECT DIS J, V19, P1127, DOI 10.1097/00006454-200012000-00002
   Patja A, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.2.e27
   Payne V, 2004, ANAESTHESIA, V59, P695, DOI 10.1111/j.1365-2044.2004.03757.x
   Ponvert C, 2003, EUR J DERMATOL, V13, P10
   Pool V, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e71
   Pumphrey RSH, 2000, J CLIN PATHOL, V53, P273, DOI 10.1136/jcp.53.4.273
   Sampson HA, 2003, PEDIATRICS, V111, P1601
   Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI [10.1016/j.jaci.2005.01.008, 10.1016/j.jaci.2005.01.009]
   Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303
   SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051
   Skowronski DM, 2003, CLIN INFECT DIS, V36, P705, DOI 10.1086/367667
   SMITH RE, 1965, ANN ALLERGY, V23, P600
   STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   WASSERMAN SI, 2001, CLIN IMMUNOLOGY
   World Health Organization, 1997, SURV ADV EV FOLL IMM
   Yergeau A, 1996, CAN MED ASSOC J, V154, P503
NR 39
TC 119
Z9 125
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD AUG 1
PY 2007
VL 25
IS 31
BP 5675
EP 5684
DI 10.1016/j.vaccine.2007.02.064
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 198QZ
UT WOS:000248643900002
PM 17448577
OA No
DA 2017-08-15
ER

PT J
AU Onyeama, CO
   Okomo, U
   Garba, D
   Njai, PC
   Tapgun, M
   Corrah, T
AF Onyeama, Charles O.
   Okomo, Uduak
   Garba, Danlami
   Njai, Pamela Collier
   Tapgun, Mary
   Corrah, Tumani
TI Staphylococcal purulent pericarditis in a malnourished Gambian child: A
   case report
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Letter
DE Pericarditis; Stapylococcus aureus; Malnutrition
AB We report a case of purulent pericarditis caused by Staphylococcus aureus in a malnourished 17-month-old child. The clinical features, diagnosis especially the usefulness of non-invasive ultrasound as well as immunological and molecular biology studies, management and outcome of this life threatening condition are discussed. (C) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 [Onyeama, Charles O.; Okomo, Uduak; Garba, Danlami; Njai, Pamela Collier; Tapgun, Mary; Corrah, Tumani] MRC Labs, Clin Serv, Banjul, Gambia.
RP Onyeama, CO (reprint author), MRC Labs, Clin Serv, Atlantic Blvd Fajara,POB 273, Banjul, Gambia.
EM oonyeama@mrc.gm
OI Onyeama, Charles/0000-0003-2465-5522
CR Bamford LC, 2003, PURULENT PERICARDITI
   Banya WAS, 1996, PEDIATR INFECT DIS J, V15, P292, DOI 10.1097/00006454-199604000-00003
   Berger J., PERICARDITIS BACTERI
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Browatzki M, 2006, INT J CARDIOL, V107, P117, DOI 10.1016/j.ijcard.2005.01.028
   Cakir O, 2002, J PEDIATR SURG, V37, P1404, DOI 10.1053/jpsu.2002.35401
   de Souza AL, 2005, INT J CARDIOL
   FADAHUNSI HO, 1988, ANN TROP PAEDIATR, V8, P22
   MABOGUNJE OA, 1981, THORAX, V36, P590, DOI 10.1136/thx.36.8.590
   Roodpeyma S, 2000, PEDIATR CARDIOL, V21, P363, DOI 10.1007/s002460010081
   SINZOBAHAMVYA N, 1987, ARCH DIS CHILD, V62, P696
   Sow D, 1984, Dakar Med, V29, P199
   Zucker J M, 1971, Ann Pediatr (Paris), V18, P189
NR 13
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD JUL 31
PY 2007
VL 119
IS 3
BP 392
EP 394
DI 10.1016/j.ijcard.2006.07.176
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA V30US
UT WOS:000208841500024
PM 17070943
OA No
DA 2017-08-15
ER

PT J
AU Faburay, B
   Geysen, D
   Munstermann, S
   Bell-Sakyi, L
   Jongejan, F
AF Faburay, Bonto
   Geysen, Dirk
   Munstermann, Susanne
   Bell-Sakyi, Lesley
   Jongejan, Frans
TI Longitudinal monitoring of Ehrlichia ruminantium infection in Gambian
   lambs and kids by pCS20 PCR and MAP1-B ELISA
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID LINKED-IMMUNOSORBENT-ASSAY; AMBLYOMMA-VARIEGATUM TICKS; CLONED
   DNA-PROBE; IN-FIELD SERA; COWDRIA-RUMINANTIUM; SOUTH-AFRICA; CAUSATIVE
   AGENT; BORNE DISEASES; HEARTWATER; CATTLE
AB Background: The epidemiology of E. ruminantium infection in extensively managed young animals is not adequately understood. Thus in this study, we monitored the onset (age at first infection) and kinetics of E. ruminantium infection and antibody response in extensively managed newborn lambs and kids at three sites in The Gambia.
   Methods: We used a nested pCS20 PCR and MAPI-B ELISA in a longitudinal study to monitor the onset ( age at first infection) and kinetics of E. ruminantium infection and antibody response respectively, in 77 newborn lambs and kids under a traditional husbandry system at three sites ( Kerr Seringe, Keneba, Bansang) in The Gambia where heartwater is known to occur. The animals were monitored for field tick infestation and the comparative performance of the two assays in detecting E. ruminantium infection was also assessed.
   Results: The infection rate detected by pCS20 PCR varied between 8.6% and 54.8% over the 162-day study period. Nineteen per cent of the animals in week 1 post-partum tested positive by pCS20 PCR with half of these infections (7/ 14) detected in the first 3 days after birth, suggesting that transmission other than by tick feeding had played a role. The earliest detectable A. variegatum infestation in the animals occurred in week 16 after birth. Antibodies detected by MAPI-B ELISA also varied, between 11.5% and 90%. Although there is considerable evidence that this assay can detect false positives and due to this and other reasons serology is not a reliable predictor of infection at least for heartwater. In contrast to the pCS20 PCR, the serological assay detected the highest proportion of positive animals in week 1 with a gradual decline in seropositivity with increasing age. The pCS20 PCR detected higher E. ruminantium prevalence in the animals with increasing age and both the Spearman's rank test (r(s) = -0.1512; P = 0.003) and kappa statistic (-0.091 to 0.223) showed a low degree of agreement between the two assays.
   Conclusion: The use of pCS20 PCR supported by transmission studies and clinical data could provide more accurate information on heartwater epidemiology in endemic areas and single-occasion testing of an animal may not reveal its true infection status. The view is supported because both the vector and vertical transmission may play a vital role in the epidemiology of heartwater in young small ruminants; the age range of 4 and 12 weeks corresponds to the period of increased susceptibility to heartwater in traditionally managed small ruminants.
C1 Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
   Univ Edinburgh, Royal Dick Sch Vet Studies, Ctr Trop Vet Med, Roslin EH25 9RG, Midlothian, Scotland.
   Univ Utrecht, Fac Vet Med, Dept Immunol & Infect Dis, Utrecht Ctr Tick Borne Dis, NL-3584 CL Utrecht, Netherlands.
   Univ Pretoria, Fac Vet Med, Dept Vet Trop Dis, ZA-0110 Onderstepoort, South Africa.
RP Faburay, B (reprint author), Int Trypanotolerance Ctr, PMB 14, Banjul, Gambia.
EM b.fabureh1@vet.uu.nl; dgeysen@itg.be; smunster@freenet.de;
   lsakyi@staffmail.ed.ac.uk; F.Jongejan@vet.uu.nl
CR Allsopp MTEP, 2007, VET MICROBIOL, V120, P158, DOI 10.1016/j.vetmic.2006.10.026
   Bell-Sakyi L, 2004, VET MICROBIOL, V100, P175, DOI 10.1016/j.vetmic.2004.02.010
   Bell-Sakyi L, 2003, CLIN DIAGN LAB IMMUN, V10, P917, DOI 10.1128/CDLI.10.5.917-925.2003
   BEZUIDENHOUT JD, 1985, ONDERSTEPOORT J VET, V52, P211
   Bezuidenhout J. D., 1988, THESIS U PRETORIA S
   CAMUS E, 1987, ONDERSTEPOORT J VET, V54, P419
   DAWSON JE, 1987, VET REC, V121, P232
   De Waal DT, 2000, ANN NY ACAD SCI, V916, P622
   Deem SL, 1996, VET PARASITOL, V61, P119, DOI 10.1016/0304-4017(95)00819-5
   Du Plessis J L, 1993, Rev Elev Med Vet Pays Trop, V46, P123
   DUPLESSIS JL, 1987, ONDERSTEPOORT J VET, V54, P333
   Du Plessis J.L., 1981, TICK BIOL CONTROL, P47
   Everitt RS, 1989, STAT METHODS MED INV
   Faburay B, 2005, CLIN DIAGN LAB IMMUN, V12, P508, DOI 10.1128/CDLI.12.4.508-512.2005
   FABURAY B, 2004, 4 ITC, P36
   FABURAY B, 2007, EXP APPL ACAROL
   FISET P, 1975, AM J EPIDEMIOL, V101, P65
   Geysen D, 2003, VET PARASITOL, V110, P171, DOI 10.1016/S0304-4017(02)00313-8
   Jaitner J, 2001, SMALL RUMINANT RES, V40, P101, DOI 10.1016/S0921-4488(00)00221-2
   Jongejan F, 2004, PARASITOLOGY, V129, pS3, DOI 10.1017/S0031182004005967
   JONGEJAN F, 1988, RES VET SCI, V44, P186
   Kakono O, 2003, ONDERSTEPOORT J VET, V70, P243
   LAWRENCE JA, 1980, VET REC, V107, P82
   MAHAN SM, 1993, J CLIN MICROBIOL, V31, P2729
   MAHAN SM, 1992, J CLIN MICROBIOL, V30, P981
   Mahan SM, 1998, ANN NY ACAD SCI, V849, P259, DOI 10.1111/j.1749-6632.1998.tb11057.x
   Mattioli R. C., 1994, Parassitologia (Rome), V36, P305
   Mattioli RC, 1997, MED VET ENTOMOL, V11, P342, DOI 10.1111/j.1365-2915.1997.tb00420.x
   Mattioli RC, 2000, EXP APPL ACAROL, V24, P957, DOI 10.1023/A:1010645927535
   Mattioli RC, 2000, ACTA TROP, V75, P263, DOI 10.1016/S0001-706X(00)00063-2
   Mboloi MM, 1999, CLIN DIAGN LAB IMMUN, V6, P66
   Mondry R, 1998, ANN NY ACAD SCI, V849, P262, DOI 10.1111/j.1749-6632.1998.tb11058.x
   NEITZ W. O., 1941, JOUR SOUTH AFRICAN VET MED ASSOC, V12, P103
   Norval R. A. I., 1983, Zimbabwe Veterinary Journal, V14, P19
   NORVAL RAI, 1995, VET PARASITOL, V58, P335, DOI 10.1016/0304-4017(94)00733-S
   Norval R. A. I., 1992, EPIDEMIOLOGY THEILER
   O'Callaghan CJ, 1998, PARASITOLOGY, V117, P49, DOI 10.1017/S0031182098002790
   OSAER S, 1999, THESIS UTRECHT U UTR
   Perry BD, 1995, PREV VET MED, V25, P107, DOI 10.1016/0167-5877(95)00546-3
   PETER TF, 1995, J CLIN MICROBIOL, V33, P166
   Peter TF, 2001, EXP APPL ACAROL, V25, P881, DOI 10.1023/A:1020424718957
   PURCHASE H. S., 1945, Veterinary Record, V57, P414
   QUINN PJ, 2002, VETERINARY MICROBIOL, P535
   Semu SM, 2001, CLIN DIAGN LAB IMMUN, V8, P388, DOI 10.1128/CDLI.8.2.388-396.2001
   Simbi BH, 2003, ONDERSTEPOORT J VET, V70, P231
   UILENBERG G, 1990, VET QUART, V12, P39
   Uilenberg G, 1971, Rev Elev Med Vet Pays Trop, V24, P239
   van Vliet AHM, 1996, ANN NY ACAD SCI, V791, P35
   VANVLIET AHM, 1995, J CLIN MICROBIOL, V33, P2405
   WAGHELA SD, 1991, J CLIN MICROBIOL, V29, P2571
   WHITELAW DD, 1979, RES VET SCI, V26, P102
   Wilson J. C., 1964, Veterinary Record, V76, P1081
   ZAUGG JL, 1985, AM J VET RES, V46, P570
NR 53
TC 7
Z9 7
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JUL 27
PY 2007
VL 7
AR 85
DI 10.1186/1471-2334-7-85
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA 203BQ
UT WOS:000248950500001
PM 17662144
OA gold
DA 2017-08-15
ER

PT J
AU Lamikanra, AA
   Brown, D
   Potocnik, A
   Casals-Pascual, C
   Langhorne, J
   Roberts, DJ
AF Lamikanra, Abigail A.
   Brown, Douglas
   Potocnik, Alexandre
   Casals-Pascual, Climent
   Langhorne, Jean
   Roberts, David J.
TI Malarial anemia: of mice and men
SO BLOOD
LA English
DT Review
ID PLASMODIUM-FALCIPARUM MALARIA; NECROSIS-FACTOR-ALPHA;
   MIGRATION-INHIBITORY FACTOR; BLOOD-STAGE MALARIA; HEMATOPOIETIC
   STEM-CELLS; COOMBS ANTIGLOBULIN REACTIONS; ERYTHROID PROGENITOR CELLS;
   PARVOVIRUS B19 INFECTION; PLACEBO-CONTROLLED TRIAL; MURINE MALARIA
AB Severe malaria is manifest by a variety of clinical syndromes dependent on properties of both the host and the parasite. In young infants, severe malarial anemia (SMA) is the most common syndrome of severe disease and contributes substantially to the considerable mortality and morbidity from malaria. There is now growing evidence, from both human and mouse studies of malaria, to show that anemia is due not only to increased hemolysis of infected and clearance of uninfected red blood cells (RBCs) but also to an inability of the infected host to produce an adequate erythroid response. In this review, we will summarize the recent clinical and experimental studies of malaria to highlight similarities and differences in human and mouse pathology that result in anemia and so inform the use of mouse models in the study of severe malarial anemia in humans.
C1 Natl Inst Med Res, London NW7 1AA, England.
   John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England.
   John Radcliffe Hosp, Natl Blood Serv Oxford St, Oxford OX3 9DU, England.
   MRC, Lab, Fajara, Gambia.
RP Lamikanra, AA (reprint author), Natl Inst Med Res, London NW7 1AA, England.
OI Casals-Pascual, Climent/0000-0002-0867-8954; Langhorne,
   Jean/0000-0002-2257-9733
FU Medical Research Council [MC_U117565359, MC_U117584248]
CR ABDALLA S, 1980, BRIT J HAEMATOL, V46, P171, DOI 10.1111/j.1365-2141.1980.tb05956.x
   ABDALLA SH, 1990, BLOOD CELLS, V16, P401
   ABDALLA SH, 1988, CLIN LAB HAEMATOL, V10, P33
   Abdalla S.H, 2004, MALARIA HEMATOLOGICA, V4, pxvi
   Angus BJ, 1997, BLOOD, V90, P2037
   Arcasoy MO, 2005, BRIT J HAEMATOL, V130, P121, DOI 10.1111/j.1365-2141.2005.05580.x
   ASAMI M, 1992, INT J PARASITOL, V22, P43, DOI 10.1016/0020-7519(92)90078-Y
   ATKINSON SH, 2006, PLOS MED, V3, P172
   Awandare GA, 2006, CLIN IMMUNOL, V119, P219, DOI 10.1016/j.clim.2005.12.003
   Berkley J, 1999, T ROY SOC TROP MED H, V93, P283, DOI 10.1016/S0035-9203(99)90024-X
   Berkley JA, 2005, BRIT MED J, V330, P995, DOI 10.1136/bmj.38408.471991.8F
   Bordmann G, 1997, PARASITOLOGY, V115, P475, DOI 10.1017/S0031182097001595
   BROWN AE, 1990, CLIN EXP IMMUNOL, V82, P97
   Burgmann H, 1996, AM J TROP MED HYG, V54, P280
   CARTER R, 1975, ANN TROP MED PARASIT, V69, P187
   Casals-Pascual C, 2006, CURR MOL MED, V6, P155, DOI 10.2174/156652406776055159
   Casals-Pascual C, 2006, BLOOD, V108, P2569, DOI 10.1182/blood-2006-05-018697
   Chaiyaroj SC, 2004, ACTA TROP, V89, P319, DOI 10.1016/j.actatropica.2003.10.010
   Chang KH, 2004, INT J PARASITOL, V34, P1501, DOI 10.1016/j.ijpara.2004.10.008
   Chang KH, 2004, KIDNEY INT, V65, P1640, DOI 10.1111/j.1523-1755.2004.00573.x
   Chang KH, 2004, J INFECT DIS, V189, P735, DOI 10.1086/381458
   Chang KH, 2004, BLOOD, V103, P3727, DOI 10.1182/blood-2003-08-2887
   Chotivanich K, 2000, J INFECT DIS, V181, P1206, DOI 10.1086/315353
   Clark IA, 2003, PHARMACOL THERAPEUT, V99, P221, DOI 10.1016/S0163-7258(03)00060-3
   Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836
   Das BS, 1999, T ROY SOC TROP MED H, V93, P58, DOI 10.1016/S0035-9203(99)90180-3
   De Maria R, 1999, BLOOD, V93, P796
   De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809
   Delahaye NF, 2006, J INFECT DIS, V193, P312, DOI 10.1086/498579
   Dondorp AM, 2003, REDOX REP, V8, P292, DOI 10.1179/135100003225002934
   Dondorp AM, 1997, AM J TROP MED HYG, V57, P507
   Dondorp AM, 2002, T ROY SOC TROP MED H, V96, P282, DOI 10.1016/S0035-9203(02)90100-8
   Douki JBL, 2003, BLOOD, V101, P5025, DOI 10.1182/blood-2002-12-3710
   Dufour C, 2003, BLOOD, V102, P2053, DOI 10.1182/blood-2003-01-0114
   Egan AF, 2002, BLOOD, V99, P3863, DOI 10.1182/blood.V99.10.3863
   ElHassan AMA, 1997, EUR J HAEMATOL, V59, P299
   English M, 1997, QJM-MON J ASSOC PHYS, V90, P563, DOI 10.1093/qjmed/90.9.563
   English M, 1996, AM J TROP MED HYG, V55, P525
   Evans KJ, 2006, BLOOD, V107, P1192
   FACER CA, 1980, CLIN EXP IMMUNOL, V39, P279
   FACER CA, 1979, CLIN EXP IMMUNOL, V35, P119
   Felli N, 2005, J IMMUNOL, V175, P1464
   Fleming AF, 1997, TRANSFUS SCI, V18, P167
   GARNHAM PCC, 1969, T ROY SOC TROP MED H, V63, P187, DOI 10.1016/0035-9203(69)90145-X
   Giribaldi G, 2004, HAEMATOLOGICA, V89, P492
   Glenister FK, 2002, BLOOD, V99, P1060, DOI 10.1182/blood.V99.3.1060
   Greenwood BM, 1997, ANN TROP MED PARASIT, V91, P763
   Griffiths MJ, 2005, J INFECT DIS, V191, P1599, DOI 10.1086/429297
   Griffiths MJ, 2001, BRIT J HAEMATOL, V113, P486, DOI 10.1046/j.1365-2141.2001.02758.x
   GROUX H, 1990, RES IMMUNOL, V141, P529, DOI 10.1016/0923-2494(90)90021-P
   HANSPAL M, 1994, BLOOD, V84, P3494
   Hunt NH, 2001, REDOX REP, V6, P389, DOI 10.1179/135100001101536508
   Hviid L, 2005, ACTA TROP, V95, P270, DOI 10.1016/j.actatropica.2005.06.012
   Jakeman GN, 1999, PARASITOLOGY, V119, P127, DOI 10.1017/S0031182099004564
   Jaramillo M, 2004, J IMMUNOL, V172, P3101
   JARRA W, 1989, PARASITE IMMUNOL, V11, P1, DOI 10.1111/j.1365-3024.1989.tb00644.x
   Jenkins NE, 2006, T ROY SOC TROP MED H, V100, P1007, DOI 10.1016/j.trstmh.2006.01.005
   Jones TR, 2002, AM J TROP MED HYG, V66, P672
   Kaul DK, 1998, AM J TROP MED HYG, V58, P240
   KRISHNA S, 1994, T ROY SOC TROP MED H, V88, P67, DOI 10.1016/0035-9203(94)90504-5
   Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200
   Kurtzhals JAL, 1998, LANCET, V351, P1768, DOI 10.1016/S0140-6736(97)09439-7
   Kurtzhals JAL, 1997, BRIT J HAEMATOL, V97, P169, DOI 10.1046/j.1365-2141.1997.82654.x
   KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5
   Ladhani S, 2002, BRIT J HAEMATOL, V119, P839, DOI 10.1046/j.1365-2141.2002.03904.x
   Lamb Tracey J., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406010581
   Landau I, 1999, PARASITE, V6, P311
   Langhorne J, 2002, CHEM IMMUNOL, V80, P204
   Layez C, 2005, BLOOD, V106, P3632, DOI 10.1182/blood-2005-04-1574
   Lee G, 2003, BLOOD, V101, P1790, DOI 10.1182/blood-2002-08-2529
   Li C, 2003, INFECT IMMUN, V71, P4850, DOI 10.1128/IAI.71.9.4850-4856.2003
   Linke A, 1996, EXP PARASITOL, V84, P253, DOI 10.1006/expr.1996.0111
   Liu Y, 2006, BLOOD, V108, P123, DOI 10.1182/blood-2005-11-4458
   LOOAREESUWAN S, 1987, NEW ENGL J MED, V317, P675, DOI 10.1056/NEJM198709103171105
   LOOAREESUWAN S, 1987, BRIT J HAEMATOL, V67, P473, DOI 10.1111/j.1365-2141.1987.tb06171.x
   Lyke KE, 2004, INFECT IMMUN, V72, P5630, DOI 10.1128/IAI.72.10.5630-5637.2004
   MAGGIOPRICE L, 1985, BLOOD, V66, P1080
   Malaguarnera L, 2002, PARASITE IMMUNOL, V24, P489, DOI 10.1046/j.1365-3024.2002.00485.x
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   Martiney JA, 2000, INFECT IMMUN, V68, P2259, DOI 10.1128/IAI.68.4.2259-2267.2000
   McDevitt MA, 2006, J EXP MED, V203, P1185, DOI 10.1084/jem.20052398
   McGilvray ID, 2000, BLOOD, V96, P3231
   McGuire W, 1999, J INFECT DIS, V179, P287, DOI 10.1086/314533
   MCNIECE IK, 1991, EXP HEMATOL, V19, P226
   Menendez C, 2000, PARASITOL TODAY, V16, P469, DOI 10.1016/S0169-4758(00)01774-9
   Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3
   MILLER KL, 1989, INFECT IMMUN, V57, P1542
   MILLER KL, 1989, EXP HEMATOL, V17, P379
   MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F
   Mohan K, 1998, EXP HEMATOL, V26, P45
   Mohan K, 1998, BRIT J HAEMATOL, V103, P942
   MOHAN K, 1995, EXP PARASITOL, V80, P54, DOI 10.1006/expr.1995.1007
   Mota MM, 1998, INFECT IMMUN, V66, P4080
   Munugalavadla V, 2005, MOL CELL BIOL, V25, P6747, DOI 10.1128/MCB.25.15.6747-6759.2005
   Naik RS, 2000, J EXP MED, V192, P1563, DOI 10.1084/jem.192.11.1563
   Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235
   Newton CRJC, 1997, TROP MED INT HEALTH, V2, P165, DOI 10.1046/j.1365-3156.1997.d01-238.x
   Nosten F, 1999, LANCET, V354, P546, DOI 10.1016/S0140-6736(98)09247-2
   Nussenblatt V, 2001, CLIN DIAGN LAB IMMUN, V8, P1164, DOI 10.1128/CDLI.8.6.1164-1170.2001
   Ocana-Morgner C, 2003, J EXP MED, V197, P143, DOI 10.1084/jem.20021072
   OCKENHOUSE CF, 1984, J IMMUNOL, V132, P424
   Omodeo-Sale F, 2005, EUR J HAEMATOL, V74, P324, DOI 10.1111/j.1600-0609.2004.00352.x
   Othoro C, 1999, J INFECT DIS, V179, P279, DOI 10.1086/314548
   PICHYANGKUL S, 1994, AM J TROP MED HYG, V51, P430
   Pouvelle B, 2000, NAT MED, V6, P1264
   Prato M, 2005, J IMMUNOL, V175, P6436
   Price R, 1999, AM J TROP MED HYG, V60, P547
   Price RN, 2001, AM J TROP MED HYG, V65, P614
   Prunescu P, 1999, Roum Arch Microbiol Immunol, V58, P79
   RENCRICCA NJ, 1979, P SOC EXP BIOL MED, V162, P424
   Roberts DJ, 2005, CURR TOP MICROBIOL, V295, P137
   ROBERTS DJ, 2005, MALARIA DRUGS DIS PO, V295
   Rodriguez-Morales AJ, 2006, J TROP PEDIATRICS, V52, P49, DOI 10.1093/tropej/fmi069
   Rowe AK, 2006, INT J EPIDEMIOL, V35, P691, DOI 10.1093/ije/dy1027
   Rudin W, 1997, PARASITOLOGY, V115, P467, DOI 10.1017/S0031182097001583
   Salmon M. G., 1997, Clinical and Experimental Immunology, V108, P471, DOI 10.1046/j.1365-2249.1997.3991297.x
   Sarfo BY, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-63
   Schellenberg D, 2003, B WORLD HEALTH ORGAN, V81, P581
   Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2
   Schofield L, 2002, NATURE, V418, P785, DOI 10.1038/nature00937
   SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145
   Scholander C, 1998, INFECT IMMUN, V66, P361
   SCHWARZER E, 1992, J EXP MED, V176, P1033, DOI 10.1084/jem.176.4.1033
   Schwarzer E, 1998, INFECT IMMUN, V66, P1601
   Schwarzer E, 2003, BLOOD, V101, P722, DOI 10.1182/blood-2002-03-0979
   Schwarzer E., 1999, Parassitologia (Rome), V41, P199
   Sexton AC, 2004, J INFECT DIS, V189, P1245, DOI 10.1086/382596
   SHEAR HL, 1979, J EXP MED, V149, P1288, DOI 10.1084/jem.149.6.1288
   SHERRY BA, 1995, J INFLAMM, V45, P85
   SILVERMAN PH, 1987, BLOOD, V69, P408
   Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   SPIRA D, 1965, J INFECT DIS, V115, P337
   Stephens JWW, 1937, BLACKWATER FEVER
   Stoute JA, 2003, J INFECT DIS, V187, P522, DOI 10.1086/367712
   Sui XW, 2000, BRIT J HAEMATOL, V110, P63, DOI 10.1046/j.1365-2141.2000.02145.x
   TERNYNCK T, 1991, INT IMMUNOL, V3, P29, DOI 10.1093/intimm/3.1.29
   TJITRA E, 2005, 16 INT C TROP MED MA
   Urban BC, 2005, INFECT IMMUN, V73, P1986, DOI 10.1128/IAI.73.4.1986-1994.2005
   Verhoef H, 2002, BLOOD, V100, P3489, DOI 10.1182/blood-2001-12-0228
   VILLEVAL JL, 1990, EXP PARASITOL, V71, P364, DOI 10.1016/0014-4894(90)90062-H
   Vryonis G, 1939, AM J HYG, V30, P41
   Waitumbi JN, 2000, BLOOD, V95, P1481
   WARRELL DA, 1990, SEVERE COMPLICATED M
   WEISS L, 1989, AM J TROP MED HYG, V41, P144
   WEISS L, 1989, AM J TROP MED HYG, V41, P135
   WICKRAMASINGHE SN, 1982, SCAND J HAEMATOL, V29, P83
   Wildig J, 2006, J INFECT DIS, V194, P146, DOI 10.1086/505082
   WINOGRAD E, 1989, BIOCHEM BIOPH RES CO, V160, P1357, DOI 10.1016/S0006-291X(89)80153-6
   YAP GS, 1994, INFECT IMMUN, V62, P357
   YAP GS, 1992, EXP PARASITOL, V75, P340, DOI 10.1016/0014-4894(92)90219-Z
   Yeats J, 1999, EUR J HAEMATOL, V63, P276
   Zermati Y, 2000, EXP HEMATOL, V28, P885, DOI 10.1016/S0301-472X(00)00488-4
   ZINGMAN BS, 1993, CLIN INFECT DIS, V16, P223
NR 154
TC 104
Z9 104
U1 0
U2 9
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JUL 1
PY 2007
VL 110
IS 1
BP 18
EP 28
DI 10.1182/blood-2006-09-018069
PG 11
WC Hematology
SC Hematology
GA 183ZN
UT WOS:000247611000010
PM 17341664
OA No
DA 2017-08-15
ER

PT J
AU Burl, S
   Hill, PC
   Jeffries, DJ
   Holland, MJ
   Fox, A
   Lugos, MD
   Adegbola, RA
   Rook, GA
   Zumla, A
   McAdam, KPWJ
   Brookes, RH
AF Burl, S.
   Hill, P. C.
   Jeffries, D. J.
   Holland, M. J.
   Fox, A.
   Lugos, M. D.
   Adegbola, R. A.
   Rook, G. A.
   Zumla, A.
   McAdam, K. P. W. J.
   Brookes, R. H.
TI FOXP3 gene expression in a tuberculosis case contact study
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE FOXP3; IL-10; T(regs); tuberculosis
ID REGULATORY T-CELLS; LINKED IMMUNOSPOT ASSAY; PERIPHERAL-BLOOD;
   IMMUNE-RESPONSES; INFECTION; CD4(+); DIAGNOSIS; GAMBIA; RNA
AB Regulatory T lymphocytes (T(regs)) that express FOXP3 are involved in the beneficial attenuation of immunopathology, but are also implicated in down-regulation of protective responses to infection. Their role in tuberculosis (TB) is unknown. We classified 1272 healthy TB contacts according to their tuberculin skin test (TST) and interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) results and 128 TB cases, and studied the expression of FOXP3 and interleukin (IL)-10 in blood samples. Compared to the uninfected contact group (TST(-), ELISPOT(-)), we observed higher levels of FOXP3 mRNA in blood from TB patients (< 0.001), but IL-10 expression was slightly lower (P = 0.04). In contrast, FOXP3 expression levels were significantly lower (P = 0.001) in the recently infected contacts (TST(+), ELISPOT(+)) but there was no difference for IL-10 (P = 0.74). We hypothesize that during early/subclinical TB, most of which will become latent, FOXP3(+) T(regs) may be sequestered in the lungs, but when TB becomes progressive, FOXP3 reappears at increased levels in the periphery. While these findings do not reveal the role, beneficial or harmful, of T(regs) in TB, they emphasize the probable importance of these cells.
C1 UCL, Ctr Infect Dis & Int Hlth, Windeyer Inst Med Sci, London W1T 4JF, England.
   London Sch Hyg & Trop Med, Clin Res Unit, Dept Infect & Trop Med, London WC1, England.
   Med Res Council UK Unit, Bacterial Dis Programme, TB Div, Banjul, Gambia.
RP Rook, GA (reprint author), UCL, Ctr Infect Dis & Int Hlth, Windeyer Inst Med Sci, 46 Cleveland St, London W1T 4JF, England.
EM g.rook@ucl.ac.uk
OI Rook, Graham/0000-0002-8041-8110; Zumla, Alimuddin/0000-0002-5111-5735
FU Medical Research Council [MC_U190071468]
CR Andersson J, 2005, J IMMUNOL, V174, P3143
   Bisikirska B, 2005, J CLIN INVEST, V115, P2904, DOI 10.1172/JCI23961
   Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918
   Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047
   Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P960
   Dheda K, 2004, BIOTECHNIQUES, V37, P112
   Dheda K, 2004, BIOTECHNIQUES, V37, P116
   Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
   GUYOTREVOL V, 2005, AM J RESP CRIT CARE, V173, P803
   Hill PC, 2005, J CLIN MICROBIOL, V43, P2070, DOI 10.1128/JCM.43.5.2070-2074.2005
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Hisaeda H, 2004, NAT MED, V10, P29, DOI 10.1038/nm975
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Jarvis LB, 2005, EUR J IMMUNOL, V35, P2896, DOI 10.1002/eji.200526162
   Jeffries DJ, 2004, INT J TUBERC LUNG D, V8, P1095
   Ji JX, 2005, J IMMUNOL, V174, P7147
   Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909
   Kinter AL, 2004, J EXP MED, V200, P331, DOI 10.1084/jem.20032069
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Morgan ME, 2005, HUM IMMUNOL, V66, P13, DOI 10.1016/j.humimm.2004.05.016
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178
   Soysal A, 2005, LANCET, V366, P1443, DOI 10.1016/S0140-6736(05)67534-4
   Stassen M, 2004, EUR J IMMUNOL, V34, P1303, DOI 10.1002/eji.200324656
   Stoop JN, 2005, HEPATOLOGY, V41, P771, DOI 10.1002/hep.20649
   Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439
NR 25
TC 35
Z9 38
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JUL
PY 2007
VL 149
IS 1
BP 117
EP 122
DI 10.1111/j.1365-2249.2007.03399.x
PG 6
WC Immunology
SC Immunology
GA 176VT
UT WOS:000247113700016
PM 17465993
OA No
DA 2017-08-15
ER

PT J
AU Gray, JC
   Corran, PH
   Mangia, E
   Gaunt, MW
   Li, Q
   Tetteh, KKA
   Polley, S
   Conway, DJ
   Holder, AA
   Bacarese-Hamilton, T
   Riley, EM
   Crisanti, A
AF Gray, Julian C.
   Corran, Patrick H.
   Mangia, Elena
   Gaunt, Michael W.
   Li, Qiuxiang
   Tetteh, Kevin K. A.
   Polley, Spencerd.
   Conway, David J.
   Holder, Anthony A.
   Bacarese-Hamilton, Tito
   Riley, Eleanor M.
   Crisanti, Andrea
TI Profiling the antibody immune response against blood stage malaria
   vaccine candidates
SO CLINICAL CHEMISTRY
LA English
DT Article
ID MEROZOITE SURFACE PROTEIN-1; CARBOXY-TERMINAL FRAGMENT;
   PAPUA-NEW-GUINEA; PLASMODIUM-FALCIPARUM; SERUM ANTIBODIES; CLINICAL
   IMMUNITY; HUMORAL RESPONSE; GAMMA-GLOBULIN; ANTIGEN; RECOGNITION
AB Background: The complexity and diversity of the antibody immune response to the antigen repertoire of a pathogen has long been appreciated. Although it has been recognized that the detection of antibodies against multiple antigens dramatically improves the clinical sensitivity and specificity of diagnostic assays, the prognostic value of serum reactivity profiles against multiple microbial antigens in protection has not been investigated.
   Methods: Using malaria as a model we investigated whether antigen reactivity profiles in serum of children with different levels of clinical immunity to Plasmodium falciparum malaria correlated with protection. We developed a microarray immunoassay of 18 recombinant antigens derived from 4 leading blood-stage vaccine candidates for P. falciparum [merozoite surface protein 1 (MSP1), MSP2, MSP3, and apical membrane antigen (AMA)-1]. Associations between observed reactivity profiles and clinical status were sought using k-means clustering and phylogenetic networks.
   Results: The antibody immune response was unexpectedly complex, with different combinations of antigens recognized in different children. Serum reactivity to individual antigens did not correlate with immune status. By contrast, combined recognition of AMA-1 and allelic variants of MSP2 was significantly associated with protection against clinical malaria. This finding was confirmed independently by k-means clustering and phylogenetic networking.
   Conclusions: The analysis of reactivity profiles provides a wealth of novel information about the immune response against microbial organisms that would pass unnoticed in analysis of reactivity to antigens individually. Extension of this approach to a large fraction of the proteome may expedite the identification of correlates of protection and vaccine development against microbial diseases. (c) 2007 American Association for Clinical Chemistry.
C1 Univ London Imperial Coll Sci Technol & Med, Fac Nat Sci, London SW7 2AZ, England.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   Natl Inst Biol Stand & Controls, Div Immunol, S Mimms, Herts, England.
   Univ Perugia, Dept Expt Med, Perugia, Italy.
   MRC Labs, Banjul, Gambia.
   Natl Inst Med Res, London NW7 1AA, England.
RP Crisanti, A (reprint author), Univ London Imperial Coll Sci Technol & Med, Fac Nat Sci, London SW7 2AZ, England.
EM acrs@imperial.ac.uk
RI Holder, Anthony/A-7554-2013; Riley, Eleanor/C-8960-2013; Polley,
   Spencer/F-7766-2013
OI Holder, Anthony/0000-0002-8490-6058; Riley, Eleanor/0000-0003-3447-3570;
   Conway, David/0000-0002-8711-3037
FU Medical Research Council [MC_U117532067, MC_U190081993]
CR ALYAMAN F, 1994, AM J TROP MED HYG, V51, P593
   Bacarese-Hamilton T, 2003, CURR OPIN MOL THER, V5, P278
   Bacarese-Hamilton T, 2002, CLIN CHEM, V48, P1367
   BACARESEHAMILTO.T, 2005, PROTEIN MICROARRAYS, P387
   BURGHAUS PA, 1994, MOL BIOCHEM PARASIT, V64, P165, DOI 10.1016/0166-6851(94)90144-9
   Cavanagh DR, 2004, INFECT IMMUN, V72, P6492, DOI 10.1128/IAI.72.11.6492.6502.2004
   COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0
   de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078
   DEHOON M, OPEN SOURCE CLUSTERI
   Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102
   EDOZIEN JC, 1962, LANCET, V2, P951
   EGAN AF, 1995, INFECT IMMUN, V63, P456
   Egan AF, 1996, J INFECT DIS, V173, P765
   Fluck C, 2004, INFECT IMMUN, V72, P6300, DOI 10.1128/IAI.72.11.6300-6305.2004
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001
   Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68
   Joos TO, 2000, ELECTROPHORESIS, V21, P2641, DOI 10.1002/1522-2683(20000701)21:13<2641::AID-ELPS2641>3.3.CO;2-X
   Kimbi HK, 2004, T ROY SOC TROP MED H, V98, P284, DOI 10.1016/S0035-9203(03)00068-3
   Kinyanjui SM, 2003, J INFECT DIS, V187, P667, DOI 10.1086/373994
   Kirkwood B. R., 2003, ESSENTIAL MED STAT
   Mezzasoma L, 2002, CLIN CHEM, V48, P121
   Okenu DMN, 2000, INFECT IMMUN, V68, P5559, DOI 10.1128/IAI.68.10.5559-5566.2000
   Polley SD, 2003, INFECT IMMUN, V71, P1833, DOI 10.1128/IAI.71.4.1833-1842.2003
   Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576
   Richie TL, 2002, NATURE, V415, P694, DOI 10.1038/415694a
   RILEY EM, 1990, T ROY SOC TROP MED H, V84, P648, DOI 10.1016/0035-9203(90)90133-Y
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   RILEY EM, 1991, T ROY SOC TROP MED H, V85, P436, DOI 10.1016/0035-9203(91)90207-F
   RILEY EM, 1993, PARASITE IMMUNOL, V15, P513, DOI 10.1111/j.1365-3024.1993.tb00639.x
   SABCHAREON A, 1991, AM J TROP MED HYG, V45, P297
   Saul A, 1999, VACCINE, V17, P3145, DOI 10.1016/S0264-410X(99)00175-9
   Struik SS, 2004, IMMUNOL REV, V201, P268, DOI 10.1111/j.0105-2896.2004.00181.x
   Targett GA, 2005, TRENDS PARASITOL, V21, P499, DOI 10.1016/j.pt.2005.08.018
   Tavazoie S, 1999, NAT GENET, V22, P281
   Taylor RR, 1998, AM J TROP MED HYG, V58, P406
   Taylor RR, 1996, INT IMMUNOL, V8, P905, DOI 10.1093/intimm/8.6.905
   Tetteh KKA, 2005, INFECT IMMUN, V73, P5928, DOI 10.1128/IAI.73.9.5928-5935.2005
   THOMSON MC, 1995, ANN TROP MED PARASIT, V89, P229
NR 39
TC 73
Z9 73
U1 0
U2 2
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD JUL
PY 2007
VL 53
IS 7
BP 1244
EP 1253
DI 10.1373/clinchem.2006.081695
PG 10
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 183FL
UT WOS:000247558000012
PM 17510307
OA No
DA 2017-08-15
ER

PT J
AU Fox, A
   Jeffries, DJ
   Hill, PC
   Hammond, AS
   Lugos, MD
   Jackson-Sillah, D
   Donkor, SA
   Owiafe, PK
   McAdam, KPWJ
   Brookes, RH
AF Fox, Annette
   Jeffries, David J.
   Hill, Philip C.
   Hammond, Abdulrahman S.
   Lugos, Moses D.
   Jackson-Sillah, Dolly
   Donkor, Simon A.
   Owiafe, Patrick K.
   McAdam, Keith P. W. J.
   Brookes, Roger H.
TI ESAT-6 and CFP-10 can be combined to reduce the cost of testing for
   Mycobacterium tuberculosis infection, but CFP-10 responses associate
   with active disease
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE tuberculosis; infection; disease; ESAT-6; CFP-10; ELISPOT
ID T-CELL RESPONSES; SECRETED ANTIGENIC TARGET; LINKED IMMUNOSPOT ASSAY;
   FILTRATE PROTEIN 10; LATENT TUBERCULOSIS; SKIN-TEST; IMMUNE-RESPONSES;
   DIAGNOSIS; ENUMERATION; CONTACTS
AB Commercial tests measuring IFN-gamma responses to ESAT-6 and CFP-10 are available for diagnosing Mycobacterium tuberculosis infection. Measures that minimize cost and complexity will facilitate their application in less-developed countries. We investigated whether overlapping peptides representing both ESAT-6 and CFP-10 are required to detect M. tuberculosis infection in a high TB-burden country, and whether they can be combined in a single pool. ESAT-6 and CFP-10 peptides were compared in IFN-gamma enzyme-linked immunospot (ELISPOT) in 183 HIV-negative smear-positive TB cases and 1673 HIV-negative household contacts. Separate peptide pools for each antigen were compared with a combined pool in 498 contacts. Forty per cent of responsive contacts recognized both antigens, 51% only ESAT-6 and 10% only CFP-10, whereas 56% of responsive cases recognized both antigens, 30% only ESAT-6 and 13% only CFP-10. Accordingly, CFP-10 response rates were higher for TB cases (odds ratio 2.409, P < 0.001). Low purified protein derivative response rates indicated that responses to CFP-10 only were nonspecific in contacts. Agreement between peptides in separate versus combined pools was good (kappa = 0.758, r = 0.840). Therefore a combined ESAT-6/CFP-10 peptide pool provided maximum sensitivity and efficiency, but CFP-10 was mainly required to detect active disease. (C) 2007 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
C1 MRC Labs, TB Div, Bacterial Dis Programme, Banjul, Gambia.
RP Fox, A (reprint author), 20 Alley 1-54 Au Co Rd, Hanoi, Vietnam.
EM afox@pacific.net.au
RI Hammond, Abdulrahman/F-1541-2011
OI Kwasi Owiafe, Patrick/0000-0002-4287-3577
CR Arend SM, 2001, CLIN DIAGN LAB IMMUN, V8, P1089, DOI 10.1128/CDLI.8.6.1089-1096.2001
   Arend SM, 2000, INFECT IMMUN, V68, P3314, DOI 10.1128/IAI.68.6.3314-3321.2000
   Arend SM, 2000, J INFECT DIS, V181, P1850, DOI 10.1086/315448
   Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008
   Colangeli R, 2000, INFECT IMMUN, V68, P990, DOI 10.1128/IAI.68.2.990-993.2000
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977
   Diel R, 2006, EUR RESPIR J, V28, P35, DOI 10.1183/09031936.06.00011806
   Dillon DC, 1999, INFECT IMMUN, V67, P2941
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6
   Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x
   Harboe M, 1996, INFECT IMMUN, V64, P16
   Hill PC, 2005, J CLIN MICROBIOL, V43, P2070, DOI 10.1128/JCM.43.5.2070-2074.2005
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968
   Jeffries DJ, 2006, INT J TUBERC LUNG D, V10, P192
   Jeffries DJ, 2004, INT J TUBERC LUNG D, V8, P1095
   Kang YA, 2005, JAMA-J AM MED ASSOC, V293, P2756, DOI 10.1001/jama.293.22.2756
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081
   Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1
   Lein AD, 1999, CLIN DIAGN LAB IMMUN, V6, P606
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC
   Mustafa AS, 1998, SCAND J IMMUNOL, V48, P535
   Simmons CP, 2006, J IMMUNOL, V176, P2007
   SORENSEN AL, 1995, INFECT IMMUN, V63, P1710
   Ulrichs T, 2000, INFECT IMMUN, V68, P6073, DOI 10.1128/IAI.68.10.6073-6076.2000
   van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000
   Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001
   Whalen CC, 2005, JAMA-J AM MED ASSOC, V293, P2785, DOI 10.1001/jama.293.22.2785
   Wrighton-Smith P, 2006, EUR RESPIR J, V28, P45, DOI 10.1183/09031936.06.00005906
NR 33
TC 10
Z9 12
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JUL
PY 2007
VL 101
IS 7
BP 691
EP 698
DI 10.1016/j.trstmh.2007.03.001
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 184TR
UT WOS:000247665700013
PM 17434194
OA No
DA 2017-08-15
ER

PT J
AU Darboe, MK
   Thurnham, DI
   Morgan, G
   Adegbola, RA
   Secka, O
   Solon, JA
   Jackson, SJ
   Northrop-Clewes, C
   Fulford, TJ
   Doherty, CP
   Prentice, AM
AF Darboe, Mornodou K.
   Thurnham, David I.
   Morgan, Gareth
   Adegbola, Richard A.
   Secka, Ousman
   Solon, Juan A.
   Jackson, Sarah J.
   Northrop-Clewes, Christine
   Fulford, Tony J.
   Doherty, Conor P.
   Prentice, Andrew M.
TI Effectiveness of an early supplementation scheme of high-dose vitamin A
   versus standard WHO protocol in Gambian mothers and infants: a
   randomised controlled
SO LANCET
LA English
DT Article
ID BETA-CAROTENE; INTESTINAL PERMEABILITY; CHILDHOOD MORTALITY; PLASMA
   RETINOL; WOMEN; METAANALYSIS; DEFICIENCY; MORBIDITY; IMPACT; TRIAL
AB Background Most developing countries have adopted a standard WHO dosing schedule for vitamin A supplementation. However, in 2002 the International Vitamin A Consultative Group (IVACG) Annecy Accord recommended a new high-dose regimen for mothers and infants. Our aim was to test whether the new high-dose regimen of vitamin A supplementation would increase maternal and infant plasma vitamin A, reduce infant Helicobacter pylori infection and nasopharyngeal pneumococcal carriage, and improve infant gut epithelial integrity.
   Methods In an area of moderate vitamin A deficiency in rural Gambia, 220 mother-infant pairs were enrolled in a randomised double-blind trial between September, 2001, and October, 2004, that compared the IVACG high dose with the WHO dose. The primary endpoints were levels of maternal and infant plasma vitamin A, H pylori infection, pneumococcal carriage, and gut epithelial integrity. The trial is registered as ISRCTN 98554309.
   Findings 197 infants completed follow-up to 12 months (99 high dose and 98 WHO dose). There were no adverse events at dosing. No differences were found in the primary outcomes for high-dose versus WHO schedule: maternal vitamin A concentration at 2 months +0.02 mu mol/L (95% Cl -0.10 to 0.15); infant vitamin A at 5 months +0.01 mu mol/L (-0.06 to 0.08); H pylori infection at 12 months -0.3% (-14.7 to 14.2); maternal pneumococcal carriage at 12 months -2.0% (-13.7 to 9-7); infant pneumococcal. carriage at 12 months -4.1% (-15.8 to 7-6); infant gut mucosal damage at 12 months 5.2% (-8.7 to 19-2). There were more clinic attendances by the high-dose group in the first 6 months of life (p=0.018).
   Interpretation Our results do not lend support to the proposal to increase the existing WHO standard dosing schedule for vitamin A in areas of moderate vitamin A deficiency. Caution is urged for future studies because trials have shown possible adverse effects of higher doses of vitamin A, and potential negative interactions with the expanded programme on immunisation (EPI) vaccines.
C1 Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   MRC Keneba, Keneba, Gambia.
   Univ Ulster, No Ireland Ctr Food & Hlth, Coleraine BT52 1SA, Londonderry, North Ireland.
   Univ Coll Swansea, Sch Med, Swansea, W Glam, Wales.
   MRC Labs, Banjul, Gambia.
   Univ Philippines Manila, Coll Publ Hlth, Manila, Philippines.
   MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge, England.
RP Prentice, AM (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Keppel St, London WC1E 7HT, England.
EM Andrew.prentice@lshtm.ac.uk
FU Medical Research Council [MC_U105960396]
CR ABDELJABER MH, 1991, AM J PUBLIC HEALTH, V81, P1654, DOI 10.2105/AJPH.81.12.1654
   BAH A, 2001, GAMBIA, P1
   BATES CJ, 1984, T ROY SOC TROP MED H, V78, P814, DOI 10.1016/0035-9203(84)90028-2
   Benn CS, 2005, BRIT MED J, V331, P1428, DOI 10.1136/bmj.38670.639340.55
   Benn CS, 2003, INT J EPIDEMIOL, V32, P822, DOI 10.1093/ije/dyg208
   BENN CS, 2006, VACCINE, V25, P777
   Campbell DI, 2003, PEDIATR RES, V54, P306, DOI 10.1203/01.PDR.0000076666.16021.5E
   COLE TJ, 1989, ANN HUM BIOL, V16, P407, DOI 10.1080/03014468900000532
   DEFRANCISCO A, 1993, LANCET, V342, P526, DOI 10.1016/0140-6736(93)91648-6
   FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898
   Filteau SM, 1999, AM J CLIN NUTR, V69, P953
   GLASZIOU PP, 1993, BRIT MED J, V306, P366
   Humphrey JH, 1998, AM J CLIN NUTR, V68, P109
   Humphrey JH, 2000, LANCET, V356, P422, DOI 10.1016/S0140-6736(00)02541-1
   Jewell VC, 2004, EUR J CLIN NUTR, V58, P90, DOI 10.1038/sj.ejcn.1601753
   LUNN PG, 1991, T ROY SOC TROP MED H, V85, P8, DOI 10.1016/0035-9203(91)90137-N
   LUNN PG, 1991, LANCET, V338, P907, DOI 10.1016/0140-6736(91)91772-M
   Martines J, 1998, LANCET, V352, P1257
   McCullough FSW, 1999, P NUTR SOC, V58, P289, DOI 10.1017/S0029665199000403
   O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI 10.1097/00006454-200302000-00009
   RAMATHULLAH L, 1991, AM J CLIN NUTR, V54, P568
   Rice AL, 1999, J NUTR, V129, P356
   ROSS DA, 1993, LANCET, V342, P7, DOI 10.1016/0140-6736(93)91879-Q
   Semba RD, 2001, ACTA PAEDIATR, V90, P1107, DOI 10.1080/080352501317061477
   SOMMER A, 1986, LANCET, V1, P1169
   Sommer A, 2002, J NUTR, V132, p2845S
   Thurnham DI, 2003, LANCET, V362, P2052, DOI 10.1016/S0140-6736(03)15099-4
   THURNHAM DI, 1988, CLIN CHEM, V34, P377
   Thurnham DI, 2000, J INFECT DIS, V182, pS23, DOI 10.1086/315912
   VILLARD L, 1987, HUM NUTR-APPL NUTR, V41A, P135
   *WHO EPI, 1998, INT VIT A SUPPL IMM
   *WHO NUT, 1996, IND ASS VIT A DEF TH
   *WHO UNICEF IVACG, 1997, VIT A SUPPL GUID THE
NR 33
TC 45
Z9 46
U1 1
U2 5
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0140-6736
J9 LANCET
JI Lancet
PD JUN 23
PY 2007
VL 369
IS 9579
BP 2088
EP 2096
DI 10.1016/S0140-6736(07)60981-7
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 182GM
UT WOS:000247493100029
PM 17586304
OA No
DA 2017-08-15
ER

PT J
AU Majambere, S
   Lindsay, SW
   Green, C
   Kandeh, B
   Fillinger, U
AF Majambere, Silas
   Lindsay, Steven W.
   Green, Clare
   Kandeh, Balla
   Fillinger, Ulrike
TI Microbial larvicides for malaria control in The Gambia
SO MALARIA JOURNAL
LA English
DT Article
ID BACILLUS-THURINGIENSIS-ISRAELENSIS; GROWTH-REGULATOR PYRIPROXYFEN;
   ANOPHELES-GAMBIAE; CULEX-QUINQUEFASCIATUS; WESTERN KENYA; SRI-LANKA;
   FIELD POPULATIONS; MOSQUITO LARVAE; SPHAERICUS; EFFICACY
AB Background: Mosquito larval control may prove to be an effective tool for incorporating into integrated vector management (IVM) strategies for reducing malaria transmission. Here the efficacy of microbial larvicides against Anopheles gambiae s.l. was tested in preparation for a large-scale larviciding programme in The Gambia.
   Methods: The impact of water-dispersible (WDG) and corn granule (CG) formulations of commercial Bacillus sphaericus strain 2362 ( Bs; VectoLex (R)) and Bacillus thuringiensis var. israelensis strain AM65-52 (Bti; VectoBac (R)) on larval development were tested under laboratory and field conditions to ( 1) identify the susceptibility of local vectors, ( 2) evaluate the residual effect and retreatment intervals, ( 3) test the effectiveness of the microbials under operational application conditions and ( 4) develop a method for large-scale application.
   Results: The major malaria vectors were highly susceptible to both microbials. The lethal concentration (LC) to kill 95% of third instar larvae of Anopheles gambiae s. s. after 24 hours was 0.023 mg/l (14.9 BsITU/l) for Bs WDG and 0.132 mg/ l ( 396 ITU/l) for Bti WDG. In general Bs had little residual effect under field conditions even when the application rate was 200 times greater than the LC95. However, there was a residual effect up to 10 days in standardized field tests implemented during the dry season. Both microbials achieved 100% mortality of larvae 24 - 48 hours post-application but late instar larvae were detected 4 days after treatment. Pupae development was reduced by 94% ( 95% Confidence Interval = 90.8 - 97.5%) at weekly re-treatment intervals. Field tests showed that Bs had no residual activity against anopheline larvae. Both microbials provided complete protection when applied weekly. The basic training of personnel in identification of habitats, calibration of application equipment and active larviciding proved to be successful and achieved full coverage and control of mosquito larvae for three months under fully operational conditions.
   Conclusion: Environmentally safe microbial larvicides can significantly reduce larval abundance in the natural habitats of The Gambia and could be a useful tool for inclusion in an IVM programme. The costs of the intervention in this setting could be reduced with formulations that provide a greater residual effect.
C1 Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
   MRC Labs, Fajara, Gambia.
   Natl Malaria Control Programme, Banjul, Gambia.
RP Majambere, S (reprint author), Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
EM silas.majambere@durham.ac.uk; s.w.lindsay@durham.ac.uk; cgreen@mrc.gm;
   ballakandeh@yahoo.co.uk; ulrike.fillinger@durham.ac.uk
OI Fillinger, Ulrike/0000-0002-4037-431X
FU NIAID NIH HHS [U01 AI058250, 1 U01 AI058250-01]
CR BECKER N, 1993, J AM MOSQUITO CONTR, V9, P221
   BECKER N, 1995, J AM MOSQUITO CONTR, V11, P329
   BECKER N, 1994, J AM MOSQUITO CONTR, V10, P527
   Bogh C, 2003, B ENTOMOL RES, V93, P279, DOI 10.1079/BER2003239
   CHARLES JF, 1986, ANN INST PASTEUR MIC, V137B, P101, DOI 10.1016/S0769-2609(86)80097-7
   Charles JF, 2000, MEM I OSWALDO CRUZ, V95, P201, DOI 10.1590/S0074-02762000000700034
   Chen H, 2006, AM J TROP MED HYG, V75, P246
   Coleman M, 2006, J MED ENTOMOL, V43, P663, DOI 10.1603/0022-2585(2006)43[663:DAEDSS]2.0.CO;2
   FILINGER U, 2003, TROP MED INT HEALTH, V8, P37
   Fillinger U, 2004, TROP MED INT HEALTH, V9, P1274, DOI 10.1111/j.1365-3156.2004.01335.x
   Fillinger U, 2006, TROP MED INT HEALTH, V11, P1629, DOI 10.1111/j.1365-3156.2006.01733.x
   Gu WD, 2005, AM J TROP MED HYG, V73, P546
   Hougard J. M., 1990, Bacterial control of mosquitoes & black flies: biochemistry, genetics & applications of Bacillus thuringiensis israelensis and Bacillus sphaericus., P295
   HOUGARD JM, 1993, B WORLD HEALTH ORGAN, V71, P367
   KARCH S, 1990, J AM MOSQUITO CONTR, V6, P47
   KARCH S, 1991, J AM MOSQUITO CONTR, V7, P176
   KARCH S, 1992, J AM MOSQUITO CONTR, V8, P376
   Killeen GF, 2002, LANCET INFECT DIS, V2, P618, DOI 10.1016/S1473-3099(02)00397-3
   Koenraadt CJM, 2004, ACTA TROP, V90, P141, DOI 10.1016/j.actatropica.2003.11.007
   Montero Lago G., 1991, REV CUBA MED TROP, V43, P39
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90171-L
   Mukabana WR, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-9
   Mulla MS, 2003, J AM MOSQUITO CONTR, V19, P39
   MULLA MS, 1971, J ECON ENTOMOL, V64, P300
   Mulla MS, 1999, J VECTOR ECOL, V24, P99
   Mutuku FM, 2006, AM J TROP MED HYG, V74, P54
   NICOLAS L, 1987, MED VET ENTOMOL, V1, P157, DOI 10.1111/j.1365-2915.1987.tb00337.x
   *NMCP, 2002, NAT MAL CONTR STRAT
   PANTUWATANA S, 1990, J INVERTEBR PATHOL, V55, P189, DOI 10.1016/0022-2011(90)90054-A
   Pinkney AE, 2000, ENVIRON TOXICOL CHEM, V19, P678, DOI 10.1897/1551-5028(2000)019<0678:EOTMLT>2.3.CO;2
   Ragoonanansingh R. N., 1992, Bulletin of the Society for Vector Ecology, V17, P45
   Ravoahangimalala O., 1994, Bulletin of the Society for Vector Ecology, V19, P169
   Robert Vincent, 2002, Malar J, V1, P4, DOI 10.1186/1475-2875-1-4
   Rojas J E, 2001, Invest Clin, V42, P131
   ROZENDAAL JA, 1997, VECTOR CONTROL METHO, P411
   Schnetter W., 1981, Mitteilungen der Deutschen Gesellschaft fuer Allgemeine und Angewandte Entomologie, V2, P195
   SCOTT JA, 1993, AM J TROP MED HYG, V49, P520
   Seng CM, 2006, J AM MOSQUITO CONTR, V22, P152, DOI 10.2987/8756-971X(2006)22[152:IOAEOA]2.0.CO;2
   SERVICE MW, 1971, B WORLD HEALTH ORGAN, V45, P169
   Seyoum A, 1997, WORLD J MICROB BIOT, V13, P21, DOI 10.1007/BF02770802
   Shililu JI, 2003, J AM MOSQUITO CONTR, V19, P251
   Skovmand O, 1997, J VECTOR ECOL, V22, P43
   Skovmand O, 1999, J MED ENTOMOL, V36, P62
   SUTHERLAND DD, 1989, NEW JERSEY MOSQUITO, V76, P84
   Thomas CJ, 2000, T ROY SOC TROP MED H, V94, P159, DOI 10.1016/S0035-9203(00)90257-8
   *US EPA, RER EL DOC TEM
   Vanek MJ, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-154
   World Health Organization, 2003, GUID INT VECT MAN
   World Health Organization, 1999, ENV HLTH CRITERIA, V217, P1
   *WHO, 1992, ENT FIELD TECHN MAL, V77
   Winstanley PA, 2002, MICROBES INFECT, V4, P157, DOI 10.1016/S1286-4579(01)01523-4
   Yapabandara AMGM, 2004, J AM MOSQUITO CONTR, V20, P395
   Yapabandara AMGM, 2002, ACTA TROP, V81, P211, DOI 10.1016/S0001-706X(01)00208-X
   Yapabandara AMGM, 2001, ACTA TROP, V80, P265, DOI 10.1016/S0001-706X(01)00178-4
   Yohannes M, 2005, TROP MED INT HEALTH, V10, P1274, DOI 10.1111/j.1365-3156.2005.01512.x
   Zahiri NS, 2002, J MED ENTOMOL, V39, P513, DOI 10.1603/0022-2585-39.3.513
NR 56
TC 53
Z9 55
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUN 7
PY 2007
VL 6
AR 76
DI 10.1186/1475-2875-6-76
PG 14
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 184KA
UT WOS:000247638800001
PM 17555570
OA gold
DA 2017-08-15
ER

PT J
AU Burton, PR
   Clayton, DG
   Cardon, LR
   Craddock, N
   Deloukas, P
   Duncanson, A
   Kwiatkowski, DP
   McCarthy, MI
   Ouwehand, WH
   Samani, NJ
   Todd, JA
   Donnelly, P
   Barrett, JC
   Davison, D
   Easton, D
   Evans, D
   Leung, HT
   Marchini, JL
   Morris, AP
   Spencer, CCA
   Tobin, MD
   Attwood, AP
   Boorman, JP
   Cant, B
   Everson, U
   Hussey, JM
   Jolley, JD
   Knight, AS
   Koch, K
   Meech, E
   Nutland, S
   Prowse, CV
   Stevens, HE
   Taylor, NC
   Walters, GR
   Walker, NM
   Watkins, NA
   Winzer, T
   Jones, RW
   McArdle, WL
   Ring, SM
   Strachan, DP
   Pembrey, M
   Breen, G
   St Clair, D
   Caesar, S
   Gordon-Smith, K
   Jones, L
   Fraser, C
   Green, EK
   Grozeva, D
   Hamshere, ML
   Holmans, PA
   Jones, IR
   Kirov, G
   Moskvina, V
   Nikolov, I
   O'Donovan, MC
   Owen, MJ
   Collier, DA
   Elkin, A
   Farmer, A
   Williamson, R
   McGuffin, P
   Young, AH
   Ferrier, IN
   Ball, SG
   Balmforth, AJ
   Barrett, JH
   Bishop, DT
   Iles, MM
   Maqbool, A
   Yuldasheva, N
   Hall, AS
   Braund, PS
   Dixon, RJ
   Mangino, M
   Stevens, S
   Thompson, JR
   Bredin, F
   Tremelling, M
   Parkes, M
   Drummond, H
   Lees, CW
   Nimmo, ER
   Satsangi, J
   Fisher, SA
   Forbes, A
   Lewis, CM
   Onnie, CM
   Prescott, NJ
   Sanderson, J
   Mathew, CG
   Barbour, J
   Mohiuddin, MK
   Todhunter, CE
   Mansfield, JC
   Ahmad, T
   Cummings, FR
   Jewell, DP
   Webster, J
   Brown, MJ
   Lathrop, GM
   Connell, J
   Dominiczak, A
   Marcano, CAB
   Burke, B
   Dobson, R
   Gungadoo, J
   Lee, KL
   Munroe, PB
   Newhouse, SJ
   Onipinla, A
   Wallace, C
   Xue, MZ
   Caulfield, M
   Farrall, M
   Barton, A
   Bruce, IN
   Donovan, H
   Eyre, S
   Gilbert, PD
   Hider, SL
   Hinks, AM
   John, SL
   Potter, C
   Silman, AJ
   Symmons, DPM
   Thomson, W
   Worthington, J
   Dunger, DB
   Widmer, B
   Frayling, TM
   Freathy, RM
   Lango, H
   Perry, JRB
   Shields, BM
   Weedon, MN
   Hattersley, AT
   Hitman, GA
   Walker, M
   Elliott, KS
   Groves, CJ
   Lindgren, CM
   Rayner, NW
   Timpson, NJ
   Zeggini, E
   Newport, M
   Sirugo, G
   Lyons, E
   Vannberg, F
   Brown, MA
   Franklyn, JA
   Heward, JM
   Simmonds, MJ
   Hill, AVS
   Bradbury, LA
   Farrar, C
   Pointon, JJ
   Wordsmith, P
   Gough, SCL
   Seal, S
   Stratton, MR
   Rahman, N
   Ban, M
   Goris, A
   Sawcer, SJ
   Compston, A
   Conway, D
   Jallow, M
   Bumpstead, SJ
   Chaney, A
   Downes, K
   Ghori, MJR
   Gwilliam, R
   Inouye, M
   Keniry, A
   King, E
   McGinnis, R
   Potter, S
   Ravindrarajah, R
   Whittaker, P
   Withers, D
   Easton, D
   Pereira-Gale, J
   Hallgrimsdottir, IB
   Howie, BN
   Su, Z
   Teo, YY
   Vukcevic, D
   Bentley, D
   Caulfield, M
   Mathew, CG
   Worthington, J
AF Burton, Paul R.
   Clayton, David G.
   Cardon, Lon R.
   Craddock, Nick
   Deloukas, Panos
   Duncanson, Audrey
   Kwiatkowski, Dominic P.
   McCarthy, Mark I.
   Ouwehand, Willem H.
   Samani, Nilesh J.
   Todd, John A.
   Donnelly, Peter
   Barrett, Jeffrey C.
   Davison, Dan
   Easton, Doug
   Evans, David
   Leung, Hin-Tak
   Marchini, Jonathan L.
   Morris, Andrew P.
   Spencer, Chris C. A.
   Tobin, Martin D.
   Attwood, Antony P.
   Boorman, James P.
   Cant, Barbara
   Everson, Ursula
   Hussey, Judith M.
   Jolley, Jennifer D.
   Knight, Alexandra S.
   Koch, Kerstin
   Meech, Elizabeth
   Nutland, Sarah
   Prowse, Christopher V.
   Stevens, Helen E.
   Taylor, Niall C.
   Walters, Graham R.
   Walker, Neil M.
   Watkins, Nicholas A.
   Winzer, Thilo
   Jones, Richard W.
   McArdle, Wendy L.
   Ring, Susan M.
   Strachan, David P.
   Pembrey, Marcus
   Breen, Gerome
   St Clair, David
   Caesar, Sian
   Gordon-Smith, Katherine
   Jones, Lisa
   Fraser, Christine
   Green, Elain K.
   Grozeva, Detelina
   Hamshere, Marian L.
   Holmans, Peter A.
   Jones, Ian R.
   Kirov, George
   Moskvina, Valentina
   Nikolov, Ivan
   O'Donovan, Michael C.
   Owen, Michael J.
   Collier, David A.
   Elkin, Amanda
   Farmer, Anne
   Williamson, Richard
   McGuffin, Peter
   Young, Allan H.
   Ferrier, I. Nicol
   Ball, Stephen G.
   Balmforth, Anthony J.
   Barrett, Jennifer H.
   Bishop, D. Timothy
   Iles, Mark M.
   Maqbool, Azhar
   Yudasheve, Nadira
   Hall, Alistair S.
   Braund, Peter S.
   Dixon, Richard J.
   Mangino, Massimo
   Stevens, Suzanne
   Thompson, John R.
   Bredin, Francesca
   Tremelling, Mark
   Parkes, Miles
   Drummond, Hazel
   Lees, Charles W.
   Nimmo, Elaine R.
   Satsangi, Jack
   Fisher, Sheila A.
   Forbes, Alistair
   Lewis, Cathryn M.
   Onnie, Clive M.
   Prescott, Natalie J.
   Sanderson, Jeremy
   Mathew, Christopher G.
   Barbour, Jamie
   Mohiuddin, M. Khalid
   Todhunter, Catherine E.
   Mansfield, John C.
   Ahmad, Tariq
   Cummings, Fraser R.
   Jewell, Derek P.
   Webster, John
   Brown, Morris J.
   Lathrop, G. Mark
   Connell, John
   Dominiczak, Anna
   Marcano, Carolina A. Braga
   Burke, Beverley
   Dobson, Richard
   Gungadoo, Johannie
   Lee, Kate L.
   Munroe, Patricia B.
   Newhouse, Stephen J.
   Onipinla, Abiodun
   Wallace, Chris
   Xue, Mingzhan
   Caulfield, Mark
   Farrall, Martin
   Barton, Anne
   Bruce, Ian N.
   Donovan, Hannah
   Eyre, Steve
   Gilbert, Paul D.
   Hider, Samantha L.
   Hinks, Anne M.
   John, Sally L.
   Potter, Catherine
   Silman, Alan J.
   Symmons, Deborah P. M.
   Thomson, Wendy
   Worthington, Jane
   Dunger, David B.
   Widmer, Barry
   Frayling, Timothy M.
   Freathy, Rachel M.
   Lango, Hana
   Perry, John R. B.
   Shields, Beverley M.
   Weedon, Michael N.
   Hattersley, Andrew T.
   Hitman, Graham A.
   Walker, Mark
   Elliott, Kate S.
   Groves, Christopher J.
   Lindgren, Cecilia M.
   Rayner, Nigel W.
   Timpson, Nicholas J.
   Zeggini, Eleftheria
   Newport, Melanie
   Sirugo, Giorgio
   Lynons, Emily
   Vannberg, Fredrik
   Brown, Matthew A.
   Franklyn, Jayne A.
   Heward, Joanne M,
   Simmonds, Matthew J.
   Hill, Adrian V. S.
   Bradbury, Linda A.
   Farrar, Claire
   Pointon, Jennifer J.
   Wordsmith, Paul
   Gough, Stephen C. L.
   Seal, Sheila
   Stratton, Michael R.
   Rahman, Nazneen
   Ban, Maria
   Goris, An
   Sawcer, Stephen J.
   Compston, Alistair
   Conway, David
   Jallow, Muminatou
   Bumpstead, Suzannah J.
   Chaney, Amy
   Downes, Kate
   Ghori, Mohammed J. R.
   Gwilliam, Rhian
   Inouye, Michael
   Keniry, Andrew
   King, Emma
   McGinnis, Ralph
   Potter, Simon
   Ravindrarajah, Rathi
   Whittaker, Pamela
   Withers, David
   Easton, Doug
   Pereira-Gale, Joanne
   Hallgrimsdottir, Ingilef B.
   Howie, Bryan N.
   Su, Zhan
   Teo, Yik Ying
   Vukcevic, Damjan
   Bentley, David
   Caulfield, Mark
   Mathew, Christopher G.
   Worthington, Jane
CA Wellcome Trust Case Control Consortium
   Biol RA Genet & Genom Study Syndicate
   Breast Canc Susceptib Collaborat
TI Genome-wide association study of 14,000 cases of seven common diseases
   and 3,000 shared controls
SO NATURE
LA English
DT Review
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; CORONARY-ARTERY-DISEASE; MITOCHONDRIAL
   C-1-TETRAHYDROFOLATE SYNTHASE; LYMPHOID TYROSINE PHOSPHATASE;
   RHEUMATOID-ARTHRITIS FAMILIES; INFLAMMATORY-BOWEL-DISEASE; MULTILOCUS
   GENOTYPE DATA; AFFECTED SIBLING PAIRS; TYPE-1 DIABETES LOCUS; BIPOLAR
   DISORDER
AB There is increasing evidence that genome-wide association ( GWA) studies represent a powerful approach to the identification of genes involved in common human diseases. We describe a joint GWA study ( using the Affymetrix GeneChip 500K Mapping Array Set) undertaken in the British population, which has examined similar to 2,000 individuals for each of 7 major diseases and a shared set of similar to 3,000 controls. Case-control comparisons identified 24 independent association signals at P < 5 X 10(-7): 1 in bipolar disorder, 1 in coronary artery disease, 9 in Crohn's disease, 3 in rheumatoid arthritis, 7 in type 1 diabetes and 3 in type 2 diabetes. On the basis of prior findings and replication studies thus-far completed, almost all of these signals reflect genuine susceptibility effects. We observed association at many previously identified loci, and found compelling evidence that some loci confer risk for more than one of the diseases studied. Across all diseases, we identified a large number of further signals ( including 58 loci with single-point P values between 10(-5) and 5 X 10(-7)) likely to yield additional susceptibility loci. The importance of appropriately large samples was confirmed by the modest effect sizes observed at most loci identified. This study thus represents a thorough validation of the GWA approach. It has also demonstrated that careful use of a shared control group represents a safe and effective approach to GWA analyses of multiple disease phenotypes; has generated a genome-wide genotype database for future studies of common diseases in the British population; and shown that, provided individuals with non-European ancestry are excluded, the extent of population stratification in the British population is generally modest. Our findings offer new avenues for exploring the pathophysiology of these important disorders. We anticipate that our data, results and software, which will be widely available to other investigators, will provide a powerful resource for human genetics research.
C1 Univ Leicester, Genet Epidemiol Grp, Dept Hlth Sci, Leicester LE1 7RH, Leics, England.
   Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
   Univ Cambridge, Juvenile Diabet Res Fdn, Wellcome Trust Diabet & Inflammat Lab, Dept Med Genet,Cambridge Inst Med Res, Cambridge CB2 0XY, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Cardiff Univ, Dept Psychol Med, Sch Med, Cardiff CF14 4XN, Wales.
   Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
   Wellcome Trust Res Labs, London NW1 2BE, England.
   Univ Oxford, Churchill Hosp, Oxford Ctr Diabet Endocrinol & Med, Oxford OX3 7LJ, England.
   Univ Cambridge, Dept Haematol, Cambridge CB2 2PT, England.
   Cambridge Ctr, Natl Hlth Serv Blood & Transplant, Cambridge CB2 2PT, England.
   Univ Leicester, Glenfield Gen Hosp, Dept Cardiovasc Sci, Leicester LE3 9QP, Leics, England.
   Strangeways Res Lab, Canc Res UK Genet Epidemiol Unit, Cambridge CB1 8RN, England.
   Natl Hlth Serv Blood & Transplant, Sheffield S5 7JN, S Yorkshire, England.
   Welsh Blood Serv, Pontyclun CF72 9WB, Wales.
   Scottish Natl Blood Transfus Serv, Edinburgh EH17 7QT, Midlothian, Scotland.
   Southampton Ctr, Natl Hlth Serv Blood & Transplant, Southampton SO16 5AF, Hants, England.
   Univ Bristol, Avon Longitudinal Study Parents & Children, Bristol BS8 1TQ, Avon, England.
   St Georges Univ London, Div Community Hlth Serv, London SW17 0RE, England.
   UCL, Inst Child Hlth, London WC1N 1EH, England.
   Univ Aberdeen, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.
   Univ Birmingham, Dept Psychiat, Div Neurosci, Birmingham B15 2QZ, W Midlands, England.
   Cardiff Univ, Dept Psychol Med, Sch Med, Cardiff CF14 4XN, Wales.
   Kings Coll London, Inst Psychiat, London SE5 8AF, England.
   Royal Victoria Infirm, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   Univ Leeds, LIGHT Res Inst, Fac Med & Hlth, Leeds LS1 3EX, W Yorkshire, England.
   Univ Leeds, LIMM Res Inst, Fac Med & Hlth, Leeds LS1 3EX, W Yorkshire, England.
   Univ Cambridge, Addenbrookes Hosp, IBD Res Grp, Cambridge CB2 2QQ, England.
   Univ Edinburgh, Western Gen Hosp, Gastrointestinal Unit, Sch Mol & Clin Med, Edinburgh EH4 2XU, Midlothian, Scotland.
   Kings Coll London, Sch Med, Guys Hosp, Dept Med & Mol Genet, London SE1 9RT, England.
   UCL Hosp Trust, Inst Digest Dis, London NW1 2BU, England.
   Guys & St Thomas NHS Fdn Trust, Dept Gastroenterol, London SE1 7EH, England.
   Newcastle Univ, Royal Victoria Infirm, Dept Gastroenterol & Hepatol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   Univ Oxford, Radcliffe Infirm, Gastroenterol Unit, Oxford OX2 6HE, England.
   Aberdeen Royal Infirm, Aberdeen AB9 2ZB, Scotland.
   Univ Cambridge, Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 2QQ, England.
   Univ Cambridge, Addenbrookes Hosp, Diabet & Inflammat Lab, Cambridge CB2 2QQ, England.
   Ctr Natl Genotypage, F-91057 Paris, France.
   Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow G12 8TA, Lanark, Scotland.
   Queen Marys Sch Med, Clin Pharmacol Ctr, William Harvey Res Inst, London EC1M 6BQ, England.
   Queen Marys Sch Med, Barts & London Genome Ctr, William Harvey Res Inst, London EC1M 6BQ, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Univ Manchester, ARC Epidemiol Res Unit, Manchester M13 9PT, Lancs, England.
   Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England.
   Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter EX1 2LU, Devon, England.
   Peninsula Med Sch, Inst Biomed & Clin Sci, Exeter EX2 5DU, Devon, England.
   Royal London Hosp, Ctr Diabet & Metab Med, London E1 1BB, England.
   Univ Newcastle, Diabet Res Grp, Sch Clin Med Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Univ Bristol, MRC Ctr Causal Anal Translat Epidemiol, Bristol BS2 8PR, Avon, England.
   MRC Labs, Fajara, Gambia.
   Univ Queensland, Diamantina Inst Canc Immunol & Metab Med, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.
   Univ Oxford, Botnar Res Ctr, Oxford OX3 7BN, England.
   Univ Birmingham, Dept Med, Div Med Sci, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England.
   Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England.
   Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
   Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 2QQ, England.
RP Burton, PR (reprint author), Univ Leicester, Genet Epidemiol Grp, Dept Hlth Sci, Adrian Bldg, Leicester LE1 7RH, Leics, England.
RI HILL, Adrian/C-1306-2008; Jones, Ian/B-4925-2009; Dominiczak,
   Anna/D-2262-2009; Todd, John/A-3542-2010; Dobson, Richard/C-9269-2011;
   turton, miranda/F-4682-2011; Prescott, Natalie/F-6490-2011; Lango Allen,
   Hana/G-9026-2012; Newhouse, Stephen/C-9330-2011; Deloukas,
   Panos/B-2922-2013; Evans, David/H-6325-2013; McGuffin,
   Peter/A-1565-2012; Rahman, Nazneen/B-8890-2012; Worthington,
   Jane/M-9770-2014; Barton, Anne/N-2053-2014; Breen, Gerome/A-5540-2010;
   Goris, An/F-2943-2010; Holmans, Peter/F-4518-2015; Burton,
   Paul/H-7527-2016; mangino, massimo/F-5134-2011; eyre,
   stephen/K-3776-2017
OI Todd, John/0000-0003-2740-8148; Dobson, Richard/0000-0003-4224-9245;
   Prescott, Natalie/0000-0002-5901-7371; Lango Allen,
   Hana/0000-0002-7803-8688; Newhouse, Stephen/0000-0002-1843-9842;
   Deloukas, Panos/0000-0001-9251-070X; McGuffin,
   Peter/0000-0002-9888-2907; Worthington, Jane/0000-0003-0544-042X;
   Thomson, Wendy/0000-0002-9022-5179; Kirov, George/0000-0002-3427-3950;
   Escott-Price, Valentina/0000-0003-1784-5483; Walker,
   Neil/0000-0001-9796-7688; Grozeva, Detelina/0000-0003-3239-8415; Evans,
   David/0000-0003-0663-4621; Bishop, Tim/0000-0002-8752-8785; Barton,
   Anne/0000-0003-3316-2527; Breen, Gerome/0000-0003-2053-1792; Goris,
   An/0000-0002-1276-6682; Holmans, Peter/0000-0003-0870-9412; mangino,
   massimo/0000-0002-2167-7470; eyre, stephen/0000-0002-1251-6974; Potter,
   Simon/0000-0003-4208-4102; Barrett, Jenny/0000-0002-1720-7724; Hunt,
   Sarah/0000-0002-8350-1235; Brown, Matthew A/0000-0003-0538-8211;
   Freathy, Rachel/0000-0003-4152-2238; Zeggini,
   Eleftheria/0000-0003-4238-659X; Dunger, Professor
   David/0000-0002-2566-9304; Wallace, Chris/0000-0001-9755-1703;
   Kwiatkowski, Dominic/0000-0002-5023-0176; Lindgren,
   Cecilia/0000-0002-4903-9374
CR Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Altshuler D, 2000, NAT GENET, V26, P76
   ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302
   Barrett JC, 2006, NAT GENET, V38, P659, DOI 10.1038/ng1801
   Battegay EJ, 2005, HYPERTENSION PRINCIP
   Begovich AB, 2004, AM J HUM GENET, V75, P330, DOI 10.1086/422827
   Benkusky NA, 2004, BIOCHEM BIOPH RES CO, V322, P1280, DOI 10.1016/j.bbrc.2004.08.033
   Bersaglieri T, 2004, AM J HUM GENET, V74, P1111, DOI 10.1086/421051
   Blackwood DHR, 2001, AM J HUM GENET, V69, P428, DOI 10.1086/321969
   Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323
   Brand OJ, 2007, CLIN ENDOCRINOL, V66, P508, DOI 10.1111/j.1365-2265.2007.02762.x
   Caulfield M, 2003, LANCET, V361, P2118, DOI 10.1016/S0140-6736(03)13722-1
   CLAYTON D, 2003, HDB STAT GENETICS, P939
   Clayton DG, 2005, NAT GENET, V37, P1243, DOI 10.1038/ng1653
   Coelho M, 2005, HUM GENET, V117, P329, DOI 10.1007/s00439-005-1322-z
   Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870
   Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8
   Craddock N, 2005, BRIT J PSYCHIAT, V186, P364, DOI 10.1192/bjp.186.5.364
   Craddock N, 1996, BRIT J PSYCHIAT, V169, P58
   Craddock N, 2005, J MED GENET, V42, P193, DOI 10.1136/jmg.2005.030718
   Devendra D, 2004, BRIT MED J, V328, P750, DOI 10.1136/bmj.328.7442.750
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Di XJ, 2005, BIOINFORMATICS, V21, P1958, DOI 10.1093/bioinformatics/bti275
   *DIAB GEN I, 2007, SCIENCE, DOI DOI 10.1126/SCIENCE.1142358
   Dominiczak AF, 2004, CLIN EXP HYPERTENS, V26, P611, DOI 10.1081/CEH-200031939
   Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245
   Falush D, 2003, GENETICS, V164, P1567
   Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634
   Frayling TM, 1999, DIABETES, V48, P2475, DOI 10.2337/diabetes.48.12.2475
   FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111
   Gaya DR, 2006, LANCET, V367, P1271, DOI 10.1016/S0140-6736(06)68345-1
   Gloyn AL, 2003, DIABETES, V52, P568
   Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732
   Graves TD, 2005, POSTGRAD MED J, V81, P20, DOI 10.1136/pgmj.2004.022012
   Green EK, 2006, BRIT J PSYCHIAT, V188, P21, DOI 10.1192/bjp.bp.105.009969
   Green EK, 2005, ARCH GEN PSYCHIAT, V62, P642, DOI 10.1001/archpsyc.62.6.642
   GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102
   Gregory JF, 2000, AM J CLIN NUTR, V72, P1535
   Groves CJ, 2006, DIABETES, V55, P2640, DOI 10.2337/db06-0355
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0
   Hayes B, 2001, GENET SEL EVOL, V33, P209, DOI 10.1051/gse:2001117
   Helgadottir A, 2006, NAT GENET, V38, P68, DOI 10.1038/ng1692
   Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311
   Helgason A, 2007, NAT GENET, V39, P218, DOI 10.1038/ng1960
   Hinks A, 2007, ANN RHEUM DIS, V66, P683, DOI 10.1136/ard.2006.060459
   HIRSCHHORN JN, 2005, NATURE REV GENETICS, V6, P108
   Hubner N, 2005, NAT GENET, V37, P243, DOI 10.1038/ng1522
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Hutchison KE, 2004, PSYCHOL BULL, V130, P66, DOI 10.1037/0033-2909.130.1.66
   Hyttinen V, 2003, DIABETES, V52, P1052, DOI 10.2337/diabetes.52.4.1052
   Janssens ACJW, 2006, GENET MED, V8, P395, DOI 10.1097/01.gim.0000229689.18263.f4
   Jawaheer D, 2001, AM J HUM GENET, V68, P927, DOI 10.1086/319518
   John S, 2004, AM J HUM GENET, V75, P54, DOI 10.1086/422195
   JONSSONRYLANDER A, 2004, ARTER THROMB VAS BIO, V25, P180
   Kalinina N, 2004, ARTERIOSCL THROM VAS, V24, P1391, DOI 10.1161/01.ATV.0000133605.89421.79
   Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023
   Kobberling J, 1982, GENETICS DIABETES ME
   Krystal JH, 2002, MOL PSYCHIATR, V7, pS71, DOI 10.1038/sj.mp.4001021
   Lennard-Jones J E, 1989, Scand J Gastroenterol Suppl, V170, P2
   Lennard-Jones JE, 1989, SCAND J GASTROENTE S, V170, P6
   Leonard EJ, 1997, CIBA F SYMP, V212, P183
   Leonard EJ, 1997, CIBA F SYMP, V212, P92
   Li N, 2003, GENETICS, V165, P2213
   Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878
   Libioulle C, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030058
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8
   Lusis Aldons J, 2004, Annu Rev Genomics Hum Genet, V5, P189, DOI 10.1146/annurev.genom.5.061903.175930
   MACGREGOR AJ, 1994, J RHEUMATOL, V21, P1420
   MacKay K, 2002, ARTHRITIS RHEUM, V46, P632, DOI 10.1002/art.10147
   Mackay TEC, 2006, ANNU REV GENOM HUM G, V7, P339, DOI 10.1146/annurev.genom.7.080505.115758
   MANTEL N, 1963, J AM STAT ASSOC, V58, P690
   Marchini J, 2005, NAT GENET, V37, P413, DOI 10.1038/ng1537
   Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088
   MATSUZAKI H, 2004, NAT METHODS, V1, P104
   MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764
   McGuffin P, 2003, ARCH GEN PSYCHIAT, V60, P497, DOI 10.1001/archpsyc.60.5.497
   McQueen MB, 2005, AM J HUM GENET, V77, P582, DOI 10.1086/491603
   Mein CA, 2004, HUM MOL GENET, V13, pR169, DOI 10.1093/hmg/ddh078
   MENOZZI P, 1978, SCIENCE, V201, P786, DOI 10.1126/science.356262
   Muller-Oerlinghausen B, 2002, LANCET, V359, P241, DOI 10.1016/S0140-6736(02)07450-0
   Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740
   Mustelin T, 2005, NAT REV IMMUNOL, V5, P43, DOI 10.1038/nri1530
   Newhouse SJ, 2005, HUM MOL GENET, V14, P1805, DOI 10.1093/hmg/ddi187
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114
   OTSU K, 1990, J BIOL CHEM, V265, P13472
   Ozeki Y, 2003, P NATL ACAD SCI USA, V100, P289, DOI 10.1073/pnas.0136913100
   Pabst O, 2000, EMBO J, V19, P2015, DOI 10.1093/emboj/19.9.2015
   Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061
   Pietravalle F, 1996, J BIOL CHEM, V271, P5965
   Power C, 2006, INT J EPIDEMIOL, V35, P34, DOI 10.1093/ije/dyi183
   Prasannan P, 2003, J BIOL CHEM, V278, P43178, DOI 10.1074/jbc.M304319200
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Pritchard JK, 2000, GENETICS, V155, P945
   Rabbee N, 2006, BIOINFORMATICS, V22, P7, DOI 10.1093/bioinformatics/bti741
   Randak C, 2000, J INHERIT METAB DIS, V23, P520, DOI 10.1023/A:1005667707355
   RICE J, 1987, ARCH GEN PSYCHIAT, V44, P441
   Rioux JD, 2001, NAT GENET, V29, P223, DOI 10.1038/ng1001-223
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Sabeti PC, 2006, SCIENCE, V312, P1614, DOI 10.1126/science.1124309
   Samani NJ, 2005, AM J HUM GENET, V77, P1011
   Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528
   Saxena R, 2006, DIABETES, V55, P2890, DOI 10.2337/db06-0381
   Schmid M, 2000, ONCOGENE, V19, P5747, DOI 10.1038/sj.onc.1203942
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   Sharfe N, 1997, P NATL ACAD SCI USA, V94, P3168, DOI 10.1073/pnas.94.7.3168
   Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577
   Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616
   Smyth D, 2004, DIABETES, V53, P3020, DOI 10.2337/diabetes.53.11.3020
   Smyth DJ, 2006, NAT GENET, V38, P617, DOI 10.1038/ng1800
   SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773
   Steinthorsdottir V, 2007, NAT GENET, V39, P770, DOI 10.1038/ng2043
   STIRLING WD, 1982, STATISTICIAN, V31, P211, DOI 10.2307/2987987
   STRACHAN DP, 2007, INT J EPIDEMIOL, DOI DOI 10.1093/IJE/DY1309
   Stumvoll M, 2005, LANCET, V365, P1333, DOI 10.1016/S0140-6736(05)61032-X
   SYMMONS DPM, 1994, BRIT J RHEUMATOL, V33, P735
   Tobin MD, 2005, CIRCULATION, V112, P3423, DOI 10.1161/CIRCULATIONHA.105.555474
   Todd JA, 2006, NAT GENET, V38, P731, DOI 10.1038/ng0706-731
   Todd JA, 2007, NAT GENET, V39, P857, DOI 10.1038/ng2068
   Topol EJ, 2006, HUM MOL GENET, V15, pR117, DOI 10.1093/hmg/ddl183
   Travis SPL, 2006, GUT, V55, DOI 10.1136/gut.2005.081950b
   TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990
   Ubeda M, 2006, J BIOL CHEM, V281, P28858, DOI 10.1074/jbc.M604690200
   Valdar W, 2006, NAT GENET, V38, P879, DOI 10.1038/ng1840
   Vawter MP, 2002, MOL PSYCHIATR, V7, P571, DOI 10.1038/sj.mp.4001158
   Vella A, 2005, AM J HUM GENET, V76, P773, DOI 10.1086/429843
   Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075
   Walkup AS, 2005, ARCH BIOCHEM BIOPHYS, V442, P196, DOI 10.1016/j.abb.2005.08.007
   Watkins H, 2006, NAT REV GENET, V7, P163, DOI 10.1038/nrg1805
   Wight TN, 2005, ARTERIOSCL THROM VAS, V25, P12, DOI 10.1161/01.ATV.0000150043.43083.aa
   Wiltshire S, 2001, AM J HUM GENET, V69, P553, DOI 10.1086/323249
   WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589
   WORDSWORTH P, 1991, ANN RHEUM DIS, V50, P343, DOI 10.1136/ard.50.6.343
   WORTHINGTON J, 1994, BRIT J RHEUMATOL, V33, P970
   Worthington J., 2005, EPIDEMIOLOGY RHEUMAT
   Yamanouchi J, 2007, NAT GENET, V39, P329, DOI 10.1038/ng1958
   Yamazaki K, 2005, HUM MOL GENET, V14, P3499, DOI 10.1093/hmg/ddi379
   Yang QH, 2005, INT J EPIDEMIOL, V34, P1129, DOI 10.1093/ije/dyi130
   Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9
   Zeggini E, 2007, DIABETOLOGIA, V50, P1, DOI 10.1007/s00125-006-0507-x
   Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a
   Zondervan KT, 2004, NAT REV GENET, V5, P89, DOI 10.1038/nrg1270
NR 144
TC 4222
Z9 4330
U1 52
U2 668
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD JUN 7
PY 2007
VL 447
IS 7145
BP 661
EP 678
DI 10.1038/nature05911
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 175RI
UT WOS:000247030700035
OA No
HC Y
HP N
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   Kaye, S
   Miles, DJC
   Waight, P
   Jeffries, DJ
   Ojuola, OO
   Palmero, M
   Pinder, M
   Ismaili, J
   Flanagan, KL
   Aveika, AA
   Zaman, A
   Rowland-Jones, S
   McConkey, SJ
   Whittle, HC
   Marchant, A
AF van der Sande, Marianne A. B.
   Kaye, Steve
   Miles, David J. C.
   Waight, Pauline
   Jeffries, David J.
   Ojuola, Olubukola O.
   Palmero, Melba
   Pinder, Margaret
   Ismaili, Jamila
   Flanagan, Katie L.
   Aveika, Akum A.
   Zaman, Akram
   Rowland-Jones, Sarah
   McConkey, Samuel J.
   Whittle, Hilton C.
   Marchant, Arnaud
TI Risk Factors for and Clinical Outcome of Congenital Cytomegalovirus
   Infection in a Peri-Urban West-African Birth Cohort
SO PLOS ONE
LA English
DT Article
AB Background. Congenital cytomegalovirus (CMV) infection is the most prevalent congenital infection worldwide. Epidemiology and clinical outcomes are known to vary with socio-economic background, but few data are available from developing countries, where the overall burden of infectious diseases is frequently high. Methodology/Principal Findings. As part of an ongoing birth cohort study in The Gambia among term infants, urine samples were collected at birth and tested by PCR for the presence of CMV DNA. Risk factors for transmission and clinical outcome were assessed, including placental malaria infection. Babies were followed up at home monthly for morbidity and anthropometry, and at one year of age a clinical evaluation was performed. The prevalence of congenital CMV infection was 5.4% (40/741). A higher prevalence of hepatomegaly was the only significant clinical difference at birth. Congenitally infected children were more often first born babies (adjusted odds ratio (OR) 5.3, 95% confidence interval (CI) 2.0-13.7), more frequently born in crowded compounds (adjusted OR 2.9, 95% CI 1.0-8.3) and active placental malaria was more prevalent (adjusted OR 2.9, 95% CI 1.0-8.4). These associations were corrected for maternal age, bed net use and season of birth. During the first year of follow up, mothers of congenitally infected children reported more health complaints for their child. Conclusions/Significance. In this study, the prevalence of congenital CMV among healthy neonates was much higher than previously reported in industrialised countries, and was associated with active placental malaria infection. There were no obvious clinical implications during the first year of life. The effect of early life CMV on the developing infant in the Gambia could be mitigated by environmental factors, such as the high burden of other infections.
C1 [van der Sande, Marianne A. B.; Kaye, Steve; Miles, David J. C.; Waight, Pauline; Jeffries, David J.; Ojuola, Olubukola O.; Palmero, Melba; Pinder, Margaret; Ismaili, Jamila; Flanagan, Katie L.; Aveika, Akum A.; Zaman, Akram; Rowland-Jones, Sarah; McConkey, Samuel J.; Whittle, Hilton C.; Marchant, Arnaud] MRC Labs, Fajara, Gambia.
RP van der Sande, MAB (reprint author), MRC Labs, Fajara, Gambia.
EM Marianne.van.der.Sande@rivm.nl
RI McConkey, Samuel/E-7307-2012
OI McConkey, Samuel/0000-0001-9085-7793
FU Glaxo Smith Kline Biologicals (Belgium); Medical Research Council (UK)
FX This study was funded by Glaxo Smith Kline Biologicals (Belgium), and
   the Medical Research Council (UK). The funders of the study were not
   involved in design, conduct, collection-analysis-interpretetation of
   data, nor in the preparation-review-approval of the manuscript.
CR Barbi M, 2003, PEDIATR INFECT DIS J, V22, P39, DOI 10.1097/00006454-200301000-00012
   BELLO C, 1991, J CLIN PATHOL, V44, P366, DOI 10.1136/jcp.44.5.366
   Boppana SB, 2005, J PEDIATR-US, V146, P817, DOI 10.1016/j.jpeds.2005.01.059
   Boppana SB, 1999, PEDIATRICS, V104, P55, DOI 10.1542/peds.104.1.55
   BOPPANA SB, 1992, PEDIATR INFECT DIS J, V11, P93, DOI 10.1097/00006454-199202000-00007
   Boppana SB, 2001, NEW ENGL J MED, V344, P1366, DOI 10.1056/NEJM200105033441804
   BURNY W, 2004, EXPERT REV ANTI-INFE, V2, P6
   Chow SSW, 2006, J MED VIROL, V78, P747, DOI 10.1002/jmv.20618
   Doyle M, 1996, PEDIATR INFECT DIS J, V15, P1102, DOI 10.1097/00006454-199612000-00010
   Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5
   Fowler KB, 2003, JAMA-J AM MED ASSOC, V289, P1008, DOI 10.1001/jama.289.8.1008
   FOWLER KB, 1992, NEW ENGL J MED, V326, P663, DOI 10.1056/NEJM199203053261003
   GABRIEL MAM, 2005, AN PEDIATR, V62, P38
   Gaytant MA, 2005, J MED VIROL, V76, P71, DOI 10.1002/jmv.20325
   Gaytant MA, 2003, EUR J PEDIATR, V162, P248, DOI 10.1007/s00431-002-1115-3
   Ismail MR, 2000, HUM PATHOL, V31, P85, DOI 10.1016/S0046-8177(00)80203-8
   Ismaili J, 2003, CLIN EXP IMMUNOL, V133, P414, DOI 10.1046/j.1365-2249.2003.02243.x
   Iwasaki S, 2007, AUDIOL NEURO-OTOL, V12, P31, DOI 10.1159/000096156
   Looney RJ, 1999, CLIN IMMUNOL, V90, P213, DOI 10.1006/clim.1998.4638
   Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI200317470
   Moore SE, 2006, P NUTR SOC, V65, P311, DOI 10.1079/PNS2006503
   Moutaftsi M, 2002, BLOOD, V99, P2913, DOI 10.1182/blood.V99.8.2913
   Mussi-Pinhata MM, 1998, J PEDIATR-US, V132, P285, DOI 10.1016/S0022-3476(98)70446-9
   NICKELL SP, 1987, PARASITE IMMUNOL, V9, P161, DOI 10.1111/j.1365-3024.1987.tb00497.x
   Numazaki K, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-22
   Okoko BJ, 2003, ACTA TROP, V87, P193, DOI 10.1016/S0001-706X(03)00097-4
   Olsson J, 2000, MECH AGEING DEV, V121, P187
   Pass Robert F, 2005, Herpes, V12, P50
   Pawelec G, 2005, IMMUNOL REV, V205, P257, DOI 10.1111/j.0105-2896.2005.00271.x
   Picone O, 2005, PRENATAL DIAG, V25, P34, DOI 10.1002/pd.944
   Rogerson SJ, 2007, LANCET INFECT DIS, V7, P105, DOI 10.1016/S1473-3099(07)70022-1
   Ross SA, 2006, J PEDIATR-US, V148, P332, DOI 10.1016/j.jpeds.2005.09.030
   Schleiss MR, 2005, EXPERT REV VACCINES, V4, P381, DOI 10.1586/14760584.4.3.381
   Schleiss Mark R, 2004, Expert Rev Anti Infect Ther, V2, P389, DOI 10.1586/14787210.2.3.389
   Schlesinger Y, 2005, ISRAEL MED ASSOC J, V7, P237
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   Vochem M, 1998, PEDIATR INFECT DIS J, V17, P53, DOI 10.1097/00006454-199801000-00012
   WHITTLE HC, 1984, NATURE, V312, P449, DOI 10.1038/312449a0
   Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6
   Wreghitt TG, 2003, CLIN INFECT DIS, V37, P1603, DOI 10.1086/379711
   Yamamoto AY, 2001, PEDIATR INFECT DIS J, V20, P188, DOI 10.1097/00006454-200102000-00014
NR 41
TC 39
Z9 39
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 6
PY 2007
VL 2
IS 6
AR e492
DI 10.1371/journal.pone.0000492
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10GC
UT WOS:000207451500002
PM 17551573
OA gold
DA 2017-08-15
ER

PT J
AU Viviani, S
   Bah, E
   Carrieri, P
   Hall, AJ
   Kirk, G
   Mendy, M
   Montesano, R
   VanderSande, M
   Whittle, H
   Hainaut, P
AF Viviani, S.
   Bah, E.
   Carrieri, P.
   Hall, A. J.
   Kirk, G.
   Mendy, M.
   Montesano, R.
   VanderSande, M.
   Whittle, H.
   Hainaut, P.
TI Assessment of the initial assumptions of the Gambia hepatitis
   intervention study (GHIS) after twenty years of operation.
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Meeting Abstract
CT 40th Annual Meeting of the Society-for-Epidemiologic-Research
CY JUN 19-22, 2007
CL Boston, MA
SP Soc Epidemiolog Res
C1 MRC, IARC, GHIS, Banjul, Gambia.
RI Kirk, Gregory/A-8484-2009; Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 1
PY 2007
VL 165
IS 11
SU S
BP S36
EP S36
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 175SO
UT WOS:000247034500142
OA No
DA 2017-08-15
ER

PT J
AU Yan, L
   Goldberg, GR
   Zhou, B
   Jarjou, LM
   Schoenmakers, I
   Prentice, A
AF Yan, L.
   Goldberg, G. R.
   Zhou, B.
   Jarjou, L. M.
   Schoenmakers, I.
   Prentice, A.
TI Ethnic differences in PTH secretion and bone metabolism in response to
   oral phosphate administration
SO BONE
LA English
DT Meeting Abstract
CT 17th Scientific Meeting of the International-Bone-and-Mineral-Society
CY JUN 24-29, 2007
CL Montreal, CANADA
SP Int Bone & Mineral Soc
C1 MRC, Human Nutr Res, Cambridge, England.
   Shenyang Med Coll, Shenyang, Peoples R China.
   MRC Keneba, Fajara, Gambia.
CR SILVERBERG SJ, 1986, J BONE MINER RES, V1, P383
   Yan L, 1999, BONE, V24, P151, DOI 10.1016/S8756-3282(98)00168-9
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD JUN
PY 2007
VL 40
IS 6
SU 2
BP S188
EP S188
PG 1
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 181GV
UT WOS:000247426100179
OA No
DA 2017-08-15
ER

PT J
AU Johnstone, EC
   Elliot, KM
   David, SP
   Murphy, MFG
   Walton, RT
   Munafo, MR
AF Johnstone, Elaine C.
   Elliot, Katherine M.
   David, Sean P.
   Murphy, Michael F. G.
   Walton, Robert T.
   Munafo, Marcus R.
TI Association of COMT Val(108/158) met genotype with smoking cessation in
   a nicotine replacement therapy randomized trial
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID CATECHOL-O-METHYLTRANSFERASE; TOBACCO DEPENDENCE; GENETIC-VARIATION;
   FUNCTIONAL POLYMORPHISM; GENERAL-PRACTICE; RECEPTOR DRD2; STOP SMOKING;
   HUMAN BRAIN; DOPAMINE; ADDICTION
AB We investigated the association of catechol O-methyltransferase (COMT) genotype with abstinence following a smoking cessation attempt among a large cohort of smokers who attempted to quit using either the nicotine transdermal patch or placebo and were followed up over an 8-year period following their initial cessation attempt. In addition, we examined the possible moderating influence of sex on any association. The genotype x treatment interaction effect at 12-week follow-up indicated a greater benefit of active nicotine replacement treatment compared with placebo on likelihood of abstinence in the COMT Met/Met genotype group (33% versus 12%), in comparison to the Met/Val + Val/ Val group (22% versus 16%). Our results indicate that COMT genotype may moderate the effect of active transdermal nicotine patch compared with placebo, with reduced relative benefit of nicotine replacement therapy in individuals with Met/Val or Val/Val genotype. Our data follow an emerging pattern of results suggesting that genetic variation in the dopamine pathway may provide a future basis for tailored smoking cessation therapies, but indicate that different genes influencing various components of this pathway may have different effects on response to smoking cessation pharmacotherapy.
C1 Univ Bristol, Dept Expt Psychol, Bristol BS8 1TU, Avon, England.
   MRC Labs, Banjul, Gambia.
   Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
   Univ Oxford, Dept Clin Pharmacol, Oxford OX2 6HE, England.
   Univ Oxford, Childhood Canc Res Grp, Oxford OX2 6HE, England.
RP Munafo, MR (reprint author), Univ Bristol, Dept Expt Psychol, 12A Priory Rd, Bristol BS8 1TU, Avon, England.
EM marcus.munafo@bristol.ac.uk
OI David, Sean/0000-0002-4922-2603; Walton, Robert/0000-0001-7700-1907;
   Munafo, Marcus/0000-0002-4049-993X
FU NIDA NIH HHS [K08 DA014276, K08 DA014276-01A2, K08 DA014276-02, K08
   DA014276-03, K08 DA014276-04, K08 DA014276-05]
CR Akil M, 2003, J NEUROSCI, V23, P2008
   Balfour DJK, 2004, NICOTINE TOB RES, V6, P899, DOI 10.1080/14622200412331324965
   BALL P, 1972, J CLIN ENDOCR METAB, V34, P736
   Berrettini WH, 2007, BIOL PSYCHIAT, V61, P111, DOI 10.1016/j.biopsych.2006.04.030
   Beuten J, 2006, NEUROPSYCHOPHARMACOL, V31, P675, DOI 10.1038/sj.npp.1300997
   BURKE P, 1994, BRIT MED J, V308, P1476
   BURKE P, 1993, BRIT MED J, V306, P1304
   Chen JS, 2004, AM J HUM GENET, V75, P807, DOI 10.1086/425589
   Colilla S, 2005, PHARMACOGENET GENOM, V15, P393, DOI 10.1097/01213011-200506000-00004
   Dahl JP, 2006, PHARMACOGENOMICS J, V6, P194, DOI 10.1038/sj.tpj.6500358
   David SP, 2002, PHARMACOGENETICS, V12, P265, DOI 10.1097/00008571-200204000-00011
   Flint J, 2007, PSYCHOL MED, V37, P163, DOI 10.1017/S0033291706008750
   Hughes JR, 2003, J GEN INTERN MED, V18, P1053, DOI 10.1111/j.1525-1497.2003.20640.x
   Johnstone EC, 2004, PHARMACOGENETICS, V14, P83, DOI 10.1097/01.fpc.0000054154.92680.6d
   Jonsson EG, 1999, MOL PSYCHIATR, V4, P290, DOI 10.1038/sj.mp.4000532
   Lachman HM, 1996, PHARMACOGENETICS, V6, P243, DOI 10.1097/00008571-199606000-00007
   Lerman C, 2001, Nicotine Tob Res, V3, P353
   Lerman C, 2004, PHARMACOGENOMICS J, V4, P184, DOI 10.1038/sj.tpj.6500238
   Lerman C, 2006, NEUROPSYCHOPHARMACOL, V31, P231
   Malaiyandi V, 2006, MOL PSYCHIATR, V11, P400, DOI 10.1038/sj.mp.4001794
   McKinney EF, 2000, PHARMACOGENETICS, V10, P483, DOI 10.1097/00008571-200008000-00001
   Munafo M, 2004, NICOTINE TOB RES, V6, P769, DOI 10.1080/1462200410001696556
   Munafo MR, 2006, CANCER EPIDEM BIOMAR, V15, P398, DOI 10.1158/1055-9965.EPI-05-0648
   Munafo MR, 2005, CURR OPIN MOL THER, V7, P202
   Munafo MR, 2005, PHARMACOGENOMICS, V6, P211, DOI 10.1517/14622416.6.3.211
   Munafo MR, 2004, NICOTINE TOB RES, V6, P583, DOI 10.1080/14622200410001734030
   Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0
   Proctor RN, 2001, NAT REV CANCER, V1, P82, DOI 10.1038/35094091
   Redden DT, 2005, CANCER EPIDEM BIOMAR, V14, P1384, DOI 10.1158/1055-9965.EPI-04-0649
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   RUSSELL MAH, 1974, J ROY STAT SOC A STA, V137, P313, DOI 10.2307/2344953
   Seamans JK, 2004, PROG NEUROBIOL, V74, P1, DOI 10.1016/j.pneurobio.2004.05.006
   Shield AJ, 2004, MOL PSYCHIATR, V9, P151, DOI 10.1038/sj.mp.4001386
   Volkow ND, 2002, NEUROBIOL LEARN MEM, V78, P610, DOI 10.1006/nlme.2002.4099
   Weinstein CH, 2000, CONTEMP TOP LAB ANIM, V39, P19
   [Anonymous], 2003, WHO FRAM CONV TOB CO
   Xie T, 1999, MOL PHARMACOL, V56, P31
   Yudkin P, 2004, BRIT MED J, V328, P989, DOI 10.1136/bmj.38050.674826.AE
NR 38
TC 41
Z9 44
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JUN
PY 2007
VL 16
IS 6
BP 1065
EP 1069
DI 10.1158/1055-9965.EPI-06-0936
PG 5
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 177OT
UT WOS:000247163100004
PM 17548664
OA No
DA 2017-08-15
ER

PT J
AU Cehovin, A
   Cliff, JM
   Hill, PC
   Brookes, RH
   Dockrell, HM
AF Cehovin, Ana
   Cliff, Jacqueline M.
   Hill, Philip C.
   Brookes, Roger H.
   Dockrell, Hazel M.
TI Extended culture enhances sensitivity of a gamma interferon assay for
   latent Mycobacterium tuberculosis infection
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID LINKED IMMUNOSPOT ASSAY; SKIN-TEST; ANTIGENS ESAT-6; IFN-GAMMA;
   DIAGNOSIS; RESPONSES; EXPOSURE; HEALTHY; CFP-10; PPD
AB To test the hypothesis that prolonged culture would enhance the sensitivity of latent tuberculosis detection by a gamma interferon release assay, blood samples from 33 household contacts of Gambian tuberculosis patients were stimulated with Mycobacterium tuberculosis-specific antigens. After 24 h of culture, 66% were positive, compared to 93% after 6 days of culture.
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   Fajara, Med Res Ctr, Banjul, Gambia.
RP Cehovin, A (reprint author), St Georges Univ London, Dept Cellular & Mol Med, Cranmer Terrace, London SW12 0RE, England.
EM a.cehovin@ucl.ac.uk
OI Dockrell, Hazel/0000-0003-1869-9107
CR Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2
   Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520
   Black GF, 2001, INT J TUBERC LUNG D, V5, P664
   Brock I, 2001, INT J TUBERC LUNG D, V5, P462
   Desem N, 1998, CLIN DIAGN LAB IMMUN, V5, P531
   Gardam MA, 2003, LANCET INFECT DIS, V3, P148, DOI 10.1016/S1473-3099(03)00545-0
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Hill PC, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000068
   Hoft DF, 2000, CLIN INFECT DIS, V30, pS217, DOI 10.1086/313864
   Leyten EMS, 2006, J CLIN MICROBIOL, V44, P1197, DOI 10.1128/JCM.44.3.1197-1201.2006
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC
   Ravn P, 2005, CLIN DIAGN LAB IMMUN, V12, P491, DOI 10.1128/CDLI.12.4.491-496.2005
   Weir RE, 1999, CLIN EXP IMMUNOL, V116, P263
   *WHO, 2005, TB COUNTR PROF
NR 14
TC 27
Z9 27
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD JUN
PY 2007
VL 14
IS 6
BP 796
EP 798
DI 10.1128/CVI.00093-07
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 186HK
UT WOS:000247769500024
PM 17460111
OA No
DA 2017-08-15
ER

PT J
AU Natividad, A
   Hanchard, N
   Holland, M
   Mahdi, O
   Diakite, M
   Rockett, K
   Jallow, O
   Joof, HM
   Kwiatkowski, DP
   Mabey, DCW
   Bailey, RL
AF Natividad, A.
   Hanchard, N.
   Holland, M. J.
   Mahdi, O. S. M.
   Diakite, M.
   Rockett, K.
   Jallow, O.
   Joof, H. M.
   Kwiatkowski, D. P.
   Mabey, D. C. W.
   Bailey, R. L.
TI Genetic variation at the TNF locus and the risk of severe sequelae of
   ocular Chlamydia trachomatis infection in Gambians
SO GENES AND IMMUNITY
LA English
DT Article
DE human; Chlamydia trachomatis; scarring trachoma; tumor necrosis factor;
   association study; single nucleotide polymorphism
ID TUMOR-NECROSIS-FACTOR; SINGLE-NUCLEOTIDE POLYMORPHISMS; ALPHA PROMOTER
   REGION; NF-KAPPA-B; HISTOCOMPATIBILITY COMPLEX; RHEUMATOID-ARTHRITIS;
   CEREBRAL MALARIA; SUSCEPTIBILITY; EXPRESSION; LIPOPOLYSACCHARIDE
AB Tumor necrosis factor (TNF) is thought to be a key mediator of the inflammatory and fibrotic response to Chlamydia trachomatis (Ct) infection. A large matched-pair case-control study investigated putative functional single nucleotide polymorphisms (SNPs) across the major histocompatibility complex (MHC) class III region, including TNF and its immediate neighbors nuclear factor of kappa light polypeptide gene enhancer in B cells (I kappa BL), inhibitor like 1 and lymphotoxin alpha (LTA) in relation to the risk of scarring sequelae of ocular Ct infection. Haplotype and linkage disequilibrium analysis demonstrated two haplotypes, differing at position TNF-308, conferring an increased risk of trichiasis. The TNF-308A allele, and its bearing haplotype, correlated with increased TNF production in lymphocyte cultures stimulated with chlamydial elementary body antigen. Thus TNF-308A may determine directly, or be a marker of a high TNF producer phenotype associated with increased risk of sequelae of chlamydial infection. Multivariate analysis provided evidence for the presence of additional risk-associated variants near the TNF locus.
C1 Univ London London Sch Hyg & Trop Med, Infect Trop Dis Dept, Clin Res Unit, London WC1E 7HT, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
   MRC Labs, Fajara, Gambia.
   Natl Eye Care Program, Banjul, Gambia.
RP Natividad, A (reprint author), Univ London London Sch Hyg & Trop Med, Infect Trop Dis Dept, Clin Res Unit, Keppel St, London WC1E 7HT, England.
EM angels.natividad-sancho@lshtm.ac.uk
OI Mabey, David/0000-0002-0031-8276; Kwiatkowski,
   Dominic/0000-0002-5023-0176
FU Medical Research Council [G19/9, G0200454, MC_U190081961]
CR ALBERTELLA MR, 1994, HUM MOL GENET, V3, P793, DOI 10.1093/hmg/3.5.793
   Allcock RJN, 2001, IMMUNOGENETICS, V52, P289
   ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411
   Bayley JP, 2004, GENES IMMUN, V5, P315, DOI 10.1038/sj.gene.6364055
   Bobo L, 1996, INFECT IMMUN, V64, P3273
   BRADE L, 1987, INFECT IMMUN, V55, P482
   Burton MJ, 2006, INVEST OPHTH VIS SCI, V47, P847, DOI 10.1167/iovs.05-0714
   Burton MJ, 2004, INFECT IMMUN, V72, P7352, DOI 10.1128/IAI.72.12.7352-7356.2004
   Conway DJ, 1997, INFECT IMMUN, V65, P1003
   Engwerda C, 2005, CURR TOP MICROBIOL, V297, P103
   Faal N, 2005, CLIN EXP IMMUNOL, V142, P347, DOI 10.1111/j.1365-2249.2005.02917.x
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769
   GREENWOOD BM, 1987, ANN TROP MED PARASIT, V81, P345
   Hanchard N, 2006, IMMUNOGENETICS, V58, P465, DOI 10.1007/s00251-006-0118-1
   HAYES LJ, 1995, J INFECT DIS, V172, P268
   HOLTMANN H, 1990, INFECT IMMUN, V58, P3168
   Kelly KA, 1997, INFECT IMMUN, V65, P5198
   Knight JC, 2003, NAT GENET, V33, P469, DOI 10.1038/ng1124
   Knight JC, 2004, NAT GENET, V36, P394, DOI 10.1038/ng1331
   Knight JC, 1999, NAT GENET, V22, P145, DOI 10.1038/9649
   Knight JC, 1999, CLIN CHEM, V45, P1860
   Koch O, 2002, J INFECT DIS, V185, P1684, DOI 10.1086/340516
   LOCK C, 1999, ANN RHEUM DIS S1, V58, P1121
   Modiano D, 1996, P NATL ACAD SCI USA, V93, P13206, DOI 10.1073/pnas.93.23.13206
   Mozzato-Chamay N, 2001, GENES IMMUN, V2, P153, DOI 10.1038/sj.gene.6363753
   Myokai F, 1999, P NATL ACAD SCI USA, V96, P4518, DOI 10.1073/pnas.96.8.4518
   Natividad A, 2005, GENES IMMUN, V6, P332, DOI 10.1038/sj.gene.6364182
   Natividad A, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-40
   Newton J, 2003, ARTHRITIS RHEUM, V48, P90, DOI 10.1002/art.10719
   Okamoto K, 2003, AM J HUM GENET, V72, P303, DOI 10.1086/346067
   Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047
   Perry LL, 1997, J IMMUNOL, V158, P3344
   PIGUET PF, 1990, AM J PATHOL, V136, P103
   PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655
   PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0
   Ramsey KH, 2005, INFECT IMMUN, V73, P6962, DOI 10.1128/IAI.73.10.6962-6973.2005
   RHOADES KL, 1992, J BIOL CHEM, V267, P22102
   Shah AA, 2005, SEX TRANSM DIS, V32, P49, DOI 10.1097/01.olq.0000148299.14513.11
   SHEMERAVNI Y, 1988, INFECT IMMUN, V56, P2503
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   WILLIAMS DM, 1990, INFECT IMMUN, V58, P1572
NR 43
TC 40
Z9 40
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD JUN
PY 2007
VL 8
IS 4
BP 288
EP 295
DI 10.1038/sj.gene.6364384
PG 8
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 176WP
UT WOS:000247115900002
PM 17330135
OA No
DA 2017-08-15
ER

PT J
AU Miles, DJC
   van der Sande, M
   Jeffries, D
   Kaye, S
   Ismaili, J
   Ojuola, O
   Sanneh, M
   Touray, ES
   Waight, P
   Rowland-Jones, S
   Whittle, H
   Marchant, A
AF Miles, David J. C.
   van der Sande, Marianne
   Jeffries, David
   Kaye, Steve
   Ismaili, Jamila
   Ojuola, Olubukola
   Sanneh, Mariama
   Touray, Ebrima S.
   Waight, Pauline
   Rowland-Jones, Sarah
   Whittle, Hilton
   Marchant, Arnaud
TI Cytomegalovirus infection in Gambian infants leads to profound CD8
   T-cell differentiation
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID ELDERLY INDIVIDUALS; LYMPHOCYTE SUBPOPULATIONS; CLONAL EXPANSIONS;
   GAMMA-INTERFERON; PROTEIN PP65; CTL CLONES; IN-VIVO; VIRUS; EXPRESSION;
   CD4(+)
AB Cytomegalovirus (CMV) infection is endemic in Gambian infants, with 62% infected by 3 months and 85% by 12 months of age. We studied the CD8 T-cell responses of infants to CMV following primary infection. CMV-specific CD8 T cells, identified with tetramers, showed a fully differentiated phenotype (CD28(-) CD62(-)LCD95(+) perforin(+) granzyme A(+) Bcl-2(low)). Strikingly, the overall CD8 T-cell population developed a similar phenotype following CMV infection, which persisted for at least 12 months. In contrast, primary infection was accompanied by up-regulation of markers of activation (CD45RO and HLA-D) on both CMV-specific cells and the overall CD8 T-cell population and division (Ki-67) of specific cells, but neither pattern persisted. At 12 months of age, the CD8 T-cell population of CMV-infected infants was more differentiated than that of uninfected infants. Although the subpopulation of CMV-specific cells remained constant, the CMV peptidespecific gamma interferon response was lower in younger infants and increased with age. As the CD8 T-cell phenotype induced by CMV is indicative of immune dysfunction in the elderly, the existence of a similar phenotype in large numbers of Gambian infants raises the question of whether CMV induces a similarly deleterious effect.
C1 MRC Labs, Banjul, Gambia.
   Natl Inst Publ Hlth & Environm, RIVM, NL-3720 BA Bilthoven, Netherlands.
   Univ London Imperial Coll Sci Technol & Med, Jefferiss Trust Lab, London SW7 2AZ, England.
   Inst Pasteur, IBL, F-59019 Lille, France.
   Bronx Lebanon Hosp Ctr, Dept Pediat, Bronx, NY 10457 USA.
   Hlth Protect Agcy, Ctr Infect, Immunisat Dept, London, England.
   Univ Libre Bruxelles, Inst Med Immunol, Charleroi, Belgium.
RP Miles, DJC (reprint author), MLW, Clin Res Programme, POB 30096, Blantyre 3, Malawi.
EM djcm1@liverpool.ac.uk
FU Medical Research Council [MC_U190081978, MC_U190085854]
CR Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379
   BELLO C, 1991, J CLIN PATHOL, V44, P366, DOI 10.1136/jcp.44.5.366
   Budd RC, 2001, CURR OPIN IMMUNOL, V13, P356, DOI 10.1016/S0952-7915(00)00227-2
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   Bunde T, 2005, J EXP MED, V201, P1031, DOI 10.1084/jem.20042384
   Chalandon Y, 2006, BLOOD, V107, P389, DOI 10.1182/blood-2005-07-2746
   Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118
   Chen SF, 2004, J INFECT DIS, V189, P1619, DOI 10.1086/383249
   De Wit D, 2004, BLOOD, V103, P1030, DOI 10.1182/blood-2003-04-1216
   Gamadia LE, 2003, BLOOD, V101, P2686, DOI 10.1182/blood-2002-08-2502
   GAVIN MA, 1993, J IMMUNOL, V151, P3971
   GERDES J, 1984, J IMMUNOL, V133, P1710
   Gillespie GMA, 2000, J VIROL, V74, P8140, DOI 10.1128/JVI.74.17.8140-8150.2000
   Goriely S, 2001, J IMMUNOL, V166, P2141
   Goronzy JJ, 2001, J VIROL, V75, P12182, DOI 10.1128/JVI.75.24.12182-12187.2001
   Hamann D, 1999, IMMUNOL TODAY, V20, P177, DOI 10.1016/S0167-5699(99)01444-9
   Hamprecht K, 2001, LANCET, V357, P513, DOI 10.1016/S0140-6736(00)04043-5
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Jaimes MC, 2002, J VIROL, V76, P4741, DOI 10.1128/JVI.76.10.4741-4749.2002
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   Kanai T, 1996, J IMMUNOL, V157, P3681
   Kern F, 1999, J VIROL, V73, P8179
   Khan N, 2002, J IMMUNOL, V169, P1984
   Komatsu Haruki, 2006, Immun Ageing, V3, P11, DOI 10.1186/1742-4933-3-11
   Lohman BL, 2005, J VIROL, V79, P8121, DOI 10.1128/JVI.79.13.8121-8130.2005
   Looney RJ, 1999, CLIN IMMUNOL, V90, P213, DOI 10.1006/clim.1998.4638
   Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI200317470
   Olsson J, 2000, MECH AGEING DEV, V121, P187
   PASS RF, 1985, J INFECT DIS, V152, P243
   Patki AH, 1996, J CLIN INVEST, V98, P616, DOI 10.1172/JCI118831
   Pawelec G, 2005, IMMUNOL REV, V205, P257, DOI 10.1111/j.0105-2896.2005.00271.x
   Pawelec G, 2006, AGING CLIN EXP RES, V18, P171
   Retiere C, 2000, J VIROL, V74, P3948, DOI 10.1128/JVI.74.9.3948-3952.2000
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   SANDBERG J, 2003, J IMMUNOL, V170, P403
   Saurwein-Teissl M, 2002, J IMMUNOL, V168, P5893
   Seder RA, 2003, NAT IMMUNOL, V4, P835, DOI 10.1038/ni969
   Solache A, 1999, J IMMUNOL, V163, P5512
   Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882
   Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947
   Tsegaye A, 2003, CLIN IMMUNOL, V109, P338, DOI 10.1016/j.clim.2003.08.008
   UTZ U, 1992, J IMMUNOL, V149, P214
   VANLIER RA, 2003, NAT REV IMMUNOL, V3, P1
   WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603
   Weekes MP, 1999, IMMUNOLOGY, V98, P443, DOI 10.1046/j.1365-2567.1999.00901.x
   Weekes MP, 1999, J VIROL, V73, P2099
   Weekes MP, 1999, J IMMUNOL, V162, P7569
   Wikby A, 2002, EXP GERONTOL, V37, P445, DOI 10.1016/S0531-5565(01)00212-1
   Wills MR, 2002, J IMMUNOL, V168, P5455
   Wills MR, 1996, J VIROL, V70, P7569
NR 50
TC 51
Z9 52
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUN
PY 2007
VL 81
IS 11
BP 5766
EP 5776
DI 10.1128/JVI.00052-07
PG 11
WC Virology
SC Virology
GA 173II
UT WOS:000246866300032
PM 17376923
OA No
DA 2017-08-15
ER

PT J
AU Hill, PC
   Brookes, RH
   Fox, A
   Jackson-Sillah, D
   Jeffries, DJ
   Lugos, MD
   Donkor, SA
   Adetifa, IM
   de Jong, BC
   Aiken, AM
   Adegbola, RA
   McAdam, KP
AF Hill, Philip C.
   Brookes, Roger H.
   Fox, Annette
   Jackson-Sillah, Dolly
   Jeffries, David J.
   Lugos, Moses D.
   Donkor, Simon A.
   Adetifa, Ifedayo M.
   de Jong, Bouke C.
   Aiken, Alex M.
   Adegbola, Richard A.
   McAdam, Keith P.
TI Longitudinal assessment of an ELISPOT test for Mycobacterium
   tuberculosis infection
SO PLOS MEDICINE
LA English
DT Article
ID LINKED IMMUNOSPOT ASSAY; CELL-BASED ASSAY; SKIN-TEST; BCG VACCINATION;
   T-CELLS; DIAGNOSIS; GAMBIA; RESPONSES; SURVEILLANCE; SENSITIVITY
AB Background Very little longitudinal information is available regarding the performance of T cell-based tests for Mycobacterium tuberculosis infection. To address this deficiency, we conducted a longitudinal assessment of the enzyme-linked immunosorbent spot test (ELISPOT) test in comparison to the standard tuberculin skin test (TST).
   Methods and Findings In tuberculosis (TB) contacts we repeated ELISPOT tests 3 mo (n = 341) and 18 mo ( n 210) after recruitment and TSTs at 18 mo ( n 130). We evaluated factors for association with conversion and reversion and investigated suspected cases of TB. Of 207 ELISPOT-negative contacts, 51 (24.6%) had 3-mo ELISPOT conversion, which was associated with a positive recruitment TST (odds ratio [OR] 2.2, 95% confidence interval [CI] 1.0-5.0, p = 0.048) and negatively associated with bacillus Calmette-Guerin (BCG) vaccination (OR 0.5, 95% CI 0.2-1.0, p 0.06). Of 134 contacts, 54 (40.2%) underwent 3-mo ELISPOT reversion, which was less likely in those with a positive recruitment TST (OR 0.3, 95% CI 0.1-0.8, p = 0.014). Between 3 and 18 mo, 35/132 (26.5%) contacts underwent ELISPOT conversion and 28/78 (35.9%) underwent ELISPOT reversion. Of the 210 contacts with complete results, 73 (34.8%) were ELISPOT negative at all three time points; 36 (17.1%) were positive at all three time points. Between recruitment and 18 mo, 20 (27%) contacts had ELISPOT conversion; 37 (50%) had TST conversion, which was associated with a positive recruitment ELISPOT (OR 7.2, 95% CI 1.4-37.1, p = 0.019); 18 (32.7%) underwent ELISPOT reversion; and five (8.9%) underwent TST reversion. Results in 13 contacts diagnosed as having TB were mixed, but suggested higher TST sensitivity.
   Conclusions Both ELISPOT conversion and reversion occur after M. tuberculosis exposure. Rapid ELISPOT reversion may reflect M. tuberculosis clearance or transition into dormancy and may contribute to the relatively low reported ELISPOT conversion rate. Therefore, a negative ELISPOT test for M. tuberculosis infection should be interpreted with caution.
C1 MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
RP Hill, PC (reprint author), MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
EM phill@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU Medical Research Council [MC_U190071468, MC_U190081982]
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   Aiken AM, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-66
   Bellete B, 2002, CLIN INFECT DIS, V34, P1449, DOI 10.1086/340397
   Carrara S, 2004, CLIN INFECT DIS, V38, P754, DOI 10.1086/381754
   COMSTOCK GW, 1969, AM REV RESPIR DIS, V100, P839
   Demissie A, 2006, CLIN VACCINE IMMUNOL, V13, P179, DOI 10.1128/CVI.13.2.179-186.2006
   EDWARDS LB, 1953, WHO MONOGRAPH SERIES, V12
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9
   Ewer K, 2006, AM J RESP CRIT CARE, V174, P831, DOI 10.1164/rccm.200511-1783OC
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6
   Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962
   Haile Y, 2002, MICROBIOL-SGM, V148, P3881
   Heifets Leonid B., 1994, P85
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Jeffries DJ, 2006, INT J TUBERC LUNG D, V10, P192
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Menzies D, 1999, AM J RESP CRIT CARE, V159, P15
   Nicol MP, 2005, CLIN INFECT DIS, V40, P1301, DOI 10.1086/429245
   Pai M, 2006, AM J RESP CRIT CARE, V174, P349, DOI 10.1164/rccm.200604-472OC
   Pathan AA, 2001, J IMMUNOL, V167, P5217
   Pouchot J, 1997, ANN INTERN MED, V126, P210
   RICHARDS NM, 1979, AM REV RESPIR DIS, V120, P59
   Soysal A, 2005, LANCET, V366, P1443, DOI 10.1016/S0140-6736(05)67534-4
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406
   WASZHOCKERT O, 1947, ANN MED FENN, V96, P764
   Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139
   Wilkinson KA, 2006, J INFECT DIS, V193, P354, DOI 10.1086/499311
   [Anonymous], 1956, BMJ, V1, P413
NR 30
TC 104
Z9 107
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1549-1277
J9 PLOS MED
JI PLos Med.
PD JUN
PY 2007
VL 4
IS 6
BP 1061
EP 1070
AR e192
DI 10.1371/journal.pmed.0040192
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 182AA
UT WOS:000247476300018
PM 17564487
OA gold
DA 2017-08-15
ER

PT J
AU Jackson-Sillah, D
   Hill, PC
   Fox, A
   Brookes, RH
   Donkor, SA
   Lugos, MD
   Howie, SRC
   Fielding, KR
   Jallow, A
   Lienhardt, C
   Corrah, T
   Adegbola, RA
   McAdam, KP
AF Jackson-Sillah, Dolly
   Hill, Philip C.
   Fox, Annette
   Brookes, Roger H.
   Donkor, Simon A.
   Lugos, Moses D.
   Howie, Stephen R. C.
   Fielding, Katherine R.
   Jallow, Adama
   Lienhardt, Christian
   Corrah, Tumani
   Adegbola, Richard A.
   McAdam, Keith P.
TI Screening for tuberculosis among 2381 household contacts of
   sputum-smear-positive cases in The Gambia
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE tuberculosis; Mycobacterium tuberculosis; screening; tuberculin skin
   test; ELISPOT; The Gambia
ID SECRETED ANTIGENIC TARGET; T-CELL RESPONSES; MYCOBACTERIUM-TUBERCULOSIS;
   PULMONARY TUBERCULOSIS; RISK-FACTORS; SKIN-TEST; INFECTION; DIAGNOSIS;
   DISEASE; ASSAY
AB Contact investigation is a key component of tuberculosis (TB) control in developed, but not developing, countries. We aimed to measure the prevalence of TB among household contacts of sputum-smear-positive TB cases in The Gambia and to assess the sensitivity of an enzyme-linked immunospot (ELISPOT) assay in this regard. Household contacts of adult smear-positive TB patients were assessed by questionnaire, purified protein derivative (PPD) skin test, ELISPOT assay, physical examination, chest X-ray and sputum/gastric aspirate. Thirty-three TB cases were identified from 2174 of 2381 contacts of 317 adult smear-positive pulmonary TB patients, giving a prevalence of 1518/100000. The cases identified tended to have milder disease than those passively detected. The sensitivity of ESAT-6/CFP-10 ELISPOT test as a screening test for TB disease was estimated as 71%. Fifty-six per cent of contacts with a PPD skin test result >= 10 mm induration had detectable responses to ESAT-6/CFP-10 by ELISPOT, 11% with a negative PPD skin test (<10 mm) had a positive ESAT-6/CFP-10 response. Active screening for TB among contacts of TB patients may have a role in TB control in The Gambia. These individuals are a high-risk group, and the disease identified is less advanced than that found through passive case detection. An ELISPOT assay was relatively insensitive as a screening test for TB. (C) 2007 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights reserved.
C1 MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Govt Gambia, Natl Leprosy & TB Control Programme, Banjul, Gambia.
   Int Union TB & Lung Dis, Paris, France.
   Inst Rech Dev, Dakar, Senegal.
RP Hill, PC (reprint author), MRC Labs, Bacterial Dis Programme, Box 273, Banjul, Gambia.
EM phitt@mrc.gm
FU Medical Research Council [MC_U190088478, MC_U190071468]
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   Aiken AM, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-66
   Andersen Ase Bengard, 1994, P307
   Arend SM, 2000, J INFECT DIS, V181, P1850, DOI 10.1086/315448
   BASS J, 1992, AM REV RESPIR DIS, V146, P1623
   Bellete B, 2002, CLIN INFECT DIS, V34, P1449, DOI 10.1086/340397
   CHAPARAS SD, 1970, AM REV RESPIR DIS, V101, P74
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977
   Delgado JC, 2002, P NATL ACAD SCI USA, V99, P7576, DOI 10.1073/pnas.062056099
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6
   GILPIN TP, 1987, S AFR MED J, V72, P260
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Hill PC, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-156
   *KNCV, 2003, GAMB NAT TB CONTR PR
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1
   LALVANI A, 2001, J INFECT DIS, V184, P1497
   Lienhardt C, 2005, INT J EPIDEMIOL, V34, P914, DOI 10.1093/ije/dyi100
   Mehra V, 1996, J INFECT DIS, V174, P431
   MLIKACABANNE N, 1995, AM J RESP CRIT CARE, V152, P794
   Otero DC, 1999, EUR J CLIN MICROBIOL, V18, P790
   Rathman G, 2003, INT J TUBERC LUNG D, V7, P942
   Riley R L, 1991, Bull Int Union Tuberc Lung Dis, V66, P95
   Salazar-Vergara RML, 2003, INT J TUBERC LUNG D, V7, pS494
   Skjot RLV, 2000, INFECT IMMUN, V68, P214
   Sodhi A, 1997, CLIN INFECT DIS, V25, P617, DOI 10.1086/513769
   Struthers EB, 1961, AM REV RESPIR DIS, V93, P808
   SUE KHK, 1963, AM J PUBLIC HEALTH, V93, P1761
   Teixeira L, 2001, INT J TUBERC LUNG D, V5, P321
   Ulrichs T, 1998, EUR J IMMUNOL, V28, P3949, DOI 10.1002/(SICI)1521-4141(199812)28:12<3949::AID-IMMU3949>3.3.CO;2-W
   Ulrichs T, 2000, INFECT IMMUN, V68, P6073, DOI 10.1128/IAI.68.10.6073-6076.2000
   Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001
   Wang PD, 2000, J INFECTION, V41, P249, DOI 10.1053/jinf.2000.0736
   Zachariah R, 2003, INT J TUBERC LUNG D, V7, P1033
NR 35
TC 27
Z9 27
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0035-9203
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JUN
PY 2007
VL 101
IS 6
BP 594
EP 601
DI 10.1016/j.trstmh.2007.02.001
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 172WE
UT WOS:000246834400012
PM 17368495
OA No
DA 2017-08-15
ER

PT J
AU Smith, H
   Bukirwa, H
   Mukasa, O
   Snell, P
   Adeh-Nsoh, S
   Mbuyita, S
   Honorati, M
   Orji, B
   Garner, P
AF Smith, Helen
   Bukirwa, Hasifa
   Mukasa, Oscar
   Snell, Paul
   Adeh-Nsoh, Sylvester
   Mbuyita, Selemani
   Honorati, Masanja
   Orji, Bright
   Garner, Paul
TI Access to electronic health knowledge in five countries in Africa: a
   descriptive study
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
ID INFORMATION
AB Background: Access to medical literature in developing countries is helped by open access publishing and initiatives to allow free access to subscription only journals. The effectiveness of these initiatives in Africa has not been assessed. This study describes awareness, reported use and factors influencing use of on-line medical literature via free access initiatives.
   Methods: Descriptive study in four teaching hospitals in Cameroon, Nigeria, Tanzania and Uganda plus one externally funded research institution in The Gambia. Survey with postgraduate doctors and research scientists to determine Internet access patterns, reported awareness of on-line medical information and free access initiatives; semi structured interviews with a sub-sample of survey participants to explore factors influencing use.
   Results: In the four African teaching hospitals, 70% of the 305 postgraduate doctors reported textbooks as their main source of information; 66% had used the Internet for health information in the last week. In two hospitals, Internet cafes were the main Internet access point. For researchers at the externally-funded research institution, electronic resources were their main source, and almost all had used the Internet in the last week. Across all 333 respondents, 90% had heard of PubMed, 78% of BMJ on line, 49% the Cochrane Library, 47% HINARI, and 19% BioMedCentral. HINARI use correlates with accessing the Internet on computers located in institutions. Qualitative data suggested there are difficulties logging into HINARI and that sometimes it is librarians that limit access to passwords.
   Conclusion: Text books remain an important resource for postgraduate doctors in training. Internet use is common, but awareness of free-access initiatives is limited. HINARI and other initiatives could be more effective with strong institutional endorsement and management to promote and ensure access.
C1 Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Grp, Liverpool L3 5QA, Merseyside, England.
   Makarere Univ, Malaria Res Grp, Kampala, Uganda.
   Ifakara Hlth Res & Dev Ctr, Ifakara, Tanzania.
   MRC Labs, Banjul, Gambia.
   Univ Ibadan, Coll Med, Dept Hlth Promot & Educ, Ibadan, Nigeria.
RP Smith, H (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Grp, Liverpool L3 5QA, Merseyside, England.
EM cjdhel@liv.ac.uk; hbukirwa@liverpool.ac.uk; oscarmukasa@hotmail.com;
   psnell@mrc.gm; adeh_nsoh@yahoo.com; mbuita@yahoo.com;
   honorati.masanja@unibas.ch; brightorji@hotmail.com; pgarner@liv.ac.uk
OI smith, helen/0000-0002-6252-3793; Garner, Paul/0000-0002-0607-6941
CR Aronson B, 2004, NEW ENGL J MED, V350, P966, DOI 10.1056/NEJMp048009
   BEMELMANS M, 2005, THESIS LIVERPOOL SCH
   *FDN RES HLTH SYST, 2002, UNPUB HLTH INF NEEDS
   *GLOB FOR HLTH RES, 2004, 1090 GLOB FOR HLTH R
   Godlee F, 2004, LANCET, V364, P295, DOI 10.1016/S0140-6736(04)16681-6
   Horton R, 2000, LANCET, V355, P2231, DOI 10.1016/S0140-6736(00)02414-4
   Katikireddi SV, 2004, BRIT MED J, V328, P1190, DOI 10.1136/bmj.328.7449.1190
   KUCKARTZ U, 2005, MAXQDA SOFTWARE VERS
   Ritchie J., 2004, QUALITATIVE RES PRAC
   Wilson P, 2001, QUAL HEALTH CARE, V10, P83, DOI 10.1136/qhc.10.2.83
NR 10
TC 27
Z9 27
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD MAY 17
PY 2007
VL 7
AR 72
DI 10.1186/1472-6963-7-72
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 175LC
UT WOS:000247014100001
PM 17509132
OA gold
DA 2017-08-15
ER

PT J
AU Wiseman, V
   Scott, A
   McElroy, B
   Conteh, L
   Stevens, W
AF Wiseman, Virginia
   Scott, Anthony
   McElroy, Brendan
   Conteh, Lesong
   Stevens, Warren
TI Determinants of bed net use in The Gambia: Implications for malaria
   control
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID INSECTICIDE-TREATED BEDNETS; PERMETHRIN-IMPREGNATED BEDNETS; RANDOMIZED
   CONTROLLED-TRIAL; HEALTH-CARE; TARGETED CHEMOPROPHYLAXIS;
   COST-EFFECTIVENESS; MOSQUITO NETS; WEST-AFRICA; RURAL AREA;
   CHILD-MORTALITY
AB Malaria is still one of the biggest health threats in the developing world, with an estimated 300 million episodes per year and one million deaths, most of which are in sub-Saharan Africa. Although the efficacy and cost-effectiveness of treated bed nets has been widely reported, little is known about the range, strength, or interaction between different factors that influence their demand at the household level. This study modeled the determinants of-bed net ownership as well as the factors that influence the number of bed nets purchased. Data was collected from 1,700 randomly selected households in the Farafenni region of The Gambia. Interviews were also held with 129 community spokespersons to explore the extent to which community level factors such as the quality of roads and access to market centers also influence demand for bed nets. The results of each model of demand and their policy implications are discussed.
C1 London Sch Hyg & Trop Med, Hlth Policy Unit & gates Malaria partnership, London WC1B 3DP, England.
   Univ Melbourne, Melbourne Inst Appl Econ & Social Res, Melbourne, Vic, Australia.
   Natl Univ Ireland Univ Coll Cork, Dept Econ, Cork, Ireland.
   MRC, Fajara, Gambia.
RP Conteh, L (reprint author), London Sch Hyg & Trop Med, Hlth Policy Unit & gates Malaria partnership, 50 Bedford Sq, London WC1B 3DP, England.
EM virginia.wiseman@lshtm.ac.uk; a.scott@unimelb.edu.au; b.mcelroy@ucc.ie;
   lesong.conteh@lshtm.ac.uk; wstevens@mrc.gm
RI Scott, Anthony/E-6636-2010
OI Scott, Anthony/0000-0002-2851-5378
CR Agyepong IA, 1999, J BIOSOC SCI, V31, P79, DOI 10.1017/S0021932099000796
   AGYEPONG LA, 1992, WOMEN TROPICAL DIS, P176
   Ahorlu CK, 1997, TROP MED INT HEALTH, V2, P488, DOI 10.1046/j.1365-3156.1997.d01-298.x
   AIKIN JS, 1995, SOC SCI MED, V40, P1527
   Aikins MK, 1998, SOC SCI MED, V46, P181, DOI 10.1016/S0277-9536(97)00145-7
   AIKINS MK, 1993, T ROY SOC TROP MED H, V87, P25, DOI 10.1016/0035-9203(93)90172-M
   Alaii JA, 2003, AM J TROP MED HYG, V68, P137
   ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O
   Binka FN, 1996, TROP MED INT HEALTH, V1, P147
   Binka FN, 1997, TROP MED INT HEALTH, V2, P499, DOI 10.1046/j.1365-3156.1997.d01-299.x
   Cham MK, 1996, HEALTH POLICY PLANN, V11, P292, DOI 10.1093/heapol/11.3.292
   Chawla M, 2000, HEALTH POLICY PLANN, V15, P76, DOI 10.1093/heapol/15.1.76
   Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X
   Curtis CF, 1996, MED VET ENTOMOL, V10, P1, DOI 10.1111/j.1365-2915.1996.tb00075.x
   Deaton A. S., 1997, ANAL HOUSEHOLD SURVE
   *DFID, 2002, MEAS HLTH SURV POV S
   Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292
   Gallup JL, 2001, AM J TROP MED HYG, V64, P85
   GILSON L, 1994, SOC SCI MED, V39, P767, DOI 10.1016/0277-9536(94)90038-8
   Goodman C., 2000, EC MALARIA CONTROL S
   Goodman CA, 1999, HEALTH POLICY PLANN, V14, P301, DOI 10.1093/heapol/14.4.301
   Grosh M., 2000, DESIGNING HOUSEHOLD
   Guyatt HL, 2002, TROP MED INT HEALTH, V7, P846, DOI 10.1046/j.1365-3156.2002.00929.x
   Habluetzel A, 1997, TROP MED INT HEALTH, V2, P855, DOI 10.1046/j.1365-3156.1997.d01-413.x
   IMOUKHUEDE EB, 2003, PROCUREMENT USE BEDN
   LITVACK JI, 1993, SOC SCI MED, V37, P369, DOI 10.1016/0277-9536(93)90267-8
   MAKEMBA AM, 1995, HEALTH POLICY PLANN, V10, P50, DOI 10.1093/heapol/10.1.50
   McKenzie David J., 2003, 042 HARV U CTR INT D
   *MED RES COUNC, 2004, FAR DEM SURV SYST PR
   Mills A, 1998, ANN TROP MED PARASIT, V92, P435
   Minujin A, 2002, DESARROLLO ECON, V42, P129, DOI 10.2307/3455980
   Mugisha F, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-40
   Nevill CG, 1996, TROP MED INT HEALTH, V1, P139
   Nuwaha F, 2002, TROP MED INT HEALTH, V7, P462, DOI 10.1046/j.1365-3156.2002.00877.x
   OKEYO AP, 1979, STUD FAMILY PLANN, V10, P337, DOI 10.2307/1966089
   Phillips-Howard PA, 2003, AM J TROP MED HYG, V68, P23
   PICARD J, 1993, T ROY SOC TROP MED H, V87, P53, DOI 10.1016/0035-9203(93)90176-Q
   POHLMEIER W, 1995, J HUM RESOUR, V30, P339, DOI 10.2307/146123
   Rashed S, 1999, SOC SCI MED, V49, P993, DOI 10.1016/S0277-9536(99)00152-5
   *RBM, 2004, ROLL BACK MAL PARTN
   REED C, 1997, MALARIA INTERVENTION
   SAUERBORN R, 1991, TROP MED PARASITOL, V42, P219
   SHEPARD DS, 1991, TROP MED PARASITOL, V42, P199
   Simon JL, 2002, B WORLD HEALTH ORGAN, V80, P892
   SNOW RW, 1987, T ROY SOC TROP MED H, V81, P563, DOI 10.1016/0035-9203(87)90408-1
   SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9
   Tanner M, 1998, SOC SCI MED, V46, P523, DOI 10.1016/S0277-9536(97)00195-0
   TURNER A, 2001, MEASURE EVALUATION M
   UNICEF, 2003, 5 UNICEF
   *UNICEF WHO, 2003, AFR MAL REP
   WARNER MW, 1996, GENDER ROLES CONCEPT
   *WHO, 2001, ANT DRUG COMB THER R, P33
   WINCH PJ, 1994, SOC SCI MED, V39, P63, DOI 10.1016/0277-9536(94)90166-X
   Wiseman V, 2006, TROP MED INT HEALTH, V11, P419, DOI 10.1111/j.1365-3156.2006.01586.x
   Wiseman V, 2003, AM J TROP MED HYG, V68, P61
   Wooldridge J, 2003, INTRO ECONOMETRICS
   WORRALL E, 2003, 0103 HEFP
   YENENEH H, 1993, B WORLD HEALTH ORGAN, V71, P763
NR 58
TC 24
Z9 24
U1 1
U2 11
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAY
PY 2007
VL 76
IS 5
BP 830
EP 836
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 165SR
UT WOS:000246326300010
PM 17488900
OA No
DA 2017-08-15
ER

PT J
AU Bogh, C
   Lindsay, SW
   Clarke, SE
   Dean, A
   Jawara, M
   Pinder, M
   Thomas, CJ
AF Bogh, Claus
   Lindsay, Steven W.
   Clarke, Sian E.
   Dean, Andy
   Jawara, Musa
   Pinder, Margaret
   Thomas, Christopher J.
TI High spatial resolution mapping of malaria transmission risk in The
   Gambia, West Africa, using landsat TM satellite imagery
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID TREATED BED NETS; SENEGAL RIVER BASIN; ANOPHELES-GAMBIAE; TARGETED
   CHEMOPROPHYLAXIS; RURAL AREA; PASSIVE ZOOPROPHYLAXIS; USAMBARA
   MOUNTAINS; COMPLEX MOSQUITOS; UNTREATED BEDNETS; VECTOR DENSITY
AB Understanding local variability in malaria transmission risk is critically important when designing intervention or vaccine trials. Using a combination of field data, satellite image analysis, and GIS modeling, we developed a high-resolution map of malaria entomological inoculation rates (EIR) in The Gambia, West Africa. The analyses are based on the variation in exposure to malaria parasites experienced in 48 villages in 1996 and 21 villages in 1997. The entomological inoculation rate (EIR) varied from 0 to 166 infective bites per person per rainy season. Detailed field surveys identified the major Anopheles gambiae s.l. breeding habitats. These habitats were mapped by classification of a LANDSAT (TM) satellite image with an overall accuracy of 85%. Village EIRs decreased as a power function based on the breeding areas size and proximity. We use this relationship and the breeding habitats to map the variation in EIR over the entire 2500-km(2) study area.
C1 Univ Durham, Sch Biol & Biomed Sci, Durham DH1 3LE, England.
   Univ Wales, Inst Rural Sci, CIRRE, Aberystwyth, Dyfed, Wales.
   London Sch Hyg & Trop Med, Gates Malaria Partnership, London WC1B 3DP, England.
   Hatfield Consultants, Vancouver, BC, Canada.
   MRC Labs, Banjul, Gambia.
RP Bogh, C (reprint author), POB 2148, Kuta 80361, Bali, Indonesia.
EM cbogh@cbn.net.id; s.w.lindsay@dur.ac.uk; sian.clarke@lshtm.ac.uk;
   adean@hatfieldgroup.com; mjawara2000@yahoo.co.uk; mpinder@qanet.gm;
   cjt@aber.ac.uk
CR AIKINS MK, 1993, T ROY SOC TROP MED H, V87, P25, DOI 10.1016/0035-9203(93)90172-M
   ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P13, DOI 10.1016/0035-9203(93)90170-U
   Balls MJ, 2004, T ROY SOC TROP MED H, V98, P400, DOI 10.1016/j.trstmh.2003.11.005
   Beck LR, 1997, AM J TROP MED HYG, V56, P99
   BECK LR, 1994, AM J TROP MED HYG, V51, P271
   Bodker R, 2003, J MED ENTOMOL, V40, P706, DOI 10.1603/0022-2585-40.5.706
   Bogh C, 2003, B ENTOMOL RES, V93, P279, DOI 10.1079/BER2003239
   Bogh C, 2002, T ROY SOC TROP MED H, V96, P593, DOI 10.1016/S0035-9203(02)90320-2
   Bogh C, 2001, J MED ENTOMOL, V38, P822
   BOGH C, 1999, THESIS U COPENHAGEN
   BRADLEY AK, 1986, LANCET, V2, P204
   BRYAN JH, 1983, ANN TROP MED PARASIT, V77, P1
   Clarke SE, 2002, T ROY SOC TROP MED H, V96, P499, DOI 10.1016/S0035-9203(02)90419-0
   Clarke SE, 2001, T ROY SOC TROP MED H, V95, P457, DOI 10.1016/S0035-9203(01)90001-X
   CONGALTON RG, 1991, REMOTE SENS ENVIRON, V37, P35, DOI 10.1016/0034-4257(91)90048-B
   Costantini C, 1996, MED VET ENTOMOL, V10, P203, DOI 10.1111/j.1365-2915.1996.tb00733.x
   Craig MH, 1999, PARASITOL TODAY, V15, P105, DOI 10.1016/S0169-4758(99)01396-4
   Diuk-Wasser MA, 2006, INT J REMOTE SENS, V27, P535, DOI 10.1080/01431160500104350
   Diuk-Wasser MA, 2004, INT J REMOTE SENS, V25, P359, DOI 10.1080/01431160310001598944
   *DOS, 1975, GAMB
   Gillies MT, 1987, PUBL S AFR I MED RES, V55, P1
   Gleiser RM, 1997, ANN TROP MED PARASIT, V91, P917
   Greenwood B.M., 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P25, DOI 10.1016/0035-9203(89)90599-3
   Hay SI, 1998, T ROY SOC TROP MED H, V92, P12, DOI 10.1016/S0035-9203(98)90936-1
   Hay SI, 1997, INT J REMOTE SENS, V18, P2899, DOI 10.1080/014311697217125
   Julvez J, 1997, B SOC PATHOL EXOT, V90, P94
   Kaya S, 2004, CAN J REMOTE SENS, V30, P560
   LINDSAY SW, 1989, MED VET ENTOMOL, V3, P253, DOI 10.1111/j.1365-2915.1989.tb00225.x
   LINDSAY SW, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90171-L
   LINES JD, 1991, B ENTOMOL RES, V81, P77
   MANGA L, 1993, J MED ENTOMOL, V30, P936
   Nihei N, 2002, JPN J INFECT DIS, V55, P160
   PETRARCA V, 1987, MED VET ENTOMOL, V1, P303, DOI 10.1111/j.1365-2915.1987.tb00359.x
   Pope K, 2005, ECOL APPL, V15, P1223, DOI 10.1890/04-0934
   REJMANKOVA E, 1995, AM J TROP MED HYG, V53, P482
   ROBERT V, 1988, ACTA TROP, V45, P351
   Roberts DR, 1996, AM J TROP MED HYG, V54, P304
   Rogers DJ, 2002, NATURE, V415, P710, DOI 10.1038/415710a
   Sawada M, 1999, B ECOL SOC AM, V80, P231, DOI DOI 10.1890/0012-9623(1999)080[0231:TT]2.0.CO;2
   Sharma V. P., 1996, Southeast Asian Journal of Tropical Medicine and Public Health, V27, P834
   Snow RW, 1999, PARASITOL TODAY, V15, P99, DOI 10.1016/S0169-4758(99)01395-2
   Thomas CJ, 2000, T ROY SOC TROP MED H, V94, P159, DOI 10.1016/S0035-9203(00)90257-8
   Thomson M, 1996, SOC SCI MED, V43, P101, DOI 10.1016/0277-9536(95)00346-0
   THOMSON MC, 1994, T ROY SOC TROP MED H, V88, P638, DOI 10.1016/0035-9203(94)90204-6
   THOMSON MC, 1995, MED VET ENTOMOL, V9, P413, DOI 10.1111/j.1365-2915.1995.tb00015.x
   Toure YT, 1996, MED VET ENTOMOL, V10, P197, DOI 10.1111/j.1365-2915.1996.tb00731.x
   TRAPE JF, 1992, AM J TROP MED HYG, V47, P181
   TRAPE JF, 1994, AM J TROP MED HYG, V51, P123
   TROLLDALEN JM, 1991, NORAGRIC OCCASIONAL, V10
   VERCRUYSSE J, 1985, ANN SOC BELG MED TR, V65, P171
   WIRTZ RA, 1987, J MED ENTOMOL, V24, P433
NR 51
TC 55
Z9 55
U1 4
U2 20
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAY
PY 2007
VL 76
IS 5
BP 875
EP 881
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 165SR
UT WOS:000246326300018
PM 17488908
OA No
DA 2017-08-15
ER

PT J
AU Faburay, B
   Geysen, D
   Munstermann, S
   Taoufik, A
   Postigo, M
   Jongejan, F
AF Faburay, B.
   Geysen, D.
   Munstermann, S.
   Taoufik, A.
   Postigo, M.
   Jongejan, F.
TI Molecular detection of Ehrlichia ruminantium infection in Amblyomma
   variegatum ticks in The Gambia
SO EXPERIMENTAL AND APPLIED ACAROLOGY
LA English
DT Article
DE heartwater; A. variegatum; ticks; Ehrlichia ruminantium; The Gambia
ID POLYMERASE-CHAIN-REACTION; LINE BLOT HYBRIDIZATION; COWDRIA-RUMINANTIUM;
   32-KILODALTON PROTEIN; DOMESTIC RUMINANTS; DNA-PROBE; HEARTWATER; ASSAY;
   SEROPREVALENCE; CATTLE
AB In West Africa, losses due to heartwater disease are not known because the incidence/prevalence has not been well studied or documented. To develop a diagnostic tool for molecular epidemiology, three PCR-based diagnostic assays, a nested pCS20 PCR, a nested map1 PCR and a nested reverse line blot (RLB) hybridization assay, were evaluated to determine their ability to detect infection in vector ticks, by applying them simultaneously to A. variegatum field ticks to detect Ehrlichia ruminantium, the causative agent of heartwater. The nested pCS20 PCR assay which amplified the pCS20 gene fragment showed the highest detection performance with a detection rate of 16.6%; the nested map1 PCR, which amplified the gene encoding the major antigenic protein1 (map1 gene) showed a detection rate of 11% and the RLB, based on the 16S rDNA sequence of anaplasma and ehrlichial species, detected 6.2%. The RLB, in addition, demonstrated molecular evidence of Ehrlichia ovina, Anaplasma marginale and Anaplasma ovis infections in The Gambia. Subsequently, the pCS20 assay was applied to study the prevalence and distribution of E. ruminantium tick infection rates at different sites in five divisions of The Gambia. The rates of infection in the country ranged from 1.6% to 15.1% with higher prevalences detected at sites in the westerly divisions (Western, Lower River and North Bank; range 8.3-15.1%) than in the easterly divisions (Central River and Upper River; range 1.6-7.5%). This study demonstrated a gradient in the distribution of heartwater disease risk for susceptible livestock in The Gambia which factor must be considered in the overall design of future upgrading programmes.
C1 Univ Utrecht, Fac Vet Med, Dept INfect Dis & Immunol, Utrecht Ctr Tick Borne Dis, NL-3584 CL Utrecht, Netherlands.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   Inst Trop Med Prince Leopold, B-2000 Antwerp, Belgium.
   Univ Edinburgh, Royal Dick Sch Vet Studies, Ctr Trop Vet Med, Roslin EH25 9RG, Midlothian, Scotland.
   Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0110 Onderstepoort, South Africa.
RP Faburay, B (reprint author), Univ Utrecht, Fac Vet Med, Dept INfect Dis & Immunol, Utrecht Ctr Tick Borne Dis, Yalelaan 1, NL-3584 CL Utrecht, Netherlands.
EM b.fabureh1@vet.uu.nl
CR Allsopp MTEP, 1999, EPIDEMIOL INFECT, V122, P323, DOI 10.1017/S0950268899002101
   Allsopp MTEP, 2001, J CLIN MICROBIOL, V39, P4200, DOI 10.1128/JCM.39.11.4200-4203.2001
   ALSOPP MTE, 2007, VET MICROBIOL, V120, P158
   ANDREW HR, 1989, VET PARASITOL, V34, P261, DOI 10.1016/0304-4017(89)90056-3
   ASSELBERGS M, 1993, TROP ANIM HEALTH PRO, V25, P144, DOI 10.1007/BF02236232
   Awa DN, 1997, VET PARASITOL, V68, P165, DOI 10.1016/S0304-4017(96)01058-8
   Barre N., 1984, Proceedings of the 13th World Congress on Diseases of Cattle, Durban, South Africa, V1, P536
   Bekker CPJ, 2002, VET MICROBIOL, V89, P223, DOI 10.1016/S0378-1135(02)00179-7
   Bekker CPJ, 2001, CLIN DIAGN LAB IMMUN, V8, P843, DOI 10.1128/CDLI.8.4.843-846.2001
   Bell-Sakyi L, 2004, VET MICROBIOL, V100, P175, DOI 10.1016/j.vetmic.2004.02.010
   BIRNIE EF, 1985, VET REC, V116, P121
   CAMUS E, 1992, ANN NY ACAD SCI, V653, P33, DOI 10.1111/j.1749-6632.1992.tb19627.x
   CAMUS E, 1987, ONDERSTEPOORT J VET, V54, P419
   Collins NE, 2005, P NATL ACAD SCI USA, V102, P838, DOI 10.1073/pnas.0406633102
   Du Plessis J L, 1993, Rev Elev Med Vet Pays Trop, V46, P123
   DUPLESSIS JL, 1985, ONDERSTEPOORT J VET, V52, P55
   Faburay B, 2005, CLIN DIAGN LAB IMMUN, V12, P508, DOI 10.1128/CDLI.12.4.508-512.2005
   GRIFFAIS R, 1991, NUCLEIC ACIDS RES, V19, P3887
   Gubbels JM, 1999, J CLIN MICROBIOL, V37, P1782
   Gueye A., 1994, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V46, P441
   Gueye A., 1993, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V46, P217
   Gueye A, 1993, Rev Elev Med Vet Pays Trop, V46, P449
   JONGEJAN F, 1989, INFECT IMMUN, V57, P3243
   Jordaan J.O., 1981, P115
   KOCK ND, 1995, J CLIN MICROBIOL, V33, P2501
   Koney EBM, 2004, VET MICROBIOL, V103, P183, DOI 10.1016/j.vetmic.2004.02.017
   Mahan SM, 1998, ANN NY ACAD SCI, V849, P85, DOI 10.1111/j.1749-6632.1998.tb11037.x
   MAHAN SM, 1992, J CLIN MICROBIOL, V30, P981
   Martinez D, 1993, Rev Elev Med Vet Pays Trop, V46, P115
   Martinez D, 1990, Rev Elev Med Vet Pays Trop, V43, P159
   Nijhof AM, 2003, J CLIN MICROBIOL, V41, P2249, DOI 10.1128/JCM.41.5.2249-2254.2003
   NORVAL RAI, 1990, VET PARASITOL, V36, P277, DOI 10.1016/0304-4017(90)90039-E
   O'Callaghan CJ, 1998, PARASITOLOGY, V117, P49, DOI 10.1017/S0031182098002790
   OLSEN GJ, 1986, ANNU REV MICROBIOL, V40, P337, DOI 10.1146/annurev.micro.40.1.337
   Oura CAL, 2004, INT J PARASITOL, V34, P603, DOI 10.1016/j.ijpara.2003.12.012
   Peter TF, 2000, J CLIN MICROBIOL, V38, P1539
   Peter TF, 1999, VET REC, V145, P304
   PETER TF, 1995, J CLIN MICROBIOL, V33, P166
   POSTIGO M, 2007, VET MICROBIOL
   REDDY GR, 1996, CLIN DIAGN LAB IMMUN, V154, P73
   SCHNITTER L, 2003, PARASITOL RES, V92, P1089
   SCOTT GR, 1990, ANIMAL DIS TROPICS, P248
   Simbi BH, 2003, ONDERSTEPOORT J VET, V70, P231
   Van Heerden H, 2004, VET MICROBIOL, V101, P279, DOI 10.1016/j.vetmic.2004.02.015
   VANVLIET AHM, 1994, INFECT IMMUN, V62, P1451
NR 45
TC 11
Z9 11
U1 1
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0168-8162
J9 EXP APPL ACAROL
JI Exp. Appl. Acarol.
PD MAY
PY 2007
VL 42
IS 1
BP 61
EP 74
DI 10.1007/s10493-007-9073-2
PG 14
WC Entomology
SC Entomology
GA 178RW
UT WOS:000247238800007
PM 17476576
OA No
DA 2017-08-15
ER

PT J
AU Jallow, S
   Kaye, S
   Schutten, M
   Brandin, E
   Albert, J
   McConkey, SJ
   Corrah, T
   Whittle, H
   Vanham, G
   Rowland-Jones, S
   Janssens, W
AF Jallow, Sabelle
   Kaye, Steve
   Schutten, Martin
   Brandin, Eleonor
   Albert, Jan
   McConkey, Samuel J.
   Corrah, Tumani
   Whittle, Hilton
   Vanham, Guido
   Rowland-Jones, Sarah
   Janssens, Wouter
TI Development and evaluation of an oligonucleotide ligation assay for
   detection of drug resistance-associated mutations in the human
   immunodeficiency virus type 2 pol gene
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID FAILING ANTIRETROVIRAL THERAPY; HIGH-LEVEL RESISTANCE;
   REVERSE-TRANSCRIPTASE; PROTEASE INHIBITORS; HIV-2 PATIENTS; INFECTION;
   DIDANOSINE; ZIDOVUDINE; AFRICA; PLASMA
AB Human immunodeficiency virus type 2 (HIV-2) is naturally resistant to several antiretroviral drugs, including all of the non-nucleoside reverse transcriptase inhibitors and the entry inhibitor T-20, and may have reduced susceptibility to some protease inhibitors. These resistance properties make treatment of HIV-2 patients difficult, with very limited treatment options. Therefore, early detection of resistance mutations is important for understanding treatment failures and guiding subsequent therapy decisions. With the Global Fund Initiative, a substantial number of HIV-2 patients in West Africa will receive antiretroviral therapy. Therefore, development of cheaper and more sustainable resistance assays, such as the oligonucleotide ligation assay (OLA), is a priority. In this study, we designed oligonucleotide probes to detect the Q151M mutation, associated with phenotypic resistance to zidovudine, didanosine, zalcitabine, and stavudine, and the M184V mutation, associated with phenotypic resistance to lamivudine and emtricitabine, in HIV-2. The assay was successfully developed and evaluated with 122 samples from The Gambia, Guinea Bissau, The Netherlands, and Sweden. The overall sensitivity of the assay was 98.8%, with 99.2% for Q151M and 98.4% for M184V. OLA results were compared with sequencing to give high concordances of 98.4% (Q151M) and 97.5% (M184V). OLA demonstrated a higher sensitivity for detection of minor variants as a mixture of wild-type and mutant viruses in cases when sequencing detected only the major population. In conclusion, we have developed a simple, easy-to-use, and economical assay for genotyping of drug resistance in HIV-2 that is more sustainable for use in resource-poor settings than is consensus sequencing.
C1 Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium.
   MRC Labs, Banjul, Gambia.
   Erasmus MC, Dept Virol, Rotterdam, Netherlands.
   Swedish Inst Infect Dis Control, Dept Virol Immunol & Vaccinol, Solna, Sweden.
   Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden.
RP Jallow, S (reprint author), Inst Trop Med, Dept Microbiol, Natl Str 155, B-2000 Antwerp, Belgium.
EM sjallow@itg.be
RI McConkey, Samuel/E-7307-2012
OI McConkey, Samuel/0000-0001-9085-7793
FU Medical Research Council [MC_U190081962, MC_U190085854]
CR Adje-Toure CA, 2003, AIDS, V17, pS49
   BABU PG, 1993, INDIAN J MED RES-A, V97, P49
   Back NKT, 1996, EMBO J, V15, P4040
   Beek IA, 2002, J CLIN MICROBIOL, V40, P1413, DOI 10.1128/JCM.40.4.1413-1419.2002
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495
   BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231
   BOYER PL, 1995, ANTIMICROB AGENTS CH, V39, P1624
   Brandin E, 2003, AIDS RES HUM RETROV, V19, P543, DOI 10.1089/088922203322230905
   CHAO SF, 1995, NUCLEIC ACIDS RES, V23, P803, DOI 10.1093/nar/23.5.803
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   Colson P, 2004, J CLIN MICROBIOL, V42, P570, DOI 10.1128/JCM.42.2.570-577.2004
   Diallo K, 2003, ANTIMICROB AGENTS CH, V47, P3377, DOI 10.1128/AAC.47.11.3377-3383.2003
   Edelstein RE, 1998, J CLIN MICROBIOL, V36, P569
   Ellis GM, 2004, J CLIN MICROBIOL, V42, P3670, DOI 10.1128/jcm.42.8.3670-3674.2004
   FRENKEL LM, 1995, J CLIN MICROBIOL, V33, P342
   Garcia-Lerma JG, 2000, J VIROL, V74, P9339, DOI 10.1128/JVI.74.20.9339-9346.2000
   GHYS PD, 1997, AIDS, V11, P85
   Ishii H., 2001, CATAL COMMUN, V2, P17, DOI 10.1016/S1566-7367(01)00002-4
   Jallow S, 2006, AIDS, V20, P1455, DOI 10.1097/01.aids.0000233582.64467.8e
   LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476
   Langley CL, 1996, AIDS, V10, P413, DOI 10.1097/00002030-199604000-00010
   LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804
   Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100
   Nkengasong JN, 2004, AIDS REV, V6, P4
   Osmanov S, 1996, ANTIBIOT CHEMOTHER, V48, P30
   POULSEN AG, 1989, LANCET, V1, P827
   Reeves JD, 2002, J GEN VIROL, V83, P1253, DOI 10.1099/vir.O.18253-O
   Rodes B, 2006, J ANTIMICROB CHEMOTH, V57, P709, DOI 10.1093/jac/dkl034
   SCHICK A, 1999, STAT INFERENCE STOCH, V2, P69, DOI 10.1023/A:1009950813472
   Smith SA, 2002, WATER SA, V28, P403
   Soriano V., 2000, AIDS REV, V2, P111
   Tobe VO, 1996, NUCLEIC ACIDS RES, V24, P3728, DOI 10.1093/nar/24.19.3728
   Vega Y, 2005, J CLIN MICROBIOL, V43, P5301, DOI 10.1128/JCM.43.10.5301-5304.2005
   Villanueva E V, 2001, BMC Med Inform Decis Mak, V1, P4, DOI 10.1186/1472-6947-1-4
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 35
TC 8
Z9 8
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD MAY
PY 2007
VL 45
IS 5
BP 1565
EP 1571
DI 10.1128/JCM.02220-06
PG 7
WC Microbiology
SC Microbiology
GA 169OA
UT WOS:000246600300029
PM 17329450
OA No
DA 2017-08-15
ER

PT J
AU Ndugwa, R
   Ramroth, H
   Mueller, O
   Momodou, J
   Kouyate, B
   Greenwood, B
   Becher, H
AF Ndugwa, R.
   Ramroth, H.
   Mueller, O.
   Momodou, J.
   Kouyate, B.
   Greenwood, B.
   Becher, H.
TI Comparison of all-cause and malaria-specific mortality from two West
   African countries with different malaria transmission patterns
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Ndugwa, R.; Ramroth, H.; Mueller, O.; Becher, H.] Univ Heidelberg, Dept Trop Hyg & Publ Hlth, Heidelberg, Germany.
   [Momodou, J.] MRC Labs, Farafenni, Gambia.
   [Kouyate, B.] Ctr Natl Rech & Format Paludisme, Ouagadougou, Burkina Faso.
   [Greenwood, B.] London Sch Hyg & Trop Med, London WC1, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAY
PY 2007
VL 12
SU 1
BP 45
EP 45
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 302FP
UT WOS:000255954500133
OA No
DA 2017-08-15
ER

PT J
AU Dunyo, S
   Sirugo, G
   Sesay, S
   Bisseye, C
   Njie, F
   Janha, R
   Adiamoh, M
   Nwakanma, D
   Diatta, M
   Joof, FS
   Temple, B
   Sey, O
   Snell, P
   Conway, D
   Walton, R
   Cheung, YB
   Milligan, P
AF Dunyo, S.
   Sirugo, G.
   Sesay, S.
   Bisseye, C.
   Njie, F.
   Janha, R.
   Adiamoh, M.
   Nwakanma, D.
   Diatta, M.
   Joof, F. Sisay
   Temple, B.
   Sey, O.
   Snell, P.
   Conway, D.
   Walton, R.
   Cheung, Y. B.
   Milligan, P.
TI Randomized trial of safety and effectiveness of chlorproguanil-dapsone
   (Lapdap) compared to lumefantrine-artemether (Coartemether) for
   uncomplicated malaria in children in The Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Dunyo, S.] MRC Labs, Farafenni Field Stn, Farafenni, Gambia.
   [Sirugo, G.; Sesay, S.; Bisseye, C.; Njie, F.; Janha, R.; Adiamoh, M.; Nwakanma, D.; Diatta, M.; Joof, F. Sisay; Snell, P.; Conway, D.; Walton, R.] MRC Labs, Banjul, Gambia.
   [Temple, B.] London Sch Hyg & Trop Med, London WC1, England.
   [Sey, O.] Govt Gambia, Dept State Hlth Social Welf & Womens Affairs, Banjul, Gambia.
   [Cheung, Y. B.] London Sch Hyg & Trop Med, Banjul, Gambia.
   [Milligan, P.] London Sch Hyg & Trop Med Epidemiol & Populat Hlt, London, England.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAY
PY 2007
VL 12
SU 1
BP 84
EP 84
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 302FP
UT WOS:000255954500239
OA No
DA 2017-08-15
ER

PT J
AU Liu, D
   Ismaili, J
   Milligan, P
AF Liu, D.
   Ismaili, J.
   Milligan, P.
TI Mixture models for analysis of immune responses in epidemiological
   studies
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Liu, D.; Milligan, P.] London Sch Hyg & Trop Med, London WC1, England.
   [Ismaili, J.] MRC Labs, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAY
PY 2007
VL 12
SU 1
BP 143
EP 144
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 302FP
UT WOS:000255954500405
OA No
DA 2017-08-15
ER

PT J
AU Joof, BM
   Dawson, A
   Palmer, A
   Dibba, A
   Yehuenou, S
   Devaney, B
   Ocran, C
   Cheung, YB
   Kasse, Y
   Milligan, P
AF Joof, B. Musa
   Dawson, A.
   Palmer, A.
   Dibba, A.
   Yehuenou, S.
   Devaney, B.
   Ocran, C.
   Cheung, Y. B.
   Kasse, Y.
   Milligan, P.
TI Peer health education for promoting knowledge and practice of malaria
   prevention among school children and their families
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Joof, B. Musa; Palmer, A.; Kasse, Y.] Ctr Innovat Against Malaria, Banjul, Gambia.
   [Dawson, A.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.
   [Dibba, A.; Yehuenou, S.; Devaney, B.] Nova Scotia Gambia Assoc, Banjul, Gambia.
   [Ocran, C.] MRC Labs, Banjul, Gambia.
   [Cheung, Y. B.; Milligan, P.] London Sch Hyg & Trop Med, London WC1, England.
RI Dawson, Angela/A-6872-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAY
PY 2007
VL 12
SU 1
BP 175
EP 175
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 302FP
UT WOS:000255954500498
OA No
DA 2017-08-15
ER

PT J
AU Loscertales, MP
   Donkor, C
   Senga, E
   Owens, S
   O'Donnell, J
   Bunn, J
   Bosch-Capblanch, B
   Brabin, B
AF Loscertales, M. -P.
   Donkor, C.
   Senga, E.
   Owens, S.
   O'Donnell, J.
   Bunn, J.
   Bosch-Capblanch, B.
   Brabin, B.
TI ABO histo-blood group phenotypes and falciparum malaria
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Loscertales, M. -P.; Brabin, B.] Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England.
   [Donkor, C.] Univ Liverpool Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Kumasi, Ghana.
   [Senga, E.] Univ Malawi, Coll Med, Dept Biochem, Blantyre, Malawi.
   [Owens, S.] Labs Med Res Council, Banjul, Gambia.
   [O'Donnell, J.] Univ Dublin Trinity Coll, Inst Mol Med, Haemostasis Res Grp, Dublin 2, Ireland.
   [Bunn, J.] Coll Med, Dept Paediat, Blantyre, Malawi.
   [Bosch-Capblanch, B.] Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Grp, Liverpool L3 5QA, Merseyside, England.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAY
PY 2007
VL 12
SU 1
BP 254
EP 255
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 302FP
UT WOS:000255954500732
OA No
DA 2017-08-15
ER

PT J
AU Cox, SE
   Doherty, C
   Atkinson, SH
   Nweneka, CV
   Fulford, AJC
   Ghattas, H
   Rockett, KA
   Kwiatkowski, DP
   Prentice, AM
AF Cox, Sharon E.
   Doherty, Conor
   Atkinson, Sarah H.
   Nweneka, Chidi V.
   Fulford, Anthony J. C.
   Ghattas, Hala
   Rockett, Kirk A.
   Kwiatkowski, Dominic P.
   Prentice, Andrew M.
TI Haplotype Association between Haptoglobin (Hp2) and Hp Promoter SNP
   (A-61C) May Explain Previous Controversy of Haptoglobin and Malaria
   Protection
SO PLOS ONE
LA English
DT Article
AB Background. Malaria is one of the strongest recent selective pressures on the human genome, as evidenced by the high levels of varying haemoglobinopathies in human populations-despite the increased risk of mortality in the homozygous states. Previously, functional polymorphisms of Hp, coded by the co-dominant alleles Hp1 and Hp2, have been variously associated with several infectious diseases, including malaria susceptibility. Methodology/Principal Findings. Risk of a clinical malarial episode over the course of a malarial transmission season was assessed using active surveillance in a cohort of Gambian children aged 10-72 months. We report for the first time that the major haplotype for the A-61C mutant allele in the promoter of haptoglobin (Hp)-an acute phase protein that clears haemoglobin released from haemolysis of red cells-is associated with protection from malarial infection in older children, (children aged >= 36 months, > 500 parasites/ul and temperature > 37.5 degrees C; OR = 0.42; [95% CI 0.24-0.73] p = 0.002) (Ir test for interaction, < 36 vs >= 36 months, p = 0.014). Protection was also observed using two other definitions, including temperature > 37.5 degrees C, dipstick positive, plus clinical judgement of malaria blinded to dipstick result (all ages, OR = 0.48, [95% CI 0.30-0.78] p = 0.003; >= 36 months, OR = 0.31, [95% CI 0.15-0.62] p = 0.001). A similar level of protection was observed for the known protective genetic variant, sickle cell trait (HbAS). Conclusions/Significance. We propose that previous conflicting results between Hp phenotypes/ genotypes and malaria susceptibility may be explained by differing prevalence of the A-61C SNP in the populations studied, which we found to be highly associated with the Hp2 allele. We report the -61C allele to be associated with decreased Hp protein levels (independent of Hp phenotype), confirming in vitro studies. Decreased Hp expression may lead to increased oxidant stress and increased red cell turnover, and facilitate the development of acquired immunity, similar to a mechanism suggested for sickle cell trait.
C1 [Cox, Sharon E.; Atkinson, Sarah H.; Fulford, Anthony J. C.; Ghattas, Hala; Prentice, Andrew M.] London Sch Hyg & Trop Med, Int Nutr Grp, MRC, London WC1, England.
   [Rockett, Kirk A.; Kwiatkowski, Dominic P.] Wellcome Trust Ctr Human Genet, Oxford, England.
   [Doherty, Conor; Atkinson, Sarah H.; Nweneka, Chidi V.] MRC Labs, MRC Keneba, Keneba, Gambia.
RP Cox, SE (reprint author), London Sch Hyg & Trop Med, Int Nutr Grp, MRC, London WC1, England.
EM Sharon.cox@lshtm.ac.uk
RI Ghattas, Hala/K-5661-2016
OI Cox, Sharon/0000-0002-9908-2936; Kwiatkowski,
   Dominic/0000-0002-5023-0176
FU UK Medical Research Council
FX Funding: This study was funded by UK Medical Research Council who had no
   part in the design or analysis of the study.
CR Arredouani M, 2003, IMMUNOLOGY, V108, P144, DOI 10.1046/j.1365-2567.2003.01569.x
   Asleh R, 2005, CIRC RES, V96, P435, DOI 10.1161/01.RES.0000156653.05853.b9
   Asleh R, 2003, CIRC RES, V92, P1193, DOI 10.1161/01.RES.0000076889.23082.F1
   Atkinson SH, 2007, CLIN INFECT DIS, V44, P802, DOI 10.1086/511868
   Aucan C, 2002, T ROY SOC TROP MED H, V96, P327, DOI 10.1016/S0035-9203(02)90114-8
   Ayi K, 2004, BLOOD, V104, P3364, DOI 10.1182/blood-2003-11-3820
   Bienzle U, 2005, TROP MED INT HEALTH, V10, P668, DOI 10.1111/j.1365-3156.2005.01444.x
   BOREHAM PFL, 1981, T ROY SOC TROP MED H, V75, P193, DOI 10.1016/0035-9203(81)90316-3
   Cabrera G, 2005, J INFECT DIS, V191, P1631, DOI 10.1086/429832
   Calderoni DR, 2006, ANN TROP MED PARASIT, V100, P213, DOI 10.1179/136485906X86356
   CLAYTON DG, SNPHAP PROGRAM ESTIM
   Delanghe JR, 1998, AIDS, V12, P1027, DOI 10.1097/00002030-199809000-00009
   Elagib AA, 1998, T ROY SOC TROP MED H, V92, P309, DOI 10.1016/S0035-9203(98)91025-2
   ElGhmati SM, 1996, J IMMUNOL, V156, P2542
   Fowkes FJI, 2006, AM J TROP MED HYG, V74, P26
   Friis Henrik, 2003, JAIDS Journal of Acquired Immune Deficiency Syndromes, V33, P74
   GRANT DJ, 1993, AM J HUM GENET, V52, P974
   GUETTA J, 2006, ATHEROSCLEROSIS
   Hunt NH, 2001, REDOX REP, V6, P389, DOI 10.1179/135100001101536508
   Imrie H, 2006, AM J TROP MED HYG, V74, P965
   Imrie H, 2004, MOL BIOCHEM PARASIT, V133, P93, DOI 10.1016/j.molbiopara.2003.07.007
   Koch W, 2003, CLIN CHEM, V49, P1937, DOI 10.1373/clinchem.2003.022442
   Koch W, 2002, CLIN CHEM, V48, P1377
   Koda Y, 1998, AM J HUM GENET, V62, P245, DOI 10.1086/301701
   Koda Y, 2000, BLOOD, V95, P1138
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   Langlois M, 1997, EUR J CLIN CHEM CLIN, V35, P199
   Langlois MR, 2000, CLIN CHEM, V46, P1619
   Langlois MR, 1997, AM J CLIN NUTR, V66, P606
   Langlois MR, 1996, CLIN CHEM, V42, P1589
   MAEDA N, 1991, AM J HUM GENET, V49, P158
   MARSH K, 1988, T ROY SOC TROP MED H, V82, P532, DOI 10.1016/0035-9203(88)90495-6
   McDermid JM, 2006, CLIN SCI, V110, P503, DOI 10.1042/CS20050273
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Minang JT, 2004, ACTA TROP, V90, P107, DOI 10.1016/j.actatropica.2003.10.016
   Mustafa S, 2004, DIABETES CARE, V27, P2103, DOI 10.2337/diacare.27.9.2103
   Okazaki T, 1997, CLIN CHEM, V43, P2012
   Okazaki T, 1997, CLIN CHIM ACTA, V258, P137, DOI 10.1016/S0009-8981(96)06468-6
   Philippidis P, 2004, CIRC RES, V94, P119, DOI 10.1161/01.RES.0000109414.78907.F9
   Quaye IK, 2006, J ATHEROSCLER THROMB, V13, P90
   Quaye IKE, 2000, HUM HERED, V50, P382, DOI 10.1159/000022944
   Quaye IKE, 2000, T ROY SOC TROP MED H, V94, P216, DOI 10.1016/S0035-9203(00)90281-5
   ROUGEMONT A, 1988, LANCET, V2, P709
   SINGH IP, 1986, HUM HERED, V36, P31, DOI 10.1159/000153596
   TAKIZAWA T, 1987, Genomics, V1, P228, DOI 10.1016/0888-7543(87)90048-6
   Teye K, 2003, CLIN GENET, V64, P439, DOI 10.1034/j.1399-0004.2003.00149.x
   Teye K, 2006, HUM BIOL, V78, P121, DOI 10.1353/hub.2006.0029
   TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P430, DOI 10.1016/0035-9203(85)90053-7
   TRAPE JF, 1988, AM J EPIDEMIOL, V127, P1282
   Williams TN, 2006, MOL BIOCHEM PARASIT, V149, P121, DOI 10.1016/j.molbiopara.2006.05.007
   Williams TN, 2005, PLOS MED, V2, P441, DOI 10.1371/journal.pmed.0020128
   Williams TN, 2005, J INFECT DIS, V192, P178, DOI 10.1086/430744
   Yano A, 1998, ACTA MED OKAYAMA, V52, P173
NR 53
TC 34
Z9 34
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 11
PY 2007
VL 2
IS 4
AR e362
DI 10.1371/journal.pone.0000362
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10DT
UT WOS:000207445400002
PM 17426810
OA gold
DA 2017-08-15
ER

PT J
AU Molyneux, M
   Marsh, K
   White, N
   Farrar, J
   French, N
   Day, N
   Rowland-Jones, S
AF Molyneux, Malcolm
   Marsh, Kevin
   White, Nicholas
   Farrar, Jeremy
   French, Neil
   Day, Nick
   Rowland-Jones, Sarah
TI Global partnership - UK doctors are already put off by changes in
   training
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Letter
C1 Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre 3, Malawi.
   Kenya Govt Med Res Ctr, Wellcome Trust Programme, Nairobi, Kenya.
   Hosp Trop Dis Wellcome Trust Major Overseas Progr, Ho Chi Minh City, Vietnam.
   Karonga Prevent Study, Chilumba, Malawi.
   Wellcome Trust Mahidol Univ, Oxford Trop Med Res Programme, Bangkok, Thailand.
   MRC Labs, Banjul, Gambia.
RP Molyneux, M (reprint author), Malawi Liverpool Wellcome Trust Clin Res Programm, Box 30096, Blantyre 3, Malawi.
EM mmolyneux@malawi.net
RI White, Nicholas/I-4629-2012
CR *GLOB HLTH PARTN, 2007, UK CONTR HLTH DEV CO
   Whitty CJM, 2007, BRIT MED J, V334, P595, DOI 10.1136/bmj.39147396285.BE
NR 2
TC 2
Z9 2
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD APR 7
PY 2007
VL 334
IS 7596
BP 709
EP 710
DI 10.1136/bmj.39169.916296.1F
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 158AO
UT WOS:000245763300008
PM 17413145
OA No
DA 2017-08-15
ER

PT J
AU Cox, SE
   Doherty, C
   Atkinson, SH
   Nweneka, CV
   Ghattas, H
   Fulford, T
   Rockett, K
   Kwiatkowski, D
   Prentice, A
AF Cox, Sharon Elizabeth
   Doherty, Conor
   Atkinson, Sarah Helen
   Nweneka, Chidi Victor
   Ghattas, Hala
   Fulford, Tony
   Rockett, Kirk
   Kwiatkowski, Dominic
   Prentice, Andrew
TI A61-C haptoglobin gene promoter polymorphism and protection from malaria
   in Gambian children.
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology 2007 Annual Meeting
CY APR 28-MAY 02, 2007
CL Washington, DC
C1 Univ London London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1E 7HT, England.
   MRC Keneba, MRC Labs, Banjul, Gambia.
   Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
RI Ghattas, Hala/K-5661-2016
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2007
VL 21
IS 5
BP A164
EP A164
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 157HD
UT WOS:000245708501219
OA No
DA 2017-08-15
ER

PT J
AU Cox, SE
   Doherty, C
   Atkinson, SH
   Nweneka, CV
   Ghattas, H
   Fulford, T
   Rockett, K
   Kwiatkowski, D
   Prentice, A
AF Cox, Sharon Elizabeth
   Doherty, Conor
   Atkinson, Sarah Helen
   Nweneka, Chidi Victor
   Ghattas, Hala
   Fulford, Tony
   Rockett, Kirk
   Kwiatkowski, Dominic
   Prentice, Andrew
TI Haptoglobin genotype, haemoglobin and malaria in Gambian children
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology 2007 Annual Meeting
CY APR 28-MAY 02, 2007
CL Washington, DC
C1 Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1E 7HT, England.
   MRC Labs, MRC Keneba, Banjul, Gambia.
   Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
RI Ghattas, Hala/K-5661-2016
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2007
VL 21
IS 6
BP A1118
EP A1119
PG 2
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 157HF
UT WOS:000245708703142
OA No
DA 2017-08-15
ER

PT J
AU de Jong, BC
   Hill, RC
   Aiken, A
   Jeffries, DJ
   Onipede, A
   Small, RM
   Adegbola, RA
   Corrah, TR
AF de Jong, B. C.
   Hill, R. C.
   Aiken, A.
   Jeffries, D. J.
   Onipede, A.
   Small, R. M.
   Adegbola, R. A.
   Corrah, T. R.
TI Clinical presentation and outcome of tuberculosis patients infected by
   M-africanum versus M-tuberculosis
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE M. africanum; radiographs; mortality; Gambia; tuberculosis
ID STRAINS; COMPLEX; DIAGNOSIS; GAMBIA
AB SETTING: A tuberculosis (TB) case contact study in the Gambia.
   OBJECTIVE: To test whether Mycobacterium africanum, which has lost around 68 kb compared with M. tuberculosis sensu stricto, causes less severe TB disease.
   DESIGN: We genotyped mycobacterial isolates and compared clinical and radiological characteristics as well as outcome data of M. africanum-infected TB patients with those infected with M. tuberculosis.
   RESULTS: Of 317 index cases, 301 had a mycobacterial isolate available, 290 of which had an interpretable spoligotype pattern. Of these, 110 isolates (38%) were M. africanum and 180 (62%) were M. tuberculosis. M. africanum cases had lower body mass indices (17 vs. 17.45 for M. tuberculosis-infected patients, P = 0.029) and their radiographic disease was more extensive (96% vs. 89% had at least moderately severe radiographic changes, P = 0.031). Outcome on treatment was similar (2.8% of human immunodeficiency virus [HIV] negative M. africanum patients died on treatment vs. 3.0% of M. tuberculosis patients, P = 0.95).
   CONCLUSION: M. africanum causes sputum smear-positive tuberculosis disease that is at least as severe as that caused by M. tuberculosis sensu stricto. Further clinical comparisons may be helpful in smear-negative patients and HIV-TB co-infected patients, and to identify whether there is any difference in time to develop disease.
C1 MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   Stanford Univ, Stanford, CA 94305 USA.
   Inst Syst Biol, Seattle, WA USA.
RP de Jong, BC (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM bdejong@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU FIC NIH HHS [TW 006083]; Medical Research Council [MC_U190071468,
   MC_U190081982]
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   BAILY DVJ, 1979, INDIAN J MED RES, V70, P349
   Borgdorff Martien W, 2004, Tuberculosis (Edinb), V84, P337, DOI 10.1016/j.tube.2003.10.002
   CASTETS M, 1969, Bulletin de la Societe Medicale d'Afrique Noire de Langue Francaise, V14, P693
   Castets M, 1968, Rev Tuberc Pneumol (Paris), V32, P179
   de Jong BC, 2006, J INFECT DIS, V193, P1279, DOI 10.1086/502977
   de Jong BC, 2005, AIDS, V19, P1714, DOI 10.1097/01.aids.0000185991.54595.41
   Heifets Leonid B., 1994, P85
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Kallenius G, 1999, J CLIN MICROBIOL, V37, P3872
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907
   *KAMP AS, 2004, ANN REP
   Kato-Maeda M, 2001, GENOME RES, V11, P547, DOI 10.1101/gr.166401
   Kumar D, 1997, THORAX, V52, P1060
   Ledru S, 1996, TUBERCLE LUNG DIS, V77, P429, DOI 10.1016/S0962-8479(96)90116-1
   Lopez B, 2003, CLIN EXP IMMUNOL, V133, P30, DOI 10.1046/j.1365-2249.2003.02171.x
   Malik AN, 2005, LANCET INFECT DIS, V5, P174, DOI 10.1016/S1473-3099(05)01310-1
   Marmiesse M, 2004, MICROBIOL-SGM, V150, P483, DOI 10.1099/mic.0.26662-0
   Mostowy S, 2004, J CLIN MICROBIOL, V42, P3594, DOI 10.1128/jcm.42.8.3594-3599.2004
   Niobe-Eyangoh SN, 2003, J CLIN MICROBIOL, V41, P2547, DOI 10.1128/JCM.41.6.2547-2553.2003
   van Crevel R, 2001, EMERG INFECT DIS, V7, P880
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406
NR 22
TC 25
Z9 26
U1 0
U2 1
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD APR
PY 2007
VL 11
IS 4
BP 450
EP 456
PG 7
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 152UU
UT WOS:000245388300015
PM 17394693
OA No
DA 2017-08-15
ER

PT J
AU Nweneka, C
   Keneba, MRC
AF Nweneka, Chidi
   Keneba, M. R. C.
TI Malaria parasitaemia in neonates in Port Harcourt, Nigeria (vol 50, pg
   114, 2004)
SO JOURNAL OF TROPICAL PEDIATRICS
LA English
DT Correction
C1 MRC Keneba, Banjul, Gambia.
RP Nweneka, C (reprint author), MRC Keneba, POB 273, Banjul, Gambia.
CR Nweneka CV, 2004, J TROP PEDIATRICS, V50, P114, DOI 10.1093/tropej/50.2.114
NR 1
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0142-6338
J9 J TROP PEDIATRICS
JI J. Trop. Pediatr.
PD APR
PY 2007
VL 53
IS 2
BP 146
EP 146
DI 10.1093/tropej/fmm028
PG 1
WC Pediatrics; Tropical Medicine
SC Pediatrics; Tropical Medicine
GA 154MM
UT WOS:000245511700020
OA No
DA 2017-08-15
ER

PT J
AU Khor, CC
   Chapman, SJ
   Vannberg, FO
   Dunne, A
   Murphy, C
   Ling, EY
   Frodsham, AJ
   Walley, AJ
   Kyrieleis, O
   Khan, A
   Aucan, C
   Segal, S
   Moore, CE
   Knox, K
   Campbell, SJ
   Lienhardt, C
   Scott, A
   Aaby, P
   Sow, OY
   Grignani, RT
   Sillah, J
   Sirugo, G
   Peshu, N
   Williams, TN
   Maitland, K
   Davies, RJO
   Kwiatkowski, DP
   Day, NP
   Yala, D
   Crook, DW
   Marsh, K
   Berkley, JA
   O'Neill, LAJ
   Hill, AVS
AF Khor, Chiea C.
   Chapman, Stephen J.
   Vannberg, Fredrik O.
   Dunne, Aisling
   Murphy, Caroline
   Ling, Edmund Y.
   Frodsham, Angela J.
   Walley, Andrew J.
   Kyrieleis, Otto
   Khan, Amir
   Aucan, Christophe
   Segal, Shelley
   Moore, Catrin E.
   Knox, Kyle
   Campbell, Sarah J.
   Lienhardt, Christian
   Scott, Anthony
   Aaby, Peter
   Sow, Oumou Y.
   Grignani, Robert T.
   Sillah, Jackson
   Sirugo, Giorgio
   Peshu, Nobert
   Williams, Thomas N.
   Maitland, Kathryn
   Davies, Robert J. O.
   Kwiatkowski, Dominic P.
   Day, Nicholas P.
   Yala, Djamel
   Crook, Derrick W.
   Marsh, Kevin
   Berkley, James A.
   O'Neill, Luke A. J.
   Hill, Adrian V. S.
TI A Mal functional variant is associated with protection against invasive
   pneumococcal disease, bacteremia, malaria and tuberculosis
SO NATURE GENETICS
LA English
DT Article
ID TOLL-LIKE RECEPTORS; TLR4; GENE; LIPOPOLYSACCHARIDE; POLYMORPHISM;
   INDUCTION; MOLECULE; TIRAP; MICE; CD36
AB Toll-like receptors (TLRs) and members of their signaling pathway are important in the initiation of the innate immune response to a wide variety of pathogens(1-3). The adaptor protein Mal (also known as TIRAP), encoded by TIRAP (MIM 606252), mediates downstream signaling of TLR2 and TLR4 (refs. 4-6). We report a case-control study of 6,106 individuals from the UK, Vietnam and several African countries with invasive pneumococcal disease, bacteremia, malaria and tuberculosis. We genotyped 33 SNPs, including rs8177374, which encodes a leucine substitution at Ser180 of Mal. We found that heterozygous carriage of this variant associated independently with all four infectious diseases in the different study populations. Combining the study groups, we found substantial support for a protective effect of S180L heterozygosity against these infectious diseases (N = 6,106; overall P = 9.6 x 10(-8)). We found that the Mal S180L variant attenuated TLR2 signal transduction.
C1 Churchill Hosp, Osler Chest Unit, Oxford, England.
   Trinity Coll Dublin, Sch Biochem & Immunol, Dublin, Ireland.
   John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.
   John Radcliffe Hosp, Dept Microbiol, Oxford OX3 9DU, England.
   Inst Rech Dev, Dakar, Senegal.
   Kilifi District Hosp, Ctr Geog Med Res, Kenya Med Res Inst, Wellcome Trust Programme, Kilifi, Kenya.
   Bandim Hlth Project, Bissau, Guinea Bissau.
   Univ Ignace Deen, Serv Pneumophtisol, Conarky 634, Guinea.
   MRC Labs, Fajara, Gambia.
   Cho Quan Hosp, Ctr Trop Dis, Ho Chi Minh City, Vietnam.
   Inst Pasteur, Serv TB, Algiers, Algeria.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England.
RP Hill, AVS (reprint author), Hammersmith Hosp, Imperial Coll London, Sect Genom Med, Du Cane Rd, London W12 0NN, England.
EM laoneill@tcd.ie; adrian.hill@well.ox.ac.uk
RI HILL, Adrian/C-1306-2008; Ling, Edmund/B-7923-2010
OI Walley, Andrew/0000-0001-7707-7549; Berkley, James/0000-0002-1236-849X;
   Talbot, Angela/0000-0002-0386-8070; Khor, Chiea
   Chuen/0000-0002-1128-4729; Kwiatkowski, Dominic/0000-0002-5023-0176;
   Maitland, Kathryn/0000-0002-0007-0645
FU Medical Research Council [G0200454, G19/9, MC_U122888468]; Wellcome
   Trust [061089, , 076934, 077092, 081835]
CR Aitman TJ, 2000, NATURE, V405, P1015, DOI 10.1038/35016636
   Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
   Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Altshuler D, 2000, NAT GENET, V26, P76
   Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748
   Clatworthy MR, 2004, J EXP MED, V199, P717, DOI 10.1084/jem.20032197
   Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577
   CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0
   Dean M, 2002, ANNU REV GENOM HUM G, V3, P263, DOI 10.1146/annurev.genom.3.022502.103149
   Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837
   Dunne A, 2003, J BIOL CHEM, V278, P41443, DOI 10.1074/jbc.M301742200
   Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578
   Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253
   Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180
   Hoshino K, 1999, J IMMUNOL, V162, P3749
   Jurinke Christian, 2002, Adv Biochem Eng Biotechnol, V77, P57
   Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200
   Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100
   Mead S, 2003, SCIENCE, V300, P640, DOI 10.1126/science.1083320
   Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a
   Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544
   Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182
NR 28
TC 289
Z9 304
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD APR
PY 2007
VL 39
IS 4
BP 523
EP 528
DI 10.1038/ng1976
PG 6
WC Genetics & Heredity
SC Genetics & Heredity
GA 151EE
UT WOS:000245271200023
PM 17322885
OA No
DA 2017-08-15
ER

PT J
AU Gillespie, GMA
   Bashirova, A
   Dong, T
   McVicar, DW
   Rowland-Jones, SL
   Carrington, M
AF Gillespie, Geraldine M. A.
   Bashirova, Arman
   Dong, Tao
   McVicar, Daniel W.
   Rowland-Jones, Sarah L.
   Carrington, Mary
TI Lack of KIR3DS1 binding to MHC class I Bw4 tetramers in complex with
   CD8(+) T cell epitopes
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID IMMUNOGLOBULIN-LIKE RECEPTORS; HLA-B; CRYSTAL-STRUCTURES; CUTTING EDGE;
   KILLER; RECOGNITION; NK; HLA-B-ASTERISK-2705; FREQUENCIES; INFECTION
AB In HIV-1 infection, the synergistic association of a subset of Bw4 MHC class I molecules and the activating killer inhibitory receptor (KIR), KIR3DS1, with prolonged AIDS-free survival has been reported. As KIRs represent a diverse group of MHC class I receptors, we questioned whether Bw4 MHC class I molecules expressing isoleucine at position 80 (Bw4Ile80) and in complex with HIV-1-derived T cell epitopes represented KIR3DS1 ligands. MHC class I tetramers are powerful tools for the detection of T cell receptor-MHC class I interactions, and have recently been used to evaluate KIR-MHC class I binding ex vivo. Specifically, this approach has been successfully utilized to assess binding of Bw4 MHC class I tetramers to KIR3DL1, an inhibitory KIR and allele of KIR3DS1. In this study we generated a diverse panel of HIV-1-specific Bw4Ile80 MHC class I tetramers and tested its ability to bind transiently expressed KIR3DS1 on 293-T cells. Using flow cytometry analysis, the expression of KIR3DS1 on 293-T cells was confirmed by anti-FLAG BioM2 staining, prior to incubation with PE-conjugated MHC class I tetramers. Despite choosing a broad array of peptide epitopes and diverse Bw4Ile80 MHC class I molecules, we were unable to detect tetramer binding to KIR3DS1. We speculate that our negative finding may be a consequence of the MHC class I molecules and peptide epitopes chosen, but could also relate to key amino acid differences that distinguish KIR3DS1 from KIR3DL1.
C1 John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England.
   Johns Hopkins Univ, Dept Med, Baltimore, MD 21231 USA.
   NCI, Expt Immunol Lab, Frederick, MD 21702 USA.
   MRC Labs, Fajara, Gambia.
   NCI, SIAC Frederick Inc, Lab Genom Divers, Frederick, MD 21702 USA.
RP Gillespie, GMA (reprint author), John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England.
EM ggillesp@hammer.imm.ox.ac.uk
RI McVicar, Daniel/G-1970-2015
FU Intramural NIH HHS; Medical Research Council [MC_U137884180]; NCI NIH
   HHS [N01-CO-12400]; Wellcome Trust
CR Boyington JC, 2002, MOL IMMUNOL, V38, P1007, DOI 10.1016/S0161-5890(02)00030-5
   Carr WH, 2005, J IMMUNOL, V175, P5222
   Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748
   CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235
   Colonna M, 1999, J LEUKOCYTE BIOL, V66, P718
   Gillespie GMA, 2000, J VIROL, V74, P8140, DOI 10.1128/JVI.74.17.8140-8150.2000
   Hickman HD, 2003, J IMMUNOL, V171, P22
   Khakoo SI, 2002, J EXP MED, V196, P911, DOI 10.1084/jem.20020304
   KLEIN MR, 1994, J INFECT DIS, V169, P1244
   Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359
   LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537
   Long EO, 1997, IMMUNOL REV, V155, P135, DOI 10.1111/j.1600-065X.1997.tb00946.x
   Maenaka K, 2000, J IMMUNOL, V165, P3260
   Maenaka K, 1999, J BIOL CHEM, V274, P28329, DOI 10.1074/jbc.274.40.28329
   Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934
   Natarajan K, 2002, ANNU REV IMMUNOL, V20, P853, DOI 10.1146/annurev.immunol.20.100301.064812
   O'Brien SJ, 2000, ANNU REV GENET, V34, P563, DOI 10.1146/annurev.genet.34.1.563
   Peruzzi M, 1996, J EXP MED, V184, P1585, DOI 10.1084/jem.184.4.1585
   Saulquin X, 2003, J EXP MED, V197, P933, DOI 10.1084/jem.20021624
   Stewart CA, 2005, P NATL ACAD SCI USA, V102, P13224, DOI 10.1073/pnas.0503594102
   Stewart-Jones GBE, 2005, EUR J IMMUNOL, V35, P341, DOI 10.1002/eji.200425724
   Thananchai H, 2007, J IMMUNOL, V178, P33
   Vilches C, 2002, ANNU REV IMMUNOL, V20, P217, DOI 10.1146/annurev.immunol.20.092501.134942
NR 23
TC 46
Z9 46
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAR
PY 2007
VL 23
IS 3
BP 451
EP 455
DI 10.1089/aid.2006.0165
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 157SE
UT WOS:000245740300013
PM 17411378
OA No
DA 2017-08-15
ER

PT J
AU Imoukhuede, EB
   Andrews, L
   Milligan, P
   Berthoud, T
   Bojang, K
   Nwakanma, D
   Ismaili, J
   Buckee, C
   Njie, T
   Keita, S
   Sowe, M
   Lang, T
   Gilbert, SC
   Greenwood, BM
   Hill, AVS
AF Imoukhuede, Egeruan B.
   Andrews, Laura
   Milligan, Paul
   Berthoud, Tamara
   Bojang, Kalifa
   Nwakanma, Davis
   Ismaili, Jamila
   Buckee, Caroline
   Njie, Tanta
   Keita, Saikou
   Sowe, Maimuna
   Lang, Trudie
   Gilbert, Sarah C.
   Greenwood, Brian M.
   Hill, Adrian V. S.
TI Low-level malaria infections detected by a sensitive polymerase chain
   reaction assay and use of this technique in the evaluation of malaria
   vaccines in an endemic area
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM INFECTION; RANDOMIZED CONTROLLED-TRIAL;
   PRIME-BOOST IMMUNIZATION; PLACEBO-CONTROLLED TRIAL; VIRUS ANKARA;
   CIRCUMSPOROZOITE PROTEIN; TANZANIAN INFANTS; FOLLOW-UP; EFFICACY; TIME
AB The feasibility of using a sensitive polymerase chain reaction (PCR) to evaluate malaria vaccines in small group sizes was tested in 102 adult Gambian volunteers who received either the malaria vaccine regimen FP9 METRAP/MVA ME-TRAP or rabies vaccine. All volunteers received the antimalarial drugs primaquine and Lapdap plus artesunate to eliminate malaria parasites. Volunteers in a further group received an additional single treatment with suffadoxine-pyrimethamine (SP) to prevent new infections. There was substantially lower T-cell immunogenicity than in previous trials with this vaccine regimen and no protection against infection in the malaria vaccine group. Using the primary endpoint of 20 parasites per mL, no difference was found in the prevalence of low-level infections in volunteers who received SP compared with those who did not, indicating that SP did not reduce the incidence of very low-density infection. However, SP markedly reduced the incidence of higher density infections. These findings support the feasibility and potential of this approach to screen pre-erythrocytic vaccines for efficacy against infection in small numbers of vaccinees in endemic areas.
C1 MRC Labs, Fajara, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England.
   Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford OX1 2JD, England.
RP Imoukhuede, EB (reprint author), European Malaria Vaccine Initiat, 12 Bell House,Ewen Crescent,Tulse Hill, London, England.
EM ebimoukhuede@hotmail.co.uk
RI HILL, Adrian/C-1306-2008; Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Gilbert, Sarah/0000-0002-6823-9750
FU Medical Research Council [G0700837]; Wellcome Trust
CR Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6
   Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   Andrews L, 2005, AM J TROP MED HYG, V73, P191
   Bejon P, 2005, J INFECT DIS, V191, P619, DOI 10.1086/427243
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Dunachie SJ, 2006, INFECT IMMUN, V74, P5933, DOI 10.1128/IAI.00590-06
   Dunachie SJ, 2006, VACCINE, V24, P2850, DOI 10.1016/j.vaccine.2005.12.041
   Greenwood B, 2002, TROP MED INT HEALTH, V7, P1012, DOI 10.1046/j.1365-3156.2002.00980.x
   Hermsen CC, 2001, MOL BIOCHEM PARASIT, V118, P247, DOI 10.1016/S0166-6851(01)00379-6
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Mangold KA, 2005, J CLIN MICROBIOL, V43, P2435, DOI 10.1128/JCM.43.5.2435-2440.2005
   Moorthy VS, 2004, PLOS MED, V1, P128, DOI 10.1371/journal.pmed.0010033
   Moorthy VS, 2004, J INFECT DIS, V189, P2213, DOI 10.1086/421118
   Pombo DJ, 2002, LANCET, V360, P610, DOI 10.1016/S0140-6736(02)09784-2
   Schellenberg D, 2005, LANCET, V365, P1481, DOI 10.1016/S0140-6736(05)66418-5
   Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2
   Vuola JM, 2005, J IMMUNOL, V174, P449
   Walther M, 2006, INFECT IMMUN, V74, P2706, DOI 10.1128/IAI.74.5.2706-2716.2006
   Walther M, 2005, VACCINE, V23, P857, DOI 10.1016/j.vaccine.2004.08.020
   Webster DP, 2006, VACCINE, V24, P3026, DOI 10.1016/j.vaccine.2005.10.058
   Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102
NR 21
TC 18
Z9 18
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD MAR
PY 2007
VL 76
IS 3
BP 486
EP 493
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 146FA
UT WOS:000244918700015
PM 17360872
OA No
DA 2017-08-15
ER

PT J
AU Erskine, J
   Fraser, S
AF Erskine, Jamie
   Fraser, Simon
TI The god delusion
SO BRITISH JOURNAL OF GENERAL PRACTICE
LA English
DT Letter
RP Erskine, J (reprint author), GP,POB 86, Banjul, Gambia.
EM simon.fraser@gp-j82088.nhs.uk
CR CURTIS S, 2006, BR J GEN PRACT, V56, P980
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ROYAL COLL GENERAL PRACTITIONERS
PI LONDON
PA 14 PRINCES GATE, HYDE PARK, LONDON SW7 1PU, ENGLAND
SN 0960-1643
J9 BRIT J GEN PRACT
JI Br. J. Gen. Pract.
PD MAR
PY 2007
VL 57
IS 536
BP 245
EP 245
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 161TI
UT WOS:000246038500019
OA No
DA 2017-08-15
ER

PT J
AU Adetifa, IMO
   Brookes, R
   Lugos, MD
   de Jong, BC
   Antonio, M
   Adegbola, RA
   Hill, RC
AF Adetifa, I. M. O.
   Brookes, R.
   Lugos, M. D.
   de Jong, B. C.
   Antonio, M.
   Adegbola, R. A.
   Hill, R. C.
TI Rising ELISPOT count prior to the onset of symptoms of full-blown
   tuberculosis disease
SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
LA English
DT Article
DE tuberculin skin test; ELISPOT; tuberculosis; Mycobacterium tuberculosis
ID LINKED IMMUNOSPOT ASSAY; MYCOBACTERIUM-TUBERCULOSIS; SKIN-TEST;
   INFECTION; DIAGNOSIS; RESPONSES; ESAT-6; CONTACTS; THERAPY; PROTEIN
AB The relationship between the T-cell response to mycobacterial antigens and the likelihood of progression to disease has not been defined. We report a rapidly rising ELISPOT count in a 55-year-old man with evidence of Mycobacterium tuberculosis infection prior to the onset of symptoms of disease. This case illustrates the possible utility of quantitative changes in the ELISPOT count in predicting progression from M. tuberculosis infection to disease.
C1 MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
RP Adetifa, IMO (reprint author), MRC Labs, Bacterial Dis Programme, POB 273, Banjul, Gambia.
EM iadetifa@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU Medical Research Council [MC_U190071468, MC_U190081968, MC_U190081982]
CR Carrara S, 2004, CLIN INFECT DIS, V38, P754, DOI 10.1086/381754
   Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002
   Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Jeffries DJ, 2006, INT J TUBERC LUNG D, V10, P192
   Langermans JAM, 2005, VACCINE, V23, P2740, DOI 10.1016/j.vaccine.2004.11.051
   Nicol MP, 2005, CLIN INFECT DIS, V40, P1301, DOI 10.1086/429245
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406
   Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001
   Vordermeier HM, 2002, INFECT IMMUN, V70, P3026, DOI 10.1128/IAI.70.6.3026-3032.2002
NR 10
TC 9
Z9 9
U1 0
U2 0
PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
PI PARIS
PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE
SN 1027-3719
J9 INT J TUBERC LUNG D
JI Int. J. Tuberc. Lung Dis.
PD MAR
PY 2007
VL 11
IS 3
BP 350
EP 352
PG 3
WC Infectious Diseases; Respiratory System
SC Infectious Diseases; Respiratory System
GA 146EY
UT WOS:000244918500022
PM 17352104
OA No
DA 2017-08-15
ER

PT J
AU Conteh, L
   Stevens, W
   Wiseman, V
AF Conteh, Lesong
   Stevens, Warren
   Wiseman, Virginia
TI The role of communication between clients and health care providers:
   implications for adherence to malaria treatment in rural Gambia
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE The Gambia; adherence; malaria; understanding; communication; caretaker;
   provider
ID SUB-SAHARAN AFRICA; ANTIMALARIAL-DRUGS; HOME TREATMENT; UNCOMPLICATED
   MALARIA; BURKINA-FASO; PLASMODIUM-FALCIPARUM; TREATMENT-SEEKING;
   CHILDHOOD FEVERS; RANDOMIZED-TRIAL; FEBRILE ILLNESS
AB OBJECTIVES One of the major barriers to the successful treatment of malaria is the non-adherence to drug regimens. Work till now has often been based on the assumption that most patients begin their treatment having received adequate or at least similar instructions and information about both the disease itself and the content and course of their treatment. This paper questions such an assumption. We ask whether people do not adhere to treatment in part because they have not understood the diagnosis and subsequent treatment from the outset.
   METHODS This study was conducted in the North Bank district of The Gambia, West Africa where a convenience sample of 1337 caretakers with children under 10 years of age were interviewed immediately after their consultation about their recommended treatment.
   RESULTS Findings show a mismatch between caretakers and healthcare providers' (HCP) interpretations of a child's clinic visit, both in terms of the diagnosis and drug regimen. Less than a third of the caretakers' responses matched the diagnosis that the HCP had written on the child's medical card. Results also showed a delay in the first important antimalarial dose. A common response was 'I'm not sure what is wrong with the child but I will start the medicine when I get home'.
   CONCLUSIONS The findings from these exit interviews lend weight to the argument that the value of pre-packaged blisters could potentially provide far greater benefits than their additional cost, especially when coupled with improved communication by HCP.
C1 Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, London WC1E 7HT, England.
   Univ London London Sch Hyg & Trop Med, Gates Malaria Partnership, London WC1E 7HT, England.
   MRC, Fajara, Gambia.
RP Conteh, L (reprint author), Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Keppel St, London WC1E 7HT, England.
EM lesong.conteh@lshtm.ac.uk
CR Afenyadu GY, 2005, TROP MED INT HEALTH, V10, P1065, DOI 10.1111/j.1365-3156.2005.01484.x
   Agyepong IA, 2002, SOC SCI MED, V55, P2215, DOI 10.1016/S0277-9536(01)00366-5
   AIKINS MK, 1993, T ROY SOC TROP MED H, V87, P25, DOI 10.1016/0035-9203(93)90172-M
   AIKINS MK, 1994, J TROP MED HYG, V97, P81
   Ansah EK, 2001, TROP MED INT HEALTH, V6, P496, DOI 10.1046/j.1365-3156.2001.00740.x
   Chen L, 2004, LANCET, V364, P1984, DOI 10.1016/S0140-6736(04)17482-5
   DEMBA A, THESIS U LONDON LOND
   DEMING MS, 1989, B WORLD HEALTH ORGAN, V67, P695
   Depoortere E, 2004, TROP MED INT HEALTH, V9, P62, DOI 10.1046/j.1365-3156.2003.01157.x
   DUNYO S, 2004, AM SOC TROP MED HYG
   Dunyo S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010014
   Gilson L, 2005, SOC SCI MED, V61, P1381, DOI 10.1016/j.socscimed.2004.11.059
   JASSEY M, 2004, PROFILE FARAFENNI DE
   Jewkes R, 1998, SOC SCI MED, V47, P1781, DOI 10.1016/S0277-9536(98)00240-8
   Kamat VR, 2006, SOC SCI MED, V62, P2945, DOI 10.1016/j.socscimed.2005.11.042
   Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0
   Krause G, 1999, HEALTH POLICY PLANN, V14, P291, DOI 10.1093/heapol/14.3.291
   Krause G, 2000, INT J QUAL HEALTH C, V12, P25, DOI 10.1093/intqhc/12.1.25
   KUROWSKI C, 2004, CASE STUDIES TANZANI
   Marsh VM, 2004, TROP MED INT HEALTH, V9, P451, DOI 10.1111/j.1365-3156.2004.01223.x
   Marsh VM, 1999, TROP MED INT HEALTH, V4, P383, DOI 10.1046/j.1365-3156.1999.00403.x
   MASSELE AY, 1993, E AFR MED J, V70, P639
   McCombie SC, 1996, SOC SCI MED, V43, P933, DOI 10.1016/0277-9536(95)00446-7
   McPake B, 1999, SOC SCI MED, V49, P849, DOI 10.1016/S0277-9536(99)00144-6
   Montgomery CM, 2006, TROP MED INT HEALTH, V11, P1661, DOI 10.1111/j.1365-3156.2006.01719.x
   Mwenesi HRA, 1993, MOTHERS DEFINITION T
   *NAT MAL CONTR PRO, 2005, GUID MAL STAND CAS M
   Nshakira N, 2002, TROP MED INT HEALTH, V7, P309, DOI 10.1046/j.1365-3156.2002.00858.x
   Nwanyanwu OC, 1996, T ROY SOC TROP MED H, V90, P66, DOI 10.1016/S0035-9203(96)90482-4
   OforiAdjei D, 1996, SOC SCI MED, V42, P1169, DOI 10.1016/0277-9536(95)00389-4
   Okonkwo PO, 2001, T ROY SOC TROP MED H, V95, P320, DOI 10.1016/S0035-9203(01)90252-4
   Osterholt DM, 2006, TROP MED INT HEALTH, V11, P1147, DOI 10.1111/j.1365-3156.2006.01666.x
   Rowe AK, 2005, LANCET, V366, P1026, DOI 10.1016/S0140-6736(05)67028-6
   Rowe AK, 2000, AM J EPIDEMIOL, V151, P1029
   Rowe AK, 2003, INT J EPIDEMIOL, V32, P296, DOI 10.1093/ije/dyg063
   Rowe AK, 2001, AM J PUBLIC HEALTH, V91, P1625, DOI 10.2105/AJPH.91.10.1625
   RUEBUSH TK, 1995, B WORLD HEALTH ORGAN, V73, P229
   Sirima SB, 2003, TROP MED INT HEALTH, V8, P133, DOI 10.1046/j.1365-3156.2003.00997.x
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Tanner M, 1998, SOC SCI MED, V46, P523, DOI 10.1016/S0277-9536(97)00195-0
   TANNER M, 1993, T ROY SOC TROP MED H, V87, P518, DOI 10.1016/0035-9203(93)90070-7
   Thera MA, 2000, TROP MED INT HEALTH, V5, P876, DOI 10.1046/j.1365-3156.2000.00652.x
   Thiede M, 2005, SOC SCI MED, V61, P1452, DOI 10.1016/j.socscimed.2004.11.076
   Whitty CJM, 2004, B WORLD HEALTH ORGAN, V82, P381
   WHO, 2000, 20 WHO EXP COMM MAL
   The World Health Organization, 2006, WORLD HLTH REP 2006
   [WHO UNICEF], 2005, WORLD MAL REP 2005
   Williams HA, 2004, SOC SCI MED, V59, P501, DOI 10.1016/j.socscimed.2003.11.010
   WISEMAN V, UNPUB J AM MED ASS
   WISEMAN V, 2002, DEMTAP STUDY
   Yeboah-Antwi K, 2001, B WORLD HEALTH ORGAN, V79, P394
   Yeung S, 2005, TROP MED INT HEALTH, V10, P121, DOI 10.1111/j.1365-3156.2004.01364.x
   Zurovac D, 2006, ANN TROP MED PARASIT, V100, P283, DOI 10.1179/136485906X105633
   Zurovac D, 2004, INT J EPIDEMIOL, V33, P1080, DOI 10.1093/ije/dyh253
NR 54
TC 22
Z9 22
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAR
PY 2007
VL 12
IS 3
BP 382
EP 391
DI 10.1111/j.1365-3156.2006.01806.x
PG 10
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 138CU
UT WOS:000244341500010
PM 17313510
OA No
DA 2017-08-15
ER

PT J
AU Owens, S
   Stokes, E
   Mueller, J
AF Owens, Stephen
   Stokes, Elizabeth
   Mueller, Jenny
TI Debate: Letter to the editors
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Letter
C1 MRC Labs, Banjul, Gambia.
RP Owens, S (reprint author), MRC Labs, Banjul, Gambia.
CR Cutts FT, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010016
   International Conference on Harmonisation (ICH), 1996, INT C HARM ICH TRIP
   Medical Research Council, 1998, MRC GUID GOOD CLIN P
   White NJ, 2006, TROP MED INT HEALTH, V11, P1483, DOI 10.1111/j.1365-3156.2006.01765.x
NR 4
TC 2
Z9 2
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAR
PY 2007
VL 12
IS 3
BP 472
EP 472
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 138CU
UT WOS:000244341500019
PM 17313519
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   Mendy, M
   Waight, P
   Doherty, C
   McConkey, SJ
   Hall, AJ
   Whittle, HC
AF van der Sande, M. A. B.
   Mendy, M.
   Waight, P.
   Doherty, C.
   McConkey, S. J.
   Hall, A. J.
   Whittle, H. C.
TI Similar long-term vaccine efficacy of two versus three doses of HBV
   vaccine in early life
SO VACCINE
LA English
DT Article
DE hepatitis B; vaccine efficacy; dosing; the Gambia; cohort
ID HEPATITIS-B-VACCINE; RANDOMIZED-TRIAL; YOUNG-ADULTS; FOLLOW-UP;
   RECOMBINANT; REGIMEN; 2-DOSE; IMMUNOGENICITY; ADOLESCENTS; PROTECTION
AB WHO currently recommends three vaccinations against hepatitis B to provide optimal protection against infection and carriage. However, immunological theory and mathematical modelling suggest that similar protection could be induced with two doses, and trials among adolescents and adults have shown comparable rates for both primary seroprotection and geometric mean titres following vaccination.
   We determined vaccine efficacy among 60 children who only received two doses of hepatitis B vaccine as infants and among 463 children who had received three doses after 4-7 years of follow-up. Vaccine efficacy among the two-dose group was 86.3% against anti-HBc positivity (infection) and 92.3% against HBsAg positivity (carriage), which was similar to the vaccine efficacy found among the participants who had received three doses. To confirm this comparable vaccine efficacy a randomised controlled non-inferiority trial with long-term follow-up is needed. (c) 2006 Elsevier Ltd. All rights reserved.
C1 MRC Labs, Fajara, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP van der Sande, MAB (reprint author), Natl Inst Publ Hlth & Environm, RIVM, Ctr Infect Dis Control, POB 1-PB 75, Bilthoven, Netherlands.
EM Marianne.van.der.Sande@rivm.nl
RI McConkey, Samuel/E-7307-2012
OI McConkey, Samuel/0000-0001-9085-7793
FU Medical Research Council [MC_U190071425]
CR Akram DS, 2005, VACCINE, V23, P5792, DOI 10.1016/j.vaccine.2005.06.013
   Banatvala J, 2000, LANCET, V355, P561
   Cassidy WM, 2001, PEDIATRICS, V107, P626, DOI 10.1542/peds.107.4.626
   EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197
   Froehlich Hervey, 2001, Ethnicity and Disease, V11, P548
   Gellin BG, 1997, J INFECT DIS, V175, P1494
   Heron LG, 2002, VACCINE, V20, P3472, DOI 10.1016/S0264-410X(02)00346-8
   JILG W, 1988, J MED VIROL, V24, P377, DOI 10.1002/jmv.1890240404
   Levie K, 2002, SCAND J INFECT DIS, V34, P610, DOI 10.1080/00365540110080881
   Marsano LS, 1998, VACCINE, V16, P624, DOI 10.1016/S0264-410X(97)00233-8
   TABOR E, 1993, J MED VIROL, V40, P204, DOI 10.1002/jmv.1890400307
   van der Sande MAB, 2006, J INFECT DIS, V193, P1528
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4
   Wilson JN, 1999, VACCINE, V17, P2667, DOI 10.1016/S0264-410X(99)00029-8
   Wistrom J, 1999, VACCINE, V17, P2162, DOI 10.1016/S0264-410X(99)00012-2
   Yuen MF, 1999, HEPATOLOGY, V29, P924, DOI 10.1002/hep.510290327
NR 17
TC 18
Z9 19
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD FEB 9
PY 2007
VL 25
IS 8
BP 1509
EP 1512
DI 10.1016/j.vaccine.2006.10.023
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 136PJ
UT WOS:000244236300019
PM 17095130
OA No
DA 2017-08-15
ER

PT J
AU Ghattas, H
   Wallace, DL
   Solon, JA
   Henson, SM
   Zhang, Y
   Ngom, PT
   Aspinall, R
   Morgan, G
   Griffin, GE
   Prentice, AM
   Macallan, DC
AF Ghattas, Hala
   Wallace, Diana L.
   Solon, Juan A.
   Henson, Sian M.
   Zhang, Yan
   Ngom, Pa T.
   Aspinall, Richard
   Morgan, Gareth
   Griffin, George E.
   Prentice, Andrew M.
   Macallan, Derek C.
TI Long-term effects of perinatal nutrition on T lymphocyte kinetics in
   young Gambian men
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE nutritional programming; T cell kinetics; lymphocytes; Gambia; stable
   isotopes
ID RECEPTOR EXCISION CIRCLES; RECENT THYMIC EMIGRANTS; ZINC DEPRIVATION;
   PRENATAL UNDERNUTRITION; POSTNATAL ENVIRONMENTS; ADULT; BIRTH; GROWTH;
   IMMUNODEFICIENCY; VACCINATION
AB Background: Nutritional status is highly dependent on season in countries such as The Gambia. In a rural Gambian setting, individuals born during periods of seasonal nutritional deprivation ("hungry seasons") are susceptible to mortality from infectious diseases in adult life.
   Objective: We investigated the hypothesis that impaired immunocompetence in those born in the hungry season results from an underlying defect in immunologic memory, similar to the immunosenescence of old age, which is likely to be reflected in the phenotype and kinetics of T lymphocytes in young adults.
   Design: T cell phenotype in terms of CD3, CD4, CD8, CD45RA, and CD45R0 expression and in vivo dynamics measured by stable isotope labeling of T cell subsets combined with gas chromatography-mass spectrometry and frequency of T cell receptor excision circles were measured in 25 young (18-24-y-old) Gambian men. Thirteen of these 25 men were exposed to perinatal malnutrition as defined by birth season and birth weight.
   Results: In persons born in the hungry season with low birth weight, no differences in the proportions of memory or naive T cells were found. Kinetic analysis showed higher proliferation rates in memory (CD45R0(+)) subsets of T cells than in nalve (CD45R0(-)) cells, which is consistent with previous studies, but no evidence was found for an effect of birth weight or season on T lymphocyte proliferation and disappearance rates. No significant correlations were found between in vivo T cell kinetics and frequency of T cell receptor excision circles. Only absolute numbers of granulocytes were elevated in those born in the nutritionally deprived season.
   Conclusion: In healthy young Gambian men, T lymphocyte homeostasis is extremely robust regardless of perinatal nutritional compromise.
C1 St Georges Univ London, Ctr Infect, Dept Cellular & Mol Med, London SW17 0RE, England.
   London Sch Hyg & Trop Med, MRC Int Nutr Grp, London WC1, England.
   MRC, Keneba, Gambia.
   UCL, Dept Immunol & Mol Pathol, London, England.
   Imperial Coll London, Dept Immunol, London, England.
   Univ Coll Swansea, Sch Clin, Swansea, W Glam, Wales.
RP Macallan, DC (reprint author), St Georges Univ London, Ctr Infect, Dept Cellular & Mol Med, Cranmer Terrace, London SW17 0RE, England.
EM macallan@sghms.ac.uk
RI Aspinall, Richard/E-4924-2013; Ghattas, Hala/K-5661-2016
OI Aspinall, Richard/0000-0002-1648-1887
CR Asquith B, 2002, TRENDS IMMUNOL, V23, P596, DOI 10.1016/S1471-4906(02)02337-2
   BEACH RS, 1983, AM J CLIN NUTR, V38, P579
   BEACH RS, 1982, J NUTR, V112, P1169
   BEACH RS, 1982, SCIENCE, V218, P469, DOI 10.1126/science.7123244
   COLE TJ, 1993, SOC ST HUM, V35, P89, DOI 10.1017/CBO9780511600517.008
   Collinson AC, 2003, ACTA PAEDIATR, V92, P1014, DOI 10.1080/08035250310004379
   Douek DC, 1998, NATURE, V396, P690
   Douek DC, 2000, LANCET, V355, P1875, DOI 10.1016/S0140-6736(00)02293-5
   Ghattas H, 2005, T ROY SOC TROP MED H, V99, P675, DOI 10.1016/j.trstmh.2005.02.005
   GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x
   Guazzi V, 2002, CLIN EXP IMMUNOL, V129, P346, DOI 10.1046/j.1365-2249.2002.01893.x
   Hazenberg MD, 2001, J MOL MED-JMM, V79, P631, DOI 10.1007/s001090100271
   Henson SM, 2004, EXP GERONTOL, V39, P673, DOI 10.1016/j.exger.2003.10.030
   King LE, 2002, J NUTR, V132, P974
   Macallan DC, 2003, EUR J IMMUNOL, V33, P2655, DOI 10.1002/eji.200324295
   Macallan DC, 2003, EUR J IMMUNOL, V33, P2316, DOI 10.1002/eji.200323763
   Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708
   Malaguarnera L, 2001, ARCH GERONTOL GERIAT, V32, P1, DOI 10.1016/S0167-4943(00)00086-8
   Malpuech-Brugere C, 1999, BRIT J NUTR, V81, P405
   McDade TW, 2004, CLIN EXP ALLERGY, V34, P44, DOI 10.1111/j.1365-2222.2004.01834.x
   McDade TW, 2001, J NUTR, V131, P1225
   McDade TW, 2001, AM J CLIN NUTR, V74, P543
   Moore SE, 2005, NESTLE NUTR WORKS SE, V55, P153
   Moore SE, 2004, AM J CLIN NUTR, V80, P453
   Moore SE, 1997, NATURE, V388, P434, DOI 10.1038/41245
   Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088
   Morgan G, 1997, LANCET, V349, P1693, DOI 10.1016/S0140-6736(96)12038-9
   Ngom PT, 2004, AM J CLIN NUTR, V80, P722
   Prentice AM, 2005, ARCH DIS CHILD, V90, P429, DOI 10.1136/adc.2004.059030
   Steffens CM, 2000, CLIN IMMUNOL, V97, P95, DOI 10.1006/clim.2000.4938
   Tsegaye A, 1999, CLIN DIAGN LAB IMMUN, V6, P410
   Tsegaye A, 2003, CLIN IMMUNOL, V109, P338, DOI 10.1016/j.clim.2003.08.008
   Wallace DL, 2004, J IMMUNOL, V173, P1787
   Worku S, 1997, T ROY SOC TROP MED H, V91, P618, DOI 10.1016/S0035-9203(97)90051-1
   Ye P, 2002, J IMMUNOL, V168, P4968
NR 35
TC 9
Z9 10
U1 0
U2 1
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD FEB
PY 2007
VL 85
IS 2
BP 480
EP 487
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 137JZ
UT WOS:000244290200023
PM 17284747
OA No
DA 2017-08-15
ER

PT J
AU Crawley, J
   Hill, J
   Yartey, J
   Robalo, M
   Serufilira, A
   Ba-Nguz, A
   Roman, E
   Palmer, A
   Asamoa, K
   Steketee, R
AF Crawley, Jane
   Hill, Jenny
   Yartey, Juliana
   Robalo, Magda
   Serufilira, Antoine
   Ba-Nguz, Antoinette
   Roman, Elaine
   Palmer, Ayo
   Asamoa, Kwame
   Steketee, Richard
TI From evidence to action? Challenges to policy change and programme
   delivery for malaria in pregnancy
SO LANCET INFECTIOUS DISEASES
LA English
DT Review
ID INTERMITTENT PREVENTIVE TREATMENT; PLACEBO-CONTROLLED TRIAL; ROUTINE
   PROPHYLACTIC SUPPLEMENTATION; INSECTICIDE-TREATED BEDNETS; RANDOMIZED
   CONTROLLED-TRIAL; SULFADOXINE-PYRIMETHAMINE; WESTERN KENYA; FOLIC-ACID;
   PLASMODIUM-FALCIPARUM; MUKONO DISTRICT
AB This paper discusses the factors that influence whether strategies for preventing and treating malaria in pregnancy are successfully translated into national policy and programme implementation, and identifies key operational research issues. Countries require guidance on how to assess the effectiveness of intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine in the context of increasing sulfadoxine-pyrimethamine resistance. At the same time, data on the safety and efficacy of alternatives to sulfadoxine-pyrimethamine for prevention and treatment are urgently needed. Systematic examination of the cultural and operational constraints to delivery and uptake of IPTp with sulfadoxine-pyrimethamine and use of insecticide-treated nets would provide a rational basis for strategies aimed at improving coverage. Standardised methodology must be used to monitor IPTp coverage and to compare different approaches for scaling-up the delivery of insecticide-treated nets to pregnant women. Adequate budgetary provision for the implementation of policy and for operational research to improve programme delivery should be included in national applications to the Global Fund to Fight AIDS, Tuberculosis and Malaria. The provision of clear policy guidance on malaria in pregnancy and its translation into evidence-based guidelines that are made widely available at a country level are central to improving malaria control in this particularly vulnerable group.
C1 WHO, Global Malaria Program, CH-1211 Geneva 27, Switzerland.
   Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England.
   WHO, Malaria Unit, Div AIDS TB & Malaria, Reg Off Africa, Harare, Zimbabwe.
   WHO, Reg Off Africa, Div Family & Reprod Hlth, Libreville, Gabon.
   JHPIEGO, Nairobi, Kenya.
   MRC, Labs Fajara, Ctr Innovat Malaria, Banjul, Gambia.
   Ctr Dis Control & Prevent, Div Parasit Dis, Malaria Branch, Atlanta, GA USA.
   Program Appropriate Technol Hlth, Batiment Avant Ctr, Fermey Voltaire, France.
RP Crawley, J (reprint author), WHO, Global Malaria Program, 20 Ave Appla, CH-1211 Geneva 27, Switzerland.
EM jane.crawley@gmail.com
CR Alaii JA, 2003, AM J TROP MED HYG, V68, P142
   Binka FN, 1997, TROP MED INT HEALTH, V2, P499, DOI 10.1046/j.1365-3156.1997.d01-299.x
   Brentlinger PE, 2006, LANCET INFECT DIS, V6, P100, DOI 10.1016/S1473-3099(06)70383-8
   English M, 2006, LANCET, V367, P90, DOI 10.1016/S0140-6736(06)67939-7
   Filler SJ, 2006, J INFECT DIS, V194, P286, DOI 10.1086/505080
   Gamble C.L., 2006, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD003755.PUB2
   Guyatt H, 2003, LANCET, V362, P1549, DOI 10.1016/S0140-6736(03)14744-7
   Guyatt HL, 2002, TROP MED INT HEALTH, V7, P846, DOI 10.1046/j.1365-3156.2002.00929.x
   Hill J, 2006, TROP MED INT HEALTH, V11, P409, DOI 10.1111/j.1365-3156.2006.01585.x
   Hill J, 2006, ADV PARASIT, V61, P77, DOI 10.1016/S0065-308X(05)61003-2
   *JHPIEGO MAT NEON, 2004, FOC ANT CAR PLANN PR
   Kalanda GC, 2006, TROP MED INT HEALTH, V11, P569, DOI 10.1111/j.1365-3156.2006.01608.x
   Kayentao K, 2005, J INFECT DIS, V191, P109, DOI 10.1086/426400
   KENGEYAKAYONDO JF, 1994, ACTA TROP, V58, P267, DOI 10.1016/0001-706X(94)90020-5
   Mbonye AK, 2006, J BIOSOC SCI, V38, P221
   Mbonye AK, 2006, HEALTH POLICY PLANN, V21, P17, DOI 10.1093/heapol/czj002
   Mbonye AK, 2006, HEALTH POLICY, V77, P279, DOI 10.1016/j.healthpol.2005.07.020
   McGready R, 2004, AM J TROP MED HYG, V70, P398
   Menendez C, 2007, LANCET INFECT DIS, V7, P126, DOI 10.1016/S1473-3099(07)70024-5
   *MIPESA, 2004, MIPESA NEWSLETTER
   *MIPESA, 2006, MAL PREGN E SO AFR C
   Mubyazi G, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-31
   Mushi AK, 2003, HEALTH POLICY PLANN, V18, P163, DOI 10.1093/heapol/czg021
   Newman RD, 2006, TROP MED INT HEALTH, V11, P462, DOI 10.1111/j.1365-3156.2006.01593.x
   Njagi JK, 2003, T ROY SOC TROP MED H, V97, P277, DOI 10.1016/S0035-9203(03)90141-6
   Nosten F, 2004, TRENDS PARASITOL, V20, P425, DOI 10.1016/j.pt.2004.06.007
   Nosten F, 2007, LANCET INFECT DIS, V7, P118, DOI 10.1016/S1473-3099(07)70023-3
   Parise ME, 1998, AM J TROP MED HYG, V59, P813
   *PATH, 2006, ZAMB NAT MAL IND SUR
   *PSI, 2005, MAL ITN DEL MOD COUN
   *PSI, 2006, MOSQ NET COV VULN GR
   *PSI, 2005, SMARTNET TANZ PUBL P
   RWAGACONDO C, 2004, 4 M RBM PARTN MAL PR
   Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2
   SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515
   Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8
   Steketee RW, 2001, AM J TROP MED HYG, V64, P28
   ter Kuile FO, 2003, AM J TROP MED HYG, V68, P50
   Tielsch JM, 2006, LANCET, V367, P144, DOI 10.1016/S0140-6736(06)67963-4
   *UNICEF, 2002, ACC CHILD SURV DEV R
   van Eijk AM, 2004, TROP MED INT HEALTH, V9, P630, DOI 10.1111/j.1365-3156.2004.01242.x
   Villar J, 2001, LANCET, V357, P1551, DOI 10.1016/S0140-6736(00)04722-X
   Ward SA, 2007, LANCET INFECT DIS, V7, P136, DOI 10.1016/S1473-3099(07)70025-7
   WEBSTER J, 2006, FRAMEWORK STRATEGIC
   World Health Organization, 2005, SUSC PLASM FALC ANT
   World Health Organization (WHO), 2006, GUID TREATM MAL
   WHO, 2003, ASS MON ANT DRUG EFF
   WHO, 2003, ASS SAF ART COMP PRE
   WHO, 2000, WHO EXP COMM MAL
   WHO, 2005, WORLD MAL REP
   World Health Organisation, 2006, MAL PREGN GUID MEAS
   *WHO, 2006, WHO EXP CONS CONTR P
   World Health Organization, 2006, REC US SULF PYR SP I
   *WHO, 2006, GLOB ANT DAT AFRO
   WHO, 2004, STRAT FRAM MAL PREV
   *WHO, 2005, SCAL INS TREAT NETT
   *WHO, 2001, IR DEF AN ASS PROV C
   Worrall E, 2005, TROP MED INT HEALTH, V10, P19, DOI 10.1111/j.1365-3156.2004.01355.x
   Worrall E, 2007, LANCET INFECT DIS, V7, P156, DOI 10.1016/S1473-3099(07)70027-0
   Yartey JE, 2006, INT J GYNECOL OBSTET, V94, P364, DOI 10.1016/j.ijgo.2006.04.026
NR 60
TC 52
Z9 53
U1 0
U2 2
PU LANCET LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1473-3099
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD FEB
PY 2007
VL 7
IS 2
BP 145
EP 155
DI 10.1016/S1473-3099(07)70026-9
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA 129RX
UT WOS:000243748900027
PM 17251085
OA No
DA 2017-08-15
ER

PT J
AU Bosso, NA
   Cisse, MF
   Van der Waaij, EH
   Fall, A
   van Arendonk, JAM
AF Bosso, N. A.
   Cisse, M. F.
   van der Waaij, E. H.
   Fall, A.
   van Arendonk, J. A. M.
TI Genetic and phenotypic parameters of body weight in West African Dwarf
   goat and Djallonke sheep
SO SMALL RUMINANT RESEARCH
LA English
DT Article
DE West African Dwarf; Djallonke; heritability; growth traits; Gambia
ID GROWTH TRAITS
AB The International Trypanotolerance Centre's small ruminant breeding programme was initiated in 1995. The aim was to increase the efficiency of meat production and the trypanotolerance of the animals (sheep and goat). To achieve that goal, selection was based on estimated breeding values for daily weight gain from 4 to 12 months of age measured on trypanotolerance challenge. The purpose of this study was to estimate genetic parameters for growth traits and to evaluate genetic trends in West African Dwarf goat and Djallonke sheep resulting from the breeding programme under a low input production environment. Data for West African Dwarf goat and Djallonke sheep included birth weight (BW), weaning weight (W120), yearling weight (W360), pre-weaning (GRO-4) and post-weaning (GR4-12) growth rate. The data were analysed using an animal model that accounted for fixed effects of sex, year of birth, season of birth, parity of the dam, type of birth and the interaction year by season of birth. Estimates of heritability for BW, W120, W360, GRO-4 and GR4-12 were 0.5, 0.43, 0.30, 0.32 and 0.11 for goats and 0.39, 0.54, 0.21, 0.54 and 0.23 for sheep, respectively. The genetic correlation between BW and W120 was high for goats (0.74) and moderate for sheep (0.47). Genetic correlations between W120 and GR4-12 were high (0.92) for goats and moderate (0.49) for sheep. Between GRO-4 and BW the correlation was positive but low for sheep (0.26) and moderate for goats (0.60). Positive trends were found in mean estimated breeding values for animals born in the period 1995-2002 which demonstrated the effectiveness of the implemented breeding programs. (c) 2005 Elsevier B.V. All rights reserved.
C1 Wageningen Inst Anim Sci, Anim Breeding & Genet Grp, NL-6700 AH Wageningen, Netherlands.
   Int Trypanotolerance Ctr, Banjul, Gambia.
   Univ Utrecht, Fac Vet, Dept Farm Anim Hlth, NL-3508 TD Utrecht, Netherlands.
   Inst Rech Agron Guinee, Conakry, Guinea.
RP Bosso, NA (reprint author), Wageningen Inst Anim Sci, Anim Breeding & Genet Grp, POB 338, NL-6700 AH Wageningen, Netherlands.
EM nguetta.bosso@wur.nl
RI van Arendonk, Johan/E-2536-2011; van der Waaij, Liesbeth/E-3968-2012
OI van Arendonk, Johan/0000-0003-2592-3947; 
CR Acharya R.M, 1992
   AGYEMANG K, 1990, B ANIM HLTH PROD AFR, V39, P129
   CLEMENT V, 1999, THESIS PARIS, P104
   DAS SM, 1996, SMALL RUMINANT RES D, P326
   EDRISS MA, 2002, P 7 WCGALP, V29, P469
   GGYEMANG K, 1997, ILRI ITC, P131
   GILMOUR AR, 2000, ASREML REFERNCE MANU, P253
   Glimp H.A., 1991, P15
   HERNESCH S, 2000, LIVEST PROD SCI, V65, P261
   Ikwuegbu OA, 1994, P 2 BIENN C AFR SMAL, P268
   INYANGALA BAO, 1992, P 1 BIENN C AFR SMAL, P505
   *ITC, 1999, 19981999 ITC, P10
   KOSGEY IS, IN PRES SMALL RUMIN
   Lebbie SHB, 1999, SMALL RUMINANT RES, V34, P231, DOI 10.1016/S0921-4488(99)00076-0
   MARTINEZ A, 1983, HAIR SHEEP W AFRICA, P105
   MAVROGENIS AP, 1980, ANIM PROD, V30, P271
   MBAH DA, 1988, P WORKSH IMPT SMALL, P95
   Mourad M, 1998, SMALL RUMINANT RES, V27, P197, DOI 10.1016/S0921-4488(97)00043-6
   *SAS, 1999, STAT ANAL SYST
   Schoeman SJ, 1997, SMALL RUMINANT RES, V26, P15, DOI 10.1016/S0921-4488(95)00847-0
   SMITH GM, 1976, J ANIM SCI, V43, P244
   Snyman MA, 1997, LIVEST PROD SCI, V48, P111, DOI 10.1016/S0301-6226(96)01418-2
NR 22
TC 46
Z9 47
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-4488
J9 SMALL RUMINANT RES
JI Small Ruminant Res.
PD FEB
PY 2007
VL 67
IS 2-3
BP 271
EP 278
DI 10.1016/j.smallrumres.2005.11.001
PG 8
WC Agriculture, Dairy & Animal Science
SC Agriculture
GA 117QH
UT WOS:000242887500023
OA No
DA 2017-08-15
ER

PT J
AU Hill, PC
   Jeffries, DJ
   Brookes, RH
   Fox, A
   Jackson-Sillah, D
   Lugos, MD
   Donkor, SA
   de Jong, BC
   Corrah, T
   Adegbola, RA
   McAdam, KP
AF Hill, Philip C.
   Jeffries, David J.
   Brookes, Roger H.
   Fox, Annette
   Jackson-Sillah, Dolly
   Lugos, Moses D.
   Donkor, Simon A.
   de Jong, Bouke C.
   Corrah, Tumani
   Adegbola, Richard A.
   McAdam, Keith P.
TI Using ELISPOT to Expose False Positive Skin Test Conversion in
   Tuberculosis Contacts
SO PLOS ONE
LA English
DT Article
AB Background. Repeat tuberculin skin tests may be false positive due to boosting of waned immunity to past mycobacterial exposure. We evaluated whether an ELISPOT test could identify tuberculosis (TB) contacts with boosting of immunity to non-tuberculous mycobacterial exposure. Methodology/Principal Findings. We conducted tuberculin and ELISPOT tests in 1665 TB contacts: 799 were tuberculin test negative and were offered a repeat test after three months. Those with tuberculin test conversion had an ELISPOT, chest X-ray and sputum analysis if appropriate. We compared converters with non-converters, assessed the probability of each of four combinations of ELISPOT results over the two time points and estimated boosting with adjustment for ELISPOT sensitivity and specificity. 704 (72%) contacts had a repeat tuberculin test; 176 (25%) had test conversion, which increased with exposure to a case (p = 0.002), increasing age (p = 0.0006) and BCG scar (p = 0.06). 114 tuberculin test converters had ELISPOT results: 16(14%) were recruitment positive/follow-up positive, 9 (8%) positive/negative, 34 (30%) negative/positive, and 55 (48%) were negative/negative. There was a significant non-linear effect of age for ELISPOT results in skin test converters (p = 0.038). Estimates of boosting ranged from 32%-41% of skin test converters with increasing age. Three converters were diagnosed with TB, two had ELISPOT results: both were positive, including one at recruitment. Conclusions/Significance. We estimate that approximately one third of tuberculin skin test conversion in Gambian TB case contacts is due to boosting of immunity to non-tuberculous mycobacterial exposure. Further longitudinal studies are required to confirm whether ELISPOT can reliably identify case contacts with tuberculin test conversion that would benefit most from prophylactic treatment.
C1 [Hill, Philip C.; Jeffries, David J.; Brookes, Roger H.; Fox, Annette; Jackson-Sillah, Dolly; Lugos, Moses D.; Donkor, Simon A.; de Jong, Bouke C.; Corrah, Tumani; Adegbola, Richard A.; McAdam, Keith P.] MRC Unit, Bacterial Dis Programme, Banjul, Gambia.
RP Hill, PC (reprint author), MRC Unit, Bacterial Dis Programme, Banjul, Gambia.
EM phill@mrc.gm
RI de Jong, Bouke/A-3636-2013
OI de Jong, Bouke/0000-0002-1017-4675
FU Medical Research Council (UK); European Commission
FX This study was funded by the Medical Research Council (UK) and the
   European Commission.
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   Aiken AM, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-66
   Centers for disease Control and Prevention (CDC), 2005, MMWR-MORBID MORTAL W, V54, P1
   COMSTOCK GW, 1969, AM REV RESPIR DIS, V100, P839
   EDWARDS LB, 1953, RESPONSE BCG VACCINA
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9
   Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6
   Godkin AJ, 2002, J IMMUNOL, V169, P2210
   Guwatudde D, 2003, AM J EPIDEMIOL, V158, P887, DOI 10.1093/aje/kwg227
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Jeffries DJ, 2006, INT J TUBERC LUNG D, V10, P192
   Jeffries DJ, 2004, INT J TUBERC LUNG D, V8, P1095
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907
   Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824
   Levy MZ, 2005, INT J TUBERC LUNG D, V9, P771
   Lienhardt C, 2003, AM J RESP CRIT CARE, V168, P448, DOI 10.1164/rccm.200212-1483OC
   Menzies D, 1999, AM J RESP CRIT CARE, V159, P15
   *NAT I HLTH CLIN E, 2006, CLIN GUIDELINE, V33, P1
   PALMER C E, 1952, Lancet, V1, P935
   Pathan AA, 2001, J IMMUNOL, V167, P5217
   Pouchot J, 1997, ANN INTERN MED, V126, P210
   TUKEY JW, 1950, AM REV TUBERC, V62, P7
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406
   Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001
   WASZHOCKERT O, 1947, ANN MED FENN, V96, P764
   [Anonymous], 1956, BMJ, V1, P413
NR 27
TC 20
Z9 23
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 31
PY 2007
VL 2
IS 1
AR e183
DI 10.1371/journal.pone.0000183
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10DH
UT WOS:000207444200007
PM 17264885
OA gold
DA 2017-08-15
ER

PT J
AU Martinez-Steele, E
   Awasana, AA
   Corrah, T
   Sabally, S
   van der Sande, M
   Jaye, A
   Togun, T
   Sarge-Njie, R
   McConkey, SJ
   Whittle, H
   van der Loeff, MFS
AF Martinez-Steele, Euridice
   Awasana, Akurn Aveika
   Corrah, Tumani
   Sabally, Saihou
   van der Sande, Marianne
   Jaye, Assan
   Togun, Toyin
   Sarge-Njie, Ramu
   McConkey, Samuel J.
   Whittle, Hilton
   van der Loeff, Maarten F. Schim
TI Is HIV-2-induced AIDS different from HIV-1-associated AIDS? Data from a
   West African clinic
SO AIDS
LA English
DT Article
DE HIV-2; HIV-1; AIDS; CD4; West Africa; mortality; The Gambia; Africa
ID INFECTED-PATIENTS; NATURAL-HISTORY; HIV-1 INFECTION; GUINEA-BISSAU;
   SURVIVAL; COHORT; MORTALITY; DISEASE; SURVEILLANCE; PROGRESSION
AB Background Although AIDS is less frequent following HIV-2 than HIV-1 infection, it is unclear whether the clinical picture and clinical course of AIDS are similar in the two infections.
   Objectives To compare the pattern of AIDS-defining events, CD4 cell count at the time of AIDS diagnosis, survival from time of AIDS, and CD4 cell count near time of death in HIV-1 and HIV-2-infected patients.
   Methods Adult patients with AIDS who attended the clinics of the MRC in The Gambia were enrolled. AIDS was diagnosed according to the expanded World Health Organization case definition for AIDS surveillance (1994).
   Results Three hundred and forty-one AIDS patients with HIV-1 and 87 with HIV-2 infection were enrolled. The most common AIDS-defining events in both infections were the wasting syndrome and pulmonary tuberculosis. The median CD4 cell count at AIDS was 109 cells/mu 1 in HIV-1 and 176 in HIV-2 (P= 0.01) and remained significantly higher in HIV-2 after adjustment for age and sex (P= 0.03). The median time to death was 6.3 months in HIV-1 and 12.6 months in HIV-2-infected patients (P=0.03). In a multivariable analysis adjusting for age, sex and CD4 cell count, the mortality rates of HIV-1 and HIV-2-infected patients were similar (P=0.25). The median CD4 cell count near time of death was 62 and 120cells/mu l in HIV-1 and HIV-2-infected patients, respectively (P = 0.02).
   Conclusions HIV-2 patients have a higher CD4 cell count at the time of AIDS, and a longer survival after AIDS. The mortality after an AIDS diagnosis is more influenced by CD4 cell count than HIV type. (c) 2007 Lippincott Williarns & Wilkins.
C1 MRC Labs, Fajara, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
RP van der Loeff, MFS (reprint author), Univ Amsterdam, Acad Med Ctr, Ctr Poverty Related Communicable Dis, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM m.schim@iatec.com
RI McConkey, Samuel/E-7307-2012
FU Medical Research Council [MC_U190081962]
CR Ariyoshi K, 1998, J Hum Virol, V1, P193
   Bakari M, 2004, SCAND J INFECT DIS, V36, P466, DOI 10.1080/00365540410016249
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   CHEQUER P, 1992, AIDS, V6, P483, DOI 10.1097/00002030-199205000-00007
   COX S, 1994, AIDS RES HUM RETROV, V12, P1725
   DECOCK KM, 1991, BRIT MED J, V303, P1185
   FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305
   French N, 1999, J ACQ IMMUN DEF SYND, V22, P509
   Gallo R C, 1998, J Hum Virol, V1, P185
   Hansmann A, 2005, JAIDS-J ACQ IMM DEF, V38, P335
   Holmes CB, 2003, CLIN INFECT DIS, V36, P652, DOI 10.1086/367655
   Jaffar S, 2004, B WORLD HEALTH ORGAN, V82, P462
   KANKI P, 1994, AIDS, V8, P85
   KARNOFSKY DA, 1948, CANCER, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
   Kitayaporn D, 1996, J ACQ IMMUN DEF SYND, V11, P77
   LEGUENNO BM, 1991, J ACQ IMMUN DEF SYND, V4, P421
   LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005
   Matheron S, 2003, AIDS, V17, P2593, DOI 10.1097/01.aids.0000096907.73209.b9
   Matheron S, 1997, AIDS, V11, P934
   Mocroft A, 1996, AIDS, V10, P1057
   Moore RD, 1996, ANN INTERN MED, V124, P633
   Morgan D, 2002, AIDS, V16, P597, DOI 10.1097/00002030-200203080-00011
   Morgan D, 2000, SEX TRANSM INFECT, V76, P193, DOI 10.1136/sti.76.3.193
   NAUCLER A, 1992, SCAND J INFECT DIS, V24, P725, DOI 10.3109/00365549209062457
   Ndour M, 2000, TROP MED INT HEALTH, V5, P687, DOI 10.1046/j.1365-3156.2000.00627.x
   Norrgren H, 1998, SCAND J INFECT DIS, V30, P323
   SALINARI RK, 1990, TROP DOCT, V20, P169
   van der Loeff MFS, 1999, AIDS, V13, pS69
   van der Loeff MFS, 2002, AIDS, V16, P1775
   van der Sande MAB, 2004, JAIDS-J ACQ IMM DEF, V37, P1288, DOI 10.1097/01.qai.0000122708.59121.03
   VANDERLOEFF MFS, 2006, INT J EPIDEMIOL, DOI DOI 10.1093/IJE/DYL037
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011
   World Health Organization, 1994, WKLY EPIDEMIOL REC, V69, P273
   World Health Organization, 1990, WKLY EPIDEMIOL REC, V65, P221
   Witvrouw M, 1999, AIDS, V13, P1477, DOI 10.1097/00002030-199908200-00006
NR 36
TC 30
Z9 31
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD JAN 30
PY 2007
VL 21
IS 3
BP 317
EP 324
DI 10.1097/QAD.0b013e328011d7ab
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 137AY
UT WOS:000244266400005
PM 17255738
OA No
DA 2017-08-15
ER

PT J
AU Hill, PC
   Onyeama, CO
   Ikumapayi, UNA
   Secka, O
   Ameyaw, S
   Simmonds, N
   Donkor, SA
   Howie, SR
   Tapgun, M
   Corrah, T
   Adegbola, RA
AF Hill, Philip C.
   Onyeama, Charles O.
   Ikumapayi, Usman N. A.
   Secka, Ousman
   Ameyaw, Samuel
   Simmonds, Naomi
   Donkor, Simon A.
   Howie, Stephen R.
   Tapgun, Mary
   Corrah, Tumani
   Adegbola, Richard A.
TI Bacteraemia in patients admitted to an urban hospital in West Africa
SO BMC INFECTIOUS DISEASES
LA English
DT Article
ID SEVERELY MALNOURISHED CHILDREN; BACTERIAL-INFECTIONS;
   STREPTOCOCCUS-PNEUMONIAE; PNEUMOCOCCAL DISEASE; CONJUGATE VACCINE;
   GAMBIA; MALAWI; KENYA
AB Background: Few studies on bacteraemia in Africa have been published. We aimed to prospectively identify the causative organisms of bacteraemia in The Gambia and their relation to clinical diagnoses, outcome and antimicrobial susceptibility.
   Methods: Between November 2003 and February 2005 we studied those admitted to the Medical Research Council hospital who were suspected of having bacteraemia. We documented clinical features, outcome, pathogens identified and their susceptibility patterns, and searched for factors associated with bacteraemia.
   Results: 871 patients were admitted and had a blood culture taken. The median age was 2 years ( range 2 months to 80 years) and 36 of 119 tested were HIV positive; 54.5% were male. 297 (34%) had a positive result and 93 (10.7% overall) were considered a genuine pathogen. Those with bacteraemia were more likely to die in hospital ( OR 2.79; 1.17 - 6.65, p = 0.017) and to have a high white cell count (WCC; OR 1.81; 95% CI 1.09 - 3.02; p = 0.022). Three organisms accounted for 73% of bacteraemias: Streptococcus pneumoniae (45.2%), Staphylococcus aureus (18.3%) and Escherichia coli (9.7%) while non-typhoidal salmonellae (NTS) accounted for 8.6%. Antimicrobial susceptibility of S. pneumoniae was very high to penicillin (97.5%); high resistance was found to cotrimoxazole. S. aureus was generally highly susceptible to cloxacillin, gentamicin and chloramphenicol. E. coli and NTS were all susceptible to ciprofloxacin and mostly susceptible to gentamicin. Thirteen (33%) S. pneumoniae isolates were of serotypes contained in a 7-valent pneumococcal conjugate vaccine and 20 (51.3%) were of the same serogroup.
   Conclusion: In The Gambia, those with bacteraemia are more likely than those without to die in hospital and to have a raised peripheral blood WCC. S. pneumoniae is the most common organism isolated. Introduction of a pneumococcal conjugate vaccine can be expected to lead to a reduction in disease incidence.
C1 MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   UCL Royal Free & Univ Coll Med Sch, London, England.
RP Hill, PC (reprint author), MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
EM phill@mrc.gm; coonyeama@gmail.com; uikumapayi@mrc.gm; osecka@mrc.gm;
   skahealthandlife@yahoo.com; naomi_simmonds@hotmail.com; sdonkor@mrc.gm;
   showie@mrc.gm; mtapgun@mrc.gm; tcorrah@mrc.gm; radegbola@mrc.gm
OI Onyeama, Charles/0000-0003-2465-5522
FU Medical Research Council [MC_U190088478]
CR Adegbola RA, 2005, LANCET, V366, P144, DOI 10.1016/S0140-6736(05)66788-8
   Adegbola RA, 2006, TROP MED INT HEALTH, V11, P1128, DOI 10.1111/j.1365-3156.2006.01652.x
   Archibald LK, 2000, J INFECT DIS, V181, P1414, DOI 10.1086/315367
   Bahwere P, 2001, Int J Infect Dis, V5, P180, DOI 10.1016/S1201-9712(01)90067-0
   Bell M, 2001, Int J Infect Dis, V5, P63, DOI 10.1016/S1201-9712(01)90027-X
   Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275
   BERKOWITZ FE, 1984, AM J DIS CHILD, V138, P551
   Brent AJ, 2006, LANCET, V367, P482, DOI 10.1016/S0140-6736(06)68180-4
   COTTON MF, 1992, S AFR MED J, V81, P87
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   DUGGAN MB, 1975, ARCH DIS CHILD, V50, P67
   Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5
   FRIEDLAND IR, 1992, ANN TROP PAEDIATR, V12, P433
   GHIORGHIS B, 1992, E AFR MED J, V69, P74
   Gordon MA, 2001, J INFECTION, V42, P44, DOI 10.1053/jinf.2000.0779
   GREEN SDR, 1993, ANN TROP PAEDIATR, V13, P45
   LEPAGE P, 1987, LANCET, V1, P1458
   MABEY DCW, 1987, J INFECT DIS, V155, P1319
   Meremikwu MM, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-110
   Mulholland EK, 2005, NEW ENGL J MED, V352, P75, DOI 10.1056/NEJMe048306
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010
   Peltola H, 2001, CLIN INFECT DIS, V32, P64, DOI 10.1086/317534
   Steenhoff AP, 2006, CLIN INFECT DIS, V42, P907, DOI 10.1086/500941
   Vidmar S, 2004, STATA J, V4, P50
   WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553
   Walsh AL, 2000, PEDIATR INFECT DIS J, V19, P312, DOI 10.1097/00006454-200004000-00010
   World Health Organization, 1998, WORLD HLTH REP 1998
NR 27
TC 53
Z9 56
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD JAN 26
PY 2007
VL 7
AR 2
DI 10.1186/1471-2334-7-2
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 134BF
UT WOS:000244056900001
PM 17257423
OA gold
DA 2017-08-15
ER

PT J
AU Cavenaugh, JS
   Snell, P
   Jeffries, D
   Waight, PA
   McConkey, SJ
AF Cavenaugh, James S.
   Snell, Paul
   Jeffries, David
   Waight, Pauline A.
   McConkey, Samuel J.
TI A relational database for management of flow cytometry and ELISpot
   clinical trial data
SO CYTOMETRY PART B-CLINICAL CYTOMETRY
LA English
DT Article
DE LIMS; ELISpot; Microsoft Access; relational database; FCS; FACS; flow
   cytometry; clinical trial
AB Background: Although relational databases are widely used in bioinformatics with deposited and finalized data, they have not received widespread usage among immunologists for managing raw laboratory data such as that generated by ELISpot or flow cytometry assays. Almost no published guidance exists for immunologists to design appropriate and useful data management systems.
   Methods: We describe the design and implementation of a Microsoft Access relational database used in a clinical trial in which the primary immunogenicity measures were ELISpot and intracellular cytokine staining.
   Results: Our data management system enabled us to perform sophisticated queries and to interpret our data as quantitatively as possible. It could easily be used without modification by other researchers using automated plate reading of ELISpot plates or four color flow cytometry.
   Conclusions: We illustrate in detail the use of a flexible data management system for two of the most widely used immunological techniques. Minor modifications for more colors or other outputs can easily be implemented. Based on this example, other modifications could be easily envisaged for any other quantitative output. (c) 2006 Clinical Cytometry Society.
C1 Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.
   MRC Labs, Banjul, Gambia.
RP Cavenaugh, JS (reprint author), Univ Rochester, Sch Med, Dept Biostat & Comp Biol, 601 Elmwood Ave, Rochester, NY 14642 USA.
EM James_Cavenaugh@URMC.Rochester.edu
RI McConkey, Samuel/E-7307-2012
OI McConkey, Samuel/0000-0001-9085-7793
FU Wellcome Trust
CR ANDERSEN V, 2000, COMPLETE REFERENCE
   Asare A L, 1998, Proc AMIA Symp, P952
   Jeffries DJ, 2004, INT J TUBERC LUNG D, V8, P1095
   KAYE P, 2003, ACDM NEWSLETTER, V45, P14
   Seamer LC, 1997, CYTOMETRY, V28, P118, DOI 10.1002/(SICI)1097-0320(19970601)28:2<118::AID-CYTO3>3.0.CO;2-B
   SMITH R, 1999, BEGINING ACCESS 2000
NR 6
TC 2
Z9 2
U1 1
U2 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1552-4949
J9 CYTOM PART B-CLIN CY
JI Cytom. Part B-Clin. Cytom.
PD JAN 15
PY 2007
VL 72B
IS 1
BP 49
EP 62
DI 10.1002/cyto.b.20146
PG 14
WC Medical Laboratory Technology; Pathology
SC Medical Laboratory Technology; Pathology
GA 123UQ
UT WOS:000243322000008
PM 17080410
OA No
DA 2017-08-15
ER

PT J
AU Polley, SD
   Tetteh, KKA
   Lloyd, JM
   Akpogheneta, OJ
   Greenwood, BM
   Bojang, KA
   Conway, DJ
AF Polley, Spencer D.
   Tetteh, Kevin K. A.
   Lloyd, Jennie M.
   Akpogheneta, Onome J.
   Greenwood, Brian M.
   Bojang, Kalifa A.
   Conway, David J.
TI Plasmodium falciparum merozoite surface protein 3 is a target of
   allele-specific immunity and alleles are maintained by natural selection
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID GLUTAMATE-RICH PROTEIN; MALARIA VACCINE; DNA POLYMORPHISM; DIVERSIFYING
   SELECTION; ANTIBODIES; RECOMBINATION; PROTECTION; COALESCENT; ANTIGEN;
   GENE
AB Background. Plasmodium falciparum merozoite surface protein (MSP) 3 is an asexual blood-stage malaria vaccine candidate antigen. Sequence polymorphisms divide alleles into 2 major types, but the adaptive and immunological significance of the types has not been defined.
   Methods. One hundred one msp3 allele sequences were sampled from 2 populations living in areas where malaria is endemic and were analyzed for evidence of natural selection. Recombinant antigens representing full-length sequences of different allelic types and a relatively conserved C-terminal region were produced, to evaluate immunization-induced antibody responses in mice and protective associations for naturally acquired antibodies in a cohort of 319 Gambian children under surveillance for malaria.
   Results. Frequency-based statistical analyses indicated that polymorphisms are maintained by balancing selection in each of the 2 populations studied. Immunization of mice with full-length MSP3 antigens induced predominantly type-specific antibodies, and a large proportion of naturally acquired antibodies to MSP3 in humans also discriminated between the alleles. Among Gambian children, antibodies to allele-specific and conserved epitopes in MSP3 were associated prospectively with protection from clinical malaria, even after adjustment for age and for the presence of antibodies to other merozoite antigens.
   Conclusions. A vaccine incorporating both major allelic types of this promising candidate antigen could be particularly useful for induction of protective immunity in infants and young children.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Conway, DJ (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM dconway@mrc.gm
RI Polley, Spencer/F-7766-2013
OI Conway, David/0000-0002-8711-3037
FU Medical Research Council [MC_U190081993]
CR Audran R, 2005, INFECT IMMUN, V73, P8017, DOI 10.1128/IAI.73.12.8017-8026.2005
   Baum J, 2003, GENETICS, V163, P1327
   Carvalho LJM, 2004, SCAND J IMMUNOL, V59, P363, DOI 10.1111/j.0300-9475.2004.01409.x
   Cavanagh DR, 1997, MOL BIOCHEM PARASIT, V85, P197, DOI 10.1016/S0166-6851(96)02826-5
   Conway DJ, 2000, NAT MED, V6, P689, DOI 10.1038/76272
   Druilhe P, 2005, PLOS MED, V2, P1135, DOI 10.1371/journal.pmed.0020344
   Escalante AA, 1998, GENETICS, V149, P189
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Gupta S, 1996, NAT MED, V2, P437, DOI 10.1038/nm0496-437
   Hey J, 1997, GENETICS, V145, P833
   Hisaeda H, 2002, J INFECT DIS, V185, P657, DOI 10.1086/339187
   Huber W, 1997, MOL BIOCHEM PARASIT, V87, P231, DOI 10.1016/S0166-6851(97)00067-4
   HUDSON RR, 1987, GENET RES, V50, P245
   Joy DA, 2003, SCIENCE, V300, P318, DOI 10.1126/science.1081449
   McVean G, 2002, GENETICS, V160, P1231
   Metzger WG, 2003, PARASITE IMMUNOL, V25, P307, DOI 10.1046/j.1365-3024.2003.00636.x
   Mills KE, 2002, MOL MICROBIOL, V43, P1401, DOI 10.1046/j.1365-2958.2002.02834.x
   Mu JB, 2005, PLOS BIOL, V3, P1734, DOI 10.1371/journal.pbio.0030335
   OEUVRAY C, 1994, BLOOD, V84, P1594
   Okenu DMN, 2000, MOL BIOCHEM PARASIT, V109, P185, DOI 10.1016/S0166-6851(00)00245-0
   Polley SD, 2003, GENETICS, V165, P555
   Polley SD, 2003, INFECT IMMUN, V71, P1833, DOI 10.1128/IAI.71.4.1833-1842.2003
   Polley SD, 2001, GENETICS, V158, P1505
   RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x
   Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359
   Singh S, 2004, J INFECT DIS, V190, P1010, DOI 10.1086/423208
   Soe S, 2004, INFECT IMMUN, V72, P247, DOI 10.1128/IAI.72.1.247-252.2004
   TAJIMA F, 1989, GENETICS, V123, P597
   TAJIMA F, 1989, GENETICS, V123, P585
   Wang J, 2005, BIOTECHNOL BIOENG, V90, P838, DOI 10.1002/bit.20491
   Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690
NR 31
TC 76
Z9 76
U1 0
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 15
PY 2007
VL 195
IS 2
BP 279
EP 287
DI 10.1086/509806
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 122OW
UT WOS:000243237300016
PM 17191173
OA No
DA 2017-08-15
ER

PT S
AU Loscertales, MP
   Owens, S
   O'Donnell, J
   Bunn, J
   Bosch-Capblanch, X
   Brabin, BJ
AF Loscertales, Maria-Paz
   Owens, Stephen
   O'Donnell, James
   Bunn, James
   Bosch-Capblanch, Xavier
   Brabin, Bernard J.
BE Muller, R
   Rollinson, D
   Hay, SI
TI ABO blood group phenotypes and Plasmodium falciparum malaria: Unlocking
   a pivotal mechanism
SO ADVANCES IN PARASITOLOGY, VOL 65
SE Advances in Parasitology
LA English
DT Review; Book Chapter
ID PAPUA-NEW-GUINEA; VON-WILLEBRAND-FACTOR; COOMBS ANTIGLOBULIN REACTIONS;
   ERYTHROCYTE-BINDING-PROTEIN; HUMAN CEREBRAL MALARIA; GROUP-A ANTIGEN;
   INFECTED ERYTHROCYTES; GENETIC-MARKERS; CELL-ADHESION; GLYCOPHORIN-A
AB Host susceptibility to Plasmodium falciparum infection is central for improved understanding of malaria in human populations. Red blood cell (RBC) polymorphisms have been proposed as factors associated with malaria infection or its severity, although no systematic appraisal of ABO phenotypes and malaria risk has been undertaken. This analysis summarises epidemiological, clinical and immunological evidence on the nature of ABO histo-blood antigens and their interaction with malaria in terms of population genetics, infection risk, severe malaria and placental malaria. In non-pregnant subjects, a meta-analysis showed no conclusive evidence associating ABO phenotypes with risk of uncomplicated malaria. There was stronger evidence that ABO phenotype modulates severity of P. falciparum malaria, with group A associated with severe disease and blood group 0 with milder disease. Among pregnant subjects, group 0 was associated with increased risk of placental malaria in primigravidae and reduced risk in multigravidae, The biological basis for ABO-related susceptibility to malaria is reviewed. Several mechanisms relate to these associations including affinity for Anopheles gambiae; shared ABO antigens with P. Falciparum; impairment of merozoite penetration of RBCs; and cytoadherence, endothelial activation and rosetting. ABO phenotypic associations with malaria are related to its pathogenesis and improved understanding of these interactions is required for understanding the glycobiology of malaria infection.
C1 [Loscertales, Maria-Paz; Owens, Stephen; Bunn, James; Brabin, Bernard J.] Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England.
   [Owens, Stephen] MRC Labs, Banjul, Fajara, Gambia.
   [O'Donnell, James] St James Hosp, Trinity Coll, Inst Mol Med, Haemostasis Res Grp, Dublin 8, Ireland.
   [Bunn, James] Univ Malawi, Coll Med, Dept Paediat, Blantyre, Malawi.
   [Bosch-Capblanch, Xavier] Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Grp, Liverpool L3 5QA, Merseyside, England.
   [Brabin, Bernard J.] Univ Amsterdam, Acad Med Ctr, Emma Kinderziekenhuis, NL-1100 DD Amsterdam, Netherlands.
   [Brabin, Bernard J.] Royal Liverpool Childrens Hosp NHS Trust, Dept Community Child Hlth, Liverpool L12 2AP, Merseyside, England.
RP Loscertales, MP (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England.
RI O'Donnell, James/A-6171-2009
OI O'Donnell, James/0000-0003-0309-3313
CR Aikawa M, 1980, MALARIA, P47
   AKINBOYE DO, 1987, T ROY SOC TROP MED H, V81, P398, DOI 10.1016/0035-9203(87)90147-7
   Allen SJ, 1999, AM J TROP MED HYG, V60, P1056
   ALYAMAN F, 1995, T ROY SOC TROP MED H, V89, P55, DOI 10.1016/0035-9203(95)90658-4
   ATHREYA BH, 1967, AM J EPIDEMIOL, V86, P292
   Awandare GA, 2006, J INFECT DIS, V194, P1438, DOI 10.1086/508547
   Barragan A, 2000, INFECT IMMUN, V68, P2971, DOI 10.1128/IAI.68.5.2971-2975.2000
   BAYOUMI RA, 1986, AM J TROP MED HYG, V35, P45
   Beeson JG, 1999, J INFECT DIS, V180, P464, DOI 10.1086/314899
   Beeson JG, 2000, NAT MED, V6, P86, DOI 10.1038/71582
   Beiguelman B, 2003, MEM I OSWALDO CRUZ, V98, P455, DOI 10.1590/S0074-02762003000400004
   BERG EL, 1991, J BIOL CHEM, V266, P14869
   BERGER SA, 1989, EUR J CLIN MICROBIOL, V8, P681, DOI 10.1007/BF01963752
   Blackwell C C, 1989, FEMS Microbiol Immunol, V1, P341
   Blann AD, 1996, BRIT J HAEMATOL, V92, P498, DOI 10.1046/j.1365-2141.1996.d01-1486.x
   BOOTH PB, 1972, VOX SANG, V22, P73
   Bowen DJ, 2003, J THROMB HAEMOST, V1, P33, DOI 10.1046/j.1538-7836.2003.00007.x
   Bulai T, 2003, FEBS LETT, V534, P185, DOI 10.1016/S0014-5793(02)03838-3
   CARLSON J, 1992, J EXP MED, V176, P1311, DOI 10.1084/jem.176.5.1311
   CARLSON J, 1994, BLOOD, V84, P3909
   CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N
   Carlson J, 1993, Scand J Infect Dis Suppl, V86, P1
   CARTRON JP, 1983, BRIT J HAEMATOL, V55, P639, DOI 10.1111/j.1365-2141.1983.tb02846.x
   Casals-Pascual C, 2006, CURR MOL MED, V6, P155, DOI 10.2174/156652406776055159
   Cavasini CE, 2006, HUM BIOL, V78, P215, DOI 10.1353/hub.2006.0034
   Chen QJ, 2000, J EXP MED, V192, P1, DOI 10.1084/jem.192.1.1
   Chen QJ, 2000, CLIN MICROBIOL REV, V13, P439, DOI 10.1128/CMR.13.3.439-450.2000
   Chester MA, 2001, TRANSFUS MED REV, V15, P177, DOI 10.1053/tm.2001.24591
   Chishti AH, 1996, BLOOD, V87, P3462
   Chotivanich KT, 1998, ANN TROP MED PARASIT, V92, P45
   Chung WY, 2005, MOL BIOCHEM PARASIT, V144, P128, DOI 10.1016/j.molbiopara.2005.08.004
   CLAUSEN H, 1989, VOX SANG, V56, P1
   CONTRERAS M, 1999, POSTGRADUATE HAEMATO, P182
   CSERTI CM, 2007, IN PRESS BLOOD
   Curtis BR, 2000, BLOOD, V96, P1574
   DOLAN SA, 1994, MOL BIOCHEM PARASIT, V64, P55, DOI 10.1016/0166-6851(94)90134-1
   Domarle O, 1999, AM J TROP MED HYG, V61, P926
   DORE C, 1975, CURR ANTHROPOL, V16, P470, DOI 10.1086/201592
   DRUILHE P, 1983, SCI VIE, V296, P339
   Duraisingh MT, 2003, EMBO J, V22, P1047, DOI 10.1093/emboj/cdg096
   FACER CA, 1984, LANCET, V2, P758
   FACER CA, 1979, T ROY SOC TROP MED H, V73, P599, DOI 10.1016/0035-9203(79)90066-X
   FACER CA, 1983, B SOC PATHOL EXOT, V76, P463
   FACER CA, 1980, CLIN EXP IMMUNOL, V39, P279
   FACER CA, 1979, CLIN EXP IMMUNOL, V35, P119
   FARR AD, 1960, J I SCI TECHNOL, V6, P32
   FIELD SP, 1994, HUM GENET, V93, P148
   Fischer PR, 1998, AM J TROP MED HYG, V58, P122
   Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502
   Fukuda M, 1999, J CELL BIOL, V147, P467, DOI 10.1083/jcb.147.3.467
   Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747
   Garratty G, 2000, TRANSFUS MED REV, V14, P291, DOI 10.1053/tmrv.2000.16228
   Gaur D, 2004, INT J PARASITOL, V34, P1413, DOI 10.1016/j.ijpara.2004.10.010
   Greenwell P, 1997, GLYCOCONJUGATE J, V14, P159, DOI 10.1023/A:1018581503164
   GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221
   Guerra CA, 2006, ADV PARASIT, V62, P157, DOI 10.1016/S0065-308X(05)62005-2
   Guerra CA, 2006, TRENDS PARASITOL, V22, P353, DOI 10.1016/j.pt.2006.06.006
   GUPTA M, 1980, B WORLD HEALTH ORGAN, V56, P913
   HADLEY TJ, 1987, J CLIN INVEST, V80, P1190, DOI 10.1172/JCI113178
   HANDUNNETTI SM, 1989, AM J TROP MED HYG, V40, P115
   HARTMANN G, 1941, THESIS US ARMY MED R
   Heddini A, 2001, INFECT IMMUN, V69, P5849, DOI 10.1128/IAI.69.9.5849-5856.2001
   HILL AVS, 1992, T ROY SOC TROP MED H, V86, P225, DOI 10.1016/0035-9203(92)90282-H
   Hollestelle MJ, 2006, BRIT J HAEMATOL, V133, P562, DOI 10.1111/j.1365-2141.2006.06067.x
   Ibhanesebhor SE, 1996, ANN TROP PAEDIATR, V16, P93
   IQBAL J, 1993, T ROY SOC TROP MED H, V87, P583, DOI 10.1016/0035-9203(93)90097-A
   JOSHI H, 1987, Indian Journal of Malariology, V24, P33
   JUNGERY M, 1985, T ROY SOC TROP MED H, V79, P591, DOI 10.1016/0035-9203(85)90164-6
   KAHANE I, 1976, ISRAEL J MED SCI, V12, P11
   KANO K, 1968, P SOC EXP BIOL MED, V129, P849
   Karlsson KA, 1998, MOL MICROBIOL, V29, P1, DOI 10.1046/j.1365-2958.1998.00854.x
   KASSIM OO, 1982, ACTA TROP, V39, P179
   Kermarrec N, 1999, IMMUNOGENETICS, V49, P517, DOI 10.1007/s002510050529
   KOMINATO Y, 1992, BIOCHEM BIOPH RES CO, V189, P154, DOI 10.1016/0006-291X(92)91538-2
   Kumar KA, 2006, EXP PARASITOL, V114, P173, DOI 10.1016/j.exppara.2006.03.009
   Kun JFJ, 1998, T ROY SOC TROP MED H, V92, P110, DOI 10.1016/S0035-9203(98)90979-8
   LANDSTEINER K, 1900, ORIGINALE, V27, P357
   Landsteiner K., 1901, KLIN WOCHENSCHR, V14, P1132
   LEE SH, 1989, BRIT J HAEMATOL, V73, P396, DOI 10.1111/j.1365-2141.1989.tb07760.x
   Lell B, 1999, CLIN INFECT DIS, V28, P794, DOI 10.1086/515193
   Li XR, 2004, J BIOL CHEM, V279, P5765, DOI 10.1074/jbc.M308716200
   LOSCERTALES MP, 2006, MALARIA J, V17, P72
   LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J
   Mackinnon M.J., 2005, PLOS MED, V12, pe340
   Martin MJ, 2005, P NATL ACAD SCI USA, V102, P12819, DOI 10.1073/pnas.0503819102
   MARTIN SK, 1979, T ROY SOC TROP MED H, V73, P216, DOI 10.1016/0035-9203(79)90217-7
   MARTINKO JM, 1993, IMMUNOGENETICS, V37, P274
   Mayer DCG, 2006, P NATL ACAD SCI USA, V103, P2358, DOI 10.1073/pnas.0510648103
   Mayer DCG, 2004, P NATL ACAD SCI USA, V101, P2518, DOI 10.1073/pnas.0307318101
   Mayer DCG, 2001, P NATL ACAD SCI USA, V98, P5222, DOI 10.1073/pnas.081075398
   Mgone CS, 1996, T ROY SOC TROP MED H, V90, P228, DOI 10.1016/S0035-9203(96)90223-0
   Migot-Nabias F, 2000, GENES IMMUN, V1, P435, DOI 10.1038/sj.gene.6363703
   Miller CH, 2003, J THROMB HAEMOST, V1, P2191, DOI 10.1046/j.1538-7836.2003.00367.x
   Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a
   MILLER LH, 1973, J EXP MED, V138, P1597, DOI 10.1084/jem.138.6.1597
   Min-Oo G, 2005, CELL MICROBIOL, V7, P753, DOI 10.1111/j.1462-5822.2005.00524.x
   Mitchell GH, 2004, INFECT IMMUN, V72, P154, DOI 10.1128/IAI.72.1.154-158.2004
   MOLINEAUX L, 1988, MALARIA PRINCIPLES P, P936
   Molineaux Louis, 1980, GARKI PROJECT RES EP
   Mombo LE, 2003, AM J TROP MED HYG, V68, P186
   Montoya Fabiola, 1994, Revista do Instituto de Medicina Tropical de Sao Paulo, V36, P33
   Moor-Jankowski J, 1969, Primates Med, V3, P64
   MOORJANKOWSKI J, 1993, J MED PRIMATOL, V22, P1
   Mourant A, 1978, BLOOD GROUPS DIS
   Mourant A. E., 1976, DISTRIBUTION HUMAN B
   Murr C, 2005, CLIN BIOCHEM, V38, P916, DOI 10.1016/j.clinbiochem.2005.07.002
   MYATT AV, 1954, AM J TROP MED HYG, V3, P981
   OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163
   OKOYE VCN, 1985, SCIENCE, V227, P169, DOI 10.1126/science.3880920
   Oliver-Gonalez J, 1944, J INFECT DIS, V74, P173, DOI 10.1093/infdis/74.3.173
   Oriol R, 1992, APMIS S, V27, P28
   ORLANDI PA, 1992, J CELL BIOL, V116, P901, DOI 10.1083/jcb.116.4.901
   OSISANYA JOS, 1983, E AFR MED J, V60, P616
   Owen R, 2000, GENETICS, V155, P995
   Pain A, 2001, P NATL ACAD SCI USA, V98, P1805, DOI 10.1073/pnas.98.4.1805
   Pant C. S., 1997, Indian Journal of Malariology, V34, P42
   Pant C. S., 1993, Indian Journal of Malariology, V30, P229
   Pant C. S., 1992, Journal of Communicable Diseases, V24, P199
   PANT CS, 1998, INDIAN J MALARIOL, V38, P225
   PANT CS, 1992, INDIAN J MALARIOL, V24, P235
   Parr LW, 1930, J INFECT DIS, V46, P173, DOI 10.1093/infdis/46.3.173
   Pasvol G, 2003, TRENDS PARASITOL, V19, P430, DOI 10.1016/j.pt.2003.08.005
   PASVOL G, 1984, LANCET, V1, P907
   PASVOL G, 1982, NATURE, V297, P64, DOI 10.1038/297064a0
   PASVOL G, 1982, LANCET, V2, P947
   Patel SS, 2001, BLOOD, V98, P3489, DOI 10.1182/blood.V98.12.3489
   Pathirana SL, 2005, ANN TROP MED PARASIT, V99, P119, DOI 10.1179/136485905X19946
   PENALBA C, 1984, B SOC PATHOL EXOT, V77, P469
   PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274
   PODBIELSKA M, 2004, ARCH BIOCHEM BIOPHYS, V429, P45
   RAPER AB, 1968, T ROY SOC TROP MED H, V62, P158, DOI 10.1016/0035-9203(68)90077-1
   Ravn V, 2000, APMIS, V108, P1, DOI 10.1034/j.1600-0463.2000.d01-1.x
   Rayner JC, 2001, J EXP MED, V194, P1571, DOI 10.1084/jem.194.11.1571
   REEDER JC, 1994, AM J TROP MED HYG, V51, P45
   RIDGWELL K, 1983, BIOCHEM J, V209, P273
   Rogerson SJ, 1997, EXP PARASITOL, V86, P8, DOI 10.1006/expr.1996.4142
   ROGERSON SJ, 1997, PARASITOL TODAY, V13, P76
   ROWE A, 1995, INFECT IMMUN, V63, P2323
   Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888
   RUSSEL PF, 1963, PRACTICAL MALARIOLOG, P365
   Saitou N, 1997, MOL BIOL EVOL, V14, P399
   SANTOS SEB, 1983, J HUM EVOL, V12, P373, DOI 10.1016/S0047-2484(83)80165-1
   Schwartz NB, 2004, GLYCOCONJUGATE J, V21, P329, DOI 10.1023/B:GLYC.0000046278.34016.36
   SERJEANTSON SW, 1989, PAPUA NEW GUINEA MED, V32, P5
   Seydel KB, 2006, J INFECT DIS, V194, P208, DOI 10.1086/505078
   Seymour RM, 2004, P ROY SOC B-BIOL SCI, V271, P1065, DOI 10.1098/rspb.2004.2674
   SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226
   SINGH IP, 1986, HUM HERED, V36, P31, DOI 10.1159/000153596
   Singh Neeru, 1995, Indian Journal of Malariology, V32, P59
   SINGH T, 1985, Indian Pediatrics, V22, P857
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Socha WW, 1995, J MED PRIMATOL, V24, P282
   SPENCER HC, 1978, AM J TROP MED HYG, V27, P664
   Stockelberg D, 1996, TRANSFUSION MED, V6, P243, DOI 10.1111/j.1365-3148.1996.tb00075.x
   Sumiyama K, 2000, GENE, V259, P75, DOI 10.1016/S0378-1119(00)00440-6
   SWEENEY JD, 1989, AM J CLIN PATHOL, V91, P79
   SZULMAN AE, 1964, J EXP MED, V119, P503, DOI 10.1084/jem.119.4.503
   TELEN MJ, 1990, BLOOD, V76, P842
   Thakur A., 1992, Indian Journal of Malariology, V29, P241
   TREUTIGER CJ, 1992, AM J TROP MED HYG, V46, P503
   UDOH AE, 1991, ACTA PHYSIOL HUNG, V78, P265
   UDOMSANGPETCH R, 1993, AM J TROP MED HYG, V48, P149
   Uneke CJ, 2007, PARASITOL RES, V100, P759, DOI 10.1007/s00436-006-0342-5
   Urquiza M, 2000, VACCINE, V19, P508, DOI 10.1016/S0264-410X(00)00185-7
   VANDERBERG JP, 1985, INFECT IMMUN, V47, P201
   VASANTHA K, 1982, P REC TRENDS IMM I H, P162
   VOS G H, 1971, South African Journal of Medical Sciences, V36, P1
   Waiz A, 1990, Bangladesh Med Res Counc Bull, V16, P46
   WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275
   WATKINS W M, 1959, Vox Sang, V4, P97
   Weir D M, 1989, FEMS Microbiol Immunol, V1, P331
   WELCH SG, 1977, T ROY SOC TROP MED H, V71, P295, DOI 10.1016/0035-9203(77)90102-X
   WOOD CS, 1972, NATURE, V239, P165, DOI 10.1038/239165a0
   WOOD CS, 1975, CURR ANTHROPOL, V16, P93, DOI 10.1086/201519
   Wu AM, 1996, BBA-MOL BASIS DIS, V1316, P139, DOI 10.1016/0925-4439(96)00016-6
   Yamamoto F, 2004, Immunohematology, V20, P3
   ZOUALI M, 1982, CLIN EXP IMMUNOL, V50, P83
NR 177
TC 19
Z9 21
U1 1
U2 12
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0065-308X
BN 978-0-12-374166-0
J9 ADV PARASIT
JI Adv.Parasitol.
PY 2007
VL 65
BP 1
EP 50
DI 10.1016/S0065-308X(07)65001-5
PG 50
WC Parasitology
SC Parasitology
GA BHE19
UT WOS:000252405100001
PM 18063095
OA No
DA 2017-08-15
ER

PT J
AU Nweneka, CV
AF Nweneka, C. V.
TI Sexual practices of church youths in the era of HIV/AIDS: Playing the
   ostrich
SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
LA English
DT Article
AB The church could be a powerful force for social and behavioural change, particularly in the current efforts to combat the HIV/AIDS pandemic. Anecdotal evidence suggests that church youths are sexually active but few studies have documented the sexual practices of these youths. We looked at the sexual practices of 341 youths in two churches in southern Nigeria. Sixty-five percent were sexually experienced; age at first sexual intercourse for males was seven years and eight years for females. By 19 years of age, 42% of the females and 44% of the males had become sexually active. In the 12 months preceding the study, 19% of the sexually experienced youths abstained from sex, 30% had one sexual partner and 28% had more than one sexual partner; 60% had used condoms 24% of whom used them always. These results suggest that sexual practices of committed church youths might be similar to those of youths in the wider society. More might be achieved by a more pro-active engagement of the church in young people's sexual and reproductive health matters.
C1 The Gambia, Pro Hope Int, Banjul, Gambia.
RP Nweneka, CV (reprint author), The Gambia, Pro Hope Int, C-O POB 273, Banjul, Gambia.
EM chidi.nweneka@gmail.com
CR *ACT, 2002, ACT BRIEF
   Anochie I C, 2001, Afr J Reprod Health, V5, P63, DOI 10.2307/3583431
   Arowojolu A O, 2002, Afr J Reprod Health, V6, P60, DOI 10.2307/3583131
   Baggaley R, 1994, AIDS Anal Afr, V4, P5
   Black B, 1997, Aidscaptions, V4, P23
   Chapman C, 1999, Educ Update, V3, P1
   Coyne-Beasley T, 2000, J ADOLESCENT HEALTH, V26, P289, DOI 10.1016/S1054-139X(99)00097-X
   *ED, 1993, PAC AIDS AL B, V6, P1
   Koniak-Griffin D, 2003, RES NURS HEALTH, V26, P4, DOI 10.1002/nur.10062
   Lindsey I, 2001, COLORECTAL DIS S, V3, P27
   MWANZA M, 2002, PSI BRINGS CHURCH LE
   Owolabi A T, 2005, J Obstet Gynaecol, V25, P174, DOI 10.1080/01443610500051460
   *POP REF BUR, 2000, WORLDS YOUTH 2000
   Sabogal F, 1996, HISPANIC J BEHAV SCI, V18, P367, DOI 10.1177/07399863960183007
   *UN METH NEWS SERV, 2001, CHURCH MUST ACT FIGH
   UNAIDS/World Health Organization, 2001, AIDS EP UPD DEC 2001
NR 16
TC 6
Z9 6
U1 0
U2 1
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 0954-0121
J9 AIDS CARE
JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv
PY 2007
VL 19
IS 8
BP 966
EP 969
DI 10.1080/09540120701249512
PG 4
WC Health Policy & Services; Public, Environmental & Occupational Health;
   Psychology, Multidisciplinary; Respiratory System; Social Sciences,
   Biomedical
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Psychology; Respiratory System; Biomedical Social Sciences
GA 222ZA
UT WOS:000250336200002
PM 17851991
OA No
DA 2017-08-15
ER

PT J
AU Howie, S
   Zaman, SMA
   Omoruyi, O
   Adegbola, R
   Prentice, A
AF Howie, Stephen
   Zaman, Syed M. A.
   Omoruyi, Osaretin
   Adegbola, Richard
   Prentice, Andrew
TI Severe pneumonia research and the problem of case definition: the
   example of zinc trials
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Letter
ID YOUNG-CHILDREN; DOUBLE-BLIND; EFFICACY
C1 MRC Labs, Banjul, Gambia.
RP Howie, S (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM showie@mrc.gm
CR ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008
   Bose A, 2006, AM J CLIN NUTR, V83, P1089
   Brooks WA, 2004, LANCET, V363, P1683, DOI 10.1016/S0140-6736(04)16252-1
   Mahalanabis D, 2004, AM J CLIN NUTR, V79, P430
NR 4
TC 6
Z9 6
U1 0
U2 0
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JAN
PY 2007
VL 85
IS 1
BP 242
EP 243
PG 2
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 125CP
UT WOS:000243419400038
PM 17209204
OA No
DA 2017-08-15
ER

PT J
AU Prentice, AM
   Fuford, TJ
   Simondon, K
   Streatfield, PK
   Zaman, A
   Jasseh, M
AF Prentice, Andrew M.
   Fuford, Tony J.
   Simondon, Kirsten
   Streatfield, Peter Kim
   Zaman, Akram
   Jasseh, Momodou
TI Changes in maternal energy flux predict human twinning rates in seasonal
   environments
SO ANNALS OF NUTRITION AND METABOLISM
LA English
DT Meeting Abstract
C1 [Prentice, Andrew M.; Fuford, Tony J.] LSHTM, MRC, Int Nutr Grp, London, England.
   [Simondon, Kirsten] IRD, Montpellier, France.
   [Streatfield, Peter Kim] ICDDRB, Dhaka, Bangladesh.
   [Zaman, Akram; Jasseh, Momodou] MRC Labs, Fajara, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-6807
EI 1421-9697
J9 ANN NUTR METAB
JI Ann. Nutr. Metab.
PY 2007
VL 51
SU 1
BP 193
EP 193
PG 1
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 192FE
UT WOS:000248185400470
OA No
DA 2017-08-15
ER

PT J
AU Conway, DJ
AF Conway, David J.
TI Molecular epidemiology of malaria
SO CLINICAL MICROBIOLOGY REVIEWS
LA English
DT Review
ID PLASMODIUM-FALCIPARUM MALARIA; POLYMERASE-CHAIN-REACTION;
   PAPUA-NEW-GUINEA; DIHYDROFOLATE-REDUCTASE GENE; MEROZOITE SURFACE
   PROTEIN-1; DIHYDROPTEROATE-SYNTHETASE GENES; SINGLE-NUCLEOTIDE
   POLYMORPHISMS; ANTIMALARIAL CLINICAL-TRIALS; SEVERE CHILDHOOD MALARIA;
   MEMBRANE ANTIGEN-1 GENE
AB Malaria persists as an undiminished global problem, but the resources available to address it have increased. Many tools for understanding its biology and epidemiology are well developed, with a particular richness of comparative genome sequences. Targeted genetic manipulation is now effectively combined with in vitro culture assays on the most important human parasite, Plasmodium falciparum, and with in vivo analysis of rodent and monkey malaria parasites in their laboratory hosts. Studies of the epidemiology, prevention, and treatment of human malaria have already been influenced by the availability of molecular methods, and analyses of parasite polymorphisms have long had useful and highly informative applications. However, the molecular epidemiology of malaria is currently undergoing its most substantial revolution as a result of the genomic information and technologies that are available in well-resourced centers. It is a challenge for research agendas to face the real needs presented by a disease that largely exists in extremely resource-poor settings, but it is one that there appears to be an increased willingness to undertake. To this end, developments in the molecular epidemiology of malaria are reviewed here, emphasizing aspects that may be current and future priorities.
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
RP Conway, DJ (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM dconway@mrc.gm
OI Conway, David/0000-0002-8711-3037
FU Medical Research Council [MC_U190081987]
CR Abdel-Muhsin AA, 2003, PARASITOLOGY, V126, P391, DOI 10.1017/S0031182003003020
   Alifrangis M, 2005, AM J TROP MED HYG, V72, P155
   Alloueche A, 2003, AM J TROP MED HYG, V68, P97
   Anderson Tim J. C., 2004, Current Drug Targets - Infectious Disorders, V4, P65, DOI 10.2174/1568005043480943
   Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467
   Anderson TJC, 2000, GENET RES, V75, P285, DOI 10.1017/S0016672300004481
   Anderson TJC, 2005, MOL BIOL EVOL, V22, P2362, DOI 10.1093/molbev/msi235
   Anderson TJC, 2003, TROP MED INT HEALTH, V8, P1068, DOI 10.1046/j.1360-2276.2003.01144.x
   Andrews L, 2005, AM J TROP MED HYG, V73, P191
   Anthony TG, 2005, J INFECT DIS, V191, P1558, DOI 10.1086/429338
   Arez AP, 1999, PARASITOLOGY, V118, P347, DOI 10.1017/S0031182099003972
   Ariey F, 2001, J INFECT DIS, V184, P237, DOI 10.1086/322012
   BABIKER HA, 1994, PARASITOLOGY, V109, P413
   Basco LK, 1998, AM J TROP MED HYG, V58, P374
   Basco LK, 2002, AM J TROP MED HYG, V67, P378
   Bates SJ, 2004, J INFECT DIS, V190, P1783, DOI 10.1086/425078
   Baum J, 2003, GENETICS, V163, P1327
   Baum J, 2003, INFECT IMMUN, V71, P1856, DOI 10.1128/IAI.71.4.1856-1863.2003
   Beck HP, 1997, J INFECT DIS, V175, P921, DOI 10.1086/513991
   Beck HP, 1999, TROP MED INT HEALTH, V4, P1, DOI 10.1046/j.1365-3156.1999.00353.x
   Beeson JG, 2004, J INFECT DIS, V189, P169, DOI 10.1086/380975
   Bejon P, 2005, J INFECT DIS, V191, P619, DOI 10.1086/427243
   BLACK J, 1994, LANCET, V343, P1095, DOI 10.1016/S0140-6736(94)90203-8
   Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005
   Bruce MC, 2000, SCIENCE, V287, P845, DOI 10.1126/science.287.5454.845
   Bruce MC, 2000, PARASITOLOGY, V121, P257, DOI 10.1017/S0031182099006356
   Bull PC, 2005, J INFECT DIS, V192, P1119, DOI 10.1086/432761
   Bull PC, 2005, PLOS PATHOG, V1, P202, DOI 10.1371/journal.ppat.0010026
   Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099
   Carret CK, 2005, MOL BIOCHEM PARASIT, V144, P177, DOI 10.1016/j.molbiopara.2005.08.010
   CARTER R, 1973, T ROY SOC TROP MED H, V67, P830, DOI 10.1016/0035-9203(73)90011-4
   Cavanagh DR, 2004, INFECT IMMUN, V72, P6492, DOI 10.1128/IAI.72.11.6492.6502.2004
   Checchi F, 2005, TROP MED INT HEALTH, V10, P146, DOI 10.1111/j.1365-3156.2004.01367.x
   Checchi F, 2002, T ROY SOC TROP MED H, V96, P664, DOI 10.1016/S0035-9203(02)90346-9
   Chotivanich K, 2000, J INFECT DIS, V181, P1206, DOI 10.1086/315353
   Chung JY, 2003, PARASITOL RES, V90, P325, DOI 10.1007/s00436-002-0777-2
   Collins WE, 2005, CLIN MICROBIOL REV, V18, P570, DOI 10.1128/CMR.18.3.570-581.2005
   Conway DJ, 2000, NAT MED, V6, P689, DOI 10.1038/76272
   Conway DJ, 2002, PARASITOLOGY, V125, pS3, DOI 10.1017/S0031182002002214
   Conway DJ, 1997, PARASITOL TODAY, V13, P26, DOI 10.1016/S0169-4758(96)10077-6
   CONWAY DJ, 1991, T ROY SOC TROP MED H, V85, P454, DOI 10.1016/0035-9203(91)90217-M
   CONWAY DJ, 1991, PARASITOLOGY, V103, P1
   CONWAY DJ, 1991, PARASITOLOGY, V103, P7
   Conway DJ, 1999, P NATL ACAD SCI USA, V96, P4506, DOI 10.1073/pnas.96.8.4506
   Cox SE, 2005, INFECT IMMUN, V73, P2841, DOI 10.1128/IAI.73.5.2841-2847.2005
   Crabb BS, 2002, DRUG RESIST UPDATE, V5, P126, DOI 10.1016/S1368-7646(02)00085-7
   Cramer JP, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-11
   Daily JP, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-30
   Daily JP, 2005, J INFECT DIS, V191, P1196, DOI 10.1086/428289
   de Roode JC, 2005, P NATL ACAD SCI USA, V102, P7624, DOI 10.1073/pnas.0500078102
   Deans AM, 2006, AM J TROP MED HYG, V74, P554
   DEPECOULAS PE, 1996, J TRAVEL MED, V3, P179
   Diourte Y, 1999, AM J TROP MED HYG, V60, P475
   Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403
   Djimde AA, 2004, J INFECT DIS, V190, P853, DOI 10.1086/422758
   Djimde AA, 2003, AM J TROP MED HYG, V69, P558
   Dokomajilar C, 2006, AM J TROP MED HYG, V75, P162
   Dondorp AM, 2005, PLOS MED, V2, P788, DOI 10.1371/journal.pmed.0020204
   Dorsey G, 2004, AM J TROP MED HYG, V71, P531
   Duffy MF, 2005, MOL MICROBIOL, V56, P774, DOI 10.1111/j.1365-2958.2005.04577.x
   Duffy MF, 2006, INFECT IMMUN, V74, P4875, DOI 10.1128/IAI.01978-05
   Dunyo S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010014
   Duraisingh MT, 2003, P NATL ACAD SCI USA, V100, P4796, DOI 10.1073/pnas.0730883100
   Duraisingh MT, 2003, EMBO J, V22, P1047, DOI 10.1093/emboj/cdg096
   Duraisingh MT, 1998, EXP PARASITOL, V89, P1, DOI 10.1006/expr.1998.4274
   Dye C, 1997, P ROY SOC B-BIOL SCI, V264, P61
   Eberl KJ, 2001, TROP MED INT HEALTH, V6, P756, DOI 10.1046/j.1365-3156.2001.00791.x
   ENGELBRECHT F, 1995, EXP PARASITOL, V81, P90, DOI 10.1006/expr.1995.1096
   ENOSSE S, 2006, TRIALS, V1, pE5
   Escalante AA, 2005, P NATL ACAD SCI USA, V102, P1980, DOI 10.1073/pnas.0409652102
   Fairhurst RM, 2005, NATURE, V435, P1117, DOI 10.1038/nature03631
   Fandeur T, 2000, PARASITOLOGY, V120, P11, DOI 10.1017/S0031182099005168
   Farcas GA, 2006, CLIN INFECT DIS, V42, P622, DOI 10.1086/500134
   Farnert A, 1997, AM J TROP MED HYG, V56, P538
   Farnert A, 2005, AM J TROP MED HYG, V73, P204
   Farnert A, 2001, T ROY SOC TROP MED H, V95, P225, DOI 10.1016/S0035-9203(01)90175-0
   Feng XR, 2003, P NATL ACAD SCI USA, V100, P8502, DOI 10.1073/pnas.1232502100
   Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(00)00084-8
   Fivelman Quinton L, 2002, Malar J, V1, P1, DOI 10.1186/1475-2875-1-1
   Francis D, 2006, J INFECT DIS, V193, P978, DOI 10.1086/500951
   Gandon S, 2001, NATURE, V414, P751, DOI 10.1038/414751a
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Gaur D, 2006, MOL BIOCHEM PARASIT, V145, P205, DOI 10.1016/j.molbiopara.2005.10.004
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Gilberger TW, 2003, J BIOL CHEM, V278, P14480, DOI 10.1074/jbc.M211446200
   Greenwood B, 2002, TROP MED INT HEALTH, V7, P1012, DOI 10.1046/j.1365-3156.2002.00980.x
   Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717
   Hanna JN, 2004, MED J AUSTRALIA, V180, P24
   Happi CT, 2005, ACTA TROP, V95, P183, DOI 10.1016/j.actatropica.2005.06.015
   Hartl DL, 2004, NAT REV MICROBIOL, V2, P15, DOI 10.1038/nrmicro795
   Haywood M, 1999, T ROY SOC TROP MED H, V93, pS65
   Horrocks P, 2004, P NATL ACAD SCI USA, V101, P11129, DOI 10.1073/pnas.0402347101
   Hviid L, 2004, PARASITE IMMUNOL, V26, P477, DOI 10.1111/j.0141-9838.2004.00733.x
   Imwong M, 2006, MOL BIOL EVOL, V23, P1016, DOI 10.1093/molbev/msj116
   Jafari S, 2002, PARASITE, V9, P187
   Jensen ATR, 2004, J EXP MED, V199, P1179, DOI 10.1084/jem.20040274
   Jongwutiwes S, 2005, MOL BIOL EVOL, V22, P1733, DOI 10.1093/molbev/msi168
   Jongwutiwes S, 2004, EMERG INFECT DIS, V10, P2211
   Joy DA, 2003, SCIENCE, V300, P318, DOI 10.1126/science.1081449
   Kaestli M, 2006, J INFECT DIS, V193, P1567, DOI 10.1086/503776
   Khalil IF, 2005, ANN TROP MED PARASIT, V99, P441, DOI 10.1179/136485905X46441
   Kissinger JC, 1998, J PARASITOL, V84, P278, DOI 10.2307/3284482
   Knowles R, 1932, INDIAN MED GAZETTE, V67, P301
   Kocken CHM, 2002, INFECT IMMUN, V70, P655, DOI 10.1128/IAI.70.2.655-660.2002
   Kofoed PE, 2004, TROP MED INT HEALTH, V9, P171, DOI 10.1046/j.1365-3156.2003.01164.x
   Kooij TWA, 2005, PLOS PATHOG, V1, P349, DOI 10.1371/journal.ppat.0010044
   Kublin JG, 2002, J INFECT DIS, V185, P380, DOI 10.1086/338566
   Kuhn S, 2005, AM J TROP MED HYG, V72, P407
   Kun JFJ, 1998, T ROY SOC TROP MED H, V92, P110, DOI 10.1016/S0035-9203(98)90979-8
   Kwiatkowski DP, 2005, AM J HUM GENET, V77, P171, DOI 10.1086/432519
   Kyes S, 1997, AM J TROP MED HYG, V57, P205
   Lavstsen T, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-27
   Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025
   Lee EAM, 2006, EUR J IMMUNOL, V36, P1168, DOI 10.1002/eji.200526010
   Lee SA, 2006, J INFECT DIS, V193, P1160, DOI 10.1086/501473
   Lobo CA, 2004, INFECT IMMUN, V72, P5886, DOI 10.1128/IAI.72.10.5886-5891.2004
   Lum JK, 2004, ACTA TROP, V90, P181, DOI 10.1016/j.actatropica.2003.09.022
   Machado RLD, 2004, J INFECT DIS, V190, P1547, DOI 10.1086/424601
   Maier AG, 2003, NAT MED, V9, P87, DOI 10.1038/nm807
   Maitland K, 1996, T ROY SOC TROP MED H, V90, P614, DOI 10.1016/S0035-9203(96)90406-X
   Mangold KA, 2005, J CLIN MICROBIOL, V43, P2435, DOI 10.1128/JCM.43.5.2435-2440.2005
   Mayxay M, 2001, T ROY SOC TROP MED H, V95, P179, DOI 10.1016/S0035-9203(01)90156-7
   MCBRIDE JS, 1982, SCIENCE, V217, P254, DOI 10.1126/science.6178159
   McCollum AM, 2006, J INFECT DIS, V194, P189, DOI 10.1086/504687
   Mehlotra RK, 2002, AM J TROP MED HYG, V67, P555
   Metzger WG, 2003, PARASITE IMMUNOL, V25, P307, DOI 10.1046/j.1365-3024.2003.00636.x
   Mockenhaupt FP, 2005, ANN TROP MED PARASIT, V99, P723, DOI 10.1179/136485905X75395
   Mockenhaupt FP, 2005, TROP MED INT HEALTH, V10, P901, DOI 10.1111/j.1365-3156.2005.01471.x
   Montgomery J, 2006, J INFECT DIS, V194, P115, DOI 10.1086/504689
   Mu JB, 2005, PLOS BIOL, V3, P1734, DOI 10.1371/journal.pbio.0030335
   Mu JB, 2005, MOL BIOL EVOL, V22, P1686, DOI 10.1093/molbev/msi160
   Mu JB, 2002, NATURE, V418, P323, DOI 10.1038/nature00836
   Musset L, 2006, J ANTIMICROB CHEMOTH, V57, P110, DOI 10.1093/jac/dki420
   Mutabingwa TK, 2005, LANCET, V365, P1474, DOI 10.1016/S0140-6736(05)66417-3
   Nair S, 2003, MOL BIOL EVOL, V20, P1526, DOI 10.1093/molbev/msg162
   Nash D, 2005, P ROY SOC B-BIOL SCI, V272, P1153, DOI 10.1098/rspb.2004.3026
   Ndam NGT, 2005, J INFECT DIS, V192, P331, DOI 10.1086/430933
   Ndiaye D, 2005, TROP MED INT HEALTH, V10, P1176, DOI 10.1111/j.1365-3156.2005.01506.x
   NERY S, 2003, MOL BIOCH PARAISTOL, V149, P208
   Niare O, 2002, SCIENCE, V298, P213, DOI 10.1126/science.1073420
   Nielsen MA, 2002, J IMMUNOL, V168, P3444
   Ochola LB, 2005, PARASITOLOGY, V131, P449, DOI 10.1017/S0031182005008085
   Okoyeh JN, 1999, INFECT IMMUN, V67, P5784
   Paganotti GM, 2004, AM J TROP MED HYG, V71, P173
   Paget-McNicol S, 2001, PARASITOLOGY, V122, P497, DOI 10.1017/S0031182001007739
   PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897
   Pearce R, 2005, MOL BIOL EVOL, V22, P1834, DOI 10.1093/molbev/msi177
   Pearce RJ, 2003, ANTIMICROB AGENTS CH, V47, P1347, DOI 10.1128/AAC.47.4.1347-1354.2003
   Pinder M, 2006, INFECT IMMUN, V74, P2887, DOI 10.1128/IAI.74.5.2887-2893.2006
   Polley SD, 2006, VACCINE, V24, P4233, DOI 10.1016/j.vaccine.2005.06.030
   Polley SD, 2004, VACCINE, V23, P718, DOI 10.1016/j.vaccine.2004.05.031
   Polley SD, 2003, GENETICS, V165, P555
   Polley SD, 2001, GENETICS, V158, P1505
   Polley SD, 2007, J INFECT DIS, V195, P279, DOI 10.1086/509806
   Price RN, 2006, CLIN INFECT DIS, V42, P1570, DOI 10.1086/503423
   Price RN, 2004, LANCET, V364, P438, DOI 10.1016/S0140-6736(04)16767-6
   Rathod PK, 1997, P NATL ACAD SCI USA, V94, P9389, DOI 10.1073/pnas.94.17.9389
   Razakandrainibe FG, 2005, P NATL ACAD SCI USA, V102, P17388, DOI 10.1073/pnas.0508871102
   Read AF, 2001, SCIENCE, V292, P1099, DOI 10.1126/science.1059410
   Read A. F, 2002, ADAPTIVE DYNAMICS IN, P165, DOI 10.1017/CBO9780511525728.016
   Recker M, 2004, NATURE, V429, P555, DOI 10.1038/nature02486
   Robert F, 1996, T ROY SOC TROP MED H, V90, P704, DOI 10.1016/S0035-9203(96)90446-0
   Roper C, 1998, PARASITOLOGY, V116, P501, DOI 10.1017/S0031182098002650
   Roper C, 2003, LANCET, V361, P1174, DOI 10.1016/S0140-6736(03)12951-0
   Roper C, 1996, AM J TROP MED HYG, V54, P325
   Roper C, 2004, SCIENCE, V305, P1124, DOI 10.1126/science.1098876
   Rottmann M, 2006, INFECT IMMUN, V74, P3904, DOI 10.1128/IAI.02073-05
   Rougemont M, 2004, J CLIN MICROBIOL, V42, P5636, DOI 10.1128/JCM.42.12.5636-5643.2004
   Rowe JA, 2004, MOL MICROBIOL, V53, P1011, DOI 10.1111/j.1365-2958.2004.04256.x
   Sakihama N, 2006, AM J TROP MED HYG, V74, P31
   Salanti A, 2004, J EXP MED, V200, P1197, DOI 10.1084/jem.20041579
   Sibley CH, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-48
   SILAMUT K, 1993, T ROY SOC TROP MED H, V87, P436, DOI 10.1016/0035-9203(93)90028-O
   Simpson JA, 2002, PARASITOLOGY, V124, P247, DOI 10.1017/S0031182001001202
   Singh B, 2004, LANCET, V363, P1017, DOI 10.1016/S0140-6736(04)15836-4
   Singh B, 1999, AM J TROP MED HYG, V60, P687
   Slater M, 2005, AM J TROP MED HYG, V73, P256
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   Snounou G, 1999, T ROY SOC TROP MED H, V93, P369, DOI 10.1016/S0035-9203(99)90120-7
   Staalsoe T, 2004, LANCET, V363, P283, DOI 10.1016/S0140-6736(03)15386-X
   Stubbs J, 2005, SCIENCE, V309, P1384, DOI 10.1126/science.1115257
   Stump AD, 2005, P NATL ACAD SCI USA, V102, P15930, DOI 10.1073/pnas.0508161102
   Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351
   Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X
   Swan H, 2005, AM J TROP MED HYG, V73, P850
   Talisuna AO, 2004, INFECT GENET EVOL, V4, P321, DOI 10.1016/j.meegid.2004.04.002
   Taylor RR, 1998, AM J TROP MED HYG, V58, P406
   THAITHONG S, 1984, T ROY SOC TROP MED H, V78, P242, DOI 10.1016/0035-9203(84)90287-6
   Triglia T, 2005, MOL MICROBIOL, V55, P162, DOI 10.1111/j.1365-2958.2004.04388.x
   Trimnell AR, 2006, MOL BIOCHEM PARASIT, V148, P169, DOI 10.1016/j.molbiopara.2006.03.012
   Uhlemann AC, 2005, J INFECT DIS, V192, P1830, DOI 10.1086/497337
   van Dijk MR, 2005, P NATL ACAD SCI USA, V102, P12194, DOI 10.1073/pnas.0500925102
   Viebig NK, 2005, EMBO REP, V6, P775, DOI 10.1038/sj.embor.7400466
   Volkman SK, 2002, SCIENCE, V298, P216, DOI 10.1126/science.1075642
   vonSeidlein L, 1997, J INFECT DIS, V176, P1113
   Watkins WM, 2005, AM J TROP MED HYG, V72, P163
   Wernsdorfer WH, 2003, CURR OPIN INFECT DIS, V16, P553, DOI 10.1097/01.qco.0000104295.87920.fd
   Wichmann O, 2004, J INFECT DIS, V190, P1541, DOI 10.1086/424469
   Win TT, 2004, EMERG INFECT DIS, V10, P1235
   Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813
   Zwetyenga J, 1998, AM J TROP MED HYG, V59, P726
NR 201
TC 49
Z9 49
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0893-8512
EI 1098-6618
J9 CLIN MICROBIOL REV
JI Clin. Microbiol. Rev.
PD JAN
PY 2007
VL 20
IS 1
BP 188
EP +
DI 10.1128/CMR.00021-06
PG 18
WC Microbiology
SC Microbiology
GA 128BR
UT WOS:000243631400009
PM 17223628
OA No
DA 2017-08-15
ER

PT J
AU Okomo, U
   Meremikwu, MM
AF Okomo, U.
   Meremikwu, M. M.
TI Fluid replacement therapy for acute episodes of pain in people with
   sickle cell disease
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID CRISIS; ANEMIA; HYPOSTHENURIA; MANAGEMENT; KETOROLAC; EMERGENCY;
   CHILDREN
AB Background Treating vaso-occlusive painful crises in people with sickle cell disease is complex and requires multiple interventions. Extra fluids are routinely given as adjunct treatment, regardless of the individual's state of hydration with the aim of slowing or stopping the sickling process and thereby alleviating pain.
   Objectives To determine the optimal route, quantity and type of fluid replacement for people with sickle cell disease with acute painful crises.
   Search strategy We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.
   We also conducted searches of EMBASE, LILACS and the website www.ClinicalTrials.gov.
   Date of most recent search of the Group's Haemoglobinopathies Trials Register: February 2007.
   Selection criteria Randomised and quasi-randomised controlled trials that compared the administration of supplemental fluids adjunctive to analgesics by any route in people with any type of sickle cell disease during an acute painful episode, under medical supervision (inpatient, day care or community).
   Data collection and analysis No relevant trials have yet been identified.
   Main results Sixteen trials were identified by the initial search. Of these, 15 were not suitable for inclusion in this review and one study is awaiting further assessment.
   Authors' conclusions Treating vaso-occlusive crises is complex and requires multiple interventions. Extra fluids, generally oral or intravenous, are routinely administered during acute painful episodes to people with sickle cell disease regardless of the individual's state of hydration. Reports of their use during these acute painful episodes do not state the efficacy of any single route, type or quantity of fluid compared to another. However, there are no randomized controlled trials that have assessed the safety and efficacy of different routes, types or quantities of fluid. This systematic review identifies the need for a multicentre randomized controlled trial assessing the efficacy and possible adverse effects of different routes, types and quantities of fluid administered to people with sickle cell disease during acute painful episodes.
C1 Med Res Coucil Labs, Clin Serv, Fajara, Gambia.
RP Okomo, U (reprint author), Med Res Coucil Labs, Clin Serv, Atlantic Blvd,POB 273, Fajara, Gambia.
EM uokomo@mrc.gm
CR ADEKILE JC, 1999, PAEDIATR CHILD HLTH, P200
   ALLON M, 1990, ARCH INTERN MED, V150, P501, DOI 10.1001/archinte.150.3.501
   Alvim RC, 2005, ACTA HAEMATOL-BASEL, V113, P228, DOI 10.1159/000084675
   Beiter JL, 2001, ARCH PEDIAT ADOL MED, V155, P496
   Brugnara C, 1995, Curr Opin Hematol, V2, P132
   CHARACHE S, 1983, AM J HEMATOL, V15, P315, DOI 10.1002/ajh.2830150402
   CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001
   CHARACHE S, 1981, BLOOD, V58, P892
   de Araujo J T, 1994, Rev Hosp Clin Fac Med Sao Paulo, V49, P13
   GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501
   GONZALEZ ER, 1991, ARCH INTERN MED, V151, P1373, DOI 10.1001/archinte.151.7.1373
   GONZALEZ ER, 1988, ANN EMERG MED, V17, P788, DOI 10.1016/S0196-0644(88)80554-7
   Guy R, 1971, CLIN RES, V21, P420
   GUY RB, 1973, AM J MED SCI, V266, P267, DOI 10.1097/00000441-197310000-00005
   Hardwick WE, 1999, PEDIATR EMERG CARE, V15, P179, DOI 10.1097/00006565-199906000-00004
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Juni P, 2001, BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42
   KALYINYAK K, 2005, DIPYRIDAMOLE MAGNESI
   KATCH FE, 1965, ARCH INTERN MED, V116, P10
   KEITEL HG, 1956, J CLIN INVEST, V35, P998, DOI 10.1172/JCI103360
   KONTESSIS P, 1992, NEPHRON, V61, P10
   Lane PA, 2001, INPATIENT MANAGEMENT
   Lane PA, 2001, CURRENT PEDIAT DIAGN, P756
   NALBANDIAN RM, 1971, AM J MED SCI, V261, P309, DOI 10.1097/00000441-197106000-00002
   Orringer EP, 2001, JAMA-J AM MED ASSOC, V286, P2099, DOI 10.1001/jama.286.17.2099
   OSKI FA, 1965, J AMER MED ASSOC, V191, P43
   PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103
   RHODES RS, 1974, JAMA-J AM MED ASSOC, V228, P112
   Saborio P, 1999, J AM SOC NEPHROL, V10, P187
   *SCIC, 2005, SICKL CELL INF CLIN
   Serjeant GR, 1992, SICKLE CELL DIS
   Steinberg MH, 1999, NEW ENGL J MED, V340, P1021
   VANEPS LWS, 1967, CLIN CHIM ACTA, V17, P449, DOI 10.1016/0009-8981(67)90222-7
NR 33
TC 5
Z9 5
U1 0
U2 0
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1469-493X
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2007
IS 2
AR CD005406
DI 10.1002/14651858.CD005406.pub2
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 157ZK
UT WOS:000245760200058
PM 17443589
OA No
DA 2017-08-15
ER

PT J
AU Juhas, M
   Power, PM
   Harding, RM
   Ferguson, DJP
   Dimopoulou, ID
   Elamin, ARE
   Mohd-Zain, Z
   Hood, D
   Adegbola, R
   Erwin, A
   Smith, A
   Munson, RS
   Harrison, A
   Mansfield, L
   Bentley, S
   Crook, DW
AF Juhas, Mario
   Power, Peter M.
   Harding, Rosalind M.
   Ferguson, David J. P.
   Dimopoulou, Ioanna D.
   Elamin, Abdel R. E.
   Mohd-Zain, Zaini
   Hood, DerekW
   Adegbola, Richard
   Erwin, Alice
   Smith, Arnold
   Munson, Robert S.
   Harrison, Alistair
   Mansfield, Lucielle
   Bentley, Stephen
   Crook, Derrick W.
TI Sequence and functional analyses of Haemophilus spp. genomic islands
SO GENOME BIOLOGY
LA English
DT Article
ID COMPLETE NUCLEOTIDE-SEQUENCE; PSEUDOMONAS-AERUGINOSA; IV SECRETION;
   HEMOPHILUS-INFLUENZAE; RESISTANCE; PLASMID; PROTEIN; FAMILY; GENES;
   RECOMBINATION
AB Background: A major part of horizontal gene transfer that contributes to the diversification and adaptation of bacteria is facilitated by genomic islands. The evolution of these islands is poorly understood. Some progress was made with the identification of a set of phylogenetically related genomic islands among the Proteobacteria, recognized from the investigation of the evolutionary origins of a Haemophilus influenzae antibiotic resistance island, namely ICEHin1056. More clarity comes from this comparative analysis of seven complete sequences of the ICEHin1056 genomic island subfamily.
   Results: These genomic islands have core and accessory genes in approximately equal proportion, with none demonstrating recent acquisition from other islands. The number of variable sites within core genes is similar to that found in the host bacteria. Furthermore, the GC content of the core genes is similar to that of the host bacteria (38% to 40%). Most of the core gene content is formed by the syntenic type IV secretion system dependent conjugative module and replicative module. GC content and lack of variable sites indicate that the antibiotic resistance genes were acquired relatively recently. An analysis of conjugation efficiency and antibiotic susceptibility demonstrates that phenotypic expression of genomic island-borne genes differs between different hosts.
   Conclusion: Genomic islands of the ICEHin1056 subfamily have a longstanding relationship with H. influenzae and H. parainfluenzae and are co-evolving as semi-autonomous genomes within the 'supragenomes' of their host species. They have promoted bacterial diversity and adaptation through becoming efficient vectors of antibiotic resistance by the recent acquisition of antibiotic resistance transposons.
C1 [Juhas, Mario; Dimopoulou, Ioanna D.; Elamin, Abdel R. E.; Crook, Derrick W.] Univ Oxford, NDCLS, Oxford OX3 9DU, England.
   [Power, Peter M.; Hood, DerekW] Univ Oxford, Weatherall Inst Mol Med, Oxford OX3 9DU, England.
   [Harding, Rosalind M.] Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
   [Harding, Rosalind M.] Univ Oxford, Dept Zool, Oxford OX1 3TG, England.
   [Ferguson, David J. P.] Univ Oxford, Dept Pathol, Oxford OX3 9DU, England.
   [Mohd-Zain, Zaini] Univ Teknol MARA, Fac Med, Shah Alam 40450, Malaysia.
   [Adegbola, Richard] MRC Labs, Banjul, Gambia.
   [Erwin, Alice; Smith, Arnold] Univ Washington, Seattle Biomed Res Inst, Seattle, WA 98109 USA.
   [Munson, Robert S.; Harrison, Alistair] Ohio State Univ, Ctr Microbial Interface Biol, Columbus, OH 43205 USA.
   [Munson, Robert S.; Harrison, Alistair] Ohio State Univ, Nationwide Childrens Res Inst, Ctr Microbial Pathogenesis, Columbus, OH 43205 USA.
   [Mansfield, Lucielle] Churchill Hosp, OCDEM, Oxford OX3 7LJ, England.
   [Bentley, Stephen] Sanger Inst, Wellcome Trust, Cambridge CB10 1SA, England.
RP Juhas, M (reprint author), Univ Oxford, NDCLS, Oxford OX3 9DU, England.
EM mario.juhas@ndlcs.ox.ac.uk
RI Munson, Jr, Robert/E-3710-2011
OI Munson, Jr, Robert/0000-0002-3204-3019; Ferguson,
   David/0000-0001-5045-819X
FU Medical Research Council [G0400039]
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Bakaletz LO, 2005, INFECT IMMUN, V73, P1635, DOI 10.1128/IAI.73.3.1635-1643.2005
   BRIGHTMAN CAJ, 1990, LANCET, V335, P351, DOI 10.1016/0140-6736(90)90634-H
   Chalmers R, 2000, J BACTERIOL, V182, P2970, DOI 10.1128/JB.182.10.2970-2972.2000
   CHEN CY, 1994, J BACTERIOL, V176, P5697
   Christie PJ, 2001, MOL MICROBIOL, V40, P294, DOI 10.1046/j.1365-2958.2001.02302.x
   Christie PJ, 2005, ANNU REV MICROBIOL, V59, P451, DOI 10.1146/annurev.micro.58.030603.123630
   Dimopoulou ID, 1997, J ANTIMICROB CHEMOTH, V39, P303, DOI 10.1093/jac/39.3.303
   DIMOPOULOU ID, 1992, J INFECT DIS, V165, P1069
   Dimopoulou ID, 2002, ANTIMICROB AGENTS CH, V46, P1602, DOI 10.1128/AAC.46.5.1602-1603.2002
   Dimopoulou ID, 2007, J MED MICROBIOL, V56, P838, DOI 10.1099/jmm.0.47125-0
   Dobrindt U, 2004, NAT REV MICROBIOL, V2, P414, DOI 10.1038/nrmicro884
   FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800
   Gaillard M, 2006, J BACTERIOL, V188, P1999, DOI 10.1128/JB.188.5.1999-2013.2006
   Galli DM, 2001, J BACTERIOL, V183, P1585, DOI 10.1128/JB.183.5.1585-1594.2001
   GRINDLEY NDF, 1983, CELL, V32, P3, DOI 10.1016/0092-8674(83)90490-7
   Harrison A, 2005, J BACTERIOL, V187, P4627, DOI 10.1128/JB.187.13.4627-4636.2005
   He JX, 2004, P NATL ACAD SCI USA, V101, P2530, DOI 10.1073/pnas.0304622101
   Hogg JS, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-r103
   Juhas M, 2007, J BACTERIOL, V189, P761, DOI 10.1128/JB.01327-06
   Klockgether J, 2004, J BACTERIOL, V186, P518, DOI 10.1128/JB.186.2.518-534.2004
   Klockgether J, 2007, J BACTERIOL, V189, P2443, DOI 10.1128/JB.01688-06
   Lawley TD, 2000, PLASMID, V43, P235, DOI 10.1006/plas.1999.1458
   Meats E, 2003, J CLIN MICROBIOL, V41, P1623, DOI 10.1128/JCM.41.4.1623-1636.2003
   Mohd-Zain Z, 2004, J BACTERIOL, V186, P8114, DOI 10.1128/JB.186.23.8114-8122.2004
   Nizet V, 1996, J INFECT DIS, V173, P180
   Pickard D, 2003, J BACTERIOL, V185, P5055, DOI 10.1128/JB.185.17.5055-5065.2003
   POWELL M, 1988, J MED MICROBIOL, V27, P81
   Qiu XY, 2006, P NATL ACAD SCI USA, V103, P19830, DOI 10.1073/pnas.0606810104
   RUTHERFORD K, 2000, BIOINFORMATICS, V16, P945
   Saveson CJ, 1999, GENETICS, V152, P5
   Shen K, 2006, INFECT IMMUN, V74, P321, DOI 10.1128/IAI.74.1.321-330.2006
   Shen K, 2006, INFECT IMMUN, V74, P5272, DOI 10.1128/IAI.00546-06
   STUY JH, 1979, J BACTERIOL, V139, P520
   Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0
   SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3737, DOI 10.1073/pnas.75.8.3737
   Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1111/j.1574-6968.1999.tb13575.x
   ZHANG HL, 1995, J BIOL CHEM, V270, P23700
   HEAMOPHILUS PARAINFL
   HAEMOPHILUS INFLUENZ
NR 41
TC 40
Z9 44
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PY 2007
VL 8
IS 11
AR R237
DI 10.1186/gb-2007-8-11-r237
PG 14
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 247SQ
UT WOS:000252101100011
PM 17996041
OA gold
DA 2017-08-15
ER

PT J
AU Weedall, GD
   Preston, BMJ
   Thomas, AW
   Sutherland, CJ
   Conway, DJ
AF Weedall, Gareth D.
   Preston, Benjamin M. J.
   Thomas, Alan W.
   Sutherland, Colin J.
   Conway, David J.
TI Differential evidence of natural selection on two leading sporozoite
   stage malaria vaccine candidate antigens
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Article
DE circumsporozoite protein (CSP); thrombospondin-related adhesive protein
   (TRAP); population genetics; acquired immunity; statistical tests of
   neutrality; vaccines
ID PLASMODIUM-FALCIPARUM INFECTION; RANDOMIZED CONTROLLED-TRIAL;
   CIRCUMSPOROZOITE PROTEIN; ADHESIVE PROTEIN; POPULATION-STRUCTURE; DNA
   POLYMORPHISM; GLIDING MOTILITY; T-CELLS; EFFICACY; TRAP
AB Experimental malaria vaccines based on two sporozoite stage candidate antigens of Plasmodium falciparum, the circurnsporozoite protein (CSP) and thrombospondin-related adhesive protein (TRAP), have undergone clinical trials of efficacy. The relevance of naturally existing polymorphism in these molecules remains unknown. Sequence polymorphism in the genes encoding these antigens was studied in a Gambian population (sample of 48 trap and 44 csp gene sequences) to test for signatures of selection that would result from naturally acquired immunity. Allele frequency distributions were analyzed and compared with data from another population (in Thailand). Patterns of non-synonymous and synonymous polymorphism in P. falciparum and in Plasmodium vivax were compared with divergence from related species. Results indicate that polymorphism in TRAP is under strong selection for amino acid sequence diversity and that allele frequencies are under balancing selection within the Gambian P. falciparum population. There was no such evidence for CSP, calling into question the idea that most polymorphisms in this gene are under immune selection. There was a weak trend for regions known to encode T cell epitopes to have slightly higher indices suggesting balancing selection. Overall, the results predict more allele-specific immunity to TRAP than to CSP and should be considered in design and efficacy testing of vaccine candidates based on these antigens. (c) 2006 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.
C1 Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1E 7HT, England.
   Biomed Primate Res Ctr, Dept Parasitol, NL-2280 GH Rijswijk, Netherlands.
   MRC Labs, Banjul, Gambia.
RP Conway, DJ (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, Keppel St, London WC1E 7HT, England.
EM dconway@mrc.gm
OI Conway, David/0000-0002-8711-3037
FU Medical Research Council [MC_U190081993]
CR Alloueche A, 2003, AM J TROP MED HYG, V68, P97
   Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6
   Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Calvo-Calle JM, 2005, J IMMUNOL, V175, P7575
   Conway DJ, 2002, PARASITOLOGY, V125, pS3, DOI 10.1017/S0031182002002214
   Conway DJ, 2001, MOL BIOCHEM PARASIT, V115, P145, DOI 10.1016/S0166-6851(01)00278-X
   Enosse S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010005
   Escalante AA, 1998, GENETICS, V149, P189
   Flanagan KL, 2006, AM J TROP MED HYG, V74, P367
   Flanagan KL, 1999, EUR J IMMUNOL, V29, P1943, DOI 10.1002/(SICI)1521-4141(199906)29:06<1943::AID-IMMU1943>3.3.CO;2-T
   Flanagan KL, 2003, AM J TROP MED HYG, V68, P421
   Forsdyke DR, 2002, TRENDS PARASITOL, V18, P411, DOI 10.1016/S1471-4922(02)02342-5
   FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287
   FU YX, 1993, GENETICS, V133, P693
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173
   GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199
   Goudet J, 1995, J HERED, V86, P485
   Hill AVS, 2006, NAT REV IMMUNOL, V6, P21, DOI 10.1038/nri1746
   HUDSON RR, 1987, GENET RES, V50, P245
   HUGHES AL, 1991, GENETICS, V127, P345
   JONGWUTIWES S, 1994, AM J TROP MED HYG, V51, P659
   Jongwutiwes S, 1998, MOL BIOCHEM PARASIT, V92, P349, DOI 10.1016/S0166-6851(98)00004-8
   Joy DA, 2003, SCIENCE, V300, P318, DOI 10.1126/science.1081449
   Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937
   Kumkhaek C, 2005, J IMMUNOL, V175, P3935
   Lee EAM, 2006, EUR J IMMUNOL, V36, P1168, DOI 10.1002/eji.200526010
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0
   Moorthy VS, 2004, J INFECT DIS, V189, P2213, DOI 10.1086/421118
   MOORTHY VS, 2004, PLOS MED, V1
   MORENO A, 1993, J IMMUNOL, V151, P489
   Polley SD, 2003, GENETICS, V165, P555
   Putaporntip C, 2001, GENE, V268, P97, DOI 10.1016/S0378-1119(01)00425-5
   Rathore D, 2003, J BIOL CHEM, V278, P40905, DOI 10.1074/jbc.M306250200
   Rich SM, 2000, P NATL ACAD SCI USA, V97, P6994, DOI 10.1073/pnas.97.13.6994
   Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359
   SCARSELLI E, 1993, INFECT IMMUN, V61, P3490
   Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5
   Sutherland CJ, 2003, AM J TROP MED HYG, V69, P19
   TAJIMA F, 1989, GENETICS, V123, P585
NR 43
TC 33
Z9 34
U1 1
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0020-7519
J9 INT J PARASITOL
JI Int. J. Parasit.
PD JAN
PY 2007
VL 37
IS 1
BP 77
EP 85
DI 10.1016/j.ijpara.2006.09.001
PG 9
WC Parasitology
SC Parasitology
GA 128NC
UT WOS:000243663500008
PM 17046771
OA No
DA 2017-08-15
ER

PT J
AU van der Sande, MAB
   Waight, PA
   Mendy, M
   Zaman, S
   Kaye, S
   Sam, O
   Kahn, A
   Jeffries, D
   Akum, AA
   Hall, AJ
   Bah, E
   McConkey, SJ
   Hainaut, P
   Whittle, HC
AF van der Sande, Marianne A. B.
   Waight, Pauline A.
   Mendy, Maimuna
   Zaman, Syed
   Kaye, Steve
   Sam, Omar
   Kahn, Abi
   Jeffries, David
   Akum, Aveika A.
   Hall, Andrew J.
   Bah, Ebrima
   McConkey, Samuel J.
   Hainaut, Pierre
   Whittle, Hilton C.
TI Long-Term Protection against HBV Chronic Carriage of Gambian Adolescents
   Vaccinated in Infancy and Immune Response in HBV Booster Trial in
   Adolescence
SO PLOS ONE
LA English
DT Article
AB Background. Chronic infection with hepatitis B virus (HBV) arising in childhood is associated with hepatocellular carcinoma in adult life. Between 1986 and 1990, approximately 120,000 Gambian newborns were enrolled in a randomised controlled trial to assess the effectiveness of infant HBV vaccination on the prevention of hepatocellular carcinoma in adulthood. These children are now in adolescence and approaching adulthood, when the onset of sexual activity may challenge their hepatitis B immunity. Thus a booster dose in adolescence could be important to maintain long-term protection. Methods. Fifteen years after the start of the HBV infant vaccination study, 492 vaccinated and 424 unvaccinated children were identified to determine vaccine efficacy against infection and carriage in adolescence. At the same time, 297 of the 492 infant-vaccinated subjects were randomly offered a booster dose of HBV vaccine. Anti-HBs was measured before the booster, and two weeks and 1 year afterwards (ISRCTN71271385). Results. Vaccine efficacy 15 years after vaccination was 67.0% against infection as manifest by anti-HBc positivity (95% CI 58.2-74.6%), and 96.6% against HBsAg carriage (95% CI 91.5-100%). 31.2% of participants had detectable anti-HBs with a GMC of 32 IU/l. For 168 boosted participants GMC anti-HBs responses were 38 IU/l prior to vaccination, 524 IU/l two weeks after boosting, and 101 IU/l after 1 year. Conclusions. HBV vaccination in infants confers very good protection against carriage up to 15 years of age, although a large proportion of vaccinated subjects did not have detectable anti-HBs at this age. The response to boosting persisted for at least a year.
C1 [van der Sande, Marianne A. B.; Waight, Pauline A.; Mendy, Maimuna; Zaman, Syed; Kaye, Steve; Jeffries, David; Akum, Aveika A.; McConkey, Samuel J.; Whittle, Hilton C.] MRC Labs, Fajara, Gambia.
   [Mendy, Maimuna; Bah, Ebrima; Hainaut, Pierre] Int Agcy Res Canc, Gambia Hepatitis Intervent Study, F-69372 Lyon, France.
   [Sam, Omar; Kahn, Abi] Dept State Hlth, Banjul, Gambia.
   [Hall, Andrew J.] London Sch Hyg & Trop Med, London WC1, England.
RP van der Sande, MAB (reprint author), Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands.
EM Marianne.van.der.sande@rivm.nl
FU MRC UK
FX The study was funded by the MRC UK. The sponsor had no role in the
   design and conduct of the study, analysis, interpretation of data, nor
   in the drafting of the manuscript.
CR Akram DS, 2005, VACCINE, V23, P5792, DOI 10.1016/j.vaccine.2005.06.013
   Banatvala J, 2000, LANCET, V355, P561
   Banatvala J, 2000, VACCINE, V19, P877, DOI 10.1016/S0264-410X(00)00224-3
   Bulkow LR, 1998, CLIN INFECT DIS, V26, P933, DOI 10.1086/513939
   Cassidy WM, 2001, PEDIATRICS, V107, P626, DOI 10.1542/peds.107.4.626
   COURSAGET P, 1994, J HEPATOL, V21, P20
   Gambia Hepatitis Study Group, 1987, CANCER RES, V47, P5782
   Gellin BG, 1997, J INFECT DIS, V175, P1494
   Heron LG, 2002, VACCINE, V20, P3472, DOI 10.1016/S0264-410X(02)00346-8
   Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
   JILG W, 1988, J MED VIROL, V24, P377, DOI 10.1002/jmv.1890240404
   Lavanchy D, 2005, J CLIN VIROL, V34, pS1, DOI 10.1016/S1386-6532(05)00384-7
   Levie K, 2002, SCAND J INFECT DIS, V34, P610, DOI 10.1080/00365540110080881
   Liao SS, 1999, VACCINE, V17, P2661, DOI 10.1016/S0264-410X(99)00031-6
   Marsano LS, 1998, VACCINE, V16, P624, DOI 10.1016/S0264-410X(97)00233-8
   van der Sande MAB, 2006, J INFECT DIS, V193, P1528
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4
   WHITTLE HC, 2004, BMJ-BRIT MED J, V325, P569
   Williams IT, 2003, PEDIATR INFECT DIS J, V22, P157
   Wistrom J, 1999, VACCINE, V17, P2162, DOI 10.1016/S0264-410X(99)00012-2
NR 21
TC 2
Z9 2
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PY 2007
VL 2
IS 8
AR e753
DI 10.1371/journal.pone.0000753
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10HN
UT WOS:000207455200029
OA gold
DA 2017-08-15
ER

PT J
AU Hill, PC
   Brookes, RH
   Fox, A
   Jackson-Sillah, D
   Lugos, MD
   Jeffries, DJ
   Donkor, SA
   Adegbola, RA
   McAdam, KPWJ
AF Hill, Philip C.
   Brookes, Roger H.
   Fox, Annette
   Jackson-Sillah, Dolly
   Lugos, Moses D.
   Jeffries, David J.
   Donkor, Simon A.
   Adegbola, Richard A.
   McAdam, Keith P. W. J.
TI Surprisingly High Specificity of the PPD Skin Test for M-tuberculosis
   Infection from Recent Exposure in The Gambia
SO PLOS ONE
LA English
DT Article
AB Background. Options for intervention against Mycobacterium tuberculosis infection are limited by the diagnostic tools available. The Purified Protein Derivative (PPD) skin test is thought to be non-specific, especially in tropical settings. We compared the PPD skin test with an ELISPOT test in The Gambia. Methodology/Principal Findings. Household contacts over six months of age of sputum smear positive TB cases and community controls were recruited. They underwent a PPD skin test and an ELISPOT test for the T cell response to PPD and ESAT-6/CFP10 antigens. Responsiveness to M. tuberculosis exposure was analysed according to sleeping proximity to an index case using logistic regression. 615 household contacts and 105 community controls were recruited. All three tests assessed increased significantly in positivity with increasing M. tuberculosis exposure, the PPD skin test most dramatically (OR 15.7; 95% CI 6.6-35.3). While the PPD skin test positivity continued to trend downwards in the community with increasing distance from a known case (61.9% to 14.3%), the PPD and ESAT-6/CFP-10 ELISPOT positivity did not. The PPD skin test was more in agreement with ESAT-6/CFP-10 ELISPOT (75%, p = 0.01) than the PPD ELISPOT (53%, p < 0.0001). With increasing M. tuberculosis exposure, the proportion of ESAT-6/CFP-10 positive contacts who were PPD skin test positive increased (p < 0.0001), and the proportion of ESAT-6/CFP-10 negative contacts that were PPD skin test negative decreased (p < 0.0001); the converse did not occur. Conclusions/Significance. The PPD skin test has surprisingly high specificity for M. tuberculosis infection from recent exposure in The Gambia. In this setting, anti-tuberculous prophylaxis in PPD skin test positive individuals should be revisited.
C1 [Hill, Philip C.; Brookes, Roger H.; Fox, Annette; Jackson-Sillah, Dolly; Lugos, Moses D.; Jeffries, David J.; Donkor, Simon A.; Adegbola, Richard A.; McAdam, Keith P. W. J.] MRC Unit, Bacterial Dis Programme, Banjul, Gambia.
RP Hill, PC (reprint author), MRC Unit, Bacterial Dis Programme, Banjul, Gambia.
EM phill@mrc.gm
FU The Medical Research Council (UK); European Commission
FX The Medical Research Council (UK) and the European Commission. Neither
   had any role in the design or conduct or collection analysis and
   interpretation of the data, or in the preparation, review or approval of
   the manuscript.
CR Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390
   ANDERSEN P, 1995, J IMMUNOL, V154, P3359
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195
   Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8
   Black GF, 2001, INT J TUBERC LUNG D, V5, P664
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   COMSTOCK GW, 1969, AM REV RESPIR DIS, V100, P839
   Crampin AC, 2001, T ROY SOC TROP MED H, V95, P481, DOI 10.1016/S0035-9203(01)90009-4
   DEJONG BC, 2006, J INFECT DI IN PRESS
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9
   Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192
   Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962
   Floyd S, 2002, J INFECT DIS, V186, P807, DOI 10.1086/342416
   Guwatudde D, 2003, AM J EPIDEMIOL, V158, P887, DOI 10.1093/aje/kwg227
   Hill PC, 2005, J CLIN MICROBIOL, V43, P2070, DOI 10.1128/JCM.43.5.2070-2074.2005
   Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362
   Hill PC, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-156
   Hoft DF, 2000, CLIN INFECT DIS, V30, pS217, DOI 10.1086/313864
   Jeffries DJ, 2004, INT J TUBERC LUNG D, V8, P1095
   Koch R., 1891, DEUT MED WOCHENSCHR, V171, P101, DOI [DOI 10.1055/S-0029-1206198, 10.1055/s-0029-1206198]
   Kunkel EJ, 2002, IMMUNITY, V16, P1, DOI 10.1016/S1074-7613(01)00261-8
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lawn SD, 2006, CLIN INFECT DIS, V42, P1040, DOI 10.1086/501018
   Lienhardt C, 2003, PEDIATRICS, V111, pE608, DOI 10.1542/peds.111.5.e608
   Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066
   Maher D, 2005, CLIN CHEST MED, V26, P167, DOI 10.1016/j.ccm.2005.02.009
   Marshall RJ, 2001, STAT MED, V20, P1077, DOI 10.1002/sim.747
   Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746
   Pitman R, 2002, INT J TUBERC LUNG D, V6, P485
   RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220
   Sester M, 2004, KIDNEY INT, V65, P1826, DOI 10.1111/j.1523-1755.2004.00586.x
   [Anonymous], 1956, BMJ, V1, P413
NR 32
TC 13
Z9 13
U1 2
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2006
VL 1
IS 1
AR e68
DI 10.1371/journal.pone.0000068
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10DB
UT WOS:000207443600068
PM 17183699
OA gold
DA 2017-08-15
ER

PT J
AU Jensen, ML
   Dave, S
   van der Loeff, MS
   da Costa, C
   Vincent, T
   Leligdowicz, A
   Benn, CS
   Roth, A
   Ravn, H
   Lisse, IM
   Whittle, H
   Aaby, P
AF Jensen, Mette Lundsby
   Dave, Sangeeta
   van der Loeff, Maarten Schim
   da Costa, Carlos
   Vincent, Tim
   Leligdowicz, Aleksandra
   Benn, Christine Stabell
   Roth, Adam
   Ravn, Henrik
   Lisse, Ida Maria
   Whittle, Hilton
   Aaby, Peter
TI Vaccinia Scars Associated with Improved Survival among Adults in Rural
   Guinea-Bissau
SO PLOS ONE
LA English
DT Article
AB Background. In urban Guinea-Bissau, adults with a vaccinia scar had better survival but also a higher prevalence of HIV-2 infection. We therefore investigated the association between vaccinia scar and survival and HIV infection in a rural area of Guinea-Bissau. Methodology/Principal Findings. In connection with a study of HIV in rural Guinea-Bissau, we assessed vaccinia and BCG scars in 193 HIV-1 or HIV-2 infected and 174 uninfected participants. Mortality was assessed after 2 1/2-3 years of follow-up. The analyses were adjusted for age, sex, village, and HIV status. The prevalence of vaccinia scar was associated with age, village, and HIV-2 status but not with sex and schooling. Compared with individuals without any scar, individuals with a vaccinia scar had better survival (mortality rate ratio (MR) = 0.22 (95% CI 0.08-0.61)), the MR being 0.19 (95% CI 0.06-0.57) for women and 0.40 (95% CI 0.04-3.74) for men. Estimates were similar for HIV-2 infected and HIV-1 and HIV-2 uninfected individuals. The HIV-2 prevalence was higher among individuals with a vaccinia scar compared to individuals without a vaccinia scar (RR = 1.57 (95% CI 1.02-2.36)). Conclusion. The present study supports the hypothesis that vaccinia vaccination may have a non-specific beneficial effect on adult survival.
C1 [Jensen, Mette Lundsby; da Costa, Carlos; Benn, Christine Stabell; Roth, Adam; Ravn, Henrik; Aaby, Peter] Statens Serum Inst, Projecto Saude Bandim, Bissau, Guinea Bissau.
   [Dave, Sangeeta; van der Loeff, Maarten Schim; Vincent, Tim; Leligdowicz, Aleksandra; Whittle, Hilton] MRC Labs, Fajara, Gambia.
   [Lisse, Ida Maria] Herlev Univ Hosp, Dept Pathol, Copenhagen, Denmark.
RP Aaby, P (reprint author), Statens Serum Inst, Projecto Saude Bandim, Bissau, Guinea Bissau.
EM p.aaby@bandim.org
OI Leligdowicz, Aleksandra/0000-0001-6055-4644
FU British Medical Research Council; Danish Medical Research Council;
   DANIDA; Novo Nordisk Foundation; Danish National Research Foundation
FX The study received financial support from the British Medical Research
   Council and the Danish Medical Research Council, DANIDA, Novo Nordisk
   Foundation and Danish National Research Foundation. PA holds a research
   professorship grant from the Novo Nordisk Foundation. These institutions
   played no role in the conduct of the study, in the collection, analysis,
   and interpretation of the data, and in the preparation, review, or
   approval of the manuscript.
CR AABY P, 1993, AM J EPIDEMIOL, V138, P746
   AABY P, 1995, BRIT MED J, V311, P481
   Aaby P, 1996, AIDS, V10, P1585
   Aaby P, 2006, VACCINE, V24, P5718, DOI 10.1016/j.vaccine.2006.04.045
   Ariyoshi K, 2003, J INFECT DIS, V188, P1648, DOI 10.1086/379780
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Ashorn P, 2002, ARCH DIS CHILD, V87, P386, DOI 10.1136/adc.87.5.386
   Bager P, 2003, J ALLERGY CLIN IMMUN, V111, P1227, DOI 10.1067/mai.2003.1483
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Cox D. R., 1984, ANAL SURVIVAL DATA
   Demkowicz WE, 1996, J VIROL, V70, P2627
   DEMKOWICZ WE, 1993, J VIROL, V67, P1538
   FINE PEM, 1989, B WORLD HEALTH ORGAN, V67, P35
   Frey SE, 2002, NEW ENGL J MED, V346, P1275, DOI 10.1056/NEJMoa013431
   Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6
   GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950
   GRUFFERMAN S, 1982, J NATL CANCER I, V68, P107
   Henderson D. A., 1999, VACCINES, P74
   Jaffar S, 2005, AIDS RES HUM RETROV, V21, P560, DOI 10.1089/aid.2005.21.560
   Knudsen KM, 1996, INT J EPIDEMIOL, V25, P665, DOI 10.1093/ije/25.3.665
   Kolmel KF, 2005, EUR J CANCER, V41, P118, DOI 10.1016/j.ejca.2004.09.023
   KOLMEL KF, 1992, MELANOMA RES, V2, P207
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Kurtzke JF, 1997, ACTA NEUROL SCAND, V96, P149
   Mercer A., 1990, DIS MORTALITY POPULA
   Moore ZS, 2006, LANCET, V367, P425, DOI 10.1016/S0140-6736(06)68143-9
   Pfahlberg A, 2002, J INVEST DERMATOL, V119, P570, DOI 10.1046/j.1523-1747.2002.00643.x
   Poulsen AG, 2000, SCAND J INFECT DIS, V32, P169
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   Shann F, 2004, PEDIATR INFECT DIS J, V23, P555, DOI 10.1097/01.inf.0000130155.42392.04
   van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012
   VELEMA JP, 1991, INT J EPIDEMIOL, V20, P474, DOI 10.1093/ije/20.2.474
   Welsh RM, 2002, NAT REV IMMUNOL, V2, P417, DOI 10.1038/nri820
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
NR 34
TC 16
Z9 17
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2006
VL 1
IS 1
AR e101
DI 10.1371/journal.pone.0000101
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10DB
UT WOS:000207443600100
PM 17183634
OA gold
DA 2017-08-15
ER

PT J
AU Garly, ML
   Bale, C
   Martins, CL
   Whittle, HC
   Nielsen, J
   Lisse, IM
   Aaby, P
AF Garly, May-Lill
   Bale, Carlitos
   Martins, Cesario Lourenco
   Whittle, Hilton C.
   Nielsen, Jens
   Lisse, Ida M.
   Aaby, Peter
TI Prophylactic antibiotics to prevent pneumonia and other complications
   after measles: community based randomised double blind placebo
   controlled trial in Guinea-Bissau
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID VACCINATION; CHILDREN; EXPERIENCE; INFECTION; EPIDEMIC; AGE
AB Objective 16 investigate whether prophylactic antibiotics can prevent complications of measles.
   Design Community based, randomised, double blind, placebo controlled trial.
   Setting Bandim Health Project stud), area in Bissau, Guinea-Bissau, west Africa.
   Participants 84 patients with measles during a measles epidemic in Bissau in 1998 (fewer than originally planned owing to interruption by war).
   Interventions Sulfamethoxazole-trimethoprim (co-trimoxazole) or placebo for seven days.
   Main outcome measures Pneumonia and admission to hospital. Also weight change during the first month of infection, diarrhoea, severe fever, oral thrush, stomatitis, conjunctivitis, and otitis media.
   Results The median age of the patients with measles was 5.4 (range 0.49-24.8) years. One of 46 participants who received co-trimoxazole developed pneumonia, in contrast to six of 38 participants who received placebo (odds ratio 0.08 (95% confidence interval 0 to 0.56), adjusted for age group). The number needed to treat was 7 (4 to 48). All three participants admitted to hospital had received placebo (P = 0.09). The weight gain during the first month after inclusion was 15 (2-29) g/day in the placebo group and 32 (23-42) g/day in the co-trimoxazole group (P = 0.04, adjusted for age group, weight for age at inclusion, measles vaccination status, and duration of disease). Significantly less conjunctivitis occurred among recipients of co-trimoxazole than placebo, as well as a non-significant tendency to less diarrhoea, severe fever, oral thrush, and stomatitis. Complications of otitis media were the same in the two groups.
   Conclusions The group that received prophylactic antibiotics had less pneumonia and conjunctivitis and had significantly higher weight gains in the month after inclusion. The results indicate that prophylactic antibiotics may have an important role in the management of measles infection in low income countries.
C1 Projecto Saude Bandim, Bissau, Guinea Bissau.
   MRC Labs, Fajara, Gambia.
RP Garly, ML (reprint author), Statens Serum Inst, Div Epidemiol, Bandim Hlth Project, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
EM mlg@ssi.dk
CR AABY P, 1986, J INFECT DIS, V154, P858
   Aaby P., 1997, PROSPECTIVE COMMUNIT, P276
   Chalmers I, 2002, PEDIATRICS, V109, P312, DOI 10.1542/peds.109.2.312
   Dietz V, 2004, B WORLD HEALTH ORGAN, V82, P852
   Garly ML, 1999, INT J EPIDEMIOL, V28, P347, DOI 10.1093/ije/28.2.347
   Helfand RF, 1997, J INFECT DIS, V175, P195
   HUTCHINS SS, 2004, J INFECT DIS S1, V189, P153
   Klugman KP, 1996, J ANTIMICROB CHEMOTH, V38, P133
   LOENING WEK, 1983, LANCET, V2, P324
   Morley DC, 1997, BRIT MED J, V314, P1692
   Nur YA, 1999, J CLIN VIROL, V12, P21, DOI 10.1016/S1386-6532(98)00002-X
   PERRY RT, 2004, J INFECT DIS S1, V18, P4
   Perry RT, 2004, J INF DIS S1, V189, P4
   Qazi SA, 1999, CLIN INFECT DIS, V28, P214, DOI 10.1086/515124
   Quiambao BP, 1998, PEDIATR INFECT DIS J, V17, P89, DOI 10.1097/00006454-199802000-00002
   SAMB B, 1995, PEDIATR INFECT DIS J, V14, P695, DOI 10.1097/00006454-199508000-00009
   SAMB B, 1993, T ROY SOC TROP MED H, V87, P697, DOI 10.1016/0035-9203(93)90301-6
   Shann F, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001477.pub2
   Shann F, 1997, BRIT MED J, V314, P334
   Van Den Hof S, 2002, PEDIATR INFECT DIS J, V21, P1146, DOI 10.1097/01.inf.0000042861.90649.97
   WHITTLE HC, 1988, LANCET, V1, P963
   *WHO, 1995, WHOCDR9515
   *WHO, 2004, INT MAN CHILDH
   1996, J ANTIMICROB CHEM SA, V38, P133
   2006, WKLY EPIDEMIOL REC, V10, P99
   2002, WKLY EPIDEMIOL REC, V77, P59
NR 26
TC 20
Z9 20
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0959-8146
J9 BRIT MED J
JI Br. Med. J.
PD DEC 16
PY 2006
VL 333
IS 7581
BP 1245
EP 1247
DI 10.1136/bmj.38989.684178.AE
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 122AB
UT WOS:000243197000016
PM 17060336
OA No
DA 2017-08-15
ER

PT J
AU Eshofonie, A
   van der Loeff, MS
   Whittle, H
   Jaye, A
AF Eshofonie, A.
   van der Loeff, M. Shim
   Whittle, H.
   Jaye, A.
TI An adaptation of recombinant vaccinia-based ELISPOT and intracellular
   cytokine staining for a comparative measurement of cellular immune
   responses in HIV-1 and HIV-2 infections in West Africa
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE cytotoxic T lymphocytes; ELISPOT; ICCS; IFN-gamma; rVV
ID CYTOTOXIC T-LYMPHOCYTES; VIRUS; CELLS; INDIVIDUALS; ASSOCIATION;
   FREQUENCY; MALARIA; VIREMIA; ASSAY; LOAD
AB An efficient and quantitative tool for rapid assessment of human immunodeficiency virus (HIV)-induced cellular immune responses is important for resource-limited settings, such as in sub-Saharan Africa. Modifications are required to previously reported methods for evaluating ex-vivo antigen-specific cellular responses based on direct recombinant vaccinia virus (rVV) stimulation of peripheral blood mononuclear cells (PBMCs) by enzyme linked immunosorbent assay (ELISPOT) and by flow cytometry intracellular cytokine assay (ICA). We made such modifications in order to detect specific responses and compared quantitative cellular immune responses in HIV-1 and HIV-2 infected Gambians. The sensitivity of the rVV-based ELISPOT assay was on average 1.25 interferon (IFN)-gamma spot forming cells (SFC) per 50 000 PBMCs specific for either infection, and 5 IFN-gamma-secreting CD8+ T cells/50 000 in the ICA. The level of IFN-gamma SFC detected by ELISPOT and by ICA were correlated (P < 0.02). ICA detected pol-specific responses in 88% and 67% of HIV-1 and HIV-2 subjects, respectively, and gag-specific responses in more than 80% of both infections. Lower proportions of responders were obtained with ELISPOT, for which pol responses were present in 60% of HIV-1 and 46% of HIV-2 infected patients, and gag responses in 55% and 69%, respectively. The assays did not show any significant difference in cellular immune responses between HIV-1 and HIV-2 infected subjects with CD4% >= 20%. These outcomes are comparable with results obtained using standard techniques and thus this method is a suitable, rapid and less expensive assessment of cellular immunity.
C1 MRC Labs, Banjul, Gambia.
RP Jaye, A (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM ajaye@mrc.gm
CR Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Berry N, 1998, J Hum Virol, V1, P457
   BORROW P, 1994, J VIROL, V68, P6103
   Boyum A., 1968, SCAND J CLIN LAB INV, V21, P97
   CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249
   Duvall MG, 2006, J IMMUNOL, V176, P6973
   GRABSTEIN K, 1980, SELECTED METHODS CEL, P124
   HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0
   Jaffar S, 1997, J ACQ IMMUN DEF SYND, V16, P327
   Jaye A, 2004, J INFECT DIS, V189, P498, DOI 10.1086/381185
   KOUP RA, 1994, J VIROL, V68, P4650
   Lalvani A, 1998, CLIN SCI, V95, P531
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Larsson M, 1999, AIDS, V13, P767, DOI 10.1097/00002030-199905070-00005
   Marlink R, 1996, AIDS, V10, P689, DOI 10.1097/00002030-199606001-00002
   McCutcheon M, 1997, J IMMUNOL METHODS, V210, P149, DOI 10.1016/S0022-1759(97)00182-8
   Moretto WJ, 2000, AIDS, V14, P2625, DOI 10.1097/00002030-200011100-00034
   Nuvor SV, 2006, J VIROL, V80, P2529, DOI 10.1128/JVI.80.5.2529-2538.2006
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   Speller SA, 2002, J IMMUNOL METHODS, V262, P167, DOI 10.1016/S0022-1759(02)00025-X
   Tan LC, 1999, J IMMUNOL, V162, P1827
   van der Loeff MFS, 1999, AIDS, V13, pS69
   WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015
   Woodberry T, 2003, J IMMUNOL, V170, P2599
   Zheng NN, 2004, J VIROL, V78, P13934, DOI 10.1128/JVI.78.24.13934-13942.2004
NR 25
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0009-9104
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD DEC
PY 2006
VL 146
IS 3
BP 471
EP 478
DI 10.1111/j.1365-2249.2006.03238.x
PG 8
WC Immunology
SC Immunology
GA 103VD
UT WOS:000241914000013
PM 17100767
OA No
DA 2017-08-15
ER

PT J
AU Crozier, SR
   Robinson, SM
   Borland, SE
   Inskip, H
AF Crozier, S. R.
   Robinson, S. M.
   Borland, S. E.
   Inskip, H. M.
CA SWS Study Grp
TI Dietary patterns in the Southampton Women's Survey
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE dietary patterns; principal component analysis; cluster analysis
ID FOOD-FREQUENCY QUESTIONNAIRE; CORONARY-HEART-DISEASE; EATING PATTERNS;
   BRITISH ADULTS; NUTRITIONAL EPIDEMIOLOGY; PRINCIPAL COMPONENTS;
   METABOLIC SYNDROME; CLUSTER-ANALYSIS; RANDOM SAMPLE; CANCER
AB Objective: Dietary pattern analysis is receiving increasing attention as a means of summarizing the multidimensional nature of dietary data. This research aims to compare principal component analysis (PCA) and cluster analysis using dietary data collected from young women in the UK.
   Design: Diet was assessed using a 100-item interviewer-administered food frequency questionnaire. PCA and cluster analysis were used to examine dietary patterns.
   Setting: Southampton, UK.
   Subjects: A total of 6125 non-pregnant women aged 20-34 years.
   Results: PCA identified two important patterns: a 'prudent' diet and a 'high-energy' diet. Cluster analysis defined two clusters, a 'more healthy' and a 'less healthy' cluster. There was a strong association between the prudent diet score and the two clusters, such that the mean prudent diet score in the less healthy cluster was -0.73 standard deviations and in the more healthy cluster was +0.83 standard deviations; the difference in the high-energy diet score between the two clusters was considerably smaller.
   Conclusions: Both approaches revealed a similar dietary pattern. The continuous nature of the outcome of PCA was considered to be advantageous compared with the dichotomy identified using cluster analysis. Sponsorship: The study was funded by the Dunhill Medical Trust, the University of Southampton and the Medical Research Council.
C1 Univ Southampton, Gen Hosp, MRC Epidemiol Resource Ctr, Southampton, Hants, England.
RP Crozier, SR (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM scrozier@mrc.gm
OI Crozier, Sarah/0000-0002-9524-1127; Robinson, Sian/0000-0003-1766-7269;
   Inskip, Hazel/0000-0001-8897-1749
FU Medical Research Council [MC_U147574227, MC_U147585827, MC_UP_A620_1014,
   U.1475.00.004.00002.01(74227)]
CR Armitage P., 2002, STAT METHODS MED RES
   Bamia C, 2005, BRIT J NUTR, V94, P100, DOI 10.1079/BJN20051456
   Beaudry M, 1998, CAN J PUBLIC HEALTH, V89, P347
   BYERS T, 2004, AM J EPIDEMIOL, V154, P1087
   Chan W, 1995, MEAT POULTRY GAME S
   Chan W, 1994, MISCELLANEOUS FOODS
   CHAN W, 1996, MEAT PRODUCTS DISHEE
   Chen HL, 2002, AM J CLIN NUTR, V75, P137
   Costacou T, 2003, EUR J CLIN NUTR, V57, P1378, DOI 10.1038/sj.ejcn.1601699
   Davies J, 1991, NUTR CONTENT FOOD PO
   *DEP HLTH, 1998, COMM MED ASP FOOD PO
   Department of Health, 1994, COMM MED ASP FOOD PO
   Fung T, 2003, ARCH INTERN MED, V163, P309, DOI 10.1001/archinte.163.3.309
   Fung TT, 2001, ARCH INTERN MED, V161, P1857, DOI 10.1001/archinte.161.15.1857
   Greenwood DC, 2000, EUR J CLIN NUTR, V54, P314, DOI 10.1038/sj.ejcn.1600941
   Holland B, 1991, MCCANCE WIDDOWSONS C
   Holland B, 1993, FISH FISH PRODUCTS 3
   Holland B, 1989, MILK PRODUCTS EGGS
   Holland B, 1992, FRUIT NUTS 1 SUPPLEM
   Holland B., 1992, VEGETABLE DISHES 2 S
   Holland B., 1991, VEGETABLES HERBS SPI
   Holland B, 1988, CEREALS CEREAL PRODU
   Hu FB, 2000, AM J CLIN NUTR, V72, P912
   Hu FB, 1999, AM J CLIN NUTR, V69, P243
   Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002
   Inskip HM, 2006, INT J EPIDEMIOL, V35, P42, DOI 10.1093/ije/dyi202
   Joliffe I T, 1992, Stat Methods Med Res, V1, P69, DOI 10.1177/096228029200100105
   Kant AK, 2004, J AM DIET ASSOC, V104, P615, DOI 10.1016/j.jada.2004.01.010
   Kant Ashima K, 2004, J Nutr, V134, P1793
   Margetts BM, 1998, PUBLIC HEALTH NUTR, V1, P193
   McCann SE, 2001, PUBLIC HEALTH NUTR, V4, P989, DOI 10.1079/PHN2001168
   Michels KB, 2005, NUTR RES REV, V18, P241, DOI 10.1079/NRR2005107
   MILLIGAN GW, 1987, APPL PSYCH MEAS, V11, P329, DOI 10.1177/014662168701100401
   Ministry of Agriculture, 1993, FOOD PORT SIZ
   Newby PK, 2004, NUTR REV, V62, P177, DOI [10.1301/rn.2004.may.177-203, 10.1301/nr.2004.may.177-203]
   Newby PK, 2004, AM J CLIN NUTR, V80, P759
   Osler M, 2001, BRIT J NUTR, V85, P219, DOI 10.1079/BJN2000240
   Pryer JA, 2001, PUBLIC HEALTH NUTR, V4, P787, DOI 10.1079/PHN200098
   Pryer JA, 2001, J EPIDEMIOL COMMUN H, V55, P29, DOI 10.1136/jech.55.1.29
   Robinson S, 1996, EUR J CLIN NUTR, V50, P302
   Robinson SM, 2004, EUR J CLIN NUTR, V58, P1174, DOI 10.1038/sj.ejcn.1601946
   Slattery ML, 1998, AM J EPIDEMIOL, V148, P4
   Stata Corporation, 2003, STAT STAT SOFTW REL
   Tsai YY, 2003, LUNG CANCER-J IASLC, V41, P269, DOI 10.1016/S0169-5002(03)00238-1
   Tucker KL, 2002, AM J CLIN NUTR, V76, P245
   van Dam RM, 2002, ANN INTERN MED, V136, P201
   Whichelow MJ, 1996, BRIT J NUTR, V76, P17, DOI 10.1079/BJN19960006
   Willett W., 1998, NUTR EPIDEMIOLOGY
   Williams DEM, 2000, BRIT J NUTR, V83, P257, DOI 10.1017/S0007114500000337
   Wirfalt E, 2001, AM J EPIDEMIOL, V154, P1150, DOI 10.1093/aje/154.12.1150
   WISHART D, 2001, CLUSTANGRAPHICS, V5
NR 51
TC 64
Z9 66
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0954-3007
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD DEC
PY 2006
VL 60
IS 12
BP 1391
EP 1399
DI 10.1038/sj.ejcn.1602469
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 112GP
UT WOS:000242514100006
PM 16804555
OA No
DA 2017-08-15
ER

PT J
AU Rowland-Jones, S
AF Rowland-Jones, Sarah
TI Protective immunity against HIV infection: lessons from HIV-2 infection
SO FUTURE MICROBIOLOGY
LA English
DT Review
DE cytopathicity; HIV-1; HIV-2; neutralizing antibody; protective immunity;
   replicative fitness; T-cell response; vaccine
ID IMMUNODEFICIENCY-VIRUS TYPE-2; CYTOTOXIC T-CELLS; GUINEA-BISSAU;
   WEST-AFRICA; NATURAL PROTECTION; HIV-2-INFECTED INDIVIDUALS; HUMAN
   RETROVIRUS; PLASMA VIREMIA; VIRAL LOAD; RURAL AREA
AB Despite two decades of intensive research, the correlates of protective immunity to HIV-1 infection remain elusive. Much less attention has been paid to the related human virus strain, HIV-2, which can cause AIDS, but does not usually do so in the majority of infected people. What can be learned from HIV-2 infection about how the human host can peacefully coexist with a pathogenic retrovirus?
C1 MRC, Sarah Rowland Jones, Fajara, Gambia.
RP Rowland-Jones, S (reprint author), MRC, Sarah Rowland Jones, POB 273, Fajara, Gambia.
EM srowland-jones@mrc.gm
CR Aaby P, 1996, AIDS, V10, P1585
   Alatrakchi N, 2006, AIDS, V20, P29, DOI 10.1097/01.aids.0000198077.30421.bf
   Andersson S, 1997, AIDS, V11, P1815, DOI 10.1097/00002030-199715000-00005
   Ariyoshi K, 1996, J INFECT DIS, V173, P245
   Ariyoshi K, 1998, J Hum Virol, V1, P193
   ARJEN KK, 2005, J VIROL, V79, P8979
   BARIN F, 1985, LANCET, V2, P1387
   Barroso H, 2004, AIDS RES HUM RETROV, V20, P1373, DOI 10.1089/aid.2004.20.1373
   Barroso Helena, 2005, Infection Genetics and Evolution, V5, P239, DOI 10.1016/j.meegid.2004.07.008
   Berry N, 1998, J Hum Virol, V1, P457
   Bertoletti A, 1998, J VIROL, V72, P2439
   BJORLING E, 1993, VIROLOGY, V193, P528, DOI 10.1006/viro.1993.1160
   Blaak H, 2005, J VIROL, V79, P1686, DOI 10.1128/JVI.79.3.1686-1700.2005
   Blaak H, 2004, JAIDS-J ACQ IMM DEF, V36, P777, DOI 10.1097/00126334-200407010-00003
   Blaak H, 2006, VIROLOGY, V353, P144, DOI 10.1016/j.virol.2006.05.029
   BRUNVEZINET F, 1987, LANCET, V1, P128
   CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903
   CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430
   CLAVEL F, 1986, NATURE, V324, P691, DOI 10.1038/324691a0
   Damond F, 2001, VIROLOGY, V280, P19, DOI 10.1006/viro.2000.0685
   DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917
   Duvall MG, 2006, J IMMUNOL, V176, P6973
   Easterbrook PJ, 1999, J INFECTION, V38, P71, DOI 10.1016/S0163-4453(99)90071-3
   GAO F, 1994, J VIROL, V68, P7433
   GOTCH F, 1993, J IMMUNOL, V151, P3361
   Gottlieb GS, 2006, AIDS, V20, P895, DOI 10.1097/01.aids.0000218554.59531.80
   Greenberg AE, 1996, SCIENCE, V272, P1959
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   Hanson A, 2005, AIDS RES HUM RETROV, V21, P791, DOI 10.1089/aid.2005.21.791
   HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0
   Jaffar S, 2005, AIDS RES HUM RETROV, V21, P560, DOI 10.1089/aid.2005.21.560
   Jaye A, 2004, J INFECT DIS, V189, P498, DOI 10.1086/381185
   Kanki PJ, 1996, SCIENCE, V272, P1959
   KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5
   KAUL R, 1999, THEORETICAL BIOL BIO
   Kokkotou EG, 2000, P NATL ACAD SCI USA, V97, P6797, DOI 10.1073/pnas.97.12.6797
   KONG LI, 1988, SCIENCE, V240, P1525, DOI 10.1126/science.3375832
   MABEY DCW, 1988, BRIT MED J, V296, P83
   MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856
   MARLINK RG, 1988, AIDS RES HUM RETROV, V4, P137, DOI 10.1089/aid.1988.4.137
   Matheron S, 2003, AIDS, V17, P2593, DOI 10.1097/01.aids.0000096907.73209.b9
   McMichael AJ, 1999, NAT MED, V5, P612, DOI 10.1038/9455
   Norrgren H, 1997, J ACQ IMMUN DEF SYND, V16, P31
   Norrgren H, 1999, AIDS, V13, P701, DOI 10.1097/00002030-199904160-00011
   Nuvor SV, 2006, J VIROL, V80, P2529, DOI 10.1128/JVI.80.5.2529-2538.2006
   O'Donovan D, 2000, AIDS, V14, P441, DOI 10.1097/00002030-200003100-00019
   Ota MOC, 2000, AIDS, V14, P435, DOI 10.1097/00002030-200003100-00018
   Popper SJ, 1999, J INFECT DIS, V180, P1116, DOI 10.1086/315010
   POULSEN AG, 1989, LANCET, V1, P827
   Poulsen AG, 2000, SCAND J INFECT DIS, V32, P169
   Poulsen AG, 1997, LANCET, V349, P911, DOI 10.1016/S0140-6736(96)04402-9
   REY F, 1986, LANCET, V2, P1391
   RICARD D, 1994, AIDS, V8, P977, DOI 10.1097/00002030-199407000-00016
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   Schramm B, 2000, J VIROL, V74, P9594, DOI 10.1128/JVI.74.20.9594-9600.2000
   SCHULZ TF, 1990, J VIROL, V64, P5177
   Sousa AE, 2002, J IMMUNOL, V169, P3400
   TEDDER RS, 1988, LANCET, V2, P927
   TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936
   van der Loeff MFS, 2001, AIDS, V15, P2303, DOI 10.1097/00002030-200111230-00012
   WEISS RA, 1988, AIDS, V2, P95, DOI 10.1097/00002030-198804000-00004
   Wiktor SZ, 1999, AIDS, V13, P695, DOI 10.1097/00002030-199904160-00010
   WILKINS A, 1993, AIDS, V7, P1119, DOI 10.1097/00002030-199308000-00015
   Xiang Z, 1997, AIDS RES HUM RETROV, V13, P501, DOI 10.1089/aid.1997.13.501
   ZAGURY JF, 1988, P NATL ACAD SCI USA, V85, P5941, DOI 10.1073/pnas.85.16.5941
   Zheng NN, 2004, J VIROL, V78, P13934, DOI 10.1128/JVI.78.24.13934-13942.2004
NR 66
TC 7
Z9 7
U1 0
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0913
J9 FUTURE MICROBIOL
JI Future Microbiol.
PD DEC
PY 2006
VL 1
IS 4
BP 427
EP 433
DI 10.2217/17460913.1.4.427
PG 7
WC Microbiology
SC Microbiology
GA 205LY
UT WOS:000249116600015
PM 17661633
OA No
DA 2017-08-15
ER

PT J
AU Wilson, JN
   Rockett, K
   Keating, B
   Jallow, M
   Pinder, M
   Sisay-Joof, F
   Newport, M
   Kwiatkowski, D
AF Wilson, J. N.
   Rockett, K.
   Keating, B.
   Jallow, M.
   Pinder, M.
   Sisay-Joof, F.
   Newport, M.
   Kwiatkowski, D.
TI A hallmark of balancing selection is present at the promoter region of
   interleukin 10
SO GENES AND IMMUNITY
LA English
DT Article
DE interleukin-10; balancing selection; population divergence; IL10
   homologue; BCRF1
ID RHEUMATOID-ARTHRITIS; STATISTICAL-METHOD; DNA POLYMORPHISM; IL-10;
   DISEASE; EXPLOITATION; EXPRESSION; HAPLOTYPES; EVOLUTION
AB As an anti-inflammatory mediator IL10 is beneficial in certain contexts and deleterious in others. As increased production of IL10 favours protection against inflammatory disease, whereas low production promotes elimination of foreign pathogens by the host, we investigated the possible influence of balancing selection at this locus. We began by resequencing 48 European and 48 African chromosomes across 2.2 kb of the IL10 promoter region, and compared this with four neighbouring gene regions: MK2, IL19, IL20 and IL24. Analysis of nucleotide diversity showed a positive Tajima's D-test for IL10 in Europeans, of borderline statistical significance (1.89, P = 0.05). Analysis of F-st values showed significant population divergence at MK2, IL19, IL20 and IL24 (P < 0.01) but not at IL10. Taken together, these findings are consistent with the hypothesis that balancing selection has played a role in the evolution of polymorphisms in the IL10 promoter region.
C1 Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.
   MRC Labs, Fajara, Gambia.
RP Wilson, JN (reprint author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.
EM jwilson@well.ox.ac.uk
OI Kwiatkowski, Dominic/0000-0002-5023-0176
FU Medical Research Council [G0200454, G19/9]
CR Bamshad M, 2003, NAT REV GENET, V4, P99, DOI 10.1038/nrg999
   Bamshad MJ, 2002, P NATL ACAD SCI USA, V99, P10539, DOI 10.1073/pnas.162046399
   Crawley E, 1999, ARTHRITIS RHEUM-US, V42, P1101, DOI 10.1002/1529-0131(199906)42:6<1101::AID-ANR6>3.0.CO;2-Y
   Dawson E, 2002, NATURE, V418, P544, DOI 10.1038/nature00864
   Eskdale J, 1998, LANCET, V352, P1282, DOI 10.1016/S0140-6736(05)70489-X
   Eskdale J, 1998, P NATL ACAD SCI USA, V95, P9465, DOI 10.1073/pnas.95.16.9465
   Fowler EV, 2005, J MED GENET, V42, P523, DOI 10.1136/jmg.2004.027425
   Harpending H, 2000, ANNU REV GENOM HUM G, V1, P361, DOI 10.1146/annurev.genom.1.1.361
   Hartl D. L., 1997, PRINCIPLES POPULATIO
   HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142
   HUDSON RR, 1992, GENETICS, V132, P583
   Kotenko SV, 2000, P NATL ACAD SCI USA, V97, P1695, DOI 10.1073/pnas.97.4.1695
   Lalani AS, 1999, CYTOKINE GROWTH F R, V10, P219, DOI 10.1016/S1359-6101(99)00018-0
   Lin M, 2003, NEW ENGL J MED, V349, P2201, DOI 10.1056/NEJMoa022060
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   OZORNEK MH, 1995, J ASSIST REPROD GEN, V12, P590, DOI 10.1007/BF02212580
   Redpath S, 1999, J IMMUNOL, V162, P6701
   Redpath S, 2001, TRENDS MICROBIOL, V9, P86, DOI 10.1016/S0966-842X(00)01919-3
   SIMONSEN KL, 1995, GENETICS, V141, P413
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Stone JR, 2001, MOL BIOL EVOL, V18, P1764
   TAJIMA F, 1989, GENETICS, V123, P585
   Tishkoff SA, 2002, NAT REV GENET, V3, P611, DOI 10.1038/nrg865
   Wall E M, 1998, Int Rev Immunol, V17, P121, DOI 10.3109/08830189809084490
   WATIER H, 1993, LANCET, V341, P612, DOI 10.1016/0140-6736(93)90364-M
   Westendorp RGJ, 2001, NAT MED, V7, P873, DOI 10.1038/90868
   Wu MY, 2001, AM J REPROD IMMUNOL, V46, P386, DOI 10.1034/j.1600-0897.2001.d01-29.x
NR 27
TC 28
Z9 29
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-4879
J9 GENES IMMUN
JI Genes Immun.
PD DEC
PY 2006
VL 7
IS 8
BP 680
EP 683
DI 10.1038/sj.gene.6364336
PG 4
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA 113SR
UT WOS:000242618100008
PM 16943796
OA No
DA 2017-08-15
ER

PT J
AU Herring, AJ
   Ballard, RC
   Pope, V
   Adegbola, RA
   Changalucha, J
   Fitzgerald, DW
   Hook, EW
   Kubanova, A
   Mananwatte, S
   Pape, JW
   Sturm, AW
   West, B
   Yin, YP
   Peeling, RW
AF Herring, A. J.
   Ballard, R. C.
   Pope, V.
   Adegbola, R. A.
   Changalucha, J.
   Fitzgerald, D. W.
   Hook, E. W., III
   Kubanova, A.
   Mananwatte, S.
   Pape, J. W.
   Sturm, A. W.
   West, B.
   Yin, Y. P.
   Peeling, R. W.
TI A multi-centre evaluation of nine rapid, point-of-care syphilis tests
   using archived sera
SO SEXUALLY TRANSMITTED INFECTIONS
LA English
DT Article
ID LATEX AGGLUTINATION-TEST; CONGENITAL-SYPHILIS; PLASMA REAGIN;
   PERFORMANCE; DIAGNOSIS
AB Objectives: To evaluate nine rapid syphilis tests at eight geographically diverse laboratory sites for their performance and operational characteristics.
   Methods: Tests were compared "head to head'' using locally assembled panels of 100 archived ( 50 positive and 50 negative) sera at each site using as reference standards the Treponema pallidum haemagglutination or the T pallidum particle agglutination test. In addition inter-site variation, result stability, test reproducibility and test operational characteristics were assessed.
   Results: All nine tests gave good performance relative to the reference standard with sensitivities ranging from 84.5-97.7% and specificities from 84.5-98%. Result stability was variable if result reading was delayed past the recommended period. All the tests were found to be easy to use, especially the lateral flow tests.
   Conclusions: All the tests evaluated have acceptable performance characteristics and could make an impact on the control of syphilis. Tests that can use whole blood and do not require refrigeration were selected for further evaluation in field settings.
C1 WHO, Sexually Transmitted Dis Diagnost Initiat, TDR, PRD, CH-1211 Geneva 27, Switzerland.
   Hlth Protect Agcy Lab, Sexually Transmitted Bacteria Reference Lab, Bristol, Avon, England.
   Ctr Dis Control & Prevent, Div AIDS STD & TB Lab Res, Atlanta, GA USA.
   MRC Labs, Fajara, Gambia.
   Natl Inst Med Res, Mwanza, Tanzania.
   Les Ctr GHESKIO, Grp Haitien Etud Sarcome Kaposi & Infect Opportun, Port Au Prince, Haiti.
   Univ Alabama, Tuscaloosa, AL 35487 USA.
   Cent Inst Skin & Venereal Dis, Moscow, Russia.
   Natl STD AIDS Control Programme, Colombo, Sri Lanka.
   Univ KwaZulu Natal, ZA-4001 Durban, South Africa.
   Natl Ctr STD, Nanjing, Peoples R China.
RP Peeling, RW (reprint author), WHO, Sexually Transmitted Dis Diagnost Initiat, TDR, PRD, 20,Ave Appia, CH-1211 Geneva 27, Switzerland.
EM peelingr@who.int
CR Conner N, 2000, J MED SCREEN, V7, P7, DOI 10.1136/jms.7.1.7
   Diaz T, 2004, CLIN DIAGN LAB IMMUN, V11, P98, DOI 10.1128/CDLI.11.1.98-101.2004
   Fears MB, 2001, CLIN DIAGN LAB IMMUN, V8, P841, DOI 10.1128/CDLI.8.4.841-842.2001
   FONN S, 1996, S AFR MED J, V1, P67
   Goel N, 2005, Indian J Med Microbiol, V23, P142
   Golden MR, 2003, JAMA-J AM MED ASSOC, V290, P1510, DOI 10.1001/jama.290.11.1510
   Montoya PJ, 2006, B WORLD HEALTH ORGAN, V84, P97, DOI 10.2471/BLT.04.018663
   Peeling RW, 2004, B WORLD HEALTH ORGAN, V82, P439
   Sato Neuza Satomi, 2003, Revista do Instituto de Medicina Tropical de Sao Paulo, V45, P319, DOI 10.1590/S0036-46652003000600004
   Schmid G, 2004, B WORLD HEALTH ORGAN, V82, P402
   Siedner M, 2004, SEX TRANSM DIS, V31, P557, DOI 10.1097/01.olq.0000137903.48413.5e
   Southwick KL, 2001, B WORLD HEALTH ORGAN, V79, P33
   Tichonova L, 1997, LANCET, V350, P210, DOI 10.1016/S0140-6736(97)01382-2
   West B, 2002, SEX TRANSM INFECT, V78, P282, DOI 10.1136/sti.78.4.282
   *WHO, WHOHIVAIDS2001
   *WHO TDR, 2003, DIAGN EV SER
   Young H, 1998, INT J STD AIDS, V9, P196, DOI 10.1258/0956462981922034
   Zarakolu P, 2002, J CLIN MICROBIOL, V40, P3064, DOI 10.1128/JCM.40.8.3064-3065.2002
NR 18
TC 13
Z9 15
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1368-4973
J9 SEX TRANSM INFECT
JI Sex. Transm. Infect.
PD DEC
PY 2006
VL 82
SU 5
BP V7
EP V12
DI 10.1136/sti.2006.022707
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 140EK
UT WOS:000244486800002
OA No
DA 2017-08-15
ER

PT J
AU Howie, SRC
   Adegbola, RA
AF Howie, Stephen R. C.
   Adegbola, Richard A.
TI Pneumonia and child mortality
SO LANCET
LA English
DT Letter
C1 MRC Labs, Banjul, Gambia.
RP Howie, SRC (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM showie@mrc.gm
CR Wardlaw T, 2006, LANCET, V368, P1048, DOI 10.1016/S0140-6736(06)69334-3
NR 1
TC 3
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD NOV 11
PY 2006
VL 368
IS 9548
BP 1646
EP 1646
DI 10.1016/S0140-6736(06)69687-6
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 106KI
UT WOS:000242099000019
PM 17098074
OA No
DA 2017-08-15
ER

PT J
AU Weedall, GD
   Preston, BM
   Thomas, AW
   Sutherland, CJ
   Conway, DJ
AF Weedall, Gareth D.
   Preston, Benjamin M.
   Thomas, Alan W.
   Sutherland, Colin J.
   Conway, David J.
TI Differential evidence of natural selection on two leading sporozoite
   stage malaria vaccine candidate antigens
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 London Sch Hyg & Trop Med, London WC1, England.
   Biomed Primate Res Ctr, Rijswijk, Netherlands.
   MRC Labs, Banjul, Gambia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2006
VL 75
IS 5
SU S
MA 219
BP 65
EP 65
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 109XW
UT WOS:000242343900220
OA No
DA 2017-08-15
ER

PT J
AU Caputo, B
   Nwakanma, D
   Jawara, M
   Dia, I
   Konate, L
   Coluzzi, M
   Petrarca, V
   Conway, DJ
   della Torre, A
AF Caputo, Beniamino
   Nwakanma, Davis
   Jawara, Musa
   Dia, Ibrahima
   Konate, Lassana
   Coluzzi, Mario
   Petrarca, Vincenzo
   Conway, David J.
   della Torre, Alessandra
TI Populations of the Anopheles gambiae M-form can have typical
   SAVANNA-form inversion karyotypes at the Northwestern limits of its
   geographical range
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 Univ Roma La Sapienza, Dept Publ Hlth Sci, Parasitol Unit, Rome, Italy.
   MRC Labs, Banjul, Gambia.
   Inst Pasteur, Unit Insects & Infect Dis, Dakar, Senegal.
   Univ Dakar, Dakar, Senegal.
   Univ Roma La Sapienza, Dept Genet & Mol Biol, Rome, Italy.
RI Caputo, Beniamino/I-2880-2015
OI Caputo, Beniamino/0000-0002-5650-8773
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2006
VL 75
IS 5
SU S
MA 231
BP 68
EP 68
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 109XW
UT WOS:000242343900232
OA No
DA 2017-08-15
ER

PT J
AU Dunyo, SK
   Milligan, P
   Edwards, T
AF Dunyo, Sam K.
   Milligan, Paul
   Edwards, Tansy
TI Gametocytaemia after drug treatment of asymptomatic Plasmodium
   falciparum
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 MRC Labs, Banjul, Gambia.
   London Sch Hyg & Trop Med, London WC1, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2006
VL 75
IS 5
SU S
MA 754
BP 218
EP 218
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 109XW
UT WOS:000242343901189
OA No
DA 2017-08-15
ER

PT J
AU Polley, SD
   Tetteh, KK
   Lloyd, JM
   Akpogheneta, OJ
   Greenwood, BM
   Bojang, KA
   Conway, DJ
AF Polley, Spencer D.
   Tetteh, Kevin K.
   Lloyd, Jennie M.
   Akpogheneta, Onome J.
   Greenwood, Brian M.
   Bojang, Kalifa A.
   Conway, David J.
TI Plasmodium falciparum merozoite surface protein 3 is a target of
   allele-specific immunity and alleles are maintained by natural selection
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 London Sch Hyg & Trop Med, London WC1, England.
   MRC Labs, Banjul, Gambia.
RI Polley, Spencer/F-7766-2013
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2006
VL 75
IS 5
SU S
MA 988
BP 284
EP 284
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 109XW
UT WOS:000242343901423
OA No
DA 2017-08-15
ER

PT J
AU Gower, EW
   Solomon, AW
   Burton, MJ
   Aguirre, A
   Munoz, B
   Bailey, R
   Holland, M
   Makalo, P
   Massae, P
   Mkocha, H
   Mabey, DC
   West, SK
AF West Gower, Emily
   Solomon, Anthony W.
   Burton, Matthew J.
   Aguirre, Aura
   Munoz, Beatriz
   Bailey, Robin
   Holland, Martin
   Makalo, Pateh
   Massae, Patrick
   Mkocha, Harran
   Mabey, David C.
   West, Sheila K.
TI Chlamydial positivity of nasal discharge at baseline is associated with
   ocular chlamydial positivity 2 months following azithromycin treatment
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article; Proceedings Paper
CT 10th International Symposium on Human Chlamydial Infections
CY JUN   20, 2002
CL ANTALYA, TURKEY
ID TRACHOMA-HYPERENDEMIC AREA; MASS TREATMENT; CENTRAL TANZANIA; INFECTION;
   RISK; COMMUNITY; CHILDREN; KONGWA; LOAD
AB BACKGROUND. Trachoma is the leading infectious cause of blindness. Routes of transmission remain unclear. In this study, the relationship between Chlamydia trachomatis Amplicor-positive nasal discharge and Amplicor-positive ocular swabs was investigated (Amplicor; Roche, Indianapolis, IN).
   METHODS. A longitudinal study was conducted in Tanzania and The Gambia. Eyes were graded for active trachoma; ocular swabs were taken to test for C. trachomatis. Children with visible nasal discharge had swabs taken of this material. Participants were offered systemic antibiotics. Two months after treatment, participants were re-examined.
   RESULTS. Of the 1128 children participating, 188 (17%) had nasal discharge. Among 188 children with nasal discharge, 64 (34%) nasal swabs were PCR positive. There was a strong correlation between active disease/ocular chlamydial positivity and positive nasal discharge. Children with Amplicor-positive ocular swabs were 9.9 times more likely to have Amplicor-positive nasal discharge than were children without ocular positivity (95% CI: 4.34 - 22.53). Two months after treatment, 16% had an Amplicor-positive ocular swab. Children with positive nasal discharge at baseline were 5.2 times more likely to have an Amplicor-positive ocular swab at 2 months than were children without Amplicor-positive nasal discharge at baseline (95% CI: 1.54 - 17.23), after adjusting for baseline ocular positivity, gender, and study site.
   CONCLUSIONS. Nasal discharge may provide a source of reinfection with C. trachomatis, after antibiotic treatment for trachoma, either through transfer of secretions from nose to eye or from nasal secretions transferred to bed sheets or dirty clothes and back to the eye; alternatively, nasal discharge may be an indicator of severe persistent ocular chlamydial infection that is not cleared with a single dose of antibiotics.
C1 Johns Hopkins Sch Med, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21287 USA.
   London Sch Hyg & Trop Med, London WC1, England.
   MRC Labs, Fajara, Gambia.
   Kongwa Trachoma Project, Kongwa, Tanzania.
RP Gower, EW (reprint author), Johns Hopkins Sch Med, Dana Ctr Prevent Ophthalmol, 116 Wilmer Bldg,600 N Wolfe St, Baltimore, MD 21287 USA.
EM ewest@jhsph.edu
RI Gower, Emily/A-9688-2009
OI Mabey, David/0000-0002-0031-8276; Burton, Matthew/0000-0003-1872-9169;
   Solomon, Anthony/0000-0001-7101-6649
FU Medical Research Council [MC_U190081961]; Wellcome Trust [059134]
CR BAILEY R, 1991, T ROY SOC TROP MED H, V85, P824, DOI 10.1016/0035-9203(91)90470-J
   Burton MJ, 2005, LANCET, V365, P1321, DOI 10.1016/S0140-6736(05)61029-X
   Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107
   Dawson CR, 1981, GUIDE TRACHOMA CONTR
   Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2
   LYNCH M, 1994, T ROY SOC TROP MED H, V88, P513, DOI 10.1016/0035-9203(94)90141-4
   MALATY R, 1981, J INFECT DIS, V143, P853
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979
   Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8
   TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821
   THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477
   West ES, 2005, INVEST OPHTH VIS SCI, V46, P83, DOI 10.1167/iovs.04-0327
   WEST S, 1993, INVEST OPHTH VIS SCI, V34, P3194
   WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1
   WEST SK, 1991, ARCH OPHTHALMOL-CHIC, V109, P855
   West SK, 1996, AM J EPIDEMIOL, V143, P73
   WEST SK, 1991, J INFECT DIS, V163, P752
NR 18
TC 10
Z9 10
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2006
VL 47
IS 11
BP 4767
EP 4771
DI 10.1167/iovs.05-1599
PG 5
WC Ophthalmology
SC Ophthalmology
GA 098XS
UT WOS:000241557500018
PM 17065486
OA No
DA 2017-08-15
ER

PT J
AU Prentice, A
   Schoenmakers, I
   Laskey, MA
   de Bono, S
   Ginty, F
   Goldberg, GR
AF Prentice, Ann
   Schoenmakers, Inez
   Laskey, M. Ann
   de Bono, Stephanie
   Ginty, Fiona
   Goldberg, Gail R.
TI Nutrition and bone growth and development
SO PROCEEDINGS OF THE NUTRITION SOCIETY
LA English
DT Article; Proceedings Paper
CT Symposium on Nutrition and Health in Chidren and Adolescents
CY JUN 14-16, 2006
CL Univ Coll Cork, Cork, IRELAND
HO Univ Coll Cork
DE bone growth and development; bone health; nutritional factors; dietary
   and lifestyle recommendations; bone measurements in children
ID X-RAY ABSORPTIOMETRY; VITAMIN-D-DEFICIENCY; YOUNG HEARTS PROJECT;
   MINERAL DENSITY; CALCIUM SUPPLEMENTATION; BIRTH-WEIGHT; FOREARM
   FRACTURES; PHYSICAL-ACTIVITY; HEALTHY-CHILDREN; CHILDHOOD GROWTH
AB The growth and development of the human skeleton requires an adequate supply of many different nutritional factors. Classical nutrient deficiencies are associated with stunting (e.g. energy, protein, Zn), rickets (e.g. vitamin D) and other bone abnormalities (e.g. Cu, Zn, vitamin C). In recent years there has been interest in the role nutrition may play in bone growth at intakes above those required to prevent classical deficiencies, particularly in relation to optimising peak bone mass and minimising osteoporosis risk. There is evidence to suggest that peak bone mass and later fracture risk are influenced by the pattern of growth in childhood and by nutritional exposures in utero, in infancy and during childhood and adolescence. Of the individual nutrients, particular attention has been paid to Ca, vitamin D, protein and P. There has also been interest in several food groups, particularly dairy products, fruit and vegetables and foods contributing to acid-base balance. However, it is not possible at the present time to define dietary reference values using bone health as a criterion, and the question of what type of diet constitutes the best support for optimal bone growth and development remains open. Prudent recommendations (Department of Health, 1998; World Health Organization/Food and Agriculture Organization, 2003) are the same as those for adults, i.e. to consume a Ca intake close to the reference nutrient intake, optimise vitamin D status through adequate summer sunshine exposure (and diet supplementation where appropriate), be physically active, have a body weight in the healthy range, restrict salt intake and consume plenty of fruit and vegetables.
C1 MRC, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   MRC, Keneba, Gambia.
RP Prentice, A (reprint author), MRC, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
EM ann.prentice@mrc-hnr.cam.ac.uk
FU Medical Research Council [MC_U105960371, MC_U123261351,
   U.1059.00.017(60371), U.1233(61351)]
CR Allgrove J, 2004, ARCH DIS CHILD, V89, P699, DOI 10.1136/adc.2003.036780
   *AM SOC BONE MIN R, 2006, PRIM MET BON DIS DIS
   ARNAUD SB, 1976, PEDIATRICS, V57, P221
   Ashraf S, 2002, ARCH DIS CHILD, V87, P263, DOI 10.1136/adc.87.3.263-a
   BARZEL US, 1995, J BONE MINER RES, V10, P1431
   Bilezikian J.P., 2002, PRINCIPLES BONE BIOL, V1
   Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18
   Bonjour J-P, 2003, NUTR ASPECTS BONE HL, P111, DOI DOI 10.1039/9781847551559-00111
   Branca F, 2003, P NUTR SOC, V62, P877, DOI 10.1079/PNS2003309
   BROOKE OG, 1981, BRIT MED J, V283, P1024
   BROOKE OG, 1980, BRIT MED J, V280, P751
   Buclin T, 2001, OSTEOPOROSIS INT, V12, P493, DOI 10.1007/s001980170095
   Bugel S, 2003, P NUTR SOC, V62, P839, DOI 10.1079/PNS2003305
   Cadogan J, 1997, BRIT MED J, V315, P1255
   Calvo M. S., 2003, NUTR ASPECTS BONE HL, P229, DOI 10.1039/9781847551559-00229
   Cashman KD, 2005, NUTR REV, V63, P284, DOI 10.1301/nr.2005.aug.284-289
   Cole TJ, 2004, J NUTR, V134, P201
   Cooper C, 2006, OSTEOPOROSIS INT, V17, P337, DOI 10.1007/s00198-005-2039-5
   Cooper C, 1997, ANN RHEUM DIS, V56, P17, DOI 10.1136/ard.56.1.17
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   COOPER C, 1995, J BONE MINER RES, V10, P940
   Cooper C, 2001, OSTEOPOROSIS INT, V12, P623, DOI 10.1007/s001980170061
   DAGNELIE PC, 1990, AM J CLIN NUTR, V51, P202
   Davies JH, 2005, ARCH DIS CHILD, V90, P373, DOI 10.1136/adc.2004.053553
   de Onis M, 2003, INT J EPIDEMIOL, V32, P518, DOI 10.1093/ije/dyg099
   Dennison EM, 2005, PEDIATR RES, V57, P582, DOI 10.1203/01.PDR.0000155754.67821.CA
   Department of Health, 1998, 49 DEP HLTH
   Dibba B, 2000, AM J CLIN NUTR, V71, P544
   Ferrari SL, 2006, J BONE MINER RES, V21, P501, DOI 10.1359/JBMR.051215
   Fewtrell MS, 2003, ARCH DIS CHILD, V88, P795, DOI 10.1136/adc.88.9.795
   Fitzpatrick L, 2003, J BONE MINER RES, V18, P1570, DOI 10.1359/jbmr.2003.18.9.1570
   Fraser DR, 2004, J STEROID BIOCHEM, V89-90, P491, DOI 10.1016/j.jsbmb.2004.03.057
   Fulkerson JA, 2004, OSTEOPOROSIS INT, V15, P929, DOI 10.1007/s00198-004-1685-3
   Ganpule A, 2006, J CLIN ENDOCR METAB, V91, P2994, DOI 10.1210/jc.2005-2431
   Gibney MJ, 2002, INTRO HUMAN NUTR
   Ginty F, 2005, P NUTR SOC, V64, p80A
   Ginty F, 2003, P NUTR SOC, V62, P867, DOI 10.1079/PNS2003307
   Ginty F, 2004, NUTR ASPECTS OSTEOPO, P45, DOI 10.1016/B978-012141704-8/50043-X
   GLORIEUX F, 2003, PEDIATRIC BONE BIOL
   Gluckman PD, 2003, J NUTR, V133, p1741S
   Goulding A, 2000, INT J OBESITY, V24, P627, DOI 10.1038/sj.ijo.0801207
   Goulding A, 2005, J PEDIATR-US, V146, P286, DOI 10.1016/j.jpeds.2004.09.029
   Goulding A, 2004, J AM DIET ASSOC, V104, P250, DOI 10.1016/j.jada.2003.11.008
   Goulding A, 2002, OSTEOPOROSIS INT, V13, P835, DOI 10.1007/s001980200116
   Goulding A, 2001, J PEDIATR-US, V139, P509, DOI 10.1067/mpd.2001.116297
   GREGORY J, NAT DIET NUTR SURVEY, V1
   Gregory JR, 1995, NATL DIET NUTR SURVE
   Heaney RP, 2001, AM J CLIN NUTR, V74, P343
   Heaney RP, 2001, NUTR REV, V59, P327
   Heaney RP, 2000, OSTEOPOROSIS INT, V11, P985, DOI 10.1007/s001980070020
   Heaney RP, 2004, NUTR ASPECTS OSTEOPO, P61, DOI 10.1016/B978-012141704-8/50044-1
   Hoppe C, 2004, EUR J CLIN NUTR, V58, P1211, DOI 10.1038/sj.ejcn.1601948
   HOPPE C, 2004, AM J CLIN NUTR, P447
   Institute of Medicine Food and Nutrition Board, 1997, DIET REF INT CALC PH
   *IR U NUTR ALL, 2006, NAT CHILDR FOOD SUR
   Jarjou LM, 2006, AM J CLIN NUTR, V83, P657
   Javaid MK, 2006, LANCET, V367, P36, DOI 10.1016/S0140-6736(06)67922-1
   Jones G, 2000, CALCIFIED TISSUE INT, V67, P304, DOI 10.1007/s002230001148
   Jones G, 2000, EUR J CLIN NUTR, V54, P749, DOI 10.1038/sj.ejcn.1601082
   Jones IE, 2004, AM J EPIDEMIOL, V159, P343, DOI 10.1093/aje/kwh052
   JUUL A, 1994, J CLIN ENDOCR METAB, V78, P744, DOI 10.1210/jc.78.3.744
   Kalkwarf HJ, 2004, AM J CLIN NUTR, V80, P1075
   Kapoor A, 2006, J PHYSIOL-LONDON, V572, P31, DOI 10.1113/jphysiol.2006.105254
   Khosla S, 2003, JAMA-J AM MED ASSOC, V290, P1479, DOI 10.1001/jama.290.11.1479
   Klein GL, 2005, J BONE MINER RES, V20, P2075, DOI 10.1359/JBMR.050901
   Koo WWK, 1999, OBSTET GYNECOL, V94, P577, DOI 10.1016/S0029-7844(99)00371-3
   Lambert J, 2004, BRIT J NUTR, V92, pS147, DOI 10.1079/BJN20041160
   Langley-Evans SC, 2006, P NUTR SOC, V65, P97, DOI 10.1079/PNS2005478
   Lanham-New SA, 2006, AM J CLIN NUTR, V83, P1254
   Lanou AJ, 2005, PEDIATRICS, V115, P736, DOI 10.1542/peds.2004-0548
   Laskey MA, 1999, BRIT J RADIOL, V72, P967
   Lawson M, 1999, BRIT MED J, V318, P28
   Leonard MB, 2004, BONE, V34, P1044, DOI 10.1016/j.bone.2003.12.003
   Levin M, 2003, SYST PRACT ACT RES, V16, P3, DOI 10.1023/A:1021976427619
   Ma D, 2004, CALCIFIED TISSUE INT, V75, P286, DOI 10.1007/s00223-004-0274-y
   Manias K, 2006, BONE, V39, P652, DOI 10.1016/j.bone.2006.03.018
   Marcus R., 1996, OSTEOPOROSIS
   MASSEY LK, 2003, NUTR ASPECTS BONE HL, P213, DOI 10.1039/9781847551559-00213
   McGartland C, 2003, J BONE MINER RES, V18, P1563, DOI 10.1359/jbmr.2003.18.9.1563
   Molgaard C, 1997, ARCH DIS CHILD, V76, P9
   *NAT OST SOC, 2003, AB OST
   Neville CE, 2002, CALCIFIED TISSUE INT, V70, P89, DOI 10.1007/s00223-001-1023-0
   New SA, 2004, OSTEOPOROSIS INT, V15, P679, DOI 10.1007/s00198-004-1647-9
   New SA, 2003, P NUTR SOC, V62, P889, DOI 10.1079/PNS2003310
   New SA, 2004, AM J CLIN NUTR, V79, P131
   Petit M. A., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P213
   Pettifor J. M., 2003, PEDIAT BONE BIOL DIS, P541, DOI 10.1016/B978-012286551-0/50024-5
   PRENDERGAST P, 1994, J STEROID BIOCHEM, V48, P1, DOI 10.1016/0960-0760(94)90245-3
   Prentice A, 2005, J CLIN ENDOCR METAB, V90, P3153, DOI 10.1210/jc.2004-2114
   Prentice A, 2004, BRIT J NUTR, V92, pS83, DOI 10.1079/BJN20041159
   PRENTICE A, 1994, AM J CLIN NUTR, V60, P837
   Prentice A, 1997, P NUTR SOC, V56, P357, DOI 10.1079/PNS19970038
   PRENTICE A, 1995, BODY COMPOSITION TEC, P1, DOI 10.1017/CBO9780511525650.001
   PRENTICE A, 2006, P 6 INT S NUTR ASP O
   Prentice A., 2001, P NUTR SOC, V60, P1
   PRENTICE A, 2003, EUROPEAN J NUTR S1, V42
   Prentice A., 2004, PUBLIC HEALTH NUTR, V7, P237
   Prynne CJ, 2006, AM J CLIN NUTR, V83, P1420
   Prynne CJ, 2004, EUR J CLIN NUTR, V58, P1462, DOI 10.1038/sj.ejcn.1602006
   RALSTON SH, 2007, IN PRESS P NUTR SOC
   RAMAN L, 1978, AM J CLIN NUTR, V21, P466
   REMER T, 1995, J AM DIET ASSOC, V95, P791, DOI 10.1016/S0002-8223(95)00219-7
   Seeman E, 2000, J BONE MINER RES, V15, P2259, DOI 10.1359/jbmr.2000.15.11.2259
   Seeman E, 2002, LANCET, V359, P1841, DOI 10.1016/S0140-6736(02)08706-8
   Seeman E, 1998, J CLIN ENDOCR METAB, V83, P1414, DOI 10.1210/jc.83.5.1414
   Seeman E, 1997, OSTEOPOROSIS INT, V7, P10, DOI 10.1007/BF03194336
   Shaw NJ, 2002, ARCH DIS CHILD, V86, P147, DOI 10.1136/adc.86.3.147
   Shenoy SD, 2005, ARCH DIS CHILD, V90, P437, DOI 10.1136/adc.2004.065268
   Skaggs DL, 2001, J BONE MINER RES, V16, P1337, DOI 10.1359/jbmr.2001.16.7.1337
   Stear SJ, 2003, AM J CLIN NUTR, V77, P985
   Storey ML, 2004, J AM COLL NUTR, V23, P18
   Szulc P, 2000, OSTEOPOROSIS INT, V11, P281, DOI 10.1007/s001980070116
   Tanner JM, 1962, GROWTH ADOLESCENCE
   Tobias JH, 2005, OSTEOPOROSIS INT, V16, P1731, DOI 10.1007/s00198-005-1912-6
   Tobias JH, 2004, J BONE MINER RES, V19, P177, DOI 10.1359/JBMR.0301235
   UNDERWOOD P, 1987, SOC SCI MED, V24, P37, DOI 10.1016/0277-9536(87)90136-5
   Whiting SJ, 2001, NUTR RES, V21, P1107, DOI 10.1016/S0271-5317(01)00324-4
   World Health Organization, 2006, WHO GLOB DAT CHILD G
   World Health Organisation and Food and Agriculture Organization, 2003, DIET NUTR PREV CHRON
   Widdowson EM, 1964, MINER METABOL, P1
   Willett AM, 2005, P NUTR SOC, V64, P193, DOI 10.1079/PNS2005420
   WINZENBERG TM, 2006, COCHRANE DATABASE SY
   Zamora SA, 1999, J CLIN ENDOCR METAB, V84, P4541, DOI 10.1210/jc.84.12.4541
NR 123
TC 83
Z9 90
U1 1
U2 21
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 2RU CAMBRIDGE, ENGLAND
SN 0029-6651
J9 P NUTR SOC
JI Proc. Nutr. Soc.
PD NOV
PY 2006
VL 65
IS 4
BP 348
EP 360
DI 10.1079/PNS2006519
PG 13
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 132YZ
UT WOS:000243980100003
PM 17181901
OA No
DA 2017-08-15
ER

PT J
AU Sarge-Njie, R
   Van der Loeff, MS
   Ceesay, S
   Cubitt, D
   Sabally, S
   Corrah, T
   Whittle, H
AF Sarge-Njie, Ramu
   Van der Loeff, Maarten Schim
   Ceesay, Saihou
   Cubitt, David
   Sabally, Saihou
   Corrah, Tumani
   Whittle, Hilton
TI Evaluation of the dried blood spot filter paper technology and five
   testing strategies of HIV-1 and HIV-2 infections in West Africa
SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; WHOLE-BLOOD; ANTIBODIES; PREVALENCE;
   SURVEILLANCE; ABIDJAN; SAMPLES; WOMEN; DISKS
AB Simple robust approaches are needed to monitor the prevalence and incidence of HIV in Africa. The aim of this study was to evaluate the use of dried blood spot (DBS) as an alternative to serum or plasma for sentinel surveillance. Paired DBS and blood samples were obtained from 200 patients attending a genito-urinary medicine clinic in West Africa. The gold standard of diagnosis was based on the combination of 3 enzyme-linked immunosorbent assays (ELISA) using serum. The presence of HIV antibodies in eluates of dried blood spots was detected by ELISA, Gelatin Particle Assay (GPA) and Pepti-Lav 1-2 in 5 different testing strategies. All 200 eluates were tested individually, and in addition pools of 5 eluates each were tested. The sensitivity of the testing strategies ranged from 95.0% (83.1-99.4%) to 100% and the specificity from 97.5% (93.7-99.3%) to 100%. Testing in pools of 5 did not affect sensitivity. Dried blood spots were easy to work with. Test kit and laboratory consumable costs varied between 492 pound and 1037 pound (unpooled strategies) and 163 pound and 421 pound (pooled). The monospecific ELISAs used in this study are no longer in production; currently available differentiating assays need to be tested. DBS are recommended for sentinel surveillance in Africa.
C1 MRC Labs, Fajara, Gambia.
   Natl AIDS Secretariat, Banjul, Gambia.
   Inst Child Hlth, London, England.
RP Van der Loeff, MS (reprint author), Univ Amsterdam, Acad Med Ctr, Ctr Poverty Related Communicable Dis, POB 22700, NL-1100 DE Amsterdam, Netherlands.
EM m.schim@iatec.com
CR BEEBE JL, 1990, J CLIN MICROBIOL, V28, P808
   BEHETS F, 1992, J CLIN MICROBIOL, V30, P1179
   Berry N, 2002, AIDS RES HUM RETROV, V18, P1167, DOI 10.1089/08892220260387904
   Boillot F, 1997, INT J TUBERC LUNG D, V1, P493
   CAHOONYOUNG B, 1989, J CLIN MICROBIOL, V27, P1893
   EVENGARD B, 1988, BRIT MED J, V297, P1178
   FARZADEGAN H, 1987, J INFECT DIS, V155, P1073
   FARZADEGAN H, 1978, LANCET, V1, P362
   HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901
   Lewensohn-Fuchs Ilona, 2003, J Clin Virol, V26, P39
   LINDHARDT BO, 1987, J VIROL METHODS, V18, P73, DOI 10.1016/0166-0934(87)90112-1
   Marlink R, 1996, AIDS, V10, P689, DOI 10.1097/00002030-199606001-00002
   MARTIN LS, 1985, J INFECT DIS, V152, P400
   Nkengasong JN, 1999, AIDS, V13, P109, DOI 10.1097/00002030-199901140-00015
   Nkengasong JN, 1998, J CLIN MICROBIOL, V36, P123
   PAPPAIOANOU M, 1993, AIDS, V7, P483, DOI 10.1097/00002030-199304000-00005
   PARKER SP, 1999, J CLIN PATHOL S, V2, P1
   PECKHAM CS, 1990, LANCET, V335, P516, DOI 10.1016/0140-6736(90)90746-R
   SHIBATA M, 1994, J VIROL METHODS, V46, P279, DOI 10.1016/0166-0934(94)90111-2
   Solomon SS, 2002, INT J STD AIDS, V13, P25, DOI 10.1258/0956462021924578
   Tamara T, 1996, LANCET, V348, P893, DOI 10.1016/S0140-6736(05)64765-4
   van der Loeff MFS, 2000, AIDS, V14, P1276
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   VANDENAKKER R, 1990, AIDS, V4, P90, DOI 10.1097/00002030-199001000-00016
   VEJTORP M, 1981, ACTA PATH MICRO IM B, V89, P369
   VERSTRAETEN T, 1998, TROP MED INT HEALTH, V9, P747
   WASSILAK SGF, 1984, PEDIATR INFECT DIS J, V3, P117, DOI 10.1097/00006454-198403000-00007
   World Health Organization, 2004, 14 WHO
NR 28
TC 13
Z9 13
U1 0
U2 1
PU TAYLOR & FRANCIS AS
PI OSLO
PA PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY
SN 0036-5548
J9 SCAND J INFECT DIS
JI Scand. J. Infect. Dis.
PD NOV
PY 2006
VL 38
IS 11-12
BP 1050
EP 1056
DI 10.1080/00365540600801645
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 111SK
UT WOS:000242474600016
PM 17148076
OA No
DA 2017-08-15
ER

PT J
AU Imoukhuede, EB
   Berthoud, T
   Milligan, P
   Bojang, K
   Ismaili, J
   Keating, S
   Nwakanma, D
   Keita, S
   Njie, F
   Sowe, M
   Todryk, S
   Laidlaw, SM
   Skinner, MA
   Lang, T
   Gilbert, S
   Greenwood, BM
   Hill, AVS
AF Imoukhuede, E. B.
   Berthoud, T.
   Milligan, P.
   Bojang, K.
   Ismaili, J.
   Keating, S.
   Nwakanma, D.
   Keita, S.
   Njie, F.
   Sowe, M.
   Todryk, S.
   Laidlaw, S. M.
   Skinner, M. A.
   Lang, T.
   Gilbert, S.
   Greenwood, B. M.
   Hill, A. V. S.
TI Safety and immunogenicity of the malaria candidate vaccines FP9CS and
   MVA CS in adult Gambian men
SO VACCINE
LA English
DT Article
DE malaria vaccines; prime-boost; immunogenicity
ID PLASMODIUM-FALCIPARUM MALARIA; RANDOMIZED CONTROLLED-TRIAL; PRIME-BOOST
   IMMUNIZATION; CYTOTOXIC T-LYMPHOCYTES; CIRCUMSPOROZOITE-PROTEIN; VIRUS
   ANKARA; PROTECTIVE EFFICACY; IMMUNE-RESPONSE; DNA; VACCINATION
AB We assessed the safety and immunogenicity of prime-boost vectors encoding the Plasmodiumfalciparunt circurnsporozoite (CS) protein expressed either in the attenuated fowl-pox virus (FP9) or modified vaccinia virus Ankara (MVA). Thirty-two adult Gambians in groups of four to eight received one, two or three doses of FP9 CS and/or MVA CS. No serious adverse event was observed following vaccination. The most immunogenic regimen was two doses of FP9 followed by a single dose of MVA 4 weeks later (an average of 1000 IFN-gamma spot forming units/million PBMCs). This level of effector T-cell responses appears higher than that seen in previously reported studies of CS-based candidate malaria vaccines. (c) 2006 Elsevier Ltd. All rights reserved.
C1 MRC Labs, Banjul, Gambia.
   Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford OX1 2JD, England.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
   Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England.
RP Imoukhuede, EB (reprint author), MRC Labs, Banjul, Gambia.
EM ebimoukhuede@hotmail.co.uk
RI HILL, Adrian/C-1306-2008; Skinner, Michael/B-7112-2012; Keating,
   Sheila/B-1652-2013; Milligan, Paul/D-8985-2017
OI Milligan, Paul/0000-0003-3430-3395; Imoukhuede, Egeruan
   Babatunde/0000-0001-6679-0904; Skinner, Michael/0000-0002-0050-4167;
   Gilbert, Sarah/0000-0002-6823-9750; Laidlaw, Stephen/0000-0002-7970-6174
FU Wellcome Trust
CR Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6
   Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Dunachie SJ, 2006, VACCINE, V24, P2850, DOI 10.1016/j.vaccine.2005.12.041
   Dunachie SJ, 2003, J EXP BIOL, V206, P3771, DOI 10.1242/jeb.00642
   GOOD MF, 1987, SCIENCE, V235, P1059, DOI 10.1126/science.2434994
   GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199
   GORDON DM, 1995, J INFECT DIS, V171, P1576
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   Lalvani A, 1999, J INFECT DIS, V180, P1656, DOI 10.1086/315074
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859
   Lalvani A, 1996, EUR J IMMUNOL, V26, P773, DOI 10.1002/eji.1830260408
   Lanar DE, 1996, INFECT IMMUN, V64, P1666
   Lopez JA, 2001, EUR J IMMUNOL, V31, P1989, DOI 10.1002/1521-4141(200107)31:7<1989::AID-IMMU1989>3.3.CO;2-D
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   Moorthy VS, 2004, PLOS MED, V1, P128, DOI 10.1371/journal.pmed.0010033
   Moorthy VS, 2004, J INFECT DIS, V189, P2213, DOI 10.1086/421118
   Moorthy VS, 2003, J INFECT DIS, V188, P1239, DOI 10.1086/378515
   Moorthy VS, 2003, VACCINE, V21, P1995, DOI 10.1016/S0264-410X(02)00771-5
   Pinder M, 2004, CLIN EXP IMMUNOL, V135, P286, DOI 10.1111/j.1365-2249.2004.02371.x
   Plebanski M, 1997, J IMMUNOL, V158, P2849
   Reece WHH, 2004, NAT MED, V10, P406, DOI 10.1038/nm1009
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   Sedegah M, 1998, P NATL ACAD SCI USA, V95, P7648, DOI 10.1073/pnas.95.13.7648
   Vuola JM, 2005, J IMMUNOL, V174, P449
   Walther M, 2006, INFECT IMMUN, V74, P2706, DOI 10.1128/IAI.74.5.2706-2716.2006
   WALTHER M, 2005, VACCINE, V23, P854
   Wang RB, 2001, P NATL ACAD SCI USA, V98, P10817, DOI 10.1073/pnas.181123498
   Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102
NR 29
TC 21
Z9 21
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD OCT 30
PY 2006
VL 24
IS 42-43
BP 6526
EP 6533
DI 10.1016/j.vaccine.2006.06.022
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 102XL
UT WOS:000241846700009
PM 16842888
OA No
DA 2017-08-15
ER

PT J
AU Campbell, DI
   Bunn, JEG
   Weaver, LT
   Harding, M
   Coward, WA
   Thomas, JE
AF Campbell, D. I.
   Bunn, J. E. G.
   Weaver, L. T.
   Harding, M.
   Coward, W. A.
   Thomas, J. E.
TI Human milk vacuolating cytotoxin A immunoglobulin A antibodies modify
   Helicobacter pylori infection in Gambian children
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
ID COLONIZATION; TOXIN; CELLS; VACA; CAGA; GROWTH
AB We collected data, including the weights, urea breath test results, and presence of maternal milk cytotoxin-associated gene-specific and vacuolating cytotoxin A-specific immunoglobulin A monthly from 48 mothers and infants (to 44 weeks of age) in The Gambia. In all, 11 children (23%) had negative urea breath test results, and 37 (77%) had positive results. Weight loss associated with Helicobacter pylori colonization was restricted to children whose mothers did not produce anti-vacuolating cytotoxin A antibodies in their milk (P = .028 by t test).
C1 Univ Newcastle Upon Tyne, Sir James Spence Inst Child Hlth, Royal Victoria Infirm, Sch Clin Med Sci, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   MRC, Dunn Human Nutr Unit, Cambridge, England.
   MRC, Human Nutr Res Unit, Elsie Widdowson Lab, Cambridge, England.
   Univ Glasgow, Royal Hosp Sick Children, Dept Paediat, Glasgow, Lanark, Scotland.
   MRC Keneba, Keneba, Gambia.
RP Thomas, JE (reprint author), Univ Newcastle Upon Tyne, Sir James Spence Inst Child Hlth, Royal Victoria Infirm, Sch Clin Med Sci, Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM j.e.thomas@ncl.ac.uk
FU Medical Research Council [MC_U105960396]
CR Atherton JC, 2000, GUT, V47, P330, DOI 10.1136/gut.47.3.330
   Dale A, 1998, J PEDIATR GASTR NUTR, V26, P393, DOI 10.1097/00005176-199804000-00006
   Guarino A, 1998, J INFECT DIS, V178, P1373, DOI 10.1086/314427
   Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147
   Ilver D, 2004, CELL MICROBIOL, V6, P167, DOI 10.1046/j.1462-5822.2003.00349.x
   Li Y, 2004, MOL BIOL CELL, V15, P1946, DOI 10.1091/mbc.E03-08-0618
   Pagliaccia C, 2000, EUR J BIOCHEM, V267, P104, DOI 10.1046/j.1432-1327.2000.00970.x
   Parsonnet J, 1999, JAMA-J AM MED ASSOC, V282, P2240, DOI 10.1001/jama.282.23.2240
   Pelicic V, 1999, MICROBIOL-UK, V145, P2043
   Puls J, 2002, MOL MICROBIOL, V43, P961, DOI 10.1046/j.1365-2958.2002.02780.x
   Rossi G, 2004, INFECT IMMUN, V72, P3252, DOI 10.1128/IAI.72.6.3252-3259.2004
   Thomas JE, 1999, PEDIATR RES, V46, P147, DOI 10.1203/00006450-199908000-00003
   Thomas JE, 2004, CLIN INFECT DIS, V39, P1155, DOI 10.1086/424514
   Thomas JE, 2004, ARCH DIS CHILD, V89, P1149, DOI 10.1136/adc.2002.015313
   Thomas JE, 1999, PEDIATR RES, V45, P218, DOI 10.1203/00006450-199902000-00010
   THOMAS JE, 1990, J CLIN MICROBIOL, V28, P2641
   Weaver LT, 1998, ARCH DIS CHILD, V78, P235
NR 17
TC 7
Z9 7
U1 0
U2 0
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 15
PY 2006
VL 43
IS 8
BP 1040
EP 1042
DI 10.1086/507524
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 086IE
UT WOS:000240666200014
PM 16983617
OA No
DA 2017-08-15
ER

PT J
AU Walther, M
   Woodruff, J
   Edele, F
   Jeffries, D
   Tongren, JE
   King, E
   Andrews, L
   Bejon, P
   Gilbert, SC
   De Souza, JB
   Sinden, R
   Hill, AVS
   Riley, EM
AF Walther, Michael
   Woodruff, John
   Edele, Fanny
   Jeffries, David
   Tongren, Jon E.
   King, Elizabeth
   Andrews, Laura
   Bejon, Philip
   Gilbert, Sarah C.
   De Souza, Joseph B.
   Sinden, Robert
   Hill, Adrian V. S.
   Riley, Eleanor M.
TI Innate immune responses to human malaria: Heterogeneous cytokine
   responses to blood-stage Plasmodium falciparum correlate with
   parasitological and clinical outcomes
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID GROWTH-FACTOR-BETA; NECROSIS-FACTOR-ALPHA; POLYMERASE-CHAIN-REACTION;
   HUMAN NK CELLS; INFECTED ERYTHROCYTES; TGF-BETA; DENDRITIC CELLS;
   UNCOMPLICATED MALARIA; INTERLEUKIN (IL)-4; PLASMA-LEVELS
AB Taking advantage of a sporozoite challenge model established to evaluate the efficacy of new malaria vaccine candidates, we have explored the kinetics of systemic cytokine responses during the prepatent period of Plasmodium falciparum infection in 18 unvaccinated, previously malaria-naive subjects, using a highly sensitive, bead-based multiplex assay, and relate these data to peripheral parasite densities as measured by quantitative real-time PCR. These data are complemented with the analysis of cytokine production measured in vitro from whole blood or PBMC, stimulated with P. falciparum-infected RBC. We found considerable qualitative and quantitative interindividual variability in the innate responses, with subjects falling into three groups according to the strength of their inflammatory response. One group secreted moderate levels of IFN-gamma and IL-10, but no detectable IL-12p70. A second group produced detectable levels of circulating IL-12p70 and developed very high levels of IFN-gamma and IL-10. The third group failed to up-regulate any significant proinflammatory responses, but showed the highest levels of TGF-beta. Proinflammatory responses were associated with more rapid control of parasite growth but only at the cost of developing clinical symptoms, suggesting that the initial innate response may have far-reaching consequences on disease outcome. Furthermore, the in vitro observations on cytokine kinetics presented here, suggest that intact schizont-stage infected RBC can trigger innate responses before rupture of the infected RBC.
C1 MRC Labs, Banjul, Gambia.
   Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Nuffield Dept Clin Med, Oxford OX1 2JD, England.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
   Univ Oxford, Wellcome Trust Ctr Human Genet, Nuffield Dept Clin Med, Oxford OX1 2JD, England.
   UCL Royal Free & Univ London Sch Med, Dept Immunol & Mol Pathol, London, England.
   Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England.
RP Walther, M (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM mwalther@mrc.gm
RI HILL, Adrian/C-1306-2008; de Souza, Joseph/D-4979-2009; Riley,
   Eleanor/C-8960-2013
OI Riley, Eleanor/0000-0003-3447-3570; Gilbert, Sarah/0000-0002-6823-9750
FU Wellcome Trust
CR Andrews L, 2005, AM J TROP MED HYG, V73, P191
   Artavanis-Tsakonas K, 2003, CLIN EXP IMMUNOL, V133, P145, DOI 10.1046/j.1365-2249.2003.02174.x
   Artavanis-Tsakonas K, 2003, J IMMUNOL, V171, P5396
   Artavanis-Tsakonas K, 2002, J IMMUNOL, V169, P2956
   Baratin M, 2005, P NATL ACAD SCI USA, V102, P14747, DOI 10.1073/pnas.0507355102
   Baum J, 2006, J BIOL CHEM, V281, P5197, DOI 10.1074/jbc.M509807200
   Bejon P, 2005, J INFECT DIS, V191, P619, DOI 10.1086/427243
   Brombacher F, 2003, TRENDS IMMUNOL, V24, P207, DOI 10.1016/S1471-4906(03)00067-X
   BUTCHER GA, 1984, T ROY SOC TROP MED H, V78, P806, DOI 10.1016/0035-9203(84)90026-9
   Chaiyaroj SC, 2004, ACTA TROP, V89, P319, DOI 10.1016/j.actatropica.2003.10.010
   Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836
   DANDREA A, 1995, J EXP MED, V181, P537, DOI 10.1084/jem.181.2.537
   Day NPJ, 1999, J INFECT DIS, V180, P1288, DOI 10.1086/315016
   Dodoo D, 2002, J INFECT DIS, V185, P971, DOI 10.1086/339408
   DUNACHIE SJ, IN PRESS INFECT IMMU
   Fell AH, 1998, PARASITOL TODAY, V14, P364, DOI 10.1016/S0169-4758(98)01298-8
   Good MF, 1999, CURR OPIN IMMUNOL, V11, P412, DOI 10.1016/S0952-7915(99)80069-7
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   HARPAZ R, 1992, J CLIN INVEST, V90, P515, DOI 10.1172/JCI115889
   Hensmann M, 2001, INFECT IMMUN, V69, P2364, DOI 10.1128/IAI.69.4.2364-2371.2001
   Hermsen CC, 2001, MOL BIOCHEM PARASIT, V118, P247, DOI 10.1016/S0166-6851(01)00379-6
   Hochrein H, 2000, J EXP MED, V192, P823, DOI 10.1084/jem.192.6.823
   Jaramillo M, 2004, J IMMUNOL, V172, P3101
   Korbel DS, 2005, J IMMUNOL, V175, P7466
   KREMSNER PG, 1995, AM J TROP MED HYG, V53, P532
   Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200
   Kurtzhals JAL, 1998, LANCET, V351, P1768, DOI 10.1016/S0140-6736(97)09439-7
   Kwiatkowski D, 1997, ANN TROP MED PARASIT, V91, P533
   KWIATKOWSKI D, 1989, CLIN EXP IMMUNOL, V77, P361
   KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5
   Li C, 2003, INFECT IMMUN, V71, P4850, DOI 10.1128/IAI.71.9.4850-4856.2003
   Lingnau K, 1998, J IMMUNOL, V161, P4709
   Luty AJF, 2000, INFECT IMMUN, V68, P3909, DOI 10.1128/IAI.68.7.3909-3915.2000
   Lyke KE, 2004, INFECT IMMUN, V72, P5630, DOI 10.1128/IAI.72.10.5630-5637.2004
   Malaguarnera L, 2002, EUR CYTOKINE NETW, V13, P425
   Malaguarnera L, 2002, PARASITE IMMUNOL, V24, P387, DOI 10.1046/j.1365-3024.2002.00478.x
   Malandain G, 2002, INT J COMPUT GEOM AP, V12, P489, DOI 10.1142/S0218195902001006
   Molineaux L, 2002, T ROY SOC TROP MED H, V96, P205, DOI 10.1016/S0035-9203(02)90308-1
   Omer FM, 2003, J EXP MED, V198, P1817, DOI 10.1084/jem.20030713
   Omer FM, 2000, PARASITOL TODAY, V16, P18, DOI 10.1016/S0169-4758(99)01562-8
   Omer FM, 1998, J EXP MED, V188, P39, DOI 10.1084/jem.188.1.39
   Omer FM, 2003, J IMMUNOL, V171, P5430
   Othoro C, 1999, J INFECT DIS, V179, P279, DOI 10.1086/314548
   Perkins DJ, 2000, J INFECT DIS, V182, P988, DOI 10.1086/315762
   Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2
   Plebanski M, 2000, CURR OPIN IMMUNOL, V12, P437, DOI 10.1016/S0952-7915(00)00117-5
   Rhee MSM, 2001, CLIN EXP IMMUNOL, V126, P503, DOI 10.1046/j.1365-2249.2001.01681.x
   Riley EM, 1999, IMMUNOL TODAY, V20, P228, DOI 10.1016/S0167-5699(99)01456-5
   SchartonKersten TM, 1997, CURR OPIN IMMUNOL, V9, P44, DOI 10.1016/S0952-7915(97)80157-4
   Scragg IG, 1999, EUR J IMMUNOL, V29, P2636, DOI 10.1002/(SICI)1521-4141(199908)29:08<2636::AID-IMMU2636>3.3.CO;2-P
   Sewell WAC, 1997, J IMMUNOL METHODS, V209, P67
   Struik SS, 2004, BLOOD, V103, P3084, DOI 10.1182/blood-2003-08-2867
   Tachado SD, 1997, P NATL ACAD SCI USA, V94, P4022, DOI 10.1073/pnas.94.8.4022
   Torre D, 2002, CLIN DIAGN LAB IMMUN, V9, P348, DOI 10.1128/CDLI..2.348-351.2002
   Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900
   VanWaarde MAWH, 1997, ANAL BIOCHEM, V247, P45, DOI 10.1006/abio.1997.2026
   Walters Scott T, 2003, Prev Sci, V4, P287, DOI 10.1023/A:1026024400450
   Walther M, 2006, INFECT IMMUN, V74, P2706, DOI 10.1128/IAI.74.5.2706-2716.2006
   Walther M, 2005, VACCINE, V23, P857, DOI 10.1016/j.vaccine.2004.08.020
   WENISCH C, 1995, J CLIN IMMUNOL, V15, P69, DOI 10.1007/BF01541734
   Wenisch C, 1999, J INFECT DIS, V179, P747, DOI 10.1086/314630
   Willmann K, 2000, J LEUKOCYTE BIOL, V67, P536
NR 62
TC 83
Z9 83
U1 0
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD OCT 15
PY 2006
VL 177
IS 8
BP 5736
EP 5745
PG 10
WC Immunology
SC Immunology
GA 092JP
UT WOS:000241093100090
PM 17015763
OA No
DA 2017-08-15
ER

PT J
AU Prentice, A
   Laskey, MA
   Goldberg, GR
AF Prentice, Ann
   Laskey, M. Ann
   Goldberg, Gail R.
TI Maternal calcium supplementation and bone accretion in infants - Reply
   to W Koo
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Letter
ID WOMEN
C1 MRC Human Nutr Res, Elsie Widdowson Lab, Cambridge CB1 9NL, England.
   MRC, Keneba, Gambia.
RP Prentice, A (reprint author), MRC Human Nutr Res, Elsie Widdowson Lab, Fulbourne Rd, Cambridge CB1 9NL, England.
EM ann.prentice@mrc-hnr.cam.ac.uk
CR BATES CJ, 1994, EUR J CLIN NUTR, V48, P660
   [World Health Organization United Nations Food and Agricultural Organization], 1985, WHO TECH REP SER, P724
   Jarjou LM, 2006, AM J CLIN NUTR, V83, P657
   Jarjou LMA, 2004, THESIS OPEN U MILTON
   Koo WWK, 1999, OBSTET GYNECOL, V94, P577, DOI 10.1016/S0029-7844(99)00371-3
   Prentice AM, 2000, AM J CLIN NUTR, V72, p1253S
   Prentice AM, 1996, EUR J CLIN NUTR S1, V50, P82
   Villar J, 2006, AM J OBSTET GYNECOL, V194, P639, DOI 10.1016/j.ajog.2006.01.068
NR 8
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL NUTRITION
PI BETHESDA
PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998
   USA
SN 0002-9165
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD OCT
PY 2006
VL 84
IS 4
BP 944
EP 945
PG 2
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 093AX
UT WOS:000241140700036
OA No
DA 2017-08-15
ER

PT J
AU Kirk, GD
   Bah, E
   Montesano, R
AF Kirk, Gregory D.
   Bah, Ebrima
   Montesano, Ruggero
TI Molecular epidemiology of human liver cancer: insights into etiology,
   pathogenesis and prevention from The Gambia, West Africa
SO CARCINOGENESIS
LA English
DT Review
ID HEPATITIS-B-VIRUS; HEPATOCELLULAR-CARCINOMA PATIENTS; IONIZATION
   MASS-SPECTROMETRY; AFLATOXIN-ALBUMIN ADDUCTS; REPUBLIC-OF-CHINA;
   HUMAN-BREAST-MILK; PLASMA DNA; C VIRUS; P53 MUTATIONS; FOLLOW-UP
AB Human liver cancer, primarily hepatocellular carcinoma (HCC), is both common and lethal. Notable variation in HCC incidence rates worldwide corresponds to the prevalence and pattern of the primary etiologic factors. In summary of decades of collaborative research centered in The Gambia, West Africa, this review explores the independent and combined effects of hepatitis B virus (HBV), hepatitis C virus (HCV) and dietary aflatoxin exposure in the etiology of HCC. Through population surveys, field trials and a series of HCC case-control studies, the patterns and natural history of HBV, HCV and aflatoxin exposures have been defined within this population. These investigations have paralleled and informed the development of molecular biomarkers of these etiologic agents and contributed to understanding the complex mechanisms involved in hepatocarcinogenesis. We discuss preventive approaches to reduce the global burden of HCC, emphasizing The Gambia Hepatitis Intervention Study, a countrywide randomized controlled trial designed to document the efficacy of HB vaccination in preventing HBV infections and HBV-related HCC. By recognizing the synergy of applying molecular techniques to population-based epidemiological studies, the portfolio of Gambian research projects presented provides a model for partnering etiologic and mechanistic investigations with applied research.
C1 Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.
   Gambia Hepatitis Intervent Study, MRC Labs, Fajara, Gambia.
RP Kirk, GD (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA.
EM gkirk@jhsph.edu
RI Kirk, Gregory/A-8484-2009
CR AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284
   Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730
   BAH E, 1990, BRIT J CANCER, V62, P647, DOI 10.1038/bjc.1990.347
   Baptista M, 1999, HEPATOLOGY, V29, P946, DOI 10.1002/hep.510290336
   *BBC, 2005, CERV CANC JAB 2 YEAR
   BEASLEY RP, 1981, LANCET, V2, P1129
   Bian JC, 2000, WORLD J GASTROENTERO, V6, P228
   BLUMBERG BS, 1982, CANCER, V50, P2657
   Brechot C, 2004, GASTROENTEROLOGY, V127, pS56, DOI 10.1053/j.gastro.2004.09.016
   Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321
   BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0
   Carlson MA, 2000, BIOSENS BIOELECTRON, V14, P841, DOI 10.1016/S0956-5663(99)00057-3
   Chan HLY, 2004, GUT, V53, P1494, DOI 10.1136/gut.2003.033324
   Chang MH, 2000, JAMA-J AM MED ASSOC, V284, P3040, DOI 10.1001/jama.284.23.3040
   Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602
   Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65
   Chen HL, 1996, JAMA-J AM MED ASSOC, V276, P906, DOI 10.1001/jama.276.11.906
   Chu CJ, 2002, HEPATOLOGY, V35, P1274, DOI 10.1053/jhep.2002.33161
   Chu CJ, 2003, GASTROENTEROLOGY, V125, P444, DOI 10.1016/S0016-5085(03)00895-3
   Chu CM, 2000, J GASTROEN HEPATOL, V15, pE25, DOI 10.1046/j.1440-1746.2000.02097.x
   Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3<347::AID-IJC4>3.0.CO;2-2
   Drucker E, 2001, LANCET, V358, P1989, DOI 10.1016/S0140-6736(01)06967-7
   Dumpis U, 2001, J MED VIROL, V65, P664, DOI 10.1002/jmv.2088
   Edmunds WJ, 1996, EPIDEMIOL INFECT, V117, P313
   EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197
   Evans AA, 1998, CANCER EPIDEM BIOMAR, V7, P559
   FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P
   FORTUIN M, 1994, J INFECT DIS, V169, P1374
   Frank C, 2000, LANCET, V355, P887, DOI 10.1016/S0140-6736(99)06527-7
   GARNER RC, 1988, INT ARCH OCC ENV HEA, V60, P145, DOI 10.1007/BF00378689
   *GHIS, 1987, CANCER RES, V47, P5782
   Gong YY, 2002, BRIT MED J, V325, P20, DOI 10.1136/bmj.325.7354.20
   GROOPMAN JD, 1988, CRIT REV TOXICOL, V19, P113, DOI 10.3109/10408448809014902
   Groopman JD., 1994, TOXICOLOGY AFLATOXIN, P259
   Hainaut P, 2000, ADV CANCER RES, V77, P81
   Hall A, 1998, TROP MED INT HEALTH, V3, P337
   Hall AJ, 1999, BRIT J CANCER, V81, P1097, DOI 10.1038/sj.bjc.6690813
   HALL AJ, 1993, T ROY SOC TROP MED H, V87, P333, DOI 10.1016/0035-9203(93)90154-I
   Hsu HY, 2004, GUT, V53, P1499, DOI 10.1136/gut.2003.034223
   HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0
   Huang XH, 2003, WORLD J GASTROENTERO, V9, P692
   Hussain SP, 1998, TOXICOL LETT, V103, P219
   IARC International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic risks to Humans, 1993, MON EV CARC RISKS HU, V56
   Ishikawa T, 2001, J GASTROEN HEPATOL, V16, P1274, DOI 10.1046/j.1440-1746.2001.02616.x
   Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
   Jackson PE, 2003, CARCINOGENESIS, V24, P1657, DOI 10.1093/carcin/bgg101
   Jackson PE, 1999, BEST PRACT RES CL GA, V13, P545, DOI 10.1053/bega.1999.0047
   Jackson PE, 2001, CANCER RES, V61, P33
   Kane M, 1998, B WORLD HEALTH ORGAN, V76, P99
   Kane MA, 2002, CURR OPIN INFECT DIS, V15, P465
   Kao JH, 2002, LANCET INFECT DIS, V2, P395, DOI 10.1016/S1473-3099(02)00315-8
   KARTHIGESU VD, 1994, J GEN VIROL, V75, P443, DOI 10.1099/0022-1317-75-2-443
   Kensler TW, 2004, GASTROENTEROLOGY, V127, pS310, DOI 10.1053/j.gastro.2004.09.046
   Kensler TW, 2002, EUR J CANCER PREV, V11, pS58
   Kensler TW, 1998, MUTAT RES-FUND MOL M, V402, P165, DOI 10.1016/S0027-5107(97)00294-7
   KENYA C, 2004, MMWR-MORBID MORTAL W, V53, P790
   Kew MC, 2005, J MED VIROL, V75, P513, DOI 10.1002/jmv.20311
   Kew MC, 2003, LIVER INT, V23, P405, DOI 10.1111/j.1478-3231.2003.00869.x
   Kimbi GC, 2005, J GASTROEN HEPATOL, V20, P1185, DOI 10.1111/j.1400-1746.2005.03951.x
   Kirk GD, 2005, CANCER EPIDEM BIOMAR, V14, P373, DOI 10.1158/1055-9965.EPI-04-0161
   Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732
   Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027
   Kirk GD, 2000, J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148
   KIRK GD, 2003, WORLD CANC REPORT, P144
   Kramvis A, 1997, HEPATOLOGY, V25, P235, DOI 10.1002/hep.510250143
   Kramvis A, 1998, J HEPATOL, V28, P132, DOI 10.1016/S0168-8278(98)80212-2
   Kuang SY, 2005, CANCER EPIDEM BIOMAR, V14, P380, DOI 10.1158/1055-9965.EPI-04-0380
   Kuang SY, 2004, P NATL ACAD SCI USA, V101, P3575, DOI 10.1073/pnas.0308232100
   Liang TJ, 2004, GASTROENTEROLOGY, V127, pS62, DOI 10.1053/j.gastro.2004.09.017
   Liang TJ, 2002, NEW ENGL J MED, V347, P208, DOI 10.1056/NEJMe020060
   Liao SS, 1999, VACCINE, V17, P2661, DOI 10.1016/S0264-410X(99)00031-6
   Lin YC, 2003, J INFECT DIS, V187, P134, DOI 10.1086/345871
   Lleonart ME, 2005, CANCER EPIDEM BIOMAR, V14, P2956, DOI 10.1158/1055-9965.EPI-05-0612
   Lu DD, 2003, J CELL MOL MED, V7, P89, DOI 10.1111/j.1582-4934.2003.tb00207.x
   Lunn RM, 1999, CANCER RES, V59, P2557
   Madhava V, 2002, LANCET INFECT DIS, V2, P293, DOI 10.1016/S1473-3099(02)00264-5
   Martinson FEA, 1998, AM J EPIDEMIOL, V147, P478
   MAYANS MV, 1990, LANCET, V336, P1107
   MAYANS MV, 1994, LANCET, V343, P761
   Mendy ME, 1999, BRIT J BIOMED SCI, V56, P34
   MENDY ME, 1998, BRIT J BIOMED SCI, V55, P92
   Ming L, 2002, HEPATOLOGY, V36, P1214, DOI 10.1053/jhep.2002.36366
   Montesano R, 1997, J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844
   MURASKIN W, 1995, WAR HEPATITIS B
   Norder H, 2004, INTERVIROLOGY, V47, P289, DOI 10.1159/000080872
   O'Brien TR, 2004, CANCER J, V10, P67
   Orito E, 2003, INTERVIROLOGY, V46, P408, DOI 10.1159/000075000
   Parkin DM, 2001, EUR J CANCER, V37, pS4
   Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387
   QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3
   ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G
   RYDER RW, 1992, AM J EPIDEMIOL, V136, P1122
   SABBIONI G, 1987, CARCINOGENESIS, V8, P819, DOI 10.1093/carcin/8.6.819
   Sell S, 2003, CANCER RES, V63, P7553
   Simonsen L, 1999, B WORLD HEALTH ORGAN, V77, P789
   SIZARET P, 1982, J NATL CANCER I, V69, P1375
   Smela ME, 2002, P NATL ACAD SCI USA, V99, P6655, DOI 10.1073/pnas.102167699
   Smela ME, 2001, CARCINOGENESIS, V22, P535, DOI 10.1093/carcin/22.4.535
   Soussan P, 2001, J GEN VIROL, V82, P367
   Stern MC, 2001, CANCER EPIDEM BIOMAR, V10, P617
   Sulkowski MS, 2002, JAMA-J AM MED ASSOC, V287, P2406, DOI 10.1001/jama.287.18.2406
   Sun ZT, 2002, J MED VIROL, V67, P447, DOI 10.1002/jmv.10094
   Szymanska K, 2004, INT J CANCER, V110, P374, DOI 10.1002/ijc.20103
   Torbenson M, 2002, LANCET INFECT DIS, V2, P479, DOI 10.1016/S1473-3099(02)00345-6
   Tsai JF, 1996, BRIT J CANCER, V73, P1498, DOI 10.1038/bjc.1996.283
   Turner PC, 2005, LANCET, V365, P1950, DOI 10.1016/S0140-6736(05)66661-5
   Turner PC, 2005, CANCER EPIDEM BIOMAR, V14, P2053, DOI 10.1158/1055-9965.EPI-04-0923
   Turner PC, 2003, ENVIRON HEALTH PERSP, V111, P217, DOI 10.1289/ehp.5753
   Turner PC, 2000, TROP MED INT HEALTH, V5, P837, DOI 10.1046/j.1365-3156.2000.00664.x
   Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4
   Whittle H, 2002, BRIT MED J, V325, P569, DOI 10.1136/bmj.325.7364.569
   WHITTLE H, 1990, J INFECT DIS, V161, P1112
   WHITTLE HC, 1987, ANN TROP PAEDIATR, V7, P6
   WHITTLE HC, 1983, LANCET, V1, P1203
   WHO, 1999, J VIRAL HEPATITUS, V6, P35
   WILD CP, 1993, ENVIRON HEALTH PERSP, V99, P115, DOI 10.2307/3431466
   WILD CP, 1993, CANCER EPIDEM BIOMAR, V2, P555
   Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1<1::AID-IJC1>3.0.CO;2-I
   WILD CP, 1990, CARCINOGENESIS, V11, P2271, DOI 10.1093/carcin/11.12.2271
   Wild CP, 2002, MUTAT RES-FUND MOL M, V499, P3, DOI 10.1016/S0027-5107(01)00290-1
   WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229
   WILD CP, 1987, INT J CANCER, V40, P328, DOI 10.1002/ijc.2910400308
   Wild CP, 2000, MUTAT RES-REV MUTAT, V462, P381, DOI 10.1016/S1383-5742(00)00027-2
   WILD CP, 1986, CARCINOGENESIS, V7, P853, DOI 10.1093/carcin/7.6.853
   WILD CP, 1992, TOXICOL LETT, V64-5, P455, DOI 10.1016/0378-4274(92)90219-A
   WILD CP, 1991, LANCET, V337, P1602, DOI 10.1016/0140-6736(91)93295-K
   Wogan GN, 1999, HEPATOLOGY, V30, P573, DOI 10.1002/hep.510300231
   Wogan GN, 2000, SEMIN CANCER BIOL, V10, P201, DOI 10.1006/scbi.2000.0320
   Wu JS, 1999, J INFECT DIS, V179, P1319, DOI 10.1086/314768
   Yang HI, 2002, NEW ENGL J MED, V347, P168, DOI 10.1056/NEJMoa013215
   Yu MW, 2005, J NATL CANCER I, V97, P265, DOI 10.1093/jnci/dji043
   Yu MW, 1999, AM J EPIDEMIOL, V149, P621
   Yu MW, 2003, J NATL CANCER I, V95, P1485, DOI 10.1093/jnci/djg051
   ZARBA A, 1992, CARCINOGENESIS, V13, P891, DOI 10.1093/carcin/13.5.891
   Zarski JP, 1998, J HEPATOL, V28, P27, DOI 10.1016/S0168-8278(98)80198-0
   Zhang MD, 2005, EMERG INFECT DIS, V11, P17
   Zuckerman JN, 2003, ANTIVIR RES, V60, P75, DOI 10.1016/j.antiviral.2003.08.013
NR 137
TC 76
Z9 78
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 2006
VL 27
IS 10
BP 2070
EP 2082
DI 10.1093/carcin/bgl060
PG 13
WC Oncology
SC Oncology
GA 090CF
UT WOS:000240927500016
PM 16679307
OA No
DA 2017-08-15
ER

PT J
AU Johnstone, E
   Benowitz, N
   Cargill, A
   Jacob, R
   Hinks, L
   Day, I
   Murphy, M
   Walton, R
AF Johnstone, Elaine
   Benowitz, Neal
   Cargill, Anna
   Jacob, Robyn
   Hinks, Lesley
   Day, Ian
   Murphy, Mike
   Walton, Robert
TI Determinants of the rate of nicotine metabolism and effects on smoldng
   behavior
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID HUMAN LIVER-MICROSOMES; ALTERS SMOKING-BEHAVIOR; GENETIC POLYMORPHISMS;
   HUMAN CYP2A6; INTERINDIVIDUAL DIFFERENCES; CYTOCHROME-P450 2A6;
   LUNG-CANCER; C-OXIDATION; POPULATION; CIGARETTE
AB Background: Studies on cytochrome P450 (CYP) 2A6 suggest that genotype affects the rate of nicotine metabolism and, consequently, cigarette consumption. However, known alleles of CYP2A6 associated with fast or slow metabolism are relatively uncommon, and there remains considerable variation in metabolic activity among those with presumed wild-type CYP2A6 alleles, suggesting that other genetic or environmental factors also influence the rate of nicotine metabolism.
   Methods. We investigated determinants of the rate of nicotine metabolism and effects on smoking behavior in a United Kingdom cohort who participated in a placebo-controlled trial of smoking cessation via nicotine replacement therapy. Those who continued to smoke cigarettes at the 8-year follow-up formed our study group (N = 545). The ratio of the nicotine metabolite trans-3'-hydroxycotinine to cotinine in plasma was used as an index of CYP2A6 activity and thus as a marker of the rate of nicotine metabolism.
   Results: The nicotine metabolite ratio was associated with sex (P < .0001), CYP2A6 genotype (*1B, *2, *4, *9, and *12) (P < .0001), CYP2B6 haplotype (*4-dominant) (P =.02), plasma nicotine concentration (P < .0001), and age (P =.02) but was not associated with dependence score (P > .20). The ratio also predicted the number of cigarettes smoked at will per day, although the association was weak (F1,492 = 4.05, P =.04).
   Conclusion: In this cohort the rate of nicotine metabolism is related to age, sex, CYP2A6 genotype, and CYP2B6 genotype and may affect the level of tobacco consumption.
C1 Univ Oxford, Dept Clin Pharmacol, Canc Res UK, Med Stat Grp,Ctr Stat Med, Oxford OX1 2JD, England.
   Univ Oxford, Childhood Canc Res Grp, Oxford OX1 2JD, England.
   Univ Calif San Francisco, Div Clin Pharmacol & Expt Therapeut, Dept Med, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Div Clin Pharmacol & Expt Therapeut, Dept Psychiat, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Div Clin Pharmacol & Expt Therapeut, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA.
   Univ Southampton, Southampton Gen Hosp, Sch Med, Div Human Genet, Southampton SO9 5NH, Hants, England.
   MRC Labs, Fajara, Gambia.
RP Johnstone, E (reprint author), Radcliffe Infirm, Dept Clin Pharmacol, Woodstock Rd, Oxford OX2 6HE, England.
EM elaine.johnstone@clinpharm.ox.ac.uk
FU NIDA NIH HHS [DA02277]
CR BENOWITZ NL, 1994, CLIN PHARMACOL THER, V56, P483
   Benowitz NL, 2006, CLIN PHARMACOL THER, V79, P480, DOI 10.1016/j.clpt.2006.01.008
   BENOWITZ NL, 1985, J PHARMACOL EXP THER, V234, P153
   Benowitz NL, 2003, NICOTINE TOB RES, V5, P621, DOI 10.1080/1462220031000158717
   Benowitz N.L., 1996, SMOKING TOBACCO CONT, V7, P93
   Bumpus NN, 2005, DRUG METAB DISPOS, V33, P795, DOI 10.1124/dmd.104.003749
   BURKE P, 1993, BRIT MED J, V306, P1304
   Dempsey D, 2004, CLIN PHARMACOL THER, V76, P64, DOI 10.1016/j.clpt.2004.02.011
   Fujieda M, 2004, CARCINOGENESIS, V25, P2451, DOI 10.1093/carcin/bgh258
   Gambier N, 2005, PHARMACOGENOMICS J, V5, P271, DOI 10.1038/sj.tpj.6500314
   Gu DF, 2000, ANN HUM GENET, V64, P383, DOI 10.1046/j.1469-1809.2000.6450383.x
   Huang SW, 2005, PHARMACOGENET GENOM, V15, P839, DOI 10.1097/01213011-200512000-00002
   JACOB P, 1991, BIOL MASS SPECTROM, V20, P247, DOI 10.1002/bms.1200200503
   Jacob RM, 2004, CLIN CHEM, V50, P1372, DOI 10.1373/clinchem.2004.031708
   Kirchheiner J, 2003, PHARMACOGENETICS, V13, P619, DOI 10.1097/01.fpc.0000054122.14659.d0
   Lang T, 2004, J PHARMACOL EXP THER, V311, P34, DOI 10.1124/jpet.104.068973
   Lea RA, 2006, J ANAL TOXICOL, V30, P386
   Loriot MA, 2001, PHARMACOGENETICS, V11, P39, DOI 10.1097/00008571-200102000-00005
   Messina ES, 1997, J PHARMACOL EXP THER, V282, P1608
   Molander L, 2001, CLIN PHARMACOL THER, V69, P57, DOI 10.1067/mcp.2001.113181
   Nakajima M, 1996, J PHARMACOL EXP THER, V277, P1010
   Nakajima M, 2002, DRUG METAB REV, V34, P865, DOI 10.1081/DMR-120015696
   Oscarson M, 1999, FEBS LETT, V448, P105, DOI 10.1016/S0014-5793(99)00359-2
   Oscarson M, 2002, HUM MUTAT, V20, P275, DOI 10.1002/humu.10126
   Patterson F, 2003, CANCER EPIDEM BIOMAR, V12, P468
   Pianezza ML, 1998, NATURE, V393, P750, DOI 10.1038/31623
   Schoedel KA, 2004, PHARMACOGENETICS, V14, P615, DOI 10.1097/00008571-200409000-00006
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Swan GE, 2005, PHARMACOGENET GENOM, V15, P115, DOI 10.1097/01213011-200502000-00007
   Tyndale RF, 2001, DRUG METAB DISPOS, V29, P548
   Tyndale RF, 2002, THER DRUG MONIT, V24, P163, DOI 10.1097/00007691-200202000-00026
   Wang J, 2006, BIOCHEM BIOPH RES CO, V340, P491, DOI 10.1016/j.bbrc.2005.12.035
   Xu C, 2002, ADV DRUG DELIVER REV, V54, P1245, DOI 10.1016/S0169-409X(02)00065-0
   Yamanaka H, 2005, DRUG METAB DISPOS, V33, P1811, DOI 10.1124/dmd.105.006254
   Yamazaki H, 1999, ARCH TOXICOL, V73, P65, DOI 10.1007/s002040050588
   YAMAZAKI H, 1992, CARCINOGENESIS, V13, P1789, DOI 10.1093/carcin/13.10.1789
   Yoshida R, 2003, CLIN PHARMACOL THER, V74, P69, DOI 10.1016/S0009-9236(03)00090-0
   YUN CH, 1991, MOL PHARMACOL, V40, P679
   Zhao JH, 2004, BIOINFORMATICS, V20, P1325, DOI 10.1093/bioinformatics/bth071
NR 39
TC 72
Z9 77
U1 0
U2 6
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0009-9236
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD OCT
PY 2006
VL 80
IS 4
BP 319
EP 330
DI 10.1016/j.clpt.2006.06.011
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 094AB
UT WOS:000241210300002
PM 17015050
OA No
DA 2017-08-15
ER

PT J
AU Ondondo, BO
   Yang, H
   Dong, T
   di Gleria, K
   Suttill, A
   Conlon, C
   Brown, D
   Williams, P
   Rowland-Jones, SL
   Hanke, T
   McMichael, AJ
   Dorrell, L
AF Ondondo, Beatrice O.
   Yang, Hongbing
   Dong, Tao
   di Gleria, Kati
   Suttill, Annie
   Conlon, Christopher
   Brown, Denise
   Williams, Patricia
   Rowland-Jones, Sarah L.
   Hanke, Tomas
   McMichael, Andrew J.
   Dorrell, Lucy
TI Immunisation with recombinant modified vaccinia virus Ankara expressing
   HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4(+)
   T cell responses
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Cytokines; HIV-1; immunotherapy; recombinant viral vectors; T helper
   cells
ID ACTIVE ANTIRETROVIRAL THERAPY; PLASMA VIREMIA; INFECTION; MEMORY;
   INDIVIDUALS; DISEASE; IMMUNOGENICITY; PROLIFERATION; VACCINATION; HUMANS
AB Virus-specific CD4(+) T cells with IL-2-secreting and/or proliferative capacity are detected readily in HIV-1-infected long-term nonprogressors and rarely in persons with untreated progressive infection. The contribution of these cells to viraemia control is uncertain, but this question might be addressed in clinical therapeutic vaccination studies. However, the quality of T helper responses induced by currently available HIV-1 vaccine candidates has not been explored in depth. We determined the effect of vaccination with modified vaccinia virus Ankara (MVA) expressing HIV-1 gag p24/p17 (MVA.HIVA) on HIV-1-specific CD4(+) T cell responses in 16 chronically infected, highly active antiretroviral therapy (HAART)-treated subjects using CD8-depleted IFN-gamma ELISPOT assays, intracellular cytokine staining assays for IL-2 and IFN-gamma, and a CFSE-based proliferation assay. Gag-specific CD4(+) T cell responses were significantly increased in magnitude and breadth after vaccination and targeted both known and new epitopes, several of which were also recognised by healthy HIV-uninfected volunteers immunised with the same vaccines. The frequencies of CD4(+) T cells expressing IL-2 or IFN-gamma, alone or simultaneously, were also augmented. These findings indicate that functional virus-specific T helper cells can be boosted by vaccination in chronic HIV-1 infection. Further evaluation of their role in viraemia control is warranted.
C1 John Radcliffe Hosp, MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
   MRC Labs, Banjul, Gambia.
   Radcliffe Infirm, Harrison Dept, Oxford Genito Urinary Med, Oxford OX2 6HE, England.
   Univ Oxford, Nuffield Dept Clin Med, Oxford, England.
RP Dorrell, L (reprint author), John Radcliffe Hosp, MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
EM lucy.dorrell@imm.ox.ac.uk
FU Medical Research Council [G0502048, MC_U137884177, MC_U137884179,
   MC_U137884180]
CR Autran B, 2004, SCIENCE, V305, P205, DOI 10.1126/science.1100600
   Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112
   Betts MR, 2005, P NATL ACAD SCI USA, V102, P4512, DOI 10.1073/pnas.0408773102
   Boaz MJ, 2002, J IMMUNOL, V169, P6376
   Boritz E, 2003, J IMMUNOL, V170, P1106
   Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316
   Ciurea A, 2001, NAT MED, V7, P795, DOI 10.1038/89915
   Cosma A, 2003, VACCINE, V22, P21, DOI 10.1016/S0264-410X(03)00538-3
   Davenport MP, 1996, IMMUNOLOGY, V88, P482, DOI 10.1046/j.1365-2567.1996.d01-693.x
   Dorrell L, 2006, J VIROL, V80, P4705, DOI 10.1128/JVI.80.10.4705-4716.2006
   Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a
   Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849
   Gerlach JT, 1999, GASTROENTEROLOGY, V117, P933, DOI 10.1016/S0016-5085(99)70353-7
   Goonetilleke N, 2006, J VIROL, V80, P4717, DOI 10.1128/JVI.80.10.4717-4728.2006
   Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774
   Harari A, 2005, J IMMUNOL, V174, P1037
   Harari A, 2004, BLOOD, V103, P966, DOI 10.1182/blood-2003-04-1203
   Harcourt GC, 1998, J EXP MED, V188, P1785, DOI 10.1084/jem.188.10.1785
   Harrer E, 2005, ANTIVIR THER, V10, P285
   Hel Z, 2002, J IMMUNOL, V169, P4778
   Jansen CA, 2006, BLOOD, V107, P1427, DOI 10.1182/blood-2005-07-2907
   Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   Jin X, 2002, J VIROL, V76, P2206, DOI 10.1128/JVI.76.5.2206-2216.2002
   Kaufmann DE, 2004, J VIROL, V78, P4463, DOI 10.1128/JVI.78.9.4463-4477.2004
   Koeppe JR, 2006, JAIDS-J ACQ IMM DEF, V41, P140, DOI 10.1097/01.qai.0000195608.32885.38
   KORBER BTM, 2005, HIV MOL IMMUNOLOGY
   Levy Y, 2006, AIDS, V20, P405
   Levy Y, 2005, AIDS, V19, P279
   Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270
   Malhotra U, 2001, J CLIN INVEST, V107, P505, DOI 10.1172/JCI11275
   MATLOUBIAN M, 1994, J VIROL, V68, P8056
   McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881
   McNeil AC, 2001, P NATL ACAD SCI USA, V98, P13878, DOI 10.1073/pnas.251539598
   McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128
   Mwau M, 2004, J GEN VIROL, V85, P911, DOI 10.1099/vir.0.19701-0
   Norris PJ, 2004, AIDS RES HUM RETROV, V20, P315, DOI 10.1089/088922204322996554
   Palmer BE, 2004, J IMMUNOL, V172, P3337
   Palmer BE, 2002, J VIROL, V76, P5925, DOI 10.1128/JVI.76.12.5925-5936.2002
   Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400
   Robbins GK, 2003, AIDS, V17, P1121, DOI 10.1097/01.aids.0000060368.78202.2f
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Suni MA, 1998, J IMMUNOL METHODS, V212, P89, DOI 10.1016/S0022-1759(98)00004-0
   Tryniszewska E, 2002, J IMMUNOL, V169, P5347
   Tubiana R, 2005, VACCINE, V23, P4292, DOI 10.1016/j.vaccine.2005.04.013
   Venturini S, 2002, J VIROL, V76, P6987, DOI 10.1128/JVI.76.14.6987-6999.2002
   WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002
   Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598
NR 49
TC 25
Z9 26
U1 0
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD OCT
PY 2006
VL 36
IS 10
BP 2585
EP 2594
DI 10.1002/eji.200636508
PG 10
WC Immunology
SC Immunology
GA 097RJ
UT WOS:000241465700003
PM 17013989
OA No
DA 2017-08-15
ER

PT J
AU Bojang, KA
AF Bojang, Kolifa A.
TI RTS,S/AS02A for malaria
SO EXPERT REVIEW OF VACCINES
LA English
DT Article
DE circumsporozoite protein; clinical trial; malaria vaccine
ID PLASMODIUM-FALCIPARUM MALARIA; CIRCUMSPOROZOITE PROTEIN VACCINE;
   RANDOMIZED CONTROLLED-TRIAL; B SURFACE-ANTIGEN; SPOROZOITE VACCINE;
   IMMUNOGENICITY TRIAL; EFFICACY; SAFETY; CHILDREN; IMMUNIZATION
AB Malaria prevention and treatment is becoming increasingly difficult as drug-resistant strains of parasites spread globally and affordable antimalarial drugs become ineffective. Therefore, there is a need for a safe and effective vaccine. In recent years, significant technological advances and an increase in funding for malaria vaccine research, including better public-private collaboration, have increased optimism that highly effective vaccines can be developed. RTS,S/AS02A is a novel pre-erythrocytic vaccine based on the Plosmodium faiciparum circurnsporozoite surface protein. Among all candidate vaccines developed thus far, only the RTS,S/AS02A vaccine has consistently been demonstrated to be well tolerated and provide significant protective efficacy in challenge studies and clinical trials in malaria-endemic countries.
C1 MRC Labs, Banjul, Gambia.
RP Bojang, KA (reprint author), MRC Labs, POB 273, Banjul, Gambia.
EM kbojang@mrc.gm
OI Bojang, Kalifa/0000-0001-7506-0938
CR Alloueche A, 2003, AM J TROP MED HYG, V68, P97
   Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6
   Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   BALLOU WR, 1987, LANCET, V1, P1277
   Ballou WR, 2002, CHEM IMMUNOL, V80, P253
   Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4
   Bojang KA, 2005, VACCINE, V23, P4148, DOI 10.1016/j.vaccine.2005.03.019
   BROWN AE, 1994, VACCINE, V12, P102, DOI 10.1016/0264-410X(94)90046-9
   BURKOT TR, 1991, PARASITE IMMUNOL, V13, P161, DOI 10.1111/j.1365-3024.1991.tb00272.x
   DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383
   Doherty JF, 1999, AM J TROP MED HYG, V61, P865
   DUNACHIE SJ, 2006, VACCINE, V5, P2850
   Garcon Nathalie, 2003, Expert Rev Vaccines, V2, P231, DOI 10.1586/14760584.2.2.231
   GORDON DM, 1995, J INFECT DIS, V171, P1576
   Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3
   Heppner DG, 2005, VACCINE, V23, P2243, DOI 10.1016/j.vaccine.2005.01.042
   HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0
   Hill AVS, 2006, NAT REV IMMUNOL, V6, P21, DOI 10.1038/nri1746
   Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409
   HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877
   Kester KE, 2001, J INFECT DIS, V183, P640, DOI 10.1086/318534
   Lengeler C, 2000, COCHRANE DB SYST REV, V2
   Luke TC, 2003, J EXP BIOL, V206, P3803, DOI 10.1242/jeb.00644
   Rogan WJ, 2005, LANCET, V366, P763, DOI 10.1016/S0140-6736(05)67182-6
   Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a
   SHERWOOD JA, 1991, T ROY SOC TROP MED H, V85, P336, DOI 10.1016/0035-9203(91)90281-3
   Sherwood JA, 1996, VACCINE, V14, P817, DOI 10.1016/0264-410X(95)00221-L
   Stewart VA, 2006, VACCINE, V24, P6483, DOI 10.1016/j.vaccine.2006.06.033
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657
   Stoute JA, 2006, AM J TROP MED HYG, V75, P166
   Sun PF, 2003, J IMMUNOL, V171, P6961
   VREDEN SGS, 1991, AM J TROP MED HYG, V45, P533
   Webster D, 2003, B WORLD HEALTH ORGAN, V81, P902
NR 34
TC 20
Z9 20
U1 0
U2 1
PU FUTURE DRUGS LTD
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND
SN 1476-0584
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD OCT
PY 2006
VL 5
IS 5
BP 611
EP 615
DI 10.1586/14760584.5.5.611
PG 5
WC Immunology
SC Immunology
GA 116NV
UT WOS:000242810500011
PM 17181435
OA No
DA 2017-08-15
ER

PT J
AU van der Loeff, MFS
   Awasana, AA
   Sarge-Njie, R
   van der Sande, M
   Jaye, A
   Sabally, S
   Corrah, T
   McConkey, SJ
   Whittle, HC
AF van der Loeff, Maarten F. Schim
   Awasana, Akum Aveika
   Sarge-Njie, Ramu
   van der Sande, Marianne
   Jaye, Assan
   Sabally, Saihou
   Corrah, Tumani
   McConkey, Samuel J.
   Whittle, Hilton C.
TI Sixteen years of HIV surveillance in a West African research clinic
   reveals divergent epidemic trends of HIV-1 and HIV-2
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE HIV-1; HIV-2; Africa; The Gambia; prevalence; CD4 lymphocyte count
ID CD4 CELL COUNTS; GUINEA-BISSAU; INFECTION; GAMBIA; PROSTITUTES;
   PREVALENCE; DIAGNOSIS; SENEGAL; AIDS
AB Background The HIV-1 epidemic in West Africa is characterized by a slower rise than that in Eastern and Southern Africa. The HIV-2 epidemic in West Africa may be declining, but few long-term data exist.
   Methods In a research clinic in The Gambia, HIV-1 and HIV-2 prevalence trends among all new patients being tested for HIV were examined over a 16 year period (1988 till 2003). In newly diagnosed patients a baseline CD4 count was done.
   Results An HIV test was done in 23 363 patients aged 15 years or older. The prevalence of HIV-1 was 4.2% in 1988-91 and rose to 17.5% in 2001-03 (P < 0.0001, chi(2)-test for trend). The prevalence of HIV-2 was 7.0% in 1988-91 and declined to 4.0% in 2001-03 (P < 0.0001). HIV-1 prevalence increased and HIV-2 prevalence decreased with time in logistic regression models adjusting for age, sex, and indication for test (P < 0.0001). Baseline CD4 counts were available for 65% of patients. The median CD4 count was 215 cells/mm(3) [interquartile range (IQR) 72-424] for HIV-1, and 274 (IQR 100-549) for HIV-2 infected patients. There was no marked trend of rise or decline in baseline CD4 count in either HIV-1 or HIV-2 infected patients over the study period. Forty-five per cent of newly diagnosed HIV patients had a CD4 count < 200 cells/mm(3).
   Conclusions These data suggest that HIV-1 prevalence is rising in The Gambia, and that HIV-2 is declining. HIV patients in The Gambia present late and almost half of patients would qualify for anti-retroviral treatment at their first visit.
C1 MRC Labs, Banjul, Gambia.
RP van der Loeff, MFS (reprint author), Int Antiviral Therapy Evaluat Ctr, Pietersbergweg 9, NL-1105 BM Amsterdam, Netherlands.
EM m.schim@iatec.com
RI McConkey, Samuel/E-7307-2012
CR Ariyoshi K, 1998, AIDS, V12, P2504
   DJOMAND G, 1995, J ACQ IMMUN DEF SYND, V10, P358
   Easterbrook PJ, 2000, AIDS, V14, P561, DOI 10.1097/00002030-200003310-00012
   Gilbert PB, 2003, STAT MED, V22, P573, DOI 10.1002/sim.1342
   Gupta SB, 2000, AIDS, V14, P853, DOI 10.1097/00002030-200005050-00012
   HAWKES S, 1995, GENITOURIN MED, V71, P224
   Larsen O, 1998, AIDS, V12, P1707, DOI 10.1097/00002030-199813000-00020
   MABEY DCW, 1988, BRIT MED J, V296, P83
   Marx PA, 2001, PHILOS T ROY SOC B, V356, P911, DOI 10.1098/rstb.2001.0867
   Meda N, 1999, AIDS, V13, P1397, DOI 10.1097/00002030-199907300-00018
   NORRGREN H, 2002, 3 VIRT AIDS C PORT
   PEPIN J, 1991, AIDS, V5, P69
   PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002
   Poulsen AG, 2000, SCAND J INFECT DIS, V32, P169
   *UNAIDS WHO, 2003, AIDS EP UPD DEC 2003
   *UNAIDS WHO WORK G, 2001, 2 GEN SURV HIV COMP
   van der Loeff MFS, 1999, AIDS, V13, pS69
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   World Health Organization, 2003, SCAL ANT THER RES LT
NR 19
TC 51
Z9 52
U1 1
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD OCT
PY 2006
VL 35
IS 5
BP 1322
EP 1328
DI 10.1093/ije/dy1037
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 097EI
UT WOS:000241429200040
PM 16543363
OA No
DA 2017-08-15
ER

PT J
AU Verra, F
   Chokejindachai, W
   Weedall, GD
   Polley, SD
   Mwangi, TW
   Marsh, K
   Conway, DJ
AF Verra, Federica
   Chokejindachai, Watcharee
   Weedall, Gareth D.
   Polley, Spencer D.
   Mwangi, Tabitha W.
   Marsh, Kevin
   Conway, David J.
TI Contrasting signatures of selection on the Plasmodium falciparum
   erythrocyte binding antigen gene family
SO MOLECULAR AND BIOCHEMICAL PARASITOLOGY
LA English
DT Article
DE natural selection; neutrality tests; antigens; invasion; immunity
ID RECEPTOR-BINDING; DNA POLYMORPHISM; DIVERSIFYING SELECTION; MALARIA
   PARASITES; HUMAN-ANTIBODIES; LIGAND DOMAINS; INVASION; EBA-175;
   RECOMBINATION; SEQUENCES
AB Erythrocyte binding antigens of Plasmodium falciparum are involved in erythrocyte invasion, and may be targets of acquired immunity, Of the five eba genes, protein products have been detected for eba-175, eba-181 and eba-140, but not for psi eba-165 or ebl-1, providing opportunity for comparative analysis of genetic variation to identify selection. Region 11 of each of these genes was sequenced from a cross-sectional sample of parasites in an endemic Kenyan population, and the frequency distributions of polymorphisms analysed. A positive value of Tajima's D was observed for eba-175 (D = 1.13) indicating an excess of intermediate frequency polymorphisms, while all other genes had negative values, the most negative being ebl-1 (D = -2.35) followed by psi eba-165 (D = -1.79). The eba-175 and ebl-1 genes were then studied in a sample of parasites from Thailand, for which a positive Tajima's D value was again observed for eba-175 (D = 1.79), and a negative value for ebl-1 (D = -1.85). This indicates that eba-175 is under balancing selection in each population, in strong contrast to the other members of the gene family, particularly ebl-1 and psi eba-165 that may have been under recent directional selection. Population expansion simulations were performed under a neutral model, further supporting the departures from neutrality of these genes. (c) 2006 Elsevier B.V. All rights reserved.
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand.
   Kilifi Dist Hosp, Ctr Geog Med Res, Kenya Med Res Inst, Wellcome Trust Programme, Kilifi, Kenya.
   MRC Labs, Banjul, Gambia.
RP Verra, F (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM federica.verra@lshtm.ac.uk
RI Polley, Spencer/F-7766-2013
OI Conway, David/0000-0002-8711-3037
FU Medical Research Council [MC_U190081987]; Wellcome Trust [071626]
CR Adams JH, 2001, TRENDS PARASITOL, V17, P297, DOI 10.1016/S1471-4922(01)01948-1
   ADAMS JH, 1992, P NATL ACAD SCI USA, V89, P7085, DOI 10.1073/pnas.89.15.7085
   Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467
   Baum J, 2003, GENETICS, V163, P1327
   Binks RH, 1999, MOL BIOCHEM PARASIT, V103, P123, DOI 10.1016/S0166-6851(99)00115-2
   CAMUS D, 1985, SCIENCE, V230, P553, DOI 10.1126/science.3901257
   Charlesworth B, 1997, GENET RES, V70, P155, DOI 10.1017/S0016672397002954
   CHITNIS CE, 2001, CURR OPIN HEMATOL, V8, P65
   Coluzzi Mario, 1999, Parassitologia (Rome), V41, P277
   Conway DJ, 2002, PARASITOLOGY, V125, pS3, DOI 10.1017/S0031182002002214
   Daugherty JR, 1997, INFECT IMMUN, V65, P3631
   DOLAN SA, 1994, MOL BIOCHEM PARASIT, V64, P55, DOI 10.1016/0166-6851(94)90134-1
   Drummond PB, 2005, MOL BIOCHEM PARASIT, V140, P241, DOI 10.1016/j.molbiopara.2005.01.003
   ESCALANTE AA, 1994, P NATL ACAD SCI USA, V91, P11373, DOI 10.1073/pnas.91.24.11373
   FU YX, 1993, GENETICS, V133, P693
   Gilberger TW, 2003, J BIOL CHEM, V278, P14480, DOI 10.1074/jbc.M211446200
   Hamblin MT, 2000, AM J HUM GENET, V66, P1669, DOI 10.1086/302879
   HUDSON RR, 1987, GENET RES, V50, P245
   Hudson RR, 2002, BIOINFORMATICS, V18, P337, DOI 10.1093/bioinformatics/18.2.337
   HUDSON RR, 1985, GENETICS, V111, P147
   Joy DA, 2003, SCIENCE, V300, P318, DOI 10.1126/science.1081449
   Liang H, 1997, MOL BIOCHEM PARASIT, V84, P241, DOI 10.1016/S0166-6851(96)02791-0
   Lobo CA, 2004, INFECT IMMUN, V72, P5886, DOI 10.1128/IAI.72.10.5886-5891.2004
   Maier AG, 2003, NAT MED, V9, P87, DOI 10.1038/nm807
   Mamillapalli A, 2006, MOL BIOCHEM PARASIT, V146, P120, DOI 10.1016/j.molbiopara.2005.09.019
   Mayer DCG, 2004, P NATL ACAD SCI USA, V101, P2518, DOI 10.1073/pnas.0307318101
   Mayer DCG, 2002, J EXP MED, V196, P1523, DOI 10.1084/jem.20020750
   Mayer DCG, 2001, P NATL ACAD SCI USA, V98, P5222, DOI 10.1073/pnas.081075398
   MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0
   McVean G, 2002, GENETICS, V160, P1231
   Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a
   MITCHELL GH, 1986, BLOOD, V67, P1519
   Mu JB, 2005, MOL BIOL EVOL, V22, P1686, DOI 10.1093/molbev/msi160
   Namy O, 2003, NUCLEIC ACIDS RES, V31, P2289, DOI 10.1093/nar/gkg330
   Narum DL, 2000, INFECT IMMUN, V68, P1964, DOI 10.1128/IAI.68.4.1964-1966.2000
   Narum DL, 2002, MOL BIOCHEM PARASIT, V119, P159, DOI 10.1016/S0166-6851(01)00428-5
   Ohas EA, 2004, INFECT IMMUN, V72, P735, DOI 10.1128/IAI.72.2.735-741.2004
   Okenu DMN, 2000, INFECT IMMUN, V68, P5559, DOI 10.1128/IAI.68.10.5559-5566.2000
   Ozwara H, 2001, MOL BIOCHEM PARASIT, V116, P81, DOI 10.1016/S0166-6851(01)00298-5
   Pandey KC, 2002, MOL BIOCHEM PARASIT, V123, P23, DOI 10.1016/S0166-6851(02)00122-6
   Peterson DS, 2000, MOL BIOCHEM PARASIT, V105, P105, DOI 10.1016/S0166-6851(99)00173-5
   Polley SD, 2001, GENETICS, V158, P1505
   Rayner JC, 2004, MOL BIOCHEM PARASIT, V138, P243, DOI 10.1016/j.molbiopara.2004.08.008
   Rozas J, 2003, BIOINFORMATICS, V19, P2496, DOI 10.1093/bioinformatics/btg359
   SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226
   TAJIMA F, 1989, GENETICS, V123, P597
   TAJIMA F, 1989, GENETICS, V123, P585
   Thompson JK, 2001, MOL MICROBIOL, V41, P47, DOI 10.1046/j.1365-2958.2001.02484.x
   Tolia NH, 2005, CELL, V122, P183, DOI 10.1016/j.cell.2005.05.033
   Triglia T, 2001, MOL BIOCHEM PARASIT, V116, P55, DOI 10.1016/S0166-6851(01)00303-6
NR 50
TC 26
Z9 27
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-6851
J9 MOL BIOCHEM PARASIT
JI Mol. Biochem. Parasitol.
PD OCT
PY 2006
VL 149
IS 2
BP 182
EP 190
DI 10.1016/j.molbiopara.2006.05.010
PG 9
WC Biochemistry & Molecular Biology; Parasitology
SC Biochemistry & Molecular Biology; Parasitology
GA 087XR
UT WOS:000240776600007
PM 16837078
OA No
DA 2017-08-15
ER

PT J
AU Nery, S
   Deans, AM
   Mosobo, M
   Marsh, K
   Rowe, JA
   Conway, DJ
AF Nery, Susana
   Deans, Anne-Marie
   Mosobo, Moses
   Marsh, Kevin
   Rowe, J. Alexandra
   Conway, David J.
TI Expression of Plasmodium falciparum genes involved in erythrocyte
   invasion varies among isolates cultured directly from patients
SO MOLECULAR AND BIOCHEMICAL PARASITOLOGY
LA English
DT Article
DE malaria; ligand; gene expression; reticulocyte binding protein
   homologues (Rh); erythrocyte binding antigens (EBA); clinical isolates
ID GLYCOPHORIN-C; RECEPTOR; PATHWAYS; EBA-175; POPULATIONS; MECHANISM;
   SWITCH; PCR
AB Plasmodium falciparum merozoites invade erythrocytes using a range of alternative ligands that includes erythrocyte binding antigenic proteins (EBAs) and reticulocyte binding protein homologues (Rh). Variation in the expression of some of these genes among culture-adapted parasite lines correlates with the use of different erythrocyte receptors. Here, expression profiles of four Rh genes and eba175 are analysed in a sample of 42 isolates cultured from malaria patients in Kenya. The profiles cluster into distinct groups, largely because of very strong negative correlations between the levels of expression of particular gene pairs (Rh1 versus Rh2b, eba175 versus Rh2b, and eba175 versus Rh4), previously associated with alternative invasion pathways in culture-adapted parasite lines. High levels of eba175 are seen in isolates in expression profile group I, and may be associated with sialic acid-dependent invasion. Groups II and III are, respectively, characterized by high levels of Rh2b and Rh4, and are more likely to be associated with sialic acid-independent invasion. (c) 2006 Elsevier B.V. All rights reserved.
C1 London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
   Univ Edinburgh, Sch Biol Sci, Inst Immunol & Infect Res, Edinburgh EH9 3JT, Midlothian, Scotland.
   Kenya Govt Med Res Ctr, Wellcome Trust Res Labs, Kilifi, Kenya.
   MRC Labs, Banjul, Gambia.
RP Conway, DJ (reprint author), London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
EM dconway@mrc.gm
RI Vaz Nery, Susana/P-4518-2014
OI Vaz Nery, Susana/0000-0002-2399-7785; Rowe,
   Alexandra/0000-0002-7702-1892; Conway, David/0000-0002-8711-3037
FU Medical Research Council [MC_U190081987]; Wellcome Trust [, 067431]
CR Baum J, 2003, INFECT IMMUN, V71, P1856, DOI 10.1128/IAI.71.4.1856-1863.2003
   Blair PL, 2002, NUCLEIC ACIDS RES, V30, P2224, DOI 10.1093/nar/30.10.2224
   Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005
   Cowman AF, 2006, CELL, V124, P755, DOI 10.1016/j.cell.2006.02.006
   Deans AM, 2006, AM J TROP MED HYG, V74, P554
   DOLAN SA, 1990, J CLIN INVEST, V86, P618, DOI 10.1172/JCI114753
   DOLAN SA, 1994, MOL BIOCHEM PARASIT, V64, P55, DOI 10.1016/0166-6851(94)90134-1
   Duraisingh MT, 2003, P NATL ACAD SCI USA, V100, P4796, DOI 10.1073/pnas.0730883100
   Duraisingh MT, 2003, EMBO J, V22, P1047, DOI 10.1093/emboj/cdg096
   Gaur D, 2006, MOL BIOCHEM PARASIT, V145, P205, DOI 10.1016/j.molbiopara.2005.10.004
   Gaur D, 2004, INT J PARASITOL, V34, P1413, DOI 10.1016/j.ijpara.2004.10.010
   Gilberger TW, 2003, J BIOL CHEM, V278, P14480, DOI 10.1074/jbc.M211446200
   Lobo CA, 2004, INFECT IMMUN, V72, P5886, DOI 10.1128/IAI.72.10.5886-5891.2004
   Lobo CA, 2003, BLOOD, V101, P4628, DOI 10.1182/blood-2002-10-3076
   Maier AG, 2003, NAT MED, V9, P87, DOI 10.1038/nm807
   Mayer DCG, 2001, P NATL ACAD SCI USA, V98, P5222, DOI 10.1073/pnas.081075398
   Okoyeh JN, 1999, INFECT IMMUN, V67, P5784
   Reed MB, 2000, P NATL ACAD SCI USA, V97, P7509, DOI 10.1073/pnas.97.13.7509
   Regis S, 2005, NEUROGENETICS, V6, P73, DOI 10.1007/s10048-005-0214-7
   SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226
   Snounou G, 1999, T ROY SOC TROP MED H, V93, P369, DOI 10.1016/S0035-9203(99)90120-7
   Stubbs J, 2005, SCIENCE, V309, P1384, DOI 10.1126/science.1115257
   Taylor HM, 2002, INFECT IMMUN, V70, P5779, DOI 10.1128/IAI.70.10.5779-5789.2002
   Tolia NH, 2005, CELL, V122, P183, DOI 10.1016/j.cell.2005.05.033
   Triglia T, 2005, MOL MICROBIOL, V55, P162, DOI 10.1111/j.1365-2958.2004.04388.x
NR 25
TC 40
Z9 40
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-6851
J9 MOL BIOCHEM PARASIT
JI Mol. Biochem. Parasitol.
PD OCT
PY 2006
VL 149
IS 2
BP 208
EP 215
DI 10.1016/j.molbiopara.2006.05.014
PG 8
WC Biochemistry & Molecular Biology; Parasitology
SC Biochemistry & Molecular Biology; Parasitology
GA 087XR
UT WOS:000240776600010
PM 16837080
OA No
DA 2017-08-15
ER

PT J
AU Anya, SE
   Ezugwu, FO
   Okaro, JM
AF Anya, S. E.
   Ezugwu, F. O.
   Okaro, J. M.
TI Gynaecologic mortality in Enugu, Nigeria
SO TROPICAL DOCTOR
LA English
DT Article
AB A retrospective review of 79 deaths in 2033 gynaecologic admissions at a referral centre showed that the leading causes of mortality were cervical cancer, choriocarcinoma, septic abortion and ovarian cancer, in that order. The results suggest a need for an organized cancer programme to limit morbidity and mortality from malignant disease of the female genital tract.
C1 Univ Nigeria, Teaching Hosp, Dept Obstet & Gynaecol, Enugu, Nigeria.
RP Anya, SE (reprint author), Univ Gambia, Fac Med & Allied Hlth Sci, Div Clin Sci, POB 3530, Serrekunda, Gambia.
EM se_anya@yahoo.co.uk
CR ADEWOLE IF, 1992, INT J GYNECOL OBSTET, V38, P115, DOI 10.1016/0020-7292(92)90046-L
   Ayinde A E, 1998, West Afr J Med, V17, P25
   BRIGGS ND, 1990, INT J GYNECOL OBSTET, V31, P157, DOI 10.1016/0020-7292(90)90714-V
   LADIPO OA, 1989, INT J GYNECOL OBSTET, P21
NR 4
TC 1
Z9 1
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0049-4755
J9 TROP DOCT
JI Trop. Dr.
PD OCT
PY 2006
VL 36
IS 4
BP 235
EP 236
DI 10.1258/004947506778604652
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 098AQ
UT WOS:000241492500025
PM 17034704
OA No
DA 2017-08-15
ER

PT J
AU Moore, SE
   Collinson, AC
   Fulford, AJC
   Jalil, F
   Siegrist, CA
   Goldblatt, D
   Hanson, LA
   Prentice, AM
AF Moore, Sophie E.
   Collinson, Andrew C.
   Fulford, Anthony J. C.
   Jalil, Fehmida
   Siegrist, Claire-Anne
   Goldblatt, David
   Hanson, Lars A.
   Prentice, Andrew M.
TI Effect of month of vaccine administration on antibody responses in The
   Gambia and Pakistan
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE vaccination; seasonality; antibody response; Gambia; Pakistan
ID RABIES-NEUTRALIZING ANTIBODY; HEPATITIS-B-VACCINE; EARLY CHILD HEALTH;
   INFANTS; ADULTS; SEASON; LAHORE; BIRTH; IMMUNOGENICITY; STANDARD
AB To explore the relationship between calendar month of administration and antibody (Ab) response to vaccination in subjects from The Gambia and Pakistan, two countries with distinct patterns of seasonality.
   Three cohorts were investigated: Responses to rabies and pneumococcal vaccine were assessed in 472 children (mean age 8 years, males 53%) from rural Gambia. Responses to tetanus, diphtheria and hepatitis B (HBsAg) were investigated in 138 infants also from The Gambia (birth to 52 weeks of age, males 54%). Responses to rabies and Vi typhoid vaccines were assessed in 257 adults from Lahore, Pakistan (mean age 29.4 years, males 57%).
   In Gambian children, significant associations were observed between month of vaccination and Ab response for the pneumococcal and rabies vaccines. As no consistent pattern by month was observed between the responses, it is assumed that different immunomodulatory stimuli or mechanisms were involved. In Pakistani adults, a significant pattern by month of vaccination was observed with both rabies and typhoid vaccine. No monthly influences were observed in the infant study to the tetanus, diphtheria or the HbsAg vaccines.
   Antibody responses to certain specific vaccines are influenced by month of administration. Further research is required to elucidate the precise mechanisms explaining these observations, but a co-stimulatory effect of seasonally variable environmental antigens is a likely cause. Future studies of Ab response to vaccination in countries with a seasonally dependent environment should consider month of vaccination when interpreting study findings.
C1 Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Nutr & Publ Hlth Intervent Res Unit,Dept Epidemio, London WC1E 7HT, England.
   MRC Keneba, MRC Labs, Banjul, Gambia.
   Royal Devon & Exeter Hosp, Directorate Child & Womens Hlth, Exeter EX2 5DW, Devon, England.
   King Edward Med Coll & Mayo Hosp, Dept Social & Prevent Paediat, Lahore, Pakistan.
   Univ Geneva, Dept Pathol Immunol, WHO, Collaborating Ctr Neonatal Vaccinol, Geneva, Switzerland.
   Univ Geneva, Dept Pediat, WHO, Collaborating Ctr Neonatal Vaccinol, Geneva, Switzerland.
   Inst Child Hlth, Immunobiol Unit, London, England.
   Univ Gothenburg, Dept Clin Immunol, Gothenburg, Sweden.
RP Moore, SE (reprint author), Univ London London Sch Hyg & Trop Med, MRC, Int Nutr Grp, Nutr & Publ Hlth Intervent Res Unit,Dept Epidemio, Keppel St, London WC1E 7HT, England.
EM sophie.moore@lshtm.ac.uk
RI Goldblatt, David/C-5972-2008
OI Goldblatt, David/0000-0002-0769-5242
CR BATES CJ, 1994, EUR J CLIN NUTR, V48, P660
   BATES CJ, 1999, MICRONUTRIENT APPROA
   BATES CJ, 1982, T ROY SOC TROP MED H, V3, P341
   BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133
   Cliquet F, 1998, J IMMUNOL METHODS, V212, P79, DOI 10.1016/S0022-1759(97)00212-3
   COLE TJ, 1995, ARCH DIS CHILD, V73, P25
   COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005
   Collinson AC, 2003, ACTA PAEDIATR, V92, P1014, DOI 10.1080/08035250310004379
   COLLINSON AC, 2002, THESIS U BRISTOL
   Da Silva JAP, 1999, ANN NY ACAD SCI, V876, P102
   Duffy PE, 2003, VACCINE, V21, P3358, DOI 10.1016/S0264-410X(03)00332-3
   Fisman DN, 2002, CLIN INFECT DIS, V35, P1368, DOI 10.1086/344271
   FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008
   FREEMAN JV, 1990, ARCH DIS CHILD, V73, P17
   GREENWOOD BM, 1986, ANN TROP MED PARASIT, V80, P537
   Jalil F, 1989, Acta Paediatr Scand Suppl, V350, P44
   Kossaczka Z, 1999, INFECT IMMUN, V67, P5806
   Lakshmi G, 2000, VACCINE, V18, P2009, DOI 10.1016/S0264-410X(99)00529-0
   Lisse IM, 1997, J PEDIATR-US, V130, P77, DOI 10.1016/S0022-3476(97)70313-5
   MAHMUD A, 1993, ACTA PAEDIATR, V82, P79, DOI 10.1111/j.1651-2227.1993.tb12908.x
   Moore SE, 2004, AM J CLIN NUTR, V80, P453
   Moore SE, 2003, ACTA PAEDIATR, V92, P170
   Moore SE, 2001, AM J CLIN NUTR, V74, P840
   Ngom PT, 2004, AM J CLIN NUTR, V80, P722
   Ota MOC, 2002, J IMMUNOL, V168, P919
   Powell G M, 1982, Ann Trop Paediatr, V2, P143
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   QUATAERT SA, 1995, CLIN DIAGN LAB IMMUN, V2, P590
   Rosen JB, 2004, LANCET, V363, P1386, DOI 10.1016/S0140-6736(04)16052-2
   ROWLAND M G M, 1985, Annals of Tropical Paediatrics, V5, P23
   Rubins JB, 1998, J INFECT DIS, V178, P431
   Shaheen SO, 1996, BRIT MED J, V313, P969
   Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7
   Siegrist CA, 2003, VACCINE, V21, P3406, DOI 10.1016/S0264-410X(03)00342-6
   Silfverdal SA, 2002, PEDIATR INFECT DIS J, V21, P816, DOI 10.1097/01.inf.0000027668.74570.96
   SMITH JS, 1973, B WORLD HEALTH ORGAN, V48, P535
   THURNHAM DI, 1988, CLIN CHEM, V34, P377
   ZAMAN S, 1993, ACTA PAEDIATR, V82, P63, DOI 10.1111/j.1651-2227.1993.tb12907.x
NR 38
TC 21
Z9 21
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD OCT
PY 2006
VL 11
IS 10
BP 1529
EP 1541
DI 10.1111/j.1365-3156.2006.01700.x
PG 13
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 086NU
UT WOS:000240681100007
PM 17002727
OA No
DA 2017-08-15
ER

PT J
AU Rowland-Jones, S
   Dong, T
AF Rowland-Jones, Sarah
   Dong, Tao
TI HIV - Tired T cells turn around
SO NATURE
LA English
DT Editorial Material
ID DISEASE PROGRESSION; EXPRESSION; INFECTION
C1 MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
   MRC Labs, Fajara, Gambia.
RP Rowland-Jones, S (reprint author), MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England.
EM sarah.rowland-jones@ndm.ox.ac.uk
CR Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   Geng H, 2006, INT J CANCER, V118, P2657, DOI 10.1002/ijc.21795
   Kostense S, 2001, EUR J IMMUNOL, V31, P677, DOI 10.1002/1521-4141(200103)31:3<677::AID-IMMU677>3.0.CO;2-M
   Kroner A, 2005, ANN NEUROL, V58, P50, DOI 10.1002/ana.20514
   Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845
   Shanker P, 2000, BLOOD, V96, P3094
   TRAUTMAN L, 2006, NAT MED, DOI DOI 10.1038/NM1482
NR 9
TC 5
Z9 5
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD SEP 21
PY 2006
VL 443
IS 7109
BP 282
EP 283
DI 10.1038/443282a
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 085RL
UT WOS:000240622000028
PM 16988698
OA No
DA 2017-08-15
ER

PT J
AU Hill, PC
   Akisanya, A
   Sankareh, K
   Cheung, YB
   Saaka, M
   Lahai, G
   Greenwood, BM
   Adegbola, RA
AF Hill, Philip C.
   Akisanya, Abiodun
   Sankareh, Kawsu
   Cheung, Yin Bun
   Saaka, Mark
   Lahai, George
   Greenwood, Brian M.
   Adegbola, Richard A.
TI Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian villagers
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID PNEUMOCOCCAL CONJUGATE VACCINE; UPPER RESPIRATORY-TRACT;
   PAPUA-NEW-GUINEA; YOUNG-CHILDREN; RISK-FACTORS; HAEMOPHILUS-INFLUENZAE;
   INVASIVE-DISEASE; HEALTHY-CHILDREN; ACQUISITION; RESISTANCE
AB Background. To prepare for the introduction of a pneumococcal conjugate vaccine of restricted valency, we studied the nasopharyngeal carriage of Streptococcus pneumoniae in Gambian villagers.
   Methods. A cross-sectional survey was conducted in 21 villages after a census. We recorded demographic characteristics, information on medical history, and data on possible risk factors for carriage from subjects. We collected a nasopharyngeal swab specimen from each subject for isolation and serotyping of S. pneumoniae and for antibiotic susceptibility testing.
   Results. The prevalence of S. pneumoniae carriage among 2872 villagers was 72%. It was highest among infants ( i.e., children aged < 1 year; 97%); the rate was 93% among babies aged < 1 month and decreased with increasing age (P < .001). Prevalence of carriage was linked to proximity to another village. Sixty-three percent of isolates P < .001 recovered from children aged < 5 years were covered by the 7-valent vaccine or were of a vaccine-related serotype, compared with 43% of isolates overall. Forty-three isolates ( 14.3%) tested were initially penicillin resistant; none had high-level resistance, and 4 had intermediate resistance. The rates of resistance to other antibiotics were as follows: trimethoprim-sulfamethoxazole, 39%; tetracycline, 32.3%; chloramphenicol, 6.3%; cefotaxime, 0.3%; and erythromycin, 0%. The rates were highest for isolates of vaccine serotypes.
   Conclusions. Pneumococcal carriage rates among Gambian villagers are very high. A pneumococcal conjugate vaccine of restricted valency should reduce the pool of antibiotic-resistant pneumococci. The large reservoir of pneumococci of nonvaccine serotypes will require close monitoring when the vaccine is introduced.
C1 MRC Labs, Bacterial Dis Programme, Banjul, Gambia.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Hill, PC (reprint author), MRC Labs, Bacterial Dis Programme, Box 273, Banjul, Gambia.
EM phill@mrc.gm
FU Medical Research Council [G0700837]
CR ABEGBOLA RA, 2006, TROP MED INT HEALTH, V11, P1128
   Brueggemann AB, 2003, J INFECT DIS, V187, P1424, DOI 10.1086/374624
   Byington CL, 2005, CLIN INFECT DIS, V41, P21, DOI 10.1086/430604
   Cutts FT, 2005, LANCET, V365, P1139, DOI 10.1016/S0140-6736(05)71876-6
   Dagan R, 2003, PEDIATR INFECT DIS J, V22, P532, DOI 10.1097/00006454-200306000-00009
   Fairchok MP, 1996, CLIN INFECT DIS, V22, P966
   Ghaffar F, 2004, CLIN INFECT DIS, V39, P930, DOI 10.1086/423379
   GRATTEN M, 1986, BIOL NEONATE, V50, P114
   GRAY BM, 1980, J INFECT DIS, V142, P923
   Greenwood B, 1999, PHILOS T ROY SOC B, V354, P777, DOI 10.1098/rstb.1999.0430
   HENDLEY JO, 1975, J INFECT DIS, V132, P55
   Huang SS, 2004, AM J EPIDEMIOL, V159, P645, DOI 10.1093/aje/kwh088
   Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060
   Kyaw MH, 2006, NEW ENGL J MED, V354, P1455, DOI 10.1056/NEJMoa051642
   Leowski J, 1986, World Health Stat Q, V39, P138
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007
   Marchisio P, 2002, EMERG INFECT DIS, V8, P479
   MASTRO TD, 1993, PEDIATR INFECT DIS J, V12, P824, DOI 10.1097/00006454-199310000-00006
   MONTGOMERY JM, 1990, REV INFECT DIS, V12, pS1006
   O'Brien KL, 2003, LANCET, V362, P355, DOI 10.1016/S0140-6736(03)14022-6
   O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI 10.1097/00006454-200302000-00009
   Pai R, 2005, J INFECT DIS, V192, P1988, DOI 10.1086/498043
   Principi N, 1999, PEDIATR INFECT DIS J, V18, P517, DOI 10.1097/00006454-199906000-00008
   Regev-Yochay G, 2004, CLIN INFECT DIS, V38, P632
   Saha SK, 2003, J CLIN MICROBIOL, V41, P5582, DOI 10.1128/JCM.41.12.5582-5587.2003
   Sandgren A, 2004, J INFECT DIS, V189, P785, DOI 10.1086/381686
   Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0
   SMITH T, 1993, EPIDEMIOL INFECT, V111, P27
   Soewignjo S, 2001, CLIN INFECT DIS, V32, P1039, DOI 10.1086/319605
   Steenhoff AP, 2006, CLIN INFECT DIS, V42, P907, DOI 10.1086/500941
   Syrjanen RK, 2005, PEDIATR INFECT DIS J, V24, P801, DOI 10.1007/01.inf.0000178072.83531.4f
   Syrjanen RK, 2001, J INFECT DIS, V184, P451, DOI 10.1086/322048
   Ussery XT, 1996, PEDIATR INFECT DIS J, V15, P986, DOI 10.1097/00006454-199611000-00011
   van der Loeff MFS, 2003, AIDS, V17, P1841, DOI 10.1097/01.aids.0000076303.76477.49
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   Yagupsky P, 1998, J INFECT DIS, V177, P1003
NR 36
TC 93
Z9 96
U1 1
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD SEP 15
PY 2006
VL 43
IS 6
BP 673
EP 679
DI 10.1086/506941
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 077SI
UT WOS:000240050000001
PM 16912937
OA No
DA 2017-08-15
ER

PT J
AU Moore, SE
   Mansoor, MA
   Bates, CJ
   Prentice, AM
AF Moore, Sophie E.
   Mansoor, M. Azam
   Bates, Christopher J.
   Prentice, Andrew M.
TI Plasma homocysteine, folate and vitamin B(12) compared between rural
   Gambian and UK adults
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE homocysteine; folate; vitamin B(12); Gambia; West Africa; United Kingdom
ID METHYLENETETRAHYDROFOLATE REDUCTASE; NORTHERN NIGERIA;
   CARDIOVASCULAR-DISEASE; WEST-AFRICAN; RISK-FACTORS; LIFE-STYLE;
   DETERMINANTS; WOMEN; SERUM; POPULATIONS
AB The disease risk indicator plasma total homocysteine (tHcy) is influenced by genetic and environmental factors, including folate and vitamin B(12) status. Little is known about the determinants of tHcy in rural West Africa. We explored the hypothesis that tHcy in rural Gambian adults might vary between the sexes and physiological groups, and/or with folate and vitamin B(12) status. Comparisons were made with a British national survey. Non-pregnant Gambian women (n 158) had tHcy concentrations (geometric mean 9.0 mu mol/l) similar to those of non-pregnant UK women (n 449; 9.4 mu mol/l), whereas pregnant Gambian women (n 12) had significantly lower values (6.2 mu mol/l). Gambian men (n 22) had significantly higher values (14.7 mu mol/l) than British men (n 354; 10.8 mu mol/l). Gambian lactating women and British men and women exhibited significant inverse relationships between log(e)(tHcy) and folate status; however, only the British subjects exhibited significant inverse relationships between log(e)(tHcy) and vitamin B(12) status. In the British sample, and in Gambian lactating women, folate and vitamin B(12) status variations together accounted for 20-25 % of the variation in log(e)(tHcy). Within the UK, black-skinned adults had folate and tHcy levels similar to those of their white-skinned counterparts, but significantly higher vitamin B(12) values. We conclude that, whereas folate and vitamin B(12) status are similar between British and rural Gambian populations, tHcy is higher in Gambian men and lower in pregnant Gambian women, and that serum vitamin B(12) values appear to be higher in black-skinned than white-skinned British subjects. Possible reasons are discussed.
C1 MRC, Human Nutr Res, Cambridge, England.
   MRC, Keneba, Gambia.
   London Sch Hyg & Trop Med, MRC, Int Nutr Grp, London WC1, England.
   Cent Hosp Rogaland, Div Clin Chem, Stavanger, Norway.
RP Bates, CJ (reprint author), MRC, Human Nutr Res, Cambridge, England.
EM Chris.Bates@mrc-hnr.cam.ac.uk
FU Medical Research Council [MC_U105960399]
CR ABDALLA SH, 1986, T ROY SOC TROP MED H, V80, P557, DOI 10.1016/0035-9203(86)90138-0
   Adjalla CE, 2003, CLIN CHEM LAB MED, V41, P1028, DOI 10.1515/CCLM.2003.158
   Amouzou EK, 2004, AM J CLIN NUTR, V79, P619
   ANDERSSON A, 1992, EUR J CLIN CHEM CLIN, V30, P377
   BATES CJ, 1994, EUR J CLIN NUTR, V48, P660
   BATES CJ, 1986, HUM NUTR-CLIN NUTR, V40C, P3
   BATES CJ, 1982, T ROY SOC TROP MED H, V3, P341
   Blom HJ, 1998, EUR J PEDIATR, V157, pS131, DOI 10.1007/PL00014297
   BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049
   Cappuccio FP, 2002, ATHEROSCLEROSIS, V164, P95, DOI 10.1016/S0021-9150(02)00024-2
   Carmel R, 1999, SEMIN HEMATOL, V36, P88
   COLE TJ, 1993, SOC ST HUM, V35, P89, DOI 10.1017/CBO9780511600517.008
   Department of Health, 1991, DIET REF VAL FOOD EN
   FISKERSTRAND T, 1993, CLIN CHEM, V39, P263
   Fokkema MR, 2003, CLIN CHEM, V49, P818, DOI 10.1373/49.5.818
   Gamble MV, 2005, AM J CLIN NUTR, V81, P1372
   Ganji V, 2003, AM J CLIN NUTR, V77, P826
   Gerhard GT, 1999, AM J CLIN NUTR, V70, P252
   Glew RH, 2004, J HEALTH POPUL NUTR, V22, P357
   Glew RH, 2002, J HEALTH POPUL NUTR, V20, P166
   Gueant-Rodriguez RM, 2006, AM J CLIN NUTR, V83, P701
   Henderson L., 2003, NATL DIET NUTR SURVE, V3
   Hendriks J.G.E., 2002, J BIOMED MATER RES B, V64, P1
   Ingenbleek Y, 2004, NUTR RES REV, V17, P135, DOI 10.1079/NRR200489
   Jacques PF, 2001, AM J CLIN NUTR, V73, P613
   Moller J, 1999, CLIN CHEM, V45, P1536
   Moore SE, 2001, DIABETIC MED, V18, P646, DOI 10.1046/j.1464-5491.2001.00565.x
   Nexo E, 2000, CLIN CHEM, V46, P1150
   Nygard O, 1998, AM J CLIN NUTR, V67, P263
   PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940
   PRENTICE AM, 1987, AM J CLIN NUTR, V46, P912
   PRENTICE AM, 1981, AM J CLIN NUTR, V34, P2790
   Prentice AM, 1999, FETAL PROGRAMMING IN, P399
   RUSTON S, 2004, NATL DIET NTUR SURVE, V4
   Shankar AH, 2000, J INFECT DIS, V182, pS37, DOI 10.1086/315906
   SHIPCHANDLER MT, 1995, CLIN CHEM, V41, P991
   Siekmann JH, 2003, J NUTR, V133, p3972S
   Simpore J, 2002, CURR THER RES CLIN E, V63, P459, DOI 10.1016/S0011-393X(02)80051-0
   Stabler SP, 2004, ANNU REV NUTR, V24, P299, DOI 10.1146/annurev.nutr.24.012003.132440
   Topley E, 1968, East Afr Med J, V45, P190
   Ubbink JB, 1996, J NUTR, V126, pS1254
   UELAND PM, 1993, CLIN CHEM, V39, P1764
   Ueland P. M., 2000, HOMOCYSTEINE VASCULA, P59
   UELAND PM, 1987, TUMOR CELL DIFFERENT, P269
   Ueland PM, 1992, ATHEROSCLEROTIC CARD, P183
   van der Sande MAB, 2001, AM J PUBLIC HEALTH, V91, P1641, DOI 10.2105/AJPH.91.10.1641
   VanderJagt DJ, 2000, J NATL MED ASSOC, V92, P334
   Vollset SE, 2001, AM J CLIN NUTR, V73, P499
   Walker MC, 1999, AM J OBSTET GYNECOL, V180, P660, DOI 10.1016/S0002-9378(99)70269-3
   Welch GN, 1998, NEW ENGL J MED, V338, P1042
NR 50
TC 12
Z9 13
U1 1
U2 1
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD SEP
PY 2006
VL 96
IS 3
BP 508
EP 515
DI 10.1079/BJN20061835
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 076QC
UT WOS:000239971800013
PM 16925856
OA No
DA 2017-08-15
ER

PT J
AU Cooper, SA
   Van der Loeff, MFS
   Sarge-Njie, R
   Kaye, S
   Vincent, T
   Cooper, MJF
   Whittle, H
   McConkey, S
AF Cooper, S. A.
   Van der Loeff, M. F. Schim
   Sarge-Njie, R.
   Kaye, S.
   Vincent, T.
   Cooper, M. J. F.
   Whittle, H.
   McConkey, S.
TI Spastic paraparesis in HTLV-1 infected individuals in a rural West
   African population
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Meeting Abstract
C1 So Gen Hosp, Inst Neurol Sci, Dept Neurol, Glasgow G51 4TF, Lanark, Scotland.
   IATEC, Dept Epidemiol, Amsterdam, Netherlands.
   Medical Res Council Labs, Dept Microbiol, Fajara, Gambia.
   Medical Res Council Labs, Dept Virol, Fajara, Gambia.
   MRC Labs, Caio, Guinea Bissau.
   Glasgow Primary Care Trust, Glasgow, Lanark, Scotland.
RI McConkey, Samuel/E-7307-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1351-5101
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD SEP
PY 2006
VL 13
SU 2
BP 32
EP 33
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 084HE
UT WOS:000240523200106
OA No
DA 2017-08-15
ER

EF